<SEC-DOCUMENT>0001564590-21-009857.txt : 20210301
<SEC-HEADER>0001564590-21-009857.hdr.sgml : 20210301
<ACCEPTANCE-DATETIME>20210301161231
ACCESSION NUMBER:		0001564590-21-009857
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		102
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210301
DATE AS OF CHANGE:		20210301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARVINAS, INC.
		CENTRAL INDEX KEY:			0001655759
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472566120
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38672
		FILM NUMBER:		21697859

	BUSINESS ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
		BUSINESS PHONE:		203-535-1456

	MAIL ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS INC.
		DATE OF NAME CHANGE:	20181001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS HOLDING COMPANY, LLC
		DATE OF NAME CHANGE:	20151015
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>arvn-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-01T20:51:00.6713815+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 7fde9e0b67904d4bbc438174819e5cd5 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:arvn="http://www.arvinas.com/20201231" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
arvn-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001655759_20200101_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001655759_20200101_20201231">2020</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001655759_20200101_20201231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000006" name="dei:EntityCentralIndexKey" contextRef="C_0001655759_20200101_20201231">0001655759</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001655759_20200101_20201231">--12-31</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000433_2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20181001" decimals="4">0.3077</ix:nonFraction>
			<ix:nonNumeric id="F_000465" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_0001655759_20200101_20201231">us-gaap:AccountingStandardsUpdate201613Member</ix:nonNumeric>
			<ix:nonNumeric id="F_000466" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001655759_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000467" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001655759_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000555" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_0001655759_20200101_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000556" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" contextRef="C_0001655759_20200101_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000599" name="arvn:DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930">P120M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000433" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20181001" decimals="4">0.3077</ix:nonFraction>
			<ix:nonNumeric id="F_000463" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001655759_20200101_20201231">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000654" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180301_20180331">2018-09-30</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="arvn:ProceedsFromSaleOfMarketableSecurities" contextRef="C_0001655759_20190101_20191231" decimals="0">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="arvn:ProceedsFromSaleOfMarketableSecurities" contextRef="C_0001655759_20180101_20181231" decimals="0">0</ix:nonFraction>
			<ix:nonNumeric id="F_000512" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231">P1Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000513" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_20201231">P1Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000514" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2023-01-01_20201231">P1Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000671" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2">0.70</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000672" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2">0.69</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000673" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="2">0.68</ix:nonFraction>
			<ix:nonNumeric id="F_000677" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P5Y3M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000678" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P5Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000679" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">P5Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000683" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="3">0.003</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000684" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="3">0.014</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000685" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="3">0.026</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000692" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="2">22.70</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000693" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="2">17.29</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000694" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231" decimals="2">14.44</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000674" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2">0.75</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000675" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2">0.71</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000676" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="2">0.70</ix:nonFraction>
			<ix:nonNumeric id="F_000680" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P7Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000681" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P7Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000682" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">P10Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000686" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="3">0.016</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000687" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="3">0.027</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000688" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="3">0.031</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000695" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="2">50.00</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000696" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="2">37.66</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000697" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231" decimals="2">16.24</ix:nonFraction>
			<ix:nonNumeric id="F_000710" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231">P8Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000711" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231">P7Y10M24D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001655759_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001655759_20191231" xsi:nil="true"></ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="arvn-20201231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001655759_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001655759_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001655759_20210224">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-24</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001655759_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesARedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesBRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesARedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesCRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesBRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesABAndCConvertiblePreferredSharesMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesABAndCConvertiblePreferredSharesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnCommonUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:CommonUnitsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:IncentiveUnitsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:IncentiveUnitsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnCommonUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:CommonUnitsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_arvnSubsidiary">
				<xbrli:measure>arvn:Subsidiary</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20181001">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2018-10-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20181001_20181001">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2018-10-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20181001_20181001">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2018-10-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20181001">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-10-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20181001_20181031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2018-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20181031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_20181001_20181001">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2018-10-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_20181001">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-10-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMaximumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMinimumMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMinimumMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorThreeMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorThreeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_arvnLaboratoryEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20130701_20130731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-01</xbrli:startDate>
					<xbrli:endDate>2013-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMinimumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_srtRangeAxis_srtMinimumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_srtRangeAxis_srtMaximumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_srtRangeAxis_srtMaximumMember_20150101_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-01-01</xbrli:startDate>
					<xbrli:endDate>2015-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnResearchFundingPaymentsMember_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapTypeOfArrangementAxis_arvnResearchFundingPaymentsMember_20221231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnResearchFundingPaymentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnDevelopmentMilestonePaymentsMember_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnSalesBasedMilestonePaymentsMember_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnStockPurchaseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_arvnContract">
				<xbrli:measure>arvn:Contract</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_us-gaapTypeOfArrangementAxis_arvnOptionExercisedToLicenseAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionExercisedToLicenseAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnOptionPaymentsToLicenseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnDevelopmentMilestonePaymentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnSalesBasedMilestonePaymentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_us-gaapTypeOfArrangementAxis_arvnSubstitutionTargetPaymentsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SubstitutionTargetPaymentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_us-gaapTypeOfArrangementAxis_arvnSubstitutionTargetPaymentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SubstitutionTargetPaymentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_20150901_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-09-01</xbrli:startDate>
					<xbrli:endDate>2015-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_20171101_20171130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-11-01</xbrli:startDate>
					<xbrli:endDate>2017-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_arvnTarget">
				<xbrli:measure>arvn:Target</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnDevelopmentMilestonePaymentsMember_20171130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_us-gaapTypeOfArrangementAxis_arvnRegulatoryMilestonePaymentsMember_20171130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_us-gaapTypeOfArrangementAxis_arvnCommercialMilestonesMember_20171130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnOptionPaymentsToLicenseAgreementMember_20171130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGAndPfizerMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGAndPfizerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
							<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
						</xbrldi:typedMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
							<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
						</xbrldi:typedMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2023-01-01_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
							<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
						</xbrldi:typedMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapInvestmentTypeAxis_arvnTwoThousandTwentyMaturityMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:TwoThousandTwentyMaturityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapInvestmentTypeAxis_arvnTwoThousandTwentyMaturityMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:TwoThousandTwentyMaturityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_arvnLaboratoryEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_arvnLaboratoryEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMinimumMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMaximumMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:LoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:ConnecticutInnovationsIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2013-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:LoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:ConnecticutInnovationsIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2013-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:LoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:ConnecticutInnovationsIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130801_20130831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:LoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:ConnecticutInnovationsIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-08-01</xbrli:startDate>
					<xbrli:endDate>2013-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:LoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:ConnecticutInnovationsIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndFourteenAssistanceAgreementMember_20140101_20141231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2014-01-01</xbrli:startDate>
					<xbrli:endDate>2014-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndFourteenAssistanceAgreementMember_20141231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180601_20180630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-06-01</xbrli:startDate>
					<xbrli:endDate>2018-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-09-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-09-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_arvnCommonUnitsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">arvn:CommonUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredStockMember_20130101_20141231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-01-01</xbrli:startDate>
					<xbrli:endDate>2014-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20150101_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesBRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-01-01</xbrli:startDate>
					<xbrli:endDate>2015-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredStockMember_20141231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesBRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180301_20180331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesCRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-03-01</xbrli:startDate>
					<xbrli:endDate>2018-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesCRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_20180901_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-09-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnPiperSandlerMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnPiperSandlerMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191101_20191130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-11-01</xbrli:startDate>
					<xbrli:endDate>2019-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191101_20191130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-11-01</xbrli:startDate>
					<xbrli:endDate>2019-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190701_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190101_20190101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180301_20180331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-03-01</xbrli:startDate>
					<xbrli:endDate>2018-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180301_20180331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-03-01</xbrli:startDate>
					<xbrli:endDate>2018-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180301_20180331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-03-01</xbrli:startDate>
					<xbrli:endDate>2018-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-09-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-09-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtTitleOfIndividualAxis_arvnConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:ConsultantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-09-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtTitleOfIndividualAxis_arvnConsultantsMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:ConsultantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-09-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180901_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-09-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerCropScienceLPMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerCropScienceLPMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnAmendedCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:AmendedCorporateSponsoredResearchAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:CorporateSponsoredResearchAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:CorporateSponsoredResearchAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:CorporateSponsoredResearchAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:ConsultingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:ConsultingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:ConsultingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001655759_20200101_20201231">10-K</ix:nonNumeric><span style="font-weight:normal;"> </span></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:1pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;"></td>
<td style="width:95.56%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000026" name="dei:DocumentAnnualReport" contextRef="C_0001655759_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001655759_20200101_20201231" format="ixt:datemonthdayyearen">December&#160;31, 2020</ix:nonNumeric></p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;"></td>
<td style="width:95.56%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:DocumentTransitionReport" contextRef="C_0001655759_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number: <span style="color:#000000;"><ix:nonNumeric id="F_000016" name="dei:EntityFileNumber" contextRef="C_0001655759_20200101_20201231">001-38672</ix:nonNumeric></span></p>
<p style="text-align:center;margin-top:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:EntityRegistrantName" contextRef="C_0001655759_20200101_20201231">ARVINAS, INC.</ix:nonNumeric></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001655759_20200101_20201231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001655759_20200101_20201231">47-2566120</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:EntityAddressAddressLine1" contextRef="C_0001655759_20200101_20201231">5 Science Park</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:EntityAddressAddressLine2" contextRef="C_0001655759_20200101_20201231">395 Winchester Ave</ix:nonNumeric>.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityAddressCityOrTown" contextRef="C_0001655759_20200101_20201231">New Haven</ix:nonNumeric>, <ix:nonNumeric id="F_000022" name="dei:EntityAddressStateOrProvince" contextRef="C_0001655759_20200101_20201231" format="ixt-sec:stateprovnameen">Connecticut</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityAddressPostalZipCode" contextRef="C_0001655759_20200101_20201231">06511</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:2pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <span style="color:#000000;">(<ix:nonNumeric id="F_000024" name="dei:CityAreaCode" contextRef="C_0001655759_20200101_20201231">203</ix:nonNumeric>) <ix:nonNumeric id="F_000025" name="dei:LocalPhoneNumber" contextRef="C_0001655759_20200101_20201231">535-1456</ix:nonNumeric></span></p>
<p style="text-align:center;line-height:2pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: <span style="font-size:6pt;font-weight:normal;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:14.95pt;">
<td valign="bottom" style="width:40%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Title of each class)</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Name of each exchange on which registered)</p></td>
</tr>
<tr style="height:14.95pt;">
<td valign="bottom" style="width:40%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000028" name="dei:Security12bTitle" contextRef="C_0001655759_20200101_20201231">Common stock, par value $0.001 per share</ix:nonNumeric>&#160;</span><span style="color:#000000;">&#160;</span></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:TradingSymbol" contextRef="C_0001655759_20200101_20201231">ARVN</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000030" name="dei:SecurityExchangeName" contextRef="C_0001655759_20200101_20201231" format="ixt-sec:exchnameen">The Nasdaq Global Select Market LLC</ix:nonNumeric></span></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">None </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Title of class) <span style="font-size:8.5pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. <span style="text-transform:uppercase;">Yes</span> <span style="font-size:9pt;font-family:Segoe UI Symbol;letter-spacing:-0.1pt;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.<span style="font-family:Times New Roman;font-size:10pt;">&#160;</span><span style="text-transform:uppercase;"><ix:nonNumeric id="F_000011" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001655759_20200101_20201231">Yes</ix:nonNumeric></span><span style="font-family:Times New Roman;font-size:10pt;">&#160;</span><span style="font-size:9pt;font-family:Segoe UI Symbol;">&#9744;</span>&#160;<span style="text-transform:uppercase;font-family:Times New Roman;"><ix:nonNumeric id="F_000015" name="dei:EntityVoluntaryFilers" contextRef="C_0001655759_20200101_20201231">No</ix:nonNumeric></span>&#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;letter-spacing:-0.1pt;">&#9746;</span> </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000012" name="dei:EntityCurrentReportingStatus" contextRef="C_0001655759_20200101_20201231">Yes</ix:nonNumeric></span>&#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;letter-spacing:-0.1pt;">&#9746;</span>&#160;<span style="text-transform:uppercase;">No</span> <span style="font-size:9pt;font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000013" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001655759_20200101_20201231">Yes</ix:nonNumeric></span>&#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;letter-spacing:-0.1pt;">&#9746;</span>&#160;<span style="text-transform:uppercase;">No</span><span style="font-size:9pt;font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-bottom:2pt;margin-top:2pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:11.5pt;">
<td valign="top" style="width:23.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityFilerCategory" contextRef="C_0001655759_20200101_20201231" format="ixt-sec:entityfilercategoryen">Large&#160;accelerated&#160;filer</ix:nonNumeric></p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:51.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="top" style="width:23.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:52.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:23.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:51.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;&#160;&#160;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntitySmallBusiness" contextRef="C_0001655759_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:23.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:51.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:23.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:51.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001655759_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.<span style="margin-left:36pt;"></span><span style="font-size:9pt;font-family:Segoe UI Symbol;letter-spacing:-0.1pt;"><ix:nonNumeric id="F_000033" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001655759_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000014" name="dei:EntityShellCompany" contextRef="C_0001655759_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;<span style="text-transform:uppercase;">No</span>&#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000031" name="dei:EntityPublicFloat" contextRef="C_0001655759_20200630" decimals="INF" format="ixt:numdotdecimal" scale="6">1,347.5</ix:nonFraction> million, based on the closing price of the registrant&#8217;s Common Stock on such date. The number of shares of registrant&#8217;s Common Stock, $0.001 par value per share, outstanding as of February 24, 2021 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000032" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001655759_20210224" decimals="INF" format="ixt:numdotdecimal">48,874,027</ix:nonFraction>. </p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p><ix:nonNumeric id="F_000379" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant&#8217;s 2021 Annual Meeting of Stockholders, which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2020.</p></ix:nonNumeric>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:2pt;">&#160;</p>
<p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><span style="text-decoration:none;">PART I</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:none;">Business</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:none;">Risk Factors</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:none;">Unresolved Staff Comments</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:none;">Properties</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:none;">Legal Proceedings</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:none;">Mine Safety Disclosures</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:none;">PART&#160;II</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:none;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><span style="text-decoration:none;">Selected Financial Data</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:none;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:none;">Quantitative and Qualitative Disclosures About Market Risk</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:none;">Financial Statements and Supplementary Data</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:none;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:none;">Controls and Procedures</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:none;">Other Information</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><span style="text-decoration:none;">PART&#160;III</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:none;">Directors, Executive Officers and Corporate Governance</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:none;">Executive Compensation</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:none;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:none;">Certain Relationships and Related Transactions, and Director Independence</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:none;">Principal Accounting Fees and Services</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><span style="text-decoration:none;">PART&#160;IV</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:none;">Exhibits, Financial Statement Schedules</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:none;">Form 10-K Summary</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;goals,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">the initiation, timing, progress and results of our current and future clinical trials of ARV-110, ARV-471 and ARV-766, including statements regarding the period during which the results of the clinical trials will become available&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">the timing of, and our ability to obtain, marketing approval of ARV-110 and ARV-471, and the ability of ARV-110 and ARV-471 and our other product candidates to meet existing or future regulatory standards&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">our plans to pursue research and development of other product candidates&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">the potential advantages of our platform technology and our product candidates&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">the extent to which our scientific approach and platform technology may potentially address a broad range of diseases&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">the potential receipt of revenue from future sales of our product candidates&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">the rate and degree of market acceptance and clinical utility of our product candidates&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">our estimates regarding the potential market opportunity for our product candidates&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">our sales, marketing and distribution capabilities and strategy&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">our ability to establish and maintain arrangements for manufacture of our product candidates&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">the potential achievement of milestones and receipt of payments under our collaborations&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">our ability to enter into additional collaborations with third parties&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">our intellectual property position&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">the impact of COVID-19 on our business and operations&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">the impact of government laws and regulations&#59; and</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.94%;text-indent:-2.27%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">our competitive position.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the &#8220;Risk Factors&#8221; section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements except as required by applicable law.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Throughout this Annual Report on Form 10-K, the &#8220;Company,&#8221; &#8220;</span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas</span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; except where the context requires otherwise, refer to </span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas</span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Inc. and its consolidated subsidiaries, or any one or more of them as the context may require, and &#8220;our board of directors&#8221; refers to the board of directors of </span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas</span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Inc.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use Arvinas, the Arvinas logo, and other marks as trademarks in the United States and other countries. This Annual Report on Form 10-K contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K, including logos, artwork and other visual displays, may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk Factor Summary</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to a number of risks that if realized could materially affect our business, prospects, operating results and financial condition. These risks are discussed more fully in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. These risks include the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">We have incurred significant losses since our inception. To date, we have not generated any revenue from product sales and may never be profitable. We expect to incur losses over at least the next several years and may never achieve or maintain profitability. Our net loss was $119.3 million for the year ended December 31, 2020, $70.3 million for the year ended December 31, 2019 and $41.5 million for the year ended December 31, 2018.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">We will need substantial additional funding. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">The ongoing COVID-19 pandemic has and may continue to affect our ability to initiate and complete preclinical studies, delay the initiation of our planned clinical trials or future clinical trials, disrupt regulatory activities, disrupt our manufacturing and supply chain or have other adverse effects on our business and operations. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business, and it has the potential to materially and adversely affect our business, financial condition, results of operations and prospects.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">Our approach to the discovery and development of product candidates based on our PROTAC technology platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">We have a limited operating history that may make it difficult to evaluate the success of our business to date and to assess our future viability and are early in our development efforts. We initiated our first Phase 1 clinical trial for a product candidate, ARV-110, in March 2019, we initiated a Phase 1 clinical trial of ARV-471 in August 2019, and we expect to initiate a Phase 1 clinical trial of ARV-766 in the first half of 2021. Both the ARV-110 and ARV-471 clinical trials remain ongoing. All of our other product candidates are still in preclinical development.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">We cannot be certain of the timely completion or outcome of our preclinical testing and clinical trials. The results of preclinical studies may not be predictive of the results of clinical trials, and the results of early-stage clinical trials may not be predictive of the results of later-stage clinical trials. In addition, interim and preliminary data from our clinical trials that we announce from time to time, such as the recently announced interim data from our ongoing Phase 1/2 clinical trials of ARV-110 and ARV-471, may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data. If we are unable to obtain, or there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, our business will be materially harmed and our ability to generate revenue from product sales will be materially impaired.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">We rely, and expect to continue to rely, on third party manufacturing organizations for the manufacture of both drug substance and finished drug product for our product candidates for preclinical testing and clinical trials, and we expect to continue to do so for commercialization. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired, and we may not be able to compete effectively in our market.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I">PART I</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">Item 1. Business.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. We use our PROTAC Discovery Engine, our proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body&#8217;s own natural protein disposal system to selectively remove disease-causing proteins. We believe that our targeted protein degradation approach is a therapeutic modality that may provide distinct advantages over existing modalities, including traditional small molecule therapies and gene-based medicines. Our small-molecule PROTAC technology has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as &#8220;undruggable&#8221; targets. We are using our PROTAC Discovery Engine to build an extensive pipeline of protein degradation product candidates to target diseases in oncology (including immuno-oncology), neuroscience, and other therapeutic areas. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have designed and optimized our PROTAC Discovery Engine for the discovery of PROTAC therapeutics to address diseases caused by abnormal proteins or aberrant protein expression. We engineer our PROTAC targeted protein degraders to tag a target protein for degradation through the ubiquitin proteasome system, one of the cell&#8217;s natural protein disposal systems, and then to iteratively degrade additional target protein molecules. The PROTAC Discovery Engine includes advanced screening capabilities, including in-house high-throughput and DNA-encoded library screening abilities that are tailored to the needs of incorporation into PROTAC protein degraders and to optimize their drug-like properties. Following selection and identification, we use tools including predictive computational modeling and privileged linkers that allow the potential for increased potency and selectivity. Finally, we have utilized our own proprietary PROTAC-specific optimization strategies, which we refer to as the Arvinas Rules, to create PROTAC degraders that, for example, are capable of being delivered through multiple routes of administration, including oral delivery, as well as PROTAC targeted protein degraders that are able to penetrate the blood brain barrier. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our two lead product candidates are ARV-110 and ARV-471. We are developing ARV-110, a PROTAC protein degrader targeting the androgen receptor protein, or AR, for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC. We initiated a Phase 1 clinical trial of ARV-110 in March 2019. This Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics of ARV-110 and also includes measures of anti-tumor activity as secondary endpoints, including reduction in prostate specific antigen, or PSA, a well-recognized biomarker of prostate cancer progression. We received Fast Track designation for ARV-110 for mCRPC in May 2019. In October 2020, we initiated ARDENT, the Phase 2 expansion portion of the ARV-110 clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also developing ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein, or ER, for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. We initiated a Phase&#160;1 clinical trial of ARV-471 in August 2019. This Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics of ARV-471 and also includes measures of anti-tumor activity as secondary endpoints.<span style="Background-color:#FFFFFF;color:#000000;"> We amended the protocol for our Phase 1 clinical trial for ARV-471 in the first quarter of 2020 to include the Phase 2 expansion cohort and in the fourth quarter of 2020 to include a </span>Phase 1b cohort expansion of ARV-471 in combination with Ibrance&#174; (palbociclib). In February 2021, we initiated VERITAC, the Phase 2 expansion portion of the ARV-471 clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our preclinical studies, these lead product candidates have demonstrated potent and selective protein degradation. We believe favorable clinical trial results in these initial oncology programs would provide validation of our platform as a new therapeutic modality for the potential treatment of diseases caused by dysregulated intracellular proteins regardless of therapeutic area. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to file an investigational new drug, or IND, application and initiate a Phase 1 trial in the first half of 2021 for ARV-766, an AR degrader developed to target and degrade wild-type and mutated AR including at least one additional, clinically relevant AR point mutation as compared to ARV-110.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our clinical product candidates, we are expanding our pipeline by utilizing our platform to potentially address currently undruggable targets. Unlike existing small molecule inhibitor therapies, our PROTAC targeted protein degraders can degrade proteins using any available binding site, including low-affinity active binding sites or non-functional binding sites, bringing biological utility to ligands that would otherwise be ineffective. While some gene-based medicines are also seeking to address undruggable targets, our PROTAC targeted protein degraders confer the advantages of traditional small molecule therapies, such as broad tissue distribution, multiple routes of administration, including oral delivery, a well-established development pathway and relative ease of manufacturing. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are further diversifying our pipeline by developing new </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROTAC targeted protein degraders</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against targets for which we believe protein degradation offers advantages to existing therapeutic modalities. For example, we are pursuing targets for the treatment of neurodegenerative diseases, including tauopathies, which are diseases associated with an aggregation of tau proteins in the brain, such as Alzheimer&#8217;s </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">isease. We have engineered </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROTAC targeted protein degraders</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that, in preclinical studies, have successfully achieved blood brain barrier penetration, a key step in developing drugs with the potential to treat neurodegenerative targets. We believe there are many other indications for which our PROTAC technology may be advantageous.</span><span style="font-size:12pt;font-family:Times New Roman;"> </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In an effort to realize the full potential of our PROTAC </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technology</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, our ongoing strategic collaborations with Pfizer Inc., or Pfizer, Genentech, Inc. and F. Hoffman-La Roche Ltd, collectively referred to as Genentech,</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> an</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Bayer AG, or Bayer</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> address targets across multiple therapeutic areas. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been a leader in the field of directed protein degradation using chimeric small molecules since our founding in 2013. Our PROTAC technology platform has its origins in work performed at Yale University, or Yale, by our scientific founder and Chief Scientific Advisor, Professor Craig Crews, a leading researcher in the field of protein degradation. We have assembled a scientific team with extensive know-how and translational medicine expertise to develop PROTAC targeted protein degraders with features not previously disclosed in published third-party studies. Our management team draws on extensive experience in all phases of drug discovery and development gained at large pharmaceutical and biotechnology companies to continue to advance our product pipeline and expand the capabilities of our platform. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to discover, develop, and commercialize therapies that improve the lives of patients suffering from cancer, neurological disorders and other serious diseases. We engineer PROTAC protein degraders that are designed to selectively remove disease-causing proteins, and we believe that our proprietary PROTAC technology is a new therapeutic modality with the potential to provide distinct advantages over existing therapies and to address a broad range of targets, including undruggable proteins. The key elements of our strategy are to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Advance clinical development of our lead programs, which address the well-understood oncology targets AR and ER.</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> Our strategy for our PROTAC platform includes the initial pursuit of oncology targets with well-understood biology, well-characterized disease models and established biomarkers. We are conducting a Phase 1 dose escalation and Phase 2 dose expansion clinical trial for ARV-110 in men with mCRPC and a Phase 1 dose escalation and Phase 2 dose expansion clinical trial for ARV-471 (and a Phase 1b cohort expansion for ARV-471 in combination with Ibrance&#174; (palbociclib)) in patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. We believe favorable clinical trial results in these initial oncology programs would validate the broader therapeutic potential of our PROTAC technology and PROTAC Discovery Engine.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Utilize our PROTAC Discovery Engine platform to address undruggable and difficult-to-drug targets.</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> We are applying our platform to develop treatments for diseases associated with a prioritized subset of the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as undruggable targets. Our platform enables us to build PROTAC targeted protein degraders with the potential to degrade these proteins through the cell&#8217;s natural protein degradation process using any available binding site, including low-affinity active binding sites or non-functional binding sites, bringing biological utility to ligands that would otherwise be inactive. We also believe that many &#8220;difficult-to-drug&#8221; targets, where prior approaches are inadequate, will also provide opportunities to apply our PROTAC Discovery Engine.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Develop new therapeutics with distinct advantages over existing modalities, including gene-based medicines. </span><span style="font-size:10pt;font-family:Arial;color:#000000;">We intend to address targets for which we believe protein degradation and the tunable features of our PROTAC targeted protein degraders offer advantages compared to existing therapeutic modalities. For example, unlike gene-based medicines, our PROTAC targeted protein degraders confer the advantages of traditional small molecule therapies, such as broad tissue distribution, multiple routes of administration, including oral delivery, a well-established development pathway and relative ease of manufacturing. In addition, we have engineered PROTAC targeted protein degraders that, in preclinical studies, have successfully achieved blood brain barrier penetration, creating potential opportunities for our PROTAC technology in neurodegenerative diseases. We also believe there are many other indications for which our technology may be advantageous, including autoimmune, anti-infective and inflammatory conditions. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Selectively collaborate to realize the full potential of our platform. </span><span style="font-size:10pt;font-family:Arial;color:#000000;">We are </span><span style="font-size:10pt;font-family:Arial;color:#000000;">using our PROTAC </span><span style="font-size:10pt;font-family:Arial;color:#000000;">Discovery Engine</span><span style="font-size:10pt;font-family:Arial;color:#000000;">.</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> to </span><span style="font-size:10pt;font-family:Arial;color:#000000;">build an extensive pipeline of product candidates for which we retain full development and commercialization rights across a wide range of diseases. </span><span style="font-size:10pt;font-family:Arial;color:#000000;">In an effort to</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> realize the full potential of our PROTAC </span><span style="font-size:10pt;font-family:Arial;color:#000000;">technology</span><span style="font-size:10pt;font-family:Arial;color:#000000;">, our ongoing strategic collaborations with </span><span style="font-size:10pt;font-family:Arial;color:#000000;">Bayer, Genentech and </span><span style="font-size:10pt;font-family:Arial;color:#000000;">Pfizer address targets across multiple therapeutic areas. </span><span style="font-size:10pt;font-family:Arial;color:#000000;">In addition to these collaborations in human therapeutics, we established a joint venture called </span><span style="font-size:10pt;font-family:Arial;color:#000000;">Oerth</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> Bio</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> LLC, or </span><span style="font-size:10pt;font-family:Arial;color:#000000;">Oerth</span><span style="font-size:10pt;font-family:Arial;color:#000000;">, with Bayer to pursue </span><span style="font-size:10pt;font-family:Arial;color:#000000;">our </span><span style="font-size:10pt;font-family:Arial;color:#000000;">PROTAC </span><span style="font-size:10pt;font-family:Arial;color:#000000;">technology i</span><span style="font-size:10pt;font-family:Arial;color:#000000;">n agricultural applications</span><span style="font-size:10pt;font-family:Arial;color:#000000;">. </span><span style="font-size:10pt;font-family:Arial;color:#000000;">We plan to continue to selectively pursue collaborations with leading biopharmaceutical companies with specialized capabilities or know-how, including </span><span style="font-size:10pt;font-family:Arial;color:#000000;">global </span><span style="font-size:10pt;font-family:Arial;color:#000000;">development and commercial expertise and capabilities. We believe this selective approach to collaboration will further broaden the therapeutic reach of our PROTAC </span><span style="font-size:10pt;font-family:Arial;color:#000000;">technology</span><span style="font-size:10pt;font-family:Arial;color:#000000;">, as well as complement and expand our internal development expertise. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Continue to expand the capabilities of our PROTAC Discovery Engine and the breadth of our intellectual property portfolio</span><span style="font-size:10pt;font-family:Arial;color:#000000;">. We are investing in our research and development activities to expand the capabilities of our PROTAC Discovery Engine and the breadth of our intellectual property portfolio. This includes: research into novel E3 ligases, key proteins in the ubiquitin proteasome system, that may have tissue-specific or disease-specific features&#59; the discovery of novel binding ligands&#59; the discovery of orally bioavailable and blood brain barrier penetrant PROTAC protein degraders&#59; and improvement of our PROTAC targeted protein degrader design and optimization processes. We have exclusive worldwide rights to our platform technology, as well as issued patents for composition of matter in the United States and patent applications pending for composition of matter in key countries for our ARV-110, ARV-471 and ARV-766 product candidates and patent applications pending for composition of matter in the United States and key countries for our exploratory programs. We also have patents and pending patent applications for broad platform coverage for other PROTAC targeted protein degraders using specific E3 ligases. </span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Product Pipeline </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our platform has generated several promising degradation product candidates that may be capable of targeting diseases in a wide range of organ systems and tissues. We and our collaborators have initiated programs across multiple therapeutic areas with the goal of developing and delivering life-changing therapies to patients in need. Our lead therapeutic programs, for which we retain full worldwide development and commercialization rights, are summarized in the table below. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000001.jpg" title="" alt="" style="width:720px;height:314px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">IND dates referenced in the table above are anticipated&#59; ER+/HER2-, estrogen receptor+/human epidermal growth factor receptor&#160;2-&#59;&#160;NSCLC,&#160;non-small-cell&#160;lung carcinoma&#59; CRC, colorectal cancer&#59;&#160;FTLD-tau,&#160;frontotemporal lobar&#160;degeneration-tau&#59;&#160;PSP, progressive supranuclear palsy&#59; AD, Alzheimer&#8217;s disease, MSA, multiple systems atrophy.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We classify our programs as in the exploratory stage of development when we are synthesizing and testing PROTAC protein degraders to evaluate degradation of the selected target, differential biology compared to inhibitors, and proof of concept pharmacodynamics and efficacy <span style="font-style:italic;">in vivo</span>. A program advances to the research stage when we have identified a lead PROTAC protein degrader that demonstrates promising activity in <span style="font-style:italic;">in vitro</span> and <span style="font-style:italic;">in vivo</span> biological models relative to defined criteria. In the research stage, we are working to optimize the PROTAC protein degraders for a desired profile, including degradation potency, selectivity, drug metabolism and pharmacokinetics, pharmacodynamic activity and <span style="font-style:italic;">in vivo</span> efficacy, and we have begun characterizing preclinical tolerability and toxicology. A program enters the IND-enabling stage once we are performing studies intended to support the submission of an IND application, including expanded toxicology, drug product optimization and IND documentation preparation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the programs above and our early-stage development collaborations with Bayer, Genentech, and Pfizer, we are conducting exploratory research and development work on multiple other undisclosed targets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Our Focus </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">The Role of Proteins in Disease </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human cells produce tens of thousands of different proteins, the entirety of which is referred to as the proteome. Proteins are responsible for many structural, functional and regulatory processes in cells. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proteins are large, complex biomolecules made through a series of steps based on instructions carried from deoxyribonucleic acid, or DNA, the genetic &#8220;blueprint&#8221; within the cell. Generally, sequences of DNA are converted into messenger ribonucleic acid, or mRNA, during a process called transcription. mRNA provides the template that specifies the assembly of a particular sequence of amino acids into proteins during a process known as translation. The amino acid sequence dictates, among other things, the conformation, or 3-D shape, of the resulting protein. Proteins can have complex shapes, with multiple chains of amino acids folding together in some cases to reach a final form. The final form of the protein, as well as the timing, location and concentration of its expression within the cell, is essential to the protein&#8217;s intended function. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In healthy cells, the transcription and translation processes contribute to producing properly folded proteins in the right amounts and at the correct times to ensure normal cell health and function. This balance can be disrupted by a variety of events and factors, such as cellular stress, genetic mutations and transcriptional or translational errors, which can then lead to cellular overexpression, abnormal production rates, misfolding or mutations of proteins. When proteins are overexpressed or mutated, a wide variety of diseases can result. For example, it is well documented that overexpression of androgen receptor, a nuclear hormone receptor, is implicated in prostate cancer. Similarly, overexpression of estrogen receptor is known to be associated with breast cancer. In neurodegenerative diseases, abnormal deposition of misfolded or aggregated proteins in the brain, including the intraneuronal aggregation of the microtubule-associated protein tau, are associated with Alzheimer&#8217;s disease. Recent genomic advances continue to implicate the role of specific proteins in many disease states. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are multiple therapeutic approaches, both approved and in development, to treat diseases caused by abnormal proteins or aberrant protein expression. Each operates at a different point in the lifecycle of the protein, as illustrated in the following graphic: </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000002.jpg" title="" alt="" style="width:394px;height:260px;" /></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Small Molecule Inhibitors, Gene Therapy and Gene Editing </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Traditional small molecules seek to block or inhibit the expression or function of an errant protein. While there are numerous examples of safe and effective small molecule therapies, their efficacy can be limited by weak or incomplete binding of the therapeutic molecule to the relevant binding site on the protein, the cell&#8217;s ability to counteract the inhibitory effect of the drug by producing more of the protein, mutation of the target, or evolution of the cell to rely on alternate pathways. These cellular responses often result in a need for higher dosing levels, which can in turn introduce safety challenges from off-target and toxic effects, or drug resistance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gene therapy approaches act by augmenting the errant protein with normal protein by using viral vectors to introduce DNA from an exogenous source that codes for a functional protein. While there have been promising advances in this field, the fundamental approach is limited by delivery, expression efficacy, pre-treatment conditioning, durability and manufacturing challenges that curtail the practical utility of gene therapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gene editing or gene silencing approaches such as CRISPR/Cas9, RNA interference and antisense act by either correcting or inactivating, or knocking out, the gene that would otherwise be transcribed and translated to express the errant protein. By correcting or knocking out the gene, the errant protein is never made, preventing its downstream negative effects. In the case of CRISPR/Cas9, the resulting modification of the gene occurs at the DNA level and is believed to be irreversible. While there are examples of approved therapies in this field that have the potential to correct specific genetic defects, gene editing and gene silencing approaches generally face delivery, stability, biodistribution, specificity and selectivity challenges, in addition to significant manufacturing hurdles. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Protein Degradation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When proteins become old, mutated, misfolded or simply have served their purpose, they are naturally degraded by the body through the ubiquitin proteasome system in which cells mark or tag a particular protein for disposal by attaching several molecules of the small regulatory protein ubiquitin to the protein to be disposed. This process generally proceeds along the following steps in rapid sequence: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">The E1 enzyme activates ubiquitin, which is then transferred to an E2 enzyme. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">An E3 ubiquitin ligase, or E3 ligase, transfers the ubiquitin from the E2 enzyme to a specific target protein. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">Once a chain of at least four ubiquitins are attached to the target protein, the proteasome recognizes the polyubiquinated protein. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">The proteasome breaks down or degrades the protein into its amino acid components. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several therapeutic approaches work at the protein level by modulating the ubiquitin proteasome system to harness the cell&#8217;s natural protein disposal system to degrade and remove a protein. Degradation can be induced by inhibiting chaperone molecules such as HSP90, which are known to facilitate correct protein folding, resulting in tagging misfolded proteins for degradation. HSP90 inhibitors, however, have shown limited efficacy in the clinic to date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some degraders use an approach that causes a conformational change in a specifically targeted protein, resulting in a misfolded protein, which triggers the cell&#8217;s innate protein degradation system to dispose of the misfolded protein. Although these compounds have shown efficacy, they only induce the degradation of those proteins able to adopt a non-native state, leaving a wide array of protein targets unaddressed. The only currently marketed protein degrader utilizing this mechanism, the breast cancer therapy fulvestrant, requires intramuscular administration, further limiting its convenience and pharmacokinetic profile. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chimeric small molecules use a different protein degradation approach. Instead of causing improper folding or inhibiting molecules that facilitate proper folding of the target protein, chimeric small molecules directly recruit an E3 ligase to tag specifically targeted proteins with ubiquitin, signaling the proteasome to degrade the targeted protein. Our PROTAC targeted protein degraders take this approach to protein degradation. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">PROTAC Targeted Protein Degraders &#8212;Our Approach to Protein Degradation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have engineered our PROTAC targeted protein degraders to utilize the cell&#8217;s naturally occurring protein disposal system, directing the proteasome to recognize and degrade specific proteins associated with disease. Our PROTAC targeted protein degraders are chimeric small molecules with two operative ends&#8212;one, a ligand that binds to the protein targeted for degradation, and the other, a ligand that binds to an E3 ligase. These two ligands are connected by a chemical chain linker. Our PROTAC targeted protein degraders bring the targeted protein and the E3 ligase together into a three-component grouping known as a trimer complex to facilitate the transfer of ubiquitin to the target protein. Once four ubiquitins are attached in a chain to the target protein, the proteasome recognizes and degrades the protein. The entire cycle from the formation of the trimer complex, which can occur in a period of nanoseconds, to degradation of the target protein by the proteasome happens over a period of minutes. After our PROTAC targeted protein degrader facilitates the tagging of a target protein molecule with ubiquitin through formation of the trimer complex, it can move on to another target protein molecule to conduct the degradation process again, potentially completing this cycle hundreds of times before eventually being metabolized or eliminated from the cell. We refer to this recycling as our PROTAC targeted protein degraders&#8217; iterative mechanism of action. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The figure below depicts our PROTAC-induced cycle from E3 ligase binding and target protein recruitment, to trimer formation and ubiquitin transfer, to degradation of the target protein by the proteasome, to the release of ubiquitin and PROTAC targeted protein degrader for further degradation cycles<span style="font-style:italic;">.</span> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000003.jpg" title="" alt="" style="width:614px;height:318px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Our Discovery Platform&#8212;PROTAC Discovery Engine</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have designed and optimized our PROTAC Discovery Engine for the discovery of PROTAC targeted protein degrader therapeutics to address diseases caused by abnormal proteins or aberrant protein expression. The PROTAC Discovery Engine includes advanced screening capabilities, including in-house high-throughput and DNA-encoded library screening abilities that are tailored to the needs of incorporation into PROTAC protein degraders and to optimize their drug-like properties. Following selection and identification, we use tools including predictive computational modeling and privileged linkers that allow the potential for increased potency and selectivity. Finally, we have utilized our own proprietary Arvinas Rules to create PROTAC degraders that, for example, are capable of being delivered through multiple routes of administration, including oral delivery, as well as PROTAC targeted protein degraders that are able to penetrate the blood brain barrier.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Design and Optimization of our PROTAC Targeted Protein Degraders </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As genomic knowledge and advances in genome mapping have increased, the understanding of proteins implicated in diseases has similarly increased. We undertake a rigorous evaluation process to prioritize protein targets for which we believe our PROTAC approach can achieve differentiated clinical outcomes for patients over existing modalities. Our PROTAC Discovery Engine is built from nearly 20 years of experience, know-how, and intellectual property and comprises three stages:</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Ligase Selection and Ligand Identification</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">E3 KnowledgeBase </span><span style="font-size:10pt;font-family:Arial;color:#000000;">- The human body has more than 600 E3 ligases, and we select ligands for E3 ligases from our proprietary library for incorporation into our PROTAC targeted protein degraders. We continue to research additional E3 ligases that are expressed in specific tissues or diseases, and identify or discover associated binding ligands, to create novel PROTAC protein degraders that recruit E3 ligases with targeted expression patterns, such as tumor or central nervous system-localized E3 ligases, that may be beneficial for the development of targeted cancer and neurologic therapies. We believe our success with the diverse set of E3 ligases that we are currently employing and the binders of other E3 ligases that we are researching provide us with a competitive advantage as we develop a range of products with different technical characteristics. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Advanced Screening Capabilities</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> - We select ligands for incorporation into our PROTAC targeted protein degraders from a variety of sources. The ligands we select, which target the desired protein for degradation or E3 ligase for incorporation into our PROTAC targeted protein degraders, may include (1)</span><span style="font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">&#160;de novo</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> ligands discovered through high-throughput screening, biophysical directed binding approaches, virtual or </span><span style="font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">in silico </span><span style="font-size:10pt;font-family:Arial;color:#000000;">computer-based screening, and affinity-based hit identification through our in-house DNA-encoded libraries that that are tailored to the needs of incorporation into PROTAC protein degraders and to optimize their drug-like properties or (2)&#160;ligands that are known to bind protein targets but may have faced therapeutic limitations that we believe our PROTAC technology can overcome, such as lack of potency or function, metabolic instability or off-target effects. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Rapid PROTAC Design</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Zone of Ubiquitination - </span><span style="font-size:10pt;font-family:Arial;color:#000000;">Bringing the targeted protein and the E3 ligase together into a trimer complex is necessary but not sufficient for degradation. We use structural and biochemical information to predict precisely which lysine residues on the target protein can be &#8220;tagged&#8221; with ubiquitin, and we design PROTAC degraders to exploit this knowledge.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">ANGLE: Arvinas Next Generation Linker Evolution</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> -We connect the selected protein-targeting ligands and E3 ligase ligands with our privileged chemical linkers. Linker selection is critical for rapid identification of protein degraders and can introduce function and selectivity to a nonfunctional or nonselective binding ligand upon incorporation into a PROTAC targeted protein degrader molecule. Linker composition can also be used to modulate properties of our PROTAC targeted protein degraders, such as membrane permeability, aqueous solubility, metabolic stability and biodistribution. We select from a proprietary library of conformationally privileged linkers to enable the efficient formation of the trimer complex essential to ubiquitin transfer and protein degradation. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Predictive Computational Modeling -</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> We use trimer structure-based computational modeling and design algorithms to rapidly identify potent degraders.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Proteomics - </span><span style="font-size:10pt;font-family:Arial;color:#000000;">A PROTAC degrader is often more selective than the targeting warhead. We have proteomics capabilities that enable us to understand that specificity in precise detail and iterate quickly to optimize the selectivity of our PROTAC degraders for the protein target.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.83%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Turning Degraders into Drugs </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Arvinas Rules- </span><span style="font-size:10pt;font-family:Arial;color:#000000;">Optimization of traditional small molecule agents tends to focus on guidelines that increase the chances of such molecules having sufficient permeability and solubility to make them orally bioavailable. Chimeric small molecules, including our PROTAC targeted protein degraders, are larger than traditional small molecule therapeutics, such that the conventional optimization parameters prevalent in traditional drug discovery do not readily apply. As such we have developed and apply our own proprietary Arvinas Rules for our PROTAC targeted protein degraders. Through our Arvinas Rules, we have made PROTAC targeted protein degraders that are orally bioavailable and that cross the blood brain barrier.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Deep knowledge of </span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">in vivo</span><span style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;"> PK/PD and efficacy relationships- </span><span style="font-size:10pt;font-family:Arial;color:#000000;">Our understanding of molecular features that impact PROTAC biodistribution and target degradation, in the body, enables us to create PROTAC degraders with drug-like properties and activities. We can use this understanding to rapidly progress from target identification to PROTAC optimization and development. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Key Features of Our PROTAC Targeted Protein Degraders</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the design, optimization and development of our PROTAC targeted protein degraders, we focus on the following key features that we believe are critical to successfully engineering PROTAC targeted protein degrader therapeutics with potentially robust application across multiple indications and therapeutic areas:&#160;potency, selectivity, and deliverability and versatility. We have harnessed these features to successfully target and degrade a wide range of protein classes, including nuclear proteins, transcription factors, epigenetic modulators, membrane proteins, cytosolic proteins and high molecular weight neuroprotein aggregates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Potency </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The potency of our PROTAC technology is driven by two key characteristics: the iterative mechanism of our PROTAC targeted protein degraders and the ability to turn weak binders into potent degraders. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.73%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Iterative Mechanism </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our PROTAC targeted protein degraders behave iteratively to repeatedly induce the ubiquitination and subsequent degradation of proteins. As a result, protein degradation may be observed with PROTAC targeted protein degrader concentrations much lower than those required for typical small molecule inhibition, even operating at picomolar concentrations. We expect that the high cellular potency of PROTAC targeted protein degrader could provide the possibility of removal of proteins at levels equivalent to the knock out effect intended by gene-based medicines currently being explored. Our PROTAC targeted protein degraders offer potentially significant therapeutic advantages, including low doses, low drug exposures and practical dosing intervals, potentially mitigating toxicity and tolerability risks. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The iterative mechanism of our PROTAC targeted protein degraders potentially leads to more complete and lasting inactivation of downstream signaling in cells. In oncology, this translates into improved inhibition of tumor cell growth and reduces the likelihood of cell compensation through activation of alternative proteins, a common risk associated with small molecule inhibitors. This enables PROTAC targeted protein degraders to operate in a broad therapeutic space between desired degradation-induced pharmacology and unwanted inhibition-induced effects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the pre-existing reservoir of the targeted protein is depleted, our PROTAC targeted protein degraders only need to degrade newly resynthesized protein to maintain their effect. Depending on the resynthesis rate of the protein, this may be achievable with low tissue concentrations of PROTAC targeted protein degrader, which could lead to safety benefits and opportunities for flexible dosing regimens. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Weak Binders Become Potent Degraders </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using our platform and know-how, we are able to engineer potent PROTAC targeted protein degraders that do not require a high degree of binding strength to their targets. This contrasts with small molecule inhibitors, which require strong binding to a target protein and function by continually occupying the protein&#8217;s active site. The potency of our PROTAC targeted protein degraders is determined by a number of kinetic factors: formation of the trimer complex, rapid ubiquitination, trafficking of the ubiquitinated target to the proteasome and release of the PROTAC targeted protein degrader to enter another iterative cycle of degradation. As a result, a PROTAC targeted protein degrader with a low level of target protein occupancy can maintain a deep and prolonged suppression of protein levels, leading to the desired pharmacological effect. This provides opportunities to use our PROTAC technology to repurpose small molecules that only weakly bind to their target to create potent degraders as PROTAC targeted protein degraders. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">published experiments where we built </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROTAC targeted protein degraders </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from the known protein kinase inhibitor </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">foretinib</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which is a relatively weak binder to the protein p38&#945;, a protein implicated in immune disorders and heart disease. We constructed a </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">foretinib</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-based </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROTAC targeted protein degrader</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we refer to as PROTAC 1, which happened to further weaken the binding affinity to p38&#945;. Binding affinity is measured by K</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">D</sub></span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or equilibrium dissociation constant. In this case, we observed that PROTAC 1 exhibited a tenfold reduction in binding affinity relative to </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">foretinib</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, decreasing from 1 micromolar, or &#181;M, to 11 &#181;M. Despite the significantly weaker binding affinity, PROTAC 1 achieved potent degradation of p38&#945; with a DC</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">50</sub></span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, a concentration that results in half maximal degradation, of 210 nanomolar, or </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nM</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which means that its degradation potency is approximately 50-fold better than its binding strength. The figure below shows a western blot of cells treated with increasing concentrations (left to right) of </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">foretinib</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the PROTAC 1, and an inactivated (non-degrading) version of PROTAC 1. The decreasing presence of the p38&#945; protein is depicted by a lighter shade of the p38&#945; band in the western blot as the doses of the PROTAC 1 increase. This demonstrates our ability to use a weak binder to create a potent PROTAC </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">targeted protein </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">degrader. Based on our experience, we believe that with additional medicinal chemistry effort, the degradation potency of this weak-binding </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROTAC targeted protein degrader </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could be further increased.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000004.jpg" title="" alt="" style="width:576px;height:154px;" /></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Selectivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When a ligand is incorporated into a PROTAC targeted protein degrader, the trimer complex initiated by the PROTAC targeted protein degrader often causes the ligand&#8217;s selectivity to increase, meaning that the degradation profile of a PROTAC targeted protein degrader can be even more selective than the binding profile of the ligand alone. By minimizing the binding of a ligand to off-target proteins and maximizing selectivity for a target protein, our PROTAC targeted protein degraders may reduce the potential for incidental degradation of normal, healthy proteins and unwanted drug effects and toxicity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We published experiments in which a ligand binding to 133 kinases degraded fewer than ten proteins when incorporated into a PROTAC targeted protein degrader with limited additional modification. The figure below on the left depicts foretinib binding to 133 protein kinases as measured by a competitive binding assay. The figure on the right depicts cells treated with a foretinib-based PROTAC targeted protein degrader degrading only a small subset of cellular proteins (lower left quadrant of the graph) as shown by mass spectrometry analysis. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000005.jpg" title="" alt="" style="width:432px;height:222px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With further modification, and based on our experience, we believe it is possible to engineer promiscuous binders such as this into more selective protein degraders, and when starting with less promiscuous, yet still unselective, binders, identify very selective PROTAC target protein degraders. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This selectivity allows for engineering of </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROTAC targeted protein degraders </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that degrade only the mutated and unwanted protein, while sparing the normal, or wild-type, protein that may be necessary for healthy function. For example, we have demonstrated degradation of abnormal, but not wild-type, forms of the BRAF protein using a </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROTAC targeted protein degrader</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Wild-type BRAF helps transmit chemical signals from outside the cell to the cell&#8217;s nucleus and is part of a pathway that regulates cell proliferation, differentiation, migration and apoptosis. Mutations of BRAF, however, have been associated with </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> different cancers. As shown in the figure below, our </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROTAC targeted protein degrader</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> degraded BRAF mutants, as depicted by a lighter shade in the columns labeled 300 </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nM</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, representative of each of the three classes of BRAF mutations, while not degrading the wild-type BRAF, as depicted by an unchanging shade in each of the columns shown on the western blot. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000006.jpg" title="" alt="" style="width:356px;height:116px;" /></p>
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:20%;text-indent:0%;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1hMito is a protein this particular PROTAC targeted protein degrader is not targeted to degrade, and is</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.33%;text-indent:6.67%;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">included as a control to ensure total protein is equivalent in each lane.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Deliverability and Versatility </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our PROTAC targeted protein degraders have the potential for delivery through multiple routes of administration to reach target proteins, and certain of our PROTAC targeted protein degraders are capable of penetrating the blood brain barrier. In addition, the broad expression of the E3 ligases we target and the potential to turn weak binding ligands into potent degraders allows the application of our PROTAC technology to develop treatments for diseases associated with proteins that cannot be addressed by existing small molecule therapies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Deliverability </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed PROTAC targeted protein degraders that are capable of being delivered orally, intravenously, subcutaneously and intrathecally, among other routes of administration, as well as PROTAC targeted protein degraders that are able to penetrate the blood brain barrier. The multiple routes of delivery for our PROTAC targeted protein degraders potentially provide many attractive clinical dosing options. For example, oral delivery can offer a differentiating, competitive and commercial advantage over other therapeutic approaches such as gene-based medicines that allows for more convenient treatment. Further, oral administration avoids risks of adverse events associated with intravenous or intramuscular administration, such as the potential for infection and blood clots at the infusion site. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Versatility </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our PROTAC targeted protein degraders may have potential application in a wide range of therapeutic areas because the E3 ligases we currently target are expressed widely across tissue types. Ligands that bind to some proteins may be of only weak affinity. However, we believe that our PROTAC technology will allow the degradation of proteins through such low affinity active binding sites or non-functional binding sites. Our ability to design weak binding PROTAC targeted protein degraders that nonetheless initiate rapid ubiquitination and subsequent degradation of targeted proteins has the potential to expand the number of disease-causing proteins targeted for drug development to include the up to 80% of proteins that cannot be addressed by existing small molecule therapies and are currently considered undruggable. We believe that rendering these targets druggable for the first time represents the true breadth and potential of our PROTAC Discovery Engine. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted an experiment designed to demonstrate that non-functional binding sites, analogous to those that may be present on proteins considered undruggable, can be used to target proteins for degradation by PROTAC targeted protein degraders. The figure below depicts a structural model of the Abl tyrosine kinase. This protein kinase possesses an enzymatic active site that is inhibited by the marketed small molecule, imatinib. The Abl kinase also has a second, non-functional active site, called an allosteric site, in its structure that can bind a different small molecule, named GNF-2, which despite binding allosterically (with a relatively weak K<sub style="font-size:85%; vertical-align:bottom">D</sub> of 500 nM), inhibits only the wild type protein (C-Abl), but not BCR-Abl-a mutated form of Abl implicated in chronic myelogenous leukemia. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000007.jpg" title="" alt="" style="width:384px;height:288px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When GNF-2 is converted into a PROTAC targeted protein degrader and used to treat cells, both BCR-Abl and C-Abl are effectively degraded. The figure below shows western blots of cells treated by increasing concentrations of our PROTAC targeted protein degrader and shows decreasing presence of each of BCR-Abl and C-Abl protein (depicted by a lighter shade of the BCR/Abl and C-Abl band in the western blot). Downstream signaling, as denoted by reduction of phosphorylated Stat5 (pStat5), is subsequently inhibited.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000008.jpg" title="" alt="" style="width:404px;height:222px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:6.67%;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1Tubulin is a protein the GNF-2 PROTAC targeted protein degrader is not targeted to degrade, and is included</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:6.67%;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as a control to ensure total protein is equivalent in each lane.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROTAC-induced degradation may offer a solution for undruggable proteins because only binders, not functional inhibitors, are needed to facilitate E3 ligase recruitment and initiation of the degradation process. The probability of finding a suitable ligand using binding-site-agnostic screening is increased because the function of the ligand itself is not required. As a result, there is the potential for PROTAC targeted protein degraders to generate therapeutics from poorly selective ligands, weak-affinity ligands, or ligands that may not be intrinsically biologically active. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Our Programs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">ARV-110 for the Treatment of Men with Metastatic Castration-Resistant Prostate Cancer </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing ARV-110, an orally bioavailable, AR degrading PROTAC targeted protein degrader, for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC. We have chosen AR degradation as our initial therapeutic focus due to the well-documented biology of AR signaling as the principal driver of this cancer. ARV-110 has demonstrated activity in preclinical models of AR overexpression and AR mutations, both common mechanisms of resistance to current standard-of-care agents in men with prostate cancer. We believe that the differentiated PROTAC pharmacology of ARV-110, including its iterative activity, has the potential to translate into significantly improved clinical outcomes over current standard-of-care agents. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Prostate Cancer </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, prostate cancer is both the second most prevalent cancer in men and the second leading cause of cancer death in men. Current estimates predict that one in nine men will be diagnosed with prostate cancer in his lifetime. The American Cancer Society estimates that in 2021 there will be over 248,000 new cases of prostate cancer in the United States and approximately 34,000 deaths from the disease. Men with mCRPC have a poor prognosis and a predicted survival rate of fewer than two years from the initial time of progression. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treatment options for prostate cancer depend on many different factors, including the stage of the cancer. Castration-resistant prostate cancer is defined by disease progression despite androgen deprivation therapy, or ADT, and is often indicated by rising levels of prostate-specific antigen, or PSA. In making treatment evaluations, physicians monitor disease burdens in several ways, including changes in PSA levels. Increased PSA blood levels are considered by many physicians as indicative of cancer progression, and alternative treatment options may be considered. Current standard of care for men with castration-resistant prostate cancer provides that patients should initially receive a combination of ADT and either abiraterone, which works by decreasing androgen levels, or enzalutamide, which works by blocking androgen binding to AR. If the disease progresses despite these second-generation hormonal therapies, chemotherapy is considered the next treatment option. Treatment with chemotherapy is generally postponed for as long as possible due to the potential for severe side effects including neuropathies, nausea, diarrhea, decreased mental capacity and increased risk of infections. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Androgen receptor remains the principal driver of castration-resistant prostate cancer progression during the transition from localized to metastatic disease, with AR gene amplification occurring in 40% to 60% of patients, amplification of a transcription regulatory region upstream of the AR gene occurring in 70% to 87% of patients, and AR point mutations occurring in approximately 15% of patients. Between 15% to 25% of patients do not respond to either abiraterone or enzalutamide and the vast majority of the responsive patients will ultimately become resistant, resulting in limited survival. There remains meaningful unmet medical need in the treatment paradigm of mCRPC, including a significant underserved set of patients who are or become resistant to current therapies. Based on our preclinical data, we believe our PROTAC targeted protein degraders may overcome these known resistance mechanisms and create meaningful clinical benefit for patients. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Preclinical Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have conducted a comprehensive preclinical program to study ARV-110 as a potential treatment for men with mCRPC and initiated a Phase 1 clinical trial in March 2019 and the Phase 2 expansion cohort of that clinical trial in October 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <span style="font-style:italic;">in vitro </span>models, ARV-110 degraded 95% to 98% of AR in multiple cell lines typically used in prostate cancer research. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARV-110 is also highly selective for AR. A proteomic analysis of VCaP cells treated <span style="font-style:italic;">in vitro</span> with ARV-110 at a 10 nM concentration for eight hours demonstrated that only AR was degraded from the nearly 4,000 measured proteins. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Importantly, in addition to AR degradation and selectivity, we have observed in preclinical studies the ability of ARV-110 to potently inhibit prostate cancer cell growth and reduce PSA levels. In addition to guiding treatment decisions, reduction in PSA is often an indicator of the effectiveness of treatment in clinical trials, although it is not recognized as a surrogate endpoint for purposes of regulatory approval. For example, ARV-110 demonstrated equivalent reduction in PSA to enzalutamide at ten-fold lower concentration levels in an <span style="font-style:italic;">in vitro </span>inhibition study of PSA synthesis in Lymph Node Cancer of the Prostate cells, which are androgen-sensitive human prostate adenocarcinoma cells, that have been engineered to overexpress AR. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <span style="font-style:italic;">in vivo </span>mouse models, ARV-110 has inhibited AR-dependent tumor growth, in a statistically significant manner. ARV-110 exhibited superior tumor growth inhibition compared to enzalutamide in both castrated and intact (non-castrated) xenograft models derived from VCaP cell lines. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To assess the ability of ARV-110 to treat enzalutamide-resistant cancers, we conducted <span style="font-style:italic;">in vivo </span>studies of ARV-110 in an enzalutamide-resistant VCaP xenograft model. These VCaP tumors acquired resistance to enzalutamide after being continuously propagated in castrated, enzalutamide treated mice for approximately three years. This resistance can be seen in the figure below, as tumors in mice dosed with enzalutamide grew at nearly the same rate as tumors in mice dosed only with the drug vehicle-a control similar to dosing a placebo. Orally delivered ARV-110 significantly inhibited tumor growth, described as tumor growth inhibition, or TGI, in these enzalutamide-resistant VCaP tumors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000009.jpg" title="" alt="" style="width:260px;height:222px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also conducted preclinical studies of ARV-110 for enzalutamide-insensitive cancers. We conducted an <span style="font-style:italic;">in vivo</span> study using a tumor line derived directly from a patient, referred to as a patient derived xenograft, or PDX, model. This model is derived from a tumor from a patient not treated with enzalutamide but that is insensitive to enzalutamide. This insensitivity can be seen in the figure below, as tumors in mice dosed with enzalutamide grew at only a slightly slower rate than tumors in mice dosed only with the drug vehicle. In contrast, orally delivered ARV-110 significantly inhibited tumor growth in these enzalutamide-insensitive tumors, achieving a TGI value of 100%. Further, PSA levels in the plasma of mice following 20 days of ARV-110 dosing significantly decreased in comparison to those dosed with only the drug vehicle or enzalutamide. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000010.jpg" title="" alt="" style="width:260px;height:222px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the activity of ARV-110 in the above VCaP and PDX models may closely reflect enzalutamide resistance or insensitivity in the clinic and shows the potential for treatment of patients whose tumors have become resistant to, or demonstrate intrinsic resistance to, a current standard-of-care agent. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARV-110 has also reduced the levels of PSA in plasma comparable to levels achieved with enzalutamide in a different VCaP xenograft mouse model but at a lower dosing level. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted IND-enabling Good Laboratory Practice, or GLP, toxicology studies with ARV-110 in rats and dogs to support advancement of ARV-110 into clinical development. Both study designs called for animals to be treated once daily, orally for 28 days, followed by a 14-day recovery period for high dose animals. We believe both studies provide favorable safety margins of approximately five to ten times higher than the anticipated therapeutic doses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the rat study, a no observed adverse effect level, or NOAEL, of 40 milligrams per kilogram, or mpk, the mid-dose, in female animals and 120 mpk, the high dose, in male animals was identified. All findings observed in male high-dose animals were considered reversible by the study director. Atrophy of the prostate and seminal vesicles was noted in male animals at all dose levels and we believe is attributable to the pharmacologic activity of ARV-110. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the dog study, the NOAEL was 10 </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mpk</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per day, the mid-dose. </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The high dose of 30 </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mpk</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per day exceeded the maximum tolerated dose, and dosing in this group was stopped prior to the planned completion to allow for collection of reversibility data. Elevations in liver function enzymes noted in some mid- and high-dose animals were considered reversible by the study director, and non-adverse as they were without microscopic correlates. In addition, at all dose levels, including animals receiving vehicle only, gastrointestinal alteration such as loose and abnormally colored stools were noted. Decreased prostate weights were noted in all male animals and we believe are attributable to the pharmacologic activity of ARV-110. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.73%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Our Phase 1/2 Clinical Trial </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2019, we initiated dosing in a Phase 1 clinical trial of ARV-110. Our Phase 1 trial is designed as an open label, dose-escalation study of ARV-110 in approximately 28 to 60 men with mCRPC whose disease has progressed on at least two prior systemic therapies, one of which must have been enzalutamide or abiraterone. The Phase 1 trial is designed to primarily investigate the safety and tolerability of ARV-110. Secondary endpoints include characterization of ARV-110&#8217;s pharmacokinetic profile and preliminary assessment of biochemical and clinical activity based on evaluation of PSA levels, and radiographic measurement of evaluable lesions. The anti-tumor effects of ARV-110 in measurable lesions will be assessed using Response Evaluation Criteria in Solid Tumors, or RECIST, a standardized set of rules for response assessment based on tumor shrinkage which is widely used in oncology clinical trials. We also will evaluate exploratory markers of disease burden, such as circulating tumor cell enumeration, as exploratory endpoints of the trial. The dose escalation portion of the trial is enrolling patients at four study centers in the United States. The protocol provided for a starting dose of 35 mg/day, administered orally. Up to a total of 20 patients (inclusive of patients previously enrolled at a given dose level) may be added to a previously studied dose escalation cohort once that dose has been deemed safe for further development. Eligible patients include those who have received at least two prior approved therapies for castrate-resistant prostate cancer (at least one of which must be abiraterone or enzalutamide). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, we shared preliminary data from the first three dose-escalation cohorts (35 mg, 3 patients&#59; 70 mg, 4 patients&#59; and 140 mg, 3 patients). ARV-110 (35 mg, 70 mg, and 140 mg) was well tolerated, with no dose-limiting toxicities and no grade 2, 3, or 4 treatment-related adverse events observed. The data presented showed dose proportionality for ARV-110 and that average plasma exposures of ARV-110 in the third (140 mg) cohort had reached levels associated with tumor growth inhibition in preclinical studies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we announced updated data from the Phase 1/2 clinical trial for ARV-110. The data showed evidence of in-tumor AR reduction. As of the April 20, 2020 data cut-off, 20 patients were evaluable for prostate-specific antigen, or PSA, response, including 12 patients treated at 140 mg or higher. These 12 patients exclude one patient who received two weeks of therapy prior to discontinuing due to a rosuvastatin-related dose limiting toxicity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the 12 patients treated at 140 mg and above, circulating tumor DNA analysis of five patients showed AR forms (L702H point mutations and AR-V7 splice variants) not degradable by ARV-110 in preclinical studies. In the group of seven remaining patients who had degradable forms of AR (other AR point mutations, AR amplification and wildtype AR), two patients achieved confirmed PSA responses that remained ongoing, as of the cut-off.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One of these patients had a 74% decline from baseline in PSA and remained without progression after 30 weeks, as of the data cut-off. This patient did not have measurable disease at baseline for assessment by RECIST. The second patient had both a deep PSA response (97% decline from baseline) and a confirmed partial RECIST response (80% decrease from baseline in tumor mass) and remained without progression after 18 weeks, as of the data cut-off. Both responses, which were in patients at the 140 mg dose, were achieved by ARV-110 despite prior treatment with enzalutamide, abiraterone, chemotherapy and other therapies. Tumors from both patients have H875Y and T878A point mutations in AR, which are known to drive resistance to current standard of care treatments and have been degraded by ARV-110 in preclinical studies. In addition to these two patients, PSA reductions were observed in other patients but did not meet a 50% reduction in PSA threshold at data cutoff, and four patients remained on ARV-110 without radiographic progression for at least 20 weeks.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A potential drug-drug interaction between ARV-110 and rosuvastatin, or ROS, was identified during the trial. Of the 22 patients enrolled, two had concurrent use of ROS. One patient receiving 280 mg ARV-110 experienced a Grade 4 dose-limiting toxicity of elevated aspartate transaminase/alanine transaminase, or AST/ALT, liver enzymes followed by acute renal failure. The second patient, receiving 70 mg ARV-110, experienced a Grade 3 AST/ALT elevation, which resolved after the removal of ROS, and the patient was retreated with ARV-110. Follow-up exploratory findings indicate that ROS concentrations, but not ARV-110 concentrations, were elevated in both patients who had liver function test increases. Subsequent <span style="font-style:italic;">in vitro</span> transport pump studies indicated that ARV-110 inhibited breast cancer resistant pump transporter, of which ROS is a substrate. Following the initial data that supported a potential interaction with ROS, concomitant use of ROS was precluded, and as of the cut-off date no other ARV-110 related Grade 3 or 4 adverse events had been reported. Six other patients had, as of the data cut-off date, received concomitant non-ROS statins without AST/ALT adverse events.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first and third quarters of 2020, we amended the protocol</span><span style="Background-color:#FFFFFF;color:#000000;"> for our Phase 1 clinical trial for ARV-110</span><span style="Background-color:#FFFFFF;color:#000000;">. These amendments </span><span style="Background-color:#FFFFFF;color:#000000;">include</span><span style="Background-color:#FFFFFF;color:#000000;">d</span><span style="Background-color:#FFFFFF;color:#000000;"> the </span><span style="Background-color:#FFFFFF;color:#000000;">addition of a </span><span style="Background-color:#FFFFFF;color:#000000;">Phase 2 expansion cohort. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we announced updated interim data from the dose escalation portion of our clinical trial. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We reported that ARV-110 exposures have risen dose proportionally, and at 420 mg oral daily dosing, exposures in nearly all patients have surpassed a threshold we associated with tumor growth inhibition with ARV-110 in enzalutamide-resistant preclinical models of prostate cancer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the dose escalation portion of the trial, 76% of patients had been treated with prior chemotherapy, and 82% previously received both abiraterone and enzalutamide. Patients had a median of five prior lines of therapy. Multiple lines of therapy in nonmetastatic and metastatic castrate resistant prostate cancer are associated with a decreased responsiveness to AR-directed therapies and an increase in tumor heterogeneity, including in genetic mutations, which reduce the tumor&#8217;s dependence on the AR signaling axis. Analysis of trial patient tumor DNA showed that 84% of patients in the trial had at least one and often several non-AR gene mutations. As such, these patients would not be expected to respond to AR-directed agents such as ARV-110. In addition, we found that rates of certain AR mutations have been found to be higher than we anticipated based on previously published studies of men with mCRPC.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have identified a molecularly defined, late-line population with a particularly strong response to ARV-110. Two of five patients (40%) with multiple AR mutations, including T878 and/or H875, had PSA reductions equal to or greater than 50%, or PSA50 response, and one patient had a tumor size reduction of 80%.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, two of 15 patients (13%) with wild-type AR also had a PSA50 response, representing activity in a broader patient population. In the full group of patients with exposures above the minimum threshold we predicted to be efficacious by preclinical studies, four of 28 (14%) had PSA reductions greater than 50%. We believe that this PSA50 response rate is substantially higher than would be expected from approved AR-directed therapies in such late line patients. Specifically, PSA50 response rates from standard-of-care AR-directed therapies generally decrease to 8%-15% in mCRPC patients with fewer prior therapies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The dual signals of ARV-110 activity in a molecularly defined population (T878/H875) and in AR wild-type patients support our two-pronged strategy for ARV-110 development and suggest a robust opportunity to address unmet need in patients with mCRPC.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, we initiated the ARDENT Phase 2 expansion portion of the trial comprising patient subgroups at a dose of 420 mg daily and with the possibility of adding a further dose or schedule. T878/H875 patients will be enriched in a subgroup to ensure sufficient patient numbers in an effort to confirm the potential for accelerated regulatory approval for ARV-110 in this population. A separate subgroup will enrich for less-pretreated patients (i.e., no prior chemotherapy and with only one previous second-generation AR-directed therapy, such as enzalutamide or abiraterone), to ensure sufficient numbers of patients whose tumors are expected to be more AR-dependent, less genetically complex, and potentially more responsive to ARV-110. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to provide complete data from the dose escalation portion of the Phase 1/2 trial in 2021 and provide interim data from the ARDENT Phase 2 expansion portion of the Phase 1/2 trial in the second half of 2021, with full data following in 2022. In 2021, we also expect to begin at least one Phase 1b combination trial with a standard-of-care prostate cancer therapy and provide data in 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">ARV-766 for the Treatment of Men with Metastatic Castration-Resistant Prostate Cancer </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing ARV-766 to target and degrade wild-type and mutated AR including at least one additional, clinically relevant AR point mutation, the L702H point mutation, which ARV-110 does not degrade. The L702H point mutation in the ligand-binding domain of AR results in activation of the AR by glucocorticoids and can cause resistance to a standard of care regimen. Recent studies have reported that between approximately 2-9% of patients with mCRPC had an L702H point mutation. We expect to file an IND application for ARV-766 and initiate a Phase 1 dose escalation clinical trial in the first half of 2021, and if ARV-766 progresses as planned, we expect to provide data from the Phase 1 clinical trial and transition to Phase 2 in 2022.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Next Generation AR Degraders</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing additional PROTAC targeted protein degraders capable of degrading certain AR splice variants. We expect that results from our Phase 1/2 clinical trials of ARV-110 and ARV-766 will provide further data on the role of androgen receptor splice variant-7, or AR-V7, in prostate cancer. ARV-110 and ARV-766 bind to full-length AR at its ligand-binding domain. AR-V7 is a truncated form of AR that lacks the ligand-binding domain necessary to bind with ARV-110 and ARV-766 and which ARV-110 and ARV-766 therefore do not degrade. AR functions as a dimer, a complex made up of two individual AR proteins. AR-V7 can form a dimer with a full-length AR, and such non-identical protein dimers are called heterodimers. We believe that ARV-110 and ARV-766, by degrading the full-length AR component of the heterodimer, could successfully inactivate AR-V7-directed signaling. Although shown to form a heterodimer preclinically, there is uncertainty as to whether AR-V7 and AR form a heterodimer in patients&#8217; tumors. It is also possible that AR-V7 signals through V7-only dimers, which would be unaffected by ARV-110 and ARV-766. Although the presence of AR-V7 has been shown to correlate with a lack of response to enzalutamide and abiraterone, a published study demonstrated that approximately 40% of patients with AR-V7 expressing circulating tumor cells show a PSA response to enzalutamide. Given the evolving potential role of AR-V7 in prostate cancer, as a follow-on to ARV-110 and ARV-766, we are exploring the identification and development of a PROTAC targeted protein degrader that can degrade AR-V7 directly, as well as other AR splice variants. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">ARV-471 for the Treatment of Patients with Locally Advanced or Metastatic ER Positive / HER2 Negative Breast Cancer </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing ARV-471, an orally bioavailable ER degrading PROTAC targeted protein degrader, as an alternative to, and potentially more potent degrader than, the intramuscular injection fulvestrant and other selective ER degraders currently in development for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. Similar to our AR program, we have chosen ER degradation as a therapeutic focus given the well-documented biology of ER signaling as a principal driver in a high percentage of breast cancers. ARV-471 has demonstrated activity in ER positive breast cancer preclinical models. We are clinically investigating ARV-471 for use as a single agent and in combination with cyclin-dependent kinase (CDK) 4/6 inhibitors such as palbociclib. We believe ARV-471 has the potential to improve clinical outcomes over current standards of care for patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Breast Cancer </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, breast cancer is the second most common cancer and the second leading cause of cancer death in women. The American Cancer Society estimates that in 2021 there will be approximately 281,000 women diagnosed with invasive breast cancer in the United States. Metastatic breast cancer accounts for approximately 6% of newly diagnosed cases. Approximately 80% of newly diagnosed breast cancers are ER+, with many patients developing resistance to current treatment options over time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treatment options for breast cancer depend on many different factors, including the stage of the cancer and whether the cancer cells contain hormone receptors. Patients with locally advanced or metastatic breast cancer are treated with systemic therapy, including hormone therapy, chemotherapy and targeted therapy, either as single-agents or in combination. Patients with locally advanced or metastatic ER positive / HER2 negative breast cancer are often treated with hormone therapy, such as tamoxifen or an aromatase inhibitor, sometimes in combination with targeted drugs such as CDK 4/6 inhibitors. In patients with aggressive disease or whose disease continues to progress with a hormonal treatment regimen, chemotherapy may be prescribed. Treatment with chemotherapy is generally postponed for as long as possible due to the potential for severe side effects including neuropathies, nausea, diarrhea, decreased mental capacity and increased risk of infections. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A current standard of care for patients with ER positive / HER2 negative locally advanced or metastatic breast cancer is fulvestrant, an ER degrader administered as a monthly intramuscular injection, either as a single-agent or in combination with another targeted therapy. While fulvestrant has validated the importance of ER degradation as a therapeutic intervention, up to 50% of ER can remain when compared to baseline levels after six months of treatment with fulvestrant, providing an opportunity for more potent ER degraders, such as ARV-471, our PROTAC targeted protein degrader. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.73%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Preclinical Development </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have conducted a comprehensive preclinical program to study ARV-471 as a potential treatment for patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. In our preclinical studies, ARV-471 was a superior degrader of ER compared to fulvestrant. ARV-471 has also shown superior tumor growth inhibition when combined with a CDK4/6 inhibitor compared to fulvestrant and the same combination partner. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <span style="font-style:italic;">in vitro</span> models, ARV-471 has induced ER degradation in multiple cell lines typically used in breast cancer research. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <span style="font-style:italic;">in vivo</span> experiments ARV-471 has achieved superior tumor growth inhibition and degradation compared to fulvestrant. We have tested ARV-471 for tumor growth inhibitory activity using an industry-standard MCF-7 xenograft mouse model.&#160;MCF-7 is a well-characterized estradiol-dependent ER positive / HER2 negative cell line that forms tumors when implanted in the mammary fat pad of female mice.&#160;As shown in the figure below, ARV-471 resulted in very high tumor growth inhibition when dosed daily orally at 10 mpk and more than 80% tumor shrinkage when dosed daily orally at 30 mpk for 28 days.&#160;At both doses, ARV-471 demonstrated superior activity compared to a clinically relevant dose of fulvestrant, which is 200 mpk twice per week for two weeks and then once per week for two weeks. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After 28 days of dosing in this efficacy study, the MCF-7 tumors were removed from the mice and processed for western blots to observe the level of ER degradation induced by oral dosing of ARV-471.&#160;ARV-471 reduced ER by 85%, on average, at 10 mpk as compared to the control tumors and by 89%, on average, at 30 mpk as compared to the control tumors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also conducted preclinical studies to test ARV-471 in a PDX model. This model is derived from a tumor with an ESR1 mutation (Y537S), which is a mutation in the ER that occurs in patients who have been treated with standard-of-care agents such as tamoxifen or an aromatase inhibitor, such as letrozole, and has been cited as a mechanism of resistance to those drugs. These studies included a comparison with fulvestrant. In this 28-day dosing study, oral ARV-471 inhibited tumor growth by 99% at the 10 mpk dosing level and by 106% at the 30 mpk dosing level which was observed to be superior at both dosing levels to a clinically relevant dose of 200 mpk of fulvestrant. Further, ARV-471 was shown to reduce ER by 79% and 88% at the 10 mpk and 30 mpk dosing levels, respectively, compared with 63% at the 200 mpk of fulvestrant dosing level. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also conducted studies of ARV-471 in combination with palbociclib, a CDK4/6 inhibitor that is standard of care when used together with fulvestrant. In these studies, we have achieved significant tumor shrinkage with ARV-471 in ER positive / HER2 negative MCF-7 xenograft models. As shown in the figure below, in a 28-day dosing study in MCF-7 xenografts, ARV-471 at 30 mpk daily in combination with palbociclib was superior in shrinking tumors, as compared to either palbociclib as a single agent at 60&#160;mpk daily, or the standard-of-care combination of palbociclib at 60 mpk daily plus fulvestrant at 200&#160;mpk twice per week for two weeks and then once per week for two weeks. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000011.jpg" title="" alt="" style="width:270px;height:222px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that ARV-471 may also show compelling activity in combination with other targeted agents currently used or in clinical trials for locally advanced or metastatic breast cancer including PI3K and mTOR inhibitors and plan to test these combinations in preclinical models. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted IND-enabling GLP toxicology studies with ARV-471 in rats and dogs to support advancement of ARV-471 into clinical development. The designs for these studies called for animals to be treated once daily, orally for 28 days, followed by a 28-day recovery period at each dose level in the rat study and for the high dose animals only in the dog study. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the rat study, animals were treated at doses of 0 (vehicle control), 3, 10, 30 and 100 mpk/day.&#160;&#160;The NOAEL was 100 mpk, the high dose.&#160;&#160;All findings observed were considered reversible by the study director.&#160;&#160;Evidence of pharmacologic activity was noted in the reproductive organs of rats at the 3 mpk dose level and higher.&#160;&#160;In the dog study, animals received 0 (vehicle control), 15, 45 or 90 mpk/day.&#160;&#160;The NOAEL was 90 mpk, the high dose.&#160;&#160;All findings observed in high-dose animals were considered reversible by the study director. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.73%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Our Phase 1/2 Clinical Trial </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2019, we initiated dosing in a Phase 1 clinical trial for ARV-471. The trial is an open-label dose-escalation study in which we expect to dose approximately 28 to 36 patients with locally advanced or metastatic ER positive / HER2 negative breast cancer who have progressed on at least two prior endocrine therapy regimens and a CDK4/6 inhibitor.<span style="color:#000000;"> Eligible patients may have also received up to three prior regimens of cytotoxic chemotherapy. The protocol provides for a starting dose of 30 mg/day, administered orally. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In the first and fourth quarters of 2020, we amended the protocol for our Phase 1 clinical trial for ARV-471, to include the Phase 2 expansion cohort and a </span><span style="color:#000000;">Phase 1b cohort expansion of ARV-471 in combination with Ibrance&#174; (palbociclib), respectively.</span><span style="Background-color:#FFFFFF;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 1/2 trial is designed to primarily investigate the safety and tolerability of ARV-471 and characterize its pharmacokinetic profile. ER degradation by comparing ER levels in pre-treatment and post-treatment tumor biopsies <span style="color:#000000;">in patients with appropriate lesions will also be evaluated as a secondary endpoint. Other secondary endpoints include the evaluation of</span> anti-tumor response in patients with measurable disease using RECIST. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, we shared preliminary data from three patients enrolled in the first dose escalation cohort (30 mg). At that dose ARV-471 was well tolerated, with no dose-limiting toxicities and no treatment-related adverse events observed. The data presented showed that average plasma exposures of ARV-471 in the 30 mg dose cohort reached levels associated with tumor growth inhibition in preclinical studies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we announced updated interim data from the dose escalation portion of our ongoing Phase 1/2 clinical trial of ARV-471 in patients with locally advanced or metastatic ER+/HER2- breast cancer. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the data cut-off date of November 11, 2020, 21 adult patients with locally advanced or metastatic ER+/HER2- breast cancer were dosed with ARV-471 (orally, once-daily) in the Phase 1 clinical trial. 100% of these patients were previously treated with a CDK 4/6 inhibitor, 71% of patients also received prior fulvestrant, and 23% of patients were also pretreated with investigational selective estrogen receptor degraders or SERDs. Overall, patients had a median of five prior therapies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One patient in the ARV-471 trial had a confirmed partial response, with a 51% reduction in target lesion size as assessed by RECIST. In addition to the confirmed partial response, two additional patients had unconfirmed partial responses and one additional patient demonstrated stable disease with greater than 50% target lesion shrinkage. For a clinical benefit rate, or CBR, evaluation, 12 patients had sufficient follow-up to be included. Five of 12 patients (42%) achieved CBR. CBR is defined to include partial responses, complete responses and stable disease at 6 months. Three of these five patients had previously received fulvestrant, and another was treated with two investigational SERDs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARV-471 was well tolerated at all dose levels, as of the data cut-off date. The most common treatment-related Grade 1-2 adverse events were nausea (24%), arthralgia (19%), fatigue (19%), and decreased appetite (14%). None of these led to discontinuation or dose reduction of ARV-471. No patients reported treatment-related Grade 3 or 4 adverse events, and no dose-limiting toxicities have been reported. A maximum tolerated dose has not been reached and dose escalation continues.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The plasma exposures of ARV-471 have been dose proportional up to and including 360 mg orally once daily and have substantially exceeded our predicted thresholds of efficacy based on preclinical studies. The estimated half-life of ARV-471 is 28 hours, supporting a once-daily schedule of administration. Analysis of five paired tumor biopsies at doses up to 120 mg provide compelling proof of mechanism for ARV-471. At those doses, we have observed ER degradation up to 90% (average of 62%).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> believe that the interim data from </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ongoing clinical trial compares favorably to previously reported Phase 1 clinical trial results of other SERDs with respect to tolerability, ER degradation and efficacy signals.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to complete the dose escalation portion of the Phase 1/2 clinical trial of ARV-471 in the first half of 2021. In February 2021, we initiated the VERITAC Phase 2 expansion portion of the trial at 200 mg daily with the possibility of adding a second dose level. We anticipate sharing interim data from the VERITAC dose expansion portion in 2022.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We initiated a Phase 1b cohort expansion of ARV-471 in combination with Ibrance&#174; (palbociclib) in December 2020. This trial will evaluate the safety and tolerability of ARV-471 in combination with palbociclib and seek to identify a recommended combination dose.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to begin two additional studies of ARV-471 in the second half of 2021: a combination trial of ARV-471 with another targeted therapy in second and/or third line metastatic breast cancer, and a window of opportunity study in early breast cancer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The combined data from these studies will inform our global development strategy and path forward toward the goal for ARV-471 to become the leading endocrine therapy in ER+/HER2- breast cancer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Our Exploratory and Research Programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.73%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Neurodegenerative Diseases </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neurodegenerative diseases are generally progressive in nature and result in the degeneration and often death of neurons in the brain, leading to cognitive decline, functional impairment and eventually death. These diseases affect a rapidly growing patient population and represent one of the largest unmet medical needs of our time. Alzheimer&#8217;s and Parkinson&#8217;s diseases encompass the largest patient populations among the neurodegenerative diseases. The Alzheimer&#8217;s Association estimated that more than 5 million Americans aged 65 and older were living with Alzheimer&#8217;s dementia in 2020, and the Parkinson&#8217;s Foundation estimated that nearly one million Americans are living with Parkinson&#8217;s disease. Alzheimer&#8217;s disease is marked by the progressive accumulation of aggregated tau protein, while aggregation of alpha-synuclein is thought to cause Parkinson&#8217;s disease. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inhibitor-based therapies targeting the proteins thought to be the cause of these neurodegenerative diseases have failed to show clinically meaningful benefit to date. While some existing products provide symptomatic relief to Alzheimer&#8217;s and Parkinson&#8217;s patients, they have significant side effect risks and over time gradually lose their effectiveness in treating the symptoms of the disease. Further, there are no approved disease-modifying treatments for Alzheimer&#8217;s or Parkinson&#8217;s. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Developing PROTAC Targeted Protein Degraders that Cross the Blood Brain Barrier </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Engineering products that cross the blood brain barrier is a highly desirable characteristic in developing effective therapeutics for patients with neurodegenerative diseases as compared with therapies delivered directly into the central nervous system, or CNS. Any product candidates for neurodegenerative disease must reach their intended targets in the brain at exposure levels that will provide a therapeutic effect, while having an acceptable safety profile. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Importantly, we have achieved brain penetration in preclinical models following parenteral administration of PROTAC degrader molecules designed to specifically target pathologic oligomers of tau and &#945;-synuclein, for the treatment of Alzheimer&#8217;s disease and other tauopathies and Parkinson&#8217;s disease and other synucleinopathies, respectively. These PROTAC degrader molecules achieved concentrations in the brain sufficient to induce degradation of the aggregated proteins, widespread penetration into different parts of the brain, and brain/plasma ratios of 0.5 to 5.0, which are comparable to approved therapeutics with CNS activity. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Developing PROTAC</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"> Targeted Protein Degrader</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">s that Degrade Proteins Associated with Neurodegenerative Diseases </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have conducted preclinical studies to establish the potential of our PROTAC Discovery Engine in the CNS for the treatment of neurodegenerative diseases, including tauopathies, the largest of which is Alzheimer&#8217;s disease. We have demonstrated that tau PROTAC protein degrader molecules could be dosed peripherally and degrade pathogenic tau in the brain of a mouse tauopathy model. The figure below shows a greater than 95% reduction in pathologic tau in the cortex of the brain of the Tg2508 mouse model 24 hours following a single parenteral administration of two different tau targeting PROTAC degraders, PROTAC-A at 15 mg per kg and PROTAC-B at 30 mg per kg. We anticipate filing an IND application for our tau program in 2022.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000012.jpg" title="" alt="" style="width:304px;height:280px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 AUC, or area under the curve, for pathologic tau was measured from the cortex region of the brain by WESTM capillary electrophoresis.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**** Tukey's multiple comparisons test p-value &#60; 0.0001</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alpha-synuclein is an abundant neuronal protein that localizes predominantly to presynaptic terminals within the brain. While the normal function of this protein is not fully understood, the pathologic aggregation of alpha-synuclein is implicated in synucleinopathies&#59; the most common of which is Parkinson&#8217;s disease.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preclinical studies, we have demonstrated that alpha-synuclein PROTAC degraders can specifically degrade aggregated forms of the protein. We have conducted <span style="font-style:italic;">in vitro</span> experiments in cells expressing the A53T mutant form of alpha-synuclein, a mutation that causes aggregation of alpha-synuclein and early-onset Parkinson&#8217;s diseases in patients. We treated these cells with alpha-synuclein targeting PROTAC degraders at 1 &#956;M for 48 hours. The table below shows that three different PROTAC molecules, P-3, P-5, and P-6, each degraded aggregated forms of alpha-synuclein in a statistically significant manner, as measured by an alpha-synuclein oligomer based enzyme-linked immunosorbent assay. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000013.jpg" title="" alt="" style="width:374px;height:300px;" /><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our tau and alpha-synuclein programs, our neuroscience programs include a program directed to mutant huntingtin&#160;(mHTT), a key protein target for Huntington&#8217;s disease. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Other Oncology, Immuno-Oncology and Undruggable Targets </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have active exploratory and research programs to evaluate additional established targets in oncology and immuno-oncology, as well as other currently undruggable targets. In line with our strategy, we assess potential exploratory programs on a target-by-target basis to decide whether our PROTAC targeted protein degraders provide a compelling differentiated approach over standard-of-care or other, existing or potential competing mechanisms of action directed against a specific target. In the case of currently undruggable targets, we assess whether the features of our PROTAC targeted protein degraders, including their potential to degrade proteins via sites other than enzymatic active sites and the ability to initiate the degradation process using only weak binders, offer us opportunities to degrade those targets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our exploratory and research activity in oncology and immuno-oncology includes programs directed to the B-cell lymphoma 6 protein (BCL6), a transcription factor implicated in B cell lymphomas&#59; Kirsten rat sarcoma (KRAS), an oncogenic cell growth regulator&#59; Myc, an oncogenic transcription factor driving tumor cell proliferation&#59; and hematopoietic progenitor kinase 1 (HPK1), a suppressor of T cell activation. We anticipate filing an IND application for our BCL6 program as well as an additional oncology-associated program in 2022.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part upon our ability to secure and maintain patent and other proprietary protection for our platform protein degradation technologies, including our PROTAC targeted protein degrader programs, product candidates, and know-how related to our business, defend and enforce our intellectual property rights, in particular our patent rights, preserve the confidentiality of our trade secrets, and operate without infringing valid and enforceable intellectual property rights of others. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions for biopharmaceutical companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protected or remain protectable by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 1, 2021, our patent estate that we own, co-own and in-license includes 20 issued U.S. patents, 36 foreign granted patents, and 344 pending patent applications. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">PROTAC Patents and Patent Applications </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our PROTAC patent portfolio is generally organized into two categories: PROTAC platform patent filings, and PROTAC product candidate or protein target-specific patent filings. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">PROTAC Platform </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 1, 2021, our PROTAC platform patent estate that we own, co-own, and in-license, and that covers our various E3 ubiquitin ligase constructs, includes two issued U.S. patents, 9 granted foreign patents, 9 pending U.S. patent applications and 80 pending foreign patent applications. This patent estate covers constructs that have ligands for the Von Hippel Lindau, or VHL, E3 ubiquitin ligase, the cereblon, or CRBN, E3 ubiquitin ligase, the inhibitor apoptosis protein, or IAP, E3 ubiquitin ligase, and the human mouse double minute homolog, or MDM2, E3 ubiquitin ligase.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We exclusively license from Yale University a portfolio of patents and patent applications describing composition-of-matter claims encompassing PROTAC targeted protein degrader compounds comprised of ligands for the VHL E3 ubiquitin ligase, as well as claims to associated methods of use. Patents have been granted in Australia, Mexico, the United States, and Russia, and patent applications are pending in the United States, Brazil, Canada, China, Europe, Hong Kong, India, Japan and South Korea. If all appropriate maintenance fees are paid, each granted patent will expire in 2033 without taking potential patent term extensions into account. We also co-own with Yale patent applications describing composition-of-matter claims encompassing PROTAC targeted protein degrader compounds comprised of ligands for the VHL E3 ligase. A patent has issued in the United States, and patent applications are pending in the United States, Australia, Canada, China, Europe, Hong Kong, India, Japan, South Korea, Mexico and Russia. Our rights to this patent and these patent applications are governed by the Yale License Agreement described below. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own three patent families with three pending U.S. patent applications describing composition-of-matter claims covering the CRBN E3 ubiquitin ligase ligand generically, the chemical linker group generically, and a small molecule or peptide ligand that binds to a target protein generically. We own granted patents in Australia, Japan, Europe, and Russia. Patent applications are pending in the United States, Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, Korea, Mexico, and Russia. If all appropriate maintenance fees are paid, each granted patent in these families will expire in 2035 without taking potential patent term extensions into account.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own a patent family describing composition-of-matter claims encompassing PROTAC targeted protein degrader compounds comprised of ligands for the IAP E3 ubiquitin ligase as well as claims to associated methods of use. Patent applications in this family are pending in the United States, Australia, Brazil, Canada, Europe, Hong Kong, India, Korea, Mexico and Russia. If granted, and all appropriate maintenance fees are paid, the expiration of these patents would be in 2036 without taking potential patent term extensions into account. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own a patent family describing composition-of-matter claims encompassing PROTAC targeted protein degrader compounds comprised of ligands for the MDM2 E3 ubiquitin ligase as well as claims to associated methods of use. Patent applications in this family are pending in the United States, Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, Korea, Mexico, and Russia. If granted, and all appropriate maintenance fees are paid, the expiration of these patents would be in 2036, without taking potential patent term extensions into account. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">PROTAC Product Candidates </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product or protein-specific patent applications were created to pursue more focused patent exclusivity around PROTAC targeted protein degrader compounds designed to target specific proteins. As of February 1, 2021, our PROTAC product patent portfolio that we own, co-own and in-license includes 15 U.S. issued patents, 26 issued foreign patents, 54 pending U.S. patent applications, and 193 pending foreign patent applications. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own seven patent families describing composition-of-matter claims encompassing PROTAC targeted protein degrader compounds addressing AR and associated methods of treating cancer. The first patent family has two issued U.S. patents, two granted foreign patents, three pending U.S. applications and 22 pending foreign patent applications describing composition-of-matter and method of use claims covering ARV-110. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2037 without taking potential patent term extension into account. The second patent family has four pending applications in the U.S., three granted foreign patents, and 26 foreign applications describing alternative composition-of-matter claims. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2036 without taking potential patent term extension into account. The third patent family has three pending U.S. applications and one pending Patent Cooperation Treaty, or PCT, application </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">describing claims directed to additional methods of treating cancer using ARV-110. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2040 without taking potential patent term extension into account. The fourth patent family has three pending U.S. applications, one pending PCT application, and one pending foreign application describing composition-of-matter claims directed to ARV-766. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2040 without taking potential patent term extension into account. The fifth patent family has a pending U.S. application describing claims directed to additional methods of treating cancer using ARV-110. Any patent granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2041 without taking potential patent term extension into account. The sixth patent family has a pending U.S. application describing claims directed to methods of manufacture, crystalline and ultrapure forms, and dosage forms of ARV-110. Any patent granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2041 without taking potential patent term extension into account. The seventh patent family has two pending U.S. applications describing claims directed to methods of treating cancer with ARV-110 in patients with specific AR mutations. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2041 without taking potential patent term extension into account.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own six patent families describing composition-of-matter claims encompassing PROTAC targeted protein degrader compounds addressing ER and associated methods of treating cancer. The first patent family has two issued U.S. patents, two pending U.S. applications, two granted foreign patents, and 20 pending foreign patent applications describing composition-of-matter and method of use claims covering ARV-471. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2037 without taking potential patent term extension into account. The second patent family has two pending U.S. applications and one pending PCT application describing claims directed to methods of treating cancer using ARV-471 as a monotherapy, and also combined with an additional anti-cancer agent. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2040 without taking potential patent term extension into account.&#160;&#160;The third patent family has a pending U.S. application describing claims directed to crystalline forms of ARV-471. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2041 without taking potential patent term extension into account. The fourth patent family has a pending U.S. application describing claims directed to methods of treating cancer with ARV-471 in patients with specific ER mutations. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2041 without taking potential patent term extension into account. The fifth patent family has one issued U.S. patent, one pending U.S. patent application, and two pending foreign applications describing alternative ER-based PROTAC compounds and methods of use to treat cancer. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2039 without taking potential patent term extension into account. The sixth patent family has one issued U.S. patent, one pending U.S. patent application, and 13 pending foreign applications describing alternative ER-based PROTAC compounds and methods of use to treat cancer. Any patents granted in this family, assuming all appropriate maintenance fees are paid, will expire in 2038 without taking potential patent term extension into account.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Yale co-own nine patent families describing composition of matter claims of PROTAC targeted protein degrader compounds addressing certain discovery and other potential protein targets, and associated methods of use. Patent applications for each of these are pending in the United States. In addition, patent applications are pending at the international stage of the PCT for six of the families and with the European Patent Office for one of the families. Our rights to these patent applications are governed by the Yale License Agreement described below. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also co-own with Genentech two pending U.S. patent applications, and 27 foreign patent applications directed to PROTAC targeted protein degrader compounds addressing a specific protein. Our rights to these patent applications are governed by the Genentech License Agreement described below. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, the term of a patent covering a drug approved by the U.S. Food and Drug Administration, or FDA, may be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering ARV-110 and ARV-471 may be entitled to patent term extensions. If our product candidates receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved product candidates. We also intend to seek patent term extensions in any jurisdiction where they are available&#59; however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States also offers Patent Term Adjustment</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PTA, whereby a </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">particular patent&#8217;s</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> term is automatically extended beyond the 20-year term if the United States Patent and Trademark Office caused delays during the underlying patent application&#8217;s examination. However, potentially available PTA will be reduced by any amount of delay caused by the applicant.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Trade Secrets </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on trade secrets, technical know-how and continuing innovation to develop and maintain our competitive advantage. Our policy requires inventors who are identified on any company-owned patent applications to assign rights to us. We also rely on confidentiality agreements with our employees, consultants and other advisors to protect our proprietary information. Our policy is to require third parties that receive material confidential information to enter into confidentiality agreements with us. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Trademarks </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own a U.S. service mark registration for PROTAC for pharmaceutical products development of new small molecules aimed at degrading disease-causing cellular proteins for treatment in the field of oncology, immunology, inflammatory diseases, and central nervous system disorders. We also own a U.S. trademark registration for the mark PROTAC for small molecule products aimed at degrading disease-causing cellular proteins for treatment in the fields of oncology, immunology, inflammatory diseases, and central nervous system disorders. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also own U.S. and Chinese service mark registrations for ARVINAS in word and logo form for pharmaceutical products development of new small molecules aimed at degrading disease-causing cellular proteins for treatment in the fields of oncology, immunology, inflammatory diseases, and central nervous system disorders.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also own U.S. service mark registrations for our &#8220;degrading dots&#8221; logo mark in both black and white and color form for pharmaceutical products development of new small molecules aimed at degrading disease-causing cellular proteins for treatment in the fields of oncology, immunology, inflammatory diseases, and central nervous system disorders.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Licenses and Strategic Collaborations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Yale University License Agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, we entered into a license agreement with Yale pursuant to which Yale granted us an exclusive, worldwide license under specified intellectual property rights for the treatment or prevention of any human or animal disease in which a product mediates degradation of one or more target proteins, which we refer to as the Field, subject to certain exceptions. These licensed intellectual property rights arose from the research conducted by Dr.&#160;Craig Crews at Yale. During the period in which Professor Crews serves as a member of our board of directors or scientific advisory board or has a similar advisory arrangement, has a consulting arrangement with us, or his laboratory is performing sponsored research for us, and so long as he is an employee or faculty member (including emeritus faculty member) at Yale, Yale will notify us of any inventions in the Field invented in Professor Crews&#8217; laboratory and such invention will be included in the licensed intellectual property, subject to the rights of any non-profit sponsor of the research to use such invention solely for non-profit purposes. In addition, the laboratory of Professor Crews is restricted from conducting any sponsored research, collaboration or other similar arrangement in the Field with a for-profit company while Professor Crews is engaged with us, except where such arrangement allows Yale to grant us licenses of any inventions developed in the laboratory of Professor Crews in the Field in the licensed territory. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are obligated to use commercially reasonable efforts to implement a written plan we agreed to with Yale setting forth a description of any research and development, testing, governmental approval and commercialization activities relating to licensed products and our financing plans. We must update this plan on an annual basis to indicate progress to date on the plan and a schedule of major events required to commercialize licensed products.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the license agreement we paid to Yale an upfront payment of $149,511. We are responsible for paying Yale an annual license maintenance fee in varying amounts (ranging from the low tens-thousands of dollars to the mid to high tens-thousands of dollars) until the first sale to a third party of any licensed product, which is creditable against our royalty obligations for the given year. As of December 31, 2020, we have paid a total of $435,000 in license maintenance fees to Yale. We are required to pay Yale, subject to the achievement of specified development and regulatory milestones, payments aggregating up to approximately $3.0 million for the first licensed product and up to approximately </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.5 million for the second licensed product. We are not required to make any milestone payments for any licensed products beyond the first two. While the agreement remains in effect, we are required to pay Yale low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions. Yale is guaranteed a minimum royalty payment amount (ranging from $200,000 to $500,000) for each year after the first sale of a licensed product that results in net sales. </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T</span><span style="Background-color:#FFFFFF;color:#000000;">he agreement requires that </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">w</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e must also pay Yale a mid-single digit to mid-</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">double digit</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> percentage</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consideration we receive from </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sublicensee</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the first licensed product</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> sublicense. We are also responsible for costs relating to the prosecution and maintenance of the licensed patents. Finally, subject to certain conditions, all payments made by us to Yale (except patent costs) will be tripled during the pendency of any patent challenge made by us against Yale. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also agreed to pay for PROTAC targeted protein degrader research support from Yale pursuant to a sponsored research agreement that we entered into with Yale in July 2016 and amended in April 2018. Under the sponsored research agreement, as amended, we agreed to pay Yale an aggregate of $3.7&#160;million over five years, ending in April 2021, and as of December 31, 2020, we had paid Yale an aggregate of approximately $3.5 million. The research is performed by and under the supervision and direction of Professor Crews for so long as he is employed by Yale. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The license agreement remains in effect until (a)&#160;for certain products, the date on which the last claim of the licensed patents expires&#59; and (b)&#160;for certain products, 10 years after the sale of such products. The expiration of the last to expire patent right licensed from Yale, if it issues as a patent and all appropriate maintenance fees are paid, is currently expected be in 2038. We could also obtain rights to additional patents, including through the issuance of pending patent applications, with later expiration dates, through our rights to any inventions in the Field invented in Professor Crews&#8217; laboratory, which could extend the term of the Yale Agreement. Either we or Yale may terminate the agreement for the other party&#8217;s uncured material breach of certain provisions, we may terminate the agreement for convenience upon six months&#8217; prior notice, and Yale may terminate the agreement if we fail to make a payment when due, fail to obtain or maintain adequate insurance coverage or fail to achieve specified financing or regulatory milestone events. The agreement will automatically terminate if we become insolvent. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Genentech License Agreement<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2015, we entered into an Option and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd, collectively referred to as Genentech, focused on PROTAC targeted protein degrader discovery and research for target proteins, or Targets, based on our proprietary platform technology, other than excluded Targets as described below. This collaboration was expanded in November 2017 through an Amended and Restated Option, License and Collaboration Agreement, which we refer to as the Restated Genentech Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collaboration is managed by a joint research committee and a joint project team, each of which is comprised of representatives from us and Genentech. Decisions of the joint research committee and joint project team are made by consensus, with each party having one vote. If the joint research committee is unable to agree, and the parties&#8217; executives are not able to resolve the dispute, then Genentech has final decision-making authority, subject to specified limitations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Restated Genentech Agreement, Genentech has the right to designate up to ten Targets for further discovery and research utilizing our PROTAC platform technology. Genentech may designate as a Target any protein to which a PROTAC targeted protein degrader, by design, binds, to achieve its mechanism of action, subject to certain exclusions. Genentech also has the right to remove a Target from the collaboration and substitute a different Target that is not an excluded Target at any time prior to us commencing research on such Target or in certain circumstances following commencement of research by us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a Target becomes subject to the collaboration, we are obligated to use diligent efforts to undertake a research program in accordance with a research plan agreed to by the parties for such Target. We are responsible for funding our activities under the research program for each Target up to the amount set forth in the budget for such Target agreed upon by the parties in the research plan. For costs incurred in excess of the budgeted amount, Genentech has the option of either having us continue the work on the Target and reimbursing us for our costs in doing so or terminating the work on such Target. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research program for each Target contemplates that the discovery and research work will occur in two stages: Stage 1, in which our objective will be to identify a PROTAC targeted protein degrader that demonstrates in vitro protein degradation of the Target&#59; and Stage 2, in which our objective will be to demonstrate certain <span style="font-style:italic;">in vitro</span> and <span style="font-style:italic;">in vivo</span> research and development activity, but not to complete toxicology studies or other necessary IND-enabling studies. For each Target, at the conclusion of Stage 1, Genentech has the opportunity to continue the research program for such Target or terminate all activities on such Target. At the conclusion of each stage, we are obligated to provide certain deliverables to Genentech, including a data package at the end of Stage 2. Genentech has an option to obtain an exclusive worldwide </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">license to the applicable </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROTAC targeted protein degraders</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> directed against the applicable Target, which we refer to as Licensed PROTACs. Each such option must be exercised within a specified time after we deliver the data package for such Licensed PROTAC to Genentech. Once Genentech exercises an option, it is responsible, at its cost, to use diligent efforts to develop and commercialize the Licensed PROTAC through first commercial sale in the United States, the European Union and Japan. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the Restated Genentech Agreement, we and our affiliates are not permitted, either directly or indirectly, to conduct any activities in the design, identification or discovery of any small molecule pharmacologically active agent directed against a Target included in the collaboration, including certain PROTAC targeted protein degraders whose intended primary mechanism of action is, by design, through induction of proteasomal degradation of such Target. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Restated Genentech Agreement, we received $11.0&#160;million in 2015 and an additional $34.5&#160;million in 2017 in upfront payments and expansion target payments. We are eligible to receive up to an aggregate of $27.5&#160;million in additional expansion target payments if Genentech exercises its options for all remaining Targets. We are also eligible to receive payments aggregating up to $44.0&#160;million per Target subject to the achievement of specified development milestones&#59; payments aggregating up to $52.5&#160;million per Target (assuming approval of two indications) subject to the achievement of specified regulatory milestones&#59; and payments aggregating up to $60&#160;million per Licensed PROTAC subject to the achievement of specified sales milestones. These milestone payments are subject to reduction if we do not have a valid patent claim covering the Licensed PROTAC at the time the milestone is achieved. We are also eligible to receive, on net sales of Licensed PROTACs, mid-single digit royalties, which may be subject to reductions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Restated Genentech Agreement will expire upon the expiration of all royalty periods for any Licensed PROTACs. The royalty period for each Licensed PROTAC expires on a country-by-country basis upon either (1) the expiration of the last-to-expire valid patent claim covering such Licensed PROTAC or (2) ten years after the first commercial sale with respect to such Licensed PROTAC, depending on whether the sale of the Licensed PROTAC is covered by an applicable valid claim. The expiration of the last to expire patent right licensed to Genentech, if it issues as a patent and all appropriate maintenance fees are paid, is currently expected be in 2038. We could also obtain rights to additional patents, including through the issuance of pending patent applications, with later expiration dates, or new Licensed PROTACs could be added to the agreement that are subject to additional royalty terms with later expiration dates, which in either case could extend the term of the Restated Genentech Agreement. Genentech has the right to terminate the Restated Genentech Agreement for convenience in its entirety or with respect to a specific Target on 60 days&#8217; prior notice. Either we or Genentech may terminate the agreement, in its entirety or with respect to a specific Target, if the other party is in material breach and such breach is not cured within the specified cure period. In addition, either we or Genentech may terminate the agreement in the event of specified insolvency events involving the other party. If Genentech terminates the agreement for convenience or if we terminate the agreement as a result of Genentech&#8217;s uncured material breach or Genentech&#8217;s insolvency, all licenses we granted to Genentech terminate (either in its entirety or with respect to a specific Target, as applicable based on the nature of the termination). If Genentech terminates the agreement as a result of our uncured material breach or our insolvency, all licenses that we granted to Genentech terminate (either in its entirety or with respect to a specific Target, as applicable based on the nature of the termination), except that Genentech has the right to elect to retain its licenses, in which case it would no longer be obligated to use diligent efforts to develop and commercialize the applicable Licensed PROTACs and its payment obligations to us would be reduced. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Pfizer License Agreement<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, we entered into a Research Collaboration and License Agreement with Pfizer, Inc., or Pfizer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of Targets using our proprietary platform technology that are identified in the agreement or subsequently selected by Pfizer, subject to certain exclusions. We refer to this agreement as the Pfizer Collaboration Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pfizer Collaboration Agreement, Pfizer has designated a number of initial Targets. For each identified Target, we and Pfizer will conduct a separate research program pursuant to a research plan. Pfizer may make substitutions for any of the initial Target candidates, which substitutions are limited subject to the stage of research for such Target. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Pfizer are obligated to use commercially reasonable efforts to complete our respective activities set forth in a research plan, including, in our case, the obligation to provide certain deliverables at the end of each stage. Under the research plan, we are required to provide compound formulation and conduct pharmacokinetic/pharmacodynamic and drug safety research and development activities in support of screening and other activities conducted by Pfizer relating to a Target. Following the provision of the deliverables by us for a stage, we will suspend the conduct of any further activities until Pfizer has exercised its right to proceed. If Pfizer does not exercise such right within the applicable time period, we will cease activities for such Target and such Target will no longer be part of the collaboration. Each party will bear its own costs in the conduct of such activities, except that any additional work that we agree with Pfizer to perform outside of the research plan will be paid for by Pfizer. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer has the right to exercise an option to obtain an exclusive worldwide license with respect to each Target for a specified </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period of time</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> after receipt of the applicable deliverables for such Target. If&#160;Pfizer does not exercise its option for a Target, such Target is no longer subject to the Pfizer Collaboration Agreement. If Pfizer exercises such option, Pfizer will have an exclusive license to develop and commercialize compounds directed against such Target, subject to certain diligence obligations. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the Pfizer Collaboration Agreement, we and our affiliates are not permitted, either directly or indirectly, to develop or commercialize any pharmacologically-active agent whose primary mechanism of action is, by design, directed to a Target, or grant any license, covenant not to sue or other right to any third party for the conduct of such activities. There are no restrictions on Pfizer from developing, manufacturing or commercializing products, programs, technologies or processes that are similar to or may compete with any covered by the Pfizer Collaboration Agreement, subject to certain limitations on Pfizer&#8217;s right to use our confidential information or know-how. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Under the terms of the Pfizer Collaboration Agreement, we received an upfront non-refundable payment and certain additional payments totaling $28.0 million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the agreement. We are also eligible to receive up to an additional $37.5 million in non-refundable option payments if Pfizer exercises its options for all targets under the agreement. Pfizer has exercised options for $4.9 million as of December 31, 2020. The options are recognized as revenue over the estimated period of performance. We are also entitled to receive up to $225 million in development milestone payments and up to $550 million in sales-based milestone payments for all designated targets. </span><span style="color:#000000;">In addition, we are eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid- to high-single digit tiered royalties, which may be subject to reductions. </span><span style="Background-color:#FFFFFF;">Pfizer paid us $1.2 million in December 2019 and $3.0 million in 2020 relating to adding additional targets into the collaboration. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Pfizer Collaboration Agreement will expire upon the expiration of all royalty obligations thereunder. The royalty period for each product developed under the Pfizer Collaboration Agreement will expire on a country-by-country basis upon the later of (1) the expiration of the last-to-expire valid patent claim that claims or covers the composition of matter of a compound contained within such product or (2) ten years after the first commercial sale with respect to such product. Pfizer has the right to terminate the Pfizer Collaboration Agreement for convenience in its entirety or with respect to a specific target on 60 days&#8217; prior notice. Either we or Pfizer may terminate the Pfizer Collaboration Agreement, in its entirety or with respect to a specific target, if the other party is in material breach and such breach is not cured within the specified cure period. In addition, either we or Pfizer may terminate the Pfizer Collaboration Agreement in the event of specified insolvency events involving the other party. If Pfizer terminates the agreement in its entirety or as a result of our uncured material breach or our insolvency, Pfizer retains its license with respect to Targets for which it has exercised an option (unless Pfizer elects otherwise), subject to reduced payment obligations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.69%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Bayer Collaboration Agreement<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, we entered into a Collaboration and License Agreement with Bayer AG, or Bayer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders, that mediate for degradation of Targets using our proprietary platform technology, which Targets will be selected by Bayer, subject to certain exclusions and limitations. We refer to this agreement as the Bayer Collaboration Agreement. The Bayer Collaboration Agreement became effective in July 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the identified Targets, we and Bayer will conduct a research program pursuant to separate research plans tailored to each Target selected by Bayer. Bayer may make substitutions for any such initial Target candidates, subject to certain conditions and based on the stage of research for such Target.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Bayer are obligated to use commercially reasonable efforts to complete our respective activities set forth in each research plan, including, in our case, the obligation to provide certain deliverables at certain stages of the research plans. The joint steering committee established under the collaboration shall determine whether the research program with respect to a given Target has been completed. In the absence of any such determination by the joint steering committee, and unless otherwise agreed by the parties in writing, for each Target for which research program activities have commenced, if no research funding is allocated to such Target for the 12 month period commencing on July 1, 2019 or any anniversary thereof, and we refer to each as a Research Program Year, the research program with respect to the relevant Target shall be deemed completed as of the end of the last Research Program Year for which funding was allocated to such Target. Bayer shall pay to the Company research funding payments of $3.0 million dollars per year in each of the first four Research Program Years. If the Company&#8217;s costs for its research activities under the research plans exceed the research funding provided by Bayer for any Research Program Year before completion of all relevant research program activities in such Research Program Year, and the Company has complied with its reporting obligations to Bayer with respect to research program costs, the Company shall not be obligated to carry out further research program activities for the given Research Program Year unless Bayer has agreed in writing to fund such additional activities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the Bayer Collaboration Agreement, </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and our affiliates</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are not permitted, either directly or indirectly, to design, identify, discover or develop any small molecule pharmacologically-active agent whose primary mechanism of action is, by design, directed to the inhibition or degradation of any Target selected or reserved by Bayer, or grant any license, covenant not to sue or other right to any third party in the field of human disease under the licensed intellectual property for the conduct of such activities. There are no restrictions on Bayer from developing, manufacturing or commercializing products, programs, technologies or processes that are similar to or may compete with any covered by the Bayer Collaboration Agreement, subject to certain limitations on Bayer&#8217;s right to use the </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217; confidential information or know-how.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Bayer Collaboration Agreement, we received an aggregate upfront payment of $17.5 million in August 2019. We are entitled to receive up to an additional $12.0 million in research funding payments, subject to increases, as described above. We are also eligible to receive up to $197.5 million in development milestones and up to $490.0 million in sales-based milestones for all designated Targets. In addition, we are eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Bayer Collaboration Agreement will expire upon the expiration of all royalty obligations thereunder. The royalty period for each product developed under the Bayer Collaboration Agreement will expire on a country-by-country basis upon the later of (1) the expiration of the last-to-expire valid patent claim that covers the manufacture, use or sale of such product or (2) ten years after the first commercial sale with respect to such product. Bayer has the right to terminate the Bayer Collaboration Agreement for convenience in its entirety or with respect to a specific target on 60 days&#8217; prior written notice. Either the Company or Bayer may terminate the Bayer Collaboration Agreement, in its entirety or with respect to a specific target, if the other party is in material breach and such breach is not cured within the specified cure period. In addition, either we or Bayer may terminate the Bayer Collaboration Agreement in the event of specified insolvency events involving the other party. If Bayer terminates the agreement in its entirety as a result of our uncured material breach or the Company&#8217;s insolvency, Bayer may elect in writing to retain its license with respect to any Targets previously identified and delivered to Bayer, subject to reduced payment obligations.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Bayer Joint Venture</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, we, Bayer and Bayer CropScience LP, or BCS, also committed to the formation of a joint venture, conditioned on terms set forth in a commitment agreement, or Commitment Agreement, among us, BCS and a newly formed Delaware limited liability company, or Oerth. In July 2019, following the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, we consummated the formation of the joint venture in which we and BCS each received an ownership interest in Oerth initially representing 50% of the ownership interests. Oerth was formed for the purpose of researching, developing and commercializing PROTAC targeted protein degraders, or PROTAC Products, for applications in the field of agriculture. A 15% ownership interest of Oerth was reserved for the future grant of incentive units to service providers of Oerth.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for their ownership interests in Oerth, we made an in-kind intellectual property contribution to Oerth and BCS made an in-kind intellectual property contribution to Oerth. In addition, BCS made a $56.0 million total cash commitment to Oerth, or the Total Cash Commitment, $16.0 million of which BCS contributed to Oerth in connection with the JV closing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our and BCS&#8217;s ownership interest in Oerth, and the accompanying rights and obligations as members of Oerth, are governed by an amended and restated limited liability company agreement, or LLC Agreement, by and among us, BCS and Oerth. Oerth is generally governed by a board of managers, or the JV Board, which is comprised of four voting members, two of which have been designated by us and two of which have been designated by BCS. JV Board decisions will generally be made by majority vote of the managers, with each manager having one vote. Certain matters will require the consent of both BCS and the Company or both of their designated managers on the JV Board.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, Oerth and BCS also entered into an option agreement, or the Option Agreement, pursuant to which the parties will agree to certain procedures for, and preferential rights relating to, the possible transfer to BCS of PROTAC Product candidates researched, developed and commercialized by Oerth under the joint venture. BCS will have a right of first negotiation, and last matching rights under certain circumstances, to enter into a license with Oerth for the exclusive right to research, develop, manufacture, use and commercialize the applicable PROTAC Product candidate in the field of agriculture for which it was developed. In addition, Oerth is allowed to receive and consider unsolicited third-party offers or seek third-party offers for the exclusive license to the applicable PROTAC Product candidate. The Option Agreement sets forth the procedures the JV Board will follow when considering and voting on any offers as well as the considerations on how to value any offer.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and BCS </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> enter</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> into </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">separate</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> service agreement</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s, or the </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services Agreements. </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and BCS will provide services to </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oerth</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as agreed from time to time by </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and BCS, as applicable, and set forth in statements of work to be delivered under the applicable Services Agreement.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and BCS each also entered into respective intellectual property contribution agreements, each, an IP Contribution Agreement, with Oerth. Pursuant to the IP Contribution Agreement by and between us and Oerth,&#160;&#160;or Company IP Contribution Agreement, in addition to certain non-exclusive licenses, we granted to Oerth an exclusive, worldwide, fully paid-up, royalty-free license, including certain rights to sublicense, to use certain of our PROTAC technology to research, develop, manufacture, use and commercialize and sell PROTAC Products in the field of agriculture.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the IP Contribution Agreement by and between BCS and Oerth, or the BCS IP Contribution Agreement, in addition to certain non-exclusive licenses, BCS and certain of its affiliates granted to Oerth an exclusive, worldwide, fully paid-up, royalty-free license, including certain rights to sublicense, to use certain of BCS&#8217; or its affiliates&#8217; intellectual property that covers ubiquitin ligases or moieties that bind ubiquitin ligase complexes, and linkers that attach ubiquitin ligase binding moieties to moieties that bind to a target, to research, develop, manufacture, use and commercialize and sell PROTAC Products in the field of agriculture.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company IP Contribution Agreement and the BCS IP Contribution Agreement also contain a non-exclusive, worldwide, fully paid-up, royalty-free license grant from Oerth to each of us and BCS, respectively, under various forms of intellectual property developed by Oerth to research, develop, manufacture, use and commercialize products outside of the field of agriculture, in each case excluding intellectual property licensed by the other contributing party to Oerth.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the joint venture and, in certain limited cases as described below, for one year following the end of the term of the joint venture, neither we, Bayer nor any of our respective affiliates may research, develop, manufacture, use or commercialize in the field of agriculture any PROTAC Products whose primary mechanism of action by design is the binding to and degradation of any Target, subject to certain exclusions for early stage research activities and minority investments. In addition, in the event either BCS or a third party licenses a PROTAC Product candidate from Oerth pursuant to the Option Agreement, the non-licensing party or parties to the Commitment Agreement will be prohibited from developing, commercializing or otherwise exploiting any product utilizing PROTAC technology to target the same Target as that of the licensed product candidate in the field of agriculture.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the joint venture will end upon the termination of the Commitment Agreement. We and BCS can terminate the Commitment Agreement upon mutual written consent. Either we or BCS may terminate the Commitment Agreement in the event of specified uncured breaches by the other party or in the event the other party becomes subject to specified bankruptcy, winding up or similar circumstances. Either party may also terminate upon a change of control of the other party, as defined in the Commitment Agreement. Either party may also terminate the Commitment Agreement in the event that Oerth runs out of funds.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon a termination by either party for specified &#8220;bad actor&#8221; breaches of the other party, the defaulting party will remain subject to the exclusivity provisions described above for a period of one year following such termination.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a termination of the Commitment Agreement, all rights licensed to Oerth pursuant to the Company IP Contribution Agreement will terminate, except for any rights licensed to BCS or third parties pursuant to license agreements entered into by Oerth prior to termination or, in certain termination events, to BCS to continue the research, development and commercialization of PROTAC Products that have reached field candidate status. Similarly, all rights licensed to Oerth pursuant to the BCS IP Contribution Agreement will terminate, except for any rights licensed to third parties pursuant to license agreements entered into by Oerth prior to termination.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All intellectual property owned by Oerth will, as of the date of termination, be assigned to be owned jointly and undividedly by the Company and BCS (with the Company&#8217;s interest to be exclusively licensed to BCS to continue the research, development and commercialization of PROTAC Products that have reached field candidate status in certain specified termination events) unless the Company or BCS terminates the Commitment Agreement for a specified bad actor breach of the other party, in which case the intellectual property owned by Oerth will thereafter be owned solely and exclusively by the non-breaching party.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Competition </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property and proprietary products. While we believe that our technology, expertise, scientific knowledge and intellectual property estate provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. Not only must we compete with other companies that are focused on protein degradation, but any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Moreover, our industry is characterized by the existence of large numbers of patents and frequent allegations of patent infringement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our platform and product focus is the discovery and development of protein degradation therapies using our small molecule PROTAC targeted protein degraders. Other companies researching chimeric small molecules for protein degradation include C4 Therapeutics, Inc., Cullgen Inc., Kymera Therapeutics, Inc. and Nurix Therapeutics, Inc. Further, several large pharmaceutical companies have disclosed preclinical or clinical investments in this field, including AbbVie, Amgen, AstraZeneca plc, Boehringer Ingelheim, Bristol Myers Squibb Company, GlaxoSmithKline plc, Genentech, Novartis International AG and Sanofi SA. In addition to competition from other protein degradation therapies, any products that we develop may also face competition from other types of therapies, such as small molecule, antibody, or gene therapies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidates target oncologic indications. The most common methods of treating patients in oncologic indications are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy. There are a variety of available drug therapies marketed for cancer, including prostate cancer and breast cancer. In many cases, these drugs are administered in combination to enhance efficacy. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. In general, although there has been considerable progress over the past few decades in the treatment of cancer and the currently marketed therapies provide benefits to many patients, these therapies all are limited to some extent in their efficacy and frequency of adverse events, and none of them are successful in treating all patients. As a result, the level of morbidity and mortality from cancer remains high. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to currently marketed drugs, there are also several product candidates in late stage clinical development for the treatment of oncologic indications, including for mCRPC and metastatic ER positive / HER2 negative breast cancer. These products in development include, in the case of metastatic ER positive / HER2 negative breast cancer, selective estrogen receptor degraders and may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain market approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates are approved for the indications for which we expect to conduct clinical trials, they will compete with the foregoing therapies and the currently marketed drugs and potentially any drugs in development. It is also possible that we will face competition from other biologic or pharmaceutical approaches as well as from other types of therapies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key competitive factors affecting the success of all our programs, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet established our own commercial organization or distribution capabilities because our product candidates are still in preclinical and clinical development. Other than our discovery collaboration agreements, we have retained commercialization rights for all of our development programs. If any of our product candidates receive marketing approval, we will need to develop a plan to commercialize them in the United States and other key markets. We currently expect that we would build our own focused, specialized sales and marketing organization to support the commercialization in the United States of product candidates for which we receive marketing approval and that can be commercialized with such capabilities. We expect to utilize a variety of types of collaboration, co-promotion, distribution and other marketing arrangements with one or more third parties to commercialize our product candidates in markets outside the United States or for situations in which a larger sales and marketing organization is required. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As product candidates advance through our pipeline, our commercial plans may change. In particular, some of our research programs target potentially larger indications. Data, the size of the development programs, the size of the target market, the size of a commercial infrastructure and manufacturing needs may all influence our strategies in the United States, Europe and the rest of the world. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing and Supply </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely on and expect to continue to rely on third-party contract manufacturing organizations, or CMOs, for both drug substance and finished drug product as well as for the synthesis of compounds in our pre-clinical research and development activities. We have engaged third-party manufacturers to supply the drug substances and building blocks for those substances for ARV-110 and ARV-471. We have also engaged third-party manufacturers to develop and manufacture finished drug product for ARV-110 and ARV-471 that we are using and plan to use in our Phase 1/2 clinical trials. We currently obtain our supplies from these manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there are a number of potential replacements, although we may incur some delay in identifying and qualifying such replacements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our drug candidates are organic compounds of low molecular weight, generally called small molecules, but which are larger than traditional small molecule therapeutics. We have selected these compounds not only on the basis of their potential efficacy and safety, but also for their ease of synthesis and reasonable cost of goods. In particular, our lead product candidates are manufactured using reliable and reproducible synthetic processes from readily available starting materials. The chemistry is amenable to scale up and does not require unusual equipment in the manufacturing process. We expect to continue to develop drug candidates that can be produced cost-effectively at contract manufacturing facilities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation and Product Approvals </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, pricing, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, sales, reimbursement, post-approval monitoring and reporting, and import and export of biopharmaceutical products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Approval and Regulation of Drugs in the United States </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, drug products are regulated under the Federal Food, Drug, and Cosmetic Act, or FDCA, and applicable implementing regulations and guidance. The failure of an applicant to comply with the applicable regulatory requirements at any time during the product development process, including nonclinical testing, clinical testing, the approval process or post-approval process, may result in delays to the conduct of a study, regulatory review and approval and/or administrative or judicial sanctions. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An applicant seeking approval to market and distribute a new drug in the United States generally must satisfactorily complete each of the following steps before the product candidate will be approved by the FDA: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">preclinical testing including laboratory tests, animal studies and formulation studies, which must be performed in accordance with the FDA&#8217;s good laboratory practice, or GLP, regulations and standards&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">completion of the manufacture, under current Good Manufacturing Practices, or cGMP, conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication, in accordance with good clinical practices, or GCP&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">preparation and submission to the FDA of a new drug application, or NDA, for a drug product which includes not only the results of the clinical trials, but also, detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labeling for one or more proposed indication(s)&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">review of the product candidate by an FDA advisory committee, where appropriate or if applicable&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities, including those of third parties, at which the product candidate or components thereof are manufactured to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">satisfactory completion of any FDA audits of the clinical trial sites to assure compliance with GCP and the integrity of clinical data in support of the NDA&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">payment of user fees and securing FDA approval of the NDA to allow marketing of the new drug product&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategies, or REMS, and the potential requirement to conduct any post-approval studies required by the FDA. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Preclinical Studies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before an applicant begins testing a product candidate with potential therapeutic value in humans, the product candidate enters the preclinical testing stage, including <span style="font-style:italic;">in vitro</span> and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish rationale for therapeutic use. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as other studies to evaluate, among other things, the toxicity of the product candidate. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and long-term toxicity studies, may continue after the IND is submitted. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">The IND and IRB Processes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. Such authorization must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved NDA. In support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, must be submitted to the FDA as part of an IND. The FDA requires a 30-day waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this 30-day period, or thereafter, the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical hold or partial clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin or recommence. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical holds are imposed by the FDA whenever there is concern for patient safety and may be a result of new data, findings, or developments in clinical, nonclinical, and/or chemistry, manufacturing, and controls, or CMC. </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, such studies must be conducted in accordance with GCP including review and approval by an independent ethics committee, or IEC, and informed consent from subjects. The GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group provides authorization as to whether or not a trial may move forward at designated check points based on certain available data from the study to which only the DSMB may access. Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by us based on evolving business objectives and/or competitive climate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on its ClinicalTrials.gov website. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Expanded Access to an Investigational Drug for Treatment Use</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational new drug products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational drugs for patients who may benefit from investigational therapies. FDA regulations allow access to investigational drugs under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings)&#59; intermediate-size patient populations&#59; and larger populations for use of the drug under a treatment protocol or Treatment IND Application. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition&#59; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated&#59; and the expanded use of the investigational drug for the requested treatment will not interfere initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no obligation for a sponsor to make its drug products available for expanded access&#59; however, as required by the 21</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup></span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Century Cures Act, or Cures Act, passed in 2016, if a sponsor has a policy regarding how it responds to expanded access requests, it must make that policy available</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. This provision requires drug and biologic companies to make publicly available their policies for expanded access for individual patient access to products intended for serious diseases. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 study&#59; or 15 days after the drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy. </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We received fast track designation for ARV-110 for </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mCRPC</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in May 2019. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, on May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without needing FDA approval under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients under the Right to Try Act.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Human Clinical Trials in Support of an NDA </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational product candidate to human subjects under the supervision of a qualified investigator in accordance with GCP requirements which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written clinical trial protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may also be required after approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1<span style="font-style:normal;">&#160;clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or in patients. During Phase&#160;1 clinical trials, information about the investigational drug product&#8217;s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase&#160;2 clinical trials. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Phase 2<span style="font-style:normal;">&#160;clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. Phase 2 clinical trials are well controlled, closely monitored and conducted in a limited patient population. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Phase 3<span style="font-style:normal;">&#160;clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 clinical trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a drug: such Phase 3 studies are referred to as &#8220;pivotal.&#8221; </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, the FDA may approve an NDA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of a larger number of patients in the intended treatment group and to further document a clinical benefit in the case of drugs approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions&#59; findings from other studies or animal or <span style="font-style:italic;">in&#160;vitro</span> testing that suggest a significant risk to humans exposed to the product&#59; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase&#160;1, Phase&#160;2 and Phase&#160;3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCPs and the integrity of the clinical data submitted. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tested</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Pediatric Studies</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pediatric Research Equity Act of 2003, or PREA, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For drugs intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of an applicant, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, the FDA will meet early in the development process to discuss pediatric study plans with sponsors and the FDA must meet with sponsors by no later than the end-of-phase 1 meeting for serious or life-threatening diseases and by no later than ninety (90)&#160;days after the FDA&#8217;s receipt of the study plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in the Food and Drug Administration Safety and Innovation Act, or FDASIA. The FDA maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population. Congress amended the FDA Reauthorization Act of 2017, or FDARA. Previously, drugs that had been granted orphan drug designation were exempt from the requirements of the PREA. Under the amended section 505B, beginning on August 18, 2020, the submission of a pediatric assessment, waiver or deferral will be required for certain molecularly targeted cancer indications with the submission of an application or supplement to an application.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA Reauthorization Act of 2017 established new requirements to govern certain molecularly targeted cancer indications. Any company that submits an NDA three years after the date of enactment of that statute must submit pediatric assessments with the NDA if the drug is intended for the treatment of an adult cancer and is directed at a molecular target that FDA determines to be substantially relevant to the growth or progression of a pediatric cancer. The investigation must be designed to yield clinically meaningful pediatric study data regarding the dosing, safety and preliminary efficacy to inform pediatric labeling for the product. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Review and Approval of an NDA </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to obtain approval to market a drug product in the United States, a marketing application must be submitted to the FDA that provides sufficient data establishing the safety and efficacy of the proposed drug product for its intended indication. The application includes all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the drug product to the satisfaction of the FDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The NDA is a vehicle through which applicants formally propose that the FDA approve a new product for marketing and sale in the United States for one or more indications. Every new drug product candidate must be the subject of an approved NDA before it may be commercialized in the United States. Under federal law, the submission of most NDAs is subject to an application user fee, which for federal fiscal year 2021 is $2,875,842 for an application requiring clinical data. The sponsor of an approved NDA is also subject to an annual prescription drug product program fee, which for fiscal year 2021 is $336,432. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation, an exception from the program fee when the program does not engage in manufacturing the drug during a particular fiscal year and a waiver for certain small businesses. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following submission of an NDA, the FDA conducts a preliminary review of the application generally within 60&#160;calendar days of its receipt and strives to inform the sponsor by the 74</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;day after the FDA&#8217;s receipt of the submission whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept the application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Under that agreement, 90% of applications seeking approval of New Molecular Entities, or NMEs, are meant to be reviewed within ten months from the date on which the FDA accepts the application for filing, and 90% of applications for NMEs that have been designated for &#8220;priority review&#8221; are meant to be reviewed within six months of the filing date. For applications seeking approval of products that are not NMEs, the ten-month and six-month review periods run from the date that the FDA receives the application. The review process and the Prescription Drug User Fee Act, or PDUFA, goal date may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an application, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities associated with an NDA submission, including component manufacturing, finished product manufacturing and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Under the FDA Reauthorization Act of 2017, the FDA must implement a protocol to expedite review of responses to inspection reports pertaining to certain applications, including applications for products in shortage or those for which approval is dependent on remediation of conditions identified in the inspection report. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events and whether the product is a new molecular entity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may refer an application for a novel product to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Fast Track, Breakthrough Therapy and Priority Review Designations </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are referred to as Fast Track designation, Breakthrough Therapy Designation, Priority Review Designation and regenerative advanced therapy designation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the development process&#59; providing timely advice to the product sponsor regarding development and approval&#59; involving more senior staff in the review process&#59; assigning a cross-disciplinary project lead for the review team&#59; and taking other steps to design the clinical trials in an efficient manner. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third, the FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">taking action</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on a marketing application from ten months to six months. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Accelerated Approval Pathway </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit. Thus, the benefit of accelerated approval derives from the potential to receive approval based on surrogate endpoints sooner than possible for trials with clinical or survival endpoints, rather than deriving from any explicit shortening of the FDA approval timeline, as is the case with priority review. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to initiate expedited proceedings to withdraw approval of the product. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">The FDA&#8217;s Decision on an NDA </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter, or CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA approves a new product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, or require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#8217;s safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for health care professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Post-Approval Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA may have imposed as part of the approval process. The sponsor will be required to report, among other things, certain adverse reactions and manufacturing problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information&#59; imposition of post-market studies or clinical trials to assess safety risks&#59; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">fines, warning letters or holds on post-approval clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">refusal of the FDA to approve pending applications or supplements to approved applications, or withdrawal of product approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">product seizure or detention, or refusal to permit the import or export of products&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">injunctions or the imposition of civil or criminal penalties. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information. In the United States, health care professionals are generally permitted to prescribe drugs for such uses not described in the drug&#8217;s labeling, known as off-label uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of off-label uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in nonpromotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manner in which</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">promotion, and</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Abbreviated New Drug Applications for Generic Drugs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress established an abbreviated regulatory scheme authorizing the FDA to approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent to, drugs previously approved by the FDA pursuant to NDAs. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application, or ANDA, to the agency. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, bioequivalence, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are &#8220;abbreviated&#8221; because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, in support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed drug, or RLD. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, the strength of the drug and the conditions of use of the drug. At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if &#8220;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug.&#8221; Upon approval of an ANDA, the FDA indicates whether the generic product is &#8220;therapeutically equivalent&#8221; to the RLD in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, a new chemical entity, or NCE, is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four years following the original product approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. Three-year exclusivity would be available for a drug product that contains a previously approved active moiety, provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product. The FDA typically makes decisions about awards of data exclusivity shortly before a product is approved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA must establish a priority review track for certain generic drugs, requiring the FDA to review a drug application within eight (8)&#160;months for a drug that has three (3)&#160;or fewer approved drugs listed in the Orange Book and is no longer protected by any patent or regulatory exclusivities, or is on the FDA&#8217;s drug shortage list. The FDA is also authorized to expedite review of &#8220;competitor generic therapies&#8221; or drugs with inadequate generic competition, including holding meetings with or providing advice to the drug sponsor prior to submission of the application. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Hatch-Waxman Patent Certification and the 30-Month Stay </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. To the extent that the Section&#160;505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, the applicant must certify with respect to each patent that: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the required patent information has not been filed&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the listed patent has expired&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the listed patent is invalid, unenforceable or will not be infringed by the new product. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the application will not be approved until all the listed patents claiming the referenced product have expired (other than method of use patents involving indications for which the applicant is not seeking approval). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the ANDA applicant. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the Section&#160;505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval of a Section&#160;505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section&#160;505(b)(2) applicant. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.73%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Pediatric Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied&#59; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Orphan Drug Designation and Exclusivity </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition, generally meaning that it affects fewer than 200,000&#160;individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a product available in the United States for treatment of the disease or condition will be recovered from sales of the product. A company must seek orphan drug designation before submitting an NDA for the candidate product. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan drug designation does not shorten the PDUFA goal dates for the regulatory review and approval process, although it does convey certain advantages such as tax benefits and exemption from the PDUFA application fee. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same drug for the same condition for seven years, except in certain limited circumstances. Orphan exclusivity does not block the approval of a different product for the same rare disease or condition, nor does it block the approval of the same product for different conditions. If a drug designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Patent Term Restoration and Extension </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A patent claiming a new drug product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted on a patent covering a product is typically one-half the time between the effective date of a clinical investigation involving human beings is begun and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The United States Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Health Care Law and Regulation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Health care providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable state and federal fraud and abuse laws and regulations (including anti-kickback and false claims laws), patient privacy laws and regulations, and other health care laws and regulations that may constrain business and/or financial arrangements. Restrictions under applicable federal and state health care laws and regulations, include the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchasing, ordering, leasing, arranging for, or recommending the purchasing, ordering, or leasing of, any good or service for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the federal civil and criminal false claims laws, including the civil False Claims Act, and Civil Monetary Penalties Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, false or fraudulent claims for payment or knowingly making, using or causing to made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program or making false statements relating to health care matters&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and the regulations promulgated thereunder, including 45 C.F.R. Parts 160 and 164, imposing rules regarding privacy, security, and data breach notifications&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the Foreign Corrupt Practices Act, or FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the federal physician transparency requirements known as the Physician Payments Sunshine Act, under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the Affordable Care Act, or the ACA, which requires manufacturers of drugs, medical devices, biological and medical supplies covered by Medicare, Medicaid, or State Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare&#160;&#38; Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to health care items or services that are reimbursed by non-government third-party payors, including private insurers. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Additionally, some state and local laws require the registration of pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Pharmaceutical Insurance Coverage and Health Care Reform </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated health care costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The containment of health care costs also has become a priority of federal, state and foreign governments and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and biologics and other medical products, government control and other changes to the health care system in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the ACA. In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2030 under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act.&#160;&#160;The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by President Trump on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Cuts and Jobs Act of 2017, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the Court of Appeals for the Fifth Circuit court affirmed the lower court&#8217;s ruling that the individual mandate portion of the ACA is unconstitutional and it remanded the case to the district court for reconsideration of the severability question and additional analysis of the provisions of the ACA.&#160;&#160;Thereafter, the U.S. Supreme Court agreed to hear this case. Oral argument in the case took place on November 10, 2020.&#160;&#160;On February 10, 2021, the Biden Administration withdrew DOJ&#8217;s support for this lawsuit.&#160;&#160;A ruling by the Court is expected sometime this year. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The costs of prescription pharmaceuticals have also been the subject of considerable discussion in the United States To date, there have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products.&#160;&#160;To those ends, President Trump issued five executive orders intended to lower the costs of prescription drug products but it is unclear whether, and to what extent, these orders and related proposed rules will remain in place under the Biden Administration.&#160;&#160;Further, on September 24, 2020, the Trump Administration finalized a rulemaking allowing states or certain other non-federal government entities to submit importation program proposals to the FDA for review and approval. Applicants are required to demonstrate that their importation plans pose no additional risk to public health and safety and will result in significant cost savings for consumers.&#160;&#160;The FDA has issued draft guidance that would allow manufacturers to import their own FDA-approved drugs that are authorized for sale in other countries (multi-market approved products).  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.&#160;&#160;We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Review and&#160;Approval of Medicinal Products in the European Union </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable non-U.S. regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. Specifically, however, the process governing approval of medicinal products in the European Union, or EU, generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Clinical Trial Approval </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the individual member states of the European Union, or EU Member States, govern the system for the approval of clinical trials in the EU. Under this system, an applicant must obtain prior approval from the competent national authority of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the competent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical Document) with supporting information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, where relevant the implementing national provisions of the individual EU Member States and further detailed in applicable guidance documents. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2014, the EU adopted a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive 2001/20/EC. The new Clinical Trials Regulation will become directly applicable to and binding in all 28 EU Member States without the need for any national implementing legislation. It will overhaul the current system of approvals for clinical trials in the EU. Specifically, the new legislation aims at simplifying and streamlining the approval of clinical trials in the EU. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial will be required to submit a single application for approval of a clinical trial to a reporting EU Member State (RMS) through an EU Portal. The submission procedure will be the same irrespective of whether the clinical trial is to be conducted in a single EU Member State or in more than one EU Member State.&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.69%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Regulation was published on June 16, 2014 but has not yet become effective.&#160;&#160;As of January 1, 2020, the website of the European Commission reported that the implementation of the Clinical Trials Regulation was dependent on the development of a fully functional clinical trials portal and database, which would be confirmed by an independent audit, and that the new legislation would come into effect six months after the European Commission publishes a notice of this confirmation. The website indicated that the audit was expected to commence in December 2020. In late 2020, the EMA indicated that it plans to focus on the findings of a system audit&#59; improving the usability, quality and stability of the clinical trial information system&#59; and knowledge transfer to prepare users and their organizations for the new clinical trial system.&#160;&#160;The EMA has indicated that the system will go live in December 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As in the United States, similar requirements for posting clinical trial information are present in other countries&#59; for the members of the European Union, the website EudraCT can be found at: <span style="text-decoration:none;">https://eudract.ema.europa.eu/</span>.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.69%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">PRIME Designation in the EU </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the European Medicines Agency, or EMA, launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises, or SMEs, may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated Agency contact and rapporteur from the Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies, or CAT, are appointed early in PRIME scheme facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Pediatric Studies </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to obtaining a marketing authorization in the European Union, applicants must demonstrate compliance with all measures included in an EMA-approved Paediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are laid down in Regulation (EC) No 1901/2006, the so-called Paediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Paediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine for children is not needed or is not appropriate, such as for diseases that only affect the elderly population. Before an MAA can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Marketing Authorization </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain a marketing authorization for a product under EU regulatory systems, an applicant must submit an MAA either under a centralized procedure administered by the EMA, or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the EU. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the EU, applicants have to demonstrate compliance with all measures included in an EMA-approved PIP covering all subsets of the pediatric population, unless the EMA has granted (1)&#160;a product-specific waiver, (2)&#160;a class waiver or (3)&#160;a deferral for one or more of the measures included in the PIP. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid across the European Economic Area (i.e. the EU as well as Iceland, Liechtenstein and Norway). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. The centralized procedure may at the request of the applicant also be used in certain other cases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the centralized procedure, the CHMP is responsible for conducting the initial assessment of a product and for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the EU, the maximum timeframe for the evaluation of an MAA is 210&#160;days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 15 calendar days of receipt of a final opinion from the CHMP, the European Commission must prepare a draft decision concerning an application for marketing authorization. This draft decision must take the opinion and any relevant provisions of EU law into account. Before arriving at a final decision on an application for centralized authorization of a medicinal product the European Commission must consult the Standing Committee on Medicinal Products for Human Use. The Standing Committee is composed of representatives of the EU Member States and chaired by a non-voting European Commission representative. The European Parliament also has a related &#8220;droit de regard.&#8221; The European Parliament&#8217;s role is to ensure that the European Commission has not exceeded its powers in deciding to grant or refuse to grant a marketing authorization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Commission may grant a so-called &#8220;marketing authorization under exceptional circumstances.&#8221; Such authorization is intended for products for which the applicant can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization under exceptional circumstances may be granted subject to certain specific obligations, which may include the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the applicant must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the benefit/risk profile&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an authorized person&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual reassessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of a marketing authorization of a medicinal product under exceptional circumstances, however, follows the same rules as a &#8220;normal&#8221; marketing authorization. Thus, a marketing authorization under exceptional circumstances is granted for an initial five years, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Commission may also grant a so-called &#8220;conditional marketing authorization&#8221; prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products), if (i)&#160;the risk-benefit balance of the product candidate is positive, (ii)&#160;it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (iii)&#160;the product fulfills an unmet medical need and (iv)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EU medicines rules expressly permit the EU Member States to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal product containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. While the products we have in development do not make use of embryonic stem cells, it is possible that the national laws in certain EU Member States may prohibit or restrict us from commercializing our products, even if they have been granted an EU marketing authorization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unlike the centralized authorization procedure, the decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose decision is binding on all EU Member States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The mutual recognition procedure similarly is based on the acceptance by the competent authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of other EU Member States. The holder of a national marketing authorization may submit an application to the competent authority of an EU Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Regulatory Data Protection in the EU </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No 726/2004 repeats this entitlement for medicinal products authorized in accordance the centralized authorization procedure. Data exclusivity prevents applicants for authorization of generics of these innovative products from referencing the innovator&#8217;s data to assess a generic (abridged) application for a period of eight years. During an additional two-year period of market exclusivity, a generic marketing authorization application can be submitted and authorized, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be placed on the EU market until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.73%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Periods of Authorization and Renewals </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five-year period of marketing authorization. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (in case of centralized procedure) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset clause). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Pediatric Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an applicant obtains a marketing authorization in all EU Member States, or a marketing authorization granted in the centralized procedure by the European Commission, and the study results for the pediatric population are included in the product information, even when negative, the medicine is then eligible for an additional six-month period of qualifying patent protection through extension of the term of the Supplementary Protection Certificate, or SPC. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Orphan Drug Designation and Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulation&#160;(EC) No.&#160;141/2000, as implemented by Regulation (EC) No.&#160;847/2000 provides that a drug can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1)&#160;a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or (2)&#160;a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once authorized, orphan medicinal products are entitled to 10 years of market exclusivity in all EU Member States and in addition a range of other benefits during the development and regulatory review process including scientific assistance for study protocols, authorization through the centralized marketing authorization procedure covering all member countries and a reduction or elimination of registration and marketing authorization fees. However, marketing authorization may be granted to a similar medicinal product with the same orphan indication during the 10-year period with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Patent Term Extensions in the European Union and Other Jurisdictions</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Union also provides for patent term extension through Supplementary Protection Certificates, or SPCs. The rules and requirements for obtaining a SPC are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of fifteen years of marketing exclusivity for a drug. These periods can be extended for six additional months if pediatric exclusivity is obtained, which is described in detail below. Although SPCs are available throughout the European Union, sponsors must apply on a country-by-country basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the European Union.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Regulatory Requirements after a Marketing Authorization has been Obtained </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In case an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">Compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose post-authorization studies and additional monitoring obligations. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">The manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">The marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the EU notably under Directive 2001/83EC, as amended, and are also subject to EU Member State laws. Direct-to-consumer advertising of prescription medicines is prohibited across the EU. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Brexit and the Regulatory Framework in the United Kingdom </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the EU, commonly referred to as Brexit. Following protracted negotiations, the United Kingdom left the EU on January 31, 2020. Under the withdrawal agreement, there is a transitional period until December 31, 2020 (extendable by up to two years). On December 24, 2020, the United Kingdom and the European Union entered into a Trade and Cooperation Agreement. The agreement sets out certain procedures for approval and recognition of medical products in each jurisdiction. Since the regulatory framework for pharmaceutical products in the United Kingdom covering quality, safety,&#160;&#160;and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit could materially impact the future regulatory regime that applies to products and the approval of product candidates in the United Kingdom, as the United Kingdom legislation now has the potential to diverge from EU legislation. It remains to be seen how Brexit will impact regulatory requirements for product candidates and products in the United Kingdom in the long-term. The Medicines and Healthcare Products Regulatory Agency has recently published detailed guidance for industry and organizations to follow from January 1, 2021 now the transition period is over, which will be updated as the United Kingdom&#8217;s regulatory position on medicinal products evolves over time.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, while the Data Protection Act of 2018 in the United Kingdom that &#8220;implements&#8221; and complements the European Union&#8217;s General Data Protection Regulation, or GDPR, has achieved Royal Assent on May 23, 2018 and is now effective in the United Kingdom, it is still unclear whether transfer of data from the European Economic Area, or EEA, to the United Kingdom will remain lawful under GDPR. The Trade and Cooperation Agreement provides for a transitional period during which the United Kingdom will be treated like an European Union member state in relation to processing and transfers of personal data for four months from January 1, 2021. This may be extended by two further months. After such period, the United Kingdom will be a &#8220;third country&#8221; under the GDPR unless the European Commission adopts an adequacy decision in respect of transfers of personal data to the United Kingdom. The United Kingdom has already determined that it considers all of the EU 27 and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the EU/EEA remain unaffected. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">General Data Protection Regulation</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the GDPR which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the U.S., and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater.&#160;&#160;The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR.&#160;&#160;Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Pricing Decisions for Approved Products </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, EU Member States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between low-priced and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Employees and Human Capital </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 179 full-time employees, including 118 employees with advanced degrees. Of these full-time employees, 143 employees are engaged in research and development activities and 36 are engaged in general and administrative activities. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;We recognize that attracting, motivating and retaining talented employees is vital to our success. We value the health and wellness of our employees. It is our goal to deliver innovative programs that provide choice, quality and value. We aim to create an equitable, inclusive and empowering environment in which our employees can grow and advance their careers, with the overall goal of developing, expanding and retaining our workforce to support our current pipeline and future business goals. Our success also depends on our ability to attract, engage and retain a diverse group of employees. Our efforts to recruit and retain a diverse and passionate workforce include providing competitive compensation and benefits packages.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards. We offer a comprehensive benefits program that provides resources to help employees manage their health, finances and life outside of work.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Available Information</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our website address is www.arvinas.com. Through our website, we make available free of charge our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act of 1934, as amended, or the Exchange Act. We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the Securities and Exchange Commission, or the SEC. We also make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. In addition, we regularly use our website to post information regarding our business, product development programs and governance, and we encourage investors to use our website, particularly the information in the section entitled &#8220;Investors + Media,&#8221; as a source of information about us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information on our website is not incorporated by reference into this Annual Report on Form 10-K and should not be considered to be a part of this Annual Report on Form 10-K. Our website address is included in this Annual Report on Form 10-K as an inactive technical reference only.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SEC also maintains a website containing reports, proxy materials and information statements, among other information, at <span style="text-decoration:none;">http://www.sec.gov</span>. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item 1A. Risk Factors. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K, before deciding to invest in our common stock. If any of the following risks actually occur, our business, prospects, operating results and financial condition could suffer materially. In such event, the trading price of our common stock could decline and you might lose all or part of your investment. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Position and Need For Additional Capital </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our net loss was $119.3&#160;million for the year ended December&#160;31, 2020, $70.3&#160;million for the year ended December&#160;31, 2019 and $41.5 million for the year ended December 31, 2018. As of December&#160;31, 2020, we had an accumulated deficit of $491.9 million. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity interests, proceeds from our collaborations, grant funding and debt financing. We are still in the early stages of development of our product candidates, and we have not completed development of any product candidates. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We anticipate that our expenses will increase substantially if and as we: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">continue a Phase 1/2 clinical trial of our product candidate ARV-110, and initiate one or more Phase 1b cohort expansions of ARV-110 in combination with standard of care agents, in men with metastatic castration-resistant prostate cancer, or mCRPC&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">continue a Phase 1/2 clinical trial of our product candidate ARV-471 and a Phase 1b cohort expansion of ARV-471 in combination with palbociclib, and initiate an additional Phase 1b cohort expansion in combination with a standard of care agent, each in patients with locally advanced or metastatic ER positive / HER2 negative breast cancer and initiate a window of opportunity study in early breast cancer&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">initiate a planned Phase 1 clinical trial of our product candidate ARV-766 in the first half of 2021&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">apply our PROTAC Discovery Engine to advance additional product candidates into preclinical and clinical development&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">expand the capabilities of our PROTAC Discovery Engine&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">seek marketing approvals for any product candidates that successfully complete clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we may obtain marketing approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">expand, maintain and protect our intellectual property portfolio&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">hire additional development, including clinical and regulatory, and scientific personnel&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">add operational, financial and management information systems and personnel to support our research, product development and future commercialization efforts and support our operations as a public company. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, or other regulatory authorities to perform trials in addition to those that we currently expect, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of any of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We have never generated revenue from product sales and may never be profitable. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We initiated clinical development of our first two product candidates in 2019 and plan to initiate development of a third product candidate in the first half of 2021 and we expect that it will be many years, if ever, before we have a product candidate ready for commercialization. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. To become and remain profitable, we must succeed in developing, obtaining marketing approval for and commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, establishing arrangements with third parties for the manufacture of clinical supplies of our product candidates, obtaining marketing approval for our product candidates and manufacturing, marketing and selling any products for which we may obtain marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We will need substantial additional funding. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research or product development programs or future commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we continue our ongoing clinical trials of ARV-110 and ARV-471, initiate our planned clinical trial of ARV-766, advance our other oncology and neurodegenerative programs and continue research and development and initiate additional clinical trials of and potentially seek marketing approval for our lead programs and our other product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. We expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had cash, cash equivalents and marketable securities of approximately $688.5&#160;million as of December&#160;31, 2020. We believe that our cash, cash equivalents and marketable securities as of December&#160;31, 2020 will enable us to fund our planned operating expenses and capital expenditure requirements into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the progress, costs and results of our ongoing clinical trials for ARV-110 and for ARV-471 and any future clinical development of ARV-110 and ARV-471&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Arial;">the initiation, progress, costs and results of our planned clinical trial for ARV-766 and any future clinical development of ARV-766</span><span style="font-size:10pt;font-family:Arial;color:#000000;">&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the scope, progress, costs and results of preclinical and clinical development for our other product candidates and development programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the number of, and development requirements for, other product candidates that we pursue, including our other oncology and neurodegenerative research programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the success of our collaborations with Pfizer, Inc., or Pfizer, Genentech, Inc. and F. Hoffman-LaRoche Ltd., collectively referred to as Genentech, and Bayer AG, or Bayer&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the costs, timing and outcome of regulatory review of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">our ability to establish additional collaboration arrangements with other biotechnology or pharmaceutical companies on favorable terms, if at all, for the development or commercialization of our product candidates. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives. Adequate additional funds may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although we may receive potential future payments under our collaborations with Pfizer, Genentech and Bayer, we do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights as common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have in the past entered into financing arrangements with the State of Connecticut and related entities. These include $4.5&#160;million in partially forgivable loans from the State of Connecticut and a loan agreement with Connecticut Innovations, Incorporated, or CII, the strategic venture capital arm and a component unit of the State of Connecticut, in an aggregate principal amount of $750,000. We also granted CII a warrant to purchase 110,116 of our Series A convertible preferred units, which it exercised in July 2018. Covenants in these financing arrangements impose certain limitations and obligations on us, including restrictions on our ability to incur additional debt, to enter into certain business combinations, and from moving our principal offices out of Connecticut. If we were to move our principal offices out of Connecticut or certain employment conditions are not met, we would be obligated to repay the full amount of our previously forgiven loans to the State of Connecticut, currently $2.5&#160;million, and prepay a portion of our unforgiven loans to the State of Connecticut, currently $2.0&#160;million, plus liquidated damages of 7.50%. Additionally, CII would be entitled to obligate us to purchase all of our outstanding securities owned by CII for a specified guaranteed return pursuant to a put agreement with CII. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Our limited operating history may make it difficult for </span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">our stockholders</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"> to evaluate the success of our business to date and to assess our future viability. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced operations in 2013, and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies, establishing arrangements with third parties for the manufacture of initial quantities of our product candidates and conducting early-stage clinical trials. In March 2019, we initiated our first Phase 1 clinical trial for a product candidate, ARV-110, and in August 2019, we initiated our Phase 1 clinical trial of our product candidate ARV-471. All of our other product candidates are still in preclinical development. We have not yet demonstrated our ability to successfully complete any clinical trials, obtain marketing approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, stockholders should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">The ongoing COVID-19 pandemic has and may continue to affect our ability to initiate and complete current or future preclinical studies or clinical trials, disrupt regulatory activities or have other adverse effects on our business and operations. In addition, this pandemic may continue to adversely impact economies worldwide, which could result in adverse effects on our business and operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ongoing COVID-19 pandemic has caused many governments to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border scrutiny, and other measures. The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred&#59; supply chains have been disrupted&#59; facilities and production have been suspended&#59; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. The future progression of the outbreak and its effects on our business and operations are uncertain.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our contract manufacturing organizations, or CMOs, and contract research organizations, or CROs, may face disruptions that may affect our ability to initiate and complete preclinical studies or clinical trials including disruptions at our facilities or disruptions in procuring items that are essential for our research and development activities, including, for example, raw materials used in the manufacturing of our product candidates, laboratory supplies for our preclinical studies and clinical trials, or animals that are used for preclinical testing, in each case, for which there may be shortages because of ongoing efforts to address the outbreak. For example, our New Haven-based laboratories were closed for part of March through May 2020 which limited the biology work we could conduct for our early-stage research programs and increased our reliance on CROs. We and our CROs and CMOs may face disruptions related to our ongoing clinical trials or future clinical trials arising from delays in IND-enabling studies, manufacturing disruptions, and the ability to obtain necessary institutional review board or other necessary site approvals, as well as other delays at clinical trial sites, including delays related to site staffing. For example, in the first quarter of 2020, production of certain building blocks for the drug substance used in the manufacture of ARV-471 were delayed at one of our China-based manufacturers. The response to the COVID-19 pandemic may redirect resources with respect to regulatory and intellectual property matters in a way that would adversely impact our ability to progress regulatory approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and approvals due to measures intended to limit in-person interactions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact our ability to raise additional funds through public offerings and may also impact the volatility of our stock price and trading in our stock. Moreover, it is possible the pandemic will significantly impact economies worldwide, which could result in adverse effects on our business and operations. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and it has the potential to adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recent changes in tax law may adversely affect our business or financial condition. On December 22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act of 2017, commonly referred to as the TCJA, that significantly revised the U.S. Internal Revenue Code of 1986, as amended, or the Code. The TCJA contains, among other things, significant changes to corporate taxation, including a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted earnings (except for certain small businesses), the limitation of the deduction for net operating losses arising in taxable years beginning after December 31, 2017 to 80% of current year taxable income and elimination of net operating loss carrybacks for losses arising in taxable years ending after December 31, 2017 (though any such net operating losses may be carried forward indefinitely), the imposition of a one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, the elimination of U.S. tax on foreign earnings (subject to certain important exceptions), the allowance of immediate deductions for certain new investments instead of deductions for depreciation expense over time, and the modification or repeal of many business deductions and credits.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of Congress&#8217;s response to the COVID-19 pandemic, the Families First Coronavirus Response Act, or FFCR Act, was enacted on March 18, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, was enacted on March 27, 2020 and COVID relief provisions were included in the Consolidated Appropriations Act, 2021, or CAA, which was enacted on December 27, 2020. All contain numerous tax provisions. In particular, the CARES Act retroactively and temporarily (for taxable years beginning before January 1, 2021) suspends application of the 80%-of-income limitation on the use of net operating losses, which was enacted as part of the TCJA. It also provides that net operating losses arising in any taxable year beginning after December 31, 2017, and before January 1, 2021 are generally eligible to be carried back up to five years. The CARES Act also temporarily (for taxable years beginning in 2019 or 2020) relaxes the limitation of the tax deductibility for net interest expense by increasing the limitation from 30% to 50% of adjusted taxable income.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory guidance under the TCJA, the FFCR Act, the CARES Act and the CAA is and continues to be forthcoming, and such guidance could ultimately increase or lessen the impact of these laws on our business and financial condition. It is also possible that Congress will enact additional legislation in connection with the COVID-19 pandemic, some of which could have an impact on our company. In addition, it is uncertain if and to what extent various states will conform to the TCJA, the FFCR Act, the CARES Act or the CAA.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We might not be able to utilize a significant portion of our net operating loss carryforwards and research and development tax credit carryforwards. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had federal net operating loss carryforwards of $205.1 million and federal research and development tax credit carryforwards of $10.1 million. To the extent they expire unused, these net operating loss and tax credit carryforwards will not be available to offset our future income tax liabilities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under Section 382 of the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income may be limited. We believe our federal net operating losses are subject to an annual limitation as a result of changes in the Company&#8217;s ownership, as defined by Code Section 382, in November 2019. Notwithstanding the limitations, we expect the federal net operating losses to be fully available under Section 382 within the next two years, subject to any other limitations under the Code. In addition, we may experience ownership changes in the future as a result of subsequent changes in our stock ownership, some of which may be outside of our control. If we determine that an ownership change has occurred and our ability to use our historical net operating loss and tax credit carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is also a risk that due to regulatory changes, such as suspensions on the use of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities. As described above in &#8220;Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition,&#8221; the TCJA, as amended by the CARES Act, includes changes to U.S. federal tax rates and the rules governing net operating loss carryforwards that may significantly impact our ability to utilize our net operating losses to offset taxable income in the future. In addition, state net operating losses generated in one state cannot be used to offset income generated in another state. For these reasons, even if we attain profitability, we may be unable to use a material portion of our net operating losses and other tax attributes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Discovery and Development of Our Product Candidates</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Our approach to the discovery and development of product candidates based on our PROTAC technology platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our PROTAC technology platform is a relatively new technology. Our future success depends on the successful development of this novel therapeutic approach. Prior to the initiation of our Phase 1 clinical trial for ARV-110, no product candidates that use a chimeric small molecule approach to protein degradation, such as our PROTAC targeted protein degraders, had been tested in humans. No product candidates of this type have been approved in the United States or Europe, and the data underlying the feasibility of developing chimeric small molecule-based therapeutic products is both preliminary and limited. We have not yet succeeded and may not succeed in demonstrating the efficacy and safety of any of our product candidates in clinical trials or in obtaining marketing approval thereafter. We have not yet completed a clinical trial of any product candidate and we have not yet completed assessment of the safety of any product candidate in humans. As such, there may be adverse effects from treatment with any of our current or future product candidates that we cannot predict at this time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our PROTAC Discovery Engine, or any similar or competitive protein degradation platforms, will result in the development, and marketing approval of any products. Any development problems we experience in the future related to our PROTAC Discovery Engine or any of our research programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate or commercializing any product candidates we may develop on a timely or profitable basis, if at all. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We are early in our development efforts. If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are early in our development efforts. In March 2019, we initiated our first Phase 1 clinical trial for a product candidate ARV-110, and in August 2019, we initiated our Phase 1 clinical trial of our product candidate ARV-471. We plan to file an IND in support of ARV-766 and initiate a clinical trial in the first half of 2021. All of our other product candidates are still in preclinical development. Our ability to generate revenue from product sales, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. The success of our product candidates will depend on several factors, including the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">successful completion of preclinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">successful initiation of clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">successful patient enrollment in and completion of clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">receipt and related terms of marketing approvals from applicable regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">obtaining and maintaining third-party coverage and adequate reimbursement&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">maintaining a continued acceptable safety profile of the products following approval&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">effectively competing with other therapies. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We initiated Phase 1 clinical development of our product candidates ARV-110 and ARV-471 in 2019 and expect to initiate a clinical trial for ARV-766 in the first half of 2021. All of our other product candidates are in preclinical development.&#160;&#160;The risk of failure for our product candidates is high. We are unable to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned Investigational New Drug Applications, or INDs, in the United States or similar applications in other jurisdictions. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or similar regulatory authorities outside the United States will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our programs. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the outcome. A failure of one or more clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical trials for various reasons, including noncompliance with regulatory requirements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate the trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">unforeseen global instability, including political instability or instability from an outbreak of pandemic or contagious disease, such as the COVID-19 pandemic, in or around the countries in which we conduct our clinical trials, could delay the commencement or timing of completion of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the cost of clinical trials of our product candidates may be greater than we anticipate&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">be delayed in obtaining marketing approval for our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">not obtain marketing approval at all&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">obtain approval for indications or patient populations that are not as broad as intended or desired&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">be subject to additional post-marketing testing requirements&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">have the product removed from the market after obtaining marketing approval. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product development costs will also increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, cancer therapies are sometimes characterized as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. Our current clinical trials for ARV-110 and ARV-471 are with patients who have received prior treatments. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval potentially as a first-line therapy, but any product candidates we develop, even if approved, may not be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">If serious adverse events, undesirable side effects, or unexpected characteristics are identified during the development of any product candidates we may develop, we may need to abandon or limit our further clinical development of those product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than our ongoing early clinical trials of ARV-110 and ARV-471, we have not evaluated any product candidates in human clinical trials. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. There can be no assurance that our PROTAC technology will not cause undesirable side effects.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A potential risk in any protein degradation product is that healthy proteins or proteins not targeted for degradation will be degraded or that the degradation of the targeted protein in itself could cause adverse events, undesirable side effects, or unexpected characteristics. It is possible that healthy proteins or proteins not targeted for degradation could be degraded using our PROTAC technology in any of our ongoing, planned or future clinical studies. There is also the potential risk of delayed adverse events following treatment using our PROTAC technology. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any product candidates we develop are associated with serious adverse events, or undesirable side effects, or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the adverse events, undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations, and prospects. Many product candidates that initially showed promise in early-stage testing for treating cancer or other diseases have later been found to cause side effects that prevented further clinical development of the product candidates or limited their competitiveness in the market. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">The results of early-stage clinical trials and preclinical studies may not be predictive of future results. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of preclinical studies may not be predictive of the results of clinical trials, and the results of early-stage clinical trials may not be predictive of the results of the later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. In particular, the small number of patients in our ongoing early clinical trials may make the results of these trials less predictive of the outcome of later clinical trials. For example, even if successful, the results of the dose-escalation portion of our Phase 1/2 clinical trial of ARV-110 and our Phase 1/2 clinical trial of ARV-471 may not be predictive of the results of further clinical trials of these product candidates or any of our other product candidates. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Our current or future clinical trials may not ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for product candidates proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publish interim top-line or preliminary data from our clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. For example, the initial safety, tolerability, pharmacokinetic and efficacy data that we have disclosed in connection with our ongoing Phase 1/2 clinical trials of ARV-110 and ARV-471<span style="font-size:9pt;"> </span>may not be indicative of the full results of those trials obtained upon completion. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our reputation and business prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States. In particular, we are conducting a Phase 1/2 clinical trial of ARV-110 for men with mCRPC and a Phase 1/2 clinical trial of ARV-471 for patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. We cannot predict how difficult it will be to enroll patients for trials in these indications. Therefore, our ability to identify and enroll eligible patients for ARV-110 and ARV-471 clinical trials may be limited or may result in slower enrollment than we anticipate. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment is affected by other factors including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the severity of the disease under investigation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the eligibility criteria for the trial in question&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the perceived risks and benefits of the product candidates under study&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the efforts to facilitate timely enrollment in clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the availability of competing therapies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the patient referral practices of physicians&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the burden on patients due to inconvenient procedures&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the ability to monitor patients adequately during and after treatment&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the proximity and availability of clinical trial sites for prospective patients. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, we announced that, as a result of the COVID-19 pandemic, two trial sites for our ongoing Phase 1/2 clinical trial of ARV-110 had publicly announced pauses in patient enrollment for clinical trials, including our trials. In addition, one trial site for our ongoing Phase 1/2 clinical trial of ARV-471 had a pause in patient enrollment for clinical trials, including our trial. While the pauses at each of the trial sites have already been lifted, we may nonetheless face difficulties recruiting or retaining patients in our ongoing and planned clinical trials if patients are affected by the virus or are fearful of traveling to, or are unable to travel to, our clinical trial sites because of the outbreak. For example, we experienced a short delay in the enrollment for one cohort of our ARV-471 trial as a result of screening slowdowns attributable to COVID-19.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We are developing and may continue to develop our product candidates in combination with other drugs. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs, or revoke their approval of such drugs, or if safety, efficacy, manufacturing or supply issues arise with the drugs we choose to evaluate in combination with our product candidates, we may be unable to obtain approval of or market our products. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.37%;text-indent:5.9%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently conducting a clinical trial of ARV-471, and intend to conduct other clinical trials for each of ARV-110 and ARV-471 and potentially other product candidates, in combination with other therapies. For example, in the fourth quarter of 2020, we initiated a Phase 1b cohort expansion with ARV-471 for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer for use in combination with palbociclib, a CDK 4/6 inhibitor that is currently approved for the treatment of patients with breast cancer. We did not develop or obtain marketing approval for, nor do we manufacture or sell, any of the currently approved drugs that we are or may study in combination with ARV-110 or ARV-471. If the FDA or similar regulatory authorities outside of the United States revoke their approval of the drug or drugs in combination with which we determine to develop ARV-471, we will not be able to market ARV-110 or ARV-471 in combination with such revoked drugs.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If safety or efficacy issues arise with any of these drugs, we could experience significant regulatory delays, and the FDA or similar regulatory authorities outside of the United States may require us to redesign or terminate the applicable clinical trials. If the drugs we use are replaced as the standard of care for the indications we choose for ARV-110 or ARV-471, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional clinical trials. In addition, if manufacturing or other issues result in a shortage of supply of the drugs with which we determine to combine with ARV-110 or ARV-471, we may not be able to complete clinical development of ARV-110 or ARV-471 on our current timeline or at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if ARV-110 or ARV-471 were to receive marketing approval or be commercialized for use in combination with other existing drugs, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the drug used in combination with ARV-110 or ARV-471 or that safety, efficacy, manufacturing or supply issues could arise with these existing drugs. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our other product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We may not be successful in our efforts to identify or discover additional potential product candidates. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A key element of our strategy is to apply our PROTAC Discovery Engine to address a broad array of targets and new therapeutic areas. The therapeutic discovery activities that we are conducting may not be successful in identifying product candidates that are useful in treating cancer or other diseases. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval or achieve market acceptance&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">potential product candidates may not be effective in treating their targeted diseases. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. If we are unable to identify suitable product candidates for preclinical and clinical development, we will not be able to obtain revenues from sale of products in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face and will continue to face competition from third parties that use protein degradation, antibody therapy, inhibitory nucleic acid, gene editing or gene therapy development platforms and from companies focused on more traditional therapeutic modalities, such as small molecule inhibitors. The competition is likely to come from multiple sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, government agencies and public and private research institutions. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of several biotechnology companies focused on developing chimeric small molecules for protein degradation including C4 Therapeutics, Inc., Cullgen Inc., Kymera Therapeutics, Inc. and Nurix Therapeutics, Inc. Further, several large pharmaceutical companies have disclosed preclinical investments in this field, including AbbVie, Amgen Inc., AstraZeneca plc, Boehringer Ingelheim, Bristol Myers Squibb Company, GlaxoSmithKline plc, Genentech, Novartis International AG and Sanofi SA. In June 2020, Bristol-Myers Squibb Company announced that it had commenced a Phase 1 clinical trial for an androgen receptor targeting protein degrader.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.19%;text-indent:5.9%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Dependence on Third Parties </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We expect to depend on collaborations with third parties for the research, development, and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate seeking third-party collaborators for the research, development, and commercialization of some of our PROTAC programs. For example, in September 2015 we entered into a collaboration with Genentech, which we amended and restated in November 2017, in December 2017 we entered into a collaboration with Pfizer, and in July 2019 we entered into a collaboration with Bayer. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies and biotechnology companies. Any such arrangements with third parties will likely limit our control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations involving our research programs or any product candidates we may develop, including our collaborations with Pfizer, Genentech and Bayer, pose the following risks to us: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">Collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations. For example, our collaboration with Genentech is managed by a joint research committee and joint project team, which is composed of representatives from us and Genentech, with Genentech having final decision-making authority. Similarly, our collaborations with Pfizer and Bayer are managed by joint research committees composed of an equal number of representatives from us and our collaborative partner, with our collaborative partner having final decision-making authority. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">Collaborators may not pursue development and commercialization of any product candidates we may develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition or business combination that diverts resources or creates competing priorities. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">Genentech, Pfizer and Bayer have broad rights to select any target for protein degradation development on an exclusive basis, even as to us, so long as not excluded by us under the terms of each collaboration and may select targets we are considering but have not taken sufficient action to exclude under the collaboration. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">Collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">Collaborators may not properly obtain, maintain, enforce, or defend our intellectual property or proprietary rights or may use our proprietary information in such a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation. For example, Pfizer, Genentech and Bayer have the first right to enforce or defend certain intellectual property rights under the applicable collaboration arrangement with respect to particular licensed programs, and although we may have the right to assume the enforcement and defense of such intellectual property rights if the collaborator does not, our ability to do so may be compromised by their actions. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">Disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">We may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. For example, each of Genentech</span><span style="font-size:10pt;font-family:Arial;color:#000000;">, </span><span style="font-size:10pt;font-family:Arial;color:#000000;">Pfizer </span><span style="font-size:10pt;font-family:Arial;color:#000000;">and Bayer </span><span style="font-size:10pt;font-family:Arial;color:#000000;">can terminate its agreement with us in its entirety or with respect to a specific target for convenience upon 60 days&#8217; notice or in connection with a material breach of the agreement by us that remains uncured for a specified period of time. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished, or terminated. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our collaborations do not result in the successful development and commercialization of products, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed, and we may need additional resources to develop product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, marketing<span style="font-weight:bold;font-style:italic;"> </span>approval, and commercialization described in this Annual Report on Form 10-K apply to the activities of our collaborators.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may in the future decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of any product candidates we may develop. These relationships, or those like them, may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of several factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We may seek to establish additional collaborations. If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To realize the full potential of our PROTAC Discovery Engine and accelerate the development of additional PROTAC programs, we plan to continue to selectively pursue collaborations with leading biopharmaceutical companies with particular experience, including development and commercial expertise and capabilities. We face significant competition in attracting appropriate collaborators to advance the development of any product candidates for which we may seek a collaboration. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or other regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, the terms of any existing collaboration agreements, and industry and market conditions generally. The collaborator may also have the opportunity to collaborate on other product candidates or technologies for similar indications and will have to evaluate whether such a collaboration could be more attractive than one with us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical companies has reduced the number of potential future collaborators. Our existing collaboration agreements limit our ability to enter into future agreements on certain terms with potential collaborators. For example, we have granted exclusive rights to Genentech, Pfizer and Bayer for the discovery, development and commercialization of PROTAC targeted protein degraders directed to certain protein targets, and during the terms of those agreements, we will be restricted from granting rights to other parties to use our PROTAC technology for those targets. Any collaboration we enter into may limit our ability to enter into future agreements on particular terms or covering similar target indications with other potential collaborators. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate revenue from product sales, which could have an adverse effect on our business, prospects, financial condition and results of operations. </span></p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We rely and expect to continue to rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely and expect to continue to rely on third-party CROs to conduct our Phase 1/2 clinical trial for ARV-110, our Phase 1/2 clinical trial for ARV-471, our planned Phase 1 clinical trial for ARV-766 and any other clinical trials and currently do not plan to independently conduct any clinical trials of ARV-110 and ARV-471 or of our other product candidates. Agreements with these third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that would delay our product development activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols in the applicable IND. Moreover, the FDA requires compliance with standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, these third parties may have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We rely on third-party contract manufacturing organizations for the manufacture of both drug substance and finished drug product for our product candidates for preclinical testing and clinical trials and expect to continue to do so for commercialization. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely on and expect to continue to rely on third-party CMOs for both drug substance and finished drug product as well as the building blocks used to manufacture drug substance. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be unable to establish agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">reliance on the third party for regulatory, compliance and quality assurance&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the possible breach of the manufacturing agreement by the third party&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the possible misappropriation of our proprietary information, including our trade secrets and know-how&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have only limited technology transfer agreements in place with respect to our product candidates, and these arrangements do not extend to commercial supply. We acquire many key materials on a purchase order basis. As a result, we do not have long term committed arrangements with respect to our product candidates and other materials. If we receive marketing approval for any of our product candidates, we will need to establish an agreement for commercial manufacture with a third party. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. Some of our manufacturers are based outside of the United States, including the manufacturers of the building blocks for our drug substances which are based in China and India. As a result of the COVID-19 pandemic, there has been an increased risk of supply interruption with our manufacturers and, in the first quarter of 2020, the production of certain building blocks for the drug substance used in the manufacture of ARV-471 was delayed at one of our China-based manufacturers. While this production delay did not delay the overall clinical development of our product candidates, other delays in the manufacture of building blocks, drug substance or drug products for our product candidates could arise, which could have a material adverse effect on our clinical development.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement manufacturer or be unable to reach agreement with any alternative manufacturer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Commercialization of Our Product Candidates </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current cancer treatments, such as chemotherapy and radiation therapy, are well established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenue from product sales and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the efficacy and potential advantages compared to alternative treatments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the prevalence and severity of any side effects, in particular compared to alternative treatments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">our ability to offer our products for sale at competitive prices&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the convenience and ease of administration compared to alternative treatments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the strength of marketing, sales and distribution support&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the availability of third-party coverage and adequate reimbursement&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the timing of any marketing approval in relation to other product approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">support from patient advocacy groups&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">any restrictions on the use of our products together with other medications. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">If we are unable to establish sales and marketing capabilities, we may not be successful in commercializing our product candidates if and when they are approved. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of biopharmaceutical products. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish sales, marketing and distribution capabilities, either ourselves or through collaboration or other arrangements with third parties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently expect that we would build our own focused, specialized sales and marketing organization to support the commercialization in the United States of product candidates for which we receive marketing approval and that can be commercialized with such capabilities. There are risks involved with establishing our own sales and marketing capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors that may inhibit our efforts to commercialize our products on our own include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to establish our own sales and marketing capabilities and enter into arrangements with third parties to perform these services, our revenue from product sales and our profitability, if any, are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to market and sell our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of these third parties may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government healthcare programs, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">particular medications</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Increasingly, government authorities and third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">decreased demand for any product candidates or products that we may develop&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">termination of clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">withdrawal of marketing approval, recall, restriction on the approval or a &#8220;black box&#8221; warning or contraindication for an approved drug&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">withdrawal of clinical trial participants&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">significant costs to defend the related litigation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">substantial monetary awards to trial participants or patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">loss of revenue&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">injury to our reputation and significant negative media attention&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">reduced resources of our management to pursue our business strategy&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the inability to commercialize any products that we may develop. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently hold $10.0 million in product liability insurance coverage in the aggregate, with a per incident limit of $10.0 million, which may not be adequate to cover all liabilities that we may incur.&#160;&#160;We will need to increase product liability insurance coverage as we expand our clinical trials and if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired, and we may not be able to compete effectively in our market. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our ability to obtain and maintain patent and other proprietary protection in the United States and other countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and product candidates. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Moreover, the patent applications we own, co-own or license may fail to result in issued patents in the United States or in other foreign countries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned, co-owned or licensed patents or pending patent applications, or that we were the first inventors to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or the USPTO, or in addition to interference proceedings, may become involved in opposition, derivation, reexamination, <span style="font-style:italic;">inter partes </span>review, post-grant review or other post-grant proceedings challenging our or our licensors&#8217; patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our owned, co-owned and licensed patent estate consists principally of patent applications, many of which are at an early stage of prosecution. Even if our owned, co-owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned, co-owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned, co-owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned, co-owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Changes in patent laws or patent jurisprudence could diminish the value of our patents in general, thereby impairing our ability to protect our product candidates. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The USPTO developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first-inventor-to-file provisions, became effective on March&#160;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. Furthermore, for applications in which all claims are entitled to a priority date before March&#160;16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years limiting where a patentee may file a patent infringement suit, narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but, the complexity and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors, or other intellectual property, which could be expensive, time-consuming and unsuccessful. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our issued patents, the patents of our licensors, or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive, time-consuming and unpredictable. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours or our licensors is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Even if we successfully assert our patents, a court may not award remedies that sufficiently compensate us for our losses. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of a third party to commercialize our own technology or products, in which case we would be required to obtain a license from such third party. A license to such intellectual property may not be available or may not be available on commercially reasonable terms, which could have a material adverse effect on our business and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. We may not be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, reexamination, and <span style="font-style:italic;">inter partes </span>review proceedings before the USPTO and oppositions and other comparable proceedings in foreign jurisdictions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference, derivation, reexamination or <span style="font-style:italic;">inter partes </span>review proceedings before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our drug candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are found by a court of competent jurisdiction to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in our current and future intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to a license agreement with Yale that provides us with the foundational intellectual property rights for our PROTAC targeted protein degradation technology. This license agreement imposes diligence, development and commercialization timelines and milestone payment, royalty, insurance and other obligations on us. If we fail to comply with our obligations, including achieving specified milestone events, Yale may have the right to terminate this license, in which event we might not be able to develop, manufacture or market any product that is covered by the intellectual property we in-license from Yale and may face other penalties. Such an occurrence would materially adversely affect our business prospects. For a variety of purposes, we will likely enter into additional licensing and funding arrangements with third parties that may also impose similar obligations on us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination of any of our current or future in-licenses would reduce or eliminate our rights under these agreements and may result in our having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. Any of the foregoing could prevent us from commercializing our other product candidates, which could have a material adverse effect on our operating results and overall financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the above risks, intellectual property rights that we license in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we do not have the right to control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not be forthcoming. For example, under the Yale license, any patent applications and issued patents under the agreement remain the property of Yale, and Yale has the right to choose patent counsel. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce our licensed and sublicensed intellectual property effectively. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We may be subject to claims by third parties asserting that our employees, consultants, contractors or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ individuals who were previously employed at universities as well as other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We have received confidential and proprietary information from collaborators, prospective licensees and other third parties. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. We may not be successful in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful, litigation could result in substantial cost and reputational loss and be a distraction to our management and other employees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Such assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent offices, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and patent offices in foreign countries in several stages over the lifetime of the patent. The USPTO and patent offices in foreign countries require compliance with a number of procedural, documentary, fee payment and other requirements during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of a patent or patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">If we are not able to obtain patent term extensions in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for our product candidates, our business may be impaired. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one of the U.S. patents covering each of such product candidates or the use thereof may be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Act. The period of extension may be up to five years beyond the expiration date of a patent but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA-approved product. Similar patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates. Nevertheless, we may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product may be shortened and our competitors may obtain approval of competing products following our patent expiration sooner, and our revenue could be reduced, possibly materially. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We only have limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In-licensing patents covering our product candidates in all countries throughout the world may similarly be prohibitively expensive, if such opportunities are available at all. And in-licensing or filing, prosecuting and defending patents even in only those jurisdictions in which we develop or commercialize our product candidates may be prohibitively expensive or impractical. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection or licensed patents to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the European Union. These products may compete with our product candidates, and our or our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may decide to abandon national and regional patent applications while they are still pending. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications may be rejected by the relevant patent office, while substantively similar applications are granted by others. For example, relative to other countries, China has a heightened detailed description requirement for patentability. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or regulations in the United States and the European Union, and many companies have encountered significant difficulties in protecting and defending proprietary rights in such jurisdictions. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets or other forms of intellectual property, which could make it difficult for us to prevent competitors in some jurisdictions from marketing competing products in violation of our proprietary rights generally. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, are likely to result in substantial costs and divert our efforts and attention from other aspects of our business, and additionally could put our or our licensors&#8217; patents at risk of being invalidated or interpreted narrowly, could increase the risk of our or our licensors&#8217; patent applications not issuing, or could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, while damages or other remedies may be awarded to the adverse party, which may be commercially significant. If we prevail, damages or other remedies awarded to us, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition in those jurisdictions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some jurisdictions, compulsory licensing laws compel patent owners to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties under patents relevant to our business, or if we or our licensors are prevented from enforcing patent rights against third parties, our competitive position may be substantially impaired in such jurisdictions. </p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Regulatory Approval and Marketing of Our Product Candidates and Other Legal Compliance Matters</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">The regulatory approval process of the FDA is lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained marketing approval for any product candidate and it is possible that none of our existing product candidates, or any product candidates we may seek to develop in the future will ever obtain marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates could fail to receive marketing approval for many reasons, including the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the FDA may disagree with the design or implementation of our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for its proposed indication&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">results of clinical trials may not meet the level of statistical significance required by the FDA for approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the FDA may disagree with our interpretation of data from preclinical studies or clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">data collected from clinical trials of our product candidates may not be sufficient to support the submission of a New Drug Application, or NDA, to the FDA or other submission or to obtain marketing approval in the United States&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. The FDA has substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar regulatory authorities outside of the United States. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company, we do not have experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party clinical research organizations or other third-party consultants or vendors to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. New cancer drugs frequently are indicated only for patient populations that have not responded to an existing therapy or have relapsed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, disruptions at the FDA and other agencies may also prolong the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.&#160;&#160;The Trump Administration also took several executive actions that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad and may limit our ability to generate revenue from product sales. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market and sell our products in the European Union and many other jurisdictions, we, and any collaborators, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. We, and any collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In many countries outside the United States, a product candidate must also be approved for reimbursement before it can be sold in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval. Obtaining non-U.S. regulatory approvals and compliance with non-U.S. regulatory requirements could result in significant delays, difficulties and costs for us and any collaborators and could delay or prevent the introduction of our product candidates in certain countries. In addition, if we or any collaborators fail to obtain the non-U.S. approvals required to market our product candidates outside the United States or if we or any collaborators fail to comply with applicable non-U.S. regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we could face heightened risks with respect to seeking marketing approval in the United Kingdom as a result of the recent withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the European Union, the United Kingdom withdrew from the European Union, effective December 31, 2020.&#160;&#160;On December 24, 2020, the United Kingdom and European Union entered into a Trade and Cooperation Agreement.&#160;&#160;The agreement sets out certain procedures for approval and recognition of medical products in each jurisdiction. Since the regulatory framework for pharmaceutical products in the United Kingdom covering quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit could materially impact the future regulatory regime that applies to products and the approval of product candidates in the United Kingdom. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of the Trade and Cooperation Agreement would prevent us from commercializing any product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union for any product candidates, which could significantly and materially harm our business.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements&#59; economic weakness, including inflation, or political instability in particular foreign economies and markets&#59; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#59; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country&#59; and workforce uncertainty in countries where labor unrest is more common than in the United States.. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Even if we, or any collaborators, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation. We, and any collaborators, must therefore comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we, and any collaborators will not be able to promote any products we develop for indications or uses for which they are not approved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our third-party manufacturers, any collaborators and their third-party manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, assuming we, or any collaborators, receive marketing approval for one or more of our product candidates, we, and any collaborators, and our respective third-party manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we, and any collaborators, are not able to comply with post-approval regulatory requirements, we, and any collaborators, could have the marketing approvals for our products withdrawn by regulatory authorities and our, or any collaborators&#8217;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Any product candidate for which we, or any collaborators, obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market and we, or any collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products when and if any of them are approved. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidate for which we, or any collaborators, obtain marketing approval, as well as the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA, EMA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a risk evaluation and mitigation strategy. New cancer drugs frequently are indicated only for patient populations that have not responded to an existing therapy or have relapsed. If any of our product candidates receives marketing approval, the accompanying label may limit the approved use of our drug in this way, which could limit sales of the product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product, including the adoption and implementation of risk evaluation and mitigation strategies. The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we do not market our products for their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, later discovery of previously unknown side effects or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">restrictions on such products, manufacturers or manufacturing processes&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">restrictions and warnings on the labeling or marketing of a product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">restrictions on product distribution or use&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">requirements to conduct post-marketing studies or clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">warning letters or untitled letters&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">withdrawal of the products from the market&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">refusal to approve pending applications or supplements to approved applications that we submit&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">recall of products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">fines, restitution or disgorgement of profits or revenues&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">suspension or withdrawal of marketing approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">damage to relationships with any potential collaborators&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">unfavorable press coverage and damage to our reputation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">refusal to permit the import or export of our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">product seizure&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">injunctions or the imposition of civil or criminal penalties&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">litigation involving patients using our products. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-compliance with European Union requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs applicable to drug manufacturers or quality assurance standards applicable to medical device manufacturers, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, any contract manufacturers we may engage in the future, our collaborators and their contract manufacturers will also be subject to other regulatory requirements, including submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements regarding the distribution of samples to clinicians, recordkeeping, and costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product such as the requirement to implement a risk evaluation and mitigation strategy. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Our relationships with health care providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other health care laws and regulations, which could expose us to civil, criminal and administrative sanctions, contractual damages, reputational harm and diminished future profits and earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Health care providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any drugs for which we obtain marketing approval. Our future arrangements with third-party payors, health care providers and physicians may expose us to broadly applicable state and federal fraud and abuse and other health care laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. These include the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">Anti-Kickback Statute, </span><span style="font-size:10pt;font-family:Arial;color:#000000;">which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchasing, ordering, leasing, arranging for, or recommending the purchasing, ordering, or leasing of, any good or service for which payment may be made, in whole or in part, under a federal health care program such as Medicare or Medicaid&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">False Claims Act</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> - </span><span style="font-size:10pt;font-family:Arial;color:#000000;">the federal civil and criminal false claims laws, including the civil False Claims Act, and Civil Monetary Penalties Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, false or fraudulent claims for payment or knowingly making, using or causing to made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">HIPAA - </span><span style="font-size:10pt;font-family:Arial;color:#000000;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any health care benefit program or making false statements relating to health care matters, and apply regardless of the payor (e.g., public or private)&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">HIPAA and HITECH - </span><span style="font-size:10pt;font-family:Arial;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which impose obligations on HIPAA covered entities and their business associates, including mandatory contractual terms and required implementation of administrative, physical and technical safeguards to maintain the privacy and security of individually identifiable health information&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">Transparency Requirements</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> - the federal physician transparency requirements known as the Physician Payments Sunshine Act, under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the ACA, which requires manufacturers of drugs, medical devices, biological and medical supplies covered by Medicare, Medicaid, or State Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare &#38; Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">Analogous State, Local and Foreign Laws</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> - analogous state, local and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may be broader than similar federal laws, can apply to claims involving health care items or services regardless of payor, and are enforced by many different federal and state agencies as well as through private actions. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements with third parties will comply with applicable health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and/or administrative penalties, damages, fines, individual imprisonment, disgorgement, exclusion from government funded health care programs, such as Medicare and Medicaid, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other health care providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded health care programs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European Union Member States, such as the U.K. Bribery Act 2010, or the Bribery Act. Infringement of these laws could result in substantial fines and imprisonment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the EU General Data Protection Regulation, or the GDPR, which took effect across all member states of the European Economic Area, or EEA, in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators.&#160;&#160;In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States.&#160;&#160;The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20 million Euros, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar actions are either in place or under way in the United States. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act, or CCPA, which went into effect on January 1, 2020, is creating similar risks and obligations as those created by the GDPR, though CCPA does exempt certain information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects (the Common Rule). Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding privacy and security of personal information could expose us to fines and penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.9%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the breadth and depth of changes in data protection obligations, preparing for and complying with such requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations.&#160;&#160;Similarly, failure to comply with federal and state laws regarding privacy and security of personal information could expose us to fines and penalties under such laws.&#160;&#160;Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by legislative initiatives. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any FDA approved product. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for prescription drugs purchased through a pharmacy by the elderly and disabled and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors. In March 2010, then-President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2030 under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the TCJA, which was signed by President Trump on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part the TCJA, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the Court of Appeals for the Fifth Circuit court affirmed the lower court&#8217;s ruling that the individual mandate portion of the ACA is unconstitutional and it remanded the case to the district court for reconsideration of the severability question and additional analysis of the provisions of the ACA.&#160;&#160;Thereafter, the U.S. Supreme Court agreed to hear this case. Oral argument in the case took place on November 10, 2020. On February 10, 2021, the Biden Administration withdrew the federal government&#8217;s support for overturning the ACA.&#160;&#160;A ruling by the Court is expected sometime this year. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Trump Administration also took executive actions to undermine or delay implementation of the ACA, including&#160;&#160;directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices.&#160;&#160;On January 28, 2021, however, President Biden rescinded those orders and issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans&#8217; access to health care, and consider actions that will protect and strengthen that access. Under this Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19&#59; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements&#59; policies that undermine the Health Insurance Marketplace or other markets for health insurance&#59; policies that make it more difficult to enroll in Medicaid and the ACA&#59; and policies that reduce affordability of coverage or financial assistance, including for dependents. This Executive Order also directs the U.S. Department of Health and Human Services to create a special enrollment period for the Health Insurance Marketplace in response to the COVID-19 pandemic.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our drug products, </span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">if and when</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"> approved.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The costs of prescription pharmaceuticals have also been the subject of considerable discussion in the United States and other jurisdictions.&#160;&#160;To date, there have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for products.&#160;&#160;To those ends, President Trump issued several executive orders intended to lower the costs of prescription drug products. Certain of these orders are reflected in recently promulgated regulations, including an interim final rule implementing President Trump&#8217;s most favored nation model, but such final rule is currently subject to a nationwide preliminary injunction.&#160;&#160;It remains to be seen whether these orders and resulting regulations will remain in force during the Biden Administration.&#160;&#160;Further, on September 24, 2020, the Trump Administration finalized a rulemaking allowing states or certain other non-federal government entities to submit importation program proposals to the FDA for review and approval. Applicants are required to demonstrate that their importation plans pose no additional risk to public health and safety and will result in significant cost savings for consumers.&#160;&#160;The FDA has issued draft guidance that would allow manufacturers to import their own FDA-approved drugs that are authorized for sale in other countries (multi-market approved products).&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, health care organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.&#160;&#160;We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In other countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we, or our collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our drug to other available therapies. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations are subject to anti-corruption laws, including the FCPA, the Bribery Act, and other anticorruption laws that apply in countries where we do business and may do business in the future. The FCPA, the Bribery Act, and these other laws generally prohibit us, our officers and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential FCPA or Bribery Act violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA, the Bribery Act, or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States, United Kingdom, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, which we collectively refer to as Trade Control Laws. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act, or other legal requirements, including Trade Control Laws. If we are not in compliance with the FCPA, the Bribery Act, and other anti-corruption laws or Trade Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. The Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Likewise, any investigation of any potential violations of the FCPA, the Bribery Act, other anti-corruption laws or Trade Control Laws by U.S., U.K. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Although we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain workers&#8217; compensation insurance to cover costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Employee Matters and Managing Growth </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on the research, development and clinical expertise of our management and scientific teams. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, manufacturing, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Future growth would impose significant added responsibilities on members of management, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">identifying, recruiting, integrating, maintaining and motivating additional employees&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">managing our internal development efforts effectively, including the clinical and FDA review process for ARV-110, ARV-471 and any product candidate we develop, while complying with our contractual obligations to contractors and other third parties&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">improving our operational, financial and management controls, reporting systems and procedures. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future financial performance and our ability to advance development of and, if approved, commercialize ARV-110, ARV-471 and any product candidate we develop will depend, in part, on our ability to effectively manage any future growth. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Our internal computer systems, or those of any collaborators, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our internal computer systems and those of any collaborators, contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading laws. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA or similar foreign regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">healthcare fraud and abuse laws and regulations in the United States and abroad&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">violations of U.S. federal securities laws relating to trading in our common stock&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">failures to reporting of financial information or data accurately. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations regulate a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Other forms of misconduct could involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct and implement other internal controls applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Common Stock</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">The price of our common stock is volatile and may fluctuate substantially, which could result in the loss of all or part of our stockholders&#8217; investment. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price is volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the degree of success of competitive products or technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">results of or developments in preclinical studies and clinical trials, of our product candidates or those of our competitors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">regulatory or legal developments in the United States and other countries&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">developments or disputes concerning patent applications, issued patents or other proprietary rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the recruitment or departure of key personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the level of expenses related to any of our product candidates or clinical development programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the results of our efforts to discover, develop, acquire or in-license additional technologies or product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">variations in our financial results or those of companies that are perceived to be similar to us&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">changes in the structure of healthcare payment systems&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">market conditions in the pharmaceutical and biotechnology sectors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">general economic, industry and market conditions&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the other factors described in this &#8220;Risk Factors&#8221; section. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of the foregoing matters were to occur, or if our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management&#8217;s attention and resources, which could seriously harm our business, financial condition, results of operations and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Our executive officers, directors and principal stockholders, if they choose to act together, </span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">have the ability </span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">to</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"> </span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">significantly influence</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"> or control</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"> all matters submitted to stockholders for approval. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our executive officers and directors, combined with our stockholders who own more than 5% of our outstanding common stock, in the aggregate, beneficially own shares representing approximately 28% of our capital stock. As a result, if these stockholders were to choose to act together, they would be able to significantly influence or control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, could significantly influence or control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">delay, defer or prevent a change in control&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">entrench our management and the board of directors&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Provisions in our corporate charter documents, under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">provide for a classified board of directors such that only one of three classes of directors is elected each year&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">allow the authorized number of our directors to be changed only by resolution of our board of directors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">limit the manner in which stockholders can remove directors from our board of directors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">provide for advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">limit who may call stockholder meetings&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our charter or bylaws. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">An active trading market for our common stock may not be sustained.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our shares of common stock began trading on the Nasdaq Global Select Market on September 27, 2018. Given the limited trading history of our common stock, there is a risk that an active trading market for our shares will not be sustained, which could put downward pressure on the market price of our common stock and therefore affect the ability of our stockholders to sell their shares.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If no or few securities or industry analysts continue coverage of us, the trading price for our stock could be negatively impacted. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our trials or operating results fail to meet the expectations of analysts, our stock price will likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">If a significant portion of our total outstanding shares are sold into the market, the market price of our common stock could drop significantly, even if our business is doing well. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. <span style="font-size:12pt;font-family:Times New Roman;">&#160;</span> Holders of a significant portion of our common stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in July 2019, we issued 1,346,313 shares of our common stock to Bayer. On October 1, 2019, we filed a registration statement on Form S-3 covering the resale of these shares. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have registered all shares of common stock that we may currently issue under our equity compensation plans. These shares can be freely sold in the public market upon issuance, subject to volume, notice and manner of sale limitations applicable to affiliates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have on file with the SEC universal shelf registration statements on Form S-3 which allow us to offer and sell registered common stock, preferred stock, debt securities, depositary shares, units and/or warrants from time to time pursuant to one or more offerings at prices and terms to be determined at the time of sale. In October 2019, we entered into an Equity Distribution Agreement, or Distribution Agreement, with Piper Sandler &#38; Co. (formerly Piper Jaffray &#38; Co.), or Piper Sandler, pursuant to which, from time to time, we may offer and sell through Piper Sandler up to $100.0 million of the common stock registered under the universal shelf registration statement pursuant to one or more &#8220;at the market&#8221; offerings. Through December 31, 2020, we sold 2,593,637 shares of common stock in an at-the-market offering for aggregate net proceeds of $64.1 million.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of substantial amounts of shares of our common stock or other securities by our stockholders, by Piper Sandler pursuant to the Distribution Agreement, under our universal shelf registration statement or otherwise could also dilute our stockholders.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we incur, and particularly now that we are no longer an emerging growth company, we will further incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and have made some activities more time-consuming and costly. For example, these rules and regulations have made it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404 of Sarbanes-Oxley, or Section&#160;404, we are required to furnish a report by our management on our internal control over financial reporting beginning with our most recent annual report. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets and restrict our future access to the capital markets due to a loss of confidence in the reliability of our financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders.&#160;&#160;Our certificate of incorporation further provides that the federal district courts of the United States of America are the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.&#160;&#160;These choice of forum provisions could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or stockholders. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty owed by our directors, officers, other employees or stockholders to the company or our stockholders, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law or as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware, or any action asserting a claim arising pursuant to our certificate of incorporation or our bylaws or governed by the internal affairs doctrine. Our certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, or the Securities Act. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, other employees or other stockholders, which may discourage such lawsuits against us and our directors, officers, other employees or other stockholders. Alternatively, if a court were to find this provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. Neither of these choice of forum provisions would affect suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder, jurisdiction over which is exclusively vested by statute in the United States federal courts, or any other claim for which United States federal courts have exclusive jurisdiction.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be our stockholders&#8217; sole source of gain. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements we may enter into may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be our stockholders&#8217; sole source of gain for the foreseeable future. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">Item 1B. Unresolved Staff Comments. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES">Item 2. Properties. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We lease approximately 63,500 square feet of office and laboratory space in New Haven, Connecticut under leases that expire in December 2024. We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_LEGAL_PROCEEDINGS">Item 3. Legal Proceedings. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not currently a party to any material legal proceedings. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART II</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock has been publicly traded on the Nasdaq Global Select Market under the symbol &#8220;ARVN&#8221; since September 27, 2018 in connection with our initial public offering, or IPO. Prior to that time, there was no public market for our common stock. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 25, 2021, there were approximately 83 holders of record of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not issue any securities that were not registered under the Securities Act of 1933, as amended, or the Securities Act, during the fiscal year ended December&#160;31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Purchases of Equity Securities</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not purchase any of our registered equity securities during the period covered by this Annual Report on Form 10-K. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Performance Graph</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:6.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The performance graph shown below compares the quarterly change in cumulative total shareholder return on our common shares with the Nasdaq Composite Index and the Nasdaq Biotechnology Index from September 27, 2018 (the first date on which shares of our common stock were publicly traded) through the quarter ended December 31, 2020. The graph assumes&#160;&#160;an investment of $100 on September 27, 2018 in our common shares, the Nasdaq Composite Index and the Nasdaq Biotechnology Index and assumes that any dividends are reinvested. All index values are weighted by the capitalization of the companies included in the index. The comparisons shown in the graph below are based upon historical data. The stock price performance included in this graph is not necessarily indicative of future stock price performance. The following performance graph and related information shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission, or SEC, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, nor shall such information be incorporated by reference into any future filing under the Exchange Act or Securities Act, except to the extent that we specifically incorporate it by reference into such filing.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gfbaqn1kfu2x000014.jpg" title="" alt="" style="width:720px;height:358px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_SELECTED_FINANCIAL_DATA">Item 6. Selected Financial Data</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of financial condition and operating results together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth in the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K, our actual results may differ materially from those anticipated in or implied by these forward-looking statements. For convenience of presentation some of the numbers have been rounded in the text below. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. We use our proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body&#8217;s own natural protein disposal system to selectively remove disease-causing proteins. We believe that our targeted protein degradation approach is a therapeutic modality that may provide distinct advantages over existing modalities, including traditional small molecule therapies and gene-based medicines. Our small-molecule PROTAC technology has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as &#8220;undruggable&#8221; targets. We are using our PROTAC Discovery Engine to build an extensive pipeline of protein degradation product candidates to target diseases in oncology, neuroscience, and other therapeutic areas. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our two lead product candidates are ARV-110 and ARV-471. We are developing ARV-110, a PROTAC protein degrader targeting the androgen receptor protein, or AR, for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC. We initiated a Phase 1 clinical trial of ARV-110 in March 2019. This Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics of ARV-110 and also includes measures of anti-tumor activity as secondary endpoints, including reduction in prostate specific antigen, or PSA, a well-recognized biomarker of prostate cancer progression. We received fast track designation for ARV-110 for mCRPC in May 2019. <span style="Background-color:#FFFFFF;color:#000000;">In October 2020, we initiated the Phase 2 expansion for ARV-110.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also developing ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein, or ER, for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. We initiated a Phase&#160;1 clinical trial of ARV-471 in August 2019. This Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics of ARV-471 and also includes measures of anti-tumor activity as secondary endpoints. <span style="Background-color:#FFFFFF;color:#000000;">We amended the protocol for our Phase 1 clinical trial for ARV-471 in the first quarter of 2020 to include the Phase 2 expansion cohort and in the fourth quarter of 2020 to include a </span>Phase 1b cohort expansion of ARV-471 in combination with Ibrance&#174; (palbociclib).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our preclinical studies, these lead product candidates have demonstrated potent and selective protein degradation. We believe favorable clinical trial results in these initial oncology programs would provide validation of our platform as a new therapeutic modality for the potential treatment of diseases caused by dysregulated intracellular proteins regardless of therapeutic area. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As a result of the COVID-19 pandemic, many companies have experienced disruptions in their operations and in markets served.&#160;We have instated some and may take additional precautionary measures intended to help ensure our employees, well-being and minimize business disruption.&#160;We temporarily shut down our laboratories in mid-March 2020 and initiated work with biology contract research organizations, or CROs, but have since reopened our laboratories. Our office-based employees continue to work remotely. We considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on our results of operations and financial position as of December 31, 2020. The full extent of the future impacts of COVID-19 on our operations is uncertain. A prolonged outbreak could have a material adverse impact on our financial results and business operations, including the timing and our ability to complete certain clinical trials and other efforts required to advance our preclinical pipeline.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced operations in 2013, and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies and clinical trials and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity interests, proceeds from our collaborations, grant funding and debt financing. Through December&#160;31, 2020, we raised approximately $887.3&#160;million in gross proceeds from the sale of equity instruments and the exercise of stock options, and had received an aggregate of $120.8&#160;million in payments from collaboration partners, grant funding and partially forgivable loans from the State of Connecticut. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019, </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entered into a </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration and License Agreement</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Agreement,</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with Bayer AG</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or, </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">together with its controlled affiliates, Bayer</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">greement became effective in July 2019</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also entered into a Stock Purchase Agreement with Bayer, or the Stock Purchase Agreement, pursuant to which we issued and sold to Bayer 1,346,313 shares of our common stock, or the Shares, for an aggregate purchase price of approximately $32.5 million. The price per share was $24.14, based on a 15% premium above our 60-day trading average from April 2, 2019 through May 31, 2019. The closing price of our stock on July 16, 2019, the closing date for the issuance of shares under the Stock Purchase Agreement, was $25.10.&#160;&#160;In connection with the closing under the Stock Purchase Agreement, we also entered into an Investor Agreement providing for registration rights, standstill and lock-up restrictions and a voting agreement with respect to the Shares. On October 1, 2019, we filed a registration statement on Form S-3 covering the resale of the Shares.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also in June 2019, we entered into a Commitment Agreement with Bayer, relating to the formation of a joint venture entity, Oerth Bio LLC, or Oerth, for the purpose of researching, developing and commercializing PROTAC targeted protein degraders for applications in the field of agriculture. We consummated the formation of the joint venture with Bayer as contemplated by the Commitment Agreement in July 2019, upon the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the reportable transactions and the satisfaction of other application closing conditions, or the JV Closing. Pursuant to the terms of the Commitment Agreement and certain other agreements entered into at the JV Closing, we and Bayer each made an in-kind intellectual property contribution to Oerth at the JV Closing. In addition, Bayer has made a $56.0 million total cash commitment to Oerth, $16.0 million of which Bayer contributed to Oerth in connection with the JV Closing. We and Bayer each hold an ownership interest in Oerth initially representing 50% of the ownership interests. A 15% ownership interest of Oerth is reserved for the future grant of incentive units to employees and service providers of Oerth. Oerth will generally be governed by a board of managers, or the JV Board, which will initially comprise four voting members, two of which will be designated by us and two of which will be designated by Bayer. JV Board decisions will generally be made by majority vote of the managers, with each manager having one vote. Certain matters will require both our consent and Bayer&#8217;s or both of our and Bayer&#8217;s designated managers on the JV Board. During the term of the joint venture and, in certain limited cases as described below, for one year following the end of the term of the joint venture, neither we, Bayer nor any of their respective affiliates may research, develop, manufacture, use or commercialize in the field of agriculture any PROTAC targeted protein degraders whose primary mechanism of action by design is the binding to and degradation of any Target, as defined below, subject to certain exclusions for early stage research activities and minority investments. Oerth and Bayer also entered into an option agreement, or the Option Agreement, pursuant to which the parties will agree to certain procedures for, and preferential rights relating to, the possible transfer to Bayer of PROTAC targeted protein degrader product candidates researched, developed and commercialized by Oerth under the joint venture. In addition, in the event either Bayer or a third party licenses a PROTAC targeted protein degrader candidate from Oerth pursuant to the Option Agreement, the non-licensing party or parties to the Commitment Agreement will be prohibited from developing, commercializing or otherwise exploiting any product utilizing PROTAC technology to target the same Target as that of the licensed product candidate in the field of agriculture.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage company. ARV-110 and ARV-471 are each in Phase 1/2 clinical trials and our other drug discovery activities are at the research and preclinical development stages. Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Since inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. Our net loss was $119.3 million for the year ended December&#160;31, 2020, $70.3 million for the year ended December 31, 2019, and $41.5&#160;million for the year ended December&#160;31, 2018. As of December&#160;31, 2020, we had an accumulated deficit of $491.9 million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our total operating expenses were $146.7&#160;million for the year ended December&#160;31, 2020, $94.5 million for the year ended December&#160;31, 2019, and $58.1 million for the year ended December 31, 2018. We anticipate that our expenses will increase substantially due to costs associated with our ongoing and anticipated clinical activities for ARV-110 and ARV-471, development activities associated with our other product candidates, research activities in oncology, neurological and other disease areas to expand our pipeline, hiring additional personnel in research, clinical trials, quality and other functional areas, increased expenses incurred with contract manufacturing organizations, or CMOs, to supply us with product for our preclinical and clinical studies and CROs for the synthesis of compounds in our pre-clinical development activities, as well as other associated costs including the management of our intellectual property portfolio. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not expect to generate revenue from sales of any product for many years, if ever. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research or product development programs or any future commercialization efforts, or to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. </span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. Our revenues to date have been generated through research collaboration and license agreements. Revenue is recognized ratably over our expected performance period under each agreement. We expect that any revenue for the next several years will be derived primarily from our current collaboration agreements and any additional collaborations that we may enter into in the future. To date, we have not received any royalties under any of the collaboration agreements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Genentech License Agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2015, we entered into an Option and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd, collectively referred to as Genentech, focused on PROTAC targeted protein degrader discovery and research for target proteins, or Targets, based on our proprietary platform technology, other than excluded Targets as described below. This collaboration was expanded in November 2017 through an Amended and Restated Option, License and Collaboration Agreement, which we refer to as the Restated Genentech Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Restated Genentech Agreement, Genentech has the right to designate up to ten Targets for further discovery and research utilizing our PROTAC platform technology. Genentech may designate as a Target any protein to which a PROTAC targeted protein degrader, by design, binds to achieve its mechanism of action, subject to certain exclusions. Genentech also has the right to remove a Target from the collaboration and substitute a different Target that is not an excluded Target at any time prior to us commencing research on such Target or in certain circumstances following commencement of research by us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the time we entered into the original agreement with Genentech we received an upfront payment of $11.0&#160;million, and at the time we entered into the Restated Genentech Agreement, we also received an additional $34.5&#160;million in upfront payments and expansion target payments. We are eligible to receive up to an aggregate of $27.5&#160;million in additional expansion target payments if Genentech exercises its options for all remaining Targets. We are also eligible to receive payments aggregating up to $44.0&#160;million per Target upon the achievement of specified development milestones&#59; payments aggregating up to $52.5&#160;million per Target (assuming approval of two indications) subject to the achievement of specified regulatory milestones&#59; and payments aggregating up to $60.0&#160;million per PROTAC targeted protein degrader directed against the applicable Target, subject to the achievement of specified sales milestones. These milestone payments are subject to reduction if we do not have a valid patent claim covering the licensed PROTAC targeted protein degrader at the time the milestone is achieved. We are also eligible to receive, on net sales of licensed PROTAC targeted protein degraders, mid-single digit royalties, which may be subject to reductions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.69%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Pfizer License Agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, we entered into a Research Collaboration and License Agreement with Pfizer, Inc., or Pfizer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of Targets using our proprietary platform technology that are identified in the agreement or subsequently selected by Pfizer, subject to certain exclusions. We refer to this agreement as the Pfizer Collaboration Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pfizer Collaboration Agreement, Pfizer has designated a number of initial Targets. For each identified Target, we and Pfizer will conduct a separate research program pursuant to a research plan. Pfizer may make substitutions for any of the initial Target candidates, subject to the stage of research for such Target. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the year ended December 31, 2018, we received an upfront non-refundable payment and certain additional payments totaling $28.0 million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the agreement. We are also eligible to receive up to an additional $37.5 million in non-refundable option payments if Pfizer exercises its options for all targets under the agreement. Pfizer has exercised options for $4.9 million as of December 31, 2020. We are also entitled to receive up to $225 million in development milestone payments and up to $550 million in sales-based milestone payments for all designated targets. In addition, we are eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid- to high-single digit tiered royalties, which may be subject to reductions. Pfizer paid us $1.2 million in December 2019 and $3.0 million in 2020 relating to adding additional targets into the collaboration. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Bayer Collaboration Agreement </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, we entered into the Bayer Collaboration Agreement with Bayer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of Targets, using our proprietary platform technology, that are selected by Bayer, subject to certain exclusions and limitations.&#160;&#160;The Bayer Collaboration Agreement became effective in July 2019. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Bayer Collaboration Agreement, we and Bayer will conduct a research program pursuant to separate research plans mutually agreed to by us and Bayer and tailored to each Target selected by Bayer. Bayer may make substitutions for any such initial Target candidates, subject to certain conditions and based on the stage of research for such Target. During the term of the Bayer Collaboration Agreement, we are not permitted, either directly or indirectly, to design, identify, discover or develop any small molecule pharmacologically-active agent whose primary mechanism of action is, by design, directed to the inhibition or degradation of any Target selected or reserved by Bayer, or grant any license, covenant not to sue or other right to any third party in the field of human disease under the licensed intellectual property for the conduct of such activities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Bayer Collaboration Agreement, we received an aggregate upfront non-refundable payment of $17.5 million, plus an additional $1.5 million in research funding payments. Bayer is committed to fund an additional $10.5 million in research funding payments through 2022, of which $3.0 million was received in 2020, subject to potential increases if our costs for research activities exceed the research funding payments allocated to a Target and certain conditions are met. We are also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated Targets. In addition, we are eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Operating Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">expenses incurred under agreements with third parties, including contract research organizations and other third parties that conduct research and preclinical activities on our behalf as well as third parties that manufacture our product candidates for use in our preclinical studies and clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">costs of outside consultants, including their fees, stock-based compensation and related travel expenses&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the costs of laboratory supplies and developing preclinical studies and clinical trial materials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">third-party licensing fees. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs as incurred. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We typically use our employee and infrastructure resources across our development programs, and as such, do not track </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all of </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our internal research and development expenses on a program-by-program basis. The following table summarizes our research and development expenses </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for our AR program, ER program and all other </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">platform and exploratory </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research and development costs</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">: </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AR program development costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,399</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,085</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,298</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ER program development costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,496</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,214</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,240</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and development costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,461</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,895</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,656</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,356</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,194</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,194</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we conduct clinical trials for ARV-110 and ARV-471, including our ongoing Phase 1/2 clinical trials, and continue to discover and develop additional product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot reasonably estimate or determine with certainty the duration and costs of future clinical trials of ARV-110 and ARV-471 or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">successful completion of preclinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">successful initiation of clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">successful patient enrollment in and completion of clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">receipt and related terms of marketing approvals from applicable regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">obtaining and maintaining third-party coverage and adequate reimbursement&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">maintaining a continued acceptable safety profile of the products following approval&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">effectively competing with other therapies. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters&#59; professional fees for accounting, auditing, tax and consulting services&#59; insurance costs&#59; travel expenses&#59; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support increased research and development activities relating to our product candidates. We also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and S</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ecurities and </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">xchange </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommission</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> requirements&#59; director and officer insurance costs&#59; and investor and public relations costs. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Interest Income (Expense)</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of interest earned on our cash, cash equivalents and short-term investments. Interest income decreased in 2020 due to declining interest rates and a decrease in our marketable securities. Interest expense consists of interest paid or accrued on our outstanding partially forgivable debt of $2.0 million. Interest expense was approximately $0.1 million in 2020 and we expect that it will remain relatively stable at that level in 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2013, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in any year or for our federal earned research and development tax credits, due to our uncertainty of realizing a benefit from those items. As of December&#160;31, 2020, we had federal net operating loss carryforwards of $205.1&#160;million, which begin to expire in 2033. As of December&#160;31, 2020, we also had federal and state research and development tax credit carryforwards of $10.1&#160;million and $2.3&#160;million, respectively, which begin to expire in 2033 and 2029, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, Arvinas, Inc. had four wholly owned subsidiaries organized as C-corporations: Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc., Arvinas Estrogen Receptor, Inc., and Arvinas Winchester, Inc. Prior to December 31, 2018, these subsidiaries were separate filers for federal tax purposes. Net operating loss carryforwards are generated from the C-corporation subsidiaries&#8217; filings. We have provided a valuation allowance against the full amount of the deferred tax assets since, in the opinion of management, based upon our earnings history, it is more likely than not that the benefits will not be realized. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We recognize revenue under Accounting Standards Codification, or ASC, 606, </span><span style="font-style:italic;Background-color:#FFFFFF;">Revenue from Contracts with Customers.</span><span style="Background-color:#FFFFFF;"> </span><span style="color:#000000;">Our revenue is generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i)&#160;licenses, (ii) research and development activities and (iii)&#160;participation in joint research and development steering committees. The terms of these agreements may include non-refundable upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones, and royalty payments based on product sales derived from the collaboration. Under ASC&#160;606, we evaluate whether the license agreement, research and development services, and participation in research and development steering committees, represent separate or combined performance obligations. We have determined that these services within our existing contracts represent a combined single performance obligation. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research collaboration and license agreements typically include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC 606. We will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is recognized ratably over our expected performance period under each respective arrangement. We make our best estimate of the period over which we expect to fulfill our performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgement is required to determine the duration of the performance period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 2020, 2019 and 2018, transaction price allocated to the combined performance obligation identified under the agreements was recognized as revenue on a straight-line basis over the estimated performance period under each respective arrangement. Straight-line basis was considered the best measure of progress in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. In accordance with ASC 606-10-55-65, we recognize revenues from sales-based milestone and royalty payments at the later of (i)&#160;the occurrence of the subsequent sale&#59; or (ii)&#160;the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). We anticipate recognizing these milestone and royalty payments if and when subsequent sales are generated by the customer from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to satisfying the above revenue recognition criteria are recorded as a contract liability in our accompanying consolidated balance sheets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and Development Contract Costs and Accruals</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met&#59; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226; vendors in connection with clinical development activities&#59; and</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226; CROs and investigative sites in connection with pre-clinical, non-clinical, and human clinical trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We base the expense recorded related to external research and development on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs and CROs that supply, conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Incentive Units </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering, we issued equity-based compensation awards to employees and non-employees through the granting of incentive units. We had periodically granted incentive units to employees and non-employees, which generally vested over a four-year period. The incentive units represented a separate substantive class of equity with defined rights within the limited liability company agreement of Arvinas Holding Company, LLC. The incentive units represented profit interest in the increase in the value of the entity over a participation threshold, as determined at the time of grant. The holder, therefore, had the right to participate in distributions of profits only in excess of such participation threshold. The participation threshold was based on the valuation of the incentive unit on or around the grant date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We accounted for unit-based compensation in accordance with ASC 718, <span style="font-style:italic;">Compensation-Stock Compensation</span>. In accordance with ASC 718, compensation cost is measured at estimated fair value and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We used a Black-Scholes option pricing model to determine the fair value of our incentive units, due to the existence of a participation threshold. The Black-Scholes option pricing model includes various assumptions, including the expected life of incentive units, the expected volatility and the expected risk-free interest rate. The fair value of the underlying common units represented the exercise price utilized in the Black-Scholes option pricing model. These assumptions reflected our best estimates, but they involved inherent uncertainties based on market conditions generally outside our control. As a result, if other assumptions had been used, unit-based compensation cost could have been materially impacted. Furthermore, if we used different assumptions for future grants, unit-based compensation cost could have been materially impacted in future periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As there had been no public market for our common units prior to our initial public offering, the estimated fair value of our common units had been determined by our board of directors as of the date of each incentive unit grant, with input from management, considering our most recently available third-party valuations of common stock units. Valuations were updated when facts and circumstances indicated that the most recent valuation was no longer valid, such as changes in the stage of our development efforts, various exit strategies and their timing, and other scientific developments that could be related to the valuation of our company, or, at a minimum, annually. Third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, <span style="font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span>. Our common unit valuation in January 2018 was prepared using a market approach, specifically the subject company transaction method. The subject company transaction method solves for the total equity value which allocates a probability-weighted present value to the series B preferred unit holders consistent with the investment amount of that financing round adjusted to account for the impact of progress or changes in the business since the closing of the series B financing. Our common unit valuation as of June 30, 2018 was prepared using the income and market approaches simultaneously. Under the income approach, the hybrid method was used, which is a combination of the probability weighted expected return method, or PWERM, and the option pricing method, or OPM. Under the market approach, the subject company transaction method was used. Within both the PWERM and OPM, the subject company transaction method was used to solve for the total equity value which allocates a probability weighted present value to the series C preferred unit holders consistent with the investment amount of that financing round. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These third-party valuations resulted in participation thresholds of $270.8&#160;million as of March&#160;31, 2018 and $292.0 million as of June 30, 2018. Fair value estimates of underlying shares are no longer necessary to determine the fair value of new equity awards because the underlying shares are traded in the public market. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately prior to the effectiveness of our registration statement on Form S-1 (File No. 333-227112) in September 2018, Arvinas Holding Company, LLC, or Arvinas LLC, our predecessor company, converted from a Delaware limited liability company into Arvinas, Inc., a Delaware corporation, which we refer to as the Conversion. <span style="font-size:3pt;font-family:Times New Roman;">&#160;</span>In connection with the Conversion, incentive units in Arvinas LLC were exchanged for common stock and restricted common stock of Arvinas, Inc. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">New Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For information on new accounting standards, see Note 2 to our consolidated audited financial statements appearing elsewhere in this Annual Report on Form 10-K. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Comparison of Years Ended December&#160;31, 2020 and 2019</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Revenues </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues for the year ended December&#160;31, 2020 were $21.8&#160;million, compared with $43.0&#160;million for the year ended December&#160;31, 2019. Revenues for the year ended December 31, 2019 included $24.7 million recognized from the contribution of the license to Oerth. The balance of the revenue increased by $3.5&#160;million over the prior year primarily related to a full year of revenue in 2020 associated with the Bayer Collaboration Agreement which was initiated in the third quarter of 2019 and an increase in activities related to the Pfizer agreement. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses for the year ended December&#160;31, 2020 were $108.4&#160;million, compared with $67.2 million for the year ended December&#160;31, 2019. The increase of $41.2&#160;million was primarily due to an increase in <span style="color:#000000;">our continued investment in our wholly-owned platform and exploratory programs of $17.6 million, expenses related to our</span> AR program of $12.3 million and our ER program of $11.3 million. The increase in spending over all of our programs was primarily due to increased personnel and personnel costs utilized across all our programs of $14.7 million, including an increase in stock compensation expense of $5.7 million. <span style="color:#000000;">Clinical&#160;trial costs and related drug manufacturing costs increased by $20.2 million as we expanded or AR and ER programs in 2020.&#160;</span>Direct expenses related to our platform and exploratory programs increased $7.0 million in 2020 as we expanded the number of protein targets in the exploratory phase.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $38.3 million for the year ended December&#160;31, 2020, compared with $27.3 million for the year ended December&#160;31, 2019. The increase of $11.0&#160;million was primarily due to an increase of $9.6&#160;million in personnel and facility related costs, including $4.8 million related to stock compensation expense, and insurance, taxes and professional fees of $1.4 million.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Other Income </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income was $5.5&#160;million for the year ended December&#160;31, 2020, compared with $5.9&#160;million for the year ended December&#160;31, 2019. The decrease of $0.4 million due to lower interest rates and a decrease in our marketable securities investments, partially offset by an increase in refundable income tax credits from the State of Connecticut of $0.4 million.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Comparison of Years Ended December&#160;31, 2019 and 2018</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Revenues </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues for the year ended December&#160;31, 2019 were $43.0&#160;million, compared with $14.3&#160;million for the year ended December&#160;31, 2018. Revenues for the year ended December 31, 2019 included $24.7 million recognized from the contribution of the license to Oerth. The remaining revenues of $18.3 million increased by $4.0&#160;million over the prior year primarily related to the revenue associated with the Bayer Collaboration Agreement which was initiated in the third quarter of 2019 and an increase in license and rights to technology fees and research and development activities related to the Pfizer Collaboration Agreement. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses for the year ended December&#160;31, 2019 were $67.2&#160;million, compared with $45.2 million for the year ended December&#160;31, 2018. The increase of $22.0&#160;million was primarily due to an increase in <span style="color:#000000;">our continued investment in our wholly-owned platform and exploratory programs of $19.2 million, expenses related to our </span>ER program of $2.0 million and AR program of $0.8 million. The increase in spending over all of our programs was primarily due to increased personnel and personnel costs of $10.9 million, including an increase in stock compensation expense of $3.6 million. Direct expenses related to our platform and exploratory programs increased $11.1 million in 2019 as we expanded the number of protein targets in the exploratory phase. <span style="color:#000000;">Clinical&#160;trial costs increased by $3.0 million but were more than offset by a decrease in lead optimization costs and IND-enabling costs for our AR&#160;and ER&#160;programs in 2019.&#160;</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">General and Administrative Expenses </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $27.3 million for the year ended December&#160;31, 2019, compared with $12.9 million for the year ended December&#160;31, 2018. The increase of $14.4&#160;million was primarily due to an increase of $10.0&#160;million in personnel and facility related costs, including $5.0 million related to stock compensation expense. Increases in other costs, including legal and other professional fees of $3.0 million and corporate insurance of $0.9 million, are primarily related to costs incurred in our first full year as a public company in 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Other Income </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income was $5.9&#160;million for the year ended December&#160;31, 2019, compared with $2.3&#160;million for the year ended December&#160;31, 2018. The increase of $3.6 million was primarily related to an increase in interest income of $2.1 million and an increase in refundable research and development credits from the State of Connecticut of $1.2 million. The increase in interest income was the result of our higher average cash, cash equivalent and short-term investment balances for the year ended December&#160;31, 2019 <span style="color:#000000;">due to the proceeds from our initial public offering in 2018, the Stock Purchase Agreement, the Bayer Collaboration Agreement and our follow-on public offering in 2019. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Loss on Equity Method Investment</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on equity method investment for the year ended December 31, 2019 was $24.7 million, generated from Oerth&#8217;s expensing intellectual property contributed to it.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Sources of Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sale of equity interests and through payments from collaboration partners, grant funding and loans from the State of Connecticut. Through December&#160;31, 2020, we raised approximately $887.3&#160;million in gross proceeds from the sale of equity interests and the exercise of stock options and had received an aggregate of $120.8&#160;million in payments from collaboration partners, grant funding and forgivable and partially forgivable loans from the State of Connecticut. In October 2018, we completed our IPO in which we issued and sold an aggregate of 7,700,482 shares of common stock, including 200,482 additional shares of common stock at a subsequent closing upon the exercise in part by the<span style="font-size:12pt;font-family:Times New Roman;"> </span>underwriters of their option to purchase additional shares at a public offering price of $16.00 per share, for aggregate gross proceeds of $123.2 million before fees and expenses. In July 2019, we sold 1,346,313 shares of common stock to Bayer AG for aggregate gross proceeds of $32.5 million. In November 2019, we completed a follow-on offering in which we issued 5,227,273 shares of common stock at a public offering price of $22.00 per share, for aggregate gross proceeds of $115.0 million before fees and expenses. In December 2020, we completed a public offering in which we issued 6,571,428 shares of common stock at a public offering price of $70.00 per share, for aggregate gross proceeds of $460.0 million before fees and expenses. During the year ended December 31, 2020, we sold 2,593,637 shares of common stock in an &#8220;at-the-market offering&#8221; for aggregate net proceeds of $64.1 million before fees and expenses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Cash Flows </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash, cash equivalents and marketable securities totaled $688.5&#160;million as of December&#160;31, 2020 and $280.9&#160;million as of December&#160;31, 2019. We had an outstanding loan balance of $2.0&#160;million as of December&#160;31, 2020 and 2019, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our sources and uses of cash for the period presented: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,757</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,626</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,118</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,250</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,097</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(179,665</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">504,669</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,744</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,061</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579,162</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,722</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Operating Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December&#160;31, 2020 was $89.8&#160;million, resulting from our net loss of $119.3 million and a decrease in deferred revenue of $13.3 million, partially offset by non-cash expenses of $35.5 million and an increase in accounts payable and accrued expenses of $12.8 million. Non-cash expenses included $30.2 million of stock compensation expense. The decrease in deferred revenue is primarily due to $21.8&#160;million of revenue recognized, partially offset by $8.5&#160;million in payments received and an accounts receivable from collaboration partners. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December&#160;31, 2019 was $40.6&#160;million, resulting from our net loss of $70.3 million and an increase in other receivables of $4.0 million, partially offset by non-cash expenses of $22.5 million and an increase in accounts payable and accrued expenses of $5.2 million and deferred revenue of $4.9 million. The increase in deferred revenue is primarily due to $23.1&#160;million in payments received from collaboration partners, partially offset by $18.3&#160;million of revenue recognized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December 31, 2018 was $16.1&#160;million, resulting from our net loss of $41.5 million and a reduction in our deferred revenue of $8.5 million, partially offset by non-cash expenses of $12.8 million and a decrease in accounts receivable of $22.2 million. The reduction in deferred revenue is primarily due to $14.3&#160;million of revenue recognized, partially offset by $5.8&#160;million in target payments received from a collaboration partner.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Investing Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities for the year ended December&#160;31, 2020 was $164.3&#160;million, attributable to the net maturities and sales of marketable securities in excess of purchases of $170.7&#160;million, offset by the purchases of property and equipment of $6.4&#160;million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December&#160;31, 2019 was $93.1&#160;million, attributable to the net investment of excess cash of $86.9&#160;million and the purchases of property and equipment of $6.2&#160;million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December&#160;31, 2018 was $179.7&#160;million, attributable to the net investment of excess cash of $176.8&#160;million and the purchases of property and equipment of $2.8&#160;million.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Financing Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December&#160;31, 2020 was $504.7&#160;million, primarily attributable to the proceeds from sales of our common stock from our public offering and at-the-market offering of $496.4 million, net of combined underwriter discounts from the public offering and offering costs of $29.2 million and the proceeds from the exercise of stock options of $8.3 million. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December&#160;31, 2019 was $139.7&#160;million, primarily attributable to the proceeds from the sales of our common stock, net of underwriter discounts and offering costs, of $137.1 million and the proceeds from the exercise of stock options of $2.8 million. We also made $0.2 million in debt payments. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December 31, 2018 was $168.1&#160;million, primarily attributable to the net proceeds from the sale of series C preferred units of $55.0 million and the sale of common stock, net of underwriter discounts and offering costs, of $111.2 million. We also received loan proceeds of $2.0 million and made $0.2 million in debt payments.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Funding Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates. In addition, we expect to continue to incur additional costs associated with operating as a public company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, we anticipate that our expenses will increase substantially if and as we: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">continue a Phase 1/2 clinical trial of our product candidate ARV-110, and initiate one or more Phase 1b cohort expansions of ARV-110 in combination with standard of care agents, in men with mCRPC&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">continue a Phase 1/2 clinical trial of our product candidate ARV-471, a Phase 1b cohort expansion of ARV-471 in combination with </span><span style="font-size:10pt;font-family:Arial;color:#000000;">palbociclib</span><span style="font-size:10pt;font-family:Arial;color:#000000;">, and </span><span style="font-size:10pt;font-family:Arial;color:#000000;">initiate </span><span style="font-size:10pt;font-family:Arial;color:#000000;">an additional </span><span style="font-size:10pt;font-family:Arial;color:#000000;">Phase 1b cohort expansion</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> </span><span style="font-size:10pt;font-family:Arial;color:#000000;">in combination with </span><span style="font-size:10pt;font-family:Arial;color:#000000;">a </span><span style="font-size:10pt;font-family:Arial;color:#000000;">standard of care agent</span><span style="font-size:10pt;font-family:Arial;color:#000000;">,</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> </span><span style="font-size:10pt;font-family:Arial;color:#000000;">each </span><span style="font-size:10pt;font-family:Arial;color:#000000;">in patients with locally advanced or metastatic ER positive / HER2 negative breast cancer</span><span style="font-size:10pt;font-family:Arial;color:#000000;">, and initiate a </span><span style="font-size:10pt;font-family:Arial;color:#000000;">window of opportunity study in </span><span style="font-size:10pt;font-family:Arial;color:#000000;">early</span><span style="font-size:10pt;font-family:Arial;color:#000000;"> breast cancer</span><span style="font-size:10pt;font-family:Arial;color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">initiate a planned Phase 1 clinical trial of our product candidate ARV-766 in the first half of 2021&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">apply our PROTAC Discovery Engine to advance additional product candidates into preclinical and clinical development&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">expand the capabilities of our PROTAC Discovery Engine&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">seek marketing approvals for any product candidates that successfully complete clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we may obtain marketing approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">expand, maintain and protect our intellectual property portfolio&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">hire additional development, including clinical and regulatory, and scientific personnel&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">add operational, financial and management information systems and personnel to support our research, product development and future commercialization efforts and support our operations as a public company.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we believe that our existing cash, cash equivalents and marketable securities, will enable us to fund our operating expenses and capital expenditure requirements into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the progress, costs and results of our ongoing clinical trials for ARV-110 and for ARV-471 and any future clinical development of ARV-110 and ARV-471&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the initiation, progress, costs and results of our planned clinical trial for ARV-766 and any future clinical development of ARV-766&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the scope, progress, costs and results of preclinical and clinical development for our other product candidates and development programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the number of, and development requirements for, other product candidates that we pursue, including our other oncology and neurodegenerative research programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;" id="fb_795a23ee90c145b28f30f0cc246b7891"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the success of our collaborations with Pfizer, Genentech and Bayer&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;" id="fe_795a23ee90c145b28f30f0cc246b7891"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the costs, timing and outcome of regulatory review of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Arial;color:#000000;">our ability to establish additional collaboration arrangements with other biotechnology or pharmaceutical companies on favorable terms, if at all, for the development or commercialization of our product candidates. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of these anticipated expenditures, we will need to obtain substantial additional financing in connection with our continuing operations. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although we may receive potential future payments under our collaborations with Pfizer, Genentech and Bayer, we do not currently have any committed external source of funds. Adequate additional funds may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the terms of these securities may include liquidation or other preferences that adversely affect </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our c</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon stockholde</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rs</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Borrowings</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2013, we entered into a Loan Agreement, or Loan, with Connecticut Innovations, Incorporated, or CII, the strategic venture capital arm and a component unit of the State of Connecticut. Under the Loan, we borrowed $750,000 for the purchase of laboratory equipment, information technology equipment and leasehold improvements. Interest on the Loan was compounded on a monthly basis at a rate of 7.50% per annum. The Loan provided for monthly, interest-only payments for ten months. Beginning on June&#160;1, 2015 we were required to make monthly principal and interest payments through July&#160;31, 2019. We could have prepaid the amount due at any time without premium or penalty. The Loan was secured by substantially all of our assets. The amount outstanding under the Loan was $0.2&#160;million as of December&#160;31, 2018. We paid the Loan in full in July 2019. In connection with the issuance of the Loan, we granted CII a warrant to purchase 110,116 of our series A preferred units at a purchase price of $0.6811 per unit, with a seven-year term from the date of issuance. The warrant was exercised in July 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2014, we entered into an Assistance Agreement with the State of Connecticut, or the 2014 Assistance Agreement. Under the terms of the 2014 Assistance Agreement, we borrowed $2.5&#160;million. Borrowings under the 2014 Assistance Agreement were forgivable if we maintained a minimum number of full-time jobs in the State of Connecticut for a minimum period at a minimum annual salary. Effective in March 2016, the full principal amount under the 2014 Assistance Agreement had been forgiven. While borrowings under the 2014 Assistance Agreement have been forgiven, we remain subject to an ongoing covenant to be located in the State of Connecticut through January 2024. Upon violation of this covenant we would be required to repay the full original funding amount of $2.5&#160;million plus liquidated damages of 7.50%. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, we entered into an additional Assistance Agreement with the State of Connecticut, or the 2018 Assistance Agreement, to provide funding for the expansion and renovation of laboratory and office space. Under the terms of the 2018 Assistance Agreement, we could borrow from the State of Connecticut a maximum of $2.0 million, provided that the funding does not exceed more than 50% of the total costs of the expansion and renovation. Borrowings under the 2018 Assistance Agreement bear an interest rate of 3.25% per annum and interest payments are required for the first 60 months from the funding date. Interest expense related to the Assistance Agreement is expected to be $65,000 annually for the first five years. Thereafter, the loan begins to fully amortize through month 120, maturing in June 2028. Up to $1.0 million of the funding can be forgiven if we meet certain employment conditions. We may be required to prepay a portion of the loan if the employment conditions are not met. The 2018 Assistance Agreement requires that we be located in the State of Connecticut through June 2028 with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated damages of 7.5% of the total amount of funding received. We borrowed the full $2.0 million under the 2018 Assistance Agreement in September 2018 and the full amount remains outstanding at December&#160;31, 2020. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents, and marketable securities. Interest income earned on these assets was $3.6 million in 2020 and $4.6 million in 2019. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. At December&#160;31, 2020, our cash equivalents consisted of bank deposits and money market funds, and our marketable securities included interest-earning securities. Such interest-earning instruments carry a degree of interest rate risk. Our outstanding debt was $2.0 million as of December&#160;31, 2020 and $2.0 million as of December&#160;31, 2019. Our outstanding debt as of December 31, 2020 carries a fixed interest rate of 3.25% per annum. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">Item 8. Financial Statements and Supplementary Data.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial statements, together with the report of our independent registered public accounting firm, appear on pages F-1 through F-24 of this Annual Report on Form 10-K. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9A_CONTROLS_PROCEDURES">Item 9A. Controls and Procedures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2020. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2020, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the company. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company&#8217;s principal executive and principal financial officers and effected by the company&#8217;s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2020. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). Based on that assessment, our management concluded that, as of December 31, 2020, our internal control over financial reporting was effective.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="keyword">Deloitte &#38; Touche LLP, the independent registered public accounting firm that audited the consolidated financial statements included in this Annual Report on Form&#160;10-K, has issued an&#160;attestation&#160;report&#160;on the effectiveness of internal control over financial reporting as of December&#160;31, 2020, included below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended December&#160;31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal control over financial reporting due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 pandemic on our internal controls to minimize the impact on their design and operating effectiveness.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">To the shareholders&#160;and the Board of Directors of Arvinas, Inc.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Opinion on Internal Control over Financial Reporting</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We have audited the internal control over financial reporting of Arvinas, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020, based on criteria established in&#160;Internal Control - Integrated Framework (2013)&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in&#160;Internal Control - Integrated Framework (2013)&#160;issued by COSO.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2020, of the Company and our report dated March 1, 2021, expressed an unqualified opinion on those financial statements.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Basis for Opinion</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Definition and Limitations of Internal Control over Financial Reporting</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company&#59; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company&#59; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">/s/ Deloitte &#38; Touche LLP</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Hartford, CT</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">March 1, 2021</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B_OR_INFORMATION">Item 9B. Other Information. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_III">PART III </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item is incorporated by reference from the information that will be contained in our Proxy Statement for our 2021 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a Code of Business Conduct and Ethics that applies to our officers, including our principal executive, financial and accounting officers, and our directors and employees. We have posted the text of our Code of Business Conduct and Ethics under the &#8220;Investors + Media &#8211; Corporate Governance&#8221; section of our website, www.arvinas.com. We intend to disclose on our website any amendments to, or waivers from, the Code of Business Conduct and Ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11_EXECUTIVE_COMPENSATION">Item 11. Executive Compensation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item is incorporated by reference from the information that will be contained in our Proxy Statement for our 2021 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item is incorporated by reference from the information that will be contained in our Proxy Statement for our 2021 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item is incorporated by reference from the information that will be contained in our Proxy Statement for our 2021 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">Item 14. Principal Accounting Fees and Services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item is incorporated by reference from the information that will be contained in our Proxy Statement for our 2021 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV">PART IV</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Item 15. Exhibits, Financial Statement Schedules. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(1) Financial Statements<span style="font-weight:normal;"> - The following financial statements are filed as part of this Annual Report on Form 10-K:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:91.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="width:91.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:none;">Report of Independent Registered Public Accounting Firm</span></a><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top" style="width:91.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:none;">Consolidated Balance Sheets as of December&#160;31, 2020 and 2019</span></a><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top" style="width:91.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><span style="text-decoration:none;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2020, 2019, and 2018</span></a><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top" style="width:91.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_REDEEMABLE_CONVE"><span style="text-decoration:none;">Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders&#8217;/Members&#8217; Equity for the years ended December&#160;31, 2020, 2019 and 2018</span></a><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top" style="width:91.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:none;">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2020, 2019, and 2018</span></a><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
<tr>
<td valign="top" style="width:91.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:none;">Notes to Consolidated Financial Statements</span></a><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(2) Financial Statement Schedules</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(3) Index to Exhibits</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518289513/d615527dex31.htm"><span style="text-decoration:none;">Restated</span><span style="text-decoration:none;font-family:Times New Roman;"> </span><span style="text-decoration:none;">Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on October 1, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518289513/d615527dex32.htm"><span style="text-decoration:none;">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on October 1, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518262944/d564688dex41.htm"><span style="text-decoration:none;">Specimen Stock Certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-227112) filed with the SEC on August&#160;30, 2018)</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019009357/arvn-ex42_866.htm"><span style="text-decoration:none;">Registration Rights Agreement among the Registrant and the other parties thereto, dated September 26, 2018</span><span style="text-decoration:none;font-family:Times New Roman;"> </span><span style="text-decoration:none;">(incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 26, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518262944/d564688dex43.htm"><span style="text-decoration:none;">Second Amended and Restated Put Agreement among the Registrant, Connecticut Innovations, Incorporated and the other parties thereto, dated March 29, 2018 (incorporated by reference to Exhibit 4.3 to the Registrant's Registration Statement on Form S-1 (File No. 333-2271121) filed with the SEC on August 30. 2018)</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.4</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex44_9.htm"><span style="text-decoration:none;">Description of the Registrant&#8217;s Securities Registered Under Section 12 of the Exchange Act (incorporated by reference to Exhibit 4.4 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 16, 2020).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.1<span style="color:#000000;">+</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518262944/d564688dex101.htm"><span style="text-decoration:none;">Incentive Share Plan, as amended by First Amendment, dated October&#160;16, 2015, Second Amendment, dated December&#160;22, 2016, Third Amendment, dated September&#160;8, 2017, and Fourth Amendment, dated March&#160;29, 2018 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-227112) filed with the SEC on August 30, 2018</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.2<span style="color:#000000;">+</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518262944/d564688dex102.htm"><span style="text-decoration:none;">Form of Incentive Share Award Agreement under Incentive Share Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-227112) filed with the SEC on August 30, 2018</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.3<span style="color:#000000;">+</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex103.htm"><span style="text-decoration:none;">Form of Restricted Stock Agreement under Incentive Share Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).</span></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.4<span style="color:#000000;">+</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518273347/d564688dex104.htm"><span style="text-decoration:none;">2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</span></a><span style="color:#000000;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.5<span style="color:#000000;">+</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518273347/d564688dex105.htm"><span style="text-decoration:none;">Form of Stock Option Agreement under 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</span></a><span style="color:#000000;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.6+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019009357/arvn-ex106_781.htm"><span style="text-decoration:none;">Form of Restricted Stock Unit Agreement under 2018 Stock Incentive Plan</span><span style="font-size:12pt;text-decoration:none;font-family:Times New Roman;"> </span><span style="text-decoration:none;">(incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 26, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.7<span style="color:#000000;">+</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518273347/d564688dex106.htm"><span style="text-decoration:none;">2018 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.8<span style="color:#000000;">+</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex107.htm"><span style="text-decoration:none;">Form of Director and Officer Indemnification Agreement (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018)</span></a><span style="text-decoration:none;">.</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.9<span style="color:#000000;">+</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518273347/d564688dex108.htm"><span style="text-decoration:none;">Employment Agreement between the Registrant and John Houston, Ph.D., dated September 13, 2018 (incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.10<span style="color:#000000;">+</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518273347/d564688dex109.htm"><span style="text-decoration:none;">Employment Agreement between the Registrant and Sean Cassidy, dated August 28, 2018 (incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.11<span style="color:#000000;">+</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518273347/d564688dex1010.htm"><span style="text-decoration:none;">Employment Agreement between the Registrant and Ian Taylor, Ph.D., dated August 28, 2018 (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.12</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1012.htm"><span style="text-decoration:none;">Lease Agreement between the Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated December 31, 2017, as amended by First Amendment to Lease, dated May 23, 2018, and second Amendment to Lease, dated September 4, 2018 (incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.13</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312519076853/d723460dex101.htm"><span style="text-decoration:none;">Third Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated March 12, 2019 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on March 15, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.14</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex1014_10.htm"><span style="text-decoration:none;">Fourth Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated January 31, 2020 (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 16, 2020).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.15</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex1015_7.htm"><span style="text-decoration:none;">Lease Agreement between Arvinas Operations, Inc. and Science Park Development Corporation, dated November 15, 2019 (incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 16, 2020).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.16</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex1016_16.htm"><span style="text-decoration:none;">First Amendment to Lease between Arvinas Operations, Inc. and Science Park Development Corporation, dated February 27, 2020 (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 16, 2020).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.17<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1013.htm"><span style="text-decoration:none;">License Agreement between Yale University and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated July&#160;5, 2013, as amended by Amendment No.&#160;1, dated May&#160;8, 2014, Amendment No.&#160;2, dated October&#160; 23, 2014, and Letter Amendment Number 3, dated April&#160;1, 2015 (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.18<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019009357/arvn-ex1016_955.htm"><span style="text-decoration:none;">Amendment No. 4 to License Agreement between Yale University and Arvinas Operations, Inc. (formerly Arvinas, Inc.) dated January 9, 2019</span><span style="text-decoration:none;font-family:Times New Roman;"> </span><span style="text-decoration:none;">(incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 26, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.19</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001655759/000119312518262944/d564688dex1014.htm"><span style="text-decoration:none;">Amended and Restated Consulting Agreement between Craig Crews and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated October&#160; 16, 2015, as amended by Amendment No.&#160;1, dated August&#160;27, 2018 (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-227112) filed with the SEC on August 30, 2018)</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.20<span style="color:#000000;">&#8224;</span> </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518262944/d564688dex1015.htm"><span style="text-decoration:none;">Corporate Sponsored Research Agreement between Yale University and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated July&#160; 1, 2016, as amended by Amendment No.&#160;1, dated April&#160;1, 2018 (incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-227112) filed with the SEC on August 30, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.21<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1016.htm"><span style="text-decoration:none;">Amended and Restated License and Option Agreement among Genentech, Inc.,&#160;F.&#160;Hoffmann-La&#160;Roche Ltd and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated November&#160;8, 2017 (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018)</span></a><span style="text-decoration:none;">.</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.22<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1017.htm"><span style="text-decoration:none;">Research Collaboration and License Agreement between Pfizer Inc. and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated December&#160;22, 2017 (incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018)</span></a><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.23<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1018.htm"><span style="text-decoration:none;">Sponsored Research Agreement between The Silverstein Foundation for Parkinson&#8217;s with GBA and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated March&#160;7, 2018 (incorporated by reference to Exhibit 10.18 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.24<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex1024_13.htm"><span style="text-decoration:none;">Amendment No. 1 to Research Collaboration and License Agreement between Pfizer Inc. and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated December 9, 2019 (incorporated by reference to Exhibit 10.24 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 16, 2020).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.25<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019028501/arvn-ex103_145.htm"><span style="text-decoration:none;">Collaboration and License Agreement between Arvinas Operations, Inc. and Bayer AG, dated June 3, 2019 (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August 5, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.26<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019028501/arvn-ex102_116.htm"><span style="text-decoration:none;">Commitment Agreement between Arvinas Operations, Inc., Protag LLC, and Bayer CropScience LP, dated June 3, 2019 (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August 5, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.27<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019028501/arvn-ex103_145.htm"><span style="text-decoration:none;">Option Agreement between Arvinas Operations, Inc. and Bayer CropScience LP, dated June 3, 2019 (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August 5, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.28<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019028501/arvn-ex104_144.htm"><span style="text-decoration:none;">Arvinas IP Contribution Agreement between Arvinas Operations, Inc. and Protag LLC, dated July 16, 2019 (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August 5, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.29<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019028501/arvn-ex105_115.htm"><span style="text-decoration:none;">Stock Purchase Agreement between the Registrant and Bayer AG, dated June 3, 2019 (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August 5, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.30<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019028501/arvn-ex106_114.htm"><span style="text-decoration:none;">Investor Agreement between the Registrant and Bayer AG, dated July 16, 2019 (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August 5, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.31<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000156459019028501/arvn-ex107_143.htm"><span style="text-decoration:none;">Amendment No. 5 to License Agreement between Yale University and Arvinas Operations, Inc. (formerly Arvinas, Inc.) dated June 3, 2019 (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August 5, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.32+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000156459020019266/arvn-ex101_177.htm"><span style="text-decoration:none;">Employment Agreement between the Registrant and Ronald Peck, M.D., dated July 18, 2019 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on April 28, 2020).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.33</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1655759/000119312519259952/d811610dex12.htm"><span style="text-decoration:none;">Equity Distribution Agreement, dated October 1, 2019, by and between the Registrant and Piper Jaffray &#38; Co. (incorporated by reference to Exhibit 1.2 to the Registrant&#8217;s Registration Statement on Form S-3 (File No. 333-234035) filed with the SEC on October 1, 2019).</span></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.34<span style="font-family:Times New Roman;">*</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex1034_590.htm"><span style="text-decoration:none;">Fifth Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated January 4, 2021.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.35<span style="font-family:Times New Roman;">*</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex1035_591.htm"><span style="text-decoration:none;">Second Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated January 4, 2021.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;21.1*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex211_11.htm"><span style="text-decoration:none;">Subsidiaries of the Registrant.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;23.1*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex231_14.htm"><span style="text-decoration:none;">Consent of Deloitte &#38; Touche LLP, independent registered public accounting firm.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;31.1*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex311_6.htm"><span style="text-decoration:none;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;31.2*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex312_15.htm"><span style="text-decoration:none;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;32.1**</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex321_8.htm"><span style="text-decoration:none;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;32.2**</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex322_12.htm"><span style="text-decoration:none;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;99.1*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arvn-ex991_751.htm"><span style="text-decoration:none;">Audited Financial Statements of Oerth Bio, LLC, as of December 31, 2020.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.INS*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.SCH*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.CAL*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.DEF*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.LAB*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.PRE*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">104</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:88.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101)</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Furnished herewith.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Management contract or compensatory plan or arrangement.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16_FORM_10K_SUMMARY">Item 16. Form 10-K Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized<span style="font-weight:bold;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARVINAS, INC.</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;John Houston, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> John Houston, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160; John Houston, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 1, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> John Houston, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(principal executive officer)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Sean Cassidy</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 1, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Cassidy</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(principal financial and accounting officer)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Timothy Shannon, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 1, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Timothy Shannon, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Linda Bain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Linda Bain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Wendy Dixon, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wendy Dixon, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Edward Kennedy, Jr.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Edward Kennedy, Jr.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Bradley Margus</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bradley Margus</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Briggs Morrison, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Briggs Morrison, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Leslie Norwalk, Esq.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Leslie Norwalk, Esq.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Liam Ratcliffe, M.D., Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Liam Ratcliffe, M.D., Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Laurie Smaldone Alsup, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laurie Smaldone Alsup, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:92.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="width:92.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:none;">Report of Independent Registered Public Accounting Firm</span></a><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top" style="width:92.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:none;">Consolidated Balance Sheets as of December 31, 2020 and 2019</span></a><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top" style="width:92.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><span style="text-decoration:none;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2020, 2019 and 2018</span></a><span style="text-decoration:none;"> </span><span style="text-decoration:none;font-family:Times New Roman;"></span></p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top" style="width:92.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_REDEEMABLE_CONVE"><span style="text-decoration:none;">Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders&#8217;/Members&#8217; Equity for the years ended December 31, 2020,</span><span style="text-decoration:none;font-family:Times New Roman;"> </span><span style="text-decoration:none;">2019 and 2018</span></a><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top" style="width:92.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:none;">Consolidated Statements of Cash Flows for the years ended December 31, 2020, 2019 and 2018</span></a><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
<tr>
<td valign="top" style="width:92.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:none;">Notes to Consolidated Financial Statements</span></a><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the shareholders and the Board of Directors of Arvinas, Inc. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Arvinas, Inc. and subsidiaries (the "Company") as of December 31, 2020 and 2019, the related consolidated&#160;statements of operations and comprehensive loss, redeemable convertible preferred shares/units and changes in stockholders&#8217;/members&#8217; equity, and cash flows, for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019 and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 1, 2021, expressed an unqualified opinion on the Company's internal control over financial reporting.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Audit Matter </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and Accrued Research and Development - Refer to Note 2 in the Consolidated Financial Statements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Critical Audit Matter Description</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various contracts with third parties to perform research and development, including clinical research and contract manufacturing. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company makes estimates of the costs incurred by third parties during the period and the outstanding obligations to those third parties as of period end. Estimates of costs incurred during the period that are included in period-end prepaid or accrued expense balances are based on a number of factors, including the Company&#8217;s knowledge of the research and development programs and clinical manufacturing activities associated with project status and milestones, invoicing to date, and the provisions in the contract. Significant judgments and estimates are made by the Company in determining the costs incurred during the period that are included in prepaid or accrued expense balances at the end of each reporting period. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We identified the measurement of the accruals and prepaid expense related to these types of research and development costs as a critical audit matter because of the judgments and estimates necessary for management to determine the status and progress of each contract. The expense recorded related to external research and development is based off of estimates as to the services received and efforts expended pursuant to quotes and contracts with the Company&#8217;s contract manufacturing vendors and contract research organizations that supply, conduct and manage clinical trials on the Company&#8217;s behalf.&#160;&#160;Assessing such estimates required an increased extent of audit effort and a high degree of auditor judgment when performing procedures to audit the prepaid and accrued expenses related to these costs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">How the Critical Audit Matter Was Addressed in the Audit:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit procedures related to the management&#8217;s estimation of costs incurred included the following, among others:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">Testing the effectiveness of controls over the accounting for prepaid and accrued research and development expenses, including the Company&#8217;s assessment and estimation of the costs incurred for significant research and development activities performed by third parties</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">On a sample basis, we tested the accrued and prepaid expense balances by:</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">inspecting related contracts and agreeing key provisions of the contracts to the Company&#8217;s analysis of estimated expenses incurred to date&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">inspecting correspondences from the third-party vendors to the Company, including status reports, and comparing such information to the amounts used in the Company&#8217;s estimates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">meeting with clinical and manufacturing operational personnel within the Company to understand the status of significant research and development activities for a sample of project activities, and comparing such information to the amounts used in the Company&#8217;s estimates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Arial;color:#000000;">comparing the estimated accrual balance as of December 31, 2020, to the invoices received after year-end to evaluate the Company&#8217;s ability to estimate the accrual.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Deloitte &#38; Touche LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hartford, Connecticut</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company's auditor since 2016.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;text-transform:uppercase;font-style:normal;font-variant: normal;">Arvinas, inc. and subsidiaries<span style="text-transform:none;"> </span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">Consolidated Balance Sheets </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">588,373,232</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">9,211,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">100,157,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">271,661,456</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Account receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other receivables</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:OtherReceivablesNetCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">7,443,654</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:OtherReceivablesNetCurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">6,280,828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">6,113,122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">3,727,294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:AssetsCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">703,087,626</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:AssetsCurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">290,880,635</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and leasehold improvements, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">12,259,515</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">8,455,411</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right of use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">1,992,669</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">2,278,623</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">28,777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">26,757</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:Assets" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">717,368,587</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:Assets" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">301,641,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders' equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">7,121,879</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">4,556,827</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">18,859,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">7,602,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">22,150,861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">19,979,525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">952,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">673,896</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">49,085,420</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">32,813,152</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">22,938,233</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">38,427,882</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term debt, net of current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:LongTermDebtNoncurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">2,000,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:LongTermDebtNoncurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">2,000,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">1,087,422</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">1,714,111</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:Liabilities" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">75,111,075</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:Liabilities" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">74,955,145</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000071">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000072">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000085" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001655759_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000086" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001655759_20191231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000087" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001655759_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000089" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001655759_20201231" decimals="INF" format="ixt:numdotdecimal">48,455,741</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000088" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001655759_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000090" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001655759_20191231" decimals="INF" format="ixt:numdotdecimal">38,461,353</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:CommonStockValue" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">48,455</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:CommonStockValue" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">38,461</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001655759_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">491,888,910</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001655759_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">372,556,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">1,133,537,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">599,097,090</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">560,796</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">107,576</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">642,257,512</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">226,686,281</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">717,368,587</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">301,641,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">ARVINAS, INC. AND SUBSIDIARIES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR">Consolidated Statements of Operations and Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Arial;text-transform:none;font-variant: normal;">Consolidated Statements of Operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:Revenues" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">21,801,777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:Revenues" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">42,976,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:Revenues" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">14,323,920</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">108,355,853</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">67,193,830</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">45,193,830</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">38,303,401</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">27,307,162</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">12,932,168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:OperatingExpenses" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">146,659,254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:OperatingExpenses" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">94,500,992</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:OperatingExpenses" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">58,125,998</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001655759_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">124,857,477</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">51,524,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">43,802,078</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expenses)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">2,004,561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">1,435,596</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">102,730</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of preferred unit warrant</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">193,779</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">3,585,852</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">4,557,260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">2,470,101</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:InterestExpense" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">65,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:InterestExpense" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">85,569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:InterestExpense" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">57,440</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">5,525,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">5,907,287</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">2,321,612</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from equity method investment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">24,675,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">119,332,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">70,292,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">41,480,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in redemption value of redeemable preferred units</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">198,366,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001655759_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">119,332,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">70,292,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">239,847,222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000133" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001655759_20200101_20201231" decimals="2" sign="-">3.02</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000134" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001655759_20190101_20191231" decimals="2" sign="-">2.13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000135" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001655759_20180101_20181231" decimals="2" sign="-">25.45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000136" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">39,534,497</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000137" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">32,927,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000138" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">9,422,799</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Arial;text-transform:none;font-variant: normal;">Consolidated Statements of Comprehensive Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">119,332,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">70,292,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">41,480,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive gain (loss):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain (loss) on available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">453,220</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">325,299</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">207,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001655759_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">118,878,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">69,966,928</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">41,688,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;text-transform:uppercase;font-style:normal;font-variant: normal;">Arvinas, inc<span style="text-transform:none;"> AND SUBSIDIARIES</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_REDEEMABLE_CONVE">Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders&#8217;/Members&#8217; Equity </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Series A</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Series B</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Series C</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Series</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Redeemable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Redeemable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Redeemable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">A, B and C</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,&#160;2017</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000148" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20171231" decimals="INF" format="ixt:numdotdecimal">22,463,665</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20171231" decimals="0" format="ixt:numdotdecimal">19,768,025</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000150" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20171231" decimals="INF" format="ixt:numdotdecimal">24,977,489</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20171231" decimals="0" format="ixt:numdotdecimal">41,712,407</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incentive unit-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of Series A redeemable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; convertible preferred warrant</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000152" name="arvn:TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">110,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="arvn:TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">319,667</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series C redeemable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; convertible preferred units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000154" name="arvn:TemporaryEquityStockIssuedDuringPeriodShareNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">16,467,066</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">55,000,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in redemption value of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; redeemable convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; preferred units</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">91,044,716</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">81,253,577</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">26,068,463</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of redeemable convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; preferred units to redeemable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; convertible preferred shares</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000159" name="arvn:TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20180101_20181231" decimals="INF" sign="-" format="ixt:numdotdecimal">22,573,781</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="arvn:TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">111,132,408</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000161" name="arvn:TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20180101_20181231" decimals="INF" sign="-" format="ixt:numdotdecimal">24,977,489</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="arvn:TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">122,965,984</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000163" name="arvn:TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180101_20181231" decimals="INF" sign="-" format="ixt:numdotdecimal">16,467,066</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="arvn:TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">81,068,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000165" name="arvn:TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesABAndCConvertiblePreferredSharesMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">64,018,336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="arvn:TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesABAndCConvertiblePreferredSharesMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">315,166,856</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of common and incentive</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; units to common and restricted</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; underwriters' discounts and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">12,048,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of redeemable convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; preferred stock to common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000167" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesABAndCConvertiblePreferredSharesMember_20180101_20181231" decimals="INF" sign="-" format="ixt:numdotdecimal">64,018,336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesABAndCConvertiblePreferredSharesMember_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">315,166,856</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock vesting</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31,&#160;2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; underwriters' discounts and issuance</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">7,497,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock vesting</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on available-for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; -sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31,&#160;2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuances of common stock, net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of underwriters' discounts and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">28,099,997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock vesting</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued in at-the-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; market offering, net of offering</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">1,584,647</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on available-for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; -sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,&#160;2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;text-transform:uppercase;font-style:normal;font-variant: normal;">Arvinas, inc<span style="text-transform:none;"> AND SUBSIDIARIES</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders&#8217;/Members&#8217; Equity </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;letter-spacing:-0.1pt;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Common</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Common</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Incentive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">/ Members&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31,&#160;2017</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000177" name="us-gaap:SharesOutstanding" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnCommonUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20171231" decimals="INF" format="ixt:numdotdecimal">1,897,544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnCommonUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20171231" decimals="0" format="ixt:numdotdecimal">6,167</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000179" name="us-gaap:SharesOutstanding" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20171231" decimals="INF" format="ixt:numdotdecimal">3,669,963</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20171231" decimals="0" format="ixt:numdotdecimal">1,186,419</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="0" sign="-" format="ixt:numdotdecimal">62,417,397</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231" decimals="0" sign="-" format="ixt:numdotdecimal">9,751</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_20171231" decimals="0" sign="-" format="ixt:numdotdecimal">61,234,562</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incentive unit-based</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000184" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">1,680,386</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">2,489,061</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">9,141,239</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">11,630,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of Series A redeemable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; convertible preferred warrant</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series C redeemable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; convertible preferred units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in redemption value of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; redeemable convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; preferred units</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">198,366,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">198,366,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">41,480,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">41,480,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of redeemable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; convertible preferred units to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; redeemable convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; preferred shares</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of common and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; incentive units to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and restricted stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000192" name="arvn:StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnCommonUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231" decimals="INF" sign="-" format="ixt:numdotdecimal">1,897,544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="arvn:StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnCommonUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">6,167</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000194" name="arvn:StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">3,692,765</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="arvn:StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">3,693</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000196" name="arvn:StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231" decimals="INF" sign="-" format="ixt:numdotdecimal">5,350,349</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="arvn:StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">3,675,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="arvn:StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">3,677,954</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; underwriters' discounts and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">12,048,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000199" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">7,700,482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">7,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">111,151,883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">111,159,583</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of redeemable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; to common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000203" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">19,697,928</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">19,698</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">315,147,158</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">315,166,856</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock vesting</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000207" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">144,283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231" decimals="0">145</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="0" sign="-">145</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">207,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">207,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31,&#160;2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000212" name="us-gaap:SharesOutstanding" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">31,235,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20181231" decimals="0" format="ixt:numdotdecimal">31,236</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">302,264,619</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="0" format="ixt:numdotdecimal">439,118,089</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">217,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_20181231" decimals="0" format="ixt:numdotdecimal">136,666,983</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">20,072,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">20,072,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuances of common stock, net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of underwriters' discounts and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">7,497,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000220" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">6,573,586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">6,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">137,082,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">137,088,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">70,292,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">70,292,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock vesting</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000226" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">475,412</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231" decimals="0">475</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="0" sign="-">475</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000229" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">176,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231" decimals="0">177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">2,824,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">2,824,641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on available-for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; -sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">325,299</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">325,299</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31,&#160;2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000235" name="us-gaap:SharesOutstanding" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">38,461,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20191231" decimals="0" format="ixt:numdotdecimal">38,461</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">372,556,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="0" format="ixt:numdotdecimal">599,097,090</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="0" format="ixt:numdotdecimal">107,576</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">226,686,281</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuances of common stock, net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of underwriters' discounts and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">28,099,997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000241" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">6,571,428</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">6,571</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">431,893,392</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">431,899,963</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">30,230,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">30,230,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">119,332,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">119,332,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock vesting</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000249" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">371,164</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231" decimals="0">371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="0" sign="-">371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000252" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">458,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231" decimals="0">458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">8,260,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">8,260,760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued in at-the-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; market offering, net of offering</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">1,584,647</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000256" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,593,637</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">2,594</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">64,055,900</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">64,058,494</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on available-for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; -sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">453,220</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">453,220</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,&#160;2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000262" name="us-gaap:SharesOutstanding" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">48,455,741</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20201231" decimals="0" format="ixt:numdotdecimal">48,455</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">491,888,910</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="0" format="ixt:numdotdecimal">1,133,537,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="0" format="ixt:numdotdecimal">560,796</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:StockholdersEquity" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">642,257,512</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#2E2E2E;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">ARVINAS</span><span style="color:#000000;">, </span><span style="Background-color:#FFFFFF;">INC</span><span style="color:#000000;">. AND SUBSIDIARIES</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">Consolidated Statements of Cash Flows </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:ProfitLoss" contextRef="C_0001655759_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">119,332,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:ProfitLoss" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">70,292,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:ProfitLoss" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">41,480,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of debt discount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">15,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">17,963</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of preferred unit warrant liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">193,779</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">3,166,139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">1,561,557</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">706,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net accretion of bond discounts/premiums</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001655759_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">1,654,516</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">154,022</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">248,069</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on sale of marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:MarketableSecuritiesRealizedGainLoss" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">395,070</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:MarketableSecuritiesRealizedGainLoss" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:MarketableSecuritiesRealizedGainLoss" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of right to use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="arvn:OperatingLeaseRightOfUseAssetAmortization" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">858,367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="arvn:OperatingLeaseRightOfUseAssetAmortization" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">691,345</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="arvn:OperatingLeaseRightOfUseAssetAmortization" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash share/unit-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:ShareBasedCompensation" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">30,230,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:ShareBasedCompensation" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">20,072,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:ShareBasedCompensation" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">11,630,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other receivables</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">1,162,826</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">4,024,862</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">1,215,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Account receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">2,775,831</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">22,224,169</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">2,387,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">1,065,005</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">2,501,383</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">2,042,342</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">1,608,735</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">2,002,163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">10,807,123</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">3,601,628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">605,340</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="arvn:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001655759_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">920,158</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="arvn:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">581,961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="arvn:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001655759_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">13,318,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">4,856,736</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">8,548,090</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001655759_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">89,756,934</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">40,626,342</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">16,117,670</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">41,196,166</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">256,548,355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">234,894,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">174,118,543</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">169,695,816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">58,059,526</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sale of marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="arvn:ProceedsFromSaleOfMarketableSecurities" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">37,775,235</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000323">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000324">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property, equipment and leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">6,447,533</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">6,244,024</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">2,830,661</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">164,250,079</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">93,096,563</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">179,665,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayments of long-term debt</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">169,610</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">173,889</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from long-term debt</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">2,000,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">459,999,960</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">137,686,006</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">114,583,172</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of common stock offering costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">27,650,184</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">597,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">3,423,589</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of common stock in at-the-market offering</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="arvn:ProceedsFromIssuanceOfCommonStockGross" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">65,643,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="arvn:ProceedsFromIssuanceOfCommonStockGross" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20190101_20191231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="arvn:ProceedsFromIssuanceOfCommonStockGross" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20180101_20181231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of common stock offering costs for at-the-market offering</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">1,584,647</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20190101_20191231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20180101_20181231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">8,260,760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">2,824,641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Series C redeemable convertible preferred units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">55,000,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of warrant</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">75,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">504,669,030</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">139,743,906</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">168,060,695</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">579,162,175</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">6,021,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">27,722,335</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, beginning of the period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">9,211,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001655759_20181231" decimals="0" format="ixt:numdotdecimal">3,190,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001655759_20171231" decimals="0" format="ixt:numdotdecimal">30,912,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, end of the period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">588,373,232</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">9,211,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001655759_20181231" decimals="0" format="ixt:numdotdecimal">3,190,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flow information:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property, equipment and leasehold improvements</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; unpaid at period end</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">522,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">189,908</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">159,494</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="us-gaap:InterestPaidNet" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">65,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="us-gaap:InterestPaidNet" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">70,420</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="us-gaap:InterestPaidNet" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">39,476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in redemption value of preferred units</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">198,366,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#2E2E2E;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">ARVINAS</span><span style="color:#000000;">, </span><span style="Background-color:#FFFFFF;">INC</span><span style="color:#000000;">. </span><span style="text-transform:uppercase;color:#000000;">and Subsidiaries </span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">Notes to Consolidated Financial Statements </p><ix:nonNumeric id="F_000380" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">1. Nature of Business and Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas, Inc. has <ix:nonFraction unitRef="U_arvnSubsidiary" id="F_000431" name="arvn:NumberOfWhollyOwnedSubsidiaries" contextRef="C_0001655759_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction> wholly owned subsidiaries, Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc., Arvinas Estrogen Receptor, Inc., and Arvinas Winchester, Inc. (collectively, the Company). Arvinas Operations, Inc. was formed in 2013, Arvinas Androgen Receptor, Inc. was formed in 2015, Arvinas Estrogen Receptor, Inc. was formed in 2016, and Arvinas Winchester, Inc. was formed in 2018. In September 2018, the Company converted from a Delaware limited liability company to a Delaware corporation. All periods prior to the date of conversion represent the results of the limited liability corporation. The Company is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases throughout the discovery, development and commercialization of therapies to degrade disease-causing proteins. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas, Inc. was incorporated in Delaware on July&#160;3, 2013. Effective January&#160;1, 2015, Arvinas Holding Company, LLC (Arvinas LLC) was formed by the shareholders of Arvinas, Inc. and Arvinas, Inc. became a wholly owned subsidiary of Arvinas LLC. In connection with this reorganization, the rights and preferences of the preferred stock of Arvinas, Inc. were exchanged for preferred stock units with similar rights and preferences of Arvinas LLC. As part of the reorganization, the employees, consultants and board members of Arvinas, Inc. exchanged their stock options in Arvinas, Inc. stock in exchange for incentive units in Arvinas LLC. Additionally, common stockholders of Arvinas, Inc. exchanged their common stock for common units in Arvinas LLC. All exchanges were made on a 1-for-1 basis. This reorganization was accounted for as a common control transaction as the common stockholders of Arvinas, Inc. formed Arvinas, LLC and transferred all the assets from Arvinas, Inc. to Arvinas LLC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000432" name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">The Company&#8217;s Board of Managers approved a <span style="-sec-ix-hidden:F_000433">one-for-3.25</span> reverse stock split of its issued and outstanding shares of common units</ix:nonNumeric> and a proportional adjustment to the existing conversion ratios for the Company&#8217;s Series A, Series B, and Series C preferred units effective as of September 14, 2018. Accordingly, all share/unit and per share/unit amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this reverse unit split and adjustment of the preferred unit conversion ratios. Immediately prior to the effectiveness of the registration statement pertaining to the Company&#8217;s initial public offering on September 26, 2018, the Company converted from a Delaware limited liability company to a Delaware corporation. Pursuant to the plan of conversion, each outstanding Series A, Series B, and Series C preferred units converted into an equal number of shares of Series A, Series B, and Series C preferred stock, each outstanding common unit converted into a share of common stock and each outstanding incentive unit converted into a number of shares of common stock and restricted common stock based on a conversion price determined by the board of directors. The Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000434" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20181001" decimals="INF" format="ixt:numdotdecimal">1,795,221</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="U_xbrlishares" id="F_000435" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20181001_20181001" decimals="INF" format="ixt:numdotdecimal">1,268,923</ix:nonFraction> shares of restricted common stock.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 1, 2018, the Company completed an initial public offering (IPO) in which the Company issued and sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000436" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20181001_20181001" decimals="INF" format="ixt:numdotdecimal">7,500,000</ix:nonFraction> shares<span style="Background-color:#FFFFFF;">&#160;</span>of common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000437" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20181001" decimals="INF">16.00</ix:nonFraction> per share. In October 2018, the underwriters of the IPO exercised in part their option to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000438" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20181001_20181031" decimals="INF" format="ixt:numdotdecimal">200,482</ix:nonFraction> additional shares of the Company&#8217;s common stock at an offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000439" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20181031" decimals="2">16.00</ix:nonFraction> per share. The Company&#8217;s aggregate gross proceeds from the sale of shares in the IPO, including the option, was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20181001" decimals="-5" scale="6">123.2</ix:nonFraction> million before fees and expenses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001655759_20181001_20181001" decimals="-5" scale="6">12.0</ix:nonFraction> million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 1, 2018, all of the outstanding shares of convertible preferred stock automatically converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000442" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20181001" decimals="INF" format="ixt:numdotdecimal">19,697,928</ix:nonFraction> shares of common stock at the applicable conversion ratio then in effect.&#160;&#160;Subsequent to the closing of the IPO, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000443" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001655759_20181001" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> shares of preferred stock outstanding.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Basis of Presentation<span style="font-weight:normal;font-style:normal;"> - The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). The accounting policies used to prepare these financial statements are the same as those used to prepare the consolidated financial statements in prior years, except as described in these notes or for the adoption of new standards as outlined below.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000381" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000381_dcnt_05f6692c-9200-4847-b671-e43ffc57a5a4">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p><ix:nonNumeric id="F_000395" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000395_dcnt_13a72fd1-cf63-4433-9aef-cd3089c2218e">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements of the Company include the accounts of Arvinas, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. </p>
</ix:nonNumeric></ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000381_dcnt_05f6692c-9200-4847-b671-e43ffc57a5a4" continuedAt="F_000381_dcnt_2881a157-b339-43e1-96b2-4258390091b2"><ix:continuation id="F_000395_dcnt_13a72fd1-cf63-4433-9aef-cd3089c2218e">
</ix:continuation><ix:nonNumeric id="F_000396" name="us-gaap:UseOfEstimates" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the financial statements and notes. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements and notes are appropriate, actual results could differ from those estimates. The most significant estimates are those used in determination of the Company&#8217;s revenue recognition, research and development expenses, fair value of its common and preferred units, preferred unit warrant liability, incentive equity compensation, and fair value of its investment in a joint venture, Oerth Bio LLC (Oerth). </p></ix:nonNumeric><ix:nonNumeric id="F_000397" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s principal financial instruments comprise cash, marketable securities, account receivable, accounts payable, accrued liabilities and long-term debt. The carrying value of all financial instruments approximates fair value. </p></ix:nonNumeric><ix:nonNumeric id="F_000398" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents. </p></ix:nonNumeric><ix:nonNumeric id="F_000399" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains its cash in financial institution accounts that, at times during the year, may exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation (FDIC) up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:FederalDepositInsuranceCorporationPremiumExpense" contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">250,000</ix:nonFraction>. Cash may also be maintained at commercial institutions that are not insured by the FDIC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, <ix:nonFraction unitRef="U_xbrlipure" id="F_000445" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001655759_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="INF" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000446" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001655759_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="INF" scale="-2">100</ix:nonFraction></ix:nonFraction>% of the Company&#8217;s revenue was attributable to three collaborators representing <ix:nonFraction unitRef="U_xbrlipure" id="F_000447" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="INF" scale="-2">37</ix:nonFraction>%, <ix:nonFraction unitRef="U_xbrlipure" id="F_000450" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="INF" scale="-2">32</ix:nonFraction>% and <ix:nonFraction unitRef="U_xbrlipure" id="F_000453" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorThreeMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="INF" scale="-2">31</ix:nonFraction>%, respectively, and one collaborator accounted for the entire accounts receivable balance. For the year ended December&#160;31, 2019, <ix:nonFraction unitRef="U_xbrlipure" id="F_000454" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="INF" scale="-2">57</ix:nonFraction>% of the Company&#8217;s revenue was attributable to a license contributed to Oerth, and two collaborators represented <ix:nonFraction unitRef="U_xbrlipure" id="F_000448" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="INF" scale="-2">19</ix:nonFraction>% and <ix:nonFraction unitRef="U_xbrlipure" id="F_000451" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="INF" scale="-2">16</ix:nonFraction>% of total revenue. For the year ended December&#160;31, 2018, two collaborators each represented over <ix:nonFraction unitRef="U_xbrlipure" id="F_000449" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231" decimals="INF" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000452" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231" decimals="INF" scale="-2">45</ix:nonFraction></ix:nonFraction>% of total revenue.&#160;&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000400" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its marketable securities as available-for-sale securities, which are carried at their fair value based on the quoted market prices of the securities with unrealized gains and losses reported as accumulated other comprehensive loss, a separate component of stockholders&#8217;/members&#8217; equity. Realized gains and losses on available-for-sale securities are included in net earnings in the period earned or incurred. </p></ix:nonNumeric><ix:nonNumeric id="F_000401" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Property, Equipment, and Leasehold Improvements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from <ix:nonNumeric id="F_000455" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231" format="ixt-sec:durwordsen">three years</ix:nonNumeric> for office equipment to <ix:nonNumeric id="F_000456" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_arvnLaboratoryEquipmentMember_20200101_20201231" format="ixt-sec:durwordsen">five years</ix:nonNumeric> for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation are removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset. </p></ix:nonNumeric><ix:nonNumeric id="F_000402" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000402_dcnt_8ec037de-d1d5-4689-a4e4-82408be629ff">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.73%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When indications of potential impairments are present, the Company evaluates the carrying value of long-lived assets. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than carrying value. <ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="C_0001655759_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="C_0001655759_20180101_20181231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="C_0001655759_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> such impairments were recorded during 2020, 2019 or 2018. </p>
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000381_dcnt_2881a157-b339-43e1-96b2-4258390091b2" continuedAt="F_000381_dcnt_0a7f19eb-3474-4731-9095-788f3c1581c2"><ix:continuation id="F_000402_dcnt_8ec037de-d1d5-4689-a4e4-82408be629ff">
</ix:continuation><ix:nonNumeric id="F_000403" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company&#8217;s tangible assets are held in the United States. To date, all of the Company&#8217;s revenue has been generated in the United States. </p></ix:nonNumeric><ix:nonNumeric id="F_000404" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000404_dcnt_c8ba76b8-1724-400e-8b8b-cba6d54e0744">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Revenue Recognition and Deferred Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Revenues from Contracts </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue under Accounting Standards Codification (ASC) 606, <span style="font-style:italic;">Revenue from Contracts with Customers.</span> The Company&#8217;s revenue is generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i)&#160;licenses, (ii) research and development activities, and (iii)&#160;participation in joint research and development steering committees. The terms of these agreements may include non-refundable upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones, and royalty payments based on product sales derived from the collaboration. Under ASC&#160;606, the Company evaluates whether the license agreement, research and development services, and participation in research and development steering committees, represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent a combined single performance obligation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research collaboration and license agreements typically include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company determined that the most likely amount to be recognized was zero, against which no constraint was applied. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is recognized ratably over the Company&#8217;s expected performance period under each respective arrangement. The Company makes its best estimate of the period over which the Company expects to fulfill the Company&#8217;s performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 2020, 2019 and 2018, the transaction price allocated to the combined performance obligation identified under the agreements is recognized as revenue on a straight-line basis over the estimated performance period under each respective arrangement. Straight-line basis was considered the best measure of progress in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale&#59; or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by the customer from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to satisfying the above revenue recognition criteria are recorded as a contract liability in the Company&#8217;s accompanying consolidated balance sheets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also recognized revenue under ASC 606 from its contribution of a license to Oerth. See Note 12. </p>
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000381_dcnt_0a7f19eb-3474-4731-9095-788f3c1581c2" continuedAt="F_000381_dcnt_94fd834c-8a5f-49e3-a04d-3bb753aa76a6"><ix:continuation id="F_000404_dcnt_c8ba76b8-1724-400e-8b8b-cba6d54e0744">
</ix:continuation><ix:nonNumeric id="F_000405" name="us-gaap:EquityMethodInvestmentsPolicy" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Equity Method Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, <span style="font-style:italic;">Investments &#8211; Equity Method and Joint Ventures</span>. The Company recognizes its pro-rata share of income and losses in the investment in &#8220;Loss from equity method investment&#8221; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment on the consolidated balance sheet until such investment is reduced to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:EquityMethodInvestments" contextRef="C_0001655759_20201231" decimals="0">0</ix:nonFraction>.</p></ix:nonNumeric><ix:nonNumeric id="F_000406" name="arvn:PreferredUnitWarrantsPolicyPolicyTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Preferred Unit Warrants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred unit warrants issued in conjunction with debt financings were initially recorded at fair value, using a Black-Scholes option pricing model, with a corresponding discount recorded against the face value of the note and a liability. The discount was then accreted against the face value of the note over its remaining term as additional interest expense. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classified warrants to purchase shares of its Series A Redeemable Convertible Preferred Units (Series A Preferred Units) as a liability on its balance sheets as these warrants were free-standing financial instruments that were exercisable for contingently redeemable shares. The preferred unit warrants were recorded in long-term liabilities at fair value, estimated using the Black-Scholes option pricing model, and marked to market at each balance sheet date. The change in carrying value was reported as the change in fair value of warrant liability in the accompanying consolidated statements of operations. The outstanding warrants were exercised in July 2018 and <ix:nonFraction unitRef="U_xbrlishares" id="F_000461" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001655759_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000462" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001655759_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> warrants were outstanding as of December 31, 2020 and 2019.</p></ix:nonNumeric><ix:nonNumeric id="F_000407" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the conversion to a C-corporation, Arvinas LLC was taxed under the provisions of Subchapter K&#8212;Partners and Partnerships of the Internal Revenue Code. Under those provisions, Arvinas LLC did not pay federal or state corporate income taxes on its taxable income. Instead, each member would include net operating income or loss for Arvinas LLC on its individual return. Arvinas LLC was converted to a C-corporation in 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, <span style="font-style:italic;">Accounting for Income Taxes</span>. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has evaluated the effect of ASC 740 guidance related to uncertain income tax positions and concluded that the Company has no significant uncertain income tax positions at December&#160;31, 2020 and 2019. </p></ix:nonNumeric><ix:nonNumeric id="F_000408" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000408_dcnt_436d4b5f-d7e6-481a-8c9e-a10e6a09c33d">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Equity-based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to its IPO, the Company periodically granted incentive units to employees and non-employees, which generally vested over a <span style="-sec-ix-hidden:F_000463">four-year</span> period. The incentive units represented a separate substantive class of equity with defined rights within the limited liability company agreement of Arvinas Holding Company, LLC (the LLC Operating Agreement). The incentive units represented profits interests in the Company, which was an interest in the increase in the value of the entity over the Participation Threshold, as defined in the LLC Operating Agreement and as determined at the time of grant. The holder, therefore, had the right to participate in distributions of profits only in excess of the Participation Threshold. The Participation Threshold was based on the valuation of the common unit on or around the grant date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounted for incentive units granted in accordance with ASC 718, <span style="font-style:italic;">Compensation-Stock Compensation</span> (ASC 718). In accordance with ASC 718, compensation expense is measured at estimated fair value of the incentive units and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures employee, board of director and consultant equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards.&#160;&#160;Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.</p>
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000381_dcnt_94fd834c-8a5f-49e3-a04d-3bb753aa76a6" continuedAt="F_000381_dcnt_474100f7-dea2-456f-b5c9-d4c7f9ab7449"><ix:continuation id="F_000408_dcnt_436d4b5f-d7e6-481a-8c9e-a10e6a09c33d">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies equity-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000409" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense&#59; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites, and consultants&#59; (iii) the cost of acquiring, developing, and manufacturing clinical study materials&#59; (iv) costs associated with preclinical and clinical activities and regulatory operations&#59; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into consulting, research, and other agreements with commercial entities, researchers, universities, and others for the provision of goods and services. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#8217;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.</p></ix:nonNumeric><ix:nonNumeric id="F_000410" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000410_dcnt_0969ef6a-a4a8-4468-9255-e86bcd44bbfe">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 820, <span style="font-style:italic;">Fair Value Measurements and Disclosures</span>, requires disclosure of the fair value of financial instruments held by the Company. ASC 825, <span style="font-style:italic;">Financial Instruments</span>, defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.94%;text-indent:-2.27%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Inputs are based upon observable or quoted prices for identical instruments traded in active markets. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:13.44%;text-indent:-7.78%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#8217;s Level&#160;2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:13.44%;text-indent:-7.78%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities consist of corporate bonds which are adjusted to fair value each balance sheet date, based on quoted prices, which are considered Level&#160;2 inputs (see Note 5). <span style="color:#000000;">During the year ended December 31, 2019, a non-recurring fair value measurement was applied to determine the fair value of the non-cash consideration of <ix:nonFraction unitRef="U_xbrlipure" id="F_000464" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20191231" decimals="INF" scale="-2">50</ix:nonFraction>% equity ownership received related to Oerth. The fair value measurement was determined using an income approach based primarily on utilizing management&#8217;s estimates of future cash flows as inputs, which are considered Level 3 measurements within the above fair value hierarchy.</span></p>
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000381_dcnt_474100f7-dea2-456f-b5c9-d4c7f9ab7449"><ix:continuation id="F_000410_dcnt_0969ef6a-a4a8-4468-9255-e86bcd44bbfe">
</ix:continuation><ix:nonNumeric id="F_000411" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Net Loss per Common Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is computed by dividing net loss, after adjusting for redeemable preferred unit dividends, by the weighted-average number of common shares outstanding during the period. The change in current redemption value of the redeemable preferred units was treated as a deemed dividend for the period during 2018 prior to conversion to common units. Diluted net loss per share was computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common shares. The effect of the conversion of redeemable preferred units into common units was excluded from the computation of diluted net loss per common share for all periods as their effect was antidilutive. Additionally, common share equivalents are excluded from the computation of diluted net loss per common share for all periods as their effect is antidilutive. </p></ix:nonNumeric><ix:nonNumeric id="F_000412" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">New Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13<span style="font-style:italic;">, Financial</span> <span style="font-style:italic;">Instruments &#8211; Credit Losses</span>, which provides a model for recognizing credit losses on financial instruments based on an estimate of current<span style="font-style:italic;"> </span>expected losses, requiring immediate recognition of credit losses expected over the life of a financial instrument. The Company adopted ASU 2016-13 in the first quarter of 2020. The adoption of the standard was immaterial to the accompanying consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s financial statements upon adoption. </p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000382" name="arvn:LicenseAgreementsTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">3. License Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the Company entered into an exclusive license agreement, including the right to grant sublicenses, with Yale University to develop protein degradation technologies. In connection with the execution of this license agreement, the Company made a non-refundable upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="arvn:NonRefundableUpfrontPayment" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20130701_20130731" decimals="0" format="ixt:numdotdecimal">149,511</ix:nonFraction>. In addition to the upfront payment, the Company paid Yale University a License Maintenance Royalty of varying amounts through the fourth anniversary of the license agreement. The minimum annual payment will be&#160;$<ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="arvn:AnnualLicenseFeePayment" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">75,000</ix:nonFraction> until the first sale to a third party of any licensed product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also required to pay Yale University success-based milestones for the development of the protein degradation technologies as well as low single-digit running royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to a minimum royalty payment that ranges from $<ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="us-gaap:PaymentsForRoyalties" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_srtRangeAxis_srtMinimumMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">200,000</ix:nonFraction> to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:PaymentsForRoyalties" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_srtRangeAxis_srtMaximumMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">500,000</ix:nonFraction>. The agreement requires that, if the Company sublicenses the protein degradation technologies to a third party, the Company must pay Yale University a mid-single digit to mid-double digit percentage of Sublicense Income (as defined in the agreement) received on the first licensed product therewith. During 2015, the Company paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="arvn:CollaborativeArrangementSublicensePayment" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_srtRangeAxis_srtMaximumMember_20150101_20151231" decimals="INF" format="ixt:numdotdecimal">750,000</ix:nonFraction> to Yale University for sublicense consideration, representing the maximum amount required to be paid for sublicense consideration for a licensed product and satisfying this obligation. During 2020, 2019 and 2018, the Company paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="arvn:CollaborativeArrangementPayment" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">150,000</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="arvn:CollaborativeArrangementPayment" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">150,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="arvn:CollaborativeArrangementPayment" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">75,000</ix:nonFraction>, respectively, under the license agreement. The Company is also required to reimburse Yale University for patent costs incurred. During 2020, 2019 and 2018, the Company reimbursed Yale University $<ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="arvn:ReimbursementOfPatentRelatedCost" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">196,167</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="arvn:ReimbursementOfPatentRelatedCost" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">352,663</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="arvn:ReimbursementOfPatentRelatedCost" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">216,093</ix:nonFraction>, respectively, for patent costs. </p></ix:nonNumeric><ix:nonNumeric id="F_000383" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000383_dcnt_685a72e0-d1f5-437b-933d-4a9666c9af67">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">4. Research Collaboration and License Agreements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (Bayer Collaboration Agreement) setting forth the Company&#8217;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras, or PROTAC&#174; targeted protein degraders, that mediate for degradation of target proteins (Targets), using the Company&#8217;s proprietary platform technology, which Targets will be selected by Bayer AG, subject to certain exclusions and limitations.&#160;&#160;The Bayer Collaboration Agreement became effective in July 2019. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront non-refundable payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190731" decimals="-5" scale="6">17.5</ix:nonFraction> million in exchange for the use of the Company&#8217;s technology license and a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnResearchFundingPaymentsMember_20190731" decimals="-5" scale="6">1.5</ix:nonFraction> million payment to fund research activities. Bayer is committed to fund an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapTypeOfArrangementAxis_arvnResearchFundingPaymentsMember_20221231" decimals="-5" scale="6">10.5</ix:nonFraction> million through 2022, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnResearchFundingPaymentsMember_20201231" decimals="-5" scale="6">3.0</ix:nonFraction> million was received in 2020. These payments are being recognized over the total estimated period of performance. <span style="Background-color:#FFFFFF;color:#000000;">The Company is also eligible to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnDevelopmentMilestonePaymentsMember_20190731" decimals="INF" scale="6">197.5</ix:nonFraction> million in development milestone payments and up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnSalesBasedMilestonePaymentsMember_20190731" decimals="INF" scale="6">490.0</ix:nonFraction> million in sales-based milestone payments for all designated Targets. In addition, the Company is eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions. </span></p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000383_dcnt_685a72e0-d1f5-437b-933d-4a9666c9af67" continuedAt="F_000383_dcnt_c78dc602-d8ec-4a02-8c99-7390f962296b">

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the Bayer Collaboration Agreement and a Stock Purchase Agreement entered into with Bayer AG at the same time should be evaluated as a combined contract in accordance with ASC 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span>, given that the agreements were entered into at the same time and have the same commercial objective to provide funding to further the Company&#8217;s research utilizing its proprietary technology. The Company identified the elements under the agreements as license and research revenue and the issuance of the common stock. The Company determined the fair value of the shares sold under the Stock Purchase Agreement to be $<ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="arvn:SaleOfStockFairValueOfSharesSold" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnStockPurchaseAgreementMember_20200101_20201231" decimals="-5" scale="6">2.9</ix:nonFraction> million less than the contractual purchase price stipulated in the agreement. In accordance with the applicable accounting guidance in ASC 815-40, <span style="font-style:italic;">Contracts in Entity&#8217;s Own Equity</span>, the Company determined that the sale of stock should be recorded at fair value. Therefore, the Company allocated the additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnStockPurchaseAgreementMember_20200101_20201231" decimals="-5" scale="6">2.9</ix:nonFraction> million of consideration received under the Stock Purchase Agreement to the Bayer Collaboration Agreement given that the <ix:nonFraction unitRef="U_arvnContract" id="F_000487" name="arvn:NumberOfContractsToBeCombined" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnStockPurchaseAgreementMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> contracts were determined to be combined contracts. This amount has, therefore, been added to the total transaction price and was included in initial contract liabilities balances.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.87%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer, Inc. (Pfizer) (the Pfizer Collaboration Agreement). Under the terms of the Pfizer Collaboration Agreement, the Company received an upfront non-refundable payment and certain additional payments totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_20180101_20181231" decimals="-5" scale="6">28.0</ix:nonFraction>&#160;million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the agreement. These payments are being recognized as revenue over the total estimated period of performance. The Company is also eligible to receive up to an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnOptionPaymentsToLicenseAgreementMember_20201231" decimals="INF" scale="6">37.5</ix:nonFraction>&#160;million in non-refundable option payments if Pfizer exercises its options for all targets under the agreement. Pfizer has exercised options for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_us-gaapTypeOfArrangementAxis_arvnOptionExercisedToLicenseAgreementsMember_20201231" decimals="-5" scale="6">4.9</ix:nonFraction> million as of December 31, 2020. The options are recognized as revenue over the estimated period of performance. The Company is also entitled to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnDevelopmentMilestonePaymentsMember_20201231" decimals="INF" scale="6">225</ix:nonFraction> million in development milestone payments and up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnSalesBasedMilestonePaymentsMember_20201231" decimals="INF" scale="6">550</ix:nonFraction> million in sales-based milestone payments for all designated targets under the Pfizer Collaboration Agreement, as well as tiered royalties based on sales. Pfizer paid the Company $<ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_us-gaapTypeOfArrangementAxis_arvnSubstitutionTargetPaymentsMember_20191231" decimals="INF" scale="6">1.2</ix:nonFraction> million in December 2019 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_us-gaapTypeOfArrangementAxis_arvnSubstitutionTargetPaymentsMember_20201231" decimals="INF" scale="6">3.0</ix:nonFraction> million in 2020 relating to adding additional targets into the collaboration. These payments are being recognized over the estimated period of performance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.87%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2015, the Company entered into an Option and License Agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together, Genentech) (the Genentech Agreement). During 2015, the Company received an upfront non-refundable payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_20150901_20151231" decimals="-5" scale="6">11.0</ix:nonFraction>&#160;million in exchange for use of the Company&#8217;s technology license and to fund Genentech-related research as defined within the Genentech Agreement. In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd (the Genentech Modification), amending the Genentech Agreement. Under the Genentech Modification, the Company received additional upfront non-refundable payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_20171101_20171130" decimals="-5" scale="6">34.5</ix:nonFraction>&#160;million to fund Genentech-related research and Genentech has the right to designate up to <ix:nonFraction unitRef="U_arvnTarget" id="F_000497" name="arvn:NumberOfMaximumDesignatedTargets" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_20171101_20171130" decimals="INF" format="ixt-sec:numwordsen">ten</ix:nonFraction> targets. The Company is eligible to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnOptionPaymentsToLicenseAgreementMember_20171130" decimals="-5" scale="6">27.5</ix:nonFraction> million in additional expansion target payments if Genentech exercises its options on all remaining targets. Upfront non-refundable payments are recognized as revenue over the total estimated period of performance. The Company is eligible to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnDevelopmentMilestonePaymentsMember_20171130" decimals="-5" scale="6">44.0</ix:nonFraction>&#160;million per target in development milestone payments, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_us-gaapTypeOfArrangementAxis_arvnRegulatoryMilestonePaymentsMember_20171130" decimals="-5" scale="6">52.5</ix:nonFraction>&#160;million in regulatory milestone payments and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_us-gaapTypeOfArrangementAxis_arvnCommercialMilestonesMember_20171130" decimals="-5" scale="6">60.0</ix:nonFraction> million in commercial milestone payments based on sales as well as tiered royalties based on sales.</p><ix:nonNumeric id="F_000413" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:6pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about contract liabilities, included as deferred revenue in the accompanying Consolidated Balance Sheets, is as follows: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">45,089,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">58,407,407</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized in the period from:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in deferred revenue in previous periods</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">18,651,649</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">14,335,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in deferred revenue as of December 31, 2020 from 2019 were due to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001655759_20200101_20201231" decimals="-5" scale="6">21.8</ix:nonFraction> million of revenue recognized on the research collaboration and license agreements and additions to deferred revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGAndPfizerMember_20200101_20201231" decimals="-5" scale="6">8.5</ix:nonFraction>&#160;million related to the Bayer Collaboration Agreement and Pfizer Collaboration Agreement.  </p><ix:nonNumeric id="F_000414" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate amount of the transaction price allocated to performance obligations that are unsatisfied as of December&#160;31, 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0001655759_20201231" decimals="-5" scale="6">45.1</ix:nonFraction>&#160;million, which is expected to be recognized in the following periods (in millions): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231" decimals="-5" scale="6">19.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_20201231" decimals="-5" scale="6">19.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2023-01-01_20201231" decimals="-5" scale="6">6.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0001655759_20201231" decimals="-5" scale="6">45.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000383_dcnt_c78dc602-d8ec-4a02-8c99-7390f962296b">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000384" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">5. Marketable Securities </p><ix:nonNumeric id="F_000415" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of the Company&#8217;s available-for-sale securities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="16" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Effective</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000516" name="arvn:AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20200101_20201231">2021</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20201231" decimals="0" format="ixt:numdotdecimal">99,596,821</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20201231" decimals="0" format="ixt:numdotdecimal">560,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20201231" decimals="0" format="ixt:numdotdecimal">100,157,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">99,596,821</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">560,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">100,157,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="16" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Effective</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000523" name="arvn:AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnTwoThousandTwentyMaturityMember_20190101_20191231">2020</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnTwoThousandTwentyMaturityMember_20191231" decimals="0" format="ixt:numdotdecimal">145,359,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnTwoThousandTwentyMaturityMember_20191231" decimals="0" format="ixt:numdotdecimal">49,722</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnTwoThousandTwentyMaturityMember_20191231" decimals="0" format="ixt:numdotdecimal">145,409,598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000524" name="arvn:AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20190101_20191231">2021</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20191231" decimals="0" format="ixt:numdotdecimal">126,194,004</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20191231" decimals="0" format="ixt:numdotdecimal">57,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000532" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20191231" decimals="0" format="ixt:numdotdecimal">126,251,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">271,553,880</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">107,576</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">271,661,456</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000416" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets and liabilities measured on a recurring basis as of:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001655759_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="0" format="ixt:numdotdecimal">100,157,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001655759_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="0" format="ixt:numdotdecimal">100,157,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001655759_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231" decimals="0" format="ixt:numdotdecimal">271,661,456</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001655759_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231" decimals="0" format="ixt:numdotdecimal">271,661,456</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The carrying value of account receivable, accounts payable and accrued expenses approximate their fair value due to the short-term nature of these assets and liabilities.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000385" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">6. Property, Equipment and Leasehold Improvements </p><ix:nonNumeric id="F_000417" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and leasehold improvements consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_arvnLaboratoryEquipmentMember_20201231" decimals="0" format="ixt:numdotdecimal">11,100,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_arvnLaboratoryEquipmentMember_20191231" decimals="0" format="ixt:numdotdecimal">8,045,179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231" decimals="0" format="ixt:numdotdecimal">1,233,823</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231" decimals="0" format="ixt:numdotdecimal">865,888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="0" format="ixt:numdotdecimal">6,058,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="0" format="ixt:numdotdecimal">2,809,205</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">18,392,339</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">11,720,272</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">6,132,824</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">3,264,861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and leasehold improvements, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">12,259,515</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">8,455,411</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="us-gaap:Depreciation" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">3,166,139</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="us-gaap:Depreciation" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">1,561,557</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:Depreciation" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">706,000</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </p></ix:nonNumeric><ix:nonNumeric id="F_000386" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000386_dcnt_09480b8b-c0a7-41c3-8958-36c1dd43f7cd">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">7. Right to Use Assets and Liabilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.73%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in the consolidated balance sheets. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.19%;text-indent:5.9%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000386_dcnt_09480b8b-c0a7-41c3-8958-36c1dd43f7cd">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate ranges from <ix:nonFraction unitRef="U_xbrlipure" id="F_000553" name="arvn:PercentageOfIncrementalBorrowingForLleasePayments" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_20201231" decimals="3" scale="-2">3.2</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="U_xbrlipure" id="F_000554" name="arvn:PercentageOfIncrementalBorrowingForLleasePayments" contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_20201231" decimals="3" scale="-2">6.6</ix:nonFraction>%. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Some of the Company&#8217;s leases include options to extend or terminate the lease. The Company includes these options in the recognition of the Company&#8217;s ROU assets and lease liabilities when it is reasonably certain that the Company will exercise the option.<span style="font-family:Times New Roman;color:#000000;"> </span>The Company has operating leases for its corporate office and certain equipment, which expire no later than <ix:nonNumeric id="F_000558" name="arvn:LesseeOperatingLeaseExpirationMonthAndYear" contextRef="C_0001655759_20200101_20201231" format="ixt:datemonthyearen">September 2024</ix:nonNumeric>. The leases have a weighted average remaining term of <ix:nonNumeric id="F_000557" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001655759_20201231" format="ixt-sec:duryear">1.9</ix:nonNumeric> years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000418" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense were as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="us-gaap:OperatingLeaseCost" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">995,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="us-gaap:OperatingLeaseCost" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">817,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;font-family:Times New Roman;">&#160;</p><ix:nonNumeric id="F_000419" name="arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to leases was as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000561" name="us-gaap:OperatingLeasePayments" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">920,158</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="us-gaap:OperatingLeasePayments" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">581,961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental non-cash information:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new lease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">572,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">571,886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-family:Times New Roman;">&#160;</p><ix:nonNumeric id="F_000420" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000420_cnt_1">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of lease liabilities for operating leases as of December 31, 2020 are as follows:</p></ix:nonNumeric><ix:continuation id="F_000420_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000565" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">1,124,684</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000566" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">1,108,065</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000567" name="arvn:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">12,041</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000568" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">2,244,790</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">204,529</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000570" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">2,040,261</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p></ix:continuation>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to January 1, 2019, the Company accounted for its leases in accordance with ASC Topic 840, Leases. At December 31, 2018, the Company was committed under operating leases for its corporate office and certain equipment. Total rent expense under operating leases for the year ended December 31, 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">606,538</ix:nonFraction>. </p></ix:continuation><ix:nonNumeric id="F_000387" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">8. Accrued Expenses </p><ix:nonNumeric id="F_000421" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">8,967,126</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">5,810,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000574" name="arvn:AccruedResearchAndDevelopmentExpenseCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">8,113,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000575" name="arvn:AccruedResearchAndDevelopmentExpenseCurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">1,186,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees and other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000576" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">1,779,671</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">605,246</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">18,859,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">7,602,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000388" name="us-gaap:DebtDisclosureTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">9. Long-Term Debt </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2013, the Company entered into a Loan Agreement (Loan) and a Stock Subscription Warrant, with Connecticut Innovations, Incorporated (CII). Under the Loan, the Company could draw up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000580" name="arvn:DebtInstrumentMaximumBorrowingCapacity" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130831" decimals="INF" format="ixt:numdotdecimal">750,000</ix:nonFraction> for the purpose of purchasing laboratory equipment, information technology equipment and leasehold improvements. Leasehold improvements are limited to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000581" name="arvn:DebtInstrumentMaximumBorrowingCapacity" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130831" decimals="INF" format="ixt:numdotdecimal">100,000</ix:nonFraction>. Interest on the Loan was compounded on a <ix:nonNumeric id="F_000582" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20200101_20201231">monthly</ix:nonNumeric> basis at a rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000583" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130831" decimals="INF" scale="-2">7.50</ix:nonFraction>% per annum and was required to be paid on a monthly basis beginning on the date of the first draw of funds for <ix:nonNumeric id="F_000584" name="arvn:DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130801_20130831" format="ixt-sec:durmonth">10</ix:nonNumeric> months, then with principal payments beginning on <ix:nonNumeric id="F_000585" name="us-gaap:DebtInstrumentDateOfFirstRequiredPayment1" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130801_20130831" format="ixt:datemonthdayyearen">June&#160;1, 2015</ix:nonNumeric> and payable monthly until the maturity date of <ix:nonNumeric id="F_000586" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130801_20130831" format="ixt:datemonthdayyearen">July&#160;31, 2019</ix:nonNumeric>. The Company had the ability to prepay the amount due at any time prior to the maturity date without premium or penalty. The Loan was secured by substantially all of the Company&#8217;s assets. As of December&#160;31, 2018, the amount outstanding under the Loan was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="us-gaap:LongTermDebt" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20181231" decimals="0" format="ixt:numdotdecimal">169,610</ix:nonFraction> <span style="color:#000000;">and the total unamortized debt discount on the Loan totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="C_0001655759_20181231" decimals="0" format="ixt:numdotdecimal">7,210</ix:nonFraction>. The Company paid the loan in full in July 2019. Interest expense recorded related to the amortization of the debt discount in the years ended December&#160;31, 2019 and 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000589" name="us-gaap:AmortizationOfFinancingCosts" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">7,210</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000590" name="us-gaap:AmortizationOfFinancingCosts" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">12,359</ix:nonFraction>, respectively.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with an Assistance Agreement with the State of Connecticut (Assistance Agreement) entered into in 2014, under which all the borrowings by the Company were forgiven in accordance with the Assistance Agreement, the Company is required to be located in the State of Connecticut through <ix:nonNumeric id="F_000591" name="arvn:DebtInstrumentMaturityMonthAndYear" contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndFourteenAssistanceAgreementMember_20140101_20141231" format="ixt:datemonthyearen">January 2024</ix:nonNumeric>, with a default penalty of repayment of the full original funding amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000592" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndFourteenAssistanceAgreementMember_20141231" decimals="INF" scale="6">2.5</ix:nonFraction>&#160;million plus liquidated damages of <ix:nonFraction unitRef="U_xbrlipure" id="F_000593" name="arvn:PercentageOfLiquidatedDamages" contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndFourteenAssistanceAgreementMember_20140101_20141231" decimals="3" scale="-2">7.5</ix:nonFraction>%. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company entered into an Assistance Agreement with the State of Connecticut (2018 Assistance Agreement) to provide funding for the expansion and renovation of laboratory and office space (Project). Under the terms of the 2018 Assistance Agreement, the Company could borrow from the State of Connecticut a maximum of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000594" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180630" decimals="INF" scale="6">2.0</ix:nonFraction>&#160;million, provided that the funding does not exceed more than <ix:nonFraction unitRef="U_xbrlipure" id="F_000595" name="arvn:PercentageOfMaximumFundingOnProjectCosts" contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180601_20180630" decimals="INF" scale="-2">50</ix:nonFraction>% of the total Project costs. In September 2018, the Company borrowed $<ix:nonFraction unitRef="U_iso4217USD" id="F_000596" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180930" decimals="INF" scale="6">2.0</ix:nonFraction> million under the 2018 Assistance Agreement, bearing interest at <ix:nonFraction unitRef="U_xbrlipure" id="F_000597" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180930" decimals="INF" scale="-2">3.25</ix:nonFraction>% per annum and interest payments will be required for the first <ix:nonNumeric id="F_000598" name="arvn:DebtInstrumentInterestPaymentsTerm" contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930" format="ixt-sec:durmonth">60</ix:nonNumeric> months from the funding date. Thereafter, the loan begins to fully amortize through month 120, maturing in <ix:nonNumeric id="F_000600" name="arvn:DebtInstrumentMaturityMonthAndYear" contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930" format="ixt:datemonthyearen">June 2028</ix:nonNumeric>. According to the terms of the 2018 Assistance Agreement, up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000601" name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930" decimals="INF" scale="6">1.0</ix:nonFraction>&#160;million of the funding can be forgiven if the Company meets certain employment conditions, as defined in the agreement. The Company may also be required to prepay a portion of the loan if the employment conditions are not met. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through <ix:nonNumeric id="F_000602" name="arvn:DebtInstrumentMaturityMonthAndYear" contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930" format="ixt:datemonthyearen">June 2028</ix:nonNumeric> with a default penalty of repayment of the full original funding amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000603" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180930" decimals="INF" scale="6">2.0</ix:nonFraction>&#160;million plus liquidated damages of <ix:nonFraction unitRef="U_xbrlipure" id="F_000604" name="arvn:PercentageOfLiquidatedDamages" contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930" decimals="3" scale="-2">7.5</ix:nonFraction>% of the total amount of funding received. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000422" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anticipated future minimum payments on long-term debt as of December&#160;31, 2020 are: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000605" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">92,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000606" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">377,516</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000607" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">389,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beyond 5 years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000608" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">1,140,034</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000609" name="us-gaap:LongTermDebt" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">2,000,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020, 2019 and 2018, interest expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000610" name="us-gaap:InterestExpenseDebt" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">65,000</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000611" name="us-gaap:InterestExpenseDebt" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">85,569</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000612" name="us-gaap:InterestExpenseDebt" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">57,440</ix:nonFraction>, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000389" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000389_dcnt_3cb385fe-ee68-4ea1-8836-0c592b3ef7e6">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">10. Members&#8217; Equity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Common Units </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each common unit entitled the holder to <ix:nonNumeric id="F_000613" name="us-gaap:CommonStockVotingRights" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_arvnCommonUnitsMember_20200101_20201231">one</ix:nonNumeric> vote on all matters submitted to a vote of the Company&#8217;s members. As noted in Note 1, in September 2018, all issued and outstanding common units were converted into common stock.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Preferred Units </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2013 and 2014, Arvinas, Inc. sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000614" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredStockMember_20130101_20141231" decimals="INF" format="ixt:numdotdecimal">22,463,665</ix:nonFraction> shares of Series A Redeemable Convertible Preferred Stock (Series A Preferred Stock) for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000616" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredStockMember_20130101_20141231" decimals="-5" scale="6">15.3</ix:nonFraction>&#160;million at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000618" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredStockMember_20141231" decimals="4">0.6811</ix:nonFraction> per share. The Series A Preferred Stock was subsequently exchanged for Series A Preferred Units in Arvinas LLC upon the reorganization. During 2015, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000615" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20150101_20151231" decimals="INF" format="ixt:numdotdecimal">24,977,489</ix:nonFraction> Series B Redeemable Convertible Preferred Units (Series B Preferred Units) in exchange for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000617" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20150101_20151231" decimals="-5" scale="6">41.6</ix:nonFraction>&#160;million at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000619" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20151231" decimals="4">1.6659</ix:nonFraction> per share.<span style="Background-color:#FFFFFF;color:#000000;"> </span><span style="Background-color:#FFFFFF;color:#000000;">In March 2018, the Company entered into a Series C Preferred Unit Purchase Agreement (the Series C Agreement) to raise additional equity. Under the terms of the Series C Agreement, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000620" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180301_20180331" decimals="INF" format="ixt:numdotdecimal">16,467,066</ix:nonFraction> units of Series C Redeemable Convertible Preferred Units (Series C Preferred Units) for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000621" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180301_20180331" decimals="-5" scale="6">55.0</ix:nonFraction> million at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000622" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180331" decimals="2">3.34</ix:nonFraction> per unit. </span>As noted in Note 1, in September 2018, after giving effect of the <ix:nonFraction unitRef="U_xbrlipure" id="F_000623" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001655759_20180901_20180930" decimals="2">3.25</ix:nonFraction> to 1 reverse split, all issued and outstanding preferred units were converted into preferred stock and subsequently into common stock upon the closing of the IPO.</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000389_dcnt_3cb385fe-ee68-4ea1-8836-0c592b3ef7e6">
</ix:continuation><ix:nonNumeric id="F_000390" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000390_dcnt_0372ad27-0cd8-422f-91fa-f3fd33fccd20">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">11. Equity </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During December 2020, the Company completed a public offering in which the Company issued and sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000624" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201201_20201231" decimals="INF" format="ixt:numdotdecimal">6,571,428</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000625" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201231" decimals="INF">70.00</ix:nonFraction> per share, which resulted in aggregate net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000626" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201201_20201231" decimals="-5" scale="6">431.9</ix:nonFraction> million, net of underwriter discounts, commissions and offering costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="us-gaap:PaymentsForUnderwritingExpense" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201201_20201231" decimals="-5" scale="6">28.1</ix:nonFraction> million.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company entered into an Equity Distribution Agreement (Distribution Agreement) with Piper Sandler Companies, formerly Piper Jaffray &#38; Co. (Piper Sandler), pursuant to which the Company may offer and sell from time-to-time in an &#8220;at-the-market offering,&#8221; at its option, up to an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000628" name="arvn:MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPiperSandlerMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20191031" decimals="INF" scale="6">100.0</ix:nonFraction> million of shares of the Company&#8217;s common stock through Piper Sandler, as sales agent. During year ended December 31, 2020, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000629" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPiperSandlerMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,593,637</ix:nonFraction> shares of its common stock resulting in proceeds to the Company of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000630" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPiperSandlerMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231" decimals="-5" scale="6">64.1</ix:nonFraction> million, net of offering costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000631" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPiperSandlerMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231" decimals="-5" scale="6">1.6</ix:nonFraction> million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2019, the Company completed a public offering in which the Company issued and sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000632" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191101_20191130" decimals="INF" format="ixt:numdotdecimal">5,227,273</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000633" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191130" decimals="INF">22.00</ix:nonFraction> per share. The Company&#8217;s aggregate gross proceeds from the sale of shares in the public offering was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000634" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191101_20191130" decimals="-5" scale="6">115.0</ix:nonFraction> million before fees and expenses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000635" name="us-gaap:PaymentsForUnderwritingExpense" contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191101_20191130" decimals="-5" scale="6">7.4</ix:nonFraction> million.</span><span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company entered into a Stock Purchase Agreement with Bayer AG pursuant to which, in connection with the closing in July 2019, the Company issued and sold to Bayer AG <ix:nonFraction unitRef="U_xbrlishares" id="F_000636" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190701_20190731" decimals="INF" format="ixt:numdotdecimal">1,346,313</ix:nonFraction> shares of the Company&#8217;s common stock (the Shares) for a contractually stated purchase price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000637" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190701_20190731" decimals="-5" scale="6">32.5</ix:nonFraction> million. The value of the shares of the Company&#8217;s common stock was based on the average of the Company&#8217;s<span style="font-size:12pt;"> </span>common stock for the preceding <ix:nonNumeric id="F_000638" name="arvn:ShareBasedCompensationArrangementAverageCommonStockPrecedingDays" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190701_20190731" format="ixt-sec:durday">60</ix:nonNumeric> days prior to the signing of the Stock Purchase Agreement plus a <ix:nonFraction unitRef="U_xbrlipure" id="F_000639" name="arvn:PriorToStockPurchaseAgreementPremium" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190701_20190731" decimals="2" format="ixt-sec:numwordsen" scale="-2">fifteen</ix:nonFraction> percent premium. On October 1, 2019, the Company filed a registration statement covering these shares. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Share-based Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the 2018 ESPP) initially providing participating employees with the opportunity to purchase an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000640" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20180930" decimals="INF" format="ixt:numdotdecimal">311,850</ix:nonFraction> shares of the Company&#8217;s common stock. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000641" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190101" decimals="INF" format="ixt:numdotdecimal">323,377</ix:nonFraction> shares, equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000644" name="arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190101_20190101" decimals="2" scale="-2">1</ix:nonFraction>% of the Company&#8217;s then-outstanding common stock, effective as of January 1, 2019, and by an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000642" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101" decimals="INF" format="ixt:numdotdecimal">390,371</ix:nonFraction> shares, equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000643" name="arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20200101" decimals="2" scale="-2">1</ix:nonFraction>% of the Company&#8217;s then-outstanding common stock, effective as of January 1, 2020. The first offering period under the 2018 ESPP commenced on January 1, 2020. During the year ended December 31, 2020, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000645" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">11,046</ix:nonFraction> shares of common stock under the 2018 ESPP. As of December 31, 2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_000646" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,014,552</ix:nonFraction> shares remained available for purchase.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the Company&#8217;s employees are eligible to participate in the 2018 ESPP, provided they meet certain employment requirements. On each offering commencement date, each participant will be granted the right to purchase, on the last business day of the offering period, a number of shares of the Company&#8217;s common stock determined by multiplying $<ix:nonFraction unitRef="U_iso4217USD" id="F_000647" name="arvn:AmountUsedAsMultiplyingFactorToGrantCommonStock" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">2,083</ix:nonFraction> by the number of full months in the offering period and dividing that product by the closing price of the Company&#8217;s common stock on the first day of the offering period. On the commencement date of each offering period, each eligible employee may authorize up to a maximum of <ix:nonFraction unitRef="U_xbrlipure" id="F_000648" name="arvn:MaximumPercentageOfCompensationReceivableByEmployee" contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="INF" scale="-2">15</ix:nonFraction>% of the compensation he or she receives during the offering period to be deducted by the Company during the offering period. Under the terms of the 2018 ESPP, the purchase price shall be determined by the Company&#8217;s board of directors for each offering period and will be at least <ix:nonFraction unitRef="U_xbrlipure" id="F_000650" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="INF" scale="-2">85</ix:nonFraction>% of the applicable closing price of the Company&#8217;s common stock. If the Company&#8217;s board of directors does not make a determination of the purchase price, the purchase price will be <ix:nonFraction unitRef="U_xbrlipure" id="F_000649" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="INF" scale="-2">85</ix:nonFraction>% of the lesser of the closing price of the Company&#8217;s common stock on the first business day of the offering period or the last business day of the offering period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the Fourth Amendment to the Company&#8217;s Incentive Share Plan (the Incentive Plan) adopted in March 2018, the Company was authorized to issue up to an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000651" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180331" decimals="INF" format="ixt:numdotdecimal">6,199,477</ix:nonFraction> incentive units pursuant to the Incentive Plan. Generally, incentive units were granted at no less than fair value as determined by the board of managers and had vesting periods ranging from <ix:nonNumeric id="F_000652" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180301_20180331" format="ixt-sec:durwordsen" continuedAt="C_3763dc41-56cc-4323-a013-9542d0b96c11">one</ix:nonNumeric> to <ix:nonNumeric id="F_000653" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180301_20180331" format="ixt-sec:durwordsen">four<ix:continuation id="C_3763dc41-56cc-4323-a013-9542d0b96c11"> years</ix:continuation></ix:nonNumeric>. The Incentive Plan was terminated in <span style="-sec-ix-hidden:F_000654">September 2018</span>. In September 2018, the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the 2018 Stock Incentive Plan (the 2018 Plan), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#8217;s IPO. The number of common shares initially available for issuance under the 2018 Plan equaled the sum of (1) <ix:nonFraction unitRef="U_xbrlishares" id="F_000655" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20180930" decimals="INF" format="ixt:numdotdecimal">4,067,007</ix:nonFraction> shares of common stock&#59; plus (2) the number of shares of common stock (up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000656" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180930" decimals="INF" format="ixt:numdotdecimal">1,277,181</ix:nonFraction>) issued in respect of incentive units granted under the Incentive Plan that are subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right&#59; plus (3) an annual </p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000390_dcnt_0372ad27-0cd8-422f-91fa-f3fd33fccd20" continuedAt="F_000390_dcnt_e22da8df-dddc-4b25-af8d-6fa78ab234b7">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increase on the first day of each fiscal year beginning with the fiscal year end</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019 and continuing to, and including, the fiscal year ending December 31, 2028, equal to the lowest of </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000657" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">4,989,593</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of the Company&#8217;s common stock, </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000658" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20190101_20191231" decimals="2" scale="-2">4</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of the number of shares of the Company&#8217;s common stock outstanding on the first day of the fiscal year and an amount determined by the Company&#8217;s board of directors.</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The increase in the number of authorized shares for the fiscal year</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ending December 31, </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 and </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 was</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000659" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,561,485</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000660" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">1,293,510</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;Common shares subject to outstanding equity awards that expire or are terminated, surrendered, or cancel</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed without having been fully exercised or are forfeited in whole or in part shall be available for future grants of awards.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2018, the Company granted <ix:nonFraction unitRef="U_xbrlishares" id="F_000661" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">1,715,368</ix:nonFraction> incentive units to employees and directors under the Incentive Plan. In September 2018, each outstanding incentive unit was converted into a number of shares of common stock based upon the IPO price. Certain of the shares of common stock issued in respect of incentive units continue to be subject to vesting in accordance with the vesting schedule that was applicable to such incentive units. The Company granted <ix:nonFraction unitRef="U_xbrlishares" id="F_000662" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930" decimals="INF" format="ixt:numdotdecimal">1,253,263</ix:nonFraction> restricted shares to employees and directors as part of the conversion. The Company also granted <ix:nonFraction unitRef="U_xbrlishares" id="F_000663" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930" decimals="INF" format="ixt:numdotdecimal">1,744,650</ix:nonFraction> stock options to purchase shares of common stock to employees and directors who were holders of incentive units at the time of the incentive unit conversion. <span style="color:#000000;">In September 2018, in connection with the conversion of the incentive units, the Company granted <ix:nonFraction unitRef="U_xbrlishares" id="F_000664" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930" decimals="INF" format="ixt:numdotdecimal">11,097</ix:nonFraction> restricted shares of common stock and <ix:nonFraction unitRef="U_xbrlishares" id="F_000665" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnConsultantsMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930" decimals="INF" format="ixt:numdotdecimal">251,010</ix:nonFraction> stock options to purchase shares of common stock to consultants.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2020, 2019 and 2018, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">30,230,858</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">20,072,710</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">11,630,300</ix:nonFraction>, respectively, of total compensation expense for awards classified as equity awards related to its stock options, restricted stock awards and restricted stock units. At December 31, 2020, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">22,647,241</ix:nonFraction> of compensation expense that is expected to be recognized over a weighted average period of approximately <ix:nonNumeric id="F_000670" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001655759_20200101_20201231" format="ixt-sec:duryear">2</ix:nonNumeric> years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000423" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the stock options granted during each of the years was determined using the Black-Scholes option pricing model with the following assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000671">70% - 75%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000672">69% - 71%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000673">68% - 70%</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000677">5.3 - 7.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000678">5.5 - 7.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000679">5.0 - 10.0</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000683">0.3% - 1.6%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000684">1.4% - 2.7%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000685">2.6% - 3.1%</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000689" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2" scale="-2">0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000690" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2" scale="-2">0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000691" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="2" scale="-2">0</ix:nonFraction>%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000692">$22.70 - $50.00</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000693">$17.29 - $37.66</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000694">$14.44 - $16.24</span></p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the Company&#8217;s common stock has not been trading for a sufficient period of time, the Company utilizes a collection of volatilities of peer companies to estimate the expected volatility of its common stock. The expected term is calculated utilizing the simplified method. </p><ix:nonNumeric id="F_000424" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity under the 2018 Plan as of December 31, 2020 is presented below. These amounts include stock options granted to employees, directors and consultants.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Stock Options</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Term (Years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000698" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20191231" decimals="INF" format="ixt:numdotdecimal">3,432,198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000704" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20191231" decimals="2">18.05</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000699" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,424,402</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000705" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231" decimals="2">43.67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000700" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">447,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000706" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231" decimals="2">17.76</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000701" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">87,605</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000707" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231" decimals="2">26.94</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000702" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">4,321,882</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000708" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231" decimals="2">26.35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000710">8.4</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000712" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231" decimals="0" format="ixt:numdotdecimal">253,193,160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000703" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,665,452</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000709" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231" decimals="2">17.50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000711">7.9</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000713" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231" decimals="0" format="ixt:numdotdecimal">112,307,482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in the stock options granted in the table above are options to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000714" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001655759_20180901_20180930" decimals="INF" format="ixt:numdotdecimal">1,995,660</ix:nonFraction> shares of common stock that were granted to employees, directors, and consultants granted at the time of the incentive unit conversion in September 2018 that have the same vesting terms as the profit units that were outstanding in September 2018 before the profit interests were converted into common stock. At the time of issuance of the stock options, <ix:nonFraction unitRef="U_xbrlishares" id="F_000715" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001655759_20180930" decimals="INF" format="ixt:numdotdecimal">357,658</ix:nonFraction> stock options to purchase shares of common stock became immediately vested, resulting in stock compensation expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000716" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180901_20180930" decimals="0" format="ixt:numdotdecimal">3,627,507</ix:nonFraction>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000390_dcnt_e22da8df-dddc-4b25-af8d-6fa78ab234b7">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of options granted during the years ended December 31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000717" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001655759_20200101_20201231" decimals="2">27.45</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000718" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001655759_20190101_20191231" decimals="2">13.28</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000719" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001655759_20180101_20181231" decimals="2">9.88</ix:nonFraction>, respectively. The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018 was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000720" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001655759_20200101_20201231" decimals="-5" scale="6">19.4</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000721" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001655759_20190101_20191231" decimals="-5" scale="6">1.9</ix:nonFraction> million and <ix:nonFraction unitRef="U_iso4217USD" id="F_000722" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001655759_20180101_20181231" decimals="-6" format="ixt-sec:numwordsen" scale="6">zero</ix:nonFraction>, respectively. The excess tax benefit classified as a financing cash flow was not significant for any of the periods presented.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000723" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231" decimals="-5" scale="6">21.5</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock options granted under the 2018 Plan is expected to be recognized over the next <ix:nonNumeric id="F_000724" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">two years</ix:nonNumeric>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000425" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000425_cnt_1">A summary of the restricted stock grant activity under the Incentive Plan as of December 31, 2020 is presented below. These amounts include restricted stock granted to employees, directors and consultants.</ix:nonNumeric> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p><ix:continuation id="F_000425_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Restricted Stock Awards</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000725" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20191231" decimals="INF" format="ixt:numdotdecimal">576,074</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000729" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20191231" decimals="2">16.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000726" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">325,818</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000730" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231" decimals="2">16.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000727" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">11,544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000731" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231" decimals="2">16.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000728" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">238,712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000732" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20201231" decimals="2">16.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:67.78%;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000426" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of restricted stock unit activity under the 2018 Plan for the year ended December 31, 2020 is presented below. These amounts include restricted stock units granted to employees.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Restricted Stock Units</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000733" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20191231" decimals="INF" format="ixt:numdotdecimal">181,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000737" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20191231" decimals="2">20.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000734" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">45,346</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000738" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231" decimals="2">20.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000735" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,977</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000739" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231" decimals="2">19.36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000736" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">133,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000740" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231" decimals="2">20.01</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000742" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber" contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">217,232</ix:nonFraction> restricted shares under the Incentive Plan, <ix:nonFraction unitRef="U_xbrlishares" id="F_000741" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">4,053,998</ix:nonFraction> stock options under the 2018 Plan, and <ix:nonFraction unitRef="U_xbrlishares" id="F_000743" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">114,243</ix:nonFraction> restricted stock units under the 2018 Plan that have vested or are expected to vest. </p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000391" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000391_dcnt_2faddf7f-6ee7-47ae-9a58-0ce41709a82b">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">12. Investment in Equity Method Investee</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company entered into an agreement to establish a joint venture (Commitment Agreement) with Bayer CropScience LP (Bayer LP) to <span style="color:#000000;">research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture</span>. In July 2019, the Company and Bayer LP completed the formation of the joint venture entity, Oerth. <span style="color:#000000;">Pursuant to the terms of the Commitment Agreement, the Company made an in-kind intellectual property contribution to Oerth in the form of a license to certain of the Company&#8217;s proprietary technology. Bayer LP has made a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000744" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerCropScienceLPMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231" decimals="-5" scale="6">56.0</ix:nonFraction> million total cash commitment to Oerth, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000745" name="arvn:EquityMethodInvestmentContribution" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerCropScienceLPMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20200101_20201231" decimals="-5" scale="6">16.0</ix:nonFraction> million of which Bayer LP has contributed to Oerth during the quarter ended September 30, 2019, and an in-kind intellectual property contribution. The Company and Bayer LP each hold an ownership interest in Oerth initially representing <ix:nonFraction unitRef="U_xbrlipure" id="F_000746" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerCropScienceLPMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231" decimals="INF" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000747" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231" decimals="INF" scale="-2">50</ix:nonFraction></ix:nonFraction>% of the ownership interests. A <ix:nonFraction unitRef="U_xbrlipure" id="F_000748" name="arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231" decimals="2" scale="-2">15</ix:nonFraction>% ownership interest of Oerth is reserved for the future grant of incentive units to employees and service providers of Oerth. </span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Commitment Agreement, the Company has no obligation to provide any additional funding and the Company&#8217;s ownership interest will not be diluted from future contributions from Bayer LP. The Company has no exposure to future losses of Oerth. The activities of Oerth are controlled by a management board under the joint control of the Company and Bayer LP. As Oerth is jointly controlled by the Company and Bayer LP, the Company accounts for its <ix:nonFraction unitRef="U_xbrlipure" id="F_000749" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerCropScienceLPMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231" decimals="INF" scale="-2">50</ix:nonFraction>% interest using the equity method of accounting. The Company determined that Oerth is a variable interest entity and, accordingly, the Company has evaluated the significant activities of Oerth under the variable interest entity model and concluded that the significant activities consist primarily of research and development activities and, as the Company does not have the sole power to direct such activities, the Company is not the primary beneficiary.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will also provide to Oerth compensated research and development services and administrative services through a separate agreement. The services rendered by the Company during the years ended December 31, 2020 and 2019 were insignificant.</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000391_dcnt_2faddf7f-6ee7-47ae-9a58-0ce41709a82b">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the fair value of the equity interest it received in Oerth in exchange for the license contributed was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000750" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231" decimals="-5" scale="6">49.4</ix:nonFraction> million. The fair value of Oerth was determined utilizing discounted cash flows based on reasonable estimates and assumptions of cash flows expected from Oerth.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000751" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20200101_20201231" decimals="-5" scale="6">24.7</ix:nonFraction> million attributable to the license contributed to Oerth and eliminated the remaining $<ix:nonFraction unitRef="U_iso4217USD" id="F_000752" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231" decimals="-5" scale="6">24.7</ix:nonFraction> million which corresponds to the Company&#8217;s <ix:nonFraction unitRef="U_xbrlipure" id="F_000753" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231" decimals="2" scale="-2">50</ix:nonFraction>% ownership in Oerth. The Company determined that the amount that was eliminated represents intra-entity profit which should be deferred until realized by Oerth. The deferral will be recognized if and when Oerth recognizes revenue associated with the license. Until such time, the remaining $<ix:nonFraction unitRef="U_iso4217USD" id="F_000754" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231" decimals="-5" scale="6">24.7</ix:nonFraction> million of revenue is indefinitely deferred and excluded from the results of operations of the Company. The amount recognized as revenue was treated as such because the licensing of its technology in connection with the formation of a joint venture is part of the Company&#8217;s major ongoing or central operations, as evidenced by previous licensing agreements.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses and net loss of Oerth for 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000756" name="arvn:EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20200101_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000758" name="us-gaap:ProfitLoss" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20200101_20201231" decimals="-5" scale="6">8.3</ix:nonFraction></ix:nonFraction> million. Total operating expenses and net loss of Oerth for 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="arvn:EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20190101_20191231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000757" name="us-gaap:ProfitLoss" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20190101_20191231" decimals="-5" scale="6">49.8</ix:nonFraction></ix:nonFraction> million, which included research and development expenses equal to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000759" name="arvn:EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20200101_20201231" decimals="-5" scale="6">49.4</ix:nonFraction> million for the fair value of the license acquired from Arvinas. The Company&#8217;s initial investment in Oerth was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000762" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231" decimals="-5" scale="6">49.4</ix:nonFraction> million which represented the fair value of shares received in exchange for the contribution of the license. The elimination of the intra-entity profit component of the revenue resulted in a reduction in the balance of the investment in Oerth, bringing its initial carrying value of the investment to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000763" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231" decimals="-5" scale="6">24.7</ix:nonFraction> million. During 2019, the Company recorded equity method losses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000760" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20190101_20191231" decimals="-5" scale="6">24.7</ix:nonFraction> million based on its proportionate share of ownership. After recognition of its proportionate share of Oerth&#8217;s losses for the period the carrying value of the investment as of December 31, 2019 was reduced to $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000764" name="us-gaap:EquityMethodInvestments" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20191231" decimals="0">0</ix:nonFraction></span>, and, as a result, <ix:nonFraction unitRef="U_iso4217USD" id="F_000761" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> additional losses were recorded against the carrying value of the investment during the year ended December 30, 2020.</p></ix:continuation><ix:nonNumeric id="F_000392" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000392_dcnt_0f4ba605-cb81-4587-9ac1-0f158b40d05e">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">13. Income Taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has had <ix:nonFraction unitRef="U_iso4217USD" id="F_000765" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000766" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> income tax expense due to operating losses incurred for the years ended December 31, 2020 and 2019. The Company has also not recorded any income tax benefits for the net operating losses incurred in each period due to its uncertainty of realizing a benefit from those items. All of the Company&#8217;s losses before income taxes were generated in the United States.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p><ix:nonNumeric id="F_000427" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000427_dcnt_fc50f854-f4ed-48d9-9b36-0a38e37da53a">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2020, 2019 and 2018 is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000767" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001655759_20200101_20201231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000768" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001655759_20190101_20191231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000769" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001655759_20180101_20181231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal research tax credit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000770" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001655759_20200101_20201231" decimals="3" scale="-2">4.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000771" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001655759_20190101_20191231" decimals="3" scale="-2">3.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000772" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001655759_20180101_20181231" decimals="3" scale="-2">2.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000773" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001655759_20200101_20201231" decimals="3" sign="-" scale="-2">1.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000774" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001655759_20190101_20191231" decimals="3" sign="-" scale="-2">2.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000775" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001655759_20180101_20181231" decimals="3" sign="-" scale="-2">3.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000776" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001655759_20200101_20201231" decimals="3" sign="-" scale="-2">23.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000777" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001655759_20190101_20191231" decimals="3" sign="-" scale="-2">22.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000778" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001655759_20180101_20181231" decimals="3" sign="-" scale="-2">20.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000779" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001655759_20200101_20201231" decimals="3" sign="-" scale="-2">0.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000780" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001655759_20190101_20191231" decimals="3" sign="-" scale="-2">0.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000781" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001655759_20180101_20181231" decimals="3" scale="-2">0.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000782" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001655759_20200101_20201231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000783" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001655759_20190101_20191231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000784" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001655759_20180101_20181231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
</ix:nonNumeric></ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000392_dcnt_0f4ba605-cb81-4587-9ac1-0f158b40d05e"><ix:continuation id="F_000427_dcnt_fc50f854-f4ed-48d9-9b36-0a38e37da53a">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and tax reporting purposes. <ix:nonNumeric id="F_000428" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000428_cnt_1">Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities are as follows at December&#160;31, 2020 and 2019:</ix:nonNumeric> </p><ix:continuation id="F_000428_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss carryforwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000785" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">43,074,539</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000786" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">21,733,983</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000787" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">8,978,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000788" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">7,871,790</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000789" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">10,070,208</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000790" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">5,121,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000791" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">5,038,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000792" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">3,580,768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000793" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">172,170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000794" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">183,118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred income tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000795" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">67,334,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000796" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">38,491,303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000797" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">43,103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000798" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">35,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000799" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">2,377,997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000800" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">1,293,932</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred income tax liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000801" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">2,421,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000802" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">1,328,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000803" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001655759_20201231" decimals="0" format="ixt:numdotdecimal">64,913,202</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000804" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001655759_20191231" decimals="0" format="ixt:numdotdecimal">37,162,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred income tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has provided a valuation allowance against the full amount of the deferred tax assets since, in the opinion of management, based upon the history of losses of the Company, it is more likely than not that the benefits will not be realized. All or a portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to utilize these potential tax benefits. The valuation allowance increased by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000805" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231" decimals="-5" scale="6">27.8</ix:nonFraction>&#160;million in 2020 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000806" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231" decimals="-5" scale="6">15.4</ix:nonFraction>&#160;million in 2019 due to the increase in the net operating loss carryforwards, stock compensation expense and research and development tax credits. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000807" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">205.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000808" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-5" scale="6">103.5</ix:nonFraction>&#160;million of federal net operating loss carryforwards as of December&#160;31, 2020 and 2019, respectively. Federal net operating loss carryforwards as of December 31, 2017 expire at various dates through fiscal year <ix:nonNumeric id="F_000809" name="arvn:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"><ix:nonNumeric id="F_000810" name="arvn:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">2037</ix:nonNumeric></ix:nonNumeric> and federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such carryforwards is limited to <ix:nonFraction unitRef="U_xbrlipure" id="F_000811" name="arvn:OperatingLossesCarryForwardMaximumDeductibilityPercentage" contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231" decimals="2" scale="-2">80</ix:nonFraction>% of the Company&#8217;s taxable income in the year in which carryforwards are used. <ix:nonNumeric id="F_000812" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">The Company believes the federal net operating losses are subject to an annual limitation as a result of changes in the Company&#8217;s ownership, as defined by Federal Internal Revenue Code Section 382, in November 2019. Notwithstanding the limitations, the Company expects the federal net operating losses to be fully available under Section 382 within the next two years.</ix:nonNumeric> The Company had approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000813" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">10.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000814" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-5" scale="6">5.1</ix:nonFraction>&#160;million of federal tax credit carryforwards as of December&#160;31, 2020 and 2019, respectively, which expire at various dates through fiscal year <ix:nonNumeric id="F_000815" name="arvn:TaxCreditCarryforwardExpirationYear" contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"><ix:nonNumeric id="F_000816" name="arvn:TaxCreditCarryforwardExpirationYear" contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">2040</ix:nonNumeric></ix:nonNumeric>. The Company estimates that its federal credits will not be subject to the Section 382 limitation and the federal tax credits will be available to offset future federal income tax within the next two years.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company complies with the provisions of ASC 740 in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense. The Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000817" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001655759_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000818" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001655759_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> accruals for interest and penalties at December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to file income tax returns in the U.S. Federal jurisdiction, and in the States of Connecticut, Massachusetts and North Carolina. The Company is a state franchise taxpayer due to the Company&#8217;s loss position. As a result, there is <ix:nonFraction unitRef="U_iso4217USD" id="F_000819" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> state income tax provision included in the financial statements. The <ix:nonNumeric id="F_000820" name="us-gaap:IncomeTaxExaminationYearUnderExamination" contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2016</ix:nonNumeric> tax year forward remain subject to future examinations by the applicable taxing authorities.  </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 20</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20, 2019</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 201</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company recorded a benefit from expected cash refunds to be provided by the State of Connecticut, equal to </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000821" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231" decimals="2" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000822" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231" decimals="2" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000823" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20180101_20181231" decimals="2" scale="-2">65</ix:nonFraction></ix:nonFraction></ix:nonFraction>%</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of research and development credits, of</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000826" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="C_0001655759_20180101_20181231" decimals="-5" scale="6">1.8</ix:nonFraction></span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000824" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="C_0001655759_20200101_20201231" decimals="-5" scale="6">1.4</ix:nonFraction></span></span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0<ix:nonFraction unitRef="U_iso4217USD" id="F_000825" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="C_0001655759_20190101_20191231" decimals="-5" scale="6">.1 </ix:nonFraction>million</span></span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively, which is included in Other Income in the accompanying consolidated statement of operations and comprehensive loss, due to the Company being a state franchise taxpayer. The benefit results from the exchange of the state research and development tax credit carryforwards for cash refunds. At December&#160;31, </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 201</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company has recorded receivables of</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000827" name="us-gaap:IncomeTaxReceivable" contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" scale="6">3.2</ix:nonFraction></span></span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and $</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000828" name="us-gaap:IncomeTaxReceivable" contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231" decimals="-5" scale="6">1.4</ix:nonFraction><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively, relating to research and development credits due to the Company. </span></p></ix:continuation><ix:nonNumeric id="F_000393" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">14. Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Consulting and Sponsored Research Agreement Commitments </p><ix:nonNumeric id="F_000833" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20200101_20201231"><p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2016, the Company entered into a Corporate Sponsored Research Agreement (SRA) with Yale University, which was amended in April 2018. The amended SRA extended the agreement until April 2021 and amended the scope of work. The amended SRA requires quarterly payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000829" name="arvn:QuarterlyResearchPayments" contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnAmendedCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">250,000</ix:nonFraction> through the end of the agreement. The total payments made under the SRA for 2020, 2019 and 2018 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000830" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000831" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000832" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">851,161</ix:nonFraction>, respectively.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into a consulting agreement with its Chief Scientific Advisor in 2018, which extends into 2021, and requires monthly payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000837" name="arvn:MonthlyResearchPayments" contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">20,833</ix:nonFraction>. During the years ended December&#160;31, 2020, 2019 and 2018, the Company paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000834" name="arvn:PaymentForConsultingService" contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">250,000</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000835" name="arvn:PaymentForConsultingService" contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">250,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000836" name="arvn:PaymentForConsultingService" contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">176,110</ix:nonFraction>, respectively, pursuant to this consulting agreement.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000394" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">15. Net Loss Per Common Share </p><ix:nonNumeric id="F_000429" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per common share were calculated as follows: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000838" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">119,332,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000839" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">70,292,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000840" name="us-gaap:NetIncomeLoss" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">41,480,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in redemption value of preferred units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000841" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">198,366,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common shares &#8211; basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000842" name="arvn:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" contextRef="C_0001655759_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">119,332,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000843" name="arvn:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" contextRef="C_0001655759_20190101_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">70,292,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000844" name="arvn:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" contextRef="C_0001655759_20180101_20181231" decimals="0" sign="-" format="ixt:numdotdecimal">239,847,222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of common shares outstanding, basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000845" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">39,534,497</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000846" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">32,927,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000847" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">9,422,799</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000848" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001655759_20200101_20201231" decimals="2" sign="-">3.02</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000849" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001655759_20190101_20191231" decimals="2" sign="-">2.13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000850" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001655759_20180101_20181231" decimals="2" sign="-">25.45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potential dilutive securities have been excluded from the computation of diluted net loss per common share as the effect would be to reduce the net loss per common share. <ix:nonNumeric id="F_000430" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001655759_20200101_20201231" escape="true" continuedAt="F_000430_cnt_1">The following common share equivalents have been excluded from the calculations of diluted loss per common share because their inclusion would have been antidilutive.</ix:nonNumeric> </p><ix:continuation id="F_000430_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:1pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000851" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">4,321,882</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000852" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">3,432,198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000853" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">2,273,024</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock awards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000854" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">238,712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000855" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">576,074</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000856" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">1,102,289</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000857" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">133,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000858" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">181,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000859" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001655759_20200101_20201231" decimals="0" format="ixt:numdotdecimal">4,693,643</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000860" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001655759_20190101_20191231" decimals="0" format="ixt:numdotdecimal">4,189,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000861" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001655759_20180101_20181231" decimals="0" format="ixt:numdotdecimal">3,375,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p></ix:continuation></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>2
<FILENAME>arvn-ex1034_590.htm
<DESCRIPTION>EX-10.34
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arvn-ex1034_590.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.34</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">FIFTH AMENDMENT TO LEASE </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIS FIFTH AMENDMENT TO LEASE<font style="font-weight:normal;"> (the &#8220;</font>Agreement<font style="font-weight:normal;">&#8221;) is entered into as of this 4th day of January, 2021 by and between </font>SCIENCE PARK DEVELOPMENT CORPORATION<font style="font-weight:normal;">, a Connecticut non stock corporation having its office at 5 Science Park, New Haven, Connecticut 06511 (the &#8220;</font>Landlord<font style="font-weight:normal;">&#8221;), and </font>ARVINAS OPERATIONS, INC.<font style="font-weight:normal;">, f/k/a Arvinas, Inc., a Delaware corporation having a principal place of business at 5 Science Park, 1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> Floor, New Haven, Connecticut 06511 (the &#8220;</font>Tenant<font style="font-weight:normal;">&#8221;) in modification of that certain Lease between the Landlord and the Tenant executed on or about January 2, 2018 (the &#8220;</font>Original Lease<font style="font-weight:normal;">&#8221;), as amended by the First Amendment to Lease between Landlord and Tenant and dated as of May 23, 2018 (the &#8220;</font>First Amendment<font style="font-weight:normal;">&#8221;), as further modified by the Second Amendment to Lease between Landlord and Tenant and dated as of September 4, 2018 (the &#8220;</font>Second Amendment<font style="font-weight:normal;">&#8221;), as further modified by the Third Amendment to Lease between Landlord and Tenant and dated as of March 12, 2019 (the &#8220;</font>Third Amendment<font style="font-weight:normal;">&#8221;), and as further modified by the Fourth Amendment to Lease between Landlord and Tenant and dated as of January 31, 2020 (the &#8220;</font>Fourth Amendment<font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;The Original Lease as modified by the First Amendment, the Second Amendment, the Third Amendment, and the Fourth Amendment are collectively referred to herein as the &#8220;</font>Lease<font style="font-weight:normal;">&#8221;.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Landlord and the Tenant are parties to the Lease which is in full force and effect; and</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Landlord and the Tenant wish to modify the Lease as more fully set forth herein; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE<font style="font-weight:normal;">, the Landlord and the Tenant agree as follows: </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Amendments to Lease.&nbsp;&nbsp; </font>As of January 1, 2021, the following modifications are made to the Lease:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 1.1(a) of the Lease is amended and restated to read, in full, as follows:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord is the owner of the real property located at Science Park, New Haven, Connecticut as described on <font style="font-weight:bold;">Exhibit A </font>attached hereto (the &#8220;<font style="font-weight:bold;">Property</font>&#8221;). The Tenant shall lease from Landlord the following premises located in Science Park Building 5 (&#8220;<font style="font-weight:bold;">Building 5</font>&#8221;), which is located on the Property: (i) approximately 7,873 rentable square feet on the first floor of Building 5, as shown on the floor plan attached hereto as <font style="font-weight:bold;">Schedule A-1 </font>(the &#8220;<font style="font-weight:bold;">First Floor Premises</font>&#8221;); (ii) approximately 10,249 rentable square feet on the second floor of Building 5, as shown on the floor plan attached hereto as <font style="font-weight:bold;">Schedule A-2 </font>(the &#8220;<font style="font-weight:bold;">Second Floor Premises</font>&#8221;); approximately 9,456 rentable square feet on the third floor of Building 5, as shown on the floor plan attached hereto as <font style="font-weight:bold;">Schedule A-3 </font>(the &#8220;<font style="font-weight:bold;">Third Floor Premises</font>&#8221;); <font style="color:#000000;">(iii) as of May 15, 2018, approximately 2,632 </font>rentable <font style="color:#000000;">square feet on the first floor of Building 5, as shown on the floor plan attached hereto as </font><font style="font-weight:bold;color:#000000;">Schedule A-4</font><font style="color:#000000;"> (the &#8220;</font><font style="font-weight:bold;color:#000000;">Part A Space</font><font style="color:#000000;">&#8221;); (iv) as of May 1, 2019, or earlier as provided in Section 2.4.G. of the Lease, approximately 3,705 </font>rentable <font style="color:#000000;">square feet on the first floor of Building 5, as shown on the floor plan attached hereto as </font><font style="font-weight:bold;color:#000000;">Schedule A-4</font><font style="color:#000000;"> (the &#8220;</font><font style="font-weight:bold;color:#000000;">Part </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.34%;">
<tr>
<td rowspan="2" valign="top"  style="width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gy33ft1zvusk000001.jpg" title="" alt="" style="width:80px;height:76px;"></p></td>
<td valign="top"  style="width:83.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:4pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:18pt;font-family:Century Gothic;letter-spacing:1pt;font-style:normal;text-transform:none;font-variant: normal;">Science Park Development Corporation</p></td>
</tr>
<tr style="height:38.1pt;">
<td valign="top"  style="width:83.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Century Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 Science Park, New Haven CT 06511-1966   ph 203.785.0840&nbsp;&nbsp; fax 203.785.0846</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;">B Space</font><font style="color:#000000;">&#8221;)</font><font style="color:#000000;">; (v) as of September 1, 2018, approximately 84 rentable square feet on the first floor of Building 5 as shown on the floor plan attached hereto as </font><font style="font-weight:bold;color:#000000;">Schedule A-5</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">(the &#8220;</font><font style="font-weight:bold;color:#000000;">September</font><font style="font-weight:bold;color:#000000;"> 2018 Space</font><font style="color:#000000;">&#8221;); (vi) as of March 1, 2019 </font><font style="color:#000000;">approximately </font><font style="color:#000000;">1,468</font><font style="color:#000000;"> rentable square feet </font><font style="color:#000000;">(subsequently reduced to</font><font style="color:#000000;"> approximately</font><font style="color:#000000;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,264 </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rentable square feet) </font><font style="color:#000000;">on the </font><font style="color:#000000;">second</font><font style="color:#000000;"> floor of Building 5 as shown on the floor plan attached hereto as </font><font style="font-weight:bold;color:#000000;">Schedule A-</font><font style="font-weight:bold;color:#000000;">6</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">(the &#8220;</font><font style="font-weight:bold;color:#000000;">March 2019</font><font style="font-weight:bold;color:#000000;"> Space</font><font style="color:#000000;">&#8221;)</font><font style="color:#000000;">; (vii) </font><font style="color:#000000;">as of </font><font style="color:#000000;">April</font><font style="color:#000000;"> 1, 2019 approximately </font><font style="color:#000000;">3,719</font><font style="color:#000000;"> rentable square feet on the </font><font style="color:#000000;">first</font><font style="color:#000000;"> floor of Building 5 as shown on the floor plan attached hereto as </font><font style="font-weight:bold;color:#000000;">Schedule A-</font><font style="font-weight:bold;color:#000000;">7</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">(the &#8220;</font><font style="font-weight:bold;color:#000000;">April</font><font style="font-weight:bold;color:#000000;"> 2019 Space</font><font style="color:#000000;">&#8221;)</font><font style="color:#000000;">; (viii) as of February 1, 2020 </font><font style="color:#000000;">approximately </font><font style="color:#000000;">9,889</font><font style="color:#000000;"> rentable square feet on the </font><font style="color:#000000;">third</font><font style="color:#000000;"> floor of Building 5 as shown on the floor plan attached hereto as </font><font style="font-weight:bold;color:#000000;">Schedule A-</font><font style="font-weight:bold;color:#000000;">8</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">(the &#8220;</font><font style="font-weight:bold;color:#000000;">February</font><font style="font-weight:bold;color:#000000;"> 20</font><font style="font-weight:bold;color:#000000;">20</font><font style="font-weight:bold;color:#000000;"> Space</font><font style="color:#000000;">&#8221;)</font><font style="color:#000000;">; and as of February 1, 2021 </font><font style="color:#000000;">approximately </font><font style="color:#333333;">10,708 </font><font style="color:#000000;">rentable square feet on the </font><font style="color:#000000;">second</font><font style="color:#000000;"> floor of Building 5 as shown on the floor plan attached hereto as </font><font style="font-weight:bold;color:#000000;">Schedule A-</font><font style="font-weight:bold;color:#000000;">9</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">(the &#8220;</font><font style="font-weight:bold;color:#000000;">February</font><font style="font-weight:bold;color:#000000;"> 20</font><font style="font-weight:bold;color:#000000;">2</font><font style="font-weight:bold;color:#000000;">1</font><font style="font-weight:bold;color:#000000;"> Space</font><font style="color:#000000;">&#8221;)</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall have exclusive use of the Landlord&#8217;s fixtures, equipment, furniture and other </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personalty</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as set forth in </font><font style="font-weight:bold;">Schedule A-1 </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">attached hereto (&#8220;</font><font style="font-weight:bold;">Landlord&#8217;s Additional Property</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The First Floor Premises, the Second Floor Premises, the Third Floor Premises, the Part A Space, the Part B Space, the September 2018 Space, the March 2019 Space, the April 2019 Space, the February 2020 Space, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the February 2021 Space, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the Landlord&#8217;s Additional Property shall be referred to herein collectively as the &#8220;Leased Premises&#8221;. Landlord&#8217;s Additional Property shall be considered part of the Leased Premises but shall remain property of the Landlord.&nbsp;&nbsp;</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">A new Section 2.4.L. is added to the Lease to provide, in full, as follows:</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;color:#333333;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">L. <font style="margin-left:36pt;"></font>The <font style="color:#000000;">February 2021 Space</font> is currently subject to a lease (the &#8220;<font style="font-weight:bold;">Clifford Beers Lease</font>&#8221;) between Landlord and The Clifford Beers Guidance Clinic, Incorporated (&#8220;<font style="font-weight:bold;">Clifford Beers</font>&#8221;). &nbsp;&nbsp; Landlord shall deliver the <font style="color:#000000;">February 2021 Space</font> to Tenant in a broom clean condition, free of any personal property of any prior tenants, except as otherwise agreed. The <font style="color:#000000;">February 2021 Space</font> shall be leased to Tenant in its then &#8220;as is&#8221; condition and Landlord shall not be required to construct any additional improvements in, or contribute anything of value in connection with any Tenant&#8217;s Work with respect to the <font style="color:#000000;">February 2021 Space</font>.&nbsp;&nbsp;Landlord shall not be liable to Tenant or otherwise be in default hereunder in the event that Landlord is delayed or is unable to deliver the <font style="color:#000000;">February 2021 Space</font> to Tenant due to the failure of Clifford Beers to timely vacate and surrender the <font style="color:#000000;">February 2021 Space</font> to Landlord, or any portion thereof.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 2.1(a) of the Lease is modified by amending and restating the last sentence thereof to read in full as follows:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless sooner cancelled or terminated or extended in accordance with the terms of this Lease, the Term will expire with respect to the entire Leased Premises as of December 31, 2024 (the "<font style="font-weight:bold;">Expiration Date</font>"). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.34%;">
<tr>
<td rowspan="2" valign="top"  style="width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gy33ft1zvusk000001.jpg" title="" alt="" style="width:80px;height:76px;"></p></td>
<td valign="top"  style="width:83.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:4pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:18pt;font-family:Century Gothic;letter-spacing:1pt;font-style:normal;text-transform:none;font-variant: normal;">Science Park Development Corporation</p></td>
</tr>
<tr style="height:38.1pt;">
<td valign="top"  style="width:83.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Century Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 Science Park, New Haven CT 06511-1966   ph 203.785.0840&nbsp;&nbsp; fax 203.785.0846</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:14.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 3.1.A. of the Lease is modified by deleting the last line of the Base Rent chart (for the months of February 2020 through December 2022) and substituting therefor the following:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:31pt;">
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months of Term</p></td>
<td valign="bottom"  style="width:20.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Base Rent Rate (Annually per RSF)</p></td>
<td valign="bottom"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Applicable RSF</p></td>
<td valign="bottom"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Monthly Base Rent</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February, 2020 - January, 2021</p></td>
<td valign="bottom"  style="width:20.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21.00</p></td>
<td valign="bottom"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,766</p></td>
<td valign="bottom"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$ 85,340.50</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February, 2021 - December, 2022</p></td>
<td valign="bottom"  style="width:20.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21.00</p></td>
<td valign="bottom"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,474</p></td>
<td valign="bottom"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$104,079.50</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2023 &#8211; December, 2024</p></td>
<td valign="bottom"  style="width:20.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.50</p></td>
<td valign="bottom"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,474</p></td>
<td valign="bottom"  style="width:25%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$116,469.91</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">e)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 3.2.A. of the Lease is modified to add the following provisions:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">"2021 Base Year"<font style="font-weight:normal;"> shall mean the calendar year 2019.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">"2021 Operating Expenses"<font style="font-weight:normal;"> shall mean the amount of Operating Expenses attributable to the 2021 Base Year.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:14.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">"2021 Property Taxes"<font style="font-weight:normal;"> shall mean the amount of Property Taxes attributable to the 2021 Base Year.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">f)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The last paragraph of Section 3.2.A. of the Lease is amended and restated to read, in full, as follows:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:15.38%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Tenant&#8217;s 2018 Proportionate Share&#8221;, &#8220;Tenant's 2019 Proportionate Share&#8221; and Tenant&#8217;s 2021 Proportionate Share&#8221; <font style="font-weight:normal;">shall mean, respectively, those fractions, the numerator of which is: (i) with respect to Tenant&#8217;s 2018 Proportionate Share, 38,877&nbsp;&nbsp;rentable square feet (the &#8220;</font>Initial Premises<font style="font-weight:normal;">&#8221;) (the &#8220;</font>2018 Numerator<font style="font-weight:normal;">&#8221;); (ii) with respect to Tenant&#8217;s 2019 Proportionate Share, 9,889 rentable square feet (the &#8220;</font>2019 Numerator<font style="font-weight:normal;">&#8221;), and (iii) with respect to Tenant&#8217;s 2021 Proportionate Share, 10,708 rentable square feet, and the denominator for each of which (the "</font>Denominator<font style="font-weight:normal;">") is the average of the total rentable square feet of floor space in Building 5 actually under lease to tenants during the calendar year in question (as such number is determined by leases, whether verbal or in writing, and pursuant to the terms of which leases rent has commenced to be payable), (said average being referred to as the "</font>Average Occupancy Figure<font style="font-weight:normal;">"). Notwithstanding the foregoing, in the event that the Average Occupancy Figure is less than ninety five percent (95%) of the total rentable square footage in Building 5 during any calendar year, then in such event (i) the Denominator described hereinabove shall be then established during such period in question at ninety five percent (95%) of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.34%;">
<tr>
<td rowspan="2" valign="top"  style="width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gy33ft1zvusk000001.jpg" title="" alt="" style="width:80px;height:76px;"></p></td>
<td valign="top"  style="width:83.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:4pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:18pt;font-family:Century Gothic;letter-spacing:1pt;font-style:normal;text-transform:none;font-variant: normal;">Science Park Development Corporation</p></td>
</tr>
<tr style="height:38.1pt;">
<td valign="top"  style="width:83.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Century Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 Science Park, New Haven CT 06511-1966   ph 203.785.0840&nbsp;&nbsp; fax 203.785.0846</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">the total rentable square footage in Building 5, and (ii) those components of Operating Expenses which relate to and are incurred as a consequence of Building 5 tenant use and occupancy (including Building 5 maintenance and repair, janitorial and cleaning expenses. Building 5 management fees and costs and Building 5 tenant electric expenses) shall be increased on a pro rata basis from the actual levels at which they are incurred during any given calendar year in question to the levels at which they would have been incurred had the Average Occupancy Figure been ninety five percent (95%) of the total square footage in Building 5 during the calendar year in question.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:15.38%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Tenant&#8217;s 2018, 2019 and 2021 Proportionate Shares&#8221;<font style="font-weight:normal;"> shall mean Tenant&#8217;s 2018&nbsp;&nbsp;Proportionate Share, Tenant's 2019 Proportionate Share, and Tenant's 2021 Proportionate Share.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:14.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">g)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 3.2.B. of the Lease is amended and restated to read, in full, as follows:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:14.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Expense and Tax Increases.</font>&nbsp;&nbsp; In addition to the Base Rent, Tenant shall pay to Landlord, as Additional Rent, as hereinafter provided, (I) Tenant's 2018 Proportionate Share of (i) increases in Operating Expenses over the Base Operating Expenses, and (ii) increases in Property Taxes over Base Property Taxes; (II) Tenant's 2019 Proportionate Share of (a) increases in Operating Expenses over 2019 Operating Expenses, and (b) increases in Property Taxes over 2019 Property Taxes, and (c) (III) Tenant's 2021 Proportionate Share of (1) increases in Operating Expenses over 2021 Operating Expenses, and (2) increases in Property Taxes over 2021 Property Taxes (collectively referred to as the "<font style="font-weight:bold;">Expense and Tax Increases</font>"). In advance of each calendar year during the Term, Landlord shall furnish Tenant with an estimate (which estimate may be changed by Landlord from time to time) of Tenant's 2018, 2019 and 2021 Proportionate Shares of the Expense and Tax Increases for the ensuing calendar year (or portion thereof). Commencing with the monthly installment of Base Rent payable for January, 2019, and thereafter on the first (1st) day of each month of calendar year 2019, Tenant shall pay to Landlord one-twelfth (1/12th) of the amount of Landlord's then current estimate of Expense and Tax Increases.&nbsp;&nbsp;Commencing with the monthly installment of Base Rent payable for January, 2020 (as to the Initial Premises) and February, 2020 (as to the February 2020 Space) and thereafter on the first (1st) day of each month of through December 31, 2021, Tenant shall pay to Landlord one-twelfth (1/12th) of the amount of Landlord's then current estimate of Expense and Tax Increases. Commencing with the monthly installment of Base Rent payable for January, 2022, and thereafter on the first (1st) day of each month of the Term, as to the entire Leased Premises, Tenant shall pay to Landlord one-twelfth (1/12th) of the amount of Landlord's then current estimate of Expense and Tax Increases.&nbsp;&nbsp;Within 180 days after the end of each calendar year and within 180 days after the end of the Term, Landlord shall submit to Tenant a statement, prepared by Landlord, of the actual </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.34%;">
<tr>
<td rowspan="2" valign="top"  style="width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gy33ft1zvusk000001.jpg" title="" alt="" style="width:80px;height:76px;"></p></td>
<td valign="top"  style="width:83.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:4pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:18pt;font-family:Century Gothic;letter-spacing:1pt;font-style:normal;text-transform:none;font-variant: normal;">Science Park Development Corporation</p></td>
</tr>
<tr style="height:38.1pt;">
<td valign="top"  style="width:83.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Century Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 Science Park, New Haven CT 06511-1966   ph 203.785.0840&nbsp;&nbsp; fax 203.785.0846</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense and Tax Increases for the preceding calendar year (or partial calendar year in the event the Term shall end on a date other than a December 31</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), and the figures used for computing </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant's 2018</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 2021</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Proportionate Shares </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the preceding calendar year, and if </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant's 2018</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 2021</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Proportionate Shares </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of Expense and Tax Increases so stated for such period is (</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) more than the amount paid for such period, Tenant shall pay to Landlord the deficiency within thirty (30) days after submission of such statement, or (ii) less than the amount paid for such period, at Landlord's sole election, Tenant shall be entitled to a credit in the amount of such excess against amounts next coming due under this Paragraph or Landlord shall refund the amount of such overpayment to Tenant (or a refund of such excess in the case of the end of the term of this Lease). Any such adjustment shall survive the expiration or earlier termination of the Term. If Landlord shall furnish such estimate subsequent to the commencement of any such calendar year, then, until the first (1st) day of the month following the month in which such estimate is furnished to Tenant, Tenant shall pay to Landlord on the first (1st) day of each month an amount equal to Tenant's monthly payment with respect to </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant's 2018</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2019</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 2021</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Proportionate Shares </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of Expense and Tax Increases for the last month of the preceding calendar year.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:14.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">h)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 3.4 of the Lease is modified by deleting the last line of the Electricity charge payable chart (for the months of February 2020 through December 2022) and substituting therefor the following:</font><font style="font-weight:bold;color:#000000;"> </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:40.56%;"></td>
<td style="width:24.72%;"></td>
<td style="width:15.82%;"></td>
<td style="width:18.79%;"></td>
</tr>
<tr style="height:49.9pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months of Term</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Electricity Charge </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Annually per RSF)</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Applicable RSF</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Monthly Electricity Charge</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February, 2020 - January, 2021</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.50</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,766</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; $10,159.58</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February, 2021 - December, 2024</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.50</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,474</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; $12,390.42</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Schedules.</font><font style="font-weight:bold;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Schedule A-9 </font><font style="color:#000000;">attached hereto is hereby made a part of the Lease as amended by this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Extended Term.</font><font style="margin-left:36pt;color:#000000;">Tenant shall continue to retain its right to an Extended Term under and subject to the provisions of Article 35 of the Lease as to the entire Leased Premises</font><font style="color:#000000;"> (inclusive of the Mandatory Expansion Premises), which Extended Term would commence immediately following the Expiration Date of the Lease as extended by this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Reaffirmation of Lease.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="margin-left:36pt;color:#000000;">In all other respects, the Lease, as hereby amended, is reaffirmed by the Parties and shall be and remain in full force and effect.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.34%;">
<tr>
<td rowspan="2" valign="top"  style="width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gy33ft1zvusk000001.jpg" title="" alt="" style="width:80px;height:76px;"></p></td>
<td valign="top"  style="width:83.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:4pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:18pt;font-family:Century Gothic;letter-spacing:1pt;font-style:normal;text-transform:none;font-variant: normal;">Science Park Development Corporation</p></td>
</tr>
<tr style="height:38.1pt;">
<td valign="top"  style="width:83.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Century Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 Science Park, New Haven CT 06511-1966   ph 203.785.0840&nbsp;&nbsp; fax 203.785.0846</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Landlord and Tenant Remain Obligated.</font><font style="font-weight:bold;margin-left:36pt;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="color:#000000;">Nothing herein shall constitute a waiver or release by the Landlord or the Tenant of any unperformed obligations of the other under the Lease as modified by this Agreement.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Brokerage.</font><font style="margin-left:36pt;color:#000000;">Landlord shall pay an agreed commission to Colliers International by way of a separate agreement. Landlord represents to Tenant that no other broker has an</font><font style="color:#000000;">y right to lease space at the Property and Landlord agrees to indemnify and hold Tenant harmless from and against the claims, losses, damages, costs and expenses (including, but not limited to, reasonable attorneys&#8217; fees) incurred by Tenant as a result of any party asserting a right to a fee or commission claiming to have acted by, under, through or on behalf of the Landlord. Tenant agrees to indemnify and hold Landlord harmless from and against the claims, losses, damages, costs and expenses (including, but not limited to, reasonable attorneys&#8217; fees) incurred by Landlord as a result of any party other than Colliers International claiming a fee or commission by, under or through Tenant on account of this Agreement and/or the extension of the Term of the Lease provided for in this Agreement.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Later Provision Controls.</font><font style="margin-left:36pt;color:#000000;">In case of any inconsistency between the provisions of the Lease and this Agreement, the provisions of this Agreement shall govern and control.&nbsp;&nbsp;Without limiting the meaning or application of the foregoing sentence in any manner, the provisions of Paragraph </font><font style="color:#000000;">5 of this Agreement supersede and replace Article 29 with respect to this Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Capitalized Terms.</font><font style="font-weight:bold;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Capitalized terms used but not otherwise defined herein shall have the same meaning as set forth in the Lease.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Entire Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement sets forth the entire agreement between the parties with respect to the matters set forth herein.&nbsp;&nbsp;There have been no additional oral or written representations or agreements.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Counterparts</font><font style="color:#000000;">. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. </font><font style="color:#000000;">S</font><font style="color:#000000;">ignatures to this Agreement transmitted by telecopy or otherwise electronically shall be valid and effective to bind the party so signing.&#160; Each party agrees promptly to deliver an execution original to this Agreement with its actual signature to the other party, but a failure to do so shall not affect the enforceability of this Agreement, it being expressly agreed that each party to this Agreement shall be bound by its own telecopied or electronic signature and shall accept the telecopied or electronic signature of the other party to this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[The Signature Page(s) Follow.]</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.34%;">
<tr>
<td rowspan="2" valign="top"  style="width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gy33ft1zvusk000001.jpg" title="" alt="" style="width:80px;height:76px;"></p></td>
<td valign="top"  style="width:83.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:4pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:18pt;font-family:Century Gothic;letter-spacing:1pt;font-style:normal;text-transform:none;font-variant: normal;">Science Park Development Corporation</p></td>
</tr>
<tr style="height:38.1pt;">
<td valign="top"  style="width:83.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Century Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 Science Park, New Haven CT 06511-1966   ph 203.785.0840&nbsp;&nbsp; fax 203.785.0846</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated as of the date and year first above written.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:21.79%;"></td>
<td style="width:2.56%;"></td>
<td style="width:6.41%;"></td>
<td style="width:69.23%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signed, Sealed and Delivered In </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Presence of:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:252pt;;text-indent:-252pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARVINAS OPERATIONS, INC.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s/ Carol Barnabei</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" >
<p style="text-align:justify;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sean Cassidy</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Witness Name:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Cassidy</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s/ Carol Barnabei</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treasurer and Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Witness Name:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SCIENCE PARK DEVELOPMENT CORPORATION</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carol Barnabei</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" >
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Clio Nicolakis</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Witness Name:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clio Nicolakis</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carol Barnabei</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Director and Controller</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Witness Name:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STATE OF CONNECTICUT)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)ss.:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New Haven January 4, 2021</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COUNTY OF NEW HAVEN)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On this date personally appeared before me, Sean Cassidy, who acknowledged himself to be the duly authorized Treasurer and Chief Financial Officer of Arvinas Operations, Inc., a Delaware corporation, and that the execution hereof was the free act and deed of such corporation and his/her free act and deed as such officer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, I hereunto set my hand.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:25.61%;"></td>
<td style="width:5.14%;"></td>
<td style="width:69.25%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carol Barnabei</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commissioner of the Superior Court/Notary Public</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.34%;">
<tr>
<td rowspan="2" valign="top"  style="width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gy33ft1zvusk000001.jpg" title="" alt="" style="width:80px;height:76px;"></p></td>
<td valign="top"  style="width:83.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:4pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:18pt;font-family:Century Gothic;letter-spacing:1pt;font-style:normal;text-transform:none;font-variant: normal;">Science Park Development Corporation</p></td>
</tr>
<tr style="height:38.1pt;">
<td valign="top"  style="width:83.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Century Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 Science Park, New Haven CT 06511-1966   ph 203.785.0840&nbsp;&nbsp; fax 203.785.0846</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STATE OF CONNECTICUT<font style="margin-left:36pt;">)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) ss.: New Haven January 4, 2021</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COUNTY OF NEW HAVEN<font style="margin-left:36pt;">)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On this date personally appeared before me, Clio Nicolakis, who acknowledged herself to be the duly authorized Executive Director and Controller of Science Park Development Corporation, a Connecticut non stock corporation, and that the execution hereof was the free act and deed of such corporation and her free act and deed as such officer.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, I hereunto set my hand.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:25.59%;"></td>
<td style="width:5.13%;"></td>
<td style="width:69.18%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carol Barnabei</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commissioner of the Superior Court/Notary Public</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.34%;">
<tr>
<td rowspan="2" valign="top"  style="width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gy33ft1zvusk000001.jpg" title="" alt="" style="width:80px;height:76px;"></p></td>
<td valign="top"  style="width:83.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:4pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:18pt;font-family:Century Gothic;letter-spacing:1pt;font-style:normal;text-transform:none;font-variant: normal;">Science Park Development Corporation</p></td>
</tr>
<tr style="height:38.1pt;">
<td valign="top"  style="width:83.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Century Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 Science Park, New Haven CT 06511-1966   ph 203.785.0840&nbsp;&nbsp; fax 203.785.0846</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gy33ft1zvusk000009.jpg" title="" alt="" style="width:624px;height:808px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.34%;">
<tr>
<td rowspan="2" valign="top"  style="width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gy33ft1zvusk000001.jpg" title="" alt="" style="width:80px;height:76px;"></p></td>
<td valign="top"  style="width:83.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:4pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:18pt;font-family:Century Gothic;letter-spacing:1pt;font-style:normal;text-transform:none;font-variant: normal;">Science Park Development Corporation</p></td>
</tr>
<tr style="height:38.1pt;">
<td valign="top"  style="width:83.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Century Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 Science Park, New Haven CT 06511-1966   ph 203.785.0840&nbsp;&nbsp; fax 203.785.0846</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 23, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andria Mcbride</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 Science Park</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New Haven, CT 06511</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Andria:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As per our discussions earlier today, I am confirming the following errors in the Fifth Amendment to Lease ("5<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Amendment") between Science Park Development Corporation and Arvinas Operations, Inc. dated January 4, 2021.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section&nbsp;&nbsp;1 (e) of the 5th Amendment should be corrected as follows:&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defined term "2021 Base Year" shall mean the calendar year 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Item 1 (h) of the 5<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Amendment should read as follows:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 3.4 of the Lease is modified by deleting the last line of the Electricity charge payable chart (for the months February 2020 through December 2022) and substituting therefor the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:40.51%;"></td>
<td style="width:22.87%;"></td>
<td style="width:14.93%;"></td>
<td style="width:21.58%;"></td>
</tr>
<tr style="height:29.2pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months of Term</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Electricity Charge </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Annually per RSF)</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Applicable RSF</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Monthly Electricity Charge</p></td>
</tr>
<tr style="height:21.55pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.1</font><font style="font-size:12pt;font-style:normal;color:#000000;"></font><font style="font-style:normal;">February, 2020 &#8211; September, 2020</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.62</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,766</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; $6,583.41</p></td>
</tr>
<tr style="height:30.1pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-1.5pt;;font-weight:normal;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.2</font><font style="font-size:12pt;font-style:normal;color:#000000;"></font><font style="font-style:normal;">October, 2020 &#8211; December, 2020</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.62 + $1750/month surcharge</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,766</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; $8,333.41</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-1.5pt;;font-weight:normal;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.3</font><font style="font-size:12pt;font-style:normal;color:#000000;"></font><font style="font-style:normal;">January, 2021</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.50</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,766</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; &nbsp;&nbsp;$10,159.58</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-1.5pt;;font-weight:normal;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.4</font><font style="font-size:12pt;font-style:normal;color:#000000;"></font><font style="font-style:normal;">February, 2021 - December, 2024</font></p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.50</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,474</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; &nbsp;&nbsp;$12,390.42</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other terms and conditions of your current lease will remain unchanged.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you for bringing it to my attention!</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sincerely,</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Clio Nicolakis</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clio Nicolakis</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Director </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:67.94%;">
<tr>
<td valign="top"  style="width:5.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cc:</p></td>
<td valign="top"  style="width:1.88%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:92.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Silverstone, President</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.88%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:92.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gary Poitras, Property Manager, The Wm. M. Hotchkiss Co.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>3
<FILENAME>arvn-ex1035_591.htm
<DESCRIPTION>EX-10.35
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arvn-ex1035_591.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.35</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">SECOND AMENDMENT TO LEASE </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIS SECOND AMENDMENT TO LEASE<font style="font-weight:normal;"> (the &#8220;</font>Agreement<font style="font-weight:normal;">&#8221;) is entered into as of this 4<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day of January, 2021 by and between </font>SCIENCE PARK DEVELOPMENT CORPORATION<font style="font-weight:normal;">, a Connecticut non stock corporation having its office at 5 Science Park, New Haven, Connecticut 06511 (the &#8220;</font>Landlord<font style="font-weight:normal;">&#8221;), and </font>ARVINAS OPERATIONS, INC.<font style="font-weight:normal;">, f/k/a Arvinas, Inc., a Delaware corporation having a principal place of business at 5 Science Park, 1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> Floor, New Haven, Connecticut 06511 (the &#8220;</font>Tenant<font style="font-weight:normal;">&#8221;) in modification of that certain Lease between the Landlord and the Tenant dated as of November 15, 2019 (the &#8220;</font>Original<font style="font-weight:normal;"> </font>Lease<font style="font-weight:normal;">&#8221;) as amended by the First Amendment to Lease between Landlord and Tenant and dated as of February 27, 2020 (the &#8220;</font>First Amendment<font style="font-weight:normal;">&#8221;). &nbsp;&nbsp;The Original Lease as modified by the First Amendment shall be referred to herein as the &#8220;</font>Lease<font style="font-weight:normal;">&#8221;.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Landlord and the Tenant are parties to the Lease which is in full force and effect; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Landlord and the Tenant wish to modify the Lease as more fully set forth herein; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE<font style="font-weight:normal;">, the Landlord and the Tenant agree as follows: </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Amendments to Lease.&nbsp;&nbsp; </font>As of the January 1, 2021, the following modifications are made to the Lease:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 2.1 of the Lease is modified by amending and restating the last sentence thereof to read in full as follows:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:14.42%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless sooner cancelled or terminated or extended in accordance with the terms of this Lease, the Term will expire with respect to the entire Leased Premises as of December 31, 2024 (the "<font style="font-weight:bold;">Expiration Date</font>"). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.81%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 3.1.A. of the Lease is modified by amending and restating the schedule of Base Rents payable by Tenant, as follows: </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:17.78%;"></td>
<td style="width:8.92%;"></td>
<td style="width:10.62%;"></td>
<td style="width:9.38%;"></td>
<td style="width:13.75%;"></td>
<td style="width:6.55%;"></td>
<td style="width:9.38%;"></td>
<td style="width:11.36%;"></td>
<td style="width:12.15%;"></td>
<td style="width:0.12%;"></td>
</tr>
<tr>
<td rowspan="2" colspan="2" valign="bottom"  style=" border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LEASED PREMISES</p></td>
<td rowspan="2" colspan="2" valign="top"  style=" border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(INITIAL) LEASED PREMISES</p></td>
<td colspan="3" valign="top"  style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ELEVATOR LOBBY SPACE</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Period</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Months of Term</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rentable Square Footage (&#8220;RSF&#8221;)</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base&nbsp;&nbsp;Rent</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Per RSF</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Monthly Base Rent </p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSF</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base&nbsp;&nbsp;Rent</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Per RSF</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Monthly Base Rent </p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Monthly Base Rent</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nov 15, 2019 -&nbsp;&nbsp;Feb 29, 2020</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 1/2</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,427</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21.00</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SATISFIED BY INITIAL</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr style="height:35.95pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2020 &#8211; May 31, 2020</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,427</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.22</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RENT PREPAYMENT</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21.00</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$162.75</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$162.75</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr style="height:31pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 1, 2020 &#8211; December 31, 2022</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,427</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21.00</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,997.25</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21.00</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$162.75</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$6,160.00</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr style="height:31pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2023 &#8211; December 31, 2024</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32-43</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,427</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.50</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6,711.21</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.50</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$182.12</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$6,893.33</p></td>
<td style="border:none;padding:0;"></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 3.4 of the Lease is modified by adding the following to the schedule of the Electricity charge payable by Tenant, as follows:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:41.9%;"></td>
<td style="width:24.25%;"></td>
<td style="width:15.52%;"></td>
<td style="width:18.43%;"></td>
</tr>
<tr style="height:49.9pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months of Term</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Electricity Charge </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Annually/RSF)</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSF</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Monthly Electricity Charge</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2023 &#8211; December 31, 2024</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.00 </p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,520</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,173.33</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Extended Term.</font><font style="margin-left:36pt;color:#000000;">Tenant shall continue to retain its right to an Extended Term under and subject to the provisions of Article 35 of the Lease as to the entire Leased Premises, which Extended Term would commence immediately following the Expiration Date of the Lease as extended by this Agreement.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Base Rent Rate Correction.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord and Tenant acknowledge and agree that this Amendment corrects an erroneous Base Rent rate for the period of June 1, 2020 through December 31, 2022 (from $26 to $21/RSF).&nbsp;&nbsp;However, as the Landlord actually billed and collected Base Rent at the correct rate of $21/RSF, no rent adjustments or refunds are due to Tenant. &nbsp;&nbsp; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Reaffirmation of Lease.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="margin-left:36pt;color:#000000;">In all other respects, the Lease, as hereby amended, is reaffirmed by the Parties and shall be and remain in full force and effect.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Landlord and Tenant Remain Obligated.</font><font style="font-weight:bold;margin-left:36pt;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="color:#000000;">Nothing herein shall constitute a waiver or release by the Landlord or the Tenant of any unperformed obligations of the other under the Lease as modified by this Agreement.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Brokerage.</font><font style="margin-left:36pt;color:#000000;">Landlord shall pay an agreed commission to Colliers International by way of a separate agreement. Landlord represents to Tenant that no other broker has an</font><font style="color:#000000;">y right to lease space at the Property and Landlord agrees to indemnify and hold Tenant harmless from and against the claims, losses, damages, costs and expenses (including, but not limited to, reasonable attorneys&#8217; fees) incurred by Tenant as a result of any party asserting a right to a fee or commission claiming to have acted by, under, through or on behalf of the Landlord. Tenant agrees to indemnify and hold Landlord harmless from and against the claims, losses, damages, costs and expenses (including, but not limited to, reasonable attorneys&#8217; fees) incurred by Landlord as a result of any party other than Colliers International claiming a fee or commission by, under or through Tenant on account of this Agreement and/or the extension of the Term of the Lease provided for in this Agreement.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Later Provision Controls.</font><font style="margin-left:36pt;color:#000000;">In case of any inconsistency between the provisions of the Lease and this Agreement, the provisions of this Agreement shall govern and control.&nbsp;&nbsp;Without limiting the meaning or application of the foregoing sentence in any manner, the provisions of Paragraph </font><font style="color:#000000;">5 of this Agreement supersede and replace Article 29 with respect to this Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Capitalized Terms.</font><font style="font-weight:bold;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Capitalized terms used but not otherwise defined herein shall have the same meaning as set forth in the Lease.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Entire Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement sets forth the entire agreement between the parties with respect to the matters set forth herein.&nbsp;&nbsp;There have been no additional oral or written representations or agreements.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Counterparts</font><font style="color:#000000;">. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. </font><font style="color:#000000;">S</font><font style="color:#000000;">ignatures to this Agreement transmitted by telecopy or otherwise electronically shall be valid and effective to bind the party so signing.&#160; Each party agrees promptly to deliver an execution original to this Agreement with its actual signature to the other party, but a failure to do so shall not affect the enforceability of this Agreement, it being expressly agreed that each party to this Agreement shall be bound by its own telecopied or electronic signature and shall accept the telecopied or electronic signature of the other party to this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[The Signature Page(s) Follow.]</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated as of the date and year first above written.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signed, Sealed and Delivered In</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Presence of:</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARVINAS OPERATIONS, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_/s/ Carol Barnabei</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: </p></td>
<td colspan="2" valign="top"  style="width:44.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sean Cassidy</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Witness Name:</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:44.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean Cassidy</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:44.88%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treasurer and Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:44.88%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carol Barnabei</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SCIENCE PARK DEVELOPMENT</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Witness Name:</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORPORATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carol Barnabei</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:5.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:43.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Clio Nicolakis</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Witness Name:</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:5.42%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:43.58%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clio Nicolakis</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:5.42%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:43.58%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Director and Controller</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STATE OF CONNECTICUT<font style="margin-left:36pt;">)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;) ss.: New Haven &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;January 4, 2021</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COUNTY OF NEW HAVEN<font style="margin-left:36pt;">)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On this date personally appeared before me, Sean Cassidy, who acknowledged himself to be the duly authorized Treasurer and Chief Financial Officer of Arvinas Operations, Inc., a Delaware corporation, and that the execution hereof was the free act and deed of such corporation and his/her free act and deed as such officer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, I hereunto set my hand.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carol Barnabei</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commissioner of the Superior Court/Notary Public</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STATE OF CONNECTICUT<font style="margin-left:36pt;">)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;) ss.: New Haven &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; January 4, 2021</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COUNTY OF NEW HAVEN<font style="margin-left:36pt;">)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On this date personally appeared before me, Clio Nicolakis, who acknowledged herself to be the duly authorized Executive Director and Controller of Science Park Development Corporation, a Connecticut non stock corporation, and that the execution hereof was the free act and deed of such corporation and her free act and deed as such officer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, I hereunto set my hand.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carol Barnabei</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commissioner of the Superior Court/Notary Public</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>arvn-ex211_11.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arvn-ex211_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:46.15%;"></td>
<td style="width:5.13%;"></td>
<td style="width:48.72%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of Subsidiary</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">State of Incorporation</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas Operations, Inc.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas Androgen Receptor, Inc.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas Estrogen Receptor, Inc.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas Winchester, Inc.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>arvn-ex231_14.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arvn-ex231_14.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Verdana;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Verdana;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in Registration Statement Nos. 333-234031, 333-234035 and 333-251326 on Form S-3 and Registration Statement Nos. 333-227555, 333-231388 and 333-237215 on Form S-8 of our report dated March 1, 2021, relating to the consolidated financial statements of Arvinas, Inc. and the effectiveness of internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Deloitte &amp; Touche LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hartford, Connecticut</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>arvn-ex311_6.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arvn-ex311_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="EXHIBIT_311"></a><a name="EXHIBIT_311"></a>Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, John Houston, Ph.D., certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">I have reviewed this Annual Report on Form 10-K of Arvinas, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John Houston, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">John Houston, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>arvn-ex312_15.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arvn-ex312_15.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="EXHIBIT_312"></a><a name="EXHIBIT_312"></a>Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Sean Cassidy, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">I have reviewed this Annual Report on Form 10-K of Arvinas, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sean Cassidy</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sean Cassidy</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer and Treasurer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>arvn-ex321_8.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arvn-ex321_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="EXHIBIT_321"></a><a name="EXHIBIT_321"></a>Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Arvinas, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John Houston, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">John Houston, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>arvn-ex322_12.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arvn-ex322_12.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Arvinas, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sean Cassidy</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sean Cassidy</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer and Treasurer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>10
<FILENAME>arvn-ex991_751.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arvn-ex991_751.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-top:40pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gxgkxz5ypye4000001.jpg" title="" alt="" style="width:346px;height:74px;"></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oerth Bio,&#160;LLC</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements as of December&#160;31, 2020 and 2019, and for the Year Ended December&#160;31, 2020 and the Period from May&#160;24, 2019 (Date of Formation) to December&#160;31, 2019, and Independent Auditors&#8217; Report</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:10pt;font-family:Arial;font-style:normal;font-variant: normal;">OERTH BIO,&#160;LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:10pt;font-family:Arial;font-style:normal;font-variant: normal;">table of contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INDEPENDENT AUDITORS&#8217; REPORT</p></td>
<td valign="bottom"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.88%;">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FINANCIAL STATEMENTS AS OF DECEMBER&#160;31, 2020 AND 2019, AND FOR THE YEAR ENDED DECEMBER&#160;31, 2020 AND THE PERIOD FROM MAY&#160;24, 2019 (DATE OF FORMATION) TO DECEMBER&#160;31, 2019:</p></td>
<td valign="bottom"  style="width:5.12%;">
<p style="text-align:right;margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.88%;">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheets</p></td>
<td valign="bottom"  style="width:5.12%;">
<p style="text-align:right;margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.88%;">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statements of Operations and Comprehensive Loss</p></td>
<td valign="bottom"  style="width:5.12%;">
<p style="text-align:right;margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.88%;">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statements of Members&#8217; Equity</p></td>
<td valign="bottom"  style="width:5.12%;">
<p style="text-align:right;margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.88%;">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statements of Cash Flows</p></td>
<td valign="bottom"  style="width:5.12%;">
<p style="text-align:right;margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.88%;">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements</p></td>
<td valign="bottom"  style="width:5.12%;">
<p style="text-align:right;margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">INDEPENDENT AUDITORS&#8217; REPORT</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Managers</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oerth Bio, LLC</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying financial statements of Oerth Bio, LLC (the "Company"), which comprise the balance sheets as of December 31, 2020 and 2019, and the related statements of operations and comprehensive loss, members&#8217; equity, and cash flows for the year then ended December 31, 2020 and for the period from May 24, 2019 (date of formation) to December 31, 2019, and the related notes to the financial statements. </p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Management's Responsibility for the Financial Statements</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Auditors' Responsibility</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor&#8217;s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Opinion</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Oerth Bio, LLC as of December 31, 2020 and December 31, 2019 and the results of its operations and its cash flows for the year ended December 31, 2020 and for the period from May 24, 2019 to December 31, 2019 in accordance with accounting principles generally accepted in the United States of America.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Deloitte &amp; Touche LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 19, 2021</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oerth</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Bio, LLC </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc372791403"></a>Balance Sheets</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, and 2019 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,638,978</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,560,832</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">402,969</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,147</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,120,947</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,592,979</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,913,244</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security deposits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261,371</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,295,562</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,592,979</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, and members&#8217; deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,358,855</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,953</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">629,679</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,988,534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,953</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies &#8211; Note 5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Members&#8217; equity:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common units, no par value, 8,500,000 units authorized, issued<br />&nbsp;&nbsp; and outstanding as of December 31, 2020 and 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,350,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,350,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incentive units, 1,500,000 authorized as of December 31, 2020 and<br />&nbsp;&nbsp; 2019, respectively, 715,000 units and -0- issued as of<br />&nbsp;&nbsp; December 31, 2020 and 2019, respectively, and 96,667 units and<br />&nbsp;&nbsp; -0- outstanding as of December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,117</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,175,089</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,908,974</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total members&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,307,028</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,441,026</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and members&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,295,562</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,592,979</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to the financial statements.</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oerth</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Bio, LLC </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statements of Operations and Comprehensive Loss</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, and the period from</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 24, 2019 to December 31, 2019 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,255,491</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">531,392</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,080,212</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,438,115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,335,703</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,969,507</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,335,703</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,969,507</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expenses):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,902</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,533</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on disposal of assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,314</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,588</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,533</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss and comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,266,115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,908,974</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to the financial statements.</p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oerth</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Bio, LLC</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statements of Members&#8217; Equity</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, and the period from</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 24, 2019 to December 31, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Common</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Incentive</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Members&#8217;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Units</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Units</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Balance May 24, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common units for Bayer<br />&nbsp;&nbsp; contribution</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,250,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common units for<br />&nbsp;&nbsp; Arvinas contribution</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,250,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,350,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,908,974</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,908,974</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Balance December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,500,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,500,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,908,974</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,441,026</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of Bayer contribution for<br />&nbsp;&nbsp; common units previously issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unit-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,667</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,117</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,117</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,266,115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,266,115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Balance December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,500,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,350,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,667</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,117</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,175,089</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,307,028</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to the financial statements<font style="font-style:italic;">.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oerth</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Bio, LLC </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statements of Cash Flows</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, and the period from </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 24, 2019 to December 31, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,266,115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,908,974</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating<br />&nbsp;&nbsp; activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense related to Arvinas IP<br />&nbsp;&nbsp; contribution (Note 2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,350,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,341</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unit-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,117</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(391,822</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,147</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security deposits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(261,371</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,206,903</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,953</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">629,679</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,899,268</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(418,168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,964,586</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,964,586</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from initial Bayer contribution for common units</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from Bayer contribution for common units previously issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,136,146</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,581,832</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash equivalents at beginning<br />&nbsp;&nbsp; of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,581,832</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash equivalents at end of<br />&nbsp;&nbsp; period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,717,978</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,581,832</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing<br />&nbsp;&nbsp; activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common units in exchange for Arvinas IP contribution</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,350,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property, plant and equipment included in accounts<br />&nbsp;&nbsp; payable and accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">853,016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to the financial statements<font style="font-style:italic;">.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">OERTH BIO, LLC </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;">NOTES TO FINANCIAL STATEMENTS AS OF DECEMBER&#160;31, 2020 AND 2019,<br />AND FOR THE YEAR ENDED DECEMBER&#160;31, 2020 AND THE PERIOD FROM MAY&#160;24, 2019 (DATE OF FORMATION) TO DECEMBER 31, 2019</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the Business and Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oerth Bio,&#160;LLC (pronounced &#8220;Earth&#8221;) (the &#8220;Company&#8221; or &#8220;Oerth&#8221;) was organized as a limited liability company (LLC) on May&#160;24, 2019, which was amended and restated as an&#160;LLC in Delaware on October&#160;1, 2019 and is located and headquartered in Durham, North Carolina. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oerth is an early-stage research and development (R&amp;D) agricultural biotechnology company developing an entirely new model for global crop protection to address one of the greatest challenges facing the world: sustainably feeding the growing global population. Oerth will be committed to leveraging Arvinas&#8217; PROTAC&#174; (proteolysis targeting chimera) protein degrader technology to create innovative, safe, and sustainable agricultural products and evaluating the potential to address resistance mechanisms in plants to existing agricultural solutions, with solutions to control weeds, insects, diseases, and abiotic stressors by leveraging the selectivity and other features of PROTAC&#174; protein degraders.</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was formed as a joint venture between Arvinas,&#160;Inc. (&#8220;Arvinas&#8221;) and Bayer CropScience&#160;LP (&#8220;Bayer LP&#8221;) to research, develop, and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. Arvinas made an in-kind intellectual property (IP) contribution to Oerth in the form of a license to certain of Arvinas&#8217; proprietary technology. Bayer&#160;LP made a $56,000,000 total cash commitment to Oerth. Arvinas and Bayer&#160;LP each hold an ownership interest in Oerth, initially representing 50% of the ownership interests.&nbsp;&nbsp;A 15% ownership interest of Oerth is reserved for the future grant of incentive units to employees and service providers of Oerth.  The activities of Oerth are controlled by a management board under the joint control of Arvinas and Bayer&#160;LP.</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&nbsp;&nbsp;These financial statements cover the period from May 24, 2019 (date of formation) to December 31, 2019 (referred to as &#8220;period ended December 31, 2019&#8221;) and the year ended December 31, 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Reclassifications</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior period amounts have been reclassified to conform to the current period presentation. Amounts previously presented separately as biology and chemistry costs, $37,503 and $50,612, respectively, in the prior year are now presented as research and development costs within the consolidated statement of operations. $21,000 of restricted cash equivalents that were presented as cash and cash equivalents in the prior year have been reclassified to conform to the current year presentation. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Risk and Uncertainties</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the agriculture biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to secure additional capital to fund operations.&#160; Product candidates resulting from the Company&#8217;s current discovery efforts will require significant additional research and development, including extensive testing and regulatory approval prior to commercialization.&#160; These efforts will require significant amounts of additional capital, adequate personnel, infrastructure, and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extensive compliance reporting capabilities.&#160; Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operations could be disrupted by large-scale regional or global events, such as the recent outbreak of the novel coronavirus (&#8220;COVID-19&#8221;). Such events could limit the ability to manage operations, disrupt the supply of product, and could affect the timing of completion of performance obligations in the affected areas. Notwithstanding, the Company is monitoring regional and global developments and proceeding with proactive strategies to minimize any impact on its operations. To date, the Company&#8217;s operations have not been affected by COVID-19.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In accordance with the Financial Accounting Standards Board, or FASB, Accounting Standards Update, or ASU, No.&#160;2014-15,&#160;</font><font style="font-style:italic;Background-color:#FFFFFF;">Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40)</font><font style="Background-color:#FFFFFF;">, the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has funded its operations to date primarily with annual drawdowns from the $56,000,000 cash commitment to Oerth from Bayer. Since its inception, the Company has incurred recurring operating losses and negative cash flows from operations.&nbsp;&nbsp; As of December 31, 2020, the Company had an accumulated deficit of $58,175,089. The Company expects to continue to generate operating losses for the foreseeable future. </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk485987646"></a>The Company expects that its existing cash and cash equivalents will be sufficient to fund its operations into early 2023.<a name="_Hlk485987646"></a> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:14pt;margin-top:0pt;margin-left:2%;text-indent:-2%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The significant estimate contained within these financial statements is the estimated fair value of the Company&#8217;s incentive units for equity-based compensation expense.&nbsp;&nbsp;Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known.</p>
<p style="margin-bottom:14pt;margin-top:0pt;margin-left:2.62%;text-indent:-2.62%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents. The Company&#8217;s cash balances exceed those that are federally insured and primarily consist of checking and savings deposits.&nbsp;&nbsp;To date, the Company has not recognized any losses caused by uninsured balances. Cash equivalents consisted of money market funds at December 31, 2020 and 2019 and are stated at fair value.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies all cash whose use is limited by contractual provisions as restricted cash.  Restricted cash arises from the requirement for the Company to maintain a short-term certificate of deposit with the Company&#8217;s financial institution as collateral for the Company&#8217;s credit card line.&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reconciles cash, cash equivalents, and restricted cash</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> equivalents</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> reported within our consolidated balance sheet and cash flows.</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,638,978</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,560,832</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,717,978</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,581,832</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company invests its excess cash in low-risk, highly liquid money market funds and certificates of deposit that management believes to be with a financial institution of high credit quality. The Company may maintain cash deposits at this financial institution that are in excess of government insured limits. The Company has not experienced any losses on cash and cash equivalents to date.  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful lives of the assets.&nbsp;&nbsp;The estimated useful lives are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:84%;">
<tr>
<td valign="bottom"  style="width:58.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.35pt;;margin-right:0.64%;text-indent:-9.35pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment </p></td>
<td valign="bottom"  style="width:41.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:58.82%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:9.35pt;;margin-right:0.64%;text-indent:-9.35pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures </p></td>
<td valign="bottom"  style="width:41.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 years</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:58.82%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:9.35pt;;margin-right:0.64%;text-indent:-9.35pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment </p></td>
<td valign="bottom"  style="width:41.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top"  style="width:58.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.35pt;;margin-right:0.64%;text-indent:-9.35pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements and capital lease assets </p></td>
<td valign="bottom"  style="width:41.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of the useful life of the asset<br />or the life of the lease</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred. </p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred during the construction of property and equipment are capitalized as construction in process. Once an asset has been placed into service, it will be depreciated on a straight-line basis over the estimated useful life of the related assets or, in the case of leasehold improvements, over the shorter of the estimated useful life and the lease term.&#160;</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment charges have been recorded since inception.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research Contract Costs and Accruals </p>
<p style="margin-bottom:10pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various contracts with third parties. These agreements and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes the progress of the studies, including the phase or completion of events, invoices </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:4pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received and contracted costs. </font></p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the Company operates as a LLC, income and expenses of the Company are passed through to the members and are reported in the individual income tax returns. As a LLC, the Company is not required to pay federal or state income taxes. There was no taxable income and, therefore, no distributions in 2019 or 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Employee Benefit Plan</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sponsors a qualified 401(k) defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. Total employer contributions made under this plan for 2020 were $40,832. There were no employer contributions under this plan in 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Incentive Units</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As incentive units are Profits Interests, management has assessed the features of the incentive units to determine the appropriate accounting model under Accounting Standards Codification (ASC) 710 <font style="font-style:italic;">Compensation</font> or ASC 718 <font style="font-style:italic;">Stock Compensation</font>. The scope of ASC 710-10 includes performance bonus, profit sharing, and specific deferred compensation contracts, but excludes stock compensation plans. Stock compensation plans are specifically addressed by ASC 718 (or ASC 505-50 <font style="font-style:italic;">Equity</font> if issued to nonemployees). Since US GAAP does not provide explicit guidance on how to account for Profits Interests, entities with Profits Interests evaluate all the terms, conditions, and characteristics of such awards and apply judgment to determine whether the awards are subject to ASC 718 or ASC 710. Management&#8217;s assessment is that the incentive units are to be accounted for in accordance with ASC 718.  In accordance with ASC 718, the Company records compensation expense over the requisite service period associated with the awards. The Company accounts for forfeitures as incurred.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the absence of an active market for the Company&#8217;s incentive units, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, <font style="font-style:italic;">Valuation of Privately Held Company Equity Securities Issued as Compensation</font>, to estimate the fair value of its incentive units. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated fair value of the incentive units was determined based upon a variety of factors, including the illiquid nature of the incentive units, the Company&#8217;s financial position and historical financial performance, the status of developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation of the Company&#8217;s competition and similar stage company values, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of incentive units at each valuation date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (&#8220;R&amp;D&#8221;) expenses include employee payroll, consulting, contract research, depreciation, rent and other corporate costs attributable to research and development activities, and are expensed as incurred. Non-refundable pre-payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense as the goods or services are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. </p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon formation of the Company, referenced in Note&#160;1 above, and pursuant to the terms of the commitment agreement, Arvinas made an in-kind IP contribution to Oerth in the form of a license to certain of the Company&#8217;s proprietary technology. The fair value of the equity interest for the license </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:14pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received was $49</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0,000</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The fair value of </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oerth</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was determined utilizing discounted cash flows based on reasonable estimates and assumptions of cash flows expected from </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oerth</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Costs of intangibles that are purchased from others for a particular R&amp;D project and that have no alternative future uses and, therefore, no separate economic values are R&amp;D </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expense</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s at the time the costs are incurred. As the license was acquired specifically for research in the agricultural space and the license itself is limited to such space, the fair value of the </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> license was expensed as R&amp;D.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes research and development expenses for our Chemistry and Biology programs.&nbsp;&nbsp;For comparability purposes, the impact of the expense related to the in-kind IP contribution from Arvinas, described above, has been removed from the 2019 results.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biology</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,503,298</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,503</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chemistry</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,576,914</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,612</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,080,212</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">General and Administrative Expense</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative costs are expensed as incurred. General and administrative expenses include compensation, employee benefits, operating leases, as well as fees paid to outside consultants.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:14pt;margin-top:0pt;margin-left:2%;text-indent:-2%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses patent costs as incurred and records such costs as general and administrative expenses within the statements of operations and comprehensive loss.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in members&#8217; equity that result from transactions and economic events other than those with stakeholders. For the year ended December 31, 2020 and the period ended December 31, 2019, there were no differences between net loss and comprehensive loss as there were no items that gave rise to other comprehensive loss.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of cash equivalents, prepaid expenses and other current assets and liabilities, accounts payable and accrued expenses. The carrying amounts of these financial instruments are considered a reasonable estimate of their fair value, due to the short-term maturity of these instruments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For fair value measurement, the Company follows ASC 820, &#8220;<font style="font-style:italic;">Fair Value Measurements and Disclosures,</font>&#8221; for the Company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1 &#8211; quoted prices in active markets for identical assets or liabilities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2 &#8211; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3 &#8211; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted&#160;Accounting Standards Codification Topic 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>&#160;(ASC 606) on January 1, 2020.&#160;ASC 606 applies to contracts with commercial substance that establish the payment terms and each party&#8217;s rights regarding the goods or services to be transferred, to the extent collection of substantially all of the related consideration is probable. The adoption of ASC 606 had no impact on the Company's financial statements.  </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements Not Yet Adopted</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02,<font style="font-style:italic;">&#160;Leases (Topic 842) (</font>&#8220;ASU&#160;2016-02&#8221;).&#160;ASU&#160;2016-02&#160;will require lessees to recognize most leases on their balance sheet as a&#160;right-of-use&#160;asset and a lease liability. Leases will be classified as either operating or finance, and classification will be based on criteria like current lease accounting, but without explicit bright lines. The guidance is effective for annual reporting periods beginning after December&#160;15, 2021 and interim periods within those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU&#160;2016-02&#160;will have on its consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">3.  Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">563,285</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,412</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,769</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,234,119</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,341</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,913,244</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $51,341 for the year ended December 31, 2020 and $-0- for the period ended December 31, 2019.&nbsp;&nbsp;As of December 31, 2020, no amounts recorded within construction in process had been placed into service, and as a result no depreciation was recorded related to these assets to date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">4. Leases</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 2, 2020, the Company entered into an agreement to lease office and laboratory space under a cancelable month&#8209;to&#8209;month operating lease. During the year ended December 31, 2020 the total rent expense recognized was $336,645.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;26, 2020, the Company entered into an agreement to lease 7,655 square feet of office space in Durham, North Carolina. The lease commenced on April&#160;1, 2020, and expires on October&#160;31, 2021, unless sooner terminated or extended. The annual base rent under the lease is $186,482 for the first lease year and is subject to annual increases of 3%. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 27, 2020, the Company entered into an amended lease agreement for the same space which extended the lease term and amended certain terms therein. The initial lease was terminated conterminously with the amended lease. The lease term commenced on August 27, 2020 and extends through the February 1, 2027. The annual base rent under the lease is $188,342 for the first lease year </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and is subject to annual increases of 3%.</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the lease amendment</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the landlord </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide a tenant improvement allowance of $306,200.&nbsp;&nbsp;During the year ended December 31, 2020 the total rent expense recognized was </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,477</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, on May&#160;26, 2020, the Company entered into an agreement to lease 7,289 square feet of office/lab space in Durham, North Carolina. The lease commenced on September&#160;1, 2020, and expires on October&#160;31, 2021, unless sooner terminated or extended. The annual base rent under the lease is $179,337 for the first lease year and is subject to annual increases of 3%.  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 27, 2020, the Company entered into an amended lease agreement for the same space which extended the lease term and amended certain terms therein. The initial lease was terminated conterminously with the amended lease. The lease term will commence on February 1, 2021 and expires on February 1, 2027. The annual base rent under the lease is $204,092 for the first lease year and is subject to annual increases of 3%.  In connection with the lease amendment the landlord will provide a tenant improvement allowance of $656,010. During the year ended December 31, 2020, no rent expense was recognized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also rents growth chambers in plant growth facility to execute its R&amp;D activities, under a cancelable month&#8209;to&#8209;month operating lease. The total expense related to these agreements in 2020 was $54,299.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments under the Company&#8217;s lease arrangements as of December&#160;31, 2020 were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Operating&#160;Leases</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">378,244</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">408,036</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">420,277</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">432,886</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943,902</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,583,345</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total rent expense recorded for all operating leases was $587,173 for the year ended December 31, 2020 and $13,574 for the period ended December 31, 2019. Rent expense is allocated between general and administrative and <font style="color:#000000;">research and development</font> in the accompanying statements of operations and comprehensive loss.&nbsp;&nbsp;Rent expense for facilities being used specifically for R&amp;D purposes, such as the expense related to growth chambers and lab space has been allocated to R&amp;D expense. All other office space, including rent being paid for assets under construction has been allocated to G&amp;A expense.<br /></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk47542811"></a>5. Commitments and Contingencies  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may become involved in various legal proceedings in the ordinary course of its business and may be subject to third-party infringement claims.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company may agree to indemnify third parties with whom it enters contractual relationships, including collaboration or licensing partners, lessors, and parties to other transactions with the Company, with respect to certain matters. The Company has agreed, under certain conditions, to hold these third parties harmless against specified losses, such as those arising from a breach of representations, other third-party claims that the Company&#8217;s products when used for their intended purposes infringe the IP rights of such other third parties, or other claims made against certain parties. It is not possible to determine the maximum potential amount of liability under these indemnification obligations due to the Company&#8217;s limited history of prior indemnification claims and the unique facts and circumstances that are likely to be involved in each claim.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company is subject to various claims that arise in the ordinary course of business. Management believes that any liability of the Company that may arise out of or with respect to these </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">matters will not materially adversely affect the financial position, results of operations, or cash flows of the Company.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">6. Accrued Expenses</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344,117</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees and other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285,562</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">629,679</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">7. Members&#8217; Equity (Deficit)</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has authorized and issued 8,500,000 common units to its two founding members.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Units have the following rights and privileges:</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Voting Rights</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of Common Units have the right to one vote per unit held by such member. In addition, Bayer and Arvinas each have the right to designate two board members, with a fifth board member being the CEO of the Company. The unrestricted Incentive Units represent Common Units, and holders of Incentive Units are not entitled to any voting rights.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Redemption</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Common Units are not redeemable.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Distributions and Liquidation Preference</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Common Units are entitled to participate in distributions as follows:</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All distributions, including in connection with a dissolution event, a change of control, an initial public offering (&#8220;IPO&#8221;), or a single asset sale, will be made to all Members holding Common Units and unrestricted Incentive Units, and accounting for any acceleration of vesting with respect to the Incentive Units, pro rata in proportion to the aggregate number of such units outstanding.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No distributions were made to the Common unitholders during the period ended December 31, 2019 and year ended December 31, 2020. </p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any liquidation, dissolution, or&#160;winding-up&#160;of the Company, the assets of the Company will be distributed in accordance with the same order of priority as distributions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">8. Equity-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is authorized to issue a class of units designated as Incentive Units.&nbsp;&nbsp;The Company is authorized to issue up to 1,500,000 units, of which 785,000 units are available future grants as of December 31, 2020. The Incentive Units are subject to time-based vesting conditions and unvested Incentive Units may not be sold or transferred by the holder. These restrictions lapse according to the time-based vesting conditions of each award. The unrestricted units represent common units, and holders </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of Incentive Units are not entitled to any voting rights. The Company and each member issued units agree that all Incentive Units are intended to constitute a &#8220;</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rofits </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nterest&#8221; in the Company within the meaning of Rev. Proc. 93-27 and Rev. Proc. 2001-43 (a &#8220;Profits Interest&#8221;).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of Profits Interest transactions as well as the Profits Interest outstanding and their corresponding hurdle values as of and for the year ended December 31, 2020. There were no issued or outstanding Profits Interests during the period ended December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Profits</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average&#160;Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Date&#160;Fair&#160;Value </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">790,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.83</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested Profits Interests forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.84</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,667</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.84</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618,333</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.83</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Profits Interest </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Hurdle Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,750,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.64%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.34%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,800,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">715,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.34%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.64%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no aggregate intrinsic value associated with restricted Profits Interest that vested during the year ended December&#160;31, 2020. As of December&#160;31, 2020, there was $460,433 of unrecognized equity-based compensation related to unvested Profits Interest, which is expected to be recognized over a weighted average period of 3.22 years.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These Profits Interest represented ownership in the Company tied solely to the accretion, if any, in the value of the Company following the date of issuance of such Profits Interest. Profits Interest participate in any increase of the Company&#8217;s value related to their Profits Interest after the hurdle value had been achieved and the Company&#8217;s Profits Interest received the agreed-upon return on their invested capital. The Profits Interest awards vested over a requisite service period. Holders of unrestricted Incentive Units are not entitled to any distributions, except as defined within the governing agreements, which contemplate distributions in connection with a dissolution event, change in control, IPO, or single asset sale. Distributions would be made pro rata in proportion to the aggregate number of such units outstanding. </p>
<p style="margin-bottom:8pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Profits Interest award contained the following material terms: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:normal;"></font><font style="font-weight:normal;color:#000000;">The </font><font style="font-weight:normal;">Profits Interest</font><font style="font-weight:normal;color:#000000;"> received</font><font style="font-weight:normal;"> distributions, that exceeded a threshold equivalent to the fair value of the Company as determined by the Board of Directors, at the grant date. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:8pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="color:#000000;"></font><font style="font-weight:normal;">The options vest over a period of continuous employment or service, such that, Twenty-five percent (25%) of the Granted Units will vest after twelve (12) months of continuous employment with the Company, and the remaining units vest monthly thereafter until fully vested after an additional three years of continuous employment with the Company (e.g., four (4) years of continuous employment total).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:normal;"></font><font style="font-weight:normal;color:#000000;">The unvested awards terminate upon employee&#8217;s service with the Company.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Profits Interest were accounted for as equity using the fair value method, which required the measurement and recognition of compensation expense for all profit interest-based payment awards made to Oerth Bio employees based upon the grant-date fair value.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P</font><font style="color:#000000;">rofits</font><font style="color:#000000;"> </font><font style="color:#000000;">I</font><font style="color:#000000;">nterest</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oerth</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Bio recognized unit-based compensation expense over the requisite service period for each separately vesting portion of the </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rofits </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nterest as if the award</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s were</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, in-substance, multiple awards. The compensation expense recognized related to the </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P</font><font style="color:#000000;">rofits </font><font style="color:#000000;">I</font><font style="color:#000000;">nterest </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s ended December 31, 2020 and 2019 was $132,117 and $</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> respectively.&nbsp;&nbsp;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oerth Bio determined the fair value of each award on the date of grant using the market approach to value the total shareholders&#8217; equity of Oerth Bio, and the option pricing model to allocate the equity value to the various classes of units (common units, and 2 tranches of Profits Interests).&nbsp;&nbsp;Key metrics used within the valuation of the Profits Interest included, a risk-free rate of 0.15% and 0.1%, volatility of 80.60% and 2.5 years to liquidity assumptions used for grants issued for the year ended December 31, 2020. </p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">9. Related Party Transactions</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;16, 2019, the Company entered into master services agreement with Arvinas and Bayer LP (collectively, MSA). The language in each agreement mirrors the other. The MSAs each outline parameters for Arvinas and Bayer LP to perform services on behalf of Oerth and be compensated therefore. The services are outlined in individual statements of work (SoWs), which outline the work performed by Bayer LP or Arvinas for a defined period. The SoWs can be amended through change order procedures outlined in the SoW and are expected to renew upon expiration.&#160;Using a defined period allows for a descriptive outline of services, such as knowledge share, assay development, biological and chemical screening, and bio and chem informatics.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the periods ended December&#160;31, 2020 and 2019, the Company paid Arvinas $37,024 and $59,330 pursuant to the MSA, respectively. For the year ended December&#160;31, 2020, the Company paid Bayer $306,520 in 2020 pursuant to the MSA. No amounts were paid to Bayer for the period ended December 31, 2019, pursuant to the MSA. As of December 31, 2020, costs of $1,260 were recorded within accounts payable and accrued expenses to Arvinas. As of December 31, 2020, costs of $292,518 were recorded within accounts payable and accrued expenses to Bayer. No amounts were recorded within accounts payable or accrued expenses as of December 31, 2019 for Arvinas or Bayer.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">10. Subsequent Events </p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluated subsequent events from December&#160;31, 2020, the date of these financial statements, through February 19, 2021, which represents the date the financial statements were issued, for events requiring recording or disclosure in the financial statements for the year ended December&#160;31, 2020. The Company concluded that the only event that occurred that would require recognition or disclosure is related to the sale leaseback arrangement described below.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Sale Leaseback Arrangement<font style="font-weight:normal;font-style:normal;">&#8212;On January 29, 2021, the Company entered a&#160;sale leaseback transaction for certain lab equipment with a total asset value of $284,208.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">******</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gfbaqn1kfu2x000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /B!W\# 2(  A$! Q$!_\0
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M\OX;)"TO05+;SK<P+*GW6Z5YGKOB2YO;9TF@,+'I[BNFM=<CTSP[:,2&D9<
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M1=6WDQ.<*Y[T =C17/:KXGBTZ:./Y3O4-4FB:Y-JD[JT&R,#Y6]: -VBBB@
MHHHH **** "BBB@ HHHH **** "HYIE@B:1^%7K4E<UXXOFL_#%XR'#;."*
M/,?B)\29XKJ6PT^8JRGU[5YQ;Z/JOB1FFW*3GG-85U=R7=V;B0EF)YS7:^&+
M_4[G:ECI[21CAF6@9B76F:IX8<3,<8/! KTKX=_$J>:XCL-1F+.QPO/:I_'P
MBC\"6IGA5+K?\P(Y[5XO9W;V5^L\9(*GC% 'VC%*LT8=#D&F37$< S(P'U-8
M'@2]:^\)V<SDEF'.:P/B+]IE/D6\SQEE_A- CT&*5)D#H00?0TV:>.",O(P
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MBB/3T$?REN@'K0!T]%<EIOB][G4$M;F$0ENF?2NL5@R@@Y!H 6BBB@ HHHH
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MYK5E=7,T3)"V3@__ %ZZ'6O"(U*Z-S%<&&4_Q+UI--\+W-I,COJ$CA#T)ZT
M<REA#=?%FZ$JY^3^IK;\5>');FZMKJR9$D@'REC6I%X86+Q5+K7G?,ZXV4:_
MX?FU:6-X[QX0G4*>M &7X9UV6;5VTV]??>(N6(Z5VM<KH/A!=)U-K]K@RR,,
M'/6NJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,D<]*\,\8QVT6N2+:#$?-.T3Q9=Z1;W,*EG\]<=>E1Z?H^H>(+\%(9'#'J*
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MF@#G/$%NL?CK1T?'RQ@$_@*7XC+.\%HD## F&W\Q72^(/"(UFYBN1<&.2)<
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M(J+T48%.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSM&C,=EM,ID_VC6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF2Q_-C:#0!ZQD8SFH+FX6*)F#KD#UKD;#Q,[:/=!E_>VZ<>I-8<']HZGI?\
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M#:X(\E,'VIPM8!%Y7E+L'\..* .!TV:RCL;F*_C8HXY %9&G7,$&K/#HR.B
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MEQOB5L# R* .#\0HQ\.Z> I_U@[>XK/UV<6MLDK@X5!_*O2WL[>1%1XE95Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 44UW5!EB *2.:.4$QN&QUQ0 ^BD+!1DG%(CJ_W6!H =1110 444UW5%W,
M< =Z '44BL&7<IR#WH9E098X% "T4BNK#*G-+0 4444 %%%(S*@RQP* %HI%
M=6^Z<TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A8*,DX%
M "T4U75_ND&G4 %%%(2%&2<"@!:*J)J=E))Y:7"%P<8%6Z "BBB@ HHHH **
MB%S"6VB0%O2I: "DP/04M% !1110 4444 %%%11W,,LC(D@9EZ@=J ):***
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M8YK48<]:LWBU)$X^Z*,4+]T4M "4M%&: "BBB@ HHHH **** "BBB@ HHHH
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MT <%8^'M6U#5(;[6 &DA.4(J._\ #^LV_BJ;5=/ 'FX!)],G_&O0,8HP#UH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW0YH 9::':6<HDC!W#UK3JE::G!<VYFWJJCO4@O[1C@3H2?>C4"P,"EK+>Z
MU9(_,X(Z5:.HV88J;A P[9I6 M44R.5)5W1L&'J*?0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&,F#:<*.E.FO>N*"]X\\GU S73#.>:T8&)C'-9FH0-:7L@>,H2QQFF?;"L8
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MQ((KI@%A. &[T^T$'_"5"2#:L.W''2E8+G2-K]BL_DF3Y\XQ4EQK%I;)ND?
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M9(V!?>G4"BF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(23$N>M<Y:ZB#.%=<?6MVWNHY/E4CBLI7,:B+G2BD'-**DQ TM(:6@ HHHH
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MFNXT+2_[/M53;@BM8H#VIZC%-12)4$F.%%+32:HL?12 \4M !11FB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHS10 449%&: "BBB@ HHHS0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;1WMI=OH<5NQ:XJ;%W_,*+S2XS:,Z2*'KE;6VG6^DWL2%-::2')IGH4?B!E
M0MR:Z.RNA/"K$\D5YM!?1F9591GWKI-.NFWKM?CTK*=.QA*.AV-2CI5>W??&
M#5D=*P.>U@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *85I]% #-
MV*-U-9>],S0!-N%+FHA2[J!$F:6H]U+NH&/HIN:7-  **3-&: $(II7-2=:2
MEU Y;Q19PSV[%NN*\<U*<Z?<LL9XZ5[IKEDUQ9OL/.*\9U?PS?7%[( CX!ZX
MKMH5>56.>M"YSLLT=Q(')YK2M%4)D=,5G7ND76G-B2-\>I%;6CVC2V_/]VNE
M3N8QC8IW%T$4[3THL-3:WEWJ1R>:9?V+PL6)^6LZ(XE]LUHE<3;3.TCU-9;M
M+@D;P*R?$#W$C+(PPI/%+:D;0^.!6]K%LEUI$+(H!5<FDK1:";;1Q<$Q#C)Y
MKJK2[-Q$D)QC&*Y:*/#GCG-=]X6L4N!\R=.YK2K)*-V<].,FR]HNBQ+<K)SB
MO1[1-D"*.@%<XC0V+B,@$UT5K,)85*^E>77UU/1I*VA:%+35IU<YL%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4&BD/2@!**.U5[FY2VC+,0,>
MM%@'LZJ>:P/$.KQ6ELQ+XK(USQ2B';"<GO@UQNI:G-J49C8MSZUV4<,[W9SU
M*MU9%>:Z>[NV?<?O9'-=#H>HW$$JH3\OUKF($$())R:T[*ZRRX&#FNRHE:QE
M"$D[GKUG()84;/)%7*P="D=K==V>E;U>1)69VA112$@#).!2 6BJAU.Q#;3=
M1Y';-2F[MUC$AE0(>C9XH FHJJNI63MM6YC+>@-3M-&B;F<!?4T /HJH-4L2
MVT746?3=4DE[;1('DG15/0DT 3T53&JV#' NHB?]ZIS<0K'YAD4(>^: ):*B
MAN8;A<PR*X]5-)-=P0#,LJI]30!-15>&]MK@XBG1S[&K% !1110 4444 %%%
M% !1110 4444 %%%% !2&EHH 3%+12'I0 TGFAF %)6?JMSY%H[CM2@FW84G
M9%HW*C//2L#4?$3P77DQ$$FL>WUHM-*&;MQFLN24W.I*PKMAA]=3FE6['7Q>
M)(2F)'PW>L;4/$LAO?+MF!!%8%Z"C\-@U%:OMF#,NX^M:JA%:D.HWH=:^LEK
M(B9L,5KE/M\UO=^>AZ>]5YWFFN0H<A2>E:TMM!:Z>7D96;TK10C#YF=W(C;Q
M')( 7;E>G-(OB.ZNF\F(@Y]ZP)&261@N%R:W]"M8;=!-)@GWIR44MAI/N:;[
M(+;S9SAR,BL%]>D\_8&^3ZU7UK56DF**2%!Q6(),MNSFG""M=BD=E)KOV:-/
M(?+,.<FKVG>*)%0-*P%</;I)*2Q)VBM^&S6:Q5E<;O2IE2AU!3D=K;>)%DF1
M P^:NCBE$B!A7F>CKNO$5CR#CFO2+9-L8&:XJ\(Q>AU4I-[ED$TZFBG5SFX4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EI* "@TM
M(U #<T9&*3([UGZC>I# Q5AD4KC2N9GB'4_)A**?8UYK<(T\YD'K5C7=;EDN
MV3:QYJ.VGCAM6DD(SUP:QE+4[HQ<8JQ7OK,R0)QTZUEWD]O%;E ?GJSJ&O1^
M6RJO;BN(NKN2:<D,<5!LJ2G&\C7M,R78V=SS747%MB(-[5A>&K;<S.Y[9&:W
MKJ4[<=J&>3B(J+LC)>(,V!UJM<VSJI;%;=E$KLS$4V_5"I4 4&=-ZG&FY;S"
M&X I'U-D&U#Q5?4CY<S =S66SD-UIGI4Z::+<MZS,<GK4#S*R]:@)S3<'TIF
MBC&!+OIR$=ZB P,FD,@%,'-$S3[3@4JR%FR:J=3FID1FZ4V0BQ%*T<P;MFMN
MVO3,0IQ5;3M+-P,LVWZUK/8):Q#:03ZBDI:FJ1IVUR([=B:6&?SW^4]:R(B\
MC>5D_-77:5HPM[>.9V!SVKH@[L#;\-V06%CCYB<BM];2,NQ<G(YJA"_EPXBC
M(..U/#3HN]BWS5M9F<D:$,:W&0_W0<5%=V,$4;-#G<!2:>"L#,9._2LS6KQD
MB.Q\$TU>YG9W,>XO[E)"J?>SP*G@2>1-Y4;F'-8EJ97E,CY/-;B77E19(Q@5
MM:PV86IS/9W8#</C@5K:5KA3;EN:R=1QJ%V)0.@Q4%M#*)\!6P#Z5I9..I:5
MT>PZ)JB74(!;DUT Z5Q/A6V945RWX5VR?=%<$TD]#DJ))BT445!F%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% "$9J%T('%3TA&10!55\'!I^X9I)
MH^,BJ^\@X- %K-&ZJX8^M/#\4")P:=GBH U/#4#) :0G-,S2YH >*=UJ,&G9
MH :Z\<]*@^SQ$D[%_*K#<BH9&$:9+ 8HUN#L<QXJT6WN[&0E!NQV%<!\FGQB
M).W!KM?$VNQ+&T2N"2.QKSF>5IY\@YR:]##P=KLYIR5]"OK%TLH*#&"*Q;:V
M:27 '&:ZB73@Z9(P<5FS6YM6# =ZZD[:&#3W+*Q&!/+QUKI7NK&/245W^<KC
M%<JTQEAW[N16=+=2L=I<X%+EYF5)VC<N#R1<DJ>,UV7A_58HQL0C/2N"MP7<
M-70Z3%(MPIVG!-55@FC"C6DW:QU=YJ$ O,3.0<5OZ!K4,Y:)'SCBN)URV9I/
M-0\X[58\*V]S#=;F#88^E<M2G%TS>-27.>KQL#TJ6H+?[@)J:O..Y"T444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !2&EHH 9@UCZW9375JR1 EC6
MW2$9IIV=P/&)_#&IPW,DGED@G/)-1+I&I/)\D0S7L4EM&Y.Y0<U%]CMHANV*
M*ZGBY=C"-'4\7O=.O;*5#,F QYJ6SN;..[4.^&STKJO&=Q;J45=I/M7"V%G]
MJU0;6[BMXSYXW9WQH+EN>UZ(4>T0Q\C;6Q63HMN;>RC7_9%:U>?+<P>X5G:S
M=?9+!WSC((K1KF/'#R+I,8B4L6?''X4EN2S@HH;:6QO[N::03HQ*#=Q4VH:K
M<)X0L6+$!I "<]N*Z/0_"A:(23ME'Y*FJ7B'3//E6PAA(BC<$8''6M+ILFSL
M9"I:QWEL;&:1YG4'!;O6QJ6K7L\$-C'_ *T, XST%4_[-?3O%&G1^465E&2!
MP.E2ZEYVG>(YKDP,\;,, "@1)KGAB'2M$?4XY)?/50V"QQDU<M;./6_",4MW
M(ZLD98;3WJ#6=6GUM$TV.V=4D4 MC@5JS6LFE^&H+55);;M.*6HSF_!GAV'5
MXIIYI9?W<I488],G_"M7Q7>/!8I8Z>Q8IPV3S5OPTKZ/X?N93&<F0MC'UKG5
MT/4-6O[FZ\UT1^0I%/=W#H:?@F[:SMS'.QY;)R:A\RY\4:U<6C$^3"W!4]JI
M:787EKJ*VK[SD_>Q4NA:C+HVN7QDM7;)X..M'F!V&D^&(-)N$>%Y& Y.XUT-
M9^DZD=3M?.,1CYQ@UH5F[]2T%%%%( HHHH **** "BBB@ HHHH **** "BBB
M@ I#TI:#TH B(-8'B+S19N%%='44L$<RXD4,/>J@^5W)E'F5CQG%PMRVX8!-
M;=C D6)Y>,5W-SH]F48B%0<=:XG6E^S*R*?P%=U.JZFAR3I*.J*DD O;AS'R
M :BN'BLH#@_.*ELKQ+>!V*Y)%<WJEX9Y3@XK=)MV(3T%.JE9&;(R.E02ZQ+=
M#$C<?6L\'ELTQ(R\NU:T5C-W+2W690 >AKI+=YY+#Y!\M36&FVD%O&951F<=
MZFU/R[6Q/E$#GH*S<[LTC YF\CERQ85FJY0CTS70P7$,\3J^-Q'>L2\@,<QQ
MTJE(;IHZW2;)+O3I"G+;:FT^RFLV+3C$>*Y_2+Z6W5@KG![5N?VF;B'R6^5O
M4U'O"9:TV>"35%"MSNKTRWXB KR31[&1=163S.-V:]6L3^X7)R:Y,4C>@RTO
M6I*8M/KC6QTA1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *5KIEO:_<4$^I%6)K=)U <<#VJ6B@"NUI$T!AQ\IZ\4^*WCAC"*HP/:I:*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4G>EI#0 AQ52\E>.,E:N8S3)(U92",T#1P6K7SEN3R3S6;=IYM
MHRIW'-=!JFGJ]TQX S63?M#;0%-R[B*QD=E)7.%U'3_L6)SGYC3K?556 @MS
M47B#4@\?E?W37,PS2&7!4[2>M2C>5.RN;]W']MY'.:SKG1C;P-(R]*Z&WMT2
MR24."2.E5;F<36[1MQ]:JQBI-,X^X1&7 ZBJF"%VDG\ZZ0Z:),[>?I5*YL6B
MC*F,@^N*&CH4HR6H[P[&XG<G.*Z"\E"G;Q7,V,LMI,!M)W&MR3S+@C:I+8J#
M@K1UT(YH"4W$<&J7EQ Y[UI,DS*(V1E[9(I8=!FE<.')'I5(F$&QLC@6PQZ5
M2M;=KJ;@5U-S91>1#"% ;&":K-:1V$?!&16<MS6.';U94GTE/(S)D8%6=)@M
MX( Q]/2F/,;C"!^O%-=3;1>43T[U>MCJC%05BK?LUS(=AX!JC%(\,A4U9FCE
M#KL!.?2K=GI5Q),LCPL 3W%$(ML3FD94^GS7(W*N:['PAX4B:$3W*D96NHTS
M1;:>%/W2C YK8?R-/@\E4 Q72H6,W4.+U+PU97!.<X'' KEKG1X-/GWQEL U
MUFO7$L88QY //%<A=223Q',G.*Z8TM+EQE=FXOB&+[+Y2OR!BLFXNE;+AN:X
M^XGDAD($G>GI<S2)]XT6L:,W8-8_TI4=OES75P3VSP*R'G%>8%VCDW$Y-=!I
MNHLRA02:I,PD=I;OF4'M6ZMW%Y&W(SBN3T]Y9G"!&!-;<<!C(#'D\4GJ3%$3
M!#<\DU9BNIMX2#D@UEZC!-%J"JA)!':NE\-6#/+ND0_B*;TC<J=DCJ/#_P!I
M-L//&#FM\=*@AC6, *,58KC;NSAD[L****!!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %)2TE !BJEU;"13@<U<I",B@#G7+6[X/>GK+D9
MK2N[(3*2!S6'*DEJ^&R12 NAZD#U02;=R*F66@"X&IP>J@EIXDI@6M]-D/[M
M\>AJ$-SUJ&ZNUA0YHC=L&[(XK7K*642'%<Q%;R+O7'05T6OZH"Q2,\GTK%,O
ME6ID;JPKU:=U'4Y9\LCCM6B*7.!5"*38X]JO7LOG.Q/7-9QX-:6ZG.]&:;70
ME3;5=5(<>YJ&/.ZM.VA\QTXZFIZE)7+UFF%!;I6QI^I_8YOD;J:M?V6L.A-<
M'&17,1.?M8&?XJT34T*I>.QZ;#<M=6?VJ11CUQ18Z]'#)('; 7I5.POXH-)\
MIP#6+>6DER6DMR0.I K!03;3*YVXIHTM<\12W<Q2!LI]:W?#>MJJ".1_F/%<
M=HMN&O0DWZUUMGHX%RCQL, YXI580BK"HSE*1W=O)YB!ATJS5*UPL87(JX.E
M>:]ST!:*,T4@"BBB@ HHHH **** "BBB@ HHHH *0]:6D/6@!:0]*,TR20(F
M30 N<5!-<I$,L<5B7WB.*'>H'(KEKWQ!+< E2P%<\J\.YO3HRD=N-3MY-Y#_
M '.M<]K6MV\T31I)7,1:C*JR#>1OJJI+S;6-5&KJ=,,.E(=<*LV3"2Q[U7MX
M9(WW2+A/6K0"VYQD'=22:;>7N!%N52?2NJ-6Z/0<XQAJ==X3DW%MIX!KMQTK
MD?"FDS6,1\TDDUUXJ);GBUFG+0****1B%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]KUO%(F
M]C\R\BO.-7GFG9EQTXXKT+Q!:W$@S&QQWQ7)WEBD-D\TF-P[&N[#M)'-6BV<
MW9.MN69NM4M3N6N)]XZ8JK>W6V9MIP,U46Y)//-=DK;G-%VT);AP\8]166V7
M/%6Y<O\ =HAB'<4EL59F>XV]:?$PSBIYX@7P*?%9$G.:EE)E>?I58-6G<0JJ
MX.*SVB/:D@:&L<$$5*A)P<U&(B>](25;%5%LB29T>D7AMKF.3/"GFN[&MVMV
MJLS_ #YS7F%LY) ]:UD=HE!!-$H*3"+:/4(?$2[HXU8=,5U=G<>?;JY/6O$8
M;QC<QD-@#K7:Q^(/L>GQMYF3GIFN2K1_E.B-2VYZ(.E.%>?)XW3RCZCWJ]HW
MB?[==%.:YY49KH:JK%]3LVZ4+3 ^Y ?44]3Q65^A8ZBBB@84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"54N[19T/'-7*2@#D+F*6RDZ?*:1)Q(,J:Z:ZM$N(R"HS7*W]E+9R%DSM]J
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M>::'K4YOA&[MMW=Z]&MG\R,'->55I\K/1ISYD3T445F:!1110 4444 %%%%
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M"<$C@55U"=+^[)!SFL+PW=@M)$6P&.*Z&:Q,)WKTSUKOI/0R>YO:*#96[$C
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M1O0Y*E1MV)$Z"GTVG5F8!12=Z6@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>,K&6[/7-(>&4.JGYEXJ/6[Z2",QCM7FNF:_=6-UO+L59LFNCD\00W[_ #D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2!,SXIBR8P*A:*19-^6'XUK)8JAZ4RXB 7&*5GN5H):W=RX #$@>];$-TXC
M?J/6L.U)C?'J:U5!84^9HI6->/5HTB*G&?I4(O%E;.1S55;4,N34T-L,TI57
M)6'8DFMQ+&2*H1Z?)YN[G'UK5=60;14BQ,(P:E7*CHQ]C^[3+CD5?WC*LG7-
M9T,P1]CKG-:MG&#(&(^4FLYQN=<)'5:3<&ZL3%-PAZD5F:H%BGCCCD8@M@<U
M=E7;8-' =K$=13XM(>ZC@+N-P.<FB,0I\L).4CJ_#<+06(WYYYYK<ZC-9UA
M8+8(7!XK13[M=$%H>+5E>;8J'BI*BQBI!TJS,6BBD)P,T <OJ\S7>J&PW$#&
M>#5 7#Z1=Q)"Q96/[S<>E,U&SNKSQ<?L\AC^7K6L^C-:Z;<R7!$D@7(-7L26
MO^$AM7E\I) 7]*27Q%; 920';][VK)T6RC?21=O%F4\9[U!8QVRVU^954M_"
M.]%D%V= ==MSI_VA'SGI5#1?$#W'VA[G"QH>"/2L9HV70HIA&0A;&W%:$]K'
M'HSB  -(F21VHL@N:DOB2U0A_,'E,< U9NM;M;=8P9,/(,J/6N2TOP^UQIT9
MDN48@YVYJU*B?;[<3C(CX&:+(+LW;3Q#;7$[0>8/-0984X:Y#++MA<,H.&KG
M=+2)_%=V5CVHR8![=Z0V?V#5T"R!T=LD+19!<Z:YUNV@09D^:FVNNVTWRO)\
MQZ5SMB8YO$5T+I<0JN5#?C4%ZN]VN;9"B1G&!WHL@N='-XEM%G:)),LGWA4?
M_"5V+1-(DP*+P367#8PBR^UO%EYABJ_]DQ0>';H&/YV;(_6BR"[.L;6+5+*.
MX:3"R?=/K5:WUZ"2\6V9QYC<@5R5Y!/<:18PAC&%8<FMS2]!$=[#=-,DC*.Q
MHL@NSJP<BBBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K9Q3,9%2$9I,4 1TWBI<
M5%*-J,1Z4M6] .:\3I9&U?S2 V/2O%=4E"7C"+E<\5VGCBZNC>>6KL%(Z5P9
M1]^Z12:]*A!J-V<U1ILW-&C62+=*<#-+?+%<3+'$<[361)?/';E8L@^U3Z*[
M.\CRGD<\UM9D)I&O):I;6V3UK,N[8R1[P.!S4EQ>/<7'E D@U:N86CM%YSD5
M2=@=F<XJGK44DY8X':IW<1 AA6?Y@$C'U-*;NA123'32GH:K^9@TL[;SQ5?.
M.#S40E852*9I03XQS6]I=\8KJ)B< 'FN6B) Z5H6\VP\UK<Q2ML>GW=RE]9
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MN*T6Q%L\IR,#O73VMXI 7J:\^K&ST.NDVT:0I:B#;AD4X$UC8V'=Z6FYYIU
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MG/>L.4 M6G<S9!K'E?#5322!OFV$;:!49P:K2S'=UIT3[C6?,BXQ98& *C(
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MC"208#4<H[G<9JK+J%O!=);2/B5^@KCL:G;WK0F]+E>H%5[NROK[6+=TN/F
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M^%.E.DL(I(_+/W:MT4@,V[T6WNX$A8E0G3%.L=)BL1\CNWU-:%%.X6"BBBD
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %)0:!0 &HGPRD>U2FF[12 X+Q-X?GO;CS(8
M]W%<E=Z')"F)X]M>TF,'J*P]<TV*6W8[1G%=5*LUHS.43QJ;3;8 A&)JO>I!
M8VZ&-CN;K717EI';ASN7@^M<QJ<+RKD<@5W1=S"2*4%^(K@.Q'%:7]L+,N&(
MP.E<Q)D9S3HF;(&#5L@L:C-YMP2O2J4:;FYJU+&<9JB\WEFH9:74L-$.E216
M 8Y;-5(YB[9S6B)2$'/2I2%(T-/TN%I0)"0*FU;0WM/+:!2589)-4+>Z=BN&
M[UU[W FL%#J20O%:.YE9',6%M.T@&"/H:Z&YE%M; %B3CO609V@?(R*C>[,R
MD.<U:0MB">_9VVYXJ'S">E03,JN:B2XP_--M$J]S3CAD9-Q7BJDD@C?BM!+Q
M?LH4#G%8LQ)<GWJ#:2Y2T]^0F!5(S;GR:C.<57!.[%(<=2W*YVY%/L7*W2DF
MA4S%4460WXTBG9:'7)<*RQ@GC/-+JAAX\HYXK'BFS$!GD4R21SR6S2MJ:1FD
MB&ZB)&:@@@9CZ59!,G![5+$AW8'%'+<SNN:Y,J-'%\W3%5'W$[DY6G:C<F*)
M4S5&VNB!L;FA.Q$]=C8L=2DMY54?=)YKKH=>58!'"PW5P2MEQ@=:T[=)$8'!
MQZUIRJ6YA[W0]=TN[CDL<!OWCKTJ>S,L$N).*XKPQ-/)/@N<*:[66:/S,,X!
MQW-<56G:5CKI3LC<MKT=":T%<,,BN3BN58_*>E:EK?;2 QKBG%Q9T*29M=Z?
M4$<JR $5-2*%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI/:G+"&4R'D$5R))'3S,QYRRG()JC<+,R!QG'7K6Q&JR705NF:ORPVR(0P4
M#UK3F2&FV<M;ZG*#LS6A,XCBCE?C<:J3+;&] B QGL:T-6MM^F0[.QS1SH?*
MUJ1ZB\G]E/(O*@=:K>';MFG0 Y.1FK%G=(MBT%PNX$U5LWC@ORT*8&> *:ZH
MUY=#URR;]POT%6P.]9&AW!GLP6!S6P*Y'H<,]QPYI0II5QBEYS2)%%.%( *4
MTAA2TVEH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ J.0X7-24UAD4 <IJ^J>6Y0D=:YS5P+FW)7KCM
M79ZEHR766 &>M<=JEK+;OL&<5E,ZJ+.)N+$Q_O&S59[H20LG'I6GJ+MN\O!Z
MU3:QVP%@.34)G1)71BNH!R#6?> L=P[5HS1.C'.<&J<L+=.QJ@@^629-I.9=
MR@<XKJ-*GEL%P5&[.1FH/"BV<$^9T4Y]:V?$EQ9PSJ\"J%"]C295:LG*Q8LK
MUYI6W\9J74K>.6T;WKD;34W>XPA(!-;SS2LNPL>129AM*Y2?15AV2@$9YIU]
M*?L1C2M&9G\A0S=JI)$KR;2010C12YM2A80%B=PZTS4K<VY,G05T$<$<8RH%
M8NN3ALQD4Q<_,[$%M?JY10>G6K-VK2#*#-8%FC+/]3Q7501'R@7_ %I-#92D
MN D:K_%BJ@O)EDY'RU<N[8"13D&F7$:BVR$YH1*%F:.6'KSBL&Y+QN0,XJTE
MR$)#5#>31M'N&*T2!HI?:I%/)J1M4E$6WM51Y496Z9%4XXYIYF"YVX]*"62+
M=/-(< 'FGO;M*1ZYYJ6UA2(-N'.:G6XCC?D=:3)N;N@F&+",!D^HK4OX0>4
MY/:L&R=01(.U;4-R)3\PS4,M,+8_9B-PJ\\@E3( J&78ZYQ4MJH;@4TBE(6R
MT\7=PJX^8U:T[3YK35'4*=N<'-/M2UO>)*O0=A5K4]238&B^23N:A;G3"4G&
MSV)-6\.17NJ1W"CD+V'TI^D33VU]]G1<A6P:;I6L&&R:>X)<J:W]%:UO)FG2
M,!CS0EJ3/GC3:EL=1$,HI;KBK0Z"JR\X XJROW174MCR!:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW$6?,Q@9YKGM9NA$K1E@32Y;RN;)J**TEQ&S;F;K5'4%26!F#'-94EP[OPW
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MGFL'2M66=0K'GWK=4AAD4"'4444 %%%% !1110 4444 %%%% !1110 4444
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M7<]*EL.I<XIG>G5@:CLTN:92YH ?FESQ4=+F@"3-+NJ+-+F@"4-3M]0@TN:
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M8Y0XR.E3 U0L3_HXJV&Q72>5)6)J*:K BE-!("EI!2T %%%% !1110 4444
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M4D#@$5O3=T>16I2A*TAZC:,4[-)UHXJS(53DTZFKUIU !1110 4444 %%%%
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M^<UH^(O!M[HTC21 F,GHHS7/0W3!MDL;J?\ :&* -0'(XI:K+)QD'BI ^>:
M):*3(Q10(4&ES3110,=FBFTM #J44VG"@0\4ZFK3J!CA3A2"G"@!PIU)2XH
M<*#0*#0,;24M)2 *3-!--- $BR%3D'%:=EJ[P,/F/YUCT>],1Z1I7B< *'<5
MUUKJL%Q&,.,XKPQ+AT.5.*VK#798"N7-(9[&C!N14E<5I7B59 NY_P!:ZFUO
MX;A<JP'XTDVPM8FFACG7:X'Y5S6M:!"8'D0#(&>!73[@3P:;)&)8V5NAK6$G
M%Z&<H\VAX=J-I)YA5 >*;9.\$+JW!KU/4=,TV&-G94W8]17G-Z(C=,L0&,]J
M]"E4<UJ<<Z:@]"G;RNUR<]ZM3V(E=3S3XK=(CO(J2&8RO@'I6K*6Q%]E2&-L
ML>AKDKI@;A@.F:Z?5)6B5N:Y*1OWI/O32NS.<K%VV )XK7MXQ,P0]ZQK0Y;B
MNS\.VL$DJF7;U[FB;44$%S%#1;8#5F4]%/%=GJVHRVI2*+[NT5B7S6MA>2R(
M!D],&L*[UR2>3DDXX%<[ASNYJY<B/1M-\00)'&LL@#'BNH@F2X0,AR#7B^BM
M)>WZJP) 8=J]BT^#R;90..!7-6IJ)M2GS%P<5(*8HYYJ2N<V"BD-%(!::U.I
MC]*8%.\<>0X/I7FNM75M%>LNX;_I7::Y.ZP,$;!Q7B^MSS?VJQ9LFLILY:\K
M'2LD3)N<XSTK$U&Z6V4B)LU7;4))(T3=SC%((-P+S\C'>LV0DA;*Y8PR2/VJ
M%D6Z9I1SD5EW%PZ;U1L+Z5JZ;)&;!?[U=%*%R9)]#"DB<N^1C!XIB0N?O#BM
M:>V8[F6J\@*VXX.:Z_8B39G/"H4\\U1F@+#(%:6QCDFH)V"(>*SE"QI&YEQN
M(S@FITF^:J+',N:G';%<]M32QK)\ZY!-3QQMD8&:JVY(2M>P9-PWBIDA6#8P
M7YABJTK<_2M+42NX>6,#%9;<]:DAD4DI9<9J6W8[<4P0Y.:L)'MQ0T*US9\/
M)&;]%DQ@^M:&KJMG?6\J\+NS7/Q77D2!U.&%=#ILD>M(ZS$%HQ\N36;06L=*
MGB'S+51"^9..*[[1KII;.,M]XKS7C<%G+'JXMT.WW/2O7?#T#QVJASD[>M73
M;-J+;O<W<XI5I!TYIPK<W%HHHH **** "BBB@ HHHH **** "D-+3&ZT !.*
MKS7:0CYC@U,W2N/\4SSV[F5&(0#FI;L3)V1U45RL@R#3Y)"$RO)KC-*U@R1#
MDYQ6];7PD7YC^=)30E,S+ZX;S'#@>U<WJ.J/; KY:_7%:VIZC#'=892>:P]<
M,5U SQ+VKHIU(MZFT:Z)[#58?)D+,-Q'2JLU]-)D)G'UK@Y+VYBO5B"N 6Q]
MTUV^D(WE*\JEA]*TE**V-561!:FZ:9@=Q4GGFEU*W@C#,6YKH2;9(6")M9AU
M-<M>V-S-=L/-4ICIFDJJ3)=>*W./NT8760.,UK6RHUL"_%5KV-HI=K \'KBI
MX64VH!('U-=#J71.DMC)U-(O-"H>M=]X \,PSI'<.3DBO/;Q?](4@@\UZ=\.
M-1Q*MNS@ +W-93B^6Z!JR/0[BS']GM JCICI7CVN>%=4.L226\+%2>QKV\'=
MCN#33#&6R5KE4FB;GC47@C470,\3YQZFLC5=#N+#(E0J!7T!@ 8%8.N:!'J<
M7W1NZU<:@U(\&CB>,Y7)-=)H)N+^7[.R<"NUL/!"++F5%(S726'ARRT^7S$A
M 8]Q0YAS%+P[H(T_#$').>:ZK8*:JXQ4E9DMW&A%'0"N6\86Z26#%P. <5U=
M<AXWD*6'#8X--;@CP740PN6P. 35_3IT9-I/(%5;QMTK+M)))YJ]:6'EQ"3I
MD5T:V-#5M9(TX."?>I6FC&<@8^E9\*DSCTHO)-@P >:N");L9VJ0QS2EH@/P
M%:ND3K9F,G&?>H;&Q-RN[('UK*>Z,-^8CD[6P*V;B--G>75XL^)"<'VJU<11
M7EM&JGYL5C6P^TZ<-HR]06]W<6L^V1B.>,U%NQK&3-BUL[C2V6?:<9QR:]-T
M:Y-Q:H3UQ7 PW1N[15D;<,UV.A2H(PJD?G6%5-K4)^\CH2.:>.E-SQ3EKF.8
M!2TG>EI@%!Z44R0D(2* &M*HX)IOGQDX#5YEXH\47.GWTB*[  XK&M_&MP3D
MS&@#VH2 ]Z=FO*K7QNVX!W)K>M?&4+XW/^M ';YHK"M_$=K*!\P_.M.*^@E7
M(D4?\"H M45&)$/1P?QIX(/>@!U%)10 M%%% !1110!%(,BN/\1Q?>('-=DU
M<EXG?RE8X)^E1):&M)ZG(6CLLCKCJ:R];G=)"H'>K,5WB1B%(Y]*>;9;R0R2
M8Y]:Q.JY2M618\@#/TJW'<1DD,V#BIH[!$C;&*PKJWG%VQ3./I06C2#J\,GS
M<YXK.^WO Q7MTJ_:QG;M<'FEN-+60@A>]%Q,RE3S"9#Q6C%+%)!Y61D"K#Z>
M$@XP.*RX-L-VV^FF2QHLY8I=R*>N:G+&=&CEZ@5J@HZ?*P_.N;U.9X)R5/>J
M1)F?V>T6I*R@FNO^U.EC&F!TQ6%8R>?(&;K6U,5$*@BAH=[E1H4E?]X>M&P1
M<1GBHF$K/D9Q]*OQ(GDG</FQ4E1E8=I\R^< ^ OK4DET8+I2K$J6[FLUF,:D
M#K4,;M)(-YR :F6AUTE=%GQ/;27ENT\"[N.U<M:QLI(/WAU'I7IEBUL;#;*
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MVGAS[Z5W47W!7!>'6_>J*[V+[@H ?1110 4444 %%%% !1110 4444 %%%%
M!1110 F*,4M%%@&XI>:6B@!!2T44 %,*9.:?10 S%+MXIU% %6XLH;F,I)&C
M9'<5P'B?X=V]XCS0 A^P48KTFFM]V@#YBU+2-0T:=E>$^6#U-5X;I)>C<U]%
MZKX?LM3B99H0Q(KRSQ)\.)[0O-9;54=A0!R*R5(K9%9\OGV,IBFC?(."=IJ:
M.X#'@T 7,T9J(2"I%8$4 +FG4WBEH =3P>*93A0 ]:D%,44\4 .%/ IHJ04
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MN ]B:M1:A%*?E.?QK9/0\=PD7N,TM0+,I;KBIQS5$V%HI,TM @HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!.U>6_$RU+6^\#^+->I5QGCFT\[3&.,XR:
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MEB:YC60<9%.=/W3)2O(Z6V\#)>Z895SOXX%:%E\-H613,[@UW>D^2MHJI@9
MXS6C@5YDEJ=J5T>=7WPUM9(BJ2-^%;>A>$;72XP&4.<?Q"NKVYHVD=:GE*(H
M;>*-<*BCZ"IP !2 =Z7!IH %.IO:G4P"BBB@ HHHH **** "BBB@!#12T4 )
M7/\ BD,='FV]<5OFJMY;I<P-'(,@TGL#U/!9MTDK(SD;?>J5PH' 8GWK?\86
M)T^\=H5*@MV%<QYF8SGK6$HF#A9W(&B,C8["HY(]G YJ<2@ U$) ?O4TA6*^
MTLW2M*U6)0,D9J!#&3@"K!@VKNIB:.@MKBU\G#%1@>E8&L.@G+1-E:K&4@XS
M5:>3>VVCE%8AY)R>]2@A1UJ,?RICL<X%4H@HD_V@KP#3EE;[V<55 Y&:5GP<
M \46!Q-"*^DC/RDG\:?(QG)D8\FLY-V<YJ0W!7Y<TK!RC9FVMC-1K(0:B=RS
M]:D5<FI:(<;%J-9'&5&:ZWP6/^)D%E<KC'&:PM,F@MXV\Y<YJ:*_,&H":W)4
M$BJB731]$VI'D( <_**G[US?A:_DO+!3)G( ZBNCP<5J=(X4ZFBG4#$;I7)>
M)='>_B.PM^!KK3TJM,0%)/I33LRHGC<OAP6P9IB0V>]8MQ;PI(P4\UV_C"9F
M=FA. !7$V;QM,_GC-=<).2-GL9T]K+("Z G':LP32I-L9<8-=DE[9P2@&,E/
M2J%Y96]]+NME"DGO5\[1-S._MV6SCV*>/K6EI=S'-()GQDG)K.O?#TJ1EG93
M6']ODL6:/<?2M-&BU(]5ENXGM<PMA_:M&WN9[N!4V<*,$UY=HVL2R7"HS'%>
MA:/JJ0J0YX/O7-RZ%+8Z32+:2.\!4L5^M=I'G8N?2N=T:Z@F17C%=%&<BL)[
MF%3<?WIU-[TZH,PHHHH **** "BBB@ HI"0*-Z_WA^= #74,,&N#\<:,MU:R
M2!>@]*[IY4 Y8?G6#K]W;MILJ9&X^] 'S[/:>3.R>E,V8K7U:,"[=E[FLQJ0
M$.*6E-)0 4444"$/6D-!H- "4444%!1110(2D[T4=Z 0E(<=,\TM-/7=ZT,&
M7--3?>QAF/6O2M/=H8<;<J!7F-JY2Z1QVKTJRN5.DJ[ @[3UK&1UT!SK%>AG
M( VG'2LV\TV-4WJ<57TV_,UZ845L,Q[5T5];K%: MCFH-(QL<?<@2V[1ASGI
MQ6;8Z2[W#99OSK=2P9Y"X^Z#5^&UV\@8-,N]HV.;O+*2SG4J6(QZUL)(YLXS
MWQ5BZMFF'/)I@LY5A S0R;Z"V+%V^8GK6C+;B6)N>@K,C@EM5\QCP*MP7P:-
MP>..]"1)B7%JQD*J"1201FUD!8XR:M&\2.3<W-0$-?3 IG:#39:TU-8M]HM<
MJ :HP6>9CGUK1ML1H(N]1SRI;Y;O31-K%.\4PRX!-7H5:2-0O7%8LMTUQ<9)
MR*W;2XC@6-B,XZXJ6;170VK2XCMK7RIL%O0UR^O+$[[D?KV%6]7O5=3=(I"F
MN>N-3AF*@ Y[TKFT8]2JDGE,.:Z[1]3MX]+N%=AN(X!KDY+5KCYXB *C!>&-
MAGIUJD$E=$MRZ37[N#P138RN[:'(K,^T$S'!Q6CI47GW W$=:&.#:.DT_4PL
M(M@0645T.@7T\#,7)(SW-9-GIEM%*92H)(]:F:;R7V+T-0G9ESY)*UCT.VUB
M*3 + &M=)%900>M>6Q>>SJT<@'(KOM)D<VH,CAF [5M&;9YN(PW(N9&SVH%9
M4NK1PN58XQ55?$$37J0C/S5?,<RI29T-)4*3JP!R.?>I P-.Y#30^BBBF(**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH 2C'%!HH X_QOHRW^ES,!EMO%>!1;]+U:2)^ #CFOJ6
M[@6>W:,CK7@/Q&T"2RNS<QK@%^P]Z );2<.@YZU;XKF-$OQ*@4GD<5T:-D4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT:UCBM5VKC@5%*+N98^47'0V >*=2 <4M=1Y 4&BB@!!2TE+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%%  :9MYI]% &?JFFQZA9O"X!#>U?/'CCPQ+I%^TT*';NZU]+US/B?P_#J]
ME(I0%MIQ0!X%H^J;U"L>1Q7212!UZUQNN:3<^'=392"%R3P*UM*U(2QJ"W-
M'04HJ-'!&:?UH GAD*MUKH](U<QNJENAKE03NJ:.0QL"#0!['IVHI<1#+#-:
M.01FO,-(UAHV4%N:[S3M2CNHP,\@4 :E%(.E+0 4444 %%%% !1110 4444
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M$QNUFZ4R1&4=#5N%T P12R@2#:!3;%%7,TSG'!QBD60GDFI3;A7Y'6FNBHV
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M!J0&D!*#3@:C!IP- #J*3-+0 4&BDH 0U&14IIAH 924IIM "TE%% "T4E%
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M-MCYR+.*8R[CDDU*5IAHNQ)M$6/FY/%,QM)]ZE(IK4$M79'12FD- PHI,T4
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M_P#!"W<<EQ;Q_-C^$5X^CW&DWC0S @ XYKZUF@29"CC*FO*/'?@..X1[BVB
M8<YH XJQOEE08:M-7#"N#1[C2;SR)LC!]*Z:QOUE0?-0!L8^6@&F1ON'6G4
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M4VG4V@ HHHH 2BEHI )1110 4444 %%+10 E+110 4"B@4 +1113&%%+BC%
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M:::>1330 T4=Z*2@!P-*#3<T4 2 U(#4(IX/-("85(#4(:GAJ )A2TP&G9H
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MRV:GJI;3>;&K#N*MUTGCVLPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGPW%Y]PVYMI7I4^LWVT&,G-0^'YTCN&8CO3: Z.]66)O,+L<#UJO>2_:K95
M&X"JNN:QB7:A.W%0Z=<^>>_XTDQ-6,Q[217^8&G,)8X^5.*T=9D,419:SX+Q
M[A-K!B /2G<0^TN4\O# 9I9G+=!Q5>1$C;.TBK"RHR@ &G<$NI!#J:6,I;<
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M8R9UT&FO=)-<!MMJQ?,I/!K1\-ZE#:1#S]HY[U(TEA=V:!XR645CPVBW6IK
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M#U44^B@")K:%NL:G\*B;3[9NL*'\*M44 46TFR;K;Q_]\U7E\/6$G_+O&/\
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MPSIZ=(: /G,:!J9/%N]2KX9U1C_Q[/7T<NB62GB.I1I5J.B4 ?.J>$-38?\
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M;^$O)8W,*_[7 KC])NW0B.3@^]?0FK6"7MG(C+GY<5X=XBT.32[]I$7"CVH
MTT = ?:D\JJ^F7'FQ8)Y K1V\9H I&/!Z59LYVMY@P)I2E-"<T"/0-#U82!5
M9JZQ'#KN!R*\ETZY,$HY[UZ#I-\)8%!- S;S2U&F>]24 %%%% !1110 4444
M %)2T4 )2T44 %%%% !28I:* $HQ2T4 )BC%+10 F**6B@!*,4M% "8HQ2T4
M %)2T4 )^%&T'M2T4 -V+Z"C8OH*=10 W8/04;%_NBG44 -V+Z"C8OH*=10
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M>X'!Y^M:B3I(,J1^= $E%)D49H 6BDS1F@!:**0G% "T4FX49H 6BF[A1O%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &,,@@]ZX
M'QUX=6\M'E5>?85Z :JWEL+F!HV&00:0'RC<1M:W4D;#&&P*<&R*Z_QYX=-C
M>^8B8#$GI7%1G!P:0$V:4\TT=:4D"@0'DA1WKL?">A&XG1V7T-<[HU@U]>H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#,%W,HK9BNX95^5P:\2AOIHB/FX%;ECXDEAQ\_% 'JX(/2E[5QMAXH#XWO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* $Q2T44 (<5AZ]HT.JVK1LHSSSBMP]*9M&,F@#P2^^'=P-4&Q6*%NPKTKPE
MX732X4+*-P'<5UQC1FSBI ,#B@ 5 HP*<*2E% "T444 %%%% !1110 4444
M%%%% !333J:>M %#4;0W,)6N(U'0[B-9!&K'=Z5Z,>:8T0;K4.-P//?"GAV2
MWO!/,IS[UZ"J#9@CBE$:J.!2U2206*<^FVUQR\2'ZBLC4/#5O<Q,J*J\=A71
M\4#!H:3 \FN? C_;,KNV@]:] \/::=.M/+8]N];&WFEXI**0 >!5*^T^*]A9
M'49/<BKM+P!3: Y*'P=;Q7!DR#GMBMZUTRW@ VQ*".X%7L#K3A4QC9BLA H
MI:44=ZL89HXHQ1B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ)GO3@<T!UN3).Z_Q&IENE')C!-5**R]C"_-8T]K*UKFK#=PR,-\2_0BJVH
M(-T* !O2J?.<UI1XEC3/1>:51+H=&&;4KME&Q@\EQ*\>2.QI\]^MPYC<X4=O
M2I+ZX/F#R<@ 5FFTVEI91G=44G)2/<BZ=O>W)8[.)[D,K BJU[9A+J)8AN+-
M@X[59MKJWABPH/F9XK1TU8#/YLXS@Y6O34]#*K65)7N=UX/L)+:S0N3^-==C
M(KD;#Q%:VZ .3M%:\/B&TF^X?UKFD[L\&O44I7-A0:>%QS5&+487YW#\ZLB[
MB;HP_.ET,D6!2U&LBMT(_.G[AZB@ S2TF11F@ I:;NI<T +129HYH 6BDYHS
MZT +129HH 6DS1D>HII90,DT .I:KFY0'K3&OXD')H M$TA.*S9-7AZ+G-4I
M=1FSG>-M &T]S&G5A5.?4@OW1FL.?4XSP<YJC)?EON&@#6N=2R#SBLB:\:3(
MJL\C.<L:;GTH =DT9XIM% !FDHIM #J #F@<U;M;9YG&* +VG6^2&QTKH[2+
M:V['XU4L[7 4*..]:J *-H[4 +CYLYI])2T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2*/MBO*Q?S_WJ>FH3Y^]0!ZD/$4?H*:WB)1T45YE]OGS]ZIEOYR/O4 >B_\
M"1K_ '136\0J1V%>?B[E/\52+,YZF@#N#JR/SYV*A?5@O DS7(JV:E4T = ^
MK$G@U$VI,:R5-/% %YKPD<"H6E=OXC40IU "]>M!P.E)10 4M)1S0 44A(IN
M[- #J3K2$XJY8V,ER0P'R^] #;:W::0  XKIK*PVJ!26%B%Z#IUK:2,** $C
M0*N ,4_%**6@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS:<J/*>* '!A@TL:O*?E%6K;39'8;AQ706FCJN-J\4 9=CII8AFY]JZ"WL<
M8&VK\-E%$HP.:LA0!B@!D<810 *DHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***0F@!::[JHRQQ1DUAZ]>O;Q#:<9%)NRN)NQLK*C_=8&JFH60NX60GJ
M*Y;1=8FDO/*9N*Z^)V8 FHC+F%&2DCE[3PI'#>>:Q!_"NGC@1$50HX%6 ,B@
M**OE121&$ /%.P&4@T_:*"HQ0@.*\2>'GO7+1DC)[54T7PBL#B24Y(/>N^*
MCI4115-2XW8FAEO$L4010,"IL;17.:[KW]F@;&(^;!JE+XN0Z<[H_P"\ XYH
M<DEJ',CK/-CW8+C/I4RX->:Q:Y=R_O@_7FMG1_$SS2"*9\MG J55B2JB;L=K
M15>&4R+FI<FM$[ECZ*!THI@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "44$
M9HQ0 PQHXY -5Y;"VD&&B7\JM@8H(S0!A7'AFRGY\I!^%8EY\/K6YSMD5/H*
M[C'%)MH \IO/A?Y8+QW1;V%<_=>#+ZW)"1R-BO=\<4UHPPP10!\[RZ+J$)P;
M=ZKM:72?>A85]#2Z7;3??2LZX\+6$P/[N@#P8B1>H(H#GUKV*X\!V4N<15DW
M/PY!_P!3&* /-EE([T[SO>NRG^'&H\^6JUFS>!-5@)+*/RH PA/Q3A/5V7PY
M?1<%?TJLVDW2=4/Y4 ()ZD%Q4/V"X'\)_*C[),.JG\J +(N*>+BJ?DR#JI_*
ME"/Z'\J -!;@5(+@5G!']#^5/"O_ '3^5 &HMP*E6X%9:1RDXVG\JM+;3'^$
M_E0!?%R*>+CFJT>GW#?PG\JO1:7+QN4_E0 GVCCK2B5SR 36E!X?DE VK6I;
M>%[@#E1B@#G4$DO8BK4-C+*VT@@>M=9!X="??7FM&'28X^JT <M;Z(P(/+9K
M:M-#7AFX]JW8[=(_NBI<4 4XK&.+' XJT$"].*7%&#0 ZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *0TM(0: $' Q7.^(+=I & ) KH@#BH;B
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH 3%+24M !1129H ***"<"@".90Z%:Y75-",P8HQ&?2NAGO8HC
MAC3XW6494@BDU<5SR"\T"]AOLQQ.PW#D5Z;X:AEAL-LN<\=:TS C'.*EB7:,
M5$8V8QY%*!0:05H =Z6BFL: 'T4@Z4M !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gfbaqn1kfu2x000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *V!.\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY$(3"$X KF9_']^;MK:WM?,DW8 %:'@O_D66_P"N9_E6'X9M8Y/$GF,,L)*
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ML/6$$/C"TV#&9.<4 3?%34]2BM##' WD \.*D\%:YK4D5O$]D_E8 WFM?XH
M?\(TG'\5:_@X+_8UOP/N"@#G/$/CRZTK7FL8X-WR@U-I7B+7;G?+)8.$/*GU
MK UBVCNOB,Z2#(V@UZ<9(=.T7S64".),GB@#C;SQ%X@>8K'IK[!SD4_P[XSO
M+F]:UOX#"P.%SWJ ^)+G5G==,.%Y'2N5@-XOB>W^TMDF7G% &O\ %K5-1CL'
M@C@86^?]8*@T#Q)XBBTF!8M-DD4*,-ZUT/Q7 _X0T\=Q6[X-"_\ ".6O _U8
M[4 <AH/C&\O/& TZ]TX12D#YB.:[;Q#KZ:+:AL@R,/D7UK@9ACXQ\#' _F:F
M^)<K_P!LZ1'SM9QG\Z!CQXK\17,9GCTV0J#V]*WO"GC!]6FEM[M!%+'Q@UT=
MA!#'IBA NTQ_TKS&W00^+93!_%+\V*!&]XE\;W.D:\+*&'>"N<UES^,O$"$3
M_P!FN(.I;C&*K>((%G\?VZ../+_PKO-6MHU\(7*A1A83CB@"3PQKZZ[I?VK@
M8X(KD[OQKJ-WJD]G8VIE,)P=M+\*.?#\BGIOJG?>']5T+5KC4K(@)(VYOI0,
MZ[P]JFJ7.U;RT://<UO7UTMG;/*W11FN6\+^+(M29;:3/G9QTKK+JUBNX&BE
M&588- CA7^)-JCLOF)P<4T_$JT(P72M1OASH+,6,').32'X<>'P,F#% '!>*
M]?TW6;-V5HTE[,.M4/ ?CJ2RU#[!(Y:/(56)K3\::7X;TJ%K2WBS<M]W;S3/
M 7P]66X&H7<?R'YDS0![/!*)H4<?Q#-2U%#$(8E1>@&!4M !1110 4444 %%
M%% !1124 +1244 +1110 4444 %%)2T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%)2T4 8/BBUENM*GCB4LQ0@ 5B>!-,N+#PX\,\91RW0UW'6C@4 >=^!](NK#
MQ-J4\T3(DC':2.M7/'.F7-]$WD1ES[5W&!Z4$ ]: .5&BM=^$H;:0$2+%C'?
M-</IE[K_ (5$EG;Z?).C.3NQ7L7M2;1Z"@#B-*EU/4=/OFNH'C:2/A34'@32
MKJP27SXF3,A/-=_BC&.@H YOQ;H(UFS!_BB^9?K7%:?K>O:&C6R:7)*H/#;:
M]9I-H]* .1\/:GJ.JF9+RT: %>,BN4UC3]0TCQ$MW;6;7(!STS7K6 .@HP/2
M@#QC78M8\1W%H9+"2((X/2O0IY+O3M!5H(F>54 VCZ5TN!Z4=J /);_6-:U:
M);:;2& /&[:*U5\.W%KX(N[559I96#;?SKT3 ]!2XXH XSPKIUQ:^'S#+&5<
MQD8-9OA[2+JWUDRR1,J[\Y(KT7\*,"@#B?B'IMQJ-G:K;QERLBDX^HK/U^%H
M/!<T$A*/Y>,5Z,:YSQ7HDNKZ;)' /WI'% 'FGA_3K@:3%(++S !D';UKH] \
M5SVNJQ:9-:^49#QQ4-A9>+=,LULXWPJC %6]&\*ZG<:M'J.K -+&?E/M0!Z*
MZ[D*^HKS'Q9H-Y9ZW#J=C&TACYVKWKT^@@=Z /,;7Q'X@U.2.";3I(5!&6Q4
M_BSPW/<S6NJP*QF@7(4=2:]'P.P%% 'E"^*/$;6WV,Z7+@C:6Q70>"/#;Z<L
ML]P#OE.[#=J[;:/2EH \W_L>[_X3F>Z\IO+)X;'%=/XKM);OPK<01*6D9, "
MN@P.O>EH X?P1H\UOX.CM+F,H^T@@]JY:.WUCP?J-PUE:27"32%S@=*]AXH(
M!Z@4 <#H.HZOJ]Z_VVT>!&3'-9&KZ)>Z%J:W=A TVYMS!17JN,=J,9H \TB\
M6:].R(VD.@R 3MKH_$5O<:AX6F01'S7B^[74;1Z"CMB@#D?A[83Z=X6CM[A"
MCCL:Q=8T:[F\46LZ1,45\D@5Z1THP/2@#E_&VE2:KH8AC4EEYXKF?"VK:U:7
M*V,NG.(E.T.1VKTZDP/2@#S:[T>\D\=->"%O+*#YL<5VNJ6C77A^>V'#/'BM
M7O10!XWIC:OX;=K2+3'F4D_/MIUKI.I76NP7DMJZ ON.1TKV' ]*7 ]* .3\
M=:1)K'ALVR*2W7 KG_"VJZU:-'I\NGN(D^7>1VKTRC:,]* /-9-'NV^)_P!O
M\EO)*CYL<5K^-O#K:M%#<1@^9 ,J!798'6E[4 >36OB7Q)96YLQI<KC[N[%:
MW@_P[/\ ;I]0O%97E.[:W:O0]H]!1C% 'F^KZ-=R^.8KI(F,03&['TKL=2MW
ME\-W,"J2[1$ >]:_>B@#@/A[IEUIFB21SQ,C;LX-5=4\1ZVEQ/;KI3RQ] =M
M>D@8I"H]* /-_".BW4NI+J-Q 8"#]S%>E4G0=** %KG_ !3>WMK8,MG"TC."
M..U;_:@@=Z /)?#/@ZZU+4?[2U3?E6/R/7JMO;1VT*QQJ%4= !4G3TI<B@ I
M::6'J/SI#(@_B'YT /HJ,S1CJZ_G5>74;:+[TB_G3LPN7**Q9O$MA#]Z0?G5
M";QWI4/WI!^=/E8N9'4T5PD_Q2T2'(,G/UK)N/BYI8)\N0_G1R,7,CU&DKQF
MY^,$*Y\N8_G61<_&&Z)_=3G\Z?(PYCWPLJCDXJ%KR!/O2**^<KCXN:RYPMP<
M?6LR;XE:S-G,Y_.GR+JPNSZ9?6+%/O7"C\:KR>)=)C^]>1C\:^7+CQMJLV<S
M'\ZSIM?O9_OR'\Z+0#WCZFG\:Z/%G%Y&?QK-D^(>G!PJ3QG)QUKY@:]F?JQ_
M.I;&=VO8LG^(4UR@U(^P=+U%=1@\Q<8QVK0KD_ G.CI_NBNLJ):,:V#O1114
MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_(&3_=%=9WIS^(F.P4445 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\QCU8TVBES,=D+G/>DHHI7&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5FP_X_8O\
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M (0/4O[C?]\U]5_8K7_G@GY4?8K7_G@GY4<T>P>]W/E3_A ]2_N-_P!\T?\
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M4]+_ ,_TO_?1H_X4]+_S_2_F:!G=_P#"QM*_O#\Z/^%C:5_>'YUPG_"GI?\
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M_,T =W_PL;2O[P_.C_A8VE?WA^=<)_PIZ7_G^E_,T?\ "GI?^?Z7\S0!W?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "T444 %><_%/_D%1_6O1J\Y^*?_ ""8_K0!5^%/.E3?[U=3K<1:%L>E<O\
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M>*P^*IPO):I8?%TSRA<MS0![1%?AVX-:]NVY<UYWX=O)+K:S9YKT&S_U0^E
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M)#D&N_\ $U^NG:-++G&VLOP-9B'2(9BN&=<FN<^*&LB.V>Q5OF?G% 'E\.O
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M* &;11L%/Q1B@ 48IU)BB@ Q1M%+10 W%&*6EH 3%-(I])B@!NT4!13L4N*
M#%%%% !1110 4444 %)2T4 )2T44 %%%% !1110 4444 %%%% !1110 4PBG
MTE #<48I]% #,4&GTF* &4HIV*,4  I:** &&HR*FQ3=M $(4YJ0#BG[:,4
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M*$J@^E2+\--6)PSS8^M>]8%&!Z"@#R?0OA>L%PDUTSL5.?FKT^SM([.!8XU
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M ,\9O^^30![7BC%>*?\ "V7_ .>,W_?)I/\ A;+_ //&;_ODT >V4WO7BO\
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M^%LO_P \9O\ ODTG_"V7_P">,W_?)H ]JQ2UXI_PME_^>,W_ 'R:/^%L2?\
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M/^%LO_SQF_[Y- 'ME%>)_P#"V7_YXS?]\FC_ (6R_P#SQF_[Y- 'ME%>)_\
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MC-_WR:/^%LO_ ,\9O^^30![92$5XI_PME_\ GC-_WR:/^%LO_P \9O\ ODT
M>RR)FH3'S7CQ^*\G_/&;_ODTA^*SX_U,W_?)H ]C"TNVO&/^%JR9_P!3-_WR
M:=_PM:3_ )XS?]\F@#VE5IV*\6_X6N__ #QF_P"^31_PM>3_ )XS?]\F@#VG
M%.Q7BG_"UW_YXS?]\FE_X6P__/&;_ODT >V"BO$_^%LO_P \9O\ ODTO_"V7
M_P">,W_?)H ]LJ*Y_P"/>3_=->,?\+9?_GC-_P!\FF2?%=WC9?)FY']TT 8U
MG_R/C_\ 7>OH.W_U"?[HKYN\+2SZCXK%R8G :7/(-?2,'$*?[HH EHHHH **
M** "BBB@ HHHH **** $I:** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "J=]817T7ERJ"/<5<KG/%7B!="LO.)QF@"!O ^G,Q/E1\_[
M-)_P@NG?\\H_^^:\T?XKW3R-Y1D(![4?\+4O_27\C0!Z7_P@NG?\\H_^^:/^
M$%T[_GE'_P!\UYI_PM2_])?R-'_"U+_TE_(T >E_\(+IW_/*/_OFC_A!=._Y
MY1_]\UYI_P +4O\ TE_(T?\ "U+_ -)?R- 'I?\ P@NG?\\H_P#OFC_A!=._
MYY1_]\UYI_PM2_\ 27\C1_PM._\ 27\C0!Z7_P (+IW_ #RC_P"^:/\ A!=.
M_P">4?\ WS7FG_"U+_TE_(T?\+4O_27\C0!Z7_P@NG?\\H_^^:/^$%T[_GE'
M_P!\UYI_PM._])?RH_X6G?\ I+^1H ]+_P"$%T[_ )Y1_P#?-'_""Z=_SRC_
M .^:\T_X6G?^DOY&C_A:=_Z2_D: /2_^$%T[_GE'_P!\T?\ ""Z=_P \H_\
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MM2_])?RH_P"%J7_I+^1H ]+_ .$%T[_GE'_WS1_P@NG?\\H_^^:\T_X6I?\
MI+^1H_X6I?\ I+^1H ]+_P"$%T[_ )Y1_P#?-'_""Z=_SRC_ .^:\T_X6I?^
MDOY&C_A:E_Z2_D: /2_^$%T[_GE'_P!\T?\ ""Z=_P \H_\ OFO-/^%J7_I+
M^1H_X6I?^DOY&@#TO_A!=._YY1_]\T?\(+IW_/*/_OFO-/\ A:E_Z2_D:/\
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MC_[YKS3_ (6G?^DOY4?\+4O_ $E_(T >E_\ ""Z=_P \H_\ OFC_ (073O\
MGE'_ -\UYI_PM2_])?R-'_"U+_TE_(T >E_\(+IW_/*/_OFC_A!=._YY1_\
M?->:?\+4O_27\C1_PM2_])?R- 'I?_""Z=_SRC_[YH_X073O^>4?_?->:?\
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M(T?\+3O_ $E_*@#TO_A!=._YY1_]\T?\(+IW_/*/_OFO-/\ A:E_Z2_D:/\
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M ,(+IW_/*/\ [YH_X073O^>4?_?->:?\+3O_ $E_(T?\+3O_ $E_(T >E_\
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MG?\ /*/_ +YKS3_A:E__ --?R-'_  M2_P#27\J /2_^$%T[_GE'_P!\T?\
M"#:=_P \H_\ OFO-/^%J7_I+^1H_X6I?]<2_D: /5K'PK96,@>.- 0<\+6^!
M@8KR;PQ\2SJ=\MO*S%BV,&O5T;<BMZB@!]%%% !1110 4444 %%%% !1110
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M</">E_\ /K%_WR*W*=VH P/^$3TO_GUB_P"^11_PB>E_\^L7_?(K>HH Y_\
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M_A$M,_Y](O\ OD5OTM '/_\ "):9_P ^D7_?(H_X1+3/^?6+_OD5OTM '/\
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MQ1F@#G_^$2TS_GUB_P"^11_PB6F?\^L7_?(K?HH Y_\ X1+3/^?2+_OD4?\
M"):9_P ^L7_?(KH*0T 8'_")Z7_SZQ?]\B@>$M,_Y]8O^^16]2B@#"_X1+2_
M^?6+_OD5%/X3TP0.?LL73^Z*Z.HKG_CWD_W: /G;2;5+7QRZ(  )\ "OHN#_
M %"?[HKY[L_^1\?_ *[U]"6_^H3_ '10!+1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G/Q3_
M .05'_O5Z-7G/Q3_ .05'_O4 0?";_D&3?[U>EUYI\)O^07-_O5Z70 444F:
M "EIN:6@!:*** "DHS10 44"G4 -I:*;F@!U)32U&Z@!U%-+"@'- #J6DHH
M6BBDS0 M)32PI-XH DHIF\4;Q0 ^C--W"DS0 ^BD!I: "DHI,T +2TE% "YH
MI** %I13:* '9IM+10 E+249H 6BDS10 M)110 4M%% !129HH 6BDS1F@!:
M2ES24 %**2B@!:*** %I*2EH **** "BDS10 M%)3L4  HS244 +1FDS10 4
M4M% "T4W-+F@ I:2EH *0T9I* %S244N*  =*#12T -I:6DH **** #%%%%
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M*0X$GZTP/2/MJ^M.%ZO]ZN"7Q K+D/5:?Q5'#U>@1Z2+Q?[PIPNU/\0KRO\
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MVG4TT )FBEQ2XH ;24^DQ0 @IXI *44 '>EHI#0 4444 +2 T44 +FD-%+0
ME+Q1BB@ HS1BDH **6B@ I*6B@ HI*6@!:3-%&* $HI:2@!*444O:@!#12TE
M !112&@".0Y4UA:E&60XK>852N(-X/% 'FFJ6,KNV,USTND3LW0UZO+I:NQR
MM1?V,F?NTQ'F$.B3 \@UK6^E.!R*[Q='0?P_I4@TI1_#0!PKZ0Q'2H5T)BWW
M:]"_LU?2GIIRCM0!RFGZ*(R"5KJ;*U$:C JW'9A>U64BV]J )8EP*G'2HT'%
M2 4ABU%<?\>\G^[4M17/_'N_^Z: /GVR_P"1\D_Z^*^A+?\ U"?[HKY[LO\
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MH Y#PCX431;-I& \UU^8UQWB3PY=7/C*&Z1&V*".GTKV4  8 IAAC9MQ12:
M*&B0M!IT2,,$"M.D"@#BEH **** "BBB@ HHHH **** "BBB@ KSGXI_\@J/
M_>KT:O.?BG_R"H_]Z@"#X3?\@R;_ 'J],KS/X3?\@R;_ 'J],H *2BB@!*6D
M- H 6DI:2@ HHI: $I:** $I:2EH *2EI* "BEI* %HI** %I*,T4 %%+10
MF!1110 "EHI* "D/2EHH C YJ048HH 6DHHH 6DHI: $I:** "FTM)0 48I<
M44 )2T44 +24"EH *2EHH 0=:6DHH 6BBB@!**6B@ HI*6@ HI*6@!****
M"C%+24 &**6B@ I:;2T %%%% !2TE% !2=Z6B@ %+24M "TE&:,T %%%&*
M4M)10 4444 %+12&@!:*;2T &*,T44 %%%% "TE+24 +2444 %%%% !1110
MM(:6DH 2EHQ2T -H%+BC% !0:*6@!M+10* $HI33: "BBB@ I:2B@!:2EI#0
M M%(*6@!:2BDH 6EIM+0 &H;G_CW?_=-35#<_P#'N_\ NF@#Y^LO^1\D_P"O
MBOH2W_U"?[HKY[LO^1\D_P"N]?0EO_J$_P!T4 2T444 %%%% !1110 4444
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MU]"6_P#J$_W17SW9?\CY)_UWKZ$M_P#4)_NB@"6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M.?BF"=)0@9P:]&K(US0XM9MO)D.!0!XWX"\:VFB6DL,X.[=7:_\ "T],]&_.
MJ;_!ZT:1F%RPR<X%)_PIZV_Y^W_.@"[_ ,+3TST;\Z/^%IZ9Z-^=4O\ A3MM
M_P _;_G1_P *=MO^?M_SH N_\+3TST;\Z/\ A:>F>C?G5+_A3MM_S]O^='_"
MG;;_ )^W_.@"Y_PM/3/1OSI?^%IZ9Z'\ZI?\*=MO^?M_SH_X4[;?\_;_ )T
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M #]O^='_  IVV_Y^W_.@"[_PM/3/1OSH_P"%IZ9Z'\ZI?\*=MO\ G[?\Z/\
MA3MM_P _;_G0!=_X6GIGH?SH_P"%IZ9Z'\ZI?\*=MO\ G[?\Z/\ A3MM_P _
M;_G0!=_X6GIGH?SH_P"%IZ9Z-^=4O^%.VW_/V_YT?\*=MO\ G[?\Z +O_"T]
M,]&_.C_A:FF>A_.J7_"G;;_G[?\ .C_A3MM_S]O^= %[_A:FF>A_.D_X6GIG
MHWYU2_X4[;?\_;_G1_PIVV_Y^W_.@"[_ ,+3TST;\Z!\5-+]&_.J7_"G;;_G
M[?\ .C_A3MM_S]O^= %[_A:FE^C?G0?BIIGHWYU1_P"%.VW_ #]O^='_  IV
MV_Y^W_.@"[_PM33/1OSI?^%J:9Z-^=4?^%.VW_/V_P"='_"G;;_G[?\ .@"[
M_P +3TST;\Z7_A:FE^C?G5'_ (4[;?\ /V_YT?\ "G;?_G[?\Z +W_"U-+]&
M_.C_ (6IIGHWYU1_X4[;?\_;_G1_PIVV_P"?M_SH O?\+4TST;\Z/^%J:7Z-
M^=4?^%.VW_/V_P"='_"G;?\ Y^W_ #H O?\ "U-,]&_.C_A:FF>A_.J/_"G;
M;_G[?\Z/^%.VW_/V_P"= %[_ (6IIGH:/^%IZ9Z'\ZH?\*=MO^?MZ7_A3MM_
MS]O^= %[_A:FF>A_.E_X6KIGH?SJA_PIVV_Y^W_.C_A3MM_S]O\ G0!?_P"%
MJ:7Z-^='_"U-+]#^=4/^%.VW_/V]'_"G;;_G[?\ .@"__P +4TST/YT?\+4T
MST;\ZH?\*>MO^?M_SH_X4[;?\_;_ )T 7O\ A:FF>C?G2_\ "U-+]&_.J'_"
MG;?_ )^W_.C_ (4[;?\ /V_YT 7O^%J:9Z-^=+_PM33/0_G5#_A3MM_S]O\
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M^G_.@"Z/BGIGHWYTR;XI:8T+* W(]:J_\*=MO^?M_P Z/^%.VW>[?\Z //=
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M_A5-I_ST'Y4?\*IM/^>@_*@"/_A;FE_W9/SH_P"%N:7_ '9/SJ3_ (53:?\
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M_=D_.I/^%4VG_/0?E1_PJFT_YZ#\J (_^%N:7_=D_.C_ (6YI?\ =D_.I/\
MA5-I_P ]!^5'_"J;3_GH/RH C_X6YI?]V3\Z/^%N:7_=D_.I/^%4VG_/0?E1
M_P *IM/^>@_*@"/_ (6YI?\ =D_.C_A;FE_W9/SJ3_A5-I_ST'Y4?\*IM/\
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M#\J (_\ A;FE_P!V3\Z/^%N:7_=D_.I/^%4VG_/0?E1_PJFT_P">@_*@"/\
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M .M5S<#=UH N@TZJ\<FX5+F@!]%-W4;AZT .I*;FC=0 ^BFYHS0 ZBF[J7-
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MZ@T 7J*1F"KD]!6/<^)=/MKCR9+F-6]": -BEJ"VN8[J)9(V#*WI4K,$4DG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M Z0T"HS+S]*]@MX\0@>U,1QOC&Y:&TD(/8U\]:KJ$EQ=O\QX)KZ'\:6QDLI
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M;-@.E '00'Y14]00?=J:D,=1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"]7IE !36&:=24 1[!Z4>6/2I,48H C"#TI=@I^*,4 1^6/2D\H#M4N**
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MVJ*&W"=JM@=J0SGM<LA/$RXZUY9J_@U+F9CMZU[9<0AQTK*ETU6)^6@#Q1/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:W0TII&Z4
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MHH **** "BBB@ HHHH **** "DI:* $I:** $-&*6B@ HHHH **** "BBB@
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MY39*BLOH1FIZ* ((+:*W7;&BJ/85/110 E%+10 4444 %%%% !1110 4444
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M-]+_ +__ (]0!TU%<S_PF^E_W_\ QZC_ (3?2_[_ /X]0!TU%<S_ ,)OI?\
M?_\ 'J/^$WTO^_\ ^/4 =-17,_\ ";Z7_?\ _'J/^$WTO^__ ./4 =-17,_\
M)OI?]_\ \>H_X3?2_P"__P"/4 =-17,_\)OI?]__ ,>H_P"$WTO^_P#^/4 =
M-17,_P#";Z7_ '__ !ZC_A-]+_O_ /CU '345S/_  F^E_W_ /QZC_A-]+_O
M_P#CU '345S/_";Z7_?_ /'J/^$WTO\ O_\ CU '345S/_";Z7_?_P#'J/\
MA-]+_O\ _CU '345S/\ PF^E_P!__P >H_X3?2_[_P#X]0!TU%<S_P )OI?]
M_P#\>H_X3?2_[_\ X]0!TU%<S_PF^E_W_P#QZC_A-]+_ +__ (]0!TU%<S_P
MF^E_W_\ QZC_ (3?2_[_ /X]0!TU%<S_ ,)OI?\ ?_\ 'J/^$WTO^_\ ^/4
M=-17,_\ ";Z7_?\ _'J/^$WTO^__ ./4 =-17,_\)OI?]_\ \>H_X3?2_P"_
M_P"/4 =-17,_\)OI?]__ ,>H_P"$WTO^_P#^/4 =-2$5S7_";Z7_ '__ !ZE
M_P"$WTO^_P#^/"@#H\45S?\ PF^E?W__ !ZC_A-]*_O_ /CPH Z2BN;_ .$W
MTK^__P"/4?\ ";Z7_?\ _'A0!TE&*YO_ (3?2O[_ /X\*/\ A-]*_O\ _CU
M'2TM<Q_PF^E?W_\ QZE_X3?2_P"__P"/4 =-45S_ ,>\G^Z:Y[_A-]*_O_\
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M^%6ZE_T$)J]&_P"%AZ)_>H_X6'HG]Z@#SG_A5FI?]!":C_A5FI?]!":O1O\
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ME_T$)J/^%6:E_P!!":O1O^%AZ)_>H_X6'HG]Z@#SG_A5NI?]!":C_A5NI?\
M00FKT;_A8>B?WJ/^%AZ)_>H \Y_X59J7_00FH_X59J7_ $$)J]&_X6'HG]ZC
M_A8>B?WJ /.?^%6:E_T$)J/^%6:E_P!!":O1O^%AZ)_>H_X6'HG]Z@#SG_A5
MFI?]!":C_A5FI?\ 00FKT;_A8>B?WJ/^%AZ)_>H \Y_X59J7_00FH_X5;J7_
M $$)J]&_X6'HG]ZC_A8>B?WJ /.O^%6ZE_T$)J3_ (5;J7_00FKT;_A8>B?W
MJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ
M/.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!
M":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_0
M0FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?W
MJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ
M/.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!
M":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_0
M0FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?W
MJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ
M/.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!
M":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_0
M0FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?W
MJ/\ A8>B?WJ /.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ
M/.?^%6ZE_P!!":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!
M":C_ (5;J7_00FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6:E_P!!":C_ (5;J7_0
M0FKT;_A8>B?WJ/\ A8>B?WJ /.?^%6ZE_P!!":E_X5;J7_00FKT7_A8>B?WJ
M/^%AZ)_>H \Y_P"%6:E_T$)J/^%6:E_T$)J]&_X6'HG]ZC_A8>B?WJ /.?\
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M/W?_ $$3^M'_  I^[_Z")_6O; !Z4A^@H \3_P"%/W?_ $$3^M+_ ,*?N_\
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MO_H(G]:]LP/2CCTH \3_ .%07?\ T$3^M'_"H+O_ *")_6O;,#THP* /$_\
MA4%W_P!!$_K1_P *@N_^@B?UKVS HP* /$_^%07?_01/ZT?\*@N_^@B?UKVS
M ]*,#TH \3_X4_=_]!$_K1_PI^[_ .@B?UKVS ]*,#TH \2_X4_=_P#01/ZT
M?\*?N_\ H(G]:]LP/2CCTH \4_X4_=_]!$_K1_PI^[_Z")_6O;,#THP/2@#Q
M/_A3]W_T$3^M'_"G[O\ Z")_6O;,#THP/2@#Q/\ X4_=_P#01/ZT?\*?N_\
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M/_A3]W_T$3^M'_"G[O\ Z")_6O;,#THP/2@#Q/\ X4_=_P#01/ZT?\*?N_\
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M"+B4?QFNA\1Z!<6EZVU#@FL VDH/*F@8GVF;^^:EBU*ZA(*2D5&+24]%-/\
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MWJ -#-*&K/%\A[T[[:@'6@"_D4FZLY]13'#4Z&Z#GK0!H9I:@\S IOVA<]:
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MOY4H\-09_P!6/RH \F\+^%7@G1W3GZ5[#HUH88U&.U/@T:.$\*/RK8MX!&,
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M $,-O';J%C7 %.DB25=K#(-244 5X;.& EHT )J<4M% !1110 4444 %%%%
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M5']MM_\ GH*/MMO_ ,]!0!+L%*!4/VVW_P">@I?MMO\ \]!0!/1@&H/MMO\
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MLO\ GV3\J /GW[5XT_YZ_P#CIH^U>-/^>O\ XZ:^@O[,LO\ GV3\J/[,LO\
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M[,LO^?9/RH ^??M7C3_GK_XZ:/M7C3_GJ/\ ODU] _V99?\ /LGY4?V99?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gfbaqn1kfu2x000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .$!+ # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M28I:* "DI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BD-+0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0T9J.65
M(D+,0/K6#>>*;6V)7J1Z&FDV!T6:,UQ#^-8RW .*$\:1]P:OV<@N=OFEKE[?
MQ?:28!&#[FMVVOX;F(.KC\ZEP: M=:* P/0T5("T444 %)2TE "&L[4M8@T^
M/+N >PI-9U./3K)Y7;D#I7DFHZW+JM\VY\Q@\"MZ5)S$V=G-XVF$N(XP5]:M
M#Q9YELV\ ,17'6<2N!5QK0$<5NZ,4*Y@:[NOM5:X SFLUED1AA:Z>6W5!\U4
MVMO,;Y5J?81*YW8S4BDE7+#%5KI?*'TK=-NZ+R*RK^!F4G!K3E21-R[X>S-*
MM>F:=;H44'TKS#0)EMI!NKM[?7XXE& >*XZB;9M3L=#>6L2)GBLD60F8@54G
M\1>>=N#@5+9ZHHD'-<\H.YVTYZ;ZD5UH;MG"9K!N]#G&?DKNGU2$1@^U95UJ
MT1S@5E*,3KH5:E]CSR[TR5,Y2L6>U92<BO2))[:YR&%<YJ]O"K'8*YIQ/;P]
M6[LSB9H1W%9TL>#TKH+F+D\5E3Q\]*F+-ZT4S/'%:%@1OYJJT?/2I8#Y9K:.
MIYE:3B;HE &*FM6_? GUK($W/6KEK-F0#-;1/-JS;/0+"<>2*OM=A4ZUSVGR
MD1C)JQ+.6.,UUT5=GE5=QUW>$D\UCW%V<]:EN7VU4CMS.V:]."LCG;*\DS,>
M*A8,1WK8%G&@^855N@BH=HQ6B9+,B1]C9'45UOAOQT=+@:*=L^F37%SM\QK*
MO03S53I*:LR5.S-_QGXOFUN=HT;$>>,&N/B7)S2$8JS;IFKITU!60Y2+$*8J
MT.E1J,4[-:F#8_-.!J*E4\T@1K:4ADN44=S7H#(+6P!:N"TB7R;E'/8UU=_J
M0N8 BURU$VSHAL9MU,99#CUJ),CK3UC).30XVBI;5BBC>7!QM%+8 \$U&\7F
M35JV\*HGTKDG,I(66X8 1H,N>@KTCP=IIAMUN'&&<<UR'AS16U#4$F=<QJ>:
M]6MH%MX5C0845S2E<HFHHHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,IC&<UT0$S<WXJ*64[:B1F(YI'!(Z5K9",R[+2'%1PVP49(K0\D Y-1L,5:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU4E3-=)%R!"0:OPGBJ"C!J]#]VADR-*&7"8JE<GJ:LPQEQ5><8R*@1ZC\+8
M"LF.2*]8KRGX7W*?+#_$!7JPKQ<3\9U0V'44E%<Z+%HI,T4 +1110 44E+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 444'I0!EZXADTV0+_=/\J^8-4C8:].._F&OJ359%CL)"_3:?
MY5\VWL0GU^=EY'F&NBA\0F:.GQD0+FKWE\4^VMB(UXJUY/%>C<@Q[F'C-8-]
MP=M=;<1_(WTKD[_F4XJ)O0#,25H),BMJTU . ":Q73-1([0OD$U,)V>HV=>D
MV>]6$D(K$L;L.H!/-:@?BN@@T$N"!UI);THO6J7F8&:(89+N8#!VU+2&B[IL
M4MU-N<DC/%==96'3BJNEV AC7BN@MP%XQ7/4D6D1FW$8'%1$<U?GY6J>W+5D
MF,9M)%*("]6H8<FK\4 QTI.5@,-[+VK.O;,^6V!VKKWMQBJ%U:!D88[5+GH%
MCS!W-O>9/&*[;1-67RE^8=*Y?7[$Q7+''%9%O?R6K8!.*YW(=CUY=57'WJ?_
M &@#_%7F47B%@,%JO0:^&XW5-QV._P#MXSUJ9+\?WJXF/5=P^]5F+4"[ 9HN
M%CK);CS.AJ,*356Q)< FMF"V+XXK:,M!6([: LXS6ZBB&'..U0VUJ$Y-6)A^
MZ(J6[L#G=1N"[D'M6+(XK2O^':N?NKC:371!"":0#/-9T]RJ9R:I7NJ!3A3S
M5.,3WK< X-:JR$)=WC3$JN:6QL'F<%@:UK+11P7'-=#:Z>B 8 J9,"+2]/6,
M+Q76V%OTXJE:6ZC'%;]K&%6N><ADZH N*SM1C4QGBM,\"L75;D(AYK$9PNMV
M,4DIRHKGY-"1U.%%='?SB24T^W0,M;TYN.PFCSG4-):V<Y7@532W].*]+U'3
M%N8C@"N.N]-:UD)P<5V1J*6C(5T[HS</''D@FLVXF9B1Y9_*NJLHEG&T@5II
MX?CEYV#\JYIX>$G<]"GC)15CS*6&20\(?RJ2WT>:8C@UZ>OA6,\[/TK0M_#:
M1#A/TJH4J<48U*\INYP%CX<;;\PK0.C-"/DXKNQIBQC[M4Y[3!Z42A"70F-:
M47>YQX5X1ALU7GG-=-<6JX.0*Q;K3U;.*\^OAE]D]C"9@HZ3.?GE/-9\UP1W
MK<FTQL'TK,GL(^F3NS7*J+.VKCH-:%O009)-S=C7HNG2JB@"N)T:Q=!P.M=A
M9VSJH/-:VL>>Y.3NSIK:0, :GF1)(\'%9D#,J@5/YK8JHNQSU8W1R/B+2%9B
M\:UQ<L1C?:1C%>JW41E4@C-<5KFFF,EPN*]/#5VG8\VK3.7<56D%6F(R?:H)
M.E>M%W.-E,C#59A-5G/-/B:K U(9M@J*7#$U&K<4I-381TW@C6AI&K[Y#\A
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1FIA6+X>ODNK%%# E%Q6T*\V2LRQ:***0!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 54U(%K"4+UQ5JH9V3RF#'M0!X
M?JUNS:LZORWO4<=IL8'%;NMP ^(Y"O*XI?LORCBM4Q%6W3I5TIA:8L&TU(YP
M,5TPEH(K2D**Q+V<<C-7;^Y\M3S7//(T[Y'2MXL3'*-S$U3U%U2(YJ]Q&E<[
MJ]R7)4&M+6),A_WEQ@=S72Z7#Y<8XK"TZV:27<1WKJ[6/  %7%60,Z71YFC=
M2O4&O1-)U!Y55).17G6DQ$R+]:]!TJ$87BN.O8N)N?8(W<. *MI;J@P!3H1A
M /:I:X6V40_9USD@4\*%Z"GTE3<!&&167>Q<&M7M5"\/%)FE)ZG,7:,":R)R
M1FM^YP<UD7* YK!L].$4T8=PQ/%9<UNSG.*WVM\M0;48Z5/,;JD<NUN5[5#Y
M94]*Z2:R]JIO9>U-2)E2,E7V=:F6Z '6G7=HP3@5@3R/"V#6B9R5(6.OTR]'
MFXS7>:5/G;S7CNFWVV<$FO1]$OP0O-4CFDM#T(/^XS6->/DFIUO 8!SVK.NI
M@03FNB".=F5>'@UR6K<@BNEO9A@US5Z0Y-=26A)SRQF.;(]:W+.X*@<U0>,9
MI\;%1BJC$3.GM;L''-;UE=C(R:X.*Y*-6G;ZCC'-*4+@F>G6EY&R8R*K:C=J
M%^4UR=MJO ^:I9K[>O7-8>S:=RKD&HWA)(S6!(QD<UH7&934*P<]*30"VD&3
MFMZVBX%9]J@%;5LN<5:V$688^*N(E-B3BK*CBLI.XRE<*!6)?Q[E-;MP,YK(
MN5)XK"1O3W,:!I(7^7.*NM=R[.AJ:*TR<U?BT_S.,5"DT=#IQ9R]UYUP",$5
MGQZ6P.Y^M=__ &,0"=M9MQ8E"1BDY,<(0N<PL"Q5G:I=B*,@=:W=0C\I&/H*
MX74YS)(W-):ER:2,FXE,ET&/K7;^'&S&M<!*?WP/O7:^&K@!5&:JVAC&>IZ5
MI^/EKJ;3'E"N.T^88%=)97/ &:(Z!5NXFHQP*JR2\X%6&^9.*S)B58YJFS"$
M=24MGO67J9(B.#5I9N:JZ@=T)HB]2Y(\WU]RVX&N2ECYKJ]<8&X*=ZYV6/!K
MV,-+W3CGN8MQ'5=1CBM.>.JAAYKM3T(L1@X-2!Q33&14;@BF2T6E&XU<M%59
M 6&15&V);K6@JX&:B3#E'7VQA\HQ64_6K\G(-49>M.)#(UZU8C7-0+P:LH<&
MJ9/4'BQ4845,[9J/O2!CD3)JW"TB8VFHH4+'%;EKI4KQ!PO%93:-8&QX5\32
MV%VD,A)5SS7LEE=I=VZR(<@^E>!3VC0_.!@CO7HO@+6&GC6U=L[17FXB"W1N
MCT#-% I:XR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@!*.F:#5'4-0ALK9Y'<# SUII7 I:YXAMM'MV>1QN'8FO*]2^)LUQ<M
M%"ORYP"*P/'6O3ZMJ+B)SY1]*S/#VCO<7"LXSS6G*HK4%J=[IL\E^1<2CYCZ
MUT"P90<57TW3UAB4 =!6PL0"]*SN5RLRGAP#D5G7'RYKH)(<@UDWT(53Q6D9
M$M'$:M.3.4SWJ"(!5IFIM_IS#T-"'.!791E=D-#+@G!Q6#<0F2XP:Z.5/D)K
M$8C[:!77H2RW9VHC08'-;%K'EA52'&!5V%]K4Y".BT_"%37H&A8D137G%G+T
MKNO#UQC:":X:Z=C2)V"C I:@%P@'6@7*FN&S*)J*C\U<9I/.7UJ;CY62UG:A
MPE71*I/!JO=IOA;Z4/8NGI+4Y6ZEP36;++FK6H920BL6:7!KF;U/9IQNDRVC
M!FQ6G;V!F7(%<_!,=]==HTP*8-$=RJK<8W1F75@T9Z50:V&>E=5J!7;6%(,O
M3DM2:<W):F/<VFY>E<OJ^G85F KOC%D<BLG5+-6B88H1-2*9YDA:*4=>M=CH
ME^P*C-<[>VACN3QQFM#3<HPK6)YU16/18K\F,?-1-=?)UK#MYSM'-6'<LM==
M,Y65[RZR3S6//+D]:=J+M$V1TK+^T[S75 AEP<TX**J"4U.DA-;V$3;*<B'/
M4T1L:LQIFDQBQEUZ$UH0%F')-0I$,=*T+6'VK&0$D<.X=*F%M[5=@M_EZ58\
MGCI7/(HRE38:U+/M5::$@Y JS: \5/,!K1#BK %00=*NQKFI; I31$@\5D7B
M%>U=4(0PY%9U]8@@X%92-82L85K(,@&NCL45E!KEY4:WG_&MW3;C@ FL[&SD
MW$VR@VGBL;4(!G(%;:N"F:RM0<<XJFM"*4G<X77UVPM@=J\XN@=S?6O4M6B\
MY'&*\[U*V,4K#;4HNI(YR:(ELUK:-=^1,HS4+0Y%5CF&0$=JHQ4M3U;2[P-&
MO/:NEL[C@<UYAH6I<*I:NXL+H,!S4M'1&5SM[67>N#274&]2:HZ?+TK8X9:I
M:HQE[LCGY 8VJO</OC(]JV+NV&,@5D3Q8SQ2V-'[R.$UNP)F,H[5SDT?'O7H
M=];%U.17+WM@%)(%=M"MRZ,Y9Q.7ECS41A&*TIH"":KE"*]&,T]C(SWBJ!X<
MUI.HJ!EK12)(;:+%:"ID5!$F*TK: N1Q2DQF?+%[5FRJ0U=K)HC/;&0>F:YB
M>WVR$'L:<)7(FC/"T_H*F,8%-*5I<RL,ZU-#;/*<*IJ6UM#*X&.M=EH^E11;
M7E K.<^5&D87,C2]#N))%8H=OTKT""UM[?3 A WU&9X((@L0&<56,KR')Z5Q
MRFY,W44C)U.!?+D(%9GAW4VTK4P_8G%:VHDF-A7."(^:347YM!GN&GZQ;7<*
M;9%+$=,UIA@1Q7AMCJ5S9R#RW(P:],\-Z\+V%8Y&_> <USU*7+J-,Z?-+2#!
M%+7.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+2'I0!E
M:WJ\6E63S.P!7UKQ;Q#XMN-5G:.-RJ9[&NI^)E^RRFU!.TC->4*X5ZZ:<;1Y
MA,T/)4\OSFNDT!%5A@5RWF[H\BMG1;W:X!-<]63;-J21Z7;'""KRL,5SUI?K
ML'-:$=ZI'6L4=$DB\_0UD:F,QGZ5;:[7UJA>R;U('I6L3EGN>>:I$PO7/O1;
MC<XK4U&T9W9L5DPMY4V#751E9F;+=R D)^E<G<EEN?,'K70WMQY@VKTK(FB#
M@C%=O.F18GM+U64 D9K3BF![URKQ20L2II\6I21G#9H]JNH6.\MKC&.:Z?2K
M\IC!KRZ#6L8R:W]-UQ<C+5E.28U<]4COV8#+5:CO">]<1:ZTCJ/G'YUJP:B"
M!\U<51HWIJYU/VSCK4+WO^U6(U^,?>JL]\?6N1R.Z%*YO_VB5;[U6UU96CPQ
M[5QK7O/6D-\<=:CVAU+!J6IH:I.'D)!KGYGY-33W.X<FLZ27)-9.5V=L*7*B
MS _[RNBTVX*8YKD[=_WE;=M+@ YIIV(G'F5CI9Y_,CJD%!;)JI]KR,9IXG]Z
MN]SG]FXEIL8K/O1N4BI]Y8=:BF&4-,B3L<O>60=B=M48H3%+TKJ&M]W45G7-
ML$).*UBC@K-"VQX%6R^!6,MZL;[#VJ;[8'Z&NRD<<A;Y0ZUB/$%;BMB1]RFL
MV<?-7=!&9"!4\=1 5-&N2*T N0+FK\,=06\1P.*T8HSW%928R2.*M&U3!J&*
M/CBK4>%K*3&:4.,5:" BL^*0#O5M)<US38T$D(84Z*';4\8W5;C@SVK*XR*,
M;15N%Q0;8XJ#:R-1<#2#_+5>9\\&HUFXQ37?-(#-O+7S#D"G6D#(0*N8!/-6
M[>)<=*FQHIDL*GR@#5*\MF.2*U H P*1T#"@2E9G&7=H>>*Y+6--WAF YKT>
M^A'/%<S>V^XD8H2$Y7/,)82CD$=*IS0AATKI]5T]HY2P7@FL:2(@=*JQ)G6D
MS6TX&<<UWNC7P=5YK@+J,JP8=JU-&U+RRJDU#1K&5CU^QN>!S6];W0*@$UY_
MINI*R#YJZ*WO,@<TBG+FW.H.V1:I36>[)%5HKTXZU9%\,4WJ)76QEW-B<$8K
M$O=(9P3M-=@CK*W-3-:QLG2A:#;74\FNM*=&.5-9LNFL> M>FZI8H,\5STEH
M%;@5I&M*.P>RN<4^CRGD*:JRZ9/'U0UWPA [4R:W1UP5%;1Q<D'U;30X**V;
M=@BM6V BQQ5VXM%BER!P:!;!AQ77"LIHPE2<'J-GU4QP%1W&*Y6ZDW2%O4UT
M=U9$KTK"N+9@3Q6\&C&29FDY-.49I[0L.U/CB;N#6W,B.5ENQ/ENIKIXI691
M@USMM$21706BG S6$VC2*L7X S=35]4(2J\"U?C3=Q7).5BS*NK<N#Q65):[
M3TKL_L6Y#Q6/J-F8QD"LHSLQV.:DB9#D=*T_#=V\6HA0V,D"G^2LBTW2K0_V
ML-HZ,*VJ231*1[%;G=;H?45)45L,6T8_V:EK@+"BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %!Z44&@# \0:@;:W:-#\QK.TBV%P1+(,LW-
M5_%HD2[$ASY8'-3Z'>H8EY'2F!U<4*QJ !4@%017"N!S4ZD&D $9%59(QFKE
M-*YIW J(FUJMCI3=F#3^U#8$-S&'@<8ZBO*?$=N8;XAAZUZX1D8]:Y3Q'X=-
M^3,G4"FF!YBT0-0_9@>U:=WI\]I*RNAP.^*@51FFP*?V0>E-DLQMZ5I!122
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M.!GFM73-->3YG!H!Z["LQ !/>O6O 4>-/C?U%>736K->1Q*.M>S^$[,VNB0
MC#8YK5/0XJBLSH.U%':BF9A1110 4444 %%%% !1110 4444 %%%% !1110
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M*64$[R1Q*NX\U<MM#MK>Y\Y(P&QBM;%+0!D1Z';1W;3A!O)R35ZYMDNH?+<
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M&T=ZU;74VBL?*%BAX]*B\<Z7)J$UAJ<49*1G>PQ[5:L_$=C_ &?\]HP?'3%
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MKB2:-0&DZT7NC6M[S)$I;U(K1HH P8/"]E#(',:G!R.*VHX4B7:@  [5)10
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M [5'4Z)OEIGJ.@:+!IEFBJ@W8Y.*VQ38_N"G5T+8\:;;8HZTM(*,TR1:***
M"BBB@"IJ$!N+-HUZFN&@L];TZ_F:W3Y#TKT.C:/04 <3]K\1?\\Z/M?B/_GG
M7;;1Z"@ >@H XG[7XC_YY_I1]K\1_P#//]*[; ]!1@>@H XG[7XC_P">?Z4?
M:_$?_//]*[; ]!1@>@H XG[7XC_YY_I1]K\1_P#//]*[; ]!1@>@H XG[7XC
M_P">?Z4?:_$?_//]*[; ]!1@>@H XG[7XC_YY_I1]K\1_P#//]*[; ]!1@>@
MH XG[7XC_P">?Z4?:_$?_//]*[; ]!1@>@H XG[7XC_YY_I1]K\1_P#//]*[
M; ]!1@>@H XG[7XC_P">?Z4?:_$?_//]*[; ]!1@>@H XG[7XC_YY_I1]K\1
M_P#//]*[; ]!1@>@H XG[7XC_P">?Z4?:_$?_//]*[; ]!1@>@H XG[7XC_Y
MY_I1]K\1_P#//]*[; ]!1@>@H XG[7XC_P">?Z4?:_$?_//]*[; ]!1@>@H
MXG[7XC_YY_I1]K\1_P#//]*[; ]!1@>@H XG[7XC_P">?Z4?:_$?_//]*[;
M]!1@>@H XG[7XC_YY_I1]K\1_P#//]*[; ]!1@>@H XG[7XC_P">?Z4?:_$?
M_//]*[; ]!1@>@H XG[7XC_YY_I1]K\1_P#//]*[; ]!1@>@H XG[7XC_P">
M='VOQ'_SSKML#T%&T>@H XAKKQ$1CRZM>'-,NX=1DN[H89QS76[1Z"C ]* %
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&;_5G%?./CQW
M/B^Y#DXX_K7T@WW>:^=?B*JIXJN&'?']:RJKW3OP#M41AQ#Y:FVBH(&&T5-N
MK@:/L*=N4@G48J'3T+7?'8U+.Q/R@9K4T/3G,A<J>:VIIGE8YK8Z2S8A%^E.
MNY\+C-3+#Y28Q5>2$R-6Z1Y,IE..)YY.!UKH=.T8L 2*=I%@"X)%=S8:<I0<
M"JL9<_4P([%8^-M7K6SS(!CBM*\L_*^857AF$9YJ6M3=3O'0VH52WA'2LC4]
M1P"JFFW-^2F :P;B<N_)IREI8FE2]Z\C)U%3*[,:QWA(:NBE4.*IBUWR8Q7*
MU=GM4:BC$BL++S0>.U4=6L,(RL.*[?3=-$<6XCJ*R]>A3YL8JG"R)CB>:I8\
M8OX/*N6 '>JA%;FNP;+@G'4UBD5*V*FKD>/F%;VFQY4'%8T:YE4>]='8IM45
M,S7#1]XU(H^!4ZI3(^ *L)BLT=[8@C!-7H+3?T%5TZUK::X\P U<4<U6;2()
MK-ECZ5C3Q8;%>A362R6A8 =*XN]BVW##T-5.-C&A74]#-6/%3HHIV/:G(*S.
MQLF2,&KD,0JO%6C;)EA5Q1S59Z&IIED)7&17866EQQ(&P.*R-)C2, G%;QNE
M6+ -=<$CY_%5)2=D3&8)P*KRSD@\U1>ZR_6G%]RUO$\V>Y5NY"0:P+I,DYK=
MG%9%R.:[*9BS'=,&JLHXJ],.:KF+=6Z8C.="QIGV8MP!6O#9-*X51FNET[PZ
M-H>0?G1*IRA8Y"T\/RW)SM.*M2>'1!RU=A?7-OIT.U ,XKC=1UUW+=:49RD#
ML4;J"* &L*[D!.!4]W>O*3S6:Y)ZUTQ7<AD9ZU)$I=@*9MYK0TV RSJ,=ZMN
MQ*5V3)ITA7.TXJ"6V:,\BO0TLH4L@649Q7*ZJ(U=MN*QC.[+<3#4[>AJ0W#E
M=I8U QY.*9DYK2R$2%=U0R1'TJ>(C>H/>NB.E12V)E!&0M)R4=PL<8Z<54F<
MI6M<1;7(JE-&#U%;)DV,B:\9>*KH7G;)S5V>V#'@5-;6N.U)HI6+NFQ", UT
M5LV0!6/;I@=*T[?(K*12-2- :T+5<,*SH":T(6P:QD,Z*P;:1S77:=+N0"N)
MLI.174Z9+R*XZJN4C>II(Q1G(JM<RA%ZUS%()K@+T-95W?!0>:I:AJ2PYRU<
MCJGB #(#5+-8V1L:AJ2X;YA7":O>^=)@'/-17&K27#;5R<TR&QDDR[YJ;&O-
MI8I[=\@K=TZ/Y:SA#MDQBMNQCX%3(Z:*))("1TJM-9[D((ZUMB+CFHI(Q6+;
M/2A%-'GVI6ABG/'%9DL==]J&GK/&2!S7*7-@\9;CBJC(YZM*QS[IM-,&":NS
MQXXJ"&U>68*HZUHF<4HV9-;H">:UK?"=*BCTNY1<A":L6VGW<D@7RF'X4BU9
M%Q9ACK78^"(H#J"2/P_;-9FD^$)IF5Y"<=<5LWVESZ2RSVRG*C&!51CU,JU5
MN/*>IKC QTIU<II/B,FT07"E6 YS6JFNVC=9%'XUI<XG%FM165+KELD997!/
MI56'Q$LAY&!ZTQ69OTM4[>^AN!\C@GTJV#1:PA:*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** (+ABL#$=<5\T^/YY'\67.[/;^M?33+N!!KPKX
MI: 8+Q[]5X<XJ)['3AI<LT<%;R'%3M)SCUJE V%QZ5()?WBY]:XK:GTZK<M,
MZ/1])-U(K..*[>STN.WC&!6)H#*L2XKJX'# 5T15D>35FY.Y1FMLFF1VHSTK
M7DC!%5R-M4<K1+8E86%=597R*@Y%<4\VTT@U1HOXJHR:.UO+U&0C-8+W2^80
M#6)/K)<8#55CO&+9S29K!\INSW&5QFJZ(7-5XF,IZUIP1X J6C>$B(VW'%2V
MMEF09%6T7UJ=&5>:E(V=1VLBT["*VQ[5R6JR;RU;]Q.60BL"[BWY)I3+P^CN
MSSCQ  9,>]<^PKH-<YN74=C6&ZUE8[>9-C($S*I]ZZ*UX K&LTS)6_;Q\"LY
MG7A]KEV/G%6D0FDM;<R=!6K%8-Z4HQN:5*J14CB.*O6J[)%/O2M&(>HJ+SL'
MBK6ASR?,=I;2(]IM)'2N7U6RQ,S+W--BU!T7 :K N1/@-6C:DCDA3E3E<PS;
M-G !H-LZC.#76V=C#*1DBM&71(GB^0 \4E2N5+&*+LSA(U(;I6K9]0<5:N=)
M:)S\M)%"4I*+3"=>,EH:<,Q4#FK7VD[>M96_ I5ER>M=$3R:[1?C<M)5]7XZ
MUF0^HJT":WB>;,GEP163<XJ\\FT<UE7,NYB!75!F;*DBY:GK#QTI\<1;DBK:
M0X'2M>82'Z5&JW*[O6NHOK@0V_R8Z5S<*[) U6KNZ+Q;3635V,P-6F:1FR:Y
M6[4DFNEO1N)K"N(ZZJ:LB68DB\U$5J_+#5<QXKH3(9$L>:ZSPUIFYC(XX S6
M)90*\@S7:6\T=K8X3 ;;BLZCZ#BBOJ^I+$AB0]!7'74[2L2:O:C(6E8D]:RV
MYHA%(&R'%+L]JLVT'FR!:Z#^PA]D\ST&:MR2$<J!M.:TXM4D2W://!%4[B/R
MW(JE(Y44TDP)YG#$G(JG)@U#+=8XI8 TIJTK ((=QZ5;AAP.E6(K8D=*O0V1
M)Z5,I#L00P^U:$-OQTJU#8D#I5V*V]JQE,I(KQ18'2K4:5.(,#I3DC(K-RT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )
M2=Z6DH \K^*UBDL7FXY5:\.*8/XU[K\4+U$@,.1EE->)2+UK&H>AATV5U'-7
MK:ZDA88-5-O-2H*QYCM5-,Z*#6G51DFIGUT[>M8"+FID@YR:M,F5-HL7&IRR
MYP35!O.D/)JX(<]!4JP'T-5<PE39FBU8]:>('7D&M00^U!B'I3N3[(33[UH7
M"L:['3K@2@<YS7$R0]QVK:T"<AMK'O3N2TT=S'$&&:M1Q$5!9ME #6K%&"*!
M6( "*Q=?N,6[1YYKHY4V(S>@S7#:Y/YURV#Q0#DTCF-0<JF!WK!6%C+DBNBF
M02OCTH6Q&<XH8HMMV&V.0JUMP-TJE#:[2.*TXH<#I6$D>I0DT3+TIKU*L9]*
MD\@XZ5FT=ZF9[J33 I%:!AP>E-,.>U"%(J@X%0RRMVJ_]F)H-EGM5(YYLS4N
M&4UIVEP<CFH)+$]A3K:V<28YK5)'%4FT=):RY45HH#(,50L+9B!706MGTXK:
M*//J5&4A99&2*JRQ^4W%=4+']V>.U<[J,9CEY%:J)RMCK5^16S!@@5S4$P5\
M9K<M9@5%5RB-5$!J01"J\4HJRL@-%@)4MQZ5.L2@=*6/[M/J+@9E^@"US-^0
M%:NGU C97(:F^-U;0 Y?46RQK&D8JN!6I>MO8XK.:(DUTP9#&VT1D;FMVUTS
MSL "J]A;8(XKJ])B"R*2*N<V@2,:YT!HTW;>U8\M@58\5Z_/9QW%IPHSBN/O
MM,V2-\O>LX5AM'%_93Z4QK8^E=')8X/2H6LO:ME4%8YQ[<XZ55>)L]*ZA[+C
MI4/]GJ6Z52J!8YL6COVJ[;Z.202M=19Z0)6 "UT*^'2L2D+VJ)5TM L<E:Z<
M(U'%:]LFRM!]/:(X*U&T!7M63G<=BS;3%.AK7MKYA@$USZG;5J*8#O64HH9U
ML%R) .:L$BN;MKH ]:T&O@$Y-8-6&2W+#GFL>ZG1>I%4=8UY+9&^85PM]XK4
MN?GJ&RXHZ^[O47/(K#NM23GG]:Y2;Q$\N0I)JJUQ<W([X-0:)I%S5=1#':G.
M:IVFXMDTZ*Q9VR_-:]K8J .* W)[0MQ6S"2%JM;VZKBM*.(%:!D19JR+\L[@
M9[UO/#M4FL*[_P!;^-,ELV-%A5 IKJX&&T5R>GL0HQ6];NQ%*Q49&NK#-6HH
MA)VK/A/K6A;/@BBQ3D-FM1GI3!9C'(K5*AEJ"7 Z461*JO8SFL$((Q69>::J
MC*CFM\M[U1O9D2,DFERE^U=B+0;AA*86/"BMR=U"YS7%6%VPOY"O2M26^8KU
MK>,#FD[NY+=W.,\UB7-YUYIUS<ELUCW#DUU0@B!9[O.>:SYIQZTV4\UGW$F!
MUK>,26PEN]N>:JMJCQYVM5*XFZG-8EYJ CSS6ZCH3<T+V_+Y+-6/)=;VPO)K
M-FOGGDV)DDUZ9X'\!?VG%'=70(!YYI3JQ@A<MS/\%Z!/J>H1R2QL(P><BO?+
M&U2SM$@085:JZ7HMKID(2) ,=P*TS7F5JW.S2*L.HHHK H**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBD- #6.!DFN9\0^*[728&&\%^F,U8\3:L-.LFPV'*\5
MXEJLLNHW#322,<]LU+E8UITW)Z%/Q'KLNLWA=V)4'BN=<<U>GMV#<55>%_2L
M)21ZN'I-%;O4B"I$MW8]#5N#3W=N1Q65T=RINVQ'"I;@ FM>STZ28]"*LV6G
MI&02*Z.TB0*,**7-V-%1TU*5GH0XWC-:BZ+ 5QL%785J]%'FJ39E.$4<GJ&A
MF-=\:UA/&4)5A@UZB\"LF&%<KKFEHJM*@Z5I<YI170Y)TI]BWE7:XZ9ILAQD
M5$DFV9>:I'--:'H.G7 <"NDM&R*XG1Y<HIS746D^,<U1B7M3D$5JW/45YK?3
M8=N><UV/B74D6U55;FN$PT\A8],U2,I/42VC+-D]ZU(H<]JCAC"C%:5O'GM4
MR9O1@V,2WY'%7(X/:K$<'%6$B'I6+9Z$%8C@MM[@>M:[:21;!@*;86I>4$#O
M770VF;;:PIQA<SK8AP:/.I[8HQXJ)8AFNGU.PV2$@5C&W(;I4.-CHA74D0+"
M*L+:[NU*D9W=*U;*VWD CK342*E16N93V.1TIB6>QLXKL&TG]WD"J+V)7^&M
M4CAE44B"QC7CBN@M4&1Q61!$8VK6A?:*W@M#AJ/4U% VXK UJT5@2,9K3%V%
M'6LK4+K?D9K2,7<Q9QER[6TW?&:U-.U ,H&ZJFHPB4&L*.62SF[[<UKRLFYZ
M%%<9%7H9,D5R>G:BLJCYN3736)WD4I*PT;T/*"GL0.:;$,)5:[FV*:PMJ,HZ
MC*-IYKB]4ER2*Z*^N,J>:Y>Z4RR&MXQ8C%="S9IJPY:M)H0O:HTC^>MXZ$EN
MS@ Q706*8<&LJU7&*V;4=*F;NAHZFS.Z'%5KW3UEY I;"3C;FM+@BN5MIE')
M3Z85)XJC)9$=J[:2%6'2JCZ>C#I6BJ@<8]I[5%]E.X<5U<FEY/ I!I/?'-7[
M010TRVVX;%=+"P* 'M6?'!Y(P13_ #MAX-92]X9+>V\93=BL*6-<G K1NK[,
M6,UB278W'FA.P6(I4P:IR2%.]6GF# X-9=VY -)S&D2#4C$>M07GB41QD;N?
M2L&_NBBGFN>\Y[B;+-Q6;D6HDFN:S/>,0A;%<V1)(^&)KH+A%5.!DUGK;N9-
MVVDE<&[%K3K$,03746UFFP "L"UD=,#%=)I\A<#(H:!.XILB/NBA$=#TK=MX
M-XY%6?[,#?PU)I8QHF/%7(IMM7?[+*]!36L"JYQ0#*MQ=JL1R:Y]F:YN?E'&
M:T=0@8MM&:O:/I6<,5ZU1GJV3:;9N5&170V\&Q1D5:M+ (@^6K;6V!TI#*/W
M:EBF /6FS+L!K,FNA$>M 7.D6Z&WK4$]VJCK7,OK:H,;JRKWQ"-IPU%A71T=
MUK*1 _,*YNZUJ2\G\F+)R>2*PFN[C49MB9Q72:-IT=L S#+'UJE8EW9H6%JT
M<88CYCUJQ*AK1C12HQZ5'-%@=*Z(R1%C"G&!6;/6O=+C-8URV,UO%B*$YP#6
M-=R=:TKF88/-8-Y.,G%=$269>HW.Q#S7,2>==SX0%B>PKMK'PW=Z]-B)"4SS
M7HGA[X86=GMFG7,GH:FK74=$"B>?>!O EQJ-VEQ<1D(AR0PKZ!TW3XM.M$@B
M4  =JDL[""RB"11JN!V%6A7GU*CFS0**,4M9 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4AZ4M% 'F'Q(N)$N(E&=I'-><M*#Q7LGC?1CJ%BTJ+EU7BO$
M)HY;:X,4JD,/6LYH[,-)7L2%-YJ:.S5ARM26T>X<UI10CTKBFV?28:*M<I)8
MH!D+4R6X7M6Q%9Y3-1R08-39G3=="K&F,<5H6XZ57" 58A.#31$C6@7.*U+>
M+@<50L%#D5N[5BAR?2MHH\ZLW>Q5F.T8K%U-0]I(/:M"YN 2>:S+J4&-AZTV
M]25&RU.!NQY<I6LYG+3!5K2UKY)F85GZ7"9[@,PX!K2)PU7J=5I<WV:V0O6B
M=:"K\O6N8NKLB3R1_":T],L9;HKN!Q6B1R2GK8BN[F:ZD);)7M46YHQ]PBNQ
MMO#XP,K4T_A]"OW/TI-EPC?4XZWN,O@UT%GAEJE>:(T#%D!IVGR.D@1JAJYU
M0DHG01Q'%6X;<LPXI;2/>H-;=E; L.*2@:RK)*Y9TJQV@,16X$PN*;!&$08%
M2,<+6T596/)J5'*1BZA%O/2L22U^;I733)O-4S;9;I4N)O"K9&&MH=W2M2Q@
MVL#BK?V/C.*L0P8/2DHCE6NK%N, I@U#/ O4"I"WEK4#S\5HD<M[.Y4>$#FJ
MKS;>*FN;@ '!K%N+@Y/-;PB1)W+<EW[U2EGW]ZI23GUJ,2FMU&Q%R:7!K)N[
M=7!XK3&7Z4C6C.O2JT0SFU:6SE!4G&:ZK1O$,8*B0[:R;BQ<G&P_E67/82)\
MPW#%-Q4D(];M]4AFC&UP>*@NY3+]WFO.=)U2:TE$<C':3BN_TR6.< D]:YY4
M^5C3,>\#<BLUDP<FNJU:V0+E?2N;=3DUI%Z"*,R?*35$/L?FM2;&VL:[8+DY
MJ93&:UK<*2*V[63.*X:UO=KX)[UTEA>@XYK/G"QV%F>16Q&<K7-V=R,#FM6.
M\ '6LY,I19HT9%4#>@=Z@EU$*.HJ+E<C-,LHZD4GFICJ*YV?5@HR6K+G\2QQ
M@_./SHYA^S9TU].BJ2"*YB^UE(&(+=/>L/4/%R;"/,_6N!U;Q%+<2GRV.*?.
M')8[^Y\2(<C>/SJF-760YW5YJ=0F/))J6#4IV;:I-*]RK(]*CU%<_>_6DN+V
M,QGD5Q,=W= <YJ</=3# SS19A="ZM=[F*IS]*KZ;97%PW"'K6QINBR74PW*3
MSSFN[T_1(K:,?(,_2M(P(<SD+7PZ[<R#-6VT%%'"UW"V:@<+4,UJ,=*T21FV
MV<$^E+&V<5=L( K5I7\(4FJUMA6J)JQ47J;MG&,"M>&('%9-HXQ6W9C>16#.
MA;%F.S#CI5>[M JGBMN% %'%5;U-PJK&;E=G'7-D'FZ5L:;;*@48I)8?WF:L
MVWR$4A&S%$ HXITBC::9#*"O6B:0;#S3)UN9%\1M-<?JT[1AB*ZB^DZUR>J*
M7S0@9R=WJ$I)QFH+*VN+^?)SMS5F[A <<=ZZ;2K%8X%95Y(S2D[%TX.3'V%A
M':QC"_-ZUH+)L:I%@..E1F @Y-3S'3[(TK6YY%:38DCK A)4UJP3#;R:TC(Y
MYPL4;R/K7,:H?*!/M777;*5)KC-9)F<QQC+&NJ,K(YVM3GW%Q=R[(5+<]JZ#
M2O 5S?QK+*Q7V-=7X0\-)#"+B9<EAGD5VR1I&N%4 >PI2K/9#2,?0M!ATB (
MJC=CDUM#%*!17.VV,,4M%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%2MJ"Q1%!4=]J(?(4U@7-T.3FF[+848.2O(NW&JA,G-85]XC"@C=^M9FIW^
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M,4M%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D(S2TAH JWUJMU:/$PR"*^>_&_A
MB;3-0DG5#L9L@U]''IBL/Q%H4&K6+HZ MMXJ)QNCIP]9TY'S##)@X/:M!)<)
MUJQXDT&;1-0>,J=H/6LP-\E<;5F?0TZG/"Y-OW-FK=M/Y9ZUGH>*FB!D8**Z
M*6K/-Q$5:YH&0W<@4= :[3PM BWD6X5SNFV&T!B.:ZK2X6256'8U[$8\L+'C
M2U9UVM*#;@+]VN&NXOF-=U.#+8KNZXKE;R#YS2IOH)HY:YCP:J[*V;J#KQ5$
M0G-=46047CJ/&*U?LN[M4,MFR]JKF%8IHY'2I=Y]:8\96HO,P<56X%C.:8U,
M#TR23CBD%AQE ZFA;E?6L^4L>E5'D=3P:ER2'8Z$7 QUJ.2X '6L'[4X'4TC
M7+L,9K-U8H=C1GO5'>L^2\+'BJX625\5H06:@985SSQ78I1*8>9FRM6T:9E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M34?V=KW_ #]-7?;%]!2;%]* ."_L[7O^?IJ/[.U[_GZ:N^V+Z4;%]!0!P/\
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M&BJ!P!71%'D5JCN9]IH-C9C$4(&*T50*, #%.HJ['/<,4M%% @HHHH ****
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M@"4G%9<.M6TURT*2*S*<$ ]*EU:]6RL7E8'@=J\.\,^)/+\6W@=G(>;B@#Z
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M04$'L*DU7PM::DV_:JN3RV*Z#%% '(VG@>V@E#2L) .QKJ+>".VB6.-0%7@
M5/BDQ0 A&1BN9O?!]M=7HN!A&W9R!UKI\44 9$NA6\]B+:9%?'<BL3_A!+?S
M,[_D_NUV5'>@#/TW2;?38@D4:@CN!6@**6@ HHHH I:O_P @FZ_ZYG^5<O\
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M %S/\JYCX<_\@F;_ *Z&@#M**** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %34O\ D'S_ .[7)^&/^0C76:E_R#Y_]VN2\,?\A&@#MZIZAIL&
MHP>5.@*U<S10!RL7@33HIO,&[KG&:N+X4L5D#JF&'.<5O44 8]QX>M+B_ANW
M7]Y$,"M1X5>!HB/E(Q4E% &59:#;64WFQ##9S6K110!FZGHMMJD92= <]ZR+
M;P-IUM*)%W'!S@FNIHH PXO"]E!J)O8TVR%=O%2?\([:?:UN,?.IR*V** ,F
MXT"UN+GSW'S5:N=.@NK;R9$!7&!D5<HH Y,^ ].,WF?-UZ9K?L=,@L(O+A0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""ZB\ZV>/\
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M3QA/"T3E-KC!YKH/!VCW&CZ88;G&\G/%=+28H 6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"*Y'QIX<76-/
M;8N7&3FNN[TUE# J1D&@:T/D[6M.FTV[:.12,' J"U!8YKVGXE>&+:2PEOE
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AI",\4ZB@"G<:
M;;7>?.B#?6J4?AK2HY/,6U0-ZXK9HI6'S,ACB2%=J* !3\ ]J=2TQ',^(?"E
MGK$3LT2F0]Z\*\3>'9=%O&!!V$\<5],X%<SXJ\+V^N6S97]X!QBIDKFU*IRL
M^;@!FGA1BNHU3P)JEE,VR+*#I67'X=U&23RQ$<_2LK,[O:1:,AR%&:H2MN>N
MFU;PIJ>GV@GFCPIKERI#<]:-B%:3T)4.!4F>*C4<4ZLW,ZXTM!36UX9T9M6U
M!85X)K$)XKT7X6P;]9CD(R*N#N<U>/*KHK2:5)97#12(1M.,D5*($QVKV'4O
M"]GJ(+.,-[5@_P#""1"; W;/K6_*CB]HSSDVSM]Q"WT%7+'PM>:BXPC(/<5Z
MK8^$;&U*MC+#UK=BMHH5"HBC'M3LD0YMG$:'X!AM0&N@LA]Z["UTNTM !#$%
MQ[5=I:";C<8Z4M+10(2EI** %HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** $HZT44 0RVL,W^L0-]:K+H]BK[EMT!^E7\44K#NS)U?1K?4+%
MX7C4C;QQ7SKXN\,7&BZ@^$)C8DY Z5]/XR*P?$'ANUUJW9)4!8CTJ9QN;4JG
M*SY94\4[->C:Q\+-2BF9K.,>7VYK(MOASK4TX3RAUYK#D=STXXJ-CDHHVN)E
MB09+'%>\_#?PTUA8QW$JX?W%4?#?PQ2TECFO(_G4@UZA;P);PB-!A0*UA"QP
MXBOSZ(E%.I*6M3C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *0CFBBA@-9%88(S48MHD.50 T4
M5)2>A(.I%. Q115"8M%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gxgkxz5ypye4000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gxgkxz5ypye4000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #H!#H# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ X>*10RL.X-35X)W!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1161X@
M\2:=X8L5O-2=TA9]@*+DYH UZ*X'_A<7A'_GXN/^_7_UZ/\ A<7A'_GXN/\
MOU_]>BPKH[ZBN!_X7%X1_P"?BX_[]?\ UZ/^%Q>$?^?BX_[]?_7HL%T=]16?
MHVLV>O:9'J%BS-;R?=+#!K0H&%%%% !1110 5Y9\2?B-K'A'6X;/3XK1XWA#
MDS(2<Y/H1Z5ZG7S[\<_^1KM?^O9?YFFA/8B_X7EXH_Y]M-_[]-_\51_PO+Q1
M_P ^VF_]^F_^*KS*BJLB+L]-_P"%Y>*/^?;3?^_3?_%4Z+XX>)WE13;:;@L
M?W3?_%5YA4D'_'Q'_OC^=%D.[/LBPG>ZTZUN' #RPH[8Z9(!JQ5+1_\ D"6'
M_7M'_P"@BKM06%%%% !1110 4444 %%%% !1110 4444 %%%<;X_\7W/A*TM
M9K:!)3-)M(8]."?Z5=.G*I)1CN*4E%79V5%>,6/QBU*ZU"VMVL80LLJH2#T!
M(%>RHVZ-6]0#5UJ$Z-N?J3"<9[#J***Q+"BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS+XX?\B?;_\
M7R/Y&O3:\R^.'_(GV_\ U\C^1IK<3V/GBBBBJ("BBB@#Z?\ A1_R3^Q_'^E=
MK7%?"C_DG]C^/]*[6H9:V"BBB@84444 %?/OQS_Y&RU_Z]E_F:^@J^??CG_R
M-EK_ ->R_P S36XI;'EM%%%40%20?\?$?^^/YU'4D'_'Q'_OC^= 'V'H_P#R
M!+#_ *]H_P#T$5=JEH__ "!+#_KVC_\ 015VH- HHHH **** "BBB@ HHHH
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MD]4^(_AK1M1EL+V\9+B(@.H0G'&:I_\ "V_"'_/^_P#W[->(_$W_ )*!J?\
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MM?C'XAB8"XBM)4'I&0?SS5O+JWD3]8@>]45Y?I7QGTVX*IJ-E+;'H71MX_+
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MB/\ WA_.HZ.1S0!Z[\1?'[+HUGX>TN;'^C1_:I%//W1\HKR*E+%CEB2?4TE
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M0G[ZCV]:\S='C<HZE74X((Y%=<J=#%QNM_Q,E*=)V9]>*P=0RD%3R"*6O#?
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M8!XXZD?6NE'KMG%$DG)Y-%%%40%%%=C\-O"H\4^*(XIE)L[?][-[@=!^)XH
MW_A_\*9->B34]9W0V).8XAPT@]?85[KI>B:;HUNL.GV<,"@8RB $_4]35R**
M."%(HD"1H-JJ!P!3ZELM*P4444AE#4]&T[6;9H-0M(9T88^= 2/H>U>!_$7X
M9/X9SJ6E[Y=.9OF4\M%]?:OHNH+VSAO[*:TN$#Q3(48$=C33$U<^,J*V_%N@
MR>&_$EYIS@[4?,9]5/(_0UB51 4=#D=J** /IOX6^*/^$B\*QI/)NO+3]W+G
MJ1V;\>?RKN:^:OA%KK:3XSBMG<B"]'E,,\;NQ_G7TK4LM/0****0SY9^)O\
MR4#4_P#>7_T$5R-==\3?^2@:G_O+_P"@BN1JT9L**** "BBE52S!5!))P *
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MHHH *^??CG_R-EK_ ->R_P S7T%7S[\<_P#D;+7_ *]E_F::W%+8\MHHHJB
MHHHH 559W5$4LS'  ')->S^!O@[%/:Q:CXB#?.-R6JL1@=MQ'\JQ/@WX6BUG
M7)-3NXP]O9?=!Z&3M^6<U]#TFRDC.L="TG38ECL].MH0HP"L2@_B<5HT45)1
M0O\ 1=,U.)H[VPMY@PP2\8)_.O%?B+\*DTBVDU?1-QME.9;<DDH/4>U>\TR:
M))X7AE4,C@JP(ZBG<35SXNHKH?'&A?\ "/>+;ZP48C#[XAZ(W(_2N>JB HHH
MH T-"OSI6O6-^"1]GF63\CFOL"!_-MXY/[RAOS%?%]?7WAFX^U^&=.GSG? I
MS29436HHHJ2@KRGXV_\ (,TW_KL?_037JU>4_&W_ )!FF_\ 78_^@FNK!?QX
MF5;X&>1Z5<1V>JVUU)R()!*!ZE3D#\Q1J>H3ZMJEQ>SLS2SN6_P%4Z[/X:^&
MQK_B9'F3-K:8EDST)[#\Z]ZI*--.H^APQ3D^5'H7PS\"QZ5:1ZQ?QAKV49C1
MA_JQZ_6O2:10%4*!@ 8 I:^;JU959N4CT8Q459!1116904444 %-=%D1D=0R
ML,$$9!%.HH \$^)G@C^PKTZG8I_H$[?,H_Y9M_A7!6=W-8W<5U;N4EB8,K#L
M:^J=8TJWUK2KC3[I<QS(5)]#ZCWKY=U?39M)U:YL)AB2%RIKW<#B/:PY);HX
M:U/E=T?2WA/7H_$?AZWOTQO8;95'\+#J*VZ\/^#NO&UU>;2)7_=7*[TSV8=A
M]<_I7N%>5BJ/LJKCT.JE/FC<****YS0\(^,O_(U6_P#U[_U-9_PE_P"1_M?^
MN4O_ *":T/C+_P C5;_]>_\ 4UG_  F_Y'^U_P"N4O\ Z":]Z/\ N7R.%_QO
MF?0]%%%>"=P445SWC3Q GASPW<7>1YS#RX@>['_)JH1<Y**ZB;25V<!\5?&S
MB1M!TZ; '_'RZ'_QW->20PR7$R0Q(7D=@JJ!R31--)<3O-,Y>1V+,QZDFO7O
MA-X.3R_[?OHLL21;*PZ=MV*]_P!S"4?ZU9PZU9FUX ^'4&B0QZCJ4:RZ@XW*
MK#(B_P#KUZ'117A5:LJLN:1VQBHJR"BBBLR@HHHH **** "O._'WPZ@UN"34
M-,B2+4%&2JC E_\ KUZ)16E*K*E+FB3**DK,^1)H9+>9X94*2(<,I'(->M?"
MKQLV]= U"3*G_CVD8_\ CM2?%GP:GE'7[&+!7BY51_X]7D,$TEO.DT3%9$;<
MK#J#7N^YBZ/]:,XM:4SZ[HKGO!7B%?$GANWO"1YZC9,!V8=:Z&O G%PDXOH=
MR::NCY;\76OV/Q;JD&,!+EPOTS6+7=_%JP^R>-))@N$N(PX/J>_\ZX2OIJ$N
M:G&7D>=-6DT%%%%:DGK?P3U#$NHZ>S8R!*H]3T/\J]CKYJ^'NKC1_&-G*S8C
ME;R7ST^;C/ZU]* @@$'(/2O!S"'+6OW.W#RO"PM%%%<!N%%%% !1110 4444
M %%%% !115'5=4MM'L)+NY;"J.!W8^@H;L*4E%7>PNJ:K::1:-<W<H1!T&>6
M/H*\D\1^,[[6Y&BB8P6@. BGEOJ:S_$'B"ZU^^::9L1@XCC'11617%4JN6BV
M/FL;F$JSY(:1_,****Q/,"BBB@ HHHH **** .P^'%KYWB7SL9$,9/YC%>OU
MY_\ "^Q*65W>L,>8WECZ#G^M>@5W45:!]3ED.3#KSU,GQ+J0T?PWJ&H'_EA"
MS#WKY$DD:65I&)+,<DFOI/XPWAM/ ,ZJ>9I5CQ['.:^::W1VR"BBBF(*^@_@
MCI2VOA>>_(_>74IP?]D<8_,5\^5U>D?$;Q%H>F0Z=8W*);P@[%*>I)_K0P3L
M?5-%?,G_  MSQ=_S^Q_]\?\ UZ/^%N>+O^?V/_OC_P"O4V*YD?3=%?,G_"W/
M%W_/['_WQ_\ 7H_X6YXN_P"?V/\ [X_^O18.9'TW17S)_P +<\7?\_L?_?'_
M ->C_A;GB[_G]C_[X_\ KT6#F1UOQWTD++IVJHN-V87([GDUXS72:]XZUSQ)
M9+::E.DD2MN "XP:YNJ1+"BBB@"Q8W,EG?P7,3;7C<,#Z5]A:9>+J&F6UVGW
M9HPX_&OC6OJ7X8WAO/ &F$G/E1^5_P!\BDRHG7T445)1\L_$W_DH&I_[R_\
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M>#5#>,=)5@"#<+D&OK<=*4BHBT445)04444 %%%% !1110 5YE\</^1/M_\
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M\^JBOF3J<5]#^'XG7PWI:E2"+.($?\ %>KF"3C$Y<.]6=O7@/Q7\.G2O$/\
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M:\7_ /01_P#(:_X5C^+?%^H>+M3-U>,%B4XBA7[J+_C7/U21#9W'_"VO%_\
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M20?\?$?^^/YU'4D'_'Q'_OC^= 'V'H__ "!+#_KVC_\ 015VJ6C_ /($L/\
MKVC_ /015VH- HHHH **** /'/CS_P >6E_[Y_D:\.KW'X\_\>6E_P"^?Y&O
M#JM;$2W"BBB@05]6?#G_ ))YH?\ U[#^9KY3KZL^'/\ R3S0_P#KV'\S28XG
M44445)85Y3\;?^09IO\ UV/_ *":]6KRGXV_\@S3?^NQ_P#0375@OX\3*M\#
M/%Z]T^#NM"\T";39'S):OE!_L'_Z^:\+KI? OB(^&_$L%RY_T>0^7,.VT\9_
M#K7M8NE[6DTMSDI2Y97/IFBF12I-$DJ'*. P/M3Z^;/0"BBB@ HHHH ****
M"O"/C!K8OO$$6FQMF.S4[O\ >/4?H*]A\2:Y#X>T.XU&8C]VOR*?XF["OEZ^
MO);^^FNYF+22N68FO3RVC>3J/H<V(G9<II>%-,;5_$]C9A<J\@+>P'>OJ4
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MNBAL:5SJ_#VB6_A[0[;3;8?)$N">['N36I114%A1110!\L_$W_DH&I_[R_\
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M'(Y-)L:5C3HHHJ2@KRGXV_\ (,TW_KL?_037JU9&N^&=*\2111:I;M,L3;D
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M^8?/,PZ>R^E=;117E3G*<N:3NSJC%15D%%%%0,**** /"/C+_P C5;_]>_\
M4UG_  E_Y'^U_P"N4O\ Z":]GUOP5H7B*[6ZU.T:695V@B5EX_ U%H_@/P]H
M.HI?Z=9O%<("JL9F;@C!X)KTUC*:P_LM;VL<SHR]IS'2T445YATA1110 444
M4 </XM^&NF^(B]S;;;2^/.]1\KGW']:\6UWPAK/A^=DO+-S&#\LJ#*L/7_\
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M8ZA1117$;!1110 4444 %%%% !1110 4444 %1S00W$9CFB21#U5U!'ZT44
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gfbaqn1kfu2x000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *V!48# 2(  A$! Q$!_\0
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M>=3EF% K$]&:8) >]+D&@0ZB@44 +1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@D;:DJL?0&@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%(:  FH)9,#%++(%%5B=QS3L
MA))HHHIC$I:**!A1110 4444" 4444 %%%% PHHHH **** "BBB@ I.]+37.
MU&/H* BKLY?Q;KRZ=:^6C?,PQ7D=Q<2W<S22L22?6MOQ;?/=:I)&3PC5@=JX
M:LVV?39?AE&";W 4M1/,J#UJN;S_ &36&IZ>BT+F,TZ&62W</&Q##WJDEWD\
MJ:LK(K#J*:NB)PC)6/6/!?B 7\7D2M\R#%;VN:FFFV#R%L-CBO(?#E\UCJ*D
M$@,PS6_XWU1Y94A5CM9 3^5=<:GN'@5,(O;V6QS6JZI-J=V[LQV$Y'-4.!30
M0J\G%1/<JO3FN63;9[E*G&$=">BJHNP3]TU,DRN.H%2S5.+T)%9HV#HQ!!SQ
M7HO@KQ,TFVUN&PQ.!7G-7-*N#:ZC'*#T-73FTSCQN'C.#/?@0PR.E.K/T:X^
MU:9%)G)(J_7>CY>:M*PM%%%! QG6,9;@5F7-Y;W$OE*<D\=*O7<330,JG!Q7
M-6.GS1ZD&=L@-4MC3=SI[:,1PA0,8J:D' I<U2 2FNZQIN<X4=:?69KSLFD3
M,GW@.*3&M78JWGBO2K9C')/AN_%<=KUKI^ON)+*0O)V&*X6_FEEOI#(3^-:/
MAJZG34XD3<5+<XK#GYG8]2E0E3I\]]3?T#P7*;P_:D(4#(KJ%T55O85C+;5/
M-;D4GE6JR$?,PQ5FRAZNPZUI&%M#BKU7-WD6X(A%$$%244E;)'$]6+10**8@
MHHHH *6DI:!B4444""BBB@ HI"0O4XHR#R#0 44FY?44;E]10 ]3BIT;-5@0
M>AS3U.*0T6*6F*V:=2&+1110 4444 %%%% !1110 4444 (*@NKE+:(NQQQQ
M5BJ&J6;7EN44X- ')W>N^(9)C]@MXWC!ZEO_ *U11ZUXK5P9[2-4SR0W;\JH
MWUGJ6ENP2] ).0N:72Y-0NK@+<78"YZ-WH [O2M1%_!N)^8=1[UHU5LK.&UA
M'EJ!D<FK0H :5!Z@4>4G]T?E3J6@!FQ1_"*7I2T4 +1110 AZ5R+?\C+)]:Z
MX]*Y%O\ D99?K0!UD?\ JU^E/ID?^K7Z4^@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:6 ZT +2&JS7
M]LC;6F0'ZU.LBNN5(/THM8#"U3PW!J4ZR.[#:V>*V;:$6\*Q@Y &*P-9\3?V
M9.D9@=MS8R!6]:3_ &F!)-I&X9YH LTE+24 8&L>'(-59&D=UVL&XK7M+=;:
M%8UY"C%8.N^)O[)D13 [[G"\#U-;ME<_:K=)=I&X9P: +5%(*6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** $J.1]HISM@53=RQH 1F+&DHHJAA1110,**** "
MBBL+6O$=OI49W$,WIFDVEJ7"#D[(W<&BO,YOB,OF?+&V ?0UK:1X[M[R01N-
MI/<U'M8LWE@ZL5=H[:BJGV^V\CS?.3&,_>KG-1\<V=E(4 #8]#5<RZF*I2;T
M.MI:X6W^(MK*V/+QS72:;KMKJ* JZ@GMFA3BRI4)15VC6I* <C(-+5&-K,*2
MEI*0"T8.*R]9U:/2[9I'ZXR*X/\ X6+^_P#N-MSZ5+FEN;T\/*HKQ/3ZCN/]
M2_T-9NAZQ'JUN'3KCFM5AE&![BJO?8SY7&5F>#Z[G^VKG/\ ?K'N)MORKUKK
M?&NFO9WKS[3AVS7$D[Y-QKSZBM(^KP<U*FD@5><GK3N*2EQ69WV$..E-YC.Y
M33\"@CC%"!JZ+^G2>;=1$'D,,UI>*KI5NX]IR0@_E7,+</:N2I(I9[B2Y7S)
M&+$5JG[MCSI0DZMQK323MCM4BQ8'6FPK\H/K4U9,[:<-!HII4@[E/(I](.#2
M-'$L6\P;Y6ZBK2<.,=:RT;;+GUKH-(M3>:A%&!D&JBKLY:\TH,]A\*Y_L.WS
M_=K=JCI-K]ETZ*+IM%7J]!;'R55WDV%)FEJO/<I;C+D4V97)F("$GTJC:$22
M,P[&GRW*RVX9".:2PBV(V>YI;LM;7+M%%(YPA-,DANIS#$67KBN=&K-?S&U;
M!4G%="5$D;;N01659V$23O,% VM4O<(IWN<QK/@B":4R)G<>HQ5C1?"T&F3I
M)C/UKJ';=,S?PGI42MG<G<]*7*KW.MU9./*R>.,S3[,?(*U54*H J"SA\J($
M\MZU9K1(XJDKL****HS"BBB@ HHHH **** "BBB@ I.E+0>E &#J.H2I=F(?
M=I+6\N)5< =.E-U1U6Y8>22<=<50TU;CSW.&"D],4P)TO[LZCY!7C&:8FKS/
M<O$W&TXJ>."3^VMY4XVGM6-+#+'J<K>6V"W'% CL;"1G0$U=K*TAV,(# CZB
MM6D4.4X-3*<U7IZ-@T@+%%-!S3J0PHHHH **** "BBB@ HHHH *:_P!T_2G4
MC?=/TH \\\0O;1>((7NY-L8ZU3U"?3[J> :;-N<.,X^M6O$L]O\ \)!#%<0[
ME/<BM338-(24,D2!C0!U=H/]$AS_ '!_*IZ;'CRUQTQQ3J "BBB@ HHHH **
M** $/2N1;_D99?K77'I7(M_R,LOUH ZR/_5K]*?3(_\ 5K]*?0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNRW=KOLIE'=:\*\3V_EZHT;CUKW6%Q-#CN1S7FGCO0W%RUY&. .PK*M&Z.C
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M!6E.+CN<&+KJI\(OE)G.T9^E/ ]J**V//NPHH[T4Q!11VHH&%%+24""BBDH
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M(&^;%>GW%K'<VFV5=V%H X73?$-Y=:TD3CY"_'->C+T%>:I D'B6 (,#?7I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSD"I]*D@@MK>X>#&\C&10!ZC#M\E-IRN.*?45N=UO&1T*BI: "BBB@ HHHH
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M>_0BL^36PSJ58-T-.KA/#^NSI="VN@V1_$:[E'#H&'<4I1Y6 ^BBBI ****
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MU!6:-&5-1!VH?0U')=!XQ%&>2*L7I'EX/<<56TW3V7,CG/.13"ZMJ7;6+RX
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MB@=[D\=O%%R33C<0)P,9ID<)Q\SYIWEQ@\J#0-)]!OVMCPG-'^D2=1Q5E(T
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M8-07-#8]%#J3C/-.KE],DNWO<R;]OO6^UY%&0C, 36JD>5<LT4U3N&1R*4X
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M*>M-JB1:***8!24M% !1110 4E+10 4444@"D*@]0*6B@!K[A]T55NO,\DG
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MS@M6U61[H)$JL>G-5K;4KBWN$\V-%!8#@4E[HLL.MI'YX)8\5:2R$-\JW1R
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MEM=6$H^6/CUI6L5=&L0#VI#&M1I<1L.H%2%TQG(Q2V!"@8%%,2:-SA7!J2D
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M/6L>PL)+3Q'())-] '?1_P"K7Z4^F1_ZM?I3Z "BBB@ HHHH **** "BBB@
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M5 'GO@@BH?+>=OFX6IA&5.>HIS$;?O!/K2YNP^4='%%&N 3FD+D'G&*B5MO
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MHHH **** "BBB@ HHHH 2HW%2TQQQ0!!10>M%62%%%% !1110 4444 %%%%
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M1;_D99?K77'I7(M_R,LOUH ZR/\ U:_2GTR/_5K]*?0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M% !1110 4E&:,T
M %(>E+10!QNOW^JP7:+:J"F[!K;33UO[9&N%&_:,X%7I8[8M^\"YSWJ= N,+
MTIIV KVEC%:(%C'XU:HHHO<#C_$M_JMM)&+-007 /TS72:=)+):HTWWBO-/G
MCMF(\T*3GO4R!0OR]*0#^U8/B6"6>PD$>>E;W:F/&LB[6&0:<79W \P2:);&
M.T8'SE//%=GX:MI8+5O,SSR,U=.B67F^9Y"EO6KZ1B-0JC JYS30$E%)168"
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M&B@T 0.,&FU+(*AJD)BT444Q!1110 4444 %%%% !1110 4444 %%%% !111
M0 E+110 4E+10 4E+10 E+11]:5QV9%/*(8&D)P%&:\C\8>));R\>"%_W?L:
M]$\47@M]+F ."5->%O*7=F8Y;-<U>=M$>SEN&4GS,">Y.3[U&7+' H.6YH0
M<UQGT:BDK#L!13?]JD)W-]*0ME]HZ47!I6-;1]9DTRY5RQV9YR:[]/B'9I&
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M[Y3VJTHVKDT M5J5;N/HPZBI+**29AM&:5@7<+C.37JG@?P[;_V:)KB$%O\
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M*** "BBB@ HHHH :3@9KEM=\02VUU]FMCF0]JZAAE2/6N%\0V$UMJGVY4,@
M^Z!5TTF]0+>D>([@S^7>G:2<"NO1MR@^HKSW3+2;5;P2F)HMISR*]!B7;&J]
MP *=1("2DQ2T5D UD##!JN+&$/N"#/TJU13NP&A0HXH-+10!R6NZ%<7URCQ@
MX#9XKI+&(PVR(>H&*@NM4MK5PLDB@DXY-78I%E0,IR",T 24E+24 <EXCT.?
M49(VBSPX)Q]:Z+3X#;VR(W4+BH;S5;:S($LBC)P,FKL,JRQAE.01F@"444"B
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M##E:DM)8FN'3>-P[5>DMA/"4;H:F06NC)T.Y2>X==HP!Z5T2]:H6>G1VCEE
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MA72V16CW;F"UK6L_VB%9 /O#- %@4444 %%%% !1110 4444 %%%% !1110
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M_(RR_6@#K(_]6OTI],C_ -6OTI] !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TG:@#(O]"MKZ17
MESD'-:4$2PQJB] *YS6?$DNG7*1+;,X+8R*Z"SG-Q;I(5*Y&<4 6:2EIIH R
M=2T*VU%E,N?E((P:T;:%;>)47HHQ7.Z]XCETJ1%2V:3<X7CZUO6%R;FW20J5
MW#.* +=%%% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI-#_ &8BJ=XSL^M 'HL))A0MUP,U)4%KG[+%GKL&:GH **** "BBB@ HHHH
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M'$S;BJXS0!>%%(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+10 E(:=1
M0!!(F>E0$$&KI%1/'D4TQ6*]%*5(--JA"T444@"BBBF 4444 %%%% !24M%
M!12446'<6DI:,4@N%%%%,04444 %%%%( HHHIC"BBDS0(6H;LX@(J8=:K7+
MRA,]:B0RK,F8XC[TR\L8KJ9%?N*L3855'H:SYM1(U&--M9.P-KJ3^1%;%4'8
MU++(@U")1CI6;=VUS//O0D FD-A<M?1R%FP*1%_(Z@'BBFP@K$ >M/K0T$IU
M)2T &:*2EH *2EI* "L36YI;7]['V%;=5;Z!9H&W 'BDU= ]BEHM_+>1 R5K
MU1T^*.*%510*O4+825D%%%%,8M%%% !1124 +124M #:6BB@!:**2@!:*2EH
M ***2@ I0,T 9J95Q0D B+4E%%4 44E+0 4444 %%%% !1110 4444 %%%%
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MWOO^@;+_ -\T =]FC-<#_P )O??] V7\J/\ A-[[_H&R_P#?- '?9HS7 _\
M";WW_0-E_P"^:/\ A-[[_H&R_P#?- '?45P/_";WW_0-E_[YH_X3>^_Z!LO_
M 'S0!WU%<#_PFU]_T#I?^^:/^$VOO^@=+_WS0!WU&:\_?QS>H,MITH'^[3(?
M'MU-G9I\AQUP* /0Z,UP/_";WW_0-E_[Y-'_  FU]_T#9?\ OF@#OLT9K@?^
M$VOO^@;+_P!\FC_A-[[_ *!LO_?- '?9HS7 _P#";WW_ $#9?^^:/^$WOO\
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M!BFVCI+JJ^;G%:B:,V_+R;E'05-+I",N8R%;UI<R"Q6FDLX[F-1G<3QBMSC
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M10 4444 %%%% "9JG=ZE!9)NE?\ 6IKABD+,.HZ5YQ=6>HZOXC:,O(D&/PH
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MHUN!NV2%8!FK-9^EF46ZK+G/O6A6J *6DHP33 *4#-*$J55H0#%2I ,4M%4
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M.7%L@"Q@[N^1712Z=;3ON>)2?4BG0Z=;0',<2@^U %H=**6B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $(S4;1@U+10!
M4:,BF$5<(S3&CIW%8K8HJ0QFF%2*8"4444""BBB@ HHHH ****8!1110 5!=
MW26T)=SBI^]5;^S-W"4SUJ9; []"+39TN'9UYS6G5#3K'[&F,\XJ]6:VU&KB
MT444QA2TE% "T44E "T4E+0 4444 %&*** #%)BEHH ;M'H*7 ]*6DHL 8'I
M1QZ444 )@>E+BBE )HL W I0*>(ZD" 4[ 1A#4@2G8I:8"8I:** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "D-+10!F:OIBZG9O _1ABN-7X:VBG(4UZ+10!P5KX @M[A9
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MCHHQ4]% !1TJE>ZI;V2G>Z@^A-9\/B."20*Q4 ]": -ZBHXIDF0.A!!]*DH
M***CEF6%"S$  4 245!;7*746^-@1GM4] "$9!%<=KO@JWUB<22*20<BNQ/2
MLZXU>"W8AF Q[T <</AS;+T5JWM!\,QZ0Y* \^M;=G?17D6^-@?I5J@!H&*=
M24M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 E&*6B@!,4TIFGT4 0&&HRA%6J0CVIW$4R#25;* ]JC,5.X
M6(:*D\LTW:?2@!M%!!]*2@0M%%+0 #K3Z:O6G5,AH***6I&%%%% !1110 4E
M+10 E+124 +12447 6DHHH *,T8I=M !24_8:<$% $8&:<$-2A1Z4N!3L!&$
M%/"@4[%%,!,4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 (>E<!XUTIY]LLA(CW\8-=_6#XJMY+C3XUC4L0^>* .9NY6CL;>U!^1DP:
M=>:-"F@QR*2&W ]:OW>D2OIRSA27C7A?6L6YU#4;NQ2Q%C(F&'S8]Z *5[.U
MUJ^FV[,=H8#K[5KZQ:)I5V;B D-CUJ+5=(GMY["]BA9FBPS*![4IEO=>OFCD
MM'A7'4B@".QU_P 07VY;4KA>.15/7]=OI+0V%ZV)QUQ71>%M-FLYIUD0@;N"
M:Y[Q1H]W<^)7ECA9D/<"@"#P??/H,DGGL0)CD9-4O&#3WFI+=HQ\DL.A]ZU]
M;\/W4UG;-"C*R)S@5--HMQ)X3B#1,9Q*,\<]J .[T+_D VO/_+,5Y?K=U;0_
M$$_:"VW8>!7J>CQ-%HUM&PPRI@BN-?1/M'C[[1/;;X=O4CB@# OH#>L9=/W[
M%Y?-5K2]MK>YQ<%R?:O5;S2[6'3YUM[=58K_  BN7T'0(GDS=6H)/=A0!R]K
MYERMU<6C'$8)Y-;WA'2XM;MA>W98RYQUJO<:-<Z1>S101L\5R<<#A13K.YO_
M  J_V>*SDG3KD"@"_P")/#]M:2V\L18$'/6JFOV45QX:%P<[PP7-)/J6H^)+
MR%6LI+=8VYXZUO>(]-<>&Q!"A9L@X% %2S@MM-\*+.#^\,61DUPT$RJS:T[-
MYZ-M'/%=7J=M>RZ7IUHD;@$;7P.E32>!2UAY8EP#R10!EZGJ[ZM%8(&X=@&P
M:ZQ?"=B]BJ_-\PR>:X)=!U".]^5)-EL<KQ]ZNA/C'4_LWDC2I 0,9P: .JT:
MQ%BS1J<J.G.:S?$T[3R_8<\-4OAFVO [75S(_P"\&=C=JK^(8S#J NR/E6@#
MF_&T8L]+TI"6P#S^M/MM0MH[='AW"0*.M:'B>U;5;73'BC,B[@3BMR[T>V71
MU\JU42;1T'/2@#G=.UCQ!<RRB,KY2#(XJ&]\5:S:QLQ9?EZX%;>F6,\-I<?(
M5)3BN-G_ +0CAFA>QDE+-P2* -\^-+A;&$EAYTAP..]68;[Q+O624KY)YZ5R
MW]D7EY#!)]G>/RF#[<=<5T2:_?W*+9G3G0 ;=^* ,G6KG46ND;/\0K0N-?NK
M"V60MR%%1ZS:7D,,,B0O(21D =*AU#2[N_L=ODNI(]* +\.L>([BU2\0K]G/
M/3M45SXQOI8BMHP\P<'CO4-MJM_9Z7'I7]G2, -N_%,L?#EQ:W(<HS"0[B,=
M* +/]O\ B"UAMYKHJ$E;'2NXDO/*TM;EC_#DUS7B.PFFTRQCBC)*R9( KH)K
M1KC1%M\D,4 H Y=M6\07-Q(]H5\D D9%9>H:WJ%_HETLK?.HQQ5M-4OM)GFM
M$L'E4J5#X]:K6VE74VD7;M$RN^2%Q0!M>!+6=-,CFE[CJ:V?$UI]HTJ8KG?C
MC%'A>![?1(8Y%(8#H:UY8UEB*,,@T <)I>M)8:&ME*V)0N#DURL6N76B:@T<
M!.9FW#-7M;T"^?Q([0A_)W< #BK6NZ)+;7EE<);&;8@W#% !!XQU!GFCO#\F
MPXP*R_#-_K>;^6Q.4WY.:UX%?4I)(VTLQ?)PV#5_P=IDUI9Z@DD17<WRY% %
M>?Q)??94CN6'F[AG%6+[Q)?0R6MO:$;Y0!S6?J.DW4ET"L3$;O2EU/3;NUO;
M*[CA:3RL$KB@#52[\0(T@O2OE[3T%8.AZX^G1:@RL?,WG%; U>_U>9X6L7A7
M'7%8MEX?NA%>3/$W#$A<=: '1^.-66)))#\I/I7HNFW_ -LT])OXBN37G-NT
MKVR0/I!X/7!KT?2H0EC&-FW*]/2@#A)]^K^-9+&=CY(7. :Z:X\*V?D@KN#*
M..:QM9TRYTG6WUFW1IMPV^6*CE\4:IJ""V73I(B_&_'2@">35+RT/]G:>P,P
M]>:J7OB;6M(DB2^(!DZ8%0)IU_HLHU%EDN9/[I%5M:^W>)I[>1K-X?).>G6@
M"[%XA\0WNH>7;%3'C/2HXM>U34K:\AE(W1 @XK9\.Z?+;SY>-A\O6LS3M+N8
MI-5<Q-\Q.WCK0!GPZUK&E^%A- 1YA<C)K7M/$&M0V,4EX5\R=<Q\5DO!>S:"
M+0VC@A\]*Z34-*EET>PE4'?;QYV^O- %$ZWK]HOG7A7R3[5GSR_VE/&23^\-
M2W%]?:S;_86L'B /W\4Y--GLC"S(VU#DF@#3T6?^S]8CTU2<$9P:[>N%TZ W
MGB:.^3[@7!Q7<B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,4M% "8%)@4Z
MDH 88P:;Y(J:B@"N8J:8SZ59HQ3N*Q6"$4NTU/BC ]*3&08-)5C I-HI6 @H
MJ?;1LH @HJ?91LH AHYJ?;1@>E $&#1M-3X]J7 HL!!M-+LJ7BBBP$8CI1&*
MDI:+ ,""G;12T4P$P*,4M% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %(0#U /UI:* $VKC&!CTQ3?*C_ .>:_P#?
M-/HH :44]5!^HI!$@/"*/H*?24  51T 'X4AC0G)52?7%+2T -V*>JC\J-BX
MQM&/3%.HH 3  I-B[MVT9]<4ZB@!.U($4= !^%.HH 845CRJD_2@Q1DY**3[
MBGT4 ,$4:G*HH_X"*4J",$ _6G44 ,\M>,JO'M3L4M% #/+3^XOY4GD1?\\D
M_P"^14E% "!0!@ #Z"J>I:?'J%J89!P?2KM% %.RLDM;9(0,J@P,U;P",$"E
MI* #:H[#\J;Y,9ZQI_WR*=2T ,\I ,!%_*CR8P<^6GY4ZEH 88T(Y13]11L3
M^XOY4^B@"/RH\_ZM/^^:=L7^Z/RIU)0 A4'J ?PI<4M% ###&3DQH3_NTH10
M,;5Q]*=10 @  P !12T4 -\M"<E5)]<4&-6^\JGZBG4E #?*C'(11]!2A%'1
M0,^@IU% #?+3^ZOY4&-#U13^%.HH 8(HP>$4?A1L09PHY]J?24 ,\F,?\LT_
M*G@=AQ2T4 -9%8890?J*3R8A_P LT_[YI]% #3&IZJI^HI!%&.B+^5/HH :$
M Z #\*-B_P!U>?:G44 ,\I/[B_E2[1C&!CTQ3J* (Q%&#D1I_P!\U'<VR3P/
M$5&&&.E3TM &=IFEQ:?%M0=\\UHTE+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)BBB@!:*** $Q1
MBBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gfbaqn1kfu2x000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *V TP# 2(  A$! Q$!_\0
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MS%]: '44WS%]:/,7UH =13?,7UH\Q?6@!U%-\Q?6CS%]: '44WS%]:/,7UH
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MG4F: &^6OI1L7TH9PHR>E)'*D@RI!^E #O+7TH\M?2FR2K&,L0*<C!UW#O0
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MTIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44
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M,#K+'4?M*?.-K>E:%<E:>>=10R*5YZ5UHZ?A2 6BBB@ HHHH **** "BBB@
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M]*/+7TH /,6CS%H\M?2CRU]* #S%H\Q:/+7TH\M?2@ \Q:/,6CRU]*/+7TH
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M%4>,J  :ZK%&*GV2%R(\NOO"4\<Y"DX]JUM+\(LJ!Y#FNY,2,<E0?PI0H P
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MIBV<*G(C7CVI@5-%MFM;/8>]:=( !P**0"T444 %%%% !1110 4444 %%%%
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MF7[9=<]C_*M=]/*3L4'RFBWTF.W=Y%'S/UI 5_#L2O<W&X \]Z-714UB!5
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MZ8I 8^E]+OZ'^52^&GMU6?>5^\>OUK3MM.CA$H_OU2CT@6S/Y0.&.30!%/\
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MWJ=+&W1MRQ@&K  % !2]J** &E!2>6OI3Z* &>6OI1Y:T^DH ;Y:T>6M/I*
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MU/JTMN@R%J6XN+^T92$.">: .KHK-L]162'=(P&!S4BZM:,VT2@F@"X2!UI
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MBA)^E84<8)#B)ORI@=+X>LY8I&F?^+FNCK&T5W*!6!P!WK9I %%%% !124M
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M2@!:*** $P.]'%+24 +1110 A4$8(S0JA1A1BEHH :R*XPPR*01(!@**?10
MF.,8XIHB0=%%/HH :5#+AAD>E(D:(,* !3Z* "BBB@!I16^\ :7:N,8XI:*
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M%9Z_\?E: ZUK#8F>XM%%%60%%%% !1110 4444 %%%% !1110 4444 %%%%
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MEE 9<&\P/7-,1V&D0PQH/+QNQSBM:LG1[1((PR2[\BM>D,*8\22#YES3Z0T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:*
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M%78@3%+113 **** $S2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI:H I*6DH8$+6Z$Y*BGI&$Z"G\T5*20[L6BBBJ$%%%% !1110 4444 %%%%
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M_LAA_LU%X:XTP9]:H_8[Z=MDCY3H16[86PM;?RP,4 6Z*** (SOSQ2?/4M%
M$7ST?/4M% $7ST?/4M% $7ST?/4M% $7ST?/4M% $7ST?/4M% $7ST?/4M%
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M#O6@-^*(["1-147ST?/5#):*B^>I>U !6)KRS&T?R20V.,5M52U"YCMX6>0
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M1M*M;>?+QG=GBNR4 * .@%1BUA!!"#(J;%(&T%%&*6@D**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(6?(/&*DFO9'BVL %QUQ3$=;;7"7$0=#D5-63H 7[ -IS6M2&%%%% !1110
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MHY84F&'7(H S[.,OIZJ.I6L:;2;ZWBF:,X4Y-=6B*@VJ, 4K*&4AAD&@#C-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HI:* "BBB@
M HHHH **** "BBB@ HHHH **** "BDI: "JEU?PVB;I#Q5NN0\82,EFVTXH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 9=WX?L+V?SIE<O[/BKUM:Q6D(BB!"
MCIDYHHH FHHHH **** $Q2T44 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gfbaqn1kfu2x000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %K!%D# 2(  A$! Q$!_\0
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M"KR2+(H9&!4]"* ''I5=KR%9 A?YCVJ9S^[;V%>3:EJEVGC2T@$I\MGP1^-
M'J\LR1)N<X%)#/',,HV:YCQQ=2VVAQO"Y5B>M5_A[=S7=E.TSEB#0!VM%%%
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M_G73>+?$;Z;91VL61(R###M0,S+WX>VL=C)=&=_.5=V-W>D\ :O<QRM82L2
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M7D>IZ3J_@[-X+Z22W#8\OM7I/A;6?[6TV-RN&VY- &Z_^K;Z5XSJO_(^6?\
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M#N/!D@O[9W,:]<FN\C\1C_A#8[W=^^:'</K6;\5;B+_A&I(LCS">!6$]K/\
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MN]5^\IZ*:]",:DY(IV!C H \WOO"U_-XD:[51Y>X'-7?&'A>XU*T66V&;A$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@ HH
MHH **** "BBB@ HHHH **** "BBB@!,4M%% !1110 4444 %%%% !1110 44
M44 %(:6B@!I4'J!0%QP*=10 A&>O2@*!T&*6B@ HHHH **** "BBB@ HHHH
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M1//'']Y@*9]M@_OB@"Q14:2I(,J<T\4 +1110 4444 %%%% !1110 444F:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M $/V:+^X/RI4B5/NBI:* (VB5SR,TS[-%_='Y5/10 Q(U4<"G48I: "BBB@
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M*[JU@F?)F*CFMP?#OQ.0#YLG(SUH ]Z_X2G2?^?N/_OH4?\ "4Z1_P _<?\
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M[1:/-*/O+&3^E $SZK:1MAIE!^M-_MBR_P">Z_G7S6_B?6=3U>6WA=BPD8
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M?SKY^\GQ1ZO2>5XH]7H ^@_[7LO^>Z_G1_:]E_SV7\Z^?/+\4>KT>5XH]7H
M^@O[7LO^>R_G1_:]E_SW3\Z^?O)\4>KU!=/XDM('FD+A5&30!](07<-P?W;A
MN,\&IZ\3^$?B:]U7Q#]DN&+(+=V_$$5[90 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %#5M1CTRRDN9" J#/-<BOQ#MY.4P:M?$ABOA2\(./EK
MC_A[X9M-4TM)9R23F@#M=/\ &]C=3+')*J,>Q-=3%*DT:NA#*>017B_C[PY#
MH2F[M'(=!D &O0O MY+=^&+1Y<[BG)- !KWC"VT:^^S2,-Y&<5GI\0;?C=@+
MZUPGCR 7?Q+MX&8A3'R,_2NXC\":?-I&\YW%* .ETGQ#9:JH\F968]LUL]J\
M%T=Y?#_CU;&)R8AVS[U[G;.9+=')Y(H K:OJ<6E6GGRL%7WK&T7QA::M,T2.
MNX' &:Y3XI:H\]JNGP,?,W\@>]<3I<-QX9\0Z9YC,%G.YLF@#Z)'(K'US7(=
M'B+RL!@=ZT+*X6YMEE4Y!%>;?%AF%HP!(X% &HGQ#MW7<H!'K6AI7C&+4;Y+
M8#EJP/!G@VQO_"UG<RYWNO-=3I_@^PTZ[6XB'SKTH Z('(I:;\J+R< 5']J@
M_P">R_G0!/25DZUJT5CI<]PLJY1<]:XG0/BC8W<GD328?<1S0!Z;15*TU*WN
MXP\<JG(SP:N#D4 +4<W^H?Z4^F3?ZA_I0!\Z_$ !O&L0->Q^&].MGT*V+1+D
MKZ5X[X^_Y':*O:O#9QH%K_N4#+3:=:#_ )9+^51FPM!_RR7\J=<7 0\FJ+:@
MNX_,*9);^P6G_/-?RH^PVG_/)?RJD=03^\*4:@O]X4 718VG_/)?RI?L%I_S
MR7\JI?V@@'WA1'J"LWWJ0&DNFVG_ #R7\J?_ &;:?\\E_*FV]P' P:M%AB@9
M4.G6G_/)?RI/[.M?^>2_E3WF /6H_M(]: #^SK7_ )Y+^5']GVG_ #R7\J/M
M(]::;D>M 7'C3[3_ )Y+^5._LZT_YY+^50_:1ZU+'<!CUH E&F6F/]2OY4G]
MF6G_ #Q7\JL*_%*6H K?V;:9_P!2OY4'3+3'^J7\JGWT;Z *_P#9MI_SR7\J
M7^S+7_GDOY5-O]Z7?[T 0_V9:?\ /)?RJO>Z;:?9),1+T]*OAZ@O&_T23Z4
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M_6OH4?\ (%/_ %S_ *4#/GG0?^2C2\?\O/\ A7TI&!Y2<#[HKYJT/CXC2_\
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MIXTRT_YXK^53@\U(#0!6_LRT_P">*_E6!XRTZV3PS>LL2@B,]JZG-8'C4_\
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M:_;/6M&[M2Q-4#8'/2F S[>WK1]O:E_L\^E._L\XZ4 0F_;UJY9W3.PYJO\
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MU)XP0'[_ .M-_P"$O7;]ZN+CT&]=@3FK/_"/W9&,&@#H7\8#/WOUJ6#Q.9G
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MW'A6VE;)C'Y54?P7:'_EF/RH ^>?)OE_O4G^FKW:OH!O ]H?^60J$^ K0_\
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M\@"U_P!RO$O'W_([15[;X9_Y -K_ +E S6Q28I]% AF*-M.HH ;MI=E/Q10
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ME7TK0VTFV@"DML!VJ3R!Z59VT[% $"1 5,%XHQ3J &[:;LJ2B@"/8*-E/HH
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M !1110 4444 %+24M !5>]_X])/I5BJ][_QYR?2@9\\:G_R4)OJ/YU[CJ/\
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M2?'FK#3M!D*-B3. *\>O-**6D>H2+S/SDT >S>#=4GU?P^+B8YD(KGHAKO\
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M]=J^@M4_Y%^X_P"N1_E7SUI)S\28"/\ GM7T)JG_ "+]Q_UR/\J /GWX=_\
M(]G_ *[/_,U]+5\T_#P_\5V?^NK_ ,S7TKF@ /6DHS2;A0 M%-W#UHWB@0ZE
MIFX>M*&H&+11FD)P* "EIFX4;J 'TE-WT;Z '4M1[QZTX,/6@"2FT$\5$TP
MH <:6JYN5'>D-VN.M %BBJOVQ/6D-XGK0!<&*Y_QK_R*]]_US-:8O%]:Q?&,
MH?PO?8_YYF@#RCX(_P#(Y'_KTD_FM?0U?//P0_Y'(_\ 7I)_-:^AJ "BBB@
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M*TN!<P"1>]>?>%OAG:Z.4F?YF'/(KT6*-8DVJ, 4"'4R;_4O]*DJ.;_4O]*
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M1'"I/]T5\ZZ+_P E$E_Z^:]\NH&>%<?W10)CVUA >M,;6T'>L22PE+GK4?\
M9TI[FF(VFUY!WIO]OIZUC_V5(>YIRZ.Y]: -J+6/-8!36I!.9 #6#9Z48W!Y
MXKH+>#8M !/(RKP:P;W4I(FZFN@FCRI%8]WIPFH QFUV7IDU&=:G/0FKQT12
M>E2)HJ#M0!F?VM<GN:8VI798 $UM#24':GKI29Z4 1Z=-/(!O-;L>=M06UHL
M8&!5X)@4#,V[=E!Q7/W5[=(YVDXKJIH0]9\VG*YSB@1S)U&[SU-+_:=WZFMW
M^RD_NBC^RD]* .>;4KS/4TK7MW);3!B?N'^5;XTE,_=IT^FHEE,0/X#_ "H
M\(T D_$2WW=?-KZ)U3_D7[C_ *Y'^5?/6C+M^(\ _P"FU?0VJ?\ ( N/^N1_
ME2&?/?P[_P"1[/\ UU?^9KZ2<X%?-WP\_P"1[/\ UV?^9KZ289% %*2=AWJ
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M$-6O]=%Q90,ZXZ@5S<6@^,88PBQ3A1TH ^BCJ-G_ ,_$?_?0IGV^S_Y^(_\
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M3?L\?]Q?RJ6B@"+[/%_<7\J3[/%_<'Y5-24 1_9XO[@_*C[/'_<'Y5)GFC-
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MX1[3_P#GBOY4?\(]I_\ SQ7\JU:,T 97_"/:?_SQ7\J/^$>T_P#YXK^5:M%
M&5_PCNG_ //!?RH_X1[3_P#GBOY5JTM &3_PCVG_ //%?RH_X1[3_P#GBOY5
MJXHX% &5_P (]I__ #Q7\J/^$>T__GBOY5JY%% &5_PCNG_\\5_*C_A'M/\
M^>*_E6IFES0!E?\ "/:?_P \5_*C_A'M/_YX+^5:M+0!D_\ "/:?_P \5_*C
M_A'M/_YX+^5:M% &5_PCNG_\\5_*C_A'=/\ ^>*_E6KQ10!D_P#".Z?_ ,\5
M_*E_X1[3_P#GBOY5JT<4 4+?2+2V8-'&H(]JOX&*** &&&,]5'Y4GV>/^X/R
MJ6B@"'[/'_<7\J7[/'_<7\JEI* (_L\?]Q?RI/(C_N+^52T4 1?9XO[@_*E^
MSQ?W!^524M $7V>+^XOY4?9X_P"X/RJ6B@"+[/'_ '!^5'V>/^X/RJ3/-&:
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M8HKG 8UR?CFXDG\36NF,YV-'S@_2K7BC0+>T\.6T\>0Z+G(% 'J+ZU:QZ?\
M;#(OED>M<?-\4+>.X:-;5F13@L.E>?2:W/+\.47>=WF$=?I756/AFU;P1)=-
MS(\.[- 'HVB:W!K-HL\1'/;-:M>/_"^YDCU!K,L2JYZU[!0 E+110 AJ*:9(
M(B[D!1W-35RGQ NWLO"UQ,A((':@#'U+XGP65W)!':--L."5K;\.>,+;7U&Q
M?+<_PGK7 >!](AU"VO+B<;FD4GD>U4?#.[3?B/\ 9(V/EXSB@#W2EIJ\C-.H
M **2EH 9(_EH6-<+K'Q%72KIX18R2;3@D5W,L8D0H3UKSKQ%JGAS3#<QSO\
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MSLM0F=B8@I*$GVK/TRS/BKQ=(US*XCVD<'ZT >M:7XGL=3)5)%#=AFMT>U>
MWUJ_A?QE806\CF.6;!S^->[V<OG6Z/[4 3T$CO2TQQN1AZT 8VJ>)+33&VNZ
MECVS46E^*['4I3&LBJP[9K"\0>'M(>\$]]<R*PZ 5YGIL!7Q@R:;*[QB0=3V
MH ][O]3MK"#S9I% 'J:Q(?&UA+<B+>HR< YKA/']]-/K$&E;RJNBYP:I^(?"
ML>EZ)97L,K^8$W&@#V9[^W2V\]I5V8ZYKGW\<6"7/E;UQG&<UY==>)[B?P%M
M$AW^:%SFM1/!4+^#Y-3:63SC%O'UH ]=L;Z&^A$L+AE([&K=>4?"34II8X[*
M5BVV(G)/IBO5Z /GGQ+9/?\ Q#M+>-MC,IP?RKT/1_A]&CI<79$I!R*U9O!-
MC)X@AU0@^;&,"NJC01H%'04 >1?%B!(=.,:+A1QC%9%]X.5O"=GJ$*@%8=QQ
M7JOB+PK:>((BEP,@U<CT2!=$&FXS$$V#Z4#/-_"MVNI^$'L5_P!:N[CO63\/
MM73P]K5[:WF(Q)(0&;CO7I.B>"[+1KII8 ?FSD?6J.N?#C3=6F,S!A)G/% B
MCX]\46+:5Y5M.DKMQA3FH?A+I<MII]U),I7S9-PR*EL/A3IL,ZR2ES@\ FN_
ML[**R@6&)0JJ,<4#/&?B;_R%[3_KN/YUZK;WBV/AZ&9^BQBJ&N^#++6[B.:<
M'<C[A6M=Z3%<Z3]A8$)MQ0(\&*WVL>+;N6W#E5?(P*C\36NIV]VFHSJ_RX7<
M17MNA>$[+1)I)84^9^N:M:]X>M-;L#;31C:3G(% 'FVM!]<\&6LD7S/%%EJL
M?#/Q/:6.E?8+N18F#?Q&NXTKPM::=8/:*N8V7;S7-ZC\*M+N;@RIO4D\[3B@
M#K+7Q%9WD_EV\JR<_P )IWB*S:]TJ1%Z[367X<\#V6@_-$7+$YY-=4R!E*GH
M: /!O VL+X>UVZM;L>6))C@MQ7J]UXJT]K=D@N(Y'9<85JS-=^'.F:O-YSJ0
M_JM5]'^&>GZ?<";,A(YY- '#&5;3Q_:S77RH6SEJVOB7J=C?QV,=K(DK%^BG
M-=?K_@/3]99)) 0Z+@8K+TWX7Z=;W"ROO8H<C)H XWQ!;RV_@LK*""67K75Z
M5;1#X;R.%&XVW6NIUKPM9ZO8"UE7Y!CI[5/;Z!;P:$=,4?NBFS\* /%O#4<L
MOAATB!)W=JW_ (;ZI8V$]\MVZ1MN/WCC-=YHG@VQT>V,,2_*?6L'4/A9IMS>
M/,FY3(<M@T =4VO645J+B-U,?J#4^C:W#K"R&$@A#CBLJ'P591:.M@"VQ>>M
M7/#GANW\/K,L&3YAR<T 1^,(FET>3:.BFN&^#TBK9WZ$_-YS_P#H1KT_4X!<
M6$Z$=4('Y5Y'X.630_$,EBX($TK,/Q- %'4XUD\?S;AG$HK0^(T2*T) P=@K
MNYO!5C+J[Z@RGS&;<:FUKPE9ZR%\]3\HQ0!YUXH_Y%C1\^W]*IZWI3?\(7]O
MB'[P'M7I]]X.LKZPMK613M@^[5@^&+1]'_LYES%0!XGX4DN/$VHVJR@D6; '
M-:\\:Q?%$J!@",5Z5X<\%6'A^:>2V3!E.31+X,L7U\ZJ5_>D8H YKXCN/[#5
M/XFCXK;^&$;)X-M0>N*Y?XA.USK=AI\()5CM/Y5Z)X9T_P#LS1HK;&-HH V:
M*2EH **** "O.OBA:R36*RHI(C&3BO1:HZGIL.IV<EO,H*NN* /-_"/B"RMO
M!C1R3(LG(VD_6L[X8VDEQJU]<!?E,I(/XUJR_"FS\_";Q&3G -=OX?\ #MKH
M,'EVZXR.:!FT*6BB@04'I110!7NI(XX6\T@)CG-><^)=.\/7UG+*L\'FC/.X
M5Z%J%DE]:O#)T88XKSJX^%UNTK!6D*,Q)^:@#C?"%Q=YU.TB9GBVE5Q5[P9>
M1Z5XK\FZ81X')8XKTOPYX+L=!B80J29!\V:RM?\ AU9:G?->*I$A].*!G$^(
MKE-9\;6)MB)%1\$K]:]KL8O*M$0]@*Y'P[\/[+2)O/VDR9SSS7;@8 'I0(*1
MCM4D]J=377>A4]QB@#E=<71=0<I>S1!\=&(KQO4TCTGQ3$=*E!5I0&">E>J^
M(/ 5OJEUYX9]WL:JZ-\,;"TO/M,H8R Y^8YH XGQ;YL?BBTU"52$6/DG\*W?
M%6M6ESX;MH8I5=Y$Q@&NY\0>$;/6[,PRKVP"*Y:S^%MG'<HTF\K&<J": .$G
MTB>V^'BLR-D29QCZ5VMAX@LAX"DMVG19$AQM)YS7<W?ANSN]*^P.G[JN(/PK
MM/M+8W^63R,T 4OAA;22:@UYM.PY&:]?K(T+0;;0[);>W7"BM>@ HHHH *Y/
MXA6KW?A2XBC4DD'@5UE0W%NES$8Y!E3U% 'CO@76+6PM;N"XE6-D0C#'':JO
MA=&U+XA_;HQF+&,CI75ZA\+=-N;QYUW R'+8-='X<\(V6@0A8%Y'.30!T2\
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M10 4444 )12T4 )WI:** "DI:* $QFBEHH 2BEHH 2EHHH 2C%+10 E%+10
ME&*6B@ I*6B@!**6B@!" 1@CK5/^RK$W N/LR>:.C8YJ[10 @I:** "DI:*
M$HQ2T4 49=)L9ITGEMD>5#\K$<BKJK@8I:* "BBB@ HHHH *2EHH 3%%+10
M4444 %%%% "44M% "<T4M% "4M%% !1110 E&*6B@ I,4M% "48I:* $I:**
M "BBB@ HHHH 2@4M% !1110 4444 %)BEHH 2CM2T4 )2T44 %%%% "44M%
M"44M% !24M% "8]J6BB@ HHHH *2EHH 2EHHH **** "D-+10 E%+10 E'>E
MHH **** "DI:* $Q1VI:* $Q1^%+10 F*6BB@ HHHH *2EHH 2C%+10 4444
M %%%% "48I:* $HI:* $H[TM% !2=J6B@!**6B@!*,4M% "8YI.M.HH 3%+1
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gfbaqn1kfu2x000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *V RT# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ I*
M6B@ I&.U23VI:@O#BTE/^S0!EWFKRH^+9-_KBGVFJ2/Q.NP^E<YIL]X\LWD+
MNPQ_G5FXNI%&+GY9>PH U;S6)HY]D";Q4UCJQGD\N0;7'455T=!+B1N36=/^
MYUJ1UZXI@:ESK,JRM'"FXJ>:L:=JC73E91M([5GZ.@>\E<\D@]:1QY%X2O=J
M0'39I:9$<Q*?:GT %%(6 I/,7UH =13?,7UH\Q?6@!U%-\Q?6CS%]: '44WS
M%]:/,7UH =13/,7UH\Q?6@!]%,\P4;Q0 ^DIOF"C>OK0 ^BF;QZTN\>M #J*
M9YB^M&]?6@!]%,WKZT>8OK0 ^BF>8M'F+0 ^BF;UH\Q: '4M,WKZT;U]: 'T
M4WS%]:/,7UH =13?,7UH\Q?6@!U%-\Q?6CS%]: '44WS%]:/,7UH =13?,7U
MH\Q?6@!U%-\Q?6CS%]: '44WS%]:/,7UH =13?,7UH\Q?6@!U%-\Q?6CS%]:
M '44WS%]:/,7UH =13?,7UH\Q?6@!U%-\Q?6CS%]: '44WS%]:/,7UH =13?
M,7UH\Q?6@!U%-\Q?6CS%]: '44WS%]:/,7UH =13?,7UH\Q?6@!U%-\Q?6CS
M%]: '44WS%]:/,7UH =13?,7UH\Q?6@!U%-\Q?6CS%]: '44WS%]:/,7UH =
M13?,7UH\Q?6@!U%-\Q?6CS%]: '44WS%]:/,7UH =13?,7UH\Q?6@!U%-\Q?
M6CS%]: '44WS%]:/,7UH =13?,7UH\Q?6@!U%-\Q?6D\Q: 'T4SS!3P<C- !
M1110 4444 %17"&2W=1W&*EI#0!REGMT>23S5^^Q/%,N;9M5O%FB'RCUKJ);
M2"8YD0-]:6*WBB&(U"T <ZDQTRX".#M'I4=M;/>:FUQC]V1Q72R6D$S9>,$^
M].C@CB&$0"@#F89#IU[*TN=AR!4UC&UY<LY^[G(K>DM()?OQ@TZ*".'[B!?I
M0 ]!M0#TIU%% "%0>M)Y:^E.HH ;Y:^E'EKZ4ZB@!OEKZ4FQ?2GTE #?+7TH
MV+Z4X]*Y_4?$B6,[1F)CCO@U$IJ.XF[&]L7THV+Z5R?_  F<?_/!O^^34<WC
M-#&P6%P2.NTU"K1;M<7.CK6>)3@D?G3P$;I7C]UX@O)9RRS.%STK>T;Q<\$.
MV96D/K@UI*5E=CNCT/8OI2;%]*Y/_A-(_P#G@_\ WR:5?&4;-CR&Y_V367MX
M$\\3;U.Z2RC5SW-68)$EMA(.XS5"Z0:IIZ2;<=\&JEA>C9- 3]P8%;)W5RRZ
MU\C3A%]:TEV;1DCI7,Z5DFXED&=I)&:C>>XU"0F&8H%/K3 ZB4HD>ZJD-W')
M-LS^M84=W-#,+>5RY/>H5MKF?4#Y4A6@#L<)@XJK;OOF93SBL;2YITOI899"
MVT5#;ZB8[R="3R>* .IPGJ/SJE=7*0RA:Q8[:^G+2+.P7KBF?O?. D8L1ZT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 4444 4M3_X]ZFM/^/9:@U/_ (]ZGM/^/=:A?$+J3T4458PHHHH
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MU5@<4 9:LME< OP&/%+J5RDU_ J'KC^5;%UIL=PJY7E>E10:3&) \B@LIXH
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MWF,T ;B@-R#FG;!6!IM_-%,+>Y/SGH*Z&@!-@I-@IQ. 2:RY=>M(I2C-R.M
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MM)$Q4L><4 5?$)#:A:[>?F'2NDB(\E!GM6%!I4DSAY6)*G(S5IO-CN8U!)%
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M10 4444 %(1ZTM% &8RC[2>!6A& %&!6>W_'T:T(_N"HCN)#Z**2K&+1124
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MXJ-/#RY!_M%^O]ZC6Q-)KQC4<5+'I\_'!IB.JTRW%O;JHD+X'4FKXJEIT;)
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M<)C@4P-^;6K:&0HQ.1UJ:SU."])$1Z5A:?;I=7LK2J&!!QFEC46-V0G 9NU
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M.Q13?,'I1Y@]*T*'T4SS!Z4>8/2@!]%,\P>E'F#TH ?24WS!Z4F\4 9FO?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,*J@^^*N8IF]?6E\Q:Z5&VB-$.JI?_Z@U8\Q1U-9VH7L(B*D\T2V'9LNV?\
MQ[K4]4+&[BDA50>:N[U]::V ?13/,6CS%I@.HIOF+2&1:!H?2$BJ5WJEO:KN
ME; KEM5\<6D8*6\HWCWJE%LTA1E+H=?+=1P#,C@"L+4O%=G;(PCE4L.U<-+K
M&L:PY2/YE)Q5W3O!TMRX>]C/)S5J*6YU1H0AK-C+SQ7J6H$QVT6Y3QD5B7F@
M:E=H9Y(6W'M7I^G^&['3P#&F"*U)5C6(CBGSI;%+$Q@[01XKIGA>\N+H)+"5
M7->E:?X1MHK= X^8=>*U+/8+GBM7>OK4RFR*^,G)V1EQ:#;1]$4_A5R/3[=!
M@1+^56=Z^M)O7UJ+G*ZLGNQ@M81_RS7\J<((QT0?E3MZT>8M*Y',P$:CL*4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[J@?A1SI;$RQ$8JT$8&E^&+:R4;T5R.YK<C@BCX1 OTJ:C%9MMG+*HY:L10
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6GTM $?E#UH\H>M244 1^4/6CRA4E% #/*%. P,4M% !1110 4444 %)2T4
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MJTN2%%%% "4449H 6BDI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHI* "@55GN&B)^6EAF:3G%3S*]AV+5%(.E+5""B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R=
M>G6/3)@6P<5K5R/BYI?)<+]W% 'G%RQDF9@2>:J,DLC;%!K5MEA,9W]<TMI
M9K_9$*P]HW)I(Z*;4&I,V] TRTM$6=V!D/4&ND.L-&NV!00/2DT_00\*M(#6
MO%HEM'SCFN>7MI,VG5B]68;7=_<](SBD33+FX.9 P_&NIBM8X_NBIPH]*%AG
M+XF8NM;9'.P^'4(R['/UK1@TB&+WK2HK>.&@NAFZDF1I B# 4?E3]H'0"G4E
M;*"1%V%%+24[(17N758R":;;2KL S4LD"2?>I$MD3I46=RM+$PY%-* TX# I
M:NQ)!);I(""HY]JS+G0H9<D'!]JV:,5E.C&70I3DMCD9](FMVS%N./>FQ7][
M:<-&<#UKKRH/456FL89OO"N:6&:UB[&JJW^)&7:ZZK$"5@*U(K^"4?*X-9=S
MH$1!,8.:S&L;ZU8F,<5*J58;HKDA+8[ ,"*7-<C#J]U VV:M:WURW< ,QS6T
M,3&6AG*FT:KL0A(ZU5^T2;MNWFHI]7M8(3([<"L,>*[(7N=YVULY7V(M;<ZM
M"2HR.:?5.SU""\0-$V<U;!JUL2+2TF:*=[@+1244 +1111<!":***+@&:8T\
M:GEJ<<5G7LD$8.YN?K2DVD4DGN7UF1ONG-/S5.S,;1AE.35NB+NA/R'44E+5
M""BDHH 6BDHH 6BDHH ,T9HJ"8N!E:3=AI$^:6J"2RLV*NKG;S24K@U86EI*
M*H0M%)10 M%)10 M%)2T %%%,<G;Q0 ZEJB9I-V*LQEB,FIC*X[$F:6DHJA"
MTE%%*X!2YI,BDR/6ES(8N:,U"TR)U-0/J4"=6J75BAJ+>Q=)IDDBQH68X%9K
MZ[:KQNYK&UO75:Q=8B<U'MX;7*]G+L.UCQ)%"61'!(J32?$L-PP1W45YZA%U
M<DRDY- /V>Z7RB?O41J)SL)Q?+<]HC<.@93P:?6=I#L]A"6/\-:%;D"T444
M%%%% !1110 4444 %%)2T %%%% !1110 4444 %%%% !1110 4444 %4-2L4
MO;=D*Y8BK]0W&?*;;UI,$>;WOA2Y6X(C8!:V] \-&UE667!-3W4=PTO&ZM+2
MTE4C>3^-91DF[&CC97N:ZJ$4*!P*6G48K6QF- I:6BF E%+10 4444 %%%%
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M]:0>Q9UFX>HHW#UKD_[:G_YY/^5+_;4__/)_RH^MH/8LZO</6ER*Y3^W)O\
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M'K0 M%)D>M&1ZT +129'K1D>M "T4F1ZT9'K0 M%)D>M&1ZT +129'K1D>M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HI:CGD$<9).* (
MY;V"'[[XI\5Q'-_JVS7-PH]_?2K+R@SBI+&62TN61C\N<"@#I:*:AW(#ZTZ@
M HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO[-=_P#/2C[-=_\ /2M2DH S/LUW_P ]*/LUW_STK4HH R_LUW_STH^S7?\
MSTK4HH R_LUW_P ]*/LUW_STK4HH R_LUW_STK1A#+"BL<L!S3Z* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBF.X1=QZ4 /HKGKW4
MKHW.RVP14NGZE*]SY$_#]Q0!N44@.12T %%%% !1110 4444 )2T4E "TF:R
M]0OWC8QPG]YV%9R:C?PG?<@".@#IJ*@M9A/ L@[U-0 M%)2T %%%% !1110
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M"I*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gfbaqn1kfu2x000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *V RT# 2(  A$! Q$!_\0
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M,:T** (OL\6<^6,_2I%4*, 8I:* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I&Z4M(W2@#!TW_ )"TWUK>K!TW_D+S_6MZ@J6XM%%%!(4444 %%%%
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M07+16J-&>IJ""Q,UN)#G)&:JZM*9]'@8?>--M[?53;#RY/EQQ3 D^TS6MRL
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MG!XP-V: -Z34K>.W69F^1NE95[K<!*B-^OO6><R:9"K_ ':FO=/MD@A=0-U
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M F!1@4M% "8%&!2T4 )@4F*=10 WBEXI:* $XHQ2T4 )BC I:* $QS1@4M%
M"8%&!Z4M% "8'I1@4M% "8%&!Z4M% "8%&!2T4 )@48%+10 F!1@4M% "8'I
M0% ["EHH 3 HP*6B@!,"C I:* $P*,#TI:* (9X%G7:P%/C0(@4=!3Z* $P/
M2C ]*6B@!,"C I:* $P*,"EHH 3 HP*6B@!"H/! H  [4M% "8'I39(ED7!I
M]% $4,"PK@ 5)@4M% "8'I1@4M% "8%&!2T4 )@48%+10 F!1@4M% "8%&!2
MT4 )@48%+10 F!1@4M% "8%&!110 8%&!110 8'I1@44F: $8A5)->?>,M?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,#UI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% "T4A8#J: 0>AS0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 )2T44 %)Q2TE !1Q1
M5>ZN$MHB[G %2Y65Q/8@U*^2SMR[$"N$F>75KISU1#FI]2O9M5O7@B.4!INI
MSQZ)8*$XDD&#7*DZL[=!TJ;J2L86L3">XAMH#G/RMBNZ\*:*-/M,,OS$9YKE
M_">CF^NGNIUS\V1FO38T"(%'85W6459'=7DH1Y$. QQ2XH'6EJ3A&[1_=%*
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M4!0!BG4-W.*4G)W$%+112)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *SM5\[[*QA&6QP*T:J7U['90-+(< 4 <C'JFJP-MDMLIZFM6TUNVR/M
M 1"?:LR[UIKX%;9@<UF+H.H7DX>1#MSFF(]$@GBF0&,Y':IJSM+LVM(%0C!
MQ6C2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% "4M%-8X1CZ"@"O=RQQ)E\"N<N=8B@BE1&!9NE9'BC7)T<QHW0XKFK.
M=[O4(4D.0S<UE--[$23>QT^E6$NI78GD!V@UN:]?Q:/I;+&0'':M"W2#2]/W
MCA0,FO.=;OI-<UDVT!W1DTZ%'EU9U82C=W>PN@:?+K&LM<S [&Q7JEM"MO D
M:C@#%9'AW2UL;",%<..M;M;3>I6(J<TK+86BBBI.8**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *K75I'=1E)%RIJS24 9T&C64!^2, U?
M6-4 "C@5B7.M+;WYA;CW-:<-];R1AO-3GWH MTE(KJX^4@TZ@!*6BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:?IUP7D:Y7[U=#BC% ',/87MF[?8UX8\U8L=/N))EFNE^<&M^B@  P*6BB@
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M6DU8:(U4=*=BEHI&-Q,48HH[4 %%+24 %%(6 /44F]3T(_.@5QU% I"0.I%
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MYK0I %%)2T %%%% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU</BRR$ \L\X]:SE+EU9+=CJF=4&6-9MSK5G;@AI/FKD9=9OKYRENYP:DM]
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M#ZBO3X]*LT'%NGY5,MG O2-1^%8.NELBWAYR=Y,\VB\*:O=<O<_G5Z#P+/\
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MTU]<QJ5;&?2O5KK3X91@Q*?PJ&UTN&!L^4OY5U*%F97;1'HFE)9VH#*"2*V
M@7H*4  8 IPK501%Q**6BJT$)2T44P"BBB@!,4N*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "DHHH 6DS110 M)F@D#K5.\OXK6(L[#CWII#L4[_5
MQ9R$,< 46&K?:WP#FO.?$>N-/>N$;Y.U5=/\1SV9RC=JKD=KB4U?E/8WGCB7
M+M@5F7FO6L*G;*,BO,;KQA?S_+DXK+;4IYGR^ZL)J>R.CZO)['H5SXFNIB4@
M7<#Z526TU#4'S(C@&N:M=3:#!7.?<5IIXLO8U"IC'TK/ZO.7Q,7U*3W9U-EX
M4B&&E8Y]S706NGP6JX4 _A7G/_"7ZF>F/RII\6ZMVQ6T,.ET+6":/4\*!Q@?
MA4%Y(J6K-G&*\R_X2K6#TQ4<WB/6)HRC_=/6M?9V!X9Q-VXU:)+HJ9/UK<L]
M;LX80TDP''>O*I999)MS9W5J6FDZEJ2*J@[*E05R*<8R=GH=EJ/C2UAR()58
M_6N=N/&&J79*01%@?2M/3_ L)YN5.:Z.S\,V5ICRTZ>HJ[Q6QT.5*GMJ>>#3
MM8U23,T<B@^];5AX"1\-.[Y[Y->@1P)&,!1^52':M'.^AG/%M;:&#8>%[2SQ
MM4''K6REK%&H 11^%1W-_!;)ND8#'O7/:AXSL85*H_S"BTF<53%=V=066)3G
M@5YYXTU\Q3&&)L@CM67?^,+^X+"W;Y:YB\>ZO9=\O+5T48QC*\F>9B:\ZD;0
M+-CKT]M<B3)X]ZZA/&VHM$!%'NKAA:2 @D5U>BVH,2X'S56)JTHKF,<+3K3?
M*3RZSK=YT@;GTJK]@U*[/[Y9%S[UTL,5VOW%&/I5KR=1DZ(M>8\P:^%'IQP#
M?Q,YNW\+QR8\^9QGU8UJ0>%=*B&YKC)]R:TETR_<_,HJ5=#F;[XK.6.K2V1M
M'!4EN5XK'3;;[CJ<>U6UU&W@&$5#^%31Z G\0-6D\/VO\0-9>UQ$S94:,3F=
M;U=I(2JHN".PKD;>&*8NS]<UZC=^'K62W<*OS8XK@KSP]>PS,(EX)K5.IRVD
MR7"%]C/M9/L>HJT1Z5W]AKY\A0YQ]:P-$\-RR7"M<KQWKKSX>M OR@U-3VEE
M9E04$]22+6K=OO.!5E=3MFZ2"LF7P^G\(JHVC7*?ZL5A[6K'=&G+3>QTRW4+
M='%3!U;H:X_[+J4704HNM3AZXXJEB9+= Z2Z,['-'6N276;I/]8:LQ:^H^^:
MTCBHLCV4CHRP49-0?;8-VW>,UQNN^*&5 MLW)X-<U_;.HAO,STYZUT>T5KD.
M+/7=PQG/%59]0@A!W. 17#:;XCO+F/RRV6-:<=A>WC;I1\IKGJUI)VBC2G33
MU;+MWKSY*P_-5 QWE\^65@#6U:Z)!$ 6'S5JQ0)&,*!6*HU*FLV6ZD8_"C#M
M- 3AG)S[ULPVD<*X"C\JL"BNN%"$3&524@VX'%&**6MDDB!,48I:*8"8I:**
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *2EHH 3%%+10*PG-&*6B@8E%+10 E+110 E+110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 44F110 M%%% !1110 4444 %%%% !1110 4444
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M4D&5.13ZQ= DD>%]_3M6U0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 87B4?Z&OUIT5RD>DQJ3R5QBM2YMUN(]C#(K(_L:8RY\S
MY >!0 GA^%HY)F/1CQ6]44$"PH% Y[U-0 4444 %%%% !24M% ',7]I=R7[,
M#^[]*S-/$Z:DZ@D<UW!16Z@52CTY$N&D"CF@"W#GRESUQ3Z ,#%+0 4444 %
M%%% !24M)0!SE[,;O439GD5NVL0@@5 ,8JL-/47_ -HP,UH4 %%%% !1110
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M+R*,;1F@#6I*YF?QC;PN5,3<'T-2R^(([C2GN(@1B@#H<C/6EKA]%U^6XO\
M:Y8K]*TY/%]O'</#Y9++UP#0!TM)7+Q^,[9RP\MN/8U9LO%$%Y*$"%3GN* .
M@HK$U'Q%!I[[&7<<=JBL/%-O>S>4$*GW% '045@7/BB"VE:,J25]!4$/B^WE
MDV>6R\]P: .D+"E%<5K^NR0W4)B+!3U KH=$OC?6GF$'\: -2EI*6@ HHHH
M*2EHH **** "BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM9R8P&&>:L:7@Z:RGD9Z5IQ^%E1)$R<,?6KEEX?2VA,0)(/O0!DZ,D*ZB1@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!KHKJ5;H:SO[ L
M?M GVOO!R/GHHH TE4*,"EQ110 4444 )BEHHH **** "BBB@ HHHH ,4444
M &*3%%% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gfbaqn1kfu2x000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1?",H# 2(  A$! Q$!_\0
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MP-(_Z!UM_P!^Q1_8&D?] ZV_[]BM*B@#-_L#2/\ H'6W_?L4?V!I'_0.MO\
MOV*TJ* ,W^P-(_Z!UM_W[%']@:1_T#K;_OV*TJ* ,W^P-(_Z!UM_W[%']@:1
M_P! ZV_[]BM*B@#-_L#2/^@=;?\ ?L4?V!I'_0.MO^_8K2HH S?[ TC_ *!U
MM_W[%']@:1_T#K;_ +]BM*B@#-_L#2/^@=;?]^Q1_8&D?] ZV_[]BM*B@#-_
ML#2/^@=;?]^Q1_8&D?\ 0.MO^_8K2HH S?[ TC_H'6W_ '[%']@:1_T#K;_O
MV*TJ* ,W^P-(_P"@=;?]^Q1_8&D?] ZV_P"_8K2HH S?[ TC_H'6W_?L4?V!
MI'_0.MO^_8K2HH S?[ TC_H'6W_?L4?V!I'_ $#K;_OV*TJ* ,W^P-(_Z!UM
M_P!^Q1_8&D?] ZV_[]BM*B@#-_L#2/\ H'6W_?L4?V!I'_0.MO\ OV*TJ* ,
MW^P-(_Z!UM_W[%']@:1_T#K;_OV*TJ* ,W^P-(_Z!UM_W[%']@:1_P! ZV_[
M]BM*B@#-_L#2/^@=;?\ ?L4?V!I'_0.MO^_8K2HH S?[ TC_ *!UM_W[%']@
M:1_T#K;_ +]BM*B@#-_L#2/^@=;?]^Q1_8&D?] ZV_[]BM*B@#-_L#2/^@=;
M?]^Q1_8&D?\ 0.MO^_8K2HH S?[ TC_H'6W_ '[%']@:1_T#K;_OV*TJ* ,W
M^P-(_P"@=;?]^Q1_8&D?] ZV_P"_8K2HH S?[ TC_H'6W_?L4?V!I'_0.MO^
M_8K2HH S?[ TC_H'6W_?L4?V!I'_ $#K;_OV*TJ* ,W^P-(_Z!UM_P!^Q1_8
M&D?] ZV_[]BM*B@#-_L#2/\ H'6W_?L4?V!I'_0.MO\ OV*TJ* ,W^P-(_Z!
MUM_W[%']@:1_T#K;_OV*TJ* ,W^P-(_Z!UM_W[%']@:1_P! ZV_[]BM*B@#-
M_L#2/^@=;?\ ?L4?V!I'_0.MO^_8K2HH S?[ TC_ *!UM_W[%']@:1_T#K;_
M +]BM*B@#-_L#2/^@=;?]^Q1_8&D?] ZV_[]BM*B@#-_L#2/^@=;?]^Q1_8&
MD?\ 0.MO^_8K2HH S?[ TC_H'6W_ '[%']@:1_T#K;_OV*TJ* ,W^P-(_P"@
M=;?]^Q1_8&D?] ZV_P"_8K2HH S?[ TC_H'6W_?L4?V!I'_0.MO^_8K2HH S
M?[ TC_H'6W_?L4?V!I'_ $#K;_OV*TJ* ,W^P-(_Z!UM_P!^Q1_8&D?] ZV_
M[]BM*B@#-_L#2/\ H'6W_?L4?V!I'_0.MO\ OV*TJ* ,W^P-(_Z!UM_W[%']
M@:1_T#K;_OV*TJ* ,W^P-(_Z!UM_W[%']@:1_P! ZV_[]BM*B@#-_L#2/^@=
M;?\ ?L4?V!I'_0.MO^_8K2HH S?[ TC_ *!UM_W[%']@:1_T#K;_ +]BM*B@
M#-_L#2/^@=;?]^Q1_8&D?] ZV_[]BM*B@#-_L#2/^@=;?]^Q1_8&D?\ 0.MO
M^_8K2HH S?[ TC_H'6W_ '[%']@:1_T#K;_OV*TJ* ,W^P-(_P"@=;?]^Q1_
M8&D?] ZV_P"_8K2HH S?[ TC_H'6W_?L4?V!I'_0.MO^_8K2HH S?[ TC_H'
M6W_?L4?V!I'_ $#K;_OV*TJ* ,W^P-(_Z!UM_P!^Q1_8&D?] ZV_[]BM*B@#
M-_L#2/\ H'6W_?L4?V!I'_0.MO\ OV*TJ* ,W^P-(_Z!UM_W[%']@:1_T#K;
M_OV*TJ* ,W^P-(_Z!UM_W[%']@:1_P! ZV_[]BM*B@#-_L#2/^@=;?\ ?L4?
MV!I'_0.MO^_8K2HH S?[ TC_ *!UM_W[%']@:1_T#K;_ +]BM*B@#-_L#2/^
M@=;?]^Q1_8&D?] ZV_[]BM*B@#-_L#2/^@=;?]^Q1_8&D?\ 0.MO^_8K2HH
MS?[ TC_H'6W_ '[%']@:1_T#K;_OV*TJ* ,W^P-(_P"@=;?]^Q1_8&D?] ZV
M_P"_8K2HH S?[ TC_H'6W_?L4?V!I'_0.MO^_8K2HH S?[ TC_H'6W_?L4?V
M!I'_ $#K;_OV*TJ* ,W^P-(_Z!UM_P!^Q1_8&D?] ZV_[]BM*B@#-_L#2/\
MH'6W_?L4?V!I'_0.MO\ OV*TJ* ,W^P-(_Z!UM_W[%']@:1_T#K;_OV*TJ*
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MJ* ,W^P-(_Z!UM_W[%']@:1_T#K;_OV*TJ* ,W^P-(_Z!UM_W[%']@:1_P!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5YA-_KY/]X_SKT^O,)O\ 7R?[Q_G0!WN@?\B_8?\ 7!?Y5I5FZ!_R
M+]A_UP7^5:5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_8?]<%_E6E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !3)7\N&20#.U2<>N*?1U&#0!Y'\%HTN]0\6:I*
MI:ZDU)TWN<LJ;C\N?3@?E7JMY9P:A9RVEU&)()5VNAZ$5X_IE_\ \*H\;ZO:
MZJDIT75IS=17:IPCL<D'T R1^%=!XF^+.A0:1+'H%ZNIZG,-D$5N"<,>Y]*
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MI8_WAZYH G^#8@N+35=2DNU?5+NX+W=L!CR#P I'X5WWB3_D5M7_ .O*;_T
MUYU\-8WU3X@>*/$UK T6E7A6.!F&#(1U.*]%\1\^%]6 _P"?*;_T T >!>%"
M?#FE^!?$ZDK!++-97(4?>W.^"?QQ7I7Q0NFU%]&\*VT@$NJ7 :5<=85!)/Y@
M5SWAK0VUK]G>&V1=MS$LLT1(Y5EE+?TJQ\-;N;QCXAF\07.]HM-L(K*))DPP
MD**78?\  E/YT 9'@/5T\)V/Q)U&*$,MG? QQCORX K:TCPEXJ\5Z);Z_?\
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M_@M;2Z#:_:=2VLL2<<9<\\^G6L;X;BZ/A'Q@;NW>&=I)2T;#D96HFU#5=*^
M%K-ICRQ2[]LDD8.]$,A!(_#- %^^\+ZI#HLNJW7CZYCU2.$S- )0(PP&=FT-
M^'2KNFW>I^//A$+VXU*6SNHHIC+) /\ 6A0PP>G!Q7,FQ^%]KX>ENX)5U769
MK<@1NQED:9EQT/H371_"_</@Y?0-&4ECBN5:/'*GY^* ,OP-;7NC_!6\U:'4
MYV9X&,41X$1#=JM:GK6N6?P]\+^*8;N:1H?+-XFXXD1AR6_'%4O"FL6%W\"+
M[3(+A6OK:W<S0<[D^?N*[/POI,6M?!ZRTRX4E+BP5",?[(_K0 _XC>*7TSP*
M;K2Y"UU?E8;5HSSELX8?E6!XF\1:OI,7A[P=9:DB:I>H!=WTIYB3CYN?7)_*
MN4\"QZIXB\5Z)H.JVKQ1>%5=9#U5W4J%!'X&M?XM:#;6_C71_$FJ63W>C.!;
M7@5<^4 >#^I_*@!=<BU?X?6"Z_IOB^36/*=1<V=S*&#J3SMY.._2O7]*OX]4
MTJUOHB"D\8<8]^M>'Z]'\,+6QA_X1_3(-:U*>14BM(6()R>YQQ7MNB6JV6BV
M=NEN+=4B'[D'.SOC- %^O(/A+_R._C#_ *^6_P#0A7K]>0_"967QMXP)4@&Y
M;&1_M"@#J_B5XJN_"OAV*33T#7MY<+:P,1D(S9.2/PKG+KP)XNLM.;5X?&%W
M+J\:>8;=Q^X9NI&/3\*N_&73+R[\.6%_9P-,=/O4N)57KL (.!^(J?4?BSX5
M;PY+<6]\LUW)%A;-0?-W$="/6@#G-;UBX\?? Z[US[7+:26]O(+B*,?+*R@9
M!]JN^!K36]&^$$&H:1--J-]<V:M;6K@;83SC&3TJAI'A^^T3]G/5[.[A9+B>
MVFG\O'S#<!@?6J:>*9H_V?[>'PW=[]4LK>.*Z6'.^!3G)]C0!HW'A/6#I3ZE
MJ/C^XM]56,RM;QR@1JPYVX!Z?A6AHGB2\\2_!S5KB_=9+F&WGA>51@/A3S^5
M<Q;6/PPAT7[;YXU?69(O]7*QD>24CI@^]6OA[()/@UXEC$1C9#<*8\8*_)G'
MZT >A?#+_DG>C_\ 7'^IKB?C_,+;2_#T[*S+%J:.0HY. 3Q7;_#,$?#S1P00
M?)[_ %-<=\=59K7PSM4G&JQYP/8T 32?'G1(DRVAZVO8%[=5&?KNIW@O2M9U
MOXA7GCO5++^SX'M/LT$!<,73C#<<=OUKT;6-(L]=TF?3KZ)9()DVD,,X]Z\L
M\!:I?>$/%5W\/M8F>2WP3IL[Y^X>B_B,<=L4 (VK:C\0?%6JV:>(3HNC:;)Y
M<;0N%>=N<G.0<<5;\/ZYJ/A3QU;>&+[6DU;2[V/-M<NP,BR?W21G.>.]<=IN
MA^%-%\::YI?C>U6(-+YMG=RC".A)[_EBN@\.6G@Z[^(5O:^%M"CN8+51-)J2
MN0D; \ <<]* (=-\,7B_&NX@.O7A:*%9S)CEUW,=AYZ<?K73^&M:U"Y^,GBC
M2YKIWL[:&,Q1$\*2%S6=<:O8Z#\<YI-3G%M'=62QQ.X^5FRW&:IC5+3P;\;=
M6O\ 69UMK'5K9&AN&SL   Y/U6@#>\;ZUJ%A\1?"UE;7+QV]R6\U%/#<-U_*
ML/Q5JOB.[^+4GAG2[][>VO+559Q_RQ&%8L/?C'XU3\2^(K3Q-\5O"\^D%KFP
MMG:-[I5^0R%6. >_!K>1"?V@KEBIQ_9RX./]R@#%\5R>)? D7AZPL]9N-1NI
MKE@7F/+@YP#]/Z5)XMT'Q3X,TMO%$'BV\N[F%P9K>5?W1!ZX7./TK9^)2L?&
M/@X@$@79S@>QK5^+H+?#?4P 2=HX% '6:1?KJFD6E^@(6>(. ?>KM87@P$>#
M-(!&#]F6MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "O,)O]?)_O'^=>GUYA-_KY
M/]X_SH [W0/^1?L/^N"_RK2K-T#_ )%^P_ZX+_*M*@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@M]:K?V!I)U?^UO[.M_[0QM^T[!OQC'7Z5?1Q)&KKT8 BL7Q'XLTSPM_9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YA-_KY/\ >/\
M.O3Z\PF_U\G^\?YT =[H'_(OV'_7!?Y5I5FZ!_R+]A_UP7^5:5 !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%9'B?6X_#GAN_P!6DP1;0LZJ
M?XB!P* /-KVV7XA?%G4-/D(?2M(LF@D1N09) PW+[]/RK5^$&K2C3K_PQ>';
M=Z/.T:H3SY1.5/ZUR_@7P/XNN=#&MV'BF33#J;&=XO)4MR>,DJ3VJ%;'5OAG
M\4-.U35]3?4+?63]GN)@@7=(>%S@#IP: .X\1>,M=D\6_P#",^%;2UEO88Q+
M<R7;850>P&1D\BI_#7B/Q7_PD+Z-XHTA$9TWPW=FI,6/1CDX/XUC^)]"\,^,
M/&DEI:ZO=:;XCM(@Q>$%!(#R.2,-U'2J&D:MXJ\&_$'2_#.LZK'K5MJ*MLD"
M8>$#)YQ]* --_&OBOQ%X@U.Q\(65@;;3)3!<2WAY,GL,CC@UN>#_ !+KNI0:
ME;>(-)-EJ%B<>8@/E2\'[I]L>O>N/D\*:#XK\2ZO?>$?$%WI>K6TQ2ZC0%4,
MF3DE6'/(/(XJUX.\1>(;;Q7J?@S7;J+4Y8;1IQ?0@?\ ?)QWY_2@#I_AKXKO
M?&/A=]3OHX8YA<R18B! PN,=2?6HM \7WVJ_$/7_  _-%"MKIX4Q,H.XYSUY
M]JPO@5-'%X,N[21U6>&^E,D9.&7.,9';I5/P#>07WQF\936TBR1?NP'0Y#<M
MT- ":3\1?&?B>?4+#0M)L9+RSN&#RS$K&(^PY/+9SW]*=IWQ'\8:C<WGAR'0
MK9O$]K)B7YL01I@'<3GOG'6K/P61?)\1/M&XZDX)]L+3?!?_ "73QU_USA_D
MM &IX-\::]=^)[[PWXKL;:UU"&,31/;GY'7CCJ<GG/6JUUXY\2^(-?N].\$Z
M?:36]@YBN;J[/R[_ $49'?BJ]XK/\<PJ_>;3F ^M<?\ #WPW<:MJ/B&UC\27
MNE7D-_(9+>+8"XW'YL,I)'O[T >C^%?&NJ3^()/#7BFPBL]85/-C:$YBE3CI
MUYY'>J-QXR\6:[XGU33/"5C8&#2Y/)N);P\E\GH,CC@UEZ;X:TJR^)M@MUXK
MU#4=:M5+K"R!@$XR&*K@=1U-+>>$M#\4^*]8O/"_B"ZTO6K:8I=HG"&7)R2&
M'/(/3B@#K?!'B77M6GU#3O$6CFROK)P#-&#Y,N<_=/MCU[UUEQ_Q[2?[IKS+
MP-XA\0V?C>Z\':]>0:I)%!YPO80..ORMCH?;K7IMQ_Q[2?[IH \?^$U])IGP
MW\4W\(5I;:[N9D#="50$9_*IM,\;_$;Q-H<.JZ#H6GBW\L[FN&(\U@3DH-P.
M.W?D50^''_)(_&G_ %UO/_15=W\* !\,-# &/W+?^AM0!'X2\<-XH\(:E?26
MPAO]/62.YA(^42*"<?3BN#USQ%K/B7]GZXU.&TLH8Y7D2[2-=H6-9,949ZY
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M'P_XKN+&6\TFTA:&<1H6\LG=\Q ^HIG@N?P=XQT"UL[R>VEN8M0GN8()'"R
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M8>-F/?:Q _0"NWKB/A+83:?\.=,2X0I-('D92,8W,2/T(KMZ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\PF_P!?)_O'
M^=>GUYA-_KY/]X_SH [W0/\ D7[#_K@O\JTJS= _Y%^P_P"N"_RK2H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME6E6;H'_ "+]A_UP7^5:5 !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5YA-_KY/]X_SKT^O,)O]
M?)_O'^= '>Z!_P B_8?]<%_E6E6;H'_(OV'_ %P7^5:5 !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Y]XE^&4FN>+1XBL]<N=.NQ"(0T(Y YSSGWKT&B@#S-OA(VHK
MY6O>)]4U*VR"8FDV@X_.N]M-&T^QT9=(M[9$L5B,7E <;3U_/)J_10!YF/A9
MJ.F22P^&_%=WI>G2L6-KLWA<]=IR,5U/A3P;IWA/2YK2VWS27+&2YFE.6F8Y
MR3^9KHZ* /.)_AA?65]</X:\376D6=RY>6U5-RY/7;R,=ZWM$\!:1I&@7FE.
MC7:WV3>2S<M,3US74T4 >8Q_"W5["-K#2/&5[9Z0>%M=I8J/0-D?RKJ-/\$:
M;I7@VZ\.6.Z.&YB=))6Y9F<8+'U-=-10!B>'/#L?A[PG:Z#',98X(FC$A&"<
MDG^M1>$?"T7A339K.*<S+),TI8C&,G.*Z"B@#E-$\$0Z+_;VRZ:3^UW=WRN-
MFX$?UKF++X2ZAHE@MGH'BR[T^%Q^_0)N#GU R,&O4J* .?\ "WA'3_"FDO96
MN^5IF+W$TARTK'J3^9KEIOA==Z??3R^%?$ESHMM<,7DMD3>F3Z#(Q7I-% ',
M>$/!5GX32YF6>6[U"[(:ZNY3\TA'3\.M+X+\'P^#K&\MH;EIQ<W+7!)7&"V.
M/TKIJ* $;)4@'!QP:\IA^#MU9:G>7VG^*[VSDNY&DD\E<9R<XZUZO10!PV@^
M!]9TG6(+VZ\7:C?0QDEK>4G:_'?FG^*/A]_;.M+KFDZK-I&KA/+:XB&0Z^A&
M1GH.]=M10!QWA7P%'H.IS:QJ&H2ZIK,R[&NY1C"^@'.!^-8>J_">XO\ Q9=^
M(;?Q+=VEU.3M,2\HI_A!STKTVB@#SW3_ (?:[9ZC;W,OC;4[B.*17:)R<. >
MAY[UK>+_  -;>*&MKN*ZEL-5M/\ 47D7WE]CZBNLHH X/0OAU):ZW%K7B#6I
M]:O[<;;=I5VK&/ID^IKO*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !114,-W;W$DD<,\<CQG#A&!VGT/I0!-1110 445'/-';0232MMCC4LQ] *
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M$\TGQ+D@U+Q5\/)$99(9[\D$<@@E*[_Q7H4?B+PI?:4RJ3-"5CR.C8^4_@:
M)=8UVWTGPU<:T[*8H[<S*"<;CMR!^/2N#UWQO_Q3GA34]4T*WDDU.^6-(I!G
MR,GAA[XP:X]]=N/%WA3P]X(C;SKXWODZBG1A'$P;=^0KI/C);I:6O@FVC&(X
MM6A1?H,"@#H?$_Q'_P"$=\5+H8TY[N::#?;I%]^1\CY?3&,G\*SK'XE:Y8>(
M;/2_%OALZ8M\Y6WFCD#*/][DU%J4,<OQ\TUW4%H[-F4^AZ4[XR=/#9_ZB:?^
M@M0!M^+?'DVBZQ!H.C:5+JFLSQEUB4@(@X^\21US6-8?$CQ#8^(=/TKQ=X:&
MG?VC)Y=O+#*&7/?=\Q]13O$7B/5KKXB-X:\+6=A#JD=J)IM0NHQD)Q\H."3U
M_2N/\=6NNV7B7PK_ ,)!KL5[=2765ABA5%0 C)X /YT >D^+O'%QH^IV^AZ'
MIIU/7+B,RI!N"JJ#NQ)'Z>E4_#OCS6IM?AT/Q1X>?3+RX4O#)$P>,@=B03S5
M+Q?X?TGQ#XPLUT_7WTWQ5!;[D5-V7C[9[8ZUFIXB\7>#O$NCZ?XM%CJD%_,(
M+>Y@0!XV) ] >XS0!Z_13/-C\P1EUWD9"YY/X4^@#Q_5?^3B-+_Z]_\ V6MK
M7_B9=:3XXN/#%GHLE_="%&@$1P69@#\V2 !6+JO_ "<1I?\ U[_^RU:L0#^T
MEJN1TTE"/_'* +FB?$C5T\2VF@>+= .EWEZ?]&>-PZ,?3.3SS6QXP\=CP]?6
MVD:=82:EK5T#Y-M&0 /0L21@5S_Q' _X6/X$..?M3?TJ.,Q1_M%R&? 9]+ B
M9AP>N0/>@#0T7XA:S%KUKI'B_0/[)FO3MM98W#HS?W3@GGD5Z-6'KNK:'IU]
MI<6K+ US<3;+/S(P[!^/N\<=1S6RLL;L45U++U4'D4 /HHHH **** "BBB@
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MKZEKN@PZEJ5BMD\_S1P@Y(3L3]1@UNU!97-M>64-Q9R(]M(@:-DZ%2.,5/0
M4444 %%%% !4<TT=O$TLK!449)-254U*R&H6$EMNV[AP:F3:3MN!4_X232O^
M?D?]\G_"C_A)-*_Y^1_WR?\ "N?_ .$-O?\ GO!^9_PH_P"$-OO^>\'YG_"N
M#VV*_D_K[R+R.@_X232O^?D?]\G_  KG-6U]IM4BEM7)AA.5[!C5;4O#]QIE
MMYTTT)!. JDY/Z5D5S5\36^"2L2Y,]!3Q+IA12UP V.1M/\ A3O^$DTK_GY'
M_?)_PKB-.T]]2N/(CDC1\9&_/-:__"&WW_/>#\S_ (5O#$XF:O&-QJ4CH/\
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M"1059V'&<]JVX+3Q]>:2;S4M?T_2--,6\QVT"LT:XZ9*_P C0!TFG>/]+O\
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MA;$SNX2)>>@)8$GC]173^"_'\'BBVOH[RV;3]0T\XN[>3^ ?WOI_A6#\!/\
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M %%%% %/5_\ D"WW_7O)_P"@FF:'_P B_IO_ %ZQ?^@"GZO_ ,@6^_Z]Y/\
MT$TS0_\ D7]-_P"O6+_T 4 7Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MS";_ %\G^\?YUZ?7F$W^OD_WC_.@#O= _P"1?L/^N"_RK2K-T#_D7[#_ *X+
M_*M*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?\ "'_(*NO^O^Y_]&M7
M05S_ (0_Y!5U_P!?]S_Z-:N@H **** "BBB@ HHHH **** "LJ3P[IDNKKJ;
MVP-RO?L3ZX]?>M6BFFUL 4444@"JFIV9U'3+BS$S0^<A3S%&2H/6K=% &'X2
M\+V?A#0(M(L69HHR6W,.6)ZU/XCT&U\3:#=Z3><17";2P&2I]1[UJT4 <2GP
MWLUM_#4+WTKC0)-]N=F-PXX//M7;444 <AI/P[TC2/&M[XGAR;JY'RIMPL>1
M@X^HJWXM\'6OBXZ7]JG>+^S[I;I-@SN8=C7244 <_-X3MIO&,/B0S.+B*$Q"
M/'!%)XI\)6OBD6 N9WB^QW G3:,Y(!&/UKH:* .*\2?#JVUS7UUVTU.[TO4Q
M&(VGMR?F4= 1D>E4)_A)I]Y%'+>ZK?76I),L@O9F+,N/X0">!]*]$HH Y+Q1
MX"L?$DUO>+=W%AJ5NNR.\MF*OM]#@C(JCHWPRMK'5X-4U;5[W6;FWY@-VQ*Q
MGU )/-=W10!Q-_I5S-\6=*U&$W/DP6CB?_GE@A@._7)]*[:BB@#F+GP5:7/C
M>W\4-<2"Y@38(P/E/&*DA\(6L/CNY\5B=S<SVPMFBQ\H QS_ ..UT=% '/:[
MX2M=>UW1]5FG=)-,D,D:J.&)]:A\6>"+#Q7]GFDGGL[ZV),%W;L5=,_0CTKI
MZ* .'T+X;6^FZM%JFJ:M>ZS=P?\ 'NUVQ(B/J 2>>G-;.E^%X]+\3ZKK:WDT
MKZB%#0O]V/'IS6_10 4444 %%%% !1110 4444 %,EB2>%XI!E'!4CVI]% '
M-?\ "!Z!_P ^K?\ ?9H_X0/0/^?5O^^S72T5/)'L;_6:W\S^\AM+6*RM(K:!
M=L42A5'H!4U%%48MMN["L'Q?X6MO&&@2:1=3/%$[JY9!D_*P/]*WJ*!$-G;+
M9V5O:H25AC6,$]P!BN1/PTT=/'L/BVW9H+I"6:)%^1SMQGVZUVE% '"ZU\-+
M?4/$,FN:9JUWI%[,NV9K;I)]1D5!#\)].BU:QUAM3O9M6M91)]JF<N7QVP3P
M*]!HH XWQ+\.[+7]6CUBWOKK3-41-GVJV8@LOH<$4SP[\.;;1=9&L7VIWFK:
MBJ[(YKIB=@]ADUVM% '!ZU\,+6_UF?5M+U>^T>[N?^/AK1R!)]0"*L>'OAOI
MOAW74U>WN9Y;KR3'*\IW&4Y/S$D]><?A7:44 >?W?PNB&KW-_HVNW^D?:FWS
MQ6Y.UV[G&1@T^P^%>E:?XDT[78[V[DOK3)DDE<N9R01\Q)]Z[VB@#B?$?PWM
M=:UDZQ8ZG>:3J#+LDFM6(WCT(!%<+IOAR+PW\<M.MDNKB[E>R9Y;BX<L\C97
MDY)KW"J3Z/ILFJIJCV4#7Z+L6X*#>%],_A0!=K#\4^$M)\7Z8++58-ZHVZ.1
M3AXSZ@]JW** /,#\'6E_<77B_6I[ \&U:5MI7T^]Z5W>D>'M,T/15TFQM42S
M"%"A&=P/7/K6I10!YM-\(H8;B;^Q_$6J:59S,6>T@D.SGKCYABNDTCP1I.A^
M'+G1[%&1+H'SYF.YY&/5B>_6NEHH Q?#GARW\.>'(M&MY7DAC4J'8<\U%X3\
M*VWA+3IK*UF>5)9FF)<8()K?HH XBY\)6N@V?BO5(9W>35(VDD5API /3\ZX
M7P!\//[7\'6M_8Z]J.E2S%O.6VD.V3GKC(YKVZ:&.XA>&9%DC<;65AD$>E0V
M&G6>EVBVMA;16UNOW8XEVJ/PH R_"_A+3?">EM8V",PD8O-)(<M(QZDFN8OO
MA/;?VA/=Z)KFHZ*+AR\T5JYV.Q[XR,5Z)10!S/A?P-I/A>SN8K</<37>?M-Q
M.=SRYZY)[5SK_"2.WFE71O$FJ:59RN7-I YV DY./F&*](HH Y.U^'^E67@^
M]\/6[2+'>J1<7#'=)(QZL2>M.N? >G7?@.#PG/)(]K!$L:2=&!48#5U5% ')
M6'@*SB\)3>'=4N[C5;65BQ>Y)++D8 !).,=JY\?" &/['+XJU>32^ALC(VW;
M_=SNZ5Z;10!4TW3K72--@T^RB$5M NR-!V%5O$>AP^(]!NM)N)&CBN%"LRC)
M&"#_ $K4HH YS4?!]KJ/@U/#4D[K;I$D8D YPN,?RK6BTV.+14TP.3&L @#=
M\8QFKM% '->&_!6G>'O"1\.9^UV3%MXF7[P;J"*YE?@]:QEK6+Q!JJ:.Q^;3
MEE;85_NYW=/PKTNB@#EO#'@33?#/A>X\/HS7-G<2.[B4=0P (_2N</P@6'?;
MZ?XHU:STULC[%'(VP ]0/FZ5Z910!RP\"Z?:^#Y?#FF2R6,$HQ)-'R[YZDGO
MGI5NQ\(:38>%/^$<2W5K$Q&-E9<[L]2??/-;U% &!X2\,)X2TC^S(+R6XMU<
MM$)>J G.,YYK?HHH **** "BBB@ HHHH **** *.HZ5;:F$^T!CLSC#8JA_P
MB>F?W9/^^S6[164J-.3O)"LC(MO#EC:7"SQ"0.IR/G-:]%%7"$8*T58=K!11
M15 <WH?@ZTT/Q!J>KPSR/+J#;G1APOTJYXG\-V/BO0I])U!,PR\AL9*-V(]Z
MV** .0MOAUI$?@;_ (12X+W%D.0S## ]B/0BLNV^%F(EM-0\2ZK>Z<HQ]D:1
ME4CT)W<CVKT.B@#D- ^'FE:'X:O= +-=:?=NSLD@^[N &!],=:PE^$)BB-G!
MXKU>+3#D?8UD;:%/5<[NE>F44 <U<>!-"N?"<?AQK7%C$/W6#\R-G.X'US7+
M2?!N"\MFM=3\2:K?6JC$,,TA*QGL<;N<#BO3J* .4U/P#I>K^#;/PW=/*8;-
M4$,RG#*R# :LB+X6)<(L.M^(M3U6U486":0JI]"PR=WXUZ%10!R>G> -+M?!
M;>%KMFO+ DX\P8*@],>F/6N+\1_"U-/\)ZM)/XBU2\LK:TDEALY96V*P4E?X
MN0*]@J*YMH;RVEMKF))8)5*21N,AE/4$4 <?\(_^26Z#_P!<3_Z&U;_B30H?
M$N@W.DW$C1Q7  9E&2,'-7K&PM-,LHK.QMX[>VB&(XHEVJHZ\"K% 'E]O\'&
MM(4@M_%VLQ0H,*B2L ![#=71>%_AWHWA>\DOX3-=:A*,/=7#EV/Y]*ZZB@#G
MM \(VF@:AK=W%*\K:M/YTJN.%// _P"^JYJ[^$MN+V>;1->U'1H9V+26]JY"
M$GK@ C%>C44 <]X5\':9X2M9([)7DGF.Z>YE.9)3[GK6;9?#RWTWQC-X@L=3
MNX!.^^:T4GRW/N,_TKLZ* . U;X665SK$VJ:/JM[HMS<',YM&(63\ 16IX4\
M!:?X6NKB^%Q/?:E<C$UW<,6=A^)..@KJZ* ."UCX86UYJTVI:1K%]HL]P<SB
MT<A9#ZD CFM/0/ >G>']-O;>*6:>YO01<7<S%I'S[FNJHH Q/"?AJW\):!#I
M%K*\L41)#.,$YJ#1O"-KHNK:YJ$4[O)J\WFRJ1PAYZ?G7144 <]X-\)6O@S1
MI--M)WFC>X><LXP<MCC]*9I/@ZTTGQ5K.O),\DVJA1+&P^5<>E=)10!YU=_"
M:W6_GN=$U[4=&CN&+S0VSG8S'J<9&*Z+PKX+TOPE930V(=YISNGN)3N>0^I-
M='10!S.@>"=/T*RU2T#M<PZE.\TJR+Q\Q)(_6N9/P?BMV>'2_$NJZ?ISL2;*
M*0[.>N/FXKTRB@#E!HVD^!O ]W;V6GM/:01%Y(0-SR^O7J:\SM-,^'TNC-=I
MXHOK329 6FTLW+J 3U4@&O=R 1@]#7-R_#_PA/<-<2^&]->9VW,[6ZDD^M '
M'?!BV&B> [W4;U?LEH]S).A?@"( 8;Z<&LR>WT?XA?&73[[3'6ZL=.M@]Q<1
MYV[PS%1^>*]BFM+>XLWLYH4DMG0QM$PRI4C&"/2JNDZ%I6@P/#I.GV]E$[;F
M2",*"?7B@#0K)\2Z##XF\/7>CW$C1Q7*A6=1DC!!_I6M10!S-YX+M+SP/_PB
MSW$@MO*6+S /FPN/\*U[#2X[#0H-*1RT4-N( QZD 8S5^B@#F?#7@G3_  YX
M4?PZ&-U9R,Y<2K]X-U&*YM?@_;1LUM#XAU6/2&/S:<LS;"O]W.[I^%>E44 <
MKX7\!Z9X8\.W>B1EKBSNI'=UE'9@ 1^0KG6^$"P[[?3O%&K66FN3_H<<C; #
MU ^;I7IE% ''S?#S3AX0_P"$;L)Y;*T<YF>/EY><G+9SS6G+X1TF7PE_PC9M
MD6P\D1;54#_@7USS6[10!D>&="_X1O0X-+%Y+=1P#"/+U"]AUZ#I6O110 44
M44 %%%% %/5_^0+??]>\G_H)IFA_\B_IO_7K%_Z *?J__(%OO^O>3_T$TS0_
M^1?TW_KUB_\ 0!0!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,)O]?)_
MO'^=>GUYA-_KY/\ >/\ .@#O= _Y%^P_ZX+_ "K2K-T#_D7[#_K@O\JTJ "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH J:?I\&FP/#;[MKRO*=QS\S,6/ZF
MK=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!'<0I<VTL$F=DJ%&QUP1@TEM;I:6D-M%GRX46-<GG &!4M% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YA-_
MKY/]X_SKT^O,)O\ 7R?[Q_G0!WN@?\B_8?\ 7!?Y5I5FZ!_R+]A_UP7^5:5
M'D/QNTR*^O/"9NL_8?M_EW+;B $8J.3V[UT_C+PUX;/P_P!022PLXH8;-GAD
M6-5(8+E<,.>H'UKH_$'A_3_$VD2Z9J</FV\G49P0>Q!KA#\'VN(X;34/%FJW
MFFQOG[)(<!@.BDYR10!QE[=WC> OASJ.H;V:.^VR.XQM7<RJ3[8Q7L'C;4K;
M3_ ^J7<LB^4;<A3GKNX&/SJQK'A;2]:\-MH5S#BSV!$"G!3'0@^V!7%P?!Y6
MEM(]3\3ZIJ&GVS96RE.$8#D G/(''Y4 <7XBTNXL_@IX3#QMB._AN'./NJP)
MR?S%>W:SJMI9>&[O4I)E^RK 7\P'@@CC%/U71+#6-#FT>ZA!LY8_+*+Q@#IC
M'3I7 1_!M-D-G=>*=5N-)C;/V!F(0KV4G.<4 6_@G92V'PSLS. HGD>=,GJK
M8Q4?QK)3P3#=JI9+>\BD;'/&>M==K7AN/4_#3:)9W,FF1;0D<EJ-IC [#&*5
M/#=K)X47P_J$DE];^1Y,DDI^>0>I/K0 ZZU*VM_",FH-*GV=+0R;P>,!:\4N
M-/G/[.^H3QQ._P!JNUN5 '.T2C)_(5V0^#2F".QE\5:K)I*2;OL6XA2O]S.<
MXKT0:18KHQTE8%6R,)A\H<#:1@T 4M$O[9/!UC>^:I@CLD9G!X^5!G^5<5\%
MH6?3->U-1_H^H:G+-"WJNYA3?^%-*D36=OXJU:#2F?=]A5CM"]USNS@UZ+I6
MEV>BZ;!I]A L-M H5$48_'Z^] %RFLH;KG\#3J* .-\80R3:IHMG%=3VZW$K
M([1N0>U2?\(,1_S'=2_[^'_&G>*/^1E\.?\ 7P?YBNLH Y+_ (0EO^@[J/\
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MO^@[J/\ WW1_PA+?]!W4?^^ZZVB@#DO^$);_ *#NH_\ ?='_  A+?]!W4?\
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M'_ONNMHH Y+_ (0EO^@[J/\ WW1_PA+?]!W4?^^ZZVB@#DO^$);_ *#NH_\
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M_?='_"$M_P!!W4?^^ZZVB@#DO^$);_H.ZC_WW1_PA+?]!W4?^^ZZVB@#DO\
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MVB@#DO\ A"6_Z#NH_P#?='_"$M_T'=1_[[KK:* .2_X0EO\ H.ZC_P!]T?\
M"$M_T'=1_P"^ZZVB@#DO^$);_H.ZC_WW1_PA+?\ 0=U'_ONNMHH Y+_A"6_Z
M#NH_]]T?\(2W_0=U'_ONNMHH Y+_ (0EO^@[J/\ WW1_PA+?]!W4?^^ZZVB@
M#DO^$);_ *#NH_\ ?='_  A+?]!W4?\ ONNMHH Y+_A"6_Z#NH_]]T?\(2W_
M $'=1_[[KK:* .2_X0EO^@[J/_?='_"$M_T'=1_[[KK:* .2_P"$);_H.ZC_
M -]T?\(2W_0=U'_ONNMHH Y+_A"6_P"@[J/_ 'W1_P (2W_0=U'_ +[KK:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<AXI_Y&C0/
M]]OZ5U]<AXI_Y&C0/]]OZ4 =?VHH[44 %>83?Z^3_>/\Z]/KS";_ %\G^\?Y
MT =[H'_(OV'_ %P7^5:59N@?\B_8?]<%_E6E0 4444 %%%% !1110 4444 %
M%%% !1110 4444 <GXH_Y&7PY_U\'^8KK*Y/Q1_R,OAS_KX/\Q764 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %<AXI_Y&C0/]]OZ5U]<AXI_P"1HT#_ 'V_I0!U
M_:BCM10 5YA-_KY/]X_SKT^O,)O]?)_O'^= '>Z!_P B_8?]<%_E6E6;H'_(
MOV'_ %P7^5:5 !1110 4444 %%%% !1110 4444 %%%% !1110!R?BC_ )&7
MPY_U\'^8KK*Y/Q1_R,OAS_KX/\Q764 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<AXI_P"1HT#_ 'V_I77UR'BG_D:- _WV_I0!U_:BCM10 5YA-_KY/]X_SKT^
MO,)O]?)_O'^= '>Z!_R+]A_UP7^5:59N@?\ (OV'_7!?Y5I4 %%%% !1110
M4444 %%%% !1110 4444 %%%% ')^*/^1E\.?]?!_F*ZRN3\4?\ (R^'/^O@
M_P Q764 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\JTJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D_%'_ ",OAS_KX/\
M,5UE<GXH_P"1E\.?]?!_F*ZR@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\
M@1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(K
MHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'
M_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_
M\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/
MM)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z
M-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S
M10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X
M$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[
M2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C
M?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_
M !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\
M@1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(K
MHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'
M_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_
M\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/
MM)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z
M-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S
M10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X
M$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[
M2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C
M?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_
M !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\
M@1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(K
MHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'
M_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_
M\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/
MM)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z
M-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S
M10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X
M$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[
M2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C
M?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_
M !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\
M@1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(K
MHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'
M_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_
M\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/
MM)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z
M-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S
M10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X
M$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[
M2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C
M?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_
M !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\
M@1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(K
MHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'
M_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_
M\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/
MM)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z
M-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S
M10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X
M$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[
M2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C
M?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_
M !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\
M@1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(K
MHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'
M_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_
M\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/
MM)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z
M-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S
M10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X
M$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[
M2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C
M?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_
M !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\
M@1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(K
MHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'
M_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_
M\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/
MM)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z
M-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S
M10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X
M$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[
M2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C
M?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_
M !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\
M@1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(K
MHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'
M_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_
M\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/
MM)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z
M-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S
M10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X
M$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[
M2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C
M?\(KHW_/M)_X$2?_ !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_
M !5'_"*Z-_S[2?\ @1)_\56S10!C?\(KHW_/M)_X$2?_ !5>8^-&LX=9:RL4
M9(X1A\R.V6[_ 'B:]7UO4DTG2+B\;&47Y0>Y["O&]$L)/$'B&.*0L_F/NE)/
M.WO73AXK6;Z%P74[OP?X3LFT*.XOH"TTQW@AW0A>P."*Z#_A%=&_Y]I/_ B3
M_P"*K6CC6*)8U&%48%/K"<G*5V2W=F-_PBNC?\^TG_@1)_\ %4?\(KHW_/M)
M_P"!$G_Q5;-%2(QO^$5T;_GVD_\  B3_ .*H_P"$5T;_ )]I/_ B3_XJMFB@
M#&_X171O^?:3_P ")/\ XJC_ (171O\ GVD_\")/_BJV:* ,;_A%=&_Y]I/_
M  (D_P#BJ/\ A%=&_P"?:3_P(D_^*K9HH QO^$5T;_GVD_\  B3_ .*H_P"$
M5T;_ )]I/_ B3_XJMFB@#&_X171O^?:3_P ")/\ XJN=UK2[/3/$VABTC9 \
MC;LR,V<8]2:[NN0\4_\ (T:!_OM_2@#K^U%':B@ KS";_7R?[Q_G7I]>83?Z
M^3_>/\Z .]T#_D7[#_K@O\JTJS= _P"1?L/^N"_RK2H **** "BBB@ HHHH
M**** "BBB@ HHHH **** .3\4?\ (R^'/^O@_P Q765R?BC_ )&7PY_U\'^8
MKK* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *X3XD:S]GL8],B;#S?-)@_PCL?KG]*[F218HFD8
MX502:\-UN_DU_P 0RRIEQ(^R,#^[VK?#PO*[Z%P5V=3\-='WSS:I(O"?)'[G
MO_2O2ZSM#TQ=(T>WLUQN11O([MW-:-15GSR;)D[L****S$%%%% !1110 444
M4 %%%% !1110 5R'BG_D:- _WV_I77UR'BG_ )&C0/\ ?;^E '7]J*.U% !7
MF$W^OD_WC_.O3Z\PF_U\G^\?YT =[H'_ "+]A_UP7^5:59N@?\B_8?\ 7!?Y
M5I4 %%%% !1110 4444 %%%% !1110 4444 %%%% ')^*/\ D9?#G_7P?YBN
MLKD_%'_(R^'/^O@_S%=90 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 444A( )/ % '*>/M8&G:&;:-L37/RC!Y"]S7(_#S1S>ZP;V1<Q6W(_WNW]
M:H>,M6.L>(9!&28H3Y48]^A_,UZ9X1TG^R= @C88ED'F/D<Y/;\*ZW^[I6ZL
MTVB;M%%%<AF%%%% !1110 4444 %%%% !1110 4444 %<AXI_P"1HT#_ 'V_
MI77UR'BG_D:- _WV_I0!U_:BCM10 5YA-_KY/]X_SKT^O,)O]?)_O'^= '>Z
M!_R+]A_UP7^5:59N@?\ (OV'_7!?Y5I4 %%%% !1110 4444 %%%% !1110
M4444 %%%% ')^*/^1E\.?]?!_F*ZRN3\4?\ (R^'/^O@_P Q764 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %87B[5AI&@S2!L2R#RXQZD]?TS6[
M7DGQ"UC[=K(LXFS%;#!P>"Q__7BM:,.:945=E'P9I)UCQ!&9!NBA_>29[_\
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MH ]-HHHH Y/Q1_R,OAS_ *^#_,5UE<GXH_Y&7PY_U\'^8KK* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2@#K^U%':B@ KS";_7R?[Q_G7I]>83?Z^3_>/\Z .]T#_D7[#_K@O\JTJS=
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MT"(6:[))R'&YN1Q[UT:^#] 1@RZ<@(Z'>W^-9_BC_D9?#G_7P?YBNLH RO\
MA&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;
M_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E
M_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_
M (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^
MV_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?
M)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*
M_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\
MOMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\
MGR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH
MRO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_
M +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_
M )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:*
M ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E
M_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'
M_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6
MB@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?
M)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K
M1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK
M5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\
MGR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$
M:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\
M:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_
M )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\
MA&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;
M_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'
M_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_
M (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^
MV_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K
M1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH
M_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\
MOMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$
M:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\
M:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_
M +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\
MA&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;
M_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E
M_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_
M (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^
MV_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?
M)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*
M_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\
MOMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\
MGR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH
MRO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_
M +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_
M )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:*
M ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E
M_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'
M_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6
MB@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?
M)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K
M1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK
M5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\
MGR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$
M:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\
M:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_
M )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\
MA&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;
M_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'
M_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_
M (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^
MV_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K
M1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH
M_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\
MOMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$
M:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\
M:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_
M +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\
MA&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;
M_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E
M_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_
M (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^
MV_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?
M)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*
M_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\
MOMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\
MGR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH
MRO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_
M +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_
M )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:*
M ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E
M_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'
M_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6
MB@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?
M)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K
M1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$:T?_ )\E_P"^V_QK
M5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\:U:* ,K_ (1K1_\
MGR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#*_P"$:T?_ )\E_P"^V_QH_P"$
M:T?_ )\E_P"^V_QK5HH RO\ A&M'_P"?)?\ OMO\:/\ A&M'_P"?)?\ OMO\
M:U:* ,K_ (1K1_\ GR7_ +[;_&C_ (1K1_\ GR7_ +[;_&M6B@#(D\/:+%&T
MDEHBHHRQ+M@#\Z\;U!EU'7)%M(]BR2[(DW9 [#FO3O'^KG3]#-O&V)KDE./[
MO?\ G7)_#S2/MNL->2KF*W&1D<%C_A7517)!U&:1T5SN=-\):5:Z?#%):!I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%8/B_5O[)\/SR(V)I!Y<>.H)[_A3BG)V0+4\R\8ZL=7\02^
M62T47[N,#O[UZ?X3TD:1H,$17$L@WR?4_P#UL5YIX*THZMXBC:0$Q0GS7..,
M]0#]:]G  &!P!73B&DE!%S=M HHHKE("BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *Y#Q3_ ,C1H'^^W]*Z^N0\4_\ (T:!_OM_2@#K^U%':B@
MKS";_7R?[Q_G7I]>83?Z^3_>/\Z .]T#_D7[#_K@O\JTJS= _P"1?L/^N"_R
MK2H **** "BBB@ HHHH **** "BBB@ HHHH **** .3\4?\ (R^'/^O@_P Q
M765R?BC_ )&7PY_U\'^8KK* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR/XA:
MO]NUH6<;9AM1C_@1Z_R%>EZ[J2Z3H]Q=MC*K\H/<^E>.Z#I\FO\ B**&3+!W
MWRG_ &>]=.'C:\WT+@NIZ1X"T@:=H2SNN)KGYB<<A>P_G75TV-%CC5%&%48%
M.K"4G)W9+=V%%%%2(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKD/%/_(T:!_OM_2NOKD/%/\ R-&@?[[?TH Z_M11VHH *\PF_P!?)_O'^=>G
MUYA-_KY/]X_SH [W0/\ D7[#_K@O\JTJS= _Y%^P_P"N"_RK2H **** "BBB
M@ HHHH **** "BBB@ HHHH **** .3\4?\C+X<_Z^#_,5UE<GXH_Y&7PY_U\
M'^8KK* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBJ]_=QV-C-=2G"1*6)HW \[^)6K
ME[F'2XV.U!YD@]3V_K6E\.-'^SZ?)J4J_O)SA,CHH[CZYK@4%QXB\0\X\VZE
MR?09->XV=K'96<5M"NV.-0JBNNK[E-01I+16)Z***Y#,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Y#Q3_R-&@?[[?TKKZY#Q3_R-&@?
M[[?TH Z_M11VHH *\PF_U\G^\?YUZ?7F$W^OD_WC_.@#O= _Y%^P_P"N"_RK
M2K-T#_D7[#_K@O\ *M*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y/
MQ1_R,OAS_KX/\Q765R?BC_D9?#G_ %\'^8KK* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N"^).L>39Q:9&WSRG<^#V';]:[J6188GD<X5%+&O#M8OI?$'B*25,MYLF
MR, ?P]OTK?#PO*[Z%P5V=7\-='W23:K*O"_NXO0^O\A7I-4-%TU-)TFWLUQF
M-0&([GN:OU%6?/)LF3NPHHHK,04444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5R'BG_ )&C0/\ ?;^E=?7(>*?^1HT#_?;^E '7]J*.U% !
M7F$W^OD_WC_.O3Z\PF_U\G^\?YT =[H'_(OV'_7!?Y5I5FZ!_P B_8?]<%_E
M6E0 4444 %%%% !1110 4444 %%%% !1110 4444 <GXH_Y&7PY_U\'^8KK*
MY/Q1_P C+X<_Z^#_ #%=90 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$@ D\ 4 <EX_P!8
M_L_1?LL;8FN3MX/(7U_2N4^'>CF]U9KZ1<Q6W3_>/3^M9WC#56UGQ#((\F.)
MO*C'N.#^9KT_PGI(TC0((2N)7&^3(YR><?A76_W=*W5FFT3;HHHKD,PHHHH
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M?,@S_,UQ7P6F=-+U[2P?]&T_4Y88%_NKN8T >GT45!<WMM9A3<3+'NZ;CUH
MYKQ1_P C+X<_Z^#_ #%=97#>)]8T\^(O#SB[CVI<$L<].E=,/$.D$X&H0DGW
MH TZ*H?VWIG_ #^Q?G1_;>F?\_L7YT 7Z*H?VWIG_/[%^=']MZ9_S^Q?G0!?
MHJA_;>F?\_L7YT?VWIG_ #^Q?G0!?HJA_;>F?\_L7YT?VWIG_/[%^= %^BJ'
M]MZ9_P _L7YT?VWIG_/[%^= %^BJ']MZ9_S^Q?G1_;>F?\_L7YT 7Z*H?VWI
MG_/[%^=']MZ9_P _L7YT 7Z*H?VWIG_/[%^=']MZ9_S^Q?G0!?HJA_;>F?\
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MG_/[%^=']MZ9_P _L7YT 7Z*H?VWIG_/[%^=']MZ9_S^Q?G0!?HJA_;>F?\
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MG_/[%^=']MZ9_P _L7YT 7Z*H?VWIG_/[%^=']MZ9_S^Q?G0!?HJA_;>F?\
M/[%^=']MZ9_S^Q?G0!?HJA_;>F?\_L7YT?VWIG_/[%^= %^BJ']MZ9_S^Q?G
M1_;>F?\ /[%^= %^BJ']MZ9_S^Q?G1_;>F?\_L7YT 7Z*H?VWIG_ #^Q?G1_
M;>F?\_L7YT 7Z*H?VWIG_/[%^=']MZ9_S^Q?G0!?HJA_;>F?\_L7YT?VWIG_
M #^Q?G0!?HJA_;>F?\_L7YT?VWIG_/[%^= %^BJ']MZ9_P _L7YT?VWIG_/[
M%^= %^BJ']MZ9_S^Q?G1_;>F?\_L7YT 7Z*H?VWIG_/[%^=']MZ9_P _L7YT
M 7Z*H?VWIG_/[%^=']MZ9_S^Q?G0!?HJA_;>F?\ /[%^=']MZ9_S^Q?G0!?H
MJA_;>F?\_L7YT?VWIG_/[%^= %^BJ']MZ9_S^Q?G1_;>F?\ /[%^= %^BJ']
MMZ9_S^Q?G1_;>F?\_L7YT 7Z*H?VWIG_ #^Q?G1_;>F?\_L7YT 7Z*H?VWIG
M_/[%^=']MZ9_S^Q?G0!?HJA_;>F?\_L7YT?VWIG_ #^Q?G0!?HJA_;>F?\_L
M7YT?VWIG_/[%^= %^BJ']MZ9_P _L7YT?VWIG_/[%^= %^BJ']MZ9_S^Q?G1
M_;>F?\_L7YT 7Z*H?VWIG_/[%^=']MZ9_P _L7YT 7Z*H?VWIG_/[%^=']MZ
M9_S^Q?G0!?HJA_;>F?\ /[%^=']MZ9_S^Q?G0!?HJA_;>F?\_L7YT?VWIG_/
M[%^= %^BJ']MZ9_S^Q?G1_;>F?\ /[%^= %^BJ']MZ9_S^Q?G1_;>F?\_L7Y
MT 7Z*H?VWIG_ #^Q?G1_;>F?\_L7YT 7Z*H?VWIG_/[%^=']MZ9_S^Q?G0!?
MHJA_;>F?\_L7YT?VWIG_ #^Q?G0!?HJA_;>F?\_L7YT?VWIG_/[%^= %^BJ'
M]MZ9_P _L7YT?VWIG_/[%^= %^BJ']MZ9_S^Q?G1_;>F?\_L7YT 7Z*H?VWI
MG_/[%^=']MZ9_P _L7YT 7Z*H?VWIG_/[%^=']MZ9_S^Q?G0!?K \7ZN-(T&
M9U($TH\N,'N3U_3-:']MZ9_S^Q?G7E_CW6UU35E@@D#V\ P"#PQ]?UK6C#FF
M5%796\%Z0=6U^-I!NAA_>/GO_DU[17#^!3I^DZ+OGN8TN)SN8$\@=OTKJ?[;
MTS_G]B_.G7GS3] D[LOT50_MO3/^?V+\Z/[;TS_G]B_.L22_15#^V],_Y_8O
MSH_MO3/^?V+\Z +]%4/[;TS_ )_8OSH_MO3/^?V+\Z +]%4/[;TS_G]B_.C^
MV],_Y_8OSH OT50_MO3/^?V+\Z/[;TS_ )_8OSH OT50_MO3/^?V+\Z/[;TS
M_G]B_.@"_15#^V],_P"?V+\Z/[;TS_G]B_.@"_15#^V],_Y_8OSH_MO3/^?V
M+\Z +]%4/[;TS_G]B_.C^V],_P"?V+\Z +]%4/[;TS_G]B_.C^V],_Y_8OSH
M OT50_MO3/\ G]B_.C^V],_Y_8OSH OUR'BG_D:- _WV_I70?VWIG_/[%^=<
MOX@O;:\\3Z$;>99-LC9VGITH [?M11VHH *\PF_U\G^\?YUZ?7F$W^OD_P!X
M_P Z .]T#_D7[#_K@O\ *M*LW0/^1?L/^N"_RK2H Y7QQXO?P;9V5Z]BT]G)
M.([F8-CR%)'S8QSU/Y5C^/O%'A:?P#>//=6URMW;L+9%(+,Y'RD?0XKO+JTM
M[ZVDMKJ%)89!AD<9!%<]:?#OPG8WBW5OHELDR'<AP3M/L,T >5:MI^JZ7\+_
M  1J5[&Y;3+L3718\I&S'!_(BN\\:>.]%7P+<365_!<3WT0CMH5<%I&; P!Z
M\G\J[N>V@NK9[>>))(77:R,."/2N=LOAYX4TZ^6]MM&MTG4[D;D[3[4 ><^+
M?"UW8?!C0D\L[M-GAO+E>ZC'S?B"U=KK'Q(\/IX)FUBUOX9?.AQ##O&]F(^[
MCU]J[62*.:)HI$5HV&&4C@BN9A^'/A*WOA>1:);+,K;E.#@'UQF@#&^&]O#X
M)^%UG+K$RVB-FXE,QV^66P<'\J@^+(;6?AN-3TDK<I!+'=JR'(9%.217>ZEI
M5CK%@]CJ%K'<6K_>B<<&GVNGVEG81V%O D=K&FQ(@/E"^E ''7?Q"T"/P"^J
MQZC <VQ5(RXW&3;]W'KFN,F\*:C-^S_=6\<&+RX87SQMP0HDWG_QT5Z(GPX\
M)1WXO5T2W$P;>.N WKC-=.$41[ HV8QMQQB@#AM&^(7AY? ,&H_VC GV:U5'
MCD<!A(JXVD>I(JI\'=-G@\.7VJW$31/JUY)=B-A@A2QQ^8(-;LOPY\)37YO7
MT2V,Q;>3@X+>N,UT\<:11K'&H5%&%4#@"@!U->-)/OJ&QZBG44 <=XHMH?\
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M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\
MGDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_
MYY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!
M%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)
M^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2
M?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9
MH/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1
M]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5
M+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_
M )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H
M/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4
M 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">
M2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_G
MDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7
MV:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY
M4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^
M52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@
M_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V
M:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M
M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\
MGDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_
MYY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!
M%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)
M^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2
M?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9
MH/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1
M]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5
M+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_
M )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H
M/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4
M 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">
M2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_G
MDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7
MV:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY
M4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^
M52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@
M_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M% $7V:#_ )Y)^5'V
M:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\ GDGY4?9H/^>2?E4M
M% $7V:#_ )Y)^5'V:#_GDGY5+10!%]F@_P">2?E1]F@_YY)^52T4 1?9H/\
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M^8KK* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P B_8?]<%_E6E6;H'_(OV'_ %P7^5:5 !1110 4444 %%%% !1110 4444
M%%%% !1110!R?BC_ )&7PY_U\'^8KK*Y/Q1_R,OAS_KX/\Q764 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N0\4_\C1H'^^W]*Z^N0\4_\C1H'^^W]* .O[44=J* "O,)O]?)_O'^
M=>GUYA-_KY/]X_SH [W0/^1?L/\ K@O\JTJS= _Y%^P_ZX+_ "K2H **** "
MBBB@ HHHH **** "BBB@ HHHH **** .3\4?\C+X<_Z^#_,5UE<GXH_Y&7PY
M_P!?!_F*ZR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%<LIN3NR&VPHHHJ1!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %%%% !7(>*?^1HT#_?;^E=?7(>*?\ D:- _P!]OZ4
M=?VHH[44 %>83?Z^3_>/\Z]/KS";_7R?[Q_G0!WN@?\ (OV'_7!?Y5I5FZ!_
MR+]A_P!<%_E6E0 4444 %%%% !1110 4444 %%%% !1110 4444 <GXH_P"1
ME\.?]?!_F*ZRN3\4?\C+X<_Z^#_,5UE !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-=UC0N
M[!5')). * '5BZ[XFL-!AS.^^8_=B0_,?\*YOQ-X_2V:2STHAY1PTW93[5Q.
MGZ5JGB;4/D#R,Q^>9^B_C713H:<T]$6H]6/UCQ!J7B.[VN7*$_)!&.!_C75^
M&?A\=R7>K@8QE8 ?YUTOA[PC8Z%&'VB:Y/65AT^E=#3G7TY8:('+HAD44<$:
MQQ(J(HP%4<"GT45S$!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)(8I1
MB2-''^TN:?10!C7GA31;XEIK&/?C[RY%<U>_#&U=&-E>2)(3P),%1^0KOJ*T
MC5G'9C4FCR&]^'>M6S'R!'<(!G<K!?T-8KP:UI;9,=W#M[X;'^%>\4QXXY5V
MR(KCT89K58F7VE<KG?4\<L?'>N63C?<"X4<;)1Q^F*Z&S^*"[ +VP)<GK$V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M U:*RO\ A)-(_P"?Q?\ OAO\*/\ A)-(_P"?Q?\ OAO\* -6BLK_ (232/\
MG\7_ +X;_"C_ (232/\ G\7_ +X;_"@#5HK*_P"$DTC_ )_%_P"^&_PH_P"$
MDTC_ )_%_P"^&_PH U:*RO\ A)-(_P"?Q?\ OAO\*/\ A)-(_P"?Q?\ OAO\
M* -6BLK_ (232/\ G\7_ +X;_"C_ (232/\ G\7_ +X;_"@#5HK*_P"$DTC_
M )_%_P"^&_PH_P"$DTC_ )_%_P"^&_PH U:*RO\ A)-(_P"?Q?\ OAO\*/\
MA)-(_P"?Q?\ OAO\* -6BLK_ (232/\ G\7_ +X;_"C_ (232/\ G\7_ +X;
M_"@#5HK*_P"$DTC_ )_%_P"^&_PH_P"$DTC_ )_%_P"^&_PH U:*RO\ A)-(
M_P"?Q?\ OAO\*/\ A)-(_P"?Q?\ OAO\* -6BLK_ (232/\ G\7_ +X;_"C_
M (232/\ G\7_ +X;_"@#5HK*_P"$DTC_ )_%_P"^&_PH_P"$DTC_ )_%_P"^
M&_PH U:*RO\ A)-(_P"?Q?\ OAO\*/\ A)-(_P"?Q?\ OAO\* -6BLK_ (23
M2/\ G\7_ +X;_"C_ (232/\ G\7_ +X;_"@#5HK*_P"$DTC_ )_%_P"^&_PH
M_P"$DTC_ )_%_P"^&_PH U:*RO\ A)-(_P"?Q?\ OAO\*/\ A)-(_P"?Q?\
MOAO\* -6BLK_ (232/\ G\7_ +X;_"C_ (232/\ G\7_ +X;_"@#5HK*_P"$
MDTC_ )_%_P"^&_PH_P"$DTC_ )_%_P"^&_PH U:*RO\ A)-(_P"?Q?\ OAO\
M*/\ A)-(_P"?Q?\ OAO\* -6BLK_ (232/\ G\7_ +X;_"C_ (232/\ G\7_
M +X;_"@#5HK*_P"$DTC_ )_%_P"^&_PH_P"$DTC_ )_%_P"^&_PH U:*RO\
MA)-(_P"?Q?\ OAO\*/\ A)-(_P"?Q?\ OAO\* -6BLK_ (232/\ G\7_ +X;
M_"C_ (232/\ G\7_ +X;_"@#5HK*_P"$DTC_ )_%_P"^&_PH_P"$DTC_ )_%
M_P"^&_PH U:*RO\ A)-(_P"?Q?\ OAO\*/\ A)-(_P"?Q?\ OAO\* -6BLK_
M (232/\ G\7_ +X;_"C_ (232/\ G\7_ +X;_"@#5HK*_P"$DTC_ )_%_P"^
M&_PH_P"$DTC_ )_%_P"^&_PH U:*RO\ A)-(_P"?Q?\ OAO\*/\ A)-(_P"?
MQ?\ OAO\* -6BLK_ (232/\ G\7_ +X;_"C_ (232/\ G\7_ +X;_"@#5HK*
M_P"$DTC_ )_%_P"^&_PH_P"$DTC_ )_%_P"^&_PH U:*RO\ A)-(_P"?Q?\
MOAO\*/\ A)-(_P"?Q?\ OAO\* -6BLK_ (232/\ G\7_ +X;_"C_ (232/\
MG\7_ +X;_"@#5HK*_P"$DTC_ )_%_P"^&_PH_P"$DTC_ )_%_P"^&_PH U:*
MRO\ A)-(_P"?Q?\ OAO\*/\ A)-(_P"?Q?\ OAO\* -6BLK_ (232/\ G\7_
M +X;_"C_ (232/\ G\7_ +X;_"@#5HK*_P"$DTC_ )_%_P"^&_PH_P"$DTC_
M )_%_P"^&_PH U:*RO\ A)-(_P"?Q?\ OAO\*/\ A)-(_P"?Q?\ OAO\* -6
MBLK_ (232/\ G\7_ +X;_"C_ (232/\ G\7_ +X;_"@#5HK*_P"$DTC_ )_%
M_P"^&_PH_P"$DTC_ )_%_P"^&_PH U:*RO\ A)-(_P"?Q?\ OAO\*/\ A)-(
M_P"?Q?\ OAO\* -6BLK_ (232/\ G\7_ +X;_"C_ (232/\ G\7_ +X;_"@#
M5HK*_P"$DTC_ )_%_P"^&_PH_P"$DTC_ )_%_P"^&_PH U:*RO\ A)-(_P"?
MQ?\ OAO\*/\ A)-(_P"?Q?\ OAO\* -6BLK_ (232/\ G\7_ +X;_"C_ (23
M2/\ G\7_ +X;_"@#5HK*_P"$DTC_ )_%_P"^&_PH_P"$DTC_ )_%_P"^&_PH
M U:*RO\ A)-(_P"?Q?\ OAO\*/\ A)-(_P"?Q?\ OAO\* -6BLK_ (232/\
MG\7_ +X;_"C_ (232/\ G\7_ +X;_"@#5HK*_P"$DTC_ )_%_P"^&_PH_P"$
MDTC_ )_%_P"^&_PH U:*RO\ A)-(_P"?Q?\ OAO\*/\ A)-(_P"?Q?\ OAO\
M* -6BLK_ (232/\ G\7_ +X;_"C_ (232/\ G\7_ +X;_"@#5HK*_P"$DTC_
M )_%_P"^&_PH_P"$DTC_ )_%_P"^&_PH U:*RO\ A)-(_P"?Q?\ OAO\*/\
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M_P ))I'_ #^+_P!\-_A1_P ))I'_ #^+_P!\-_A0!JT5E?\ "2:1_P _B_\
M?#?X4?\ "2:1_P _B_\ ?#?X4 :M%97_  DFD?\ /XO_ 'PW^%'_  DFD?\
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M^^&_PH_X232/^?Q?^^&_PH U:*RO^$DTC_G\7_OAO\*/^$DTC_G\7_OAO\*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"O@_S%=90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@XR$]A6U_P (KH/_ $"K;_OBL)UJ=]KD.43S7_A86O\ _/:'_OW2CXB:^/\
MEK ?K%7I/_"*Z#_T"K7_ +XH_P"$4T'_ *!5K_WQ4^UI?RAS1['F_P#PL77_
M ._;_P#?JG_\+'USU@_[]UZ+_P (IH/_ $"K;_OBHO\ A#]!_P"@=#^5'M:7
M\HN:/8X%?B1K0ZB _P# *7_A9.L_W8/^^*[M_!>@OC_0$'T%-_X0C0?^?(4>
MTH_RCO'L<3_PLK5?^>4/Y4J_$O5!U@A-=C_P@>@_\^S?]]?_ %J8_@#06_Y8
MRCZ/_P#6H]I1[!>)R?\ PLS4O^?:*G?\+.O_ /GSB_[Z_P#K5U'_  KW0?\
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MGIUNXC]&!J!_$>F1]9\_[HS7*CPMJI&?)3_OX*EB\(Z@_P#K"B?CFCZQB7M
M+R[&Z?%FF#HTA_X :AD\86:_<AD?\<51_P"$+G_Y_(_^^34L7@P#_776?]T8
MHY\8^E@O(<?&D?:S;_OL?X5!+XRF.?*MU7TW'-7O^$.L?^>T_P"8_P *FB\*
M:='C=YC_ .\:.3&/=A:1A?\ "7ZC_<@_[X/^-0R^)]3EZ2JG^X,5U@\.Z6/^
M753^)J:/1M.B^Y:1C\Z/J^)>\PY9=SA?[>U3_G]E_.F-?:C<_>FF?->B+9VR
M]((Q_P !J00Q#I&@_P" BCZE4>\PY7W/-A;:C)]V*X;Z T]=)U.3_EVF_P"!
M UZ0% Z #\*6FLOCUDPY#S.[TR[LHA)<)L5C@9/)JE77>(=.U/4;T>5%F!!A
M?F'/O6/_ ,(WJG_/ ?\ ?0KAJX>2FU!.Q+6NA#HM^=/U&.3)V,=KC/45Z0K!
MU#*<J1D&O/?^$;U3_G@/^^A79:(EW%IR17BXD3@'.<BNW ^TC>$D[%0OL:-%
M%%>B6%%%% !1110 4444 %<AXI_Y&C0/]]OZ5U]<AXI_Y&C0/]]OZ4 =?VHH
M[44 %>83?Z^3_>/\Z]/KS";_ %\G^\?YT =[H'_(OV'_ %P7^5:59N@?\B_8
M?]<%_E6E0 R::*WB:6:1(XU&6=V  'N37GEE\5;36/B1:^&=)CCGM720RW1S
M]Y5)PO8]*[37=$M?$.E2:;>[_L\A&]48J6 [9'8UYC-H^GZ%\=?#-CIMK';V
MZ:9+A4'7B3DGN?K0!Z#XO\4V_A+0GU"9/-E+"."$'F1R< #\ZXNY\>>-]$M;
M?5M=\-6<>CN09F@D)DA4G )&X^H[4[XN(LVJ>#XGY0ZH#CZ"NV\86\5UX/U6
M&9 T9MF)!'' R/Y4 ,UKQ78:/X4?Q S"2W,2R1*#@R;L;0/?FN(E\>^.K'28
M]>O_  O:)HY DD"2'SDC/0D;NOMBN+UZZFN/@IX/:5B3_:<4?/\ = 8#^5>^
MZI;Q7.D7<$J*T30L"I'&,4 )I.J6NM:3:ZE9/OMKF,21MC&0:K^(]?M/#.@W
M6K7I_<P(6V@X+GL![FN+^!<\L_PSM_-<MY=Q)&N>RC&!2?&M1+X/M8'_ -7+
M?PAAZC- %27QWX\MM(77IO"]G_9(_>.JR'SEB'.[&[&<9KNHO%6FR^$?^$D$
MJBR,!FRS8Z _+SWR,5:G@CE\./;NH,;6NP@],;:\'NII&_9YU6$Y"0Z@L:#T
M7SA_C0!VB>//'EUI3:[:>%K0Z3RZB20B9HAU;&[TSVKOO#/B*S\4Z!;:M8D^
M3,.588*L."#]#D5)HD2/X7TZ%E!C:SC4KC@@H,UP/P7=A!XGM02(;?5I4B3L
MHW-P* /4:**AGNHK8 RL1GIA2?Y4 <SXH_Y&7PY_U\'^8KK*X?Q1JEI_PD/A
M^3>^U+@EOW;>WM72KX@TUV"K-)D_],'_ ,* -.BJ7]K6?_/1_P#OTW^%']K6
M?_/1_P#OTW^% %VBJ7]K6?\ ST?_ +]-_A1_:UG_ ,]'_P"_3?X4 7:*I?VM
M9_\ /1_^_3?X4?VM9_\ /1_^_3?X4 7:*I?VM9_\]'_[]-_A1_:UG_ST?_OT
MW^% %VO.M9^(=_INKW%G%9VSI$V S;LGCZUW']K6?_/1_P#OTW^%>,ZCC5/%
M%S(J,J-)DAA@X'_ZJPKS<(\R.[ PI2<G56B1UR>--7FA6[\J%" 3Y(!VM]>]
M0V/Q)U&YOX;=[&U57<*2-V1^M4  JA0. ,"J::;%'>+<H2'5MP^M>;3QDDWS
M,RH5\/>7M8[['LU%>>MXFU8]+D#_ ( O^%1-XBUDGB_(_P"V:_X5V_7J/<Y.
M9'H]%>:'7=9(_P"0BW_?M?\ "FG6-7/749/^^%I_7J'?\!\R/3:*\N;4M4<8
M.HR_@!4#7%^Y).HW'/HU/Z[0[_@'-'N>L49'K7D++=N,'4;O\)2/ZTSR+C_H
M(WG_ '^;_&G]=P_\S^X.:/<]@W+_ 'A^=(9$'5U'XUX_]FG_ .@A=_\ ?UO\
M:0VLQZWUU_W]/^-'UW#_ ,S^X.:/<]>-U;K]Z>(?5Q49U"R7K=VXQZRC_&O(
MCIY;[UU.?JYIATF-NLTASZFG]=PW\S^X?-'N>O?VKIW_ #_VO_?Y?\:3^U=.
M_P"?^V_[_+_C7C_]B6_]YJ/[$M_[S4_KN%_F?W!S0[GL']K:=_S_ -M_W]7_
M !J&3Q!I,8.Z_@XZX<&O)?[$M_[S4?V);_WFH^NX7N_N#FAW/47\7:''C=?)
MSZ FJ[>.O#RL0;[D?],V_P *\V_L2W_O-1_8EO\ WFI_7L)W?W!S0/2/^$\\
M._\ /\?^_3?X4?\ ">>'?^?X_P#?IO\ "O-_[$M_[S4?V);_ -YJ?U[!]V/F
M@>@7GQ!T6*W<VTYEE"DJ"C $_E7GVM>)]1\2RQ12A8HP<"./.#[TO]B6_P#>
M:I;;3(+:7S%R6'3/:N:OCZ:=Z+9TT:V'A"7,KOH4+VU;3O)N+8E&3&64]_6N
MZ\)^.9-2N/LFI&"+9'D2DX+$8ZYXKGIH5GA:-^C"LEM!_N3?F*SP^-<FE6EH
M%*K0E0<:B][HSVN*^M)CB*Z@<^BR U8!!Z&O"DTJ]@.Z&?:?5&(J6&?7[23=
M%<W!(]9<C\B:])5,/+X:B,%%/9GN%%>/1^,/$UH?GE+KZ&,'^E:,/Q)U.(?O
M["-QZ\@UHH)_#)/YA[.5KGJ%%<!;_%"U(Q<6,H/^P1C]36M:_$#0YQ^]F:W_
M -]2?Y4>RGV$X26Z.IHK#B\8:!,<1ZC&?JK#^8JS'X@TJ9ML5VKGT52?Z5#3
M6Y)IT52_M:S_ .>C_P#?MO\ "C^UK/\ YZ/_ -^F_P *0%VBJ7]K6?\ ST?_
M +]-_A1_:UG_ ,]'_P"_3?X4 7:*I?VM9_\ /1_^_3?X4?VM9_\ /1_^_3?X
M4 7:*I?VM9_\]'_[]-_A1_:UG_ST?_OTW^% %VBJ7]K6?_/1_P#OTW^%']K6
M?_/1_P#OTW^% %VBJ7]K6?\ ST?_ +]-_A1_:UG_ ,]'_P"_3?X4 7:*I?VM
M9_\ /1_^_3?X4?VM9_\ /1_^_3?X4 7:*I?VM9_\]'_[]-_A1_:UG_ST?_OT
MW^% %VBJ7]K6?_/1_P#OTW^%']K6?_/1_P#OTW^% %VBJ7]K6?\ ST?_ +]-
M_A1_:UG_ ,]'_P"_3?X4 7:*I?VM9_\ /1_^_3?X4?VM9_\ /1_^_3?X4 7:
M*I?VM9_\]'_[]-_A1_:UG_ST?_OTW^% %VBJ7]K6?_/1_P#OTW^%']K6?_/1
M_P#OTW^% %VBJ7]K6?\ ST?_ +]-_A1_:UG_ ,]'_P"_3?X4 7:*I?VM9_\
M/1_^_3?X4?VM9_\ /1_^_3?X4 7:*I?VM9_\]'_[]-_A1_:UG_ST?_OTW^%
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M/_OD4?\ "Q=;_O1_]\BCV\0_LROY'K]%>0?\+%UO^]'_ -\BC_A8NM_WH_\
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M.!CO._\ 7H;Q^*.G_P#/A<G_ ($M5YOBE'_RPT]_^!L/Z543P'IG_+35)_\
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MA_6II/"_A*;_ %3NG^[O-59? VA/S'J%TG_;$G^E.U7HP]I@);JQ=3XGZ:S
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MGR2,Y\S+$D_-7+BZ4ZL5& ^:2BXKJ<'3HT#S1J3@%@#]*[C_ (1+3L_\M/\
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M+8C^07U[%?S& /#?AL'F\N2/3;_]>IE\.>%L@FYG/M_DUK_\(?>?\]8OS_\
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M[?JB\?:;D?\  C1_:6I_\_5S_P!]&G]=I_R!];J_S/[SK/\ A"]"_P"?(?\
M?1H_X0O0O^?(?]]&N575]33_ )>9C]234Z^(]4C_ .6V?]Y<U2QM+K$/K53^
M9_>='_PA>A?\^0_[Z-'_  A>A?\ /D/^^C6!_P )7JO_ #TC_P"_8H_X2O5?
M^>D?_?L4_KM#M^ ?6JG\S.@7P;H2L"+)>/4U)_PBFB_\^,?Y5SZ>+M0'WA&W
MX8J=?&5R!\ULC?\  L?TJEC,/_2#ZS4?VF;/_"*:+_SXQ_E1_P (IHO_ #XQ
M_E61_P )I-_SYI_WV?\ "G#QI)GFR3'^^?\ "J^MX?O^ ?69_P S-7_A%-%_
MY\8_RH_X131?^?&/\JH)XRC/W[8CZ&IAXPL\<Q2CZ"J6)H/J'UB?\S+:>%M%
M1MPL(C]5!J3_ (1S1_\ H'V__?L52'C"P[I-_P!\C_&GKXMTUNTP^JC_ !JE
M7H=T'MYO[1:_X1S1_P#H'V__ '[%8GBW0M.@\-W<MM8Q+*J_*409K67Q/IC?
M\M6'U%/.OZ5(I5YT*GJ&%-U*+5KHJGB)1DI7V/"_(F_YY/\ ]\FGR6D\3[&B
M8G&>!FO6M=U336T\Q60B:23@E5Z"LOP_?6UI=.EVJ&%QU89P:XI3@JBA?3N>
MB\X]Y>[H5OAK91R->M<6RL0%VF2/..O3->D(B1KA%"CT Q6'_P ))I-L"(@V
M/^F:BHG\860'R12GZC%=<:]&"MS(\_$8CVU1S.CHKD7\:/N^2T4CU+__ %J@
ME\8W;C]W"D9]<YJ7C:*ZG/S([6BN!_X2O5?^>D?_ '[%59-9U.8Y^TRC_<)%
M9O,*?1,7.CT<D#J0/K3//B'65/\ OH5YP;O4IOE,UP_L6-(NFZC-R+>5LU/U
M]OX8!SGH4FHV</\ K+B,?C5=]?TM!S=H?8 UQB>'M3;_ )=67ZU9C\)ZBXR?
M*7_>8_X4?6L0_A@',^QT#^*M.3H7;Z"JS^,;0?<@E/U _P :H1^#KHG]Y-&H
M_P!GFK8\%Q8YO'_[X'^-'/C);*P>\12>,WS^[M5/^\U5W\8WC#Y(8U_'-:T7
MA"P0?O'DD_'%3KX6TM6R(G/U<FCV>+>\K!:1S+>*=48\2H!Z;!5>76M3N>#/
M)_P#C^5=RFCZ<B@"TA./5 :FCL;2$YCMHD_W5 H^J5G\4PY7W/.OM&I-QYMT
M<_[34X:9J,YW?9Y7)[FO2@ .@ I:/[/3^*3#D/.D\.ZH_P#RZLOU(JU'X2U!
M^IC7ZDUW=%6LOI+>X<B.-3P;<?\ +2XC'^[FJNKZ%!I5JKM<L\K'"ICK[UWE
M8VJ^'UU6Y65[IT"C 4+D"E5P<%!^SC=@XJVAY_178_\ "%P_\_C_ /? _P :
M/^$+A_Y_'_[X'^-<7U*MV)Y65]/\-6>HV,=PERX+#Y@!T-3MX,B_ANW_ !45
MKZ3I(TF)XUG:16.<$8Q6E7H0PE-Q7/'4M11Q[>#9/X;E?Q%1-X.O/X9X?Q)_
MPKM:*;P5'L'*CA6\):@O1HC]":A;PQJ2](@WT->@45+P%+S#D1YRWA_5%_Y<
MW/XBHSHNHKUM)/TKTJBH_LZGW8N1'F?V;48.B3I]":/M&ICCSKO_ +Z:O3*3
M /44OJ%MI,.0\T%YJ2'/GW/XLU3IKVIP])V_X$,UZ$T4;##(I^HJ!M.LG^_:
MPM]4%'U*HOAF'*^YQ \3ZJ/^6R_]\"I$\5ZF/O.C?\  KL?[)T__ )\H/^^!
M44FAZ=)UM8Q_NC%'U;$+:8<K[G-+XQO .88S^-//C&9EVO9Q,IZ@FMEO"VEL
M<^6X^CFD/A32\<))_P!]FCV6+_F_K[@M(P3KNG2MNFT6T9O7RU/]*;-?^'[E
M<2Z/&O\ USC5?Y5L/X/LV^Y+(OZU%_PA</\ S^/_ -\#_&ERXM=G]Q:J55LS
MG_L/A"0_-I]R"?20_P"-02Z#X5ESY;7,/ISG'ZUTC^"TQ\EXQ/NG_P!>JS^#
MKD'Y)HS]>*EK$K>*-5B\2OM,Y\^$O#[CY=8E0_[4=<WJFB-9WK16CFYA !$@
M&,UZ ?!^H=GA_P"^C_A6=J.D7&F!?M#1_-T"G-9SG6BKRA8VIYGB(.\M3#L+
M06]F(W4;FY:LE]'G-RP5?W>[AO:NBJ>SMOM=TD&]4+G +=*Y85)<VG4QI8ZK
M3G*:WD$&F>&8(5$EK<SRXY8N0,_@:OQZEIMM&([?1;0J.C2(&/YD5L1^#%*Y
MDNV#>@3-7(O"6GHN)#)(?7=BN]4\4^R^XF=>O/XI,P&\47X 6'RH4'1508%5
MIM8U.[ZSR?\ ;/C^5=I!H&FVXPMLK_[_ ,U7(K*U@_U5O&G^ZH%5]5KR^*9C
MRM[L\YV:C=G:?M$OLQ)_G4\?A_4Y#_QZLH]217HW3I1367Q^U)L.0X:+PC?O
MRSQ)]2:NQ>#,_P"NNB/]T9KK**UC@J*Z#Y4<]%X0L4/[QY)/QQ5R'P[ID+;E
MM\G_ &F)_G6K16L</2CM%#LBNMC:(<K:PJ1W""K'3I116J26PPHHHI@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<AXI_P"1
MHT#_ 'V_I77UR'BG_D:- _WV_I0!U_:BCM10 5YA-_KY/]X_SKT^O,)O]?)_
MO'^= '>Z!_R+]A_UP7^5:59N@?\ (OV'_7!?Y5I4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% ')^*/^1E\.?]?!_F*ZRN3\4?\ (R^'/^O@_P Q764
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MF[WPJU[=R7$E\V7/0IG ].M0?\(4/^?X_P#?O_Z]=717,\)1;NU^9/*CE/\
MA"A_S_'_ +]__7KHM/M#964=N93)L& Q&*LT5=.A3IN\$-)(****V&%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4V0L(G*#+!3@>].HH \\GTC
M5KB=YI+20LY)/%1?V#J?_/G)^5>D45P/+X-W;9'(CS^STO5K.[CN$LY-R'/3
MK7?J25!(P<<TM%=%"@J*:3*2L%%%%;C"BBB@!" >HIIAC/5%/X4^BBP$#6=L
MWWH$/U%1-I5@WWK2$_5:N45+A%[H"@=$TP_\N4/_ 'R*:="TP_\ +G%_WS6C
M12]E#LA61E-X<TQO^7<#Z5"WA33&_@D'T>MNBI="D_LH+(PO^$2TSTE_[[IK
M>$=.(^7S0?\ >K?HJ?JU+^5!RHYI_!UL?N3NOU&:A/@M<\7I_P"_?_UZZNBI
M>$HO[(N5'*?\(4/^?X_]^_\ Z]1OX,8?<N]WU3']:Z^BE]3H]@Y4<0_@^]&=
MDD;?4XJ)O"FHHA8F$ #)^?\ ^M7>5E>(#='2VCM(GD>0[2%&2!653!T8Q<K,
M3BCSPC!(R#CN*2KW]CZE_P ^,_\ WP:/['U+_GQG_P"^#7E>SGV9G9E[2O#K
MZG;B<7"HA.#@9(K2'@M<\WI(_P"N?_UZ;X7AU"SNWBFMI4A<9RRD $5UM>IA
M\-2G33E'4TC%6.?C\(V 7$C2,?4-BIX_"^F1G/ENW^\V:V:*ZEAZ2^RBN5&>
MNAZ8O_+G$?JM6([&UB_U=O&OT6K%%6J<%LAV$"@#  %+115@%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %</K]OJ-]JDA6VE,:':F!P1ZUW%%8UZ*JQY6
M[":N>9_V1J'_ #Z2_P#?-*FEZE&ZNMI,&4Y!VUZ7@>E&!Z5R?V=#^9D\A6L)
M)9;&%YD*2%?F4]:LT45Z"5E8L****8!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *Y#Q3_R-&@?[[?TKKZY#Q3_R-&@?[[?TH Z_M11VHH *
M\PF_U\G^\?YUZ?7F$W^OD_WC_.@#O= _Y%^P_P"N"_RK2K-T#_D7[#_K@O\
M*M*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y/Q1_R,OAS_KX/\Q76
M5R?BC_D9?#G_ %\'^8KK* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N0\4_\C1H
M'^^W]*Z^N0\4_P#(T:!_OM_2@#K^U%':B@ KS";_ %\G^\?YUZ?7F$W^OD_W
MC_.@#O= _P"1?L/^N"_RK2K-T#_D7[#_ *X+_*M*@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Y/Q1_R,OAS_KX/\Q765R?BC_D9?#G_7P?YBNLH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *Y#Q3_ ,C1H'^^W]*Z^N0\4_\ (T:!_OM_
M2@#K^U%':B@ KS";_7R?[Q_G7I]>83?Z^3_>/\Z .]T#_D7[#_K@O\JTJS=
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M ZVBN2_X3:3_ * .H_\ ?'_UJ/\ A-I/^@#J/_?'_P!:@#K:*Y+_ (3:3_H
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MG_0!U'_OC_ZU'_";2?\ 0!U'_OC_ .M0!UM%<E_PFTG_ $ =1_[X_P#K4?\
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M1_[X_P#K4?\ ";2?] '4?^^/_K4 =;17)?\ ";2?] '4?^^/_K4?\)M)_P!
M'4?^^/\ ZU '6T5R7_";2?\ 0!U'_OC_ .M1_P )M)_T =1_[X_^M0!UM%<E
M_P )M)_T =1_[X_^M1_PFTG_ $ =1_[X_P#K4 =;17)?\)M)_P! '4?^^/\
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M3:3_ * .H_\ ?'_UJ .MHKDO^$VD_P"@#J/_ 'Q_]:C_ (3:3_H ZC_WQ_\
M6H ZVBN2_P"$VD_Z .H_]\?_ %J/^$VD_P"@#J/_ 'Q_]:@#K:*Y+_A-I/\
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M7)?\)M)_T =1_P"^/_K4?\)M)_T =1_[X_\ K4 =;17)?\)M)_T =1_[X_\
MK4?\)M)_T =1_P"^/_K4 =;17)?\)M)_T =1_P"^/_K4?\)M)_T =1_[X_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MF$W^OD_WC_.O3Z\PF_U\G^\?YT =[H'_ "+]A_UP7^5:59N@?\B_8?\ 7!?Y
M5I4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 444F1G&>: %J)+JWDD\M)XF?^Z'!-<)\5_$-]HVDZ;9V,YM6U.[2VDNQU
M@0D L/P)KC/&G@K2_ ^B6_B/0-5N8]8CECP[SD_:BS '/UR?7B@#W.BLK0-9
MM]9TJWGCN899O*7SA&V=KX&X?GFM6@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHI 0>A!QUH 1W2-2SLJJ.I8X%-BGAF&8I4D Z[&!
MKS#Q1*WBOXCP^$;^]DL])2W,KQ1R%&NVYXSZ#CCVK%BM;/X:_%'2M.TG4GCT
M>]B9KV&>3<L>,X.>W('YT >VT5%!<0W4*S02+)&PR&4Y!J6@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHZ44 1RW$$&/.FCCSTWL!_
M.G)(DJ!XW5U/0J<BO%?#^E6?Q0UWQ#<>*9Y7&GWC6UM:K+M1$ QNQ5SX;:Q8
M>'->UOPZVMQR:;!.$LQ-)R">JCZ<_E0![!12 AE!4@@]"*6@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHR!U-<O\0]>N/#7@74]4M/
M^/B&,!#Z%F"Y_6@#HS<P*^QIXP_]TN,U+7D^E_"NSUCPY:ZO=ZKJ,NMW=NER
M+OSR-K,H8#'H,XJ;X8^/+J]U*]\):]+YFK:?(\:7&>)U4[23[]/K0!ZE1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A( R3@"C(S
MC//I7G/Q'U>_E\0:#X1L;M[%=7=O.N8_O!%!)4>F<=: /0H[B"5ML<T;GT5@
M:EKR'Q3\/8O!FA3^(/"M_?6M[9 2.KS%EF7NI%=I\/\ QG;^-O#45_'A+I $
MN8O[C]_PZXH ZJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ IKR)$NZ1U1?5C@4H(/0@UY/-"_P 1_'^JZ5?WL\.BZ6H06D,A1I).
M['U'7\Z /5HY8Y5W1NKCU4YI]>(>)([SX.ZUIVH:1=W,WA^Y?R[FSGD+!#QR
M/<\_2O9M/O[;5-/@OK259;>= \;J>"#0!9HHHH **** "BBB@ HHHH ****
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MWB2R\5:#;ZI9,2L@PZ'AD;N#6S0 4444 %%%% !1110 4444 %%%% !1110
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MDRO%%*?XD4X'Z5Z#573M.M=)L(;&RA6&WA4*B+T %6J "BBB@ HHHH ****
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M&#\AZ<X]>*VX(4M[>.&,82-0BCV P*DH **** "BBB@ HHHH **** "BBB@
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MA[3-3UBPU>Y@WWEEDP/N/RY!SQ^->=^.]-O/!GB>#QUHL0-NQ$6IVZ\!D/\
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M%%% !1110 4444 %%%% !13))8X5W2R*BYQEC@5Q7C3Q1JMIK.G>&_#\<?\
M:E^"_GS#*0H.I(YR>G:@#N*\H^,FN:I VC:-H(E;5)Y_/3RFY4)CK['=W]*<
MNO>,O"7C;2=+UZ\M]3T[5&,:R1Q!&B;WP!7H#^'M-E\11ZZT&;^.(PK)GC:<
M=OPH SO OBR'Q=X=BO0!'=)^[N8>\;CK6#;+_P ([\8;B+!6UURV\P'MYJ9S
M^FVL7Q#;S?#/QRGB>S3_ (D.I.(]1C'2%L_?Q^)Z>E='X_L9]4TS1];T:)[J
MZL;N.:)(2,R(6&X9SZ"@#(^.E]]E\)6<,D;O;37L?GJO4JK*<?C6?90>*_B.
MEO"HF\/^%XHU50#B>X5>/J.1[<5ZI<:?:ZO9PKJ-G'*!MD\N50VUN#^AJZJA
M%"J % P !P* (+&T2PL(+2-F9(8PBESDD 8Y-6*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HIAEC$@C+J'(R%SR1]*\WF\0>*/%WB34M-\+W=O8
M6.FOY,]S+&'9Y.> "#W!H [O7=2&CZ%>ZB4+_9HC)M'?%>4Z+X)UGQUHD/B:
M^\6ZC;7=ZOFPPVK[8XU[ CU]:W/".MZUJ>HZQX.\71Q37<"<3Q* DL9SS@8]
M*H_#C5;CPKKUYX"UC*&)S+I\[MQ+&>P]ACCZT 6_!_BF\N-1O? WBX#^TD0K
M'*5PMU&1V]^M:'PPNI8+'4O#UR0)M)NFB4?[!PP/_CV*ROC1:)I^DV'BRV_=
MZCIEU'L91S(I8?*3W'M[UJZ?IU_;?$:VUBVM&:QU73U^V2@\)( 6!Q[\"@#D
M/B#XA.C_ !=TNZ:RN+V2ULV%K;PC.^1MP!/MS6_X>\+^)O$.K6OB3Q;?26IB
M)>WTRW?"QCD?/CKU]37H3Z98R:BFH/:PM=HFQ9B@+*/8U;H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HJAJ6K6FF:7=W\TJ&*U0M)@YQCL:\
MVM+WXC>)]$_X2/3=0LK"WE7SK2S>(,63K\QV_2@#I?B3KNH:/H5O!I,B0W]_
M<+;132#Y8]W&37*WGPW\1:%9MK.@^*M2N]3B3S#;W3[HY>Y '3)[5-<FZ^+'
MP@>=(S%JD;%HPG&9D'8]@2:Z3X<>,8_%/A]([C]UJEI^YNH&&"&'<#TH YN^
MUE/B)\,;JXA AUC3&$\L/\4<D1#X_' _.O0/#>JIK'AFQU&,[O-@!;_> P?U
M!KS^XTV+PY\;+?[(JK9Z[:N+N!>[@-SCL.!72?#W3=3T2#5=*OH2MK;WC&S?
MC#1M\W'XL1^% 'D_A7Q=KL.O^(K+0]*>]UB^U%U^T.,1P1J2HR?48!Q7K/@G
MP;?:!+<ZCK&KS:AJEW_K27/EI[*O3]*Z>RTNQTXRFSM(8&E8O(8T +D\DG'6
MK= !1110 4444 %%%% !1110 4444 %%%% !1110 444C,J*68@*.22>E "T
M5RGCCQ:WAOPRM_81K=7%S*L-L ?E+-G!SZ<5Q7B.]\?^"])M_$MUJ]OJ$:N/
MMEF(E50#_=..G6@#>^,E_<VO@<VNGS/'J%Y<1PVZQN5=R3@@'\:E^%_C&3Q%
MHIL-3#1:SI_[JYB<88^C?Y]*Z*;2=.\2'2-4NX-\EH?/@!/"L0.<?@*X3XB:
M7<^%==MO'NBQL6B8)J,,8_UL9."V.YP3U]* -3X@AM&\0>'O$\29^SW M;@C
M_GF^5&?^!-6A\4=0DLOAGK%U;M\QA4*P]&91_(U8U9;/QW\/IVLI/-CN[?S(
M2O4..0/J&&*G\/6LVJ>";.RU_3]DGDK%-;S8;.W@$]>N : /+O#VI^)O%OAK
M3_#_ (5M'TG2X(42ZU&88+G:-P0<]3DYQ7K_ (<T-/#NB0::EU/=>5UFG8L[
M'N2:T+:V@L[=+>VA2*%!A410 !]!4M !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7F$W^OD_WC_.O3Z\PF_U\G^\?YT =[H'_(OV'_7!
M?Y5I5FZ!_P B_8?]<%_E6E0 4444 %%%% !1110 4444 %%%% !1110 5"UY
M;(Q5[B%6'4%P#6'X[UFX\/\ @C5=4M!^_MX=R>QR!_6N&\+_  Q\/^)?!EKJ
MFJB6\U/4H5N);MGRZN1G@]N30!TWQ1M[B3P5+J-C*$N=,D6^C8#.=F3@5)H6
MA:?J>OV_CBUNI6>[LDC\O&%(YY//O7%^ O%$]AXCU'X?>(+DW0C=H;2XEY\P
M#C:?TP*ZCX87+VMAJ'AJYEWW.D731 8_Y9G&W]<T 9GQ(7^V?&WA'0H6'FQW
M7VR1?]A<'_V4UZ-+J%E;75O9RW,23SDK%&6Y; R<?A7C?BZZ\16WQE\S0M+^
MU7QL!% [?<B!+#<>.G)_*NL\+_#86VH+KWB:[;5=;/(>3E(?90?3UH NP>#;
MJP^)TWB6QN(X[.[MMEW$1R[#& /0< YKM:** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 0D*"6( '4FHDN[:1@J7$+,>@#@FO._BKJ]VD^B>'
M;>=[6+5I]DUPAP50=1^.?TJAXH^%.CZ3X=?4_#?FZ?JVGQ^9#/&^"Y']X^OO
M0!K^)0=!^)V@ZWNF:#4E.GSH/N \>63^+FN@T7PK;^%]%OK/0W:.6X9YE:4[
M@)&'!QZ<#BO.H?$LGQ&^$]^C2%==TO$[QQ_>+IRK8]"0?RKT;2M2N==\#P7V
MF.B7<]J?),@R!( 0,_B* //+[X7ZUHFEW^N6/BR]751NNY@N5CE*C.#SSP,5
M;TW15^*/A'2?$;S/INOP JMU!URK$<],@X_6I'E^*&JZ;)HEUI]A TH,4U^'
M.TH>"57'7!]:[WPMX?M_"_ARST>V9GCMUY9NK,3DG\R: .1M?A[J^J:G9W?B
MW6_[0BL7WP6R1[4+= S<\FO1J** "BBB@ HHHH **** "BBB@ HHHH ****
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M'96L1W+;@]3GUZ]N]>@T 9'AOPY8>%='CTO31(+9"6 D<L<GZUKT44 %%%%
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M]#1HVD6N@Z1;Z99!Q;6Z[8P[;B!]:OT4 %%%% !1110 4444 %%%% !1110
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MG>%?^\3QSP.W:O1Z ,3PQX8L?"FFM8V#2F%I&DP[$A<GHH[#VK;HHH ****
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MINHHDNP'E90%!X^@KK:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%NMT0;@1J)2.F['/ZU/110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNK(RM87=U]HMOFY4MDN,?4BF^'?A[I/A_4GU(37=]?,,+/>2!V0>BX Q76T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '">/O ]
MWK]U8ZWH=X+/7+ _N9#T=>ZG\ZQ[;PMXZ\47]LGC6YL(]+MW\PV]D/\ 7D=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5B:9X4TK2-;O]6LX?+N;W'G8/RG'M
M6W10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %(0&4JP!!&"#WI:* ,30O"NE^')[Z7383$;R4RRKDXW'K@=JVZ
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KS";_7R?[Q_G7I]>83?Z^3_ 'C_ #H [W0/^1?L/^N"_P J
MTJS= _Y%^P_ZX+_*M*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\PF_U\G^\?YUZ?7F$W
M^OD_WC_.@#O= _Y%^P_ZX+_*M*LW0/\ D7[#_K@O\JTJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KS";_ %\G^\?YUZ?7F$W^OD_WC_.@#O= _P"1?L/^N"_RK2K-T#_D
M7[#_ *X+_*M*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *\PF_U\G^\?YUZ?7F$W^OD_WC
M_.@#O= _Y%^P_P"N"_RK2K-T#_D7[#_K@O\ *M*@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *\PF_U\G^\?YUZ?7F$W^OD_P!X_P Z .]T#_D7[#_K@O\ *M*LW0/^1?L/
M^N"_RK2H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O,)O]?)_O'^=>GUYA-_KY/]X_SH [
MW0/^1?L/^N"_RK2KEM%\1V4&B6<3I,&2%0<*/3ZU>_X2BP_NS_\ ?(_QH VZ
M*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+
M#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/
M[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\
MC_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/
M\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK
M$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/
M[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_N
MS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/
M\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_Q
MH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3
M_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_N
MS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/
M_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_Q
MH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C
M_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^
M$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/
M_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__
M 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@
M#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^
M$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2
MBP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__
M 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\
M?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -
MNBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2
MBP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+
M#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\
M?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\
MC_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ
M*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+
M#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/
M[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\
MC_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/
M\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK
M$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/
M[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_N
MS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/
M\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_Q
MH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3
M_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_N
MS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/
M_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_Q
MH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C
M_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^
M$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/
M_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__
M 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@
M#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^
M$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2
MBP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__
M 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\
M?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -
MNBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2
MBP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+
M#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\
M?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\
MC_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ
M*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+
M#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/
M[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\
MC_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/
M\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK
M$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/
M[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_N
MS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/
M\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_Q
MH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3
M_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_N
MS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/
M_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_Q
MH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C
M_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^
M$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/
M_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__
M 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@
M#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^
M$HL/[L__ 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2
MBP_NS_\ ?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__
M 'R/\: -NBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\
M?(_QH_X2BP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -
MNBL3_A*+#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2
MBP_NS_\ ?(_QH VZ*Q/^$HL/[L__ 'R/\:/^$HL/[L__ 'R/\: -NBL3_A*+
M#^[/_P!\C_&C_A*+#^[/_P!\C_&@#;HK$_X2BP_NS_\ ?(_QH_X2BP_NS_\
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/R70>1F$;X8DCI_C0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gy33ft1zvusk000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gy33ft1zvusk000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #N /H# 2(  A$! Q$!_\0
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MW=Z$Y^]7A?@&#7-(\*>-;FTAU"SO!90>1)&CH^?.&=I'.<9Z5V'P/UCQ=?\
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MRWM2PD&95!P5YZ9KP[PUJ/B_5_#GC"VUFYUF[C_L@F*.[:1QO\Q/NAN^,]*
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M?S%6=<\+^'M9#7&M:?#=+&-Q,Y)50!UQG XH OZ1>OJ.B6%](JH]S;1S,J]
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MU2WTG3_#-U#?0!]*2(B:)R6!0]0<GISZTNC^&=&T#(TFPCLU((*1$A>?;.*
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MTU)DWK D[22J#TW?* #[9->2:M^T3>:;K-]8+X<@D%M<20AS=$;MK$9QM]J
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M@,I4#U Y_(50\+Z]H^OZ--J^B+*]M+,[/F,JS2# /![\"M^L_2=(M]'6\2V
M$=S=/<E0N K/@M^N3^- &)'XOT._\6V6A3VU]!JR[Y[9+FU>,<(P+!NA&TL.
MXJYXC\6V'A>W>YU*VOQ:H 7N(;9I$7/J5Z?C5^]TB"]U73-1< 3Z?([1MMY(
M=&1ESV'(/_ 15R>"*YMY()XUDBE4HZ,,AE(P0: ,VQOK*'PS87>FVT\E@UM&
MUO%#&6<1%1MX//3'O7'ZKXC\->+?#7C&.*:[LIK:Q%OJ,L]FXDA3]X5_=G&<
M9<XXZUVVG6MOX?T"SLGN%6WLK>.#SI2%&%4*"<],XKE/%.F6&JZ+XKETB\LY
MM0U/2U@:-)T )C\S:S-G _U@&3TP* /GK2M!\#+K%BT7CBZDD%Q&50Z(XW'<
M,#/F<5]>7 !MI0QP"AR<9QQ7R'I7PP\3P:Q8RO#I^Q+B-FQJ=N3@,#T#U]>7
M"EK:51U*$#\J /CC_A'_  '_ -#Y=_\ @B?_ ..U])1>*/#WAMM"L&%Y=:A>
MZ;"ML;>T=WEB4<':,[>I/MFOFW_A5?BK_GCIW_@TMO\ XY7T_H]KI>F/IM[?
MWUG%J$.DP6>QYDR@ W-@YZ$X_P"^10!IZUJFFVOA>XU35X9H["%1+*DB'>H5
M@1E1[@&C0/$EKXCMDNK*UODMG3?'-<6[1*X]MW)J?5M.M?$6B2V4DBR6MR%W
M%<,KJ&!Q[@XQ^-:( 4    < "@#D[7QCH<?B+4="T^TOY[^WE+W:V]J[*KL
M<EN@S]:N>+/$6B>&(-/U#61+S<^5;>5$TC>:R,. OJNX?C6CIFD6^ES:A+$
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M_<1/H4XBCO#,ZM)N3&T-_%C/3GK0!B:5\.[N'6+&4^(?"[!+B-BJ:Q$6.&'
M&>37UY<#=;2KD#*$9)XZ5\3Z-X:UY-<T]WT34E5;F,DFT< #</:OM>Y!-K,
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gfbaqn1kfu2x000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,M!- # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "D[TM% !1110 44E+0 44E H 6BBDH 6BBB@ HI*6@ HHHH **** "BBB@
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M _-+FF@Y% ZT .S1FBB@ HS133UH 7/-+FHF< \D4]3E>M #Z*2B@!:*2B@
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MB5B"5KU7Q5;)>V+1EE#;2!DUX^LE[X8E=)<M;EB3@9ZTKCL=[X-\9O?,;:\
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M1%_>%<%]HO0?]8/SIXNKW'^L_6CZS$?L6=UYT9[TX,I'6N%%YJ /^LJ9=0U
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M1W\TD)P#D9ITEA<W?B]9O+(4"O6(=)M('=T0 MUH32K19O.5/G]:0V>$:O\
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M G&:XCQO<177B>UAN#F(OAL&H]9TWP];62M K>9VP:E=QL]>'B>U;3S=!U(
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MJMT(JKH5F2YHS3<CU%+3N(7-%)10 M)2T4 %%)2T %&:** %HI** %I**0T
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M4EXQ+/L7T-9UU?Q6XV1+EO454NKV2Y;;%]S/:G6VFN_S$&O*K8IWLCJC22(
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MX !ISX52?2N%N_%;Q^*&T]2,"@#N?+4G. <4\"H(IQ]GC9CRPS4RR*5R.E#
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MY31U#Q!;6\!?<"Q'8UQ,^HW>MW7EQLQ4G&*Y^]^UM'O!<@^]7O"FKOIMQF5
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M5F-+VB&JBL<E ,.I]Z]!T#Y[6N5ET&XMW^XQP:Z71'\BW*OP:ENYC.29<UM
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M2A>:DP*3@').*$[B;2///B!=SVL;F D&L?P++?S7#-*#@GN*[S6]#AU:0EG
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MCL;49VP 54NSQ5K_ )8U3N1G%<='XT:LX/QH3]EQ_M5+X04#2;H_[%1>-/\
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MKCN0ZQJJ:?"0&^<\ 5A:9ITVJW N[H'K3;.RGUJ],\Q/E@Y -=?!"D$01%
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M/2TW=2@UL9BT4F:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP&<8JQ;V,< &!S5FN2K6;T1ZV&P6EY@%"+@4A-*3QQ3"R@<US;[GIJ*2T%.
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M^U<Y<:+J%HQ*QN .]>N#BF2013##J#6T:[ZD.F>20:A?6C88N,>];MCXN>/
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M71Q5EJ6:4=*2E%=)@+1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKHZ6G4VG5Z!R!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(Z5W=JD'A32!U=ORJKHDYUO&=P>D;U _BR^;[JR"NL'AK1E_C;\J>-#T>/\
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ME>HMCB%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6)J&J^<N I+-723Q"]4NXKFY;:.WO5SR-W>HI)QIZG=+&QC/4S8+"YEDW[6
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ML4N*=B1N*,4ZDI@-(IN*DH(I 144\BDQ0 VEH*TF*0"TE%%%@%HHHI %%%%
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M5NJL'U)LT6O,I?-JGYAI#+[U7,@NR]YU+]HK/\WWH\WWIZ!<O_:L=Z0W7O5
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M/.OU.,Y:O3=/C\NW48QQ7=A5>5R,5:,%%%SO2TX 4M>LCS1E.'2EHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#0
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M[MCEZU,*@'6I0:HD?124"@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M#P:=NJ*DR:0B;- J,&G!J8A^:<#3*4&@"2BF@TM "]Z4TW-&:8@IAZU)3&I
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 -[T444 %)2BB@!*,TM%
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M,M7H&I^%[+PS:2/:*0TJD'BL7PMX%M=9MI9;J,Y+GM[T+<'L8UOMUKQ(3:1
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M-]:]4G\+7-II:FV4F3;R/>N._P"$7UO4KQ4N(,(&!R![T=1=#U'P<(AIP,(
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M(U'M3Z6$+BEHI:0!1110 4E+10 F,T8I:* "DI:* "BBB@ I*6B@ I,"EHH
M2EHHH **** "BBB@ HHI* %HHHH *::=28H AEB#K61<0[6/%;N*KS6RR TT
MP.;E@!JG);]>*Z">S9>0*I20GTJDR'$PI(#Z55>/':MN2$^E4Y8?:G<3N93)
MQ5=H^:T)(R.U5F4YK*I14T73JN+*9!4TFZK++4#)7FU<%;5'HTL6]F-W5(K
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M-JCM5K%% %6ZM8;R/RYUW+Z5DGP9H;L6-KR?>M\KD4;2*2W S;/0=/T\YMX
MM/N-'LKJ42RQ99>AK0Q28H"Y7:R@:W$!3Y/2JT&AV%LC+%#@.<FM+%&* *%M
MI5G:2M+#$%<]34]S:Q7<1AE4%".14Q!I0IS0!3M=-M;/B"/:*;-I-G-.)I(L
MR#H:O8I<4V"*5QIMK<PB*6/<@&,57LM TVPDWV\&UO6M7;1MHV JW>GVU\H6
MX0,!3;6PMK%/+@C"BKA%,V$T 4;W1[+41_I,(<"DM=$T^R79!#M%:('%)@YH
M I0:1903&6*(*[')-:0Z5&!S4E "T444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** $HI<44 -(IAC'I4E+0%BNT(J)H*N8H(H$9K6WM436^.U:N
MW--:(&G<+&,T'M3?(]JUC;BF&#VHN*QDM!49B/I6L;?VIGV?VIW"QEF(^E-,
M1]*U3![5&8/:BX6,TQ>U)Y=:)@]J;Y'M0%BAY='E^U7_ "*3R<=J+BL4?+/I
M2>6?2K_E>U)Y5 6*.P^E*(_:KGDTHB]J+A8I[:7;[5;\GVH\GVHN.Q4V>U.\
MNK8A]J/)HN%BIL-.$=6?*IXBHN!4$=/$=6?*IPC]J+A8JB.G!#Z5:\KVI1$?
M2@+%;RZ<(_:K7E'TI5B-(+%81GTIXCJUY-2+#ZT7 J+'3]A[5:\L>E*$%%RB
MNL1]*D6*IL"G 47 B$>*< !4F*3%(!,4ZBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** $Q2T44 %%%% !2&EHH ;2X%+1
M0 FT4A44ZB@!A0$5'Y0S4]% %?R11Y*U8HP* *AA%'D>U6L#TI<"@"F8/:D^
MSY[5<P*,#TH HF#VI?(/I5W ]*,#TH I?9SZ4>1[5>Q28'I1<"GY/M2^35O
M]*,#THN!4\FE$-6L#THP/2BX%<0BE\H5/@48% $/EBG!*EQ10!'MI0HI]% #
M<"EI:* $HQ2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gfbaqn1kfu2x000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /8",H# 2(  A$! Q$!_\0
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M_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/^-'_  M#7O[EI_W[/^-<510!VO\
MPM#7O[EI_P!^S_C1_P +0U[^Y:?]^S_C7%44 =K_ ,+0U[^Y:?\ ?L_XT?\
M"T->_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/^-'_  M#7O[EI_W[/^-<510!
MVO\ PM#7O[EI_P!^S_C1_P +0U[^Y:?]^S_C7%44 =K_ ,+0U[^Y:?\ ?L_X
MT?\ "T->_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/^-'_  M#7O[EI_W[/^-<
M510!VO\ PM#7O[EI_P!^S_C1_P +0U[^Y:?]^S_C7%44 =K_ ,+0U[^Y:?\
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M_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/^-'_  M#7O[EI_W[/^-<510!VO\
MPM#7O[EI_P!^S_C1_P +0U[^Y:?]^S_C7%44 =K_ ,+0U[^Y:?\ ?L_XT?\
M"T->_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/^-'_  M#7O[EI_W[/^-<510!
MVO\ PM#7O[EI_P!^S_C1_P +0U[^Y:?]^S_C7%44 =K_ ,+0U[^Y:?\ ?L_X
MT?\ "T->_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/^-'_  M#7O[EI_W[/^-<
M510!VO\ PM#7O[EI_P!^S_C1_P +0U[^Y:?]^S_C7%44 =K_ ,+0U[^Y:?\
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M_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/^-'_  M#7O[EI_W[/^-<510!VO\
MPM#7O[EI_P!^S_C1_P +0U[^Y:?]^S_C7%44 =K_ ,+0U[^Y:?\ ?L_XT?\
M"T->_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/^-'_  M#7O[EI_W[/^-<510!
MVO\ PM#7O[EI_P!^S_C1_P +0U[^Y:?]^S_C7%44 =K_ ,+0U[^Y:?\ ?L_X
MT?\ "T->_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/^-'_  M#7O[EI_W[/^-<
M510!VO\ PM#7O[EI_P!^S_C1_P +0U[^Y:?]^S_C7%44 =K_ ,+0U[^Y:?\
M?L_XT?\ "T->_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/^-'_  M#7O[EI_W[
M/^-<510!VO\ PM#7O[EI_P!^S_C1_P +0U[^Y:?]^S_C7%44 =K_ ,+0U[^Y
M:?\ ?L_XT?\ "T->_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/^-'_  M#7O[E
MI_W[/^-<510!VO\ PM#7O[EI_P!^S_C1_P +0U[^Y:?]^S_C7%44 =K_ ,+0
MU[^Y:?\ ?L_XT?\ "T->_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/^-'_  M#
M7O[EI_W[/^-<510!VO\ PM#7O[EI_P!^S_C1_P +0U[^Y:?]^S_C7%44 =K_
M ,+0U[^Y:?\ ?L_XT?\ "T->_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/^-'_
M  M#7O[EI_W[/^-<510!VO\ PM#7O[EI_P!^S_C1_P +0U[^Y:?]^S_C7%44
M =K_ ,+0U[^Y:?\ ?L_XT?\ "T->_N6G_?L_XUQ5% ':_P#"T->_N6G_ '[/
M^-'_  M#7O[EI_WZ/^-<510!Z!I?Q&UJ]U>TM9$MO*FE5&*QD'D_6O6%^IKY
MY\/C_BHM/Y/_ !\)U^M?0PH 6BBB@ HHHH \S^+/_,,_X'_2O,J]-^+/_,,_
MX'_2O,J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBK
M>G:=<ZI>):VJJTKG W' HCJP>BN5**Z'5_!>KZ)9F[NTB\D'G8^[%8$<;22H
MB<LY 'IS0M78'HKC:*ZZ/X<:_+&KH+8*RY!,O/Y8JK?^!=<TZ#SI8(W0#YC&
M^X_EBCJQ7T1S=%=!8>#M5O\ 3&OK=(C ,Y!D^88]JP70QOM=?F3(]#^5!5M+
MC:*W-'\*:KKEK)<VB1&.,X8R-M]Z-)\*:GK,D\=F(F\KABS8'X&G82U5S#HK
M3UG0+_09EBO$4%N05;(J;1_#&HZ[;S3V0B9(^6WOM(I1U5PEH[&-13YHV@ED
MB?[RMM/'I5G3=.N-4ODM+8 NW3-"U!Z%.BNP'PT\0C^&USV'F]?TK'U?PSJF
MB?-=V^%/\2'<OYTK[CL8]%'U'/;/2CKQTQVIB"BC@C.,?0T<^G'N: "BCCOC
MVYHZ=_IQ0 44'U/([G.,4HZ@9[XQB@%J)11CCI^&:..F?TH **.,=@?7-*??
MY3GIUH 2B@]O?I1T]??B@ HHZ<XXHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HK6T3P[?Z^\B60C)0<[WVU3U#3Y],O
M7M;@*)$(SM;</SH>CL'2Y5HH_'Z'UH/7U/>AZ %%'4<$G\*T]"TL:QJ\-D9#
M$)"?F R>GI32N!F45TFO>%ET;6[>P2Z:43% 69-N,FK/BGP:GAVRAN%O3,)#
MC#+MQ^-2W9#MK8Y*B@9.<8XZ\T>YP![TV(**.O../4&CD<D9H#K8**GM;*YO
M9?+M8'FD'\,8W<4VYM)[21H;J&2*0'E6&*&'<BHKLY/ R)X9&K&^Y*!_+VCO
M[YKC,CKG'IZ4 ]%<**.>O%!QM)X''K26KL#V"B@=1W/ITQ1GCDGVXI]0Z7"B
MCZT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44Z-&DE2-.6<
M@#TYKK(_AOKTL:R(MOM8 C,O_P!:CH*^IR-%=1?^ =;TZSENIUMQ$@R=LF3_
M "KE\>I[XQ0,**3I@XX] <TN0#UZ]J "BC!__50!N(PO4XY-.VH!178WW@A+
M3PNFL"]9V**WE[!QGWS7'?C2^URATN%%&>_+?A1ST_(4=;!TN%%+]>*3OS@>
MAHZ@%%+T'L?6A5+.$1268_*!SDT=;!TN)15NZTO4+*/?=VDT2OT9D(&:I_B!
M1UL'2XM%'7N<>H%'N2,]N: ZV"BCN.Q]/6C/;! [4( HI,>P]LFEZCOGN* "
MBCVZ9HH **** "BBB@ HHIT4;32K%&?G=MH&.*=M; ]!M%=>OPV\0,-P2VVD
M<?O>?Y54U#P/K>FP&66!9%Y)\H[L?7TJ6[7#K8YNB@_*?F ],9H'6F 44>I'
M3OF@#'//XT=+AUL%%'&< C/N:._7)]A0M@"BCB@9/O\ 04( HHXZGBE[]J&
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M:?>RVT^T21G#!6SS5>I3N 4444P"BBB@ HHHH **** "BBB@ HHHQ[G'N,4
M%%=!I'@W5M:M!=6J0^63QNDQ5V;X<^((86<Q0L%YPDF2?PQ0]'8%JKG)45H6
MFE32ZQ'I\X:&1FVMD9(_"MCQ;X27PREN4NVG\YB#E,8XHZ7';WN4Y>BCGO@#
MWH^A'TS1UL(**/S'X4=1\HSZT %%+TYS^!%)QGJ,^YH **.,<Y]L4=#S0 44
MHYKH--\%:UJL*S06ZI&_(:5MO%.P'/45T&I^"]:TFW-Q<VZ.B]?*?=_2N?\
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M3W.,\6<>*=0_ZZFL6MKQ;_R-6H?]=36+41V+EN%%%%42%%%% !1110 4444
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M*F^'\-A%>Q-=+$@*<YXJ+P[XMTVXT/\ LG6 40+CS#T [5YT,]>!0."<<>]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444P"BBBE8 HHHI@%%%%( HHHH **** "
MBBBF 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH"P4444!8****!A1110+4**** "BBB@ HHHH
M**** "BBB@ HHHH"X4444 %%%% !1110 4444 %%%% (****+ %%%%%@"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****=@N%%%%+4+H****-0
MT"BBBC4- HHHHU#0****-0T"BBBC4- HHHHU#0****-0T"BBBC4- HHHHU#0
M****-0T"BBBC4- HHHHU#0****-0T"BBBC4- HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ****$ 4444@"BBBF 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &EX?_Y&+3_^OA/YU]#U\\>'^/$6G=<_
M:$SQ[U]#"@!:*** $I&Z4M% F<QXU@B;03*T:F1'4*Q'(Y]:\WKTSQM_R+K_
M /71?YUYG6<F>9C6_::!1112N<=Y=PHHHHN%Y=PHHHHN%Y=PHHHHN%Y=PHHH
MHN'-+N+V)QGC\J[?P7IMC>Z=*US:03,),!GC!/05P]>A^ O^05-_UU_H*<7J
M=6#YG/5FW_8&D?\ 0,M/^_*T?V!I'_0,M/\ ORM:5%:'K&;_ &!I'_0,M/\
MORM']@:1_P! RT_[\K6E10!F_P!@:1_T#+3_ +\K1_8&D?\ 0,M/^_*UI44
M9O\ 8&D?] RT_P"_*T?V!I'_ $#+3_ORM:5% &;_ &!I'_0,M/\ ORM']@:1
M_P! RT_[\K6E10!F_P!@:1_T#+3_ +\K1_8&D?\ 0,M/^_*UI44 9O\ 8&D?
M] RT_P"_*T?V!I'_ $#+3_ORM:5% &;_ &!I'_0,M/\ ORM']@:1_P! RT_[
M\K6E10!F_P!@:1_T#+3_ +\K1_8&D?\ 0,M/^_*UI44 9O\ 8&D?] RT_P"_
M*T?V!I'_ $#+3_ORM:5% &;_ &!I'_0,M/\ ORM']@:1_P! RT_[\K6E10!F
M_P!@:1_T#+3_ +\K1_8&D?\ 0,M/^_*UI44 9O\ 8&D?] RT_P"_*T?V!I'_
M $#+3_ORM:5% &;_ &!I'_0,M/\ ORM']@:1_P! RT_[\K6E10!F_P!@:1_T
M#+3_ +\K1_8&D?\ 0,M/^_*UI44 9O\ 8&D?] RT_P"_*T?V!I'_ $#+3_OR
MM:5% &;_ &!I'_0,M/\ ORM']@:1_P! RT_[\K6E10!F_P!@:1_T#+3_ +\K
M1_8&D?\ 0,M/^_*UI44 9O\ 8&D?] RT_P"_*T?V!I'_ $#+3_ORM:5% &;_
M &!I'_0,M/\ ORM']@:1_P! RT_[\K6E10!F_P!@:1_T#+3_ +\K1_8&D?\
M0,M/^_*UI44 9O\ 8&D?] RT_P"_*T?V!I'_ $#+3_ORM:5% &;_ &!I'_0,
MM/\ ORM']@:1_P! RT_[\K6E10!F_P!@:1_T#+3_ +\K1_8&D?\ 0,M/^_*U
MI44 9O\ 8&D?] RT_P"_*T?V!I'_ $#+3_ORM:5% &;_ &!I'_0,M/\ ORM'
M]@:1_P! RT_[\K6E10!F_P!@:1_T#+3_ +\K1_8&D?\ 0,M/^_*UI44 9O\
M8&D?] RT_P"_*T?V!I'_ $#+3_ORM:5% &;_ &!I'_0,M/\ ORM']@:1_P!
MRT_[\K6E10!F_P!@:1_T#+3_ +\K1_8&D?\ 0,M/^_*UI44 9O\ 8&D?] RT
M_P"_*T?V!I'_ $#+3_ORM:5% &;_ &!I'_0,M/\ ORM']@:1_P! RT_[\K6E
M10!F_P!@:1_T#+3_ +\K1_8&D?\ 0,M/^_*UI44 9O\ 8&D?] RT_P"_*T?V
M!I'_ $#+3_ORM:5% &;_ &!I'_0,M/\ ORM']@:1_P! RT_[\K6E10!F_P!@
M:1_T#+3_ +\K1_8&D?\ 0,M/^_*UI44 9O\ 8&D?] RT_P"_*T?V!I'_ $#+
M3_ORM:5% &;_ &!I'_0,M/\ ORM']@:1_P! RT_[\K6E10!F_P!@:1_T#+3_
M +\K1_8&D?\ 0,M/^_*UI44 9O\ 8&D?] RT_P"_*T?V!I'_ $#+3_ORM:5%
M &;_ &!I'_0,M/\ ORM']@:1_P! RT_[\K6E10!F_P!@:1_T#+3_ +\K1_8&
MD?\ 0,M/^_*UI44 9O\ 8&D?] RT_P"_*T?V!I'_ $#+3_ORM:5% &;_ &!I
M'_0,M/\ ORM']@:1_P! RT_[\K6E10!F_P!@:1_T#+3_ +\K1_8&D?\ 0,M/
M^_*UI44 9O\ 8&D?] RT_P"_*T?V!I'_ $#+3_ORM:5% &;_ &!I'_0,M/\
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MRM:.?>DS[T70?(H?V!I'_0,M/^_*T?V!I'_0-M/^_*UH?C11= 9_]@:1_P!
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MM:/'K2\>M%PU,W^P-(_Z!EI_WY%']@:1_P! RT_[\BM+CUHS1<-3-_L#2/\
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M:+^8%#^P-(_Z!EI_WY6C^P-(_P"@9:?]^5J_O'K1O'K1?S H?V!I'_0,M/\
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M444P"BBB@ I*6DI= "EI*6@ HHHI@%)FBB@ S2TE'>@!:*** "BBB@ HHHH
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M#C/-_P ]G_[Z-)Y\W_/9_P#OHTRDI<S[CY(]A_VB;_GL_P#WT:/M$W_/5_\
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M_P">\G_?1I/M=Q_SWD_[Z-1TAJ?:3[C]G#L2&ZN/^>\O_?9I/M5Q_P ]Y?\
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M%'M)]P]G#L3?:[G_ )^)O^^S1]KN?^?B;_OLU#11[2?</9P[$WVNY_Y^)O\
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MCVG_ #S%:%%'LXA[:IW,_P#L:T_YYBD_L:T_YYBM&BE[*'8/;5.YG?V-:?\
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M:E_*'UFM_,S$_P"$6TS_ )X"C_A%M,_YX"MNBCZM2_E#ZS6_F9B?\(MIG_/
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M_P#Z#T?_ (!K_C1_9VO_ /0>C_\  -?\: ZW-OO16)_9VO\ _0>C_P# -?\
M&C^SM?\ ^@]'_P" :_XT ;E%8?\ 9VO_ /0>C_\  -?\:/[.U_\ Z#T?_@&O
M^- &Y16'_9VO_P#0>C_\ U_QH_L[7_\ H/1_^ :_XT ;E%8?]G:__P!!Z/\
M\ U_QH_L[7_^@]'_ . :_P"- &Y16'_9VO\ _0>C_P# -?\ &C^SM?\ ^@]'
M_P" :_XT ;E%8?\ 9VO_ /0>C_\  -?\:/[.U_\ Z#T?_@&O^- &Y16'_9VO
M_P#0>C_\ U_QH_L[7_\ H/1_^ :_XT ;E%8?]G:__P!!Z/\ \ U_QH_L[7_^
M@]'_ . :_P"- &Y16'_9VO\ _0>C_P# -?\ &C^SM?\ ^@]'_P" :_XT ;E%
M8?\ 9VO_ /0>C_\  -?\:/[.U_\ Z#T?_@&O^- &Y16'_9VO_P#0>C_\ U_Q
MH_L[7_\ H/1_^ :_XT ;E%8?]G:__P!!Z/\ \ U_QH_L[7_^@]'_ . :_P"-
M &Y16'_9VO\ _0>C_P# -?\ &C^SM?\ ^@]'_P" :_XT ;E%8?\ 9VO_ /0>
MC_\  -?\:/[.U_\ Z#T?_@&O^- &Y16'_9VO_P#0>C_\ U_QH_L[7_\ H/1_
M^ :_XT ;E%8?]G:__P!!Z/\ \ U_QH_L[7_^@]'_ . :_P"- &Y16'_9VO\
M_0>C_P# -?\ &C^SM?\ ^@]'_P" :_XT ;=&*Q/[.U__ *#T?_@&O^-']G:_
M_P!!Z/\ \ U_QH VMOXT;><UB_V=K_\ T'H__ -?\:/[.U__ *#T?_@&O^-"
M V=O%+M[UB_V=K__ $'H_P#P#7_&C^SM?_Z#T?\ X!K_ (T!TL;6WTI<5B?V
M=K__ $'H_P#P#7_&C^SM?_Z#T?\ X!K_ (T ;6#BC;U]#6+_ &=K_P#T'H__
M  #7_&C^SM?_ .@]'_X!K_C0!M8.>U 4XQ6+_9VO_P#0>C_\ U_QH_L[7_\
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M (T?V=K_ /T'H_\ P#7_ !H VZ*Q/[/U_P#Z#L?_ (!K_C2?V=K_ /T'8_\
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M[/U__H/1_P#@&O\ C0!N9HS6'_9^O_\ 0=C_ / -?\:/[/U__H.Q_P#@&O\
MC0*YN9HS6'_9VO\ _0=C_P# -?\ &C^SM?\ ^@['_P" :_XT:#-S-&:P_P"S
MM?\ ^@['_P" :_XT?V=K_P#T'H__  #7_&C0#<S1FL/^S]?_ .@]'_X!K_C1
M_9^O_P#0>C_\ U_QH W:2L/^SM?_ .@]'_X!K_C2_P!G:_\ ]!Y/_ -?\: -
MNBL3^SM?_P"@\G_@&O\ C1_9VO\ _0>3_P  U_QH VZ*Q/[.U_\ Z#R?^ :_
MXT?V=K__ $'D_P# -?\ &@#<HS6'_9VO_P#0>3_P#7_&D_L[7_\ H/1_^ :_
MXT ;N:*PO[.U_P#Z#T?_ (!K_C2_V=K_ /T'D_\  -?\: -NBL3^S]?_ .@\
MG_@&O^-']GZ__P!!Y/\ P#7_ !H VZ*Q/[/U_P#Z#R?^ :_XT?V=K_\ T'D_
M\ U_QH VZ*Q/[.U__H/)_P" :_XT?V=K_P#T'D_\ U_QH W**PO[.U__ *#L
M?_@&O^-']G:__P!!V/\ \ U_QH W:2L/^SM?_P"@['_X!K_C1_9^O_\ 0>C_
M / -?\: -RBL/^S]?_Z#T?\ X!K_ (T?V?K_ /T'H_\ P#7_ !H W**P_P"S
MM?\ ^@['_P" :_XT?V?K_P#T'8__  #7_&BP&Y2UA?V?K_\ T'8__ -?\:/[
M/U__ *#L?_@&O^- &[16%_9^O_\ 0=C_ / -?\:/[/U__H.Q_P#@&O\ C0!N
MT5A?V?K_ /T'8_\ P#7_ !H_L_7_ /H.Q_\ @&O^- &[16%_9^O_ /0=C_\
M -?\:/[/U_\ Z#L?_@&O^- &Y16'_9^O_P#0=C_\ U_QH_L_7_\ H.Q_^ :_
MXT ;E+6%_9^O_P#0=C_\ U_QH_L_7_\ H.Q_^ :_XT ;E+6%_9^O_P#0=C_\
M U_QH_L_7_\ H.Q_^ :_XT ;E%8?]GZ__P!!V/\ \ U_QH_L_7_^@['_ . :
M_P"- &Y1FL/^S]?_ .@['_X!K_C2_P!GZ_\ ]!V/_P  U_QH W**P_[.U_\
MZ#T?_@&O^-']GZ__ -!Z/_P#7_&@#;HK$_L[7_\ H/1_^ :_XT?V=K__ $'H
M_P#P#7_&@#;HK$_L[7_^@]'_ . :_P"-']G:_P#]!Z/_ , U_P : -NBL3^S
MM?\ ^@]'_P" :_XT?V=K_P#T'H__  #7_&@#;Q1BL3^SM?\ ^@]'_P" :_XT
M?V=K_P#T'H__  #7_&@#;Q1BL3^SM?\ ^@]'_P" :_XT?V=K_P#T'H__  #7
M_&@#;Q1BL3^SM?\ ^@]'_P" :_XT?V=K_P#T'H__  #7_&@#;Q1BL3^SM?\
M^@]'_P" :_XT?V=K_P#T'H__  #7_&@#;Q1BL3^SM?\ ^@]'_P" :_XT?V=K
M_P#T'H__  #7_&@#;Q1BL3^SM?\ ^@]'_P" :_XT?V=K_P#T'H__  #7_&@#
M;Q1BL3^SM?\ ^@]'_P" :_XT?V=K_P#T'H__  #7_&@#;Q1BL3^SM?\ ^@]'
M_P" :_XT?V=K_P#T'H__  #7_&@#;Q[4F/:L7^SM?_Z#T?\ X!K_ (T?V=K_
M /T'H_\ P#7_ !H VL>U&/:L7^SM?_Z#T?\ X!K_ (T?V=K_ /T'H_\ P#7_
M !H VL>U&/:L7^SM?_Z#T?\ X!K_ (T?V=K_ /T'H_\ P#7_ !H VL>U&/:L
M7^SM?_Z#T?\ X!K_ (T?V=K_ /T'H_\ P#7_ !H VL>U&/:L7^SM?_Z#T?\
MX!K_ (T?V=K_ /T'H_\ P#7_ !H VL>U&/:L7^SM?_Z#T?\ X!K_ (T?V=K_
M /T'H_\ P#7_ !H VL>U&/:L7^SM?_Z#T?\ X!K_ (T?V=K_ /T'H_\ P#7_
M !H VL>U&/:L7^SM?_Z#T?\ X!K_ (T?V=K_ /T'H_\ P#7_ !H VL>U&/:L
M7^SM?_Z#T?\ X!K_ (T?V=K_ /T'H_\ P#7_ !H VL>U&/:L7^SM?_Z#T?\
MX!K_ (T?V=K_ /T'H_\ P#7_ !H VL>U&/:L7^SM?_Z#T?\ X!K_ (T?V=K_
M /T'H_\ P#7_ !H VL>U&/:L7^SM?_Z#T?\ X!K_ (T?V=K_ /T'H_\ P#7_
M !H VL>U&/:L7^SM?_Z#T?\ X!K_ (T?V=K_ /T'H_\ P#7_ !H VL>U&/:L
M7^SM?_Z#T?\ X!K_ (T?V=K_ /T'H_\ P#7_ !H VL>U&/:L7^SM?_Z#T?\
MX!K_ (T?V=K_ /T'H_\ P#7_ !H VL>U**Q/[.U__H/1_P#@&O\ C1_9VO\
M_0>C_P# -?\ &@#<HK#_ +.U_P#Z#T?_ (!K_C1_9VO_ /0>C_\  -?\: -R
MBL/^SM?_ .@]'_X!K_C1_9VO_P#0>C_\ U_QH W**P_[.U__ *#T?_@&O^-'
M]G:__P!!Z/\ \ U_QH W**P_[.U__H/1_P#@&O\ C1_9VO\ _0>C_P# -?\
M&@#<HK#_ +.U_P#Z#T?_ (!K_C1_9VO_ /0>C_\  -?\: -RBL/^SM?_ .@]
M'_X!K_C1_9VO_P#0>C_\ U_QH W**P_[.U__ *#T?_@&O^-']G:__P!!Z/\
M\ U_QH W**P_[.U__H/1_P#@&O\ C1_9VO\ _0>C_P# -?\ &@#<HK#_ +.U
M_P#Z#T?_ (!K_C1_9VO_ /0>C_\  -?\: -RBL/^SM?_ .@]'_X!K_C1_9VO
M_P#0>C_\ U_QH W**P_[.U__ *#T?_@&O^-']G:__P!!Z/\ \ U_QH W**P_
M[.U__H/1_P#@&O\ C1_9VO\ _0>C_P# -?\ &@#<HK#_ +.U_P#Z#T?_ (!K
M_C1_9VO_ /0>C_\  -?\: -RBL/^SM?_ .@]'_X!K_C1_9VO_P#0>C_\ U_Q
MH W**P_[.U__ *#T?_@&O^-']G:__P!!Z/\ \ U_QH W**P_[.U__H/1_P#@
M&O\ C1_9VO\ _0>C_P# -?\ &@#<HK#_ +.U_P#Z#T?_ (!K_C1_9VO_ /0>
MC_\  -?\: -RBL/^SM?_ .@]'_X!K_C1_9VO_P#0>C_\ U_QH W**P_[.U__
M *#T?_@&O^-']G:__P!!Z/\ \ U_QH W**P_[.U__H/1_P#@&O\ C1_9^O\
M_0>C_P# -?\ &@#;R*6L_3[>_@#?;;];IC]W$(3'Y5>3..3D^N* '4444 )2
M4M)0#V.=\;?\BZ__ %T7^=>9UZ9XV_Y%U_\ KHO\Z\SK.1Y.-_B!1114G&+Q
M]:3@#D\T?3KGFM7038C4A]N91$>['BG%7*BN:21E@$KFD!!KO9_"FEZD#+8W
M(!/0*>*P;WPCJEKDHGG*/[@S0XV-JF&E'WEJ8'..:*?+#)"Y1T9&'4,*92,&
MFMPHHHH8N@=J]#\!?\@J;_KK_05YYVKT/P%_R"IO^NO]!5Q.O!_&=;1115GK
MAUHQ110 F*6BB@ HHHH **** "BBB@ HHHH ***,T %%)D4M !129%&10 M%
M)D49% "T4F11D4 +129%&10 M%)D49% "T44F10 M%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !111F@ HI,BC(H 6BBB@ HHHH **3(I: "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMI%_%/8:C/Y88;XY3G(_*NP'7K0 ZBBB@ HHHH **** "BBB@ HHHH ****
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MPQVNCS6\>\"4S]E[XX%=D.#1:PMAU%%% PHHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,9O45@_\)5;?] _5/_ 1J/\ A*K;_H'ZI_X"-0!O<8Q16#_PE5M_T#]4_P#
M1J7_ (2JV_Z!^J?^ C4 ;F![TM8/_"56W_0/U3_P$:C_ (2JV_Z!^J?^ C4
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M]N]J7K6=INJ1ZDK&."ZAV'D3Q%"?IFKZG(X!'UH =1110 E%%)0#V.=\;?\
M(NO_ -=%_G7F=>F>-O\ D77_ .NB_P Z\SK.1Y.-_B!1114G&7]*TQ]4NQ &
M"CKFNC'@24\BY'Y5R5O<2VLH>%RK^M:,.L:O<2K%#<2%V.  *N)O2=-:25SH
MX_".H0#$6HR >FZJ]YX2NO*>2:^>0*I;#'/2K4&B:_+&&FOPI[#/_P!:L[5K
M37]/A9Y+@RQ$8.WGBAJQV."Y;I6.6(VL>^*2COR<Y[T5!YK5F%%%%#%T#M7H
M?@+_ )!4W_77^@KSSM7H?@+_ )!4W_77^@JXG7@_C.MHHHJSUPHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,T +244
M4 %%%+Q2 2EI**8"T4E%*X!1113#42BES1FE=!J)11D>M&1ZT<R"S%HHR*,B
MC?8-MPHHH-,7FA:***!A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 E)2T4 ]CG/&W_(NO_UT7^=>9UZ9XV_Y%U_^NB_SKS.LY'DXW^(%%%%2
M<8'I]*Z3P9&CZK([@91<J*YOO5[2M1?3;])T4MSRH[BKB:4I<LS8UKQ'JB:E
M+#%,T*(W&!6SX?U"XU;3+J.]R^U3\[#K4QO_  YJ(\R\CB$G4B0'(J#4?$&G
MV6GR0Z9'NW#&4' S0ST+>]S.6G8X:=0DTH7E Y J*E9MS[C]YN325!YLW[P4
M444$AVKT/P%_R"IO^NO]!7GG:O0_ 7_(*F_ZZ_T%7$Z\'\9UM%%%6>N%%%%
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M%9OA/5=?O?%#6MQJ4ES;P[@Y'W3BA:@]#U"BDYYH[4 +124M !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E)2TE
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCV4.P_K%3N8Y\/6A[O\ ]]4P^&;,]=__ 'U6W14.A3?0?UFK_,8)\*V1[O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]E:U_P!#$W_@(E']E:U_T,3?^ B5N44 8?\ 96M?]#$W_@(E']E:U_T,3?\
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M_H8F_P# 1*/[*UK_ *&)O_ 1*V\T9H Q/[*UK_H8F_\  1*/[*UK_H8F_P#
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MAB;_ ,!$K;HH Q/[*UK_ *&)O_ 1*/[*UK_H8F_\!$K;HH Q/[*UK_H8F_\
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M*UK_ *&)O_ 1*/[*UK_H8F_\!$K<HH P_P"RM:_Z&)O_  $2C^RM:_Z&)O\
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M)O\ P$2MRB@##_LK6O\ H8F_\!$H_LK6O^AB;_P$2MRB@##_ +*UK_H8F_\
M 1*/[*UK_H8F_P# 1*W** ,/^RM:_P"AB;_P$2C^RM:_Z&)O_ 1*W** ,/\
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MZ_I=U?-907B/<J3N0 Y&/PI@:E%,8\'MQUK.M->TR^NFM+6\26=/O( >/TH
MU**;G@?I37=(D:1R%51\Q/84 245BVWBC1KR[6UM[^.29NB@'G]*?J'B32-*
MN/(OKZ."7&=I![_A0!KT5SW_  FWAP==5A]_E;_"M:TOK6\M1<V\RO"3P_0?
MK0!;HK(?Q+HT=\MDVH1"Y8X"<G/Z8K5!!&1T- "TM%% !1110 4444 %%%%
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M9U)1[:0?5Z?8TO[9G_NK^=)_;,_]U?SK-I*/;2']6I]C2_MJ?^ZOYT?VU/\
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M[XB%P!:73;9!P&/>NI!X]J^EHUH5HJ<3YJM1E1GR2'44@I:W,@HHHH ****
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M\K9AV;P2*>T$Q?:/-/'-AI5K>VNEZ980PW$C#>8QR0<8KN[;0(3X<@TUWD1
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M+,>H[4XQ<GRI$RE&*NQ;.">>X5+;/F9X;TKU/3XYHK&))VW2 <FL[0]#BTV
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M?@+_ )!4W_77^@JXG7@_C.MHHHJSUPHHI <T +129I: "BBB@ HHHH ****
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M_P!^A_A0!YM_PMFY_P"@3#_W]/\ A1_PMFY_Z!,/_?T_X5Z3_9]E_P ^=O\
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M *!,/_?T_P"%'_"V;G_H$P_]_3_A7I/]GV7_ #YV_P#WZ'^%']GV7_/G;_\
M?H?X4 >;?\+9N?\ H$P_]_3_ (4?\+9N?^@3#_W]/^%>D_V?9?\ /G;_ /?H
M?X4?V?9?\^=O_P!^A_A0!YM_PMFY_P"@3#_W]/\ A1_PMFY_Z!,/_?T_X5Z3
M_9]E_P ^=O\ ]^A_A1_9]E_SYV__ 'Z'^% 'FW_"V;G_ *!,/_?T_P"%'_"V
M;G_H$P_]_3_A7I/]GV7_ #YV_P#WZ'^%']GV7_/G;_\ ?H?X4 >;?\+9N?\
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M7_/G;_\ ?H?X4 >;?\+9N?\ H$P_]_3_ (4?\+9N?^@3#_W]/^%>D_V?9?\
M/G;_ /?H?X4?V?9?\^=O_P!^A_A0!YM_PMFY_P"@3#_W]/\ A1_PMFY_Z!,/
M_?T_X5Z3_9]E_P ^=O\ ]^A_A1_9]E_SYV__ 'Z'^% 'FW_"V;G_ *!,/_?T
M_P"%'_"V;G_H$P_]_3_A7I/]GV7_ #YV_P#WZ'^%']GV7_/G;_\ ?H?X4 >;
M?\+9N?\ H$P_]_3_ (4?\+9N?^@3#_W]/^%>D_V?9?\ /G;_ /?H?X4?V?9?
M\^=O_P!^A_A0!YM_PMFY_P"@3#_W]/\ A1_PMFY_Z!,/_?T_X5Z3_9]E_P ^
M=O\ ]^A_A1_9]E_SYV__ 'Z'^% 'FW_"V;G_ *!,/_?T_P"%'_"V;G_H$P_]
M_3_A7I/]GV7_ #YV_P#WZ'^%']GV7_/G;_\ ?H?X4 >;?\+9N?\ H$P_]_3_
M (4?\+9N?^@3#_W]/^%>D_V?9?\ /G;_ /?H?X4?V?9?\^=O_P!^A_A0!YM_
MPMFY_P"@3#_W]/\ A1_PMFY_Z!,/_?T_X5Z3_9]E_P ^=O\ ]^A_A1_9]E_S
MYV__ 'Z'^% 'FW_"V;G_ *!,/_?T_P"%'_"V;G_H$P_]_3_A7I/]GV7_ #YV
M_P#WZ'^%']GV7_/G;_\ ?H?X4 >;?\+9N?\ H$P_]_3_ (4?\+9N?^@3#_W]
M/^%>D_V?9?\ /G;_ /?H?X4?V?9?\^=O_P!^A_A0!YM_PMFY_P"@3#_W]/\
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M_P!^A_A0!YM_PMFY_P"@3#_W]/\ A1_PMFY_Z!,/_?T_X5Z3_9]E_P ^=O\
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M *!,/_?T_P"%'_"V;G_H$P_]_3_A7I/]GV7_ #YV_P#WZ'^%']GV7_/G;_\
M?H?X4 >;?\+9N?\ H$P_]_3_ (4?\+9N?^@3#_W]/^%>D_V?9?\ /G;_ /?H
M?X4?V?9?\^=O_P!^A_A0!YM_PMFY_P"@3#_W]/\ A1_PMFY_Z!,/_?T_X5Z3
M_9]E_P ^=O\ ]^A_A1_9]E_SYV__ 'Z'^% 'FW_"V;G_ *!,/_?T_P"%'_"V
M;G_H$P_]_3_A7I/]GV7_ #YV_P#WZ'^%']GV7_/G;_\ ?H?X4 >;?\+9N?\
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M7_/G;_\ ?H?X4 >;?\+9N?\ H$P_]_3_ (4?\+9N?^@3#_W]/^%>D_V?9?\
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M/^%>D_V?9?\ /G;_ /?H?X4?V?9?\^=O_P!^A_A0!YM_PMFY_P"@3#_W]/\
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M_P!^A_A0!YM_PMFY_P"@3#_W]/\ A1_PMFY_Z!,/_?T_X5Z3_9]E_P ^=O\
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M *!,/_?T_P"%'_"V;G_H$P_]_3_A7I/]GV7_ #YV_P#WZ'^%']GV7_/G;_\
M?H?X4 >;?\+9N?\ H$P_]_3_ (4?\+9N?^@3#_W]/^%>D_V?9?\ /G;_ /?H
M?X4?V?9?\^=O_P!^A_A0!YM_PMFY_P"@3#_W]/\ A1_PMFY_Z!,/_?T_X5Z3
M_9]E_P ^=O\ ]^A_A1_9]E_SYV__ 'Z'^% 'FW_"V;G_ *!,/_?T_P"%'_"V
M;G_H$P_]_3_A7I/]GV7_ #YV_P#WZ'^%']GV7_/G;_\ ?H?X4 >;?\+9N?\
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M7_/G;_\ ?H?X4 >;?\+9N?\ H$P_]_3_ (4?\+9N?^@3#_W]/^%>D_V?9?\
M/G;_ /?H?X4?V?9?\^=O_P!^A_A0!YM_PMFY_P"@3#_W]/\ A1_PMFY_Z!,/
M_?T_X5Z3_9]E_P ^=O\ ]^A_A1_9]E_SYV__ 'Z'^% 'FW_"V;G_ *!,/_?T
M_P"%'_"V;G_H$P_]_3_A7I/]GV7_ #YV_P#WZ'^%']GV7_/G;_\ ?H?X4 >;
M?\+9N?\ H$P_]_3_ (4?\+9N?^@3#_W]/^%>D_V?9?\ /G;_ /?H?X4?V?9?
M\^=O_P!^A_A0!YM_PMFY_P"@3#_W]/\ A1_PMFY_Z!,/_?T_X5Z3_9]E_P ^
M=O\ ]^A_A1_9]E_SYV__ 'Z'^% 'FW_"V;G_ *!,/_?T_P"%'_"V;G_H$P_]
M_3_A7I/]GV7_ #YV_P#WZ'^%']GV7_/G;_\ ?H?X4 >;?\+9N?\ H$P_]_3_
M (4?\+9N?^@3#_W]/^%>D_V?9?\ /G;_ /?H?X4?V?9?\^=O_P!^A_A0!YM_
MPMFY_P"@3#_W]/\ A2'XLW./^03#_P!_C_A7I7]GV7_/G;_]^A_A1_9]E_SY
MV_\ WZ'^% '/>#O%4GB6.Y+VJP>21T<MG.:ZD=*CBMH( ?)ACCSUV*!FI: "
MBBB@!*2EI* >QSOC;_D77_ZZ+_.O,Z],\;?\BZ__ %T7^=>9UG(\G&_Q HHH
MJ3C#OG/2M/0[VWL=1$URF]!UXK,'IZU?T?3AJE_Y#2;!ZTXZ%03YD=C_ ,)5
MHF.+8_\ ?(JW)>6-[H\US9P(_P I4C:,CBLL>!H3_P OI_3_  K3M=.M/#VF
M7&Z<.74_>-4SU(1DW[R5CS9C\Q/OC%)4DSJ\TC*=JEC@5'4'F324K(****"&
M':O0_ 7_ ""IO^NO]!7GG:O0_ 7_ ""IO^NO]!5Q.O!_&=;1115GKA1110 4
M444 %%%% !1110 4444 %%%% !1110 44G;BF@CD \TKZ@/HIM&1G QFF ZD
MR*3(]:0YH ?FBF9'4=Z=0 M%-I: %HH[44 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %)D4'ZTW/&: 'T4S/'>G>
ME "T4=J2@!:*.U)2 6BFMP.N!3%E23.QU;'7!S3N!+1422QN<(ZMCKM8&GD]
M\C% #J,TW/<T4 .S1FF'FC.!TQ]:!#Z*0=*#2;LAAD"ES47FQE]GF+O'50>:
M=R?44P'T4WIV_&EI +12=Z6F 4444 %%)12N M%)13 ,T9%(:0'YL8/UH ?1
M110 444E "T444 %%%% !1156>1E?AL4F[#2NRU1FLXSR9^_3?/D_OU/,:>R
M9IYHS67]HE_YZ4AN)?\ GI1[1![&1J9I:R/M,W_/2D^TS?\ /0_A2]HA^PD;
M%%8OVJ?_ )Z-33=3_P#/1J7M45]7D;E%87VR<?\ +1J3[;/_ ,]&H]J@^K3-
MZBN?^VW'_/1J0WMQ_P ]6H]JA_59G09I:YPWUS_SV:F_;KK_ )[/2]LBOJD^
MYTM&:YDW]U_SV>F_VA=_\]WI>WB'U.?<ZBC-<M_:%W_SW>D_M&[_ .>[T>WB
M/ZE4[G549KD_[1N_^>[TAU&\_P">[TGB8C^HU.YUM%<>=2O?^?AZ0ZG>X_X^
M&J'BX(?U"IW1V&:,CUKB_P"UK[M</34U+4)955)W+,<4EC(/H/\ L^IU:.VR
M*,CUKC;F\U:U&99I!GIC%.276Y4#J\NTC/:FL4F[*+(^IM*_,K'89%&17!OJ
MNHJQ4W$H93R.*DDN]9CA\]Y91&>0W%1]>CJ[/0MX"2M[RU.XR*,BN'AN->N(
M]\,LI7L>*<[^(E7<6FQ^%-8Q-746)X%IV<T=MD49KSI]9U:-BK7$RD>N*C_M
MW5#_ ,ODOZ5B\TI+1IFRRFJU=-'I.1ZT9%><1:KK5R^R&ZF<_P"SBK#OXG1,
MLUP .K9%-9E%JZ@S.67N+M*:._W#.*,BO+V\0:NI93>3!@<$'%6X+GQ)=(&A
MEG*^HQS4PS2,U[L67+*ZD%S2DCT7(HR*\UN-3U^R.)[B9#_MX_I1;ZCX@N_^
M/>>X<>HQBB.9Q;Y>5W%_9L^7FYE8]*) ZFC(KSJ:X\301[Y7N47U^6JD>NZQ
M(P1+R4L>P I/-8*7*XNX0RR<U>,D>H9%&17GPD\4E=P:?;V(Q5&76]:@<I+>
M3(P[$"G+,XP5Y0:00RV<W:,D>GY%&1ZUY:?$.K9Q]NE/Y5:TWQ1?6]TK74LD
ML1/(..*F&;TI22M8J>4UHPYKIGI&X4N:JVEU#>0K-"P8,.HJS]:]2,U)71YC
MBT[,6BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 E)2TE /8YWQM_R+K_\
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MXQU[2-3B@UZRB5)2 IB]_?)HCK$):,]&HID4BRQ+(IRK#(I] !1110 4444
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M12>0U=!I_P#R+;?[I_E7%'I^( K#%5*D.1QV-\-2A4<^9=3J]<LX[S35O(U
M<#)Q^M<<0 :[I_W/ADASC,?]*X; !'T-<F8J"FG'=G1ES;4HO9%JUU6YL8FA
M@(!8Y+=Q72^%=2N;UITN'+@<Y:N0CB>:41QC+L>*[:SA@\/:2TLI'F$9]S6F
M!E53<IOW43F"I<J45[S,B_L(Y_%$4*+@,=S"I_$FJSZ=+#;6K&, 9.VJ>B7C
M7GB+SY3R_P!WVJ/QB"-74^L8_G3G/EH>TIZ79FJ;=:%*IV-N8?VMX9\V4;I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCE3^ZZ@BFV]A:6G_ ![6T,7KL0"A:(;U9):Q>1:Q1?W%"U-249I +129HS0
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MNTF<[S&"?SJ1+*VCF,R01+(1@L% /YT1T^X):GFU@,?%&XY[\<9]*2[&?BM
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M!T2T]&_[ZI/["M,\A_\ ONH>%D5]>A8Y1AQ4]@P2]A+$ *P.<UTG]@67H_\
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M_P"_@H_X2;0_^@K:?]_!7FG_  J_7?\ GI:_]]G_  H_X5?KO_/2U_[[/^%
M'I?_  D^A_\ 05M/^_@H_P"$GT/_ *"MI_W\%>:?\*OUW_GI:_\ ?9_PH_X5
M?KO_ #TM?^^S_A0!Z7_PDVA_]!6T_P"_@H_X2;0_^@K:?]_!7FG_  J_7?\
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M^@K:?]_!7FG_  J_7?\ GI:_]]G_  H_X5?KO_/2U_[[/^% 'I?_  DVA_\
M05M/^_@H_P"$FT/_ *"MI_W\%>:?\*OUW_GI:_\ ?9_PH_X5?KO_ #TM?^^S
M_A0!Z7_PDVA_]!6T_P"_@H_X2;0_^@K:?]_!7FG_  J_7?\ GI:_]]G_  H_
MX5?KO_/2U_[[/^% 'I?_  DVA_\ 05M/^_@H_P"$FT/_ *"MI_W\%>:?\*OU
MW_GI:_\ ?9_PH_X5?KO_ #TM?^^S_A0!Z7_PDVA_]!6T_P"_@H_X2;0_^@K:
M?]_!7FG_  J_7?\ GI:_]]G_  H_X5?KO_/2U_[[/^% 'I?_  DVA_\ 05M/
M^_@H_P"$FT/_ *"MI_W\%>:?\*OUW_GI:_\ ?9_PH_X5?KO_ #TM?^^S_A0!
MZ7_PDVA_]!6T_P"_@H_X2;0_^@K:?]_!7FG_  J_7?\ GI:_]]G_  H_X5?K
MO_/2U_[[/^% 'I?_  DVA_\ 05M/^_@H_P"$FT/'_(5M/^_@KS3_ (5?KO\
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M1_PJ_7?^>EK_ -]G_"@#TO\ X2;0_P#H*VG_ '\%+_PDVA_]!6T_[^"O,_\
MA5^N_P#/2U_[[/\ A1_PJ_7?^>EK_P!]G_"@#TO_ (2;0_\ H*VG_?P4?\)/
MH?\ T%;3_OX*\T_X5?KO_/2U_P"^S_A1_P *OUW_ )Z6O_?9_P * /2_^$FT
M/_H*VG_?P4?\)/H?_05M/^_@KS3_ (5?KO\ STM?^^S_ (4?\*OUW_GI:_\
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MAZ7_ ,)-H?\ T%;3_OX*/^$FT/\ Z"MI_P!_!7FG_"K]=_YZ6O\ WV?\*/\
MA5^N_P#/2U_[[/\ A0!Z7_PDVA_]!6T_[^"C_A)M#_Z"MI_W\%>:?\*OUW_G
MI:_]]G_"C_A5^N_\]+7_ +[/^% 'I?\ PD^A_P#05M/^_@H_X2;0_P#H*VG_
M '\%>:?\*OUW_GI:_P#?9_PH_P"%7Z[_ ,]+7_OL_P"% ,]*_P"$FT/_ *"M
MI_W\%'_"3Z'_ -!6T_[^"O-?^%7Z[_STM?\ OL_X4?\ "K]=_P">EK_WV?\
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MS_GI:_\ ?9_PI7"QZ7_PDVA_]!6T_P"_@H_X2;0_^@K:?]_!7FG_  J_7/\
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MM?\ OL_X4?\ "L-<_P">EK_WV?\ "BP:]3TS_A)M#_Z"MI_W\%'_  DVA_\
M05M/^_@KS/\ X5?KG_/2U_[[/^%'_"L-<_YZ6O\ WV?\* Z'IG_"3:'_ -!6
MT_[^"D_X2;0\?\A6T_[^"O-/^%7ZY_STM?\ OL_X4?\ "K]<_P">EK_WV?\
M"CT!:JS/3/\ A)M#_P"@K:?]_!1_PDVA_P#05M/^_@KS3_A5^N_\]+7_ +[/
M^%'_  J_7?\ GI:_]]G_  H ]+_X2;0_^@K:?]_!1_PDVA_]!6T_[^"O-/\
MA5^N_P#/2U_[[/\ A1_PJ_7?^>EK_P!]G_"@#TO_ (2;0_\ H*VG_?P4?\)-
MH?\ T%;3_OX*\T_X5?KO_/2U_P"^S_A1_P *OUW_ )Z6O_?9_P * /2_^$FT
M/_H*VG_?P4?\)-H?_05M/^_@KS3_ (5?KO\ STM?^^S_ (4?\*OUW_GI:_\
M?9_PH ]+_P"$FT/_ *"MI_W\%'_"3:'_ -!6T_[^"O-/^%7Z[_STM?\ OL_X
M4?\ "K]=_P">EK_WV?\ "@#TO_A)M#_Z"MI_W\%'_"3:'_T%;3_OX*\T_P"%
M7Z[_ ,]+7_OL_P"%'_"K]=_YZ6O_ 'V?\* /2_\ A)M#_P"@K:?]_!1_PDVA
M_P#05M/^_@KS3_A5^N_\]+7_ +[/^%'_  J_7?\ GI:_]]G_  H ]+_X2;0_
M^@K:?]_!1_PDVA_]!6T_[^"O-/\ A5^N_P#/2U_[[/\ A1_PJ_7?^>EK_P!]
MG_"@#TO_ (2;0_\ H*VG_?P4?\)-H?\ T%;3_OX*\T_X5?KO_/2U_P"^S_A1
M_P *OUW_ )Z6O_?9_P * /2_^$FT/_H*VG_?P4?\)-H?_05M/^_@KS3_ (5?
MKO\ STM?^^S_ (4?\*OUW_GI:_\ ?9_PH ]+_P"$FT/_ *"MI_W\%'_"3:'_
M -!6T_[^"O-/^%7Z[_STM?\ OL_X4?\ "K]=_P">EK_WV?\ "@#TO_A)M#_Z
M"MI_W\%'_"3:'_T%;3_OX*\T_P"%7Z[_ ,]+7_OL_P"%'_"K]=_YZ6O_ 'V?
M\* /2_\ A)M#_P"@K:?]_!1_PDVA_P#05M/^_@KS3_A5^N_\]+7_ +[/^%'_
M  J_7?\ GI:_]]G_  H ]+_X2;0_^@K:?]_!1_PDVA_]!6T_[^"O-/\ A5^N
M_P#/2U_[[/\ A1_PJ_7?^>EK_P!]G_"@#TO_ (2;0_\ H*VG_?P4?\)-H?\
MT%;3_OX*\T_X5?KO_/2U_P"^S_A1_P *OUW_ )Z6O_?9_P * /2_^$FT/_H*
MVG_?P4?\)-H?_05M/^_@KS3_ (5?KO\ STM?^^S_ (4?\*OUW_GI:_\ ?9_P
MH ]+_P"$FT/_ *"MI_W\%'_"3:'_ -!6T_[^"O-/^%7Z[_STM?\ OL_X4?\
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MOUW_ )Z6O_?9_P * /2_^$FT/_H*VG_?P4?\)-H?_05M/^_@KS3_ (5?KO\
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M_"3:'_T%;3_OX*\T_P"%7Z[_ ,]+7_OL_P"%'_"K]=_YZ6O_ 'V?\* /2_\
MA)M#_P"@K:?]_!1_PDVA_P#05M/^_@KS3_A5^N_\]+7_ +[/^%'_  J_7?\
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M]]G_  H ]+_X2;0_^@K:?]_!1_PDVA_]!6T_[^"O-/\ A5^N_P#/2U_[[/\
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M!6T_[^"O-/\ A5^N_P#/2U_[[/\ A1_PJ_7?^>EK_P!]G_"@#TO_ (2;0_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI5X'FJUE%:1PYLUC$;DMF/H2:LCK5/<2'4444AA1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6S>?] NW_P"_A_PH_P"%LWG_ $"[?_OX?\* /4\&@9[C%>6?\+9O/^@7;_\
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M_A;-Y_T"[?\ [^'_  H ]5HKRK_A;-Y_T"[?_OX?\*/^%LWG_0+M_P#OX?\
M"@#U6BO*O^%LWG_0+M_^_A_PH_X6S>?] NW_ ._A_P * /5/?%'Z5Y7_ ,+9
MO/\ H%V__?P_X4?\+9O/^@7;_P#?P_X4 >I\_7WI>>U>5_\ "V;S_H%V_P#W
M\/\ A1_PMF\_Z!=O_P!_#_A0!ZGBEZUY7_PMF\_Z!=O_ -_#_A1_PMF\_P"@
M7;_]_#_A0!ZGSZ4<CIZ]Z\L_X6S>?] NW_[^'_"C_A;-Y_T"[?\ [^'_  H
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MV_\ W\-'_"V+S_H%V_\ W\-,-#U2DKRS_A;%Y_T"[?\ [^&C_A;%Y_T"[?\
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M_A;-Y_T"[?\ [^'_  H_X6S>?] NW_[^'_"@#U6BO*O^%LWG_0+M_P#OX?\
M"C_A;-Y_T"[?_OX?\* /5:*\J_X6S>?] NW_ ._A_P */^%LWG_0+M_^_A_P
MH ]5HKRK_A;-Y_T"[?\ [^'_  H_X6S>?] NW_[^'_"@#U6BO*O^%LWG_0+M
M_P#OX?\ "C_A;-Y_T"[?_OX?\* /5:*\J_X6S>?] NW_ ._A_P */^%LWG_0
M+M_^_A_PH ]5HKRK_A;-Y_T"[?\ [^'_  H_X6S>?] NW_[^'_"@#U6BO*O^
M%LWG_0+M_P#OX?\ "C_A;-Y_T"[?_OX?\* /5:*\J_X6S>?] NW_ ._A_P *
M/^%LWG_0+M_^_A_PH ]5HKRK_A;-Y_T"[?\ [^'_  H_X6S>?] NW_[^'_"@
M#U6BO*O^%LWG_0+M_P#OX?\ "C_A;-Y_T"[?_OX?\* /5:*\J_X6S>?] NW_
M ._A_P */^%LWG_0+M_^_A_PH ]5HKRK_A;-Y_T"[?\ [^'_  H_X6S>?] N
MW_[^'_"@#U6BO*O^%LWG_0+M_P#OX?\ "C_A;-Y_T"[?_OX?\* /5:*\J_X6
MS>?] NW_ ._A_P */^%LWG_0+M_^_A_PH ]5HKRK_A;-Y_T"[?\ [^'_  H_
MX6S>?] NW_[^'_"@#U6BO*O^%LWG_0+M_P#OX?\ "C_A;-Y_T"[?_OX?\* /
M5:*\J_X6S>?] NW_ ._A_P */^%LWG_0+M_^_A_PH ]5HKRK_A;-Y_T"[?\
M[^'_  H_X6S>?] NW_[^'_"@#U6BO*O^%LWG_0+M_P#OX?\ "C_A;-Y_T"[?
M_OX?\* /5:*\J_X6S>?] NW_ ._A_P */^%LWG_0+M_^_A_PH ]5HKRK_A;-
MY_T"[?\ [^'_  H_X6S>?] NW_[^'_"@#U6BO*O^%LWG_0+M_P#OX?\ "C_A
M;-Y_T"[?_OX?\* /5:*\J_X6S>?] NW_ ._A_P */^%LWG_0+M_^_A_PH ]5
MHKRK_A;-Y_T"[?\ [^'_  H_X6S>?] NW_[^'_"@#U6BO*O^%LWG_0+M_P#O
MX?\ "C_A;-Y_T"[?_OX?\* /5:*\J_X6S>?] NW_ ._A_P */^%LWG_0+M_^
M_A_PH ]5HKRK_A;-Y_T"[?\ [^'_  H_X6S>?] NW_[^'_"@#U6BO*O^%LWG
M_0+M_P#OX?\ "C_A;-Y_T"[?_OX?\* /5:*\J_X6S>?] NW_ ._A_P */^%L
MWG_0+M_^_A_PH ]5HKRK_A;-Y_T"[?\ [^'_  H_X6S>?] NW_[^'_"@#U6B
MO*O^%LWG_0+M_P#OX?\ "C_A;-Y_T"[?_OX?\* /5:*\J_X6S>?] NW_ ._A
M_P */^%LWG_0+M_^_A_PH ]5HKRK_A;-Y_T"[?\ [^'_  H_X6S>?] NW_[^
M'_"@#U6BO*O^%LWG_0+M_P#OX?\ "C_A;-Y_T"[?_OX?\* /5:*\J_X6S>?]
M NW_ ._A_P */^%LWG_0+M_^_A_PH ]5HKRK_A;-Y_T"[?\ [^'_  H_X6S>
M?] NW_[^'_"@#U6BO*O^%LWG_0+M_P#OX?\ "C_A;-Y_T"[?_OX?\* /5:*\
MJ_X6S>?] NW_ ._A_P */^%LWG_0+M_^_A_PH ]5HKRK_A;-Y_T"[?\ [^'_
M  H_X6S>?] NW_[^'_"@#U6BO*O^%LWG_0+M_P#OX?\ "C_A;-Y_T"[?_OX?
M\* /5:*\J_X6S>?] NW_ ._A_P */^%LWG_0+M_^_A_PH ]5HKRK_A;-Y_T"
M[?\ [^'_  H_X6S>?] NW_[^'_"@#U6BO*O^%LWG_0+M_P#OX?\ "C_A;-Y_
MT"[?_OX?\* /5:*\J_X6S>?] NW_ ._A_P */^%LWG_0+M_^_A_PH ]5HKRK
M_A;-Y_T"[?\ [^'_  H_X6S>?] NW_[^'_"@#U6BO*O^%LWG_0+M_P#OX?\
M"C_A;-Y_T"[?_OX?\* /5:*\J_X6S>?] NW_ ._A_P */^%LWG_0+M_^_A_P
MH ]5HKRK_A;-Y_T"[?\ [^'_  H_X6S>?] NW_[^&@#U6BO,]/\ B==WVI6U
MI_9T 6:159A(<J":]+6@!:*** $HHI* >QSOC;_D77_ZZ+_.O,Z],\;?\BZ_
M_71?YUYG6<CR<;_$"BBBI.,,<?C6GHNH0Z=J GGB+H.H K,[8K2T731JVH+
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M:_\ /M#_ -^Q1]BM?^?:'_OV*GHH @^Q6O\ S[0_]^Q1]BM?^?:'_OV*GHH
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M8W DQVQ@_D: -.BLW4M>T[21F]N%CXSCJ?RJOIOBS1M6F\JTNPS^C K_ #H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG"O(,1H"VQ?>O55& O)XI)OE!_$24444QA1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.R\DKM*YPS.9&+'JQS24K8#-CD X!I*@\R6["BBBABZ!VKT/P%_R"IO^NO\
M05YYVKT/P%_R"IO^NO\ 05<3KP?QG6T4459ZX4F:#TJM>WUKI\!GO)T@B! W
MN<#- %JBL0>+O#Q'&L6A_P"VE'_"7>'_ /H+VG_?R@#;HK$_X2[P_P#]!>T_
M[^4?\)=X?_Z"]I_W\H VZ2L7_A+O#_\ T%[3_OY1_P )=X?_ .@O:?\ ?R@#
M:HQ6+_PEWA__ *"]I_W\H_X2[P__ -!>T_[^4 ;!4YSGFC!K'_X2[P__ -!>
MT_[^4?\ "7>'_P#H+VG_ '\HZW V ,4N*QO^$N\/_P#07M/^_E'_  EWA_\
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M"]I_W\H_X2[P_P#]!>T_[^4 ;=%8G_"7>'_^@O:?]_*/^$N\/_\ 07M/^_E
M&W2$ GH*Q?\ A+O#_P#T%[3_ +^4?\)=X?\ ^@O:?]_* -G:OH*3RU]!6/\
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MRH7,S4^S0_\ /*/_ +Y%'V:+/^J3'^Z*R_\ A+O#_P#T%[3_ +^4?\)=X?\
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MM/\ OY1_PEWA_P#Z"]I_W\H VZ*Q/^$N\/\ _07M/^_E'_"7>'_^@O:?]_*
M-NBL3_A+O#__ $%[3_OY1_PEWA__ *"]I_W\H VZ*Q/^$N\/_P#07M/^_E'_
M  EWA_\ Z"]I_P!_* -NBL3_ (2[P_\ ]!>T_P"_E'_"7>'_ /H+VG_?R@#;
MHK$_X2[P_P#]!>T_[^4?\)=X?_Z"]I_W\H VZ*Q/^$N\/_\ 07M/^_E'_"7>
M'_\ H+VG_?R@#;HK$_X2[P__ -!>T_[^4?\ "7>'_P#H+VG_ '\H VZ*Q/\
MA+O#_P#T%[3_ +^4?\)=X?\ ^@O:?]_* -NBL3_A+O#_ /T%[3_OY1_PEWA_
M_H+VG_?R@#;HK$_X2[P__P!!>T_[^4?\)=X?_P"@O:?]_* -NBL3_A+O#_\
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MI_W\H VZ*Q/^$N\/_P#07M/^_E'_  EWA_\ Z"]I_P!_* -NBL3_ (2[P_\
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M /H+VG_?R@#;HK$_X2[P_P#]!>T_[^4?\)=X?_Z"]I_W\H VZ*Q/^$N\/_\
M07M/^_E'_"7>'_\ H+VG_?R@#;HK$_X2[P__ -!>T_[^4?\ "7>'_P#H+VG_
M '\H VZ*Q/\ A+O#_P#T%[3_ +^4?\)=X?\ ^@O:?]_* -NBL3_A+O#_ /T%
M[3_OY1_PEWA__H+VG_?R@#;HK$_X2[P__P!!>T_[^4?\)=X?_P"@O:?]_* -
MNBL3_A+O#_\ T%[3_OY1_P )=X?_ .@O:?\ ?R@#;HK$_P"$N\/_ /07M/\
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M<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\
M^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1
M^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H
M)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_
M /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/X
MT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\
MZ"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT
M_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#
M^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_
M .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J
M-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>
M@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3
M_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_P
MJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+
M7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*H
MT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?
M\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?
M"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"
MJ-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM
M'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\
MWPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_
MPJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\
M+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_
M -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >?
M?\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\
M?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<
M_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- '
MGW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_
M 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)
M7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0
M!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S
M_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z
M"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'X
MT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E
M<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\
M^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1
M^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H
M)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_
M /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/X
MT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\
MZ"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT
M_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#
M^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_
M .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J
M-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>
M@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3
M_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_P
MJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+
M7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*H
MT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?
M\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?
M"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"
MJ-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM
M'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\
MWPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_
MPJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\
M+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_
M -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >?
M?\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\
M?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<
M_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- '
MGW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_
M 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)
M7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0
M!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S
M_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z
M"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'X
MT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E
M<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\
M^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1
M^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H
M)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_
M /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/X
MT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\
MZ"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT
M_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#
M^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_
M .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J
M-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>
M@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3
M_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_P
MJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+
M7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*H
MT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"J-/_ .@E<_\ ?"T?
M\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM'_"J-/\ ^@E<_P#?
M"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\ WPM>@_C1^- 'GW_"
MJ-/_ .@E<_\ ?"T?\*HT_P#Z"5S_ -\+7H/XT?C0!Y]_PJC3_P#H)7/_ 'PM
M'_"J-/\ ^@E<_P#?"UZ#^-'XT >??\*HT_\ Z"5S_P!\+1_PJC3_ /H)7/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ_:8/^>T?_?0I/M-O_SVC_[Z%>1O]*9QZ5B\[_N%_P!BO^<]@%S"QP)4.?\
M:%2<$5X]%*T,JNAPRG(KT#P_KZ7\0BF;;,.,'O77A<SCB)<C5F<F*RV=!<R=
MSH?K10#FCZUZGD>:.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** $I*6B@'L<YXV_Y%U_^NB_SKS.O3/&W_(NO_UT7^=>9UG(\G&_Q HH
MHJ3C#V]:GM+J2RG2>!L.IXJ#DCCKTK9\.:6FJ:CY<G^KC&6 /6JB5&*E)6-V
MV\=IY2BXM6W <L&ZU2U;QC+?0/#;PF,'KDYK?N)O#FGR&WEBAW+U&P&JEQJ?
MAIK:01PH'*G:?*]J<CT)J=K<QP>3G)[]:2E?!9B!D$\=J2H/.;UU"BBBABZ!
MVKT/P%_R"IO^NO\ 05YYVKT/P%_R"IO^NO\ 05<3KP?QG6T4459ZX4444 %%
M%% !1110 4444 %%%% !1110 4E+1WH 2FM3C33T%*6PT>46UJ+SX@W]NV#Y
MD<H'Y&M7X?W?V*]U#1Y3CRG+*#Z#.:IZ-@?%&?YATD_K5+QH;G0O%37MH0@F
MCP#C';FK[1[B>K)V+>(/%FH71^:*UB8)Z C'^%.\'0W$VB:VMI*8Y]YV,O!!
MQZUK^%-/-KX-NKJ4?OKD,[';SWJO\,E&W4AG/[W\ZE=1O5%OP!KD]Y;7EK>S
MO)+"V0SMDXJEI&J7VJ^-[R6.[F^P6V7\O?\ *5Z=/K6)J[R>$?%%VT((CN$.
MP5TG@+2V7P]=W+C][<@[3[8H6L;BM9V**7^M^,-9N+;3[PV=I!_&G!Q^==7X
M=L-9TYYK?4[O[7$ /+E/4G\ZXWP)?0Z+K-]8W[BWD;@-)P"0?4UZ'9ZS8ZA=
M26]I<+,\8RQ3E?SHZ ]S1'2BD'2EH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 1NE<9\0=%NM4TQ);9=[0<LG<BN
MS;I69J&M6&FW4,%Y-Y;R@E,],>YI,:.&T+X@_88XK'6+=XRGRB3:1Q]*Z_6?
M$,&GZ ^IQD2JRYC /6N8\>3Z)<:06@>VFO&/R&+!;]*I7&F7S?#6 ,K%D^?:
M1VZ47!+6Y)I^G^*?$5H=2&LM:J_S(BYP1^=:'A'Q%?OJL^C:FV^6(D*YZFK'
MA#Q!IJ>&H(I;F&)X$VE7< UA^%U?5/'5[J4"GR S$/MX.<TVO>L0OAOYB^'\
M_P#"S;Y?XMTF,?C5Q=3OA\239FYE-OLSY>[Y?RJGH'/Q-NV&?O29_6A0?^%I
MX[E>>:$]4_(MO5EC7M:U35_$RZ'I=U]F"\O(.H]>:Q/&-IK6G6\%IJ%U]KML
M[DEQ\V?KFK=K.-$^)$CWI"Q2$J&88^\>#FIOB+K5G>I!:VLJS[3EG0Y4>U%M
M8L(]4>BZ3_R#+;_KF/Y5R_Q*_P"1>0=/WG]*ZC2?^09;?]<Q_*N7^)7_ "+T
M?'/F=_I14W)AL<E>V[:=I7A_6(LC"*K$#W-=7XXUH?\ "-0"W?F]("X/;BH&
MT\ZA\,;>-0#(L =?0<UR/A@W7B#6;"SN"&@M1D#&0 .E/XO=!^[[Q)JM@--F
MT&' $A9&;ZDBO0]>BUB>&"+3[J.T@*_O9G;!7Z<BN5\>@#Q+I84 8D3C';(I
M?'%U</K%A8RSO#8N%W$' .<9I<WNW\QJ-W;R*>J76K^&98;L>(H]04G#1JV?
MTS6]XYN3>^"(9RN2[(Q'X&N1\5Z9X=TVVA&ES&6X;ECYF\8[_2NC\4_\DZM/
MO<E/Y&BUDO4:U9>M[B6V^&/FP2M'(L)(=."O/:JV@Z_>6_@BZU":5[B6+[A<
MY/YU( ?^%6-W_<'^=8^E3-#\.+W;$926P0!TZ4Y/5DQ5XKYBI:>(]2T*36QK
MSQ9&X0JQ 'MUK0\&OJ<^@WVHW&IS3 QLJQL3E2!G(-<C93:9]EBBGUV\B5A^
M\MTB8KGZYKTO3/[,'A6:+2Y \*Q-W^;..]+:_D,Y#PY/XE\0VDEK#J+Q1(Q)
MED)9_IG-:/AG6-5L?%#:)J-VUPF&*R/DDXJ;X8<Z===.'/?-9P7/Q3QG^'UH
M^TD*_NMG2>(;;6[J]:.WU.'3[+:,2DX;/?N*Y8ZIJGAO7+2&36EU*"4\D-NQ
M^IHUY_[1\<&QU2Z>"Q ! !P#_A63KUCHNG:[9PZ/(74G+OYF\9^M$=6$M$=C
MX_U2\LK*RGM)Y8F+ XC?&[ZUG:A:>*7T?^V7U4P^7'O$$8."/?FI?B-_R"M-
MSGJO/X5TNJ_\B5,?^G<=/PJ6_=<NS&MTBKX9\2/>>%I+Z[8>9;Y5R.YQ7.:<
MWB+QE)+=6^IM86Z-A=N>?R-+X2MWN? NIPH!N9SC'.>!4WP]UBSLM/GLKN9(
M9EE+$.<>G>M)+5@EK8U+_P#MG2_"-V+V[S<(WR3(<$C\Z;X8UR>'P2VH7TSS
M2(7Y<Y)QTYJ?Q/J5KJ/A6^-K*)%5@I(Z=:P=&M);WX8SQP_?#NP[]*F^C&M4
M06<VL>)H9+YO$,6G+N/EQ"4#('J,UK^$?$]Y/<W6FWTJW$L()21/X@*YSPIH
MWAC4K!O[3E,5TC$,&G\NNMT'3O"^GWTLVER2/+&I#GS-PQWIDW.=L[W6?%.I
M7.W7%TX1.52/.-WZUZ%H<.H0:>(]1E$DP_B!ZUPFN:1X<N8;C4].U%;:Z7+!
M?,QEO9<UM_#W4;V_TB7[8S.(WVJ[=6&*2U!NQV=+35]?6G4#"BBB@ JE=_?J
M[5*[^_4RV-*7Q%1JB:I6J(UA([(D;=*C;I4C5$W2LV:Q1$:B:I3435FS>*(V
MJ!ZG:H'-93>AM%%=NM5Y*L-5=ZXJAT12*[U7>K#]ZKM7%,Z8-%=^M,I[]:97
M)*YMH%/BF>"59HF(D6F4L:-*PC0$N3QZTX\U_=W%)1M[VQZ%X?UY-000R'$H
M_6NAZ]:YKPYX?^QJMS.!YQY'M73"OL,'[1TE[3<^0Q?LU5?LMA:***ZCF"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJBL,$XR3^-:5)3 YJX\!Z!<W1N)+5]Y.<"0@?E6[:V4%E L-O&(T7H *LT4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR_\ X6IJ7_0*M_\ OIJ/^%J:E_T"K?\ [Z:O4/LMO_SPC_[X%'V6W_YX1_\
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MJ7_0*M_^^FH_X6IJ7_0*M_\ OIJ]0^RV_P#SPC_[X%'V6W_YX1_]\"@#R_\
MX6IJ7_0*M_\ OIJ/^%J:E_T"K?\ [Z:O4/LMO_SPC_[X%'V6W_YX1_\ ? H
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MR_\ X6IJ7_0*M_\ OIJ/^%J:E_T"K?\ [Z:O4/LMO_SPC_[X%'V6W_YX1_\
M? H \O\ ^%J:E_T"K?\ [Z:C_A:FI?\ 0*M_^^FKU#[+;_\ /"/_ +X%'V6W
M_P">$?\ WP* /+_^%J:E_P! JW_[Z:E_X6IJ7_0*M_\ OIJ]/^RV_P#SPC_[
MX%'V6W_YX1_]\"@#R_\ X6IJ7_0*M_\ OIJ7_A:FI?\ 0*M_^^FKT_[+;_\
M/"/_ +X%'V6W_P">$?\ WP* /,/^%J:E_P! JW_[Z:D_X6IJ7_0*M_\ OIJ]
M0^RV_P#SPC_[X%'V6W_YX1_]\"@#R_\ X6IJ7_0*M_\ OIJ/^%J:E_T"K?\
M[Z:O4/LMO_SPC_[X%'V6W_YX1_\ ? H \O\ ^%J:E_T"K?\ [Z:C_A:FI?\
M0*M_^^FKU#[+;_\ /"/_ +X%'V6W_P">$?\ WP* /+_^%J:E_P! JW_[Z:C_
M (6IJ7_0*M_^^FKU#[+;_P#/"/\ [X%'V6W_ .>$?_? H \O_P"%J:E_T"K?
M_OIJ/^%J:E_T"K?_ +Z:O4/LMO\ \\(_^^!1]EM_^>$?_? H \P_X6IJ7_0*
MM_\ OIJ3_A:FI?\ 0*M_^^FKU#[+;_\ /"/_ +X%'V6W_P">$?\ WP* /+_^
M%J:E_P! JW_[Z:C_ (6IJ7_0*M_^^FKU#[+;_P#/"/\ [X%'V6W_ .>$?_?
MH \O_P"%J:E_T"K?_OIJ/^%J:E_T"K?_ +Z:O4/LMO\ \\(_^^!1]EM_^>$?
M_? H \O_ .%J:E_T"K?_ +Z:C_A:FI?] JW_ .^FKU#[+;_\\(_^^!1]EM_^
M>$?_ 'P* /+_ /A:FI?] JW_ .^FH_X6IJ7_ $"K?_OIJ]0^RV__ #PC_P"^
M!1]EM_\ GA'_ -\"@#R__A:FI?\ 0*M_^^FH_P"%J:E_T"K?_OIJ]0^RV_\
MSPC_ .^!1]EM_P#GA'_WP* /+_\ A:FI?] JW_[Z:C_A:FI?] JW_P"^FKU#
M[+;_ //"/_O@4?9K?_GA'_WP* /+_P#A:>I?] JW_P"^FH_X6IJ7_0*M_P#O
MIJ]0^RV__/"/_O@4?9;?_GA'_P!\"@#R_P#X6IJ7_0*M_P#OIJ/^%J:E_P!
MJW_[Z:O4/LMO_P \(_\ O@4?9;?_ )X1_P#? H \O_X6IJ7_ $"K?_OIJ/\
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M^%J:E_T"K?\ [Z:O4/LMO_SPC_[X%'V6W_YX1_\ ? H \O\ ^%J:E_T"K?\
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MX6IJ7_0*M_\ OIJ]0^RV_P#SPC_[X%'V6W_YX1_]\"@#R_\ X6IJ7_0*M_\
MOIJ/^%J:E_T"K?\ [Z:O4/LMO_SPC_[X%'V6W_YX1_\ ? H \O\ ^%J:E_T"
MK?\ [Z:C_A:FI?\ 0*M_^^FKU#[+;_\ /"/_ +X%'V6W_P">$?\ WP* /+_^
M%J:E_P! JW_[Z:C_ (6IJ7_0*M_^^FKU#[+;_P#/"/\ [X%'V6W_ .>$?_?
MH \O_P"%J:E_T"K?_OIJ/^%J:E_T"K?_ +Z:O4/LMO\ \\(_^^!1]EM_^>$?
M_? H \O_ .%J:E_T"K?_ +Z:C_A:FI?] JW_ .^FKU#[+;_\\(_^^!1]EM_^
M>$?_ 'P* /+_ /A:FI?] JW_ .^FH_X6IJ7_ $"K?_OIJ]0^RV__ #PC_P"^
M!1]EM_\ GA'_ -\"@#R__A:FI?\ 0*M_^^FH_P"%J:E_T"K?_OIJ]0^RV_\
MSPC_ .^!1]EM_P#GA'_WP* /+_\ A:FI?] JW_[Z:C_A:FI?] JW_P"^FKU#
M[+;_ //"/_O@4?9;?_GA'_WP* /+_P#A:FI?] JW_P"^FH_X6IJ7_0*M_P#O
MIJ]0^RV__/"/_O@4?9;?_GA'_P!\"@#R_P#X6IJ7_0*M_P#OIJ/^%J:E_P!
MJW_[Z:O4/LMO_P \(_\ O@4?9;?_ )X1_P#? H \O_X6IJ7_ $"K?_OIJ/\
MA:FI?] JW_[Z:O4/LMO_ ,\(_P#O@4?9;?\ YX1_]\"@#R__ (6IJ7_0*M_^
M^FH_X6IJ7_0*M_\ OIJ]0^RV_P#SPC_[X%'V6W_YX1_]\"@#R_\ X6IJ7_0*
MM_\ OIJ/^%J:E_T"K?\ [Z:O4/LMO_SPC_[X%'V6W_YX1_\ ? H \O\ ^%J:
ME_T"K?\ [Z:C_A:FI?\ 0*M_^^FKU#[+;_\ /"/_ +X%'V6W_P">$?\ WP*
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M7_0*M_\ OIJ/^%J:E_T"K?\ [Z:O4/LMO_SPC_[X%'V6W_YX1_\ ? H \O\
M^%J:E_T"K?\ [Z:C_A:FI?\ 0*M_^^FKU#[+;_\ /"/_ +X%'V6W_P">$?\
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MJ7_0*M_^^FH_X6IJ7_0*M_\ OIJ]0^RV_P#SPC_[X%'V6W_YX1_]\"@#R_\
MX6IJ7_0*M_\ OIJ/^%J:E_T"K?\ [Z:O4/LMO_SPC_[X%'V6W_YX1_\ ? H
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MR_\ X6IJ7_0*M_\ OIJ/^%J:E_T"K?\ [Z:O4/LMO_SPC_[X%'V6W_YX1_\
M? H \O\ ^%J:E_T"K?\ [Z:C_A:FI?\ 0*M_^^FKU#[+;_\ /"/_ +X%'V6W
M_P">$?\ WP* /+_^%J:E_P! JW_[Z:C_ (6IJ7_0*M_^^FKU#[+;_P#/"/\
M[X%'V6W_ .>$?_? H \O_P"%J:E_T"K?_OIJ/^%J:E_T"K?_ +Z:O4/LMO\
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M\"@#SC3_ (E7]YJ=M:RZ; BS.J;@S9&37I:U$+6 '(AC!'.=HJ4#% "T444
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MIU&Y?4?G1N7U'YUR;7$W_/1OSJ%KF?\ YZM^=)XE+H4L WU.RWKZC\Z3>O\
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MSP,9HMK85]+CM S_ ,+.O,?WI,G\ZNPV-@OQ":7^TG-P03Y'EM_Z%TJEX?\
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MNO\ 05YYVKT/P%_R"9CZR_T%7'<ZL)&2GJ=;1115GJA1129% "T444 %%%%
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MLJLX7(_E6SX&T*YT73)?M7RR3/O\O^[76TF/TXH6@"C.3FEI%&!BEH ****
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M_A,/#W_07MO^^J/^$P\/?]!>V_[ZKF_^%4:;_P!!"[_)?\*/^%4:;_T$+O\
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M "7_  H Z3_A,/#W_07MO^^J/^$P\/?]!>V_[ZKF_P#A5&F_]!"[_)?\*/\
MA5&F_P#00N_R7_"@#I/^$P\/?]!>V_[ZH_X3#P]_T%[;_OJN;_X51IO_ $$+
MO\E_PH_X51IO_00N_P E_P * .D_X3#P]_T%[;_OJC_A,/#W_07MO^^JYO\
MX51IO_00N_R7_"C_ (51IO\ T$+O\E_PH Z3_A,/#W_07MO^^J/^$P\/?]!>
MV_[ZKF_^%4:;_P!!"[_)?\*/^%4:;_T$+O\ )?\ "@#I/^$P\/?]!>V_[ZH_
MX3#P]_T%[;_OJN;_ .%4:;_T$+O\E_PH_P"%4:;_ -!"[_)?\* .D_X3#P]_
MT%[;_OJC_A,/#W_07MO^^JYO_A5&F_\ 00N_R7_"C_A5&F_]!"[_ "7_  H
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M =)_PF'A[_H+VW_?5'_"8>'O^@O;?]]5S?\ PJC3?^@A=_DO^%'_  JC3?\
MH(7?Y+_A0!TG_"8>'O\ H+VW_?5'_"8>'O\ H+VW_?5<W_PJC3?^@A=_DO\
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MW_?5)_PE_A[_ *"UM_WU7.?\*HTW_H(7?Y+_ (4?\*HTW_H(7?Y+_A0!T?\
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M =)_PF'A[_H+VW_?5'_"8>'O^@O;?]]5S?\ PJC3?^@A=_DO^%'_  JC3?\
MH(7?Y+_A0!TG_"8>'O\ H+VW_?5'_"8>'O\ H+VW_?5<W_PJC3?^@A=_DO\
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M_A1_PJC3?^@A=_DO^% '2?\ "8>'O^@O;?\ ?5'_  F'A[_H+VW_ 'U7-_\
M"J--_P"@A=_DO^%'_"J--_Z"%W^2_P"% '2?\)AX>_Z"]M_WU1_PF'A[_H+V
MW_?5<W_PJC3?^@A=_DO^%'_"J--_Z"%W^2_X4 =)_P )AX>_Z"]M_P!]4?\
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M+VW_ 'U1_P )AX>_Z"]M_P!]5S?_  JC3?\ H(7?Y+_A1_PJC3?^@A=_DO\
MA0!TG_"8>'O^@O;?]]4?\)AX>_Z"]M_WU7-_\*HTW_H(7?Y+_A1_PJC3?^@A
M=_DO^% '2?\ "8>'O^@O;?\ ?5'_  F'A[_H+VW_ 'U7-_\ "J--_P"@A=_D
MO^%'_"J--_Z"%W^2_P"% '2?\)AX>_Z"]M_WU1_PF'A[_H+VW_?5<W_PJC3?
M^@A=_DO^%'_"J--_Z"%W^2_X4 =)_P )AX>_Z"]M_P!]4?\ "8>'O^@O;?\
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M@O;?]]4?\)AX>_Z"]M_WU7-_\*HTW_H(7?Y+_A1_PJC3?^@A=_DO^% '2?\
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M>_Z"]M_WU7-_\*HTW_H(7?Y+_A1_PJC3?^@A=_DO^% '2?\ "8>'O^@O;?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBO?^A<U/\D_QH_X2*]_Z%S4_R3_&@#?HK _X2*]_Z%S4_P D_P :/^$BO?\
MH7-3_)/\: -^BL#_ (2*]_Z%S4_R3_&C_A(KW_H7-3_)/\: -^BL#_A(KW_H
M7-3_ "3_ !H_X2*]_P"A<U/\D_QH WZ*P/\ A(KW_H7-3_)/\:/^$BO?^A<U
M/\D_QH WZC>)7/-8G_"17O\ T+FI_DG^-)_PD-[_ -"YJ?Y)_C0U<:;1M?9T
M]*3[-'Z5C?\ "0WO_0N:G^2?XT?\)#>_]"YJ?Y)_C2Y1\TC9-K'Z4GV2/TK'
M_P"$AO?^A<U/\D_QH_X2&]_Z%S4_R3_&E9!SR-?['%_=-)]BB_NFLG_A(;W_
M *%S4_R3_&C_ (2&]_Z%S4_R3_&BR#GD:OV*+^Z:/L,7I65_PD-[_P!"YJ?Y
M)_C1_P )#>_]"YJ?Y)_C1RH/:2-7[!#_ ':;_9\/]TUF?\)#>_\ 0N:G^2?X
MTO\ PD5[_P!"YJ?Y)_C1RQ'[21I?V=#_ '32?V=#_=-9W_"0WO\ T+FI_DG^
M-)_PD-[_ -"YJ?Y)_C1RQ#VDNYI?V;!_=H_LRW_N_K6;_P )#>_]"YJ?Y)_C
M1_PD5[_T+FI_DG^-')$/:3[FC_95O_=_6C^RK;^[^M9W_"17O_0N:G^2?XT?
M\)%>_P#0N:G^2?XTN2(_:3[FA_9-M_<_6C^R+;^Y^M9__"17O_0N:G^2?XT?
M\)%>_P#0N:G^2?XT>SB'M:G<O_V1:_W/UH_L>U[I^M4/^$BO?^A<U/\ )/\
M&C_A(KW_ *%S4_R3_&CV<0]K/N7O[&M#_!^M-_L6T_N?K5/_ (2&]_Z%S4_R
M3_&C_A(;W_H7-2_)/\:3IPZH/;5.Y;_L.T/\'ZT?V%:?\\_UJI_PD-[_ -"Y
MJ7Y)_C1_PD5[_P!"YJ?Y)_C2]E#L/V]3N6?[ L_^>?ZTG_"/V7_//]35?_A(
M;W_H7-3_ "3_ !H_X2&]_P"A<U/\D_QH]C3[![>IW+'_  CMC_SR/YFC_A'+
M#O%^IJO_ ,)#>_\ 0N:G^2?XT?\ "0WO_0N:G^2?XTO84^P>WJ=R?_A&]/\
M^>7ZFC_A&M/_ .>7ZFJ__"0WO_0N:G^2?XT?\)#>_P#0N:G^2?XTOJ]+L/V]
M3^8F_P"$9TX_\LOU-)_PB^G?\\OU-1_\)#>_]"YJ?Y)_C1_PD-[_ -"YJ?Y)
M_C1]6I=@^L5?YB3_ (1;3?\ GE^II/\ A%--/_+']33/^$AO?^A<U/\ )/\
M&C_A(;W_ *%S4_R3_&CZK2_E#ZS5_F%_X1/3/^>/ZFE_X1/3/^>/ZFF_\)%>
M_P#0N:G^2?XT?\)%>_\ 0N:G^2?XTOJM+^4?UFK_ ##O^$3TS_GC^IH_X1/3
M/^>/ZFF_\)%>_P#0N:G^2?XT?\)%>_\ 0N:G^2?XT?5:7\H?6:O\P[_A$],_
MYX_J:/\ A$],_P">/ZFF_P#"17O_ $+FI_DG^-'_  D5[_T+FI_DG^-'U2E_
M*'UFK_,._P"$3TS_ )X_J:/^$3TS_GC^IIO_  D5[_T+FI_DG^-'_"17O_0N
M:G^2?XT?5*7\H?6:O\P[_A$],_YX_J:GLM L;&7S(H@&]2:K?\)%>_\ 0N:G
M^2?XT?\ "0WO_0N:G^2?XTUAJ2=TA/$59*S9NCTXIU8'_"0WO_0N:E^2?XT?
M\)%>_P#0N:G^2?XUMY(Q\SH**P/^$BO?^A<U/\D_QH_X2*]_Z%S4_P D_P :
M8&_16!_PD5[_ -"YJ?Y)_C1_PD5[_P!"YJ?Y)_C0!OT5@?\ "17O_0N:G^2?
MXT?\)%>_]"YJ?Y)_C0!OT5@?\)%>_P#0N:G^2?XT?\)%>_\ 0N:G^2?XT ;]
M%8'_  D5[_T+FI_DG^-'_"17O_0N:G^2?XT ;]%8'_"17O\ T+FI_DG^-'_"
M17O_ $+FI_DG^- &_16!_P )%>_]"YJ?Y)_C1_PD5[_T+FI_DG^- &_16!_P
MD5[_ -"YJ?Y)_C1_PD5[_P!"YJ?Y)_C0!OT5@?\ "17O_0N:G^2?XT?\)%>_
M]"YJ?Y)_C0!OT5@?\)%>_P#0N:G^2?XT?\)%>_\ 0N:G^2?XT ;]%8'_  D5
M[_T+FI_DG^-'_"17O_0N:G^2?XT ;]%8'_"17O\ T+FI_DG^-'_"17O_ $+F
MI_DG^- &_16!_P )%>_]"YJ?Y)_C1_PD5[_T+FI_DG^- &_16!_PD5[_ -"Y
MJ?Y)_C1_PD5[_P!"YJ?Y)_C0!OT5@?\ "17O_0N:G^2?XT?\)%>_]"YJ?Y)_
MC0!OT5@?\)%>_P#0N:G^2?XT?\)%>_\ 0N:G^2?XT ;]%8'_  D5[_T+FI_D
MG^-'_"17O_0N:G^2?XT ;]%8'_"17O\ T+FI_DG^-'_"17O_ $+FI_DG^- &
M_16!_P )%>_]"YJ?Y)_C1_PD5[_T+FI_DG^- &_16!_PD5[_ -"YJ?Y)_C1_
MPD5[_P!"YJ?Y)_C0!OT5@?\ "17O_0N:G^2?XT?\)%>_]"YJ?Y)_C0!OT5@?
M\)%>_P#0N:G^2?XT?\)%>_\ 0N:G^2?XT ;]%8'_  D5[_T+FI_DG^-'_"17
MO_0N:G^2?XT ;]%8'_"17O\ T+FI_DG^-'_"17O_ $+FI_DG^- &_16!_P )
M%>_]"YJ?Y)_C1_PD5[_T+FI_DG^- &_16!_PD5[_ -"YJ?Y)_C1_PD5[_P!"
MYJ?Y)_C0!OT5@?\ "17O_0N:G^2?XT?\)%>_]"YJ?Y)_C0!OT5@?\)%>_P#0
MN:G^2?XT?\)%>_\ 0N:G^2?XT ;]%8'_  D5[_T+FI_DG^-'_"17O_0N:G^2
M?XT ;]%8'_"17O\ T+FI_DG^-'_"17O_ $+FI_DG^- &_16!_P )%>_]"YJ?
MY)_C1_PD5[_T+FI_DG^- &_16!_PD5[_ -"YJ?Y)_C1_PD5[_P!"YJ?Y)_C0
M!OT5@?\ "17O_0N:G^2?XT?\)%>_]"YJ?Y)_C0!OT5@?\)%>_P#0N:G^2?XT
M?\)%>_\ 0N:G^2?XT ;]%8'_  D5[_T+FI_DG^-'_"17O_0N:G^2?XT ;]%8
M'_"17O\ T+FI_DG^-'_"17O_ $+FI_DG^- &_16!_P )%>_]"YJ?Y)_C1_PD
M5[_T+FI_DG^- &_16!_PD5[_ -"YJ?Y)_C1_PD5[_P!"YJ?Y)_C0!OT5@?\
M"17O_0N:G^2?XT?\)%>_]"YJ?Y)_C0!OT5@?\)%>_P#0N:G^2?XT?\)%>_\
M0N:G^2?XT ;]%8'_  D5[_T+FI_DG^-'_"17O_0N:G^2?XT ;]%8'_"17O\
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MJY#J<DGTQ56#XB1'4([>\TV>UB<X61P>?PQ0,[C=WIU1(ZRJLB?=8 J?6I:
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M>_817>FR-\T+_(N.@KT 54B$+6?JNLV>C6WVB^D,<><9 S6A7!?%'/\ 8MN
M1_K#GWZ5+=BT:D?Q"\.R.J+=MEFP,Q,*Z*WNH;J,202I(AZ%3FN-LM"TN[\#
MI-):0B7[-O\ ," -D+GK6/\ #K46M+34/-9C;PC<.X'6JMH2SU#-&:X2?XAR
MQ[G@T.[EMQSYN"!_*NCT'Q#:Z_:&6 %67AT/:D,V,UC^(M?3P_8K=/ TP+;=
MJM@US[_$2!)[B V$C7$3;4C0[B_Y"J'B_4WU7PE'=2VLEJWF_P"K?(/2D^@T
M=WIM^-2TV&\5"@E7<%)Y%)J.J6VDVC7-XY2$=P,_I7-0>((/#_@[3YI5WR-&
M L8;EJ9JVJQZIX+DO]1TV1821^Z$N&QD<YQ3GI<4=3JM/U*WU.T6ZM'WQ-P#
MC%6LG.,?C7*:!J%I9^#OMEI;-'#&"1&6R3QW-4$^(T<]DLMOIL\T_>),G'X@
M4^MA)Z'= Y-&3G%<YX:\66_B#?&(C!<1GYHF-4]7\<PZ??/9V=E-?3I]Y8\\
M?H:3&CK\\>WK2YK#T+Q FLP2O);26KQ\,D@/'YUBWGQ!B6[:#3=.FOBAPQC!
MP/TI/<#M2<4N:Y?0?&=KK=PUH\+VMR#@Q/UINL>,X-%UM-/N+8E'7=YJMGU[
M?A3 ZG)Q5'5=332M.FO'0NL8SM!QFN2;XC)'=*)]+N(;=CA9FR,_ABKOB^XG
MO]%M[6QC>0WA7#*A("^Y[=:3&C7\.:\OB'3OMB0-"-Q&UFS6ONY_^M6%I-E;
M^&/#P21L+$A>0CUZFL+_ (6(7F/V?2+J:U!QYR@X'Z54B8G=;J=5:SNEO;2.
MX0$*XS@CFK-( HHHH&%%%)0 C?=-9SL<GDUHOT-9K]36<C:DEU(V8^IJ)G/K
M4C5"U8MLZHJ(PNWJ:C9V]33S43&H;D;12[#&=_[Q_.HFD?\ O'\Z>QJ)C6;E
M+J;1BNPQI'_O&H&D?^\?SJ5J@?I6-1Z;F\8KL1/+)C[Y_.J[S2_WV_.I7JL]
M<4Y/N=$(Q[$;S2C^-OSJ!YY?^>C?G4DE5WKBG4EW-XTX]AOVB;/^L;\Z3[1/
MGB5AZ\U'WI#R:YW4G>]V:N$+6L;FB>();"8).S-"3C)[5Z%!<I<1*\;!E(SD
M&O(.GN!VK<T'79--F6*4EK9NOJM>K@,PY7R2ZGDX_ <R]I ]*!R**AMIX[B!
M98V#*PR"#4U?1IIJY\\TT["T444P"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&TJ3R_M+*>C?*#CUJ7P=HUYH>C_9;P1^9O)^0Y'-#W9/1>IR/AD^5\1;J.,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD5N;4Z>AQ_7BEHYX]NM%=VEM#FZA1111T8D%>I^'/^1?LO\ KG7EE>I^'/\
MD7[+_KG7-B?A1O0-6BBBN(Z0HI#P*;G R.E #Z#TK";QAX?B=HWU6W5U)##)
MX/Y4?\)GX<_Z"UO^O^% &U_#Q^M&.^*Q?^$S\.?]!:W_ %_PH_X3/PY_T%K?
M]?\ "CJ'0V^U)CJ>]8O_  F?AS_H+6_Z_P"%'_"9^'/^@M;_ *_X4 ;../7W
MKG].\*PV&OS:JMS)))*"-A4 #-3?\)GX<_Z"UO\ K_A1_P )GX<_Z"UO^O\
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M)GX<_P"@M;_K_A2_\)GX<_Z"UO\ K_A0@-K('4^U+CC![UA_\)EX<_Z"UO\
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M^KTND4/V]7^9FI;V<%J@2&)47T%6*P_^$S\.?]!:W_7_  H_X3/PY_T%K?\
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M_P!?\*/^$S\.?]!:W_7_  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\
M"@#=HK"_X3/PY_T%K?\ 7_"C_A,_#G_06M_U_P * -VBL+_A,_#G_06M_P!?
M\*/^$S\.?]!:W_7_  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\ "@#=
MHK"_X3/PY_T%K?\ 7_"C_A,_#G_06M_U_P * -VBL+_A,_#G_06M_P!?\*/^
M$S\.?]!:W_7_  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\ "@#=HK"_
MX3/PY_T%K?\ 7_"C_A,_#G_06M_U_P * -VBL+_A,_#G_06M_P!?\*/^$S\.
M?]!:W_7_  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\ "@#=HK"_X3/P
MY_T%K?\ 7_"C_A,_#G_06M_U_P * -VBL+_A,_#G_06M_P!?\*/^$S\.?]!:
MW_7_  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\ "@#=HK"_X3/PY_T%
MK?\ 7_"C_A,_#G_06M_U_P * -VBL+_A,_#G_06M_P!?\*/^$S\.?]!:W_7_
M  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\ "@#=HK"_X3/PY_T%K?\
M7_"C_A,_#G_06M_U_P * -VBL+_A,_#G_06M_P!?\*/^$S\.?]!:W_7_  H
MW:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\ "@#=HK"_X3/PY_T%K?\ 7_"C
M_A,_#G_06M_U_P * -VBL+_A,_#G_06M_P!?\*/^$S\.?]!:W_7_  H W:*P
MO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\ "@#=HK"_X3/PY_T%K?\ 7_"C_A,_
M#G_06M_U_P * -VBL+_A,_#G_06M_P!?\*/^$S\.?]!:W_7_  H W:*PO^$S
M\.?]!:W_ %_PH_X3/PY_T%K?]?\ "@#=HK"_X3/PY_T%K?\ 7_"C_A,_#G_0
M6M_U_P * -VBL+_A,_#G_06M_P!?\*/^$S\.?]!:W_7_  H W:*PO^$S\.?]
M!:W_ %_PH_X3/PY_T%K?]?\ "@#=HK"_X3/PY_T%K?\ 7_"C_A,_#G_06M_U
M_P * -VBL+_A,_#G_06M_P!?\*/^$S\.?]!:W_7_  H W:*PO^$S\.?]!:W_
M %_PH_X3/PY_T%K?]?\ "@#=HK"_X3/PY_T%K?\ 7_"C_A,_#G_06M_U_P *
M -VBL+_A,_#G_06M_P!?\*/^$S\.?]!:W_7_  H W:*PO^$S\.?]!:W_ %_P
MH_X3/PY_T%K?]?\ "@#=HK"_X3/PY_T%K?\ 7_"C_A,_#G_06M_U_P * -VB
ML+_A,_#G_06M_P!?\*/^$S\.?]!:W_7_  H W:*PO^$S\.?]!:W_ %_PH_X3
M/PY_T%K?]?\ "@#=HK"_X3/PY_T%K?\ 7_"C_A,_#G_06M_U_P * -VBL+_A
M,_#G_06M_P!?\*/^$S\.?]!:W_7_  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_
MT%K?]?\ "@#=HK"_X3/PY_T%K?\ 7_"C_A,_#G_06M_U_P * -VBL+_A,_#G
M_06M_P!?\*/^$S\.?]!:W_7_  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?
M]?\ "@#=HK"_X3/PY_T%K?\ 7_"C_A,_#G_06M_U_P * -VBL+_A,_#G_06M
M_P!?\*/^$S\.?]!:W_7_  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\
M"@#=HK"_X3/PY_T%K?\ 7_"C_A,_#G_06M_U_P * -VBL+_A,_#G_06M_P!?
M\*/^$S\.?]!:W_7_  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\ "@#=
MHK"_X3/PY_T%K?\ 7_"C_A,_#G_06M_U_P * -VBL+_A,_#G_06M_P!?\*/^
M$S\.?]!:W_7_  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\ "@#=HK"_
MX3/PY_T%K?\ 7_"C_A,_#G_06M_U_P * -VBL+_A,_#G_06M_P!?\*/^$S\.
M?]!:W_7_  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\ "@#=HK"_X3/P
MY_T%K?\ 7_"C_A,_#G_06M_U_P * -VBL+_A,_#G_06M_P!?\*/^$S\.?]!:
MW_7_  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\ "@#=HK"_X3/PY_T%
MK?\ 7_"C_A,_#G_06M_U_P * -VBL+_A,_#G_06M_P!?\*/^$S\.?]!:W_7_
M  H W:*PO^$S\.?]!:W_ %_PH_X3/PY_T%K?]?\ "@#=HK"_X3/PY_T%K?\
M7_"C_A,_#G_06M_U_P * -VBL+_A,_#G_06M_P!?\*/^$S\.?]!:W_7_  H
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M@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\
M"JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\H
MH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_
MPJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#
M@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\
MA1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@
M_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'
M_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB
M@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\
M"JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\H
MH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_
MPJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#
M@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\
MA1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@
M_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'
M_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB
M@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\
M"JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\H
MH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_
MPJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#
M@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\
MA1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@
M_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'
M_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB
M@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\
M"JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\H
MH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_
MPJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#
M@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\
MA1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@
M_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'
M_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB
M@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\
M"JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\H
MH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_
MPJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#
M@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\
MA1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@
M_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'
M_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB
M@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\
M"JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\H
MH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_
MPJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#
M@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\
MA1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@
M_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'
M_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB
M@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\
M"JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\H
MH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_
MPJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#
M@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\
MA1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@
M_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'
M_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB
M@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\
M"JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\H
MH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_
MPJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#
M@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\
MA1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@
M_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'
M_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB
M@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\
M"JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\H
MH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_
MPJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#
M@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\
MA1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@
M_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'
M_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB
M@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\
M"JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\H
MH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_
MPJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#
M@_\ A56D_P#/Y=_FO^%'_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\
MA1_PJK2?^?R[_-?\*[RB@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@
M_P#A56D_\_EW^:_X4?\ "JM)_P"?R[_-?\*[RB@#@_\ A56D_P#/Y=_FO^%'
M_"JM)_Y_+O\ -?\ "N\HH X/_A56D_\ /Y=_FO\ A1_PJK2?^?R[_-?\*[RB
M@#@_^%5:3_S^7?YK_A1_PJK2?^?R[_-?\*[RB@#@_P#A56D_\_EW^:_X4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG0%I>YW.C_\ ('M?^N8K"^(?_(IW'^\O\Q6[HX(TFU!'\ K#^(0SX4N/JO\
M,42U81T0WX>?\BI#_P!=&_I76=ZY3X>?\BG#P<[V/-=6.M4]0%HHHI %%%%
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M%?786BZ5-09\CBJJK5'-"T445TF 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2@T4 <9X[_Y<_\
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M/^%EZ]_T"X?^^'KU38O]U?RHV+_=7\J /*_^%EZ]_P! N'_OAZ/^%EZ]_P!
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MZ]4V+_=7\J-B_P!U?RH \K_X67KW_0+A_P"^'H_X67KW_0+A_P"^'KU38O\
M=7\J-B_W5_*@#RO_ (67KW_0+A_[X>C_ (67KW_0+A_[X>O5-B_W5_*C8O\
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MKW_0+A_[X>O5-B_W5_*C8O\ =7\J /*_^%EZ]_T"X?\ OAZ/^%EZ]_T"X?\
MOAZ]4V+_ '5_*C8O]U?RH \K_P"%EZ]_T"X?^^'H_P"%EZ]_T"X?^^'KU38O
M]U?RHV+_ '5_*@#RO_A9>O?] N'_ +X>C_A9>O?] N'_ +X>O5-B_P!U?RHV
M+_=7\J /*_\ A9>O?] N'_OAZ/\ A9>O?] N'_OAZ]4V+_=7\J-B_P!U?RH
M\K_X67KW_0+A_P"^'H_X67KW_0+A_P"^'KU38O\ =7\J-B_W5_*@#RO_ (67
MKW_0+A_[X>C_ (67KW_0+A_[X>O5-B_W5_*C8O\ =7\J /*_^%EZ]_T"X?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@ HHHH **** "BBB@ HHHH 1NE>11Z4FL^)-9M2!N:-BI]^*]=/2O./"_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% "44M)0!QGCO_ES_P"!?TKB
MZ[/QW_RY_P# OZ5QE>A0^ XZOQ!1116QG8****-0L%%%%&H!1111J%@HHHH0
MPKU/PY_R+]E_USKRSO7J?AS_ )%^R_ZYURXK9(VH(U:***XSI"BBB@ HHHH
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M+K3XY'[G)'\C2UO<?0\YM$M8_&]LGA]W:S#@MM8E?S]*[W6_"%AKKB=V:"Y
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MZ<<U0O7;^6G]Q?RI/+C_ .>:_E42PK?4T6/M]DX%ZKO7HWDQ?\\T_*CR(O\
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M_P"@M#^3?X4?\)MX;_Z"T/Y-_A6+_P *MT7_ )^+O_OH?X4?\*MT7_GXN_\
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M_P"@M#^3?X4?\)MX;_Z"T/Y-_A6+_P *MT7_ )^+O_OH?X4?\*MT7_GXN_\
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M_P"@M#^3?X4?\)MX;_Z"T/Y-_A6+_P *MT7_ )^+O_OH?X4?\*MT7_GXN_\
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MK&_X5;HO_/Q=_P#?0_PH_P"%6Z+_ ,_%W_WT/\* -K_A-O#?_06A_)O\*/\
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MF_PH_P"$V\-_]!:'\F_PK%_X5;HO_/Q=_P#?0_PH_P"%6Z+_ ,_%W_WT/\*
M-K_A-O#?_06A_)O\*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\ A5NB
M_P#/Q=_]]#_"@#:_X3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\_%W_
M -]#_"C_ (5;HO\ S\7?_?0_PH VO^$V\-_]!:'\F_PH_P"$V\-_]!:'\F_P
MK%_X5;HO_/Q=_P#?0_PH_P"%6Z+_ ,_%W_WT/\* -K_A-O#?_06A_)O\*/\
MA-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\ A5NB_P#/Q=_]]#_"@#:_X3;P
MW_T%H?R;_"D_X3;PW_T%8?R;_"L;_A5NB_\ /Q=_]]#_  H_X5;HW_/Q=_\
M?0_PH V?^$V\-_\ 05A_)O\ "E_X3;PW_P!!6'\F_P *Q?\ A5NC?\_%W_WT
M/\*/^%6Z-_S\7?\ WT/\* -G_A-O#?\ T%8?R;_"C_A-?#?_ $%8?R;_  K&
M_P"%6Z-_S\7?_?0_PH_X5;HW_/Q=_P#?0_PH V?^$U\-_P#05A_)O\*/^$U\
M-_\ 05A_)O\ "L;_ (5;HW_/Q=_]]#_"C_A5NC?\_%W_ -]#_"@#8_X37PY_
MT%8?R;_"C_A-?#G_ $%H?R;_  K'_P"%7:+_ ,_%W_WT/\*/^%6Z+_S\7?\
MWT/\*5D!L_\ ":^'/^@M#^3?X4?\)MX<_P"@K#^3?X5C?\*MT;_GXN_^^A_A
M1_PJ[1O^?B[_ .^A_A3 V?\ A-O#G_05A_)O\*/^$V\.?]!:'\F_PK&_X5;H
MW_/Q=_\ ?0_PH_X5;HW_ #\7?_?0_P * -G_ (3;PW_T%8?R;_"D_P"$U\-_
M]!6'\F_PK'_X5;HW_/Q=_P#?0_PH_P"%6Z-_S\7?_?0_PHL@T-G_ (37PW_T
M%8?R;_"E_P"$V\-_]!6'\F_PK%_X5;HW_/Q=_P#?0_PH_P"%6Z+_ ,_%W_WT
M/\* -K_A-O#?_06A_)O\*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\
MA5NB_P#/Q=_]]#_"@#:_X3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\
M_%W_ -]#_"C_ (5;HO\ S\7?_?0_PH VO^$V\-_]!:'\F_PH_P"$V\-_]!:'
M\F_PK%_X5;HO_/Q=_P#?0_PH_P"%6Z+_ ,_%W_WT/\* -K_A-O#?_06A_)O\
M*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\ A5NB_P#/Q=_]]#_"@#:_
MX3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\_%W_ -]#_"C_ (5;HO\
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M/\* -K_A-O#?_06A_)O\*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\
MA5NB_P#/Q=_]]#_"@#:_X3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\
M_%W_ -]#_"C_ (5;HO\ S\7?_?0_PH VO^$V\-_]!:'\F_PH_P"$V\-_]!:'
M\F_PK%_X5;HO_/Q=_P#?0_PH_P"%6Z+_ ,_%W_WT/\* -K_A-O#?_06A_)O\
M*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\ A5NB_P#/Q=_]]#_"@#:_
MX3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\_%W_ -]#_"C_ (5;HO\
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M/\* -K_A-O#?_06A_)O\*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\
MA5NB_P#/Q=_]]#_"@#:_X3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\
M_%W_ -]#_"C_ (5;HO\ S\7?_?0_PH VO^$V\-_]!:'\F_PH_P"$V\-_]!:'
M\F_PK%_X5;HO_/Q=_P#?0_PH_P"%6Z+_ ,_%W_WT/\* -K_A-O#?_06A_)O\
M*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\ A5NB_P#/Q=_]]#_"@#:_
MX3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\_%W_ -]#_"C_ (5;HO\
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M/\* -K_A-O#?_06A_)O\*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\
MA5NB_P#/Q=_]]#_"@#:_X3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\
M_%W_ -]#_"C_ (5;HO\ S\7?_?0_PH VO^$V\-_]!:'\F_PH_P"$V\-_]!:'
M\F_PK%_X5;HO_/Q=_P#?0_PH_P"%6Z+_ ,_%W_WT/\* -K_A-O#?_06A_)O\
M*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\ A5NB_P#/Q=_]]#_"@#:_
MX3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\_%W_ -]#_"C_ (5;HO\
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M/\* -K_A-O#?_06A_)O\*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\
MA5NB_P#/Q=_]]#_"@#:_X3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\
M_%W_ -]#_"C_ (5;HO\ S\7?_?0_PH VO^$V\-_]!:'\F_PH_P"$V\-_]!:'
M\F_PK%_X5;HO_/Q=_P#?0_PH_P"%6Z+_ ,_%W_WT/\* -K_A-O#?_06A_)O\
M*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\ A5NB_P#/Q=_]]#_"@#:_
MX3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\_%W_ -]#_"C_ (5;HO\
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M/\* -K_A-O#?_06A_)O\*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\
MA5NB_P#/Q=_]]#_"@#:_X3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\
M_%W_ -]#_"C_ (5;HO\ S\7?_?0_PH VO^$V\-_]!:'\F_PH_P"$V\-_]!:'
M\F_PK%_X5;HO_/Q=_P#?0_PH_P"%6Z+_ ,_%W_WT/\* -K_A-O#?_06A_)O\
M*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\ A5NB_P#/Q=_]]#_"@#:_
MX3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\_%W_ -]#_"C_ (5;HO\
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M/\* -K_A-O#?_06A_)O\*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\
MA5NB_P#/Q=_]]#_"@#:_X3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\
M_%W_ -]#_"C_ (5;HO\ S\7?_?0_PH VO^$V\-_]!:'\F_PH_P"$V\-_]!:'
M\F_PK%_X5;HO_/Q=_P#?0_PH_P"%6Z+_ ,_%W_WT/\* -K_A-O#?_06A_)O\
M*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\ A5NB_P#/Q=_]]#_"@#:_
MX3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\_%W_ -]#_"C_ (5;HO\
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M/\* -K_A-O#?_06A_)O\*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\
MA5NB_P#/Q=_]]#_"@#:_X3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\
M_%W_ -]#_"C_ (5;HO\ S\7?_?0_PH VO^$V\-_]!:'\F_PH_P"$V\-_]!:'
M\F_PK%_X5;HO_/Q=_P#?0_PH_P"%6Z+_ ,_%W_WT/\* -K_A-O#?_06A_)O\
M*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\ A5NB_P#/Q=_]]#_"@#:_
MX3;PW_T%H?R;_"C_ (3;PW_T%H?R;_"L7_A5NB_\_%W_ -]#_"C_ (5;HO\
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M/\* -K_A-O#?_06A_)O\*/\ A-O#?_06A_)O\*Q?^%6Z+_S\7?\ WT/\*/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gfbaqn1kfu2x000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -K [8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN X>3@]V->DUQOBP_O/QH Z;3&+6$)/=:N52TO\ Y!\/^Y5V@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *YSQ0/W8/M71USGBC_4CZ5RXS^#(ZL%_'B2>&#_H$
M?TK?KG_#'_'C'704\'_!B+&?QI!11172<P4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% ",H88(!^M-\F+_GFG_?-/HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5QGBS_ %OXUV=<9XL_UOXT =-I?_(/A_W*NU2TO_D'P_[E7: "BBB@
M HHHH **** $)PI/H*X;7/B+8Z-=>3*DI.<< UW)&1CUKGM0\(V.HS>9*B$Y
M[B@#D_\ A;NF_P!R?_OD_P"%'_"W=-_N3_\ ?)_PKH?^$!TW_GG'_P!\T?\
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MZ2N;\+?\>J#VKI*6"_@1*QO\>04445U'(%%%% !1110 4444 %%%% !1110
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M^%C^X7Z5TU3@?X$2L=_'D%%%%=9R!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%5/[1M_-\O?\V<8H MT4A.!DUER
M^(M.AG$+RX<G&* -6BHXIDFB$B'*FJ5[K=EI[;;B3:: -&BJUI?P7L8>!MRF
MK- !7&>+/];^-=G7&>+/];^- '3:7_R#X?\ <J[5+2_^0?#_ +E7: "BBB@
MHHHH **** "BBB@ HHHH *X3XH?\BO=?3^AKNZX3XH?\BO=?3^AH 3X;?\@J
M/_<KO*X/X;?\@J/_ '*[R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=%%%:F04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\P5^U>G*NU OH,4  # I: &[%]!7'>*P!)P.]=G7&>+/];^- '3:7_R#X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8WB#_CR?\
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M '%>*O\ CX'TKCV^\:[#Q5_Q\#Z5Q[?>-?*8[^/(^MP'^[Q&T445RG6%%%%
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M !1110 4444 %%%% !7&>+/];^-=G7&>+/\ 6_C0!TVE_P#(/A_W*NU2TO\
MY!\/^Y5V@ H/2B@]* .*\5?\? ^E<>WWC78>*O\ CX'TKCV^\:^4QW\>1];@
M/]WB-HHHKE.L**** "BBB@ HHHH **** "BBB@ HHHH **** 'Q_?KO/"OW'
M^E<'']^N\\*_<?Z5W9;_ !T<&9_[NSJ****^G/E@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *R]<&=/E_W:U*S-;_Y!\O\ NUE7_AR-:'\2)A>$_P#78_V:["N/\*?Z
M_P#X#785S9?_  $=.8_QV%%%%=QPA1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** *5UI5I=G,T>[%4VT'24'S1J
M/JPK/\0^*/[+(2/:6/&#7)R:EK6M,?*A8(>ZF@#J[B;0]+RX0$KZ,*GT?Q+;
M:E<&&!'  SS7F<FF7AU**"Y>1?,;'+&O3/#WAR'2XUD5B6QCF@#HAR*6BB@
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M@D=T(XR: .ZHI!T%+0 4444 %%%% #)$$B%6&0:I6FC65G(TD,(5F.2:T**
M&2Q),A1QD$8KG9_!.DSS>8UJIR<FNEHH I:?I5KIL82VB"8&.*NT44 %<9XL
M_P!;^-=G7&>+/];^- '3:7_R#X?]RKM4M+_Y!\/^Y5V@ H/2B@]* .*\5?\
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M]OO&OE,=_'D?6X#_ '>(VBBBN4ZPHHHH **** "BBB@ HHHH **** "BBB@
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M !\#Z5Q[?>-?*8[^/(^MP'^[Q&T445RG6%%%% !1110 4444 %%%% !1110
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MSX<X\U/^^A0!)12!E895@?H::TL:?>D1?JV* 'T4U75QE6!^AIU !7&>+/\
M6_C79UQGBS_6_C0!TVE_\@^'_<J[5+2_^0?#_N5=H *#THH/2@#BO%7_ !\#
MZ5Q[?>-=AXJ_X^!]*X]OO&OE,=_'D?6X#_=XC:***Y3K"BBB@ HHHH ****
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MJ_X^!]*X]OO&NP\5?\? ^E<>WWC7RF._CR/K<!_N\1M%%%<IUA1110 4444
M%%%% !1110 4444 %%%% !1110 ^/[]=YX5^X_TK@X_OUWGA7[C_ $KNRW^.
MC@S/_=V=11117TY\L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2[66997C!8'(-7% 48%+10 4444 %%%% !1110 4444 %%%% !1110 4444
M%<9XL_UOXUV=<9XL_P!;^- '3:7_ ,@^'_<J[5+2_P#D'P_[E7: "@]**#TH
M XKQ5_Q\#Z5Q[?>-=AXJ_P"/@?2N/;[QKY3'?QY'UN _W>(VBBBN4ZPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ?']^N\\*_<?Z5P<?WZ[SPK]Q_I7=
MEO\ '1P9G_N[.HHHHKZ<^6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"[_ ./63Z5/
M4-W_ ,>S_2IE\+*A\2.*LO\ D./]*[F/_5K]*X:T^777_"NYC_U:_2O/R[:7
MJ>AF7Q1]!U%%%>D>:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%%% !1110 4444 %%%% #X_OUWGA7[C_ $K@X_OUWGA7[C_2N[+?XZ.#,_\
M=V=11117TY\L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4-U_Q[/]*FJ*Y_X]W^E3+9
ME1^)'$VW_(=>NYC_ -4OTKAH.-=?\*[B+_5+]*\_+MI>IZ.8[Q]!]%%%>D>8
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 9VL:?)J-IY,<IC)/45YIXK\&OIFE7%\M_B1%W#U_E7K$\R01,[D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBOISY8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "HKC_4-]*EJ.?_4M]*4MAQW.'7C7
MW_"NYB_U2?2N&/\ R'W_  KN8O\ 4I]!7G9?O/U/2S#:'H/HHHKTCS HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KC/%G^M_&NSKC/%G^M_&@#IM+_P"0?#_N5=JEI?\
MR#X?]RKM !0>E%!Z4 <5XJ_X^!]*X]OO&NP\5?\ 'P/I7'M]XU\ICOX\CZW
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MU/S3)?\ 5M2>PUN<-/\ +KS_ %'\Z[B'_4)_NBN'N?\ D/-]1_.NX@_U$?\
MNBO.P'Q3]3TL?\,/0DHHS1FO2/,"BC-&: "BC-&: "BC-&: "BC-&: "BC-&
M: "BC-&: "BC-&: "BC-&: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KC/%G^M_&NSKC/%G^M_&@#IM+_Y!\/^Y5VJ6E_\@^'_ '*NT %!Z44'
MI0!Q7BK_ (^!]*X]OO&NP\5?\? ^E<>WWC7RF._CR/K<!_N\1M%%%<IUA111
M0 4444 %%%% !1110 4444 %%%% !1110 ^/[]=YX5^X_P!*X./[]=YX5^X_
MTKNRW^.C@S/_ '=G44445].?+!1110 4444 %%%% !1110!C:OJ,MF5V=ZQO
M^$BNJZN:UCG^^H/UJ#^R[;_GFOY5PUJ%>4[PE9'=1KT(QM.-V<W_ ,)%=4?\
M)%=5TG]EVW_/-?RH_LNV_P">:_E67U;$_P YK]9PW\AS?_"175'_  D5U72?
MV7;?\\U_*C^R[;_GFOY4?5L3_.'UG#?R'-_\)%=4?\)%=5TG]EVW_/-?RH_L
MNV_YYK^5'U;$_P X?6<-_(<W_P )%=4?\)%=5TG]EVW_ #S7\J/[+MO^>:_E
M1]6Q/\X?6<-_(<W_ ,)%=4?\)%=5TG]EVW_/-?RH_LNV_P">:_E1]6Q/\X?6
M<-_(<W_PD5U1_P )%=5TG]EVW_/-?RH_LNV_YYK^5'U;$_SA]9PW\AS?_"17
M5'_"175=)_9=M_SS7\J/[+MO^>:_E1]6Q/\ .'UG#?R'-_\ "175'_"175=)
M_9=M_P \U_*C^R[;_GFOY4?5L3_.'UG#?R'-_P#"175'_"175=)_9=M_SS7\
MJ/[+MO\ GFOY4?5L3_.'UG#?R'-_\)%=4?\ "175=)_9=M_SS7\J/[+MO^>:
M_E1]6Q/\X?6<-_(<W_PD5U1_PD5U72?V7;?\\U_*C^R[;_GFOY4?5L3_ #A]
M9PW\AS?_  D5U2-XANBI'K72_P!EVW_/-?RH_LNV_P">:_E1]6Q/\X?6<-_(
M<%)/.]X9\<FMA/$-TJ*OH,5TW]EVW_/-?RI/[+MO^>:_E40P->#;C/<TGCJ$
MTE*&QS?_  D5U1_PD5U72?V7;?\ /-?RH_LNV_YYK^57]6Q/\YG]9PW\AS?_
M  D5U1_PD5U72?V7;?\ /-?RH_LNV_YYK^5'U;$_SA]9PW\AS?\ PD5U1_PD
M5U72?V7;?\\U_*C^R[;_ )YK^5'U;$_SA]9PW\AS?_"175'_  D5U72?V7;?
M\\U_*C^R[;_GFOY4?5L3_.'UG#?R'-_\)%=4?\)%=5TG]EVW_/-?RH_LNV_Y
MYK^5'U;$_P X?6<-_(<W_P )%=4?\)%=5TG]EVW_ #S7\J/[+MO^>:_E1]6Q
M/\X?6<-_(<W_ ,)%=4?\)%=5TG]EVW_/-?RH_LNV_P">:_E1]6Q/\X?6<-_(
M<W_PD5U1_P )%=5TG]EVW_/-?RH_LNV_YYK^5'U;$_SA]9PW\AS?_"175+_P
MD5U71_V7;?\ /-?RH_LNV_YYK^5'U;$_SA]9PW\A%I5[)=KE_2M.HH;>.$81
M0/I4M>A3C*,4I.[//J2C*5XJR"BBBK("BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H);N&'[\
MBCZM5?5[]=/L9)6('RG'Y5Y+9KJ?C"XFF2:6)(W*_(?>@#V:.:.5<HZGZ&GU
MY%X;UV\T;7Y=.NF9D4[59SUKUM&W1JWJ : '5QGBS_6_C78>:@.-U<?XJ9#)
MU[T =-I?_(/A_P!RKM4-,DC&GP_-_#5SSD_O4 /H/2F><G]ZD\Y,?>H X[Q5
M_P ? ^E<>WWC78>*2K7 P<\5R31Y:OE<<G[>1]9@&OJ\2*BI/+H\NN2S.RZ(
MZ*D\NCRZ+,+HCHJ3RZ/+HLPNB.BI/+H\JBS"Z(Z*D\JCRZ+,+HCHJ3RZ/+HL
MPNB.BI/+H\NBS"Z(Z*D\NCRZ+,+H2/[]=YX5^X_TKAD3#9KN/"S*J/D]J[\M
M3]NCS\S:]@SJ:*9YR?WJ/.3^]7TQ\N/HIGG)_>H\Y/[U #Z*9YR?WJ/.3^]0
M ^BF><G]ZCSD_O4 /I,CU%9VK:B+*QEF7DJN0*\NF^)UW',5%N.*VI4)U%>)
ME4K1I_$>Q9'J*,CU%>-?\+1O/^?<?G1_PM&\_P"?<?G6OU*J9_6Z9[+D>HJ*
M>ZBMDW2, /<UX_\ \+1O/^?8?G6)XC\<ZAK%JL4:-$1W4T?4JH?6Z9[=_;UC
M_P ]4_[Z%']O6/\ SU3_ +Z%?+?F:MDG[7/R<_>H\W5O^?N?_OJE]3J]A_6J
M9]2?V]8_\]4_[Z%']O6/_/5/^^A7RWYNK?\ /W/_ -]4>9JW_/W/_P!]4?4Z
MO8/K5,^I/[>L?^>J?]]"C^WK'_GJG_?0KY<WZM_S]S_]]4GFZM_S]S_]]4?4
MZO8/K5,^I/[>L?\ GJG_ 'T*/[>L?^>J?]]"OEOS=6_Y^Y_^^J/-U;_G[G_[
MZH^IU>P?6J9]2#7;(D#S4Y_VA5^*9)DW(P(^M?)R2ZJLJO\ :I_E.?O5WVC?
M$.^T^R\EXBY'=C3^IU1?6J9[MD>HHR/45XU_PM&\_P"?<?G1_P +1O/^?<?G
M1]2JA];IGLN1ZBC(]:\:_P"%HWG_ #[BKND_$6ZO;X1/  #BAX.JE<%BJ;=C
MUFBJ]O<I);QN3@LH-2^<G]ZN0Z1]%,\Y/[U'G)_>H ?13/.3^]1YR?WJ 'T4
MSSD_O4><G]Z@!]%,\Y/[U5;C5+:W;#R@&FDWL)R45=EVBLO^W;+_ )[+1_;M
ME_SV6J]G+L1[6'<U**R_[=LO^>RTV37[-(RPF4D4>SEV#VL.YK45Y;J'Q2GM
M;MXH[9656P#57_A;-S_SZ+4\K*YH]SURBO(_^%LW/_/HM'_"V;G_ )]%HY6/
MF7<]<HKR/_A;-U_SZ+1_PMFZ_P"?1:.5BYEW/7**\C_X6S<_\^BT?\+9N?\
MGT6CE8^9=SURBO(_^%LW7_/HM;GA[XA'59&6XC6( T<K$YQ74] HK,.N60/^
MN6D_MVR_Y[+5>SEV)]K#N:E%9?\ ;ME_SV6D_MZR_P">RT>SEV#VL.YJT56@
MOH+A<HX-3><G]ZH:L6FFKH?13/.3^]1YR?WJ!CZ*8)4)P&I] !1110 4444
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MH **** "JMQI]M=-NFB#$5:HH CB@C@0)&NU1VJ2BB@ HHHH **** "BBB@
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M44 %%%% !1110 4444 %%%% !6?J^I#2[3SRFX9Z5H52U.UM[VU:&X(VD>M
M&=IWB>UU&WEDC9=T?50:J:;XI6_UR6P$>"@SFO/]7TF^\)W$ES9'_17.Z3G-
M8>A>*C'X@FOXR<N.?UH ^A!R,TM<-HWCRVU"YCMR6WMQTKMXWWH&'>@!U%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!C'(KUV&$+$F[[P'- $%CIEO8(%AC5 /05=HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBJFH:A#IMJT\Q^4>] $EW=1V=L
M\TC *@R2:\IU?5[OQ/JTEIIT[J@&0T9K;G\<:3KJW&F&-PTGR MP*XZ"*X\!
MZXUUG-ET CY_E0!-#?7VDW2Z=JL3RQ3'!DE["GOX9%GJ8U&Q@^T6\K!0JC@#
M/_UZF\2^(+/Q6($M%8S;<9/8UZ'X/L9;3PU;6]Q]]>OZ4 /TS0[)$BG%K''(
M%!X%;H 48%  48%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC4?=#?A0!#;_  [N4D%N0XM0<\$UZ'H^CP:3;".(<D<YK3HH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBHS]*DZ=*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFA>$[E-4FO+YDDWG(Q5_5/!Z7FLI?QJH=5P":;X/UBZU:>622/$)&4([UV%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4!8-(1SZ D4Q]!UO0KMYM$FC6"0\ '/% '3_ !/@L7T=G#1BYW#ZUL^!3/\
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M,DB?96XQ[?G7?^%_"L&B1+(4 N",,: .DA!$$8/4*,_E3Z** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ;)(L2%W.%'4UPWB/QP]H[0:;&+B53RHK
MKM6MY;K39H82!(PP":\7M"?#/BNXEU>-Y8V&T%1QGF@#;M/$_P#PD!.F:S:I
M;O*< L.<5RVOZ;JGA^^7[/)*UC(^W.> M;6K&TUKQ/9RZ8F/EZCG'2O2VT.+
M4=!2UO$#N$('UH \^TWP=I^LZ;YME?D2GKLZYK>\+^'KW3;J1+EY)HP<*7.:
MD\,>$;WP_J8VR(+7<6*CZUWM #(XDC4!$"_2GT44 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !61KNOVNBVKR2R*'7L:UZ\\^)/
MAN\U6PEFMF'3&.] &%?>,-<EF,\6GL]J#G=V(J*[LX_%FE&_LSY%]TV1\&DT
MSQ?8VVARZ/=0R"=(_+RPP":U_ASI$L;B['$))XH Y#PQ!%)>S6>NR;) VV(R
M<DUUUS\/B+A;JQOI0FX?*AP*V_$7@6#4[^&[MD598SN)/K73:1:366GI#.P9
MQU(H -+MFM[2-)"695 R:OT44 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4UW5%RQP*5G5%+,0 .I-<!XZ\2/:VFRT<YW8W+0!W,-W#<$B-MV.#6+
MXG\,6VO6#QN K@$AE'.:Y;1?$\.CV?F7#B9I!NX/2NST;7[;685>(@$C.W/-
M 'C^@6MUX*UX6MPA:-W+!Y.2!GWKV^QN5N[1)DQM8<8JIJ&AV6HRB6>%7D P
M":NVUNEK;K#&,*O04 38HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBL_4=1BM8RID42$<#/- "W.L65K((Y90K$X JVI2
M>/) 93ZBO%)-<F/B6X:[1WB5LH"*ZBT^(\*WL=N]I)&F/O,,"@"GX\^'Z73K
MJ-GN$D1WE5X!K0^'NLSO EA<Q+'(#T KNX)8[^R60 &.1>E06^C65K<>?#"%
M?UH OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112-TH 6BN'F\;BP
MU=[6Y@*)OVAVZ53\2^.'AD\G3HC<DC.8^: )OB'XGFT6W2!"!YPQ5/PMH5OX
MD\+Q2W+,68]>M4+?7;3Q7;R6>IVRV\X&V-I>N:I:7<:AX-UG[)B2XM!P"/NT
M 7-:\(Z5HEG-YDTHD890$_\ UZL_#?2[F&[-U\QMF3"DFNY>R@UN"&>:($%<
M[36A:6<%G"(X8PBCH!0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BL;Q)?3:?I_G0QM(P/1:YFS^($$MA<&91%-'P$8\
MF@#N;IWCMI'3[RH2/RKQ4:_/JWCB""\;:H8J I[9JU+XQU9+LW7V2=[5SC&.
M,5+J=C:>(;,ZGIK);W<0QL3[Q- ';7?@_3+N$3N6&SYL@5P^KZ6VK:JMC9H#
M&1C(&#71>!M;O9PVFWT$FZ)<%W_BKMXM.M(I!*D"J_J* (=%LVL=*M[=L[D7
M!S6A110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ J(W$8;:7&3[U(WW3]*\%\5ZOK%IXD22
MS&..7)4'@B@#W>:))XRCC*D8KR'QWX#DAG_M'3D(5/F>NQ\*^,(-2M$2Z989
M^Z$\UU)-O>PLGRR(>HH \\\&ZK8ZKHR:1= ?:$0[@1[5#!X0O]&U^.33U_T1
MB6?-6]5\#R0ZO]OL9FBW.,HGIFN\LXR+:-9!E@H&30!!9:=%&?/*@2M][ K1
MHZ=** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9+*D,;.[  #/)KC
M[CXD:3;Z@+1E?<3C(Z5/XW6^FTY(K-6+%\':>W%<?<_#H'0YKF29Q<$9'J*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gfbaqn1kfu2x000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'B!P@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#GO$WB>W\.Q*\^[YAD8KCU^+VGL,K%<
M$>RG_"K'Q1 9K0$9!_\ KUI>!]%TV?P]&\ME"[$]2M %&R^+6DSS+$\4X+'
M+*1_2NZL-1@U&V$\+ J?>N>\1>$-/NM-F:WMXX9%7@HN#7&> -1GT[7QH<TC
M/M&<L: .YU'Q9;V.J6]FR2%IGV@@<5TH.0#ZUQ>KZK90:W:0R0QM([X4D<CK
M6UKGB&WT>VWEU,@_A- &W17G8^(-\'W/8XA_O^U=;HFNVVL6BS1R*2>PH UZ
M*Y77/&4&FR"*W*RRGC;[UA_\+$O8G!NK'RH\_>- 'H%W.MK:23M]U!DUA:1X
MIMM5O?L\6[=[T^;58-5\.7,L+ACY62!VKR[0=>32M9)3#R@?=H ]QJM?7:65
MN97Z"N)MOB!-]J2.\MA"C' 8UT&KWD-]H;30.'0@\CZ4 'AWQ+;Z]-<I!G,!
MP<UOUYA\*R!>ZP3_ ,]#_2NFUWQA;Z9*T$+++<#_ )9]Z .IHKS^V\?W)G47
MEH(8R?O'TKM;+4+>_M!<02!XSW% %NLG7]:AT.P^U39VYQQ6%K/CF*SG\FR"
MSR X8#L:Y#QCXN?4M"6"ZA$+[^0: /3]&U>+5H/-BSC&>:TZX[X?D'3,CH5%
M=C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2.2H_P#K5T_@* W-OX@A7DN2!^8K,T1+/1_%#6NJ11K$!]]Q0!=U[Q3X;O\
M2I8X[&X\X)B,[3P?RJ/P=KUS:>&5A =%P>"".U=3JNI^&;.P>6%;:27;E$V]
M:K:0S>(?#WF"P2WR"1M&.U &5\/-$MM3U'4;J\3>PDW*?RJ]\3/#-B=%%S%%
MB;?UJAX$UF+0]2U&WU%A!NDPF[OTJ]\1_%%A-H@@M)TEDW_=% &Y\/D\O2PG
MHH%=E7&_#]B^F;B,$J*[*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM.D\C<Y'K7H**$147HHP*=10!#=Q^;9S1_WD8?I7E?AU3X;\1FP;Y?M$I?\
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MMH!&@P!7,>&O#7V"\NKB;+-(^X;N<5UM !1110 4444 %%%% !1110 4444
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M^>\OYF@-#EO^%MZE_P _#_D:/^%MZE_S\/\ D:ZG_A1]C_SWE_,T?\*/L?\
MGO+^9H#0Y;_A;>I?\_#_ )&C_A;>I?\ /P_Y&NI_X4?8_P#/>7\S1_PH^Q_Y
M[R_F: T.6_X6WJ7_ #\/^1H_X6WJ7_/P_P"1KJ?^%'V/_/>7\S1_PH^Q_P">
M\OYF@-#EO^%MZE_S\/\ D:/^%MZE_P _#_D:ZG_A1]C_ ,]Y?S-'_"C['_GO
M+^9H#0Y;_A;>I?\ /P_Y&C_A;>I?\_#_ )&NI_X4?8_\]Y?S-'_"C['_ )[R
M_F: T.6_X6WJ7_/P_P"1H_X6WJ7_ #\/^1KJ?^%'V/\ SWE_,T?\*/L?^>\O
MYF@-#EO^%MZE_P _#_K7J'PT\4W'B/3Y)9Y"Q5\<US'_  H^Q_Y[R_F:[KP3
MX-A\*6;P1.S!FSS0!U]%%% @HHHH **** ///B/XLG\.6<<D+LI9L<5YI_PM
MV_\ ^>[_ )&O6?''@N/Q3;)$[,-K9XKA/^%)6W_/63\S0,P?^%NWW_/=_P C
M1_PMV^_Y[O\ D:WO^%)6W_/63\S3A\$;7_GK+^9H Y__ (6[??\ /=_R-'_"
MW;[_ )[O^1KH?^%(VG_/:7]:/^%(VG_/:7]: .>_X6[??\]W_(T?\+=OO^>[
M_D:Z'_A2-I_SVE_6C_A2-I_SVE_6@#GO^%NWW_/=_P C1_PMV^_Y[O\ D:Z'
M_A2-I_SVE_6C_A2-I_SVE_6@#GO^%NWW_/=_R-'_  MV^_Y[O^1KH?\ A2-I
M_P ]I?UH_P"%(VG_ #VE_6@#GO\ A;M]_P ]W_(T?\+=OO\ GN_Y&NA_X4C:
M?\]I?UH_X4C:?\]I?UH Y[_A;M]_SW?\C1_PMV^_Y[O^1KH?^%(VG_/:7]:/
M^%(VG_/:7]: .>_X6[??\]W_ "-'_"W;[_GN_P"1KH?^%(VG_/:7]:/^%(VG
M_/:7]: .>_X6[??\]W_(T?\ "W;[_GN_Y&NA_P"%(VG_ #VE_6C_ (4C:?\
M/:7]: .>_P"%NWW_ #W?\C1_PMV^_P">[_D:Z'_A2-I_SVE_6C_A2-I_SVE_
M6@#GO^%NW_\ SW?\C3?^%N:A_P ]W_(UT?\ PI&T_P">TOZT?\*1M/\ GM+^
MM :'._\ "W-0_P">[_D:/^%N:A_SW?\ (UT7_"D;3_GM+^M'_"D;3_GM+^M
M:'._\+<U#_GN_P"1H_X6YJ'_ #W?\C71?\*1M/\ GM+^M*/@A9_\]I?S- :'
M.?\ "W-0_P">[_D:/^%N:A_SW?\ (UT?_"D+/_GM+^9H_P"%(6?_ #VE_,T!
MH<Y_PMS4/^>[_D:/^%N:A_SW?\C71_\ "D+/_GM+^9H_X4A9_P#/:7\S0&AS
MG_"W-0_Y[O\ D:/^%N:A_P ]W_(UT?\ PI"S_P">TOYFC_A2%G_SVE_,T!H<
MY_PMS4/^>[_D:/\ A;FH?\]W_(UT?_"D+/\ Y[2_F:/^%(6?_/:7\S0&AS?_
M  MS4/\ GN_Y&E_X6YJ'_/=_R-='_P *0L_^>TOYFC_A2%G_ ,]I?S- :'.?
M\+<U#_GN_P"1I/\ A;FH?\]W_(UTG_"D+/\ Y[2_F:/^%(6?_/:7\S0&ASG_
M  MS4/\ GN_Y&C_A;FH?\]W_ "-='_PI"S_Y[2_F:/\ A2%G_P ]I?S- :'.
M?\+<U#_GN_Y&C_A;FH?\]W_(UT?_  I"S_Y[2_F:/^%(6?\ SVE_,T!H<Y_P
MMS4/^>[_ )&C_A;FH?\ /=_R-='_ ,*0L_\ GM+^9H_X4A9_\]I?S- :'-GX
MN:C_ ,]W_(TW_A;>I?\ /P_Y&NF_X4A9_P#/:7\S1_PI"S_Y[2_F: T.9_X6
MWJ7_ #\/^1H_X6WJ7_/P_P"1KIO^%(6?_/:7\S1_PI"S_P">TOYF@-#F?^%M
MZE_S\/\ D:/^%MZE_P _#_D:Z;_A2%G_ ,]I?S-/_P"%'V/_ #WE_,T!H<M_
MPMO4O^?A_P C1_PMO4O^?A_R-=3_ ,*/L?\ GO+^9H_X4?8_\]Y?S- :'+?\
M+;U+_GX?\C1_PMO4O^?A_P C74_\*/L?^>\OYFC_ (4?8_\ />7\S0&ARW_"
MV]2_Y^'_ "-'_"V]2_Y^'_(UU/\ PH^Q_P">\OYFC_A1]C_SWE_,T!H<M_PM
MO4O^?A_R-'_"V]2_Y^'_ "-=3_PH^Q_Y[R_F:/\ A1]C_P ]Y?S- :'+?\+;
MU+_GX?\ (T?\+;U+_GX?\C74_P#"C['_ )[R_F:/^%'V/_/>7\S0&ARW_"V]
M2_Y^'_(T?\+;U+_GX?\ (UU/_"C['_GO+^9H_P"%'V/_ #WE_,T!H<M_PMO4
MO^?A_P C1_PMO4O^?A_R-=3_ ,*/L?\ GO+^9H_X4?8_\]Y?S- :'+?\+;U+
M_GX?\C1_PMO4O^?A_P C74_\*/L?^>\OYFC_ (4?8_\ />7\S0&ARW_"V]2_
MY^'_ "-'_"V]2_Y^'_(UU/\ PH^Q_P">\OYFC_A1]C_SWE_,T!H<J?BWJ?:X
M?\C2?\+:U3_GY?\ (UU?_"C['_GO+^9H_P"%'V/_ #WE_,T <I_PMK5/^?E_
MR-'_  MK5/\ GY?\C75_\*/L?^>\OYFC_A1]C_SWE_,T <I_PMK5/^?E_P C
M1_PMK5/^?E_R-=7_ ,*/L?\ GO+^9IW_  HVP_Y^)?S- ')?\+:U3_GY?\C1
M_P +:U3_ )^7_(UUO_"C;#_GXE_,T?\ "C;#_GXE_,T <E_PMK5/^?E_R-'_
M  MK5/\ GY?\C76_\*-L/^?B7\S1_P *-L/^?B7\S0!R7_"VM4_Y^7_(T?\
M"VM4_P"?E_R-=;_PHVP_Y^)?S-'_  HVP_Y^)?S- ')?\+:U3_GY?\C1_P +
M:U3_ )^7_(UUO_"C;#_GXE_,T?\ "C;#_GXE_,T <E_PMK5/^?E_R-'_  MK
M5/\ GY?\C76_\*-L/^?B7\S1_P *-L/^?B7\S0!R7_"VM4_Y^7_(T?\ "VM4
M_P"?E_R-=;_PHVP_Y^)?S-'_  HVP_Y^)?S- ')?\+:U3_GY?\C1_P +:U3_
M )^7_(UUO_"C;#_GXE_,T?\ "C;#_GXE_,T <E_PMK5/^?E_R-'_  MK5/\
MGY?\C76_\*-L/^?B7\S1_P *-L/^?B7\S0!R7_"VM4_Y^7_(T?\ "VM4_P"?
ME_R-=;_PHVP_Y^)?S-'_  HVP_Y^)?S- '('XLZK_P _+_D:/^%LZM_S\O\
MK77_ /"C;#_GXE_,T?\ "C;#_GXE_,T!H<A_PMG5O^?E_P!:/^%LZM_S\O\
MK77_ /"C;#_GXE_,T?\ "C;#_GXE_,T!H<A_PMG5O^?E_P!:/^%LZM_S\O\
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MWE_,T?\ "C['_GO+^9H#0Y;_ (6WJ7_/P_Y&C_A;>I?\_#_D:ZG_ (4?8_\
M/>7\S1_PH^Q_Y[R_F: T.6_X6WJ7_/P_Y&C_ (6WJ7_/P_Y&NI_X4?8_\]Y?
MS-'_  H^Q_Y[R_F: T.6_P"%MZE_S\/^1H_X6WJ7_/P_Y&NI_P"%'V/_ #WE
M_,T?\*/L?^>\OYF@-#EO^%MZE_S\/^1H_P"%MZE_S\/^1KJ?^%'V/_/>7\S1
M_P */L?^>\OYF@-#EO\ A;>I?\_#_D:/^%MZE_S\/^1KJ?\ A1]C_P ]Y?S-
M'_"C['_GO+^9H#0Y;_A;>I?\_#_D:/\ A;>I?\_#_D:ZG_A1]C_SWE_,T?\
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M^9H#0RO#OQ/U"_UZTM7G<K(^".:]^'2O)-'^#UGIFK6]XLTA:)MP!S7K8X%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHK
MB=;>(R.< 4 $\Z6\+2.P 49Y-8]AXHL]0U 6D/+'N#FO.O%WC'5=0%Q9Z;")
M(TRKL.PK.^%JSIKL8G+%^^3F@#W.L?6/$5IH\3-*P9A_"#S5_4)_LMA-/_<7
M->,V\,GC'QMF65UMR,?*3CK0!W%M\2=/N+@1>1(F3C<P(%=A:7<5Y")(G5E/
MH<UQ.N^ [/\ L:1HI&62),J5X)K%^&VK36URNCS.6;.?F.30!ZO1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5'/"D\91QE34E% '.7WA_3;'3+Z:
M"W"R.A+'UKSWP'_R-:_Y[UZMK7_(&N_^N9KRGP)_R-:_Y[T >H>)6V^'+\CM
M$:\R^%8$MPLK?>W&O3_$*&3P_?(.IB(KR_X9,+74UM&X;<3C\: /6M0&[3YP
M>ZUXWX<)B^*RQC[NW^M>Q:FXCTRX<] F:\?\*I]I^)2W2\KC&?QH ]K[4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-)E1^-<)X)\*IXA6>\U=1/\ O#MW>F:U/C)*8]'L<'K.H_45T7@.,1Z,N!U
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M$>ML>E<S\5,?\(O=>NW^E &SX$O3>^%+.1CEBO-=-7$?#+/_  BMGGILKMZ
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MRW?A4QPKN;?TH =\.?\ D$K_ +@KMJX[P!;RV^EJLBX.P5V- !1110 4444
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M==Z%IUZQ:XME<GUI+70=-LW#6]LJ$>E:5% "8&,=JJ-I=F]PL[0@R+T-7**
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MA?6[:^TJ/]\@**JD$^@K1UG2(-8LVAF'8XXKS+_A#=:T65X]+C>2)F+?,QH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5:L/\ CZ7ZU5JU8?\ 'TOU
MIQW)EL?3GPW_ .08/]RNYKAOAO\ \@P?[E=S55/B(I_"%%%%06%%%% !1110
M 4444 %0W-K#=Q>7,@=?0U-10!%!;16Z[8D"CVJ6BB@ HHHH **** "BBB@
MHHHH **** "BBB@ IDD22KM=<BGT4 5[:QM[0L8(PA;KCO5BBB@"I=Z;:WPQ
M<1!Q[U5@\-Z5;/OBM$5O45JT4 (JA5"J, =*6BB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH
M ,TM)2T %%%)0 M%%% !24M% "9I:2B@!:*** $S1FBDH =124M "9HS12&@
M!U%(*#0 M%)1F@!:*2EH ***2@!:*2EH **** "BBB@!,TM)10 M%)0* %HH
MHH **** "BBDH 6BBB@ HHHH **2CO0 M%%% "4M)2T %%%'>@ I*6DH 6BB
MB@!LC^7&SXS@9Q7,S>+FB=E^PRG!QTKJ#R,&H#:0DY*+^55%I;HF2;V.3D\<
MNG_,-F/_  $U7?Q[,>FF3C_@)KL_L4'_ #S3_OD4GV&W_P">2?\ ?(J^:'8C
MEGW.$?QO=-]VPG'_  $U6?QAJ#=+.<?\!->B?8;?_GDG_?(H^PV__/)/^^13
M]I#^47LY]SS&3Q5JK?=MYQ_P&JS^(];;I'<#_@->K?8;?_GDG_?(I?L-O_SR
M3_OD57M8_P HO92[GCTFN^(#]T7 _P" U3DUCQ(W0W'_ 'S7MOV&W_YY)_WR
M*/L-O_SR3_OD4_;Q_E%[!]SPE]0\2O\ Q7'_ 'S5=YO$C?Q7'_?->_?8;?\
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M:'8+3[GRC_PA&I?\\9/^^:/^$(U+_GC)_P!\U]7?8;?_ )Y)_P!\BC[#;_\
M/)/^^11S0[!:?<^4?^$(U+_GC)_WS1_PA&I?\\9/^^:^KOL-O_SR3_OD4?8;
M?_GDG_?(HYH=@M/N?*/_  A&I?\ /&3_ +YH_P"$(U+_ )XR?]\U]7?8;?\
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M7?8;?_GDG_?(H^PV_P#SR3_OD4<T.P6GW/E'_A"-2_YXR?\ ?-'_  A&I?\
M/&3_ +YKZN^PV_\ SR3_ +Y%'V&W_P">2?\ ?(HYH=@M/N?*/_"$:E_SQD_[
MYH_X0C4O^>,G_?-?5WV&W_YY)_WR*/L-O_SR3_OD4<T.P6GW/E'_ (0C4O\
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MI: $I:2EH **3O2T %%(:!0 49HHH 6BBB@ HI*6@ I*6DH 6BBB@!*6DI:
M$I:** "DI:2@!:*2EH **** $Q2T44 %%%)F@ I:2EH *2EI* %HHHH 2EI*
M6@ I*6B@ HHI,T +1124 +124M !24M)0 M%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% "44M)0 M%%% !1110 4444 %%%% !1110
M 4444 %)BEHH **** "BBB@ HHHH **** "BDI: $HI:2@!:0TM)0 9I:3%
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M %)2TE !1110 4444 %%%% "T444 %%%% !24M)0 M%%% !28I:* $HS110
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M85<M;V&\3=$V10!8HHJI>:C;V(S,^* +=%9MIKEE>OLADR:T0<C(H 6BBB@
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M0!)^M=39:NDV,-UH ZQ) 12EA6;!<AP.:LALTADI:HFDQWI&; JA=7 C!YH
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MM S5W>]+NK-6['K3OM0]: +^\4FZJ'VD>M+]H'K0!>WTNX>M9_VD>M*+H>M
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M=R7%U(68D9JG4DXVSN/0U'2+"BBB@ !(IWF..C&FT4 /\U_[QI/,?^\:;10
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MD_#.@S&979&'/I7M&A6IBA4&JFFZ*L07"=/:NIM+7RU'%,1=MTPM/=>*DB7
MISCBD,P;Z+<#7%:YI'VA6&.M>AW$6[M67<68?.13$>$ZIX3D,A* ]>PK)'A6
MXST;\J]XFT=6.=M5SHB?W/TH'<\>MO"<G&X'\JU[?PN47I^E>EKI"@_=J<:8
M,?=H$>7R: XZ _E5630I,=#7JSZ4#_#4#Z./[M 'C]QX=E)R :H2^'I_1J]K
M.B*1]VJSZ$N?N?I0.YXC-HMQ&/N,:IFRG7K&U>Y2^'T9?N?I6?)X6C=O]7^E
M(+GC?V:;./+:MC1].N#,K885Z(WA&-6SY?Z5H67A]8B,)^E,+EKPU#)'&@.>
ME>@6.0HK"TRP\L#BNDMH\ 4"-&,_+39>E*HXH8<4AF7<@X-8%]NR>M=//'D&
MLBYMMQ/%,1S+(V>]-VM6V]E[4S[%[4 92JWO3@C^]:JV7/2IQ9#'2@#%"/[U
M($8#O6K]CYZ4[[)QTH Q65O>D"-UYK8-G[4?8^.E &*^['>JCJ_O70M8^U1_
MV?[4 <^L<F[O6E:QL".M: T\>E6(;3!Z4 6+/.!6S!D@51MX,8XK2B7%(9:C
M'%/-(G2G4 0R#BLZ<5IR#BJ<J9H PYE.XU7V'-;$D&3TJ(V_M3$9NTT\(:OB
MV]J=]G]J *04T_8<59\GVIXAXZ4 4"IS2>6:O^1STI_D<=* ,W8:0H:T?(]J
M:UOGM0!G!2#5B%RK"IOL_M2B#VH MP35>27BLV-,584D4#-$,"*<*J1M5I>E
M(!:1NE+36Z4 5)SQ6;,I-:4@S4!BSVIB,OR234RP5=6#GI4HB&* *0AXI?)J
MX4I E %7R:0PU>V4FRD,H^1[4?9ZO[*7RZ8C,,'M2?9\UI&*@1XH H+;8JPD
M>*LA*=LI $8Q4Q^[2*O%*10,H70RIKAO$]A]HMW&*[Z=,BL+4+;S%(Q3$?->
MMZ-/;W<C!&(+5BF&0=5->^:IX?2?=E.OM7+S^#8BY(CHL.YY5Y;_ -TT];>5
MNB&O44\%1=XZLQ>#XHSQ'^E(=SRH:?<GI$U']G7/_/%J]DC\.(!C9^E/;P['
MC[GZ4Q7/%_L-Q_SR:D-G..L;5[(?#49_@_2H9/"T;?\ +/\ 2@+GCIAD'5#2
M"&0_P&O5I/!\3'_5TB^#HA_RSHL%SRHPR#^$TGEO_=->K-X-A(_U=59/!J=H
MZ0[GF>QO0T;&_NFO1#X.']RG1^#1GE* N<+8Z?-<SH C8)KV+P?I+VL$8(.:
MKZ3X;CMW'R=_2N\TRS$:KQ3$V;5BA6,?2KQ&5J&!,+5G;Q2 Q-1@WHU>=>)=
M&-S$PQ7JUQ%N!KG[^Q$@/%,1\[ZEH,UO*=JL<GTK-&FW1_Y8O^5>YWN@K(W*
M553PZ@_@_2BP[GC\>B7+C_5L*F3P]<,<;6KV)=!0#[GZ4]=#0'[GZ4!<\D3P
MK.1GYJL1^$Y<\Y_*O7%T=<?=J5-)4'[M 7/+$\(MCD'\J<WA,XX'Z5ZP-+']
MVE_LI?[M CQN7PC(3QG\JA7PA-GJWY5[,VEK_=I!I*Y^[0!XV_@^;'5ORJLW
MA2=3_%^5>W'25(^[43:,I/W/TH'<\6C\*SEQG=^5=5H?A?RF5F7)^E=^-&4'
M[M:%KIH0CY: N5](T[R@HQTKKK:+"BJEK;[<<5JQ+@4"'QK^\6BID&&%%(9:
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*3%.I* $HI32
M4 (13=M28I,4 1;::4J?%)B@" I2%*L8I"!0!6*4TI[5:VTW90!4\OVI1'[5
M;V"F[* *^RG!/:IME."4 0A:<$J8"EQ0 P"@BGXI* (66H73VJT1496@"DT>
M>U,$/M5TIFC90!3\@>E A]JN;*7RZ!%3R>.E-\FKFVE\N@95$(QTI# /2KFS
M%&V@"CY&.U'DCTJX5I E %3[/[4?9QZ5>"T%*!&>;<>E-^S#/2M#91LH&41;
MCTJ9(@.U6 M."4 (B5*%I56G4 1MTJM(H-6F%0E* *+P U ;89Z5IE*C,?-,
M11%J/2I%ME Z5;$=.V4 4C /2FBV&>E7_*I?*H H&V'I1]F'I6AY5)Y= &<;
M4'M33:"M/RZ/*]J0&4;04W[(*U3'3?+I@9GV-?2E%HH/2M+RZ/+H KQ6P':K
MB0X%*B8J=1Q2&0E>*K31Y'2KS#BHV3(H YVZM=Y/%9,^D(^<J*ZZ2 $]*K-;
M#TIB.+?0(B?N#\J9_P (]$?^68_*NS-J/2@6H]* .+_X1V//W!^52+H,8_@'
MY5V!MAZ4GV;VH Y4:+&/X1^5/&BQG^ 5TWV;VIPM_:@#EFT2/'W!^51_V''G
M[@KK?LP]*!:^U ''OH,?]P?E5:3PY$?^68_*NY-J/2F_9 >U '$0^'(U;/EC
M\JVK71TCQA16^MF,]*L1VX':@"M9V@3'%:L<>!1'&!VJR%P*0QFSBHG3-633
M2N: ,R:'/:J$EF&ZBMUTJ$Q4Q& VFH?X10--7T%;AB]J!#[4 8PT]<=*4:>O
M]VMGRO:E\J@#'^P+CH*:;!?2MKRA1Y0H Q?L"X^Z*;]@7TK;\JD\F@#&&GK_
M ':7^SEQ]T5M"$>E!BH Q?[.3^Z*<NG*.PK7\KVI1'0!3AM@O:KT<>!TIRI4
MZ)BD,15H9:DQBC% %1XZKM"/2M!DJ,I0!G&W![4PVH]*TS'3?*]J8C,^R#TI
MWV4>E:/E4>5Q2 S3;#TIGV4>E:?ET>73 S/LH]*8;)3VK6\JFF*@#'-@OI33
MIZ^@K9\KVI/*H Q&TY3VI4T\ ]*W/*% @]J *<%J%[5>CCQ3TBQ4RI2&*J\4
M,O%2"@T 5'CS566 &M%Q412@#,-M[4?91Z5H^72^73$9HMAZ4_[/[5?\NCRZ
M *'V?VH^S^U7_+]J/+I#*'V<>E)]G]JT-E'E^U &=]G'I2?9QZ5H^71Y=,1G
M_9QZ4]+< ]*N^72A:0$<<0':K"H*55J0"@8 8I:6B@!A&:B:.IR*3% %-HJ;
MY0JX5INSB@"N(12>35H+3MM %/R*7RJM%:3;0!6$5+Y?%6-M+B@"KY5'DU:V
MT8H J>3[4AA]JM[:-HH I^7[4X)5K8*-@H B1>:L 4@6G4 .IK=*=3: (62F
M[*L8I,4 0A*4KBI<4FV@"+;2;*FQ2XH C"4A3FI:,4 ,"4;*DHH CV4FRI:*
M &*E+M'I3J* $Q1CBEHH @D2J$\((Z5IOS5=TH P9K0,>E5#IZG^&N@>')Z5
M&8/:F(Q!8+_=IXL%Q]T5L>1[4[R..E &(;$#M2?8AZ5M&#VH\CCI0!B?8AZ4
M&Q7TK:^S\]*#![4 87]GKZ4?V>OI6YY'M1Y'M0!B?V>N/NU&VG*?X16_Y/M3
M#![4 8']F)_=% TM0?NUO"W]J>(1Z4 8\.GA3]VM6WM]N.*G6$>E6$3% "Q)
MBI]O%"+3\<4AE25<U0F@W5K,F:A:'VIB,.2S![5&+,?W:VVAIGD>U &3]B'I
M0+(9Z5K^3[4"'VH SELQZ4&T'I6IY6!2>70!G+; =J<;8>E7_+H\N@#+:VYZ
M4HM?:M+RJ!'0!G?9O:C[*/2M()3O+H S!:^U31VP':KWEBG*E $4<.*M(F*<
MJ5*!2&-4?,**D'6B@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %)2T4 ,)I12D4 4 ':B@TE "TAHHH 2BEHH 2C%+10 F*3%/HH ;BB
MEHQ0 E+12XH 2DQ3L4E "8II6GT4 ,VTA6I*0B@!@44['%+BC% $>*>!2[:*
M &D48I<4H% #-M&VGT8H :%H(IV** (]M.VBG8HQ0 S;3P*6B@ I*6EQ0 W;
M32M24AH A*TW9S4^*,"@" )2A>:FQ28YH 3;Q31UJ2DQS0 F*:14E)B@!@6E
MQ3\48H B*TW94^*3% $.REV5-2T 1!*?C%.HH 9BD(J2DH K,O-,,>:LLM)M
M% %7RJ7RJL;12XH$5?*H\JK6VDVT#*OE>U!BJV$H\N@"JL5.\K%6 F*4K0!4
M\NE$0JSLI"E $*Q>U/$52@4^@"-1BI!28%**  BDIU% #"N:C,=3TE $ 2EV
M5-BC% $.RDV5-1B@"'9[4NRI<4N* (-E&RI\48H @VTNRI=M&* (O+HV5-BC
M% $2K4H%&*6@!,4N*** $(I,4ZC% #"*0"GXHQ0 W;2;>*DHH BV4FRI<4F*
M &[!BD\L5)10!%Y=)LJ:B@"#92A>:FQ1B@!H%.Q2T4 )2XI:* &$4FVI"*;0
M W%&*?BD% ";:-M.HH ;MI-HI])0 W:*-M.HH ;MHVTZB@!NVC;3J6@!H%/%
M)BEH *2EI* "C%+10 F*3%+10 F**=BDH 3%*!110 8I,4[%&* &XHQ3L44
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M@ HHHH **** "BBB@ HHHH **** "BBB@!#1110 M(:6DH 2BEHH 2BEH%
M**6CM0 VEQ0*6@!,49I:3% !FEI,4E "T8HI: $Q24ZDQ0 E%+BC%  ****
M$HHHH **44N* &TN*** $I<44M #:44E.H 2C-+3: "BBB@ HI<44 &*3O2T
ME !24[M24 )12FB@ H%%% "XI*** "BEHH 2BEHH 2BBB@!"*3%/Q24 -Q1B
MG44 )1BBG4 -Q12T4 -HI:* "C&:7%+0 W%%+24 +2XH%+0 E%+2&@!***6@
M!**7%)0 E.Q24M "4444 %%+1B@ HQ1BB@!*448HH ,48I:* $Q1BEI#0 8H
MI** %HQ24M "44N** $HQ2TM "4E%+B@!**=BDQ0 VEI<44 %%%% !1124 *
M:2BEH 2E I*=VH 3%&*** #%)2T8H 2BEQ1B@ Q1BBB@ Q1124 .HI*6@ I,
M4M% "4AIU)B@ %+110 4AI:* &THHQ10 M%)10 4"BEH *2EHH 2DIU% " 4
MM%% !124M !1110 4444 )1BEHH **** "BBB@!*6D[TM "&DI324 %%% H
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M%&*6B@!,4=Z6D[T %%+10 F*,4M% #:,TIIM "T8H%+0 E%+24 +BD-.I#0
MVEHHH 7%&*!2T )24ZC% #:6EI* "BBEH 2C%+10 F*,44M "&DI:2@!:2EH
MH **,44 &:,T44 +1110 4E+28H 6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHI#0 M%)FEH *3-+10 F:6BB@ HHHH **** "
MDI:* $[44M% !1110 44E+0 4444 %)110 M%)10 M%)2T %%%% !124M !1
M110 4444 %%%% "9I:** "BDS10 M%%)0 M%%% !1110 44E&: %HHHH *;3
MJ3% "4M+24 %%%% "T444 %%%% !1110 4444 %)2TE !1110 4"BEH *2EI
M* #-&:** #-+3:6@!:*** "BD-&: %HHHH 2C-+28H *2EHQ0 4M)2T %)2T
ME  *6D%+0 44E% "T444 %%)2T %)2T4 %%%% "4M%% !1110 E+124 +111
M0 4444 %%%% !1110 4444 %%%% !2=Z6B@ HHHH **2EH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!*6BB@ I*** %HI*6@ HHHH **2EH *3O2TG>@!:*** "BBB@ I,4M% ""E
MI*6@!**** "EHHH 2BEI*  4M)10 M%)2T %%%% !1124 +124M "44M)0 4
M444 %%+10 4444 )112T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %(:6B@!M**6B@ HHI* %HHHH **** "DS2T
M4 )FBEHH **2B@!:0T4M "9HHQ2T %)FBB@ S2TF** %HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH @O/^/*;_ '#7@6O?\A%_]X_SKWV\YLYL?W#7@^NVT[:@Y$$A
M^8]$->A@-V<&.V1C45-]EN/^?>7_ +X-'V6X_P"?>7_O@UZ=T>=9D-%3?9;C
M_GWE_P"^#1]EN/\ GWE_[X-%T%F0T5-]EN/^?>7_ +X-'V6X_P"?>7_O@T70
M69#14WV6X_Y]Y?\ O@T?9;C_ )]Y?^^#1=!9D-%3?9;C_GWE_P"^#1]EN/\
MGWE_[X-%T%F0T5-]EN/^?>7_ +X-'V6X_P"?>7_O@T7069#14WV6X_Y]Y?\
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gfbaqn1kfu2x000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfbaqn1kfu2x000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .J!)$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBC(]: "BBC- !1110 4444 %%%% !1110 4444 %%%% !11D44 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %4-6U)=+M#.P! S5^N5\=_\@8#U
M)K2C%3FHL3V.<_X6FSR.(M/+A6(R/_UU>TOX@S7]T(3IS)DXS_DUE^ -"TRZ
ML+EY\;O,/4CUKMK?P]I=N_F1 ;ASP17H5_JU.3@HZHE<S'>(M;72-&>\(R0
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M16UK5N]KX0MHG'S+UK5RJ)4G/XA::E7X;:#9MITLYB0NLA ./<UZ2B!$"@8
MKBOAI_R!9_\ KJ?YFNWKS\;*4J\KLJ.QQ/Q))'AR8CKFN T7Q5KL%L8(--D=
M ,!A7H'Q&_Y%^7ZU9\'V<#:7$VSG9771JPIX7WHWU$U>1P^D>'-3\0:V+W4%
MEB0\[6Z5TOCZ/[)X>\M.3'%@5WJ(J+A1Q7$_$/\ Y![ CC;44\3*M7C=62Z
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MBP\)WVG@R6VUP<'<P']*[E*FL/S6>K>Q.MSEH[YXO$UI_9Z8C>7Y@G3%=?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 45ESZW!#?FT)&\>]:2-O0,.XIN+6
MX#J***0!14,]U#; &614STR:?%*DR[D8,/44[/<!]%%%( HHHH **0D*,DX%
M4YM6L8#B2ZB4^A--)O8"[15.'5+*X.([F-C[&K1<!"V> *&FMP'45DIKMN^H
MK9@KO/O5^:\@M]OFRJF[IDTW"2W0$]%,CD25=R,"/44^I **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBJ5_J,=@H,A'/K32;=D!=HJM8WB7UL)DQM/
MI5FAJSLP"BBBD 4444 %%%% !116;J&L0Z>P$A')QR::BV[(#2HJ.&431*XZ
M,,U)2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDDR1+EC@4KN$7<
MQP*\LO=?N=<\0M86S,BPR;6*GK6]"A*JW;9";L>F0WL,YPC4^6ZBA95=L%NE
M<Y)I-Q80"5+AF(&<"N)O?$%SJ?B&SMHG9?+DVO@]:NEAO:-\KT0F['KRL&&1
MTI:K1,MK;#SG  [FHQJ^GEMHNH\^F:Y^5O8HN$@#)JL^H6Z2!"XW'WKGO&FL
MOI^D)+;9;S#MRO:O/=-T34M;ADO8]7E#!N$!_P#K5UT<(IP]I.5D2Y:V/:&N
M(U0,3P:=%*DJ[D.17&FTOH?#K(\LADBC)W'O6?\ #O6YKF)K:Y9C)YA W=>M
M1]6;A*<7>P7U/0I)5B&6.*C^UQ>7OW?+7#>/M;EM9[.VMV.Z5MIV_C5'6I[S
M3?!0D,C^;NZ]Z<,(Y1B[_$',>CO=11IN9ACZTL-U%.,QL#^->)Z/;Z]XEC;-
MQ<0*O0^M+9:CJ?A3Q(UI<S2SQ A06/'7%=#R[>*DG)=!<Y[>\BQKN8X I(Y5
ME&5.17-^);R0>%WN8V*L8PPQ4/@>ZEN=+B>5RQ*]ZXO8OV;GYV*OK8ZB6=(O
MOG%/5PZA@>#7GGQ$U"XLV/DR,OR]JUH-9:R\&PW$AW2-$2,]2:OZM+V<9KJ%
M]3IY[V&W_P!8X'XTZ&YBN%S&P/XUXQI]GK/C"5K@74]M'N(QVKH- T76-)U#
M;+<S31ENIZ5O4P<()IS7,N@E*Y'K!;_A.WY/0=_>O2K3_CTB_P!VO-=8_P"1
MZ;Z#^==-XCUT:1H@ ^^T?%%:#FJ<5V$G:YT4U_! <.X'XU)%/',N48$5XM:6
M-UX@A^V/K3P;AG83_P#6JQHFLW.A:[#82WC7*N?O$U4L!HU&5VN@<YZ-XDTS
M^T(X@21M;/!J]I4"V-EM)X'J:Y7QYJ<T.GV<T#LN^09V_6K5K>3-X2DF+G>,
M<_@:Q]E-T8N^EQWU.L%S$03N''7FF17T$K[%<9^M>&:9?ZWJ^LW=K%).$#8W
M ]*L:Q8ZSX4<7SWL\T8/()XKH_LVTN1S5WL+GZGNE':L3PSJG]IZ3!*?O; 3
M6S(<1L?8UYLHN,G%EG#^-_%;Z8!9VK#[1*/E%<IIWA77==C%U? A7&1M)HU6
M,W_C>S\PY57Q@U[!;1+! L: !1V%>G.HL+2BH+5ZW(MS/4\9U70]<\+H;RU!
M\J,9))-=QX2\3?VWI+1R-F=8R7%=%K5K'=Z9+%(H(([UYMX-C^R^(=4B0X4*
M0 /I1[58BBW->]'J%K,+$M_PL:#YCC![^XKM?$&D_;WMF)(V'/!KBK'_ )*+
M;_0_S%;/Q U">SFT\0R,NYN<?C3JQE*M!1WL"V.TTR 6UFL>>E23WL%N?WC@
M9]ZYV+5VLO#'VJ0EFZ<_2O/;:QU?Q9=74B7LT"QMP >M<U/"^T<I3=DAN5CU
MX:O:'_EH/SJY'*LB[E/%?.[Z;K-IXF-A)J4VU"/F)Z\UZAK&JR^'O#H02&69
MXP5]:TKX%0<5"5[B4NYV,U_;P'#N ?K4L-Q'.N48'\:\9TW0=<\21_;&OIX%
M<9"T0W6K>$M;BAN9IIX3R6;I3> B[QC-.2Z!S'M#R+&,L:C-W"(C(6&T>]<Q
MKVIO+X9%W"Q4M&2,5YCX;;7?$B/")[B*,N1OS[UG1P3J0=23LD-RL['NL-Y#
M/G8P./>B:\A@^^P'XUX/JEUK7@V[1&FGN?.; R?\^E:MOIVN^);;[:;F>V!&
M=E;2RY12FYKE?47.>SQRI*N5(-.)"C).*\@\$>(+VSU233KUW<^9L5G-;7CG
MQ0UO(;"!RD@;!(//-8RP,U5]FOO'S*USNCJ5L)-A<9^M6E=77*G(KQ9]!NFM
M3>?V^X<C<$S_ /6K=\">))9;Z739I#(8E^^3UJJF"2@YPE>VXE+4]):XC601
ME@&-,-["'V[QGZUY%\0]9U"S\3PPV;2'='G:I^E7M"\/:S=O!>S7TR@D,4-'
MU%1I*K.5DPYM;'JX.1FN+\>DB*+!(XKKX%*1*K') KD/'O\ JHOI7/AOXJ*E
ML:'@G/\ PCT636_+/'"I9V  ]ZYGPK<"U\*)*QZ _P JX&\U:Y\2ZI)#'?/:
MHCE20:V6&=:K)WLD*]D>P07T%P<(X/XU)+.D(RYP*\3OK>[\-/'<)K#W(+@;
M<^_TKK-4U2?5_"$UU;.R/&H'R_2G/!6<7&5TP4CT*.19$#*<@TDLR0C+G%<?
MX"U=KS3TMYG+21K\Q/6LGQQJ]Q_:PTZU=@SKD;:RCA9.JZ?8.;2YZ.DBNNX'
MBJ\NHV\3[6<9^M</K?B!]%T"RA9CYTR;2<\@URUOH]WJD!NGUUXF/.TG_P"M
M6E/!W7--V0.1[3'*DJY4@BO.?'Q(G3!(_>CO[UE>%/$<^GZK_9\]PT^Y]H9C
M6KX^YF0C_GJ/YUI2P[HXA)B;NCN]).-+MR3_ ,LQ4CZA;QOL9QGZURGB#5I=
M)\)+)"I+"$'(^E<+I.DZGXBM8[]=5EC9OF\L'I^E13PBG%U)RLKC<NA[<K!Q
ME3D4M<[X3@N[:P:.[=W8' +5T5<<X\LFD[E(****@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM=,\XT/PEK=SI,3PRQ[#TYK3LO .H_VM#=7;QDIZ&LRWG\2>'6^R06<LT2#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4UT5QAA3J* (4MHHVRJX-2-&KCD4ZBBX#50(,*.*
M=110 A (P:B%M$&W!>:FHH  ,#%>>?$"WN]1+64.=C#TXKT.F-#&[99%8^I%
M:T*OLI\XFKHR?#.G#3]'MTVX?9AJV&4,,$4  # &!2U$Y.4G)C$"A1Q36C5C
MDBGT5(!T&*B:"-SEAFI:* &>6NW&.*<  ,"EHH C>".3[PS2I&L?W1BGT4 ,
M,:EMQ'-/HHH B>WCD.67-.2)(QA1BGT47 :R*_44;!C&.*=10 U453D#K0R!
MQ@BG44 (JA1Q2T44 %1/;QN<LN:EHH 8D21_=&*?110 SRUW;L<TK(K8R.E.
MHH YGQEH\NJ:,T$. V<\UYE8W^K:&TL&V4\X&U#7N1 (P1FH396K'+6\1/NH
MKMH8OV<.24;HEQN[GBG]GZKXJO567<(PP;#J1WKV/2;'[#810]U4 U:2V@C.
M4A13[*!4M3B,4ZR44K) HV(FMXW.66GJBH,**=17)<H1E##!I%14&%%.HH :
MT:L<D=*4  8%+10 SRUSG'-/(S110!";6(MDKS4JJ%&!2T4 ,,:EMQ'-/HHH
M *1E#=12T4 (JA1@4CQJXPPS3J* (DMXT.57%2T44 -=%?[PS2JH08%+10 5
M$UM$YRRU+10 U$5!A10R*W44ZB@!-HQCM47V:+=NV\U-11<  P,4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YCQ]_P B?J'_ %RKIZYCQ]_R)^H?]<J .)^"
M_P#R"8/]W^E>NUY%\%_^03!_N_TKUV@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF/'
MW_(GZA_URKIZYCQ]_P B?J'_ %RH XGX+_\ ()@_W?Z5Z[7D7P7_ .03!_N_
MTKUV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBFF1!U=1]30 ZBF>=%_P ]
M$_[Z%'G1?\]$_P"^A0 ^BF>=%_ST3_OH4HD1NCJ?H: '4444 %%%% !1110
M4444 %%%% !1110 4444 %<QX^_Y$_4/^N5=/7,>/O\ D3]0_P"N5 '$_!?_
M )!,'^[_ $KUVO(O@O\ \@F#_=_I7KM !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 (>E>*^-/$GB2RU-TLK7?&&P#FO:ZH3Z-8W+[I8 Q- 'S[_P )CXQ_Y\?U
M_P#K4?\ "8^,?^?']?\ ZU>]2:%I,2;G@15'<FLF67PQ"Y5GMP1_MB@#QO\
MX3+QC_SX_K_]:NV\ Z_K^H7.-0MO+7=ZUU7VKPM_STMO^^Q5O2]0T5Y]ED(R
M2>JMF@#IJ*** "BBB@ HHHH **** "BBB@ HHHH **** "N8\??\B?J'_7*N
MGKF/'W_(GZA_URH XGX+_P#()@_W?Z5Z[7D7P7_Y!,'^[_2O7: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /,_BOXEN-(T:6.W(W]N:\+U#PUXEF@349
M/.$<PW@B1J]>^,UG+)I\DJH67(Z"M"%8-2^'R"(*TL%MR!U!S0!XE;^!?$MU
MI*ZA%YYB)Z^8U>E?!_2A'),9YI3+&^"&8GFH/#/CJVTK1#IE[&-R@\,?:G?#
M2[FO==N984983,3QTQ0![U1110 4444 %%%% !1110 4444 %%%% !1110 5
MS'C[_D3]0_ZY5T]<QX^_Y$_4/^N5 '$_!?\ Y!,'^[_2O7:\B^"__()@_P!W
M^E>NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 96NZ+;ZW8-;7"Y5JR-
M \*V^D0W4'_+.88P3VXJ+QWXM7PUI4DP4,Z]J\7?XC>([V9Y+:PN&0G(*D?X
MT =QXB^$-IJ6J-<PK\I/8UVOA#P?9^&[79"N&/6O$O\ A./%?_0.NOS'^-=S
M\/O$>MZE<[;ZTFC7=_%0![!1110 4444 %%%% !1110 4444 %%%% !1110
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M=U_WU7>?#JQU^&YSJ"S ;OXVS0![)1110 4444 %%%% !1110 4444 %%%%
M!1110 5S'C[_ )$_4/\ KE73US'C[_D3]0_ZY4 <3\%_^03!_N_TKUVO(O@O
M_P @F#_=_I7KM !1110 4444 %%%% %:[L8+U-DRY!K+_P"$1TG_ )XUNT4
M87_"(Z3_ ,\:Y.7PUI@UET\HXW5Z37&S?\AV3_>H TT\):247]SVIW_"(Z3_
M ,\:VT_U:_04Z@"E8Z5:Z>@6W3:!5VBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,K5=6L].0M<E0!ZG%8O_  F6B?\
M/2/_ +[%<S\8+(2Z)-(LTB-_LL17E?ASX:ZSK"F25[D1'E2)&Y% 'O7_  F6
MB?\ /2/_ +[%/C\::,&PLD8_X&*\*\1_"[5])M_.@DNF7/4R-3?#_P /)]:M
M)6CNKHS1\$"1NOYT ?2MCJUIJ"@PS1MGL&!J]7S;X8N-4\'>*6LKII#&"%&]
MR>O'>OHRUE\ZUBD_O(#^E $U%%9&N^(;'0K5YKJ4(%]: +MYJ$%BH::15!]6
MQ266H07\>^%U9?8YKYG^(7Q*N-<N5@M),1(V R'&17IOP:FEF\/QM)(SDGJQ
MS0!ZL2 ,FLV]URQL3B6>($=BX%4_%>LKH^BW$^X!E3(KYLSKGC_6Y#;-+L89
M&QR/Y4 ?3UGKMC>G$5Q$3Z!Q6GD$<5\G>5KO@/6+=KEI@F<G>Y/\Z^BO#7B.
M/5?#"WQ8;_++''L* -R\U&VLD+331KC^\P%48/$NG7$FQ+F+/_705\]^-?$N
MJ>*?$0TZQ9N25^1B.G':LJ^\*^(O#4$%^YN.NX[I&Q0!]8(ZNNY6!'J#3J\U
M^%GBZ37-*6.<CS VVO2J "N8\??\B?J'_7*NGKF/'W_(GZA_URH XGX+_P#(
M)@_W?Z5Z[7D7P7_Y!,'^[_2O7: "BBB@ HHHH **** "BBB@ KC9O^0[)_O5
MV5<;-_R'9/\ >H [!/\ 5K]!3J:G^K7Z"G4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 457NYG@@9
MT&6 XKGCXAO@V/*6@#J:*Y7_ (2&^_YY+56Y\7W-LRB1%&XX% ':45RB>([U
MUW")<&E_X2&^_P">2T =516-I>J7-Y(%E0*/:MF@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#Q[XSM=KILAB#% >@%:G@+QKIG]BV]O(\<4D<8#;FQDUV^O:%;:[
M8/;7 RK>U>,ZE\'+N*[DDL!+M9L\,10!W?C+QKI46E.GFQRD@@ -7!_"J^NY
M-1O)MS+;F4GGIBH(/@YJ5S,IO!+MSS\QKU'1_!=OH6@S6UJI\QUYSZT >:^,
M+F+4?&C0VP#2+*I)7G^*O<=+4KIMN#U$:_RKSK0?AT]OXEEU.[1LN._/K7I\
M:A(U0=%&* '5POC?PE<^)6:*.8)&PP0:[JC ]* /G#X@^"K/PYI5IMC3S2/F
M8=^M=M\%?^1=C_WJJ?&W_CSMOQ_K5KX*_P#(O1_[U %_XO3M'HKJ#PT9S7,?
M VUC%M%-M&XKR?PKI/C C-HS$#@1\U@? UU^P0KGG;_2@ ^.4$?EJ^WY@G6J
M_@2]EC\"A58_ZAO_ $&KGQR(\A1_L5G>!8'?P/E1_P L&_\ 0: .7^&*+=^-
MM\PW,)WY/^]7N7CVTBE\/2AE!"QG%>'_  K^3QGANOGO_P"A5[KXZ=5\/SY/
M6,T >/\ P=NC#KHMQG:9#Q^-?0DUY;VR@SS)'G^\<5\[_""%G\2+*H^42'^=
M>O>,O#MUK442V^_Y>NTD4 =%_;6F_P#/[!_WW7-^.]6L)?"6H*EW"S&+@!JX
M<?#75?\ IM_WV:R?$OP_U.ST*ZN'\W:B9.6- '2?!?\ Y!$&/[O]*]=KR#X*
M#;HMNIZ[?Z5Z_0 4444 %&<451U6X:VLFD3J*F<E"+D^A48N4E%%S>O]X4;U
M_O"O/)?$MVLC#CK3/^$GN_:O(>=X9.QZ2RFNU<]&WK_>%&]?[PKSG_A)[OVH
M_P"$GN_:C^W,,/\ LBN>C;U_O"N.E(_MQSG^*LO_ (2B[]JSVU29KDS<;B<T
M?VYAO,/[(KGJB.OEK\PZ"EWK_>%><CQ/=X XXH_X2>[]J/[<PP?V17/1MZ_W
MA1O7^\*\Y_X2>[]J/^$GN_:C^W,,']D5ST;>O]X4H(/0UYROB>[)'2NOT"]D
MO;=FDZBNG"YE1Q,^2!SXC U:$>:9L4445Z!Q!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 -=%=<,,@U!_9]MG_5"K-% %;^
MS[;_ )Y"N4\2V5L)[?\ =C[XKM*Y+Q-_K[?_ *Z"@#=M+"V-NO[H=!4_]GVW
M_/(4MG_Q[K]!5B@"&.UAB.40"IJ** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]*\@UW
MQ5K%KXF2VAM9VB,H7<.F*]@K/ET:TEF\UD!;.<XH X/QIXAU/3M',UK!*[X'
M"]>E>:#XA^)O^@?=_E_]>OH:_L[-K<_: -@]:QK6RT.[,OE(I\O[W2@#Q/\
MX6'XF_Z!]W^7_P!>NW^'_BG6-5N=MY:SQC=CYZZ&]U+PO8W1MY0-X^E=)HT&
MFR1B:S P>>,4 ;5%%% !1110!XY\:U=K2VVJ3]/QJU\%E9?#T892/FKO-?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,3Q+H$&OZ:]M*!\W?%>
M26_P8VZVL[3RF-9,@$G&*]VHH X+7_ 4.HZ(FG([*BMG*UM>%?"UMX<L_*B
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M*R>959BHZ 5Y/XF^(#PO"%#H0XR"/>@#V8$$9%#,%!)/ KB_#'BS^V'A18Y
M" "2#BH_$_BMM-BG0HXX(!Q0!VL<T<HRC9J2O'/"OCYY$\IQ)(Y;L#7K5C.;
MBU24@C<,X- %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 5S'C[_D3]0_ZY5T]<QX^_P"1/U#_ *Y4 <3\%_\ D$P?[O\
M2O7:\B^"_P#R"8/]W^E>NT %%%% !69KW_(,>M.LS7O^08]8XC^%+T-:'\6/
MJ>87/^N;ZU#4US_KF^M0U^=R^)GW</A04445)04444 %%%% !1110 Y/O"O1
M/"G_ !Z/7G:?>%>B>%/^/1Z]S(O]X9XV<_P3HJ***^P/E@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K(\1_\@B3Z&M>LCQ'_ ,@B3Z&@
M#XYU7_D<9O\ KN:]4TS_ )!R5Y7JO_(XS?\ 7<UZIIG_ "#DH M4444 %%%%
M !1110 4444 <KXY_P"04O\ O5W?P#_Y!=U_O_UKA/'/_(*7_>KN_@'_ ,@N
MZ_W_ .M 'MU%%% !1110 4444 %%%% $-T";=L*&/H17D6M> KG7M5N)IHBB
M)\R;>YKV,C(YIH11T'6@#B/ &FWFFV30W<"H0^ <<XIWC72;G55C@AA!5CAB
M!SBNU6-5Z#%!12<D4 >1>'O!-UX=U]#%"7@QDE^>:];@&(4R #CH*<8U)R1S
M3NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y5\7]$N+S2
M))X4S@UR"?$C3X_"CZ3<28FCA\O&.]>VZS=Z<L+0W\D:QGKOKS75/A7I&O3&
MXLKZ% QSA/\ ]5 ''^&?B1I^C^'Q:B7]\<C'U%=%\,-.N-0U*XU&1?E,N]3[
M5=TKX(6UI.LDMRL@'8C_ .M7J.E:/:Z3;+#;Q*F!@[1UH T:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "N8\??\ (GZA_P!<JZ>N8\??\B?J'_7*@#B?
M@O\ \@F#_=_I7KM>1?!?_D$P?[O]*]=H **** "LS7O^08]:=9FO?\@QZQQ'
M\*7H:T/XL?4\PN?]<WUJ&IKG_7-]:AK\[E\3/NX?"@HHHJ2@HHHH **** "B
MBB@!R?>%>B>%/^/1Z\[3[PKT3PI_QZ/7N9%_O#/&SG^"=%1117V!\L%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9'B/_ )!$GT-:]9'B
M/_D$2?0T ?'.J_\ (XS?]=S7JFF?\@Y*\KU7_D<9O^NYKU33/^0<E %JBBB@
M HHHH **** "BBB@#E?'/_(*7_>KN_@'_P @NZ_W_P"M<)XY_P"04O\ O5W?
MP#_Y!=U_O_UH ]NHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "LCQ'_R")/H:UZR/$?\ R")/H: /CG5?^1QF_P"NYKU33/\
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MO!R,T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5_Y'&;_KN:]4TS_D')0!:HHHH **** "BBB@ HHHH Y7QS_R"E_WJ[OX!_\
M(+NO]_\ K7">.?\ D%+_ +U=W\ _^07=?[_]: /;J*** "BBB@"O??\ 'E-_
MNU\K^+_^2DO^'\Z^J+[_ (\IO]VOE?Q?_P E)?\ #^= 'O6D_P#('M/^N8JW
M532?^0/:?]<Q5N@ HHHH **** "BBB@ [UY?\8O^/9/]RO4.]>7_ !B_X]D_
MW* ,'X%_\AQ_^N?]#7TPGW%^E?,_P+_Y#C_]<_Z&OIA/N+]* %HHHH ****
M"BBB@"*==T+#&:\QU/P =;UBXFF.U/O*".]>IT4 <=X,T232+=X9%)P_!/I5
M/Q7X9DUN8( 57=R:[VB@#S;P[X-;0=:BV M%C)..*WO%NDOJ4,,$:':PPQ':
MNKHH \BL?ARVDZ@+J-BWL!7JUE'Y5I$N,$+S4]% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% "'I7BOC7Q)XAL=3=+.T=T#8!!KVN
MJ$^CV5R^Z6+)H ^??^$Q\6_\^$OYT?\ "8^+/^@?)^=>]OH.EQKN:(*!W)KG
M-1U3PSITFR18V(]'% 'D_P#PF/BS_H'R?G7:^ =?US4+G;?6KQKN[FNJM;GP
M_=6*W:Q 1L<<L*W=+@TUEWV@7\&!H U:*** "BBB@ HHHH XWQ[JM[I.G-/:
M1%]JY.*X#PA\75=A%J16$@<[C7LVH:?!J-I)!.FY7&"*\JUGX,6US<M+9QQH
M#ZD4 <9\3?%\/B:ZBM;$K+N7'RUW_@#PU)!X+ F4AC"PP?I3/#WP@M-.NTN+
MJ*-V0Y!!%>HP6L5M;B"-<1@8Q0!\M6%U)X,\<*\Z;(_,9LGZUW/C?XEV=]HB
M0VLJ/)(I4@5VWB[X<6'B)S*(5\W& 3BN3L?@I'%=*\Z1LBG(&10!5^"VC3!!
M?2QD?O">?K7MTD,4O^L16^HJCHVC6VC6:V]M&$4=A6E0!7^PVO\ S[Q_]\US
M7CRTMD\(:@5@0'RNN*ZVN8\??\B?J'_7*@#B?@O_ ,@F#_=_I7KM>1?!?_D$
MP?[O]*]=H **** "LS7O^08]:=9FO?\ (,>L<1_"EZ&M#^+'U/,+G_7-]:AJ
M:Y_US?6H:_.Y?$S[N'PH****DH**** "BBB@ HHHH <GWA7HGA3_ (]'KSM/
MO"O1/"G_ !Z/7N9%_O#/&SG^"=%1117V!\L%%%% !1110 444C,JC+$ >YH
M6BHOM$'_ #VC_P"^A1]I@_Y[1_\ ?0H EHJ+[3!_SVC_ .^A1]I@_P">T?\
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M-:'\6/J>87/^N;ZU#4US_KF^M0U^=R^)GW</A04445)04444 %%%% !1110
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M G%<;'XX\3E?M@@NC%G\*]<\">/H=9LI!=$120K\VX\T <5I?P1$=PIN1*J
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MHBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"/OK_P!<_P"E>\4@"BBB@ K(\1_\@B3Z&M>LCQ'_ ,@B3Z&@#XYU7_D<9O\
MKN:]4TS_ )!R5Y7JO_(XS?\ 7<UZIIG_ "#DH M4444 %%%% !1110 4444
M<KXY_P"04O\ O5W?P#_Y!=U_O_UKA/'/_(*7_>KN_@'_ ,@NZ_W_ .M 'MU%
M%% !1110!7OO^/*;_=KY7\7_ /)27_#^=?5%]_QY3?[M?*_B_P#Y*2_X?SH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<QX^_P"1/U#_ *Y5T]<QX^_Y$_4/^N5
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M7^M 'T11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !5>]_X]9/]TU8JO>_\>LG^Z: /CCQO_P C3/\ ]=C70Z+_ ,@J.N>\;_\
M(TS_ /78UT.B_P#(*CH OT444 %%%% !1110 4444 97B#_D'?C76? O[TW_
M %U_K7)^(/\ D'?C76? O[TW_77^M 'T11110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7,>/O\ D3]0_P"N5=/7,>/O^1/U#_KE0!Q/P7_Y!,'^[_2O
M7:\B^"__ ""8/]W^E>NT %%%% !69KW_ "#'K3K,U[_D&/6.(_A2]#6A_%CZ
MGF%S_KF^M0U-<_ZYOK4-?G<OB9]W#X4%%%%24%%%% !1110 4444 .3[PKT3
MPI_QZ/7G:?>%>B>%/^/1Z]S(O]X9XV<_P3HJ***^P/E@HHHH H:S_P @:Z_Z
MYFOE2;_D?F_SWKZKUG_D#77_ %S-?*DW_(_-_GO0!ZQ!_P >D7^[3Z9!_P >
MD7^[3ZH HHHH **** "BBB@!17E?Q/\ ]?#]*]4%>5_$_P#U\/TI =U\"/OK
M_P!<_P"E>\5X/\"/OK_US_I7O%( HHHH *R/$?\ R")/H:UZR/$?_((D^AH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 444C$*I)Z 9H 6BO.O&GQ+L_#TA@4LTI&1L.:X[3_C6I
MNT6X2<([8&5(_I0![M165H>MVVMV*W-NPVGWK5H *YCQ]_R)^H?]<JZ>N8\?
M?\B?J'_7*@#B?@O_ ,@F#_=_I7KM>1?!?_D$P?[O]*]=H **** "LS7O^08]
M:=9FO?\ (,>L<1_"EZ&M#^+'U/,+G_7-]:AJ:Y_US?6H:_.Y?$S[N'PH****
MDH**** "BBB@ HHHH <GWA7HGA3_ (]'KSM/O"O1/"G_ !Z/7N9%_O#/&SG^
M"=%1117V!\L%%%% %#6?^0-=?]<S7RI-_P C\W^>]?5>L_\ (&NO^N9KY4F_
MY'YO\]Z /6(/^/2+_=I],@_X](O]VGU0!1110 4444 %%%% "BO*_B?_ *^'
MZ5ZH*\K^)_\ KX?I2 [KX$??7_KG_2O>*\'^!'WU_P"N?]*]XI %%%% !61X
MC_Y!$GT-:]9'B/\ Y!$GT- 'QSJO_(XS?]=S7JFF?\@Y*\KU7_D<9O\ KN:]
M4TS_ )!R4 6J*** "BBB@ HHHH **** .5\<_P#(*7_>KN_@'_R"[K_?_K7"
M>.?^04O^]7=_ /\ Y!=U_O\ ]: /;J*** "BBB@"O??\>4W^[7ROXO\ ^2DO
M^'\Z^J+[_CRF_P!VOE?Q?_R4E_P_G0![UI/_ "![3_KF*MU4TG_D#VG_ %S%
M6Z "BBB@ HHHH **** #O7E_QB_X]D_W*]0[UY?\8O\ CV3_ '* ,'X%_P#(
M<?\ ZY_T-?3"?<7Z5\S_  +_ .0X_P#US_H:^F$^XOTH 6BBB@ JO>_\>LG^
MZ:L57O?^/63_ '30!\<>-_\ D:9_^NQKH=%_Y!4=<]XW_P"1IG_Z[&NAT7_D
M%1T 7Z*** "BBB@ HHHH **** ,KQ!_R#OQKK/@7]Z;_ *Z_UKD_$'_(._&N
ML^!?WIO^NO\ 6@#Z(HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-UR]%EI<\A./W;8_*M
M*N:\;?\ ("F_W&_E0!\\Z/:MXP\<*)Y&,8D9>N>]>A>.OAS9VVA));C#Q*3E
M1BN(^$__ "./_;=__0J]W\<?\@"?_KF: /,O@KJLJXL9)&/[PCD^]>[5\V_"
M)F_X2E0.GF-_.O4/B)XJNO#T$#6\<K%QSL!/K0!Z%7,>/@?^$/U#_KE7BW_"
MW-7_ .?>Z_[X-4-8^)FK:IIDUH;>ZQ(N#E#0!Z%\& ?[)@_W?Z5Z[7R7X6\:
MZGX=MDB6VN<*,<(:Z3_A;FK_ //O=?\ ?!H ^D**^;_^%N:O_P ^]U_WP:/^
M%N:O_P ^]U_WP: /I"LS71G37Q7@7_"W-7_Y][K_ +X-5[SXJZO<VYC^SW7/
M^P:SK1<J;BC2E)1FFSM[E3YS?6H=IKRR3QEJ[N6\BXY_V#3?^$OU;_GA<?\
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M\+,UO_GE=?\ ?!H ][\M_2CRW]*\$_X69K?_ #RNO^^#1_PLS6_^>5U_WP:
M/>_+?TH\M_2OG^3XK:G"<2><A]&!%2)\3]9D7<D=RP/<*: /?/+?TH\M_2O!
M/^%F:W_SRNO^^#1_PLS6_P#GE=?]\&@#WSRWSTKRWXQHPMDR/X*Y;_A9FM_\
M\KK_ +X-8'B7Q1JWB% LL%P<#'*&@#JO@6/^)X__ %S_ *&OI=/N+]*^-/"6
MMZCX9NS,EM.,C'"&N\'Q<U8 #[/=?]\&@#Z0HKYO_P"%N:O_ ,^]U_WP:/\
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MSS7_ +X%'_"":1_SS7_O@5U%% '+CP)I _Y9+_WP*\?^(OA^RL=9L4B4 /.
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M!-(_YYK_ -\"NHHH Y?_ (032/\ GFO_ 'P*/^$$TC_GFO\ WP*ZBB@#E_\
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M&^@X]ZFM?%^DWDHCAO(F8G  - '044BL&7(I: "BBB@ HHHH **** "BBB@
MHJCJ&JVVFINN)508S\U8_P#PG.B?\_\ !^= '35E:KH%GK!C-R"?+.15&+QK
MHLL@47\//O6W;7MM>+N@F60>U "VEI'9PB*(?**GIKR)&NYV"J.YK%NO%FD6
MLGER7T(;.,$T ;E%4;'5K+44#6UPDF?[M7J "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,EC$L3(PR&&#7
M&7OPWT>^N#++:1LQ/4UVU% ' ?\ "J]"_P"?*.M;2O FC:6X>*S16'<5U-%
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MF6NF0B*VB"*!CBKE% !1110 4444 %%%% !1110 4444 8.M^%[+6V!N85?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44F1ZT9'
MK0 M%)D>M+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !69KFH-INF37")N*)NQ6G5>\LXKVW:
M&9=R,,$4 >'S?&2_CE9?[..![_\ UZKGXXSAMIL_F],__7KTRX^&WAXQR/\
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M%[X[TNRA21]S*XXVF@#J:*YS3/&>EZFF8I OLS"JM_\ $#2K"81R;CSC(/%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+")QT6.KGP79!X;M077.WIGVH ]2@A$$*QKT48J6BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>(](E/AAK*V4NPB*C->:?"WPCJVD:\L]Y;%$WDY_&O=F4,,,,TQ((XSE5 H
MQO%=I+>^'[J"%=SO&0!7C/PS\&:QI/B[[5=6Q2+'6OH)E##!'%1I;Q(VY5 -
M '%_$+PW-KNCND*%I F !7EWA.P\9>'9HK2.P_<J0,DGI^5?1) (P:B^RP[M
MVP9H BT]IFLXS.NV0J,CWJW0!@8%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gy33ft1zvusk000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gy33ft1zvusk000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" G=!YX# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH #TKB-7/_ !<S0U[>5)_Z":[8]*XO5E_XN=H?/_+"4_\ CIH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 (>AKB]48'XFZ%_P!<)?\ T$UVM<1J8Q\3-"_ZX2_^
M@F@#MZ*2EH **** "BBB@ HHHH **** $KC?%9_XK'PL/^FDW\EKLJXOQ7_R
M.?A;_KI-_): .Q3O3Z:E/H **** "N.^(9QHD'_7U'_.NQKD/B$,Z)!_U]1_
MSH ZNWYMX_\ =%24R$8A0?[(I] !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%%  :XK5.?B;HF/^>,G_ *":[0UQM_\ \E*T7_KWE_\
M030!V=%%% !1110 4444 %%%% !1110 E<9XK_Y'+PO_ -=)OY+79UQOBO\
MY&_PQ_UTE_DM '8)3Z8G4_2GT %%%% !7(_$'_D"6_\ U]1_SKKJX_XB?\@>
MT_Z^X_YT =;%_J4_W13Z9%_JE^E/H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH 0_UKB[W_DJ.C_]>TO_ *":[0]#7%Z@=OQ0T=NQ
MMY!_XZ: .UHI*6@ HHHH **** "BBB@ HHHH 0UP_BDG_A.?#0]Y?Y+7<&N*
M\4[5\:>&6(ZM*/T6@#M5Z4M,4G]*=0 M%%% !7'_ !$_Y ]I_P!?<?\ .NPK
MC_B)_P @>T_Z^X_YT =;%_JE^E/ID7^J7Z4^@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.IV]TG.=C8(P<'@\]ZU\YH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_A[I]_JNC07-T[RJTA9@6P[ =".PKMO^%1^ ^WANV_[[D_\ BJ\B^'_Q5O\
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M_HB^'H;WQ-:27^J7:B6;[2[9BR/NC!YZ]?Y5=^./ANYUSP$UQ: EM-E^U&(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7F-C\0]13XMWWA/6X+>"U8,=/9$(=\<J6);&"H.,#KBO3J\
MW^)GPR'C5[?4;"]^P:M:*?+DV\2=P"1@@Y PV3CGB@#T0QQRPM'(BNC@JZL,
MA@>H-<!\1O OA:^\)ZC>W&G6UK<6EI))!/ !$58#<!QP<D <COQ7&VVN_&G0
MU?3GT6WU3RF(%V\6[<.V"&7(_#-0R^&OB5\2KZ*'Q4PTC18Y4,UO$ N_ /*C
M)))Z<G R#@XH TO!=I=>-/@)?:?>RSW$A,L<05QO/EX:-,D<_, .?7K6W\$=
M?&I>"X]+GD@6]TUF@:!>'6,'Y21^?2N[T?1['0-+AT_3K=8+6$;50=_<GN:\
MT\7_  PU:+Q)'XD\!W<>F:C(6%PC':A!'W@,$?@01SGC% 'KQZ5Q?Q&\<1^!
MO#8OE1)KN69(X8CT;G+9YR!M#<\X)%<)_P )=\:8AY1\)V<A7Y?,\D_-[_ZS
MO5GP_P##/7M=\2IKOQ"O([W[.H-O:(V5#'G#<  #T'4XR>,$ ]2T+4)]6T:S
MO[FR>QEN(A(UNSARF>@SCGCFO)O@)_R%/&O_ %^Q_P Y:]G"K&BA0 JC  '\
MJ\M^#GAO6/#^H>*I-6L)K1;NZ22 OC#J#)SQ_O#\Z /6.U<1\7O^25:__P!<
M4_\ 1BUVRG(KD_B9IUYK'P\UC3M/MWN+J>)1'$F,L0ZGO[ T 5?A+_R2O0?^
MN!_]#:N)^!'_ ",OCG_K\3_T.:O0/AQIUYI'P\T:POH3!=0Q%98W'*G<Q_K7
MCVA6?Q-\%:[KT^B>&%FCU&Y+EKA-P(5G*[<..NXT ?1U%>(?\)E\:O\ H3[+
M_ORW_P =H_X3+XU?]"?9?]^6_P#CM '=_%G_ ));X@_Z]_\ V9:C^#W_ "2?
M0?\ KE)_Z->I/&UGJ>N?"S4+1+4OJ=U9IN@3_GH=I8#Z'/>O,/#FJ?%_POX?
MM-%L?"5N]M:J51IHB6.6+<D2 =2>U 'T QPWKQ7BGQVUI+V/2/"=I-'+<75R
M))T"%WC' 0\'W;CVJ&Y\4?&N_MI+5?#5M9M* HN(H?FCSW&7(_0UM_#_ .%=
M_H>NR>)O$6HI?:M,I_=JNY8V)^]N/). ,8 QR* .B\6Z)<+\);_1K7==7$.G
M+ NT;=Y10,@'IP,]:S_@C>6]S\,=-A@F#O:M+#,HZH_F,V#^# _C7H$J)+"T
M3C<CJ48'N".:\5N/A_XS\!ZU=ZCX!NHIM+D(F?3ISDEO[F._L05., DXS0![
MC7B7QR!U+6O"FCVF9M0>Y:5;=?O;25 /IU4_E3?^$O\ C5)^[_X1*R3=QO\
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M?3WN%6YF6(@HF?F(_>'H/8UZ_0!&<G//0]/6O ?&VG7GQ2^++^';.^$.GZ7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6 S_ ,OB5V]<5\2$!TJQ..?ML= '8Q?ZI/\ =%24R(8B7Z4^@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"I>SWL5F\EC:1W-P"-D3S>6
M&Y_O8./RK#&I>*SR?#%@3_V%O_M5=+M(/!'/M2@<<X_*@#FO[2\5_P#0L6/I
M_P A;_[51_:7BO\ Z%BQ_P#!M_\ :JZ7'THQ]* .:_M+Q7U_X1FRSZ_VO_\
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M=)CZ48^E '-_VGXLQ_R+%C_X-O\ [531J/BL #_A&;'C_J+?_::Z;'THQ]*
M.:&I>+._AFQ/N=6_^TTO]I^+/^A8L?\ P;?_ &JNDQ]*,?2@#FO[1\5EL_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 AZ5Q%YQ\4]+_Z])/Y5W%<+>_\ )5-)_P"O63_T$T :FJV6KWMX&B,/V5#D
M)GEOK6KIBS1V^V>!(6]$%6/M,.^2,2#<@RU+;SPW0WQ2AU'7% $Z_=%+0.G%
M% !1110 4444 %%%% "&N)\2?\C]X;^DW\EKMC7#^)ESX_\ "Y_Z[_R6@#ME
M^[^%+N4<EA^=4[ZY-LD>U-[.VP#\ZSYY)[9HDO84>)V&708"^U &]13$QUW9
M!Z#TI] !7%_$0XTRQ_Z_8Z[2N)^(X_XEE@?2^2@#LT^XOTI],C.44^U/H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TKA+[_DK6
MECM]DD_E7=&N&O@/^%LZ9[6C_P J -C;-87=PPM//CF/!+<__JJ[H]I]GB:0
MHJ%_X%Z"L?6;RP6\^S# E88+EF 7\C6AH$%I:VBI;7!F)^\6D9CG\30!N#@"
MEI!P,4M !1110 4444 %%%% "&N%\5$CQ[X7P>\W\EKNC7#>)P#\0/"X/_3;
M^2T =1JBQ-8_O97BPV0RCD&L6*_MSJ$-K>ZF]PY;Y(S&!GZX%;FJ-=I8M]AB
M$DQZ GI[UDZ=87D<BSW5E%),3DRELD?AVH Z)1AN%Q4E,'\.<YI] !7%_$09
MTNQ_Z_8Z[2N,^(I(TRPQ_P _L= '81C"*/:GTT=!]*=0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 AZ5PM\?^+M:6/6TD_E7='H:
MX:\&?BSIISC;:/\ RH N:Y<7MA*\^Z(6H^]A$+?D16GH-Q%>V9FB<ON.3OB"
M$?D!6?K&A_VA?>=%:B*=>1<2/\H_"M;1X[B.T"75XMR_8HNT4 :@Z4M(.@S2
MT %%%% !1110 4444 (:X?Q(,_$/PP/03G]%KN#TKB?$9_XN'X9]EF_DM '9
M%P,9.#VI6PJ[F.W'I67J\\MJL$L<)E DPRAL=:QXM<O;JYFTZ6R>.=G#*3(#
MA>U '6Y/RX[]:?4<9X53U YJ2@ KC?B& VGZ<I[WL==E7&?$,XLM,SQ_IJ4
M=D.@^E+34/RCZ4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ K@-6/V?XI:.1UD@=?TKOZX#7@3\4= ../+?^1H UO$6GZC<R2/#
M([PF/B)6P<UH^'Y6;2[>-X629$PX8=#7-:OJMQ#=76R^\F1)E"9/&W/)^E=3
MI,D4MOYD=TMQ(?OLIR": -,'(S2T@Z4M !1110 4444 %%%% "&N&\6GR_&G
MAF7U>5?T6NY-<+XS(_X2SPP,\^=)_(4 =-JUM),D4J N(9-Y0?Q5F%8K_4HY
MK>U>*X5AYDC#;QZ5LZDMU)9LMDZ+,<X+5S>FO?)K&-8%P,#$;'[OZ<4 =@I)
M/4#'6GU&G(S@8SQBGT +7&?$<#^Q+61N"EVA%=G7&?$G_D7H1ZW,?\Z .N@;
M=!&WJHJ6H;8$6L61_ /Y5-0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%03SQ08:4@ X S0!/135P2<4Z@ HHHH **** "BBB@ HH
MHH **** "BBB@ HIC=?Y5&EQ%([HI!93AA[T 3T4U<]#3J "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@]
M<_Y*5H/./W<G_H)KNR"1P<5YCX\U*;2O&^B74-HUTWER?NE')^4T =08I+^^
MO0+M84B.TG:M7=(E9+F>V=XW"C=N05Q#^(6NG9Y/ EW)(P^\8<_TJS8>*;BR
M7;!X)OXQWVQ4 >C+CM3JX-O'>I)ROA/4?^_=1?\ "P=3_B\(ZD3_ -<S0!Z#
M25YZ?B#J&#N\):B% S]PU5;XI7,=Y%:-X8OQ/*,QIMY./_K4 >F4M< /'NJ<
M'_A%-1Z<84TG_">ZKG_D4]3_ "- 'H%%<%_PGFJ?]"IJ?Y&F'X@:M_T*FH?]
M\F@#OS7!^+QN\:>&!_TTD_D*C/C_ %;'_(J:A_WR:Y3Q%XNU.[\1Z%<'P[?Q
M202/M4@_."!G^5 'JVL7,UM%;)!*L9EEV$GZ&H=,O!++/:W5PDC1,"#^=<;=
M^-;N]86USX.O9!U&]":K)KGDRAX_ ]R"><HG- 'J@ R.,^AI]>>_\)WJHV*/
M".H!1TPIJ4>.M5_Z%34_R- '>UQOQ(_Y -M_U]Q_SJG_ ,)YJO\ T*>I_D:Y
MWQ;XIOM4TZVMY="N[6/[4F6ES0!Z[#_J(_\ =%/J&V_X]HO]P?RJ:@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YKQL[1Z5;LC%6^U
M1C(/:NEKF/'/_($@/<74?]: .CBZ'ZC^0J2HH?N_E_*I: "BBB@ HHHH ***
M* "BBB@ HHHH **** &]S[5S>E,Q\4ZPA8[592!G@<5TIX!-<SI8_P"*LUCZ
MK_*@#IA2T@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5S/CCG18!ZW<?]:Z:N9\<?\@>
MW_Z^X_ZT =%",*?P_E4E1Q=#_GL*DH **** "BBB@ HHHH **** "BBB@ HH
MHH 0\Y%<QI3$^+M8!'=?Y5T_<UR^E?\ (X:Q^'\J .H'7%+31][\*=0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[[5XIU-+U#:W#D!(YFPQX["@#T(?>_"EIJ$$8STZTZ@ HHHH **** "BBB@
MHHHH *0,",CM0> :JWE[#8VLMS-(J1QKDEC@4 6MPQGG\J3>#Z_E7'6U_P"*
M-1B:YM5M8+5SF+S5(.W_ .O3(O$.J:/J?V77XU^SS ;+F)?D#$],]J .UR#2
MTR,AHU((((R".].H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /\ ]5='>2^*-(T^1OLUK=QHI^<$9(XQD5;\/:)</<QZUJ3HUS)'A8U7A :
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M'B08\.W_ '_=$T -T/Q!:ZY&[6S9V'FM@9YS^%>7?"0DQ:F?1UQ^5>H].*
M@'J*0@ =.E.I#TH P4 _X2\C PUL"?<UN[%QC K#3_D<!_UZC^9K>H ****
M"BBB@ HHHH **** "BBB@ HP*** *6JJO]DW? _U3']*;I*C^S+7C_ED*?JW
M_()N_P#KDW\J;I/_ "#;7_KD* +N!^=+110 4444 %%%% !1110 4444 %%%
M% %#6 /[*N>.L9S3M, &G6^!_ *35_\ D%7'^X:=IO\ R#K?_<% %L4M%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (W
M3\:XG4?^2I:-_P!>\O\ Z":[9NGXUQ6H_P#)4=%_Z]Y?_030!VU%%% !1110
M C=#]*X?5/\ DJ>BCL+:7^5=P?YUP^J_\E3T3WMI?Y4 =QZ4O:D["@G@T 5-
M00O87"#EF1OY54\/1-'X?M(W!#(I!_.LZ3QII?VZ2R5+F6=<J42%C]>U6K/Q
M-97#K#'#<+VP8F&/TH W#7$>*>?'?A?/]Z;^2UVZD,H(S@^HQ7%>*ACQUX5/
MJTW\EH [./I^%/J./T]O\:DH 6BBB@ KBOB2,Z)9_P#7['7:UQGQ(.-$L_\
MK\C_ )T =?&,1J/:I*9'S&I]A3Z "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH JWX_T*?_KFU0:'_P @:U_W/ZU-J#8LI_\
MKDQJ#0N=%M?]S^M &E1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M '4AZ4M(>E &$G_(WC_KU'\S6]6&BG_A+=WI:C^9K<H **** "BBB@ HHHH
M**** "BBB@ HHHH IZK_ ,@F[_ZXM_(TW2?^09:G_ID*=JO_ "";O_KB_P#(
MTW2?^07:_P#7(4 7J*** "BBB@ HHHH **** "BBB@ HHHH HZO_ ,@JY_W#
M3M-_Y!UO_P!<Q3=8_P"03<_[AIVF#_B76_\ N"@"Y1110 4444 %%%% !129
M&<4%L9]J %HI-PSC/6EH **** "BBB@ HHHH **** "BBB@ HHHH **** $(
MS7$Z@<_%/11ZVTI_\=-=L3@5P^H''Q7T5>XM9?\ T$T =S1110 4444 (>HK
MA]4Y^*6B'_IVE_E7<'J#Z5P^I<_%'1O:WE_E0!W'84A-+Z4V1"RD XR* .);
M7;--2E?2M%N+J<ML>14P!Z\FK]OXBB2>..]TJXMGD8*K&,8S]:HZ5J2^'#-9
M7UG= "4NLRIN4YS^-2WNHRZ]-:06-E,8XIP[RN %P/UH [!"2.0 ?:N+\4G/
MCKPL/1IOY+7:)P,XQGM7%>)SGQYX7'^U-_): .TCYY]JDJ.+ICV_K4E !111
M0 5Q?Q)_Y EG_P!?D?\ .NTKC/B1_P @2S_Z_8_YT =A'_JU'L*?3$^XOT%/
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FLZJ0">3TXIU
M4=6ODT_3I[IQE8D+G% #[K5+"Q(%U=PPL>@=P"?PI+75;"^)%K>02D=0C@G\
MJ\XL+RY4O>7FB7&H/(#(DA*[40\]2:BAUF+6A+<:3HUW8R6H+M)M&Q\=L@F@
M#U8.&Z9_*G5CZ-KMMJ&G6\[S1)(\89U,@R#6A]NL_P#G[@_[^"@"Q15?[?9_
M\_<'_?P4W^T++_G\M_\ OZO^- %JBJZW]F[;5NX&;T$@-3%EZY'YT .IK=!]
M:@:_LT.&NX ?0R"LWQ'JYTS09K^U,4CQXV$G(R3CM]: '6; ^)+['_/-?YUL
M9'K7EMSKVO:5>7U_+)8';"LCQB3#$'L,_6KUO\3X)(H_,TNY&4W':5Z_B: /
M1,T;AZC\ZX'_ (6A9_\ 0-O/_'?\:7_A:%E_T"[S\T_^*H [W(HR/45P#?%*
MRCY.FWG/^Y_\53E^)UF1D:7>-GOE/_BJ .]W#U%&X>HK@_\ A9MKVTF\_-/_
M (JD_P"%G6PZZ3=_G'_\50!WNX>HHR/6N!'Q.MF.%TJZ+=OFC_\ BJLQ>.[B
MX7,/AW4)!ZH4/\FH [;(HS7#3_$&2V(%QH-]$3T$C1KG\VJ.+X@R3OLAT2[D
M)[)(A/Z&@#O-P]15>YACN0$E V@A@?>N5D\;W-M%NF\.ZA&H_B8H!^9:L35O
MB5<&&)+.P\AY) OF3RI@?D30!V.GL3XEU3.,;(\<_6MH$9KQZZU[7-(U+4[S
M^TK&0HJ'8K#YLYZ5T$7CS4G@MW^P6LADB#%OM2#GZ9H ]#R/44;AZBN!'C74
M_O#3K3C_ *>T_P :<?&VI@9_LZS_ / Q* .]KC(X([CXD7ZR*&4VJ@J>G2J/
M_"<ZGC/]F6O_ (&1_P"-4_#FOB[\?7DUZUM"3;KC]\I'3IG- &G/;W'@V\:Z
MM5>72I6_>0]3'ZD#Z\UUMG?V][:K<02J\+#(?T^M127^FS(R2W=JRD8.95Z?
MG7'3Z$RW3Q:3K,<5C<']Y"'R1]* +VIZM>:[?OI.C@-;IQ<7*G@#T'K^%4?$
M>C6^CZ?I%K:*,"Z0LV.6.>M=9IUC8:!IL<$+1QQ@<NQQN/KFN0^(6LQ+9V+V
MDT$DB3JV/,'K0!Z%_0BI*\\C\;:J[#-OI^T@$?Z2O-2'QKJF<?9++'_7TM '
M?Y%)N'J*X*3QQJ:]+.R/_;TM-7QKJAVYM; %CT-R,T =3XC.[19U&#D#'/O5
MNS6/R4G5<,Z#) Z\5Y'?^*-<U:SU,'4+&T6%@%AW[B*N:/\ $#4[*]EL;E(M
M05 NV2)PH48Z'- 'K*X'?K3LCUKSU?B/<8/_ !)V//\ SV7_ !I3\29E&3HS
MX]ID_P : /0<BC->>'XF/@_\2>3/;,J_XU$?B5<C_F"'_O\ +_C0!Z1D>M&:
M\.3XM>()[R:#[':H(SU,JBNFL_B7>2V\9DT</(5^9DG7!/YT >EY%&1_D5YZ
M?B+<#_F"G_O^O^- ^(T_?13_ -_U_P : /0LC_(HR*\]_P"%C3G[NC$GVG7_
M !H/Q%N ,G1& ]I5- 'H611D9Q7F%Q\6&MYDA?2&5W^ZK2 $U:'Q(N2,_P!B
M-TS_ *Y>GYT =SJ/_'A<'MY3"H=!8'1;4=PN.GO7F-UXRUC6-0NH4E338X;<
ML8F^;=S[5'IWB[5=/O+*T2_MKD-&3M8D ?I0![)D?Y%+FO/3XNU@8RNFC(S@
MRM_\32?\)AJ^.FF?]_G_ /B: /0LT;A[_E7GZ>+-;=U5(M.<DXP)6_\ B:U'
MOO%9C#K::>$(SS(Q_P#9: .LR/\ (HR*X-_$FOHY3;IA8'! =\C_ ,=J[#J'
MBFYBS!;Z=GT,K?\ Q- '7[AG'/Y4$UP=WKOB:R<).--&>#R_'_CM-_X2375&
M0-/;Z&3_ .)H [X,/?\ *C<!U->?#Q9K)&6CL/\ R)_\33O^$KUD\(M@">G$
MG_Q- '?[AC//Y4M<!!XYGM+J./58X%A8_--&'VK]21C%=3'KUA+ LR391NC!
M21CM0!K4F1ZUEG7+$8S<GGI\AYI?[=LO[S?]\&@#3R/6C(K+_MVS/0N?^V9J
MW;7<=V/D5P/4J10!9R,XS1N7UJI<WT%F</NS[*33+?5;>YE\N(.?4E"!0!>R
M,_6C<,D9Y%1S3)#&7D.%'?&:S1X@L#G+.,=3L- &MN'O^5&:R_[?TW_GH_\
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MC,<UJP]5C<_TH ]KI,CU%>*+\6]2/_+2U_[]/_A2M\8+N,@23VBL?6)^?TH
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MH T_X17$^)O^1^\+_6;^2UVQY7BN)\2_\C]X7^LW\EH [2/O]/ZFI*9'WI]
M!1110 5QGQ'_ .0+9CN;V/\ G79UQGQ'_P"038_]?L= '8)]Q?I3Z9'_ *M:
M?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGF$XXJU?^*K6R^'T<UG?GSX81\L7//;->1ZYXF\0^(/#7VB]*21"4;58?,*
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M&@#QRRT'Q3?1>9:VQF4.1]Y>U6G\+>+KW#2Z7)E>G*UZG\,AGPXQ/)\PUVX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3
M'-&!2T4 '2BBB@ HHHH **** "LSQ"VWP_?^]N__ *":TZS/$0SX>U 'O;R?
M^@F@#YVTP,->3@%?.CY_.O9+GEP?0#%>(Z/!,GB5&\[,?G1_*?QKV^X^]^ H
M AI*,T4 .#8%(3NZ=::>G%.''- #6[4B\GFG$<T@P* %*C'2DP/2G9H % !@
M#I2'DY-+24 &><U%=$FTF';834M0W?%M)[J10!S7P=YU[6">Q'\S7LJGK[5X
MY\'AC7=;]F'\S7L8X_$4 .HHHH **C:18T9I'55!Y8\"E65& 96#(1PRG(H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%JVS]YUI;&ZUTZ#"#90^6;_Y3OZMSD5LRG&J>'P1G-H_]*EL4_XI>RXZ:HU
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MMG]FB:1X[7<5!'0#DU!!HD4^BZ%-)/<IYUTH*J_W:['6"C^)$RP8#3G!(/\
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M&/\ G@_\JU:RO$O_ "+6I?\ 7N_\C0!\U:).W_"1QH8NLR?-^->YW)_?_P#
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MGPS9?VC'?23R89$R"K8S7>?#F*..2]5 >V<G/84 >A.>0/4YKGO%]R\&AS!
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M*2&]CPOWAG@UMVWQ*T"?4([$W.)I#@?W: .THJ-'$F'5@P/0CH14E !1110
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M^OY*[6N(^(QQIVF_]?JT =J.@^E.IB'**?84^@ HHHH **** "BBB@ HHHH
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MA7/B;Q"ORM#9EOHW^-*'\0D9\NR_)O\ &@#HA@C.:8QP>M8/F:__ ';/]?\
M&E\W7_[EF?P/^- &YNI,D]ZPS-X@'2.R_(_XTUI?$)&-MBON0W^- &^>>C4
M#N:Y\-KRC):Q_)O\:RX]8U^XU6>QC2SWQIN!VMS_ ./4 =+J=^FFV4UU(0%3
MH#WKC?"MG=ZKKKZY=EFAY\M&Z#GBJUO=:EXI\0?8M3C$,-J?WB)GYZ]#C@AM
MXUCMT"1JN H]* 'D9&#S2J!D_A2@<4Y1S]: ,*R9AK]Z,\';G]:VAW^M9%H@
M'B"\QGD*?YUKCJWUH .:!2]J2@ R:Y#XB+$_AYFE4Y!XQ77U5O;"WU" PW*!
MT/8T >$Z-I\RWA%JMP;=E'F-'[UZ1X$T^6TO+QBL@A?[OF#D\5U&GZ19Z6C)
M;1!0W7-7P @4JH '  % "CH,]<<T=>M+QN(+ D<D ]*!M/*GB@! H'3^=&33
MJ3 H !@#"\4G3B@'%!/- &;KI_XE$OL015ZV)-I#G^X*I:V VDS U<M?^/.'
M_<% $O0%O3]:\_E\=WD6N?V:;<',P3>>PS7H';H37A^I7T?_  DU]._F+,CD
MH%(QD?A0![<I;Y2V.!SCO3MQSGM7BNF>./$$EU:EKB(QF4*5VGD$_6O98F,E
MLK'[Q4'B@"?<:"Q[&DS2?UH =G-&::.*4&@!<YI:2ES0 [)Q3#3LTFT&@#S?
MXF;1);D)_":W_@K+ON;M?X?+'%8OQ,5C]GP!RC'\JV/@I&5NKECU,8S0![4.
ME+@>E(.E+0 8%)BEHH 3 HP*6B@!,#THP/2EHH 3:/2C:/2EHH 3:!VI:**
M#%%%% !1110 4444 %%%% !1110 F!2T44 '?-)BEHH 3 HQ2T4 )BEHHH *
M*** #%)@&EHH 3 IC#((/0]:DIN,T ?(_B !/'TP48Q<G&/QKN/!;'R;R-N5
M+]JX;Q&3_P + F'_ $]$?SKN_ Z@6U\P'(EQ0!=D\*VLU_)>))*DS<$@]J>/
M#-BQ'G;Y&!SEI&S^AK;'!ZFEP/2@#+'AS343*6RN<]"Q/]:R->\$6MTOVBT
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M.O\ PF:,'7!ML8KHPY/I0 ^N6\?S26WA"[EB<I(@RK ]#73[CZ#\ZY+XC?\
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M@ HHHH **** $/2N%UH^5\3=#=/E9XG5SZC!KNZX77%W?$C0?7RY,?\ ?)H
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MG3B#VH 2ES249YH 7/M1R1QQ5"[UC3[&<PW-W'%(.2&-0'Q+HJC)U&#KC[U
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M.,_PJ!0!(>48>HKBIO <<GB5=4$I&&R0*[6@=:  97A1A0,44ZFT %':BC%
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M8XH ].3PMX>D19$TZW9&Z$#K3SX0T%_^8=$/PJ+P?,)=!MW52J\@*3G%=$*
M,3_A$-"_Z!D'Y&J&N>%M%AT*\=-/C1EC)!6NLK,\0_\ (O:A_P!<C0!\\O'M
MTJWVCY=[@?3(KZ-^$&!X&B'_ $T:OG696.CVV/[[_P Q7T1\'P1X)CS_ ,]#
M0!Z#10.E% !1110 444E "T4@/%)O4G 8$_6@!U%)2T %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !5._O(=/M9;J=L1(N6YJY7,^,(%GMK59%)B^T(6'9AZ&@"A!J^
MOZQ']JL#96UN3\@FY8C\ZNZ=K]['?+9:I! C-PLL)^5C7.>,/">BQ6TMVNJ3
M6,@&519CM/L%S5#2C&?"4;_9)H9UG0122RG+\CIF@#UCG=[4ZLE;G4BJF.S0
MG'5G.*7[1K'_ #Z0?]_* -2EK*^T:Q_SYP?]_*/M&L?\^D'_ '\H U:*S(Y]
M3+8DM8P#UPU74+A?F4#_ (%F@":L_7'2/0KYG^Z(&S^51O/J?F,$MXV7/RDM
MBLCQC+<'P??>='L;8 =C]1N&: / ['4H/[:9-P :1-I_X&*]MF*L48#=D#FO
M/O$&E6,#R26&GVJE;5&!P,[N.?K70Z?<ZN--MV:V4L$ .3UH W:2LW[1JO\
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MB@#T:YUFP@E:*2X1&7J":=9ZK;WI*6\JR 'G:>E>9VT\^JKJ%Q<+9"9F^3>
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M]<Q%_F 20@8^E &QX)B,?ABSSQM# CT-=**P[7P^]G%Y4%_.$';-3_V7<?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "L_5].35;"6T9RA<<,.JFM"DVC.>_>@#QF^\"ZN-1+W,%SJ+(?W<HE(
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M 8&!BES0&YH ?CCJ?SIE.W4W- "8&,<_G2X&,<_G1FC- "$?G[T.J2IMD16
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY\/'_EU(X[,<UT5EI\.G6RVUMN$*C&&.35JDXH YO7_"J:Y*DC7US R]1$Y
M-<[/\(]+N&+/>7))[E^:]$-*!Q0!Y_:?";1+:X$DADF_WF-:8^''AM>EF3]6
M-=8>H&,D^E)D'I0!RW_"N_#?_/D#]6-'_"NO#9_Y<1^!-=6!1B@#E/\ A7'A
MK_GR_P#'C1_PKGPS_P ^7_CQKJZ7% '*?\*[\-_\^0_[Z-,G^'OAM;=W6RPR
MHQSN]JZ[%0W/_'M*/6-OY4 ?.FHVR6UNJ1@!!*X 'U%?1'P>3;X&C]Y6/\J^
M?];4^2#V$TG\UKZ#^$)!\"0$?\]&_I0!WE%%% !1110 4444 %%%% !1110
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MZKZ!7_5CZ"OG3P_=2/XE$9C&TS)S_P "KZ,7[B_7^E "T444 %%%% !1110
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MK0U* 13*(KF(?.G<^];':@!,&EI,TM !4%SGR7_ZYM_*IZAO 39RXZB-OY4
M?/NL?<93U\Z3C\17T#\(E*^!( 1C]XW]*^:=3:>75)H]W E8U]+_  CW?\(-
M!N_OF@#NZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *X?4_P#DJ&B?]<9/_037<5PVJ?\ )4=$_P"N,G_H)H [FBBB
M@ HHHH **** "BBB@ HHHH 0UP_BS_D=_"W^_-_):[BN'\6_\COX6_WYOY+0
M!VR=*=34Z4^@ HHHH *XWXB_\@.U_P"OV/\ G795QOQ%&=#M?^OV/^= '81_
MZM?I3J;'Q&OTIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !5+5\?V-?9_Y]Y/\ T$U=K.UW_D!7V/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZKI&O6&M0K)9R[LC+*>"OU%:>:X"*6-/&FDW%C"T,5["Q>-E*GCVKO1\S9H
M?1110 4444 %%%% ",P523T%<UXE\;:5X9 2\=FF89$2?>(KI)#A":\JM]>T
M.+6]2N=?V-(9_*AWQE\ ?04 2Q_%2>[U9H[/2Y/L<1'FR=2M>C66HVNH6D=S
M;2"2)Q\I%>530Z%;^(;*X\/WJXO9,2*&RF?I77>'%DT[Q+JU@"#"NV3:#T)'
M;VH [.BDI: "BBB@ HHHH *;NYZ'KBG57NY3#:3.HY5"U '*^(_B)I'A^6:W
M+O-=Q?>A0<C\>E4M*^(,UX8Y[O29K6QDZ7#X*@>IQ7)Q>(_#RZ9.MQ:&]U._
ME<21X^8<X&*Z3P;ID#+/8>;(+8(5DL9AR,]P: /0+:YANH$G@8-&XRK#O4]<
MGX+>1+>]M7<M';SE(N>BUUE !1110 4444 %%%% ",<#I7$>(?BCH'A^Z%K)
M(\TW.5BYQBM'QY>W%EX<8VSE'ED6,L.H!ZUYYKT7@>/3&M9VF.I>6,LL+;B3
MWSB@#M_#WQ L=<N?+:">T5E#1/.,"7/I77,PV%AR,9'O7C=B\-YH#P"Y:X6Q
MC$EM*T94J1SU(_#\:]3T2>2XT&TEE&7:,;B#F@#Y9UN3=XNN^#_KV_F:]'^'
M@_XEMP?62O-]=POBZZ]YFQ^9KTGX=C_B43MV$E '<9R,T4@^Z*2@"CK%H][I
M=Q%&N7*<9KBH?!E_"]I/;JS$R;G4GH*]$P-P)S28[$,%Z#!ZT <'XNO[ZTE#
MVDXV*H5D!YS6CX&N;J>RE:Y9FD!Y4@\5D^)(D.KJ$M9'F)&T]OQK<\*"X_TM
MKNV"'?T4]#B@#IE8=SBG;JAV _>)%28P* .:\<.6TF%>QG7^=>I:8!_9=J1W
MB7^5>6>-A_Q*83Z3K7J>F C2K0'J(E_E0!:;A2:Y/XB/M\'7GN176,,H0.]<
MC\1A_P 4==9[G- ''> A&VG2S*/F,A/T%=+J>JVVE0+-=-MC8XS7$_#F=EBD
M@'(,G>M;QTL+VL,-QGR"V2?2@#1T[Q/8:O/]F@9B3G&1P<5S&JSZ?%-=-;ZA
M.DL4I81KW)YXJIH#V2^(K>.P+LJY5L]![U%XT2V\/ZBE[%IYF2<X)5OXNG2@
M#N/#-W+=:+#++(S.XSE^M9OC]S)X8N4'<8KF].\7:O;VJ1V^@RM$O (Z55U[
M7==UW3VL%TB6$N>I% &IX3VMX;MUQ@A<55DDO;'6;N:.SEF6<8&SMQ6EX=L)
M=/T>&WGX<#GGI6JPP.&XH X30HM3TJ^O)VT^=_M!)4*1QFLZZ\$ZI-"MQ$N)
MMQ8J:])D*QQ[Y'"KC/7FL(>)M.:5U0SD(2"PC8CC\* ,.[\(:I<PM<M.ANFC
M\HY'R[?\:BM= U/2C97DL:S>0WW4ZXKM+/4[2\@29)AM< C)Q2ZI#Y^G2B*7
M#[<CYN,T 8\_B::WD59M*N,NV HQWJPFNWI9E72+@<8&<5EK?W=E<(MS&DIE
M<8.X';77("\>YVY% '.:K<W][IUU!%IDZ/*F"QQ@5SGAK2[FZOUM5CC9HU.=
MX[UW&LZA%INGR%I<2,N% K.\!Z+?PWSZG<29613@9]: )8/"%U$7)M;$[FW$
ME#T_*NE\/Z9/IYN6F9/WN-BQC 6MD%L]:>>>U "@XI<Y;/MBF<TH(Q0!R%DV
M?B1=^T-=B#Q7%Z?S\1KUNPBYKLNP^E #+C/V>7 !.P\'H>*\&US67N;B2R6R
M@BDC8D%%YSFO=;T;K*4+((VV'!(]J\:BTZXO/$<$=N\#3ARV[(YQS0!7\%IJ
M,/BZP>]B*!@<97&:]WSFN3AT/5;C4+2\OY( (#\JH*ZP4 &ZJU\V+.4_[#?R
MJ<\56OR/L,Q]$/\ *@#Y^U-<;AZ2O_,?X5]#?",_\4+ /^FC'^5?/.J$;F_V
MI6Q7T)\(P1X'A_WS0!WM%)2T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 AZ5PVI\?%;1_^O>3_P!!-=R>E</J?S?%71L=
MK>0_^.F@#N:*** "BBB@ HHHH **** "BBB@!#TKB?%/'CGPN?>;^2UVQKB/
M%3#_ (3?PP/0S?R6@#M8QA:?34X6G4 %%%% !7&_$9"^BV@!Q_IL==E7(?$'
M_D#V@];R.@#K$^XOTI],0?*/I3Z "BBB@ HHHH **** "BBB@ HHHH ****
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M4 ?(^O#/BZXS_P ]F_F:])^'G&AW(]9>*\VU]O\ BK[A?^FS?S->E?#_ /Y
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M"Q1=0TZXLK>4OLRJN#GBN<T[1Y[JTMF*8B5%V'UK?TY+[3](NG(6)@Q*_2@
MC\,RHL,CR%MC@]:U]1U&+2%7?\\K?<C'4_A7'6?BK4+B\\J"3?.#@Q]B*FB7
M7;;46N9M)-S*?]62W ]Z -RVT1[PR7&IN6>3E(Q_!]:[+28U2 QJN @P.*X2
M;6O$$2!Y=(&Y1DD,#FK_ (,\:C5KJ6VN;7R)ADXH [P=>M/Q3$*N-RU)0 ;6
M]#3<'TJ![NWAX:XC_P"^JC.J6(;!N(NG]Z@#FM.X^(6H9XS$*[$?='TKB;34
M;;_A.[QUN(0GE#DM75#4[#K]N@Z?WJ +$T(GA>)\A7!4FN<TCP38:1J;7L3,
MTHSC/O6X-6L>U[ ?^!4[^UK/M=P?]]4 6L?*!Z4X52_M6T[W<'_?5']JV'_/
M]!_WU0!;8U5OO^0?<?\ 7-J;_:^F_P#/]!_WU5:\U73FLK@+>0N?+/ ;VH \
M(U3Y60MP/-?DU]%?"<?\4/;D=W-?.FJRQW$68R"HD?H?I7T5\(SGP#:'_:-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA3>*[_6]4.G2Z=$C7#1Q%P<X&?\ ZU>Y6^AV,%G!$8%+*H!XZ\4 6/[4LO\
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M_&FO\.F8<S1]<CY!_C0 :EXAN;TW4<%W;FW1PIP,_K6EH7B3;<3VVHWUJHB
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8I^0>E,:@#*U\*VF2;AQQTJ_:IBWCX&-@Q^54M=!.DOZYJ[;-FWB_P!P?RH
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M]2NSKC/B&"--L9#]Q+U"Q]* .R7E12TU"&C4CH1D4Z@ HHHH **** "BBB@
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M!I/(CW;2B_7:*EI* ,?Q#!')H5V"@^6,X&*X#X.N6CU)50HBRGKWXKT;7?\
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M<#&A[\%OWBX ^M>FZ+DZ'8D]X5_E7F_C'_D!G_KHO\Z]*T;_ ) MG_UQ7^5
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M !1110 4444 %%%% !1110 4444 %%%% "5Y=H__ "6G4O\ KFU>HUYAI?\
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M** "BBB@ HHHH **** "BBB@ HHHH *HZQ_R!;W_ *X/_(U>JGJR[M'O0?\
MG@__ *": /G#2+E%\084@OO3 /\ OBO4;^_MM/\ 'L-W=S%(C:XR$)%>7:/8
MPCQ$)L,6#(?;[XKZ%EL;6Y$9GMXY"% &Y: ,?_A,M!QC^TD_[X-4=6U7PCK5
MJ+>_O$>,'/"MS70_V+IG_/C!_P!\4'1]/(P;*# _V!0!Y9K]WHEE>:'#H^][
M:"<R$(I( Q6IXLU+P]XFL(K>:YO;?9R?+A;%>@1Z581/N2SA#>NP5.MI;*.+
M>(?\ % '%Z+XM\/Z1I5M9(][*(UP':!O\*RO%E[9>,?L.FVJW#;YPS9C(VJ
M>>?J*])^R6W_ #PBX_V!0+2W5PZPH&'0A: /'/%WP[U5X;"*RNI+E(3TQ]P5
MU,/@&6?2[;[5J4TTD,158B.A(KO]JELXYQBC:...E 'CT?PYUV'#6URD;'*'
M#D9'Y5Z1X=T;^P]%AMCAIB,NW<GO6S@9S2X''M0 W/ /H*\J^+7A]Y_LVKQO
MADQ'M]LD_P!:]6/3':N,^)@;_A%LJ,?O0,T 9'PLTZ>WAFN)%PCX"GUP3G^=
M>DJ<BN+^'%S&_AR.)9-TBL2WXG_ZU=H!@XH =24M% !1129H S?$'_(%NO\
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MH"I]T 8H 0J6(&1]#WKQ^6Q-OXWD-Q8B>&27E2,BO8L#//:J[65N;@3^6OF
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M7L!_'-6_ 1 T63':7-3^-%0:)+D_.-N/SJMX"7&BR\_\M* .MW=J*3'-+UH
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MV^T.7*R+DC]:JGPS#G'VA_\ O@4[_A&HP /M+\# ^44 =+_:\B==?M#]$_\
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M#;O!:_\ 74_TKPKQ'N8S8_Y^9/YK7N7P<!'@I<]Y30!Z%1110 4444 %%%%
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MPKD/B+_R+B#UNH_YT =5;?\ 'K%_N#^52U' ,6\0_P!@?RJ2@ HHHH ****
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MAH'M#)G_ +Y-:G@_=_9C;ATN'K-U? ^)^A>\,G_H)H [FBBB@ HHHH ****
M"BBB@ HHHH 2N-\6C/BKPQ[32G]!79&N-\6,H\5>&<GK++_): .PCX3'I3Z8
MG4T^@ HHHH *X_XB_P#(O0^]W'_.NPKC_B("= @ Z_:X_P"= '6P_P"HC_W1
M3Z9#Q!'_ +HI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH *@NXFFMV1" 2*GJGJDDD6G3/']X(<>U %
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9DE&Z)MR^M/=T1=[MM [GI0 [)[$BD YIJR+*NZ-U(]5/%*&.[% #Z&YHHH
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M[DY&\#/6@# _X1V=88XQ>!HU_AQ5Z;2(9EA5V)V#%:&Y!C:0<=<4 [<MCZ4
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MI/YUCZO_ ,E/T/\ ZXR?^@F@#N*6DI: "BBDP<]: %HI,XHSF@!:*3\:/QH
M6BDI: $KBO&'_(V^%O\ KM+_ "6NU-<5XNY\7>&/:67^2T =FG4T^FITIU !
M1110 5R'Q"_Y < _Z>H_YUU]<;\1B1H-N0?^7N/^= '7P_ZB/_=%/ID/^HC_
M -T4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6P[.<$[NXKT3P?J]@;"]MM1O'0S((A(XR>]8'C+P0NA6UO(EVTR2Y97(X(H
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MQJ#^)KF!S)]U%&T5R^K:YJ^J2[9K)HD>,-D+T%=KX(\96>CZ,MK+!<L=V=P
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M76]?T\ZE;Q>9&\A^\><U]+Z];Q#0;XF-"!"W&!Z5SWPMC"^#(P)"-\[G [4
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MP^J6RCVBK'N/ S^'I[BPU!XIFE@+QR1*1T/UKZ'KA?'=EOO]-F5<[RT3'ZT
M8&D_#.VU'1[2YBU6Z$<D8.UL<>U;EK\-K>V4F*Z#!NOF1AC^9Z5I>!9]^@BW
M)_>6\C1LO=<,?Z8KJ@, "@#QGXD>#Y[#0XKR"],2PN 1$N"<U+I/PGEO-.MK
MD>)=342QA\++C&:[[QU9B^\*7D6-S!=RCZ5#\/+X7O@^T8L"R QGVQ0!R?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 E%+10 4444 %%%% !1110 50UK_D!W_P#U[O\ ^@FK]4M6_P"0
M1>?]<)/_ $$T ?.>D\:DV>S1_P#H8KIIK&\O_AO>PV47FS->$XQDURFG749U
M=XL_,73'_?0KV#X??\@:;_KY:@#P:W\*>)=RH;&;YF^ZT>17LGAF#Q9H&E1V
M"Z3;R(1NSNQ7HFVC;0!R,FI>+1M":1"-W!)D/%<1=?"_7-2OI-4FF@@G9V^0
M_-P:]GQQ2&@#Q/5?AOXFN+&.'%DWV<97:F"W3_"NMT[6->T[3K:RD\.R.88P
MN\-P:[^C&: .$O=9\27]E-:1>'3'YR%-Y;IFJ_AO0O%>AZ<+.%[,1\N5E7)!
M->A;<4M '%:CIOBK58?L\\MFD)QN(4_XU-XC\)2ZUX?2VBNY(;J% %,;8!P*
MZ^EH \=\/>$K'4)9+2]U34(KV+AU$Q&3[5T@^%^EMR][>W&.HEE)Q70:YX?A
MOW^V6K^3J2+^[E7K5/P]XAE>;^R]5_=7D9VAC_RT]Z )= ABTVYGTBW3$%N%
M923U+9_PKI,?-FLZWT\0ZK=78/\ K552/0C/^-:75<T %-/ )IU-;[ISZ4 ?
M,GCZ4MXSNNZF0X]JN-X>M/\ A'[/,[&[EC\SKVSTIWBC3Y5\4:BHM[@B23,8
M(XYI%\*:XVGV[+#=_:4; 4L<!?;VH ]L\.:7:+X9MXDME430CS"!UXK(E^&6
MC.\CQS75NS=5BE*@UT^A6\UKI%I#,I5TB4,">^*BUC7+;28LE?-N&_U40ZDT
M <1K/@K0=(MU\W4;XRD?(GG$DFKW@GPI/I=S+?W-Y,ID'R1.V0%-7M#T:ZN+
MMM:UY UT3NBC/2,5GZOXK36=5;2+&ZC@BA/[^<G!/L* -#6=7GU:\_L;1BS,
M#MFF]!WYK6T;PY::3 B+$)+CJ\I'.:BTNY\/Z9;>5;7=NK$?.Y?K6Q;7EM>#
M?;7"R@?W6H M4@. U+4?_P 50!QOB?X@6?AZ^6QP'N691CTS776TWGVL4IX+
MJ":^?/'TD,'C*XFEB5@CJQ/<8]*[/1_B]I<R06BP-MP$WMUS0!ZLO7K0W3\:
MBBF6=%E5<;U!!]J>WW30!P?Q0_Y%Y/\ KJO\ZP_!_P#R XS[FMWXHX/AY=W3
MS4S^=8/@W+>'=K= 3MH X75?&VH1P3P)>CS%FVCCWJ&QU/71J=C)<74K+)(-
MN#PPK,\0Z1-#?RAH%0R3XWH?>MF*Q^RRV -U+*8)DS$QXH B^)^3K-F&.695
MSFO4O#X"Z'9[APL8KROXF8&M6SO&%(12,5V%CXRTVRT&W\Z?]XB#* ]: .A\
M43X\.7N<E#&1@5X;;:A-ICEK:<H&7I^-=EXC^(MIJ>BR0P6[Q;CMW>M<391Q
M'RS.5*M*"2IZ"@#IO#FNZK-K]E'/>,T<C9VFO9KA<V0D_P!@UY/9K9GQ!9-"
ML61* I'7&*]='_(-/X_RH \4UD[?,/\ TT?^5>D_ Y]VGWWU%>=:Z$?<GI(_
M\J]$^!F!87P'3B@#V*BE'2B@!*6BB@ /2N9\9H/[$:<#Y[=UD!_2NFK,UR#[
M5H=Y"/XHR/ZT <KX'FV:QJ=KD?,5F_[Z4&N[!XS7EOAB1+;7],N2<?:;<Q/]
M58@5Z>[)&C,WW ,F@"IJLT(M&@E(_?*R@'OQ7G?PQU=;6?4-&,9_=7+X-=-X
MJ>UO+&TF6]2W8.?*8CO7DVBKXBLO%M];Z/>1R-<N2)"O?O0!]!,P1,MC\ZS[
MG7=+L\^=>1QXZ@L*X5? OB74=K:IXFN%!'W(6VBM"W^%7A] 'NUEO9@<[I9"
M<T 2WWQ1\-62/MO'N'4\K&M<Y/\ &%I"5TO19I@[81GSBNY7PAH5O;R1VNEV
M\3;<;MF:X1XE3PI<1?Q:=?L!],T 5?\ A*_'&L75Q%;0):- F]E(YP>:P_[+
M\17EA%JFH:[<>7<7'DR+&<;><5Z"OEQ>,["Y'34+4 ?E6!)OCTK7-/7K:W7G
M)]#R: ,NR\ 6-W=ZWIU[/<37,"!XC(YY7%+;Z3IUEHNC:K;6L221W&R4D9W8
M..:ZJ"?/B[3;K^#4+58V_P"^:SH[96T'7M+'WK.9I$_ YH T7LK:#QO>QHR"
M/4;3<JJN #BN?A=_^$/L[EY/FT^\V].@S6U=7//AG6GZ.JQM526!1<>)=+QD
M2*9T'N>: -/RX#XQU"+:'CU&UW#'KBLD(LG@.[@Q^^TVX^4^@!J:"^4#PSJH
M3DKY,G\JNQ0*-<U[1N]RK2K^/- %<3))XJTZ[Q^[OK,(X]3MQ6*T3CPQ?6Y^
M]IMV7'MSFK*S%- T34C_ *VSNO*?Z9Q5F=K9=:\16DERD,=U"9L$_>XH U/.
M%OXMT74,_P#']$JL?7BN0\?1'3/',5V@.'(;CZT7?BG2!X9T>66\Q<V,R[43
MJ<&JGC7Q7IOB/[%+8"9KA0=^W@Y]Z /0;:3*1R'NH-8?BM2D,%XO_+"0-6'8
M^-;C[##%'9?O50 M)STK+UCQ+J&HV4R_* <CRHEH ]+^'MQY5SJ&GY^7S-Z?
M3K7H0KPGX1WNKS>*YEOX9$B$!W9'MQ7N_:@ HHHH 0UC>*W9/"VHLAPPA.*V
M36'XQ_Y%+4O^N1H R?AJ[/X.M<_>#L":J_%#_D!6W_7TM6OAF?\ BB[7_>:J
M_P 33_Q([;_KZ2@#YYU) ?$<K?\ 32O5?A@,:;>'_;%>3:H?^*BD_P!^O6/A
MB?\ B4W7_7;^E 'H"?=%/%(GW12GK0 M%(*6@ Z48S2$X'/2JNJ7T.G6,ES,
M[JH]* +1^4[:P_& _P"*5OO]RJ4'CC2I8MP>5V_W*I:[XIM=0T:YM+:"X:>1
M!D%?O4 =[X+_ .13TS_K@*WAW^M8?@Z)XO"^GI(I5A%RI'(Y-;><YH 4]*R]
M>LX+_0[RVN9U@BEC*-(W85J=.:YSQS"USX1OD1&=F3 55SF@#R&+P])H5U<0
MV6H6T\2VOR@@$D$FM'P(?+%XVTG:4RW_  $9K+T7PU=:Q+/<R9M"N%V&, UU
M5EX>.CV5Z5N'9I3C]* );'QCI^I:HVE1<3(=I/TK<W8[]*\$T:^?1?$LTD""
M63S&7<[>]>F1>*M1^V6L$]K;E9GYVGF@#L.35>\O(;.%#,<+(VT'WK!EU'Q'
M)=W @M8XX8W.PGJPJ+4+F.]\,K+JPEA99.%C. #GK0!T,-PES*#;N"BG:>>]
M4/%>?^$7O<]?*:N;T=[6'5(5L7F*2L=VXYR?6NC\6%O^$:O@0.(S]>E &3\-
M_P#D&W0_Z:UMZ_XHL?#EO%)>9_>'&*POAS@V5V"<#S:ROBE/$KV:21"1<_Q4
M >AZ=J,&JV,=]$2(Y4!4>@JY\N?E^[VKRCPSXCU/^R_LUN]M!#;QY"OU:NQT
M_6;J_P#"TVH^4#.I8!5Z'!H Z8J?,7T-4)=4MTNI;6:18PB[R3U KE4U?Q+Y
M DBA1S,W.X<H*37X-.FO7^U7$Z730YD"' H Z2\FN/L%\[NAB$1,>WTQ7/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX%LU7+WEV>AQ]H?_ !H ZSSHA_RT'YTX8*X8GGH17G/B+1(= 6PO;:^N$W7
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M&1G)R"<X-4]6AFO+&2"(HQ;HKYP*N@<4C9Q@'% &+8V%[&\+70@;RQM"QI@
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M7&F^);>WDG&NABB%@AB&#@?2@#J]WN,TN1[UYUX4N?$OB#3YIY=36)ED* ;
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MC*.0* *?PJN4N[C4YH<;689X[@<UZ=7/>%O"-EX5AE2S8GS3ELUT- !124M
M&5XDS_8-YC_GD:X3X/ _V/?D_P#/P?Y"NZ\1#_B1WAS_ ,LCQ7$?"!@VC:@O
M\0N#Q^ H ]*9PJMDX%<;XU\<Q^'HXH[01/</C:#S757K%;.8@ D*>OTKYD\2
M75UJNNE?+8R*^V,#OS0!Z3X;^(6M:OXO2QN8H5@D&W"]:SK:_CTWXC7%W=;D
M@6X<%L9[UC>$M,N['QMILTK[@^<^Q]ZTY=/&M>/;BQ=Y$A:Y8D)QGF@#T?\
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M "BBB@",PHTHD*@LO0^E/ P*6B@ HHHH **** "BBB@ HHHH **** "BBB@
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M(Z .NB_U2#VI]1Q_<7Z5)0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 52U?_ ) ]Y_UP?_T$U=JAK8)T
M*_ .#]G?_P!!- 'SKI[*NIREC@9C_P#0Z]4\ V\4NARJY24&Z8@.,XKQ[3;6
M9=?,I;*ATS^=>S_#L9T!_P#KX>@#J$M;>)\K'&&_V4%2^4AY\M/RJ2B@"/RX
MST5 ?I7GWQ<'E^%%&T$^8"!CK7HM>=?&(;O"J^TH(H \4T*VFO-8(2T,OR_/
M&.@],UZ_\)+%8;74TEMT0B8<%<XZUY-X4U.6V_M.V,0=YT Y'3!!KVKX77B7
MUGJ,B,,K*JL,'L* .\2&%3\J(#VPM28Q12T %%%% "4>OTHS7*^/=2OM,T)9
M]/E>.?S ,J: +>F_\C1?_P"XG]:Z#^]]:\;\(2>(-9O+F=]0E67C<=PYY/K7
M:+I'B!]P_M6<<]G% '7TF:Y(Z'X@QSJ]Q_W\%,_L'7O^@O<?]_!0!V5%<=_8
M6O?]!:Z_[^BD70O$&&_XFUQ_W\% &YXA_P"0'??]<S_*N%^#O_'CJ/\ UW/\
MA5S6-$UY-&NS-J%Q)&$/!D&*H_!M&CTJ\5R2WG'K]!0!Z5-"+B.2)C@.",_A
M7D>N_#>31Q_:FCLUY<^;YFP\]Z]A3[@I3TH \:\+:=KTFO6EQ>Z6T$<<I=V(
MIVE?\E6<N=J^<]>PL,J1G'%>0:+&_P#PM6;Y_P#EN_\ .@#U^G#I2TV@#(\2
M_P#('G^E:%A_QY0_]<U_E5#Q(V-%F_"KM@^ZRA^8CY!T/M0!:;I3>X^M/S[D
M_4TE '!_% X\/1G_ *;+_.K?PX7/A>!O]HU3^)__ "+<7_7=?YUH?#K_ )%2
M#_>H ZZF]Z=10 @Z4C4IIO?)[4  IPZT!H3R3S3N/X: $JO<_P#'O-]&_E5F
MJUQ_Q[S?[K?RH ^=M?1_*N.?^6LG]*[SX%@C3+W/J*X77ER)/^NLG]*[WX'#
M&FWP_P!H4 >OBEI!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4;_ '3]*DIAH ^2
M_$:9\7W;?]-V_P#0A7IGPN.=+N_^NM>9^(97_P"$QN%_Z>'_ /0A7IOPP3&E
MW?\ UW_I0!Z!WI'*<\_-CI2CI03@#U8T >?>-M4;3-5AEDA#JT>U..=V1C^M
M3^&]5FU+5IGDM(XD$(\S(ZBMS6_#EMJMU%=NI9D/8U6C\,:=87$UR$?]ZN)-
MIYH =!/X=9YUA\G<K?/]:WH6BDCA>$90#C%>:1QZ$8I[&"WD,GG;OG5J]$TJ
M%+?3[=5&%V\+Z4 7:P_%G/AB]_ZY_P!:VC6%XQ/_ !3-_P#[@H Z;P1_R*.F
M_P#7'^IK>'?ZU@>!_P#D4M-_ZX_U-=!WH .U<KX\!;PG> >W\ZZD\#-<SX^7
M?X8N#SPH/'UH ^?[V-#XFO"_8+_*L)K^SM]8NA(H*D82MB;R+WQ+?&4,^<?>
M]A4K:79$_P"I_2@#!N+NSNKRU6W0 @_-75>6FW)*8'2JW]FV@^ZE/&FVVS<R
MI@4 /_<=<#\*IZ@(/LY; XQ2I;V<TI1,<>E-N=+BDA*"@"62]ACV*(]Y88 %
M1VMBTLLDOS1\' SQ45OIDD2#RV*E?0U;\BYCMY"\K9*G^*@ $K6BHCQ 9XSB
MF'RYKZ(G'W:@\FYFW#S6V[N>:>NDH/FE&Z@"\@CB3;Q\U"JBG'R<5#]@MQ_!
M3Q96^/N4 22F/'+H!Z4@%OE6!4X':J5Y#8Q)^_*JON*A671T48:,_C0!>NVB
MEAD QPM0^' ?[>\-#G'V@<#ZU4GGTLP/Y<B(^."*GT6ZBBU?P[<&0Q+%,K-*
M!C(SS0!].W>HVNG:<;F[?RXU7./7BN<T[3)->U1=<U&0O"I_T: _='N169I*
M7/C/59;Z_#-I4!Q'&. _H<=:]"554#"X!P%'H* '*-GRBO+_ (S\:;8_]=A7
MJ-8WB'PW8^)K+['?PETZ@A\8H ET-T_L.T^9?]6._M5_S$_OK^=<1%\+M-2,
M1FYO51>%43' KF?$W@RPL%6WL;VZGO)6"^67+$#U]J /8%(/(.:=6/X6TU])
MT2"TE:1I$7DN>:VZ &TE/HH *8?XOH:?3'Z?@: /#/CB?]/TW_<;^:UW_P )
MS_Q1,/\ UT;^E<!\<>-1TX_],V_FM=_\)?\ D18#ZRM_2@#N:*** "DI:* "
MBBB@ HHHH **** "BBB@ HHHH *K7UN+JT>$G&X59JM?,$MR=VW) !H @^SV
MC>6)8T9HUVY([ 5#<7^E13%;AH?,48Z=JR-2@2TO4FA %TH.]_[V>E229TBV
MC2WA1[B0;Y3W&: -A(EN+R&ZB=3$B8 %>=Z /^+RZI]&KM(F2+4;1[0^7;3+
MD@=ZY#0S_P 7DU3Z-0!Z>.@I:0=*6@ H/2BD/2@#G?"7&CY_Z;R5SM[# GQB
MTME7YGMY#_XZ:Z+PCC^QQG_GXDK!N[Q)_B_IT /,4$G_ *": /0:*** "JNH
M7D%A9R7-R=L48RQ]*M5PWQ8N9K?P-=B!L&7"&@#C=8^-4\=[)%IEHDL*G =A
MUI=)^-<SW<46HVD<4;G!9>U;7PK\.:>_AB.^EM8Y)I?O%AZ5)\3/"FG'PK<W
MMO9QI<1 ,I0<]<4 >A65[%?6L-S 0T4@RIJU7!_">=I?!4*%L^6Q7Z5W8H 6
MBBB@!#TKB?%7_(Z^&/\ ?E_DM=L:X?Q4,^._"I_VIOY+0!VR??;Z#^M/J./J
M?I_C4E !1110 5QWQ$_Y UK_ -?D==C7&?$C_D"6?_7['_.@#KXO]6OTJ2F)
M]U?H*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5GZ[_P @*^_ZX/\ R-:%9VO?\@&^&<9@<?H: /G:
MQW_VA(PQM#QY_P"^A786OC6/P=X:C=K=I/-NG'X8K@M.M[E==5B_[G<I<?\
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M5-&O1C&9LXSG^$4 >HI]T_6G48"DBB@!#C!S7C6A(3\4IFW'_CX?O[U[(_\
MJV^E>/:#'CXFR@G!-P_\Z /8,GWIPZ4VG#.* .?\:326_A>^EC"Y2,L,CTKR
MC1/&FO\ B36K/3H;Q;:'R\,449->I^.S_P 4CJ&><Q$8KQ?X;QQ?\)/8>6FQ
ML$'YNM 'JVAW.I6GBZ;3;N^-S$L 89 ZY%=NJ]"3WZ5QMOD?$B16Z&W'\Z[$
M'[IH X/XI<>'H\?\]E_G5_X;G/A.#/\ >JA\4@3H$?IYR_SJU\-')\*19[,<
M4 =G12TE #') 9E4E@,^HKQ#7OB?K5O=7=I X3RF*[L $<U[?(YBC=UR6VG
M%?-.K31-XCU 7D8+EF ).,'- 'H\T_B"U\-VVKIK)D,VW=&4!P"17I%D[RV%
MO))D2%03QC/%<#K&7^&EG& ''R88?P\UW>DQXTRV)?</)7GU- %WM4,_$$_^
MXW\JE^E1S#=;S$_W6'Z4 ?.NNR!5G]?-?'Y5WOP-.=.O#ZM7GOB)?W\Z]O,:
MO0?@;Q87RCL10![ *6@=** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK=#3J8QXH
M^2?$)QXPN3W\]OYUZC\,3_Q*;K_KM_2O+_$0 \6W6[KY[?S->F_#(_\ $HN1
M_%YN: /0,\4=\^G2C%.(XXH ;P!CMG-5+Y)#:2^00LA'!QWJV?+ R[!0.Y/%
M<KJ?B>YAUAK&RMX)%"Y#M)0!D?V)K4F^?:PF#94@XSS7;V"2PVL7FY,@7!!K
M-\/:W-JZ7!FA6.2!]ORMD5M%RW6@!:P/%XSX3U ]]HK?K!\7Y/A>^4=-@)H
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M2H9L$ CL3ZTZN+^(OB>\\,Z7!):11LUQ((MSG[N: -'5_$2V]XFFV0$VH..
M.B>YI=$\,I8W+7UZ[3WTGS-)_=]J9X3T:*"QBU";$US<*':1N2#Z"NE'WB>F
M: %7H>O7O2TG?-+0 4444 %,/WA]#3Z8WWO^ F@#PWXW#.IZ>#R/+;^:UWOP
ME_Y$>$?]-6_I7!?&[(U&S8] AQ^8KNOA)('\$Q@=1*V?TH [VBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ JM?1O+;E8\;NH!&<U9JO>S_9K9Y0!E1WH
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M88-C!CT\L4@T/2QTL8!_P 5H<8S1GG &: (8;>*WC$<2!%'0#I4P%&>.E+0
MAKB?&9V^)/#('>>3G\!7;5Q/C09\4>%Q_P!-Y/Y"@#M%Z9I],0Y%/H ****
M"N1^(*@^&P3U%S'BNNKC_B(=OAU!_>NHQ0!U-K_QZ0Y_YYK_ "J>H;88MHAZ
M(!^E34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEII&L#5;BZ14$4"K)MW<GG.*]<\'>';&'1TDU"*$SRGS"&P3@T ,7XK:.?\
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MJ:'>Q0RGYIHU88;'/]* ._&&R!V&33)AF"0>B$G\JXS3_B9H;1 7]XD5R/\
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MXI/[;TX\&^M\?]=!0!H[AZT;AZUG_P!L:7_S^6__ '\%']L:7_S^6_\ W\%
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MBD; _6O,/$?Q>BTJ]$-M;>;;N,+*1P37F&I_$C6-3OF-U,);19@5@;C(ST%
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M4&F6EH0\%O&K@8!  KS?1U ^-NI?]<VH ]5'2EI!TI: "D89Q]:6@]* .?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:;%_J82X&?>@"K8:"GB;4?MSV0ATR)L)&,@R8X)_.NZ@\/Z79@-;V:(1T"G
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M*=/Q]^3_ +X-!\5:<",R/C/W2AYH YF#2KBTUG5?L A2.-#@'G-=)\-]7O\
M4O$UD+H(H6!E^48Z"JNGDW%SJU[$C"&5"5R*M?"EF;Q!#DD8BDY% 'MA!+-O
M /H-M.V(!D( W^SBJM[?VUA;B6[EV+],YKS"\^(Z7GB^;3H=6^Q6L:_*[1G&
M: /6CG[IQ^6:\S^,:(GA^U;8!BX7E1C/-;?@;5KO4H]0%U>?;%AF*H_M6+\8
M_P#D 67_ %\"@#N/#\49T"R(09,(Z@5!=:+'=Z['/*B&-(R,%1U.*L^'L?\
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MMQ00I.<#CU%.%+0 S:OHOY"C:OHOY"GT4 ,V#_9_*HI8$E1D8?*00W':K%%
M'"6ERW@^[GL[R.0Z?-)NAE495,]<U1NKS1_[7CU%=6EOKI&)AMXQD9[5Z++$
MDHVNBLOH1FJ\>F64,ADCMHD;N57!- &/X4TZ>SM9[F[!6YNY3+(G89KHQTH'
MTI: "BBB@ HHHH **** "DQ2T4 )7E>D?\EMU'_=:O5:\MTG_DM.I?\ 7-J
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M=:_\>D/^XO\ *I:@M?\ CUA_ZYK_ "J>@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>1.?>NY^"VX>#-IZ!^* /2:*2EH **** "BBB@ HHHH **** "BBB@ HHHH
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M:X\Q/W74X_X&*]I^':XT2;_KX;^5>/V2,-4E^J?^ABO8?A[_ ,@27_KY;^5
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M2?\ 7RU '7UA>(/$ T06ZBUFN6FDVX0BMS-<=XM#'7M%9&"[9&P#W.* )?\
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M)M)I<AE^]'BO:+8_Z-%SGY1S7DOQ)M(K;Q-I(C157<.0,=Z];@ $$8'3:,4
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M@? ULVMZ/I_.N#O_ )K*9F/S":3^5=W\#,_9;TGVH ]BH%+10 4444 %%%%
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M8CD_3BGZ-KGAZWTBWBD*[A$N1Y!)/'?BKNBZWX>U^YDM[!(S*.2&BK?&GV1
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M@=!Z2M_(5\]2C?I-NO7$CG^5?0WP?Y\&*?\ IH?Y4 >@4444 %%%% !1110
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M" ALG;5O19K6TU*\CU"58[MI6*&3CY3TP:D\275E.MO#%*DET)E92@W8'X4
M=3&N$5?117(_$8_\4];_ /7W'_.NO3B-1_LBN2^(R[O#D?M=1_SH ZRW_P"/
M>/\ W14E16W_ !ZQ?[HJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/0#UO(P: .NMO^/6+_=%2U';X^SQXZ;14E !1110 4444 %%(32]J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.LX_L6]S
MV@?_ -!-7JHZS_R!+[_K@_\ (T ?,5K<R?\ "0" IE&V@G/^T*]B^'O&C2@=
M&N&_"O*+2%?[2=^-P*_^ABO6/A[QHSY[3M_*@#K\>]5;^R2[M'B(SN&,XJWD
M4F6!XZ4 >(^)-$FT+4C<KG ?*L/\*]%\&^)8]8TY(YG(N$XP1U%7O$VCQ:OI
MTH*KYBJ2,UX3:ZU?Z!K+F,D&.0C9GK0!](KDY(7*BD.UUY!KRO2_BM<W5_;V
M\MH4\Y@G3O7J:,9$5R<9'(H 1XU=&1AE2,$5YAXPT66R6:;;MB93@BO4CTK#
M\3V NM#N/-;)5&Q^5 'C_@CQ7'H5Q>*;=I1*@781G-=$_B?0-A!\/1%B<DY
M.:XK0UBMM1D>1?,V8]J]CTK3=&U&T6>.T1\@;L*,@T <Q9>*=*M9TNK70U20
M="95JIXO\;G5=(^RKIY#;@P <8KT4>'=((RMG"1_N4UO#6D$Y:RC]L#B@#Q?
M0+VTM[F=[[2DN78*?]=@CK70#7M$R<Z!&5]Y16ND&DP>+[FT:VCPRJ,%1[UV
M%KX;T@1D_88CNY!VC% 'GHU[00N5T*(L.BB7K2_\)'H9CQ_PCZ#U E%>C'PY
MH_7[!%GV05EZQ9:1I&EM<'38SS_<&: .*C\3:"S2*N@0@DY&7%/'B30UP!X<
MB !YQ(.?UKK]&L/#VL6RSPV<&>^(_P#Z]:A\-Z3GBPM\?[E 'F]SK&D7%A.D
M6B1Q.P.',F<?E6W\'8]EA?C YFSG.<\"N@UC0=+CT:ZVV<:,(R05%<]\'%"V
M>ID?=$YP/P% 'J>3D\\9Z4C' ZXH'-'XXH YCQ-KZVJ?8+("6]F^0C(PN?6L
MCX>P2V+:JC%3,UUEE!ZT_5_AM#?ZQ-J,>H7,;RCD*W3Z5SB>%/%>CZA<"P>:
M:WD?<&\P!OU% #OB>P?Q!I!4C[RY]J]4M?\ CTA_W!7AFN07L&M64>KK*)RZ
M[&>08_2O<[/YK:%>A* \_2@"AX@)&C7)SCC-7K%R;&#/]P?RK/\ $?.AW6.P
MQ5ZP_P"0=;G_ *9C^5 %O=1FF;@,G!J&XOK:T:-9YE0R?=W'% %FDQ[U#!<P
MW*[H9%=?5>:EW4 +BE'2FT4 *:44VE!% "MTIM*2#24 8NM^&K?76C>XGFC:
M,_*8SC%9-QX L1$2+V[.%/5_:NQJ.X($#Y_NG^5 'SGJL"65M)##G"S,,MSG
MBN_^!QS:7I/M_.N&\0X#3KW\]S^E=Q\#6!MKX#MC^= 'L(Z4M(O3\:6@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*6DI: "BBB@ HHH
MH **** "BBB@ HHHH **** "D[4M)0!\G>) ?^$SNP3G$Y_G7IOPQ4&RU \8
M\X#%>:>)9$'C2\][@_S_ /K5Z5\+?^0?J!_Z:YH [X(,T[;@]J7L*7! Y- #
M=O7WIW2/;S^%&.,@@XZXI>J]* (P@P0<G/J:3R5Z\?E0\T<3JKL S\ $]:@:
M]B^U?9P6,G7IQ0!Y=\8=G^A#:1UZ&N+\&!6U- 5ROFJ,'GO79_&/*FRX+=>@
MZ5QO@SY=4C!4_P"N7M0!]165G;V\:-#"D;% ,J*G%M"LQE$:"0C[VWFB#_4I
M_NBI30!7:TA=_,>*-G_O%>:26SMIB6F@1R!U(JP>WUQ6+XIU1-(\/7=TY(94
M.S'<T >-?$_4K"7Q((-.A#/&NTJBXYK4\+>.;:PFT[2;_38E5_E\TKSGTZ5F
M^ K.#5/$UQ>74)<E=P+\Y)J_\0X([75-#DMT2-GN-Q 7WH ],U_2;?7=$DT^
M*X2-9!D # KSV;0=.\!:2\UY$FHW$A"I!_A79WNH1:;IR7-PZK\F47UK&TNS
MEUR\;5]2C8HF/)C<< =N* &Z3XBTW3K(SV?AF[AE,>XE8U(S^=9,7Q&N9B7?
M1+93DC#9!_'Y37? )EEV@@_W>!4?V"TS\MO$/^ @T <6OQ%N4;<FC6@(_P!H
M_P#Q-2O\5;^)V\RRM$VIN ,C?_$UUS6%KCFVA/\ P "O//'45O;:W;B*,('4
M=%% &F/BOJ+'*Z?:D#W?_P")I?\ A:^H_P#0.M?S?_XFNPL=/M#90@VT6=H)
M.T<\?2K8TVR'6UB_[X% '!GXKZF/^89;?]]-_P#$TH^+.I8_Y!MM_P!]-_\
M$UW/]G6O_/K!_P!\"E_LRS_Y]8/^^!0!PO\ PM?4C_S#K7\6?_XFAOBQJ"D!
MK*R0G@;G<9_\=KMFTRR+?\>\0^B"N=\7^"8-?TORH%5)T.Y-G!- &%?_ !8N
MY+-XGMK+]XA!VR,<?^.U#:_%^:UTR-1:V>Y1Q\[<_P#CM9.G^"-&N+&=;AYX
M;Z!2)(V;D_2NDT?X6>'I;.VGE,SX&<ALT 16WQ;U2Y3>NFVH7_?;_P")J?\
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ME,CEF_"O2O@?_P @^^['(XH ]>'?ZTM(#U^M+0 4444 %%%% !1110 4444
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M(5R?Q%/_ !3]OCO=Q_SH ZV$CR(_]T5)44(Q#'_NBI: "BBB@ HHHH ****
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MI@ WE0J!@5>_X0OQ/CCQA<X'3,2T :S:EXP##&CV9'_78_X4IU/Q60/^)/;
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M-,CO4;/F#Y@1C!K3&"<'I6';^')K9=L.IRH/144?TJ<:1>#_ )B\_P#WRO\
MA0!L#8*,XK*&EWF,?VK-_P!\+_A2?V/>_P#07G_[Y7_"@#6RE4]3DC33IRSX
M 1B!^%4SHUY_T%Y_^^5_PK'\1Z7=Q:!>R-J<[[$)^Z* /$;VSO+^:Z^R023+
M;R,S%!GK7M/PEU6*VT2'1[E9([D!I=LBXXX'%>;>!-;L=*M]6%]<,AG4%'(R
M3@\_SKI],L+KQ)XJL[C1M5D\J.#YY-@&T9''O0![@#G/UI:JVT3PP!))VE8<
M;B!FH+FSNI9 8]1FB7^ZJK_44 :--S69_9UY_P!!:Z_[Y3_"F_V5=_\ 07NO
M^^4_PH U<TR1U4$L<*HW%O2LS^RKS_H-7/\ WPG^%5[[1KZ6QF1=9N260@#:
MF#^E '&WOBY-5UB\BGU.2QTN!@JO&,&0]^:NP+8H^-(\174UV!N2.4E@WM7,
M;XX?#<FB+ICW%_#<;G(4$L,]>:[[3M0M?W+-H[6>U!NDDC48P.Q% &KX=U9M
M6L2TJ%)XCY<JD?Q#K6R.E<IX+87"ZE=Q[O)FNF:/=UQTKJQTH 6BBB@ HHHH
M **** "BBB@!*\MT+GXRZI]&KU*O,=% _P"%QZKQ_ U 'IJ_=%!SN'I2TG\0
MY_"@"A=:E:6DY2XD$9(R&-6%N89#'A@3(N1[BL37M%759@'A<A1D%7Q_2GZ=
M8W,-W;_:$PL:%5^?/;Z4 ,\';O[&(;M.^/SK*U?_ )*?H?\ UQD_]!-:OA1@
MNDON;"F>2N3&JR:E\5=*^3$*Q2;&]>#0!ZA1110 5B>*-=3P[I+Z@\7F!2!C
M-;=<%\7?^1%N#_TT6@#H_#6NCQ%I"7Z1>6K'&,U;U'5+/3(/,O)1&A;;D^M<
MM\*?^1"M?]YOZ5D?&ABOAFW*DC][V/L: /1K:>.ZC6XAD#Q./EJQ7,^ 26\'
M:>223Y?4UT] !1110 AKB_%7_(Y>%_\ KI-_):[0UQ7BO_D=/"W_ %TF_DM
M'9K0XRN*(Z<PR.U '+Z=?39UB[N90(X9&14/0 #BLE7U9M/AUJ2_*&24 0A?
ME"$UM7WAA[FX9HKUX8)&S+&%&&JW?Z0+JWM[:%PD$3 F/'#8H UT.Y$;VKD?
MB%_R!(/^OJ/^==>@VC;Z5QOQ'XT*T_Z_$_G0!V$'^HC_ -T5)4<'^HC_ -T5
M)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#"-+IUMI+2(T.S>IZ'%&EW&LV&BBVDT>1BJD$EZ ,;X8JG_"2DJ,?(:]H
MXKQCX8(W_"2/_LJV:]G .* ,W7X7GT:>-!DGBKMFI6Q@4]50 T^5E2!FDP$'
M4FG+C:![4 !X(.,XYZ5DRVD[Z[:W38\M8V_45L9QWQD$5AW$\J>)+6 $F,QG
M/Y4 ;>W !SUHQ1U"T[;0 44H%)0 C>N.E>6>))[G3O&DEW:7,".(NDM>IDG:
M1Z\5YQ="P/Q E344#1>7C)&<4 7O"FNZEJFHO%/=6\B+$3MC'0Y'-9.J^*-:
MM=6GABN[81J<*K'']*['2UT*WF;["D:.W5E!Y'I5:^A\,+.QNDA,Q.>?_P!5
M %?P[K5]>:/=37%S$94Z%1D5S%WXLUW=(K7MIY;94\=J[[2AI/V-DLDAV'[V
M!63J4/AW[)< PP^<$)!"=Z /(O$5K%_9T#--YSRASE!D?_6KO/@: --O0O3<
M *X37X([/2+>2%]R.'.$[5W?P/.;"]R,'(.!0!Z^*6DS2T %%%% !1110 5#
M=#_1I3Z(W\JFJO=NJ6<Y8@ (W\J /"]&_P"18UP?WM0Q^M>W:<,:;;#_ *9+
M_*O#=(FC'A[5TWC>U_N"YY(S7N6FD-IUL0<CRE_E0!9(R,5ESZ#9W.JKJ$ZE
MY57"@G@5K8I.@H C<*B;NI4?I7G=W\8="M+F:!H;IWB=HVV+GD''K7HV-V0>
MAKS75M$L?#WB?^TC812V-X<3*8Q\C=S0!&WQJT0,"EG?8'4>6>?UK#U?XC^$
M]6)FFTN]2=3_ *Q4*DCWQ7JEKH^C/;K+%86S)(,J1$#Q7(:C*;C7Y--TG1=.
MF\J/+^;'@YH \YUN^\.ZI86TFEK<Q3?:%+K,2:]&\!*T>CZOD<><VWGKQ7-^
M,/[3LK&V^TZ3ID0EE56\E<$5U/@;:='U51QB5\?E0!YDYLUU/1OMC?N%=VEQ
MV&XUHS^(?!D5ZT MM3GB1OW>68J:I07<EEJNFI'9171D+@"497DFNZN!KEO9
MF[ET#25@0<@)SCVH CB^,FB0VZPPZ;>($QA5CJ7_ (75HZG#65Z"!D_N^E=9
MH<.F:MIEM>KI=HAD7IY8YK%\306DLO\ 8NG65N]W+C>Z1#,:T =1H&NVOB+1
MXM1M0WDRYVD\'@U9O]*MM4BV72AL?=8#!%0Z+ID&C:1#9P(H6(8POJ>IK4&
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M_P!C@CR@!CU_*KO_  L;6_\ H#?I76:?-%);01A4RT08C:*NB%#_  )_WP*
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MVP( )9\_F*^C?A(,>!8%])&_I0!W=%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM%"B.)LE>YKR7X:ZKJ4GC69+JY=H-YVIDF@#WP4A( SGH:;G=SV[4O' /<T
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M%%% !1110 AX&:XG4/\ DJ6B>UM+G_ODUVQY%</K!\CXG:#.?NRQ2(!_P$T
M=S124M !3&(4ECP,<GTI]8'C*_.F^%[ZY5]K",[?K0!RGB?XKV.BW$MI:0FX
MG7C=G/-<%)\0_'6JR,]E;LD74 1GI6Q\*_"%MK:3:[JD0G=B0F\]\U[/#;1P
M1B.)!&@'"K0!X%9_$CQEIDP^U6HE ^\'C.:]#\'_ !/L/$$@M;B(VMT>S=#7
M<R6L,JD/ K \'=WKQ?XF>#$T2=/$6FGR51QF)1WSUH ]P!!&0>*6L#P?JW]L
M^&+.\)RS+M;ZBM^@!#7%^)\?\)QX7_WIOY+7:&N&\9-Y'BOPQ/GCSI%_,"@#
MLUD1%!9@,\#/XU*KJ3@,"<9QFLJYNK2:YF@G'R0;'_$Y J:.2!-6,:#$CPAL
MXZ@&@#1HI :6@ KB_B2P&BV8)Y-['BNTKB_B3'NT"W?_ )YW2-^M '8I]Q3[
M"GU%:MOM(6]8U/Z5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD9]J .#^&AWZM>_[@_G7JQ5<8;O7E?PL7-]J#-QTKTF^OK;3[1KJZ<B-!R:
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M'FLX/S' Q0!Z7 OEVPC<DE5P,UP/CX'^U;0]M@KT",'[,BNVYQC)KS_Q^?\
MB86XS_!0!ZAI7_('L_\ KDO\JNBJ6EC;I5I_UR7^56\T .SBF[D&5<C)Y'2N
M7\<:[=Z%H37EHR!O,&-PS7F%AXTCUGQ++)KNIR6L?EC:(3M&?PH ]W\X$;5^
M^*4$GKUK@? &HQWM[J(M[V6YMT;Y#(Q)Z5WS_P"L) (S0!!?2O!I]Q*C8*1D
M_I7"^+[AI_!EO+*^2T@XKMM4_P"05=9_YY-_*N"\4@'P78D ?ZQ>,>] &_X
M8GPO;[>E=77*> 7QX:A&T#D]JZH&@!<5S7C+3]5U'2!!I>TR!PQ)["NEI<X'
M'% '.Z!K9GM4LKM/*O81MYZ-70@ C(Q[@=JQ-<T87\2M;OY%VAS'(OK[U7T#
MQ!-+<MINJQK;W:?+G& ^.] &QJ+%;"<KU"-C\J^9+M8V-T5)\Y[@CCKUKZB,
M:36TRMPK#:.:X&Z^%VF23O<I,8Y"V\8' .?2@#SSP]IEW:^*=%>>*5"YPI)Z
M"OH-1B.N2M_"5_\ VG:W-]J G6 9C3RE3&/H*Z]?2@!1TJAJ]T;73+J0=5C8
M_I5ZLGQ&,Z#>G_IDU 'SAJ4[7<37+=6G?^E>]?!H?\4?GU>OGN:4"P49R1*_
M'Y5]"_!D[O!F_&,RG^5 'HM+24M !1110 4444 %%%% !1110 4444 %%%%
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M*O&5(D)P1@UWXH *X;QWM_MSPQNQ_P ?;=1GL*[FN(\;%/\ A(_#(<\>>_\
M(4 7/$-M#',\YMKHJZ@$PN1FI?#@@GG>YC:9F"!/WKY(]JM:RVKL0MBT,2=&
M>49R*A\.0"&2=?*BW _-*A^\>] '1#I2T@Z4M !7)?$,?\4K)_UVC_G76UR7
MQ%_Y%=O^N\?\Z .FLO\ CQM_^N2_RJ>H+/\ X\H/^N:_R%3T %%%% !1110
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MQ]HUE67(^U$8K)UGQ;IM]-I$T;LQAEWN,=.*/"WB;3;*[U-YG=5GG++\O44
M)XET"33-2?4K5"T<@^8+5;0];_<7=O)G8T;9)]<&NJF\9Z#)#)$\C.I'3RS7
MFFO:M86M_(]ID0R+G&,<F@#H_AHP^V:B%Z;0:YWQSXKOI[VXTI+A=J$C: <X
MK4^%MXAU*]0D R*-M9_BCP9K+:G?ZBX7R =PV#G\Z .5TFPN(-0TW<0 )%;
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M>T8[5T^EZM!J=OOC8"3^*'N*TM==?^$GA&\;_*XSWKG-2T0V%[)JVEDHW5T
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M%%% !1110 4444 %%%% !7E^F ?\+GOCCK$U>H5Y;ILBCXUWJ'KY34 >H+R
M:=2 8&*6@ HHHH 0]*X7Q !_PL3PX?\ 9?\ D:[H_P!:X7Q ?^+B>&_H_P#(
MT =U2TE+0 5!<PPS(5N%1XB/F5P"/UJ>N>\8Z9>ZKH,UMI\ACN&QA@2,4 6C
MI.B9YL[+';]VM*-*T)>1967_ '[6O&I/AOXYWY75788[2'BD;X;>.MO_ "$Y
M/^_AH ]G_L[1<8^QV/\ W[7_  I/[,T/.?L5AGU\M/\ "O$+OP#XRLH3/<:P
MT<*C+,TAXKB9[_78KUK:'4[F<@X5D<T ?65O%!%"%MU5(P> G JP*Y#X=Q:C
M%X5C&IN[3'GY^N*Z\#B@ KB?&IQXC\,G8&_?R?R%=M7$^-0?^$D\,\D#SY.G
MT% &OKFF3WS1LMX$53GRV.!3O#R-;PO:20(DD1)+(<ALU%KUUIZ2I'<G]Z0<
M9) I= M[."222&?S9I!D_.2 /I0!T(Z4M(.E+0 5R/Q%_P"17/\ UWC_ )UU
MU<C\1?\ D5S_ -=X_P"= '3V?_'E!_US7^53U#9_\>4'_7-?Y5-0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 54U3']E7>?^>+_R-6ZIZL=ND7A_Z8O_ "- 'R;#.;;Q0)XE^>-]P_[Z
M%=S)K[>*]?T^QU*W#1!\9X],5PUE%]H\6I%T#2 $_5A7:>*-$?P[J]G<Q;E0
MME6]3B@#KSHTGA5WN;:W6[TYOO*T:Y7Z<5U.E2Z9J=KYMM% 5/WAY:Y'X8JM
MX7UZ'6]+1&*>?&,8;K]1574/#<UE??VGHTAB<<R1 \/^% '0G3[-"&-M 0>_
MECFN-\;>&4>T-[9PQJZ]0JCI71:5XAAO'%O/&(;H#YXVX.:UYXXGB*>4 L@P
M<F@#S3P;?V($D-U##YAP.8QVS7H:6ED\2M':0$%>#Y:_X5Y1XBTN;1-<:YC)
M6!N00.*VM*\6WFJ0+I=FFV1AAI2.@]O>@#H-4O[6V<6UE:V\MZ^5150$9]_2
MN-\4^%C:>%+B_OE1KHD<*.!FN_T/P_:Z,C.!YUQ*?GDD.2:R?B0X7PC=-M !
M(QB@#R?PC=G3M5=P2N$!S7N.E:E;ZOIH!2-V(^92.M>.^$M)&K"Z*C=(L8Z5
MT&A7T^CZHL4K,.=NTB@#T2/PWI*OYAT^!6#;QA1P:T%S@C '..*9;W"W,*NG
MIDU,2N : .?MR?\ A*K[ &[R4 S^-<_XT\/B6/[?$F)  K #K[UT,'_(V79'
M>)3_ #K8GB6YB,,B@JRT >9>$M?:QN4M)&/E,=I!/2O3(W5XED#9#=*\C\3Z
M2^BZH9(UQ&QSD5V7A#7VOK5;>4#S%X4'O0!UN*9(NY'0X.Y<4[G=M[TX+\QS
MZ4 >(>(;.:T\47D5O/)"F5.5''*@UJ:2FH2M'$^NW,:]@#^E=7KW@=-7O);P
M7<D;OC*KVP,5P]SX=N-,U!()+J;D[D)/:@#J=4M+M]2T[3)M0N0K=71L%N/6
MGZSX*C2PGE&H7CB-=VUY"PXJ;P^L5Y+;O<3/)<6S$JS=QTKL)K<3P2P2$@3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2I[.1+YCNCPN58<\YKT#XCJ3X8\,8(4#DG'^[7:VNJZ/'H4&^X@:58,$9YH
MS/A$LB>"TBEW^8DK @CBN_ .*\^\!:S80:7<">\6(-<.5W2GUKK?^$@TC/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444PL0
M3R,#KSTH ?168VN:=')L>_M\C@C>*O0S).@>)PZ'H5.10!+124M !1110 44
M44 %4=98KHMZ1_SP?_T$U>JCK(SHMZ,X_</_ .@F@#YNTM@^LHW<2Q_^ABO5
M/%)_XJ+0/^NG]*\JTJ-%UM&W])4./^!BO5/%4T<6M:'/(4$2R$EC]* .OFB#
MV^9$4K_M5XAXQMHK+5Y)+$E]QY;&<5W5YJ^J>(I_L6CD+:JV);@C('TK2_X1
M.WCT*6VCBS(P^9W.230!RWPY%C/=.UROGW8Z22C<4^GI7I^-ISG/OG->(2&Z
M\+:NL8W(B\[F/6O6= U6'5]-CF63G'S?6@#4ECCG@>.0*R-P5(ZUY[XFTZZ\
M-65U>Z4TB0LA#QJ>!GO7H@*%?E89K"\6VR7'AN\B>39E>"IYH ^:WN3J%WF7
MS)'92QW5H:83!I.J8.WS%7C\:HJ)[?4S&^T'85A.SECFG)</Y$]LZ'><9XH
M]0^$O_'W<_\ 7,5ZQVKR3X1RC[9= _W17K2\'GI0!EZ]I4>J6+(\8RHX->?6
M-[+H=XZ,"%5L#->L$XSCO7$^,=':<K<P1 E%RX ZC)H L:%>_;O$EW-ZQ1_^
MS5UIY8UY=X9U40:M)*PV(X5,?3/^->EQS";#H?E89H EQ36CC=2'[BES2<=P
M* /,?%NA"PF^V)%^[;IM'W:O^#-=4D6=U-\N/EW5V6IV"ZA9- <'<."*\EU>
MQET35-F&&P_*: /9P>.V.V*<3\GXUSWAC6X]5L%\PA)47&T5NJ>.O6@".^A%
MROEL@92.<]J\UU16T_6EC;>D6>"*]/9F'(4-ZYK#U[3%U&$R1*/.3D#% %;1
M=;62Y^QER5(PN?6M]Q\I^E>9V]Z]K=AI$*S1MD?A7<Z9J)U"R9\C<!S0!P'A
M*TM-1\5SI<6Z/AF^^F:]'&A:5&/^0=:YSE2L0S7G7@>54\73,5V*S-UZUZQ)
M/']T-P.G(H IZUMCT*1%4*H P ,5I6'_ !YQ?[@_E5"98KJ$P,PVGJ..:T+-
MHEC6%7!91ZT 6**3.5S[TA+ 9 S]: %I*@%["WR;UXZG-+]HA_YZ#_OH4 2Y
MI149EC]4_P"^A2?:81_&/S% $O#-M-8%WXJMK+4Q8F&25B#]P9Q6LU[ "1O7
M..N[%<!<*)O'NQ;AK="N2T9X/UH WM0U./4K.:&;2IVC88!VXQ6%8:%<VEK&
M(X+Q[=W^ZS' 'TKJK>"2TF,IU=I$!X5L4EQ:?:Y3+%JKQ9ZH#_2@"[IVFVMF
M%-K;)"S#YB$YJU.J/;NDKMMV'O69I\+Q.PEU!I$QCDBJ%]8E[:Y;^UWV;#M7
MC(H \D\:1J))(TGD:-9"4P:ZWX&8W7N,_='7ZUQWB5+1=.A6WF\V7<<L3S78
M_ SY1>[NN* /:12TT=3]:6@!:*2B@!:*** "N;\<\>%KL^N*Z.N;\<_\BK>9
M_P!G^= &5=ZIH]AX<TF+5K3[4)808X_*W\BJSWWA/&6\/9PH/%CCK^%-U'_C
MX\(@="A!'X"N\$:-&#M&03VH \[O=9\$V%DDEQHZ0(QQ\]IC^E<YXCU[PGJ>
MF8T2QV7LCA0T<.,X_"NO^*FG07/@^:X?Y3'R"O4'-7?A]:6S^#K%_*C8[>K*
M"3S0!T&B@C1;)GW;A$,@]:TJ8..GTI: $<_>^E>!)J6CZ?\ $34GU:+S8\G"
M^5OKW#4]1MM,M9+F[<11!>6/<^U>;^"]%O;KQ==ZW+;%+28DIN_B'KB@"9/%
M_@C:O_$K// Q:9X_*K5G\0_"EA"\-G:SHI/.V KG]*ZS6U@M-$N[D*JE(R1L
M7'->+^$O&%U;>)&75A)-;O\ <1%W$T =G+XS\&3,TEQI*LY!^9K/)_/%8/BK
MQ-X/G\.S6UEIJI*PX;[*!GVSBN^TWQ/I>IZDM@;"5)GYQ)%CBK'BW0AJ?AN:
MWLH8DD(X^49S0!A?"78?#LVP9!F.-O&VO1*\Q\!S2>%Y6T368S;32-N1VZ/7
MIG+8&1SR".] #AT->6>.)H;3QK8W6H6[3V$<&'4IN YKU0<CIC-0SV\,H DB
M1P>"&7.10!YK9>+?!$]U]B@TP&7^[]E!_I5XW_A>.7 \.$J>K?8__K5@6-G%
M_P +DF"*J*JG"@8%>O;0$VX&* .'MO$'AF&_M+=-(\B:60)$WV;9@GCKBK$W
M_)2[4@9;R#SZC%1>-%"ZCHI4 '[0G(^M2,2/B; ,\"V.!^% ';T4E+0 44E%
M "T444 %)2TS..O>@#Y4\3'?XQN#_=O!_.K_ ,06;[>?1(T*_I6=XDP/'$RN
MV%-X,@=3S6M\0HS'J#*/F0PIDGL..E '>V]\VNZ%IF@Z9%!+,(0\AECWA1^/
M0UJ7'PQ34+**VO=5O6A0[O)#D(#]!4/@?6O#NB>';6-KHB5P"Y<<].AKHO\
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M-?Y58H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7N?".JV<FR34(!Z*9FS_ #KL;?6[^U&V#PM-&OHH6FS:Q=3RB2;PI.[CN=M
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MZT6WFGN&=ROS$J>36(?"_B">8%WM$C,00?(<UV6CZ9]@TZ"T:2-FC7!(4#-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5!<VT=RNR6-'0]0PZU/24 <W+X(T
M>5R2DJH3DHLA"UKV.EVVFQ^5:01QIC&1U-7:*  +C@=!2T44 %%%% !1110
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M@<4 (?0TW;D8 7'?-/Q10!4FT^TF4K+;Q/GKE :RKKP?HMU'L:RC0>L8P:Z
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MF1^%77_2[; ^[BV7_"D7X4F.,@7D SW%NN?Y5Z<!@YIV3GD<4 >7I\+'W?\
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MNUK^/-2CU#P1YH^^S GZT <!XIT]I],TZ<2Q@+;@[,<U1TK3(Y--)\P$RYW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML'PZE_>QW)O)]8O?+?:DEM@KCGOF@#W/(&/FS1G!/3V%>51Z?)GY8/$(..Y
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MQ#TX?\N]Y_WZ- '4W\336DT2_>:,C\:\"U7P3J5M(UU<!UMS,=SD=!FO4_\
MA8FEOC;#=Y_ZXFH;CQSH]Y$T,]A<R1DYP830!R$&D:-9:MI#Z9>--/N!?"G
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M]: .KM^;:(^J#^52U%;_ /'M$/1!_*I: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6L'&BWQ]('_\
M035VJ&M$_P!B7P R3 __ *": /FRSM8+G5]C1*VYD!!]V%>U?\(;HWEJ@L4
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M/"^NQW=KL9_G& <GK0!U6%/4 ^Q[UYYKND7^D:C+?:9&1')\TH'3 YKT4;0
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M ,([I&/^0?;_ /?%7K:T@M(_*MH4BC_NJ,58HH ;MXXP#5.\TNTOTVW<$<V
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M3C'6DQ0!SP\':)C_ (\DK*U[PGHMMH=[-'9J'2,L#[UVV!6)XK!'AR_QWB-
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M!O#I2T@Z4M !7'_$7_D78O\ K[C_ )UV%<=\1_\ D78O^ON/^= '60_ZF/\
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M^6^\0P[KKSK?[S#_ )YUF:CJ\D,<FFQC<6/W?6O3O NAQ:7I,;NFZ:4;G?\
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MN'/->;/I=U;>+XEBTJ\A+MYOE!E!SUI_CN^OM3\2:']KTZ2U82( '<$L-PH
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M=U3:2V?%6J#_ &5_]!H Z<]SVS1@XS4;R+#"'DVA/4FF+?6TA$:W$3,W10U
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M/X:UM718GS@],T =DP^8XIK*I4A\;3QS2KC:#G.:<.#0!Y=XO\)K!J:ZE!&
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M!XWE=O'KS77^++-[[0IXHXC))C*@M@$UYOX4L[JTUV..ZDEM7#?*J'<I/H:
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MFVYCD>8E3]: .O#'...*=6#X<U*XOX[F"[51<VDOE2%>AX!R/SK=% "T444
M%%%% !1110 4444 %>6Z9Q\:-0';RVKU*O+K'Y/C3>CKNC;^5 'J%+2=Z6@
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MOPWG+66[ZN:#\.O#1/\ QXX_X&?\: -S^V=-_P"?^U_[_"E_MG3?^?\ M?\
MO\*P?^%<>&O^?(_]]G_&E_X5SX:_Y\3_ -]G_&@#:_MS2O\ H(VO_?T5R7Q
MU6PN=$MXHKNW>5KJ,HJR YP:T_\ A7?AK_H'C_OL_P"-<WXW\&Z+IFAQ7=K;
M%)H9DV'<3CF@#TJW)^SQY_N#^52U!9Y:R@+'),:Y_*IZ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME<-XDY\?^'#ZES^AKNJX7Q%_R/WAK_@?\C0!W(I:04M !1110 4444 %%%%
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MO!^E7;CPMH$]W)=F9HWE;DQ3E<_K0!G'Q%XE@1$30+95'!!N>E3?\)-XG_Z
M=I_X%?\ UJL'P5X>EY:XN7_[>C2_\(7X?'_+6Y_\"C0!4'B3Q23_ ,@2S_\
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M_KDW\J /3UIU(.M+0 4444 %<)X@_P"2@>&_H_\ (UW1KA?$/_)0_#_T;^5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"J>K?\@>]_ZX/_Z":N52U@XT:]_ZX/\ ^@F@#Y?C=K;5S.N<HP. ?]H5Z+X?
M\9W0UM8+Z63RYB!&&  6N&L(!-JP#$$&1!@_[XKL?&F@26%PMS$N$X(('W:
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M=]Y@P/\ .J=QX?MKDE9]0ED ]745KRR64ULIDGC6-^^<9J@-+TAI=B2)(3R
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M(0O>,7$2= /\:]94EAC. .!0 UO;BO#/'VJW?_"97> A^QHA4D>M>YOD=*\
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M0!\UZ]_KI_3[2_\ 2O=/@T<^#V]I3_*O"-;D69I)$^ZT[D?F*]U^#'_(GO\
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M4 ><S^'R=%M;H0O_ &I<SAGE+-\@],5Z);*4MXU/4* 3Z\4_8O' X.13@ *
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MKZ$^#C9\&=/^6IH ]#HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%% !1110 4444 %%%% !1110 4444 %%%% !7F%D OQGN_[QA)KT^O+[?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "6RX_ZY'^5>GUYA:\_&NX_ZXM_Z#0!Z:*=2#K2T %%%% !7 ^*O^1]\,_\
M71OY&N]/W3]*X/Q/_P E"\.?[S?RH [P4M)2T %%%% !28I:* $J.7_5/_NF
MI:BD^XWTH SO#XQI$?\ O-_,U96_A-_):AOWR(&9?09JOH/_ "#(_P#>;^9K
MF]4LO$-OXFN+[3+:)XYH@A+'F@#I9=7M8K(7F_*>9L)SWK1A=9(ED0Y5AD5Y
MG'IOBN71O[,FTZ 1F<2LX/)YYKTBUC,5M%&0 50# ^E $]%%% !1110 5R?Q
M!_Y%27_KLG\ZZRN1^(O_ "*DG_7:/^= '2V'_(/MO^N*?R%6:KV/_(/M_P#K
MDO\ *K% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&\B,BX4EMO'M7:?!$E7U),\ ?UH ]E'2EH'2B@ HHHH **** "BBB@ HHHH
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M1XJM7_B*J/UH ]0M_P#CWB_W!_*IJBM\?9H?^N:_RJ4^U "$#J>U>-ZJ9/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ KRZT_Y+9<?]<C_ "KU&O,+0?\
M%[+C_KBW\J /313J04M !1110 5P7B?_ )*%X;_WV_D:[VN!\4\>/O#)[F1O
MY&@#OJ*** "BBB@!"<?2JMS=P6<+23S"*,<EI#@"DU.>XMM/FFM8A),B$JI[
MFOG#Q%K7B+6=<^RZ_,]C:,QS&N0".U 'JFH?%FPCU:#3["!KDO*J/)VP3C(K
MOBX: N,[60D>U>#_  @LK0^*KY'E2Z1$_<E\'%>]/_J&XV_+Q[4 4- _Y!$?
M^\W\S6IM!Z@?E67H'_('C_WF_F:TP3CU]Z %  [#GK2@#'2F_P# S2AL]* '
M4444 %%%% !7)?$3_D59/^NT?\ZZVN2^(G_(JR?]=H_YT =-9?\ 'A;_ /7)
M?Y5/4%E_QX6__7)?Y5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 54U7/\ 9-Y@\^2_\C5NJ6K_ /((
MO."?W+]/]TT ?-.DQ2KXDW$@J9$S_P!]BOHH#Y4^F/TKYXTMMFO9.<>8G_H8
MKZ'3<T:,%[9_2@!)469-CJ"*\T\6^&)H)EOK4#Y3GY:]+JK?6OVF!HV^ZP[4
M >,^+]9%[X.MX)B/.BE Y[5F:%I<\ FD*6K1F)6W21[NM:GQ \+FW0>0&8%M
MQ&>]<]I<>L(74RR)%)&$.Q=W3I_.@#UOX<;?[#FVA5*SD$(,"KOBG0?[4MF>
M,#S!SSTQ5+X;6MU;Z!,+O?YCS$@L,<=N*[,JI0JPSF@#Q;PYJMSX7UQH)V/D
M.^'KV&"3[3 LD;AMPR"#Q7G?B_PP[32W4?W<9P!2> O$,L,QTR]D(+'Y=QZ8
MH J?$E1)KUBK#HO]:]-TM,Z;;^T2_P A7F?Q'(/B"S /.WI^->GZ7QIUO_UR
M7^0H ;?6JW<7E.NY2*\IU73Y-"\0+-"I16(/'?FO83SR*P_$6D)J%NS;09$7
M(XH R/#NHC5O$%Q,-H(B16 _&NR3!_#BO&]#OVT+Q3(LS%(F W?F:]@MYDFM
MTDC(*.,@YZT 2MPI(!)':L7Q#I@U*R^4 2 9R>M;.X@\4F.26Y^M 'C FN])
MU*.YC0@*?G4=Z]7T?5H-7L$GA/S%1N7T.*Y;QEH>Z$W< ;:WW@O:N<\*:S_8
M]^(Y6;R'..3WH ]=92JER1M[^U>2?$Z=[?7=+D2/>Z $ #)/S&O0]3UJ#3XH
MGW;II!E$SD-GI6-;^%6U341J^L@^<>8XP>%% '$ZQK7B?6MB2Z4VQ1\AV=>*
MP(-:U[2KX;(I(I$SQC KZ"5 J@8S@8''2N,\9:$LD;7\(.]?O#UH Y2'QUXI
MU"QEMA9&2-U(9@O.*L> ]#O'EOA?6SQ(Z;0SCK2>%]973KD)*3M9L8/0UZK#
M(DT$<L9 5ADXZ4 <GX5\#VWAPEG?S9LY5BI^7Z5#XMT#=OOH(P2?OBNYR=NT
M\_4YJ&:"-X71AG<,>U 'DMGJBZ?I\UODLK#&">F:]2TH[M-MV[%!C\J\G\6Z
M6^DWDR)_JFPP;'KUKN_"6OVU[8PVQF!E50 OX4 =5BD/TS2M@' .?I2JQ!XZ
MT <;XVT$WMI]KMXQYB?,QQS@5F^"M>=C]@N9"#G ![5Z#)&)49).4(P1[5YA
MXIT>71K\7]HI$8.25% 'IX(8_*#CU-*>M87AKQ!_:D#1OC<HK>"D<&@!C ,"
M#R/2O.O&.@;9ENK1-IP2V*]'8#H#4-Q!'/$8V0'([B@#A?"'B41,+&[X., ^
M]>@9Q@8^8C/X5X[XATV72M5:ZC#*H/''%=UX0\3)JNGA;A\3+\O/\7M0!U63
M360$\C-/QCK2D4 ><?%(+!_9Y1,DE\X^E5_@<2YU%R",]OQJ_P#$EBMSIR\'
M(<\_2JWP5^9M2/ .>WUH ]A'2EI!TI: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK
M-M4MZ#-.J*7F-QTRI% 'SY=RF[NM8N.%_?=/^!BO7]*&-+M_^N2UXU;*=VL#
M<"!/T;_?%>RZ6P_LVW&0#Y8[T 71]W-1SRM';2N.NTX]J?P."R_G4%X\?V*;
M+J/E/?VH S_"VHSZGI;SSMEEE9 !Z"MJN8\"AO[#EP,@W#FNF ;/2@!W3FL#
MQ3J5QIVG1S0-@F8+CZUOE6(P%-<EXY<'18EY#+<*.E '36Q:2UB=CR5!KS'X
M@?-XHM1_LJ?UKT^SXLX5_P!@?RKS'QX0GBFU!YRJ_P Z /3;4YM8?^N:_P J
MGZ-FH+4?Z-%_N#^53F@ SG.>AZBN9USP=8:F\EW&/*N\?(X/0UTFX \\#UH)
M_=[A@9'&: //=)U6]B\6P:?JR[9(H_*20_QCL:]"5<G;N&X<D>U</XDT<:OK
MD<+3!91&"L@/(-6]"UU[>4:5JSA+E?ECE/\ &* .MXW %1@#'(INW:W'3TQ2
MEN@7!!Z-FG#(X(Z>] " ';S2@8H,J+P3@^E*64XPP- !7EWQ,!>YL0/[AKU'
MC&<C ZGTKS#XDE?MUJ X^2,\GO0!W^DHRZ5;#'!C4_I5\52TN1#I=J!(I_=#
MO[5<5@3C(H :H SGG/Z4]?E0#).#GDTP$>HI<^X_.@!P_K03FFY I"ZCJ<4
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M6](2/R% 'IHIU-%.H **** $/ -<%XJ/_%P/#*^CM_*N]/0UP7B@9^(7AO\
MWV_D: .^HHS10 4444 (PSW-8NO^&-*\16I@U"T23/1\<C\:VZ0C- 'B'_"H
M-3T'Q+;WVAWNV 2#<@R,*2,_I7LY#BVV,VYMF2?I4Q3@_,WYU'*,1/Z!3B@"
MAX?YTB/_ 'F_F:S=8LO$!NO.M-6@MK<#)#19K1\/'_B41_[S?S-9OBC0]6UG
M9'9WZV\&<NN.30!E:0_BF_U-E>^0VD38:0Q ;OI7=1A@H#-N([XQ7(V.A^);
M9HTDU5##&,!0N./\:ZZ)7$:ASE@.3ZT 24444 %%%% !7(_$7_D59/\ KM'_
M #KKJY'XB_\ (JR?]=H_YT =-8_\>%O_ -<E_E5BJ]CQ86X_Z9+_ "JQ0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$X&:6D;D&@ !!'
M%+35&%IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2;
M@#C-+7%>,-3N$NFL(7:*-8O/FE7J%% '3/K6F1N4>^@5@<$%QQ5M)XY(Q)&X
M9",@CFN*TJW\-7=TMBEDDTK0B8RS+DL#WS5/1=3DL?%,UK$DGV%Y?)13T4]>
M* /1,BEJF;ZV5@#(JG/.3TI?M]K_ ,_$?_?0H MT54^WVO\ S\1_]]"D_M&U
M_P"?B/\ [ZH MY'K1D&J:ZA;.^U;F,GT!JT#E<YS0 ^J6K'&CWI'_/!__032
MO?6J/LDF0-Z;JR_%=[]G\*WT]NR[O+V@D^IQ_6@#YTL-3MH];?S9 ,.IP?9Q
M7OFE:[:ZK;Y@G5F3 *KZ5X->^$KJRN9;J:YB9T02[ !G!-:7AGQ/_8VJ),Q"
MP.0'91QC- 'O=.W$=*X__A9'AP$ WW)Z<T__ (6/X:S@WZY_W: -77M+74K1
M\HNX#@XKS_1[EO#FN^3=(K1RG SVKI9/B3X8!*F^0Y]JY?Q+XD\-ZE 9+:Z5
MG XVCG- 'JD#H\8=0 I (([U*>5R#7E_AGXA:9;V/V;4+AEV8V9/4=_Z5T ^
M)'A@#B^ ]SS0!U<T8GA>.2,,&&*\7\2:=-I&KO-&&4AMRL*[MOB7X;'W;],_
M2LC6_$OA76[8L;@-)CC H XS5]7.L7UC.[9F50C+^->Z::"--@.#CRU_E7SG
M<30QZJCP+^[5A\U>\:'KFGWFGP1P7&^0(H(SWQ0!N' ') II*%220RXP14<U
MQ% -\AQ[FN<\0^*X+337:RN8#.6"_.!QF@#E_%&FQ_VQ<$+@+&K8 ]<UH^#O
M$:H?[-N3@XRA/\JY[4-9U"&]NKA]1M&_=(&  ]ZS[^<6[V]ZDT#2,H;(- 'N
M" L@;'6EP?2N3\.>+]-N[!%GG19P,,36T=>TH#)O8_RH OS0I+"T;#*MU6O'
M_&FG1Z3J8$.,-\P7/0UZ<==TL]+R/\JX?Q#X7T37-3?4)-9<.!D('X% %;P%
M-%=7TDVIEI9^D0D/"XZ5Z@DL;@XD7<!\P!Z5\ZS6*V%]($U.<*&^5E8\U<@U
M:6QU>Q%MJEQ*DC 2!F/7- 'T&#\I(P/K44L:3QM'-'N5NV*B2^M_LR,\JC #
M=>O%4W\2Z6I)%\%9>,9H \\\5^'FTJ\:X@5O+D/"X^[6_P""=;,T'V*Y?##A
M0:Z>]AMM9THL/WH=<*^:\CNY)-!UUA(Y5@?D/M0![<#GI2GTKF]$\9Z;?6YS
M=KN'45>.OZ9E&-VF&/I0!6\56<,VE2L\(=U0D<5YKI\TNEZA',(C&<@%<=:V
M==\3W=W+J-O;:A!%;1 !25YYK#ENI;RXFCDO$D,48*E%]J /7].O8;JW!3 8
M#YN:N@C/6O)O"WBZWM)GBGN&;/ XKOX/$NE3(K"Y SZT ;@P#DBJ>H6,5_92
M6\@#*W8U6&O:9U%W&<>U(WB/3!_R\0_E0!YR)I_"VME6W&-FXR.*]-TS4H]4
MM$FC8<KD@'I6#KUG9>(M.>:V9'>,9!'>N5\,^(1HMZUE=2&-6."2/NT >J<?
M_KHQSD<UFVNL6MVP2&3S2>GK5J>[M;-=]P_E'L&% %;6=(35K)HB@#]1Q7DM
MW#?>'-2V*64!PP Z<'->KC7],\T$W29_NXQ7-^*1H^H'SXYD+ 'IZT =!X9U
ME-8L]QD!E&"5]ZWARH..IQ7AFA:VVAZPKL2L;'!%>K0^)]*F1'%Y'TS@"@#F
M?B5S?:>!R51\@?2H/@IR=2^O]:H^-=0&M>(H[6/4EBCB@+>8HY_&H/ ;1^&O
M$<22:DCK=@D\=: /=0:6L@>(=+_Y_4%*-?TQNEXAH UJ3(Q6:FM6#N%CN$9C
MVJ_E63?GY30 \D"EJA)JMG"^QY54^YJQ#.EP,HP/TH GSBDR*J37]O;G$LI7
MZBH#KEB#S/\ I0!I9%&16;_;MA_S\#\J/[=L/^?@?E0!I9%&X>M9O]MV+<"X
M_2E_M>QQG[3^E &EFDW"LS^V[#_GY_2C^W;#_GO^E &GD>M&X5E?V]I^?]<?
MRJU:W\%YQ"V1ZT 6\C.*,BJUU?P6>!,^WC/2HH-5M[IML,F\]^* +VX8S1FH
M994MX_-D;"BJ7]NV62/./'M0!J9I,CUK,_MZQ_Y[_I2?V[I__/8_E0!J9'K1
MD>M91U[3Q_RV/Y4W_A(-.[S'\J -?(]:,CUK)&OZ<?\ EL?RH_M[3_\ GL?R
MH ULCUI:R/[>L#QYK'\*DCUBSD=51F+,<"@#2SQ0#D=Z:O\ >K/;6;1'V[SF
M@#3I,BHXY!-$KIRK#(JG=:K:6<OES$AL9^[F@#0R*7-8XU^P[%ORQ0?$%CZM
M^6: -<D8IIP?RK(;Q!I^TYW$?[E8_BGQ/%;^'+N6T9XY47@[#D>] 'E][;+]
MKUXJ0JB?  ]S7<6/A-9M/MI);^_Y0<"9A7"WFEPPR33-JTP,\'G-D?Q8S5GP
MU\4H['3%@U"&6=T. PH [L^#X?\ H(7X]O/;_&H+CP;"T,@2]O6D S_K"2>M
M8)^+^GAB/L%P?H30?B_8< 65VI![9Q0!-X<U&X\-Z?)93Z3?L1*Q#[2=PK73
MQD<Y_L>__"-JQ!\5]/E<G^SYV'^[2M\4].CY_LV?_OF@#?\ ^$S4K@Z1J _[
M9M63X@UF?6[2.VM])O$Q,K;C&>E55^+.FE@/[-GY_P!FI3\4[6!=Z:?-M/;%
M '?VW%K%DCA!_*O+O'N6\6VH'. F<?4U=_X6]8G)%C<@!>!BN5U3Q);Z_K<=
MW':O'L"9#=>IH ]MMF'V:+K]T5/FL&#Q+;K$B*DXPHX4$CI4A\16S\LESG_<
M- &N3A3\N?I7CWB_7M>?79HH-0>WMXFVA48*:]*&NP,#L6Y7CGY#7AWBS4?-
M\2WAB#C,H^;^+\J %GUS4_M8D?5+S<% SYH!J==4DDO[:XO;ZZE\K[I,XS5F
M728D6*5[JY/[@,R-'7::#=:))H=F+C3-[E>6\CGK]* &'XC)'$BI9!@G0^>*
M/^%F[CG[",G_ *;BMV&+P^6VKI:+];>M-=%T?R3(NFP'(R/W0H Y2/XE2$';
M89 _Z;T)\2GD&3IZ^V9Q6V3I5K(R_P!EQX(QQ%5^ST[2KNW5ETR+/?,72@#D
MF^)N#@Z<I'?]\#7+^)==;Q#>1SFWBA6./(4S!<UZ3>)HUA*4?2XF_P!V*O._
M'-UIZ:I;&VM'B#)RHBH V[;XBM#;1PQV2_(HP1-U&*M#XDS!,_9!_P"!%7]-
MNM(&G0@Z:Y;RAD^3GM]*MM=Z1Y?_ "#3_P" W_UJ ,(?$J7_ )]1_P"!%+_P
MM!AP; ''?[16W]MTO_H%2?\ @/\ _6H^U:4>?[(_.V_^M0!BCXF,_/V1%]C.
M*:_Q*D7I9JW':<5M?:=(W\Z/_P"2W_UJ>UQI!X32]O<_N /Z4 <U>?$>2XLK
MB'[(J%HR"3-DC(KG=1\2R:OX<M;'R50HX^8/G.*T-<6QU'Q)=1HD\"+%G")C
MFN5U,"S^RQQRW31L,\C@T >N^ ,_\(K;#T)KJP?0UQ7@F^6T\*6K,)N"<BNF
MMM9BGEQY,P'^Y0!HYYQ@_E7G_P 6%WZ);JO)$R@X]S7=W5PL";G21OH*X?QI
MK=N^GHAAF 69"<KZ&@#JO#ZD:%:#!.(P#BM(@]P1]:YZS\1V_P!CB,=G=,NT
M8*ID&I_^$@C/_+G>+_VSH VA@=:"1C@UB'Q$BC(M+L_6,U&_BRVAC#RVTZ(3
M@,4Q0!O@T[-<R/&=@TH15G+'H O-71XB0C(L[S'_ %S- &P<BJ]T UI/D$C9
M@\?6LMO$"'_EUO/^_9IL>M12DAK2X&3@E@1F@#P'6\)YR<+MN7X/X5[E\')%
M;P;\IS^^/3Z"O,;+PO:ZWXB\0?:'F$5N?,10>YZ_R%=5X,GA\.ZY:V=J]TUO
M+;2,\39.&RO- 'M (/2C-06THFMU=%91Z,.:JW.H-;O_ ,>MRX]54D4 :5)N
M'J*Q_P"V_P#J'W7_ 'P:=_;!_P"@?=_]^C0!K;AZBDR/6LK^V#_T#[O_ +]&
MH9]<*12M]CN5V(3@QG.: %U/Q):V-Q]EB!N;O&?(C&6Q50>)[E0LEUH]W!#_
M !.1]WZUY7I'B.\@US4[\%A-(P"F5.V>@KT[5]2?S]"B^5OMDG[U3TP0* .D
ML[RWO;=)K:59(V&00<U9KE?":K!>:Q:QN6BBN<(.R_*O%=2.E "T444 %%%%
M !1110 4444 %>7V9Q\:+H=S$?Y5ZA7F%H,_&JY(Z"(YH ].'K2T@^Z*6@ H
MHHH *X#Q.P'Q"\-C_:;^1KOZ\\\3Y/Q%\-@#H30!Z$*6BB@ HHHH 0G%&X>M
M5-3U"#2K&6]N9-D,*[G-<AK'Q/T'3-(AU*-_M$4QP-O:@#NLBHIO]2_T->::
M5\9]'U748+1;656G944D>IQ7I$O$#'/\!P: */AX8T>+/=F_F:U0H] #67H/
M_('@^K?S-: FC+L@==R_>&>E $@7^]S2@ #@8I>U% !1110 4444 %<E\1?^
M16<>LT?\ZZVN1^(O_(KG_KO'_.@#IK(?Z#;_ /7)?Y58J"S_ ./*#_KFO\JG
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O./']C<17\VH
M)YDD<UJ8-B=B:]'J*6*.56210ZL,%2,B@#R+0K_6K74H]1BM()85M1#C?@KC
MU%/\*+J6K^*V>6 QV\5P9V.,@]L5WDG@OP\\IE?3+<D]04&#6Q8Z=:Z?#Y5I
M;QPI_=08% $)TJQDD9WM(G+'^),_I2_V/IW_ $#[7_OR*OXHH H?V/IW_0/M
M?^_(H_LC3O\ GUB_*M"B@#/72;!'W):H&]=M70JA-NT;?0=*?10!G-HVGR2^
M9):1ENQ(S67XNL2_A._@M8U!$>[ 'IS_ $KI#6?KF[^PK[: ?W#]?I0!\\2^
M*AK%X^G_ -GIYMQ&MN)!U!!&?T%;'B+P,FEZ3'=0Q,=B@./>N8\/0 >)4D:-
M>)5Z?[U?0.HV<=U:&VFPT3I@#WQ0!XIX1T?2+J]^S:@IW?>4E^_I7?CX<:"_
MS[6YY^]7">(-#FT/42^"%)_=D=J]'\&Z_'J>E+#(W[].M %$_#'07.=C<_[5
M!^%^B>60BL#_ +]=N68GB3Y>PIN4+89XU(YY:@#QK7_ MKIA$D2L5!.[Y^E;
MGAWP=X<UC3PVP^8/O?-7<ZMIR:K8R1B-?]X'.:\]A-SX3UR)@&\ECL;T /\
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M0Z;X,N]4LS.D2Q#<<NI;/'UJ?PEK+VT$UG=280QG&:[/P7C^PD;?D>8VW\Z
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M61D1T[XYKMG2*88*[\GK7D.NZ=<>&M86ZA9Q&&!P.E>CZ!K%OJ]DKALR@#-
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M359%,NCR'  /W">F* .IU3<-*NF0D,(R00.E?.-[X@OY9&BNKIKB".?)1NF
M>E?0U[=)<:3/.C^8LD1(VG(QBOG!UMKIY;8(WVF6;:FX<9)H ['1]9L-0\4:
M4+/2HK20GYV4#YA7N*AA%U_2O#=*\+ZAH_BG1'O!&L;-GY3^5>WJ,4 /P/7]
M*R?$,SP:#?2QLRR)&2..WK6L3Q6+XJ.?#=]_UQ- 'SO;:]J>G"ZGMKAXOM#$
M$]VKV?X3V]UK,*Z]?732-&A@5&7IT/\ 2O"KB-3IR$_\]&_I7T/\%E"^">/^
M>Q_D* /14!.22>O IVWG-%+0 F/I2;5]!3J* &[5]!4<L8DB:,C<K#!'M4U)
MB@#R'5? MIIVO37,]O/)87'4P$Y4_A4S66CR+ ^E1ZI-=0G]UYK.=I_&O6,4
M8H Y[PII$FE64C7+$W5PYED#=1V_I70CI1BEH **** "BBB@ HHHH **** "
MO,=+S_PN:^W?\\FKTZO+[(D?&BZ ^[Y= 'IZ_=&*6FC&!CI3J "BBB@ K@/$
M@_XN1X=_X%_*N_K@?$?_ "4?P[_P+^5 '?4444 %)2T4 <'\7&N5\"7!MP6^
M==X'=>]>9:-X8L_&'@:TBLY[:.ZMI2S1NW;%?0%]:0W]I):W"!XI%((->*:I
M\%=4CU&:71=0^SPR,3Y>>* .;U*WM;+7]#TVWAA-U#,FZ6+US7T;S_9K!OO>
M7_2O.? _PFMO#T_]H:FXN+W.0WH:](G&+:;GJAP/PH I>'N=%@_X%_.N0N+7
M6I/'&HMIMPD">6OS.N0>:[#0/^0-:_1OYFM0#!H Y&&R\5BX4S:K;E ?F0(*
MZN(%8U#8W8YP.]244 (*6BB@ HHHH *Y'XB?\BR/^OF/^===7)?$+_D61_U\
MQ_SH Z:U_P"/2'_<'\JGJ*U_X](?]P?RJ6@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ-X&ZMBO/O%29\<7@[?:3_/_ .O7J'PH!%A?_P#72@#TE>5!(YIU'8'VIM
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M;+-_#1U/TZCWH *0@>E*H)&]E94'MUINX,3M.1V- "' (XZUY7\2!_Q.+/\
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MU<A\0_\ D6!_U\Q_SH ZBU_X]8?]P?RJ>H+3_CTA_P!P?RJ>@ HHHH ****
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M7BD4;6!!S7DVM:-<Z%JCID?O3^[*]J]@X')&1W%<KXJGTN5);4RQB\1=RY-
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MKT R1BNHH 0C->=_%H?\22U'I./ZUZ+7G?Q94_V-;_\ 74&@#K?#JYT&S/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8_I7>_ ['V6]_"N#UP_-=YZF1J[SX&D?9;WD=J /8!2T@[TM !1110 4444
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M_7(#]*N 53T[_CRM_P#KFO\ *KGXT 1GCK7+^/69?#4^T9SC^==40#7+^/G
M\-3 #.,?SH Y/2'FB\!ZE/;.4G#LR8 /(-,\"^+KV>YFCUB[2&+R@09"%YS5
M[PY9W>H^!KV&T.)"[[1D"O.-<\.ZMX;6*]O$\UGP!&S9W&@#V^^U>QOM+O%@
MNH)I(XG.(W!.,>U<CXMVCP/8Y^Z&5@?7FN8\#WDUUKNH-<VZP[;=]T:KC/RF
MO3'T&SUWPI;V5P&"8!R.HH / K*/"]JN]=W.1N%='YT98C>H(]3BO-F^%<T
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MF<@_B*][^$ QX)3WE;^E '?T444 %%%% !1110 4444 %%%% !1110 4444
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M"O5[6YBN88Y87#*PSQVKD?%OAU9%-ZJY8\#'I6?X2UW[!='2[IB$SE'/;VH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP@5YC\30%N[5^_EF@#T73AFQMC_TR'\JM5G:(V[1K7_KF/Y5>- #JY7QX?\
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MZTM !1110 5P>N?\E,T#_KF_\C7=G[IK@_%AV>-O#4J_?:;:?H: .\I:2EH
M**** ,+Q?)J47AN[DTH$W:IE !U->:Z;\6;[1TCA\36,RLW <+7JGB#4CI&C
M7.H!-_D(6V^M>(:A8>)?B7Y4OV1[:V).PNFT4 >P:)XRT3Q# K65Y&7;^ GY
MJV;DD6DI^\"A_E7FOA+X/V6A727EW=--<)A@H/"D<UZ;P8_E&,]0: *>C?\
M()M_H?ZUH]165X?_ .04O^^W\S6DS!>6*A>Q)H J7>F6=Y,DDT*O(GW3C&*N
M(H50HZ#BD5MP!X_"GB@!:*** "BBB@ KCOB0?^*=B_Z^8_YUV-<G\0T#>$YF
M/42)C\Z .GM_^/6+_<'\JEJMIQSIEH?^F*?^@BK- !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS7_&G+\2H?\ H'W'YK_C6@VA^%8Y&CDCM(Y%/W6'-71X4T)@&2PA*D9! ZT
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M29UL8PP0D8'M7%:[I%C;^"HIXK=5DWCY@/>@#I/AN0WA@?+@F3BNVZ5QOP\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKV)EU.V^UIN\V?E,YXS73!I=-U)X/,*C.& .*S?$3Q0WVEGSE;:PW$'I\Q-
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MR%=G\#QM:_7.>.OXT >S#I2T"B@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6&83PB0#(89JGJB&XTN9$!.5^4BK5@FS3X(S]Y4 - '(>+_#Z3P->QQ_..H
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M[^Y\<ZJNR\L6D7_<H ]=\*>((M9TU?GQ*BX8$UO9'8YKYNM]0\1^'KDM;K-
M^<.I7@5T$'B?QY=V[36D<DJDXR$[T >XX4G<201TQ6-X@TJ/5=.EC95\SJI[
MYKRTZ_\ $7^.WG!Q_#'43:]\0W! M[DD<_ZO% &!J-G+I/B",2]8W!/TS7T!
MI-S;W6FVTL,NX.HROOBOGS5Y=;OM0+ZK Z3!!A6&,\UV'@GQ-+I%]%:W1)M9
M#M53U4T >RXI#S6==SWKA7L5B*-_>-0VXUOS/]), C_V 30 [6]-34;%D*9=
M1\IKS-I)O#VI),VZ/!PQ]1Z5ZS*9O)/V?#28ZMP*\U\>Z7JLFFFZN1;QKO"_
M*>U '70>+-'GMEE>\AB<K]U@>OX51T.QTS47OI9DCF+3EE<-GCZ5X]YTEB;B
M-?(E65 %.>015C3].\7^0L]H)PC#Y0HX(H ]UFTG3Y(%2:"/RE^[D5Y/KNFV
MEMXMN;>&!1"JY]JH3IX\>(0E+D+W./\ Z]9=QX;\93/Y_E7&X\%BN<T =QX'
MUV/3YGL+M&\N7B-F:NHUBWLX);66"--QE&XB3J:\6ET7Q-9L#)#-O3^+%3:?
M'XDO;K;')/+,IR%+8P: /HR-AN&*\I^)2)+XBTU9/NL0/U-9\5W\0AP5G0#C
M 4'^M9>H67B[5+U#=PRS2Q+N0%0,<]>M &Y>03>']92=6VPD UZ;HFLV^I6:
M.KY;%>1:LGB"X6UM[U+EIBO'F;?3ZUB6&H>*-*G,5J\R,I(VX&?YT ?1GFI2
MB1*\@MKSQG+ 'W79)')VK_C44\OCPG]S+<CZJO\ C0!['(D,L,D?E[N/XJ\G
M\26,MAJC2JFQ=Y(Q]:H)<?$9H_F-P,>R_P"-9T__  FNLB99$E?RCM;*CM^-
M 'I/A_QC8-IOD7=W$LR\$,W-=)8:SI^H.5M[B-R./D.:^=D-S8W$WVQ%2<,
M0XK:237AJ['P_*Y!C&[R0,9QWS0![V"J@JK@L3SFJ6J6L5_82PN4Z5Y$!\1/
M+ 5[K=U)PO\ C373XC;>7NN?0+_C0 ZX6]T'56"$@!LJ17J/AO6H-5TU09/W
MRCYZ\=O]%\=2IYMU%+( ,\A?Z&LFSU'Q#IET5ADG@F[@8Q0!])X!Y\RE#<=<
MUXWITOC.>(RO->N#_="_XU+,WCK;BW:\'IN"_P"- 'JU[;PWMO);2 'S%QST
M%>+:O8R>&]:+(S!0V58=#5R!/B TF9VN]WL%_P :@U/1?$^HPG[7%<R;1P3M
M&* /3?"NNQ:KIZ N&D49([UT#E,@YQ[U\VP77B'0KEHH)[B M\N  3706TOQ
M NH]]M=7,J'N O\ C0![CO0#(DYJG-:V[O\ :2D;R*A^M>1?9?B*RDF6ZSCU
M3_&ECM_B*^"TDXQUY7_&@#(\4RM]NN;81OYGFE_E7MBNK^"-VL5S=02%HY)!
MA5<8W5@:6NI#Q!.-5N+<R+"W^M/.[\*W]&M;H>(M)^PW=F)&#[F1"<?6@#VU
M/NYQC)Y%.%8*VOB 9!U&W'/_ #Q/^-/%MK__ $$;;_OP?\: -RBL/[-KW_01
MMO\ OP?\:/LVO?\ 01MO^_!_QH W**P_LVO?]!&V_P"_!_QH^S:\?^8C;?\
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M\_A0!L9IN5R=SX]!67_8LHZZM=?]]#_"N8\;W5[X<TM;FVO9IB[A<-(!C]*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR!GFCKV H X?_A7%@/\ E[F_3_"E'PZLO^?R;_QW_"NWVTN!0!P?_"N+3/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_A\W[Q&'SFV!.O0]: /3A2T@I: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KE/B'_ ,BE/_UT3^==77*?$(_\4A<?]=%_G0!T6F_\@NT_ZXI_Z"*L
MU4TS_D%6?_7%/Y"K= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN-3;Q_H$E]%'#"9"$51GVZT >H"EI!2T %%%% !1110 4444 %%%% !1110
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M)+.V*Z>VOS/K,UO]Y4160CH1S6PP5P.H.* /*?$V@:C?:>UY-;(DP&3M;/\
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M^90>.* /+_%7A_Q!=RRWD:0+$A+#YOF(_*G^%_$&I6]DT*E//7@!SQ7J)C!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_015J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9\]%->G'BO,/B8/]-MC_ +)H ]"TG_D%VW_7-?Y5>JCI'_(+M?\ KDO\JO4
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MMO%='"@G.*LW">;<W"2//.L7)56P* -&RAD;6KR\60&&155?PKAH^?C<^?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\J]!P5!9/F8>O3%?.FCRW.FR17=H<+&Y/J#TKW3P_K2:OI,<RRJ7(_>(.QH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?B3H@U"&*.W$AV%5'- 'K0I:04M !1110 4444 %%%% !1110 4444 %%%%
M!1110 5R/Q'_ .1.F_ZZ)_.NNKD?B/\ \B=-_P!=$_G0!TFF?\@JS_ZX)_Z"
M*M54TW_D%6?_ %P3_P!!%6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]Y0WU% 15^XBK]!0!!<:A!;#,LF,>@JH/$-@1_K3_P!\FM,J"/FY^M*$4#
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M8^AKL/[(L/\ GSA_[X%.&BZ7CFQ@Y_V!0!QK?%C30<"SN/\ ODTW_A;&G_\
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M!PH]!^-/Q(!RW'TH QCKDF<_8[O_ +YIO]OMC'V.]_6MO!]?TI0/=O\ OHT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5B^*O$-KX8\-7NKW++L@C)52P4NW903W)K8?&WDX
MQ7@7QYUF\U/6]+\(Z:_FO+AY8H6)9G8_*C*.O&&'UH H_!309_$_B^^\8ZNJ
M2-'*S*?+7:T[_,6VXXQG(([U]&USW@_PW#X1\*V&C0MGR$'FL"</(>789Z L
M2<5T- !1110 4444 %%%% !1110 4444 %4-;;;HEZ<9_</_ .@FK]9^N;O[
M"OMI _</R?\ =- 'RQ#>7,&NB2.U5V1U('K\PKI_$NJWFH7\<G]GM Y&2=OW
M<51TA<Z\&WJ2)(__ $*O?9HHY$*8QN3!XSVH \=TCXFWVGVW]GFU,SKP"1FM
M;_A96N8_Y S?]\FLOQ;HEQH>LK>6R91C][;Q7H7A36(==TY2W$T> 1ZT <FW
MQ+UPH -'?_ODUC:SXIU77(/)FT9@!SNP<U[05R<B+CZ4AB!&2N* / ]%\2ZM
MX5N&-O"=C\LDB]<>GYUU47Q.UJ:+>NE9W'(8*2*Z#Q]H#7FG17$*Y:(,<8YQ
MQ_A6+X&\2K;M_9UP I)^4%: &CXB:^,.-')],QMBN9\6ZSJNK0>==:4(D!^\
M(R,5[F%5HU^3.3D'M7)?$)57PS(Q7K(!P: .*^&7B""P9[&?'[YL9/:O95(*
MC8<C'%> '1Y(]*ANXXV"&1ON]>*]/\#>(EU+3(X)R1/'\HR>PH [( $57OK2
M.[MS#*,QL,8]ZG#$C)&#2[0P^Z<]C0!X;K>G77AOQ')- "%!S&5_6NG&MGQ!
MH<"R2^6B.#,.YQ72^(=.M=<AFLPRBYB&<]^?_P!5>17,%Q8:A]DN=T:AMK@'
M Q0![=86UBFEHEI$C0LO)KC[F_;3_%UO:VDV;<'YUSQFH-&TC5Q !I=V&M9^
M20V=HK;'AHVUI&8UWW1ER\K4 =-=P17=L\$J @]S7SYXAMQIGB6=5X"3$J/;
M-?0[5X3X[GBN_$MPBJ%*-M)^E '2+\3UL- 0J'>X4$$9..O%5="^*^I:GK-I
M9O&@65L'':O,V53(8RY\LM73>'].@CUJQN8?X90I_2@#Z%W[\GDFL+Q/H*:K
M9,4XD SD5NQCY<^M.V[A@]* /'=%U"X\.ZP(\%4SAA[5ZQ972W<4<X(VL.<5
MQ'C?P^H;[9", <MBHO!GB1X)/[-N3M0_=)H ]%<XKPSQS(4\8SD<8D'WCQUK
MW!CFO"_'B[O&<V8Q(OF+D'ZT =5>:<-;T28HT$<L4><X&6KA]+NVL_%5D7\M
M2OR,4ZGFO5]/DL[329KC^SE"[,-LKS'Q3!'%XDADM+811R#?@=2: /=(9%:!
M3N# C(;OBLSQ,&.AS*IP3C'YBL7P9K:SVYM)VS*!P#VKH=:EABTV5IUW(,<?
MC0!R?A6P2ZTR_M9?FS(>:\[\8Z$VCW?(.QVX/:O5?!Y!2]:+ 4S<"L'XK(#:
M0$1C=GTH V/AYJMO?:##;1C:\?)KK;F98;:2XE*^6@R<5X/X<U"31+VWN/-9
M8V/*@UN^(_B)?_;#:V>TV\BX84 ;\GQ7T/[2T+Q2?(V,]16?KGB#0_%L*VMH
MS&\)S%D]#7EEQ#<2S*R89FDW, .*Z#P_9W4>O6,XMUBC$H#.* .H\):A)8ZN
M+>9PL@.QN>#7K:N&12#GO7F_C?PXZ>3JUDNV16RVWTQ6KX-\2M=6?E7#Y9>,
M&@#M0<]*>%]J0,IC5U[T]3F@#ROXPJ2+7 S\AJQ\#?\ 47P]A3?BX/EL_P#<
M-2? \8BOC[#^= 'L5+0.E% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4G:EI* /D7Q
MQ%(WC"\",<^8>GUK6\(V=]>SM!IB,EW$GSN)V&?UJCXKY\:W7_74_P S75_"
MG_D9KW_=- &N/#'B\*,7$ZCT^UM_C2_\(OXO//G2M[F[;_&O5 ,@4X+@4 >4
M_P#"*>+#]^5Q_P!O;_XTC>$?%..)G_\  MS_ %KU@KFDV4 >3_\ "(>*R/EF
M8'M_I+_XTS_A#_%39$DDC?\ ;T_^->M[:* /(O\ A"?$I&3-)G_KY?\ QK#U
M#3+K2=7ACO4S.64Y)W''UKW?%>5^/A_Q5EM_N)_Z$: /3K3/V.#(P?+7^56*
M@MSBWB_W%_E4XY% "'BHY'2)2\C;5 R3[5*1R!ZUR6O%M5UF'1<X23YF^@H
MSYTD\6:Z3:,8K6$%&F'0_C78:;I=OIT"PVRK&!U9>,GU-5;.6+3KB'2X5Y\O
MD]./\:U1Q0!)BF<9ZT[=39)X8ES))''[EZ '@<9H./6JJWUI(V([N!SZ!LFK
M Y&: %."I%>6_$X8U*Q]AS7J)X(KR[XG\ZG:_P"Z: /1-+_Y!EI_UR7^57OK
M5+2Q_P 2JU_W%_E5V@ R!UI-WO33*J?>J-KVV7K-&OL7Q0!-SFESDJ%(!#9W
M>E0I+'<<Q2!C_LG-2%ST(P10!C^(/#R:RDDB$1WAX1UXS65X7U22T8Z+J*^3
M<Q'C=_%73W4OEVSR,?E49('>N0\56L6J>%WU13Y5Q I967@\=,T =J"#T-.X
MK)\.;_[!LO.E:=R@)+=CBM:@!*\\^+'&BV^?^>HKT.O._BY_R K;_KLO\Z .
ML\, CPY8Y'_+(5L<5E>&_P#D7[/_ *YBM0T 5]0*#3YRQXV'./I7S-JCL;B6
M>!)$$<YPY&>:^F+]2]A<*!DF,C'X5\Z7FA:C]I>":VD6W,_SN,\<T :>A:W?
MZMXBT=;FZ=V!P%QGI7T F-JD_P!VO$=.T#2+#7M'DTN:>1DD_>9)X->V+_JZ
M '@UF:]*T6C7DB_>6)B/RK2[5E>(SC0;S_KDU 'S;,6DM6E<_.\K$U[U\%P1
MX1D/K+7@CG-EG_IJU>_?!G_D3W_Z[G^0H ]&HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** $VCTHYI:* $Q6:-%LEU8ZIY7^DGC=6G28H 0#%.HHH
M *3 %+10 5P7BK_D??#(^;_6-U.>QKO37!^*O^2@^&?]]OY&@#NQ2T44 %%%
M% !112$X&: #(HX]:S-;O1IVG^>6"CS%R3VY%.76M.*JWVF+GWH T>,XI:ST
MUG3I)=B7,>[ZU?!R 1WH 6BBB@ HHHH **** "N1^(W_ "*LG_79/YUUU<E\
M1?\ D5'_ .NR?SH Z33_ /D&VO\ UQ3^0JS5>P_Y!MK_ -<4_D*L4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !113)&V@9.%[F@"GK>J6^B:+>:G=-M@MHFD<X
M)X ]!7SY\*],O?'GQ+NO%VIJ_DVLWG*,MM5_X$5O11C@]L5L?M >+&=;3PC9
MR(TDA6:Z"D'']Q3W![^X->F?#KPDG@WPE::<8E%VP$MVX ^:4\GD=0.@/H!0
M!UU%%% !1110 4444 %%%% !1110 4444 %4=9Q_8=_G_GWD_P#035ZJ&M_\
M@*__ .O=_P#T$T ?.&B!1KP4=2\?_H8KZ%=<;/H*^;;&Y^Q:I]H/.PAC^#5]
M :%K]OKNFI=0%25 5AWS0 :KIMOJ5I)%(E>36]Q>>$?$N&4BW9NOM7M?7KWK
ME/&GAE-6L244"=!D,@ZT ;^FW\>JVD-Q!*"C+E@#TJ\/Z\5X]X.UZ;0-4;3;
MV4!#\NTCI7KL<JS1))&VY6&0: %GC6:%H7Z/QBO(O&7AZ71]4CO8,J X(V]!
M7KQY&#R*I:IIL.J6,EO,!@C@XY% &3X3UM=9TM?WJ^;&,%2><^M87Q/E8:/:
MP;^7<M^5<F)9?!OB3?&6%J6P^[O5WQSJ2:O-IIMF#0-COR": .N\.Z'%?>"[
M>VG_ .6JEOSK@KZRN_".MK)#E$! *CN*]<TF'[-I-M%C!C0"LOQ?HT6J:<\J
MKNF4=0* -+1-7CUK3$GB8!\#<H[5IC<,MO!/<5XKX6UVY\.ZN;6>0"V9L-D=
M#7JNJ2YT2>:.09:(NK+Q0!4MXY/^$ING>$F)T7;\W7KFL;QIX;M[J*6_A&V:
M/^ 'G%5?!^EW>H67V]=3E$I+ [G)Q6\OA-YY9I;N]GE9EQ@,5'- '$>#==GT
MC4192N6M9CD GA37>ZUJGV:T@GCD 5GYPU>=^*?!<NDHUU;R%HQRVT]J7PW!
M'K=G_9EY+*)0<H?,/% 'I0US3/*_X^E_.O$_$<<&H>*[L1.%\R7 8=Z]&/PY
MMR@Q?2_=]*\WU#3%L/%?D!MQ255R>IQ0!?U7X=WECIANES*BC</4YYK#\/+-
M!K=EO=E19-[(W05]$(L4MDB2 ,-BC:1TXKRWQQX>;3;Y;RU3;"_) '?- 'JU
MO,)X%E4C:W3%2XS7GW@CQ0LD8TRY8"4?=->A)GD-PPZ8[T 13P)<1-'(H9&&
M&![BO*O%.@RZ5?&YA)52<JR<8KUP<'C K*U?3;?5K)[><9/;% &+X1\1'5K3
M[/<2@SIU9CR:X?Q)'!-XZ99H'DS," *K20W6@:RK-(4V'))[TZ#4%U3QI!='
M+%I5)*T >@-81OH-P(;.<,P^6//'%85KX<?4=;BDEM9$C6':_F>OM7HFY%B#
MDN$5>A:GJ_RJ2.HZF@#Q[4K*Y\-ZGYD&Y &R*[ :NNN>&7Z22_+N'?J*VO$.
MD0ZK8.9 2ZC*D'FO*H+Z?PW<R+DHN['(H [WP4A5;V/;LQ)FLGXHJW]GVWS_
M ,5:O@>^6^BO)^3ND[5C_%(?Z!;'MNH QY/"\ESX9M+ZW&6$?S8KSFZ26+5B
M3$)"HP<CI7T#X1Q-X4MX2H*F/!KS_P 8:(^E:DUW%$#$[< #@4 >=Q7<4=QD
MV\HFW _+D#%=5H>IR3ZQ8VQMY=KS!RW)Q7:^"O[/U0>7+91/,@Y+*.:[R#2K
M"%@\5E#&_?""@"8VT$MF89 &C=?F##K7D^OZ;<>&-5\VS1U@E;<-G0=Z]BP-
MN,54O=*@O[=XY45]RD -VH QO"OB"'5K,*2#+CG-=(*\>\JY\%^(53YOL[-]
M[&1^=>KV-[#>6ZRQ2;MP'?I0!YW\7#\MG_N&I/@<?W5__N_UJ/XO#"V?T-+\
M#3_Q^C_9_K0![,O I10*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH ^3O%W_
M "/MU_UW-=?\*58>)=0E6,[44 UQ_B_/_">W7_7<UZ;\*8U5=2?:-Q;DXYH
M]+&,<#%!I4^903SD4K#F@!HI32,=J%B,X]ZX[5_B+I.EF6!V)NHS@)V)H [&
MEKAT\::A]FM;R?2VB@N'"J_;FNTB?S-I_O<T 25Y1X\_Y'*'_KFG_H1KU8&O
M,?'-L\GC'3]B[C* ,?0T >D6P_T>+_<7^53&HH%*P1J>H0 _E4M "%MN"6(Y
M[5YY>:ZB_$N"$N3L0)S[UZ(3\IKQ[4MO_"SE8[?]:G)% 'I3V;'7XKL?=$>*
MV <U66>-9(X2Z%RF0.]6%XZ4 5[V1EL9FC&UE0U\[:CK6JS77^DW4LMM%.V8
M\G &>E?0^HAO[/N"Y.YD/2OF>8QRO?6K.Z7+SL$!7'<T =C9ZSI4^JZ6EE:S
M02-(-[CH>:]P7&.&W#UKPG3_  =JV@7^CW5U.KI,RG;NSBO=44A>WX4 '\0K
MS3XF#_B9VO\ NFO3.]>:?$?F^L2><H<T =_I7_(+M_\ <7^57A5+2?\ D&6_
M^XO\JNT </\ $V\O['PVUQ8SR0SK(N2IVY%>2:3XDA;7)+C7VGN8G4!0S%NE
M>J_%<C_A%"6?:BOU[UX_I6B-XGUFWL-+E .,L648H ]7^&^IV>I:CJ<EA#Y-
MN&&U,8[5Z(C;D!]J\U^&^D2Z'J>I6DCAW#A2P'M7I,8VJ%]!UH AU")IM-N(
MT^\T9 _*N*\7376D^!!:QKEY,1D?7BN[ED6.)G)QM&:X?XCW N?#4<\;?*TZ
MD8/O0!K>!KZ6^\,6LUQE2@V 5TV<UR/P[8GPG;J22"2<5UH(H ;7 ?%>-I=
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M0 4444 %%%% !1110 5R7Q%_Y%63_KLG\ZZVN2^(?_(J2_\ 79/YT =)8?\
M(.M?^N*?R%6:K:?_ ,@VU_ZXI_(59H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"JVH7UMIMA->7<J16\*%Y'=@H 'J35@GG'&3TKQGX^^+FT_1K?PW:LPNM0&Z
M7:2"(LXQQUR<@B@#E/A[YOQ&^,]UXENX";>U8SJ"0K1 ?+"#CJ0  :^D0H'0
M?C7!_"3PA_PB/@NWBN(RFH7?^DW*L""I;HI!Z$# /N#7>T %%%% !1110 44
M44 %%%% !1110 4444 %4-;_ .0)>_\ 7!__ $$U?K/US=_8=[MQGR'Z_0T
M?,D$/G7KH!EB0H'U8"NIT'4;CPEXA\BY1EBD(!STP:YO19B?$4<>/F\Y /\
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MVSVK1^)\J2:?:[&#J7XKSZ\OY;2_D$!VINX&.]7)]>O=?@@L[EU$<)R 4/-
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MH ]VLK.T6TB400GY!U6K!L;?_GA$/HM<WX,\11ZGIR12X\Y1CWKK2?D7=Z4
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M #7MH2!^ZC]SMYKS;Q]X=*,M_ 6V+G(7UKU#:<5!=6D5W"T,L>]6&,4 >?\
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MGR7(F9YD;"J$)!->CZ'\.(-<TR*^^U,"P*TMC\*-0AU!E\Z-(XSNB=&ZGW%
M&)X6L;R'7-)DN['R4>4$.5QFNZ^+!V^'[<8QB=>E:4/A35I;ZUFO[]'CMVRJ
M*.E9OQ;4CP_ ,$XE7^= '9>&Q_Q3MB/2(5K8K)\-_+X?LPW!$8K6R* $'6E'
M6@X52QZ#K44ES#$@=Y453T)/% $^:3-54O[1W")<Q,QZ ,#5G_#- "XJI>Q+
M/9W$,@RC(0?RJWQ4-R0()/\ =)_2@#YDUR)8%FB0?*)W4?I7NOP<&/!@_P"N
MI_D*\/\ $ ^>;WN9,?I7N/P='_%&9]93_(4 >AT4E+0 4444 %%%% !1110
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M!U>D:BNI6*W(P0.I%:.01D=*\9\)Z_-HNK&RGF+0N,;<]*]A259X4DC^ZRT
M>9_%Z/;%9OU&#5;X%3;KB^7&./ZU>^+H_P! LOQK.^!J_P"F79_V?ZT >Z@8
MH%% H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\ND7Y4?V#IHX^P1'_@- ''M\3ESQ9?\ D1/\:%^)N>E@3])$_P :[ Z!IO\
MSX1?]\U@^+=$FBT9I-$M;>*Z4D[FCSD8Z4 9%[\1ENK": V942(5W>8IZ_C7
M,W7BH:KX?@TYH"I63.=P/2I=)T;6]4LIIXKFR0K_ *R.2+!!_*GV7@;7-8TC
M8UW9I&6RQ1,-U[4 =E\-G?\ X1U48'ACQZ5V:* ^ZL7POH(\.Z,EF)#*<Y,@
M-;=  <US'CF"*?0@)%W'S$P/QKI\UF:UHL&NV1MIW.,\;'P: +5@$%E;JF/]
M6, 5:'/2N4/@MK:)1I]]/;RH/E>5\J*6Q\075E>+9:VF'Z)<+]USVH Z:8[H
MI%#?PG/Y5\Z>(M8ODOOLTM[(T$=UD1 \D9YKZ'NVS9R,W):,G*G':OFG4MD>
MHW$.PF2:?:K$9 R>YH [*V\1Z5>ZCI*:?;-%*LOSL2/FKVI&+)&WJO->%6W@
M^^T672)YY8&#3 @*><&O=8CB(+]/Y4 .S534)?*L9Y,?=C;^56\52UG_ ) ]
MU_UR;^5 'S3K%R;M+EU_AG;]<5[7\#Y';PS=1L<A)1C\C7ADI_T>\'_38U[G
M\#Q_Q3=W_P!=%_K0!ZG124M !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 (>AK@?&S>3XO\,S+U-QL_.N^/W3]*X/QLF[Q'
MX7/I=#^= '=J<IFG4@X6EH **** "D;[I^E+10!C>(Y!!H,\K-M";6)QTP17
M)^*?%%G>>'EBT^\\RX#H^4/0#K7H,L23QLDBAE88(/0UG?V#I>!_Q+[8E>,E
M* .+\0^)--U'P[:0070:Y$T38ZG(ZUZ);MNMHCG)*#^54$T/3D.X6,65.Y?E
M%:2J !@8]J '4444 %%%% !1110 5ROQ 7=X3NC_ '"K#\ZZJN8\>?\ (HWW
MT% &SI#F31[)S_% A_05>JAH?_(!T_\ Z]T_]!%7Z "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** (G;9EG=54 GYCC KYGU^XD^+GQDATVV?\ XEULYA1E*G]TA^=P<X8$
MY([X(KV'XK^)8_#?@>^E6X:*\N5-O;[& ?<>XSS@=\>M<K\ ?#,6G^%Y/$$N
M&N-2D,:8SE$1BN",<'<&/T(H ]@MK>*TMH[:"-8X84"1QJ,!% P /H*FIJ=,
M8QBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !534\?V9=9&?W3_R-
M6ZK:C_R#+O\ ZXO_ "- 'RR;J,:RR%&(+8.!GC<*Z'4KB#1]7AO=)GE15 9Q
ML/)'.*RHK))=88D Y('YN!73_$;1['0/#L#VL!6>5U!9FSC- '4Z=\2],ELX
MC.7,S?>&QO\ "KI^(>A_WI?^_+_X5XMHDEM;ZA;M>_-&[?,P.*]GM?!.A7=N
M+B*$NK#(PYH )/'^AM"V8YV##!/DO_A7D_BNZMI-:6ZTQ66,*&&]2OS9.>M>
MN'P#I&S889/IO-<)X^\$R6*P3:>A6S) DSEMOO0!B6WQ!\6PPA+=8\#@?+N_
ME6C9?$;Q2)E^WPJ\>1D!".]<G<:?=V,Z>245),8E!RI_PKN= ^'FHZDD5Y-J
M4;PD<A#^E ';:[I:>(O#8N1"!.R!@/>N&\'ZY=^']9^PWF0CM@[N@KURRLTM
M+*.V+,VT8]JX7QWX8>6-]1MUPRGHHZ4 >AQ,K0^8L@=&]#2]J\\^'_B;SD?3
M+]R)%_U9SUKT('B@#.UK2H]9M#:2XR0=I]*\:F>?PSJTMJX81Y() X8&O=N#
MQC\:Y#QOX:&H:>9X5 DC&<@<T 8?A73%MM8W6-UNCEC61OQSQ7<:DDGV/S/M
MOE*@_.O*O VM?V7X@,%X2%(V_-VQ7H?BNW74--B9)MD0D#,P/44 </K,5[JZ
M.T<4LPBS\Y3BJ7@[6IM!U,6TIV*YYS7JNFPVG]GQK;;7B*X)CYR?>O*O'MK;
M0ZKOTX!BO^MP>5- 'LL;)+%'*D@=67M7B/Q"%M!XDD,#98KEAWS74> ?%2W"
M_P!G3R99>%)%<GXQC!\=R,R_*< $T <+;OG489I'=;</\^Y<5M7,L$FIN]JI
M \SY??@<UZW?^!=,US28XE18)&4$N@'/%5;3X7V]O-'+<3/)'&NU0$P: %\!
M>*!,HT^Z.TJ!MS]:]$)7=A>17ANJ:==^&]?\R-7"JVY1GM7JGA?7;?6K%6$@
M$H'S#- &]2=>M*H+9YZ4N* /,/'OAU89?[1MHR#U;;7#6%^TWB*T,F<*5'->
M_7%F+VUDAE13&1R17@GBFP&B>)W$&[:'ROTS0!ZGK-M,]Q+=PQAHQ;8S^%7_
M  ?;36NA1QRIM)Y%<CIGBB74+*:U:55Q"2<^U=AX0O9;[0XY9B"W3 [4 7M8
MTQ=4L'MV4'(XS7C]V+SP[>.@8IL;*\=J]Q.,9R!CU%<CXXT&'4-,DGB&)E .
M?;O0!P'A.\DO_'4-P,9>3+$U[;7SOX?N&TGQ;:3S@I&D@SZ=:^@[69;J&.>)
M@T;C.[/% %C%9&N:2FJ6<BLIW*.*ULTI8[<9H \=MKVZ\.:TJ,2D6[H:]7L[
MI+VV6=2#N'.#7+^-/#/]IVWVF%<.@SQWQ6)X*\0M:7#:==MC<>"3TQ0!Z3UX
MHV!N" 0?6G+L9%=#N!'6E(&.E 'EWC7PS+;W)U*T!&.3M%:G@7Q0UY'_ &?>
MR#SE'&XXR/2NVF@6:$Q.H,9&"#7B_B/3;KP]X@^U1810VZ,CO0!T7Q;+?9+7
M XYJ#X&_\?5]GTK*\9:\NN>'[&4[UF7B0$=*UO@=S<WY'3% 'MU%(*6@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *.U%% 'RO\03_Q7-U_UTKL/A5IRR:U?7C=8\5Q
MOQ#4_P#">W8'3S17H/PJ&U]6!]1_*@#U'KS2$4#/'/:E)H 2CYOX!D]^*1CA
M"1VKRWQ7\1-3TS4[W3X+12@("R=-M 'J)&PYP??BDQCYJ\D@UVZ_LRTO1XAB
M:ZDE4/!GH,BO6(26B0NP)* Y!P* %E020E7 ^;UKD),Z%XNM(8"?LUT.8A]S
M/<_6NS/.,\XK@O%VHP:?XMT663Y@I)(],T =V"3],T_ '2H89!+"KJ<JPW#\
M:D'% "D9XIK81""H(ZG/;WIV]5Z]>U<?XFUZ[6YBTFU0++<#;O[XH SO$&I/
MJ&OV]CH\V9]N&?L*Z/0/#\6C0R.YW74OWI>NXUD6.CV^EZ[9)LS/)&6=B*[$
M <^_)H  -ORT_J,5'(Q"^8W"#DD5S=_X\T6QB9Q=)))N*B)3DT =/TI17)IX
MTW7-KYNG7$,%P=JRNN :ZP  ':VX'D&@ [CZUYC\4<;[+/\ <->G#[RBO-?B
MBH,U@".,-0!VVAG_ (DED .#&/Y5ICBL[01_Q)+/_KD/Y5H_6@!N,4N]NPJK
M>ZC;Z=;^?=-LC'!+5S5Q\0+$:B+.QBFO'(Z0KG% '7Y)ZTG?D?)CFL/3/$BZ
MI<R6PMI;>2-,D2C!K=#9!R!SZ4 <GK.A-$9]0TQVBG"$D#HPQTIW@?6+.\TE
M80X6="?-1N#GVKI+M?\ 0+@9&TQMD'Z5YU-IKV7A_P#MS325N8"791P'QV-
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M G<*QDN_&1BC*6%CL"C.9AF@#L12US%K=>*_-S=6%HD7J)A72H254MU(YQ0
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M(;\>*MZ/K=T;_P#LS5(?+O-NX,I^5OH: .DHINX=^OI1O% #J*9Y@I=XS_\
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MU 'L>%:-2&Z]165XD!;0Y\#D =/K6C$T;H&0'D9SVQ4&I20QZ?,]PA,07D4
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M[X]\ ?K74UROQ!;;X-ON,\+_ #H V]#_ .0#I_\ U[I_Z"*OUGZ&?^)#I_\
MU[I_Z"*T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHI",C% "%O\^E?.'Q@UNX\9>/=/\(Z4?.CM
MY!$=KKAYFY;!SC@8&#C!!KVCQYXGB\*>$;W57QYJC9"IR-TA^Z,@''XUY1\!
M?#,M_?7_ (RU++R,[)"\@(+N3EWY&""3C(/4-0![?I&E)I.BV.FQ-N6U@2$/
MMV[MH SCL3C-: &!CTH'04M !1110 4444 %%%% !7#^)[DV_BVRD>,RQQV[
MR*AZ%ATQ[UV]8?B/17U>UQ _E7$?S1R8Z^U 'F7AW59O&FHZC)J%VUK<1 ^0
MBR;<8]16UIVL#4O[&>Z=#?079B9E;)90#UQVJ >&[RRE)/A6"XF(XE2<+G/K
M6SX3\%/9:@VJWMO';2L.($;<%YZT =1-)JRW)^SVUN\9/5G(_I2>=K?_ #YV
MO_?X_P"%:O/'%+CVH Q_.US_ )\[3_O\?\*9YWB''_'K9_\ ?T_X5M\^E'X4
M 8L4VOL^);.T"CN)3_A6I$LOEYD2,-Z*Q(_E4NT=:7H.!0!DW,FK[B+>"W9?
M]IB/Z5E^*?M2^#-1>YAC$@B_A;/<5U6,\XJAK%O%/I%XDRAHVA;(/TH \>U*
MQM_L"QVEM8MML?,Y;G=D5TV@7&N_V'9H(+504X)D.2?RKQFV6[_X2*.,2N8O
M,"L=W&PL!C]:]C\5VMYIUMIMW89\BVVED4]1ZT ;"R^(L\VEJ/K)_P#6J&ZC
MUNZ@DADM+-E<8)+FK_A_7$UK3_,XW#J,<UK;/FV[1G\* /#-3MM7\(:T+R*.
M-><X7E2*[_1M9US6+".YMX;,*W56?!K<U_1H-6LVCD16<#"\5YKX<U2;PMXB
MELKICY!; !' H ]!5O$>X'[/9J ,Y5R<_I7G'Q+36Y9[1KF&%80"=R'OZ5[#
M%<1S1*T;!E<9&.U0SV%K?*4NK=) !A=PS0!\XV^KW>FW,%Q;IY;1-G=G@UO7
M_P 1-2U&T1)2\80\,O&:]7U7PIIEWILEO%90H^WY65>:\:OK3^R;Z>UNH\J,
M[05- 'J/A74[[5/#%O-;2*\P)5O--4?$OA[6M5B%Q.L(>(9( ZUE?#G6K.+4
METZ$GRY4W]>C#J*]8(5U;< RMVH \A\(:_<Z7<2:=.PC!.%W=%/I6]XKCUJ;
M1"SO;^7O!!)(R*I>._#K6TAU"Q3 +;B!VK0\)ZQ:^)=,;2=0C+2(,88\GWH
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ME*C"Y=1_,U[/JNE)J=A) X7<RD MVKQ^Y2Z\+ZXSE1\I^48ZT :\6K_$5_\
MF'K_ -_$_P :R[O1O%FI7;7=S8@39S]Y3S^=>K:%K-IK>G)+&=LG< =*U-J8
M)!!S[4 >+:;'J*7NJ-J?V6&X$:_+*!TQ[5E7VG21ZPTMN\3#8&)B' KV;4O"
M^F:P)!<09DDP"ZG&:2/POI=K:M#'  Q7;D\T <?X2UK5;B/[$+N,%1E6?//M
M757>GZW?6DEL]W#AAS@'_"N$UK2[CPYJ*20%MI;J.U>A^'-835K ;F'F(OSX
M/)H \GU+P5XBAUKS[:Q6<HP99-R]CGD$U)?:!XGOHP)M,C]]H0?UKVR.--NX
M-R3W%/VY/(&* /G&%]8TR\!2U$=PAX&!FNTLM2\=7MO'-%"&#CLZ<?K6_P"-
M/#?VF WUHHC9>6/<UC>#M<>SN4LY2P1FP<]J %:Y^(2,0+4D>S(?_9JA>\^)
M 8&.UY]V3_XJO5<AAOR=IZ4\+QP3S0!XOJ6F^--14S7MD"4^;ADZ_G6';:WK
MNBS%%'EL3@C.<5]"-"&4C(/L1UKSWQGX4,D@N+./L3( !Q0!BV>I>.;Z$36L
M0EB/\8= /U-3^;\0C_R[C_OM/_BJA\$>(9-.U(Z=<#,+' ![>]>LC;C.U<8S
MU% 'C$,NL2>)U76WA201G'F$''Y9K8L$N+G7M(-E>VK2>8ZN43H,=Z=\6;""
M&*UN8H52X;/S@XR*H_!&%7U.[:4%F"G&3G;[T >Q):ZOM -_"#[1YJ1;75!]
MZ_C/TB_^O6B!Q3J ,TVVI=KZ/_OU_P#7I#;:H1C[?&/^V7_UZTZ2@#-%KJ??
M4$_[]?\ UZ3['JG_ $$4_P"_7_UZTZ6@#+^Q:E_T$$_[]?\ UZ7[%J7_ $$$
M_P"_7_UZTZ* ,S[%J/\ T$$_[]?_ %Z46>H_]!!?^_7_ ->M*B@#.^QZC_T$
M%'_;+_Z])]CU'_H)#_OS_P#7K2HH S/L6I?]!(?]^?\ Z])]@U'_ *"?_D$?
MXUJ44 9GV'4/^@E_Y!'^-'V+4>VI#_OS_P#7K3HH S#8ZB?^8G_Y!_\ KTT:
M?J6?^0I_Y!_^O6K10!F"PU$'G4\_]L1_C2_8;_\ Z"7_ )!'^-:5% &9]AOO
M^@F?^_(_QI/L&H_]!/\ \@C_ !K4HH R_P"SM0_Z"A_[\C_&E&GW^/\ D)G_
M +\C_&M.B@#,_L^^_P"@F?\ OR/\:/[/OO\ H)$_]L\?UK3HH S/[/O?^@@?
M^^*0Z??8_P"0@1_P"M2B@#)_LW4/^@H?^_0_QI?[.O\ _H*'_OR/\:U:* ,G
M^S+[_H*/_P!\?_7H_LR^_P"@I)_WS6M10!D_V9??]!23_OFC^R[T]=4E_P"^
M:UJ* ,C^RKS'_(3E_P"^:Y+Q_H&KW?ANX%GJDB@#YU(.3],5Z(>E1L@8$.H*
MD<@T >(WNKV=O9Z=;?VX#&ENRS*4/#8Z5R7P\>.+Q#<,;S:C;F$I( QFL_Q^
MJQ^-;NWC.V(R?= K3\&:5+JNMSV"7*1+#'M'[OJ#0!ZND]OL^7Q&F/9A_C2"
M[MR.?$:#ZLO^-9$?PT5<EM1DS[(,?SIR_#6,CF_FZ_W!_C0!J_:;<\#Q+%G_
M 'U_QI!/;9P_B.,D<Y$HK.7X;0AN;Z;_ +Y'^-#_  UAW9%]+C_='^- &I]J
MM6'_ ",2 CI\PIK7$)0AO$ZG_@8K.;X;0;>+Z7/TIJ_#:+_G^E_(4 : O+/_
M *&1/^^Q7#>-T\W4[=X;XW2[!\P[<UU9^'"]K^7_ +X'^-<KXATC^P-4B@$A
ME#H#D_[U 'HMGI%RUC;D:C*H,:G [<5/_8UUC_D*35H6/%A;C_IFO\JGYH Q
M6T6\96 U.?I7C7CZU,?B.8/=2,VY1G</2OH' .0<\CM7EWBKPGJ=YXCENK:S
M#QMC# \T 9T6K6\5O;VHU5P?(P4V'&<=N*ZKP9I4TGAZWECOY5'ISD5RDOAO
M7<><]M(JQ@Y+2+P![5O?#?4;FZNKJ"2;?&B+M3TH ZQ=$F4$G4KG=]::_A^:
M1=K:A(4/4$9S6X0?2C'UH YQ?"<$3J8YV4KR"!@YJW_8TN.-0N"3UW&M@]>_
MY4G&: ,5]#G."=0FZ^M<%\1-.>&6TWWDK?*W>O5VY  YKS/XF-BXLPW *M0!
MTFDZ&6TNT9-0ND_=C@'VJ[_84I_YBMU^=7-&Q_8]J/\ ID/Y5=!_SB@#&_L6
MXW\:C.!]:CE\+BY/^DWLKX.1Q70[>.G--Y[@T <]!X7CM"S07EPCD]5P!BIF
MT*3/F#4;L\]&85MY;LM-9BQV;>3T.W/ZT >7ZW#%I?B9FN]1N1'Y#!6*DC=^
M%<5XHN8[^PTYX[R:1D_UBE",?7-;DLFLZ]XJO].0,70L%)DP%Q3U\%^(7M_*
M>W4QDY.Z4$Y^F* -[P#H_P!HT!66ZF0%OX#77C0".NH77_?55?!NESZ1HRPS
MA4?/*H*Z3B@#%.@'_H(7/_?5']@$#/\ :%S_ -]5LDTO:@##_P"$>+<_VE=C
M_@5.'AXJ/^0C='_@5;/TI10!B?V!SSJ%U^#5A>,=$E@T.>:&_G:5%W L>@[U
MV^.<]AUJ*:WBNX729=T3#;CUH \RT2P\//I"27&INMPP&\L>:E\,61NM8NH8
M+VX^S)RK]<_2MBX\!V>^0QSLJN"-H2N@TG2;72;58+903MP6]: .8U?1Y8=?
ML%M;J60L#]^7%,U>QUF#3KB4ES&B-N_?5JZ^MS+XDTX6KHN%.3MJ'Q!%J\6@
M7FZ>+9Y9S@<T >4^&-4L;?6KNZO[N6"-X2BE 6P_UKJK+3X?%NH:1_9FHW>;
M8GSI"I'>O,2Q7296 60-+G(&"#7NGP36-O#MQ)LR^\?,1]>* .WC\.A(U5[^
M[+8&<2<5(/#Z]?MUW_W\K7P3@TX4 8_]@C_G^N_^_E']@C_G^N_^_E;%% &3
M_8:?\_EU_P!]U#-H$<G_ "^7.X<#YZVZ0@[NO [4 ?.VNZ/KJ:E>Z?:0SS,)
MV=E1Q\ZG&.N/0UU,<>NFST23^PIH)=/ \RX9U *=P<G.:]'U+PU9:E,)R'AN
M/^>B'!%9Q\(W$B^7<:U=3Q[LE648QZ=: (_!UXVIWNIWYA$:22!5'7I]*Z\=
M*JV5C;Z?;K;VL*QQCLM6Q0 4444 %%%% !1110 4444 %%%% !1110 4444
M(>AK@_&G_(V>&%[_ &D5WAZ5P7C7_D<?#'_7R* .]%+2"EH **** "BBB@"O
M=6JW4#PR?<<8.#@U@GP1I)#<W/S')_>FNER,9[49'K0!S</@O38)EE62Z++T
M!E.*Z-%VJ%'0#%&Y2>OZ4Z@ HHHH **** "BBB@ KE?B#C_A#[X>R_SKJJY3
MXA?\BC>_1?YT ;NC#&AV'_7O'_Z"*O52T?C1+'_KWC_]!%7: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ I&/&,BD?E<&L3Q3XAMO#/AZ]U6Z(Q!&2H!&6;L!DC)]J /%OCIK(UWQ7I
M7A.QW226S!I_+#%M\F,+MQSA=K9![U[AX?T2U\.Z#9:3:KB&UB$?"X#GJS8]
M223^->#_  4\/W'B?QAJ/C'4OG$$Q*-C(:=OF..<C:",<8Y]J^CJ $'04M%%
M !1110 4444 %%%% !1110 W!!X -+2T4 )2T44 %%%% !1110 55U+_ )!=
MW_UQ?^1JU5/5CC2;O_KBW\J /F^T*?VQC9D[E_\ 1BU[[/:PW&GB G"21A6S
MV!'-?/=C+GQ !_MK_P"ABOHD$>5#GIM'\J /);RZNO!'B)?+8FQ=OO5ZC87L
M.J6J75H^48#)S5#Q/H<>LZ8494+#[HV\UYWX/UV;P_JC:1?N8XW8A=W\/- '
M8>/-<OM!TN.YLRO#8R37A.L>(]2U?5M]RHW2# V=!7K?Q9N%?P] D<R%&<&O
M-M/L--EBN)IIQYL,:F-0P&3F@#O_ (8^)&:W_LZ]=FD#83=VKU#:ZDYQM/0=
MZ^?]/L9X;1=3M [".4DLK=,XKV/PUK=OJNG1L),W"KA@3F@#;P3R.OM7$_$#
MPZ+ZS%Q;0$S+R:[@9'3J:CD19@4?N,4 ?.FE3_V1=NRH%N%<2 YZ>HKW_2;W
M^T=/AO 1\T:Y /?%>5_$/PP;2Y^U6D7RG[VVIOAQXK2WF_LFZE*(?NE_Y4 >
MK7-JMU:M#(!M8<'K7DFN65SX4U^*[A7;&W)(Z8S7L*D%01T/2L?Q%HT>KZ<Z
M.BLP'RYZT 4] \4)K#;$.=B+G'OFND8$G(->*Z!>S>&/$C0S(5B+ .3Z=J]E
MM;J.XC$D)W1N,AJ 'O&DD;)(N0PP<UY#XMT&70M1-[ Q"LVY-O:O8N3P,?C6
M?K.F1:KIS12%-P!Q0!E>$M>_M6QV.?WB?>YKI5.3\O/TKPVWDO?"GB$(PDV%
M_FQTKVJQO8[ZVCGM^C("WY4 1:E80:G;F&X *L/E/I7D=_#/X5\0A^1%GY?<
M9KV9P-Q45SWBK0TU72W  ,RCY>.U &EHNJ1:G91R(V6QDYK38_.*\8\/:U/X
M?U/[+,3L)VMD]*]@AN8Y[9'B.Y7&0: +'!XKE?%WATZO:&9%47"?=Q73K2GF
M@#Q/POK4_A[5EBERJRG]XOI7L\,BW$*2QG*NH88]#7G/CSPV\;_VC:1 D_>"
M_P -+X%\2_=TRZE8-C",W8>E 'H=Y<"ULWE[H,TL$K7%I&X&"PW'-4==;.C3
M\@_)U%7-/_Y!]O\ ]<Q_*@"AXBTA=5TYUX$P&4..]>;V$]UX?U81 DKG]YS7
ML& 5;/I7">--%(*WMHN2/O4 =C:W:WD,<R<(15OMFO-/"?B@07(LKUMJD[5'
MO7I0E5A&5^ZU #9(XY+<PR+N!KRCQ9H[Z/JGVV#(C=^ !TKUJLO6--35+*2V
M9!DC(=NU &=X2UL:G8JC\LHQ]:Z1?NUY!%+>>&]0\E@8XPW!]:]0TJ^%]9)+
MWQR?6@"^0".<^U-V91E<;@PQTS3L\4!N>_X4 >5>,_#TMA<?:[5<#/+#M6[X
M&\2)>V2VEVQ\Y>$)/7%===V,5[:M%-C!_O5XYJ]K<^%O$2219"H^XGM@T =+
M\7C_ *'8_0UF_!#G4+TC^Y_6JWC[78==T.P:/_6+G-7/@8H^U7Y'I0![@.E+
M2"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y7^()7_A/[KC_EK70?#'_D=;
M_P#ZYBN<\?\ /CRY_P"NU=%\+\OXQO)5^[L - 'MH'%+TH'3CI2T '6D)[4X
M]*;WH 2G <444 )FO+_B+_R';;_KF/\ T*O4#7EGQ$/_ !4-K_N#^= 'I-C_
M ,>$'_7,?RJP*KV9_P!!M_\ KFO\JL*>* % )(Q4%QJ-K;%DDND5P/XCBIBX
M4CU/3BO-?B1X?5O^)I!,P=QM**QQ0!TFM:[;*ODI- XDB<\/7&_#B[M(-2NS
M/*(B8EQD]>*S;/P%<W-U:I<7A3S(01R<\U;F^%NHQRXAOL+G;D'F@#U+^UK#
M_G]@_.FG6=-4X.H6X/H6KR-/AWJ0U<V;Z@W3=]XU$WP^U*;5IK47PW",$<GI
M0![$-:TW_G^@/_ J/[9TQS\M_!^#5XE:>"=3NO$<FGK=G:@ )!/I763?"H"R
M6.+4W6Y!YQF@#T(ZQIJ\G4+<8]6KSWXB75A=/:%+J&4A7. :I3_"^]MHGF.I
M-(JKDJ,UGI\/M0_LXZD;Y77!X/.!0!Z;HVK:<FDVP>\MT81@;2WM5[^W-+_Y
M_P"W_P"^J\@OO 5_9Z5_:1O&9-F<$X^E7O#GPVEU&PBNI[TJI7/4T >IMK6F
MC_F(6_\ WU2C7M*Q@ZA;?]]UYO=?"JX=V:/46VY]ZSKSX<W4.IPVPO\ AP#W
MH ]6?7M'!YU"W_[ZJ/\ MW1GPO\ :<(Y[-7EES\.KL:G#8B_&Z521UK+?P)?
M#Q -*6^PY7+-DC% &WX;U"UM/&FJW#3PK'\Q21FZUZ%8>(+&:R622^MQ)G@*
MW.*X/_A520:7+YU\[28/*CVJA8_#F[ETP30WQVJ#]X^E 'L4%U%<@2PMYB,/
MX:G! .">?2O-?#6@:O9Z1'.E\O[M6/4]JGN8==N=,FO_ +<%\N//RGTH ]"/
M!YIV#7/>#;J2Z\.P2W4OFRX^=C70D\]<T &*44@-!H 1B IW$@8[5POBG6-:
MMO$%G8:2%"RH6)<]*[ENG/3O6)?1Z:/$%J9Y!]KV_(OM0!CVQ\8Q7"-*T#Q]
M2*EG/BR>[W6ZP1+[FNMR S?W<<44 ><:A'XK/B"R5Y8/-V-C!J36;;Q@VE72
MW$UNT7E'<!UK?U .?%ED?2)ZTM8).C7N>ODG^5 'S,G&BR+SN$I!^M>\? X'
M_A%KG/\ SU']:\&=]EI.O_38U[U\#VSX7N?^NH_K0!ZE124M !1110 4E+10
M E%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-]TUP'C4X\
M8>&">GVD5W[?=-<#XY&?$_A@_P#3R* .^%+31RJTZ@ HHHH *1NE+2&@"AJD
M=Y+9M]AD5)\?*6Z9KB]:N?%NB:8;MKRW<[U7&#Q7?RL(XV=B0 ,D@9KA_'&H
M6EWH8@@\YW,RD[8V[?A0!=LXO%<K0227EMY+!6?CIFNN3.T9Y..:Q=/UJSFM
MH8E=T(C"G=&>H K:1MP% #J*** "BBB@ HHHH *Y7X@_\BC>_1?YUU5<MX__
M .10N_JO\Z -W2/^0-8_]>\?_H(JY5+1_P#D"V/_ %P3^0J[0 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/0UPOC,?\
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M>Y<0V4TD@!A6(LU<WHWA2>&Z;4=5F6>[!R'0\#%=#K$3W&B7D4 W,8B,=,T
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MKX(\>%K@?]-1_6@#U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%ZI\L8]* /15UWQ8<EO#D0QZW/\ ]:GG6_%73_A'8L_]?/\ ]:O+SXD^(/\
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M2Q[NNWN?6I@!M(8DGUIV,4E $,UO'=1>5.H:,]14$&EVEO)NCMT&.]7,4O-
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MA(!(7=P>E>1W.H6MGI&KZ7+YD=U=W),:XZT >E>&3GPY8X_YY"M:LGPU&8M
MLT;@B,<8Z5/K4]S;:3/-:*6G5"54#J: +Q('7BN?\9\>$+X^D>:YZS\8&9S!
MJEO=1C<H5U7 +9YKH/%Y#^#+\K]PP\9H \_N[BWB?P^\K[!]G;G..U9J./\
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M>E:_CC1]+N&EU&.\,;NP&.N3[4 ;G@73/LK33"[\Z(KP,]/:N2^(0'_"6Q8
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M,YH ^9YMWV60OU\XU[[\$S_Q3-S_ -=!_6O!9%(M9MW($IQ7N_P/.?#%R?\
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MBBB@ KEOB#_R*-W]5_G74UR_CT9\*7@/^S_.@#<TG_D#67_7!/Y"KE4M(_Y
MUE_UP3^0J[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP9XB>VGD<V,Y^3/8]J /5D!63AB"!1(NX$9.#UQWJ.&=9XUECP4<<'-3 XH
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MS.TE_!<'R?FP5'L* /3Y]'T^^E6>>UCD8?=8\_C5/Q-81'PS=Q(1$OE[<@
M"H?!VN0ZCI4=LQ=;J!0CH_7CO6[>6D>H6<UK,/W<@P<&@#RK2--M=/2(V6M1
M[0REH98P0QSV-=MXSW'P=?,N/]5UP*#X%TG[,D6PY1@P8>QS3O&J!?!]\.<+
M%P!0!PX_X^=";CFV;/'M6)=NL7@];CS&0)>\],]:W6XN-!'_ $[-_*N6EO;:
M\T-M( ;_ (^#-*2.P- %36[DWK27>&,A4+&>/E KI(H$5O#<@4C>K%@>YQ7G
M]WJ5Q#?S*598#'M5<9)7L:[+^WHG;PZ&BG)C1AD1\'CZT 6!L/AJ\]KX#/XU
M?O88VUZX&,A; L!_P&N=DU2/_A%KQ8[>=F:]#?<]ZO2Z_"VM7,C6]PJG3ROW
M,\XH ]/\%MY7A6T?("E0.37 ?'&7?9640E"J),GYN#3K?Q9!'\.3!&MRLH!V
MGR\9Z]Z\RU*X&HVD4UR]Y,T+_OO..0,^E &7;Z;<ZHX^SF%V"[CEC]*]'^&M
MZGA235;K45(2.(/A?K7 "]BT:\CELYPL4B=X^IKH;/4&O]!UR?9C,:KNQVS0
M![!I?Q,T[7+B&""VF G4[&;N16\#NYP1GL>U>':;;:KIOA*R\01749AM'(5=
MG/.*]@T&]DU+1K:\D #RIN8@8!]Z -!@""I!.1VKQ;QWH5_?Z^UP(Y%BC4G=
MMKVW9D9W$'M@XJO+!'-&\<R"16&#F@#P*U\(/9V5IJ,E\KEYP!$O7J.O->]6
M(VVL*8SE,<>M9">$M(CDW"W8\[@-QP#6Y$K1J0O'I[4 244G/H?RI-WL: '9
MH4X<GKD8IN[VIIDVL..O% ''^-Y&$FGP@X5I1DYKK;5@MO&#C9L R#7#?$1/
MM T]%G:(O)C*]:NZ;X7O+9HY1KEY(C*#Y9QB@";Q7;R7>H6-I:7:PW!.1QVI
M++P?NNO/U.9+LJW[O@@U7O-#8^)K=7U"<R%<A\ 8%)#I^HSZQ=6T6NSQI%@J
M H/:@#LLH(54878F.G3%<9X.N!+J^INQRR2D9)QTXJKI^G:Q?B]W:[<8C=E^
MZ.:PO"WANYO;O40=9N$993RI SS]* /63*6CQN4* <Y-<#8>'[S59+A[?5'A
MA,IR@7[PK?M_#KQ6XBDU6Y=\\MD<C\JJ:GHLNF:=))9:I<Q+G)VX_P * -C1
MM#L=&3$*QEV/SOGDFL;Q[*Z:=#LDPK2 ,!TZUFWND:I!IT$ZZY<MYKJ.0!UK
M-\8:%>1:7%Y^LW#;I%Z "@#T?3BHT^VVNF BY!K%\90M=06T$$R1-YG+'M65
M8>#[F6"&0^(+S;L4[01_A6[=>&(;F--]]<MM_P!H?X4 9UKX0#NC:M??;8XQ
M\BGBNJMU$* 1*HC50 N>E<5-I5]+KSV<6L7$2A=W&#BH+'1[VYU"Z@EUN[8Q
M/@$$#- %O06:;QE?AR2$^Z2:[(,X (V@ X.3G\J\OT;0)[CQ5?0OJERNT]5<
M<_I776OA<PARVJ7<ASQN?- &$=&N=2U#5)XM3:V5'R!U[UTN@Z/86$'VB-A)
M</\ ?D/<U5G\,0PP7$D5U,A<$GYNO%<[#HU_%X<EO(M7NE$89MF0<XH Z7QD
M_EZ#,4W)M7D[N]6/#4A_L*V^[]T#[U<5KFAWH\,M<S:U<,KA<J<')-7-!\)?
M:-*AN?[8OE(7.T.,?RH WO%ZB>R@B\QXV:8<J*K6_@^)YEEO[QIXLY\N3I_.
MKDGAVVD*^;=7+[6W#+]*R]4TF=]6MX(]1NHT<$Y5O2@#L[:)+>.." ((U& !
MQ4H<'@XS[5YY#H=\^MM:MKMYY2IN'3-;WAJ*XMKN\MY;J6X5&&UI#SWH Z;<
M0< XK+U[2DU72I[8L<L"1]:TN6.[@9'K2!E# ;N<^E 'FD5WXJTRU6QM+-##
M']TLO6NB\*:/<P^;J%X +F8?,@'3Z5U+;23D9RV1GM2XD+950* .9UB-W\06
M"AC#@-SD56UNQEMM&OIUU)W(0D)N'^%/UY()/$5D)YR, YPV*J>(-.TZ/0KV
M2*Z;>4/'F9H \.FED;3WWCDRGK7N_P #1CPS=#TD']:\$(9M/;)Z.3^5>^_!
M#_D6;D^L@_K0!ZC2T44 %%%% !1110 44FX X- 8&@!:*3//2EH **** "BB
MB@ HHHH **** "BBB@ HHHH **** $/0UPOC+_D:?#'_ %\BNZ/2N%\9?\C7
MX8'_ $\T =U2TE+0 4444 %%%%  1D4W8/FY/-.HH I76EV5ZRM/ CNIRK$<
MBKBJ%4 =ABC%+0 4444 %%%% !1110 5RWCX[?"=V?=?YUU-<I\03CPC=_5?
MYT ;^D#&C67_ %P3^0JY5+2#G1K(_P#3!/Y"KM !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 =JXKXF>*U\)>#+R[4H+J8?9
M[8$$Y8@\G!!X&>>QQ7:$@@\U\V_&'57\9_$'3?"FF1"1K-_*+A26,CX+=\%0
MH4]N] '1? 'PG)#9W?BV^5FGO,PVQ?.[8#EWSG#;FXY&?D]Z]P'2L[2-,72=
M'L=/B"".WA6(B- JD@#)P.F3D_C6B!@8H 6BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ I"P7J<4M<IXDGGN]9L]'AF:&.7YYF4\E1[T ;3Z[I<<IB>^A
M5P<%2W2KL<\4R[HI%=?53FN(N]7\(Z/BV6"*\F/&$02,3[Y[TW3YIM.UBTN8
M[66TLKU_*%NY^Z>N<=J .\SSBEJ 31*3NE0'/0M3OM$/_/:/_OH4 2T5%]HA
M_P">T?\ WT*//A_YZI_WT* ):*B\^'./-3_OH5)D8SGB@!:J:H0-)O/^N+_R
M-2M<0J<&5!CU85D>*+PP>&+^:%TR(B-V>.>/ZT ?/>F3Q+KX1G 8R*H!]?,6
MOH@<(I]A7SK<^$KW3=274'N4=HX?M(7/7D&NPLOC4Q6*W>R1F5!GG% 'K?/]
MTTM>:CXN.>E@G_?X?X4P_&!?^@>G_?X?X4 >B7]E#J%E);2QET=><]C7F6F7
M%QX)\2/;2JYL;@\$CA<U<7XM_)N%A'SV\T?X5A^)/'%KKNGF&:R2-ARCK)R#
M0![#'(L]L'1E97 ()JMJEC;W^G26TL2R;UQ^->6>'_B9)INEI:36ZSF/HSOV
MK4'Q<SGR[& ,.YD'^% $&@ZC=>&?$1T>8,;69L(6_A[\5Z;'N95(!PPSFO%/
M$GCQ-8VM]EMX;A.5F5^GZ5=T_P"+US;6BVTD,<FP8#;^M 'L0!)P :9-$K(T
M7EC#C#''6O+8OC')C)M+;/\ O&I)/C ^0?LEM_WT: *OC#PS)H6IC5=.A9=Y
MRVS^&N[\/ZI_:?AY)-X>0+M;'7/O7":C\5WN[22$VEH5=<9+9Q7':5XUO],F
MD2TFB43O@KV&: .P\#A&^(&JG/5L5W'BSP_%K.GY"XEC7*D#TKR^T74O#U]=
M:E#=PF:1?,<'O6S9_&"Z-K&LUM;%@.79B* -?X?ZQ.L\^E7Y8/&<1[Z]"KQM
M/B/!'J+WBV%DTK="9#Q5P_&2>/@6-F?^!&@#UDGUKD/B&EH/#4L]P1G^'BN6
M_P"%Q7'>QL_^^C5?5/B4NKV;VMU96LD+KT+#@_E0!R_A#Q?+H=ZLX#-:$_,%
M->KV/Q'T*^D18A)NE; !8\&O$=/EM+7[5&\<1,A)7Y^E7?#E]'HE]]I=;:8*
M=RK*_>@#Z,#Q3P%_+.#QBO+_ !?H<VE7IU.T0!2<DTJ?%>Y:-V-O8HQ'\,E9
MK?$F2Y@E@N8+:57.<%^!^E &[I7Q*TJTT]?MV_SP,'!K+U#XSI%<[+2V5X\]
M6%>?ZO)%>7T4JQVR1AP2 ]+K$]E<W-K+'!9KY0 *J2 ?K0!ZQXKO4UGP6+J(
M\R@$XKS58;JU9&CA; .Y6!'(KJH_'UM'I_V%+'3Q JX +54F\6Z=)&P.E:>"
MP^\O6@#?M?&T5YH[6%S#^^";0?6O0=,?S-.@\ON@X].*^>[)&N[JXO(94@\C
ME0.0,UU\/Q!U30+A+.::UN<H&#-Q@4 >L7UNEW8R0R)G<,#VKR355G\(ZL;F
M(,5[''%75^+-V<@Q67'^T:S-?\>#6K-H9[:S&X?>0G(H O:9\7A-J @O[,+&
MHY<>GK710?$_09U#1+<,"<<)7C>CW<>G:DTLT4,\<G!$G0 U:TN[CT_7'O";
M0VV[<(0YQ0!])PGS$#@<$9YK-UW1X=6L9('502,@XKSE_BK>Q@!8K+ _VC0W
MQ5O,(YCL>1TW&@#&M+RZ\&^(7C9SY+$ @CC%6O%U[%?>)K*XC92K!2,?45C>
M*/%2:YY3S06B,IYVDUS;ZJ]O/ Y>)RIRH4DC&>] 'T]8?\>,)Q_ /Y58+%>B
MY..E>/V?Q6O8;81B&PVJ!@\@T_\ X6[>G.(K$''J: .P\=23#2%6%V3>VP@>
M]8FD^'W\*^)M*,%RQ2[ :0$\9K O_B3=ZBD,4DEBG[Q3]VNK\1ZJGVO1]3M4
M2Y-JOSQ\X)(H ]/OF'V"5CT"&LKPLP;2. >96/2O-I_'FJZMJB6"R#3HVA8D
M!<Y_.J%IXTUC0A:)%>_:TED8;"H&?TH ]IU'3;35;0P7D8ECR.,]#6;IOA/1
M]%N6GLK(+*PP6)SP:YK2/B?IT]W);:K&MC)C(W-P:W6\=^&A@#5[?.,\O0!Q
MLOEB\\4QB-"RJ .!Q5#3S'_;.E@1 ![1AR.]5-8\0645]J(TVX@NY-3(4*CG
M(JQ:V'B>*>RN?[,1E@@*C+'O0!RNM^'+C5+4%90I-\4W;>@K';X<:Q_;<]I:
MW$3;%#,Q'0>]=7-/K,$8@>R7='=>:<$_-6S;1^(]4GU*[LM)"-=((\EL=._2
M@"OX;T*XT#6[6VGF#2"V<D+T)/I4MGQ;6.1R=2?^E5IK_4O#>MZ<-;M([=1
M8S,9">M63J&@6L%INUB)F6[,YR<D X_PH ]IC8!0<]:<Q (SR/T->=:S\4]+
MM?LXT@PWLCD[DS]WIC^M51\2M7.1_8J9 &%!;F@#T2_OH-.MWN+F39&HS_\
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MH:X;QD#_ ,)1X9/I<B@#N12T@I: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KE/B'_ ,BA=_5?YUU=<I\0^?"%W]5_G0!NZ-_R!+'_ *X)_(5>JCHW
M_($L?^N"?R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "D;[II:1ONF@#F/'/B6'PCX4OM6E?$@3RX$! W2'.,9!YZG_@->3?
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M0H.-JC@5/28H 9MC'\-&Q?[M244 ,X]:4?[)IU% #, GD9^E'WCD >V13Z*
M&'DC(Y]J4@]OQS3J* &X]J3'N/RI]% #-H]*-H_NT^B@")E'7;GCH:Y?4_!-
MK>7YO;.>2QF?EWA Y_,5UF*,4 <8W@J]8C=XEU(XZ<)_\32KX.O.I\2:E^2?
M_$UV=% '('P==E?F\2ZGM]G4?TII\&W>X;_$FH$]ON_X5V%+0!QS^#;ANGB+
M5 W<AEY_2F?\(-<,>?$6IX]V7_"NSQ2T <:/!$W0>(=2X]U_PH;P1,PP?$&H
MGZL!_(5V)HH XH^ Y#_S'=0_[^56O/AW)=6DT)UV_&Y< EZ[[%+0!Y+/X6UJ
M+5++3O[6A:(0LFYHQNQ6Y8?#I+2S6/\ MF_VJ,_))CG-;MZ,^+;'_KFU= *
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M% &!X8TJXTZUDEO7S=7+F1QZ'TK?%&*6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 0\BN'\9<>*/#8_P"GH5W!Z5PWB\_\5?X;_P"OB@#N12T@I: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE?B!_R)]Y]5_G755RWC_\
MY%"[^J_SH VM&_Y EC_UP3^0J_5+1_\ D"V/_7!/Y"KM !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW@G_ *&?3_\ O[1_PL[P3_T,^G_]_:X7_AG#PW_T&-6_./\ ^)H_X9P\-_\
M08U;\X__ (F@#NO^%G>"?^AGT_\ [^T?\+.\$_\ 0SZ?_P!_:X7_ (9P\-_]
M!C5OSC_^)H_X9P\-_P#08U;\X_\ XF@#NO\ A9W@G_H9]/\ ^_M'_"SO!/\
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M:X7_ (9P\-_]!C5OSC_^)H_X9P\-_P#08U;\X_\ XF@#NO\ A9W@G_H9]/\
M^_M'_"SO!/\ T,^G_P#?VN%_X9P\-_\ 08U;\X__ (FC_AG#PW_T&-6_./\
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M:=]NTBX\R,.4=6&UD(]1VKF-7^-'A326U6 RS27NG.T36^S:9'!*X4GKR.M
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M10 4A&1BEI": ,74.->T[W!%;58NH9_MW3SCH"36SGG'ZT .HI,TM !1110
M4444 %%%% !1110 444A..@R: $D4-&RGH1BL;PPY;258_WV'ZUL.V,@<D5C
M>&%*:2%.<B1CT]Z -NEIH8'D<CUIU !1110 4444 %%%% !1110 444F><=Z
M (;Q0UG,#W0UF^&6)T=?:1A6C=R*MK-N(4;#R365X8D4Z.-IW?O6SCM0!NT4
M@/7VI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH 0]*X/QZ=FI^'G'47JC]:[TUP/C_G4?#P_Z?D_G0!W:#$:CV%/IJ_=
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M9_CQ_P _&G?E;_\ Q-'V?X\?\_&G?E;_ /Q- 'M>:,UXI]G^/'_/QIWY6_\
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MVHZB=0\!V=U>.3<I<* >Y(- 'HRMN I]5[,DV<#$Y)0$_E5B@ HHHH ****
M"BBB@ HHHH 0G! P>:S=8U:WTNS:65AO(^1.[GTK1?.W@XKAO&$9N/%&B0^8
M(XVW?,>F>U %J";Q)J317B16EG$5PB2IEA[U=LM;N8K\6&K*J2L?D<#Y6KS/
MQ;=^([&<"YN9HX[8G8ZD_.,UJVFL+K?AS1)+J??>I<8SGYBN>] 'K0I:04M
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MA/'8SJ?AT>M\A_6NZ-<+XYXU7PYG_G]7^= '<CH*=35Z#Z4Z@ HHHH ****
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M:)I.FW<]S8Z;:6UQ<G=-+#$JM(<DY8CKU_6O+_V<?^1#U'_L)O\ ^BXZ]BH
M**** ,+4/"?A[5+V2ZO]"TVZN9"-TTUJCLV!@9)'-6].T;3M&@D@TJQM;".1
M][);0K&"W3) ')QBM*B@#-U'1M,U=(UU/3[2[CB):/SX@^T^HST-5+[PGX?U
M2ZDO+_0]/NKE\%IIK9'9L<#)(R>,"MVB@"K;V\5O:Q6T,4<<$2A$C50%50.
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M^OU/YT =N.GY4ZF <?@*?0 4444 %%%% !1110 4444 %%%% !1110 4444
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M O\ H)7'_@))_A0!Z317FW_"]_ 7_02N/_ 23_"C_A>_@+_H)7'_ ("2?X4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH \U_P"%#^ _^?"Z_P# M_\ &C_A0_@/_GPNO_ M_P#&O2J* /-?^%#^ _\
MGPNO_ M_\:/^%#^ _P#GPNO_  +?_&O2J* /-?\ A0_@/_GPNO\ P+?_ !H_
MX4/X#_Y\+K_P+?\ QKTJB@#S7_A0_@/_ )\+K_P+?_&C_A0_@/\ Y\+K_P "
MW_QKTJB@#S7_ (4/X#_Y\+K_ ,"W_P :/^%#^ _^?"Z_\"W_ ,:]*HH \U_X
M4/X#_P"?"Z_\"W_QH_X4/X#_ .?"Z_\  M_\:]*HH \U_P"%#^ _^?"Z_P#
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M_P#&O2J* /-?^%#^ _\ GPNO_ M_\:/^%#^ _P#GPNO_  +?_&O2J* /-?\
MA0_@/_GPNO\ P+?_ !H_X4/X#_Y\+K_P+?\ QKTJB@#S7_A0_@/_ )\+K_P+
M?_&C_A0_@/\ Y\+K_P "W_QKTJB@#S7_ (4/X#_Y\+K_ ,"W_P :/^%#^ _^
M?"Z_\"W_ ,:]*HH \U_X4/X#_P"?"Z_\"W_QH_X4/X#_ .?"Z_\  M_\:]*H
MH \U_P"%#^ _^?"Z_P# M_\ &C_A0_@/_GPNO_ M_P#&O2J* /-?^%#^ _\
MGPNO_ M_\:/^%#^ _P#GPNO_  +?_&O2J* /-?\ A0_@/_GPNO\ P+?_ !H_
MX4/X#_Y\+K_P+?\ QKTJB@#S7_A0_@/_ )\+K_P+?_&C_A1'@3I]ANL?]?;_
M .->E44 97AWP[I_A;1X]*TM'2UC9F57<N<L<GDUJT44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MAKAO'AQJWA[_ *_%_G7=5PGCP?\ $W\/?]?B_P Z .Y7H/I3J:.GY4Z@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *Y[QK_ ,BI?C_8_K70USWC3_D5
M;[_<'\Z +WAT;?#FGC_I@O\ *M.LSP^?^*>T_P#ZX)_*M.@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EI* %HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0UP_CO_ )"WA[_K\7^=
M=PW3\:X?QU_R%O#_ /U^K_.@#MQT_"G4T=!]*=0 4444 %%%% !1110 4444
M %%%% !1110 4444 %<]XT_Y%:_]HQ_.NAKG?&G_ "*VH?\ 7,?SH O^'Q_Q
M3VG_ /7!/Y5IUF^'_P#D7M/_ .O=/Y5I4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 (>GXUPWCPXU;P]_P!?J_SKN6Z?C7#>._\
MD+>'O^OU?YT =PO0?2G4U>@^E.H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N>\:?\BM??[@_G70USOC?_ )%+4/\ KF/YT :'A_\ Y%[3_P#K@G\J
MTJSM _Y%[3O^O=/Y"M&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@!#T_&N&\=G_B;>'O^OU?YUW5<)X\&=8\._\ 7ZO\Z .Y7H/I
M3J:.@^E.H **** "BBB@ HHHH **** "BBB@ HHHH **** "N=\;_P#(HW_^
MY_6NBKG/&_\ R*6H>R#^= &AX?\ ^1>T_P#Z]T_E6G6;X?'_ !3VG_\ 7NG\
MJTJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)9?,"@G&?3I7HPX&0O49)H S+R\TZ&:2&Y"*ZKN^9?O5F0>)+2Y8P26T\"$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7">//^0OX=_Z_%_G7=UPG
MCL9U'P\W?[:@_6@#N1T_ 4%0>HH7I^5.H H74]I9LCW!5,G"G'4U!<6<-_=P
M2^>X"-N"J1@D5G^,'D6P3RK07+!P<&39M]\X-8EM*UFJ3R7^YT<%;<=\]LY_
MI0!WF%7.#CN2:H:O:+J6DS0K*1NQM=><<U%%<3:A9SQ7$2VLKH0OSYP/6LO3
M]"U:TBV)KH*=?]1G]<T 8K67DW^G!9K0F.0 AP0Y.1TKT/GVR>M<O>:3J5Q=
MVSNEA.(G!\PY5\9&>U=/T]!@9 H RM2T?[45EBO)+60?W6XJ"+2+^0E;K4O-
MCX*[8\,/QK0U"SBN+9FD9U..6C/-<?%JT-O-_9JW=ZETSC:94XQ^= '=Q+LC
M5,Y*C&:KS:?$Z3A05:=<,R^W_P"NK,1(BC5VRVWD@=:S;W5/[.G_ -)5_)()
M#KC ^M % :3IVG[;:"9HKXJ6#YY;VK;L&E-I%YHP^#N^M<;!>WNI:LNK_8DD
ML8BR+(LWS?\ ?./ZUVEI<+<Q+*F0".A&#0!9HI*6@ KGO&@SX6O_ /KF/YUT
M-<_XT./"E^?]C^M %_0./#VG_P#7!/Y5HUF>'6W>'-/)[P+_ "K3H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .U<+X]XOO#_M>I
M_.NY/2N&\>\ZCH"]S>I_.@#N%^Z#["G4U?N@>U.H Y;QM),FE*(Q-AI '$<>
M_*Y^HQ6!%;&\O((+:UA2-L9>3*NI'MS77>)!.VD2BWF\J?JF>]<CI5Y>-JUJ
MUY=&5\[6 @(Q0!V4&F,EI)').9I&4J&(Z52M=$O[.W95U>3/\.^,$ >G6M]!
MMZ'(/3BLW7[N2RTN6X4L"N/N)N)R<4 926GBJ*[4?;+*:U# ME"'(SVKI@,?
M?Y)]!TKF=*\6VUP8[>02K-N"D.A4UU!.!D#(- %6\S-92I#@L5('..:Y>YM-
M/2.TN9IEBNU< @_,36UJ3)I]E-Y=O,4?)+H>AKE$830V\<4T<S[P3]HC((Y]
M: /0(_N(QYXX-<IK5_J7GS1QQ6AMQ@;+ACF3UQQ]*ZF GR$+?>]!TKE=6N[V
M;7)(+;3[>Z,"!]CL0><YQV[4 4-/-M=LSPZ?J%O#$</&"H0^I'-=M8F$VL1@
M!$97Y0>M<Y&;/4#&;CS=/N!D-"3P:Z:VC2&&-$7Y0O!H GI:2EH *YSQP<>$
MM0_W!_.NCKG/'/\ R*.H?[@_G0!>\.#;X;TX=?\ 1T_E6K67X>_Y%W3O^O=/
MY5J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>G
MXUPWCL_\37P\?^GU?YUW5<'X]XO] ;L+Y.?QH [I>@^E#N%4DD #J:1>1^ J
M*[B6>U>(@_,,8!H Y#Q7J^F7!AM9+V:-U;<##&6S^-7-*GN7DA2WGM[J,<L=
MH5U!]12IJ.F:0T=A=0".1> [)NR/K1G3YM:MI=._UI/[QHA@%?>@#IAPW/'N
M36?K:B?2IMHWC Q@GU]JMSQM)%*JDJSK@'KBL*[":5IZ+<ZHZ, <!0,D_2@#
M&BALYYK:Z:=HKJ%PCQ?WSD<UW>?D ^]D=ZXC2)=3U+4$DB@@-JI!>6:'#OSV
M-=P#R/4#''2@"O=.D%K([D*@'/&?TKE3JLU]=,EOI\<T"$'S,@8_"NFU5YX]
M/G:W16?;T;I7GMF[O&LDZSK-N&5M6'3/?- 'I5O@PIM   Z YP:8(H([AY5"
M^<PQGN:?;LIMXV52JX'!&#6)<Z7_ *9=7$U_Y&]0L9W8V&@#5NK&"\"B:($C
MY@15B)51%5,A0.E8<5A(D,<L>H2RM&"6^8$-6O97!N;=9F4 M0!:%%%% !7-
M^./^11U#_<'\ZZ2N>\9KO\*:@N.D>?UH N^'O^1=T[_KW3^5:E9/AH[O#>G'
M_I@O\JUJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH 0G KA/B*<1:,?34(_YUW;=*X3XC#,.CC_J(Q_SH [E#
M^[7Z?TI],3_5+]*?0 4444 %%%% !1110 F*,4M% !0*** "BBB@ HHHH *Q
M?%7_ "*^I>\)K:K$\5?\BOJ7M": #PA_R*.F?]<!6W6)X/\ ^10TO_K@*VZ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% #7^Z1Z\5P7Q,=(K'39'#E$O8V8H
M/NC/4UW]0S6T,X"RPQR*#G#J"* .77X@^'55 UX=QX^X>PI?^%C^&?\ G^;_
M +X-=$=+T\G)L;;_ +\K_A3?[)TW_H'VG_?E?\* .?\ ^%B^&CTO6_[X-+_P
ML3PW_P _K?\ ?!K?_LG3O^?"U_[\K_A2C2M._P"?"U_[\K_A0!@?\+"\-_\
M/ZW_ 'P:&^(?AM1G[8Q_X :Z#^R]/_Y\;;_ORO\ A1_9>G_\^-M_WY7_  H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>28
<FILENAME>arvn-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-01T20:51:00.6703813+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 7fde9e0b67904d4bbc438174819e5cd5 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:arvn="http://www.arvinas.com/20201231" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arvinas.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.arvinas.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity" id="Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders&apos;/Members&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical" id="Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical">
        <link:definition>100060 - Statement - Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders&apos;/Members&apos; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>100080 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreements" id="Role_DisclosureLicenseAgreements">
        <link:definition>100100 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreements" id="Role_DisclosureResearchCollaborationAndLicenseAgreements">
        <link:definition>100110 - Disclosure - Research Collaboration and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>100120 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovements" id="Role_DisclosurePropertyEquipmentAndLeaseholdImprovements">
        <link:definition>100130 - Disclosure - Property, Equipment and Leasehold Improvements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilities" id="Role_DisclosureRightToUseAssetsAndLiabilities">
        <link:definition>100140 - Disclosure - Right to Use Assets and Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100150 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebt" id="Role_DisclosureLongTermDebt">
        <link:definition>100160 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquity" id="Role_DisclosureMembersEquity">
        <link:definition>100170 - Disclosure - Members&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquity" id="Role_DisclosureEquity">
        <link:definition>100180 - Disclosure - Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvestee" id="Role_DisclosureInvestmentInEquityMethodInvestee">
        <link:definition>100190 - Disclosure - Investment in Equity Method Investee</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100200 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100210 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShare" id="Role_DisclosureNetLossPerCommonShare">
        <link:definition>100220 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100230 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTables" id="Role_DisclosureResearchCollaborationAndLicenseAgreementsTables">
        <link:definition>100240 - Disclosure - Research Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables" id="Role_DisclosureMarketableSecuritiesTables">
        <link:definition>100250 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsTables" id="Role_DisclosurePropertyEquipmentAndLeaseholdImprovementsTables">
        <link:definition>100260 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesTables" id="Role_DisclosureRightToUseAssetsAndLiabilitiesTables">
        <link:definition>100270 - Disclosure - Right to Use Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100280 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtTables" id="Role_DisclosureLongTermDebtTables">
        <link:definition>100290 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables" id="Role_DisclosureEquityTables">
        <link:definition>100300 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareTables" id="Role_DisclosureNetLossPerCommonShareTables">
        <link:definition>100320 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsSummaryOfContractLiabilitiesDetails" id="Role_DisclosureResearchCollaborationAndLicenseAgreementsSummaryOfContractLiabilitiesDetails">
        <link:definition>100370 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails" id="Role_DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails">
        <link:definition>100380 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetailsDefault" id="Role_DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetailsDefault">
        <link:definition>100380 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails1" id="Role_DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails1">
        <link:definition>100390 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details1)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails" id="Role_DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails">
        <link:definition>100400 - Disclosure - Marketable Securities - Summary of Company&apos;s Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="Role_DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>100410 - Disclosure - Marketable Securities - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails" id="Role_DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails">
        <link:definition>100420 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsAdditionalInformationDetails" id="Role_DisclosurePropertyEquipmentAndLeaseholdImprovementsAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails" id="Role_DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Right to Use Assets and Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesComponentsOfLeaseExpenseDetails" id="Role_DisclosureRightToUseAssetsAndLiabilitiesComponentsOfLeaseExpenseDetails">
        <link:definition>100450 - Disclosure - Right to Use Assets and Liabilities - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" id="Role_DisclosureRightToUseAssetsAndLiabilitiesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails">
        <link:definition>100460 - Disclosure - Right to Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" id="Role_DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>100470 - Disclosure - Right to Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2" id="Role_DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2">
        <link:definition>100480 - Disclosure - Right to Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails">
        <link:definition>100490 - Disclosure - Accrued Expenses - Components of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails" id="Role_DisclosureLongTermDebtAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Long-Term Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails" id="Role_DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails">
        <link:definition>100510 - Disclosure - Long-Term Debt - Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails" id="Role_DisclosureMembersEquityAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Members&apos; Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" id="Role_DisclosureEquityAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails" id="Role_DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails">
        <link:definition>100540 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails" id="Role_DisclosureEquitySummaryOfStockOptionActivityDetails">
        <link:definition>100550 - Disclosure - Equity - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails" id="Role_DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails">
        <link:definition>100560 - Disclosure - Equity - Summary of Restricted Stock Grant Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails" id="Role_DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Investment in Equity Method Investee - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100580 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
        <link:definition>100590 - Disclosure - Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails">
        <link:definition>100600 - Disclosure - Income Taxes - Summary of Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100610 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails" id="Role_DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails">
        <link:definition>100620 - Disclosure - Net Loss Per Common Share - Basic and Diluted Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails" id="Role_DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails">
        <link:definition>100630 - Disclosure - Net Loss Per Common Share - Common Share Equivalents Excluded from the Calculations of Diluted Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised" name="TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised" name="TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" name="TemporaryEquityStockIssuedDuringPeriodShareNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" name="ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" name="TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" name="TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" name="StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_SeriesARedeemableConvertiblePreferredUnitsMember" name="SeriesARedeemableConvertiblePreferredUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" name="SeriesBRedeemableConvertiblePreferredUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" name="SeriesCRedeemableConvertiblePreferredUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_SeriesABAndCConvertiblePreferredSharesMember" name="SeriesABAndCConvertiblePreferredSharesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_CommonUnitsMember" name="CommonUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_IncentiveUnitsMember" name="IncentiveUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" name="StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" name="IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_OperatingLeaseRightOfUseAssetAmortization" name="OperatingLeaseRightOfUseAssetAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_ProceedsFromMaturitiesOfMarketableSecurities" name="ProceedsFromMaturitiesOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_ProceedsFromSaleOfMarketableSecurities" name="ProceedsFromSaleOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" name="ProceedsFromIssuanceOfCommonStockInAPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_LicenseAgreementsTextBlock" name="LicenseAgreementsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_LicenseAgreementsAbstract" name="LicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_ResearchCollaborationAndLicenseAgreementsAbstract" name="ResearchCollaborationAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_PreferredUnitWarrantsPolicyPolicyTextBlock" name="PreferredUnitWarrantsPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_NumberOfWhollyOwnedSubsidiaries" name="NumberOfWhollyOwnedSubsidiaries" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_NatureOfBusinessLineItems" name="NatureOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_NatureOfBusinessTable" name="NatureOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_CollaboratorOneMember" name="CollaboratorOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_CollaboratorThreeMember" name="CollaboratorThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_CollaboratorTwoMember" name="CollaboratorTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_OerthBioLimitedLiabilityCorporationMember" name="OerthBioLimitedLiabilityCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_NonRefundableUpfrontPayment" name="NonRefundableUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_AnnualLicenseFeePayment" name="AnnualLicenseFeePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_YaleUniversityMember" name="YaleUniversityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_CollaborativeArrangementSublicensePayment" name="CollaborativeArrangementSublicensePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_ReimbursementOfPatentRelatedCost" name="ReimbursementOfPatentRelatedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_CollaborativeArrangementPayment" name="CollaborativeArrangementPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" name="ResearchCollaborationAndLicenseAgreementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_ResearchCollaborationAndLicenseAgreementsTable" name="ResearchCollaborationAndLicenseAgreementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_BayerAGMember" name="BayerAGMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_ResearchFundingPaymentsMember" name="ResearchFundingPaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_DevelopmentMilestonePaymentsMember" name="DevelopmentMilestonePaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_SalesBasedMilestonePaymentsMember" name="SalesBasedMilestonePaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_PfizerIncorporationMember" name="PfizerIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_OptionExercisedToLicenseAgreementsMember" name="OptionExercisedToLicenseAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_OptionPaymentsToLicenseAgreementMember" name="OptionPaymentsToLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_SubstitutionTargetPaymentsMember" name="SubstitutionTargetPaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_RegulatoryMilestonePaymentsMember" name="RegulatoryMilestonePaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_CommercialMilestonesMember" name="CommercialMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" name="GenentechIncorporationAndFHoffmanLaRocheLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_BayerAGAndPfizerMember" name="BayerAGAndPfizerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_SaleOfStockFairValueOfSharesSold" name="SaleOfStockFairValueOfSharesSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_NumberOfContractsToBeCombined" name="NumberOfContractsToBeCombined" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_NumberOfMaximumDesignatedTargets" name="NumberOfMaximumDesignatedTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" name="AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_CorporateBondsMaturingTwoThousandTwentyMember" name="CorporateBondsMaturingTwoThousandTwentyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_CorporateBondsMaturingTwoThousandTwentyOneMember" name="CorporateBondsMaturingTwoThousandTwentyOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_TwoThousandTwentyMaturityMember" name="TwoThousandTwentyMaturityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_PercentageOfIncrementalBorrowingForLleasePayments" name="PercentageOfIncrementalBorrowingForLleasePayments" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="arvn_LesseeOperatingLeaseExpirationMonthAndYear" name="LesseeOperatingLeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" name="SupplementalNonCashInformationRelatedToLeasesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds" name="DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_DebtInstrumentMaximumBorrowingCapacity" name="DebtInstrumentMaximumBorrowingCapacity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_LoanAgreementMember" name="LoanAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_ConnecticutInnovationsIncorporatedMember" name="ConnecticutInnovationsIncorporatedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_TwoThousandAndFourteenAssistanceAgreementMember" name="TwoThousandAndFourteenAssistanceAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_TwoThousandAndEighteenAssistanceAgreementMember" name="TwoThousandAndEighteenAssistanceAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_DebtInstrumentMaturityMonthAndYear" name="DebtInstrumentMaturityMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_PercentageOfLiquidatedDamages" name="PercentageOfLiquidatedDamages" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_DebtInstrumentInterestPaymentsTerm" name="DebtInstrumentInterestPaymentsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" name="DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_PercentageOfMaximumFundingOnProjectCosts" name="PercentageOfMaximumFundingOnProjectCosts" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_PiperSandlerMember" name="PiperSandlerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_StockIncentivePlanMember" name="StockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_TwoThousandEighteenStockIncentivePlanMember" name="TwoThousandEighteenStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_ConsultantsMember" name="ConsultantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" name="MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays" name="ShareBasedCompensationArrangementAverageCommonStockPrecedingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_PriorToStockPurchaseAgreementPremium" name="PriorToStockPurchaseAgreementPremium" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" name="IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock" name="AmountUsedAsMultiplyingFactorToGrantCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_MaximumPercentageOfCompensationReceivableByEmployee" name="MaximumPercentageOfCompensationReceivableByEmployee" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_EmployeesDirectorsAndConsultantsMember" name="EmployeesDirectorsAndConsultantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_EmployeesMember" name="EmployeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="arvn_EquityMethodInvestmentContribution" name="EquityMethodInvestmentContribution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" name="FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="arvn_BayerCropScienceLPMember" name="BayerCropScienceLPMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" name="EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense" name="EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" name="OperatingLossesCarryForwardMaximumDeductibilityPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arvn_QuarterlyResearchPayments" name="QuarterlyResearchPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_AmendedCorporateSponsoredResearchAgreementMember" name="AmendedCorporateSponsoredResearchAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_CorporateSponsoredResearchAgreementMember" name="CorporateSponsoredResearchAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_ConsultingAgreementMember" name="ConsultingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arvn_PaymentForConsultingService" name="PaymentForConsultingService" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arvn_MonthlyResearchPayments" name="MonthlyResearchPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" name="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>29
<FILENAME>arvn-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-01T20:51:00.6703813+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 7fde9e0b67904d4bbc438174819e5cd5 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="arvn-20201231.xsd#TemplateLink" roleURI="http://www.arvinas.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="arvn_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OperatingLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="arvn_OperatingLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromSaleOfMarketableSecurities" xlink:type="locator" xlink:label="arvn_ProceedsFromSaleOfMarketableSecurities" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:type="locator" xlink:label="arvn_ProceedsFromMaturitiesOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" xlink:type="locator" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="arvn_ProceedsFromIssuanceOfCommonStockGross" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="arvn_ProceedsFromMaturitiesOfMarketableSecurities" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="arvn_ProceedsFromSaleOfMarketableSecurities" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="arvn_OperatingLeaseRightOfUseAssetAmortization" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="10250.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10260.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10270.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10290.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="arvn_IncreaseDecreaseInOperatingLeaseLiabilities" order="10300.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10310.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails" xlink:href="arvn-20201231.xsd#Role_DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails">
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:type="locator" xlink:label="arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:href="arvn-20201231.xsd#Role_DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="arvn_AccruedResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="arvn_AccruedResearchAndDevelopmentExpenseCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10100.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:type="locator" xlink:label="arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>30
<FILENAME>arvn-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-01T20:51:00.6713815+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 7fde9e0b67904d4bbc438174819e5cd5 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="arvn-20201231.xsd#TemplateLink" roleURI="http://www.arvinas.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" xlink:type="locator" xlink:label="arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" xlink:type="locator" xlink:label="arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" xlink:type="locator" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" xlink:type="locator" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" xlink:type="locator" xlink:label="arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:type="locator" xlink:label="arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised" xlink:type="locator" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised" xlink:type="locator" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="arvn_AtTheMarketOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MemberUnitsMember" xlink:type="locator" xlink:label="us-gaap_MemberUnitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncentiveUnitsMember" xlink:type="locator" xlink:label="arvn_IncentiveUnitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommonUnitsMember" xlink:type="locator" xlink:label="arvn_CommonUnitsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesABAndCConvertiblePreferredSharesMember" xlink:type="locator" xlink:label="arvn_SeriesABAndCConvertiblePreferredSharesMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" xlink:type="locator" xlink:label="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" xlink:type="locator" xlink:label="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesARedeemableConvertiblePreferredUnitsMember" xlink:type="locator" xlink:label="arvn_SeriesARedeemableConvertiblePreferredUnitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesARedeemableConvertiblePreferredUnitsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesABAndCConvertiblePreferredSharesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_CommonUnitsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_IncentiveUnitsMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_MemberUnitsMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arvn_AtTheMarketOfferingMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" order="12260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" order="12460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" order="13360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" order="13380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" order="13660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" order="13840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="13960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="14180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="14260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="14400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="14860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="15080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="15160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="15300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="15460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" xlink:type="locator" xlink:label="arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="arvn_AtTheMarketOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arvn_AtTheMarketOfferingMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" xlink:type="locator" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromSaleOfMarketableSecurities" xlink:type="locator" xlink:label="arvn_ProceedsFromSaleOfMarketableSecurities" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:type="locator" xlink:label="arvn_ProceedsFromMaturitiesOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="arvn_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OperatingLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="arvn_OperatingLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="arvn_AtTheMarketOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10320.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arvn_AtTheMarketOfferingMember" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="arvn_OperatingLeaseRightOfUseAssetAmortization" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="arvn_IncreaseDecreaseInOperatingLeaseLiabilities" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="arvn_ProceedsFromMaturitiesOfMarketableSecurities" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="arvn_ProceedsFromSaleOfMarketableSecurities" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="12310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="12370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="12490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="arvn_ProceedsFromIssuanceOfCommonStockGross" order="12550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="12730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="12790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="13090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="13210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="13270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="13330.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables" xlink:href="arvn-20201231.xsd#Role_DisclosureEquityTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NumberOfWhollyOwnedSubsidiaries" xlink:type="locator" xlink:label="arvn_NumberOfWhollyOwnedSubsidiaries" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NatureOfBusinessTable" xlink:type="locator" xlink:label="arvn_NatureOfBusinessTable" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NatureOfBusinessLineItems" xlink:type="locator" xlink:label="arvn_NatureOfBusinessLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="arvn_NatureOfBusinessTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_NatureOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_NatureOfBusinessTable" xlink:to="us-gaap_AwardTypeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_NatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="arvn_NumberOfWhollyOwnedSubsidiaries" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11070.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="arvn_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember" xlink:type="locator" xlink:label="arvn_OerthBioLimitedLiabilityCorporationMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaboratorTwoMember" xlink:type="locator" xlink:label="arvn_CollaboratorTwoMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaboratorThreeMember" xlink:type="locator" xlink:label="arvn_CollaboratorThreeMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaboratorOneMember" xlink:type="locator" xlink:label="arvn_CollaboratorOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="arvn_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="arvn_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="arvn_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arvn_CollaboratorOneMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arvn_CollaboratorThreeMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arvn_CollaboratorTwoMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arvn_OerthBioLimitedLiabilityCorporationMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arvn_LaboratoryEquipmentMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="11870.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ReimbursementOfPatentRelatedCost" xlink:type="locator" xlink:label="arvn_ReimbursementOfPatentRelatedCost" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaborativeArrangementPayment" xlink:type="locator" xlink:label="arvn_CollaborativeArrangementPayment" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaborativeArrangementSublicensePayment" xlink:type="locator" xlink:label="arvn_CollaborativeArrangementSublicensePayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AnnualLicenseFeePayment" xlink:type="locator" xlink:label="arvn_AnnualLicenseFeePayment" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NonRefundableUpfrontPayment" xlink:type="locator" xlink:label="arvn_NonRefundableUpfrontPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_YaleUniversityMember" xlink:type="locator" xlink:label="arvn_YaleUniversityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_YaleUniversityMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arvn_NonRefundableUpfrontPayment" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arvn_AnnualLicenseFeePayment" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arvn_CollaborativeArrangementSublicensePayment" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arvn_CollaborativeArrangementPayment" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arvn_ReimbursementOfPatentRelatedCost" order="10850.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NumberOfMaximumDesignatedTargets" xlink:type="locator" xlink:label="arvn_NumberOfMaximumDesignatedTargets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NumberOfContractsToBeCombined" xlink:type="locator" xlink:label="arvn_NumberOfContractsToBeCombined" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SaleOfStockFairValueOfSharesSold" xlink:type="locator" xlink:label="arvn_SaleOfStockFairValueOfSharesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_BayerAGAndPfizerMember" xlink:type="locator" xlink:label="arvn_BayerAGAndPfizerMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:type="locator" xlink:label="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommercialMilestonesMember" xlink:type="locator" xlink:label="arvn_CommercialMilestonesMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_RegulatoryMilestonePaymentsMember" xlink:type="locator" xlink:label="arvn_RegulatoryMilestonePaymentsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SubstitutionTargetPaymentsMember" xlink:type="locator" xlink:label="arvn_SubstitutionTargetPaymentsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OptionPaymentsToLicenseAgreementMember" xlink:type="locator" xlink:label="arvn_OptionPaymentsToLicenseAgreementMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OptionExercisedToLicenseAgreementsMember" xlink:type="locator" xlink:label="arvn_OptionExercisedToLicenseAgreementsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PfizerIncorporationMember" xlink:type="locator" xlink:label="arvn_PfizerIncorporationMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockPurchaseAgreementMember" xlink:type="locator" xlink:label="arvn_StockPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SalesBasedMilestonePaymentsMember" xlink:type="locator" xlink:label="arvn_SalesBasedMilestonePaymentsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DevelopmentMilestonePaymentsMember" xlink:type="locator" xlink:label="arvn_DevelopmentMilestonePaymentsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ResearchFundingPaymentsMember" xlink:type="locator" xlink:label="arvn_ResearchFundingPaymentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_BayerAGMember" xlink:type="locator" xlink:label="arvn_BayerAGMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:type="locator" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsTable" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:type="locator" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="arvn_ResearchCollaborationAndLicenseAgreementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_BayerAGMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_ResearchFundingPaymentsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_DevelopmentMilestonePaymentsMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_SalesBasedMilestonePaymentsMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="srt_RangeAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="srt_StatementScenarioAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_StockPurchaseAgreementMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_PfizerIncorporationMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_OptionExercisedToLicenseAgreementsMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_OptionPaymentsToLicenseAgreementMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_SubstitutionTargetPaymentsMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_RegulatoryMilestonePaymentsMember" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_CommercialMilestonesMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_BayerAGAndPfizerMember" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="arvn_SaleOfStockFairValueOfSharesSold" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="arvn_NumberOfContractsToBeCombined" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="arvn_NumberOfMaximumDesignatedTargets" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12390.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10170.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetailsDefault" xlink:href="arvn-20201231.xsd#Role_DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetailsDefault" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetailsDefault">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10070.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" xlink:type="locator" xlink:label="arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandTwentyMaturityMember" xlink:type="locator" xlink:label="arvn_TwoThousandTwentyMaturityMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyOneMember" xlink:type="locator" xlink:label="arvn_CorporateBondsMaturingTwoThousandTwentyOneMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyMember" xlink:type="locator" xlink:label="arvn_CorporateBondsMaturingTwoThousandTwentyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="arvn_CorporateBondsMaturingTwoThousandTwentyMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="arvn_CorporateBondsMaturingTwoThousandTwentyOneMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="arvn_TwoThousandTwentyMaturityMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10650.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10780.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails" xlink:href="arvn-20201231.xsd#Role_DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="arvn_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arvn_LaboratoryEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LesseeOperatingLeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="arvn_LesseeOperatingLeaseExpirationMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PercentageOfIncrementalBorrowingForLleasePayments" xlink:type="locator" xlink:label="arvn_PercentageOfIncrementalBorrowingForLleasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arvn_PercentageOfIncrementalBorrowingForLleasePayments" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arvn_LesseeOperatingLeaseExpirationMonthAndYear" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureLongTermDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" xlink:type="locator" xlink:label="arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentInterestPaymentsTerm" xlink:type="locator" xlink:label="arvn_DebtInstrumentInterestPaymentsTerm" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PercentageOfMaximumFundingOnProjectCosts" xlink:type="locator" xlink:label="arvn_PercentageOfMaximumFundingOnProjectCosts" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PercentageOfLiquidatedDamages" xlink:type="locator" xlink:label="arvn_PercentageOfLiquidatedDamages" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentMaturityMonthAndYear" xlink:type="locator" xlink:label="arvn_DebtInstrumentMaturityMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds" xlink:type="locator" xlink:label="arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentMaximumBorrowingCapacity" xlink:type="locator" xlink:label="arvn_DebtInstrumentMaximumBorrowingCapacity" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:type="locator" xlink:label="arvn_TwoThousandAndEighteenAssistanceAgreementMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CT" xlink:type="locator" xlink:label="stpr_CT" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:type="locator" xlink:label="arvn_TwoThousandAndFourteenAssistanceAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember" xlink:type="locator" xlink:label="us-gaap_SecuredDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ConnecticutInnovationsIncorporatedMember" xlink:type="locator" xlink:label="arvn_ConnecticutInnovationsIncorporatedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LoanAgreementMember" xlink:type="locator" xlink:label="arvn_LoanAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_LoanAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_ConnecticutInnovationsIncorporatedMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="arvn_TwoThousandAndFourteenAssistanceAgreementMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementGeographicalAxis" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CT" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="arvn_TwoThousandAndEighteenAssistanceAgreementMember" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_DebtInstrumentMaximumBorrowingCapacity" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_DebtInstrumentMaturityMonthAndYear" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_PercentageOfLiquidatedDamages" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_PercentageOfMaximumFundingOnProjectCosts" order="12100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_DebtInstrumentInterestPaymentsTerm" order="12220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" order="12260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="12340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="12530.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureMembersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" xlink:type="locator" xlink:label="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" xlink:type="locator" xlink:label="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="arvn_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommonUnitsMember" xlink:type="locator" xlink:label="arvn_CommonUnitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="arvn_CommonUnitsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesARedeemableConvertiblePreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10750.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails">
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_MaximumPercentageOfCompensationReceivableByEmployee" xlink:type="locator" xlink:label="arvn_MaximumPercentageOfCompensationReceivableByEmployee" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock" xlink:type="locator" xlink:label="arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:type="locator" xlink:label="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PriorToStockPurchaseAgreementPremium" xlink:type="locator" xlink:label="arvn_PriorToStockPurchaseAgreementPremium" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" xlink:type="locator" xlink:label="arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:type="locator" xlink:label="us-gaap_PaymentsForUnderwritingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ConsultantsMember" xlink:type="locator" xlink:label="arvn_ConsultantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="locator" xlink:label="arvn_TwoThousandEighteenStockIncentivePlanMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockIncentivePlanMember" xlink:type="locator" xlink:label="arvn_StockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_BayerAGMember" xlink:type="locator" xlink:label="arvn_BayerAGMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PiperSandlerMember" xlink:type="locator" xlink:label="arvn_PiperSandlerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="arvn_AtTheMarketOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arvn_AtTheMarketOfferingMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_CounterpartyNameAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_PiperSandlerMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_BayerAGMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arvn_StockIncentivePlanMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arvn_TwoThousandEighteenStockIncentivePlanMember" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="arvn_ConsultantsMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsForUnderwritingExpense" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="12310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_PriorToStockPurchaseAgreementPremium" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="12400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" order="12580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="12760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock" order="12850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_MaximumPercentageOfCompensationReceivableByEmployee" order="12870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="12890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="12960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="13000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="13100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" order="13220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="13260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="13300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="13410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="13450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="13540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="13600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="13790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="13900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="13960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="14120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber" order="14180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" order="14240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="10700.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureEquitySummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="locator" xlink:label="arvn_TwoThousandEighteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arvn_TwoThousandEighteenStockIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11890.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails">
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EmployeesMember" xlink:type="locator" xlink:label="arvn_EmployeesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="locator" xlink:label="arvn_TwoThousandEighteenStockIncentivePlanMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EmployeesDirectorsAndConsultantsMember" xlink:type="locator" xlink:label="arvn_EmployeesDirectorsAndConsultantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockIncentivePlanMember" xlink:type="locator" xlink:label="arvn_StockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arvn_StockIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="arvn_EmployeesDirectorsAndConsultantsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arvn_TwoThousandEighteenStockIncentivePlanMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="arvn_EmployeesMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" order="11830.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" xlink:type="locator" xlink:label="arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:type="locator" xlink:label="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EquityMethodInvestmentContribution" xlink:type="locator" xlink:label="arvn_EquityMethodInvestmentContribution" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember" xlink:type="locator" xlink:label="arvn_OerthBioLimitedLiabilityCorporationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_BayerCropScienceLPMember" xlink:type="locator" xlink:label="arvn_BayerCropScienceLPMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_BayerCropScienceLPMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arvn_OerthBioLimitedLiabilityCorporationMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_2" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="arvn_EquityMethodInvestmentContribution" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ProfitLoss" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="11440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="arvn-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReceivable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="arvn_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:type="locator" xlink:label="arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="arvn_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="arvn_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="arvn_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="arvn_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="arvn_OperatingLossCarryforwardsExpirationYear" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="arvn_TaxCreditCarryforwardExpirationYear" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationYearUnderExamination" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxReceivable" order="11110.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="arvn-20201231.xsd#arvn_MonthlyResearchPayments" xlink:type="locator" xlink:label="arvn_MonthlyResearchPayments" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PaymentForConsultingService" xlink:type="locator" xlink:label="arvn_PaymentForConsultingService" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_QuarterlyResearchPayments" xlink:type="locator" xlink:label="arvn_QuarterlyResearchPayments" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ConsultingAgreementMember" xlink:type="locator" xlink:label="arvn_ConsultingAgreementMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CorporateSponsoredResearchAgreementMember" xlink:type="locator" xlink:label="arvn_CorporateSponsoredResearchAgreementMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AmendedCorporateSponsoredResearchAgreementMember" xlink:type="locator" xlink:label="arvn_AmendedCorporateSponsoredResearchAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_YaleUniversityMember" xlink:type="locator" xlink:label="arvn_YaleUniversityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="arvn_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="arvn_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arvn_CommitmentsAndContingenciesLineItems" xlink:to="arvn_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arvn_YaleUniversityMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arvn_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="arvn_AmendedCorporateSponsoredResearchAgreementMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="arvn_CorporateSponsoredResearchAgreementMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="arvn_ConsultingAgreementMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_CommitmentsAndContingenciesLineItems" xlink:to="arvn_QuarterlyResearchPayments" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_CommitmentsAndContingenciesLineItems" xlink:to="arvn_PaymentForConsultingService" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arvn_CommitmentsAndContingenciesLineItems" xlink:to="arvn_MonthlyResearchPayments" order="10610.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>31
<FILENAME>arvn-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-01T20:51:00.6713815+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 7fde9e0b67904d4bbc438174819e5cd5 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:type="locator" xlink:label="arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
    <link:label xml:lang="en-US" xlink:label="arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:to="arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Account receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, equipment and leasehold improvements, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right of use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term debt, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 48,455,741 and 38,461,353 shares issued and outstanding as of December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Par Or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expenses)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of preferred unit warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from equity method investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in redemption value of redeemable preferred units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Accretion To Redemption Value Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive gain (loss):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised" xlink:type="locator" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised" />
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issued during period shares redeemable convertible preferred warrants exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised" xlink:to="arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised" xlink:type="locator" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised" />
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issued during period value redeemable convertible preferred warrants exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised" xlink:to="arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:type="locator" xlink:label="arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" />
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period share new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:to="arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" xlink:type="locator" xlink:label="arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" />
    <link:label xml:lang="en-US" xlink:label="arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in redemption value of redeemable convertible preferred units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" xlink:to="arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" xlink:type="locator" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" />
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issued during period shares conversion of redeemable convertible preferred units to redeemable convertible preferred shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" xlink:to="arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" xlink:type="locator" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" />
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issued during period value conversion of redeemable convertible preferred units to redeemable convertible preferred shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" xlink:to="arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" xlink:type="locator" xlink:label="arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" />
    <link:label xml:lang="en-US" xlink:label="arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value conversion of common and incentive units to common and restricted stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" xlink:to="arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesARedeemableConvertiblePreferredUnitsMember" xlink:type="locator" xlink:label="arvn_SeriesARedeemableConvertiblePreferredUnitsMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesARedeemableConvertiblePreferredUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_SeriesARedeemableConvertiblePreferredUnitsMember" xlink:to="arvn_SeriesARedeemableConvertiblePreferredUnitsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesARedeemableConvertiblePreferredUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Units</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesARedeemableConvertiblePreferredUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Units [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" xlink:type="locator" xlink:label="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" xlink:to="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Units</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Units [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" xlink:type="locator" xlink:label="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C redeemable convertible preferred units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" xlink:to="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Redeemable Convertible Preferred Units</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Redeemable Convertible Preferred Units [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesABAndCConvertiblePreferredSharesMember" xlink:type="locator" xlink:label="arvn_SeriesABAndCConvertiblePreferredSharesMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesABAndCConvertiblePreferredSharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A,B and C convertible preferred shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_SeriesABAndCConvertiblePreferredSharesMember" xlink:to="arvn_SeriesABAndCConvertiblePreferredSharesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesABAndCConvertiblePreferredSharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A,B and C Convertible Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesABAndCConvertiblePreferredSharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A B And C Convertible Preferred Shares [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommonUnitsMember" xlink:type="locator" xlink:label="arvn_CommonUnitsMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_CommonUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_CommonUnitsMember" xlink:to="arvn_CommonUnitsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_CommonUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Units</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CommonUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Units [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncentiveUnitsMember" xlink:type="locator" xlink:label="arvn_IncentiveUnitsMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_IncentiveUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_IncentiveUnitsMember" xlink:to="arvn_IncentiveUnitsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_IncentiveUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive Units</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_IncentiveUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Units [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MemberUnitsMember" xlink:type="locator" xlink:label="us-gaap_MemberUnitsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MemberUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Member Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MemberUnitsMember" xlink:to="us-gaap_MemberUnitsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MemberUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Member Units [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="arvn_AtTheMarketOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_AtTheMarketOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_AtTheMarketOfferingMember" xlink:to="arvn_AtTheMarketOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_AtTheMarketOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_AtTheMarketOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Units/Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Units/Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive unit-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Share Based Compensation Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive unit-based compensation Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Series A redeemable convertible preferred warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issued During Period Value Redeemable Convertible Preferred Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Series A redeemable convertible preferred warrant, Units</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issued During Period Shares Redeemable Convertible Preferred Warrants Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series C redeemable convertible preferred units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series C redeemable convertible preferred units, Units</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Share New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in redemption value of redeemable convertible preferred units</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Redemption Value Of Redeemable Convertible Preferred Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred units to redeemable convertible preferred shares</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issued During Period Value Conversion Of Redeemable Convertible Preferred Units To Redeemable Convertible Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred units to redeemable convertible preferred shares, Units/Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issued During Period Shares Conversion Of Redeemable Convertible Preferred Units To Redeemable Convertible Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of common and incentive units to common and restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Common And Incentive Units To Common And Restricted Stock</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" xlink:type="locator" xlink:label="arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" />
    <link:label xml:lang="en-US" xlink:label="arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares conversion of common and incentive units to common and restricted stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" xlink:to="arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of common and incentive units to common and restricted stock, Units/Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Conversion Of Common And Incentive Units To Common And Restricted Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of underwriters&apos; discounts and issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of underwriters&apos; discounts and issuance costs, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock vesting, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Units/Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Units/Shares</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" xlink:type="locator" xlink:label="arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock, underwriters&apos; discounts and issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" xlink:to="arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, underwriters&apos; discounts and issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Underwriters Discounts And Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OperatingLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="arvn_OperatingLeaseRightOfUseAssetAmortization" />
    <link:label xml:lang="en-US" xlink:label="arvn_OperatingLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of amortization expense attributable to right-of-use asset from operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_OperatingLeaseRightOfUseAssetAmortization" xlink:to="arvn_OperatingLeaseRightOfUseAssetAmortization_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="arvn_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="arvn_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="arvn_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:type="locator" xlink:label="arvn_ProceedsFromMaturitiesOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="arvn_ProceedsFromMaturitiesOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from maturities of marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:to="arvn_ProceedsFromMaturitiesOfMarketableSecurities_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromSaleOfMarketableSecurities" xlink:type="locator" xlink:label="arvn_ProceedsFromSaleOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="arvn_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from sale of marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ProceedsFromSaleOfMarketableSecurities" xlink:to="arvn_ProceedsFromSaleOfMarketableSecurities_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" xlink:type="locator" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock in a public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" xlink:to="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockGross" />
    <link:label xml:lang="en-US" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock in an at-the-market offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ProceedsFromIssuanceOfCommonStockGross" xlink:to="arvn_ProceedsFromIssuanceOfCommonStockGross_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Discount Premium</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of preferred unit warrant liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net accretion of bond discounts/premiums</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on sale of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Realized Gain Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_OperatingLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right to use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_OperatingLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash share/unit-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Account receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ProceedsFromMaturitiesOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ProceedsFromMaturitiesOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Maturities Of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property, equipment and leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayments of long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Long Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock In A Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of common stock offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of common stock in at-the-market offering</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Series C redeemable convertible preferred units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Warrant Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property, equipment and leasehold improvements unpaid at period end</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in redemption value of preferred units</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LicenseAgreementsTextBlock" xlink:type="locator" xlink:label="arvn_LicenseAgreementsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="arvn_LicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_LicenseAgreementsTextBlock" xlink:to="arvn_LicenseAgreementsTextBlock_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LicenseAgreementsAbstract" xlink:type="locator" xlink:label="arvn_LicenseAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="arvn_LicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_LicenseAgreementsAbstract" xlink:to="arvn_LicenseAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_LicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_LicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_LicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements [Text Block]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research collaboration and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:to="arvn_ResearchCollaborationAndLicenseAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration And License Agreements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration and License Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Equipment and Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right to Use Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Members&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments And Joint Ventures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in Equity Method Investee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Equipment, and Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition and Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Method Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments Policy</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PreferredUnitWarrantsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="arvn_PreferredUnitWarrantsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="arvn_PreferredUnitWarrantsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred unit warrants policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_PreferredUnitWarrantsPolicyPolicyTextBlock" xlink:to="arvn_PreferredUnitWarrantsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_PreferredUnitWarrantsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Unit Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_PreferredUnitWarrantsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Unit Warrants Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Contract Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset And Liability Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Price Allocated to Performance Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company&apos;s Available for Sale Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property, Equipment and Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental cash flow information related to leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Maturities Of Long Term Debt Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Grant Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Deferred Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Diluted Loss per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Share Equivalents Excluded from the Calculations of Diluted Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NumberOfWhollyOwnedSubsidiaries" xlink:type="locator" xlink:label="arvn_NumberOfWhollyOwnedSubsidiaries" />
    <link:label xml:lang="en-US" xlink:label="arvn_NumberOfWhollyOwnedSubsidiaries_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of wholly owned subsidiaries.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_NumberOfWhollyOwnedSubsidiaries" xlink:to="arvn_NumberOfWhollyOwnedSubsidiaries_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NatureOfBusinessLineItems" xlink:type="locator" xlink:label="arvn_NatureOfBusinessLineItems" />
    <link:label xml:lang="en-US" xlink:label="arvn_NatureOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="arvn_NatureOfBusinessLineItems_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NatureOfBusinessTable" xlink:type="locator" xlink:label="arvn_NatureOfBusinessTable" />
    <link:label xml:lang="en-US" xlink:label="arvn_NatureOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_NatureOfBusinessTable" xlink:to="arvn_NatureOfBusinessTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_NatureOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_NatureOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_NatureOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_NatureOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_NumberOfWhollyOwnedSubsidiaries_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of wholly owned subsidiaries</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_NumberOfWhollyOwnedSubsidiaries_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Wholly Owned Subsidiaries</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price, issued and sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from sale of shares in Initial public offering before fees and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fees and expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued for conversion of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock outstanding</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="arvn_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="arvn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="arvn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="arvn_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="arvn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant of accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="arvn_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Revenue Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Equity Method Investment Equity Method Investee Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investee Name [Domain]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaboratorOneMember" xlink:type="locator" xlink:label="arvn_CollaboratorOneMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_CollaboratorOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborator one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_CollaboratorOneMember" xlink:to="arvn_CollaboratorOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_CollaboratorOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborator One</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CollaboratorOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborator One [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaboratorThreeMember" xlink:type="locator" xlink:label="arvn_CollaboratorThreeMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_CollaboratorThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborator three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_CollaboratorThreeMember" xlink:to="arvn_CollaboratorThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_CollaboratorThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborator Three</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CollaboratorThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborator Three [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaboratorTwoMember" xlink:type="locator" xlink:label="arvn_CollaboratorTwoMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_CollaboratorTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborator two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_CollaboratorTwoMember" xlink:to="arvn_CollaboratorTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_CollaboratorTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborator Two</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CollaboratorTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborator Two [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember" xlink:type="locator" xlink:label="arvn_OerthBioLimitedLiabilityCorporationMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_OerthBioLimitedLiabilityCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Oerth Bio LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_OerthBioLimitedLiabilityCorporationMember" xlink:to="arvn_OerthBioLimitedLiabilityCorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_OerthBioLimitedLiabilityCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Oerth</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_OerthBioLimitedLiabilityCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Oerth Bio Limited Liability Corporation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="arvn_LaboratoryEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_LaboratoryEquipmentMember" xlink:to="arvn_LaboratoryEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal deposit insurance corporation premium expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Deposit Insurance Corporation Premium Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Percentage1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets To Be Disposed Of</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive units vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity method investment ownership percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NonRefundableUpfrontPayment" xlink:type="locator" xlink:label="arvn_NonRefundableUpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="arvn_NonRefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_NonRefundableUpfrontPayment" xlink:to="arvn_NonRefundableUpfrontPayment_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AnnualLicenseFeePayment" xlink:type="locator" xlink:label="arvn_AnnualLicenseFeePayment" />
    <link:label xml:lang="en-US" xlink:label="arvn_AnnualLicenseFeePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license fee payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_AnnualLicenseFeePayment" xlink:to="arvn_AnnualLicenseFeePayment_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_YaleUniversityMember" xlink:type="locator" xlink:label="arvn_YaleUniversityMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_YaleUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Yale University.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_YaleUniversityMember" xlink:to="arvn_YaleUniversityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_YaleUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Yale University</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_YaleUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Yale University [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_NonRefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_NonRefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_AnnualLicenseFeePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual payment for license</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_AnnualLicenseFeePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Fee Payment</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaborativeArrangementSublicensePayment" xlink:type="locator" xlink:label="arvn_CollaborativeArrangementSublicensePayment" />
    <link:label xml:lang="en-US" xlink:label="arvn_CollaborativeArrangementSublicensePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement sublicense payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_CollaborativeArrangementSublicensePayment" xlink:to="arvn_CollaborativeArrangementSublicensePayment_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ReimbursementOfPatentRelatedCost" xlink:type="locator" xlink:label="arvn_ReimbursementOfPatentRelatedCost" />
    <link:label xml:lang="en-US" xlink:label="arvn_ReimbursementOfPatentRelatedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement of patent related cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ReimbursementOfPatentRelatedCost" xlink:to="arvn_ReimbursementOfPatentRelatedCost_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaborativeArrangementPayment" xlink:type="locator" xlink:label="arvn_CollaborativeArrangementPayment" />
    <link:label xml:lang="en-US" xlink:label="arvn_CollaborativeArrangementPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_CollaborativeArrangementPayment" xlink:to="arvn_CollaborativeArrangementPayment_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Royalties</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CollaborativeArrangementSublicensePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for sublicense agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CollaborativeArrangementSublicensePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Sublicense Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CollaborativeArrangementPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CollaborativeArrangementPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ReimbursementOfPatentRelatedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursed patent costs</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ReimbursementOfPatentRelatedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement Of Patent Related Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:type="locator" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research collaboration and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="arvn_ResearchCollaborationAndLicenseAgreementsLineItems_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:type="locator" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsTable" />
    <link:label xml:lang="en-US" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research collaboration and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="arvn_ResearchCollaborationAndLicenseAgreementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration And License Agreements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration And License Agreements [Table]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_BayerAGMember" xlink:type="locator" xlink:label="arvn_BayerAGMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_BayerAGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bayer AG.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_BayerAGMember" xlink:to="arvn_BayerAGMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_BayerAGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bayer A G</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_BayerAGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bayer A G [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ResearchFundingPaymentsMember" xlink:type="locator" xlink:label="arvn_ResearchFundingPaymentsMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_ResearchFundingPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research funding payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ResearchFundingPaymentsMember" xlink:to="arvn_ResearchFundingPaymentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_ResearchFundingPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Funding Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ResearchFundingPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Funding Payments [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DevelopmentMilestonePaymentsMember" xlink:type="locator" xlink:label="arvn_DevelopmentMilestonePaymentsMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_DevelopmentMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_DevelopmentMilestonePaymentsMember" xlink:to="arvn_DevelopmentMilestonePaymentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_DevelopmentMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_DevelopmentMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone Payments [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SalesBasedMilestonePaymentsMember" xlink:type="locator" xlink:label="arvn_SalesBasedMilestonePaymentsMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_SalesBasedMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales-based milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_SalesBasedMilestonePaymentsMember" xlink:to="arvn_SalesBasedMilestonePaymentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_SalesBasedMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales-based Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_SalesBasedMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Based Milestone Payments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Forecast [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockPurchaseAgreementMember" xlink:type="locator" xlink:label="arvn_StockPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_StockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_StockPurchaseAgreementMember" xlink:to="arvn_StockPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_StockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_StockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_BayerAGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Bayer Collaboration Agreement</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PfizerIncorporationMember" xlink:type="locator" xlink:label="arvn_PfizerIncorporationMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_PfizerIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer, Incorporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_PfizerIncorporationMember" xlink:to="arvn_PfizerIncorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_PfizerIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_PfizerIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer Incorporation [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OptionExercisedToLicenseAgreementsMember" xlink:type="locator" xlink:label="arvn_OptionExercisedToLicenseAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_OptionExercisedToLicenseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercised to license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_OptionExercisedToLicenseAgreementsMember" xlink:to="arvn_OptionExercisedToLicenseAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_OptionExercisedToLicenseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_OptionExercisedToLicenseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercised To License Agreements [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OptionPaymentsToLicenseAgreementMember" xlink:type="locator" xlink:label="arvn_OptionPaymentsToLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_OptionPaymentsToLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option payments to license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_OptionPaymentsToLicenseAgreementMember" xlink:to="arvn_OptionPaymentsToLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_OptionPaymentsToLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_OptionPaymentsToLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Payments To License Agreement [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SubstitutionTargetPaymentsMember" xlink:type="locator" xlink:label="arvn_SubstitutionTargetPaymentsMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_SubstitutionTargetPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Substitution target payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_SubstitutionTargetPaymentsMember" xlink:to="arvn_SubstitutionTargetPaymentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_SubstitutionTargetPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Substitution Target Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_SubstitutionTargetPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Substitution Target Payments [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_RegulatoryMilestonePaymentsMember" xlink:type="locator" xlink:label="arvn_RegulatoryMilestonePaymentsMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_RegulatoryMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_RegulatoryMilestonePaymentsMember" xlink:to="arvn_RegulatoryMilestonePaymentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_RegulatoryMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_RegulatoryMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Payments [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommercialMilestonesMember" xlink:type="locator" xlink:label="arvn_CommercialMilestonesMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_CommercialMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_CommercialMilestonesMember" xlink:to="arvn_CommercialMilestonesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_CommercialMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CommercialMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestones [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:type="locator" xlink:label="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Genentech, Incorporation. and F. Hoffman-La Roche Limited.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:to="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genentech, Inc. and F. Hoffman-La Roche Ltd.</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Genentech Incorporation And F Hoffman La Roche Limited [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_BayerAGAndPfizerMember" xlink:type="locator" xlink:label="arvn_BayerAGAndPfizerMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_BayerAGAndPfizerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bayer AG and Pfizer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_BayerAGAndPfizerMember" xlink:to="arvn_BayerAGAndPfizerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_BayerAGAndPfizerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bayer and Pfizer Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_BayerAGAndPfizerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bayer A G And Pfizer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration And License Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration And License Agreements [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract revenue receivable if milestones achieved or options for all targets exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SaleOfStockFairValueOfSharesSold" xlink:type="locator" xlink:label="arvn_SaleOfStockFairValueOfSharesSold" />
    <link:label xml:lang="en-US" xlink:label="arvn_SaleOfStockFairValueOfSharesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock, fair value of shares sold.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_SaleOfStockFairValueOfSharesSold" xlink:to="arvn_SaleOfStockFairValueOfSharesSold_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NumberOfContractsToBeCombined" xlink:type="locator" xlink:label="arvn_NumberOfContractsToBeCombined" />
    <link:label xml:lang="en-US" xlink:label="arvn_NumberOfContractsToBeCombined_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of contracts to be combined.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_NumberOfContractsToBeCombined" xlink:to="arvn_NumberOfContractsToBeCombined_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_SaleOfStockFairValueOfSharesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of the shares sold</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_SaleOfStockFairValueOfSharesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Fair Value Of Shares Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional consideration received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Consideration Received Per Transaction</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_NumberOfContractsToBeCombined_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of contracts to be combined</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_NumberOfContractsToBeCombined_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Contracts To Be Combined</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront non-refundable payment and certain additional payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Collaborators</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NumberOfMaximumDesignatedTargets" xlink:type="locator" xlink:label="arvn_NumberOfMaximumDesignatedTargets" />
    <link:label xml:lang="en-US" xlink:label="arvn_NumberOfMaximumDesignatedTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of maximum designated targets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_NumberOfMaximumDesignatedTargets" xlink:to="arvn_NumberOfMaximumDesignatedTargets_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_NumberOfMaximumDesignatedTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of designated targets</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_NumberOfMaximumDesignatedTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Maximum Designated Targets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amounts included in deferred revenue in previous periods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Changes in deferred revenue due to additions to deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized on research collaboration and license agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unsatisfied performance obligations expected to be recognized as revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, remaining performance obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" xlink:type="locator" xlink:label="arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" />
    <link:label xml:lang="en-US" xlink:label="arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale debt securities effective maturity period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" xlink:to="arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyMember" xlink:type="locator" xlink:label="arvn_CorporateBondsMaturingTwoThousandTwentyMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_CorporateBondsMaturingTwoThousandTwentyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate bonds maturing 2020.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_CorporateBondsMaturingTwoThousandTwentyMember" xlink:to="arvn_CorporateBondsMaturingTwoThousandTwentyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_CorporateBondsMaturingTwoThousandTwentyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds Maturing 2020</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CorporateBondsMaturingTwoThousandTwentyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bonds Maturing Two Thousand Twenty [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyOneMember" xlink:type="locator" xlink:label="arvn_CorporateBondsMaturingTwoThousandTwentyOneMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_CorporateBondsMaturingTwoThousandTwentyOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate bonds maturing two thousand twenty one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_CorporateBondsMaturingTwoThousandTwentyOneMember" xlink:to="arvn_CorporateBondsMaturingTwoThousandTwentyOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_CorporateBondsMaturingTwoThousandTwentyOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds Maturing 2021</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CorporateBondsMaturingTwoThousandTwentyOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bonds Maturing Two Thousand Twenty One [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandTwentyMaturityMember" xlink:type="locator" xlink:label="arvn_TwoThousandTwentyMaturityMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_TwoThousandTwentyMaturityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 maturity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_TwoThousandTwentyMaturityMember" xlink:to="arvn_TwoThousandTwentyMaturityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_TwoThousandTwentyMaturityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds Maturing 2020</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TwoThousandTwentyMaturityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Maturity [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective Maturity</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Effective Maturity Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurements of assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, equipment and leasehold improvements, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, equipment and leasehold improvements, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PercentageOfIncrementalBorrowingForLleasePayments" xlink:type="locator" xlink:label="arvn_PercentageOfIncrementalBorrowingForLleasePayments" />
    <link:label xml:lang="en-US" xlink:label="arvn_PercentageOfIncrementalBorrowingForLleasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of incremental borrowing for lease payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_PercentageOfIncrementalBorrowingForLleasePayments" xlink:to="arvn_PercentageOfIncrementalBorrowingForLleasePayments_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_PercentageOfIncrementalBorrowingForLleasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of incremental borrowing for lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_PercentageOfIncrementalBorrowingForLleasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Incremental Borrowing For Llease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to terminate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Terminate</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LesseeOperatingLeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="arvn_LesseeOperatingLeaseExpirationMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="arvn_LesseeOperatingLeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease expiration month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_LesseeOperatingLeaseExpirationMonthAndYear" xlink:to="arvn_LesseeOperatingLeaseExpirationMonthAndYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, weighted average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_LesseeOperatingLeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_LesseeOperatingLeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Expiration Month And Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:type="locator" xlink:label="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental non-cash information related to leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:to="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental non-cash information:</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Non Cash Information Related To Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for new lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total rent expense under operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Net</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="arvn_AccruedResearchAndDevelopmentExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="arvn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expense current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="arvn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds" xlink:type="locator" xlink:label="arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds" />
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument interest only payment period upon first draw of funds.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds" xlink:to="arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentMaximumBorrowingCapacity" xlink:type="locator" xlink:label="arvn_DebtInstrumentMaximumBorrowingCapacity" />
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument maximum borrowing capacity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_DebtInstrumentMaximumBorrowingCapacity" xlink:to="arvn_DebtInstrumentMaximumBorrowingCapacity_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LoanAgreementMember" xlink:type="locator" xlink:label="arvn_LoanAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_LoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_LoanAgreementMember" xlink:to="arvn_LoanAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_LoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_LoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan Agreement [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ConnecticutInnovationsIncorporatedMember" xlink:type="locator" xlink:label="arvn_ConnecticutInnovationsIncorporatedMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_ConnecticutInnovationsIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Connecticut innovations incorporated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ConnecticutInnovationsIncorporatedMember" xlink:to="arvn_ConnecticutInnovationsIncorporatedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_ConnecticutInnovationsIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Connecticut Innovations, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ConnecticutInnovationsIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Connecticut Innovations Incorporated [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember" xlink:type="locator" xlink:label="us-gaap_SecuredDebtMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecuredDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secured Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecuredDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Secured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:type="locator" xlink:label="arvn_TwoThousandAndFourteenAssistanceAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_TwoThousandAndFourteenAssistanceAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and fourteen assistance agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:to="arvn_TwoThousandAndFourteenAssistanceAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_TwoThousandAndFourteenAssistanceAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Assistance Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TwoThousandAndFourteenAssistanceAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Fourteen Assistance Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CT" xlink:type="locator" xlink:label="stpr_CT" />
    <link:label xml:lang="en-US" xlink:label="stpr_CT_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State of Connecticut</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CT" xlink:to="stpr_CT_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CT_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CONNECTICUT</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:type="locator" xlink:label="arvn_TwoThousandAndEighteenAssistanceAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_TwoThousandAndEighteenAssistanceAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and eighteen assistance agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:to="arvn_TwoThousandAndEighteenAssistanceAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_TwoThousandAndEighteenAssistanceAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Assistance Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TwoThousandAndEighteenAssistanceAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Assistance Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, maximum borrowing capacity</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, frequency of periodic payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Frequency Of Periodic Payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest rate per annum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest only payment period upon first draw of funds</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Only Payment Period Upon First Draw Of Funds</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, date of first required payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Date Of First Required Payment1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, outstanding amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unamortized debt discount on Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Financing Costs</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentMaturityMonthAndYear" xlink:type="locator" xlink:label="arvn_DebtInstrumentMaturityMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentMaturityMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument maturity month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_DebtInstrumentMaturityMonthAndYear" xlink:to="arvn_DebtInstrumentMaturityMonthAndYear_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PercentageOfLiquidatedDamages" xlink:type="locator" xlink:label="arvn_PercentageOfLiquidatedDamages" />
    <link:label xml:lang="en-US" xlink:label="arvn_PercentageOfLiquidatedDamages_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of liquidated damages.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_PercentageOfLiquidatedDamages" xlink:to="arvn_PercentageOfLiquidatedDamages_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentMaturityMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentMaturityMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Month And Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument face amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_PercentageOfLiquidatedDamages_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of liquidated damages</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_PercentageOfLiquidatedDamages_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Liquidated Damages</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentInterestPaymentsTerm" xlink:type="locator" xlink:label="arvn_DebtInstrumentInterestPaymentsTerm" />
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentInterestPaymentsTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument interest payments term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_DebtInstrumentInterestPaymentsTerm" xlink:to="arvn_DebtInstrumentInterestPaymentsTerm_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" xlink:type="locator" xlink:label="arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" />
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument amortization period after interest payments period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" xlink:to="arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PercentageOfMaximumFundingOnProjectCosts" xlink:type="locator" xlink:label="arvn_PercentageOfMaximumFundingOnProjectCosts" />
    <link:label xml:lang="en-US" xlink:label="arvn_PercentageOfMaximumFundingOnProjectCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of maximum funding on project costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_PercentageOfMaximumFundingOnProjectCosts" xlink:to="arvn_PercentageOfMaximumFundingOnProjectCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_PercentageOfMaximumFundingOnProjectCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of maximum funding on total project costs</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_PercentageOfMaximumFundingOnProjectCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Maximum Funding On Project Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentInterestPaymentsTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument interest payments term</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentInterestPaymentsTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Payments Term</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument amortization period after interest payments period</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Amortization Period After Interest Payments Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forgiveness of funding on achieving certain employment conditions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Decrease Forgiveness</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt By Maturity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beyond 5 years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal After Year Five</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense, Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="arvn_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="arvn_SeriesARedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock issued, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock issued, value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued, price per share/unit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_AtTheMarketOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">At The Market Offering</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PiperSandlerMember" xlink:type="locator" xlink:label="arvn_PiperSandlerMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_PiperSandlerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Piper Sandler.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_PiperSandlerMember" xlink:to="arvn_PiperSandlerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_PiperSandlerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Piper Sandler</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_PiperSandlerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Piper Sandler [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 ESPP</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockIncentivePlanMember" xlink:type="locator" xlink:label="arvn_StockIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_StockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_StockIncentivePlanMember" xlink:to="arvn_StockIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_StockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_StockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="locator" xlink:label="arvn_TwoThousandEighteenStockIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen stock incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:to="arvn_TwoThousandEighteenStockIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ConsultantsMember" xlink:type="locator" xlink:label="arvn_ConsultantsMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_ConsultantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consultants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ConsultantsMember" xlink:to="arvn_ConsultantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_ConsultantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consultants</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ConsultantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consultants [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Shares issued and sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:type="locator" xlink:label="us-gaap_PaymentsForUnderwritingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fees and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForUnderwritingExpense" xlink:to="us-gaap_PaymentsForUnderwritingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Underwriting Expense</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" xlink:type="locator" xlink:label="arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" />
    <link:label xml:lang="en-US" xlink:label="arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate offering price of common stock under equity distribution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" xlink:to="arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Offering Price Of Common Stock Under Equity Distribution Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from sale of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays" />
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement average common stock preceding days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays" xlink:to="arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PriorToStockPurchaseAgreementPremium" xlink:type="locator" xlink:label="arvn_PriorToStockPurchaseAgreementPremium" />
    <link:label xml:lang="en-US" xlink:label="arvn_PriorToStockPurchaseAgreementPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prior to stock purchase agreement premium.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_PriorToStockPurchaseAgreementPremium" xlink:to="arvn_PriorToStockPurchaseAgreementPremium_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued in period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Issued For Services</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average common stock preceding days</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement Average Common Stock Preceding Days</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_PriorToStockPurchaseAgreementPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior to stock purchase agreement premium</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_PriorToStockPurchaseAgreementPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prior To Stock Purchase Agreement Premium</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:type="locator" xlink:label="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" />
    <link:label xml:lang="en-US" xlink:label="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:to="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance represented as percentage on outstanding common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares remained available for purchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock" xlink:type="locator" xlink:label="arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock" />
    <link:label xml:lang="en-US" xlink:label="arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount used as multiplying factor to grant common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock" xlink:to="arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_MaximumPercentageOfCompensationReceivableByEmployee" xlink:type="locator" xlink:label="arvn_MaximumPercentageOfCompensationReceivableByEmployee" />
    <link:label xml:lang="en-US" xlink:label="arvn_MaximumPercentageOfCompensationReceivableByEmployee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of compensation receivable by employee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_MaximumPercentageOfCompensationReceivableByEmployee" xlink:to="arvn_MaximumPercentageOfCompensationReceivableByEmployee_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount used as multiplying factor to grant common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Used As Multiplying Factor To Grant Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_MaximumPercentageOfCompensationReceivableByEmployee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of compensation receivable by employee</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_MaximumPercentageOfCompensationReceivableByEmployee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Compensation Receivable By Employee</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price under ESPP as percentage of closing price of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive units authorized for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based award, vesting period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based award, expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Expiration Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase in reserved shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase in reserved shares as percentage of outstanding common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive units authorized for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based award, non-option equity instruments granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based award, stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation expense, total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation expense not yet recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation expense not yet recognized, period of recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options, Outstanding, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options, Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options, Outstanding, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options, Exercisable, Ending Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (Years), Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (Years), Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options vested</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Total intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EmployeesDirectorsAndConsultantsMember" xlink:type="locator" xlink:label="arvn_EmployeesDirectorsAndConsultantsMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_EmployeesDirectorsAndConsultantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees, directors and consultants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_EmployeesDirectorsAndConsultantsMember" xlink:to="arvn_EmployeesDirectorsAndConsultantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_EmployeesDirectorsAndConsultantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees, Directors and Consultants</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_EmployeesDirectorsAndConsultantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employees Directors And Consultants [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EmployeesMember" xlink:type="locator" xlink:label="arvn_EmployeesMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_EmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_EmployeesMember" xlink:to="arvn_EmployeesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_EmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_EmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employees [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested Restricted Stock, Shares, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted Shares, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Restricted Shares, Granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted Shares, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested Restricted Stock, Shares, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value Per Share, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Weighted Average Grant Date Fair Value Per Share, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Weighted Average Grant Date Fair Value Per Share, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Weighted Average Grant Date Fair Value Per Share, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value Per Share, Ending Balance</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted Shares, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options exercises weighted average grant date fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" xlink:to="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, restricted shares vested and expected to vest, exercisable number.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber" xlink:to="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award restricted stock units vested and expected to vest exercisable number.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:to="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted shares vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Restricted Shares Vested And Expected To Vest Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Vested And Expected To Vest Exercisable Number</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EquityMethodInvestmentContribution" xlink:type="locator" xlink:label="arvn_EquityMethodInvestmentContribution" />
    <link:label xml:lang="en-US" xlink:label="arvn_EquityMethodInvestmentContribution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity method investment contribution.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_EquityMethodInvestmentContribution" xlink:to="arvn_EquityMethodInvestmentContribution_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:type="locator" xlink:label="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" />
    <link:label xml:lang="en-US" xlink:label="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Future grant of incentive units to service providers, percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:to="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity Method Investments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_BayerCropScienceLPMember" xlink:type="locator" xlink:label="arvn_BayerCropScienceLPMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_BayerCropScienceLPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bayer CropScience LP.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_BayerCropScienceLPMember" xlink:to="arvn_BayerCropScienceLPMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_BayerCropScienceLPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bayer LP</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_BayerCropScienceLPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bayer Crop Science L P [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Method Investment, Nonconsolidated Investee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Method Investment, Nonconsolidated Investee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Method Investment, Nonconsolidated Investee or Group of Investees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Nonconsolidated Investee Or Group Of Investees [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity Method Investments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash commitment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Aggregate Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_EquityMethodInvestmentContribution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributed to joint venture entity</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_EquityMethodInvestmentContribution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Contribution</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership interest in joint venture</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future grant of incentive units to service providers, percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Future Grant Of Incentive Units To Service Providers Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Deferred revenue</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" xlink:type="locator" xlink:label="arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity method investment, summarized financial information, operating expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" xlink:to="arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity method investment, summarized financial information, research and development expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense" xlink:to="arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Summarized Financial Information Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Summarized Financial Information Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Equity method investments</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="arvn_IncomeTaxDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="arvn_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="arvn_IncomeTaxDisclosureLineItems_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="arvn_IncomeTaxDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="arvn_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_IncomeTaxDisclosureTable" xlink:to="arvn_IncomeTaxDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Tax Credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax expense (benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal research tax credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Reconciliation of effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred income tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property, equipment and leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred income tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred income tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="arvn_TaxCreditCarryforwardExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="arvn_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_TaxCreditCarryforwardExpirationYear" xlink:to="arvn_TaxCreditCarryforwardExpirationYear_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="arvn_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="arvn_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_OperatingLossCarryforwardsExpirationYear" xlink:to="arvn_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:type="locator" xlink:label="arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" />
    <link:label xml:lang="en-US" xlink:label="arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating losses carry forward, maximum deductibility as a percentage of taxable income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:to="arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating losses carry forward, maximum deductibility percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Losses Carry Forward Maximum Deductibility Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, limitations on use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Limitations On Use</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, income tax penalties and interest accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:to="us-gaap_IncomeTaxExaminationYearUnderExamination_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Year Under Examination</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Effective income tax rate reconciliation, tax credit, research and development, percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Effective income tax rate reconciliation, tax credit, research and development, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReceivable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income taxes receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReceivable" xlink:to="us-gaap_IncomeTaxReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Receivable</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_QuarterlyResearchPayments" xlink:type="locator" xlink:label="arvn_QuarterlyResearchPayments" />
    <link:label xml:lang="en-US" xlink:label="arvn_QuarterlyResearchPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Quarterly research payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_QuarterlyResearchPayments" xlink:to="arvn_QuarterlyResearchPayments_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="arvn_CommitmentsAndContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="arvn_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_CommitmentsAndContingenciesLineItems" xlink:to="arvn_CommitmentsAndContingenciesLineItems_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="arvn_CommitmentsAndContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="arvn_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_CommitmentsAndContingenciesTable" xlink:to="arvn_CommitmentsAndContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AmendedCorporateSponsoredResearchAgreementMember" xlink:type="locator" xlink:label="arvn_AmendedCorporateSponsoredResearchAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_AmendedCorporateSponsoredResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended Corporate sponsored research agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_AmendedCorporateSponsoredResearchAgreementMember" xlink:to="arvn_AmendedCorporateSponsoredResearchAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_AmendedCorporateSponsoredResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Corporate Sponsored Research Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_AmendedCorporateSponsoredResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended Corporate Sponsored Research Agreement [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CorporateSponsoredResearchAgreementMember" xlink:type="locator" xlink:label="arvn_CorporateSponsoredResearchAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_CorporateSponsoredResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate sponsored research agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_CorporateSponsoredResearchAgreementMember" xlink:to="arvn_CorporateSponsoredResearchAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_CorporateSponsoredResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Sponsored Research Agreement (SRA)</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CorporateSponsoredResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Sponsored Research Agreement [Member]</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ConsultingAgreementMember" xlink:type="locator" xlink:label="arvn_ConsultingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arvn_ConsultingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_ConsultingAgreementMember" xlink:to="arvn_ConsultingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_ConsultingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_ConsultingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_QuarterlyResearchPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quarterly research payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_QuarterlyResearchPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Research Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total research payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party agreement, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Description Of Transaction</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PaymentForConsultingService" xlink:type="locator" xlink:label="arvn_PaymentForConsultingService" />
    <link:label xml:lang="en-US" xlink:label="arvn_PaymentForConsultingService_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for consulting service.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_PaymentForConsultingService" xlink:to="arvn_PaymentForConsultingService_lbl" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_MonthlyResearchPayments" xlink:type="locator" xlink:label="arvn_MonthlyResearchPayments" />
    <link:label xml:lang="en-US" xlink:label="arvn_MonthlyResearchPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Monthly research payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_MonthlyResearchPayments" xlink:to="arvn_MonthlyResearchPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="arvn_PaymentForConsultingService_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for consulting service</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_PaymentForConsultingService_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Consulting Service</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_MonthlyResearchPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly research payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_MonthlyResearchPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Monthly Research Payments</link:label>
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:type="locator" xlink:label="arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net income (loss) available to common stockholders basic and diluted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Change in redemption value of preferred units</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common shares &#8211; basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of common shares outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common share/unit equivalents excluded from the calculations of diluted loss per common share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>32
<FILENAME>arvn-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-01T20:51:00.6713815+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 7fde9e0b67904d4bbc438174819e5cd5 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arvinas.com/20201231/role/TemplateLink" xlink:href="arvn-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="arvn-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" xlink:type="locator" xlink:label="arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" xlink:type="locator" xlink:label="arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" xlink:type="locator" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" xlink:type="locator" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" xlink:type="locator" xlink:label="arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:type="locator" xlink:label="arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised" xlink:type="locator" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised" xlink:type="locator" xlink:label="arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="arvn_AtTheMarketOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MemberUnitsMember" xlink:type="locator" xlink:label="us-gaap_MemberUnitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncentiveUnitsMember" xlink:type="locator" xlink:label="arvn_IncentiveUnitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommonUnitsMember" xlink:type="locator" xlink:label="arvn_CommonUnitsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesABAndCConvertiblePreferredSharesMember" xlink:type="locator" xlink:label="arvn_SeriesABAndCConvertiblePreferredSharesMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" xlink:type="locator" xlink:label="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" xlink:type="locator" xlink:label="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesARedeemableConvertiblePreferredUnitsMember" xlink:type="locator" xlink:label="arvn_SeriesARedeemableConvertiblePreferredUnitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesARedeemableConvertiblePreferredUnitsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesABAndCConvertiblePreferredSharesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_CommonUnitsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_IncentiveUnitsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_MemberUnitsMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arvn_AtTheMarketOfferingMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" order="13350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares" order="13370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" order="13650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock" order="13830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="13950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="14170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="14250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="14390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="14850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="15070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="15150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="15290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="15450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="15750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="15770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="20550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="20570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" xlink:type="locator" xlink:label="arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="arvn_AtTheMarketOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arvn_AtTheMarketOfferingMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="arvn-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" xlink:type="locator" xlink:label="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromSaleOfMarketableSecurities" xlink:type="locator" xlink:label="arvn_ProceedsFromSaleOfMarketableSecurities" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:type="locator" xlink:label="arvn_ProceedsFromMaturitiesOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="arvn_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OperatingLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="arvn_OperatingLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="arvn_AtTheMarketOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arvn_AtTheMarketOfferingMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="arvn_OperatingLeaseRightOfUseAssetAmortization" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="arvn_IncreaseDecreaseInOperatingLeaseLiabilities" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="arvn_ProceedsFromMaturitiesOfMarketableSecurities" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="arvn_ProceedsFromSaleOfMarketableSecurities" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="arvn_ProceedsFromIssuanceOfCommonStockGross" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="13200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="13260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="13320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="arvn-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="arvn-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreements" xlink:href="arvn-20201231.xsd#Role_DisclosureLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreements">
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LicenseAgreementsTextBlock" xlink:type="locator" xlink:label="arvn_LicenseAgreementsTextBlock" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LicenseAgreementsAbstract" xlink:type="locator" xlink:label="arvn_LicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_LicenseAgreementsAbstract" xlink:to="arvn_LicenseAgreementsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreements" xlink:href="arvn-20201231.xsd#Role_DisclosureResearchCollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecurities" xlink:href="arvn-20201231.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecurities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovements" xlink:href="arvn-20201231.xsd#Role_DisclosurePropertyEquipmentAndLeaseholdImprovements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilities" xlink:href="arvn-20201231.xsd#Role_DisclosureRightToUseAssetsAndLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpenses" xlink:href="arvn-20201231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpenses">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebt" xlink:href="arvn-20201231.xsd#Role_DisclosureLongTermDebt" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebt">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquity" xlink:href="arvn-20201231.xsd#Role_DisclosureMembersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquity" xlink:href="arvn-20201231.xsd#Role_DisclosureEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvestee" xlink:href="arvn-20201231.xsd#Role_DisclosureInvestmentInEquityMethodInvestee" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvestee">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="arvn-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="arvn-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShare" xlink:href="arvn-20201231.xsd#Role_DisclosureNetLossPerCommonShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="arvn-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PreferredUnitWarrantsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="arvn_PreferredUnitWarrantsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="arvn_PreferredUnitWarrantsPolicyPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTables" xlink:href="arvn-20201231.xsd#Role_DisclosureResearchCollaborationAndLicenseAgreementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="arvn-20201231.xsd#Role_DisclosureMarketableSecuritiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsTables" xlink:href="arvn-20201231.xsd#Role_DisclosurePropertyEquipmentAndLeaseholdImprovementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesTables" xlink:href="arvn-20201231.xsd#Role_DisclosureRightToUseAssetsAndLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="arvn-20201231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtTables" xlink:href="arvn-20201231.xsd#Role_DisclosureLongTermDebtTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables" xlink:href="arvn-20201231.xsd#Role_DisclosureEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="arvn-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:href="arvn-20201231.xsd#Role_DisclosureNetLossPerCommonShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NumberOfWhollyOwnedSubsidiaries" xlink:type="locator" xlink:label="arvn_NumberOfWhollyOwnedSubsidiaries" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NatureOfBusinessLineItems" xlink:type="locator" xlink:label="arvn_NatureOfBusinessLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NatureOfBusinessTable" xlink:type="locator" xlink:label="arvn_NatureOfBusinessTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="arvn_NatureOfBusinessTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessTable" xlink:to="arvn_NatureOfBusinessLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="arvn_NumberOfWhollyOwnedSubsidiaries" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_NatureOfBusinessLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="arvn_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="arvn_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember" xlink:type="locator" xlink:label="arvn_OerthBioLimitedLiabilityCorporationMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaboratorTwoMember" xlink:type="locator" xlink:label="arvn_CollaboratorTwoMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaboratorThreeMember" xlink:type="locator" xlink:label="arvn_CollaboratorThreeMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaboratorOneMember" xlink:type="locator" xlink:label="arvn_CollaboratorOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="arvn_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="arvn_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arvn_CollaboratorOneMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arvn_CollaboratorThreeMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arvn_CollaboratorTwoMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arvn_OerthBioLimitedLiabilityCorporationMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arvn_LaboratoryEquipmentMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="arvn_SummaryOfSignificantAccountingPoliciesLineItems" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ReimbursementOfPatentRelatedCost" xlink:type="locator" xlink:label="arvn_ReimbursementOfPatentRelatedCost" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaborativeArrangementPayment" xlink:type="locator" xlink:label="arvn_CollaborativeArrangementPayment" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CollaborativeArrangementSublicensePayment" xlink:type="locator" xlink:label="arvn_CollaborativeArrangementSublicensePayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AnnualLicenseFeePayment" xlink:type="locator" xlink:label="arvn_AnnualLicenseFeePayment" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NonRefundableUpfrontPayment" xlink:type="locator" xlink:label="arvn_NonRefundableUpfrontPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_YaleUniversityMember" xlink:type="locator" xlink:label="arvn_YaleUniversityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LicenseAgreementsAbstract" xlink:type="locator" xlink:label="arvn_LicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_LicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_YaleUniversityMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arvn_NonRefundableUpfrontPayment" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arvn_AnnualLicenseFeePayment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arvn_CollaborativeArrangementSublicensePayment" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arvn_CollaborativeArrangementPayment" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arvn_ReimbursementOfPatentRelatedCost" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NumberOfMaximumDesignatedTargets" xlink:type="locator" xlink:label="arvn_NumberOfMaximumDesignatedTargets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NumberOfContractsToBeCombined" xlink:type="locator" xlink:label="arvn_NumberOfContractsToBeCombined" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SaleOfStockFairValueOfSharesSold" xlink:type="locator" xlink:label="arvn_SaleOfStockFairValueOfSharesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:type="locator" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_BayerAGAndPfizerMember" xlink:type="locator" xlink:label="arvn_BayerAGAndPfizerMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:type="locator" xlink:label="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommercialMilestonesMember" xlink:type="locator" xlink:label="arvn_CommercialMilestonesMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_RegulatoryMilestonePaymentsMember" xlink:type="locator" xlink:label="arvn_RegulatoryMilestonePaymentsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SubstitutionTargetPaymentsMember" xlink:type="locator" xlink:label="arvn_SubstitutionTargetPaymentsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OptionPaymentsToLicenseAgreementMember" xlink:type="locator" xlink:label="arvn_OptionPaymentsToLicenseAgreementMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OptionExercisedToLicenseAgreementsMember" xlink:type="locator" xlink:label="arvn_OptionExercisedToLicenseAgreementsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PfizerIncorporationMember" xlink:type="locator" xlink:label="arvn_PfizerIncorporationMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_BayerAGMember" xlink:type="locator" xlink:label="arvn_BayerAGMember_li0l2" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockPurchaseAgreementMember" xlink:type="locator" xlink:label="arvn_StockPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SalesBasedMilestonePaymentsMember" xlink:type="locator" xlink:label="arvn_SalesBasedMilestonePaymentsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DevelopmentMilestonePaymentsMember" xlink:type="locator" xlink:label="arvn_DevelopmentMilestonePaymentsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ResearchFundingPaymentsMember" xlink:type="locator" xlink:label="arvn_ResearchFundingPaymentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_BayerAGMember" xlink:type="locator" xlink:label="arvn_BayerAGMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:type="locator" xlink:label="arvn_ResearchCollaborationAndLicenseAgreementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="arvn_ResearchCollaborationAndLicenseAgreementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_BayerAGMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_ResearchFundingPaymentsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_DevelopmentMilestonePaymentsMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_SalesBasedMilestonePaymentsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="srt_StatementScenarioAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_StockPurchaseAgreementMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_BayerAGMember_li0l2" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_PfizerIncorporationMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_OptionExercisedToLicenseAgreementsMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_OptionPaymentsToLicenseAgreementMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_SubstitutionTargetPaymentsMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_RegulatoryMilestonePaymentsMember" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_CommercialMilestonesMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_BayerAGAndPfizerMember" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="arvn_SaleOfStockFairValueOfSharesSold" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="arvn_NumberOfContractsToBeCombined" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="arvn_NumberOfMaximumDesignatedTargets" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsSummaryOfContractLiabilitiesDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureResearchCollaborationAndLicenseAgreementsSummaryOfContractLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsSummaryOfContractLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails1" xlink:href="arvn-20201231.xsd#Role_DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails1" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails1">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" xlink:type="locator" xlink:label="arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandTwentyMaturityMember" xlink:type="locator" xlink:label="arvn_TwoThousandTwentyMaturityMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyOneMember" xlink:type="locator" xlink:label="arvn_CorporateBondsMaturingTwoThousandTwentyOneMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyMember" xlink:type="locator" xlink:label="arvn_CorporateBondsMaturingTwoThousandTwentyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="arvn_CorporateBondsMaturingTwoThousandTwentyMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="arvn_CorporateBondsMaturingTwoThousandTwentyOneMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="arvn_TwoThousandTwentyMaturityMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails" xlink:href="arvn-20201231.xsd#Role_DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="arvn_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arvn_LaboratoryEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosurePropertyEquipmentAndLeaseholdImprovementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LesseeOperatingLeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="arvn_LesseeOperatingLeaseExpirationMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PercentageOfIncrementalBorrowingForLleasePayments" xlink:type="locator" xlink:label="arvn_PercentageOfIncrementalBorrowingForLleasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arvn_PercentageOfIncrementalBorrowingForLleasePayments" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arvn_LesseeOperatingLeaseExpirationMonthAndYear" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesComponentsOfLeaseExpenseDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureRightToUseAssetsAndLiabilitiesComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesComponentsOfLeaseExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureRightToUseAssetsAndLiabilitiesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:type="locator" xlink:label="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:type="locator" xlink:label="arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="arvn_AccruedResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="arvn_AccruedResearchAndDevelopmentExpenseCurrent" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureLongTermDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" xlink:type="locator" xlink:label="arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentInterestPaymentsTerm" xlink:type="locator" xlink:label="arvn_DebtInstrumentInterestPaymentsTerm" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PercentageOfMaximumFundingOnProjectCosts" xlink:type="locator" xlink:label="arvn_PercentageOfMaximumFundingOnProjectCosts" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PercentageOfLiquidatedDamages" xlink:type="locator" xlink:label="arvn_PercentageOfLiquidatedDamages" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentMaturityMonthAndYear" xlink:type="locator" xlink:label="arvn_DebtInstrumentMaturityMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds" xlink:type="locator" xlink:label="arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_DebtInstrumentMaximumBorrowingCapacity" xlink:type="locator" xlink:label="arvn_DebtInstrumentMaximumBorrowingCapacity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:type="locator" xlink:label="arvn_TwoThousandAndEighteenAssistanceAgreementMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CT" xlink:type="locator" xlink:label="stpr_CT" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:type="locator" xlink:label="arvn_TwoThousandAndFourteenAssistanceAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember" xlink:type="locator" xlink:label="us-gaap_SecuredDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ConnecticutInnovationsIncorporatedMember" xlink:type="locator" xlink:label="arvn_ConnecticutInnovationsIncorporatedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_LoanAgreementMember" xlink:type="locator" xlink:label="arvn_LoanAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arvn_LoanAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_ConnecticutInnovationsIncorporatedMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="arvn_TwoThousandAndFourteenAssistanceAgreementMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementGeographicalAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CT" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="arvn_TwoThousandAndEighteenAssistanceAgreementMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_DebtInstrumentMaximumBorrowingCapacity" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_DebtInstrumentMaturityMonthAndYear" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_PercentageOfLiquidatedDamages" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_PercentageOfMaximumFundingOnProjectCosts" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_DebtInstrumentInterestPaymentsTerm" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="12520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebt" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureMembersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" xlink:type="locator" xlink:label="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" xlink:type="locator" xlink:label="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="arvn_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommonUnitsMember" xlink:type="locator" xlink:label="arvn_CommonUnitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="arvn_CommonUnitsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesARedeemableConvertiblePreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesBRedeemableConvertiblePreferredUnitsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arvn_SeriesCRedeemableConvertiblePreferredUnitsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails">
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_MaximumPercentageOfCompensationReceivableByEmployee" xlink:type="locator" xlink:label="arvn_MaximumPercentageOfCompensationReceivableByEmployee" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock" xlink:type="locator" xlink:label="arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:type="locator" xlink:label="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PriorToStockPurchaseAgreementPremium" xlink:type="locator" xlink:label="arvn_PriorToStockPurchaseAgreementPremium" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" xlink:type="locator" xlink:label="arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:type="locator" xlink:label="us-gaap_PaymentsForUnderwritingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ConsultantsMember" xlink:type="locator" xlink:label="arvn_ConsultantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="locator" xlink:label="arvn_TwoThousandEighteenStockIncentivePlanMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockIncentivePlanMember" xlink:type="locator" xlink:label="arvn_StockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_BayerAGMember" xlink:type="locator" xlink:label="arvn_BayerAGMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PiperSandlerMember" xlink:type="locator" xlink:label="arvn_PiperSandlerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="arvn_AtTheMarketOfferingMember_li0l2" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="arvn_AtTheMarketOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arvn_AtTheMarketOfferingMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arvn_AtTheMarketOfferingMember_li0l2" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_PiperSandlerMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_BayerAGMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arvn_StockIncentivePlanMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arvn_TwoThousandEighteenStockIncentivePlanMember" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="arvn_ConsultantsMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsForUnderwritingExpense" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_PriorToStockPurchaseAgreementPremium" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" order="12570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_MaximumPercentageOfCompensationReceivableByEmployee" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="12880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="12950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="12990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="13090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" order="13210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="13250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="13290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="13400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="13440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="13530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="13590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="13780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="13890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="13950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="14110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber" order="14170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" order="14230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureEquitySummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="locator" xlink:label="arvn_TwoThousandEighteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arvn_TwoThousandEighteenStockIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails">
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:type="locator" xlink:label="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EmployeesMember" xlink:type="locator" xlink:label="arvn_EmployeesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="locator" xlink:label="arvn_TwoThousandEighteenStockIncentivePlanMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EmployeesDirectorsAndConsultantsMember" xlink:type="locator" xlink:label="arvn_EmployeesDirectorsAndConsultantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_StockIncentivePlanMember" xlink:type="locator" xlink:label="arvn_StockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arvn_StockIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="arvn_EmployeesDirectorsAndConsultantsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arvn_TwoThousandEighteenStockIncentivePlanMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="arvn_EmployeesMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" xlink:type="locator" xlink:label="arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:type="locator" xlink:label="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_EquityMethodInvestmentContribution" xlink:type="locator" xlink:label="arvn_EquityMethodInvestmentContribution" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember" xlink:type="locator" xlink:label="arvn_OerthBioLimitedLiabilityCorporationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_BayerCropScienceLPMember" xlink:type="locator" xlink:label="arvn_BayerCropScienceLPMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arvn_BayerCropScienceLPMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="arvn_OerthBioLimitedLiabilityCorporationMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="arvn_EquityMethodInvestmentContribution" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ProfitLoss" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="arvn-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReceivable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="arvn_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:type="locator" xlink:label="arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="arvn_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="arvn_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="arvn_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arvn_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureTable" xlink:to="arvn_IncomeTaxDisclosureLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="arvn_OperatingLossCarryforwardsExpirationYear" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="arvn_TaxCreditCarryforwardExpirationYear" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationYearUnderExamination" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxReceivable" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="arvn-20201231.xsd#arvn_MonthlyResearchPayments" xlink:type="locator" xlink:label="arvn_MonthlyResearchPayments" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_PaymentForConsultingService" xlink:type="locator" xlink:label="arvn_PaymentForConsultingService" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_QuarterlyResearchPayments" xlink:type="locator" xlink:label="arvn_QuarterlyResearchPayments" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="arvn_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_ConsultingAgreementMember" xlink:type="locator" xlink:label="arvn_ConsultingAgreementMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CorporateSponsoredResearchAgreementMember" xlink:type="locator" xlink:label="arvn_CorporateSponsoredResearchAgreementMember" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_AmendedCorporateSponsoredResearchAgreementMember" xlink:type="locator" xlink:label="arvn_AmendedCorporateSponsoredResearchAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_YaleUniversityMember" xlink:type="locator" xlink:label="arvn_YaleUniversityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="arvn_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="arvn_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arvn_YaleUniversityMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="arvn_AmendedCorporateSponsoredResearchAgreementMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="arvn_CorporateSponsoredResearchAgreementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="arvn_ConsultingAgreementMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_CommitmentsAndContingenciesTable" xlink:to="arvn_CommitmentsAndContingenciesLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_CommitmentsAndContingenciesLineItems" xlink:to="arvn_QuarterlyResearchPayments" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_CommitmentsAndContingenciesLineItems" xlink:to="arvn_PaymentForConsultingService" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arvn_CommitmentsAndContingenciesLineItems" xlink:to="arvn_MonthlyResearchPayments" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="arvn-20201231.xsd#arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:type="locator" xlink:label="arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails" xlink:href="arvn-20201231.xsd#Role_DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>arvn-10k_20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arvn="http://www.arvinas.com/20201231"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arvn-20201231.xsd" xlink:type="simple"/>
    <context id="C_0001655759_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0001655759_20210224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2021-02-24</instant>
        </period>
    </context>
    <context id="C_0001655759_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesARedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesBRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesARedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesCRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesBRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesABAndCConvertiblePreferredSharesMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesABAndCConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnCommonUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:IncentiveUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:IncentiveUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnCommonUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20181001_20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20181001_20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20181001_20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="C_0001655759_20181001_20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="C_0001655759_20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMaximumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMinimumMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMinimumMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorThreeMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_arvnLaboratoryEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20130701_20130731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-01</startDate>
            <endDate>2013-07-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMinimumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_srtRangeAxis_srtMinimumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_srtRangeAxis_srtMaximumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_srtRangeAxis_srtMaximumMember_20150101_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnResearchFundingPaymentsMember_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapTypeOfArrangementAxis_arvnResearchFundingPaymentsMember_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnResearchFundingPaymentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnDevelopmentMilestonePaymentsMember_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnSalesBasedMilestonePaymentsMember_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnStockPurchaseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_us-gaapTypeOfArrangementAxis_arvnOptionExercisedToLicenseAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionExercisedToLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnOptionPaymentsToLicenseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnDevelopmentMilestonePaymentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnSalesBasedMilestonePaymentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_us-gaapTypeOfArrangementAxis_arvnSubstitutionTargetPaymentsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SubstitutionTargetPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_us-gaapTypeOfArrangementAxis_arvnSubstitutionTargetPaymentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SubstitutionTargetPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_20150901_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_20171101_20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnDevelopmentMilestonePaymentsMember_20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_us-gaapTypeOfArrangementAxis_arvnRegulatoryMilestonePaymentsMember_20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_us-gaapTypeOfArrangementAxis_arvnCommercialMilestonesMember_20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnOptionPaymentsToLicenseAgreementMember_20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGAndPfizerMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGAndPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2023-01-01_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapInvestmentTypeAxis_arvnTwoThousandTwentyMaturityMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:TwoThousandTwentyMaturityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapInvestmentTypeAxis_arvnTwoThousandTwentyMaturityMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:TwoThousandTwentyMaturityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">arvn:CorporateBondsMaturingTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_arvnLaboratoryEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_arvnLaboratoryEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMinimumMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMaximumMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:ConnecticutInnovationsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-08-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:ConnecticutInnovationsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-08-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:ConnecticutInnovationsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130801_20130831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:ConnecticutInnovationsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-08-01</startDate>
            <endDate>2013-08-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:ConnecticutInnovationsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndFourteenAssistanceAgreementMember_20140101_20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndFourteenAssistanceAgreementMember_20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180601_20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_arvnCommonUnitsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">arvn:CommonUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredStockMember_20130101_20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20150101_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesBRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredStockMember_20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesBRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180301_20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesCRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">arvn:SeriesCRedeemableConvertiblePreferredUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="C_0001655759_20180901_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnPiperSandlerMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnPiperSandlerMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191101_20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191101_20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190701_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190101_20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180301_20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180301_20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180301_20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtTitleOfIndividualAxis_arvnConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtTitleOfIndividualAxis_arvnConsultantsMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180901_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerCropScienceLPMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtCounterpartyNameAxis_arvnBayerCropScienceLPMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnAmendedCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:AmendedCorporateSponsoredResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:CorporateSponsoredResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:CorporateSponsoredResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:CorporateSponsoredResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">arvn:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_arvnSubsidiary">
        <measure>arvn:Subsidiary</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_arvnContract">
        <measure>arvn:Contract</measure>
    </unit>
    <unit id="U_arvnTarget">
        <measure>arvn:Target</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001655759_20200101_20201231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="C_0001655759_20200101_20201231" id="F_000003">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001655759_20200101_20201231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001655759_20200101_20201231" id="F_000006">0001655759</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001655759_20200101_20201231" id="F_000007">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20181001"
      decimals="4"
      id="F_000433_2"
      unitRef="U_xbrlipure">0.3077</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:AccountingStandardsUpdateExtensibleList contextRef="C_0001655759_20200101_20201231" id="F_000465">us-gaap:AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted contextRef="C_0001655759_20201231" id="F_000466">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect contextRef="C_0001655759_20201231" id="F_000467">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend contextRef="C_0001655759_20200101_20201231" id="F_000555">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate contextRef="C_0001655759_20200101_20201231" id="F_000556">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <arvn:DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod
      contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930"
      id="F_000599">P120M</arvn:DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20181001"
      decimals="4"
      id="F_000433"
      unitRef="U_xbrlipure">0.3077</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="C_0001655759_20200101_20201231" id="F_000463">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180301_20180331"
      id="F_000654">2018-09-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <arvn:ProceedsFromSaleOfMarketableSecurities
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000323"
      unitRef="U_iso4217USD">0</arvn:ProceedsFromSaleOfMarketableSecurities>
    <arvn:ProceedsFromSaleOfMarketableSecurities
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000324"
      unitRef="U_iso4217USD">0</arvn:ProceedsFromSaleOfMarketableSecurities>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231"
      id="F_000512">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_20201231"
      id="F_000513">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2023-01-01_20201231"
      id="F_000514">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="2"
      id="F_000671"
      unitRef="U_xbrlipure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="2"
      id="F_000672"
      unitRef="U_xbrlipure">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="2"
      id="F_000673"
      unitRef="U_xbrlipure">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000677">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      id="F_000678">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      id="F_000679">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="3"
      id="F_000683"
      unitRef="U_xbrlipure">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="3"
      id="F_000684"
      unitRef="U_xbrlipure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="3"
      id="F_000685"
      unitRef="U_xbrlipure">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231"
      decimals="2"
      id="F_000692"
      unitRef="U_iso4217USD_xbrlishares">22.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231"
      decimals="2"
      id="F_000693"
      unitRef="U_iso4217USD_xbrlishares">17.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231"
      decimals="2"
      id="F_000694"
      unitRef="U_iso4217USD_xbrlishares">14.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="2"
      id="F_000674"
      unitRef="U_xbrlipure">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="2"
      id="F_000675"
      unitRef="U_xbrlipure">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="2"
      id="F_000676"
      unitRef="U_xbrlipure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000680">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      id="F_000681">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      id="F_000682">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="3"
      id="F_000686"
      unitRef="U_xbrlipure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="3"
      id="F_000687"
      unitRef="U_xbrlipure">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="3"
      id="F_000688"
      unitRef="U_xbrlipure">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231"
      decimals="2"
      id="F_000695"
      unitRef="U_iso4217USD_xbrlishares">50.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231"
      decimals="2"
      id="F_000696"
      unitRef="U_iso4217USD_xbrlishares">37.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231"
      decimals="2"
      id="F_000697"
      unitRef="U_iso4217USD_xbrlishares">16.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231"
      id="F_000710">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231"
      id="F_000711">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001655759_20201231"
      id="F_000071"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001655759_20191231"
      id="F_000072"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="C_0001655759_20200101_20201231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001655759_20200101_20201231" id="F_000026">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001655759_20200101_20201231" id="F_000002">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="C_0001655759_20200101_20201231" id="F_000027">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001655759_20200101_20201231" id="F_000016">001-38672</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001655759_20200101_20201231" id="F_000005">ARVINAS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001655759_20200101_20201231" id="F_000017">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001655759_20200101_20201231" id="F_000018">47-2566120</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001655759_20200101_20201231" id="F_000019">5 Science Park</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001655759_20200101_20201231" id="F_000020">395 Winchester Ave</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001655759_20200101_20201231" id="F_000021">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001655759_20200101_20201231" id="F_000022">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001655759_20200101_20201231" id="F_000023">06511</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001655759_20200101_20201231" id="F_000024">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001655759_20200101_20201231" id="F_000025">535-1456</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001655759_20200101_20201231" id="F_000028">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001655759_20200101_20201231" id="F_000029">ARVN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001655759_20200101_20201231" id="F_000030">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001655759_20200101_20201231" id="F_000011">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001655759_20200101_20201231" id="F_000015">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001655759_20200101_20201231" id="F_000012">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001655759_20200101_20201231" id="F_000013">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001655759_20200101_20201231" id="F_000008">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001655759_20200101_20201231" id="F_000009">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001655759_20200101_20201231" id="F_000010">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001655759_20200101_20201231" id="F_000033">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001655759_20200101_20201231" id="F_000014">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001655759_20200630"
      decimals="INF"
      id="F_000031"
      unitRef="U_iso4217USD">1347500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001655759_20210224"
      decimals="INF"
      id="F_000032"
      unitRef="U_xbrlishares">48874027</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000379">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant&#x2019;s 2021 Annual Meeting of Stockholders, which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2020.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000034"
      unitRef="U_iso4217USD">588373232</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000035"
      unitRef="U_iso4217USD">9211057</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000036"
      unitRef="U_iso4217USD">100157618</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000037"
      unitRef="U_iso4217USD">271661456</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000038"
      unitRef="U_iso4217USD">1000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000039"
      unitRef="U_iso4217USD">7443654</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000040"
      unitRef="U_iso4217USD">6280828</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000041"
      unitRef="U_iso4217USD">6113122</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000042"
      unitRef="U_iso4217USD">3727294</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000043"
      unitRef="U_iso4217USD">703087626</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000044"
      unitRef="U_iso4217USD">290880635</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000045"
      unitRef="U_iso4217USD">12259515</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000046"
      unitRef="U_iso4217USD">8455411</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000047"
      unitRef="U_iso4217USD">1992669</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000048"
      unitRef="U_iso4217USD">2278623</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000049"
      unitRef="U_iso4217USD">28777</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000050"
      unitRef="U_iso4217USD">26757</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000051"
      unitRef="U_iso4217USD">717368587</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000052"
      unitRef="U_iso4217USD">301641426</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000053"
      unitRef="U_iso4217USD">7121879</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000054"
      unitRef="U_iso4217USD">4556827</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000055"
      unitRef="U_iso4217USD">18859840</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000056"
      unitRef="U_iso4217USD">7602904</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000057"
      unitRef="U_iso4217USD">22150861</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000058"
      unitRef="U_iso4217USD">19979525</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000059"
      unitRef="U_iso4217USD">952840</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000060"
      unitRef="U_iso4217USD">673896</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000061"
      unitRef="U_iso4217USD">49085420</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000062"
      unitRef="U_iso4217USD">32813152</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000063"
      unitRef="U_iso4217USD">22938233</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000064"
      unitRef="U_iso4217USD">38427882</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000065"
      unitRef="U_iso4217USD">2000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000066"
      unitRef="U_iso4217USD">2000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000067"
      unitRef="U_iso4217USD">1087422</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000068"
      unitRef="U_iso4217USD">1714111</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000069"
      unitRef="U_iso4217USD">75111075</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000070"
      unitRef="U_iso4217USD">74955145</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001655759_20201231"
      decimals="INF"
      id="F_000085"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001655759_20191231"
      decimals="INF"
      id="F_000086"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001655759_20201231"
      decimals="INF"
      id="F_000087"
      unitRef="U_xbrlishares">48455741</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001655759_20201231"
      decimals="INF"
      id="F_000089"
      unitRef="U_xbrlishares">48455741</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001655759_20191231"
      decimals="INF"
      id="F_000088"
      unitRef="U_xbrlishares">38461353</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001655759_20191231"
      decimals="INF"
      id="F_000090"
      unitRef="U_xbrlishares">38461353</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000073"
      unitRef="U_iso4217USD">48455</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000074"
      unitRef="U_iso4217USD">38461</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000075"
      unitRef="U_iso4217USD">-491888910</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000076"
      unitRef="U_iso4217USD">-372556846</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000077"
      unitRef="U_iso4217USD">1133537171</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000078"
      unitRef="U_iso4217USD">599097090</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000079"
      unitRef="U_iso4217USD">560796</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000080"
      unitRef="U_iso4217USD">107576</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000081"
      unitRef="U_iso4217USD">642257512</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000082"
      unitRef="U_iso4217USD">226686281</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000083"
      unitRef="U_iso4217USD">717368587</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000084"
      unitRef="U_iso4217USD">301641426</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000091"
      unitRef="U_iso4217USD">21801777</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000092"
      unitRef="U_iso4217USD">42976478</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000093"
      unitRef="U_iso4217USD">14323920</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000094"
      unitRef="U_iso4217USD">108355853</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000095"
      unitRef="U_iso4217USD">67193830</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000096"
      unitRef="U_iso4217USD">45193830</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000097"
      unitRef="U_iso4217USD">38303401</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000098"
      unitRef="U_iso4217USD">27307162</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000099"
      unitRef="U_iso4217USD">12932168</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000100"
      unitRef="U_iso4217USD">146659254</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000101"
      unitRef="U_iso4217USD">94500992</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000102"
      unitRef="U_iso4217USD">58125998</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000103"
      unitRef="U_iso4217USD">-124857477</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000104"
      unitRef="U_iso4217USD">-51524514</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000105"
      unitRef="U_iso4217USD">-43802078</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000106"
      unitRef="U_iso4217USD">2004561</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000107"
      unitRef="U_iso4217USD">1435596</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000108"
      unitRef="U_iso4217USD">102730</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000109"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000110"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000111"
      unitRef="U_iso4217USD">193779</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000112"
      unitRef="U_iso4217USD">3585852</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000113"
      unitRef="U_iso4217USD">4557260</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000114"
      unitRef="U_iso4217USD">2470101</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000115"
      unitRef="U_iso4217USD">65000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000116"
      unitRef="U_iso4217USD">85569</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000117"
      unitRef="U_iso4217USD">57440</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000118"
      unitRef="U_iso4217USD">5525413</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000119"
      unitRef="U_iso4217USD">5907287</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000120"
      unitRef="U_iso4217USD">2321612</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000121"
      unitRef="U_iso4217USD">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000122"
      unitRef="U_iso4217USD">-24675000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000123"
      unitRef="U_iso4217USD">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000124"
      unitRef="U_iso4217USD">-119332064</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000125"
      unitRef="U_iso4217USD">-70292227</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000126"
      unitRef="U_iso4217USD">-41480466</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000127"
      unitRef="U_iso4217USD">0</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000128"
      unitRef="U_iso4217USD">0</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000129"
      unitRef="U_iso4217USD">198366756</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000130"
      unitRef="U_iso4217USD">-119332064</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000131"
      unitRef="U_iso4217USD">-70292227</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000132"
      unitRef="U_iso4217USD">-239847222</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001655759_20200101_20201231"
      decimals="2"
      id="F_000133"
      unitRef="U_iso4217USD_xbrlishares">-3.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001655759_20190101_20191231"
      decimals="2"
      id="F_000134"
      unitRef="U_iso4217USD_xbrlishares">-2.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001655759_20180101_20181231"
      decimals="2"
      id="F_000135"
      unitRef="U_iso4217USD_xbrlishares">-25.45</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000136"
      unitRef="U_xbrlishares">39534497</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000137"
      unitRef="U_xbrlishares">32927697</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000138"
      unitRef="U_xbrlishares">9422799</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000139"
      unitRef="U_iso4217USD">-119332064</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000140"
      unitRef="U_iso4217USD">-70292227</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000141"
      unitRef="U_iso4217USD">-41480466</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000142"
      unitRef="U_iso4217USD">453220</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000143"
      unitRef="U_iso4217USD">325299</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000144"
      unitRef="U_iso4217USD">-207972</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000145"
      unitRef="U_iso4217USD">-118878844</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000146"
      unitRef="U_iso4217USD">-69966928</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000147"
      unitRef="U_iso4217USD">-41688438</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20171231"
      decimals="INF"
      id="F_000148"
      unitRef="U_xbrlishares">22463665</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20171231"
      decimals="0"
      id="F_000149"
      unitRef="U_iso4217USD">19768025</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20171231"
      decimals="INF"
      id="F_000150"
      unitRef="U_xbrlishares">24977489</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20171231"
      decimals="0"
      id="F_000151"
      unitRef="U_iso4217USD">41712407</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <arvn:TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20180101_20181231"
      decimals="INF"
      id="F_000152"
      unitRef="U_xbrlishares">110116</arvn:TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised>
    <arvn:TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20180101_20181231"
      decimals="0"
      id="F_000153"
      unitRef="U_iso4217USD">319667</arvn:TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised>
    <arvn:TemporaryEquityStockIssuedDuringPeriodShareNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180101_20181231"
      decimals="INF"
      id="F_000154"
      unitRef="U_xbrlishares">16467066</arvn:TemporaryEquityStockIssuedDuringPeriodShareNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180101_20181231"
      decimals="0"
      id="F_000155"
      unitRef="U_iso4217USD">55000001</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20180101_20181231"
      decimals="0"
      id="F_000156"
      unitRef="U_iso4217USD">-91044716</arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits>
    <arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20180101_20181231"
      decimals="0"
      id="F_000157"
      unitRef="U_iso4217USD">-81253577</arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits>
    <arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180101_20181231"
      decimals="0"
      id="F_000158"
      unitRef="U_iso4217USD">-26068463</arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits>
    <arvn:TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20180101_20181231"
      decimals="INF"
      id="F_000159"
      unitRef="U_xbrlishares">-22573781</arvn:TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares>
    <arvn:TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20180101_20181231"
      decimals="0"
      id="F_000160"
      unitRef="U_iso4217USD">-111132408</arvn:TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares>
    <arvn:TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20180101_20181231"
      decimals="INF"
      id="F_000161"
      unitRef="U_xbrlishares">-24977489</arvn:TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares>
    <arvn:TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20180101_20181231"
      decimals="0"
      id="F_000162"
      unitRef="U_iso4217USD">-122965984</arvn:TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares>
    <arvn:TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180101_20181231"
      decimals="INF"
      id="F_000163"
      unitRef="U_xbrlishares">-16467066</arvn:TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares>
    <arvn:TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180101_20181231"
      decimals="0"
      id="F_000164"
      unitRef="U_iso4217USD">-81068464</arvn:TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares>
    <arvn:TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesABAndCConvertiblePreferredSharesMember_20180101_20181231"
      decimals="INF"
      id="F_000165"
      unitRef="U_xbrlishares">64018336</arvn:TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares>
    <arvn:TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesABAndCConvertiblePreferredSharesMember_20180101_20181231"
      decimals="0"
      id="F_000166"
      unitRef="U_iso4217USD">315166856</arvn:TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares>
    <arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000169"
      unitRef="U_iso4217USD">12048129</arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesABAndCConvertiblePreferredSharesMember_20180101_20181231"
      decimals="INF"
      id="F_000167"
      unitRef="U_xbrlishares">-64018336</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesABAndCConvertiblePreferredSharesMember_20180101_20181231"
      decimals="0"
      id="F_000168"
      unitRef="U_iso4217USD">-315166856</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000171"
      unitRef="U_iso4217USD">7497131</arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts>
    <arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000173"
      unitRef="U_iso4217USD">28099997</arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231"
      decimals="0"
      id="F_000175"
      unitRef="U_iso4217USD">1584647</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:SharesOutstanding
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnCommonUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20171231"
      decimals="INF"
      id="F_000177"
      unitRef="U_xbrlishares">1897544</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnCommonUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20171231"
      decimals="0"
      id="F_000178"
      unitRef="U_iso4217USD">6167</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20171231"
      decimals="INF"
      id="F_000179"
      unitRef="U_xbrlishares">3669963</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20171231"
      decimals="0"
      id="F_000180"
      unitRef="U_iso4217USD">1186419</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231"
      decimals="0"
      id="F_000181"
      unitRef="U_iso4217USD">-62417397</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231"
      decimals="0"
      id="F_000182"
      unitRef="U_iso4217USD">-9751</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_20171231"
      decimals="0"
      id="F_000183"
      unitRef="U_iso4217USD">-61234562</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231"
      decimals="INF"
      id="F_000184"
      unitRef="U_xbrlishares">1680386</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231"
      decimals="0"
      id="F_000185"
      unitRef="U_iso4217USD">2489061</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="0"
      id="F_000186"
      unitRef="U_iso4217USD">9141239</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000187"
      unitRef="U_iso4217USD">11630300</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="0"
      id="F_000188"
      unitRef="U_iso4217USD">198366756</arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits>
    <arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000189"
      unitRef="U_iso4217USD">198366756</arvn:ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="0"
      id="F_000190"
      unitRef="U_iso4217USD">-41480466</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000191"
      unitRef="U_iso4217USD">-41480466</us-gaap:NetIncomeLoss>
    <arvn:StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnCommonUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231"
      decimals="INF"
      id="F_000192"
      unitRef="U_xbrlishares">-1897544</arvn:StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock>
    <arvn:StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnCommonUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231"
      decimals="0"
      id="F_000193"
      unitRef="U_iso4217USD">-6167</arvn:StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock>
    <arvn:StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000194"
      unitRef="U_xbrlishares">3692765</arvn:StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock>
    <arvn:StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="0"
      id="F_000195"
      unitRef="U_iso4217USD">3693</arvn:StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock>
    <arvn:StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231"
      decimals="INF"
      id="F_000196"
      unitRef="U_xbrlishares">-5350349</arvn:StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock>
    <arvn:StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnIncentiveUnitsMember_us-gaapStatementEquityComponentsAxis_us-gaapMemberUnitsMember_20180101_20181231"
      decimals="0"
      id="F_000197"
      unitRef="U_iso4217USD">-3675480</arvn:StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock>
    <arvn:StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="0"
      id="F_000198"
      unitRef="U_iso4217USD">3677954</arvn:StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock>
    <arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000170"
      unitRef="U_iso4217USD">12048129</arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000199"
      unitRef="U_xbrlishares">7700482</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="0"
      id="F_000200"
      unitRef="U_iso4217USD">7700</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="0"
      id="F_000201"
      unitRef="U_iso4217USD">111151883</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000202"
      unitRef="U_iso4217USD">111159583</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000203"
      unitRef="U_xbrlishares">19697928</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="0"
      id="F_000204"
      unitRef="U_iso4217USD">19698</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="0"
      id="F_000205"
      unitRef="U_iso4217USD">315147158</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000206"
      unitRef="U_iso4217USD">315166856</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000207"
      unitRef="U_xbrlishares">144283</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="0"
      id="F_000208"
      unitRef="U_iso4217USD">145</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="0"
      id="F_000209"
      unitRef="U_iso4217USD">-145</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231"
      decimals="0"
      id="F_000210"
      unitRef="U_iso4217USD">-207972</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000211"
      unitRef="U_iso4217USD">-207972</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20181231"
      decimals="INF"
      id="F_000212"
      unitRef="U_xbrlishares">31235458</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20181231"
      decimals="0"
      id="F_000213"
      unitRef="U_iso4217USD">31236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="0"
      id="F_000214"
      unitRef="U_iso4217USD">-302264619</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="0"
      id="F_000215"
      unitRef="U_iso4217USD">439118089</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="0"
      id="F_000216"
      unitRef="U_iso4217USD">-217723</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_20181231"
      decimals="0"
      id="F_000217"
      unitRef="U_iso4217USD">136666983</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="0"
      id="F_000218"
      unitRef="U_iso4217USD">20072710</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000219"
      unitRef="U_iso4217USD">20072710</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000172"
      unitRef="U_iso4217USD">7497131</arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000220"
      unitRef="U_xbrlishares">6573586</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="0"
      id="F_000221"
      unitRef="U_iso4217USD">6573</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="0"
      id="F_000222"
      unitRef="U_iso4217USD">137082302</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000223"
      unitRef="U_iso4217USD">137088875</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="0"
      id="F_000224"
      unitRef="U_iso4217USD">-70292227</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000225"
      unitRef="U_iso4217USD">-70292227</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000226"
      unitRef="U_xbrlishares">475412</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="0"
      id="F_000227"
      unitRef="U_iso4217USD">475</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="0"
      id="F_000228"
      unitRef="U_iso4217USD">-475</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000229"
      unitRef="U_xbrlishares">176897</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="0"
      id="F_000230"
      unitRef="U_iso4217USD">177</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="0"
      id="F_000231"
      unitRef="U_iso4217USD">2824464</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000232"
      unitRef="U_iso4217USD">2824641</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="0"
      id="F_000233"
      unitRef="U_iso4217USD">325299</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000234"
      unitRef="U_iso4217USD">325299</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000235"
      unitRef="U_xbrlishares">38461353</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20191231"
      decimals="0"
      id="F_000236"
      unitRef="U_iso4217USD">38461</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="0"
      id="F_000237"
      unitRef="U_iso4217USD">-372556846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="0"
      id="F_000238"
      unitRef="U_iso4217USD">599097090</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="0"
      id="F_000239"
      unitRef="U_iso4217USD">107576</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000240"
      unitRef="U_iso4217USD">226686281</us-gaap:StockholdersEquity>
    <arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000174"
      unitRef="U_iso4217USD">28099997</arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000241"
      unitRef="U_xbrlishares">6571428</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="0"
      id="F_000242"
      unitRef="U_iso4217USD">6571</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="0"
      id="F_000243"
      unitRef="U_iso4217USD">431893392</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000244"
      unitRef="U_iso4217USD">431899963</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="0"
      id="F_000245"
      unitRef="U_iso4217USD">30230858</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000246"
      unitRef="U_iso4217USD">30230858</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="0"
      id="F_000247"
      unitRef="U_iso4217USD">-119332064</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000248"
      unitRef="U_iso4217USD">-119332064</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000249"
      unitRef="U_xbrlishares">371164</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="0"
      id="F_000250"
      unitRef="U_iso4217USD">371</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="0"
      id="F_000251"
      unitRef="U_iso4217USD">-371</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000252"
      unitRef="U_xbrlishares">458159</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="0"
      id="F_000253"
      unitRef="U_iso4217USD">458</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="0"
      id="F_000254"
      unitRef="U_iso4217USD">8260302</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000255"
      unitRef="U_iso4217USD">8260760</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231"
      decimals="0"
      id="F_000176"
      unitRef="U_iso4217USD">1584647</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231"
      decimals="INF"
      id="F_000256"
      unitRef="U_xbrlishares">2593637</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231"
      decimals="0"
      id="F_000257"
      unitRef="U_iso4217USD">2594</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231"
      decimals="0"
      id="F_000258"
      unitRef="U_iso4217USD">64055900</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231"
      decimals="0"
      id="F_000259"
      unitRef="U_iso4217USD">64058494</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="0"
      id="F_000260"
      unitRef="U_iso4217USD">453220</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000261"
      unitRef="U_iso4217USD">453220</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000262"
      unitRef="U_xbrlishares">48455741</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20201231"
      decimals="0"
      id="F_000263"
      unitRef="U_iso4217USD">48455</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="0"
      id="F_000264"
      unitRef="U_iso4217USD">-491888910</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="0"
      id="F_000265"
      unitRef="U_iso4217USD">1133537171</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="0"
      id="F_000266"
      unitRef="U_iso4217USD">560796</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000267"
      unitRef="U_iso4217USD">642257512</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000268"
      unitRef="U_iso4217USD">-119332064</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000269"
      unitRef="U_iso4217USD">-70292227</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000270"
      unitRef="U_iso4217USD">-41480466</us-gaap:ProfitLoss>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000271"
      unitRef="U_iso4217USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000272"
      unitRef="U_iso4217USD">15149</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000273"
      unitRef="U_iso4217USD">17963</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000274"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000275"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000276"
      unitRef="U_iso4217USD">193779</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000277"
      unitRef="U_iso4217USD">3166139</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000278"
      unitRef="U_iso4217USD">1561557</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000279"
      unitRef="U_iso4217USD">706000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000280"
      unitRef="U_iso4217USD">-1654516</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000281"
      unitRef="U_iso4217USD">-154022</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000282"
      unitRef="U_iso4217USD">-248069</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000283"
      unitRef="U_iso4217USD">395070</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000284"
      unitRef="U_iso4217USD">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000285"
      unitRef="U_iso4217USD">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <arvn:OperatingLeaseRightOfUseAssetAmortization
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000286"
      unitRef="U_iso4217USD">858367</arvn:OperatingLeaseRightOfUseAssetAmortization>
    <arvn:OperatingLeaseRightOfUseAssetAmortization
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000287"
      unitRef="U_iso4217USD">691345</arvn:OperatingLeaseRightOfUseAssetAmortization>
    <arvn:OperatingLeaseRightOfUseAssetAmortization
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000288"
      unitRef="U_iso4217USD">0</arvn:OperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000289"
      unitRef="U_iso4217USD">30230858</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000290"
      unitRef="U_iso4217USD">20072710</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000291"
      unitRef="U_iso4217USD">11630300</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000292"
      unitRef="U_iso4217USD">1162826</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000293"
      unitRef="U_iso4217USD">4024862</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000294"
      unitRef="U_iso4217USD">1215514</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000295"
      unitRef="U_iso4217USD">1000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000296"
      unitRef="U_iso4217USD">-2775831</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000297"
      unitRef="U_iso4217USD">-22224169</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000298"
      unitRef="U_iso4217USD">2387848</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000299"
      unitRef="U_iso4217USD">1065005</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000300"
      unitRef="U_iso4217USD">2501383</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000301"
      unitRef="U_iso4217USD">2042342</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000302"
      unitRef="U_iso4217USD">1608735</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000303"
      unitRef="U_iso4217USD">2002163</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000304"
      unitRef="U_iso4217USD">10807123</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000305"
      unitRef="U_iso4217USD">3601628</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000306"
      unitRef="U_iso4217USD">605340</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <arvn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000307"
      unitRef="U_iso4217USD">-920158</arvn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <arvn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000308"
      unitRef="U_iso4217USD">-581961</arvn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <arvn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000309"
      unitRef="U_iso4217USD">0</arvn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000310"
      unitRef="U_iso4217USD">-13318313</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000311"
      unitRef="U_iso4217USD">4856736</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000312"
      unitRef="U_iso4217USD">-8548090</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000313"
      unitRef="U_iso4217USD">-89756934</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000314"
      unitRef="U_iso4217USD">-40626342</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000315"
      unitRef="U_iso4217USD">-16117670</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000316"
      unitRef="U_iso4217USD">41196166</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000317"
      unitRef="U_iso4217USD">256548355</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000318"
      unitRef="U_iso4217USD">234894225</us-gaap:PaymentsToAcquireMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000319"
      unitRef="U_iso4217USD">174118543</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000320"
      unitRef="U_iso4217USD">169695816</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000321"
      unitRef="U_iso4217USD">58059526</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <arvn:ProceedsFromSaleOfMarketableSecurities
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000322"
      unitRef="U_iso4217USD">37775235</arvn:ProceedsFromSaleOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000325"
      unitRef="U_iso4217USD">6447533</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000326"
      unitRef="U_iso4217USD">6244024</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000327"
      unitRef="U_iso4217USD">2830661</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000328"
      unitRef="U_iso4217USD">164250079</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000329"
      unitRef="U_iso4217USD">-93096563</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000330"
      unitRef="U_iso4217USD">-179665360</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000331"
      unitRef="U_iso4217USD">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000332"
      unitRef="U_iso4217USD">169610</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000333"
      unitRef="U_iso4217USD">173889</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000334"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000335"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000336"
      unitRef="U_iso4217USD">2000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000337"
      unitRef="U_iso4217USD">459999960</arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering>
    <arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000338"
      unitRef="U_iso4217USD">137686006</arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering>
    <arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000339"
      unitRef="U_iso4217USD">114583172</arvn:ProceedsFromIssuanceOfCommonStockInAPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000340"
      unitRef="U_iso4217USD">27650184</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000341"
      unitRef="U_iso4217USD">597131</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000342"
      unitRef="U_iso4217USD">3423589</us-gaap:PaymentsOfStockIssuanceCosts>
    <arvn:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231"
      decimals="0"
      id="F_000343"
      unitRef="U_iso4217USD">65643141</arvn:ProceedsFromIssuanceOfCommonStockGross>
    <arvn:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20190101_20191231"
      decimals="0"
      id="F_000344"
      unitRef="U_iso4217USD">0</arvn:ProceedsFromIssuanceOfCommonStockGross>
    <arvn:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20180101_20181231"
      decimals="0"
      id="F_000345"
      unitRef="U_iso4217USD">0</arvn:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231"
      decimals="0"
      id="F_000346"
      unitRef="U_iso4217USD">1584647</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20190101_20191231"
      decimals="0"
      id="F_000347"
      unitRef="U_iso4217USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20180101_20181231"
      decimals="0"
      id="F_000348"
      unitRef="U_iso4217USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000349"
      unitRef="U_iso4217USD">8260760</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000350"
      unitRef="U_iso4217USD">2824641</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000351"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000352"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000353"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000354"
      unitRef="U_iso4217USD">55000001</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000355"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000356"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000357"
      unitRef="U_iso4217USD">75000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000358"
      unitRef="U_iso4217USD">504669030</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000359"
      unitRef="U_iso4217USD">139743906</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000360"
      unitRef="U_iso4217USD">168060695</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000361"
      unitRef="U_iso4217USD">579162175</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000362"
      unitRef="U_iso4217USD">6021001</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000363"
      unitRef="U_iso4217USD">-27722335</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000364"
      unitRef="U_iso4217USD">9211057</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001655759_20181231"
      decimals="0"
      id="F_000365"
      unitRef="U_iso4217USD">3190056</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001655759_20171231"
      decimals="0"
      id="F_000366"
      unitRef="U_iso4217USD">30912391</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000367"
      unitRef="U_iso4217USD">588373232</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000368"
      unitRef="U_iso4217USD">9211057</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001655759_20181231"
      decimals="0"
      id="F_000369"
      unitRef="U_iso4217USD">3190056</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000370"
      unitRef="U_iso4217USD">522710</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000371"
      unitRef="U_iso4217USD">189908</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000372"
      unitRef="U_iso4217USD">159494</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000373"
      unitRef="U_iso4217USD">65000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000374"
      unitRef="U_iso4217USD">70420</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000375"
      unitRef="U_iso4217USD">39476</us-gaap:InterestPaidNet>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000376"
      unitRef="U_iso4217USD">0</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000377"
      unitRef="U_iso4217USD">0</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000378"
      unitRef="U_iso4217USD">198366756</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000380">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;1. Nature of Business and Basis of Presentation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arvinas, Inc. has four wholly owned subsidiaries, Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc., Arvinas Estrogen Receptor, Inc., and Arvinas Winchester, Inc. (collectively, the Company). Arvinas Operations, Inc. was formed in 2013, Arvinas Androgen Receptor, Inc. was formed in 2015, Arvinas Estrogen Receptor, Inc. was formed in 2016, and Arvinas Winchester, Inc. was formed in 2018. In September 2018, the Company converted from a Delaware limited liability company to a Delaware corporation. All periods prior to the date of conversion represent the results of the limited liability corporation. The Company is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases throughout the discovery, development and commercialization of therapies to degrade disease-causing proteins. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arvinas, Inc. was incorporated in Delaware on July&#160;3, 2013. Effective January&#160;1, 2015, Arvinas Holding Company, LLC (Arvinas LLC) was formed by the shareholders of Arvinas, Inc. and Arvinas, Inc. became a wholly owned subsidiary of Arvinas LLC. In connection with this reorganization, the rights and preferences of the preferred stock of Arvinas, Inc. were exchanged for preferred stock units with similar rights and preferences of Arvinas LLC. As part of the reorganization, the employees, consultants and board members of Arvinas, Inc. exchanged their stock options in Arvinas, Inc. stock in exchange for incentive units in Arvinas LLC. Additionally, common stockholders of Arvinas, Inc. exchanged their common stock for common units in Arvinas LLC. All exchanges were made on a 1-for-1 basis. This reorganization was accounted for as a common control transaction as the common stockholders of Arvinas, Inc. formed Arvinas, LLC and transferred all the assets from Arvinas, Inc. to Arvinas LLC. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s Board of Managers approved a &lt;span style="-sec-ix-hidden:F_000433"&gt;one-for-3.25&lt;/span&gt; reverse stock split of its issued and outstanding shares of common units and a proportional adjustment to the existing conversion ratios for the Company&#x2019;s Series A, Series B, and Series C preferred units effective as of September 14, 2018. Accordingly, all share/unit and per share/unit amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this reverse unit split and adjustment of the preferred unit conversion ratios. Immediately prior to the effectiveness of the registration statement pertaining to the Company&#x2019;s initial public offering on September 26, 2018, the Company converted from a Delaware limited liability company to a Delaware corporation. Pursuant to the plan of conversion, each outstanding Series A, Series B, and Series C preferred units converted into an equal number of shares of Series A, Series B, and Series C preferred stock, each outstanding common unit converted into a share of common stock and each outstanding incentive unit converted into a number of shares of common stock and restricted common stock based on a conversion price determined by the board of directors. The Company issued 1,795,221 shares of common stock and 1,268,923 shares of restricted common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 1, 2018, the Company completed an initial public offering (IPO) in which the Company issued and sold 7,500,000 shares&lt;span style="Background-color:#FFFFFF;"&gt;&#160;&lt;/span&gt;of common stock at a public offering price of $16.00 per share. In October 2018, the underwriters of the IPO exercised in part their option to purchase 200,482 additional shares of the Company&#x2019;s common stock at an offering price of $16.00 per share. The Company&#x2019;s aggregate gross proceeds from the sale of shares in the IPO, including the option, was $123.2 million before fees and expenses of $12.0 million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 1, 2018, all of the outstanding shares of convertible preferred stock automatically converted into 19,697,928 shares of common stock at the applicable conversion ratio then in effect.&#160;&#160;Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;span style="font-weight:normal;font-style:normal;"&gt; - The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). The accounting policies used to prepare these financial statements are the same as those used to prepare the consolidated financial statements in prior years, except as described in these notes or for the adoption of new standards as outlined below.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <arvn:NumberOfWhollyOwnedSubsidiaries
      contextRef="C_0001655759_20200101_20201231"
      decimals="INF"
      id="F_000431"
      unitRef="U_arvnSubsidiary">4</arvn:NumberOfWhollyOwnedSubsidiaries>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      id="F_000432">The Company&#x2019;s Board of Managers approved a one-for-3.25 reverse stock split of its issued and outstanding shares of common units</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20181001"
      decimals="INF"
      id="F_000434"
      unitRef="U_xbrlishares">1795221</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20181001_20181001"
      decimals="INF"
      id="F_000435"
      unitRef="U_xbrlishares">1268923</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20181001_20181001"
      decimals="INF"
      id="F_000436"
      unitRef="U_xbrlishares">7500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20181001"
      decimals="INF"
      id="F_000437"
      unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20181001_20181031"
      decimals="INF"
      id="F_000438"
      unitRef="U_xbrlishares">200482</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20181031"
      decimals="2"
      id="F_000439"
      unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20181001"
      decimals="-5"
      id="F_000440"
      unitRef="U_iso4217USD">123200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001655759_20181001_20181001"
      decimals="-5"
      id="F_000441"
      unitRef="U_iso4217USD">12000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20181001"
      decimals="INF"
      id="F_000442"
      unitRef="U_xbrlishares">19697928</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001655759_20181001"
      decimals="INF"
      id="F_000443"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000381">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;2. Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements of the Company include the accounts of Arvinas, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. &lt;/p&gt;


&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the financial statements and notes. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements and notes are appropriate, actual results could differ from those estimates. The most significant estimates are those used in determination of the Company&#x2019;s revenue recognition, research and development expenses, fair value of its common and preferred units, preferred unit warrant liability, incentive equity compensation, and fair value of its investment in a joint venture, Oerth Bio LLC (Oerth). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s principal financial instruments comprise cash, marketable securities, account receivable, accounts payable, accrued liabilities and long-term debt. The carrying value of all financial instruments approximates fair value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company maintains its cash in financial institution accounts that, at times during the year, may exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Cash may also be maintained at commercial institutions that are not insured by the FDIC. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2020, 100% of the Company&#x2019;s revenue was attributable to three collaborators representing 37%, 32% and 31%, respectively, and one collaborator accounted for the entire accounts receivable balance. For the year ended December&#160;31, 2019, 57% of the Company&#x2019;s revenue was attributable to a license contributed to Oerth, and two collaborators represented 19% and 16% of total revenue. For the year ended December&#160;31, 2018, two collaborators each represented over 45% of total revenue.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Marketable Securities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies its marketable securities as available-for-sale securities, which are carried at their fair value based on the quoted market prices of the securities with unrealized gains and losses reported as accumulated other comprehensive loss, a separate component of stockholders&#x2019;/members&#x2019; equity. Realized gains and losses on available-for-sale securities are included in net earnings in the period earned or incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Property, Equipment, and Leasehold Improvements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from three years for office equipment to five years for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation are removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.73%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When indications of potential impairments are present, the Company evaluates the carrying value of long-lived assets. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than carrying value. No such impairments were recorded during 2020, 2019 or 2018. &lt;/p&gt;


&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Segment Information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company&#x2019;s tangible assets are held in the United States. To date, all of the Company&#x2019;s revenue has been generated in the United States. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Revenue Recognition and Deferred Revenue &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Revenues from Contracts &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue under Accounting Standards Codification (ASC) 606, &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers.&lt;/span&gt; The Company&#x2019;s revenue is generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i)&#160;licenses, (ii) research and development activities, and (iii)&#160;participation in joint research and development steering committees. The terms of these agreements may include non-refundable upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones, and royalty payments based on product sales derived from the collaboration. Under ASC&#160;606, the Company evaluates whether the license agreement, research and development services, and participation in research and development steering committees, represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent a combined single performance obligation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The research collaboration and license agreements typically include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company determined that the most likely amount to be recognized was zero, against which no constraint was applied. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue is recognized ratably over the Company&#x2019;s expected performance period under each respective arrangement. The Company makes its best estimate of the period over which the Company expects to fulfill the Company&#x2019;s performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December&#160;31, 2020, 2019 and 2018, the transaction price allocated to the combined performance obligation identified under the agreements is recognized as revenue on a straight-line basis over the estimated performance period under each respective arrangement. Straight-line basis was considered the best measure of progress in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale; or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by the customer from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts received prior to satisfying the above revenue recognition criteria are recorded as a contract liability in the Company&#x2019;s accompanying consolidated balance sheets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also recognized revenue under ASC 606 from its contribution of a license to Oerth. See Note 12. &lt;/p&gt;


&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Equity Method Investments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, &lt;span style="font-style:italic;"&gt;Investments &#x2013; Equity Method and Joint Ventures&lt;/span&gt;. The Company recognizes its pro-rata share of income and losses in the investment in &#x201c;Loss from equity method investment&#x201d; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment on the consolidated balance sheet until such investment is reduced to $0.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Preferred Unit Warrants &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred unit warrants issued in conjunction with debt financings were initially recorded at fair value, using a Black-Scholes option pricing model, with a corresponding discount recorded against the face value of the note and a liability. The discount was then accreted against the face value of the note over its remaining term as additional interest expense. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classified warrants to purchase shares of its Series A Redeemable Convertible Preferred Units (Series A Preferred Units) as a liability on its balance sheets as these warrants were free-standing financial instruments that were exercisable for contingently redeemable shares. The preferred unit warrants were recorded in long-term liabilities at fair value, estimated using the Black-Scholes option pricing model, and marked to market at each balance sheet date. The change in carrying value was reported as the change in fair value of warrant liability in the accompanying consolidated statements of operations. The outstanding warrants were exercised in July 2018 and no warrants were outstanding as of December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the conversion to a C-corporation, Arvinas LLC was taxed under the provisions of Subchapter K&#x2014;Partners and Partnerships of the Internal Revenue Code. Under those provisions, Arvinas LLC did not pay federal or state corporate income taxes on its taxable income. Instead, each member would include net operating income or loss for Arvinas LLC on its individual return. Arvinas LLC was converted to a C-corporation in 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, &lt;span style="font-style:italic;"&gt;Accounting for Income Taxes&lt;/span&gt;. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management has evaluated the effect of ASC 740 guidance related to uncertain income tax positions and concluded that the Company has no significant uncertain income tax positions at December&#160;31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Equity-based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to its IPO, the Company periodically granted incentive units to employees and non-employees, which generally vested over a &lt;span style="-sec-ix-hidden:F_000463"&gt;four-year&lt;/span&gt; period. The incentive units represented a separate substantive class of equity with defined rights within the limited liability company agreement of Arvinas Holding Company, LLC (the LLC Operating Agreement). The incentive units represented profits interests in the Company, which was an interest in the increase in the value of the entity over the Participation Threshold, as defined in the LLC Operating Agreement and as determined at the time of grant. The holder, therefore, had the right to participate in distributions of profits only in excess of the Participation Threshold. The Participation Threshold was based on the valuation of the common unit on or around the grant date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounted for incentive units granted in accordance with ASC 718, &lt;span style="font-style:italic;"&gt;Compensation-Stock Compensation&lt;/span&gt; (ASC 718). In accordance with ASC 718, compensation expense is measured at estimated fair value of the incentive units and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures employee, board of director and consultant equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards.&#160;&#160;Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies equity-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses include (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites, and consultants; (iii) the cost of acquiring, developing, and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into consulting, research, and other agreements with commercial entities, researchers, universities, and others for the provision of goods and services. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#x2019;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#x2019;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC Topic 820, &lt;span style="font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;, requires disclosure of the fair value of financial instruments held by the Company. ASC 825, &lt;span style="font-style:italic;"&gt;Financial Instruments&lt;/span&gt;, defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.94%;text-indent:-2.27%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&#x2014;Inputs are based upon observable or quoted prices for identical instruments traded in active markets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:13.44%;text-indent:-7.78%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&#x2014;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#x2019;s Level&#160;2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:13.44%;text-indent:-7.78%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&#x2014;Inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s marketable securities consist of corporate bonds which are adjusted to fair value each balance sheet date, based on quoted prices, which are considered Level&#160;2 inputs (see Note 5). &lt;span style="color:#000000;"&gt;During the year ended December 31, 2019, a non-recurring fair value measurement was applied to determine the fair value of the non-cash consideration of 50% equity ownership received related to Oerth. The fair value measurement was determined using an income approach based primarily on utilizing management&#x2019;s estimates of future cash flows as inputs, which are considered Level 3 measurements within the above fair value hierarchy.&lt;/span&gt;&lt;/p&gt;


&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Net Loss per Common Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per common share is computed by dividing net loss, after adjusting for redeemable preferred unit dividends, by the weighted-average number of common shares outstanding during the period. The change in current redemption value of the redeemable preferred units was treated as a deemed dividend for the period during 2018 prior to conversion to common units. Diluted net loss per share was computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common shares. The effect of the conversion of redeemable preferred units into common units was excluded from the computation of diluted net loss per common share for all periods as their effect was antidilutive. Additionally, common share equivalents are excluded from the computation of diluted net loss per common share for all periods as their effect is antidilutive. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13&lt;span style="font-style:italic;"&gt;, Financial&lt;/span&gt; &lt;span style="font-style:italic;"&gt;Instruments &#x2013; Credit Losses&lt;/span&gt;, which provides a model for recognizing credit losses on financial instruments based on an estimate of current&lt;span style="font-style:italic;"&gt; &lt;/span&gt;expected losses, requiring immediate recognition of credit losses expected over the life of a financial instrument. The Company adopted ASU 2016-13 in the first quarter of 2020. The adoption of the standard was immaterial to the accompanying consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#x2019;s financial statements upon adoption. &lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000395">
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements of the Company include the accounts of Arvinas, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. &lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001655759_20200101_20201231" id="F_000396">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the financial statements and notes. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements and notes are appropriate, actual results could differ from those estimates. The most significant estimates are those used in determination of the Company&#x2019;s revenue recognition, research and development expenses, fair value of its common and preferred units, preferred unit warrant liability, incentive equity compensation, and fair value of its investment in a joint venture, Oerth Bio LLC (Oerth). &lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0001655759_20200101_20201231" id="F_000397">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s principal financial instruments comprise cash, marketable securities, account receivable, accounts payable, accrued liabilities and long-term debt. The carrying value of all financial instruments approximates fair value. &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000398">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001655759_20200101_20201231" id="F_000399">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company maintains its cash in financial institution accounts that, at times during the year, may exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Cash may also be maintained at commercial institutions that are not insured by the FDIC. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2020, 100% of the Company&#x2019;s revenue was attributable to three collaborators representing 37%, 32% and 31%, respectively, and one collaborator accounted for the entire accounts receivable balance. For the year ended December&#160;31, 2019, 57% of the Company&#x2019;s revenue was attributable to a license contributed to Oerth, and two collaborators represented 19% and 16% of total revenue. For the year ended December&#160;31, 2018, two collaborators each represented over 45% of total revenue.&#160;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FederalDepositInsuranceCorporationPremiumExpense
      contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_20200101_20201231"
      decimals="INF"
      id="F_000444"
      unitRef="U_iso4217USD">250000</us-gaap:FederalDepositInsuranceCorporationPremiumExpense>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001655759_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="INF"
      id="F_000445"
      unitRef="U_xbrlipure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001655759_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="INF"
      id="F_000446"
      unitRef="U_xbrlipure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="INF"
      id="F_000447"
      unitRef="U_xbrlipure">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="INF"
      id="F_000450"
      unitRef="U_xbrlipure">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorThreeMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="INF"
      id="F_000453"
      unitRef="U_xbrlipure">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="INF"
      id="F_000454"
      unitRef="U_xbrlipure">0.57</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="INF"
      id="F_000448"
      unitRef="U_xbrlipure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="INF"
      id="F_000451"
      unitRef="U_xbrlipure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorOneMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231"
      decimals="INF"
      id="F_000449"
      unitRef="U_xbrlipure">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnCollaboratorTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231"
      decimals="INF"
      id="F_000452"
      unitRef="U_xbrlipure">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001655759_20200101_20201231" id="F_000400">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Marketable Securities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies its marketable securities as available-for-sale securities, which are carried at their fair value based on the quoted market prices of the securities with unrealized gains and losses reported as accumulated other comprehensive loss, a separate component of stockholders&#x2019;/members&#x2019; equity. Realized gains and losses on available-for-sale securities are included in net earnings in the period earned or incurred. &lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000401">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Property, Equipment, and Leasehold Improvements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from three years for office equipment to five years for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation are removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231"
      id="F_000455">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_arvnLaboratoryEquipmentMember_20200101_20201231"
      id="F_000456">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000402">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.73%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When indications of potential impairments are present, the Company evaluates the carrying value of long-lived assets. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than carrying value. No such impairments were recorded during 2020, 2019 or 2018. &lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_0001655759_20190101_20191231"
      decimals="INF"
      id="F_000458"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_0001655759_20180101_20181231"
      decimals="INF"
      id="F_000459"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_0001655759_20200101_20201231"
      decimals="INF"
      id="F_000457"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000403">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Segment Information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company&#x2019;s tangible assets are held in the United States. To date, all of the Company&#x2019;s revenue has been generated in the United States. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000404">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Revenue Recognition and Deferred Revenue &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Revenues from Contracts &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue under Accounting Standards Codification (ASC) 606, &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers.&lt;/span&gt; The Company&#x2019;s revenue is generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i)&#160;licenses, (ii) research and development activities, and (iii)&#160;participation in joint research and development steering committees. The terms of these agreements may include non-refundable upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones, and royalty payments based on product sales derived from the collaboration. Under ASC&#160;606, the Company evaluates whether the license agreement, research and development services, and participation in research and development steering committees, represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent a combined single performance obligation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The research collaboration and license agreements typically include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company determined that the most likely amount to be recognized was zero, against which no constraint was applied. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue is recognized ratably over the Company&#x2019;s expected performance period under each respective arrangement. The Company makes its best estimate of the period over which the Company expects to fulfill the Company&#x2019;s performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December&#160;31, 2020, 2019 and 2018, the transaction price allocated to the combined performance obligation identified under the agreements is recognized as revenue on a straight-line basis over the estimated performance period under each respective arrangement. Straight-line basis was considered the best measure of progress in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale; or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by the customer from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts received prior to satisfying the above revenue recognition criteria are recorded as a contract liability in the Company&#x2019;s accompanying consolidated balance sheets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also recognized revenue under ASC 606 from its contribution of a license to Oerth. See Note 12. &lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="C_0001655759_20200101_20201231" id="F_000405">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Equity Method Investments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, &lt;span style="font-style:italic;"&gt;Investments &#x2013; Equity Method and Joint Ventures&lt;/span&gt;. The Company recognizes its pro-rata share of income and losses in the investment in &#x201c;Loss from equity method investment&#x201d; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment on the consolidated balance sheet until such investment is reduced to $0.&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestments
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000460"
      unitRef="U_iso4217USD">0</us-gaap:EquityMethodInvestments>
    <arvn:PreferredUnitWarrantsPolicyPolicyTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000406">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Preferred Unit Warrants &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred unit warrants issued in conjunction with debt financings were initially recorded at fair value, using a Black-Scholes option pricing model, with a corresponding discount recorded against the face value of the note and a liability. The discount was then accreted against the face value of the note over its remaining term as additional interest expense. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classified warrants to purchase shares of its Series A Redeemable Convertible Preferred Units (Series A Preferred Units) as a liability on its balance sheets as these warrants were free-standing financial instruments that were exercisable for contingently redeemable shares. The preferred unit warrants were recorded in long-term liabilities at fair value, estimated using the Black-Scholes option pricing model, and marked to market at each balance sheet date. The change in carrying value was reported as the change in fair value of warrant liability in the accompanying consolidated statements of operations. The outstanding warrants were exercised in July 2018 and no warrants were outstanding as of December 31, 2020 and 2019.&lt;/p&gt;</arvn:PreferredUnitWarrantsPolicyPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001655759_20201231"
      decimals="INF"
      id="F_000461"
      unitRef="U_xbrlishares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001655759_20191231"
      decimals="INF"
      id="F_000462"
      unitRef="U_xbrlishares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000407">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the conversion to a C-corporation, Arvinas LLC was taxed under the provisions of Subchapter K&#x2014;Partners and Partnerships of the Internal Revenue Code. Under those provisions, Arvinas LLC did not pay federal or state corporate income taxes on its taxable income. Instead, each member would include net operating income or loss for Arvinas LLC on its individual return. Arvinas LLC was converted to a C-corporation in 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, &lt;span style="font-style:italic;"&gt;Accounting for Income Taxes&lt;/span&gt;. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management has evaluated the effect of ASC 740 guidance related to uncertain income tax positions and concluded that the Company has no significant uncertain income tax positions at December&#160;31, 2020 and 2019. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001655759_20200101_20201231" id="F_000408">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Equity-based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to its IPO, the Company periodically granted incentive units to employees and non-employees, which generally vested over a &lt;span style="-sec-ix-hidden:F_000463"&gt;four-year&lt;/span&gt; period. The incentive units represented a separate substantive class of equity with defined rights within the limited liability company agreement of Arvinas Holding Company, LLC (the LLC Operating Agreement). The incentive units represented profits interests in the Company, which was an interest in the increase in the value of the entity over the Participation Threshold, as defined in the LLC Operating Agreement and as determined at the time of grant. The holder, therefore, had the right to participate in distributions of profits only in excess of the Participation Threshold. The Participation Threshold was based on the valuation of the common unit on or around the grant date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounted for incentive units granted in accordance with ASC 718, &lt;span style="font-style:italic;"&gt;Compensation-Stock Compensation&lt;/span&gt; (ASC 718). In accordance with ASC 718, compensation expense is measured at estimated fair value of the incentive units and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures employee, board of director and consultant equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards.&#160;&#160;Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies equity-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001655759_20200101_20201231" id="F_000409">
&lt;p style="margin-bottom:0pt;margin-top:8pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses include (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites, and consultants; (iii) the cost of acquiring, developing, and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into consulting, research, and other agreements with commercial entities, researchers, universities, and others for the provision of goods and services. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#x2019;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#x2019;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000410">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC Topic 820, &lt;span style="font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;, requires disclosure of the fair value of financial instruments held by the Company. ASC 825, &lt;span style="font-style:italic;"&gt;Financial Instruments&lt;/span&gt;, defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.94%;text-indent:-2.27%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&#x2014;Inputs are based upon observable or quoted prices for identical instruments traded in active markets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:13.44%;text-indent:-7.78%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&#x2014;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#x2019;s Level&#160;2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:13.44%;text-indent:-7.78%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&#x2014;Inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s marketable securities consist of corporate bonds which are adjusted to fair value each balance sheet date, based on quoted prices, which are considered Level&#160;2 inputs (see Note 5). &lt;span style="color:#000000;"&gt;During the year ended December 31, 2019, a non-recurring fair value measurement was applied to determine the fair value of the non-cash consideration of 50% equity ownership received related to Oerth. The fair value measurement was determined using an income approach based primarily on utilizing management&#x2019;s estimates of future cash flows as inputs, which are considered Level 3 measurements within the above fair value hierarchy.&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20191231"
      decimals="INF"
      id="F_000464"
      unitRef="U_xbrlipure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000411">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Net Loss per Common Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per common share is computed by dividing net loss, after adjusting for redeemable preferred unit dividends, by the weighted-average number of common shares outstanding during the period. The change in current redemption value of the redeemable preferred units was treated as a deemed dividend for the period during 2018 prior to conversion to common units. Diluted net loss per share was computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common shares. The effect of the conversion of redeemable preferred units into common units was excluded from the computation of diluted net loss per common share for all periods as their effect was antidilutive. Additionally, common share equivalents are excluded from the computation of diluted net loss per common share for all periods as their effect is antidilutive. &lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000412">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13&lt;span style="font-style:italic;"&gt;, Financial&lt;/span&gt; &lt;span style="font-style:italic;"&gt;Instruments &#x2013; Credit Losses&lt;/span&gt;, which provides a model for recognizing credit losses on financial instruments based on an estimate of current&lt;span style="font-style:italic;"&gt; &lt;/span&gt;expected losses, requiring immediate recognition of credit losses expected over the life of a financial instrument. The Company adopted ASU 2016-13 in the first quarter of 2020. The adoption of the standard was immaterial to the accompanying consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#x2019;s financial statements upon adoption. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <arvn:LicenseAgreementsTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000382">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;3. License Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2013, the Company entered into an exclusive license agreement, including the right to grant sublicenses, with Yale University to develop protein degradation technologies. In connection with the execution of this license agreement, the Company made a non-refundable upfront payment of $149,511. In addition to the upfront payment, the Company paid Yale University a License Maintenance Royalty of varying amounts through the fourth anniversary of the license agreement. The minimum annual payment will be&#160;$75,000 until the first sale to a third party of any licensed product. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is also required to pay Yale University success-based milestones for the development of the protein degradation technologies as well as low single-digit running royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to a minimum royalty payment that ranges from $200,000 to $500,000. The agreement requires that, if the Company sublicenses the protein degradation technologies to a third party, the Company must pay Yale University a mid-single digit to mid-double digit percentage of Sublicense Income (as defined in the agreement) received on the first licensed product therewith. During 2015, the Company paid $750,000 to Yale University for sublicense consideration, representing the maximum amount required to be paid for sublicense consideration for a licensed product and satisfying this obligation. During 2020, 2019 and 2018, the Company paid $150,000, $150,000 and $75,000, respectively, under the license agreement. The Company is also required to reimburse Yale University for patent costs incurred. During 2020, 2019 and 2018, the Company reimbursed Yale University $196,167, $352,663 and $216,093, respectively, for patent costs. &lt;/p&gt;</arvn:LicenseAgreementsTextBlock>
    <arvn:NonRefundableUpfrontPayment
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20130701_20130731"
      decimals="0"
      id="F_000468"
      unitRef="U_iso4217USD">149511</arvn:NonRefundableUpfrontPayment>
    <arvn:AnnualLicenseFeePayment
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_20200101_20201231"
      decimals="0"
      id="F_000469"
      unitRef="U_iso4217USD">75000</arvn:AnnualLicenseFeePayment>
    <us-gaap:PaymentsForRoyalties
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_srtRangeAxis_srtMinimumMember_20200101_20201231"
      decimals="0"
      id="F_000470"
      unitRef="U_iso4217USD">200000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_srtRangeAxis_srtMaximumMember_20200101_20201231"
      decimals="INF"
      id="F_000471"
      unitRef="U_iso4217USD">500000</us-gaap:PaymentsForRoyalties>
    <arvn:CollaborativeArrangementSublicensePayment
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_srtRangeAxis_srtMaximumMember_20150101_20151231"
      decimals="INF"
      id="F_000472"
      unitRef="U_iso4217USD">750000</arvn:CollaborativeArrangementSublicensePayment>
    <arvn:CollaborativeArrangementPayment
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000473"
      unitRef="U_iso4217USD">150000</arvn:CollaborativeArrangementPayment>
    <arvn:CollaborativeArrangementPayment
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000474"
      unitRef="U_iso4217USD">150000</arvn:CollaborativeArrangementPayment>
    <arvn:CollaborativeArrangementPayment
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000475"
      unitRef="U_iso4217USD">75000</arvn:CollaborativeArrangementPayment>
    <arvn:ReimbursementOfPatentRelatedCost
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20200101_20201231"
      decimals="0"
      id="F_000476"
      unitRef="U_iso4217USD">196167</arvn:ReimbursementOfPatentRelatedCost>
    <arvn:ReimbursementOfPatentRelatedCost
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20190101_20191231"
      decimals="0"
      id="F_000477"
      unitRef="U_iso4217USD">352663</arvn:ReimbursementOfPatentRelatedCost>
    <arvn:ReimbursementOfPatentRelatedCost
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnYaleUniversityMember_20180101_20181231"
      decimals="0"
      id="F_000478"
      unitRef="U_iso4217USD">216093</arvn:ReimbursementOfPatentRelatedCost>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000383">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;4. Research Collaboration and License Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (Bayer Collaboration Agreement) setting forth the Company&#x2019;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras, or PROTAC&#xae; targeted protein degraders, that mediate for degradation of target proteins (Targets), using the Company&#x2019;s proprietary platform technology, which Targets will be selected by Bayer AG, subject to certain exclusions and limitations.&#160;&#160;The Bayer Collaboration Agreement became effective in July 2019. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront non-refundable payment of $17.5 million in exchange for the use of the Company&#x2019;s technology license and a $1.5 million payment to fund research activities. Bayer is committed to fund an additional $10.5 million through 2022, of which $3.0 million was received in 2020. These payments are being recognized over the total estimated period of performance. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;The Company is also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated Targets. In addition, the Company is eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions. &lt;/span&gt;&lt;/p&gt;


&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the Bayer Collaboration Agreement and a Stock Purchase Agreement entered into with Bayer AG at the same time should be evaluated as a combined contract in accordance with ASC 606, &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;, given that the agreements were entered into at the same time and have the same commercial objective to provide funding to further the Company&#x2019;s research utilizing its proprietary technology. The Company identified the elements under the agreements as license and research revenue and the issuance of the common stock. The Company determined the fair value of the shares sold under the Stock Purchase Agreement to be $2.9 million less than the contractual purchase price stipulated in the agreement. In accordance with the applicable accounting guidance in ASC 815-40, &lt;span style="font-style:italic;"&gt;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;, the Company determined that the sale of stock should be recorded at fair value. Therefore, the Company allocated the additional $2.9 million of consideration received under the Stock Purchase Agreement to the Bayer Collaboration Agreement given that the two contracts were determined to be combined contracts. This amount has, therefore, been added to the total transaction price and was included in initial contract liabilities balances.  &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.87%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer, Inc. (Pfizer) (the Pfizer Collaboration Agreement). Under the terms of the Pfizer Collaboration Agreement, the Company received an upfront non-refundable payment and certain additional payments totaling $28.0&#160;million in 2018 in exchange for use of the Company&#x2019;s technology license and to fund Pfizer-related research as defined within the agreement. These payments are being recognized as revenue over the total estimated period of performance. The Company is also eligible to receive up to an additional $37.5&#160;million in non-refundable option payments if Pfizer exercises its options for all targets under the agreement. Pfizer has exercised options for $4.9 million as of December 31, 2020. The options are recognized as revenue over the estimated period of performance. The Company is also entitled to receive up to $225 million in development milestone payments and up to $550 million in sales-based milestone payments for all designated targets under the Pfizer Collaboration Agreement, as well as tiered royalties based on sales. Pfizer paid the Company $1.2 million in December 2019 and $3.0 million in 2020 relating to adding additional targets into the collaboration. These payments are being recognized over the estimated period of performance.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.87%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2015, the Company entered into an Option and License Agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together, Genentech) (the Genentech Agreement). During 2015, the Company received an upfront non-refundable payment of $11.0&#160;million in exchange for use of the Company&#x2019;s technology license and to fund Genentech-related research as defined within the Genentech Agreement. In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd (the Genentech Modification), amending the Genentech Agreement. Under the Genentech Modification, the Company received additional upfront non-refundable payments of $34.5&#160;million to fund Genentech-related research and Genentech has the right to designate up to ten targets. The Company is eligible to receive up to $27.5 million in additional expansion target payments if Genentech exercises its options on all remaining targets. Upfront non-refundable payments are recognized as revenue over the total estimated period of performance. The Company is eligible to receive up to $44.0&#160;million per target in development milestone payments, $52.5&#160;million in regulatory milestone payments and $60.0 million in commercial milestone payments based on sales as well as tiered royalties based on sales.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Information about contract liabilities, included as deferred revenue in the accompanying Consolidated Balance Sheets, is as follows: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,089,094&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58,407,407&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues recognized in the period from:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts included in deferred revenue in previous periods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,651,649&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,335,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in deferred revenue as of December 31, 2020 from 2019 were due to $21.8 million of revenue recognized on the research collaboration and license agreements and additions to deferred revenue of $8.5&#160;million related to the Bayer Collaboration Agreement and Pfizer Collaboration Agreement.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate amount of the transaction price allocated to performance obligations that are unsatisfied as of December&#160;31, 2020 was $45.1&#160;million, which is expected to be recognized in the following periods (in millions): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190731"
      decimals="-5"
      id="F_000479"
      unitRef="U_iso4217USD">17500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnResearchFundingPaymentsMember_20190731"
      decimals="-5"
      id="F_000480"
      unitRef="U_iso4217USD">1500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapTypeOfArrangementAxis_arvnResearchFundingPaymentsMember_20221231"
      decimals="-5"
      id="F_000481"
      unitRef="U_iso4217USD">10500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnResearchFundingPaymentsMember_20201231"
      decimals="-5"
      id="F_000482"
      unitRef="U_iso4217USD">3000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnDevelopmentMilestonePaymentsMember_20190731"
      decimals="INF"
      id="F_000483"
      unitRef="U_iso4217USD">197500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnSalesBasedMilestonePaymentsMember_20190731"
      decimals="INF"
      id="F_000484"
      unitRef="U_iso4217USD">490000000.0</us-gaap:ContractWithCustomerAssetNet>
    <arvn:SaleOfStockFairValueOfSharesSold
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnStockPurchaseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000485"
      unitRef="U_iso4217USD">2900000</arvn:SaleOfStockFairValueOfSharesSold>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnStockPurchaseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000486"
      unitRef="U_iso4217USD">2900000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <arvn:NumberOfContractsToBeCombined
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_us-gaapTypeOfArrangementAxis_arvnStockPurchaseAgreementMember_20200101_20201231"
      decimals="INF"
      id="F_000487"
      unitRef="U_arvnContract">2</arvn:NumberOfContractsToBeCombined>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_20180101_20181231"
      decimals="-5"
      id="F_000488"
      unitRef="U_iso4217USD">28000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnOptionPaymentsToLicenseAgreementMember_20201231"
      decimals="INF"
      id="F_000490"
      unitRef="U_iso4217USD">37500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_us-gaapTypeOfArrangementAxis_arvnOptionExercisedToLicenseAgreementsMember_20201231"
      decimals="-5"
      id="F_000489"
      unitRef="U_iso4217USD">4900000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnDevelopmentMilestonePaymentsMember_20201231"
      decimals="INF"
      id="F_000491"
      unitRef="U_iso4217USD">225000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnSalesBasedMilestonePaymentsMember_20201231"
      decimals="INF"
      id="F_000492"
      unitRef="U_iso4217USD">550000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_us-gaapTypeOfArrangementAxis_arvnSubstitutionTargetPaymentsMember_20191231"
      decimals="INF"
      id="F_000493"
      unitRef="U_iso4217USD">1200000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPfizerIncorporationMember_us-gaapTypeOfArrangementAxis_arvnSubstitutionTargetPaymentsMember_20201231"
      decimals="INF"
      id="F_000494"
      unitRef="U_iso4217USD">3000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_20150901_20151231"
      decimals="-5"
      id="F_000495"
      unitRef="U_iso4217USD">11000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_20171101_20171130"
      decimals="-5"
      id="F_000496"
      unitRef="U_iso4217USD">34500000</us-gaap:ProceedsFromCollaborators>
    <arvn:NumberOfMaximumDesignatedTargets
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_20171101_20171130"
      decimals="INF"
      id="F_000497"
      unitRef="U_arvnTarget">10</arvn:NumberOfMaximumDesignatedTargets>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnOptionPaymentsToLicenseAgreementMember_20171130"
      decimals="-5"
      id="F_000501"
      unitRef="U_iso4217USD">27500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arvnDevelopmentMilestonePaymentsMember_20171130"
      decimals="-5"
      id="F_000498"
      unitRef="U_iso4217USD">44000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_us-gaapTypeOfArrangementAxis_arvnRegulatoryMilestonePaymentsMember_20171130"
      decimals="-5"
      id="F_000499"
      unitRef="U_iso4217USD">52500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnGenentechIncorporationAndFHoffmanLaRocheLimitedMember_us-gaapTypeOfArrangementAxis_arvnCommercialMilestonesMember_20171130"
      decimals="-5"
      id="F_000500"
      unitRef="U_iso4217USD">60000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000413">
&lt;p style="margin-bottom:6pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Information about contract liabilities, included as deferred revenue in the accompanying Consolidated Balance Sheets, is as follows: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,089,094&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58,407,407&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues recognized in the period from:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts included in deferred revenue in previous periods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,651,649&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,335,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000502"
      unitRef="U_iso4217USD">45089094</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000503"
      unitRef="U_iso4217USD">58407407</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000504"
      unitRef="U_iso4217USD">18651649</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000505"
      unitRef="U_iso4217USD">14335188</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001655759_20200101_20201231"
      decimals="-5"
      id="F_000507"
      unitRef="U_iso4217USD">21800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGAndPfizerMember_20200101_20201231"
      decimals="-5"
      id="F_000506"
      unitRef="U_iso4217USD">8500000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000414">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate amount of the transaction price allocated to performance obligations that are unsatisfied as of December&#160;31, 2020 was $45.1&#160;million, which is expected to be recognized in the following periods (in millions): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0001655759_20201231"
      decimals="-5"
      id="F_000508"
      unitRef="U_iso4217USD">45100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231"
      decimals="-5"
      id="F_000509"
      unitRef="U_iso4217USD">19400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_20201231"
      decimals="-5"
      id="F_000510"
      unitRef="U_iso4217USD">19200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2023-01-01_20201231"
      decimals="-5"
      id="F_000511"
      unitRef="U_iso4217USD">6500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0001655759_20201231"
      decimals="-5"
      id="F_000515"
      unitRef="U_iso4217USD">45100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000384">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Marketable Securities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of the Company&#x2019;s available-for-sale securities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,596,821&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;560,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,157,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,596,821&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;560,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,157,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;145,359,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,722&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;145,409,598&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,194,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,251,858&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271,553,880&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,576&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271,661,456&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets and liabilities measured on a recurring basis as of:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,157,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,157,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271,661,456&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271,661,456&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The carrying value of account receivable, accounts payable and accrued expenses approximate their fair value due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000415">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of the Company&#x2019;s available-for-sale securities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,596,821&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;560,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,157,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,596,821&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;560,797&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,157,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;145,359,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,722&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;145,409,598&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,194,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,251,858&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271,553,880&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,576&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271,661,456&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <arvn:AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod
      contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20200101_20201231"
      id="F_000516">2021</arvn:AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20201231"
      decimals="0"
      id="F_000517"
      unitRef="U_iso4217USD">99596821</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20201231"
      decimals="0"
      id="F_000519"
      unitRef="U_iso4217USD">560797</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20201231"
      decimals="0"
      id="F_000521"
      unitRef="U_iso4217USD">100157618</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000518"
      unitRef="U_iso4217USD">99596821</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000520"
      unitRef="U_iso4217USD">560797</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000522"
      unitRef="U_iso4217USD">100157618</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <arvn:AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod
      contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnTwoThousandTwentyMaturityMember_20190101_20191231"
      id="F_000523">2020</arvn:AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnTwoThousandTwentyMaturityMember_20191231"
      decimals="0"
      id="F_000525"
      unitRef="U_iso4217USD">145359876</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnTwoThousandTwentyMaturityMember_20191231"
      decimals="0"
      id="F_000528"
      unitRef="U_iso4217USD">49722</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnTwoThousandTwentyMaturityMember_20191231"
      decimals="0"
      id="F_000531"
      unitRef="U_iso4217USD">145409598</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <arvn:AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod
      contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20190101_20191231"
      id="F_000524">2021</arvn:AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20191231"
      decimals="0"
      id="F_000526"
      unitRef="U_iso4217USD">126194004</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20191231"
      decimals="0"
      id="F_000529"
      unitRef="U_iso4217USD">57854</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001655759_us-gaapInvestmentTypeAxis_arvnCorporateBondsMaturingTwoThousandTwentyOneMember_20191231"
      decimals="0"
      id="F_000532"
      unitRef="U_iso4217USD">126251858</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000527"
      unitRef="U_iso4217USD">271553880</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000530"
      unitRef="U_iso4217USD">107576</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000533"
      unitRef="U_iso4217USD">271661456</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000416">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets and liabilities measured on a recurring basis as of:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,157,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,157,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271,661,456&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271,661,456&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001655759_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231"
      decimals="0"
      id="F_000534"
      unitRef="U_iso4217USD">100157618</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001655759_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231"
      decimals="0"
      id="F_000535"
      unitRef="U_iso4217USD">100157618</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001655759_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231"
      decimals="0"
      id="F_000536"
      unitRef="U_iso4217USD">271661456</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001655759_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231"
      decimals="0"
      id="F_000537"
      unitRef="U_iso4217USD">271661456</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000385">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;6. Property, Equipment and Leasehold Improvements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, equipment and leasehold improvements consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,100,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,045,179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,233,823&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;865,888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,058,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,809,205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,392,339&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,720,272&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,132,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,264,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, equipment and leasehold improvements, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,259,515&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,455,411&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense totaled $3,166,139, $1,561,557 and $706,000 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000417">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, equipment and leasehold improvements consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,100,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,045,179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,233,823&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;865,888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,058,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,809,205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,392,339&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,720,272&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,132,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,264,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, equipment and leasehold improvements, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,259,515&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,455,411&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_arvnLaboratoryEquipmentMember_20201231"
      decimals="0"
      id="F_000538"
      unitRef="U_iso4217USD">11100116</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_arvnLaboratoryEquipmentMember_20191231"
      decimals="0"
      id="F_000539"
      unitRef="U_iso4217USD">8045179</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231"
      decimals="0"
      id="F_000540"
      unitRef="U_iso4217USD">1233823</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231"
      decimals="0"
      id="F_000541"
      unitRef="U_iso4217USD">865888</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="0"
      id="F_000542"
      unitRef="U_iso4217USD">6058400</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001655759_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231"
      decimals="0"
      id="F_000543"
      unitRef="U_iso4217USD">2809205</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000544"
      unitRef="U_iso4217USD">18392339</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000545"
      unitRef="U_iso4217USD">11720272</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000546"
      unitRef="U_iso4217USD">6132824</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000547"
      unitRef="U_iso4217USD">3264861</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000548"
      unitRef="U_iso4217USD">12259515</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000549"
      unitRef="U_iso4217USD">8455411</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000550"
      unitRef="U_iso4217USD">3166139</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000551"
      unitRef="U_iso4217USD">1561557</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000552"
      unitRef="U_iso4217USD">706000</us-gaap:Depreciation>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000386">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;7. Right to Use Assets and Liabilities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.73%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in the consolidated balance sheets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.19%;text-indent:5.9%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate ranges from 3.2% &#x2013; 6.6%. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Some of the Company&#x2019;s leases include options to extend or terminate the lease. The Company includes these options in the recognition of the Company&#x2019;s ROU assets and lease liabilities when it is reasonably certain that the Company will exercise the option.&lt;span style="font-family:Times New Roman;color:#000000;"&gt; &lt;/span&gt;The Company has operating leases for its corporate office and certain equipment, which expire no later than September 2024. The leases have a weighted average remaining term of 1.9 years. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;font-family:Times New Roman;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease expense were as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;995,228&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;817,057&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information related to leases was as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;920,158&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;581,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental non-cash information:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets obtained in exchange for new lease&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;572,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;571,886&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities of lease liabilities for operating leases as of December 31, 2020 are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,124,684&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,108,065&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,041&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,244,790&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(204,529&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,040,261&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to January 1, 2019, the Company accounted for its leases in accordance with ASC Topic 840, Leases. At December 31, 2018, the Company was committed under operating leases for its corporate office and certain equipment. Total rent expense under operating leases for the year ended December 31, 2018 was $606,538. &lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <arvn:PercentageOfIncrementalBorrowingForLleasePayments
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_20201231"
      decimals="3"
      id="F_000553"
      unitRef="U_xbrlipure">0.032</arvn:PercentageOfIncrementalBorrowingForLleasePayments>
    <arvn:PercentageOfIncrementalBorrowingForLleasePayments
      contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_20201231"
      decimals="3"
      id="F_000554"
      unitRef="U_xbrlipure">0.066</arvn:PercentageOfIncrementalBorrowingForLleasePayments>
    <arvn:LesseeOperatingLeaseExpirationMonthAndYear contextRef="C_0001655759_20200101_20201231" id="F_000558">2024-09</arvn:LesseeOperatingLeaseExpirationMonthAndYear>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001655759_20201231" id="F_000557">P1Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000418">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease expense were as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;995,228&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;817,057&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000559"
      unitRef="U_iso4217USD">995228</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000560"
      unitRef="U_iso4217USD">817057</us-gaap:OperatingLeaseCost>
    <arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000419">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information related to leases was as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;920,158&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;581,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental non-cash information:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets obtained in exchange for new lease&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;572,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;571,886&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000561"
      unitRef="U_iso4217USD">920158</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000562"
      unitRef="U_iso4217USD">581961</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000563"
      unitRef="U_iso4217USD">572413</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000564"
      unitRef="U_iso4217USD">571886</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000420">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities of lease liabilities for operating leases as of December 31, 2020 are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,124,684&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,108,065&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,041&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,244,790&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(204,529&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,040,261&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000565"
      unitRef="U_iso4217USD">1124684</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000566"
      unitRef="U_iso4217USD">1108065</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <arvn:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000567"
      unitRef="U_iso4217USD">12041</arvn:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000568"
      unitRef="U_iso4217USD">2244790</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000569"
      unitRef="U_iso4217USD">204529</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000570"
      unitRef="U_iso4217USD">2040261</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000571"
      unitRef="U_iso4217USD">606538</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000387">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;8. Accrued Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,967,126&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,810,723&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,113,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,186,935&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,779,671&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;605,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,859,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,602,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000421">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,967,126&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,810,723&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,113,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,186,935&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,779,671&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;605,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,859,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,602,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000572"
      unitRef="U_iso4217USD">8967126</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000573"
      unitRef="U_iso4217USD">5810723</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <arvn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000574"
      unitRef="U_iso4217USD">8113043</arvn:AccruedResearchAndDevelopmentExpenseCurrent>
    <arvn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000575"
      unitRef="U_iso4217USD">1186935</arvn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000576"
      unitRef="U_iso4217USD">1779671</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000577"
      unitRef="U_iso4217USD">605246</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000578"
      unitRef="U_iso4217USD">18859840</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000579"
      unitRef="U_iso4217USD">7602904</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000388">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;9. Long-Term Debt &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2013, the Company entered into a Loan Agreement (Loan) and a Stock Subscription Warrant, with Connecticut Innovations, Incorporated (CII). Under the Loan, the Company could draw up to $750,000 for the purpose of purchasing laboratory equipment, information technology equipment and leasehold improvements. Leasehold improvements are limited to $100,000. Interest on the Loan was compounded on a monthly basis at a rate of 7.50% per annum and was required to be paid on a monthly basis beginning on the date of the first draw of funds for 10 months, then with principal payments beginning on June&#160;1, 2015 and payable monthly until the maturity date of July&#160;31, 2019. The Company had the ability to prepay the amount due at any time prior to the maturity date without premium or penalty. The Loan was secured by substantially all of the Company&#x2019;s assets. As of December&#160;31, 2018, the amount outstanding under the Loan was $169,610 &lt;span style="color:#000000;"&gt;and the total unamortized debt discount on the Loan totaled $7,210. The Company paid the loan in full in July 2019. Interest expense recorded related to the amortization of the debt discount in the years ended December&#160;31, 2019 and 2018 was $7,210 and $12,359, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with an Assistance Agreement with the State of Connecticut (Assistance Agreement) entered into in 2014, under which all the borrowings by the Company were forgiven in accordance with the Assistance Agreement, the Company is required to be located in the State of Connecticut through January 2024, with a default penalty of repayment of the full original funding amount of $2.5&#160;million plus liquidated damages of 7.5%. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the Company entered into an Assistance Agreement with the State of Connecticut (2018 Assistance Agreement) to provide funding for the expansion and renovation of laboratory and office space (Project). Under the terms of the 2018 Assistance Agreement, the Company could borrow from the State of Connecticut a maximum of $2.0&#160;million, provided that the funding does not exceed more than 50% of the total Project costs. In September 2018, the Company borrowed $2.0 million under the 2018 Assistance Agreement, bearing interest at 3.25% per annum and interest payments will be required for the first 60 months from the funding date. Thereafter, the loan begins to fully amortize through month 120, maturing in June 2028. According to the terms of the 2018 Assistance Agreement, up to $1.0&#160;million of the funding can be forgiven if the Company meets certain employment conditions, as defined in the agreement. The Company may also be required to prepay a portion of the loan if the employment conditions are not met. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through June 2028 with a default penalty of repayment of the full original funding amount of $2.0&#160;million plus liquidated damages of 7.5% of the total amount of funding received. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anticipated future minimum payments on long-term debt as of December&#160;31, 2020 are: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;377,516&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;389,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beyond 5 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,140,034&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&#160;31, 2020, 2019 and 2018, interest expense was $65,000, $85,569 and $57,440, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <arvn:DebtInstrumentMaximumBorrowingCapacity
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130831"
      decimals="INF"
      id="F_000580"
      unitRef="U_iso4217USD">750000</arvn:DebtInstrumentMaximumBorrowingCapacity>
    <arvn:DebtInstrumentMaximumBorrowingCapacity
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130831"
      decimals="INF"
      id="F_000581"
      unitRef="U_iso4217USD">100000</arvn:DebtInstrumentMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20200101_20201231"
      id="F_000582">monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130831"
      decimals="INF"
      id="F_000583"
      unitRef="U_xbrlipure">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <arvn:DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130801_20130831"
      id="F_000584">P10M</arvn:DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds>
    <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130801_20130831"
      id="F_000585">2015-06-01</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20130801_20130831"
      id="F_000586">2019-07-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LongTermDebt
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnConnecticutInnovationsIncorporatedMember_us-gaapLongtermDebtTypeAxis_us-gaapSecuredDebtMember_us-gaapTypeOfArrangementAxis_arvnLoanAgreementMember_20181231"
      decimals="0"
      id="F_000587"
      unitRef="U_iso4217USD">169610</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_0001655759_20181231"
      decimals="0"
      id="F_000588"
      unitRef="U_iso4217USD">7210</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000589"
      unitRef="U_iso4217USD">7210</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000590"
      unitRef="U_iso4217USD">12359</us-gaap:AmortizationOfFinancingCosts>
    <arvn:DebtInstrumentMaturityMonthAndYear
      contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndFourteenAssistanceAgreementMember_20140101_20141231"
      id="F_000591">2024-01</arvn:DebtInstrumentMaturityMonthAndYear>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndFourteenAssistanceAgreementMember_20141231"
      decimals="INF"
      id="F_000592"
      unitRef="U_iso4217USD">2500000</us-gaap:DebtInstrumentFaceAmount>
    <arvn:PercentageOfLiquidatedDamages
      contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndFourteenAssistanceAgreementMember_20140101_20141231"
      decimals="3"
      id="F_000593"
      unitRef="U_xbrlipure">0.075</arvn:PercentageOfLiquidatedDamages>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180630"
      decimals="INF"
      id="F_000594"
      unitRef="U_iso4217USD">2000000.0</us-gaap:DebtInstrumentFaceAmount>
    <arvn:PercentageOfMaximumFundingOnProjectCosts
      contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180601_20180630"
      decimals="INF"
      id="F_000595"
      unitRef="U_xbrlipure">0.50</arvn:PercentageOfMaximumFundingOnProjectCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180930"
      decimals="INF"
      id="F_000596"
      unitRef="U_iso4217USD">2000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180930"
      decimals="INF"
      id="F_000597"
      unitRef="U_xbrlipure">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <arvn:DebtInstrumentInterestPaymentsTerm
      contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930"
      id="F_000598">P60M</arvn:DebtInstrumentInterestPaymentsTerm>
    <arvn:DebtInstrumentMaturityMonthAndYear
      contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930"
      id="F_000600">2028-06</arvn:DebtInstrumentMaturityMonthAndYear>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930"
      decimals="INF"
      id="F_000601"
      unitRef="U_iso4217USD">1000000.0</us-gaap:DebtInstrumentDecreaseForgiveness>
    <arvn:DebtInstrumentMaturityMonthAndYear
      contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930"
      id="F_000602">2028-06</arvn:DebtInstrumentMaturityMonthAndYear>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180930"
      decimals="INF"
      id="F_000603"
      unitRef="U_iso4217USD">2000000.0</us-gaap:DebtInstrumentFaceAmount>
    <arvn:PercentageOfLiquidatedDamages
      contextRef="C_0001655759_srtStatementGeographicalAxis_stprCT_us-gaapDebtInstrumentAxis_arvnTwoThousandAndEighteenAssistanceAgreementMember_20180901_20180930"
      decimals="3"
      id="F_000604"
      unitRef="U_xbrlipure">0.075</arvn:PercentageOfLiquidatedDamages>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000422">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anticipated future minimum payments on long-term debt as of December&#160;31, 2020 are: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;377,516&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;389,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beyond 5 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,140,034&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000605"
      unitRef="U_iso4217USD">92480</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000606"
      unitRef="U_iso4217USD">377516</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000607"
      unitRef="U_iso4217USD">389970</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000608"
      unitRef="U_iso4217USD">1140034</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000609"
      unitRef="U_iso4217USD">2000000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000610"
      unitRef="U_iso4217USD">65000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000611"
      unitRef="U_iso4217USD">85569</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000612"
      unitRef="U_iso4217USD">57440</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000389">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;10. Members&#x2019; Equity &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Common Units &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each common unit entitled the holder to one vote on all matters submitted to a vote of the Company&#x2019;s members. As noted in Note 1, in September 2018, all issued and outstanding common units were converted into common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Preferred Units &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2013 and 2014, Arvinas, Inc. sold 22,463,665 shares of Series A Redeemable Convertible Preferred Stock (Series A Preferred Stock) for $15.3&#160;million at a price of $0.6811 per share. The Series A Preferred Stock was subsequently exchanged for Series A Preferred Units in Arvinas LLC upon the reorganization. During 2015, the Company sold 24,977,489 Series B Redeemable Convertible Preferred Units (Series B Preferred Units) in exchange for $41.6&#160;million at a price of $1.6659 per share.&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt; &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;In March 2018, the Company entered into a Series C Preferred Unit Purchase Agreement (the Series C Agreement) to raise additional equity. Under the terms of the Series C Agreement, the Company sold 16,467,066 units of Series C Redeemable Convertible Preferred Units (Series C Preferred Units) for $55.0 million at a price of $3.34 per unit. &lt;/span&gt;As noted in Note 1, in September 2018, after giving effect of the 3.25 to 1 reverse split, all issued and outstanding preferred units were converted into preferred stock and subsequently into common stock upon the closing of the IPO.&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_arvnCommonUnitsMember_20200101_20201231"
      id="F_000613">one</us-gaap:CommonStockVotingRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredStockMember_20130101_20141231"
      decimals="INF"
      id="F_000614"
      unitRef="U_xbrlishares">22463665</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredStockMember_20130101_20141231"
      decimals="-5"
      id="F_000616"
      unitRef="U_iso4217USD">15300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredStockMember_20141231"
      decimals="4"
      id="F_000618"
      unitRef="U_iso4217USD_xbrlishares">0.6811</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20150101_20151231"
      decimals="INF"
      id="F_000615"
      unitRef="U_xbrlishares">24977489</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20150101_20151231"
      decimals="-5"
      id="F_000617"
      unitRef="U_iso4217USD">41600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesBRedeemableConvertiblePreferredUnitsMember_20151231"
      decimals="4"
      id="F_000619"
      unitRef="U_iso4217USD_xbrlishares">1.6659</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180301_20180331"
      decimals="INF"
      id="F_000620"
      unitRef="U_xbrlishares">16467066</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180301_20180331"
      decimals="-5"
      id="F_000621"
      unitRef="U_iso4217USD">55000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesCRedeemableConvertiblePreferredUnitsMember_20180331"
      decimals="2"
      id="F_000622"
      unitRef="U_iso4217USD_xbrlishares">3.34</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001655759_20180901_20180930"
      decimals="2"
      id="F_000623"
      unitRef="U_xbrlipure">3.25</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000390">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;11. Equity &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Common Stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;During December 2020, the Company completed a public offering in which the Company issued and sold 6,571,428 shares of common stock at a public offering price of $70.00 per share, which resulted in aggregate net proceeds of $431.9 million, net of underwriter discounts, commissions and offering costs of $28.1 million.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2019, the Company entered into an Equity Distribution Agreement (Distribution Agreement) with Piper Sandler Companies, formerly Piper Jaffray &amp;amp; Co. (Piper Sandler), pursuant to which the Company may offer and sell from time-to-time in an &#x201c;at-the-market offering,&#x201d; at its option, up to an aggregate of $100.0 million of shares of the Company&#x2019;s common stock through Piper Sandler, as sales agent. During year ended December 31, 2020, the Company sold 2,593,637 shares of its common stock resulting in proceeds to the Company of $64.1 million, net of offering costs of $1.6 million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In November 2019, the Company completed a public offering in which the Company issued and sold 5,227,273 shares of common stock at a public offering price of $22.00 per share. The Company&#x2019;s aggregate gross proceeds from the sale of shares in the public offering was $115.0 million before fees and expenses of $7.4 million.&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2019, the Company entered into a Stock Purchase Agreement with Bayer AG pursuant to which, in connection with the closing in July 2019, the Company issued and sold to Bayer AG 1,346,313 shares of the Company&#x2019;s common stock (the Shares) for a contractually stated purchase price of $32.5 million. The value of the shares of the Company&#x2019;s common stock was based on the average of the Company&#x2019;s&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;common stock for the preceding 60 days prior to the signing of the Stock Purchase Agreement plus a fifteen percent premium. On October 1, 2019, the Company filed a registration statement covering these shares. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Share-based Compensation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the 2018 ESPP) initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company&#x2019;s common stock. The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by an additional 323,377 shares, equal to 1% of the Company&#x2019;s then-outstanding common stock, effective as of January 1, 2019, and by an additional 390,371 shares, equal to 1% of the Company&#x2019;s then-outstanding common stock, effective as of January 1, 2020. The first offering period under the 2018 ESPP commenced on January 1, 2020. During the year ended December 31, 2020, the Company issued 11,046 shares of common stock under the 2018 ESPP. As of December 31, 2020, 1,014,552 shares remained available for purchase.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All of the Company&#x2019;s employees are eligible to participate in the 2018 ESPP, provided they meet certain employment requirements. On each offering commencement date, each participant will be granted the right to purchase, on the last business day of the offering period, a number of shares of the Company&#x2019;s common stock determined by multiplying $2,083 by the number of full months in the offering period and dividing that product by the closing price of the Company&#x2019;s common stock on the first day of the offering period. On the commencement date of each offering period, each eligible employee may authorize up to a maximum of 15% of the compensation he or she receives during the offering period to be deducted by the Company during the offering period. Under the terms of the 2018 ESPP, the purchase price shall be determined by the Company&#x2019;s board of directors for each offering period and will be at least 85% of the applicable closing price of the Company&#x2019;s common stock. If the Company&#x2019;s board of directors does not make a determination of the purchase price, the purchase price will be 85% of the lesser of the closing price of the Company&#x2019;s common stock on the first business day of the offering period or the last business day of the offering period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the Fourth Amendment to the Company&#x2019;s Incentive Share Plan (the Incentive Plan) adopted in March 2018, the Company was authorized to issue up to an aggregate of 6,199,477 incentive units pursuant to the Incentive Plan. Generally, incentive units were granted at no less than fair value as determined by the board of managers and had vesting periods ranging from one to four years. The Incentive Plan was terminated in &lt;span style="-sec-ix-hidden:F_000654"&gt;September 2018&lt;/span&gt;. In September 2018, the Company&#x2019;s board of directors adopted and the Company&#x2019;s stockholders approved the 2018 Stock Incentive Plan (the 2018 Plan), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#x2019;s IPO. The number of common shares initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181) issued in respect of incentive units granted under the Incentive Plan that are subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;increase on the first day of each fiscal year beginning with the fiscal year end&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ed &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019 and continuing to, and including, the fiscal year ending December 31, 2028, equal to the lowest of &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,989,593&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares of the Company&#x2019;s common stock, &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;% of the number of shares of the Company&#x2019;s common stock outstanding on the first day of the fiscal year and an amount determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The increase in the number of authorized shares for the fiscal year&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;s&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; ending December 31, &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020 and &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019 was&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,561,485&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,293,510&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, respectively&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&#160;Common shares subject to outstanding equity awards that expire or are terminated, surrendered, or cancel&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;l&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ed without having been fully exercised or are forfeited in whole or in part shall be available for future grants of awards.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2018, the Company granted 1,715,368 incentive units to employees and directors under the Incentive Plan. In September 2018, each outstanding incentive unit was converted into a number of shares of common stock based upon the IPO price. Certain of the shares of common stock issued in respect of incentive units continue to be subject to vesting in accordance with the vesting schedule that was applicable to such incentive units. The Company granted 1,253,263 restricted shares to employees and directors as part of the conversion. The Company also granted 1,744,650 stock options to purchase shares of common stock to employees and directors who were holders of incentive units at the time of the incentive unit conversion. &lt;span style="color:#000000;"&gt;In September 2018, in connection with the conversion of the incentive units, the Company granted 11,097 restricted shares of common stock and 251,010 stock options to purchase shares of common stock to consultants.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December 31, 2020, 2019 and 2018, the Company recognized $30,230,858, $20,072,710 and $11,630,300, respectively, of total compensation expense for awards classified as equity awards related to its stock options, restricted stock awards and restricted stock units. At December 31, 2020, there was $22,647,241 of compensation expense that is expected to be recognized over a weighted average period of approximately 2 years. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of the stock options granted during each of the years was determined using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000671"&gt;70% - 75%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000672"&gt;69% - 71%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000673"&gt;68% - 70%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000677"&gt;5.3 - 7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000678"&gt;5.5 - 7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000679"&gt;5.0 - 10.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000683"&gt;0.3% - 1.6%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000684"&gt;1.4% - 2.7%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000685"&gt;2.6% - 3.1%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000692"&gt;$22.70 - $50.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000693"&gt;$17.29 - $37.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000694"&gt;$14.44 - $16.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Given the Company&#x2019;s common stock has not been trading for a sufficient period of time, the Company utilizes a collection of volatilities of peer companies to estimate the expected volatility of its common stock. The expected term is calculated utilizing the simplified method. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the stock option activity under the 2018 Plan as of December 31, 2020 is presented below. These amounts include stock options granted to employees, directors and consultants.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,432,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.05&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,424,402&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43.67&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(447,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(87,605&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,321,882&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000710"&gt;8.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;253,193,160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,665,452&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000711"&gt;7.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,307,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Included in the stock options granted in the table above are options to purchase 1,995,660 shares of common stock that were granted to employees, directors, and consultants granted at the time of the incentive unit conversion in September 2018 that have the same vesting terms as the profit units that were outstanding in September 2018 before the profit interests were converted into common stock. At the time of issuance of the stock options, 357,658 stock options to purchase shares of common stock became immediately vested, resulting in stock compensation expense of $3,627,507.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average grant date fair value of options granted during the years ended December 31, 2020, 2019 and 2018 was $27.45, $13.28 and $9.88, respectively. The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018 was approximately $19.4 million, $1.9 million and zero, respectively. The excess tax benefit classified as a financing cash flow was not significant for any of the periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December 31, 2020, $21.5 million of total unrecognized compensation cost related to non-vested stock options granted under the 2018 Plan is expected to be recognized over the next two years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the restricted stock grant activity under the Incentive Plan as of December 31, 2020 is presented below. These amounts include restricted stock granted to employees, directors and consultants. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average Grant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;576,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(325,818&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;238,712&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:67.78%;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of restricted stock unit activity under the 2018 Plan for the year ended December 31, 2020 is presented below. These amounts include restricted stock units granted to employees.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average Grant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock units at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,346&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,977&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock units at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;133,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.01&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December 31, 2020, there were 217,232 restricted shares under the Incentive Plan, 4,053,998 stock options under the 2018 Plan, and 114,243 restricted stock units under the 2018 Plan that have vested or are expected to vest. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201201_20201231"
      decimals="INF"
      id="F_000624"
      unitRef="U_xbrlishares">6571428</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201231"
      decimals="INF"
      id="F_000625"
      unitRef="U_iso4217USD_xbrlishares">70.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201201_20201231"
      decimals="-5"
      id="F_000626"
      unitRef="U_iso4217USD">431900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201201_20201231"
      decimals="-5"
      id="F_000627"
      unitRef="U_iso4217USD">28100000</us-gaap:PaymentsForUnderwritingExpense>
    <arvn:MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPiperSandlerMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20191031"
      decimals="INF"
      id="F_000628"
      unitRef="U_iso4217USD">100000000.0</arvn:MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPiperSandlerMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231"
      decimals="INF"
      id="F_000629"
      unitRef="U_xbrlishares">2593637</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPiperSandlerMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231"
      decimals="-5"
      id="F_000630"
      unitRef="U_iso4217USD">64100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnPiperSandlerMember_us-gaapSubsidiarySaleOfStockAxis_arvnAtTheMarketOfferingMember_20200101_20201231"
      decimals="-5"
      id="F_000631"
      unitRef="U_iso4217USD">1600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191101_20191130"
      decimals="INF"
      id="F_000632"
      unitRef="U_xbrlishares">5227273</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191130"
      decimals="INF"
      id="F_000633"
      unitRef="U_iso4217USD_xbrlishares">22.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191101_20191130"
      decimals="-5"
      id="F_000634"
      unitRef="U_iso4217USD">115000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="C_0001655759_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191101_20191130"
      decimals="-5"
      id="F_000635"
      unitRef="U_iso4217USD">7400000</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190701_20190731"
      decimals="INF"
      id="F_000636"
      unitRef="U_xbrlishares">1346313</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190701_20190731"
      decimals="-5"
      id="F_000637"
      unitRef="U_iso4217USD">32500000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <arvn:ShareBasedCompensationArrangementAverageCommonStockPrecedingDays
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190701_20190731"
      id="F_000638">P60D</arvn:ShareBasedCompensationArrangementAverageCommonStockPrecedingDays>
    <arvn:PriorToStockPurchaseAgreementPremium
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerAGMember_20190701_20190731"
      decimals="2"
      id="F_000639"
      unitRef="U_xbrlipure">0.15</arvn:PriorToStockPurchaseAgreementPremium>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20180930"
      decimals="INF"
      id="F_000640"
      unitRef="U_xbrlishares">311850</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190101"
      decimals="INF"
      id="F_000641"
      unitRef="U_xbrlishares">323377</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190101_20190101"
      decimals="2"
      id="F_000644"
      unitRef="U_xbrlipure">0.01</arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101"
      decimals="INF"
      id="F_000642"
      unitRef="U_xbrlishares">390371</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20200101"
      decimals="2"
      id="F_000643"
      unitRef="U_xbrlipure">0.01</arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      decimals="INF"
      id="F_000645"
      unitRef="U_xbrlishares">11046</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231"
      decimals="INF"
      id="F_000646"
      unitRef="U_xbrlishares">1014552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <arvn:AmountUsedAsMultiplyingFactorToGrantCommonStock
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231"
      decimals="INF"
      id="F_000647"
      unitRef="U_iso4217USD">2083</arvn:AmountUsedAsMultiplyingFactorToGrantCommonStock>
    <arvn:MaximumPercentageOfCompensationReceivableByEmployee
      contextRef="C_0001655759_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      decimals="INF"
      id="F_000648"
      unitRef="U_xbrlipure">0.15</arvn:MaximumPercentageOfCompensationReceivableByEmployee>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      decimals="INF"
      id="F_000650"
      unitRef="U_xbrlipure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      decimals="INF"
      id="F_000649"
      unitRef="U_xbrlipure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180331"
      decimals="INF"
      id="F_000651"
      unitRef="U_xbrlishares">6199477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180301_20180331"
      id="F_000652">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180301_20180331"
      id="F_000653">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20180930"
      decimals="INF"
      id="F_000655"
      unitRef="U_xbrlishares">4067007</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001655759_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180930"
      decimals="INF"
      id="F_000656"
      unitRef="U_xbrlishares">1277181</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="C_0001655759_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20190101_20191231"
      decimals="INF"
      id="F_000657"
      unitRef="U_xbrlishares">4989593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20190101_20191231"
      decimals="2"
      id="F_000658"
      unitRef="U_xbrlipure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000659"
      unitRef="U_xbrlishares">1561485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20190101_20191231"
      decimals="INF"
      id="F_000660"
      unitRef="U_xbrlishares">1293510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180101_20181231"
      decimals="INF"
      id="F_000661"
      unitRef="U_xbrlishares">1715368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930"
      decimals="INF"
      id="F_000662"
      unitRef="U_xbrlishares">1253263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930"
      decimals="INF"
      id="F_000663"
      unitRef="U_xbrlishares">1744650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930"
      decimals="INF"
      id="F_000664"
      unitRef="U_xbrlishares">11097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnConsultantsMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180901_20180930"
      decimals="INF"
      id="F_000665"
      unitRef="U_xbrlishares">251010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000668"
      unitRef="U_iso4217USD">30230858</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000667"
      unitRef="U_iso4217USD">20072710</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000666"
      unitRef="U_iso4217USD">11630300</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000669"
      unitRef="U_iso4217USD">22647241</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001655759_20200101_20201231" id="F_000670">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000423">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of the stock options granted during each of the years was determined using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000671"&gt;70% - 75%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000672"&gt;69% - 71%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000673"&gt;68% - 70%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000677"&gt;5.3 - 7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000678"&gt;5.5 - 7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000679"&gt;5.0 - 10.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000683"&gt;0.3% - 1.6%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000684"&gt;1.4% - 2.7%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000685"&gt;2.6% - 3.1%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000692"&gt;$22.70 - $50.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000693"&gt;$17.29 - $37.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000694"&gt;$14.44 - $16.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="2"
      id="F_000689"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="2"
      id="F_000690"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="2"
      id="F_000691"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000424">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the stock option activity under the 2018 Plan as of December 31, 2020 is presented below. These amounts include stock options granted to employees, directors and consultants.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,432,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.05&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,424,402&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43.67&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(447,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(87,605&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,321,882&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000710"&gt;8.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;253,193,160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,665,452&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000711"&gt;7.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,307,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20191231"
      decimals="INF"
      id="F_000698"
      unitRef="U_xbrlishares">3432198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20191231"
      decimals="2"
      id="F_000704"
      unitRef="U_iso4217USD_xbrlishares">18.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000699"
      unitRef="U_xbrlishares">1424402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000705"
      unitRef="U_iso4217USD_xbrlishares">43.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000700"
      unitRef="U_xbrlishares">447113</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000706"
      unitRef="U_iso4217USD_xbrlishares">17.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000701"
      unitRef="U_xbrlishares">87605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000707"
      unitRef="U_iso4217USD_xbrlishares">26.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000702"
      unitRef="U_xbrlishares">4321882</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231"
      decimals="2"
      id="F_000708"
      unitRef="U_iso4217USD_xbrlishares">26.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231"
      decimals="0"
      id="F_000712"
      unitRef="U_iso4217USD">253193160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000703"
      unitRef="U_xbrlishares">1665452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231"
      decimals="2"
      id="F_000709"
      unitRef="U_iso4217USD_xbrlishares">17.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231"
      decimals="0"
      id="F_000713"
      unitRef="U_iso4217USD">112307482</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001655759_20180901_20180930"
      decimals="INF"
      id="F_000714"
      unitRef="U_xbrlishares">1995660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001655759_20180930"
      decimals="INF"
      id="F_000715"
      unitRef="U_xbrlishares">357658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180901_20180930"
      decimals="0"
      id="F_000716"
      unitRef="U_iso4217USD">3627507</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001655759_20200101_20201231"
      decimals="2"
      id="F_000717"
      unitRef="U_iso4217USD_xbrlishares">27.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001655759_20190101_20191231"
      decimals="2"
      id="F_000718"
      unitRef="U_iso4217USD_xbrlishares">13.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001655759_20180101_20181231"
      decimals="2"
      id="F_000719"
      unitRef="U_iso4217USD_xbrlishares">9.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001655759_20200101_20201231"
      decimals="-5"
      id="F_000720"
      unitRef="U_iso4217USD">19400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001655759_20190101_20191231"
      decimals="-5"
      id="F_000721"
      unitRef="U_iso4217USD">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001655759_20180101_20181231"
      decimals="-6"
      id="F_000722"
      unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231"
      decimals="-5"
      id="F_000723"
      unitRef="U_iso4217USD">21500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231"
      id="F_000724">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000425">A summary of the restricted stock grant activity under the Incentive Plan as of December 31, 2020 is presented below. These amounts include restricted stock granted to employees, directors and consultants.
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average Grant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;576,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(325,818&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;238,712&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:67.78%;"&gt;&#160;&lt;/p&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20191231"
      decimals="INF"
      id="F_000725"
      unitRef="U_xbrlishares">576074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20191231"
      decimals="2"
      id="F_000729"
      unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000726"
      unitRef="U_xbrlishares">325818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000730"
      unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000727"
      unitRef="U_xbrlishares">11544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000731"
      unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000728"
      unitRef="U_xbrlishares">238712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20201231"
      decimals="2"
      id="F_000732"
      unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      id="F_000426">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of restricted stock unit activity under the 2018 Plan for the year ended December 31, 2020 is presented below. These amounts include restricted stock units granted to employees.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average Grant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock units at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,346&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,977&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock units at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;133,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.01&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20191231"
      decimals="INF"
      id="F_000733"
      unitRef="U_xbrlishares">181372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20191231"
      decimals="2"
      id="F_000737"
      unitRef="U_iso4217USD_xbrlishares">20.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000734"
      unitRef="U_xbrlishares">45346</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000738"
      unitRef="U_iso4217USD_xbrlishares">20.00</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000735"
      unitRef="U_xbrlishares">2977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000739"
      unitRef="U_iso4217USD_xbrlishares">19.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000736"
      unitRef="U_xbrlishares">133049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231"
      decimals="2"
      id="F_000740"
      unitRef="U_iso4217USD_xbrlishares">20.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber
      contextRef="C_0001655759_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000742"
      unitRef="U_xbrlishares">217232</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000741"
      unitRef="U_xbrlishares">4053998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber
      contextRef="C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000743"
      unitRef="U_xbrlishares">114243</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000391">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;"&gt;12. Investment in Equity Method Investee&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2019, the Company entered into an agreement to establish a joint venture (Commitment Agreement) with Bayer CropScience LP (Bayer LP) to &lt;span style="color:#000000;"&gt;research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture&lt;/span&gt;. In July 2019, the Company and Bayer LP completed the formation of the joint venture entity, Oerth. &lt;span style="color:#000000;"&gt;Pursuant to the terms of the Commitment Agreement, the Company made an in-kind intellectual property contribution to Oerth in the form of a license to certain of the Company&#x2019;s proprietary technology. Bayer LP has made a $56.0 million total cash commitment to Oerth, $16.0 million of which Bayer LP has contributed to Oerth during the quarter ended September 30, 2019, and an in-kind intellectual property contribution. The Company and Bayer LP each hold an ownership interest in Oerth initially representing 50% of the ownership interests. A 15% ownership interest of Oerth is reserved for the future grant of incentive units to employees and service providers of Oerth. &lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Commitment Agreement, the Company has no obligation to provide any additional funding and the Company&#x2019;s ownership interest will not be diluted from future contributions from Bayer LP. The Company has no exposure to future losses of Oerth. The activities of Oerth are controlled by a management board under the joint control of the Company and Bayer LP. As Oerth is jointly controlled by the Company and Bayer LP, the Company accounts for its 50% interest using the equity method of accounting. The Company determined that Oerth is a variable interest entity and, accordingly, the Company has evaluated the significant activities of Oerth under the variable interest entity model and concluded that the significant activities consist primarily of research and development activities and, as the Company does not have the sole power to direct such activities, the Company is not the primary beneficiary.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will also provide to Oerth compensated research and development services and administrative services through a separate agreement. The services rendered by the Company during the years ended December 31, 2020 and 2019 were insignificant.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the fair value of the equity interest it received in Oerth in exchange for the license contributed was $49.4 million. The fair value of Oerth was determined utilizing discounted cash flows based on reasonable estimates and assumptions of cash flows expected from Oerth.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized revenue of $24.7 million attributable to the license contributed to Oerth and eliminated the remaining $24.7 million which corresponds to the Company&#x2019;s 50% ownership in Oerth. The Company determined that the amount that was eliminated represents intra-entity profit which should be deferred until realized by Oerth. The deferral will be recognized if and when Oerth recognizes revenue associated with the license. Until such time, the remaining $24.7 million of revenue is indefinitely deferred and excluded from the results of operations of the Company. The amount recognized as revenue was treated as such because the licensing of its technology in connection with the formation of a joint venture is part of the Company&#x2019;s major ongoing or central operations, as evidenced by previous licensing agreements.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating expenses and net loss of Oerth for 2020 was $8.3 million. Total operating expenses and net loss of Oerth for 2019 was $49.8 million, which included research and development expenses equal to $49.4 million for the fair value of the license acquired from Arvinas. The Company&#x2019;s initial investment in Oerth was $49.4 million which represented the fair value of shares received in exchange for the contribution of the license. The elimination of the intra-entity profit component of the revenue resulted in a reduction in the balance of the investment in Oerth, bringing its initial carrying value of the investment to $24.7 million. During 2019, the Company recorded equity method losses of $24.7 million based on its proportionate share of ownership. After recognition of its proportionate share of Oerth&#x2019;s losses for the period the carrying value of the investment as of December 31, 2019 was reduced to $&lt;span style="color:#000000;"&gt;0&lt;/span&gt;, and, as a result, no additional losses were recorded against the carrying value of the investment during the year ended December 30, 2020.&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerCropScienceLPMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231"
      decimals="-5"
      id="F_000744"
      unitRef="U_iso4217USD">56000000.0</us-gaap:EquityMethodInvestmentAggregateCost>
    <arvn:EquityMethodInvestmentContribution
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerCropScienceLPMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20200101_20201231"
      decimals="-5"
      id="F_000745"
      unitRef="U_iso4217USD">16000000.0</arvn:EquityMethodInvestmentContribution>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerCropScienceLPMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231"
      decimals="INF"
      id="F_000746"
      unitRef="U_xbrlipure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231"
      decimals="INF"
      id="F_000747"
      unitRef="U_xbrlipure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231"
      decimals="2"
      id="F_000748"
      unitRef="U_xbrlipure">0.15</arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_0001655759_srtCounterpartyNameAxis_arvnBayerCropScienceLPMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231"
      decimals="INF"
      id="F_000749"
      unitRef="U_xbrlipure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231"
      decimals="-5"
      id="F_000750"
      unitRef="U_iso4217USD">49400000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20200101_20201231"
      decimals="-5"
      id="F_000751"
      unitRef="U_iso4217USD">24700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231"
      decimals="-5"
      id="F_000752"
      unitRef="U_iso4217USD">24700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231"
      decimals="2"
      id="F_000753"
      unitRef="U_xbrlipure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231"
      decimals="-5"
      id="F_000754"
      unitRef="U_iso4217USD">24700000</us-gaap:ContractWithCustomerLiability>
    <arvn:EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20200101_20201231"
      decimals="-5"
      id="F_000756"
      unitRef="U_iso4217USD">8300000</arvn:EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses>
    <us-gaap:ProfitLoss
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20200101_20201231"
      decimals="-5"
      id="F_000758"
      unitRef="U_iso4217USD">8300000</us-gaap:ProfitLoss>
    <arvn:EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20190101_20191231"
      decimals="-5"
      id="F_000755"
      unitRef="U_iso4217USD">49800000</arvn:EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses>
    <us-gaap:ProfitLoss
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20190101_20191231"
      decimals="-5"
      id="F_000757"
      unitRef="U_iso4217USD">49800000</us-gaap:ProfitLoss>
    <arvn:EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20200101_20201231"
      decimals="-5"
      id="F_000759"
      unitRef="U_iso4217USD">49400000</arvn:EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231"
      decimals="-5"
      id="F_000762"
      unitRef="U_iso4217USD">49400000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231"
      decimals="-5"
      id="F_000763"
      unitRef="U_iso4217USD">24700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20190101_20191231"
      decimals="-5"
      id="F_000760"
      unitRef="U_iso4217USD">24700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20191231"
      decimals="0"
      id="F_000764"
      unitRef="U_iso4217USD">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20200101_20201231"
      decimals="INF"
      id="F_000761"
      unitRef="U_iso4217USD">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000392">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;13. Income Taxes &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has had no income tax expense due to operating losses incurred for the years ended December 31, 2020 and 2019. The Company has also not recorded any income tax benefits for the net operating losses incurred in each period due to its uncertainty of realizing a benefit from those items. All of the Company&#x2019;s losses before income taxes were generated in the United States.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate for the years ended December&#160;31, 2020, 2019 and 2018 is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal research tax credit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and tax reporting purposes. Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities are as follows at December&#160;31, 2020 and 2019: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,074,539&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,733,983&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,978,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,871,790&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,070,208&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,121,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,038,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,580,768&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;172,170&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;183,118&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred income tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67,334,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,491,303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43,103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(35,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, equipment and leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,377,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,293,932&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred income tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,421,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,328,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(64,913,202&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,162,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred income tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has provided a valuation allowance against the full amount of the deferred tax assets since, in the opinion of management, based upon the history of losses of the Company, it is more likely than not that the benefits will not be realized. All or a portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to utilize these potential tax benefits. The valuation allowance increased by $27.8&#160;million in 2020 and $15.4&#160;million in 2019 due to the increase in the net operating loss carryforwards, stock compensation expense and research and development tax credits. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had approximately $205.1&#160;million and $103.5&#160;million of federal net operating loss carryforwards as of December&#160;31, 2020 and 2019, respectively. Federal net operating loss carryforwards as of December 31, 2017 expire at various dates through fiscal year 2037 and federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such carryforwards is limited to 80% of the Company&#x2019;s taxable income in the year in which carryforwards are used. The Company believes the federal net operating losses are subject to an annual limitation as a result of changes in the Company&#x2019;s ownership, as defined by Federal Internal Revenue Code Section 382, in November 2019. Notwithstanding the limitations, the Company expects the federal net operating losses to be fully available under Section 382 within the next two years. The Company had approximately $10.1&#160;million and $5.1&#160;million of federal tax credit carryforwards as of December&#160;31, 2020 and 2019, respectively, which expire at various dates through fiscal year 2040. The Company estimates that its federal credits will not be subject to the Section 382 limitation and the federal tax credits will be available to offset future federal income tax within the next two years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company complies with the provisions of ASC 740 in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense. The Company had no accruals for interest and penalties at December&#160;31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to file income tax returns in the U.S. Federal jurisdiction, and in the States of Connecticut, Massachusetts and North Carolina. The Company is a state franchise taxpayer due to the Company&#x2019;s loss position. As a result, there is no state income tax provision included in the financial statements. The 2016 tax year forward remain subject to future examinations by the applicable taxing authorities.  &lt;/p&gt;
&lt;p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;F-23&lt;/p&gt;
&lt;hr style="page-break-after:always"/&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December&#160;31, 20&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20, 2019&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and 201&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company recorded a benefit from expected cash refunds to be provided by the State of Connecticut, equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65%&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; of research and development credits, of&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.8&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;,&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and &lt;/span&gt;&lt;span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, respectively, which is included in Other Income in the accompanying consolidated statement of operations and comprehensive loss, due to the Company being a state franchise taxpayer. The benefit results from the exchange of the state research and development tax credit carryforwards for cash refunds. At December&#160;31, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and 201&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company has recorded receivables of&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million and $&lt;/span&gt;1.4&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, respectively, relating to research and development credits due to the Company. &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000765"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000766"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000427">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate for the years ended December&#160;31, 2020, 2019 and 2018 is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal research tax credit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001655759_20200101_20201231"
      decimals="INF"
      id="F_000767"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001655759_20190101_20191231"
      decimals="INF"
      id="F_000768"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001655759_20180101_20181231"
      decimals="INF"
      id="F_000769"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001655759_20200101_20201231"
      decimals="3"
      id="F_000770"
      unitRef="U_xbrlipure">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001655759_20190101_20191231"
      decimals="3"
      id="F_000771"
      unitRef="U_xbrlipure">0.035</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001655759_20180101_20181231"
      decimals="3"
      id="F_000772"
      unitRef="U_xbrlipure">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001655759_20200101_20201231"
      decimals="3"
      id="F_000773"
      unitRef="U_xbrlipure">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001655759_20190101_20191231"
      decimals="3"
      id="F_000774"
      unitRef="U_xbrlipure">-0.022</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001655759_20180101_20181231"
      decimals="3"
      id="F_000775"
      unitRef="U_xbrlipure">-0.033</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001655759_20200101_20201231"
      decimals="3"
      id="F_000776"
      unitRef="U_xbrlipure">-0.233</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001655759_20190101_20191231"
      decimals="3"
      id="F_000777"
      unitRef="U_xbrlipure">-0.220</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001655759_20180101_20181231"
      decimals="3"
      id="F_000778"
      unitRef="U_xbrlipure">-0.203</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001655759_20200101_20201231"
      decimals="3"
      id="F_000779"
      unitRef="U_xbrlipure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001655759_20190101_20191231"
      decimals="3"
      id="F_000780"
      unitRef="U_xbrlipure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001655759_20180101_20181231"
      decimals="3"
      id="F_000781"
      unitRef="U_xbrlipure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001655759_20200101_20201231"
      decimals="3"
      id="F_000782"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001655759_20190101_20191231"
      decimals="3"
      id="F_000783"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001655759_20180101_20181231"
      decimals="3"
      id="F_000784"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000428">Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities are as follows at December&#160;31, 2020 and 2019:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,074,539&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,733,983&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,978,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,871,790&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,070,208&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,121,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,038,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,580,768&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;172,170&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;183,118&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred income tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67,334,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,491,303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43,103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(35,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, equipment and leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,377,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,293,932&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred income tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,421,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,328,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(64,913,202&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,162,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred income tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000785"
      unitRef="U_iso4217USD">43074539</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000786"
      unitRef="U_iso4217USD">21733983</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000787"
      unitRef="U_iso4217USD">8978710</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000788"
      unitRef="U_iso4217USD">7871790</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000789"
      unitRef="U_iso4217USD">10070208</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000790"
      unitRef="U_iso4217USD">5121644</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000791"
      unitRef="U_iso4217USD">5038675</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000792"
      unitRef="U_iso4217USD">3580768</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000793"
      unitRef="U_iso4217USD">172170</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000794"
      unitRef="U_iso4217USD">183118</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000795"
      unitRef="U_iso4217USD">67334302</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000796"
      unitRef="U_iso4217USD">38491303</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000797"
      unitRef="U_iso4217USD">43103</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000798"
      unitRef="U_iso4217USD">35011</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000799"
      unitRef="U_iso4217USD">2377997</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000800"
      unitRef="U_iso4217USD">1293932</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000801"
      unitRef="U_iso4217USD">2421100</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000802"
      unitRef="U_iso4217USD">1328943</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001655759_20201231"
      decimals="0"
      id="F_000803"
      unitRef="U_iso4217USD">64913202</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001655759_20191231"
      decimals="0"
      id="F_000804"
      unitRef="U_iso4217USD">37162360</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231"
      decimals="-5"
      id="F_000805"
      unitRef="U_iso4217USD">27800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231"
      decimals="-5"
      id="F_000806"
      unitRef="U_iso4217USD">15400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000807"
      unitRef="U_iso4217USD">205100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231"
      decimals="-5"
      id="F_000808"
      unitRef="U_iso4217USD">103500000</us-gaap:OperatingLossCarryforwards>
    <arvn:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000809">2037</arvn:OperatingLossCarryforwardsExpirationYear>
    <arvn:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231"
      id="F_000810">2037</arvn:OperatingLossCarryforwardsExpirationYear>
    <arvn:OperatingLossesCarryForwardMaximumDeductibilityPercentage
      contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      decimals="2"
      id="F_000811"
      unitRef="U_xbrlipure">0.80</arvn:OperatingLossesCarryForwardMaximumDeductibilityPercentage>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000812">The Company believes the federal net operating losses are subject to an annual limitation as a result of changes in the Company&#x2019;s ownership, as defined by Federal Internal Revenue Code Section 382, in November 2019. Notwithstanding the limitations, the Company expects the federal net operating losses to be fully available under Section 382 within the next two years.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000813"
      unitRef="U_iso4217USD">10100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231"
      decimals="-5"
      id="F_000814"
      unitRef="U_iso4217USD">5100000</us-gaap:TaxCreditCarryforwardAmount>
    <arvn:TaxCreditCarryforwardExpirationYear
      contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000815">2040</arvn:TaxCreditCarryforwardExpirationYear>
    <arvn:TaxCreditCarryforwardExpirationYear
      contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231"
      id="F_000816">2040</arvn:TaxCreditCarryforwardExpirationYear>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001655759_20201231"
      decimals="INF"
      id="F_000817"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001655759_20191231"
      decimals="INF"
      id="F_000818"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231"
      decimals="INF"
      id="F_000819"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="C_0001655759_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000820">2016</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231"
      decimals="2"
      id="F_000821"
      unitRef="U_xbrlipure">0.65</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231"
      decimals="2"
      id="F_000822"
      unitRef="U_xbrlipure">0.65</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20180101_20181231"
      decimals="2"
      id="F_000823"
      unitRef="U_xbrlipure">0.65</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0001655759_20180101_20181231"
      decimals="-5"
      id="F_000826"
      unitRef="U_iso4217USD">1800000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0001655759_20200101_20201231"
      decimals="-5"
      id="F_000824"
      unitRef="U_iso4217USD">1400000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0001655759_20190101_20191231"
      decimals="-5"
      id="F_000825"
      unitRef="U_iso4217USD">100000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReceivable
      contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231"
      decimals="-5"
      id="F_000827"
      unitRef="U_iso4217USD">3200000</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable
      contextRef="C_0001655759_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231"
      decimals="-5"
      id="F_000828"
      unitRef="U_iso4217USD">1400000</us-gaap:IncomeTaxReceivable>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000393">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;14. Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Consulting and Sponsored Research Agreement Commitments &lt;/p&gt;&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2016, the Company entered into a Corporate Sponsored Research Agreement (SRA) with Yale University, which was amended in April 2018. The amended SRA extended the agreement until April 2021 and amended the scope of work. The amended SRA requires quarterly payments of $250,000 through the end of the agreement. The total payments made under the SRA for 2020, 2019 and 2018 were $1,000,000, $1,000,000 and $851,161, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company entered into a consulting agreement with its Chief Scientific Advisor in 2018, which extends into 2021, and requires monthly payments of $20,833. During the years ended December&#160;31, 2020, 2019 and 2018, the Company paid $250,000, $250,000 and $176,110, respectively, pursuant to this consulting agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20200101_20201231"
      id="F_000833">In July 2016, the Company entered into a Corporate Sponsored Research Agreement (SRA) with Yale University, which was amended in April 2018. The amended SRA extended the agreement until April 2021 and amended the scope of work. The amended SRA requires quarterly payments of $250,000 through the end of the agreement. The total payments made under the SRA for 2020, 2019 and 2018 were $1,000,000, $1,000,000 and $851,161, respectively.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <arvn:QuarterlyResearchPayments
      contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnAmendedCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20200101_20201231"
      decimals="0"
      id="F_000829"
      unitRef="U_iso4217USD">250000</arvn:QuarterlyResearchPayments>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20200101_20201231"
      decimals="0"
      id="F_000830"
      unitRef="U_iso4217USD">1000000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20190101_20191231"
      decimals="0"
      id="F_000831"
      unitRef="U_iso4217USD">1000000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnCorporateSponsoredResearchAgreementMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arvnYaleUniversityMember_20180101_20181231"
      decimals="0"
      id="F_000832"
      unitRef="U_iso4217USD">851161</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <arvn:MonthlyResearchPayments
      contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20200101_20201231"
      decimals="0"
      id="F_000837"
      unitRef="U_iso4217USD">20833</arvn:MonthlyResearchPayments>
    <arvn:PaymentForConsultingService
      contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20200101_20201231"
      decimals="0"
      id="F_000834"
      unitRef="U_iso4217USD">250000</arvn:PaymentForConsultingService>
    <arvn:PaymentForConsultingService
      contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20190101_20191231"
      decimals="0"
      id="F_000835"
      unitRef="U_iso4217USD">250000</arvn:PaymentForConsultingService>
    <arvn:PaymentForConsultingService
      contextRef="C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20180101_20181231"
      decimals="0"
      id="F_000836"
      unitRef="U_iso4217USD">176110</arvn:PaymentForConsultingService>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000394">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;15. Net Loss Per Common Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted loss per common share were calculated as follows: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(119,332,064&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(70,292,227&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,480,466&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in redemption value of preferred units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(198,366,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common shares &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(119,332,064&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(70,292,227&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(239,847,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of common shares outstanding, basic&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,534,497&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,927,697&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,422,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per common share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.02&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25.45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s potential dilutive securities have been excluded from the computation of diluted net loss per common share as the effect would be to reduce the net loss per common share. The following common share equivalents have been excluded from the calculations of diluted loss per common share because their inclusion would have been antidilutive. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:1pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,321,882&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,432,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,273,024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock awards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;238,712&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;576,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,102,289&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;133,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,693,643&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,189,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,375,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000429">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted loss per common share were calculated as follows: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(119,332,064&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(70,292,227&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,480,466&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in redemption value of preferred units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(198,366,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common shares &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(119,332,064&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(70,292,227&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(239,847,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of common shares outstanding, basic&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,534,497&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,927,697&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,422,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per common share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.02&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25.45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000838"
      unitRef="U_iso4217USD">-119332064</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000839"
      unitRef="U_iso4217USD">-70292227</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000840"
      unitRef="U_iso4217USD">-41480466</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000841"
      unitRef="U_iso4217USD">198366756</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <arvn:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000842"
      unitRef="U_iso4217USD">-119332064</arvn:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <arvn:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000843"
      unitRef="U_iso4217USD">-70292227</arvn:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <arvn:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000844"
      unitRef="U_iso4217USD">-239847222</arvn:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000845"
      unitRef="U_xbrlishares">39534497</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000846"
      unitRef="U_xbrlishares">32927697</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000847"
      unitRef="U_xbrlishares">9422799</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001655759_20200101_20201231"
      decimals="2"
      id="F_000848"
      unitRef="U_iso4217USD_xbrlishares">-3.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001655759_20190101_20191231"
      decimals="2"
      id="F_000849"
      unitRef="U_iso4217USD_xbrlishares">-2.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001655759_20180101_20181231"
      decimals="2"
      id="F_000850"
      unitRef="U_iso4217USD_xbrlishares">-25.45</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001655759_20200101_20201231" id="F_000430">The following common share equivalents have been excluded from the calculations of diluted loss per common share because their inclusion would have been antidilutive.
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:1pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,321,882&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,432,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,273,024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock awards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;238,712&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;576,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,102,289&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;133,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,693,643&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,189,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,375,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="0"
      id="F_000851"
      unitRef="U_xbrlishares">4321882</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="0"
      id="F_000852"
      unitRef="U_xbrlishares">3432198</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="0"
      id="F_000853"
      unitRef="U_xbrlishares">2273024</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20200101_20201231"
      decimals="0"
      id="F_000854"
      unitRef="U_xbrlishares">238712</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20190101_20191231"
      decimals="0"
      id="F_000855"
      unitRef="U_xbrlishares">576074</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20180101_20181231"
      decimals="0"
      id="F_000856"
      unitRef="U_xbrlishares">1102289</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="0"
      id="F_000857"
      unitRef="U_xbrlishares">133049</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001655759_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231"
      decimals="0"
      id="F_000858"
      unitRef="U_xbrlishares">181372</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001655759_20200101_20201231"
      decimals="0"
      id="F_000859"
      unitRef="U_xbrlishares">4693643</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001655759_20190101_20191231"
      decimals="0"
      id="F_000860"
      unitRef="U_xbrlishares">4189644</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001655759_20180101_20181231"
      decimals="0"
      id="F_000861"
      unitRef="U_xbrlishares">3375313</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286793112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 24, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARVINAS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001655759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2566120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5 Science Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">395 Winchester Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">535-1456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARVN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,347,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,874,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant&#8217;s 2021 Annual Meeting of Stockholders, which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2020.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366285680488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 588,373,232<span></span>
</td>
<td class="nump">$ 9,211,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">100,157,618<span></span>
</td>
<td class="nump">271,661,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Account receivable</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">7,443,654<span></span>
</td>
<td class="nump">6,280,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,113,122<span></span>
</td>
<td class="nump">3,727,294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">703,087,626<span></span>
</td>
<td class="nump">290,880,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and leasehold improvements, net</a></td>
<td class="nump">12,259,515<span></span>
</td>
<td class="nump">8,455,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">1,992,669<span></span>
</td>
<td class="nump">2,278,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">28,777<span></span>
</td>
<td class="nump">26,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">717,368,587<span></span>
</td>
<td class="nump">301,641,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,121,879<span></span>
</td>
<td class="nump">4,556,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">18,859,840<span></span>
</td>
<td class="nump">7,602,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">22,150,861<span></span>
</td>
<td class="nump">19,979,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">952,840<span></span>
</td>
<td class="nump">673,896<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">49,085,420<span></span>
</td>
<td class="nump">32,813,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">22,938,233<span></span>
</td>
<td class="nump">38,427,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term debt, net of current portion</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,087,422<span></span>
</td>
<td class="nump">1,714,111<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">75,111,075<span></span>
</td>
<td class="nump">74,955,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 48,455,741 and 38,461,353 shares issued and outstanding as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">48,455<span></span>
</td>
<td class="nump">38,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(491,888,910)<span></span>
</td>
<td class="num">(372,556,846)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,133,537,171<span></span>
</td>
<td class="nump">599,097,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">560,796<span></span>
</td>
<td class="nump">107,576<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">642,257,512<span></span>
</td>
<td class="nump">226,686,281<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 717,368,587<span></span>
</td>
<td class="nump">$ 301,641,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366279024040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Par Or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued</a></td>
<td class="nump">48,455,741<span></span>
</td>
<td class="nump">38,461,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock Shares Outstanding</a></td>
<td class="nump">48,455,741<span></span>
</td>
<td class="nump">38,461,353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366362909256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 21,801,777<span></span>
</td>
<td class="nump">$ 42,976,478<span></span>
</td>
<td class="nump">$ 14,323,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">108,355,853<span></span>
</td>
<td class="nump">67,193,830<span></span>
</td>
<td class="nump">45,193,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">38,303,401<span></span>
</td>
<td class="nump">27,307,162<span></span>
</td>
<td class="nump">12,932,168<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">146,659,254<span></span>
</td>
<td class="nump">94,500,992<span></span>
</td>
<td class="nump">58,125,998<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(124,857,477)<span></span>
</td>
<td class="num">(51,524,514)<span></span>
</td>
<td class="num">(43,802,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">2,004,561<span></span>
</td>
<td class="nump">1,435,596<span></span>
</td>
<td class="nump">102,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred unit warrant</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(193,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">3,585,852<span></span>
</td>
<td class="nump">4,557,260<span></span>
</td>
<td class="nump">2,470,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(65,000)<span></span>
</td>
<td class="num">(85,569)<span></span>
</td>
<td class="num">(57,440)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">5,525,413<span></span>
</td>
<td class="nump">5,907,287<span></span>
</td>
<td class="nump">2,321,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,675,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(119,332,064)<span></span>
</td>
<td class="num">(70,292,227)<span></span>
</td>
<td class="num">(41,480,466)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Change in redemption value of redeemable preferred units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(198,366,756)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shares</a></td>
<td class="num">$ (119,332,064)<span></span>
</td>
<td class="num">$ (70,292,227)<span></span>
</td>
<td class="num">$ (239,847,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted</a></td>
<td class="num">$ (3.02)<span></span>
</td>
<td class="num">$ (2.13)<span></span>
</td>
<td class="num">$ (25.45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted</a></td>
<td class="nump">39,534,497<span></span>
</td>
<td class="nump">32,927,697<span></span>
</td>
<td class="nump">9,422,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366280644120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (119,332,064)<span></span>
</td>
<td class="num">$ (70,292,227)<span></span>
</td>
<td class="num">$ (41,480,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">453,220<span></span>
</td>
<td class="nump">325,299<span></span>
</td>
<td class="num">(207,972)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (118,878,844)<span></span>
</td>
<td class="num">$ (69,966,928)<span></span>
</td>
<td class="num">$ (41,688,438)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366274651928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders'/Members' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-the-Market Offering</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>At-the-Market Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Series A Redeemable Convertible Preferred Units</div></th>
<th class="th"><div>Series B Redeemable Convertible Preferred Units</div></th>
<th class="th"><div>Series C Redeemable Convertible Preferred Units</div></th>
<th class="th"><div>Series A,B and C Convertible Preferred Shares</div></th>
<th class="th">
<div>Common Units </div>
<div>Member Units</div>
</th>
<th class="th"><div>Common Shares</div></th>
<th class="th">
<div>Common Shares </div>
<div>At-the-Market Offering</div>
</th>
<th class="th">
<div>Incentive Units </div>
<div>Member Units</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,768,025<span></span>
</td>
<td class="nump">$ 41,712,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance, Units/Shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,463,665<span></span>
</td>
<td class="nump">24,977,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="num">$ (61,234,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (62,417,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,186,419<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Units/Shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,897,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,669,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Incentive unit-based compensation</a></td>
<td class="nump">11,630,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,141,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,489,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Incentive unit-based compensation Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,680,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised', window );">Exercise of Series A redeemable convertible preferred warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised', window );">Exercise of Series A redeemable convertible preferred warrant, Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series C redeemable convertible preferred units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues', window );">Issuance of Series C redeemable convertible preferred units, Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,467,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits', window );">Change in redemption value of redeemable convertible preferred units</a></td>
<td class="num">(198,366,756)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198,366,756)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,044,716<span></span>
</td>
<td class="nump">$ 81,253,577<span></span>
</td>
<td class="nump">$ 26,068,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(41,480,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,480,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares', window );">Conversion of redeemable convertible preferred units to redeemable convertible preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (111,132,408)<span></span>
</td>
<td class="num">$ (122,965,984)<span></span>
</td>
<td class="num">$ (81,068,464)<span></span>
</td>
<td class="nump">$ 315,166,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares', window );">Conversion of redeemable convertible preferred units to redeemable convertible preferred shares, Units/Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,573,781)<span></span>
</td>
<td class="num">(24,977,489)<span></span>
</td>
<td class="num">(16,467,066)<span></span>
</td>
<td class="nump">64,018,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock', window );">Conversion of common and incentive units to common and restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,677,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,167)<span></span>
</td>
<td class="nump">$ 3,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,675,480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock', window );">Conversion of common and incentive units to common and restricted stock, Units/Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,897,544)<span></span>
</td>
<td class="nump">3,692,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,350,349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of underwriters' discounts and issuance costs</a></td>
<td class="nump">111,159,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,151,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of underwriters' discounts and issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock to common stock</a></td>
<td class="nump">315,166,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,147,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (315,166,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock to common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,018,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,697,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(207,972)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(207,972)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">136,666,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(302,264,619)<span></span>
</td>
<td class="nump">439,118,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(217,723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Units/Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,235,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20,072,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,072,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(70,292,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70,292,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of underwriters' discounts and issuance costs</a></td>
<td class="nump">137,088,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,082,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of underwriters' discounts and issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,573,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">2,824,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,824,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">325,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">226,686,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(372,556,846)<span></span>
</td>
<td class="nump">599,097,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Units/Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,461,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">30,230,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,230,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(119,332,064)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,332,064)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of underwriters' discounts and issuance costs</a></td>
<td class="nump">431,899,963<span></span>
</td>
<td class="nump">$ 64,058,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,893,392<span></span>
</td>
<td class="nump">$ 64,055,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,571<span></span>
</td>
<td class="nump">$ 2,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of underwriters' discounts and issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,571,428<span></span>
</td>
<td class="nump">2,593,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">8,260,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,260,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">453,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 642,257,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (491,888,910)<span></span>
</td>
<td class="nump">$ 1,133,537,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Units/Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,455,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in redemption value of redeemable convertible preferred units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of common and incentive units to common and restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of common and incentive units to common and restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issued during period shares conversion of redeemable convertible preferred units to redeemable convertible preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issued during period shares redeemable convertible preferred warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issued during period value conversion of redeemable convertible preferred units to redeemable convertible preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issued during period value redeemable convertible preferred warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period share new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366279311800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders'/Members' Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts', window );">Issuance of common stock, underwriters' discounts and issuance costs</a></td>
<td class="nump">$ 28,099,997<span></span>
</td>
<td class="nump">$ 7,497,131<span></span>
</td>
<td class="nump">$ 12,048,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, offering costs</a></td>
<td class="nump">$ 1,584,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, underwriters' discounts and issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366288528232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (119,332,064)<span></span>
</td>
<td class="num">$ (70,292,227)<span></span>
</td>
<td class="num">$ (41,480,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,149<span></span>
</td>
<td class="nump">17,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred unit warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">193,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,166,139<span></span>
</td>
<td class="nump">1,561,557<span></span>
</td>
<td class="nump">706,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of bond discounts/premiums</a></td>
<td class="nump">1,654,516<span></span>
</td>
<td class="nump">154,022<span></span>
</td>
<td class="nump">248,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Gain on sale of marketable securities</a></td>
<td class="num">(395,070)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_OperatingLeaseRightOfUseAssetAmortization', window );">Amortization of right to use assets</a></td>
<td class="nump">858,367<span></span>
</td>
<td class="nump">691,345<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash share/unit-based compensation</a></td>
<td class="nump">30,230,858<span></span>
</td>
<td class="nump">20,072,710<span></span>
</td>
<td class="nump">11,630,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(1,162,826)<span></span>
</td>
<td class="num">(4,024,862)<span></span>
</td>
<td class="num">(1,215,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Account receivable</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="nump">2,775,831<span></span>
</td>
<td class="nump">22,224,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,387,848)<span></span>
</td>
<td class="num">(1,065,005)<span></span>
</td>
<td class="num">(2,501,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,042,342<span></span>
</td>
<td class="nump">1,608,735<span></span>
</td>
<td class="nump">2,002,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">10,807,123<span></span>
</td>
<td class="nump">3,601,628<span></span>
</td>
<td class="nump">605,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(920,158)<span></span>
</td>
<td class="num">(581,961)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(13,318,313)<span></span>
</td>
<td class="nump">4,856,736<span></span>
</td>
<td class="num">(8,548,090)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(89,756,934)<span></span>
</td>
<td class="num">(40,626,342)<span></span>
</td>
<td class="num">(16,117,670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(41,196,166)<span></span>
</td>
<td class="num">(256,548,355)<span></span>
</td>
<td class="num">(234,894,225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ProceedsFromMaturitiesOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">174,118,543<span></span>
</td>
<td class="nump">169,695,816<span></span>
</td>
<td class="nump">58,059,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ProceedsFromSaleOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="nump">37,775,235<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, equipment and leasehold improvements</a></td>
<td class="num">(6,447,533)<span></span>
</td>
<td class="num">(6,244,024)<span></span>
</td>
<td class="num">(2,830,661)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">164,250,079<span></span>
</td>
<td class="num">(93,096,563)<span></span>
</td>
<td class="num">(179,665,360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(169,610)<span></span>
</td>
<td class="num">(173,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">459,999,960<span></span>
</td>
<td class="nump">137,686,006<span></span>
</td>
<td class="nump">114,583,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of common stock offering costs</a></td>
<td class="num">(27,650,184)<span></span>
</td>
<td class="num">(597,131)<span></span>
</td>
<td class="num">(3,423,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">8,260,760<span></span>
</td>
<td class="nump">2,824,641<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of Series C redeemable convertible preferred units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">55,000,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrant</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">504,669,030<span></span>
</td>
<td class="nump">139,743,906<span></span>
</td>
<td class="nump">168,060,695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">579,162,175<span></span>
</td>
<td class="nump">6,021,001<span></span>
</td>
<td class="num">(27,722,335)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">9,211,057<span></span>
</td>
<td class="nump">3,190,056<span></span>
</td>
<td class="nump">30,912,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">588,373,232<span></span>
</td>
<td class="nump">9,211,057<span></span>
</td>
<td class="nump">3,190,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, equipment and leasehold improvements unpaid at period end</a></td>
<td class="nump">522,710<span></span>
</td>
<td class="nump">189,908<span></span>
</td>
<td class="nump">159,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">70,420<span></span>
</td>
<td class="nump">39,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Increase in redemption value of preferred units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">198,366,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember', window );">At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of common stock offering costs</a></td>
<td class="num">(1,584,647)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from sale of common stock in at-the-market offering</a></td>
<td class="nump">$ 65,643,141<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock in an at-the-market offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock in a public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromMaturitiesOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturities of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromMaturitiesOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromSaleOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromSaleOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366363485016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">1. Nature of Business and Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas, Inc. has four wholly owned subsidiaries, Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc., Arvinas Estrogen Receptor, Inc., and Arvinas Winchester, Inc. (collectively, the Company). Arvinas Operations, Inc. was formed in 2013, Arvinas Androgen Receptor, Inc. was formed in 2015, Arvinas Estrogen Receptor, Inc. was formed in 2016, and Arvinas Winchester, Inc. was formed in 2018. In September 2018, the Company converted from a Delaware limited liability company to a Delaware corporation. All periods prior to the date of conversion represent the results of the limited liability corporation. The Company is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases throughout the discovery, development and commercialization of therapies to degrade disease-causing proteins. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas, Inc. was incorporated in Delaware on July&#160;3, 2013. Effective January&#160;1, 2015, Arvinas Holding Company, LLC (Arvinas LLC) was formed by the shareholders of Arvinas, Inc. and Arvinas, Inc. became a wholly owned subsidiary of Arvinas LLC. In connection with this reorganization, the rights and preferences of the preferred stock of Arvinas, Inc. were exchanged for preferred stock units with similar rights and preferences of Arvinas LLC. As part of the reorganization, the employees, consultants and board members of Arvinas, Inc. exchanged their stock options in Arvinas, Inc. stock in exchange for incentive units in Arvinas LLC. Additionally, common stockholders of Arvinas, Inc. exchanged their common stock for common units in Arvinas LLC. All exchanges were made on a 1-for-1 basis. This reorganization was accounted for as a common control transaction as the common stockholders of Arvinas, Inc. formed Arvinas, LLC and transferred all the assets from Arvinas, Inc. to Arvinas LLC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Board of Managers approved a <span style="-sec-ix-hidden:F_000433">one-for-3.25</span> reverse stock split of its issued and outstanding shares of common units and a proportional adjustment to the existing conversion ratios for the Company&#8217;s Series A, Series B, and Series C preferred units effective as of September 14, 2018. Accordingly, all share/unit and per share/unit amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this reverse unit split and adjustment of the preferred unit conversion ratios. Immediately prior to the effectiveness of the registration statement pertaining to the Company&#8217;s initial public offering on September 26, 2018, the Company converted from a Delaware limited liability company to a Delaware corporation. Pursuant to the plan of conversion, each outstanding Series A, Series B, and Series C preferred units converted into an equal number of shares of Series A, Series B, and Series C preferred stock, each outstanding common unit converted into a share of common stock and each outstanding incentive unit converted into a number of shares of common stock and restricted common stock based on a conversion price determined by the board of directors. The Company issued 1,795,221 shares of common stock and 1,268,923 shares of restricted common stock.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 1, 2018, the Company completed an initial public offering (IPO) in which the Company issued and sold 7,500,000 shares<span style="Background-color:#FFFFFF;">&#160;</span>of common stock at a public offering price of $16.00 per share. In October 2018, the underwriters of the IPO exercised in part their option to purchase 200,482 additional shares of the Company&#8217;s common stock at an offering price of $16.00 per share. The Company&#8217;s aggregate gross proceeds from the sale of shares in the IPO, including the option, was $123.2 million before fees and expenses of $12.0 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 1, 2018, all of the outstanding shares of convertible preferred stock automatically converted into 19,697,928 shares of common stock at the applicable conversion ratio then in effect.&#160;&#160;Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Basis of Presentation<span style="font-weight:normal;font-style:normal;"> - The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). The accounting policies used to prepare these financial statements are the same as those used to prepare the consolidated financial statements in prior years, except as described in these notes or for the adoption of new standards as outlined below.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366281185288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements of the Company include the accounts of Arvinas, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. </p>


<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the financial statements and notes. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements and notes are appropriate, actual results could differ from those estimates. The most significant estimates are those used in determination of the Company&#8217;s revenue recognition, research and development expenses, fair value of its common and preferred units, preferred unit warrant liability, incentive equity compensation, and fair value of its investment in a joint venture, Oerth Bio LLC (Oerth). </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s principal financial instruments comprise cash, marketable securities, account receivable, accounts payable, accrued liabilities and long-term debt. The carrying value of all financial instruments approximates fair value. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains its cash in financial institution accounts that, at times during the year, may exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Cash may also be maintained at commercial institutions that are not insured by the FDIC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, 100% of the Company&#8217;s revenue was attributable to three collaborators representing 37%, 32% and 31%, respectively, and one collaborator accounted for the entire accounts receivable balance. For the year ended December&#160;31, 2019, 57% of the Company&#8217;s revenue was attributable to a license contributed to Oerth, and two collaborators represented 19% and 16% of total revenue. For the year ended December&#160;31, 2018, two collaborators each represented over 45% of total revenue.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its marketable securities as available-for-sale securities, which are carried at their fair value based on the quoted market prices of the securities with unrealized gains and losses reported as accumulated other comprehensive loss, a separate component of stockholders&#8217;/members&#8217; equity. Realized gains and losses on available-for-sale securities are included in net earnings in the period earned or incurred. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Property, Equipment, and Leasehold Improvements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from three years for office equipment to five years for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation are removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.73%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When indications of potential impairments are present, the Company evaluates the carrying value of long-lived assets. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than carrying value. No such impairments were recorded during 2020, 2019 or 2018. </p>


<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company&#8217;s tangible assets are held in the United States. To date, all of the Company&#8217;s revenue has been generated in the United States. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Revenue Recognition and Deferred Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Revenues from Contracts </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue under Accounting Standards Codification (ASC) 606, <span style="font-style:italic;">Revenue from Contracts with Customers.</span> The Company&#8217;s revenue is generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i)&#160;licenses, (ii) research and development activities, and (iii)&#160;participation in joint research and development steering committees. The terms of these agreements may include non-refundable upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones, and royalty payments based on product sales derived from the collaboration. Under ASC&#160;606, the Company evaluates whether the license agreement, research and development services, and participation in research and development steering committees, represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent a combined single performance obligation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research collaboration and license agreements typically include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company determined that the most likely amount to be recognized was zero, against which no constraint was applied. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is recognized ratably over the Company&#8217;s expected performance period under each respective arrangement. The Company makes its best estimate of the period over which the Company expects to fulfill the Company&#8217;s performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 2020, 2019 and 2018, the transaction price allocated to the combined performance obligation identified under the agreements is recognized as revenue on a straight-line basis over the estimated performance period under each respective arrangement. Straight-line basis was considered the best measure of progress in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale; or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by the customer from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to satisfying the above revenue recognition criteria are recorded as a contract liability in the Company&#8217;s accompanying consolidated balance sheets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also recognized revenue under ASC 606 from its contribution of a license to Oerth. See Note 12. </p>


<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Equity Method Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, <span style="font-style:italic;">Investments &#8211; Equity Method and Joint Ventures</span>. The Company recognizes its pro-rata share of income and losses in the investment in &#8220;Loss from equity method investment&#8221; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment on the consolidated balance sheet until such investment is reduced to $0.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Preferred Unit Warrants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred unit warrants issued in conjunction with debt financings were initially recorded at fair value, using a Black-Scholes option pricing model, with a corresponding discount recorded against the face value of the note and a liability. The discount was then accreted against the face value of the note over its remaining term as additional interest expense. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classified warrants to purchase shares of its Series A Redeemable Convertible Preferred Units (Series A Preferred Units) as a liability on its balance sheets as these warrants were free-standing financial instruments that were exercisable for contingently redeemable shares. The preferred unit warrants were recorded in long-term liabilities at fair value, estimated using the Black-Scholes option pricing model, and marked to market at each balance sheet date. The change in carrying value was reported as the change in fair value of warrant liability in the accompanying consolidated statements of operations. The outstanding warrants were exercised in July 2018 and no warrants were outstanding as of December 31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the conversion to a C-corporation, Arvinas LLC was taxed under the provisions of Subchapter K&#8212;Partners and Partnerships of the Internal Revenue Code. Under those provisions, Arvinas LLC did not pay federal or state corporate income taxes on its taxable income. Instead, each member would include net operating income or loss for Arvinas LLC on its individual return. Arvinas LLC was converted to a C-corporation in 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, <span style="font-style:italic;">Accounting for Income Taxes</span>. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has evaluated the effect of ASC 740 guidance related to uncertain income tax positions and concluded that the Company has no significant uncertain income tax positions at December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Equity-based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to its IPO, the Company periodically granted incentive units to employees and non-employees, which generally vested over a <span style="-sec-ix-hidden:F_000463">four-year</span> period. The incentive units represented a separate substantive class of equity with defined rights within the limited liability company agreement of Arvinas Holding Company, LLC (the LLC Operating Agreement). The incentive units represented profits interests in the Company, which was an interest in the increase in the value of the entity over the Participation Threshold, as defined in the LLC Operating Agreement and as determined at the time of grant. The holder, therefore, had the right to participate in distributions of profits only in excess of the Participation Threshold. The Participation Threshold was based on the valuation of the common unit on or around the grant date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounted for incentive units granted in accordance with ASC 718, <span style="font-style:italic;">Compensation-Stock Compensation</span> (ASC 718). In accordance with ASC 718, compensation expense is measured at estimated fair value of the incentive units and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures employee, board of director and consultant equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards.&#160;&#160;Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies equity-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites, and consultants; (iii) the cost of acquiring, developing, and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into consulting, research, and other agreements with commercial entities, researchers, universities, and others for the provision of goods and services. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#8217;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 820, <span style="font-style:italic;">Fair Value Measurements and Disclosures</span>, requires disclosure of the fair value of financial instruments held by the Company. ASC 825, <span style="font-style:italic;">Financial Instruments</span>, defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.94%;text-indent:-2.27%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Inputs are based upon observable or quoted prices for identical instruments traded in active markets. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:13.44%;text-indent:-7.78%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#8217;s Level&#160;2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:13.44%;text-indent:-7.78%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities consist of corporate bonds which are adjusted to fair value each balance sheet date, based on quoted prices, which are considered Level&#160;2 inputs (see Note 5). <span style="color:#000000;">During the year ended December 31, 2019, a non-recurring fair value measurement was applied to determine the fair value of the non-cash consideration of 50% equity ownership received related to Oerth. The fair value measurement was determined using an income approach based primarily on utilizing management&#8217;s estimates of future cash flows as inputs, which are considered Level 3 measurements within the above fair value hierarchy.</span></p>


<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Net Loss per Common Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is computed by dividing net loss, after adjusting for redeemable preferred unit dividends, by the weighted-average number of common shares outstanding during the period. The change in current redemption value of the redeemable preferred units was treated as a deemed dividend for the period during 2018 prior to conversion to common units. Diluted net loss per share was computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common shares. The effect of the conversion of redeemable preferred units into common units was excluded from the computation of diluted net loss per common share for all periods as their effect was antidilutive. Additionally, common share equivalents are excluded from the computation of diluted net loss per common share for all periods as their effect is antidilutive. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">New Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13<span style="font-style:italic;">, Financial</span> <span style="font-style:italic;">Instruments &#8211; Credit Losses</span>, which provides a model for recognizing credit losses on financial instruments based on an estimate of current<span style="font-style:italic;"> </span>expected losses, requiring immediate recognition of credit losses expected over the life of a financial instrument. The Company adopted ASU 2016-13 in the first quarter of 2020. The adoption of the standard was immaterial to the accompanying consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s financial statements upon adoption. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366281288856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_LicenseAgreementsTextBlock', window );">License Agreements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">3. License Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the Company entered into an exclusive license agreement, including the right to grant sublicenses, with Yale University to develop protein degradation technologies. In connection with the execution of this license agreement, the Company made a non-refundable upfront payment of $149,511. In addition to the upfront payment, the Company paid Yale University a License Maintenance Royalty of varying amounts through the fourth anniversary of the license agreement. The minimum annual payment will be&#160;$75,000 until the first sale to a third party of any licensed product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also required to pay Yale University success-based milestones for the development of the protein degradation technologies as well as low single-digit running royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to a minimum royalty payment that ranges from $200,000 to $500,000. The agreement requires that, if the Company sublicenses the protein degradation technologies to a third party, the Company must pay Yale University a mid-single digit to mid-double digit percentage of Sublicense Income (as defined in the agreement) received on the first licensed product therewith. During 2015, the Company paid $750,000 to Yale University for sublicense consideration, representing the maximum amount required to be paid for sublicense consideration for a licensed product and satisfying this obligation. During 2020, 2019 and 2018, the Company paid $150,000, $150,000 and $75,000, respectively, under the license agreement. The Company is also required to reimburse Yale University for patent costs incurred. During 2020, 2019 and 2018, the Company reimbursed Yale University $196,167, $352,663 and $216,093, respectively, for patent costs. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366279253144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract', window );"><strong>Research Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research Collaboration and License Agreements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">4. Research Collaboration and License Agreements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (Bayer Collaboration Agreement) setting forth the Company&#8217;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras, or PROTAC&#174; targeted protein degraders, that mediate for degradation of target proteins (Targets), using the Company&#8217;s proprietary platform technology, which Targets will be selected by Bayer AG, subject to certain exclusions and limitations.&#160;&#160;The Bayer Collaboration Agreement became effective in July 2019. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront non-refundable payment of $17.5 million in exchange for the use of the Company&#8217;s technology license and a $1.5 million payment to fund research activities. Bayer is committed to fund an additional $10.5 million through 2022, of which $3.0 million was received in 2020. These payments are being recognized over the total estimated period of performance. <span style="Background-color:#FFFFFF;color:#000000;">The Company is also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated Targets. In addition, the Company is eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions. </span></p>


<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the Bayer Collaboration Agreement and a Stock Purchase Agreement entered into with Bayer AG at the same time should be evaluated as a combined contract in accordance with ASC 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span>, given that the agreements were entered into at the same time and have the same commercial objective to provide funding to further the Company&#8217;s research utilizing its proprietary technology. The Company identified the elements under the agreements as license and research revenue and the issuance of the common stock. The Company determined the fair value of the shares sold under the Stock Purchase Agreement to be $2.9 million less than the contractual purchase price stipulated in the agreement. In accordance with the applicable accounting guidance in ASC 815-40, <span style="font-style:italic;">Contracts in Entity&#8217;s Own Equity</span>, the Company determined that the sale of stock should be recorded at fair value. Therefore, the Company allocated the additional $2.9 million of consideration received under the Stock Purchase Agreement to the Bayer Collaboration Agreement given that the two contracts were determined to be combined contracts. This amount has, therefore, been added to the total transaction price and was included in initial contract liabilities balances.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.87%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer, Inc. (Pfizer) (the Pfizer Collaboration Agreement). Under the terms of the Pfizer Collaboration Agreement, the Company received an upfront non-refundable payment and certain additional payments totaling $28.0&#160;million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the agreement. These payments are being recognized as revenue over the total estimated period of performance. The Company is also eligible to receive up to an additional $37.5&#160;million in non-refundable option payments if Pfizer exercises its options for all targets under the agreement. Pfizer has exercised options for $4.9 million as of December 31, 2020. The options are recognized as revenue over the estimated period of performance. The Company is also entitled to receive up to $225 million in development milestone payments and up to $550 million in sales-based milestone payments for all designated targets under the Pfizer Collaboration Agreement, as well as tiered royalties based on sales. Pfizer paid the Company $1.2 million in December 2019 and $3.0 million in 2020 relating to adding additional targets into the collaboration. These payments are being recognized over the estimated period of performance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.87%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2015, the Company entered into an Option and License Agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together, Genentech) (the Genentech Agreement). During 2015, the Company received an upfront non-refundable payment of $11.0&#160;million in exchange for use of the Company&#8217;s technology license and to fund Genentech-related research as defined within the Genentech Agreement. In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd (the Genentech Modification), amending the Genentech Agreement. Under the Genentech Modification, the Company received additional upfront non-refundable payments of $34.5&#160;million to fund Genentech-related research and Genentech has the right to designate up to ten targets. The Company is eligible to receive up to $27.5 million in additional expansion target payments if Genentech exercises its options on all remaining targets. Upfront non-refundable payments are recognized as revenue over the total estimated period of performance. The Company is eligible to receive up to $44.0&#160;million per target in development milestone payments, $52.5&#160;million in regulatory milestone payments and $60.0 million in commercial milestone payments based on sales as well as tiered royalties based on sales.</p>
<p style="margin-bottom:6pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about contract liabilities, included as deferred revenue in the accompanying Consolidated Balance Sheets, is as follows: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,089,094</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,407,407</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized in the period from:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in deferred revenue in previous periods</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,651,649</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,335,188</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in deferred revenue as of December 31, 2020 from 2019 were due to $21.8 million of revenue recognized on the research collaboration and license agreements and additions to deferred revenue of $8.5&#160;million related to the Bayer Collaboration Agreement and Pfizer Collaboration Agreement.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate amount of the transaction price allocated to performance obligations that are unsatisfied as of December&#160;31, 2020 was $45.1&#160;million, which is expected to be recognized in the following periods (in millions): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366285866328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">5. Marketable Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of the Company&#8217;s available-for-sale securities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Effective</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,596,821</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">560,797</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,157,618</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,596,821</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">560,797</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,157,618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Effective</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,359,876</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,722</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,409,598</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,194,004</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,251,858</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271,553,880</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,576</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271,661,456</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets and liabilities measured on a recurring basis as of:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,157,618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,157,618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271,661,456</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271,661,456</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The carrying value of account receivable, accounts payable and accrued expenses approximate their fair value due to the short-term nature of these assets and liabilities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366279244984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Leasehold Improvements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">6. Property, Equipment and Leasehold Improvements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and leasehold improvements consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,100,116</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,045,179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,233,823</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">865,888</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,058,400</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,809,205</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,392,339</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,720,272</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,132,824</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,264,861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and leasehold improvements, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,259,515</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,455,411</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense totaled $3,166,139, $1,561,557 and $706,000 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286286072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right to Use Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Right to Use Assets and Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">7. Right to Use Assets and Liabilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.73%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in the consolidated balance sheets. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.19%;text-indent:5.9%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate ranges from 3.2% &#8211; 6.6%. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Some of the Company&#8217;s leases include options to extend or terminate the lease. The Company includes these options in the recognition of the Company&#8217;s ROU assets and lease liabilities when it is reasonably certain that the Company will exercise the option.<span style="font-family:Times New Roman;color:#000000;"> </span>The Company has operating leases for its corporate office and certain equipment, which expire no later than September 2024. The leases have a weighted average remaining term of 1.9 years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense were as follows:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">995,228</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">817,057</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to leases was as follows:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">920,158</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">581,961</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental non-cash information:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new lease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">572,413</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571,886</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of lease liabilities for operating leases as of December 31, 2020 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,124,684</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,108,065</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,041</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,244,790</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(204,529</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,040,261</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to January 1, 2019, the Company accounted for its leases in accordance with ASC Topic 840, Leases. At December 31, 2018, the Company was committed under operating leases for its corporate office and certain equipment. Total rent expense under operating leases for the year ended December 31, 2018 was $606,538. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286919304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">8. Accrued Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,967,126</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,810,723</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,113,043</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,186,935</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees and other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,779,671</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">605,246</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,859,840</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,602,904</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366369677960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">9. Long-Term Debt </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2013, the Company entered into a Loan Agreement (Loan) and a Stock Subscription Warrant, with Connecticut Innovations, Incorporated (CII). Under the Loan, the Company could draw up to $750,000 for the purpose of purchasing laboratory equipment, information technology equipment and leasehold improvements. Leasehold improvements are limited to $100,000. Interest on the Loan was compounded on a monthly basis at a rate of 7.50% per annum and was required to be paid on a monthly basis beginning on the date of the first draw of funds for 10 months, then with principal payments beginning on June&#160;1, 2015 and payable monthly until the maturity date of July&#160;31, 2019. The Company had the ability to prepay the amount due at any time prior to the maturity date without premium or penalty. The Loan was secured by substantially all of the Company&#8217;s assets. As of December&#160;31, 2018, the amount outstanding under the Loan was $169,610 <span style="color:#000000;">and the total unamortized debt discount on the Loan totaled $7,210. The Company paid the loan in full in July 2019. Interest expense recorded related to the amortization of the debt discount in the years ended December&#160;31, 2019 and 2018 was $7,210 and $12,359, respectively.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with an Assistance Agreement with the State of Connecticut (Assistance Agreement) entered into in 2014, under which all the borrowings by the Company were forgiven in accordance with the Assistance Agreement, the Company is required to be located in the State of Connecticut through January 2024, with a default penalty of repayment of the full original funding amount of $2.5&#160;million plus liquidated damages of 7.5%. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company entered into an Assistance Agreement with the State of Connecticut (2018 Assistance Agreement) to provide funding for the expansion and renovation of laboratory and office space (Project). Under the terms of the 2018 Assistance Agreement, the Company could borrow from the State of Connecticut a maximum of $2.0&#160;million, provided that the funding does not exceed more than 50% of the total Project costs. In September 2018, the Company borrowed $2.0 million under the 2018 Assistance Agreement, bearing interest at 3.25% per annum and interest payments will be required for the first 60 months from the funding date. Thereafter, the loan begins to fully amortize through month 120, maturing in June 2028. According to the terms of the 2018 Assistance Agreement, up to $1.0&#160;million of the funding can be forgiven if the Company meets certain employment conditions, as defined in the agreement. The Company may also be required to prepay a portion of the loan if the employment conditions are not met. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through June 2028 with a default penalty of repayment of the full original funding amount of $2.0&#160;million plus liquidated damages of 7.5% of the total amount of funding received. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anticipated future minimum payments on long-term debt as of December&#160;31, 2020 are: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377,516</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389,970</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beyond 5 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,140,034</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020, 2019 and 2018, interest expense was $65,000, $85,569 and $57,440, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286743896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Members' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Members' Equity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">10. Members&#8217; Equity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Common Units </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each common unit entitled the holder to one vote on all matters submitted to a vote of the Company&#8217;s members. As noted in Note 1, in September 2018, all issued and outstanding common units were converted into common stock.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Preferred Units </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2013 and 2014, Arvinas, Inc. sold 22,463,665 shares of Series A Redeemable Convertible Preferred Stock (Series A Preferred Stock) for $15.3&#160;million at a price of $0.6811 per share. The Series A Preferred Stock was subsequently exchanged for Series A Preferred Units in Arvinas LLC upon the reorganization. During 2015, the Company sold 24,977,489 Series B Redeemable Convertible Preferred Units (Series B Preferred Units) in exchange for $41.6&#160;million at a price of $1.6659 per share.<span style="Background-color:#FFFFFF;color:#000000;"> </span><span style="Background-color:#FFFFFF;color:#000000;">In March 2018, the Company entered into a Series C Preferred Unit Purchase Agreement (the Series C Agreement) to raise additional equity. Under the terms of the Series C Agreement, the Company sold 16,467,066 units of Series C Redeemable Convertible Preferred Units (Series C Preferred Units) for $55.0 million at a price of $3.34 per unit. </span>As noted in Note 1, in September 2018, after giving effect of the 3.25 to 1 reverse split, all issued and outstanding preferred units were converted into preferred stock and subsequently into common stock upon the closing of the IPO.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366279233256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">11. Equity </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During December 2020, the Company completed a public offering in which the Company issued and sold 6,571,428 shares of common stock at a public offering price of $70.00 per share, which resulted in aggregate net proceeds of $431.9 million, net of underwriter discounts, commissions and offering costs of $28.1 million.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company entered into an Equity Distribution Agreement (Distribution Agreement) with Piper Sandler Companies, formerly Piper Jaffray &amp; Co. (Piper Sandler), pursuant to which the Company may offer and sell from time-to-time in an &#8220;at-the-market offering,&#8221; at its option, up to an aggregate of $100.0 million of shares of the Company&#8217;s common stock through Piper Sandler, as sales agent. During year ended December 31, 2020, the Company sold 2,593,637 shares of its common stock resulting in proceeds to the Company of $64.1 million, net of offering costs of $1.6 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2019, the Company completed a public offering in which the Company issued and sold 5,227,273 shares of common stock at a public offering price of $22.00 per share. The Company&#8217;s aggregate gross proceeds from the sale of shares in the public offering was $115.0 million before fees and expenses of $7.4 million.</span><span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company entered into a Stock Purchase Agreement with Bayer AG pursuant to which, in connection with the closing in July 2019, the Company issued and sold to Bayer AG 1,346,313 shares of the Company&#8217;s common stock (the Shares) for a contractually stated purchase price of $32.5 million. The value of the shares of the Company&#8217;s common stock was based on the average of the Company&#8217;s<span style="font-size:12pt;"> </span>common stock for the preceding 60 days prior to the signing of the Stock Purchase Agreement plus a fifteen percent premium. On October 1, 2019, the Company filed a registration statement covering these shares. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Share-based Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the 2018 ESPP) initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company&#8217;s common stock. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by an additional 323,377 shares, equal to 1% of the Company&#8217;s then-outstanding common stock, effective as of January 1, 2019, and by an additional 390,371 shares, equal to 1% of the Company&#8217;s then-outstanding common stock, effective as of January 1, 2020. The first offering period under the 2018 ESPP commenced on January 1, 2020. During the year ended December 31, 2020, the Company issued 11,046 shares of common stock under the 2018 ESPP. As of December 31, 2020, 1,014,552 shares remained available for purchase.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.73%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the Company&#8217;s employees are eligible to participate in the 2018 ESPP, provided they meet certain employment requirements. On each offering commencement date, each participant will be granted the right to purchase, on the last business day of the offering period, a number of shares of the Company&#8217;s common stock determined by multiplying $2,083 by the number of full months in the offering period and dividing that product by the closing price of the Company&#8217;s common stock on the first day of the offering period. On the commencement date of each offering period, each eligible employee may authorize up to a maximum of 15% of the compensation he or she receives during the offering period to be deducted by the Company during the offering period. Under the terms of the 2018 ESPP, the purchase price shall be determined by the Company&#8217;s board of directors for each offering period and will be at least 85% of the applicable closing price of the Company&#8217;s common stock. If the Company&#8217;s board of directors does not make a determination of the purchase price, the purchase price will be 85% of the lesser of the closing price of the Company&#8217;s common stock on the first business day of the offering period or the last business day of the offering period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the Fourth Amendment to the Company&#8217;s Incentive Share Plan (the Incentive Plan) adopted in March 2018, the Company was authorized to issue up to an aggregate of 6,199,477 incentive units pursuant to the Incentive Plan. Generally, incentive units were granted at no less than fair value as determined by the board of managers and had vesting periods ranging from one to four years. The Incentive Plan was terminated in <span style="-sec-ix-hidden:F_000654">September 2018</span>. In September 2018, the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the 2018 Stock Incentive Plan (the 2018 Plan), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#8217;s IPO. The number of common shares initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181) issued in respect of incentive units granted under the Incentive Plan that are subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual </p>

<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increase on the first day of each fiscal year beginning with the fiscal year end</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019 and continuing to, and including, the fiscal year ending December 31, 2028, equal to the lowest of </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,989,593</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of the Company&#8217;s common stock, </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of the number of shares of the Company&#8217;s common stock outstanding on the first day of the fiscal year and an amount determined by the Company&#8217;s board of directors.</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The increase in the number of authorized shares for the fiscal year</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ending December 31, </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 and </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 was</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,561,485</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,293,510</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;Common shares subject to outstanding equity awards that expire or are terminated, surrendered, or cancel</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed without having been fully exercised or are forfeited in whole or in part shall be available for future grants of awards.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2018, the Company granted 1,715,368 incentive units to employees and directors under the Incentive Plan. In September 2018, each outstanding incentive unit was converted into a number of shares of common stock based upon the IPO price. Certain of the shares of common stock issued in respect of incentive units continue to be subject to vesting in accordance with the vesting schedule that was applicable to such incentive units. The Company granted 1,253,263 restricted shares to employees and directors as part of the conversion. The Company also granted 1,744,650 stock options to purchase shares of common stock to employees and directors who were holders of incentive units at the time of the incentive unit conversion. <span style="color:#000000;">In September 2018, in connection with the conversion of the incentive units, the Company granted 11,097 restricted shares of common stock and 251,010 stock options to purchase shares of common stock to consultants.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2020, 2019 and 2018, the Company recognized $30,230,858, $20,072,710 and $11,630,300, respectively, of total compensation expense for awards classified as equity awards related to its stock options, restricted stock awards and restricted stock units. At December 31, 2020, there was $22,647,241 of compensation expense that is expected to be recognized over a weighted average period of approximately 2 years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the stock options granted during each of the years was determined using the Black-Scholes option pricing model with the following assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000671">70% - 75%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000672">69% - 71%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000673">68% - 70%</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000677">5.3 - 7.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000678">5.5 - 7.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000679">5.0 - 10.0</span></p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000683">0.3% - 1.6%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000684">1.4% - 2.7%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000685">2.6% - 3.1%</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000692">$22.70 - $50.00</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000693">$17.29 - $37.66</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000694">$14.44 - $16.24</span></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the Company&#8217;s common stock has not been trading for a sufficient period of time, the Company utilizes a collection of volatilities of peer companies to estimate the expected volatility of its common stock. The expected term is calculated utilizing the simplified method. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity under the 2018 Plan as of December 31, 2020 is presented below. These amounts include stock options granted to employees, directors and consultants.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Stock Options</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Term (Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,432,198</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.05</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,424,402</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.67</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(447,113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.76</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,605</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.94</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4,321,882</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">26.35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000710">8.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">253,193,160</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,665,452</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000711">7.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">112,307,482</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in the stock options granted in the table above are options to purchase 1,995,660 shares of common stock that were granted to employees, directors, and consultants granted at the time of the incentive unit conversion in September 2018 that have the same vesting terms as the profit units that were outstanding in September 2018 before the profit interests were converted into common stock. At the time of issuance of the stock options, 357,658 stock options to purchase shares of common stock became immediately vested, resulting in stock compensation expense of $3,627,507.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of options granted during the years ended December 31, 2020, 2019 and 2018 was $27.45, $13.28 and $9.88, respectively. The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018 was approximately $19.4 million, $1.9 million and zero, respectively. The excess tax benefit classified as a financing cash flow was not significant for any of the periods presented.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020, $21.5 million of total unrecognized compensation cost related to non-vested stock options granted under the 2018 Plan is expected to be recognized over the next two years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the restricted stock grant activity under the Incentive Plan as of December 31, 2020 is presented below. These amounts include restricted stock granted to employees, directors and consultants. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Restricted Stock Awards</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">576,074</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(325,818</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">238,712</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:67.78%;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of restricted stock unit activity under the 2018 Plan for the year ended December 31, 2020 is presented below. These amounts include restricted stock units granted to employees.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Restricted Stock Units</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,372</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,346</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,977</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.36</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">133,049</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20.01</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020, there were 217,232 restricted shares under the Incentive Plan, 4,053,998 stock options under the 2018 Plan, and 114,243 restricted stock units under the 2018 Plan that have vested or are expected to vest. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366287113464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Equity Method Investee<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments And Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investment in Equity Method Investee</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">12. Investment in Equity Method Investee</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company entered into an agreement to establish a joint venture (Commitment Agreement) with Bayer CropScience LP (Bayer LP) to <span style="color:#000000;">research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture</span>. In July 2019, the Company and Bayer LP completed the formation of the joint venture entity, Oerth. <span style="color:#000000;">Pursuant to the terms of the Commitment Agreement, the Company made an in-kind intellectual property contribution to Oerth in the form of a license to certain of the Company&#8217;s proprietary technology. Bayer LP has made a $56.0 million total cash commitment to Oerth, $16.0 million of which Bayer LP has contributed to Oerth during the quarter ended September 30, 2019, and an in-kind intellectual property contribution. The Company and Bayer LP each hold an ownership interest in Oerth initially representing 50% of the ownership interests. A 15% ownership interest of Oerth is reserved for the future grant of incentive units to employees and service providers of Oerth. </span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Commitment Agreement, the Company has no obligation to provide any additional funding and the Company&#8217;s ownership interest will not be diluted from future contributions from Bayer LP. The Company has no exposure to future losses of Oerth. The activities of Oerth are controlled by a management board under the joint control of the Company and Bayer LP. As Oerth is jointly controlled by the Company and Bayer LP, the Company accounts for its 50% interest using the equity method of accounting. The Company determined that Oerth is a variable interest entity and, accordingly, the Company has evaluated the significant activities of Oerth under the variable interest entity model and concluded that the significant activities consist primarily of research and development activities and, as the Company does not have the sole power to direct such activities, the Company is not the primary beneficiary.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will also provide to Oerth compensated research and development services and administrative services through a separate agreement. The services rendered by the Company during the years ended December 31, 2020 and 2019 were insignificant.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the fair value of the equity interest it received in Oerth in exchange for the license contributed was $49.4 million. The fair value of Oerth was determined utilizing discounted cash flows based on reasonable estimates and assumptions of cash flows expected from Oerth.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized revenue of $24.7 million attributable to the license contributed to Oerth and eliminated the remaining $24.7 million which corresponds to the Company&#8217;s 50% ownership in Oerth. The Company determined that the amount that was eliminated represents intra-entity profit which should be deferred until realized by Oerth. The deferral will be recognized if and when Oerth recognizes revenue associated with the license. Until such time, the remaining $24.7 million of revenue is indefinitely deferred and excluded from the results of operations of the Company. The amount recognized as revenue was treated as such because the licensing of its technology in connection with the formation of a joint venture is part of the Company&#8217;s major ongoing or central operations, as evidenced by previous licensing agreements.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses and net loss of Oerth for 2020 was $8.3 million. Total operating expenses and net loss of Oerth for 2019 was $49.8 million, which included research and development expenses equal to $49.4 million for the fair value of the license acquired from Arvinas. The Company&#8217;s initial investment in Oerth was $49.4 million which represented the fair value of shares received in exchange for the contribution of the license. The elimination of the intra-entity profit component of the revenue resulted in a reduction in the balance of the investment in Oerth, bringing its initial carrying value of the investment to $24.7 million. During 2019, the Company recorded equity method losses of $24.7 million based on its proportionate share of ownership. After recognition of its proportionate share of Oerth&#8217;s losses for the period the carrying value of the investment as of December 31, 2019 was reduced to $<span style="color:#000000;">0</span>, and, as a result, no additional losses were recorded against the carrying value of the investment during the year ended December 30, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366279258920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">13. Income Taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has had no income tax expense due to operating losses incurred for the years ended December 31, 2020 and 2019. The Company has also not recorded any income tax benefits for the net operating losses incurred in each period due to its uncertainty of realizing a benefit from those items. All of the Company&#8217;s losses before income taxes were generated in the United States.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2020, 2019 and 2018 is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal research tax credit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and tax reporting purposes. Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities are as follows at December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,074,539</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,733,983</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,978,710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,871,790</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,070,208</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,121,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,038,675</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,580,768</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,170</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,118</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred income tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,334,302</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,491,303</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,011</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,377,997</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,293,932</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred income tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,421,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,328,943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,913,202</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,162,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred income tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has provided a valuation allowance against the full amount of the deferred tax assets since, in the opinion of management, based upon the history of losses of the Company, it is more likely than not that the benefits will not be realized. All or a portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to utilize these potential tax benefits. The valuation allowance increased by $27.8&#160;million in 2020 and $15.4&#160;million in 2019 due to the increase in the net operating loss carryforwards, stock compensation expense and research and development tax credits. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had approximately $205.1&#160;million and $103.5&#160;million of federal net operating loss carryforwards as of December&#160;31, 2020 and 2019, respectively. Federal net operating loss carryforwards as of December 31, 2017 expire at various dates through fiscal year 2037 and federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such carryforwards is limited to 80% of the Company&#8217;s taxable income in the year in which carryforwards are used. The Company believes the federal net operating losses are subject to an annual limitation as a result of changes in the Company&#8217;s ownership, as defined by Federal Internal Revenue Code Section 382, in November 2019. Notwithstanding the limitations, the Company expects the federal net operating losses to be fully available under Section 382 within the next two years. The Company had approximately $10.1&#160;million and $5.1&#160;million of federal tax credit carryforwards as of December&#160;31, 2020 and 2019, respectively, which expire at various dates through fiscal year 2040. The Company estimates that its federal credits will not be subject to the Section 382 limitation and the federal tax credits will be available to offset future federal income tax within the next two years.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company complies with the provisions of ASC 740 in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense. The Company had no accruals for interest and penalties at December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to file income tax returns in the U.S. Federal jurisdiction, and in the States of Connecticut, Massachusetts and North Carolina. The Company is a state franchise taxpayer due to the Company&#8217;s loss position. As a result, there is no state income tax provision included in the financial statements. The 2016 tax year forward remain subject to future examinations by the applicable taxing authorities.  </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p>
<hr style="page-break-after:always"/>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 20</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20, 2019</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 201</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company recorded a benefit from expected cash refunds to be provided by the State of Connecticut, equal to </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65%</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of research and development credits, of</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</span></span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1 million</span></span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively, which is included in Other Income in the accompanying consolidated statement of operations and comprehensive loss, due to the Company being a state franchise taxpayer. The benefit results from the exchange of the state research and development tax credit carryforwards for cash refunds. At December&#160;31, </span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 201</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company has recorded receivables of</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</span></span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and $</span>1.4<span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively, relating to research and development credits due to the Company. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286446536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">14. Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Consulting and Sponsored Research Agreement Commitments </p><p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2016, the Company entered into a Corporate Sponsored Research Agreement (SRA) with Yale University, which was amended in April 2018. The amended SRA extended the agreement until April 2021 and amended the scope of work. The amended SRA requires quarterly payments of $250,000 through the end of the agreement. The total payments made under the SRA for 2020, 2019 and 2018 were $1,000,000, $1,000,000 and $851,161, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into a consulting agreement with its Chief Scientific Advisor in 2018, which extends into 2021, and requires monthly payments of $20,833. During the years ended December&#160;31, 2020, 2019 and 2018, the Company paid $250,000, $250,000 and $176,110, respectively, pursuant to this consulting agreement.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286130232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">15. Net Loss Per Common Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per common share were calculated as follows: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(119,332,064</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,292,227</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,480,466</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in redemption value of preferred units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(198,366,756</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common shares &#8211; basic and diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(119,332,064</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,292,227</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(239,847,222</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of common shares outstanding, basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and diluted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,534,497</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,927,697</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,422,799</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.02</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25.45</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potential dilutive securities have been excluded from the computation of diluted net loss per common share as the effect would be to reduce the net loss per common share. The following common share equivalents have been excluded from the calculations of diluted loss per common share because their inclusion would have been antidilutive. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:1pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,321,882</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,432,198</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,273,024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock awards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238,712</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">576,074</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102,289</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,049</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,372</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,693,643</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,189,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,375,313</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366370748536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements of the Company include the accounts of Arvinas, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. </p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the financial statements and notes. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements and notes are appropriate, actual results could differ from those estimates. The most significant estimates are those used in determination of the Company&#8217;s revenue recognition, research and development expenses, fair value of its common and preferred units, preferred unit warrant liability, incentive equity compensation, and fair value of its investment in a joint venture, Oerth Bio LLC (Oerth). </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s principal financial instruments comprise cash, marketable securities, account receivable, accounts payable, accrued liabilities and long-term debt. The carrying value of all financial instruments approximates fair value. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains its cash in financial institution accounts that, at times during the year, may exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Cash may also be maintained at commercial institutions that are not insured by the FDIC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, 100% of the Company&#8217;s revenue was attributable to three collaborators representing 37%, 32% and 31%, respectively, and one collaborator accounted for the entire accounts receivable balance. For the year ended December&#160;31, 2019, 57% of the Company&#8217;s revenue was attributable to a license contributed to Oerth, and two collaborators represented 19% and 16% of total revenue. For the year ended December&#160;31, 2018, two collaborators each represented over 45% of total revenue.&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its marketable securities as available-for-sale securities, which are carried at their fair value based on the quoted market prices of the securities with unrealized gains and losses reported as accumulated other comprehensive loss, a separate component of stockholders&#8217;/members&#8217; equity. Realized gains and losses on available-for-sale securities are included in net earnings in the period earned or incurred. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Equipment, and Leasehold Improvements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Property, Equipment, and Leasehold Improvements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from three years for office equipment to five years for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation are removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.73%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When indications of potential impairments are present, the Company evaluates the carrying value of long-lived assets. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than carrying value. No such impairments were recorded during 2020, 2019 or 2018. </p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company&#8217;s tangible assets are held in the United States. To date, all of the Company&#8217;s revenue has been generated in the United States. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Deferred Revenue</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Revenue Recognition and Deferred Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Revenues from Contracts </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue under Accounting Standards Codification (ASC) 606, <span style="font-style:italic;">Revenue from Contracts with Customers.</span> The Company&#8217;s revenue is generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i)&#160;licenses, (ii) research and development activities, and (iii)&#160;participation in joint research and development steering committees. The terms of these agreements may include non-refundable upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones, and royalty payments based on product sales derived from the collaboration. Under ASC&#160;606, the Company evaluates whether the license agreement, research and development services, and participation in research and development steering committees, represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent a combined single performance obligation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research collaboration and license agreements typically include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company determined that the most likely amount to be recognized was zero, against which no constraint was applied. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is recognized ratably over the Company&#8217;s expected performance period under each respective arrangement. The Company makes its best estimate of the period over which the Company expects to fulfill the Company&#8217;s performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December&#160;31, 2020, 2019 and 2018, the transaction price allocated to the combined performance obligation identified under the agreements is recognized as revenue on a straight-line basis over the estimated performance period under each respective arrangement. Straight-line basis was considered the best measure of progress in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale; or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by the customer from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to satisfying the above revenue recognition criteria are recorded as a contract liability in the Company&#8217;s accompanying consolidated balance sheets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also recognized revenue under ASC 606 from its contribution of a license to Oerth. See Note 12. </p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Equity Method Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, <span style="font-style:italic;">Investments &#8211; Equity Method and Joint Ventures</span>. The Company recognizes its pro-rata share of income and losses in the investment in &#8220;Loss from equity method investment&#8221; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment on the consolidated balance sheet until such investment is reduced to $0.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_PreferredUnitWarrantsPolicyPolicyTextBlock', window );">Preferred Unit Warrants</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Preferred Unit Warrants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred unit warrants issued in conjunction with debt financings were initially recorded at fair value, using a Black-Scholes option pricing model, with a corresponding discount recorded against the face value of the note and a liability. The discount was then accreted against the face value of the note over its remaining term as additional interest expense. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classified warrants to purchase shares of its Series A Redeemable Convertible Preferred Units (Series A Preferred Units) as a liability on its balance sheets as these warrants were free-standing financial instruments that were exercisable for contingently redeemable shares. The preferred unit warrants were recorded in long-term liabilities at fair value, estimated using the Black-Scholes option pricing model, and marked to market at each balance sheet date. The change in carrying value was reported as the change in fair value of warrant liability in the accompanying consolidated statements of operations. The outstanding warrants were exercised in July 2018 and no warrants were outstanding as of December 31, 2020 and 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the conversion to a C-corporation, Arvinas LLC was taxed under the provisions of Subchapter K&#8212;Partners and Partnerships of the Internal Revenue Code. Under those provisions, Arvinas LLC did not pay federal or state corporate income taxes on its taxable income. Instead, each member would include net operating income or loss for Arvinas LLC on its individual return. Arvinas LLC was converted to a C-corporation in 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, <span style="font-style:italic;">Accounting for Income Taxes</span>. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has evaluated the effect of ASC 740 guidance related to uncertain income tax positions and concluded that the Company has no significant uncertain income tax positions at December&#160;31, 2020 and 2019. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Equity-based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to its IPO, the Company periodically granted incentive units to employees and non-employees, which generally vested over a <span style="-sec-ix-hidden:F_000463">four-year</span> period. The incentive units represented a separate substantive class of equity with defined rights within the limited liability company agreement of Arvinas Holding Company, LLC (the LLC Operating Agreement). The incentive units represented profits interests in the Company, which was an interest in the increase in the value of the entity over the Participation Threshold, as defined in the LLC Operating Agreement and as determined at the time of grant. The holder, therefore, had the right to participate in distributions of profits only in excess of the Participation Threshold. The Participation Threshold was based on the valuation of the common unit on or around the grant date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounted for incentive units granted in accordance with ASC 718, <span style="font-style:italic;">Compensation-Stock Compensation</span> (ASC 718). In accordance with ASC 718, compensation expense is measured at estimated fair value of the incentive units and is included as compensation expense over the vesting period during which an employee provides service in exchange for the award. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures employee, board of director and consultant equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards.&#160;&#160;Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies equity-based compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include (i) employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites, and consultants; (iii) the cost of acquiring, developing, and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into consulting, research, and other agreements with commercial entities, researchers, universities, and others for the provision of goods and services. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#8217;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.67%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 820, <span style="font-style:italic;">Fair Value Measurements and Disclosures</span>, requires disclosure of the fair value of financial instruments held by the Company. ASC 825, <span style="font-style:italic;">Financial Instruments</span>, defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.94%;text-indent:-2.27%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Inputs are based upon observable or quoted prices for identical instruments traded in active markets. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:13.44%;text-indent:-7.78%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#8217;s Level&#160;2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:13.44%;text-indent:-7.78%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities consist of corporate bonds which are adjusted to fair value each balance sheet date, based on quoted prices, which are considered Level&#160;2 inputs (see Note 5). <span style="color:#000000;">During the year ended December 31, 2019, a non-recurring fair value measurement was applied to determine the fair value of the non-cash consideration of 50% equity ownership received related to Oerth. The fair value measurement was determined using an income approach based primarily on utilizing management&#8217;s estimates of future cash flows as inputs, which are considered Level 3 measurements within the above fair value hierarchy.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Net Loss per Common Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is computed by dividing net loss, after adjusting for redeemable preferred unit dividends, by the weighted-average number of common shares outstanding during the period. The change in current redemption value of the redeemable preferred units was treated as a deemed dividend for the period during 2018 prior to conversion to common units. Diluted net loss per share was computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common shares. The effect of the conversion of redeemable preferred units into common units was excluded from the computation of diluted net loss per common share for all periods as their effect was antidilutive. Additionally, common share equivalents are excluded from the computation of diluted net loss per common share for all periods as their effect is antidilutive. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">New Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.67%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13<span style="font-style:italic;">, Financial</span> <span style="font-style:italic;">Instruments &#8211; Credit Losses</span>, which provides a model for recognizing credit losses on financial instruments based on an estimate of current<span style="font-style:italic;"> </span>expected losses, requiring immediate recognition of credit losses expected over the life of a financial instrument. The Company adopted ASU 2016-13 in the first quarter of 2020. The adoption of the standard was immaterial to the accompanying consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s financial statements upon adoption. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PreferredUnitWarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred unit warrants policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PreferredUnitWarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286632424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract', window );"><strong>Research Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Contract Liabilities</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about contract liabilities, included as deferred revenue in the accompanying Consolidated Balance Sheets, is as follows: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,089,094</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,407,407</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized in the period from:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in deferred revenue in previous periods</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,651,649</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,335,188</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Transaction Price Allocated to Performance Obligations</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate amount of the transaction price allocated to performance obligations that are unsatisfied as of December&#160;31, 2020 was $45.1&#160;million, which is expected to be recognized in the following periods (in millions): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366287261448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Company's Available for Sale Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of the Company&#8217;s available-for-sale securities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Effective</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,596,821</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">560,797</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,157,618</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,596,821</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">560,797</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,157,618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Effective</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,359,876</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,722</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,409,598</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,194,004</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,251,858</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271,553,880</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,576</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271,661,456</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets and liabilities measured on a recurring basis as of:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,157,618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,157,618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271,661,456</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271,661,456</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366279241928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Equipment and Leasehold Improvements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and leasehold improvements consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,100,116</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,045,179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,233,823</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">865,888</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,058,400</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,809,205</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,392,339</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,720,272</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,132,824</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,264,861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and leasehold improvements, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,259,515</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,455,411</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366280757320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right to Use Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense were as follows:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">995,228</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">817,057</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.93%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to leases was as follows:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">920,158</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">581,961</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental non-cash information:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new lease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">572,413</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571,886</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.67%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of lease liabilities for operating leases as of December 31, 2020 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,124,684</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,108,065</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,041</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,244,790</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(204,529</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,040,261</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366279253976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Components of Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,967,126</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,810,723</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,113,043</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,186,935</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees and other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,779,671</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">605,246</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,859,840</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,602,904</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366362962200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anticipated future minimum payments on long-term debt as of December&#160;31, 2020 are: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377,516</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389,970</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beyond 5 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,140,034</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286341944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the stock options granted during each of the years was determined using the Black-Scholes option pricing model with the following assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000671">70% - 75%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000672">69% - 71%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000673">68% - 70%</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000677">5.3 - 7.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000678">5.5 - 7.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000679">5.0 - 10.0</span></p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000683">0.3% - 1.6%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000684">1.4% - 2.7%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000685">2.6% - 3.1%</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000692">$22.70 - $50.00</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000693">$17.29 - $37.66</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000694">$14.44 - $16.24</span></p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.73%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity under the 2018 Plan as of December 31, 2020 is presented below. These amounts include stock options granted to employees, directors and consultants.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Stock Options</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Term (Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,432,198</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.05</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,424,402</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.67</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(447,113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.76</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,605</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.94</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4,321,882</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">26.35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000710">8.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">253,193,160</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,665,452</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000711">7.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">112,307,482</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of Restricted Stock Grant Activity</a></td>
<td class="text">A summary of the restricted stock grant activity under the Incentive Plan as of December 31, 2020 is presented below. These amounts include restricted stock granted to employees, directors and consultants.
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Restricted Stock Awards</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">576,074</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(325,818</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">238,712</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:67.78%;">&#160;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of Restricted Stock Grant Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.73%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of restricted stock unit activity under the 2018 Plan for the year ended December 31, 2020 is presented below. These amounts include restricted stock units granted to employees.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Restricted Stock Units</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,372</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,346</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,977</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.36</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">133,049</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20.01</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366287445512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2020, 2019 and 2018 is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal research tax credit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Deferred Income Taxes</a></td>
<td class="text">Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities are as follows at December&#160;31, 2020 and 2019:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,074,539</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,733,983</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,978,710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,871,790</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,070,208</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,121,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,038,675</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,580,768</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,170</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,118</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred income tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,334,302</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,491,303</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,011</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,377,997</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,293,932</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred income tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,421,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,328,943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,913,202</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,162,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred income tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366285759464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Loss per Common Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.67%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per common share were calculated as follows: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(119,332,064</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,292,227</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,480,466</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in redemption value of preferred units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(198,366,756</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common shares &#8211; basic and diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(119,332,064</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,292,227</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(239,847,222</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of common shares outstanding, basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and diluted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,534,497</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,927,697</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,422,799</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.02</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25.45</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Common Share Equivalents Excluded from the Calculations of Diluted Loss Per Common Share</a></td>
<td class="text">The following common share equivalents have been excluded from the calculations of diluted loss per common share because their inclusion would have been antidilutive.
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.67%;font-family:Times New Roman;font-size:1pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,321,882</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,432,198</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,273,024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock awards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238,712</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">576,074</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102,289</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,049</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,372</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,693,643</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,189,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,375,313</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366285253448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Subsidiary </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_NumberOfWhollyOwnedSubsidiaries', window );">Number of wholly owned subsidiaries | Subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Fees and expenses | $</a></td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,650,184<span></span>
</td>
<td class="nump">$ 597,131<span></span>
</td>
<td class="nump">$ 3,423,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Restricted shares issued</a></td>
<td class="nump">1,268,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company&#8217;s Board of Managers approved a one-for-3.25 reverse stock split of its issued and outstanding shares of common units<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">0.3077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Common shares issued</a></td>
<td class="nump">1,795,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from sale of shares in Initial public offering before fees and expenses | $</a></td>
<td class="nump">$ 123,200,000<span></span>
</td>
<td class="nump">$ 431,900,000<span></span>
</td>
<td class="nump">$ 115,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for conversion of convertible preferred stock</a></td>
<td class="nump">19,697,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of underwriters' discounts and issuance costs, Shares</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">6,571,428<span></span>
</td>
<td class="nump">5,227,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price, issued and sold | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 70.00<span></span>
</td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of underwriters' discounts and issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price, issued and sold | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NatureOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NatureOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NumberOfWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of wholly owned subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NumberOfWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366285825704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Incentive units vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember', window );">Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Customer Concentration Risk | Collaborator One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Customer Concentration Risk | Collaborator Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Customer Concentration Risk | Collaborator Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Customer Concentration Risk | Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Revenue Benchmark | Customer Concentration Risk | Collaborator One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Revenue Benchmark | Customer Concentration Risk | Collaborator Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense', window );">Federal deposit insurance corporation premium expense</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalDepositInsuranceCorporationPremiumExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366366244856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CollaborativeArrangementPayment', window );">Payment for license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_AnnualLicenseFeePayment', window );">Annual payment for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_NonRefundableUpfrontPayment', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 149,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ReimbursementOfPatentRelatedCost', window );">Reimbursed patent costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,167<span></span>
</td>
<td class="nump">$ 352,663<span></span>
</td>
<td class="nump">$ 216,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CollaborativeArrangementSublicensePayment', window );">Payment for sublicense agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AnnualLicenseFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual license fee payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AnnualLicenseFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborativeArrangementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborativeArrangementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborativeArrangementSublicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement sublicense payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborativeArrangementSublicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ReimbursementOfPatentRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of patent related cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ReimbursementOfPatentRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_YaleUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366285594552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($) </div>
<div>Target</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Contract</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Changes in deferred revenue due to additions to deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13,318,313)<span></span>
</td>
<td class="nump">$ 4,856,736<span></span>
</td>
<td class="num">$ (8,548,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized on research collaboration and license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Unsatisfied performance obligations expected to be recognized as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Research Funding Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Research Funding Payments | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Sales-based Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SaleOfStockFairValueOfSharesSold', window );">Fair value of the shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Additional consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_NumberOfContractsToBeCombined', window );">Number of contracts to be combined | Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront non-refundable payment and certain additional payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Sales-based Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Option Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Option Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Substitution Target Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront non-refundable payment and certain additional payments received</a></td>
<td class="nump">$ 34,500,000<span></span>
</td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_NumberOfMaximumDesignatedTargets', window );">Number of designated targets | Target</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="nump">$ 44,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Option Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="nump">27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Regulatory Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="nump">52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved or options for all targets exercised</a></td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGAndPfizerMember', window );">Bayer and Pfizer Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Changes in deferred revenue due to additions to deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NumberOfContractsToBeCombined">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of contracts to be combined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NumberOfContractsToBeCombined</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NumberOfMaximumDesignatedTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of maximum designated targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NumberOfMaximumDesignatedTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_SaleOfStockFairValueOfSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, fair value of shares sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_SaleOfStockFairValueOfSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_OptionExercisedToLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_OptionExercisedToLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SubstitutionTargetPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SubstitutionTargetPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerAGAndPfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerAGAndPfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286017784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Summary of Contract Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 45,089,094<span></span>
</td>
<td class="nump">$ 58,407,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amounts included in deferred revenue in previous periods</a></td>
<td class="nump">$ 18,651,649<span></span>
</td>
<td class="nump">$ 14,335,188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366366331496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 45.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 19.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 19.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 6.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286239480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details1)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 45.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366281177928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Summary of Company's Available for Sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 99,596,821<span></span>
</td>
<td class="nump">$ 271,553,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">560,797<span></span>
</td>
<td class="nump">107,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 100,157,618<span></span>
</td>
<td class="nump">$ 271,661,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=arvn_CorporateBondsMaturingTwoThousandTwentyOneMember', window );">Corporate Bonds Maturing 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod', window );">Effective Maturity</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 99,596,821<span></span>
</td>
<td class="nump">$ 126,194,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">560,797<span></span>
</td>
<td class="nump">57,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 100,157,618<span></span>
</td>
<td class="nump">$ 126,251,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=arvn_TwoThousandTwentyMaturityMember', window );">Corporate Bonds Maturing 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod', window );">Effective Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,359,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,409,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale debt securities effective maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=arvn_CorporateBondsMaturingTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=arvn_CorporateBondsMaturingTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=arvn_TwoThousandTwentyMaturityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=arvn_TwoThousandTwentyMaturityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286854056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value measurements of assets</a></td>
<td class="nump">$ 100,157,618<span></span>
</td>
<td class="nump">$ 271,661,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value measurements of assets</a></td>
<td class="nump">100,157,618<span></span>
</td>
<td class="nump">271,661,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value measurements of assets</a></td>
<td class="nump">$ 100,157,618<span></span>
</td>
<td class="nump">$ 271,661,456<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366277954664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">$ 18,392,339<span></span>
</td>
<td class="nump">$ 11,720,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(6,132,824)<span></span>
</td>
<td class="num">(3,264,861)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and leasehold improvements, net</a></td>
<td class="nump">12,259,515<span></span>
</td>
<td class="nump">8,455,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">11,100,116<span></span>
</td>
<td class="nump">8,045,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">1,233,823<span></span>
</td>
<td class="nump">865,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">$ 6,058,400<span></span>
</td>
<td class="nump">$ 2,809,205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366285979576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 3,166,139<span></span>
</td>
<td class="nump">$ 1,561,557<span></span>
</td>
<td class="nump">$ 706,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286635848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right to Use Assets and Liabilities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Operating lease, existence of option to terminate</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_LesseeOperatingLeaseExpirationMonthAndYear', window );">Operating lease expiration month and year</a></td>
<td class="text">2024-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Total rent expense under operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 606,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_PercentageOfIncrementalBorrowingForLleasePayments', window );">Percentage of incremental borrowing for lease Payments</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_PercentageOfIncrementalBorrowingForLleasePayments', window );">Percentage of incremental borrowing for lease Payments</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_LesseeOperatingLeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_LesseeOperatingLeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PercentageOfIncrementalBorrowingForLleasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of incremental borrowing for lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PercentageOfIncrementalBorrowingForLleasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286726840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right to Use Assets and Liabilities - Components of Lease Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 995,228<span></span>
</td>
<td class="nump">$ 817,057<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366285894792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right to Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 920,158<span></span>
</td>
<td class="nump">$ 581,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract', window );"><strong>Supplemental non-cash information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new lease obligations</a></td>
<td class="nump">$ 572,413<span></span>
</td>
<td class="nump">$ 571,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental non-cash information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_SupplementalNonCashInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366280773864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Right to Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 1,124,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,108,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo', window );">Thereafter</a></td>
<td class="nump">12,041<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,244,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(204,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 2,040,261<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366279320808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Components of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee expenses</a></td>
<td class="nump">$ 8,967,126<span></span>
</td>
<td class="nump">$ 5,810,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development expenses</a></td>
<td class="nump">8,113,043<span></span>
</td>
<td class="nump">1,186,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees and other</a></td>
<td class="nump">1,779,671<span></span>
</td>
<td class="nump">605,246<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 18,859,840<span></span>
</td>
<td class="nump">$ 7,602,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366280863912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Aug. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt instrument, outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total unamortized debt discount on Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,210<span></span>
</td>
<td class="nump">12,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="nump">$ 85,569<span></span>
</td>
<td class="nump">57,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndFourteenAssistanceAgreementMember', window );">2014 Assistance Agreement | State of Connecticut</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_DebtInstrumentMaturityMonthAndYear', window );">Debt instrument maturity month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_PercentageOfLiquidatedDamages', window );">Percentage of liquidated damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember', window );">2018 Assistance Agreement | State of Connecticut</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate per annum</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_DebtInstrumentMaturityMonthAndYear', window );">Debt instrument maturity month and year</a></td>
<td class="text">2028-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_PercentageOfLiquidatedDamages', window );">Percentage of liquidated damages</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_PercentageOfMaximumFundingOnProjectCosts', window );">Percentage of maximum funding on total project costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_DebtInstrumentInterestPaymentsTerm', window );">Debt instrument interest payments term</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod', window );">Debt instrument amortization period after interest payments period</a></td>
<td class="text">120 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember', window );">2018 Assistance Agreement | State of Connecticut | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Forgiveness of funding on achieving certain employment conditions</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arvn_LoanAgreementMember', window );">Loan Agreement | Connecticut Innovations, Inc. | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_DebtInstrumentMaximumBorrowingCapacity', window );">Debt instrument, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Debt instrument, frequency of periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">monthly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds', window );">Debt instrument, interest only payment period upon first draw of funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1', window );">Debt instrument, date of first required payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  01,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt instrument, outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arvn_LoanAgreementMember', window );">Loan Agreement | Connecticut Innovations, Inc. | Secured Debt | Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_DebtInstrumentMaximumBorrowingCapacity', window );">Debt instrument, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument amortization period after interest payments period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest only payment period upon first draw of funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentInterestPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest payments term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentInterestPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentMaturityMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument maturity month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentMaturityMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument maximum borrowing capacity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PercentageOfLiquidatedDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of liquidated damages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PercentageOfLiquidatedDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PercentageOfMaximumFundingOnProjectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum funding on project costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PercentageOfMaximumFundingOnProjectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt agreement requires the first payment to be made, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDateOfFirstRequiredPayment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndFourteenAssistanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndFourteenAssistanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_ConnecticutInnovationsIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_ConnecticutInnovationsIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366280524248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long Term Debt By Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">$ 92,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">377,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">389,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Beyond 5 years</a></td>
<td class="nump">1,140,034<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366281629688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Members' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Preferred stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 431,899,963<span></span>
</td>
<td class="nump">$ 137,088,875<span></span>
</td>
<td class="nump">$ 111,159,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=arvn_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Preferred stock issued, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,463,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Preferred stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock issued, price per share/unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=arvn_SeriesBRedeemableConvertiblePreferredUnitsMember', window );">Series B Redeemable Convertible Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Preferred stock issued, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,977,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Preferred stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock issued, price per share/unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=arvn_SeriesCRedeemableConvertiblePreferredUnitsMember', window );">Series C Redeemable Convertible Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Preferred stock issued, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,467,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Preferred stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock issued, price per share/unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=arvn_CommonUnitsMember', window );">Common Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=arvn_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=arvn_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=arvn_SeriesBRedeemableConvertiblePreferredUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=arvn_SeriesBRedeemableConvertiblePreferredUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=arvn_SeriesCRedeemableConvertiblePreferredUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=arvn_SeriesCRedeemableConvertiblePreferredUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=arvn_CommonUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=arvn_CommonUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366271599976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,650,184<span></span>
</td>
<td class="nump">$ 597,131<span></span>
</td>
<td class="nump">$ 3,423,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based award, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,995,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,230,858<span></span>
</td>
<td class="nump">$ 20,072,710<span></span>
</td>
<td class="nump">$ 11,630,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Compensation expense not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,647,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,647,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense not yet recognized, period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.45<span></span>
</td>
<td class="nump">$ 13.28<span></span>
</td>
<td class="nump">$ 9.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,400,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,627,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Incentive units authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,199,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-based award, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Incentive units authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561,485<span></span>
</td>
<td class="nump">1,293,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based award, non-option equity instruments granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,715,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based award, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,744,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based award, non-option equity instruments granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,253,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber', window );">Restricted shares vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan | Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based award, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan | Consultants | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based award, non-option equity instruments granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,067,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase in reserved shares as percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based award, stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,424,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Compensation expense not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense not yet recognized, period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,665,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,665,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Stock options vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,053,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,053,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber', window );">Restricted stock units vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Annual increase in reserved shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,989,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,277,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer A G</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,346,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays', window );">Average common stock preceding days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_PriorToStockPurchaseAgreementPremium', window );">Prior to stock purchase agreement premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember', window );">At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,584,647<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember', window );">At-the-Market Offering | Piper Sandler</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,593,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement', window );">Common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2018 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">390,371<span></span>
</td>
<td class="nump">323,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock', window );">Common stock reserved for issuance represented as percentage on outstanding common stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares remained available for purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock', window );">Amount used as multiplying factor to grant common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_MaximumPercentageOfCompensationReceivableByEmployee', window );">Maximum percentage of compensation receivable by employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2018 ESPP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price under ESPP as percentage of closing price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from sale of shares in Initial public offering before fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,200,000<span></span>
</td>
<td class="nump">431,900,000<span></span>
</td>
<td class="nump">$ 115,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,100,000<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">6,571,428<span></span>
</td>
<td class="nump">5,227,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price, issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 70.00<span></span>
</td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount used as multiplying factor to grant common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate offering price of common stock under equity distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_MaximumPercentageOfCompensationReceivableByEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of compensation receivable by employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_MaximumPercentageOfCompensationReceivableByEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PriorToStockPurchaseAgreementPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prior to stock purchase agreement premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PriorToStockPurchaseAgreementPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement average common stock preceding days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, restricted shares vested and expected to vest, exercisable number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award restricted stock units vested and expected to vest exercisable number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=arvn_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=arvn_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PiperSandlerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PiperSandlerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366363039800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details) - Stock Options - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 22.70<span></span>
</td>
<td class="nump">$ 17.29<span></span>
</td>
<td class="nump">$ 14.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 50.00<span></span>
</td>
<td class="nump">$ 37.66<span></span>
</td>
<td class="nump">$ 16.24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366281654104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted</a></td>
<td class="nump">1,995,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable, Ending Balance</a></td>
<td class="nump">357,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,432,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,424,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(447,113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87,605)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,321,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,665,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,193,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,307,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366285540504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Restricted Stock Grant Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted Shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,715,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted Shares, Granted</a></td>
<td class="nump">1,253,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan | Restricted Stock | Employees, Directors and Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested Restricted Stock, Shares, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted Shares, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(325,818)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted Shares, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested Restricted Stock, Shares, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan | Restricted Stock Units | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested Restricted Stock, Shares, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted Shares, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested Restricted Stock, Shares, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Restricted Shares, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercises weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=arvn_EmployeesDirectorsAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=arvn_EmployeesDirectorsAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=arvn_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=arvn_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286016024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Equity Method Investee - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 18,651,649<span></span>
</td>
<td class="nump">$ 14,335,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">45,089,094<span></span>
</td>
<td class="nump">58,407,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(119,332,064)<span></span>
</td>
<td class="num">(70,292,227)<span></span>
</td>
<td class="num">$ (41,480,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (24,675,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember', window );">Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Cash commitment</a></td>
<td class="nump">$ 49,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest in joint venture</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage', window );">Future grant of incentive units to service providers, percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 24,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">24,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">49,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 24,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember', window );">Oerth | Equity Method Investment, Nonconsolidated Investee or Group of Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">8,300,000<span></span>
</td>
<td class="nump">49,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">8,300,000<span></span>
</td>
<td class="nump">$ 49,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember', window );">Bayer LP | Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Cash commitment</a></td>
<td class="nump">56,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_EquityMethodInvestmentContribution', window );">Contributed to joint venture entity</a></td>
<td class="nump">$ 16,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest in joint venture</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_EquityMethodInvestmentContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_EquityMethodInvestmentContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment, summarized financial information, operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment, summarized financial information, research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future grant of incentive units to service providers, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366362895448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, income tax penalties and interest accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Effective income tax rate reconciliation, tax credit, research and development, percent</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Effective income tax rate reconciliation, tax credit, research and development, amount</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 205,100,000<span></span>
</td>
<td class="nump">$ 103,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards, expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage', window );">Operating losses carry forward, maximum deductibility percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss carryforwards, limitations on use</a></td>
<td class="text">The Company believes the federal net operating losses are subject to an annual limitation as a result of changes in the Company&#8217;s ownership, as defined by Federal Internal Revenue Code Section 382, in November 2019. Notwithstanding the limitations, the Company expects the federal net operating losses to be fully available under Section 382 within the next two years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards, expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Income tax examination year</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 27,800,000<span></span>
</td>
<td class="nump">$ 15,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Effective income tax rate reconciliation, tax credit, research and development, percent</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income taxes receivable</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating losses carry forward, maximum deductibility as a percentage of taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationYearUnderExamination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year being audited in the income tax examination, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationYearUnderExamination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286242056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal research tax credit</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
<td class="num">(3.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(23.30%)<span></span>
</td>
<td class="num">(22.00%)<span></span>
</td>
<td class="num">(20.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Reconciliation of effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366281651224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Deferred Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Loss carryforwards</a></td>
<td class="nump">$ 43,074,539<span></span>
</td>
<td class="nump">$ 21,733,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">8,978,710<span></span>
</td>
<td class="nump">7,871,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">10,070,208<span></span>
</td>
<td class="nump">5,121,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">5,038,675<span></span>
</td>
<td class="nump">3,580,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">172,170<span></span>
</td>
<td class="nump">183,118<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">67,334,302<span></span>
</td>
<td class="nump">38,491,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred income tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(43,103)<span></span>
</td>
<td class="num">(35,011)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, equipment and leasehold improvements</a></td>
<td class="num">(2,377,997)<span></span>
</td>
<td class="num">(1,293,932)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(2,421,100)<span></span>
</td>
<td class="num">(1,328,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">$ (64,913,202)<span></span>
</td>
<td class="num">$ (37,162,360)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366287032504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=arvn_ConsultingAgreementMember', window );">Consulting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_PaymentForConsultingService', window );">Payment for consulting service</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 176,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_MonthlyResearchPayments', window );">Monthly research payments</a></td>
<td class="nump">20,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=arvn_YaleUniversityMember', window );">Yale University | Amended Corporate Sponsored Research Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_QuarterlyResearchPayments', window );">Quarterly research payments</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=arvn_YaleUniversityMember', window );">Yale University | Corporate Sponsored Research Agreement (SRA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Total research payments</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 851,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party agreement, description</a></td>
<td class="text">In July 2016, the Company entered into a Corporate Sponsored Research Agreement (SRA) with Yale University, which was amended in April 2018. The amended SRA extended the agreement until April 2021 and amended the scope of work. The amended SRA requires quarterly payments of $250,000 through the end of the agreement. The total payments made under the SRA for 2020, 2019 and 2018 were $1,000,000, $1,000,000 and $851,161, respectively.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_MonthlyResearchPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly research payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_MonthlyResearchPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PaymentForConsultingService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for consulting service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PaymentForConsultingService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_QuarterlyResearchPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Quarterly research payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_QuarterlyResearchPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919370-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121603689&amp;loc=d3e36975-112693<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918703-209980<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121606570&amp;loc=SL77919784-209982<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=arvn_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=arvn_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=arvn_YaleUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=arvn_YaleUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=arvn_AmendedCorporateSponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=arvn_AmendedCorporateSponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=arvn_CorporateSponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=arvn_CorporateSponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366286540072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Basic and Diluted Loss per Common Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (119,332,064)<span></span>
</td>
<td class="num">$ (70,292,227)<span></span>
</td>
<td class="num">$ (41,480,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Change in redemption value of preferred units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(198,366,756)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted', window );">Net loss attributable to common shares &#8211; basic and diluted</a></td>
<td class="num">$ (119,332,064)<span></span>
</td>
<td class="num">$ (70,292,227)<span></span>
</td>
<td class="num">$ (239,847,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">39,534,497<span></span>
</td>
<td class="nump">32,927,697<span></span>
</td>
<td class="nump">9,422,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share</a></td>
<td class="num">$ (3.02)<span></span>
</td>
<td class="num">$ (2.13)<span></span>
</td>
<td class="num">$ (25.45)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income (loss) available to common stockholders basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140366363226840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Common Share Equivalents Excluded from the Calculations of Diluted Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common share/unit equivalents excluded from the calculations of diluted loss per common share</a></td>
<td class="nump">4,693,643<span></span>
</td>
<td class="nump">4,189,644<span></span>
</td>
<td class="nump">3,375,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common share/unit equivalents excluded from the calculations of diluted loss per common share</a></td>
<td class="nump">4,321,882<span></span>
</td>
<td class="nump">3,432,198<span></span>
</td>
<td class="nump">2,273,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common share/unit equivalents excluded from the calculations of diluted loss per common share</a></td>
<td class="nump">238,712<span></span>
</td>
<td class="nump">576,074<span></span>
</td>
<td class="nump">1,102,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common share/unit equivalents excluded from the calculations of diluted loss per common share</a></td>
<td class="nump">133,049<span></span>
</td>
<td class="nump">181,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>97
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M#KB_?F:_\=ZMEQ4S.%?B*Z^IF07G =2X9IV@>[7[A(,?+[!2POA?V/6Y^32
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MJ;4LZI];P5.AC #^7TNI3Q?F =WAV/)_4$L#!!0    ( (Z!85).ID$TZ0(
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M6)(-54]\]P6:?/J&+^-4VE^TJVW[D8.RC52\:L Z@JID]9>\-CH< /QS -P
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M3PDA2D(1&XU30CY0$<G%7)(:-0(-BX2OQ\Q4&$C"ITD)I>97\D4"2Q\_ R-
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M:TB:-O1S6!D;W2<O,];H:$ESH^-AE2B7Q]$A-%&<MI$DVGQD_VZ\]5M XB+
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M;+P7X]P$27I5L2X4=;I*GP^:3^=0J\1RR%XHPT#(BU9P%6UTK:D6KBZ ;"M
M"\;+"-= 1\=1[?!RG7H<)XR>'(HZ)BTD#$,H=5C"$:XXG6CC.UX"UQPYBBKI
MS-/E-0X%>+3^2C[+,;'L"&,$R$(2#R)'G8>2_*0T#A,3$,I4!1S4!X<2E^<5
M@_GZ'NF31$-[(]@@U-DZP5L#5K&)]G6A-><IS3C3PC*6)YR[P>!A$7>G$!S,
MY'ZS.&S!2,D6H<KV7;RP(3?]]0@[_]'C3@@9^Q+]:&R^2L'[["#L@*U_G%-G
M!WGWWXJOTE@B;L0#0 HA/1(HU.51F8I>L] ;PM5IUDRLD -K2C9*LH=;6OH%
MV+@ED/+?; ;/7GR$NV\(AA(QX<O:;&/J]HJ4DK0SA(B7N/$Y=$.VH&Z!M,F0
MH,IP[P*YU5 A)'#"[%?A&#KD3CL^O-<N?&%)EV=S+K/KHIJ)0$FY0-UQQT-(
MEU"&/R6Y)A*R.6E^&\IJWII*VBA@]9OY#D?E CSH'?&?Y$"R>_]DCPXCF)B"
M]2FA(+\AM;L,WI%-AY0G(J-F)%4T%P\Z1NKD[)X]0=QV,9PUD*T/J86%,$[(
MRTI@HZ5QAEJ.9"VUZHVXTRS;%,/8C![%E5E)6%+:R8;D3\S1!"M.NT)9\L#V
M6PMV#ZJ.N'$/ZRZSCH^D1W055Q]_'::D!<;YE-N*-)?U.K20<-<)UR8VV]K>
M:QU:<9JC^$L(DP2QTCJ^-X'=70'N]^T1%QXG((]'E.,=$R63:.891>+Y*8^N
MJ9PV//@@K2)QJHOGF*F%+5H6+RG!,*SE.Z/*!W<$Y2S-FVB88J[?!3?@TQZ
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MMA)^UZ_ J)Z.,T/K0DFV[-J>L9U>TDE./'%RSD.G#Q )B6A(@@5 R^JO[[<
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M-$U<(KL[O-MHT=A[<RTTWL)V6>*S!Z1AP/-""'W8& 7#0VKY+U!+ P04
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ME$7J\]L:_S6@G0+>5TK9!\$YF/Y>FY]02P,$%     @ CH%A4B,9@SAM!0
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M[_&1$C4_2O6L&P!#7CLN],)OC.EO@D"7#71,3V0/ G=JJ3IFT%3[0/<*6.5
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M!^VT"<T)/E5O3<%QZ8JRLII..=G9Z0.6:]3F!_C\7'/[.HXL@;JC*&L!Y@U
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M,/1:<86B_HRRTJU,,[E"@B9<M5"'*+"#(P;N(P:BA,K2FY3&4Z1TD:7:+#\
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M"@\P,:4XCQ9GT]?]@:MCRE(\MR/)(0AZ=G%,5!JDU_>O)WX!XR3'MM-)#AE
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MZ_.)\NEK6[J(KI8O7$L7HZOD9T'\88 7X/G*N=A=L(/^D^?U?P%02P,$%
M  @ CH%A4I5/((++"0  _1D  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&ULI5E;<]NX%7[GK\!HG4YVAI5YD2PY:WO&<9II9C;93)RT#YT^0"0D8D,2
M6@"TK/[Z?@<@*>IB.^T^2.+EG(-S^<X%T-5&Z>^F$,*RQZJLS?6HL';]YOS<
M9(6HN!FKM:CQ9JETQ2UN]>K<K+7@N6.JRO,DBB[.*R[KT<V5>_99WURIQI:R
M%I\U,TU5<;U]*TJUN1[%H^[!%[DJ+#TXO[E:\Y6X%_;;^K/&W7DO)9>5J(U4
M-=-B>3VZC=^\G1"](_B'%!LSN&9DR4*I[W3S(;\>1:20*$5F20+'SX.X$V5)
M@J#&'ZW,4;\D,0ZO.^GOG>VP9<&-N%/E/V5NB^O1?,1RL>1-:;^HS=]%:\^4
MY&6J-.Z;;3QMFHY8UABKJI89&E2R]K_\L?7#@&$>/<&0M R)T]LOY+1\QRV_
MN=)JPS110QI=.%,=-Y23-07EWFJ\E>"S-Q_J3%6"?>6/PER=6TBDY^=9R_W6
M<R=/<,<)^ZAJ6QCVMSH7^;Z <ZC2ZY-T^KQ-GI7X3F1CEL8A2Z(D>D9>VMN7
M.GGIB_:Q=])DI3*-%NQ?MPMC-1#Q[V>6F/1+3-P2D__3A<]R4]*],6N>B>L1
MLLH(_2!&-W$Z9D.Q[&LAV)VJUKS>LH(;?')6*R8]C85UXA%Y:@3+&]PKAJS5
MW,IZQ6"R@020-EJ+G"&1F86XK>#:,$%Q8_"ZJ!9"]YYGO,YQ$5^.CY;FI5%8
MVR(E,Z6)F]X,-%F(6BRE-?U*-6K+T_K(F@F>%0P$4N6=_L3?U)G0%H7%;IE:
M8CU>RO^0"-ZMP99:55A#P7!I167&[+8LB=CNM/[+3_,DGOUBNI47 HJ)@<9X
MMA%XLH)0*.EU(@'?:DEW]Q8/2;0SN<YD*;DK*>TZW\;W8[84.9A+9D#<6*7W
M7$)2R:I36HGE4KC2=,3P0Y$*79BZ>,V91(3(]27*K7D3$$E %/0U#]X?:4DK
M!4D\CH)7!S\=+:&2:T2(%,L0,FF#R3@&13J>$KG[OK<J^\Y@ ,'0N2=X'8]G
MP<^O@M?).'&_Z3BEW[N"URLRESWPLO&NY*0O1\!!W9*]3A+HX2XB_^0W>$,'
MKR,L3H_;IY'3)7(Z#[[AJJ5H$3:(M!8NS6KK7.LRQP7 !5-SZ.[:A<%K;AD'
M+,"A=(N*7()8$[>'JP?Y4M907<)7% 87/\=#6%TW>@UX CY?186'Z'R]E SZ
M$$?&M=Y"T(;KO%UX18#0TCC8<&;DJI9+F7%:F23OT)<?F[E+09(.M"X 62MI
M-=BS@P?#0D^G_A \)WP).4980.Q7I-6^"<%9,$G#:#8)I^DE;I(XG*5I>#E/
M=X*T>!!U(X)Y>#F;A[,X"F;A? ;"RRCXV@/-!'$$05&81/-@&L:0=#&9G +;
M-(S2>7@QFP9I.)U'X>QBWN(EGB5A/(N">)Z&,7+@J[*(U"FW>8N"BUF8II,P
MC9( (B>7,2[3DRX8N+8#)PR/0?TST Z58B U^*RI^MEMR,0?C5Q7!!\7&(%Q
MHE E1%9KK1X$O3& >YC.9N'EY8RDQ&%R"=>ER*!G-!\J OX)_!1'D>=/$_AX
M0BK]*A"IDSEW,0DOXQ1>3ISFLS"^@!87).$3JO<SSCH+7"5+?AE<';8,,DZZ
M3G%J=<97J/'&)^2R0?WFE6IJ>P3PW:K(!S"&79U6:UFW&5'Q&K,D.3)TTUK.
MFK7R5(4TKN*!JNT$^WT"XBR5SXJZ0RF_BW)+N5B[9N>2DHC[U-I(:$JO%J)M
M32)OVX^&H0=9J@5-R%003GF@XELO)F\R7VB6C:5!Q9=^;PAQU,X!QC@,031>
MDU XI%FB/$A7UQ1KK"1]:&54D+6R>$[E:5@;?&<_I0U\JX5;<K%E9\EL/,?D
M699$!,WZ&G$63\>3_3=H1&W_)IL[.5V8CN> _;(1HBT=YG4_U]"*?2>BFQP%
MI%0^FW:=R1P.+ #=&OA[E)C@*:)G230=Q[W:WI (G:Q_!+=VS?PEC:F6@OSI
M&AJ2SFO?W\OMF+W_4X+C&;E#4@VWB!P:4&-83L,)_*M5LRK0BDP&^80;,*0S
MI\G3YAP,8FZ"((Y#!+8 )1VEGR%)39 A.25-22729]'8-F$!8RM=07+I9AK$
M;-\^Y%DI*S=> 2WSZ-530QM"RQ=E/QRU4'+VX7I3R"/1U.,:0\DX1,)"E!*(
M,;[*/.<0XC?-XG<:"JCY$DCJ!M1.X3990$:AQ=Z/%,_<1&,Z[0YM4!L,EJ:0
MZY 8G<M\<G5P^%!;H6M<?/%=$1)RP>[;G6LZ3URI^T0M@M#@!_-/RFXD]EX6
M 2/U:>6=BLBF@2HNC3+[ ];#XH4OPUO&'[@LG?<;!%H/%6*T=)_7C_#41GFL
MO)B <728?\.$'&3?+JO_5-:%+4K^M]291/N&"&.=!>U\YO8WK9YMY=GK" ,
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M_V>#O[%J[0[X%\I:5;G+0G#4.R+ ^Z7"!K"]H07Z?WQN_@M02P,$%     @
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MG+5H=<!7>@(,4]U[!8C"G;'[-E9O0#05?-UXI6!G814Z',)(Q@H(XD '>&:
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M)K\.-RVG7Q\I1V=K@F'XZ.]Q.V;^'L!)<7E2I#F 61C8I,$L\ABP0IX/89.
M"XLT"-RN0+Q[Q);_2<%B^?PCH+0:LP=D4OAEJ_>QY7*%S@*]1LCL+T$3YV"S
MO 4.RJ5-N@25FL;V$ V%H0G$E*06(AQ#A9Y'0X?W5@^_D 7R=W,:X5*RG+&B
M<XM2W-&P7ZAR85<Q%50'&BDY:7X;K/#?ZI(G""$VUO,#CK( ?*[2XS_J)U>Z
M_^;@+ '/V#KQE;Q@5Z$ELPX8@EP:MT0CHV:H[?@N?-%0@H60X.DC2+<ONF]U
M=.M#FMY$:!IZ%)R/*IX9Q3E@7DML6LV@(RL2QNI#1H^@814NCF.UT(2:72RM
MA>B"NX(1Y_6(;RW83)GT)#Q, VZ+Z0DW1DP>TE]F$Y.#!OX#(VZC&R1K1X6Y
M^OAKMXG$.8*OYV[0[Y%7##.>-!9*G<_=OC+W2H59V?HD?A)R<$Z'<!T_^D9@
M08*.M/:$)D8&X*M/5_H[)DH&D>E3+//DISRYQD&#[L$[-3LN@KAXCIE8&6G)
M"+C!2SD3:1;V56ED-V=I/N5*%--D0PBBOJ8&>4?!<0F_VW 4Z4QHT&<4.7O1
MC\R#8;6\P[K^7+P=W3^TH;L5J%C9H)H;:+<*E918D_3M5-I@Q@YMG4$%.-=:
M:8+P\SB3WOF8TK]VS^&7ZEQ!@7P5*I[6STTCJ>"0XNA3YXQLO3XSR:L*!<)>
M#D"YLF8%D$%^Q,TU 3FL>X<.;+_\'?W&X+9<15\A]MCB!'HY@F#=A))$(=4A
M+1T +EW<$A"/DSN:@Z\1;-=9%9G8AFS0>^!I$Q-K!\#,WG?F#+!%[P<9$MXV
MW[M>T)M8-NJL,^T4TTCG8GJF\U-> 'R3%0#?^NGU0>?XOUQ3?/K6S'P,^ _U
M<?07)X&O:;*>'\,H2.RGH:T5^, U3=(W%M2:>UOD#B94Y#GLA%M]]4#HFU/]
M<?C$ [&\%!]:*AH$2Q4R)(LZ[#+5,M,6QFYD'2J/J;@]\Q4%7]O#VQ+@3WQ%
M-OE(1Z3K8X\D7<.@ DO^P)=9()Y^YLRB;M?H&:BC'WM^KFE+[*M0A:FB16^/
M@P;WFD6CC</4RN@W"Y.!/:>O'L;%(Q_I%D9B- W*-*K"&X#HQ?9^:FH.+J#_
M'G"C5EF)8%1Z.8&^1%T[SHO2,%'N9G!4TN*7C0D\)TZ&'?Q<*@WE97T)HB(;
MQ<7 RFH07J3:/01: O[^<D%8*9L)"J@;V;$QIF3&ANK\'- ^#2AFNI>JH@@#
M"G2J-+7'56\+01AT"7\'U*[]J(+W,31"WF%N8#;YGM38B+Q/H:8..#-O)X5>
M!S$/K%B%;WT3N@ 8Z&Y<WFZ)YL$YL\ZF-DB8LI',E3+5?+,6#:0OI;$=SS!4
M!4UJKYO4O^:STSG9C!B6,-2O_2_#)A$/!+1]P>XB8?<[4%_\?XV@;2\U8>MP
M_2#H!,=!'P-C.R-YAQH\VE96Z]YT!XT&*DZ*2;14X,8;>!OJ,X6PX7/,&$Z8
M=\BBD;!.M[=T\K*"YZSI1DO\+,L5FL2[P,CP.'8(^JNA*D6U21?-4I<XWM+R
MY\6+P8$]T=V&X^3N,F\F>,S 1I4 D!<6< FB16HK]9K+!O!O')F.K5=TFL8G
MT6%P*[M21A 9YX7N)TL0:7YZ,3U _0ZQZ>^$33\P<AZO9?_02H3B?X/(4(AG
MV,$=>XRB>':3</C.U7OTLF+A*PY7];YM<EF3AIH5BHV<#VB&GY3V(]*4@5"W
MM^B7]*PL0QI"-LX5,3?W>RXG]SS<)4@_W^-@\=DD>>.K^->[URUX:1]^L<;G
M@4ARF-28TG^V*F\=8.\NSZ'SZY:X=,9.#UI]K1"KG1+=!E6P#8T+L+?,7O'/
MDD,EMK0K+++Y*CK5GUN<C*"QT,YD+M9;4M5SN&/K1=-IB@3'FJY:4;P))2)_
M^1-XM((<@'^BZ[(;S*KJ.#@!#J,N[K/9\Z (YX>*D )A6V=GISL8<83*JC6"
MC&\ZHX/[MV'(/W3#*?)3O:KEI",4=E,5*..=;P;D5[CX7BJ$6!"(RJ>7.!CF
MNI-I#-$2 /-021FG!-*4:)P*C5\2I/#ZG-;%@ERD@0I-66T[CQUMHRN*'(/Z
M[#GU%=;_2^4-V8[ZLL30/F"O_I,=V?EG?5BC(?(&*TG.#TW&H!OP"ET81AB'
M<@)$Q#?*+-XHTT-I:GZQ<DBUAR^39*@AJ30K<KI%PF&#PV96>Q@I[,]2G.PX
MH\Z]E 3*DLD1@QZZT&!]? Q8H7O7;?S6DZ3"DL6#V:[00P&'^)3-OAV.%1V6
M57!-TKON%!I\^_CL02A(8 F5ZM*I29[!#-\V[IK, 4T'-B-CQ9%NSS*G'?,R
M>*':JS 9S#><P.%H->4.R/))N9SGI'8&[+CAGYT)H(M%Z#<)));I5LQR^E;,
M+Z!.[[$^#B (E1DOGE]CTVL(2DRO-5SW'-U O)8.T 76N*KPO;_Y3ETWNL\"
MUM7ZZ$1U>A1"> /4<8V-#+:;4.S.FG>]AATM *J-50".87?TAUU4>2(AAH!@
M1=V2PI.9)DI<I\>470S-IY*R%AL-ZC1$"4>$KKJ/4L@C8@UD8>%JE\ G<<+>
MD]Z[#I(F[Q?/TLA(MV'D#T+K@Z7KBOC9X3JSFUL=GM^I)_E_PR/TWC,<V"F1
M ,([^>+B</%TUR*UFSL;,MM3QZ+7*X-/)ACM4_;$&CJ^^NJ;%G$\B!D2_5$Y
MQ+Z.TJ[]6)4?[?$]5;!>3RBY1CA7X,-<7,2V/%YD[2S6N=1.%8G_=_ITG[PI
M+Y/N]"RG[_3\HNXZ?W?(FMI@TV<T:9E>;\S33&R"@__<W;\H 04!C\8?O<*>
M,T0K,*LGK*<IJQF<\']-G8J'[RZN7Q^'X93!!S]381XO 7P^AO [IRU.%N=B
M-I(XA8$>?]/]/=^W_)4K2FD'%W=(!7L:.O/$A*O<0"""3*Y(Q9=. 'O2,BM3
MQI*#OX?GQX/!R7KLB#M6V#3B4$?G":E,/M3IFP:A9DC7A]!0AP?/!O_H"Z5H
M8>-A33S-_CS63MD-_1$PC^GX+V7%3^,?&KO@/Z^5'N>_4O9!V@W>:ZW4&EX]
MFS]]?,1SL>&7QNSICVVM3-.8'?VX59!]6GP OE\;<%G^%]P@_OFU5_\#4$L#
M!!0    ( (Z!85*>^XBO6 ,  'X'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;)5538_;-A"]ZU<00@X)(%@?EG9MPS9@;UHT0(,:NTE[*'J@I)%$
MA")5DEIM^NL[I&2M WA=]&!Y^#%O'N<-A]M!JF^Z 3#DI>5"[_S&F&X3AKIH
MH*5Z(3L0N%))U5*#0U6'NE- 2^?4\C")HKNPI4SX^ZV;.ZG]5O:&,P$G173?
MME1]/P*7P\Z/_?/$(ZL;8R?"_;:C-3R!^=J=%(["&:5D+0C-I" *JIU_B#?'
MS.YW&WYG,.@+F]B3Y%)^LX-/Y<Z/+"'@4!B+0/'O&1Z <PN$-/Z>,/TYI'6\
MM,_H/[NSXUERJN%!\C]8:9J=O_))"17MN7F4PR\PG<<1+"37[DN&<6]V[Y.B
MUT:VDS,R:)D8_^G+E(<+AU7TAD,R.22.]QC(L?Q(#=UOE1R(LKL1S1KNJ,X;
MR3%A17DR"E<9^IG](VB@JF@('HO37"HZ)DN4Y%=68/*!'&H%@#H83=Y_H3D'
M_6$;&HQM$<)BBG,<XR1OQ(D3\ED*TVCRDRBA_!$@1-(S\^3,_)C<1/P(Q8(L
MXX D41+=P%O.F5@ZO.7_R\3A>B;^/.3:**RIOVZ$3N?0J0N=OA'Z:;P11%88
M7#A8C$ESQIEAH*]E^S;@)S%>5R=ECG>1%&=<_HH;$"8*WJ,<A&I;RJ 4V@J>
M0?2 B\0T@/>FD&U'Q7<F:DM/2\Y*:G#CD7(J"B!/MOHLFK8X%:9/#GKCH4#0
MYJ"L2)X5"3_QVGNXPL1[YZ59$*W60;1.<9"M@C2ZMS_O<62CD58A:\'^P< 3
MLPX4DR6IE&PWWJ&5O15F/A)NNG8D;%W/3/9Z\M9>O KNLCBX2]=>G ;+91;$
MJ]4-4;-9U.RF!E\4%9J.O>>DL(+( 1-3N,P924Z@G$8V@;_EG-5.K:M:_T<<
MJU&-E8D(:+DTV$JR&3(7'#K'@5YRZ"XXR%<.Z$H-H0I(C]Z&Z8J-)8*HEZ*Z
MFT<&7'B79HL8VQ/GZ!^0H6%XC[ <X*7#[CL&R^&*A&.QV,J:Y"#O<64"TA\V
MMFYB+(AXO4BMG5@KL=;2NUMDKFX6\36UPHN>V(*J7>?7> \P/6-[G&?GQ^4P
M]M37[>/+])FJFF%:.%3H&BWN41 U=OMQ8&3G.FPN#?9K9S;X0(*R&W"]DM*<
M!S; _.3N_P502P,$%     @ CH%A4I.1<$&] P  = D  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&ULQ59+;^,V$+[K5Q!JT6X!)7K8\B-K&["3[':!
M! CB[/90]$!)(XL()7I)RE[WUW=(R;*3C=T6/?1@BX]Y?#.<C\/)5LAG50!H
M\JWDE9JZA=;K*]]7:0$E59=B#17NY$*65.-4KGRUED SJU1R/PJ"@5]25KFS
MB5U[D+.)J#5G%3Q(HNJRI'*W "ZV4S=T]PN/;%5HL^#/)FNZ@B7HS^L'B3._
MLY*Q$BK%1$4DY%-W'EXM8B-O!;XPV*JC,3&1)$(\F\FG;.H&!A!P2+6Q0/&S
M@6O@W!A"&%];FV[GTB@>C_?6/]C8,9:$*K@6_#>6Z6+JCER204YKKA_%]E=H
MX[$ 4\&5_2?;1G88NR2ME19EJXP(2E8U7_JMS<.1PB@XH1"U"I'%W3BR*&^H
MIK.)%%LBC31:,P,;JM5&<*PRA[+4$G<9ZNG9/97/H&G"@2PAK273#!1Y]V16
MU"\37Z,/(^FGK;U%8R\Z82^,R+VH=*'(;95!]M* C^ ZA-$>X2(Z:_$&TDO2
M"ST2!5%PQEZOB[AG[?5.V/M4;4!IK"NMR TDFLRKC-Q^K9G>':?@]WFBM,2B
M^>.,SW[GLV]]]D_X7#8E3T1.KD6YIM7N9T7F&\JXS3QRBRSIBR-X*_/G?3P5
MQA!'EK%J19@B=,\TXU;C;NOZIQ]&43A\CP)[ !<(X$(9 *H#<.E@XJ%,0';)
MQQ652K8V=')N\QPLH\@]U49GY\Q+(37[$S+TI+3S40JER.<*[PIN5S_B':&^
M7[[#.2CG V62?*&\!N=:R+605 -)1)4I!YV'SH_.>.S%XX$WLI-X$'C#\1!'
M%_@+@\ +XZ$W"$?.D]"4_W/Q5V&&X_\SS," Z\=>+QY[H^$ 9_VQ-XPB'-AC
MB]ZW OW 1#=Z.U5A-/#"<=\+@KZ#48[B?J=MMJ(XQ+5#HJ)AZ,5QSQN-K/M@
MZ,76]<&CD1@,0J\?#\ZP(>[8$)]G W:6K,9JP[H\I,,C<TP0DI(B'^\831AO
MF'@/5-42,XB7^*.I3VD*?$$5>Y,EYWV_9(F]^%3+$SPE2Y/<0-H82 T6#AO@
M"N]E7;#JE00I&$@JTV)'<&];L+1X+5$V\)L+)Z><6[K30ZS\*-;R*%:*36\?
M;6*B125,V=7?$//.P"5A^XW:;Z\][2;'5]_5S8OZ.F+'J?7SK/GO&(XJ[M]4
MHG_4"4N0*]OO%4E%7>FF*7:KW9-BWG32@WCS'L'.N$(BX_'GJ!I<F@XNFQ[?
M3+18V[Z:"(U=V@X+?!:!- *XGPNA]Q/CH'MHS?X"4$L#!!0    ( (Z!85+"
M%X(HRP(  !$&   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;)5536^C
M,!"]\RLLM(=6L@HVD)(HB=2OU59JM5&['X?5'AP8 JK!J6V:]M_O&!*:2FU6
MO8#'GGEOYID9IANE'TP)8,ES+1LS\TMKUY,@,%D)M3 G:@T-GA1*U\*BJ5>!
M66L0>1=4RX"'X2BH1=7X\VFWM]#SJ6JMK!I8:&+:NA;ZY1RDVLQ\YN\V[JI5
M:=U&,)^NQ0KNP?Y<+S1:P8"25S4TIE(-T5#,_#,V.8^=?^?PJX*-V5L35\E2
MJ0=G7.<S/W0)@83,.@2!KR>X "D=$*;QN,7T!TH7N+_>H7_M:L=:EL+ A9*_
MJ]R6,S_U20Z%:*6]4YMOL*TG<7B9DJ9[DDWOFXQ]DK7&JGH;C!G45=._Q?-6
MA[V -/P@@&\#>)=W3]1E>2FLF$^UVA#MO!'-+;I2NVA,KFK<I=Q;C:<5QMGY
M0N/]:OM"R=5C6ZU1;DM$DY,;P%)+)7-R7:^U>@)W8LC1#[&48(ZG@45R!Q%D
M6Z+SGHA_0,0XN56-+0VY:G+(WP($F/60.M^E?LX/(EY"=D(B1@D/>7@ +QJD
MB#J\Z#]2D(44J,(9JO"JR9^SI;$:OZ&_!YCB@2GNF.(/F.ZQM?)6 E$%^=P%
MO*?[8:Y7?'B#+P?\:O^",X7]9JS+S)9 "B6Q;:MF-?%0;JB7H)WDGI,<'VSL
MW8BETL(J_?)*X'WQ&*,L#"EC(S12&L8)9:=C[WM15!GL>3+*HXBF//+244+3
M-/5NWDW,&]$P26D<(BU-PS'E8>*QE$9C3J-H[/A.>4CY*4< 8R;8[EE;MU)8
MR+%+<6!EE7!SP#L:418A!H^]8^\HHGP4TW3$T/B<5)0TT%7**4_&-&%)5VF<
M)#1F[+VO)-AKTQKTJAM&3O*VL7W'#KO#O#OKV_S5O1^6MT*OJL9@:@6&AB>G
MB4]T/X!ZPZIUU_1+97&$=,L29S9HYX#GA5)V9SB"X2\P_P=02P,$%     @
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M&O\$0+L-^+U2RKY,G(/AWV+S+U!+ P04    " ".@6%2X3EKU(T"  !#!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q]5$UOVS ,O?M7",8.&R#4
MG[&=(@F0M!VV0X&@W<=AV$&QZ=BH+'F2TK3_?I2<N-G0Y&*+%-_C(R5JMI?J
M23< AKQT7.BYWQC37P>!+AOHF+Z2/0C<J:7JF$%3;0/=*V"5 W4\B,,P"SK6
M"G\Q<[ZU6LSDSO!6P%H1O>LZIEY7P.5^[D?^T?'0;AMC'<%BUK,M/(+YWJ\5
M6L'(4K4="-U*0134<W\97:]2&^\"?K2PUR=K8BO92/EDC:_5W ^M(.!0&LO
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MQ8WL>BE &$UD3?[O[GM-O<QW9(#C^902!T(;="&_:8#4DN-DM6)[[6&_H-N
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M-O9: ^4<['HEI3D8;H/QHES^!E!+ P04    " ".@6%2>TX:X1<%  #F#0
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M$$D?(O$ADC="/$"NFEQ64GC!J9+8%9"O@_F W$$!6E1D;H7=6*5WY(#/@[!
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MLO@\U8<S$%@(-P#O3Y2RSR?.0;M_>_8_4$L#!!0    ( (Z!85(:9->%G ,
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M>0_9&W1-4SRF[HG<,5B3E&Z!TKL:@U.R>)\4'2T.]CZ]$1INY[:YAS<=E<8
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M.:8D4U575 V,+%UC,9>&VA3WN:).$I7=0.L+*<W3P#IH>M/Q;U!+ P04
M" ".@6%2EGAJJ$H"   @!0  &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6R-5,MNVS 0_!5"Z"$!6NMA.W$"68 ?*5H@08,$;@]%#[2TMHA0I$JN'_W[
M+BE9==/8Z$7BDCO#F267Z4Z;%UL"(-M74MEQ4"+6MV%H\Q(J;GNZ!D4K*VTJ
MCA2:=6AK [SPH$J&211=A147*LA2/_=HLE1O4 H%CX;9355Q\VL*4N_&01P<
M)I[$ND0W$69IS=?P#+BH'PU%8<=2B J4%5HQ ZMQ,(EO9P.7[Q.^"MC9HS%S
M3I9:O[C@<S$.(B<().3H&#C]MC #*1T1R?C9<@;=E@YX/#ZP?_3>R<N26YAI
M^4T46(Z#4< *6/&-Q">]^P2MGZ'CR[6T_LMV;6X4L'QC45<MF!140C5_OF_K
M< 2(KTX DA:0O 8,3@#Z+:#OC3;*O*TY1YZE1N^8<=G$Y@:^-AY-;H1RI_B,
MAE8%X3#SQ\90LX4%-K$6T#*N"G8O^%)(@0(L^\!FNJJU D6+>L7N@>K&[O9T
MD^A_,0?D0MI+REL\S]G%N\LT1)+F-@CS5L:TD9&<D!$G[$$K+"V[4P44?Q.$
MY*DSEAR,39.SC'/(>ZP?OV=)E$1O")K]-SR^.2.GW]6Y[_GZ)_A\S2S[/EE:
M-'1W?YSA''2< \\Y.,'YI0;#4:@UD_Y$<FWQK=(W+$//XKIZF]W<#)-DE(;;
MXX+\FS:*KZ/A=9?6B R/+EL%9NU[T-+F&X7-\72S79M/_.U^-3^E]F^Z]0]-
M\W8\<+,6RI*M%5%&O6L299I^; +4M;_22XW4('Y8TA,&QB70^DIK/ 1N@^Y1
MS'X#4$L#!!0    ( (Z!85)XH,D;U (  ,D&   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;(U5[V_:,!#]5T[1/K32:$B E%: 5&#5)K5:5=3MLTDN
MQ*IC9[93NO]^9R=-*06T+XE_W#V_>\^Y3+9*/YL"T<)K*:29!H6UU748FK3
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MOP:U"Z#]7"G[-G$'='^OV3]02P,$%     @ CH%A4I9T'(UO @  - 8  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#@N>&ULA55?3]LP$/\J5K0')@V2N&E:
M4%H)J*9- @G1L3U,>W";2VOAQ)E]I?#M.3LA*C0M+XTO]N^?8U^SK3:/=@V
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MX9K:.ABW@.8+K?&M<*VF^Z.8O@)02P,$%     @ CH%A4C^9:M6' @  ?@8
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MY5[.Q*U8SBEL_T$1N"VL/5$!SZ("F%1$B)7(/9,!$( BTYQU''U+HQ .'N2
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M_#UI%?F&$/P?U"JZ]-NM(FZ[XKNR"#+*(=E^5/?:(D@1XHAWT)QO^,(?\ N
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M>E16@/:74IK]Q!JH_E,8_P]02P,$%     @ CH%A4L,)*I9$ P  > D  !D
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MYR<X1155JRX8PMZ^QPFIV+*;]6 .HIW5VS_,]CR_2=A_645_ 5!+ P04
M" ".@6%2EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (Z!85(EBAEEJ@8  +<:   8
M          " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " ".@6%2*H]C8OT%  #8%@  &               @('L#@  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ CH%A4G0;H;]7 @  [@4
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M965T-RYX;6Q02P$"% ,4    " ".@6%2"#>MM5\)  "?*   &
M    @('[+   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
MCH%A4L2P7G15!@  SP\  !@              ("!D#8  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( (Z!85+*\;"PI18   I#   9
M          " @1L]  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#
M%     @ CH%A4D?71XBU!   >PL  !D              ("!]U,  'AL+W=O
M<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " ".@6%252+$QTD(  !@
M&0  &0              @('C6   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;%!+ 0(4 Q0    ( (Z!85)+Z"\HRP,  %0)   9              " @6-A
M  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ CH%A4EW3
M4-$2 P  R08  !D              ("!964  'AL+W=O<FMS:&5E=',O<VAE
M970Q-"YX;6Q02P$"% ,4    " ".@6%2(QF#.&T%   D#0  &0
M    @(&N:   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M (Z!85*3P3&M?0(  $ %   9              " @5)N  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ CH%A4A@W3 #<!@  !Q$  !D
M             ("!!G$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " ".@6%2[!=\D<D#  "L"   &0              @($9>   >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( (Z!85*4\KG:IPX
M )DL   9              " @1E\  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ CH%A4LB"I*3L!P  _A0  !D              ("!
M]XH  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " ".@6%2
ME4\@@LL)  #]&0  &0              @($:DP  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( (Z!85(AI4?R9 ,  - '   9
M      " @1R=  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ CH%A4L#\#CW9 P  :@@  !D              ("!MZ   'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " ".@6%2R::OO?87  "*30
M&0              @(''I   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( (Z!85*>^XBO6 ,  'X'   9              " @?2\  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ CH%A4I.1<$&]
M P  = D  !D              ("!@\   'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " ".@6%2PA>"*,L"   1!@  &0
M@(%WQ   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( (Z!
M85+D"C=,EP,  &<(   9              " @7G'  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ CH%A4N$Y:]2- @  0P4  !D
M         ("!1\L  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " ".@6%2<X#&/7@"   T!0  &0              @($+S@  >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( (Z!85)[3AKA%P4  .8-
M   9              " @;K0  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ CH%A4@-*;.U6!   T@D  !D              ("!"-8
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " ".@6%2?M1C
ML\L#  "&"   &0              @(&5V@  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( (Z!85*&4^<%404  (<4   9
M  " @9?>  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
MCH%A4@Z92GZ,!0  RQT  !D              ("!'^0  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " ".@6%2&F37A9P#   Q#@  &0
M            @('BZ0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( (Z!85+)-O2B$@<  #,K   9              " @;7M  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ CH%A4NC/=6"6 @
M' 8  !D              ("!_O0  'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " ".@6%2OMDMM_0"  !0#   &0              @('+
M]P  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (Z!85+0
M%T2A* (  $8$   9              " @?;Z  !X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ CH%A4@X2+K", P  # T  !D
M     ("!5?T  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (Z!85*6>&JH2@(  " %   9              "
M@40- 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ CH%A
M4GB@R1O4 @  R08  !D              ("!Q0\! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " ".@6%2EG0<C6\"   T!@  &0
M        @('0$@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( (Z!85(_F6K5AP(  'X&   9              " @785 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ CH%A4@HLE$CO!0  M!H
M !D              ("!-!@! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " ".@6%2HSR8#F@"  #5!0  &0              @(%:'@$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( (Z!85)W #,L
M @0   ,0   9              " @?D@ 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ CH%A4LXH1694"@  W3H  !D
M ("!,B4! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " ".
M@6%28:!'L=T#  #!#P  &0              @(&]+P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( (Z!85+DR-W3+00  %80   9
M          " @=$S 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#
M%     @ CH%A4F3!9PU8!   KA,  !D              ("!-3@! 'AL+W=O
M<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " ".@6%2VC ^I+0$  #=
M$@  &0              @('$/ $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM
M;%!+ 0(4 Q0    ( (Z!85(M'.31.P4  * 4   9              " @:]!
M 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ CH%A4JCS
M9K0> P  +0L  !D              ("!(4<! 'AL+W=O<FMS:&5E=',O<VAE
M970U.2YX;6Q02P$"% ,4    " ".@6%2N(0>.F\#  #<"@  &0
M    @(%V2@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M (Z!85)-23G\\@,  #4,   9              " @1Q. 0!X;"]W;W)K<VAE
M971S+W-H965T-C$N>&UL4$L! A0#%     @ CH%A4L,)*I9$ P  > D  !D
M             ("!15(! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"
M% ,4    " ".@6%2.#<5?5(#  !C#   &0              @(' 50$ >&PO
M=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( (Z!85)5I,JQ8P(
M &8-   -              "  4E9 0!X;"]S='EL97,N>&UL4$L! A0#%
M  @ CH%A4I>*NQS     $P(   L              ( !UUL! %]R96QS+RYR
M96QS4$L! A0#%     @ CH%A4J$P%KGY!   ]BD   \              ( !
MP%P! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( (Z!85(G9=6E# (  (0E
M   :              "  >9A 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<U!+ 0(4 Q0    ( (Z!85+NU>T8Y@$  /4D   3              "  2ID
K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !' $< :!,  $%F 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>236</ContextCount>
  <ElementCount>429</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders'/Members' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders'/Members' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders'/Members' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders'/Members' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Research Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreements</Role>
      <ShortName>Research Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Property, Equipment and Leasehold Improvements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovements</Role>
      <ShortName>Property, Equipment and Leasehold Improvements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Right to Use Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilities</Role>
      <ShortName>Right to Use Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Members' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquity</Role>
      <ShortName>Members' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Investment in Equity Method Investee</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvestee</Role>
      <ShortName>Investment in Equity Method Investee</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Research Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTables</Role>
      <ShortName>Research Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsTables</Role>
      <ShortName>Property, Equipment and Leasehold Improvements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Right to Use Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesTables</Role>
      <ShortName>Right to Use Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsSummaryOfContractLiabilitiesDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Summary of Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails1</Role>
      <ShortName>Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Marketable Securities - Summary of Company's Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Company's Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Marketable Securities - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Marketable Securities - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails</Role>
      <ShortName>Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsAdditionalInformationDetails</Role>
      <ShortName>Property, Equipment and Leasehold Improvements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Right to Use Assets and Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Right to Use Assets and Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Right to Use Assets and Liabilities - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Right to Use Assets and Liabilities - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Right to Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails</Role>
      <ShortName>Right to Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Right to Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Right to Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Accrued Expenses - Components of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Components of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Long-Term Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Long-Term Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Long-Term Debt - Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Members' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails</Role>
      <ShortName>Members' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails</Role>
      <ShortName>Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Equity - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails</Role>
      <ShortName>Equity - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Equity - Summary of Restricted Stock Grant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails</Role>
      <ShortName>Equity - Summary of Restricted Stock Grant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Investment in Equity Method Investee - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails</Role>
      <ShortName>Investment in Equity Method Investee - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Income Taxes - Summary of Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Net Loss Per Common Share - Basic and Diluted Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share - Basic and Diluted Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="arvn-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Net Loss Per Common Share - Common Share Equivalents Excluded from the Calculations of Diluted Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share - Common Share Equivalents Excluded from the Calculations of Diluted Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="arvn-10k_20201231.htm">arvn-10k_20201231.htm</File>
    <File>arvn-20201231.xsd</File>
    <File>arvn-20201231_cal.xml</File>
    <File>arvn-20201231_def.xml</File>
    <File>arvn-20201231_lab.xml</File>
    <File>arvn-20201231_pre.xml</File>
    <File>arvn-ex1034_590.htm</File>
    <File>arvn-ex1035_591.htm</File>
    <File>arvn-ex211_11.htm</File>
    <File>arvn-ex231_14.htm</File>
    <File>arvn-ex311_6.htm</File>
    <File>arvn-ex312_15.htm</File>
    <File>arvn-ex321_8.htm</File>
    <File>arvn-ex322_12.htm</File>
    <File>arvn-ex991_751.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gfbaqn1kfu2x000001.jpg</File>
    <File>gfbaqn1kfu2x000002.jpg</File>
    <File>gfbaqn1kfu2x000003.jpg</File>
    <File>gfbaqn1kfu2x000004.jpg</File>
    <File>gfbaqn1kfu2x000005.jpg</File>
    <File>gfbaqn1kfu2x000006.jpg</File>
    <File>gfbaqn1kfu2x000007.jpg</File>
    <File>gfbaqn1kfu2x000008.jpg</File>
    <File>gfbaqn1kfu2x000009.jpg</File>
    <File>gfbaqn1kfu2x000010.jpg</File>
    <File>gfbaqn1kfu2x000011.jpg</File>
    <File>gfbaqn1kfu2x000012.jpg</File>
    <File>gfbaqn1kfu2x000013.jpg</File>
    <File>gfbaqn1kfu2x000014.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>103
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arvn-10k_20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 27,
   "contextCount": 236,
   "dts": {
    "calculationLink": {
     "local": [
      "arvn-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arvn-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "arvn-10k_20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arvn-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arvn-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "arvn-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 572,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 40,
    "http://www.arvinas.com/20201231": 3,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 48
   },
   "keyCustom": 60,
   "keyStandard": 369,
   "memberCustom": 43,
   "memberStandard": 29,
   "nsprefix": "arvn",
   "nsuri": "http://www.arvinas.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arvn:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - License Agreements",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arvn:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Research Collaboration and License Agreements",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreements",
     "shortName": "Research Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Marketable Securities",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Property, Equipment and Leasehold Improvements",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovements",
     "shortName": "Property, Equipment and Leasehold Improvements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Right to Use Assets and Liabilities",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilities",
     "shortName": "Right to Use Assets and Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Accrued Expenses",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Long-Term Debt",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Members' Equity",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquity",
     "shortName": "Members' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Equity",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Investment in Equity Method Investee",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvestee",
     "shortName": "Investment in Equity Method Investee",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Income Taxes",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Commitments and Contingencies",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Net Loss Per Common Share",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Research Collaboration and License Agreements (Tables)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTables",
     "shortName": "Research Collaboration and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsTables",
     "shortName": "Property, Equipment and Leasehold Improvements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Right to Use Assets and Liabilities (Tables)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesTables",
     "shortName": "Right to Use Assets and Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Long-Term Debt (Tables)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Equity (Tables)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Net Loss Per Common Share (Tables)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "arvn:NumberOfWhollyOwnedSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_arvnSubsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Nature of Business and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "arvn:NumberOfWhollyOwnedSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_arvnSubsidiary",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
       "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
       "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "arvn:LicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "arvn:CollaborativeArrangementPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - License Agreements - Additional Information (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
     "shortName": "License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "arvn:LicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "arvn:CollaborativeArrangementPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Research Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Liabilities (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsSummaryOfContractLiabilitiesDetails",
     "shortName": "Research Collaboration and License Agreements - Summary of Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails",
     "shortName": "Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details1)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails1",
     "shortName": "Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details1)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Marketable Securities - Summary of Company's Available for Sale Securities (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails",
     "shortName": "Marketable Securities - Summary of Company's Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Marketable Securities - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "shortName": "Marketable Securities - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails",
     "shortName": "Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsAdditionalInformationDetails",
     "shortName": "Property, Equipment and Leasehold Improvements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Right to Use Assets and Liabilities - Additional Information (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails",
     "shortName": "Right to Use Assets and Liabilities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Right to Use Assets and Liabilities - Components of Lease Expense (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesComponentsOfLeaseExpenseDetails",
     "shortName": "Right to Use Assets and Liabilities - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Right to Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
     "shortName": "Right to Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Right to Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "Right to Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Accrued Expenses - Components of Accrued Expenses (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Components of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Long-Term Debt - Additional Information (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails",
     "shortName": "Long-Term Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20181231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Long-Term Debt - Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails",
     "shortName": "Long-Term Debt - Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Members' Equity - Additional Information (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
     "shortName": "Members' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredStockMember_20130101_20141231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20181001_20181001",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Equity - Additional Information (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
     "shortName": "Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails",
     "shortName": "Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20180901_20180930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Equity - Summary of Stock Option Activity (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails",
     "shortName": "Equity - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_us-gaapPlanNameAxis_arvnTwoThousandEighteenStockIncentivePlanMember_20191231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20180101_20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Equity - Summary of Restricted Stock Grant Activity (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails",
     "shortName": "Equity - Summary of Restricted Stock Grant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_srtTitleOfIndividualAxis_arvnEmployeesDirectorsAndConsultantsMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_us-gaapPlanNameAxis_arvnStockIncentivePlanMember_20191231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Investment in Equity Method Investee - Additional Information (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails",
     "shortName": "Investment in Equity Method Investee - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_arvnOerthBioLimitedLiabilityCorporationMember_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentAggregateCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20171231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders'/Members' Equity",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity",
     "shortName": "Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders'/Members' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_us-gaapStatementClassOfStockAxis_arvnSeriesARedeemableConvertiblePreferredUnitsMember_20171231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Income Taxes - Summary of Deferred Income Taxes (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of Deferred Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "arvn:PaymentForConsultingService",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_us-gaapRelatedPartyTransactionAxis_arvnConsultingAgreementMember_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "arvn:PaymentForConsultingService",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Net Loss Per Common Share - Basic and Diluted Loss per Common Share (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails",
     "shortName": "Net Loss Per Common Share - Basic and Diluted Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "lang": null,
      "name": "arvn:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Net Loss Per Common Share - Common Share Equivalents Excluded from the Calculations of Diluted Loss Per Common Share (Details)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails",
     "shortName": "Net Loss Per Common Share - Common Share Equivalents Excluded from the Calculations of Diluted Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders'/Members' Equity (Parenthetical)",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical",
     "shortName": "Consolidated Statements of Redeemable Convertible Preferred Shares/Units and Changes in Stockholders'/Members' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "arvn:IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Nature of Business and Basis of Presentation",
     "role": "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arvn-10k_20201231.htm",
      "contextRef": "C_0001655759_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "arvn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AmendedCorporateSponsoredResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Corporate sponsored research agreement.",
        "label": "Amended Corporate Sponsored Research Agreement [Member]",
        "terseLabel": "Amended Corporate Sponsored Research Agreement"
       }
      }
     },
     "localname": "AmendedCorporateSponsoredResearchAgreementMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_AmountUsedAsMultiplyingFactorToGrantCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount used as multiplying factor to grant common stock.",
        "label": "Amount Used As Multiplying Factor To Grant Common Stock",
        "terseLabel": "Amount used as multiplying factor to grant common stock"
       }
      }
     },
     "localname": "AmountUsedAsMultiplyingFactorToGrantCommonStock",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AnnualLicenseFeePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license fee payment.",
        "label": "Annual License Fee Payment",
        "terseLabel": "Annual payment for license"
       }
      }
     },
     "localname": "AnnualLicenseFeePayment",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At-the-Market Offering",
        "verboseLabel": "At The Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale debt securities effective maturity period.",
        "label": "Available For Sale Debt Securities Effective Maturity Period",
        "terseLabel": "Effective Maturity"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesEffectiveMaturityPeriod",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "arvn_BayerAGAndPfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer AG and Pfizer.",
        "label": "Bayer A G And Pfizer [Member]",
        "terseLabel": "Bayer and Pfizer Collaboration Agreement"
       }
      }
     },
     "localname": "BayerAGAndPfizerMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_BayerAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer AG.",
        "label": "Bayer A G [Member]",
        "terseLabel": "Bayer A G",
        "verboseLabel": "Bayer Collaboration Agreement"
       }
      }
     },
     "localname": "BayerAGMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_BayerCropScienceLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer CropScience LP.",
        "label": "Bayer Crop Science L P [Member]",
        "terseLabel": "Bayer LP"
       }
      }
     },
     "localname": "BayerCropScienceLPMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in redemption value of redeemable convertible preferred units.",
        "label": "Change In Redemption Value Of Redeemable Convertible Preferred Units",
        "negatedLabel": "Change in redemption value of redeemable convertible preferred units"
       }
      }
     },
     "localname": "ChangeInRedemptionValueOfRedeemableConvertiblePreferredUnits",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CollaborativeArrangementPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement payment.",
        "label": "Collaborative Arrangement Payment",
        "terseLabel": "Payment for license agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementPayment",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CollaborativeArrangementSublicensePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement sublicense payment.",
        "label": "Collaborative Arrangement Sublicense Payment",
        "terseLabel": "Payment for sublicense agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementSublicensePayment",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CollaboratorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborator one.",
        "label": "Collaborator One [Member]",
        "terseLabel": "Collaborator One"
       }
      }
     },
     "localname": "CollaboratorOneMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CollaboratorThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborator three.",
        "label": "Collaborator Three [Member]",
        "terseLabel": "Collaborator Three"
       }
      }
     },
     "localname": "CollaboratorThreeMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CollaboratorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborator two.",
        "label": "Collaborator Two [Member]",
        "terseLabel": "Collaborator Two"
       }
      }
     },
     "localname": "CollaboratorTwoMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestones.",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_CommonUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common units.",
        "label": "Common Units [Member]",
        "terseLabel": "Common Units"
       }
      }
     },
     "localname": "CommonUnitsMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ConnecticutInnovationsIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Connecticut innovations incorporated.",
        "label": "Connecticut Innovations Incorporated [Member]",
        "terseLabel": "Connecticut Innovations, Inc."
       }
      }
     },
     "localname": "ConnecticutInnovationsIncorporatedMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants.",
        "label": "Consultants [Member]",
        "terseLabel": "Consultants"
       }
      }
     },
     "localname": "ConsultantsMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting agreement.",
        "label": "Consulting Agreement [Member]",
        "terseLabel": "Consulting Agreement"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CorporateBondsMaturingTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate bonds maturing 2020.",
        "label": "Corporate Bonds Maturing Two Thousand Twenty [Member]",
        "terseLabel": "Corporate Bonds Maturing 2020"
       }
      }
     },
     "localname": "CorporateBondsMaturingTwoThousandTwentyMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CorporateBondsMaturingTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate bonds maturing two thousand twenty one.",
        "label": "Corporate Bonds Maturing Two Thousand Twenty One [Member]",
        "terseLabel": "Corporate Bonds Maturing 2021"
       }
      }
     },
     "localname": "CorporateBondsMaturingTwoThousandTwentyOneMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CorporateSponsoredResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate sponsored research agreement.",
        "label": "Corporate Sponsored Research Agreement [Member]",
        "terseLabel": "Corporate Sponsored Research Agreement (SRA)"
       }
      }
     },
     "localname": "CorporateSponsoredResearchAgreementMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument amortization period after interest payments period.",
        "label": "Debt Instrument Amortization Period After Interest Payments Period",
        "terseLabel": "Debt instrument amortization period after interest payments period"
       }
      }
     },
     "localname": "DebtInstrumentAmortizationPeriodAfterInterestPaymentsPeriod",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "arvn_DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest only payment period upon first draw of funds.",
        "label": "Debt Instrument Interest Only Payment Period Upon First Draw Of Funds",
        "terseLabel": "Debt instrument, interest only payment period upon first draw of funds"
       }
      }
     },
     "localname": "DebtInstrumentInterestOnlyPaymentPeriodUponFirstDrawOfFunds",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "arvn_DebtInstrumentInterestPaymentsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest payments term.",
        "label": "Debt Instrument Interest Payments Term",
        "terseLabel": "Debt instrument interest payments term"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaymentsTerm",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "arvn_DebtInstrumentMaturityMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument maturity month and year.",
        "label": "Debt Instrument Maturity Month And Year",
        "terseLabel": "Debt instrument maturity month and year"
       }
      }
     },
     "localname": "DebtInstrumentMaturityMonthAndYear",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "arvn_DebtInstrumentMaximumBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument maximum borrowing capacity.",
        "label": "Debt Instrument Maximum Borrowing Capacity",
        "terseLabel": "Debt instrument, maximum borrowing capacity"
       }
      }
     },
     "localname": "DebtInstrumentMaximumBorrowingCapacity",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_DevelopmentMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestone payments.",
        "label": "Development Milestone Payments [Member]",
        "terseLabel": "Development Milestone Payments"
       }
      }
     },
     "localname": "DevelopmentMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_EmployeesDirectorsAndConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees, directors and consultants.",
        "label": "Employees Directors And Consultants [Member]",
        "terseLabel": "Employees, Directors and Consultants"
       }
      }
     },
     "localname": "EmployeesDirectorsAndConsultantsMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees.",
        "label": "Employees [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_EquityMethodInvestmentContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment contribution.",
        "label": "Equity Method Investment Contribution",
        "terseLabel": "Contributed to joint venture entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentContribution",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment, summarized financial information, operating expenses.",
        "label": "Equity Method Investment Summarized Financial Information Operating Expenses",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment, summarized financial information, research and development expense.",
        "label": "Equity Method Investment Summarized Financial Information Research And Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationResearchAndDevelopmentExpense",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future grant of incentive units to service providers, percentage.",
        "label": "Future Grant Of Incentive Units To Service Providers Percentage",
        "terseLabel": "Future grant of incentive units to service providers, percentage"
       }
      }
     },
     "localname": "FutureGrantOfIncentiveUnitsToServiceProvidersPercentage",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech, Incorporation. and F. Hoffman-La Roche Limited.",
        "label": "Genentech Incorporation And F Hoffman La Roche Limited [Member]",
        "terseLabel": "Genentech, Inc. and F. Hoffman-La Roche Ltd."
       }
      }
     },
     "localname": "GenentechIncorporationAndFHoffmanLaRocheLimitedMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_IncentiveUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive units.",
        "label": "Incentive Units [Member]",
        "terseLabel": "Incentive Units"
       }
      }
     },
     "localname": "IncentiveUnitsMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10300.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.",
        "label": "Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock",
        "terseLabel": "Common stock reserved for issuance represented as percentage on outstanding common stock"
       }
      }
     },
     "localname": "IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock, underwriters' discounts and issuance costs.",
        "label": "Issuance Of Common Stock Underwriters Discounts And Issuance Costs",
        "terseLabel": "Issuance of common stock, underwriters' discounts and issuance costs"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUnderwritersDiscountsAndIssuanceCosts",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_LesseeOperatingLeaseExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease expiration month and year.",
        "label": "Lessee Operating Lease Expiration Month And Year",
        "terseLabel": "Operating lease expiration month and year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExpirationMonthAndYear",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "arvn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year two.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Two",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_LicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementsAbstract",
     "nsuri": "http://www.arvinas.com/20201231",
     "xbrltype": "stringItemType"
    },
    "arvn_LicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementsTextBlock",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arvn_LoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan agreement.",
        "label": "Loan Agreement [Member]",
        "terseLabel": "Loan Agreement"
       }
      }
     },
     "localname": "LoanAgreementMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate offering price of common stock under equity distribution agreement.",
        "label": "Maximum Aggregate Offering Price Of Common Stock Under Equity Distribution Agreement",
        "terseLabel": "Common stock aggregate offering price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPriceOfCommonStockUnderEquityDistributionAgreement",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_MaximumPercentageOfCompensationReceivableByEmployee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of compensation receivable by employee.",
        "label": "Maximum Percentage Of Compensation Receivable By Employee",
        "terseLabel": "Maximum percentage of compensation receivable by employee"
       }
      }
     },
     "localname": "MaximumPercentageOfCompensationReceivableByEmployee",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_MonthlyResearchPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly research payments.",
        "label": "Monthly Research Payments",
        "terseLabel": "Monthly research payments"
       }
      }
     },
     "localname": "MonthlyResearchPayments",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_NatureOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of business.",
        "label": "Nature Of Business [Line Items]",
        "terseLabel": "Nature Of Business [Line Items]"
       }
      }
     },
     "localname": "NatureOfBusinessLineItems",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_NatureOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of business.",
        "label": "Nature Of Business [Table]",
        "terseLabel": "Nature Of Business [Table]"
       }
      }
     },
     "localname": "NatureOfBusinessTable",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net income (loss) available to common stockholders basic and diluted.",
        "label": "Net Income Loss Available To Common Stockholders Basic And Diluted",
        "totalLabel": "Net loss attributable to common shares \u2013 basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_NonRefundableUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable upfront payment.",
        "label": "Non Refundable Upfront Payment",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontPayment",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_NumberOfContractsToBeCombined": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of contracts to be combined.",
        "label": "Number Of Contracts To Be Combined",
        "terseLabel": "Number of contracts to be combined"
       }
      }
     },
     "localname": "NumberOfContractsToBeCombined",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arvn_NumberOfMaximumDesignatedTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of maximum designated targets.",
        "label": "Number Of Maximum Designated Targets",
        "terseLabel": "Number of designated targets"
       }
      }
     },
     "localname": "NumberOfMaximumDesignatedTargets",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arvn_NumberOfWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of wholly owned subsidiaries.",
        "label": "Number Of Wholly Owned Subsidiaries",
        "terseLabel": "Number of wholly owned subsidiaries"
       }
      }
     },
     "localname": "NumberOfWhollyOwnedSubsidiaries",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arvn_OerthBioLimitedLiabilityCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oerth Bio LLC.",
        "label": "Oerth Bio Limited Liability Corporation [Member]",
        "terseLabel": "Oerth"
       }
      }
     },
     "localname": "OerthBioLimitedLiabilityCorporationMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from operating lease.",
        "label": "Operating Lease Right Of Use Asset Amortization",
        "terseLabel": "Amortization of right to use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards, expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating losses carry forward, maximum deductibility as a percentage of taxable income.",
        "label": "Operating Losses Carry Forward Maximum Deductibility Percentage",
        "terseLabel": "Operating losses carry forward, maximum deductibility percentage"
       }
      }
     },
     "localname": "OperatingLossesCarryForwardMaximumDeductibilityPercentage",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_OptionExercisedToLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercised to license agreements.",
        "label": "Option Exercised To License Agreements [Member]",
        "terseLabel": "Option Exercised"
       }
      }
     },
     "localname": "OptionExercisedToLicenseAgreementsMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_OptionPaymentsToLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option payments to license agreement.",
        "label": "Option Payments To License Agreement [Member]",
        "terseLabel": "Option Payments"
       }
      }
     },
     "localname": "OptionPaymentsToLicenseAgreementMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_PaymentForConsultingService": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for consulting service.",
        "label": "Payment For Consulting Service",
        "terseLabel": "Payment for consulting service"
       }
      }
     },
     "localname": "PaymentForConsultingService",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_PercentageOfIncrementalBorrowingForLleasePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of incremental borrowing for lease payments.",
        "label": "Percentage Of Incremental Borrowing For Llease Payments",
        "terseLabel": "Percentage of incremental borrowing for lease Payments"
       }
      }
     },
     "localname": "PercentageOfIncrementalBorrowingForLleasePayments",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_PercentageOfLiquidatedDamages": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of liquidated damages.",
        "label": "Percentage Of Liquidated Damages",
        "terseLabel": "Percentage of liquidated damages"
       }
      }
     },
     "localname": "PercentageOfLiquidatedDamages",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_PercentageOfMaximumFundingOnProjectCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of maximum funding on project costs.",
        "label": "Percentage Of Maximum Funding On Project Costs",
        "terseLabel": "Percentage of maximum funding on total project costs"
       }
      }
     },
     "localname": "PercentageOfMaximumFundingOnProjectCosts",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_PfizerIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer, Incorporation.",
        "label": "Pfizer Incorporation [Member]",
        "terseLabel": "Pfizer, Inc."
       }
      }
     },
     "localname": "PfizerIncorporationMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_PiperSandlerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Piper Sandler.",
        "label": "Piper Sandler [Member]",
        "terseLabel": "Piper Sandler"
       }
      }
     },
     "localname": "PiperSandlerMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_PreferredUnitWarrantsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred unit warrants policy.",
        "label": "Preferred Unit Warrants Policy Policy [Text Block]",
        "terseLabel": "Preferred Unit Warrants"
       }
      }
     },
     "localname": "PreferredUnitWarrantsPolicyPolicyTextBlock",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arvn_PriorToStockPurchaseAgreementPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior to stock purchase agreement premium.",
        "label": "Prior To Stock Purchase Agreement Premium",
        "terseLabel": "Prior to stock purchase agreement premium"
       }
      }
     },
     "localname": "PriorToStockPurchaseAgreementPremium",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock in an at-the-market offering.",
        "label": "Proceeds From Issuance Of Common Stock Gross",
        "terseLabel": "Proceeds from sale of common stock in at-the-market offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_ProceedsFromIssuanceOfCommonStockInAPublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock in a public offering.",
        "label": "Proceeds From Issuance Of Common Stock In A Public Offering",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockInAPublicOffering",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_ProceedsFromMaturitiesOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from maturities of marketable securities.",
        "label": "Proceeds From Maturities Of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesOfMarketableSecurities",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_ProceedsFromSaleOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of marketable securities.",
        "label": "Proceeds From Sale Of Marketable Securities",
        "terseLabel": "Sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMarketableSecurities",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_QuarterlyResearchPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quarterly research payments.",
        "label": "Quarterly Research Payments",
        "terseLabel": "Quarterly research payments"
       }
      }
     },
     "localname": "QuarterlyResearchPayments",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_RegulatoryMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payments.",
        "label": "Regulatory Milestone Payments [Member]",
        "terseLabel": "Regulatory Milestone Payments"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ReimbursementOfPatentRelatedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of patent related cost.",
        "label": "Reimbursement Of Patent Related Cost",
        "terseLabel": "Reimbursed patent costs"
       }
      }
     },
     "localname": "ReimbursementOfPatentRelatedCost",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and license agreements.",
        "label": "Research Collaboration And License Agreements [Abstract]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.arvinas.com/20201231",
     "xbrltype": "stringItemType"
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and license agreements.",
        "label": "Research Collaboration And License Agreements [Line Items]",
        "terseLabel": "Research Collaboration And License Agreements [Line Items]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementsLineItems",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and license agreements.",
        "label": "Research Collaboration And License Agreements [Table]",
        "terseLabel": "Research Collaboration And License Agreements [Table]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementsTable",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ResearchFundingPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research funding payments.",
        "label": "Research Funding Payments [Member]",
        "terseLabel": "Research Funding Payments"
       }
      }
     },
     "localname": "ResearchFundingPaymentsMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SaleOfStockFairValueOfSharesSold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, fair value of shares sold.",
        "label": "Sale Of Stock Fair Value Of Shares Sold",
        "terseLabel": "Fair value of the shares sold"
       }
      }
     },
     "localname": "SaleOfStockFairValueOfSharesSold",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_SalesBasedMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based milestone payments.",
        "label": "Sales Based Milestone Payments [Member]",
        "terseLabel": "Sales-based Milestone Payments"
       }
      }
     },
     "localname": "SalesBasedMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental cash flow information related to leases.",
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arvn_SeriesABAndCConvertiblePreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A,B and C convertible preferred shares.",
        "label": "Series A B And C Convertible Preferred Shares [Member]",
        "terseLabel": "Series A,B and C Convertible Preferred Shares"
       }
      }
     },
     "localname": "SeriesABAndCConvertiblePreferredSharesMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SeriesARedeemableConvertiblePreferredUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred units.",
        "label": "Series A Redeemable Convertible Preferred Units [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Units"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredUnitsMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SeriesBRedeemableConvertiblePreferredUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred units.",
        "label": "Series B Redeemable Convertible Preferred Units [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Units"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredUnitsMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SeriesCRedeemableConvertiblePreferredUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C redeemable convertible preferred units.",
        "label": "Series C Redeemable Convertible Preferred Units [Member]",
        "terseLabel": "Series C Redeemable Convertible Preferred Units"
       }
      }
     },
     "localname": "SeriesCRedeemableConvertiblePreferredUnitsMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ShareBasedCompensationArrangementAverageCommonStockPrecedingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement average common stock preceding days.",
        "label": "Share Based Compensation Arrangement Average Common Stock Preceding Days",
        "terseLabel": "Average common stock preceding days"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementAverageCommonStockPrecedingDays",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period",
        "negatedLabel": "Restricted Shares, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercises weighted average grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, restricted shares vested and expected to vest, exercisable number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Restricted Shares Vested And Expected To Vest Exercisable Number",
        "terseLabel": "Restricted shares vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award restricted stock units vested and expected to vest exercisable number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Vested And Expected To Vest Exercisable Number",
        "terseLabel": "Restricted stock units vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arvn_StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock incentive plan.",
        "label": "Stock Incentive Plan [Member]",
        "terseLabel": "Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares conversion of common and incentive units to common and restricted stock.",
        "label": "Stock Issued During Period Shares Conversion Of Conversion Of Common And Incentive Units To Common And Restricted Stock",
        "terseLabel": "Conversion of common and incentive units to common and restricted stock, Units/Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "arvn_StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value conversion of common and incentive units to common and restricted stock.",
        "label": "Stock Issued During Period Value Conversion Of Common And Incentive Units To Common And Restricted Stock",
        "terseLabel": "Conversion of common and incentive units to common and restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfCommonAndIncentiveUnitsToCommonAndRestrictedStock",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement.",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock Purchase Agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SubstitutionTargetPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Substitution target payments.",
        "label": "Substitution Target Payments [Member]",
        "terseLabel": "Substitution Target Payments"
       }
      }
     },
     "localname": "SubstitutionTargetPaymentsMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant of accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_SupplementalNonCashInformationRelatedToLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental non-cash information related to leases.",
        "label": "Supplemental Non Cash Information Related To Leases [Abstract]",
        "terseLabel": "Supplemental non-cash information:"
       }
      }
     },
     "localname": "SupplementalNonCashInformationRelatedToLeasesAbstract",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforwards, expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "arvn_TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity issued during period shares conversion of redeemable convertible preferred units to redeemable convertible preferred shares.",
        "label": "Temporary Equity Issued During Period Shares Conversion Of Redeemable Convertible Preferred Units To Redeemable Convertible Preferred Shares",
        "terseLabel": "Conversion of redeemable convertible preferred units to redeemable convertible preferred shares, Units/Shares"
       }
      }
     },
     "localname": "TemporaryEquityIssuedDuringPeriodSharesConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "arvn_TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity issued during period shares redeemable convertible preferred warrants exercised.",
        "label": "Temporary Equity Issued During Period Shares Redeemable Convertible Preferred Warrants Exercised",
        "terseLabel": "Exercise of Series A redeemable convertible preferred warrant, Units"
       }
      }
     },
     "localname": "TemporaryEquityIssuedDuringPeriodSharesRedeemableConvertiblePreferredWarrantsExercised",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "arvn_TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity issued during period value conversion of redeemable convertible preferred units to redeemable convertible preferred shares.",
        "label": "Temporary Equity Issued During Period Value Conversion Of Redeemable Convertible Preferred Units To Redeemable Convertible Preferred Shares",
        "terseLabel": "Conversion of redeemable convertible preferred units to redeemable convertible preferred shares"
       }
      }
     },
     "localname": "TemporaryEquityIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredUnitsToRedeemableConvertiblePreferredShares",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity issued during period value redeemable convertible preferred warrants exercised.",
        "label": "Temporary Equity Issued During Period Value Redeemable Convertible Preferred Warrants Exercised",
        "terseLabel": "Exercise of Series A redeemable convertible preferred warrant"
       }
      }
     },
     "localname": "TemporaryEquityIssuedDuringPeriodValueRedeemableConvertiblePreferredWarrantsExercised",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_TemporaryEquityStockIssuedDuringPeriodShareNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period share new issues.",
        "label": "Temporary Equity Stock Issued During Period Share New Issues",
        "terseLabel": "Issuance of Series C redeemable convertible preferred units, Units"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodShareNewIssues",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "arvn_TwoThousandAndEighteenAssistanceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and eighteen assistance agreement.",
        "label": "Two Thousand And Eighteen Assistance Agreement [Member]",
        "terseLabel": "2018 Assistance Agreement"
       }
      }
     },
     "localname": "TwoThousandAndEighteenAssistanceAgreementMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_TwoThousandAndFourteenAssistanceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen assistance agreement.",
        "label": "Two Thousand And Fourteen Assistance Agreement [Member]",
        "terseLabel": "2014 Assistance Agreement"
       }
      }
     },
     "localname": "TwoThousandAndFourteenAssistanceAgreementMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_TwoThousandEighteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen stock incentive plan.",
        "label": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenStockIncentivePlanMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_TwoThousandTwentyMaturityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 maturity.",
        "label": "Two Thousand Twenty Maturity [Member]",
        "terseLabel": "Corporate Bonds Maturing 2020"
       }
      }
     },
     "localname": "TwoThousandTwentyMaturityMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_YaleUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yale University.",
        "label": "Yale University [Member]",
        "terseLabel": "Yale University"
       }
      }
     },
     "localname": "YaleUniversityMember",
     "nsuri": "http://www.arvinas.com/20201231",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r51",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investee Name [Domain]",
        "terseLabel": "Investment, Name"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r276",
      "r278",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r488",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r276",
      "r278",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r488",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r266",
      "r276",
      "r278",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r488",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r266",
      "r276",
      "r278",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r488",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Forecast [Member]",
        "terseLabel": "Scenario Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Equity Method Investment Equity Method Investee Name [Axis]",
        "terseLabel": "Investment, Name"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r180",
      "r181",
      "r261",
      "r264",
      "r489",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r261",
      "r264",
      "r489",
      "r520",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r229",
      "r277",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r183",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONNECTICUT",
        "terseLabel": "State of Connecticut"
       }
      }
     },
     "localname": "CT",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r348",
      "r349",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update Extensible List",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r22",
      "r184",
      "r185"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Account receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Net accretion of bond discounts/premiums"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r41"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Professional fees and other"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35",
      "r221"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r54",
      "r55",
      "r56",
      "r479",
      "r498",
      "r502"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r53",
      "r56",
      "r57",
      "r109",
      "r110",
      "r111",
      "r371",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r23",
      "r320"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r279",
      "r281",
      "r323",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r237",
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Issuance of common stock, offering costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r281",
      "r309",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Compensation expense, total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r73",
      "r89",
      "r399"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization Of Debt Discount Premium",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r69",
      "r89",
      "r401"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization Of Financing Costs",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Common share/unit equivalents excluded from the calculations of diluted loss per common share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r161",
      "r171",
      "r177",
      "r204",
      "r365",
      "r372",
      "r389",
      "r454",
      "r477"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r50",
      "r102",
      "r204",
      "r365",
      "r372",
      "r389"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r191"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r189",
      "r216"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r187",
      "r190",
      "r216",
      "r459"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Fair value measurements of assets",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r282",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r108",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "Nature of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Purchases of property, equipment and leasehold improvements unpaid at period end"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r31",
      "r91"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "positiveLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r92",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r83",
      "r91",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r83",
      "r391"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r112",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r313",
      "r314",
      "r315",
      "r347",
      "r376",
      "r390",
      "r406",
      "r439",
      "r440",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r113",
      "r124",
      "r213",
      "r320",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r100",
      "r102",
      "r127",
      "r128",
      "r129",
      "r132",
      "r134",
      "r140",
      "r141",
      "r142",
      "r204",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r359",
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Research Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r228",
      "r460",
      "r483"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common Stock Par Or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common Stock Shares Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value, 48,455,741 and 38,461,353 shares issued and outstanding as of December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock, voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62",
      "r68",
      "r463",
      "r486"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r182",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r182",
      "r387",
      "r388",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r182",
      "r387",
      "r388",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r145",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r149",
      "r150",
      "r182",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r182",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract With Customer Asset And Liability Table [Text Block]",
        "terseLabel": "Summary of Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r246",
      "r248",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract With Customer Asset Net",
        "terseLabel": "Contract revenue receivable if milestones achieved or options for all targets exercised"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r246",
      "r247",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "positiveTerseLabel": "Deferred revenue",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsSummaryOfContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r246",
      "r247",
      "r262"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r246",
      "r247",
      "r262"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Revenue recognized",
        "verboseLabel": "Amounts included in deferred revenue in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsSummaryOfContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate Bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r148",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r455",
      "r457",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentDateOfFirstRequiredPayment1": {
     "auth_ref": [
      "r45",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the debt agreement requires the first payment to be made, in CCYY-MM-DD format.",
        "label": "Debt Instrument Date Of First Required Payment1",
        "terseLabel": "Debt instrument, date of first required payment"
       }
      }
     },
     "localname": "DebtInstrumentDateOfFirstRequiredPayment1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.",
        "label": "Debt Instrument Decrease Forgiveness",
        "terseLabel": "Forgiveness of funding on achieving certain employment conditions"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseForgiveness",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r400",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Debt instrument face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "auth_ref": [
      "r45",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).",
        "label": "Debt Instrument Frequency Of Periodic Payment",
        "terseLabel": "Debt instrument, frequency of periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Debt instrument, interest rate per annum"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r44",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt Instrument Maturity Date",
        "terseLabel": "Debt instrument, maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r45",
      "r105",
      "r238",
      "r239",
      "r240",
      "r241",
      "r399",
      "r400",
      "r402",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r399",
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument Unamortized Discount",
        "terseLabel": "Total unamortized debt discount on Loan"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Table [Text Block]",
        "terseLabel": "Summary of Company's Available for Sale Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r16",
      "r17",
      "r336",
      "r456",
      "r475"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "negatedTotalLabel": "Total deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r342",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Net [Abstract]",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities Property Plant And Equipment",
        "negatedLabel": "Property, equipment and leasehold improvements"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r89",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r89",
      "r219"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per common share, basic and diluted",
        "verboseLabel": "Net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Reconciliation of effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r330",
      "r353"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r330",
      "r353"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r330",
      "r353"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r330",
      "r353"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r330",
      "r353"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Research",
        "terseLabel": "Federal research tax credit",
        "verboseLabel": "Effective income tax rate reconciliation, tax credit, research and development, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Employee expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesComponentsOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Compensation expense not yet recognized, period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Compensation expense not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "2018 ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r114",
      "r121",
      "r123",
      "r139",
      "r212",
      "r237",
      "r242",
      "r317",
      "r318",
      "r319",
      "r348",
      "r349",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment Aggregate Cost",
        "terseLabel": "Cash commitment"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r0",
      "r102",
      "r204",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r0",
      "r102",
      "r204",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": {
     "auth_ref": [
      "r0",
      "r102",
      "r204",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment Nonconsolidated Investee Or Group Of Investees [Member]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment Ownership Percentage",
        "terseLabel": "Ownership interest in joint venture",
        "verboseLabel": "Equity method investment ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r32",
      "r162",
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "positiveTerseLabel": "Equity method investments",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments And Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments Disclosure [Text Block]",
        "terseLabel": "Investment in Equity Method Investee"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvestee"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r32",
      "r82",
      "r98",
      "r202",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments Policy",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r89",
      "r236"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10070.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment Of Warrants",
        "negatedLabel": "Change in fair value of preferred unit warrant",
        "terseLabel": "Change in fair value of preferred unit warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r378",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r377",
      "r378",
      "r380",
      "r381",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r267",
      "r268",
      "r273",
      "r275",
      "r378",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r267",
      "r268",
      "r273",
      "r275",
      "r378",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r378",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r382",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r98",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalDepositInsuranceCorporationPremiumExpense": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.",
        "label": "Federal Deposit Insurance Corporation Premium Expense",
        "terseLabel": "Federal deposit insurance corporation premium expense"
       }
      }
     },
     "localname": "FederalDepositInsuranceCorporationPremiumExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10130.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r89",
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment Of Long Lived Assets To Be Disposed Of",
        "terseLabel": "Impairment of long lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r217",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r66",
      "r89",
      "r159",
      "r200",
      "r461",
      "r484"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income Loss From Equity Method Investments",
        "terseLabel": "Loss from equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r331",
      "r334",
      "r341",
      "r351",
      "r354",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationYearUnderExamination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year being audited in the income tax examination, in CCYY format.",
        "label": "Income Tax Examination Year Under Examination",
        "terseLabel": "Income tax examination year"
       }
      }
     },
     "localname": "IncomeTaxExaminationYearUnderExamination",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r122",
      "r123",
      "r160",
      "r329",
      "r352",
      "r355",
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r98",
      "r327",
      "r328",
      "r334",
      "r335",
      "r340",
      "r346",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReceivable": {
     "auth_ref": [
      "r30",
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.",
        "label": "Income Tax Receivable",
        "verboseLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncomeTaxReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Income Tax Reconciliation Tax Credits Research",
        "verboseLabel": "Effective income tax rate reconciliation, tax credit, research and development, amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10280.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10260.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Account receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10290.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10310.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Changes in deferred revenue due to additions to deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10250.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase Decrease In Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10270.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r64",
      "r158",
      "r398",
      "r401",
      "r465"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10090.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r73",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense Debt",
        "terseLabel": "Interest expense, Debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r80",
      "r85",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r71",
      "r157"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10080.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r199",
      "r453",
      "r470",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases Of Lessee Disclosure [Text Block]",
        "terseLabel": "Right to Use Assets and Liabilities"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Operating lease, existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Terminate",
        "terseLabel": "Operating lease, existence of option to terminate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r102",
      "r172",
      "r204",
      "r366",
      "r372",
      "r373",
      "r389"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r102",
      "r204",
      "r389",
      "r458",
      "r481"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "verboseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r102",
      "r204",
      "r366",
      "r372",
      "r373",
      "r389"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r233",
      "r457",
      "r478"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt",
        "terseLabel": "Debt instrument, outstanding amount",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt By Maturity [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r107",
      "r231"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal After Year Five",
        "terseLabel": "Beyond 5 years"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r107",
      "r231"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r107",
      "r231"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r107",
      "r231"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtScheduleOfAnticipatedFutureMinimumPaymentsOnLongTermDebtExcludingDiscountOnDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Noncurrent",
        "terseLabel": "Long term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Longterm Debt Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r45",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Longterm Debt Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r4",
      "r40"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities Realized Gain Loss",
        "negatedLabel": "Gain on sale of marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MemberUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest in limited liability company (LLC).",
        "label": "Member Units [Member]",
        "terseLabel": "Member Units"
       }
      }
     },
     "localname": "MemberUnitsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r83",
      "r87",
      "r90"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r58",
      "r60",
      "r67",
      "r90",
      "r102",
      "r113",
      "r117",
      "r118",
      "r119",
      "r120",
      "r122",
      "r123",
      "r130",
      "r161",
      "r170",
      "r173",
      "r176",
      "r178",
      "r204",
      "r389",
      "r462",
      "r485"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails": {
       "order": 10010.0,
       "parentTag": "arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
       "weight": 1.0
      },
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120",
      "r125",
      "r126",
      "r131",
      "r134",
      "r161",
      "r170",
      "r173",
      "r176",
      "r178"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Basic",
        "totalLabel": "Net loss attributable to common shares"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity Table [Text Block]",
        "terseLabel": "Summary of Restricted Stock Grant Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r161",
      "r170",
      "r173",
      "r176",
      "r178"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r412",
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r409",
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r415",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Operating lease, weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases Rent Expense Net",
        "terseLabel": "Total rent expense under operating leases"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards Limitations On Use",
        "terseLabel": "Net operating loss carryforwards, limitations on use"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r363",
      "r364",
      "r370"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]",
        "terseLabel": "Other comprehensive gain (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r52",
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10060.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income (expenses)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10230.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables Net Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments For Royalties",
        "terseLabel": "Royalty payment"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForUnderwritingExpense": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.",
        "label": "Payments For Underwriting Expense",
        "terseLabel": "Fees and expenses"
       }
      }
     },
     "localname": "PaymentsForUnderwritingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "negatedLabel": "Payment of common stock offering costs",
        "terseLabel": "Fees and expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments To Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchase of property, equipment and leasehold improvements"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r282",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10240.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds From Collaborators",
        "terseLabel": "Upfront non-refundable payment and certain additional payments received"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Gross proceeds from sale of shares in Initial public offering before fees and expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "verboseLabel": "Proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds From Issuance Of Long Term Debt",
        "terseLabel": "Proceeds from long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds From Issuance Of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of Series C redeemable convertible preferred units"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r76",
      "r312"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds From Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrant"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r58",
      "r60",
      "r81",
      "r102",
      "r113",
      "r122",
      "r123",
      "r161",
      "r170",
      "r173",
      "r176",
      "r178",
      "r204",
      "r363",
      "r368",
      "r369",
      "r374",
      "r375",
      "r389",
      "r466"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r224",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Equipment and Leasehold Improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r220"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property, equipment and leasehold improvements, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r222",
      "r482"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property, equipment and leasehold improvements, net",
        "totalLabel": "Property, equipment and leasehold improvements, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r98",
      "r222",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property, Equipment, and Leasehold Improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property, Equipment and Leasehold Improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r274",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r274",
      "r423",
      "r424",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "auth_ref": [
      "r15",
      "r403",
      "r418",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.",
        "label": "Related Party Transaction Description Of Transaction",
        "terseLabel": "Related party agreement, description"
       }
      }
     },
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction Expenses From Transactions With Related Party",
        "terseLabel": "Total research payments"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r274",
      "r423",
      "r426",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments Of Long Term Debt",
        "negatedLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r326",
      "r534"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10120.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r98",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research [Member]",
        "terseLabel": "Research and Development Tax Credits"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r242",
      "r320",
      "r480",
      "r497",
      "r502"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r114",
      "r121",
      "r123",
      "r212",
      "r317",
      "r318",
      "r319",
      "r348",
      "r349",
      "r493",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r155",
      "r156",
      "r169",
      "r174",
      "r175",
      "r179",
      "r180",
      "r182",
      "r260",
      "r261",
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Revenue recognized on research collaboration and license agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue Recognition and Deferred Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue Remaining Performance Obligation",
        "terseLabel": "Revenue, remaining performance obligation",
        "verboseLabel": "Unsatisfied performance obligations expected to be recognized as revenue"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]",
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]",
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTransactionPriceAllocatedToPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Table [Text Block]",
        "terseLabel": "Transaction Price Allocated to Performance Obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r65",
      "r102",
      "r155",
      "r156",
      "r169",
      "r174",
      "r175",
      "r179",
      "r180",
      "r182",
      "r204",
      "r389",
      "r466"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r414",
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureRightToUseAssetsAndLiabilitiesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale Of Stock Consideration Received Per Transaction",
        "terseLabel": "Additional consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r149",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Sales Revenue Net [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Components of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareCommonShareEquivalentsExcludedFromCalculationsOfDilutedLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Common Share Equivalents Excluded from the Calculations of Diluted Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule Of Available For Sale Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCompanySAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Summary of Deferred Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Basic and Diluted Loss per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule Of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r0",
      "r102",
      "r203",
      "r204",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule Of Equity Method Investments [Table]",
        "terseLabel": "Schedule Of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureInvestmentInEquityMethodInvesteeAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]",
        "terseLabel": "Schedule of Anticipated Future Minimum Payments on Long-Term Debt Excluding Discount on Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosurePropertyEquipmentAndLeaseholdImprovementsScheduleOfPropertyEquipmentAndLeaseholdImprovementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r282",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r289",
      "r299",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Non-cash share/unit-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Incentive units vesting period",
        "verboseLabel": "Share-based award, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Restricted Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "positiveVerboseLabel": "Weighted Average Grant Date Fair Value Per Share, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "positiveTerseLabel": "Restricted Shares, Granted",
        "verboseLabel": "Share-based award, non-option equity instruments granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "positiveVerboseLabel": "Weighted Average Grant Date Fair Value Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Unvested Restricted Stock, Shares, Ending Balance",
        "periodStartLabel": "Unvested Restricted Stock, Shares, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Restricted Shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "positiveVerboseLabel": "Weighted Average Grant Date Fair Value Per Share, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the equity-based award expires, in CCYY-MM-DD format.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Expiration Date",
        "terseLabel": "Share-based award, expiration date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized",
        "terseLabel": "Incentive units authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Incentive units authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Common stock, shares remained available for purchase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Options, Exercisable, Ending Balance",
        "verboseLabel": "Stock options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "positiveLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Options, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Options, Granted",
        "verboseLabel": "Share-based award, stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period",
        "terseLabel": "Annual increase in reserved shares of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r291",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Options, Outstanding, Ending Balance",
        "periodStartLabel": "Options, Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number",
        "terseLabel": "Stock options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Annual increase in reserved shares as percentage of outstanding common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r280",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r98",
      "r282",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Equity-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r306",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityScheduleOfAssumptionsUsedToDetermineFairValueOfAndStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Purchase price under ESPP as percentage of closing price of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Share price, issued and sold",
        "verboseLabel": "Stock issued, price per share/unit"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance, Units/Shares",
        "periodStartLabel": "Balance, Units/Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r100",
      "r102",
      "r127",
      "r128",
      "r129",
      "r132",
      "r134",
      "r140",
      "r141",
      "r142",
      "r204",
      "r237",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r49",
      "r109",
      "r110",
      "r111",
      "r114",
      "r121",
      "r123",
      "r139",
      "r212",
      "r237",
      "r242",
      "r317",
      "r318",
      "r319",
      "r348",
      "r349",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r139",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityTables",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r48",
      "r237",
      "r238",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock, Shares",
        "verboseLabel": "Common stock issued for conversion of convertible preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r20",
      "r21",
      "r237",
      "r238",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period Shares Conversion Of Units",
        "terseLabel": "Common shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r20",
      "r21",
      "r237",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r237",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "positiveTerseLabel": "Shares issued and sold",
        "terseLabel": "Issuance of common stock, net of underwriters' discounts and issuance costs, Shares",
        "verboseLabel": "Preferred stock issued, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r20",
      "r21",
      "r237",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures",
        "terseLabel": "Restricted stock vesting, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r237",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Shares Share Based Compensation",
        "terseLabel": "Restricted shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Shares Share Based Compensation Gross",
        "terseLabel": "Incentive unit-based compensation Units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r237",
      "r242",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Options, Exercised",
        "terseLabel": "Proceeds from exercise of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquitySummaryOfStockOptionActivityDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r49",
      "r237",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period Value Issued For Services",
        "terseLabel": "Common stock issued in period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r237",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock, net of underwriters' discounts and issuance costs",
        "verboseLabel": "Preferred stock issued, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r237",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures",
        "terseLabel": "Restricted stock vesting"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Value Share Based Compensation Gross",
        "terseLabel": "Incentive unit-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r49",
      "r237",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r26",
      "r27",
      "r102",
      "r186",
      "r204",
      "r389"
     ],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r242",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Members' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders Equity Note Stock Split Conversion Ratio1",
        "terseLabel": "Reverse stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureMembersEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders Equity Reverse Stock Split",
        "terseLabel": "Reverse stock split, description"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails": {
       "order": 10020.0,
       "parentTag": "arvn_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
       "weight": -1.0
      },
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Temporary Equity Accretion To Redemption Value Adjustment",
        "negatedLabel": "Change in redemption value of redeemable preferred units",
        "negatedTerseLabel": "Change in redemption value of preferred units",
        "terseLabel": "Increase in redemption value of preferred units"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Balance, Units/Shares",
        "periodStartLabel": "Balance, Units/Shares",
        "verboseLabel": "Preferred stock outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of Series C redeemable convertible preferred units"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredSharesUnitsAndChangesInStockholdersMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, income tax penalties and interest accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r143",
      "r144",
      "r146",
      "r147",
      "r151",
      "r152",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted average common shares outstanding, basic and diluted",
        "verboseLabel": "Weighted average number of common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arvinas.com/20201231/taxonomy/role/DisclosureNetLossPerCommonShareBasicAndDilutedLossPerCommonShareDetails",
      "http://www.arvinas.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31010-122693"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121603689&loc=d3e36975-112693"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918703-209980"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919370-209981"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121606570&loc=SL77919784-209982"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r535": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r537": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r538": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r539": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r540": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r541": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r542": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r543": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>104
<FILENAME>0001564590-21-009857-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-009857-xbrl.zip
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M12WB8C,!H7%K1QI0&36-_12I6Y\H!&"\Q$1R%HP ]<<9!/H35+.OGO/,@I#
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M]D$@&MS4 :2Q8Z3IZ[]BV-L7%@U\N^4] ^P0 -/?,I9Y^#T+HL%GQ[]UA@Y
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M#S;KC# 8 P"40&KV \9PY]GHWXSGAI_'ZB_):_XT7?;5<YY9$)*3?7_TFSD
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ME[\MFY4R<+I.%%:,G"Y81L<:,#MV9]OW,YZJK?#]8+:[ML+KM7?(RG?)O/5
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M,-I-IL6-%C=:W&AQ4R3**:2XF4ALM@;8BDL6R,!](']@";(G0I(-,#+'7/;
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ML.!FM+*FE36MK&EE32MK[T%9ZV'3'S47,&GRY"M1A;$B5LD3$"91#1*$2G"
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MGGX>2K89B4LS,<M=I\>JT0!X-XAZ_-)V0C2<,3!/S9BS=1"5J;J#:<.4*P_
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M"\C8?+F+Z2,3%1<2%?%!3D!^^RH6!I+D9 %OAWTC.\)*0>1S_P$WLF6.'N7
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M/"I!GRO&KX#+'NY+&0Q^<VC\!C(6\*9Z:P("67 XMY%=H0<K"429E)+T086
M#6RD$.LHAF0T/IMC./WFKW3V]*$0ZRH*K@@+7FJ!IA7@(+[$9L[-(DK2[4MG
MXDG]J,N8AYTY&3D$$S<B<VWNP@7).RO7C[MX>%(C "7KFE#G-?9\/AP*']^H
MU8]X[MV<#M68=>=098C3%WHPS3,?L0!_QW!69/QINC0"GJQ###H!5N-W%;0+
M\;64"D8Y)7P%.&(".-LE* D]HY/^V+2?G= '/O@0^#U  7C.):@.??A_]H)I
M0 0=,7J9!D[E0&J6VYYW/@U#-NRZ%(935A4Q<\@Y<YHS]\WS7ZH#_T5.*?="
M-TEQ$1XH\B0'D1,R=;348@<3O:G',.V)\0(:+/YT0+/ G"8GM%P_)+<\F$32
MQT/%K55>W"LT+WYZ(!A *R'KB+9A!^8+C>Q(MT++I&P\&@6/@GU 5A B%A;U
MSFYPWN=U/NA<QOT8$\G(>'G7\174X>G)(N<W,SR%AU$S);6) T%4-\NV;6K*
MU60H9-6XP_GN,]-A]1VN#XS+F?"(.^C[/.",F"[0)4D#K^35<Z7)WS1SG3+4
MV7+YZ3*QA51\Z46VD3<D:6Y<D0_A)B";Q*[/YCG.S)/+S>=>(1\[*0Z;RLF>
MSCU3^:HS-XJ7;^PLGYR=S;6>EQZ=DPBM^LO3M'/,F40##4 SI(,2Q!A*=*;4
M1?^C49K:;Z2?M19YG1:TR*M1D-KO5\%G#H?3M=_[4OM=;,K95>WW2GK)Y%.;
M0LG*Z^$N>;=,BZ$,E,0Y+HTN8/@47R0U/8QHD(Q,6Y$66;--$N:ZO<@1MMRB
M>0&0E"A)LI<0WLFP')F3EH[/<T7(@&]M<I4D3B?WPJ/2E#T./UB@S9H6-E#%
M)%!9)D09[%R(JE'6)$<TK<?!S#?,/,4 >Y('8F-%$0L!^FFZB,S,XK^E^6;Y
MB6PB,3=-"*8$4LK.6^-;,!'LA\Q#<U+7)G+K5LE=^]'@30@VE5*Y_CPLD7\E
M<N%199HH6IKE#YWH*3"CRF3)K@!:ARJ8)- ZE-:AM [U;G2HK[R>;&X9IYH"
MF)=Q1FXT.3@)#JI*;C89GUR/UB2+)7",;UYJHO1')MD3/-8Y.P4"J_7\ $0D
M*D/8 Y ETWJW6@^=FS5YK^Z.4>,CS&U,"YZ7=+M.^5=DPB17$92]I56M\ZM5
MLW74-!&K;#F7IDRX%/F4&;<6Q<U%C?H43D]4JJ,Y@?%VPJ2D!X%(U83WV.RO
MF.9P4?]%>I?T;_DC+%:(/5$7ZW/$GD>%6I\JIU30^I36I[0^]6[TJ2NAATS$
M/80\?FW/F?Q6,FO1K*A<$S2$3 QEY;Q8&<N,1)?&)-X[X3J8K:]09JT*%[5
M9[4,VYC7G.0!35=%3%1%9.9XO4QGKR[796$SZ9+4>H(BD:DG*J,W37A/U=BC
M-R=U.D_U6REO<G["I'IPR*2H91"U!HJ<JN.)@A]16-=SS>&0C^)"_RH=1#;'
M9U];:I[N74M-K=EJS59KMEJS74VS7>7(5SKF7:K!'26]*,T)9\OEW:O);^O1
M<%&RK^594ST)U_+425_/6AZZ)L<KG-A:'K2X46/>9!6E41FU>2>$6=R.-4#4
M39*I313G+$T(2_7 M>QLHK!D/6#?;'7*Y.O>6%TR^;A5JD/6\D(J*U J2@@M
MUO)D4;SRAC3]-^.6TMR!N^TGP AD,8B!XV?\#63,J0:B:?R+>F#@V)V8&O6Y
M[FNK$R=7><^":+ >O/_LK(F ;F\O*3>_8!NL<*SG13&8\(HY/6L23DATZT'Z
MC; 6PUG+ [%V.:"P#$6FE%XUKRMBG9*;:],Z0(_Q)@L#U+QK<?9Y7%&6?LSJ
MB.XP<2'U_3-Y2]!L(4&0%'6H#HFU[*WO^EU8REJ>-5N8*P4G](.RNXFB5R=4
M.EDEO< )\@IH>1A.]G?@&4^\G$;EWL"\T<M3 AFK]$)%I.!)ZVIQ">X ?;N!
M-Y$;F0!V64>3]KT4S(+4OA?M>]&^EW<35;Q4-(@%E8.SDKCD/>A?!Y8@+T?Y
M0)7U,<_R0<$PIDZ:/=]=DRZ>9)"+SH.\)!??+BM;IRHQ1<]51S;8V>*61>]9
MF8'_,5TDM:/WX!6N<7U$B4;4AP=+QB9[Y\P=#9",(J'@&(\.*DW;DZRU]#L9
M3OV/?YQ<_#0]4H&O2>9)B0RH&==B*!'GUCE^FJU%A:VSHW%P'K.*"_E+*)3%
M2Q[5VHM%L4-1D*@.E,ADE@D]CX<DO\-QD-?HQ0]<FSMTN)='-#U,LP$312NC
M(Q&8;3'?+Y1S=GD*/F^"-#21M<@C_.HYN.A.Q%NH>_+6C,6!("*@SWT<8H@%
M7"8*U*AETFI=[4@L>F;F=G%_RQ+R=Y2_," W%UD?!B5ET4 :,Z7CD%"D-8GW
MYZT-'\F#X,GQ$"KBM"=Z'>GBBX/,W.^:T$-*?BN'2B>KI0LVKHRJCQ_$X3](
M!VEIZZ@SO15$*![S;1GB ''?H1/R,1'S!_1(EMG-C)A(&Z&K<WLF_;TT$%S.
M5^%2@9B!0&IA*:6V(@[P)"Q/.T\GM3,+'7]IXBW5D*.[.>WSQ,4<I7%P3MUC
M6);%\UDS \224B+*9& VSPFF:K9,C4Y2V3;36Y[RRV7]YGR21Q@/ :G(L2#X
MAS#UX!DO;^V'7-L!/O[L#(&%!-8O!_U>U_S+JW_KQ8WOI*34#_\UZA\ 6D2X
ME0-@=!'^D[&ASAJUT?>?!GP]1_5C^("9"4NW%5W+]/$)H$T,(W_UP/.LQI:^
MY'P[!S-?)1<-] \^M>ZN#,X.*(>>45%=!C>!?I]%H0#.SG50)-E<1[EN_^<'
M++*K5J8')OSG!^Y 9R,@$UR4 2MXP;8EH(?Z07(=!W:C2D_D'^XZE[>7%?XW
MYJWST6X\AQZ_<V,:J@14YL$!\J5<MB^IH96/76[0I4=E?LI#;QYOKZJ1&8OG
M]@* &TC$X8CRP-#Y)I:2IC?!J^$&Y1D/G8=*.LR#DK!&<!JQ!3P$^#*(\C%?
M3?.JDM/;4?#3BO$%9X@D["YAH@#!T6"L)J6_!?^60_F+.1A?Q@RHLXUT\RT
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M#DD#:& $Q.10A8T?\&(%$*2Q1;D0%4.IFN7%'S3T2/CQN$N5&IO@#DK*F3(
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M\()X%(EYZ 9N7H@1]IP$8KBW2BD_3*;< 8>#7582=B4'H84I0"2(T&<=3+0
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MAU.I3?+M$ZI1)>F12_FA,Y^EL@J9OHZ+DL.V1>6ZQ[L;48DJ:+9#/K" O'+
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MQ."]NU6KG=S-CA\ ._][TI\V,:):SJ-4,"KQ6J,[ 2L6&77A2II^XXJ3%LG
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M+_AD$"0)=E!7N=%@'))6P-/I%!51[7[][ 3D5 +@;@@FJ-T")EO^>HP#'OD
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M]./'E[M$!$!0I$A E9_9UY4B@(B[^/7KR_'CYP$D-GJ()_Q ?_#;T&7T[.;
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M_1[91PYPJK4F-LQ?_OLUC;L9W18O]*44$HP'\CK  I$U<R@,B9PQRP4T1@+
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M4BV+:28)K@W26$KCS,BQ530?II&#)_O1DKS3<M.% >!2#FBWY2GM9SP0_3+
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M)>(RZ:R; 7@Y-LIMO K56ZQK)FD*ICZH!IZU-2&,HDUOR(%E(\:-VC-^XFG
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M"RXV"7S46'(C667YG# &S5U <_9&3HXT'L@7/3*XDA4?!H\"1Z94@P(T$3N
M](U%PNG()'!SKM.-0\]MP/**DLQ^TN(V>?"=JET>%X:[2>YQ.'C^+";?<O9.
M9#)+&"!T[F6_7QQ]&Z;OG)$C,98@I<7\@%$=T;LXT@2Z+.Z.JC%*?J&0S/B0
M\/[@5R.A:7_$,E7D <,:7MGEY ZK,=HI.D;HM*0L"6JH/(T8,V8PA<B>H*"B
MC""?A-R9\#[P<YEB.<"UQ@0C :MTS@QL&&<0R#2GASE!>,_P%(=2,/8"I QR
M(W(+*+X_9>0\G 717[F(S3/R$6*- _.Y?W$2RX-C+L-/>:O"-"9'>)A@Q&@U
M8=(:GYR;"F<ND&(?ML.,UTPRJ2T&X V.M>5(P/X6+K+R?5NZWKER$8CL&E'!
MQM)@9:*-@*V%>$A!'D1^]"=<;1"B]:]CL+Y#+ 1ROVA&LZRZ9 "9JS^-(3>K
M-,G67PN\0$',([$&>:R_E2]V.( GM<=ASD6Q:%3EZ GB8*G] @@]DDX7,>4-
MMI38=='-4CPY.?CVJ:ZDG?Z81=Z?(\0,(93?D60CDCADD6T%X<B7%GIVOCZ@
MY72G3P^^M138Z4&0 V,I#X(SHK$4L4*[$;>(>G'P[6YN=G2&:MF*P]-@(PZ/
M;2.03=G3=(KU:F2>MM;*N2:DK)""E@')8%06W&[(%M6+C4L231MA1Y),4<#<
MB!BT,R:D&E" U;E <D.SP=--R]%.I\@+C7%R$</J">P.)8 *;^D%<N(TZ1XI
M:DM.7Y\!4KOQBDCMLG8)PQTDU+J1NF&-&&I#*>$VX$G_E9,IP)6;#<@Q=/2)
M'S3-*V9:SX T&M\I,^Q_E>>P=7D.\(1^NP<Z3R#-&&$8[Y80>VLRP>4"=O*4
M<-H>"D1NV@A-$4MXCYX,E>,3**OOH*6>*M</<[.YD^73M%I@!Z&D8[FW@ +E
MNP:;=Q&C/\*FQM)E^>("\42DRT? &A7\L";7=L_:Q%A)2XVL--Z]';[ WL;<
MCBV\KMA,K]_\=MY#&MF+U6/>2R$O-\5%1YEUE-1D.9B=^D'B DD&6BD)A.'9
MH5:A<YD;P*'6^ ETM0!XTX"VP$E*B[X66B(O,P;H"&>5CB5H7%8U4'BB8HT$
M@KME&P,:*41(5UU8>K.GX#D9CU,K<^AA<(LDT*H>0H5.-F:* MXZ]4,4G"8/
MGW^/MN$DVRY6'V .]]-]-!'K<4/\RC)] =_2:I?U\'QW%=K20S_7 ):!&.A;
M4%O(E57@VFP^#>X?^GL:<8\->>9F_VLY BI!/@WC1MWT ?\X8#,.C:>=/)]_
MV/H(Z%OJ;+40)MT\#A.CKARM*W?&$-"V/+D_P+.I"NAY0^VS79?);*HAUD,%
M";(!(^]RB1 9UA$;.?I5!2[[A1BE%UD>>UKZ[E%$OB_#4"N[<WVWW=OPR-B"
M\.!L2/<5['C8]F?/GSU[S/9GW75X_AA9[O[N9U@;WUV>2],$WQ#8&1PGT<[@
MS/3KJJTB3U\] \2,S&#FB ^RFWG=!6))K6,?HLP"&YZY1JK3;&R20^[[I9TX
MZ5&X9_T?)@40#@H,$]9VN=Q@CB7A":;/R>:_F#7C8HRS/2ZRB9*2)[GV_HD1
M)/Y<.>P(6/2Y&]#[="S@$O'Y%3P>1E$-6="JRME[^6W7H['..1P[ZIL]>QA>
M26A%"B@>\/R9H=WL+L;>ASS:04U2!U[?(<3V>:18K?$#I^[Y08\-I&&ED)$U
M6E>K]V)DVZ_FK)5OH4 _-ZV\2DGM9!+TY0,E01^AXN\QFY[]AJ8L?PWMO<%K
MZU3P.3646ZO;O3;>H$4#&KP /8FR)]?M,@B&ME"]D9H1Y*MH5#Z[1530V2K"
MBGSA?.+4!)OZCD7%W!SH PU<EX6,+^GT:HD'M_=<L$E (P][Z.;W>U^/>X(U
M)IEC>[,TOY".*^"YJZO^RV1?$<\,:*G+)A>T#+9*[QE>FEDR_EBMN9+R%+V(
M4>4"JR[+8P12-$AV9*)[,?P4*Y9.8?UK=Q1W5P*]K<BA2O@#)W0[E4-MTD!N
MQ&"."U^": CK88BT$XAAX-9V!.\R8UR$/$U]D)F7\>(--;@PON2(O\2'QT&'
M;/ZM]L@23A])?LC?N\&RGDD/I6.42:Q%!(,=Q 3IW.2UW>_!.P 80B2-QH@]
MP"\1EU&;()79>G?0Y4W  :-$Y\B+\!VDZQ$\/8P;SI9!$V<DE/EDH4:5<T37
M]#-!'6%YM7U.SQ.#L(NF>!QC[-O:-2!P[:%TU1B6KY&H^K+D<=.\V!N6M?:-
MM#2PV.0)EXC&(-=@X8,E$'@(0KA2F"(O=(5W;H5<0;^)"TZ&]G%U<?Y.PYX(
M.IRTTBC+G@X&L1UU<M!C1LD(K>LL-%UO2:=4/TC(>N4@]P=_Y?I%K$)Z5<P8
MPN@C(Z:U5%5TM-%0SJ/X?GO6=*!'SJ]3BQ3,"H<HM9Q+4,00!O<8ZG&3\I=5
MPY$VNU_&:F2D/$*N;P-XS2HJ.A?"?5V:#^L8GCP_['<,WT4"\TLAKLR9\)>A
M$#;T&-^\'[PKE-'SN\%/;]X?#7Y++Z15WP^"DOSJW$9:N55-L[$>M^F9+2P&
M47_#8D5<2_X0R:YZD>!(3.9-Q=%T^M<_E Z%E#K( <I$@]TBP;XYBQLKFT$"
MN>9;(#I)O6V]8Z4R4QE) AF91S*R:,E(;C(2(6D!'G6<Y3"EY (6?K/KN OX
MFTX7\"1BBI/>WQ=.0:UI_?VFU?H[Z;:]X_ QTP MTA*.E#81C89?[9MXK&\(
M'JY'C"3NHFZD<+],PZB"YWP())+WJ1%V&71(RR]FRH1IZ9,P-";M%Y=X:-#F
MX2/CVP=/7KW^^>G@Y+MGAAM"K-;BP+0HHV*<T2]'D9D2SCR.D-->:C/O37MY
M5U&_SB\E:SO8-^T.&G5+NJ6][>U6'9^"K H#Q]RFFH1ECDB,(I%NV9SZNN"
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M7;=TD&>5ZI/>WF:V6)(JET=SPQ&.J*[5/-*!2V#"&F\'N1>WKQ!L%NPE+@U
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M95VP(10!F?J;@%4KFX =K&\"]ED=)_MSEX]L46Y&@]I#G@L2*!*\C=ES-R7
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M^L-7,L[3)*?W31N?5$&0F8/A0JX$>C.RXK*JUK@:XLR5B[E5R_FB1O4I64X
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M8O(Y';U+-WN2$LY4UB1G0U_GO^[))'ZH7TVRF0^ N:C.]65*V]70L^P+*C5
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M[[FV-.0+%T__G[^3M5O C]I)"?F]*6W+G"6R1LWXG!;:-; NYG8:0K[%P=W
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M:*(\W?G-LV7GL#V2G(>GT%\7W?/XU"@TV@4_&'I<?])['[<[+[B;R!6<]%Q
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M.2*&JU.5#_(RL%[\]7>[2.1F8B'(!!@_ZY.FF1GS)%@_^U$!E8N1VR%0"_-
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MWB9))Z3(<F9NI=/9D/8Q=C#FR198JP$M[L"YM0^1O(>SK6,+3Y[!^0'PS6]
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M8 <HZ,X1(>[J5)_7"=Q]"48RWZK6$<43M1,F51C# !A(M+9JB"Q+?W.$BEB
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M& 38!<6G#3.[ ="0Y]<ND\/0,Y->M.L*#<=7L\_N6P_IR7&,YBU+,A^ IQ,
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M5-)SHBI)?$5@91:6DE$=+<6(:AHR$1."VT8FLJ+KFD5%F>+E!<C/PBE]Z:[
MKE:6EE[923NZ]XTRE[@C$%\HY+TH5J)/%\N'8^6_8[5,<LO)RF!(7#8MX<LH
MB=^!T@CT1I6GITKL955Z]'R2-TTYRTI(O7DJRU&"%R.&;B);W$U:V U35T[Q
M0].T=#?7]: @.KB9+:M\HR@3]:ZGKB[0]H+?;-J+H.G^97:+GII\$X)?6["?
M>] V05YC>?)]68.6PX7SC?GME?P JC1A72J15)"(_O5E*1R;LAZRG*/7"Q>)
M+;E6174(&-")=OP1\27@;DYGO;*B,#]>?CFR:OGW%_OA+(2Q/P[(G0LRE(Z*
MS4D62""X ,VL*T4VI Z_;B]PMLI?"UT1_-6".W6)^1A<3C@9(KH_7*B3R#HB
M69%5_&:Z&;6[X Q7& R '$+-NI-\#0Z#7=*)"6'-R063U@",NMK1/+V.T;5T
M'<'^/1>-&^-W!=9V@T9<^VCN0LAJNQ&I%Z=@\1P6B=6CL^.0&GHE<JT[RGKU
MM)9202XJ;) ;!6#DW3 >8U;\<PU]]Q%>@R"S@%F,W([@#5,^9.79%YNM W6-
MVEI-:?@4HQ*NW/B6Y4:(!?KRAL,Z?3S=C9H/[58[U#F)OV0"*= MZ2>3D4S?
MF"8BG-^?4-9R&0SK3F19+M0[3YX&C@3HQS)&5-=[G4DA),=D[8P3 9-+Y'T_
M!_W%2*;ST5S>J]*+K07Z (2YL4(U1;R#\;-6R9O:@C@"F[B=6%52^!>I,*58
M@DC&V(?81 %*:JZ-!KCF2,$6R2)(W _15!@:ZBJ,HR\3)PS'X&;9'#G^*KI+
MUA+A@,;@&3*6TB10HZ,F9#_Y4$1WI$J:-QQ/,$MVK8I[)8P3R<;74T)-:KWQ
MS<O.L+EQU'U8[1N^#/X>=0Z<)Q!6B0I,SHZX84W[D1!-?_FG$TW_F5+[[<))
MO_?;7U%>UA"/EC49&=QRL*6_T *>:R'D5>KB:C!A/A'02L9HBE6HT>(-;PHD
MZ5T4OKK8J:D*XBTZIJ>S']R#^&DA3?2^L*5-2'P9Y :OBY@H08GX.9I!/ A>
M+<IHS5#T)1(;1CC\)91KZ?**TCS@O.NK?F<Q!SI"SJR!@&PB<U'^PJ3M_$ W
MP?)##$0D1.&^32+I.$8H77(CB)+U 0RE.(I]&[(7IN>+6EF)R%0;+>I[UV0@
M*.%=J2Y>;U300FNY+JU)Q,C6.DV^>!SGD YJ+--%Q0;C%LU>J &DG\#I[(DZ
M6PFK<[NC!R788V75IB&_F3)R3S&G16-'^0Z9PSI'U!CRWEAXQY8#:!ZZ;FIH
MV=0/3?>\3(<W=;Q9[1 +._V]*-^_?A]R[A5)SOU5KW=(6#H1XDBA /IJ.@"[
ME+:1^A'D?ZOR6BG_$OC8Y(H08PRC?7CJ>=4,?FN;/I?C+I?C1IW-I+H]C6ET
M']<<.DUS[XKKM7,?EW,=(Q5>Z';[KB\WD^[ZNWLF[V7O@V?RK&C#M7IX_\']
M^>QYD#DD99_]?%YL"HIQ'O:P&.OB^G=&7)"K-:(N[ %2+78 @X'+'GN *.CB
M=/8TN1ISW<4UXLQKQH_CCJ8C+H=8K6Z*[W2E!U&8*O;R>W1&)N>R+A;2JB4,
M:W<!^LBP> ^$&_R[W?*B[(-4E5.E-6_R]ZE:-:M[,X$O^FJK?#/T)D19A.4+
M#[T('X&ZFOVM"7LR>RE$YX^:#:DKV0K[<0G@91\64+\;!E9TK\NEZ)N,SR:X
M-PA08 !+_5I\)75&3U:;?O:_'IP^1/N;]=J3:,IE#Y/[+/S8DB'_X?V'8:98
MIEUMU)U28Q"]/A#QD\,O2!T<BK:ZN"B3)+%]:Q*$);8(=*.C)WTUS)68 <&H
M5)=V7N,.8:\O+B"<Z*K$M0TSC4&V+$N2DB!&9?OPWQ%I#5Y6!XF"!; @Q[4B
M1!KSUL)Q.@NB;RT+9*6(2J&*O^KGTM)]=M\!FQXU;7#8KJHVJ,@S!/Q>E.NJ
M7(G%$2M,7EI&PP.1'IV]>/(2OSDUU [^"X/R; /#)UBUKXI?PTS#J^2I[J ^
MG#ZHXM@NIQ?*=B+GE-0(6:ETM\)!A;=0K%O5BS#VVI'R.<W&.EO,\)_IC5$S
MIRW+G&C8#@!30E#?XC'[H$2Q]F<@_"$+M/J4&'^YVNF=L3\2G%S8'D;S^5JX
MEC6P8;$<..J[=BI:D2R;_)N.[3CQH<LBK=AE Q Z7FFUB^J]-N*="G.[?(!2
M8]Q1A?62\I@RV#=((?:NSPV9N=KN<#9VI7"2S&';E"VR_$'2($IB_83ES)J,
ME?-1Z.&0W&JI%DOXY[I8:(ZT,PDB9M#U*0#ZC/=N$9H3&W\XVG#[9H]VZGK]
MK3GOW/W[*@H4( M$_P8QF33SJW:WV8JD7Q!8-GL8[JQ\TX:OP]6KI]UX'"4:
M:-]!NFQ=>5XQ,\L9<HA5EV8WQC0B9&:21++G18MC.D.,>X.LKX5+?&8"J;\Y
M'%7VU/1=V<+8O\G"0FEJ#S[GU+Y&U(IU!8\K<:W"5,/G@T>UO(BTM#\U?$*=
M/A2&\"KL1<>BN&7*!HR78H;4N6-YAK9G0\!96$YM/2-"382=,*86Y%;W9U"=
MZ59:Z&"V.VUV8R_"OL;M00MCEUV[Y6#T&07W^/QAT+[_MH(:P:WMEO1K+NDW
M<U4S.WG]V19#2OF=[ZL5[#2DPID6P,>"M*O:C9ZJ=7,MR<PV47J'98ZMF=YJ
MG7<UZ6S52;>U[CE;Z1)UJ>U!U2Q?VA;+R%9*U2?AWHRO6_=+S$JC[%;#+VH"
M@'_VVJY!(X#CM1VJTZ#=$..2A>3I?+G;(O"@JUJ$NRAA[G /6KE6F /:IY"<
M]V)G" \WO>;U3.1+&.5/0?/)IMW'ICV\GPTA[.KWY7F[0RA;/V!F*$3%[&R)
M"QG1%I!%RS8X:8]__EO<,0",F]9"GU5G/5"S%YW9QJH1+].K.FV$A21SLRE)
M4L]G0 6?SOY>14Y\ D*293>++0+MQ*ZKUZ7 H4Q>J^S<U6%%$3+AC<-S8E[9
MHN"G=U*1O8KY$,:<''MV[@ZKV\)(W[FC_R>W-2/2>N:Q/NBNM>M\U]K<FWG5
MD&Q_I"JC!8?P23B1/,R+3!=6-7%'98Z5SAPI]8PFN+7]WDLG'-Z+:5/S7-!-
MD)]9O0"24\(JSGC"W)IV*<Y*#$K MJU1@@4>-!\>P5*.E-OBC9JWZ?VF2%1!
M+/+,-FP%IC+V.P:A">G$P8"$&GH9*WHN3B#64!Z'KI;SD;JONFZ'^%C%'L_D
M,6&K*1K!OI6>2.7^X.'*>=FUL:8(X#6$E&;L59$UTL!(@ X\-5U\JZR$P,OB
M,9#B\X&C(^(LN393TBE;#&\*O$0_4S%S/A<9*").UF4@XI#]6H=+#.(W#,6:
M[RDSN9Q,8MI,ALC1 YQR GH7J?#@X[ _!//KK?8XL%U/(3'7BUPTTJBKW"D4
MK72![A37F;*A>>Y5="@+"MP[U["Y6$A9-YDO4W5L6[[=G8?'F^7%N!U;#7D/
MU%PA'Z5G(K0KKMBL9"7L=AULY6[D16)Z2#KHH5RV00TF5",'SJ[HLNYCG*+,
M1R>';$%XX$F,3<NUB[A7A?3\RV6\)Z!4LWOLMG&BC8U&@>Y/3F=WT]\YZZ/W
MK&G(N;>J]$"/ "F,<W2=&MC;HB,FQ(MA!8ND;(SGHG R.D9(IV.W5K1D7F<4
MSL,,3I/$[B!O:GT,$)F% L.>3B1Z[,;&/IJ+A?8\<,%^GF+M,;E3<9TID2QS
M,T^03_3]G&?S#A\/9@[A0.[^,> P/'Q<B]WZM2.''@0E 7OE-?7A9(=64]\B
M[FNL3!IOK1!=GE=+7=QF$717*T+*\N>ER.T#@741!73JM+[,$N7G90J5B0%1
MM1/ZXR!F. N^Q9AF!HWH?4\B:4 F:9\4'D$]&21)PN;A\.P(GY4\/TQ(%T[1
M0Y<)JG]8FU85):[!^L@\<6$>U>UQ[!&^D >))>\SGV708)FGY.@(;=KP*,L
MQID4GX/-@&EN.)- KWGVOB3.+48WO:H^Z(2HE&]%+G:2+>_8HKZ3Z(2O_BQT
MPGO 5K_/-M@OHE6CWJ%KUT@[F6Q]S^WDZHUYL@-;1!AT\$C8/^EW29B^ETH3
M#^<S@\/A]9I=#]O= @>#9M,.K(?4$?TZ7WT2XY.XPN'=>Z>;I?6=0S<@K#RA
MBW*<0<K&_G=0+22 <B9A;$J)'T0D22N$J6R5<5GU6%>61L0LNYIIVMC!H9,%
M5TW**<9LSB,.(Z$0_J$X8877!?DI4?!NW" X@K_FL]3QKE:DMF$?-8:.Y4]H
MOP@AM#"& QI&WA(?=G?J65MB5P+SDA3:HAPN2%XL,X"2<SRPV]->A8]G6R5@
MZF$#:M^*]DJ86LS#O6G;&?PNK!]AF0M\19:676\.L@^&.:?JRIK%::9&Q\A8
MSP20,_6U&YOHXR$*J-57U-"20FRQOK 6NM2>!S"CR:MZ,9$NP1AJ6^_]<+43
M>+ D<'XRXX(I20?:.9UE\(17:YH@0+JC11K>$OEL#CSCIF$(9O>BT*1V,#8+
MS2BYA]E1L&5%K86BLP74>1G\_BN+1=JGXW7.6NINHHS>WBBC:78]^67N"D>D
MQU>GP*(-XG:L=ILN80@V,'WHL&)=^'A?=7 #&RN:*Y,<*.-%,DBR'$F%E=)>
M+=?K$_5%$#D?7CU8[+&$0<8WEG&#*PEYPN1TC%]XJ/E3E<XQ\:&1-VN\J<Y^
M5N)7]H,R%.F1>4!.YMT^P;9PIBD$]LE3(7+XZR+'NG)*5/EY+MB&5!^CP;HN
M& IQWW^YDSV ([7B*Z*EHQWRSD;%-^\I'IQ/J)L]9D,DR."']^\_^/3A_4^?
M/)(;GOWEBT\??AW^ J_HAT?/?>TI@W."IH8@\N[^.,/ADS42<;-PV>JP= @6
M'S]JYHVKO%2TE"64O @:7EYW#G_1,"$:H_(! SU/JTE5@'1J3>:!81[338QS
MMQL29<!PZ-* 2<JXAHJ=G8(;+2C C7(P=L2IYS9!&R/2^&CE&A:P[7VK8'D<
M_-%470.1%SY:0=#!*QE,(5A&P+,M(LC'A=X*!V=LME5-N?5J/'[?UM4:WA8+
MJX!&@CDW^);-@JDIADGR_L8\'0,%$CX?1&+XWCW)#FTV1HK*,3S6IWTB%JZF
MG' (??6M@R@$N39]]*>./;SALG5RF&?9'_5X"&X\\Z,#01]:@;=+D-2MQ?]W
M/3-CT#,NV$%!:B0--SO*3OC\F;[R4X=5^GQN]\-B'M)^?"B<7#/<>T]^^63V
M4S/[XK,O/Y4GR$W"'2X5R2-) ![M7=OB8+^)M)/3?,OK-49#!'SL*#=L'XUH
MI2!XL(7A"P^_'F\YSF=PW]1QT) S?+5I&>KBJ307.! (P,MBM\[FJK(0VCQZ
M(0RR'Q:$N7W7ZS)D(5SP2@19TF%0U6IOIGR'TN'-.A4<OJ7HE3<MF@9>H^5W
M),KX)M)<!MMMPS4CB>18_EE0S5OUFE\!YK2^6$]THG8O'#V0'7R$_@!S'NSK
M[-Z+9R\_B4"[(-'"!]BM8"WGRQEU::8VR&CK5F$K(;0E];:*Q:UOI"]XZFQN
MP_%)RS_)>%X6XBX,/I/%-N^BB,$Z^SN+Y/&.UCHP:?7L;[LPZ0=?$IOR.7TM
MZ#FX9_NRM]N="O4R> +%^=^*6I 0/DMX79Y3L0Y-&$)F9<?EV&3H(+OC&8[D
M)@%4=%HD3I"7W*@EDC7-UG!?056S"\5J5R]4E@RO(K,,$B$&._=YT<66G9)/
MDP.E&!R4)[+/97QQ$5RG6+16]),R0Q[$Q?1@U:[Z%1VK^LO.V2!3JV5[AD)?
MT(8ORH@8TZ&I.'SE5E^]*K_&'*O@J0U#(C0L$EBI/+P-N!>D4V#.NKU]\NQL
M^&0TY5@K*$WJE70S5B+[U1U3:<PQ""L;R6RO3%[N.L4+S2UD9F%[A1'ID1C>
M>F?-R"L2Y1OJHX/]<%%&VCH!LJ+*'2],C=B9%/4%^U'F4BKGKY37C#*T6!J:
MB>.%U[E3NETTP8&_&JWV@W=&U+P7#^IL.@HQAWZL4$<^*@P+/K]D#0_OHY%R
M*$YK$-.2_;7]49Z_0_Z2ET=/=LNV>/3*//,5V+""*O]V=GO+H+_\W\N^WW;?
M?OIIB8<L^M-R4YR6>!G^[U.-K+_E'DXPQGSSISOTSU\\??8D'$4D82,ECQJC
M;S6=+S^,$^FK:[Z<YX=",R7@[;Y 9EK\Z6=G\R#F@HJX9)@FS+_J*PG#0J05
MJ(CI)7.::9>)'%]5NV@64JID(FI)')I YRC:8M2=D+!B2ZY1,5K7RMLBLCSL
MC?C/SY[HP#EB;MG<FB95.1@II="9-O9CKGBU"BFMJ#=E[X@&-$*E*/^.F?ZU
MUC4675=VW6#:CC&**!_4>Q:"V:WJ.EB-RH6%.':Y=$@D)#-;10Q%R^\TY:X8
M4>C"9JY/9D;+NMOP#+$W=MD&KZG3I7CY[ E3(GM1&JN]QA=;)-CQZ78O.K>7
MY0Q'W7I-P>A;HQ2G3;1DI^'LU'MK-L55:'?*RT'3NCNP\72RY?G+=)4\(@/6
M%2PKIJH5B8=Q[FW=BX5&_F, >EF!'6]7)HHTGE4M1>@=\E# &KE$E7'XHCQ_
M%@Q'58K5956U;M??('Z:G0RB!V)40@JD@7*DCR'%6X+IJ'MA1%B6IBCE-DKI
M]4(+B@L&+(*(32&F5'.%3182VW'R4XAQ?WSV7/Z1?>=L>870P1*W2RZ>?.CL
MU5R 3^&E%6M-96O"C<D.310&XM-:K0T/-X[_<B('%6R L&T1_)L&1&01"LM
M8'C2K) E*/7)E$ 2_NYRI&6L\P%B!!9A7Q9T<@G&PI&HPO[4L,IAY:%GC5HA
M,% <O4.,HZBYQG)/,B^E4^+H%W$@!29W44V57MY)N,+7[PA7B&K\5O?O+> *
M-ZW 'PU7^)W>_9QDS*CW?ZFYI9NQ!V_L17_U'D[)<T:\8Q)4BC@/2<<#6;TB
M 5 9"_:H4T<]2$&/2QBQ4!X:AB#*,X?:?%[$97[JP\6SY\$?$TOAZ?.Y%'(K
M))=ZNNQ3S45\PK;9JFL-JG>6[??.JV%RC'%)E6LG,99^753,@B)"%!1"_)G
M@649W*Y6<02>9D ',#E1*NNGST^U1BH&@$;.!)?JP$XXE!ZK'4">O@3RM:KS
M..HCQE$??,/XYWVU&;OF!%' ?)73U\CHU?D!2=ZR4.KXZTL6]1OLY+K0*LIB
M::'=9"?.AYA!HN$ 96ZT>+,8(*ZYLIH14/ OZJ;606PM]PZ]JU9DFH"K6EXE
M@P('Y?&CG\6.XD;';=/B:(0N['TP%0S;G69(("12\P,C6?981\KHJY+EAT/6
M5VLMBD!92\U H?<#!^AL&&0Y_95#6K/(E)4I,N<P'Z'\)35I*_R@.)>Z-Z-(
MT?0@*PF'P3Z6,D[]!>]@L$-9V&&L@:PV"*8I<*VR*TQ(N7K5<AT,!;1PCY?M
M=/:=Y(YARYR=1><4B0^Y0G7B*SETU/5+6O:?(C41FJK#<?V(%KVT'QB2\&K]
ME(<$Q"L*ZCFYH%I=KLD?7M4[2);Z+"[G6;:<[^KVO@]\W*L$!SIX3'(>+_'(
M@I?O#3P&JKJI]*_E"N28EA4]"GE&,>W31;%E332\P*$JB(9R%-2#;TS#.U*
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MJ.-:X$&F5G)< 3$"& D(7)!7TC9;WDW6O=T>OA@F0 /D/3<;>/<&6K1R=?7
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M5N-9C6<U_D^@QM.4_2"SD57X&0MB5N%9A6<5_D^@PG<T NF#;TE!(HM3UC'
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M"E&V!)FPXM-%I#1-OP>W$@/R" P6X]+TM6#5Q&A>T?$(B$P!>PN5+!$!T&*
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M%2T ?&A*+<U!6.J:N?T]]$C+G^5O1[V<N@H+)["' =<*2F" 7I&TR_-V@:Y
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MV#V*RI]IAJC(Z")^TEU;*FY$MIAG>NZSQ<P6,UO,QVHQHQ#P*% 3Y%0@1T2
MIV+T + M"+%3];2)^:L1P;U=5CW*3U 2,)?2JT+3I/-9U\PJ%%EU,*KX^$JB
M1+)GM'1ZO<"1.E+=@%(<7)0H;*F.TY N D@%5\R@1FC1[V6*,.#%&QI*A+9>
M+,78-3:,Z/W)&[-A.]/CF0U;-FS9L#U6PW8<"@J,_5$)*1>8<1$EE^IY[6_A
MDN#W#*(R#=OFW)&X&\$&;CV)1C$&D]ZZG2LT(A0<2 X6C^O*6]_ 6N 3O*E<
M7VF1ZDB':5HC*]7KV3Z=Z2G+]BG;IVR?_CGLDY2V<W&-5))R_;8O3@$%2U+
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MW:XJM'@B50>M5==+<UH\D+E'V$J8PPS+1$,N7:.98@>3P\J,.RIFO5=>7JV
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M2(;)4,.RC/P]>JW#O8\O6E?>.$5O,ONGM711[?RTD NORL"\)'C(XV#YM/9
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MQAT\,*'V'>SZ=HFZ3[@HTG]P,;OBOD2IN)H/:\$9K@('52GY@+,9C^Q^$XL
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M"*LO/D]5T=?+C;%BQR=0_H+TT?':'BTM#W,P+%3?^F,W/E\>NZ'+L=YHZ%?
MAV2V='_X&42/846]H$$9[9CJGO630&?WM6'7E)6B=:&^%V5<(X2F6#'=1@%K
M UFU(I,))/?<HS\)T[U@<8FL,\1PMU>R3P4[:QT4$E!/=TU7BEKHV]%])SU*
MLZI==:;ZX%M!+%'83""D;<I%N1]P?T^S?7<&C<<G0V!/7 8]^5B]Z1R'YC@T
MQZ&/-0X5&Q?U1:I-GXO3(<!A8MU\M86 5\'YDD9Y]C].6KI\EW3&8IP-0#8
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M/3SE#F(@%4#B:M>2:RK(F(S+IPCMSOO:BH$D6RZ2OC[H&_'@ FK!'PC#'10
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MUWCF$=Z%/%I?DXUSE5'WXG@*@O66O/&X?[\S!H]M9X <&FK,WCB9:N/;T_0
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M4 Y4/1OIC GL=WB-?@=G#XQ> D<7- ?YK]Z_)L]X9B(LR9].*!_L'/0PCMX
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M!"VL"=2F<O7.B\:D/##15FN17:8V[10ABJ)%])Z9L7!5?F3X'GV>++3831@
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M^J,=IU_B0%YU0I!%R&\(CM8$+G/4["VF BD,8^AV83XE!U)W*L;9&\%"C#>
M19+AN'CV7S@03:;06R+P_EW>(N9\>YW7<LX-G%WTI<"5AQ\ &2L$QQ8I]PC
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MH5M*I3.Z,?I%0B]4H ]$E^=\,_E5F,01/PK.3RD8C/./03X@?.*V*>%%X(R
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M<K,APQ6F4FD?,')0L?<"GP5M_F;G9/J@Y]$%/=Y[EW>$XGBW ^^7@ =Y#M3
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M9;?#%FPP&0BO0NY%TZ+]6F,<'D--,P0Y039R^([GJ@!3VM&TZ+[LP.?A8W\
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MX@J2A9W[$^W(VQ*,[^H=/%D%__^OO_[DLR]6KYO+U;_C5CMP1>43?P');.&
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M#VA WB>F*T3NSH7>Y#>\@4Q\^,X>%6411@*# 48H4^!8 Q[(12-R2;GZ;F!
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M"_9BUA"/00&G96?D?QI9-;\81IG@OZO<B&N0%R6&*,I,?%6L)OP;8<NDQ^!
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M30Z4BTTS39=Y):FRW!/:X:TN)]%)@'-@\$6%<?021#Z1#O%4))SH-O:4-&D
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M]#6JJT-J),UZ,+)&TJSY 3629I&A>> ?'#Y;2F C:=;M&C62YKE/H)$T&WM
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M%$NWJ6:2G?;4'.EQ8!';4S,7;R;=YR7KH"%@RH?5IS84KWKQF1R!TI\$0'_
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MVFP?TB)"Z;/7&(MZTRPW ;>>BB/X,7%;TWL!\?)#)=&V*.N7HYSR^"4KWZ%
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MZZ5+G5.GDPRY/JF%TQ1R[CKA9OQH![2NL;+;XV-4CNP'TAON7)'PV('.ISG
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MN"WD*LHG>:%&C)YB.#TZ@/*2JAS(%D# E"#K#WT3:G!A4/!1 5)QO4:"R3V
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M"V*3-[@/H+L/$.>B=AQ80*[B:^9BXWFRL8_4D,VPJ5E&YC*N]E_FL:DI/O:
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M,3. _;F*KDE"1P-6+#A$JY!)CZ(D&L'E-&7,1/-;=('_3'NH-L[= LX7-4,
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MEU7,;O/J6V9D* &V(ELV7H]@GN?5\<T:CDU<ECTB4V"VO:IC=SK@Y'+/.=*
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MPSG;(7,"\QF0"=!/T$^T$RMAQ927DA$44UH5DU1(E4;1;!2+C5*E=L3]1_=
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MX;"F3*D5P\L#//+>D(?C#Y^KJ(81I4DM[MR[DM%L&;&*G9V^%E)]WA&*9U_
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M#1/WVJ3;@[C79K_BR'PMCB:[H)YJH-UJZ:!:M@RK(C60B=OE*4<2;I?/MP?
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M?<369<#E5?!5&+!B&A5)@A5S>TO/($ 08 KL3!5B08"4O0,"W"8!SO0@6YL
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MK8.PQK[=-?:97FDW$D$]G_O/T?)ZT[9]H3[KQKL>H^NKVY^QU1LK[N#0G'D
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M\$X2*9,HAFV4$ONEHJ3] TA+J3?5XA,@#9 V/]RS:'= 54J]J:KRB4,5I0L
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MV@+*K;M[3XYGB6-:9V?%L]8.,FMN[[PM&'T#&V_QEM:OO,==6S >LA-AZ^N
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M3\PA2 ;(_#P8&D$.Q ?B(QD@\W-C:\0Y0!^@CV0@8'L8&D&>;=L#\8DY!,E
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M)N-&^+]\F5Y^\$_6<0);AE(8,.YVF!-;)ML6L+U CE<Z_[??G2?UMC.?V^H
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M)$,&DP$3,81\SD(>^$_,(4@&B'^ /^(=X _P1S) _&?>[ AYX#_P'\E P/8
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M@#_B/3?Q#O GYA D \0_\!\A#_P'_B,9(/YS8'/$.\ ?X(]D@/@'_B/D@?_
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M QC>('0\%Q=@I(B)<?@K@[8'$Q-S")(!)^&!_PAYX#_P'\D \9\#FR/> ?X
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M#*:$-8RF:S%W&^_@.BFQ">=U>-@\W^K(TT%KFT>HF6(, 5X!K]14I+\IQSM
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MU3V*X:I'D;=JY[Z;3R3O*8Z[XD]T36LP,*TN2I\4$2)5U1H !DG7@_@ L.H
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M;1Q)R*6E[5*#0<(QV0N3&NB\U#^-6Q7F3UW0+V,7_,.+[R^6$24."1,WYNG
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M%;;ME:97Y7;.74;1TO8=<F(!7*AU(]4:  9)UX/X +#J %8>_?\R *L>R06
M*2I$JJHU  R2K@?Q 6#5 :P\??^% +;[W&!Z'?8/<$P-64)!KAJ174\J(2O.
M=8+Y/& [+@/GAWJY#G@82"SI07QX&-4]C'1#@1T^^!O<BPMNU^Z86;OTSV^6
MDYGG7$^G)*3D/\RXW5Y_;([']!^%A@I!V954=L :)%T/X@/6JL/:Z)"PMGM!
M;W=H#D8#>HX> -;4$"U5E1VP!DG7@_B M>JP-CXHK.U<[VOUS/ZH:UK##F!-
M#=':5W@8A;^UP\.BT'XU'DQ_%RI(7XWBG??$(0'=B!RHIC9(#>+KZW#4;R7J
ME0;/WZ2-1,+%D'['!;-JAPD&=^BAN=\VK9$Z*]\UU^RC;7<'?"E!;"V$7%7B
M [YJP%=I\M#.\+5ST+<_'II65YV%ZYJK-;!+;_.IA9"K2GQ@5PWL*DT?VAV[
M=HWL=LU>IVOV]SC+ 8J]/_1"Q>\Q*GXC>U:J]C4\W[#IY>Y)BS[0#Q*GX5[U
M\A_P-I!LTH/X^GH;]9V-;KW,\C_"(-KF<TB7Y6XYB3S7L\.G.VHUI=]R_M.+
M_F1?<QY_O2>_<WN9)*A_)_,)"5\2+1[TS4&O:UJ]_9VX81X::1X A)!T/8@/
M(*P.A#W%@%"%F1,P"XTT"P! 2+H>Q < 5@? OFH 6#EX#0!45 A1C:QV-3+3
MHCW'KY$M;T3"5E/SI ;Q]?5:=LB6ET=E[98M/U[DVC+[HYXYZ V1;%=#"E$J
MIK?]U4+(526^ON!7'_N&JF"?"L%JV(-&V@,@'R1=#^(#^:HCWT@9Y%,@2@U[
MH$24&@76+RNP)C])Z'@1+[*6T>H%TXN=AV8@@]Z()*ZF1D@-XL,IJ>Z4C+=M
M;> NQ;4P:)^DI7,/,SAC9'8&;7.(&<JJB)*JR@T8@Z3K07S 6&48ZY='/[T(
MQG8>H-$Q1QV6%T5#CR*BI*IR \8@Z7H0'S!6'<;*(Z!>!F,*!'JAU4H$>E&.
M_+) ;WYWWAT)/1(9%T9(7$+F]F1&F!8^D##VV,^+D$Q)2/_(-1[SDT\!_Y"/
M:B3QX7Q4=S[*,[S6]E/=ID;O(K-Y-XG)XT[*GD+$R#XK*ENJ:CMP#9*N!_&!
M:]5QK?LZN(9ZXI.7+56U';@&2=>#^,"UZKC6>R5<VW4@<[]OT@O1?[!/0!$9
M4Z5J.!\Y-B9!Z)(P(6L4S#S7$.\S^%,M[)#2K_D1YGPI\:,=TBO$Q\JYY-V.
M5^#/B>B**EFO;1Q)R*6E,5.#0<*%V0N3X.90-Z>_S<WY0QC*)!V^KZU^ZJ;#
M*UF!O%V&)0!8-IP# ,N391# <K]@69XLM2M8JA#.!E@VS1( +(_- 8#ER3((
M8+E?L"R/HMH9+'>-D0]YC!R J;!<J5*!_<I!<R5Y<45BPZ&NIK$(@P?/):XQ
M>3*FGF_[#J66P;3GP8L]<K2::_@WZN:6,XXP4J[%33A 2G.PZ  =EHOPD*B'
M5!I91@WP!;6_-]+\?GCZ%A'WTO^<F.#SU (?9DQ(O]TS!X.QV>[NSVG:D\V'
MTZ2,!0$*'YL#0.'F<A H_,HH7)K1M2<4WGG*B=4=F\->UQRW!T!AA44-**PW
M!X#"S>4@4/AU47A0&C&V+Q3>-7=@#49F>] V!^,^4%AA45.EZGZC+7GQ"!<E
MR<YR!9[OA,2.B/&6:@W_Z1U]3:00;-\5/Y#_+#W* 3:)7[V<+UK_CE(!L1%/
MM;17:G"GHL<#;Z:*-U.:-,=<&?;/I\P:WI(H#CTG)B[[P[GO%E_(O?.&A%Y
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M3HJ?SAUJ\=BUO@:WJ<'[%[-WY^Z_EU',FBSV%,W]BX2!:T?W3*%'':OS*Q+
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MYFI9Q:,=ANSNTSH$,Y=()_SLS!-I2?I3I/?+7^GYE(NB?L-C6?)_!Q0:#?I
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MEG5%\$P:_>5WF^+L<KZQLKU.)49_?5'3F< 3QB-ZG8 >;E(A8$>G.->@562
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M%5Z-)LSQ^I)X74\O),J4F>;--$F]NZ>,+F?&[RR_1WR>&17S8Q84:"(I4F[
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M[&SD)YF%?#=BTG#&B4?M'4G^*ANO'2.VHQ]1ON<M-2(B'^/E9@UQ,6?5J#(
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MH<L[$--"&;.2%VXY<]IGPW[NQ:^L3T^\).Y@,#@;_OU7^9B)D'"*&>)]H@"
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MZ63WB2$WK@V4^CP!V>_BN<;95GAEUQ+F\&_'7X3QZ8S2HY=@DB@T=)7$OUF
MKA_JK=3W)@WUQD&I[VE(ZDA31X=JOZ>K_6ZQ?9I\PD::3IAV&\0F22=,NP1,
M*[26:A#3]I\\W54[G9ZJ#X>$:9L%2XC1?&/=\"G.T[_R:^'P6[PEOC[MYY"9
M,^FLU%->N[_GW<?"TF/KAA:T8EP+[Z8H&L\OV)ZM@P;KFA@KF^AZ553*#S@'
M%&42&R>$V'W7_+FOB[G6HD=O%Q4O.P\AH4FV4Z%(MZ;-JZQ"N_?"*'71W0/U
M2C3LX3VMUJB^3P>QGE;H(/;)LP)FA@S8Q__WD[=OE4:%$0EWGBVZ5]8?1#'<
MV3$EZ1)6:;"$F79+W_21> ;!YM8=A3-/"@%Q6Z5OJWY'7\=@C$W1$7K.A]D^
M.#/XR-?)#_AM.!$;.D5;C]WVY6PSK<Q'H/TCMFV+)T_$/0Y+!DNLQKGXV;92
MBI_2.1130[!AU0*^C41V1#>0C*U*KZ0+@X6S*O;0J4*[J4J"4+/,=ZV'4Z^M
M;U>'9"0=]M:*12Z>]U&L!!%]36"A2=11^07^$C\H?/7ZL)GB6DZ<C#5Q6F_<
ML3907(X6*V<*A0^O\V *XJV3LTH5MX+N_;;1IR-I-:0IM,T[%&GBYQSLN?R(
MP.5[#XC,/3Y4\):&_U<!RO11F^ZF2"*1TA?I7B\B&E0/(8G(RT%\@L7*L*@7
M>II*"XM&'5@LSBN13TQOU$:<IV8JAX%G:W5S?JSLR.@>5NE=<Y.Z(@>#!)XV
MPB3"7,#<PC@':3&W4QES^R4YAG-)<B6[DK7S-VE;SG,\W8;#MK_ 4+71OG8<
MEO7@5+_-7(YE-P35>P>#CWWJ/0T#"<8!Q@M%3F?*79Z]Y6%5,TX530=6-&U*
M#V\;Y)!M$[FN0VL)8UP6"J?C+4PA6;M[A::%$,6%;UGI233Z8TOOQ3N;!LE&
MYN8C:XT#9O[5,B>PC]>F^VPNPQ?*K]P"9+>_TO7.L/.G;7G1G]9@:%M]S6C9
M0V:UNB;\:VB-1JU!9Z1-1GW#&/7'-46Z+C_+N5?"NPW%-YUAH?CFD_?$PH@7
M3WWRWK,QSLOYW0S^8EQH/_QGX43+'\Q:!+SK)/SQG@41F+B'P$PJQ:+PO1-:
MKA\N@A-7X0PWT# K]]5*<O:5LUY;65%+61%J1PU4 3Z0\ADR/YF.BT_\Z <X
MHOL,!4[]N13UDP^Y,AL<)Z2$BQFL<[EIDJN9T*X%#V_A+"DE3 G;KE>2LX4(
M]=54FJJ<$SD'W6Z[)]7PBCJ,NZY37W)=1]\Q64?.5N_EK&J2$6G3=UV*&4B]
M3KMS!3.0&N5;>>GIV8\_4G=\/[+BG&TXTD;%V0TYY7IS3B8U,BDLM *'#RDF
MA)%F-((4&C%JC[HT0*0* S],)LR*G">V?D*XNIW^;D9X'%K*9"OVDLS;,B9R
M328:DF&IWL(HB/#:T-4;EGL_C,@COVI'@VPWV>X;LMV_!7X87KW=_L,+&.SG
M%B#J-]/Q]FX.2!AU?1AU_70G[+E,9A+V7-E6/_O85N?LX"-38;1TQI) BD"*
M0*I&G9WI!,H_37?!R*Y)PA)9;EU6S-*>SNB=N<C\W@_FV"T-*[\\*3O4(Q9=
MN2I(0>F*2=E;N791J(_MZ6F[16R"^'J]'#9?+)LF;I.\YC?>C&WWE<E5Z?/#
M<K[JN9CJZ3M44_%0[_'AV7^8^HO0].R'9_C*\JO'-G9CC%MUY2O]I1-#4GB:
M6WP9%^>.QIA!-4M,=^*JW(DKM!O>;K?3O#BFC=^9H1.>UF37:R ^&JF]45\=
M&LW=P:.F:U=IZPE5"54)50E5&T+50N_2':AJ68O9@G=TYPFD57X%4]_O&*R0
M;6_K?W:H[?4U=3 :$,[*(;*R6G_"6<)9PEG"V5)FM:1C%H$%@06!!8$%@85T
MS*I]*#,*73S7#V6K UG^>";SN4O7-%7O#=2^3D,2)9%,N3IWEEZO/T;C3KW3
M'LC(C@<_,EV9*@:/R(,+T8?3<R!?O5&/ U<(GC*PA)1"PM83U%'X^*>%HS&O
MXFF!&@HWE>8I#$-ML'A"BFJ'6^DX?#N6G[#WW!P@["7L)>P].)I7F(-W[!*+
M\]=$$!I?&Q80&I^; X3&A,:$QDT58A!"79M])(0Z-P<(H0BA"*$./B\:1ZC^
MD*-<XU9 5[JQ<+6VG-MA;BB3L;:E]0D0-(^(YA%)X(=(,2U"1D^0!A%)/P>G
M;!"1/CH[X$K=U8H&$574FPN_DT"#B,[/ TDC##2(B 81T2"B2^,0]6J](G6C
M043DD5^-HT&VFVSW#=EN&@9Q95NE042$4=<;""+LN2931=AS75NE0412L8-
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MT%U5?"!]-8]>PN+'F%DPO>2DP[N%90\?:A*\<4TP@N-%Z. 8= P^)/M>,XR
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M$&!$ N?.;,;@S! Q7L60J3.JH]K\!>SGW,$KM:EU1 \=W^K#-X-G;,44+H(
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M8<AS%];D'\+BYFIY2AGY&S:6:MQV[<^;0;>K]DMO=XLXF]A#[H+\!O7?PCJ
M8%$-EY3!E!@&D5+F#5X3%J]9M2S'M_9)*K&8FUH#I8\L?V?8&$X6NZN?WW*$
M0?2 0U^_3CYY_*[*PG0S,U<][.*)C\J;#7D-C:YJHY+:F:*5*336\_;B:7F/
M]I.9BOW8=R)F&#V\L=B07;%6FVG2'3^Y _XQ#K_SNL?--Y+39'714P>+ZC]Z
M/*1?_YY>OY /NW-=W\+C:;GD[FZ>MS5PMWUR?$=3#?C_8:_H.*O[;*Z0M&Y@
M<UNB,MLW!VS4!@:<#$HT #F[Q_X*Y7=-[&_SL6?[_L#6]H%YG9(FF_D(C\J!
MU8],-W\U+F[_*/K#B?B)A?/'G(F#M;3A6FPE$,.,^&V'*,P;$35GX85!%]]"
M2A?^%I\([J(-S0# 3=FO?V>_$'U/[_F(=G/E?/J"/DB([2#XHA^05MF_8^?E
M+W[T+P9O3Y1_]23QI7478(?&UI1E0^UW!ZK1+>FF(8QUD:W\<.:$_&<K9MR8
M9<T7MNV"4ZFPKOS6NFA7EUPJFHA:Z9^P!EX3N;'Z?E (^AZ-[ *7P8K'O\+/
M;1__5K".)07UB 9 Y<*5 XX2-3N9%:_MIT!7?[K4)I)W2V;FQ:?R^*Y/P<'A
M3D8LG-B*43A&8;B8B=\]X/&]B9EDAY JG=UQ2I^ ]SQ9709*0BPY+RDY=\1W
M@.-[MQE7XCE_AV@1)E>%W[FF]5<+N./C[ 3Q/![5P0_,?)NYF4)#'P#E&?]@
MKACS^B#QJSS9K%\<; 8N+?Y/Q ,[8S^ @R.W5%BK#"X@[B#]>8Z=C^*?<^M\
M;2XB_XWX-K9$=\UYR%XG_W@#F[>C*; :%LI%)PKX?VWDAO/H_;\78I_I4\>;
M&JS'*Q#3U9 ,R2^^<TG1VH->YI</2"OQ*[&"GM$V7KZ)MYD0-_1=QU;$YQ0N
M37/0+2]ZDY?RC870U4;!X<]YIN$OZMB,IE4B8X%^C>SS,$1O]_9F2 /DSY*4
MSS;<E#H8;C92ETG^Y%?O5M2+.=)M=[=S9!4!.KIZG),_B'RD'*0<I!P;:LQ(
M.4@Y2#G*E6.8Y<ZOL;N[[O3";K;PZ?[C1^WC_1'X))S@QC7BS$WK/B0AD"??
MA6.OZT3+?37D:)07-NO:*'^8.3H>L7/F"*E9SQ;Q:[--F*(SLV=WOX:!CJ.#
M7RHM9=![F4G\R,7.$MVY0FZ1,DG-G@K*9+QXVQ]Q9=))F4B92)D.4:8.*-.0
M*Y-6IDS[>=9'.P%=N6>-B0_E%YX*>27?Z9-\ZU,?]<E ]0>#%V][[0X:*)S*
M>1#:GU0UKI!;I"N2Z\H0=:5'NB(!MTA7)->5$>J*!KJB:Z7*0C'E$_#INQ/^
MI4P"AO<5<'AR&"F!&3'Y#I3D^Y[Z]$XVJC^$P[G6[N#I7&_W*=9%VD+:LD5;
MNB_>ZD +T!:C/2!M(6TA;=FB+;T7;PT %="63KLTCT*AWU.&?OG%1^;9RM)A
MKBW?N9$<8#JD-VVD:K9!'3;7%>ZCZ01X?8=EKNXDJO@^UL3O<!#=LUU%;BZ6
MN"U4I4%<OOMI\4;B2_DDE9P9LA.RV8E1<]WSSF@G*G=))CLAC:22G;@H.]%<
MS[=SVHG-K0]JV0G*=YSDN"<Z/(J&=/)%1^B41Z&HDX>B1F"<_F88[0%F8__6
MT]K:H<4+%+PEC;E<ZE?0F YHC#YH&R/4F,Z@W>^3QI#&D,9LUI@N:@Q0HXL:
MH_?;1G=SRN-7WJL%?HNM6];;&1VQA=%:XYB#7W/*]C^_X6#/W?..IF8(WXE$
MUW-X,HJMZ)VFA(O)Q+$<'/^YZIV%;53SG0,7>/7TO]B:5<'V-W$G5/AH>BW5
M$<T7YXP%O*F7Z3EQ1]XPXEVXQ#C2XG56WLXURJ]8-.5EN0I]!SYBNM9"M'(3
M"W+B1D6A V<UT?QMQJ*I;XO&5YM;4!4;JI:TH,H>1[,MJ.ZP.QVL_ QMITIZ
M49ZE[]0=3F"&=2W+6DXI9DR@TC'.)I>30O<\Y.\\8"'CO:K&S/6?N13 L4W,
MW0KC48N;VEME.PBKV<[/8FYCI@5H RVIJ.T41@NT]FA':X2S-ZO8"8B-H!__
MGLTL7\Q4?LWEWG7@VR_>BA'ML>DX<WUXXAUV).?:25N,P/N1*3QR)T'86&MW
MAM1O!#:7JLQ9=>7EF^>I$[$66F_<Q7-@SF] *<@DD4DBD[3.K/^+^PVO^Y!7
MM]$[T4_YZO>9IH:^'9(:(JBY'F,W:O?[9.O(UEW?/K^SF>EX(/17O]-[^#66
M6RQ,]^KW^L"[E_SKK-U+4ORJZL$3SIT=YW1]9_#N1H#N[O$Q8(_Q!>BKWNDG
M,(N.%SJ6PLOFSFXN;L\,R%;O)R+XUU9[]C4SW-8L3&K:O\7W$>LU.M?'!5FK
M,RKT*#R%82+NE!^_LZ'&_1ETC?4VM6>,C@HC&P^=,9JQK%_X1/ ]AA$_//L/
M4W\1PF,^\! #VSI%M' 19]?PT([:[1BJ/BI.AI1.VD_D Y&I(= ]NZ 3Z+YX
M^S?I&$-XNP_>KD:X;H#>@=;<R/8B]":A^3ARG22Q> [K#(!LO'BK#]M:C_!6
M#L$E#"#NU.;.,)?W)""0GV-DS,B8$7<V5:R-JLPB(6LF#\MNU)K)UO#O.C-"
MOXE+0O(UB:$8U.EH?:,61@KBBSC3+>+M'FF;YEHNQK$C;O["3]XW?L7WM\ /
MPZ/'B;:T7-R5P='5KM%5NYK16$2)C,HU&A5"3Q)T21(T!)R2Y5]ZM3$TK 6B
M9\W!;&UG_+;;:?<'!)UR2#&9<R)^>:[E%FVZI PA;2#BWRCQ1;R7;)$\'+E1
M=:"K,:?LA;UW*H3*<2G92L2GB,X^#/FE=BYDH!7'RO"P2!@NF/U^$0"%13R&
MAV[";)O.U-3)G.KH=@>JKG>H=%8."=V[A0+!XA58YMN0<5DOH=PB(AZ6X^@W
MGN-(,/,2TASZH#WH$W#*(<ADT8GXE.:0G"&D#43\&R4^I3EDX\B-JL-Y[GO(
M,;#CS,SXZ <3YISQ&H@,O>ZE4PA9DJY5.F'>I,62@D&CRB,(;A'C]TFL-#>'
M.XX=Q>9U$:RB1S)G7H8#M=]@SY*K[*%\J=D8 NH+QP'2!HGNIE1%X%K\N$(4
M/BR9,V@\F5,"R!*G<XP^'$X)CB66;X($XDB1(\.= Y-N'1=DX!+I#7&$.+*#
M(_7"XV3*2'%DY,AY+M)LRS#9_F+L,L5H7WO09/O@&4,[5Q9V<SSK9E@C;QI\
M9Y?*;2P[968JRY)-H[1VLO3*^%>Q?WXC+#R&/W%6GNZ1M3(N?Z+-'I>$U(ZA
MJ\-A<_W0&@*4ZG!"]HD _M8!_J;Q6]9;1X3,S:>RCCEV[LP9K/+$54>>V3>$
MS 0,Q)ZF+B\1.I2B \ZQ3W;7"IG5<GZVIHX-RWLM($#77KP=MKM__Q4_2;90
M&LY)JFQD"V5UDLMS8F0'JWO)6<]8/V;XZI,7!8X7.M8_37=Q#E]8VQK$,GH=
M51_!__<U<I:E%>GJZ<0397MO/*,8GV]-W&V3&<7C5<C?#&LDO2FUEE$LA6IR
MMN3E7S&C>#P6WI)'MBE8V6G:)<N8;&DSBKK:[_?4;D^>"4ODBLEEGPC@904(
M GC9+\P1MLN7DVQ\IF(&YN7+2>J#=J^Y, MA^W5A.T'+]4%+/E])T-)T0E-_
M\7;0'AV8T"1#2H:4#*G<AG0MXTF6],@IT?+XVWBW8S[>[9CG4Z*Z=#E173?4
MCC90NPV6]M\LQ@@)3@2X1,*;3HG^&J&,P6]MY^EMPK\OBQF#<U\] F3WVVOW
M!R]S>WAP9BQ4OK!GY;L_,[UU?<VNL(FWKEF"(B$;#+&!&KD+F]F*XRG1E,'2
M0;<47RBR\H@3EU=_C$06=.P_P7\#EGXL\I7Y(K"F8 ^4^@D O=MT9" _*/JW
MP _#+98';,90&_&^./B/CE8OCC\:]=1^24F%(G:J^!-X]6SF>S%MHZD9*<\,
MR)=0%\C'9G/77S(6JHKM!,R*_ #^"38/EQTNW @WE'X!'L#9 6*)C\=_.XDY
MY 3';SVQ($0& .]^L'DDLM:X1;&"J0F?Y1P'TBM/+(SPSFS$@EFHF"'_RSSP
M)_ L?&"86;:?N6-;?/B8 ;58]OL.K!D( <_@7Q=+$U(%.\_2IJW<Y7?FA.'"
MA)TEN\Q)I[J/K-6?2MY@LFD? >OT!FJ_-RP1KYRF9E5P@^"-F86L=F8S9CMF
MQ-PE9SNS504^#C(6,U1\VLI00V$_\=^<#7^K[V 4IJ3<N:YOP0KL<N)_$&_;
M[2QP/CPLY\);B'_Y(5:ES"2RU#W8HNC;_82.VC<&:D\K3G5O'V3UM>U LX8L
M^&ZDB>,M3.&BE/FQ: A8D'VK;LS+'-LM"SE-.^B6*)^!G4V#9"-S\Y&UQ@$S
M_VJ9$]C':]-]-I>@Q+]RUS:[_96,=4;:G[;E17\RP[#-H3UIV;9MM;ICHP=/
M&=JM_L0<#,VQT>F.!S5]HQKL.K)?<$K>/("U?8ZCZBU3A-4%_B@V:*XR,9T
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MS?[]W@^C+W[T+P9OMWQ@^7^S1ROQI:_ ].!A:GJQ(IPA%)NW%H;>+CH[J;E
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M2["/)H!+S2"C:F-(\FNJ^#6%V5S%RV!H*IM-8 \,51_(/RKDEL=]4XO>V^8
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MBKYD#L1139?4#*([8LTZ,-L:@V<<F,2R?G/AC7>>_2&QKXT>P@VU,QBHH]&
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M9,6@.\ >P![ 'L!>D["7B4.?#GO%J22GP)XQ1LI,08IB .J)(4& >H!Z@'J
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M**3!**3^DQ44C9C,HC[!SA6-2+W8Q3HYW:3LYIX;?L'NFU>5M2F27#88H?*
M3)CDW<.0)0R/$8L[)[9[&V*\L7R1T20S.:9FE&"^)E)0-$LF>D[-Q]R\'E]@
M_L/VXT=\6&\=]Q5CIMKOF&;_"].2J3J]032D*C*:3L5)]RW28Z"F +&'0&Q
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M39R=GIX/HD)-H%)12KA"/RPP7I=VD"PHLP*FCBB77!7)'OI0E)V6FP[$?SN
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ME6QT5@U5*%FE,ZUGH_9%4\5(S2M;2V:C;O"RR;WL> &#BMJR&VU=N?0Y]Y_
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MQE<@'F(R&T25I/3L3_N 3CFV-EZ!%? P-_H4T%00TII#%+<JM=>8\[(>^:\
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M2CQ,I 9?-3%-]3YG,)#5$NFWM'!IK_G<F^"Q\V<("2@\Z"6%0H*JTNI#Z3D
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M2B4M4\U,]L_&R%Y1HT:6Z";URZSW50'V;"QF3S$TS/?<M8=&SC1F@)@?H"
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M7U4&(/)V&F4FY.<>:[O"5%<F>2^4'%_.<B;TEUXH,NZL<R:WN39J<ZLF5PJ
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MN,UNDU 25$64#:TA-2(LNO\=^4XP<VQ8/"LW*17R7!,H@]"QXS@/?PV7HH2
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M)>G,O 4WP-@!SL\7.^^'""GJS5,XDG%(V'.$7V&2_%>*/J?W,,A1"J/K/#_
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M6Q,E;'F5H"65)=4O''3TW7'Q2:;E9KI *4MS/ '_UW=OOOON'=@'&7@F_$[
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MF94Z"R>'51PK5'=-<E;+)0 [(@(]-7_!0OAP3&4 -#+4]A0'4W5I?H7Q]JF
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ME#N=<UC/RT&TPT$%8T X \8:5+QM+PYF> &K9LHZ[U]?@5*&K(&((L(TC]N
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M84;Z5UYA6O$S3&$^XBU;*S%K.6K'Q.U;MD1<),[RV28(GV+X3)\@P:P(XA1
MVBN.@H[G^"BF18A]/%SJP[@[][!+W=[CV>&8@A^0&,Z8.77V(HZ*5X]8QB T
MSJ5JHV0GU>>8LL/D'W#V4IV>_R88>O*J5!&YCO2K+CU.T1)'EH-+$9/&R&)"
M7F]NLS@-XWV07*?DJN(!<]=*>#7E8,=&U3FZ>(G__GO_[-, Y0Z[U=7M,A%M
MCT:5%* 2@[X'%(+@R87>[0$JRXQ3B9+"2.DWIU[-&$QH H2A$Y_^XT)]N@;Q
M&)>N-+M(.$<[-!'%>W_&2UBW_DP93&D F*$3?_YAJ?XL0SS*GTO-+A+.\?Z,
M1?'7G^GID&.7;O"8Q QJ/.T[]AE\06D$?J!Y8YZ<NXQ&W<S+6S2]5(2-?9V=
ML2JXNZ$J['<CIR]L)@Y+X@SZDG5 UWW"U_IU<U-K(6<_3I3'[KSK^XE';6OZ
MX$ *>O)0]4E#ZYS!'._[[@L4_OZ$D@A;P^7?#W'Q\A$5T.2X=8C2B!9"O90M
M%\&N6 '&"Q!FWAVV*N*&]+1HE'US#S,\Z:SN8 3ACG1X/D?I,\R*&/]XB[\(
MLPQ&E+MF/5I]PH8)'+J,G&3E,"' "F2E&.3.3,@!]D(0D!-)?$C+,48>C5+\
MHE"6I]D2XDH&( D!2BD %6-\ L \0TZ,1CM7M=ISM-NAE(KP"RKB='M':NIJ
MW?!WDC"?\SI(NFA^3!BQF'("GBDOD%%F?LQT0_@@1:5YBD52@X%Y N,"[A10
MT%E"7>?Y 487>)>8;EE:S?U3@&7^"#_3/UD:$7;P1U2E*-:G+1!3(4Y 3EF[
M'-PO07* LXSMF7"V,S2J)38VO(\/(1X:_9V+X=S7!K$G[&@-2 K5VT,:3[XY
M"9]@=$C@>D/'?!;D,,*.0C9+=-&TRC*L05KK/#][J3[#D\=6GX,L>B#SCM8^
MQA[3$5L>6T(X6,1PT<C1$F4,*&<@BP=D^4C2BOQ!47R0"@E^HV+ZLJNR;G#(
M&::OQKB2^>Q*90V]*AZ>X(<@^QT6ZPT.]WA^L;E8KH?@50$P-\#8 <%O[#/#
MVQB'\?L@C1*8:>[!V[YJ^DSBB)2;URV$#>!\?-@E]V@?#:C&,TW7GI[(:K;P
MIL21R$F+M'/M-"]I,C2$FF=AO5\WGP5:R#GJPW-Y?WOKQ_S>AP!24(V'VN8&
M+NC/>Y9RBQ5!^C*K=BEM_YZYEF4Z#D(>INY1Y^]69:,^9?BDV*2ATWE:VXMQ
MZ3>T;WYSO&Y=]1;UU&R[V]2W*<0O]1X;KZ4^].PH*R4O7>-G2.CKWIEU$C"]
M->D@Z.8.C)U "6Y@C]GYL(0?A 4I:<M+".IY($+SA(N%^R>GDLMW]J NNOX"
M:+C7JNBU.-I'M6B.[\ YQ,-]?]6RMVKNJ7^;H-S25U5-TTM!]&@?9R<F3#X.
M'B9JO5/+OJEV@D?K8E2IZ_U#7)"#V.LTBI_CZ! DJENGGB^;M5UO)>:@9CIA
M0]Z-5XSF;WC?CP(:5)!W&D]D9:]E95O99YF9]J]Q\70'$SI#Y$_Q_@%=8J<K
M7M0W7T9D+8'3S^9K=11%3+M<2$6I"\*OQ^T(>R#S!P\(, FL[1[/,>5#4@1I
MD6LN25N^:;A,.:+D9'DI<?%A_=BM>-2O%K^47,\+*UF,7_,YDC<Y$M6+JYWU
MGACIR N>.A%+%P\R40>9(70MS7AXDCPXC$O7M<^QJKS%H/T*B/&9RR$&,TNZ
M$DMNXA1>%W"G=7]D@]N(?)K1W!WXHD(&S4 "#9$.4/%\R<ZR9U/(/GK+MY]D
M>M/Q,'UYC_*8' 4]-+TIYZFQM!%'CI*IBQ**DHA7*/N41C#[3%[[IEO^>%#K
M[G* THC+ME[*#FH10@P+/6)F'#Q9=BA"A?04YS<LXDY4O#S'O(#,3+QR';O)
MY:5_5]MM!K>T)S-+DJ3I\>N-]%B#<F=/'2_BO,CBQP,-K/B+-(@I[XYMLC3<
M\=D3P<E^7-1C#H1\ '$!^3L"M &A]-(('(B4 +(7MI$D)R;!!?5A8^_ V) C
M1%^)876]3>LTK?&G$[ZI@$=2X5.E7&4^.*"2D0/&VK,Q*IUXM2[+!TH!IUZR
M9"B$,,JOL$>1-5J0-A2JM6H9)C9BAAPB[N;]&&,*2,0!>9 <Q4E/EC/*,")M
MC7H/6=+ BK #@E_3!T?G?PUM!5?8@H(ME$9YF\$0D@K<%\&+>H>3\8Q,DYE&
M,G:3=T:WLH]T*QO*6]Y VO(&3+#Z.F8O9 ,1%LZ')8LU$T)6$3-K[(-W^=D#
M8C0QQD]8BG(NPTQV\4&]0YH:,=,G-PK$W3QW(HQ!@80]<M[5,IJ8*.'N@VUJ
MX8FT53M%K?"^Q^;LUWCC>P^S9[Q"TSO#UB,\LIR2*B/'BWI^HA:G2CU/)BVN
MI(UQL]:2GHH7A:<X*6;)<PQ#QENT<Z'<Q9_(49 0P$)2L1<K"-FD5\,K@]<R
M;)T[ J&6VB:UE E<6%'+=!-O[4V-ZJR[I $F\M@>D !,C*UD"FZ'QJ:VNKM.
M6;>9Z_0\V,=%D+!KECN8XUA!H];5H3AD4&RV[B!6:HX%@-$JEYK0I>M#D1<!
M;4.D>;8PC1R&:TK'<CE9C@J9R90>,JEYJ1^0<;G!!IO7ADI.YW^ZC\XJV4%
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MWV)NKG7@,UG<M2F60ZNV)Z;]=>=@Y%4Z7?,FQ#HP5)TP:QOIK\@H-<)M;E@
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MW-P1]Y&)1&LFHTHH$)12^1%L31@-,HC2C TD[K -$BGJ2YE<)5@M#"VL9.*
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MD:A]8.I'G+B%V3:-CN2?ZQWWW<2.>2]I\_NT/:SL[:H?*?CU-'P!PD8$KX.
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M?"FHGTTW[IO!*I'_F4+[99"Z5!;8JE3@M%O\V2#=)4U50$5".$=6G7(U40_
MJ62P;:&RKC%'?V7I"8Z@V=9^@Z(?&83+"Y>D.%Z:[AQ1@Z1(.1N.Z2#-4D%$
MI6L@I?"^-]MQHDA@*VMB<2P':NPK%=9]R;04U ^#-/,;:-2:#L<7'T>%*GM$
M"15;3('^-*I6&-#YXIT<R]%"E;X]%19X39']K%Z_GM[M27<1X13]+Z/;NG']
M:PZF\I,M[KU,9^$% X+TN%?ZI?JV=*?:_UNT8C^'SNR#"]H5X4!$1=L[I&!>
MF.V?;@!FKND'Q\QL<[\!9E+-7U)<+S58]ZTW.F(Q^@[QZ=[[QA[>Z!7G*O2I
M O19T/Z5Y6-_NGS,C)[ 6-GN2)9HATV/P"QK*&>0<'"#?-O#VWTJ2P$S<XK
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M@14P=>?'[2[\V-L$=2X7?=N+O7_(F99&1U1*F-\E'?4;"9I>.P!$1P6A24$
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MRLQ#N"%2!V_-/"'7S+.C*58\1L#T#'D)I "Q'AP],V]@*@QCH3"?PV/ULW%
MRH10B6!8:# ;6H5 )KR.U 8$\JQY,X\*2=3J8D '4:Y!4O/)Q?D.HNZ ;%0U
M:1+_S9$U.-5> ;+5>0.#*%B@ $6A=)(T$?K]X W'2C !F4<II!]&^:R"M#0]
M+0704$M(F9JL353D2'X8D:PKCZ,LX35%_=/@35()!5"8;<TA55XWID]53A2
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MD?[XUW"SL;S=OJ!L[&V:V &5S6#7**Q5G&Z?HE4%N.YSF%0^2^PPL45/F)0
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M3:.): @=S?,4B3\D)K24A([0UWN7+@-Z(+Y_1Y6+@MD($I1+WBFD%E= PO]
MBSLJ5ZZ-#V1A1D65ZM3UQ%W<H!?DD"W[YO:5:3?QND(MC*PE3-TC2QP\ 'MO
M9K_2MDY3:@G1/[BK/4!"'*L<3<=Z)/4.V6/L=>@'=*=X#]AZQ@Z= 62):@AU
M/I<9%7@WI,>F358N6P1EDRN@+"6C=R&[T47F!WLFWT=E1*$"<_*$Z!EE([H1
M7C"U17QJ7+)?H/:*L%1*T]>Q=L5;9OK#I;RL\18V70FB"K5*)"SX.62[NJ'*
M."35W3I,5BLONFJP;(KF*W!$3F_248D!D+^"@+**ZJEVMWK?"+6 7)\X>&%%
MWMW84)UZOWHDW#)=$/\ D&JL>,#>80//^9,BW[MY0[,')8A+:=HI\H+U%28/
M>,/><=.S]YIX6^)%!A0PMQ1 L:U4\J+;(RSA5(1*6]S7Z;XROB#Y\LW&D)*T
M*VN'O&N/;)]LC*B1]/ (%*QR FVMQ QM0WJKLWPTH><JB@V'T V0M[6\8 <7
M*0#!MN9T/!Y$:HJ_[865T2!ON9IB=R<)B[K_#X+=X#?Z%_8D)9.%#";=N:];
M%HS"/./JM1U>$K'0[B%5N]WT+.%:'4G JMST!&*YHY+4'NO#RRN&;,]F)ISI
M^<7*#&DB=AG@>87F[G'!:Q6!7P1-S\J4W^D-_ &F)PDW]\/(XIO;](8W2FKB
MX9/%N-RGR=-WS,SI;*XL(-YSCJ;A"<GP=XI:T3UZ;N%0&M[03@I*X=<X#J/R
MA!0#8)1X@FTCW]$<0)L]X?,,13/=(6J$%1KFP7/2S#:L6D0UFQ"F/I2]E\FS
MJH\E<%P91WQ4M.5BFXTYY"E1H_I4*)LU\:@<]='"*I=3P?!FG@6F+N'=/##K
MX7NOOG1*Z2FE-1.$2='<>D5^10(#..<#0K0GV1U"+&O+@Z"<4(L3X1=HX$#A
MY_KR-^*!"=7X#HZ HS^XICN"U3W;:WW9V=00U1()L5PBULB:B\O,"I#*"<N.
MH'6%;U^M#=U:C)>_T?&_TVWH97XFM<"U-'7,\+OKI=<\RM,5<A&U!?V4R4=$
MM4* $0OWN&>OQ_2@F-BV%\+2"AH-(]<B*1&9:\OS=E2K1:F2KUOLI8@+![H)
MT=*Q6H6,3#;L71^R&I5D=,PCO:HQ8R[+A!^]3<:%$J?N=[$L,1FJ<K&YV0%0
M/,1=/,17ZQ5OPLT-M<BH,HMO_!*9*PU&:#ZC \@DMXHXP6[E3(U<Z9D%2\V.
M+Q:.0W[0NR6ZV5O=="-/J)P$UVN6)'[OPE4!G+;F<S>Z(>_/"\EC]I"$U#Y)
MJ7'[.7^[JML;U42T1.U2)<C*^#Y0)IW_"#WL+[ -2RD0)J6E>1#%TP^P'46V
M>3OX+$H(:)7Q24COX.R"#4_%*:?1S0R@235E%#2U"8QN$E+] 0^^[,SRD^O9
M5DNJ.TL6*#X51%1I>>$TAAH"6O<C'UTF0Z&23.=>3Y%)DMKE,#W10$R<B=!6
M,CW!0%PEU>$UI!P#Z,%$RL]/T],*P)NQS"PR/4= T+"L1&IH#<5JKQ&D]K8S
ME*9@$*AJK[<I:)=F!CT+*RT!UP;OL63F7A1W$16IKF,'%4=+N;WUTH_JM5)X
MP3V5IO>:DH*QRIG- 3,S# D$&/ Y(\7NHYE11PVQ@[UE<3#-3-Q0O'/SSYL<
M0#,#7Z4 K'SVYJF#9GHYX/M7*.J!PS8>&6JB74S/_VMJ+-<$39F>_R,%GVR,
M'0=3N6?NE*\B@!A-GCBE?#>;@F :L]MB?E015MW$G!^*S'3Y_>D.T6E;#O,X
MA0'Q=@=[=$Z*]ZYL:X*6^>A;9+OB6786<,TR"[$;4N-_?PN@IG[S(.MBJGT)
M*X_:F$P6_QW*]'60HM^7F2>.K&,'EY_W@:D&!31T7_#Z1ICRB%P)#MJ[4XO;
MZ8"K>K<P>E]0,S=M0X2W25!Y$JB&HG:X,4!(;X"0TL4;2K!'"]A67CN'\G:O
M#D[H83240G\M0 TRE5*<+\STZK6(<]Y.-SWV0BF8Q9<\#J'Z$XL$EM,#3TM<
MD6,W728;-/-OC=TG .)]\XF(L*XC=^=8;2:5DC#ROR&005I+2DLNDMK+>F\N
MX#DIR8 K,Z%B.II7*#/VHT>H7@QVCX[E!A,W:J<;5>>17"TQTMW--SI.F\]M
M3Z:[>="-+7-Y%2#6B;;XU0-V"BVCT GW383J@$(GW#,+:_^S_97IH 6WNTA>
M\-4X%=L9OROD\C$BS<2XC&0G\SL\M!K-ZYA4-_M424$$$-E.YMG\<"B@,[IH
MN[G75J\*]V"9&7@+DO$JU(0BOPTOE-H8Q&,MSOUZ9H:;*0.N[%CG )H90*H2
MP.9&(G?[C<JR6EG&UQ&.EYF)",KPVE\^.5[JSY&<6_DD+9@RIT.+67]]E;0:
M9TXM?L=[](,ZG?8E1LZ-FLDL#,2NPC7)\52G\PS$L]B/S<%3IP /P9N;H0<%
MGLH_JM.$_92_IN@=/W-QY-3;TET^ZE([=H/3KM/Q@_8*N3:N+%T.?=UM.$HO
MGGEEYR!3+>TKI;YV=DG8UJ.U$P[3KOY>JG;;_O,[XM%9^Z'#)K[O$R7,424-
M/34)'::?'EF'YKEGT:N;':^2;WMX&Z<P9'X.\0B"27<XWZ2!#VOSD?FQS_HJ
M93]1,'_QH:2D\O^&]&/D-=@E%12D.*K0$ _@BK9BQ"3Y3'9@VK]<O%)G'05)
MCN(VR>AIR]JCTI,S[>HCS:$P12F.)YOH:%'/.)QPE]H37"&UAE"'<X%62*TD
M(R53?[,<UH;Q!7E^U#\()#?%'^O&LYE ]$ *_*M=]E\4"44A5=5G#*R>;CTA
M':M0P46S5UH@X<[OJW) $.'%'$157N'-0>1V[%#*]4KHQA)$AU:RM^(L))4'
M]2 *]2K<G\.JVBMBLM9CEJ_?.YS-6'YI(=(7KZ$D^,%PE 'PPNQD,RB I<X5
M#IB9$@<^)0"N,AX_,4P+..^"3/"K\(-RT,RT>*5 4^;W;C.DQU1TRU]5>)B/
MF0%E\AN\\O&-AU68F3XO#UOI*RH/!M!@MV@,!OB& A; _H@\AA=QDW!7;%/0
M;K 3L@"/W"_(A00H&:L7@0'-9J*C9I/EN53<&0-%O$'<JK6D=#B-?T=XM::C
M35Z09ZW0MY 9Q]-EQ- T#/S <A>4R0;3E!U!RJ5/Y2>.5F)",GFA4L&LW#G9
M"TM [#_7Q*$:QY>84=,1M#0L1!MV8_1V+%(RV+%RS2BJ7T1F:$'_C?V91;,A
M7JD$LIA2Y'7,^V!9(#,Z^E!+W;>CC2_S)E-.H_,;>NWT2"GZ0WD4@$ DM>4X
MD*W%]YX:GDVU-_=0JK\2]2E6&B*;LF<[][TIS^_J2;EQ&31K#<(6DQ [KCQ>
M:/=G_LATWXOEL"OC[:OMA/3"P5Q"UY9CA\Z^I<Q2QZVJ+9[Z>_M2/F,-%M;$
M#?""\8%?T!.R0R]*/CC@F6RV8; OMY[;I/MF.^+FF*(!=5B?#5G-NWC:A^=!
M-$A753@;U='8ID(<&03?75;U]>F[>!"A(*$.YM)X#CIYOZ7*D.P0B@:>1@<;
MG/\*(MWMMH+&T]*[*$OK!/3'U:Z8 #0ZM%4V=.#X9*_1(G30=-EP*L*QJFV-
M//I,M%X35"^?Z>&L+6\XHDDG#<4WIN-\J5VS[*$ZE'A;85.%"%E7ID?A-H&M
MQ*CF+D:S8_@40'9\EQI*+X[>'V(/!5&"YV9&P[3F45&W&KFVT2T\7@"B;/;_
MPO[GV?+1O_Y_4$L#!!0    ( (Z!85*I=K[7"B<   #= 0 3    87)V;BUE
M>#$P,S1?-3DP+FAT;>T]:5/CR)+?-V+_0SVFYPW$&F'YPH:>CG!SS+"O&PA@
MIN/%QL9&62IC3<N2GPYHOU^_F56ERY9MV8 MFYJ(:<#6D969E5?E\?%OYS=G
M#_^\O2"_/WS]0F[_^/SEZHSL'1X=?:N?'1V=/YR++QI:52</'G5\*[!<A]I'
M1Q?7>V1O$ 2CDZ.CY^=G[;FNN=[CT</=T2 8VHTCVW5]IIF!N??I/__C(W[&
M?S)JXL_ "FP&OU#OR3ED/_1JO?%_S4Y5@^O@VZ/HZX]'T0U_.SPDU[^1,]=Y
M8E[ //+4U*I:36M6R>$A7M!SS3'\_(^/(^('8YO]NA>P'\$AM:U'Y\2S'@?!
MZ9!ZCY9SV'.#P!V>5$?Q)X$[XG_R.RS'9$YP4OWYM.\ZP>$SPWM/>JYMB@]\
MZ]_L1*_!Y?S//AU:]OCDP1HRGURS9W+G#JDC+T5 3AS7&U);/#Q '/;A _C4
M8>*J)^I9%-Y(Y(5[GRY^#*R>%1"]JM4;'X]&GUY]57.AY@O$._<^_=WI^:/3
MV2 8\%#F;0]F/^+GF768S' ]BEQ]$@)\GFW!W7N?+J\N'WXGW:\7U^?P_P-Y
MN"%?+KKW%^3C$3[BTVR4_!7Z@=4?;Y8N*P%QK+4Z&Z3-P^]7]V06WC.$2X,8
MWT[V@P$C?_^I7:M53R65NH\>8T-8V^+;^8WZZ0&Q?,*9FIG$<@*74)^X?1(,
MX/-&," F'>/?_TV=D'KC"JE5:SKIC0EU3-)CP3-C3L0C]V=7%]=G%^2V>_</
M<G[QY\67FUN^J+.;N]N;N^[#U<WU8L JA*+8<Y@16$88 +X<N-XUOA-@W)'D
M73*@3Y;S2*P H>U;!B,T($UR;UC,@3]NJ?>]P@GU.WUB3B7SQ&JKJ>MYZ/L"
MB[)=SRR.O0K'0X3]NS^OKKOWY.;V0BSVOD*NKL^T(FON'WT_HJ3KP:JH#[<Y
MAH:(.&<V?:8>RUL[)2//<@QK1&TRLBFL&NC4"WW8T+Z?AP[]HQ^.,G!P+F\W
M?SY%*7 X$%#I-=B=J'4L@]IR?\'VV?OD!Q^/X F?R"4H.V]Y]#XPAR['F@X9
MNJ8%Y!4+YWP)"S, . I??F'49S$7X@LC"G*RX ?BG83]8  :L#@^Q2.TYP*@
MDJ=)#;E:;^>!? ,Z!RABBU<MQ1=  MB))KP3=@L^^=+R_(!T\4/<H@3V6G8!
M&> EX/BK21%RL2^_PG:LU6<#//&2)2'NAQX\TI-83T"_!Z4!@+P0]GLV"MBP
M!\]OS%[ Y*M>:04/ \M[\0*^4L\8$%WP2R>7Q;.O65:0S%G I8M?O'0%$<O7
M=2[)J[DL-/&FXHO0A)H6_S[ @[/;!V&86E:67RNY[%;)(V$EWN-3J!$"T[91
M(CTQ>TP\UF<>:CA &B"7@>P 6'(4P%*[7%.VT5O91M]^O[@#,ZB(YIPG]I$1
M1A0T&4 &I.>7<DY\'EBPD\'$ 4[HA[9- "*T(>!VUN\#WYSB[_GT5<3<##&?
M+7^ 5.0B9)PB)A<K0&DDY)CX+$!J@D 0.WT.)5\1K^^9OM<WWRKD 8E\>7-7
MP'-9L&?1A^&:$"2X^^R?O!,7= E"91'Z(MKI6>]$@FJS?G!2;_%U1]B?15;.
M:GN?8NWKQY9)QAR(G:2,'2+,$%UPA" XNC9IJ]_G4GQ(3981X2>"$J;U1#C^
M?]U#H/?@HX#V;+"*@+68]^M>=0_<!=OV1]2 )\=_CZAI1G]'JQ*W'*+E0$?P
MANB74Q ]9C  1@">X6_P\!^3/,DWHW<4/22Z5&NV?SX%-1.P0WPWTN;9HZ.]
MEW!/PAV+. ! =[V3GV@8N,6YP69! .N7J.(O+[A#:A,[Y.-18"Y"45U#Q[,4
M&%IB_[T$F7NS-]'\K9R*V?$7?J;&]T?/#1WS,+V,C2R)'J3$<S[==YCE,P2=
M099<$N;+57E;E?\'U]RC!^,Z1-?T?7H@XA^1U6,E 0;4H![S ^[H@9#T&#4K
MD6E;2>O225K!/Q[^@R(3?H(T+4:LF#0SB<=5B-[4ZB &\]3N9M1=;'18POUS
MGQWPM25> 6TV&7GNB'G!F-BN(1SGH%A4$;!L,M_PK)X(,RU2F-&A1S?2C#0(
MJ#& F]%N!2IF7/,%#[N54,M'Q0XY>4@,*W] P=&Q.?/T/7>86&!9Y3ORV-#R
M@0P1!H"1TA@@GT/+1N5)FF2_('S)+1,05A)7+'J=*T)YT9).R+YU0.@("//#
M&L(58.,?5]K'=:"7(W2]_Z\0;80^ ]-?WMWG<84^!BJ1O,G[^7;P!T#X^%)^
MT<BF#IDD 5RZ:&7W>'T(0'0/]8B2RU!.!$!X1!66+# _@:-3P, 4"O1JI=;H
MS,6!+\(HZT5";14DR(#/ BQD$="I-)JMN>L/>,!HO<NOK[)\$=E:L/JYB@(8
M!#DD#A'K31%AK4P@K59IU6,*Q;B;^^@WW5Q%?(LII9A@NU%$B>;%.)=[(T@]
ME-/W:*46>6-ZXSYER"(BQQ4\@V#4LRU0/O M4.C),J6DE2J_IC6TW[2,RI\D
M9KUR7&TJ8JY"S+F1O3G&S>L$$# QQ(M>.J*/[+ 'ML?W0]H'8_2$VL]T[)].
M^)S"-%O:MY5FN,A;V"OJZ78Z6KV1]74],!]'%!Y5V\LZ=1..;TO3:^+.%Z1P
MI&U(_#N+=_Q@@S;D1VOX2'S/^'7O<5RO]P/]WT^A_YVSEZ[]-7K<(SR=Y]<]
MQ'Z /S(8:E='/T[E4>MQ"W[?F^,Z36"W#4XSV-.2 2($^JYMF:2J'3=' 4D8
M/9^Q&Q$7%W3"%M%@1L"Q/4&4,[@K],;D-Q>TLC'I=^G1U:O2)&.?GK,G9KLC
M?A1TEIR;I[!\)+@ZWH.2'/6VIO.MNB0=$*^+B;!*K'"IC3#IO4[@_+7WP<QL
M"W+V()( #O5.JT4(&0U [=6UXW93J[8;U4Q8L$]_I+]L35%IEG-:IF#O<N[P
M)F774JKR\_(F3Y%KP2R*K:(D)T#/MUC;C=7\O#4;+\V5'I#[VBG;_J463XSC
MU6#DF1JKV+Y/*9>$)T[(O(DBC\DR09$[]$JCU2YD0N;R4R%*^&'/9_\*X7Z>
M5&"&!@^X%7IK9D6%[IA)K@T=%55JK4;9@,JCY4$A8DJQ4.12$4@I1+/-2Z*5
M[F^56'P)X8&28S4@WTR'8<BED"SC,K#(E=V19]F%^"R2I<O+R7KE.!^3Q>3D
M$MN&Z^9=WC7')=XU,UFID,+OO.6NB<V"2];S4FD U3>R##J5=GL]',\CSKO,
M\;D&5DDX/N*F59E^I?M6O.VMMI=,(I[>6_KK[JTZ_P^-PFKEN-HN]/"7;J[=
MM\)6-'!V>'>M=)=>HBV9R8$KF>^4R0L8T"=&V _##GT+?@M]%I\]R30!7+9^
M?.J3OO4C"#WF5PCXPM9()./W0\^Q\&,N@UQ>PU"R]8Z8YV,Q;S";B3<#&)=-
M<=JRY123/OFY!V59TU0VRS+")TG4B9FN:YJR%IM,)+N49<6Y53 E@_$A+KG)
M9AMDZF[ROLI+41#?I _'4Y]\3G^21'F38*+X)G'NTY]RYV7JT]BDX;Z"_*)D
M")Z$4R\IG%'2?9%])C5$C^75467JK+)%53QIP8S9):J:6O*=P)*^9?+Z9"SE
MR61$) \GO3#29/ )%H?&B7P3:BQW>ZI<\I(EUJI<\G>82]Y3N>1OETO>)0Z\
M.YU>]D7C2>2F*01ZDEH.?\B4M-?((I]>RB7_;[5RK55.Z5>'8'$R>S8@LD&-
M#M0L6,J%1N!<5LDQ8.2MR#!&Z'GB!-0/>W\!/R&_4)E8ODS:ZYEM]?N8?_Z9
M@6<F6RQDTUYG%+?#.R9N_BVT3(JY*/"Y8QF\@X9,_0'N+IJFGGWH5#)])G$E
MADA8'2:SP0;R1#1K1>0"'J5/C@7JI.>Y[I 8@%@TLQQA(X&GC?618-109TPB
MES9C[? O/ LL]8 _#1WU'P:8X#PTB)[YLX5ELUAH:8H2@54ACJTT6YACF15@
M<Q9XFQ/Q [S=BJS 9$&<HA/(=-Q F)O_"BUI;J(9&'BA$?#ET<1BM(8HJY@H
M/;0<GEL+%P>>!28A1B/&P0 C@( 84"0A(]QH%74;\/9G"UQN?*2 .[9)O[G>
M=_&EQ_R1Y/(7$#=C=N8OU[:XM9G@$&.8,;EZ''*3]6EH!]SZYOV;\$,$BSWQ
MIA#8'B5=Y )L2<=85.'A7Z$3O>%UV=4,X^+,/K5LC (!NB>V*%X ,A#DQA/%
M2@].>)\+$_/ED$2+YO3G.\#U.($1@<SM:\K&+YO!HVS\=VCC&\K&?SL;/['N
M<^M%T\UW>.TH;R,6%X_B7WB]37UX U8,H$$EY6=45QIW3%%5I;'I_8=C8\LU
MWW6QFM1 .]2VA=(%;AE:CJAK], ,"T3%+MIW!E!8V*S<S. 5:W!UTGY/%OV(
MWAC>$"X#M+,?(S")<BT30 1^-1D9$^?!Y\P0$5C9^JDA3/6]Q66J\#[1?NT<
MEB%)O0?6<-$NF4N6TVR&A+6/1W1#C7Y4-9"J!E+50*H:2%4#[4@U4,%P8D-K
MU/*MF%7@>E>.;<S;I33R2^#7KH0@Y=:NOB3S;=W:<C/\FKS:NJ9K76VN5VLR
M6$O&C\7.UM$MG_&..S0$C &F$NSW71%W',+;!]FT69YC$@Q@(8^#Q'F"3VL'
M,G#9 [H%8?0VCT4/BSOI+.D7KU^%K>V-:W574MIITJ++L>?$XB=-ND:U@#U7
MQ/".KN$J?^X5W!E:SG L.HVBH-VX[B$9VPW6)CJM?HWE% :$\E5-/D/7JEJM
M]@YY>A-42M3,'1YS[7<=)Z38FG@$&N3N_O)@&<+I346UM5"M.QK9EL%5%-!H
MJ;WU'DFDI')6*L/VCO?]XMA23==:NV6+[$(L-S+^937J87;JD5*W9:7;!]A.
MU:K2JJ4D3J-=.6ZUE#XM)7$^D':S4F]4M695*:WM)&%&:>F@M*)@%?^@IK16
M60FGM%:)B=/L5!K'#:6U2DF<#WJU4:D>=Y36VEH2ICVK.B\0T/73K.I:;O<I
MU;56U57/[CVENLI#'*6Z2DR<#[K>JC1:':VC%\YM>G&FT8)\Z=8;)CD5>/4Z
MT9].-IN83J>2J$J54Z*2J-Y?$A53251K2**JS4VBPEIN<WHDF/MD^3B,\[5S
MF@HJB\UFZLZ&:Q/'C7L\SL</&__)J#>[@B>^0Y89#[&0' EK4)LY)O7(&.[G
M;99FC#)7Y'LK\MV,F"<J[BY^C)CC,W\%.M(A2 C>$6GZ<=C4DI? 1Q7?>$.6
M<UYQ?OT;)K;O-A_$_:X>Z(\7\D#V4>NEOZIBV#E[1!G@[\\ [RL#_,T,\(>H
M(F%$/?H(6V,@YA_--<LW-^%94K"5I6"KW#I5-AJ::.7#>XZB=A0=83 G]WY
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M7=/J6U@","8F ^Z)_&J;^@%!"D2W7-CP&,\RK&!,C $LGI$1'7/%AG\&9!\
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MSX]'/=<<8U_/HT$PM.&7_P=02P,$%     @ CH%A4I-=%6$#%0  7 4! !,
M  !A<G9N+65X,3 S-5\U.3$N:'1M[5W[;]I*]O_]2OL_S')[KUH)#.:1!\FM
M1 GYEMT4$-!65ZO5U6 /8;;&]HY-*/O7?\^9L<$0() '.(XKE8"?<\[GO,<^
M<_GWJW:]_V>G03[WO]R0SM=/-\TZR>3R^>^E>CY_U;]2.\I:02=]06V/^]RQ
MJ97/-UH9DAGYOEO-YZ?3J38M:8ZXS?>[^9$_MLIYRW$\IIF^F?GXMU\N<9O\
MRZB)?WWN6PR^4'%GY]A/O5"J_%4YUS4X#O;FP]V7^?"$O^=RI/5_I.[8=TSX
M3)"[BE;0BEJE0'(Y/&#@F#/X^\NE2SQ_9K$_,C[[Z>>HQ6_MJN"W(_]B3,4M
MMW,#Q_>=<;7@SK?XCBM_RC.X;3+;KQ9^NQ@ZMI^;,CRW.G L4VWP^/]852_"
MX?+GD(ZY-:OV^9AYI,6FI.N,J1T<B@.IVHX84TM=W$<>#F$#;+69.NJ."D[A
MCB0X,/.Q\7/$!]PG>D$K52[S[L=GIVKKJ"6!>&;FX^_VP',O-@_!@(LR\7HX
M>XG;E^@PF>$(BE)=G<#XA,7A[,S'7J/>;EV1VI=&ZPK^]TF_36X:M5Z#7.;Q
M&A\W\^0_$\_GP]EQ@7G4($ZUD_,C@M/_W.R1C8Q?@BXZQOGYY+T_8N3W7\^*
MQ<)% %/M5C V!N(>/EV>J%]\(-PC4JR92;CM.X1ZQ!D2?P3;RY?>Q%VZBN3+
M6>6W"Q2<W$A=4R\"GFBHN$&M !%@>.:C/[K,PQ4^$I/.\*+_H/:$BEF6% M%
MG0QFA-HF&3!_RI@=2EJOWFRTZ@W2J77_2:X:WQHW[8[D3+W=[;2[M7ZSW7J8
MNBRA:#UM9L"@)CYPW8;C'>,' ?EW Q4@(WK'[5O"?21YR U&J$\JI&=P9L./
M#A4_LA+NS_2.V=FE*Q9.*KJ^#H,;(,IRA+D[!%G)AQ#"[K=FJ]8C[4Y#$=O+
MDF:KKNU"\S#_(T])30!5U(/3;$-#1EPQBTZI8.MHI\05W#:X2RWB6A2H!IP&
M$P_@];QU[-"?*!.>'\C$-?A,L3][^\RF^\FW3<:.R0%>1;@4;B#,@,%1V'G#
MJ,?F4H@W#!&4L. &=4^08A^41.E'R[ECXP%X9KV"XJR?KQMK&WP60&'MH,RA
M\.!@]B .!D-!WTT8%Z@3CN":"\\G-=R(AH" 1B]3N$1=0!E^C5)WS08"-944
M3Z6R%M91MW*GW4>M$67/U6<?+APR*A@J#$)!MIDL;T0M"V@B@@V90.,%A([
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M7Z?=1G W+6/2WF'%I+TL^P902P,$%     @ CH%A4NOJ#%K8 @  )PD  !$
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MOH<BC:!-8%L.,F7@(M=B3A) $U(5:2O$$IL9L<R-KH',D<L?EE$B%2  K%0
M-->=<?J$U$S(2*B968!4LS$W.*B64"ST>H.6Y1P/S4*9%6T+)!9(?#1##@LD
M/BDD#J[QXS\FPUV6=L(02XU&' X=4WJ$:N;H!33B>/6#SP@S2 )N)BB.8C&$
MEQABXG'$32B42:$>!IY:"8^Q1*N015!LR!Y0*V* 08^F[J=P0N68D3;$=/U4
M@(1+FA[ML7U7U25-\<@?<DQZ2H]/;)]@X)>CJJ<<ZK)U1Z-K'8V@([3S)FM!
M I?LS9WGY^:\Z=?-@VY,N^8WF-9#Y.&L?,QT\(:+^8%[WZ/[=X+U$YPFI\R
MJG"YNR7E9A:5<;4;TM1L7P67G4,&7,EZ\@M9E6IH $*O*3<NH ,I)ET[F,I?
MAH+Y<%(S01VHLI7L$C;E+-3$DQS"0M#%*,$C:IVB0\,C#MY! [A?;[L 5V)+
MJ<$UL..Z<0MF%_XIPT A"^$F5DHH$#),!<6H%<QR2BS7TE##K\SS"07X-F0H
M"($EU&=1JR!@0<#=(N!PQPBX=:RT L+MHZRM>0@,G?((,4>-D@X%U  B,2&(
M[*,Z6G (R,CID MNY[CJ7=<M4MDAR]'( _6::"ZAZ*+63YE!2:H3H*%QJ_00
M0N_(*>!2BV,F8?$M (IPAB5(6Q1)I?7@ RKS! +' GT%^G8,?>&S1U\7=$U=
MA(1<8*,1"RV?PA5MUJ3.?OGY]T;]MY;9)N+SA^NS:8YT4!&B->-S=D.5VMLU
MV"8FI5?2#!.2H\W;'&2X2'4Z>#/O"="GA8T7L"I@M5NPVB[Y]<!:1$]"BV>/
M[5-/Q%6RXH9UEK%S9VYD+N\0H>(*7(5AJI&<N>7NM?9B92R4X$.5T(H)H8E_
M4NJ>KMY;$1X!]B%>O"&7J1D"C-W..FZZNP=ZO"[[7I,)-5?Y (PTW6V"12X$
M=]9GX?&<"/Z1B6R;_89\^1X.V?&;0K']\V2V?XZ*[9]GO?WC'E&,%H N+\-,
MC'KSP%Q&G B^.Z0=5E*?H!1-(VZ5-E=K?%< C<4QAT%AJ]$\5!HJJEVP'''0
MR57? Z!"V&PP+(=/'/ %^=D_*0>5'>M3&;KM]OUB9Z>(EW<S7G[^.SMM(0AF
M&#G@"7=C<5\WY QXDBW0KW989HQ^Q!6WS_"Y-;?+3;H'&Q?/UMR)4MEFB-\+
M7Q.<T0@J&G85FZTA6I;+!&&-N >4N@6_@=6^26/P+YCJS,ABW[7/'^UXW/8$
M9UT!IV+391LXP4IUI"%**0,JF NI #;NV>6,2F6_].-RJL24X?I/TG'V"+;.
MHC 6)T+-&9R=390/O>@UY@&C[KD4KGZ>'MN_+)P=(F.R:9]_E:[BB[:,EQO)
MS5>(O39W!E<V8?QKD:5[8\Q;#SP\>=.Y.+OHORQE+U9>-9UU[MV ;ED4]-W<
MJU5_.\H5#M!WOBCCQ5'U\-<7K<S$A;?=1C_Q@L1-4-QME[:U[BK8;H3P^/J[
MCEBPYNW.Q[SN3^'2:)(_J89;:[U,&K5&?3T 'GP<ZM_M&&R\OSV8SP^JM</O
MUNTG\^:C3_5%T<G2;1F%?MU(H64"X;,OHC__@0E,<.V%[-PH!?[V\'CWB-L'
MS-\V=NR:^!R*OH67Z]^5AV,>18(]KH?]+>!K.SGOM=M^Q&*CUW=E$M]@.WKQ
M&X']FPY+@?0G!YP"Z;OHX0+ICX7T'2=V9\+9B+R^RF!=Y+8E!YB$3S73&W\9
MZ[E[8>^=?^(8'+!T!;J@O7PH.?/,_LI][8MS>U_V0X"K6;RO\SM<=_CMP>,@
M^]G#XR#[?<7_ U!+ P04    " ".@6%2N$ACN%0%  "I)   $    &%R=FXM
M97@S,C%?."YH=&WM6FUSVC@0_MZ9^P];=YI)9O ;+VD+)#,$2,-=&C+@SK6?
M.L(66'.VY),%A/OUM_(+I4V3M&E+TR0,8^/56MI]M/NL9-Q^VAMVO??G?3CQ
MWIS"^=NCTT$7#-.V_ZYU;;OG]?*&NN6XX$G"4Z:8X"2R[?Z9 4:H5-*T[>5R
M:2UKEI SVQO9H8JCNAT)D5(K4(%Q^,>3MI9E9TH"?59,111_$+G@)KVH5=T/
M+RU4PB:[;&O;I?93TX2SU] 5?$&EHA(6#<NQJE;# =/4"A,1K/#\I)U JE81
M/3!B(F>,FQ.AE(B;3J):A42))+M4]$*9C >4JZ;SO#457)E3$K-HU?183%,X
MHTL8B9CPO"UE_]&FZ^*=QN$.GZ1)JVTGAQLC9AV2B,UX4[)9J%I'Q/]G)L6<
M!Z8O(B&;SXZS3^M6MBVI[K0Y$5'0*KISLL^F>?KF34\ZDI&H4-!6-KF0,4JR
M 92>SRD*4,IIKK4@> >."H6B<=@FP$F,_O7?G0R.!MX'G"N4VN2:EOY%R"9,
M0:UJN5>CY*-[5-X2)K=ZQW#J]D?>X'C0[7B#X1EFTFC\MG/F@3?\20#<M3AQ
M7\);:VQU+1CWNQD&;JWA5* SADYO>.[U>P\0E!**5\X^#(_!.^G#N#,ZZISU
MQ^;PW6G_/72ZGFZI.D[U,TP^#_;+CF]Z6K<:]>=7FO^I?P4:A97?Y>" @R\X
MI[XN"[!D*@054NAP/B<1C&@BI (QA8Y<,$[2"@RX;\&NUMEY]K):=5I=$2>$
MK[(KM[4'V,TQ]@ZN8_X%.'[67T(E$P%0]#6 'O5I/,$J4',K"%S5 9+"E$78
MM#9@3/VYQ%J%/$YX /T+/R1\1K&$Q#%+4VTL?K5F0!2%D$J*5F[:E=M>FH6&
M@X^UATU7%4CF,ITC#J $? S[G6?N_HM6$?5H$0E$HM"F3>U"1X<##I<92N2$
M<)J:PXN(KJ#C9W#I<*A@.U'-/"H"MH L/PZ,B$Z5@2)%)A&%B9 !E0>&8Z!]
M490FQ&=\MKY.2!"4UV5@Y;?HM(I(DM)F^:.%\ 4JQ$#!M,E&D/H0P*(8&4/1
M*#O)5?.H6X9,45,/K4-H*4EB?%L@_]BHO#$)-@LX+C>";7JYS>1L:WEIW]9'
MWW7WVK9N.[P:YSL>)AXF:,%ATWD4K9#KXB32I+(F&DG_G3-)8^3@5&=N6E"A
M6]LE2&82W,9NL+?.]H^TM*:D(N7=5[5Z2Y/5&BT\2'W0>8YGI(!'(G@D@M^0
M"*KW@@@8U_V0++MQS:,(XUC=6;Z**%F",(DTD4B::D*HZ&8218"W4=TSTD6:
M($.DE>RN*:Z)N*_EV&&0;:VSY0IJS:.,%02N?+(ATY)"BO62=3U-?/T^N+C4
M9%+$]^:RTKR\KKQF=UR]M#O.K?EFABHB(]\+&-_-5[GW2'Q'K[O#T^'HP"AV
M$^NNB\%S&#0LI6"4!9ECO6AL"#V-72XJB*%AU?>?MPH72[13$;$ <D7((C$A
M$EUJ?2G<OVZ&]/6G.QPM^,*69IL)WL/H;L(;(OT0\B6Y^^5,_^GSX#[8.;BQ
MD/TTS&N64W^PL!^MFEL/]5)T]!&V@H7V;V2A$BCC^J<OO__$V*D-?XJ0PXF8
MITKP"IR'5L_:F"P[KQ+;*Q57SUM>/>Y9:ES'2+\"9?=!(1RS((CH=A'.*\&/
M!OEK'N#>B/I]">+/*%ZC^(OX_9=.RR.SWU7>>63V^XCP([-OB]GO.7&?2YHR
M;4OVG*L;,CJ%_@7UYXHM* RG4^93>>.?P[\["KOGDG&?)22Z[/S>I4)VZT=[
MMWO%Y?)#O%O^)7W[MVK:=O%"3]LN7ASZ'U!+ P04    " ".@6%25<M_*T8%
M  !<)   $0   &%R=FXM97@S,C)?,3(N:'1M[5I9;]LX$'XOL/]AJJ)% EB7
MC[25G ".[;3!IG%@J]CMTX*6:)M8B50IVH[WU^]0A^,V5T\W36(8DC4<DC,?
M9SX>5OMI;] -/ISUX6WP[@3.WA^>''?!,&W[KT;7MGM!KRAH6HX+@20\8XH)
M3F+;[I\:8,R42CW;7BZ7UK)A"3FU@Z$]4TG<M&,A,FI%*C(._GC2UK+\3DFD
M[XJIF.(/(A?<I.>->OT?MVZA%I;956';KM2?FB:<OH&NX LJ%96P:%F.5;=:
M#IBF5AB+:(7W)^T4,K6*Z;Z1$#EEW!P+I43B.:GR2XD2:?ZHZ+DR&8\H5Y[S
MW)\(KLP)25B\\@*6T Q.Z1*&(B&\*,O8?]1S7:QI'+S@XRSUVW9ZL-%CWB")
MV91[DDUGRC\DX;]3*>8\,D,1"^D].\H__C?9MJ2Z46\LXL@OFW/RSZ9YNO*F
M)QW)2%PJ:"L]+F2"DKP#I0=T@@*4<EIH+0C6P%ZA5#0.^N<S-F8*&G6K?KW'
M(9I*Y3>Z[-;OF,_=_C X/CKN=H+CP2FFQ7#TOG,:0##X20#<M3%W7\%[:V1U
M+1CUNSD&;J/EU* S@DYO<!;T>P\0E J*U\X>#(X@>-N'46=XV#GMC\S!WR?]
M#]#I!KJD[CB?9\KGP7[9\4U/FU:K^?Q:\S_UKT2CM/*['#SF$ K.::@Y'I9,
MS4#-*'0XGY,8AC054H&80$<N&"=9#8YY:,&.UGGQ[%6][OA=D:2$K_(GU]\%
M;.8(6P?7,?\$[#]O+Z62B0@H^AI!CX8T&2.C-]P: E=W@&0P83$6K0T8T7 N
M<>)!3B8\@OYY."-\2G$Z2!*69=I8_&K-B"@*,RHI6KEI5V%[918:#B'.(VRR
MJD$ZE]D<<0 EX"+L7SQS]U[Z9=2C1202J4*;-K5+'1T.V%UN*)%CPFEF#LYC
MNH).F,.EPZ&&Y41Y151$; %Y?NP;,9TH T6*C&,*8R$C*O<-QT#[XCA+2<CX
M=/V<DBBJGJO *JKHM(I)FE&O^N$C?)&:8:!@VN0]2'V)8%'VC*%H5(T4JD74
M+6=,45-WK4-H*4EJ?%T@_]BHO#4)-B=C7#I$V_1RF\G9UO+*OJWWON/NMFU=
M=G ]SG<\3 ),T)+#)O,X7B'7)6FL265--))^G#-)$^3@3&=N5E*AV]@A2&82
MW-9.M+O.]@M:6E-2F?+NZT;3UV2U1@LO4E]TGN,=*>"1"!Z)X#<D@OJ]( +&
M=3LDSVY<\RC".,[NK%A%5"Q!F$2:2"7--"'4=#&)8\!J5+>,=)&ER!!9+:\U
MP341#[4<&XSR?7*^7$&M>9RS@L"53]YE5E%(N5ZR;J:)+]_3EH^:3,KXWEQ6
MFI?7E3?L=.N7=KJ%-5_-4&5D%'L!X[OYJO >B>_P37=P,ACN&^5N8MUTV7D!
M@X:E$@SS('.LEZT-8:"Q*T0E,;2LYMYSOW2Q0CL3,8N@4(0\$E,BT27_JG#_
MLA'2SY_N<+3@BBW--A.\A]'MP3LBPQD42W+WZDS_Z>/@/M@QN'4B^VF8-RRG
M^6!A/UQY6P_U2G1X 5O)0GNWLE %E''SZ<OO/S!V9N-JFW#H$MSN1ZN-4;*+
MZ6%[<\3U U9,&_<L)VZBHE^!LON@$$Y8%,5TNP@74\"/!OE+3FYO1?V^!/%G
MW*Y1_$7$_DN'Y9'2[QSA/%+Z?43XD=*W1>GWG+&[,T8G<+0^Z1I,)BRD,C_G
M"B0EV5Q2>>O?P;\["CMGDJ'_*0)P 86&H!.&8LX5!DB%S.ZE>>V;S_:N^BO\
MNI.Z:UK=/(&]\;V+KW\/IFV7K^"T[?)=G_\!4$L#!!0    ( (Z!85)KWJ)8
M<FP  &;1"0 2    87)V;BUE>#DY,5\W-3$N:'1M[+WK<MLZLC;\?ZKF'O!F
M'79212NB9,E2DEE5CN/,>'])G'*<V36_IB 2LC"A2"T>[&BN_NL&0(J2)5MV
M8A$B>]>>%4OB >AN/$\W#MUO_M^[\Y/+?WT^9?^X_/B!??[Z]L/9"7MV\/+E
M_W5/7KY\=_E._W#8:KOL,N9A(E,9A3QX^?+TTS/V;)*FLU<O7][<W+1NNJTH
MOGIY>?%RDDZ#PY=!%"6BY:?^LS_^^I<W^)WZ5W ?_TUE&@CX@\?7X8'X/ARZ
M_S[JN2VX#'Y\F?_ZYF5^_?\[.&"?_LY.HO!:Q*F(V76OU6YU6KTV.SC "T:1
M/X=___)FQI)T'HB_/9OR^$J&!Z,H3:/IJ_8L?6V^2:.9^IB*[^F!#'T1IJ_:
MO[T>1V%ZD,C_BE<N_JH^COE4!O-7Q['D@?[F1LBK2?HJC.)I_I5Z7_Z->FB*
MDAK#%_!M*/15UQP> F]BYL)G?_S^B]MOOW[S<O9'J=7J?A[(J_!5C&]Z_:AN
MF%:.HL#?LE^/[<3I]XD<R90-ARUWI2NE=AZ6VEWJ2=4:>".G5RR)O;\]N_I^
M]>W[?WOSV5P<MO'_W-9_9E?/F++$OSU[QGB0XC^F:S?23R>ONH?]V??7$]V>
MHT/X&QZY40;NP$H9G,-XFK"W,G*T/7[X<')''SI6]N&]#'GHP9/9EY2G8@KM
M2!A/6#1F[X0GIB,1Z\YU78=UVITVXZ$/?[A#1_T%+V#I1+!_"1ZS4^B'?]=]
M>.5G$<L(;HRC*?O(Y_JJSJ&C'LJ>OX-6X-O?8PL1,5^P-%K[S+P)9_#6F5 B
M9,>9+],H3G[_9=!QCUZS"S&+XO2G:,6HX5).1<(^B1MV$4UY6-:8"W<"-H6C
M9+:*3?1*>B6]DE[9M%>:5Y3?:C$9+MQ*]+?CO"\S?B4.1K'@WP[X&#SH5SRX
MX?/DM79EW#8T]=GFON^+^[RBL<.'N\LK+<AF,Q%[/!&/\:,WN5RG%Y?_8&_/
MSN]SN1[O].^@%RD?!<K)\>!W]+A^1A]TRSJWAJ0OK^&_^I6C*/9%_+=G[6?,
M$T&0S+@GPZOB\XS[?OY9!5)_>^;!*T1<>._Z 0=>% 1\EHA7^1^OV<I@2&/\
MC\^NS7.@Y<_8<@PP/&P-!@\=.N9C(,:I^KPL"OSBD=@%H;._W&3=B-56]UIN
M9Z71#P\\M^S%[F+1SP!Q)2F\U.JK5H>[1,2S3^]./Y_"?SY=LN.O[\XNSR^^
M%#'$Z>?SBTM;;6274G)_LHDH5V#]_(:%O7]_]NGXT\G9\0?VY?+X\O0CV,H7
M=OR%G;]G[TY/3C^^/;U8"7F//[TS<2K^]?[\@EW^XY3]Z_3X@J&MO;OK/KSR
M\^G%V3G<>''^D7T\_M>M4!E:@6^'!W\\OCP[__2"79ZO?:8[?/5$]OOC*GPT
M5#?/ M_R@(>>8%\F0FBGP4J-[E(DG48;1&G.#KS)<_!4U919HN;%3J+I+!83
M$2;R6K /44(6@S+KDL44%O-13:H6LZ6G?V8RG9.50(<.R4H**SGAR82]#Z(;
M A 43J_1IO$I2L%/2R.V;N6([ ,ZU+]E'R_5[ M\I^=B?FR>YR=.R^[^C301
MO&\3P;NWD<%V;]S=Y-AVDT,_VI_=2W"7EG8Y$>QMQ&-?N9T\A)$4WSWM;6$G
M%AL^V'T+#Q:V_O\$FW"(!#GND1!Z,P;W/(@2>3B7X14;%XR>+,>52]UFS_'&
M9R?ZOF<O''8SD=Z$X8-BF0CUW)&9J4C43,7*AA*V82\)WAB+@&/CEEL0+4>V
MWE)D&T!DZ[#I<B@C5"BCG^NA_SI&_[78KC+'[2KP1\C$TIZ5Y:;E5\^6MZRP
MQ12<;W:KC-?N5F'+&U7*_0MS-PJ_7"?X%MLOD-1C&IO^/PF[$,D,E"5',@ M
M%'+<Y#+NTRA:])/)!-1I.AJ(A;7$8L:UN6HKXC+&+Q.X1W\+!@,7)NL5SV2H
MAF7LJQ%T(V'LX><L3'&0PAB#.V8!6,^5"&%8!,$<?Q<S-"NX%YOP-50C7$E9
M#:#C*9BPQU_#KQ+?X 69C_8'U\*_X' [3$[AH=.\C=IBIUSB J5J"#P%/\0A
MM!;7+>,H0&L6UR"?W)"WZOK:3J<3GC(>@TAB(?1(@P$E4(5L*I/B2D0; :^*
MF9\)?.TX!CQC('H1QU'<VJ]!DV]7^Y^5$;-O@^(\BQ=#08]YJ=!-?$?M(VH#
MALM064!XE_&/> *&BY?!(Q53 1("<X'%^9F'1KWX8>U(P5]PG, S0Q_\C<<,
MDQ:[G$30PL4S8N236&@SO0%#!WI3%@[4@-+19(KOQEY'HQ0&#MS$DRA4"^\\
M2;)8M9*/HBPMC'@3^F\S%'Z*K>_22HY#(R(97D?!-8C<2$_C6N0)/XLU*QH)
MZLO%M80V%[)3HIXB'FIOP)>)!SZ NM4H=CVA7BJ$*EZ3 '@IB]+;1XUAZG=&
ML7$D$O:?S+_2R*-A$QNKKDL2L&Q%!!K/&7@_WY09K557?M6ZMMV':NPLA(=^
MTZ]&R\17E5H #R@U'0=+ B*+D_L1V[AQP-G;TM9&TE);0_"YFE&,\LIZS3&>
MS^!;(#)TGHS&/!E[V10'G">@-R/0,[A("T[-XAGV&YI@( 5E<0M5F!B/0:?@
M%8:(.J;!BSZNBJ/%CA5^P,,"<!9A8.> %48LR<"K-<^'"_,.\2")%@P*P@PR
MGA9&L>A9WH(R=T>!]"3<E2'(+5S"'";R6U!\<@Q !'HJW2Z25$X55$VY#S[V
M'/[-G1$'?>P;$03X[TJCHFN%?ULK<^^ !?AA) (IK@U +\"X@(X;$_QH8$$*
M  #(QF/4!TH9=%&V2K!B^( W,XZ<)'7H4'!/81?[Y6^<ZU;OFW[/M#M@9.YL
M1J%8C $P,;:-D"RN16[S"LUPB".IP% H$!J]%D",9/6A@#8R'R<K\>]=P>RM
MR*\TRI,LT-$LNBXK$2U^M2E,_:$(=5TT^I01QMYAQ\OD)4@HB&0*P_YW/IV]
M9I<1(+\ 77_^>?LR=[1%28SBC,=SAE,.8"1ZPQ9G(9]"\_]]?'IV_O4#3](+
MM"D8)[CM[RW.9ZM?.G@&BV]8D-$;07]H[O[VWM3[7V2OK%V454.7"$KJPI4W
M^Y7U!K_/6U_-O/&;E_AKQ2U9L%C>G'U7; %NEY'7/>H<#=W#=E<#V>WM<OO<
MT^/U;H=33*+?/6'\A.MX=IPP*'89O/W[R?F'\XN_/?OEO?J_9PML5B]?;!;(
MO[A02FJWCGJE+R]12OHK_>9^OS4<_/;:=#&7:P(QG<_TA4QI$J)HZ-+&G0W;
M\MLCS@B K*+XU2_J%';[B4.)K4Y./)4JW%:_0YJX0Q/P?N@]J*+S;!=:R;]Z
MNY"A4517;7NZ2U.YD&JN)<3JJD;+;Z]O)A"N'2 :8]MO8CY[FC,[-HT!0B-;
M-$%H9)N6T%\D--K9&+AKF_ .[=]XL+62]7&2W'\6:I<8H\B@5B*^BURGTO<#
ML6,1+R <);@6OW<%,5JF,@5Q>(]2RO(,P3YKI;-$KJ09>S2S.\:U4^@UXP$[
MA4Q,0%HA)K!<,XUD@GI'7S\NVQ\*#DZR.%8[J%0<=E^:D;TGX(JEW4Q (:&O
MXU<2/%G[CH5..$Z634(G'-]WP3=2Z'4)@]QNZ\A&@:LT2<5Y<SPP"#+>(BL.
M<6G-')8FH,NO%LE[.QK=E%QJCY70<9U^=^ ,CP86::,)UF\=Y!"NDV43KM<%
MU]V>T^NWG4&W8Y$VFF#]%#/M6. 7(DECJ;)P4-1$[-HX?*E:Z(VEV*.A ^^U
M2!-D_@3L]10R638!^T[GQ C8*S?_W<9-/WX^OQ;!U&?,X >=%=]G(DR$SBP5
MJ;2"WM(NO?T[)UO#(5(]+FUS#K:!V%6U8CI;'U)N(+T?MCO.L%_AV>5MX8L&
M#G%)S21/7+)WBB$NN6N9S77<PR.BDNHU4=MU-RNE?1FEF *]VI"0)F4M8>PJ
MC^>25I[DX'0-N;K3<=Q.VQE6P-<TM6O5&"%Z('IHJ%:('C:&<CVG-^PXPZ/=
MSPP2/5#DUEA$(C(F'*FGT!N[@<8Z39#Y$[#74\ADV03L#=9$(\V?XJ,GW0&)
M=373N=KYB&?)9KHV;BA2B^R>N)7 I9Y";RRW=IRAVW4ZAX<6*8-& &'[DPG9
MLI).=<>7 XM,O)&X4NL#35:JX(OPLEB"+^^+691(.K5DQ3BH'GQHI[F5BJ&=
MYG>%!WW7Z1ZYM-6\>E70J26;)&]9&/$CE6'K@E6[#S4HKK AKO"C;!0(UFG5
M'(;TZ1?[$B$T1?[6>:Y;[*B]2U7-B3GLRPV[$\75D.,[/:<SQ"2SNT\PNRDD
MV0A_]1]7]H4DQ$7$179KCKBH+EQ4X=$=XB+; M2&[5>SCG^:LGW!(I)O*(%;
MIY7;+$X,;:FJ&CE37+70B1J(&AJJ%:*&O5%5(ZFAWC%:67RC*/ ?)?['ROJ#
MY",9R%2*Q%&GBJ9B.A)Q\OLO@XY[])KY8BP]6?O3197J@$#&!I"I6NC;G2TB
MP9.UUT'H%&V19==3Z(3C9.T4&I%;OB><22)N/(94+71B3++VY@B=(A^R['H*
MG7"<K)TBGUI(^\043PH6RT.O+#)XXE!"E7H*O;$9YJS3!)D_ 7L]A4R63<#>
M8$TTTOSK$BVYW=:1C0(_]KPH"].$S?B<CP)AD;T3IQ*H_!2AVW<FN8%TZCK=
MWL 9]'H6*:,)QF\=XA"LDV43K-<&UGNN,^QU+5)%$TS?XG2%3Y UU>+8*<Z$
MS\3WF0@38576PB8GK[7DI/ Z3=!A84L."_^(<FI(X_W.T.E;E.F)$J$3EU@A
M>4J$;IV:*!%Z?2.+AFU7TSG/O=N;UBSRFVB^SH[\L@W$GJJULF4"V0;&"ZXS
M' R<7I?JJC9\B! [$#LT5"O$#K0H9)/4*71K-!P1$Q..U%/HC=U<89TFR/P)
MV.LI9+)L O8&:Z*1YD_QT5-F8HBF4YE.!9XMPOS<'EP&W1>A)T7"5)IN]S7[
M%*6"V70D@,B6T*:>0B>RM4439/X$[/44,EDV 7N#-=%(\Z<HZ@FE_7&YJI'X
M,Y/IG#+:$:[\?%PI2Y$2JE='JJ0',OWZ03J)F*R: )WTT$33KTN$9&L>!EQJ
MBD*6A3)-'/B:S7B,8LZ$PP9.K]UVH%GZ9\:S=!+%T#C?83)),N&_&<7LI5&:
M_J]:KXJR-$GA#Q EXPF+QNR=\%0TQKJNPSKM3EM=UVF[NS\V3?%8_3&,A&X+
M@5>LB0&FSE,89I$V: @0N-=3R&39!.X[3+S3(W"W8PA0E/:T C\+/6B*O!9Y
MH.86H=DB*+LKU%H3J&'PY;!8)#/AX:.#N<..W%XYWH,0[:!]8&(]_?@U#]H<
MVZT^'K\?]IU^_VCQAC4/Q'<^)(1<?HU%6$ ^!P%N/87>6)_#[78<USVR2!5D
M_X3L3R9DRU+XU1U==I^>CW"%<H%7K85CS\NF6<!3"#)\,9:>3"F%JP6#H7H$
MHG3@5BJ&TH'?H:WGO8'C'O6<]H!2@EN@CA=$)8181"6V*H:HY"XJ.1PZP_;
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M^6P<1U.V;\SWD<]9YQ![Y Z1[U:ZZ0Y_1H<>XSQHIT6Y,,;1^]NS]C/FB2!
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M/A\90#&-V>. 3X'1"0^9!6 Y5P+,6 T'^%W,4GTOVL;74'FN7_ ]2I+'@%B
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M0ZY<G8F8@B<<8SR3H#?[:_?(Z;6[ZL=?>VVG[W8<Y,N9\ECA"4X^O'5GU(A
M8@NCF](;>;(YO%)O4K!GG@3]5.MJ*OHMQC^.:G2"M"FVV*\=5_DA\/5=%>G2
M"4_!1X_%<FO4=:K'JS?<[LZ#-:+N6M;';H?.SUQ<V9T;<"&3;THG7T/CK^89
M.BV:T;!PRJP<38$?E62C_\#H5 $-2%1S=%86:9[6!MW8T@2(=EU*C%V*4U9F
M.Z"W&<*$8W9F@AOA )^GN!I6S*.ED;,TT$=ZED2D,HVTAXRS(L53@66"8BY
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MC5\XM)\??SEYP8[<-KNG=+K>/Y!#@G&A=%7V$[A_</_]7]+(^\;6/,64U/3
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MFAB$ ;EQW4MY%V;%*9_8-&WUE]?"/D7A02SP;(]Z*#3FH%AF0Z_D*HI\M5_
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M"+2*=OJ6S^'*#Y]QU 5!#I\.^_CE^(7V. ,>7F5<[R#44%,\;2KC.$(31QS
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M '8! *;M @ 6    9V9B87%N,6MF=3)X,# P,# Q+FIP9^R\!5B46]\W.HB
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M+'&9;PK'2O<3&]_-U:CZVUDV-1I%-/MDO98^!(B2)"<')]N(-\/MWE/]E6B
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M7'W]H[TR2;Z3#]56"_)UM%ZN[22%9)/X7(S4A#>1G!<.S.CJ#>7AP*%&PG6
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M"[8[MR%AO7[6]SM-3LO7W6UT/=43TY,R=NW$_+D5<^J(?OTWTV]&B$*4.C>
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M:B%CS]*YI>HWIQ8#]A^XJ^@+83.X]$\<5/M_K_A]/Z&7Q32>ME[@[_E"L7K
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MO:47W@.#[\<:RYL!8VV<1O&]KS&UG'@(5O[ZHZ4YKAD@)4PX-+N)]-NA7_+
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MWN#>]:OO94&,E\[5M1V7@ZS<#P<L+'/R9'-YC\BM=CSX#>;CR*@>C.<7<#C
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MX$9\DEID'KAH0'C^,&.WUU<0>-#T3+IR[4&<:??U%<90I8Q.&I.,B?JH:K*
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M+G\JYA N!MU5A:+STF9)&QQ8*)F.[C59\>)M9MK:(],S1G&[+F@K7*+6<&*
M?7]!D]:E:@,8AZR)%*]W_2P^FJ%J"FR71P^/&\'T96;U*T/4P[G4Z&]9S?F
MHLV7VQPP\KE%>J-%A6EIZ'(<;O3_8BB\1[!':?H9<6CMNZ .3;Y+$X-H0Q4K
M*V-\DM8QRD\<UQJU2/O< %;.<G9&9[U'E_L7OFY+:-PX,(14!6+E+/]3'T(:
M*9BC/!":$PJ^:'!Y5-#>JV+E3H8MP^1B92!@"$WKY6S2O5O]NIT$FSX'?0$9
MUVPOO.3MY'VOBN4T_+RG7A="^@(R]A> '^" \KH0R@#@ ?YV=MPE@9/8RA&1
M,RMPUG2:?L*M>8$2<AG*>=VRD6G8-&3R0=#J9FQ!VBPM[>6OB$(,O;%!UIX9
M4IGO\ 5Z9RJ029:PGRFV0NHH96SPA)L##E"(.VA-/F%F_Z6477<)\VGM;E\Z
M)8OXX0#N\ZYEK0!0UQNT' 1<]^JX7-=JF5/G;0H_Q^V)P &.7NC%!'" +/!L
MFY;Q<F%F_5_.Z\:-W-NX?2Z,?^'%5-3S5AL!RI<X^+/WBGP[8A49^TI<_,"S
M3>K4+@0[=]#)K(+99;EF]H/E$\G5CU;;VLV0<FK>)N33+7_8$6[4S_1E(91/
MW09F=@NI.]WTAAWB./E-PFQ;+H3JO%Q\4VPGQ%CU3L:"S^=*T[Y0VOVB]W!
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M?@'XR@0-O $>D'G=&_F2*B5UWG>L!S']7YBL14W%C=*P1?DA<1,6M^^);UD
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MS5G*&]J4S5\<6D0_@5IC9I^GW<")IAKFP,"K0T)]/L2<;Y_>>9HM!K%CXQ7
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M?,4X_;!3$C6> PNP0E6W"+GA$@8!V&&]C]\[_UR!DC\KY-*-DID>;@6&XG4
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MJ*9W;>HA7Y@_0U5(<Z6XIN&&-*:TD[79JW)O*47?:\'[7XQYG]5N08C8Y(K
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M4&O9CDT?5,WEDO_%K%27NWF2]: %J_*1]@,C_M3P$<4D'@DJN+=V=M3=FI+
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MR\I_LC*5EVEK 3CWM]324E;UQ+XH8Z5MH7F%X\!MDY[;,#_X8_?5'D$L@$_
M/_E[)XI7_!E-\A8LRQRT,*(YQ?]HQ=FP8FT[06QB:R($(XFFW1J13N=>\OV
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M>&S"^?ULK*'0+FS4B&+*,X=5K6^W51!59>=O.OC)Z!NT?41,02+?<8Z;F(@
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M"]3,T3O9C8)D*&450MM(#T1=J$+D^MH]N:+U8 %N6O<<P> +,3$J<TH%<EC
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M%A,'5(6(+*X,*2SCV[WH-.7<ZL$)]1A<]*NR&*<FPU'JG@F".%6IL5X2"YW
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M=$FO\U-5CAZ10+4E0G6V= 2+_(;)\'0=6T1 =["](H1\I7HG:KL<V+F.]_[
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MP \ZR)[=;:?MPW5MS]'6 3M]@11BNI_3^$^4O0=0DUW;-1J1)@@JTIM(DQ!
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M=/YY FDC(?UCL+>QL;&-?7XU(BT^^T #8\]657K\N:K,U=#GBHH[F$Y>2#Z
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M"Z7_@'\:TN+?>CKQ82;CZH_)84!]QO>.^CS THKGC.C;XLQ%%7!O2Z7A%,N
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M/!*D!AY2:)XD+?K>E&3.M.'+2 X28[4=%BQPU^8D=;PN8^A'/==UT@*:QYJ
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M^#JMZOO6A20E&M*!],]4]XM#LY2*(A11*,M'T##?O.NG_3OUIK=F]@$\@^5
M1[+%0CK]*\X05G(,%DQG-[V8E8=QWD9!A<JN8($Y,+)9,T^L$P-F5T\+P%86
MM0<5UJ:?ER9*5Q7JY3+V,K\M0VL0,XIH)M&,;??.JF\A.+#NXYJ:IR;C%\8$
MK#(B_8)CUUI*TW7D3ZWID>W+FWPJ,PMP.LTD_R/;DEL/S_J5Z^;ZI=C'-1J
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M<&*-:I+X3"8C'J3;_#TE"2'@:$5Z8=OZM%<"%]/\F5=IQ)BE16AX[-&TP*I
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M8N_[0F^NW([?U5N]C=QZ^$A1N8>9O87F;-=Y0XRM%&SO&[7GY']DG<4WQ:G
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MD'8T]X0:/;50$F:.IJTF5Q01-.:7%'QO*LD'DN->[X,1&;K6R@XRN#^C5*'
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MXL>^[5"XWP]MJ.!LOH<-,3[/U$XQ]CO;]_6< DN50>7L]9)S4F.'A%R#YJ)
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MS(9'<E)=U%F1C0<S:2C\0?;,NZ(V=)Q*D:5H/U$-;8#P)RC2F[)0O$UO=Y#
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M'))@^DI3+1/C/OIB4%6VAH1>VOM+ 1NU5&%P@P&NZ7[I-I>.N4MS4S5/L?/
MG6;4R^E:"0 G0^W+T3F?%7;6,:<V$\W"VO&KH!OIGG;WH3B%DB R'()ZU<D[
M)WQIP7>-"N3,ZB9G +=]-"I9.;.J85NP'1@GD4 $B0/1N1250G!2E@6,2& ,
M_5O>YO\82Y]V0"1H2S.R?1!OU?W<9B4TYC]?-Q#I)1N/8\SP45.#VJR:-@=X
MN7]R:.'%#TUVR9)J"SOB*PE-C]H*:2:<C=?V#DD52E19@F^D>^>)X'2FZEMF
M>M<% F^16B@;6R?N:R.#^-\ENTT>#(NFF"UG#:V9<*$7-?F=UF:Z5/M?G[N\
M/MU5,"2A2/7\FKO*/)V]],2AX=<6%1#)<->?0]IWHTM_8:CCR396TO4M_U:7
MP5IJ_2Q\O4<B>+B$RV"9*\)?"O2F0VH@2J=N1K-5PJC.8^I#W'0A*G75<7*"
M;3U?E"]D7MM+8\>Q.7[4*S;;5E^]3OMKP:J<GO$CGT9G'FI "W\MX;=@EW)#
M?RU&+H%^E'Q^(&#[8^R@;/#U'O_).SJ56Q/5\SG"[: M#:YD/%+2X5'KMXR\
M5 -YU@BG19L'VX_/'8I7-CH8_4C:<[)^O$:^K 75WOBX;$ %1(2\V3'N8ICI
MLKXLC&W]T+"@.*Q5:#G_*@E:(!UM!_!&,\TQK=/.?ZF[\"DWU<]/,D>S=<3"
M?.?*5;KH],S\TKBX-ICA_8_N+=7 Z]IE7S__^N@6OSNNQ3[[!Q#;L2UW5Q9S
M8?W6F(BV5(C&5",U/+YTS3B7OMK2Y/USA?] EC5[-YOX8P"]S[AA$.$W'"4;
MNS>4^.&@,F'.D04Z]-5OE:=<A;SN-)*.,^3R]$P[I,*.-LVPG^O._-3M:NI,
MD1;\N9OD4F47]M'J-]VR:#PGBARSX^,IJVQ3K*TT/G['=;G],??7-^^];_+L
M_I@[WTKQYV]-"I;=57!8RLR(DC9!"M>5+]=6U9J?9I_TTN54F3'H;P-,A:9_
M&?3R&K"OX8<_,'G'6O)]ZG:]=!HT?_Q8$W%]\7HAM7=$V1B3X5XO/=AUN"NX
MU_1J@=#FEP86P^?<#Z#O)/_3D3, MX\T6^4L:4T]\O@UKUA[?YSZV7$3XS_T
MA>!&:[O=DX X2J!5-Y/'$?L;>SUD)9-)[EBUE[+$"2W#5RI(B;EO]S/A'>PO
M9E4J?C0SS3.&VZ\<WA"Z?BJ7)_E'LQIT)LS,08.NXS:2QHE1TW<HRWHK3*#-
M,DT<ZU_>H-HRXQLZYLVM@KA!6X1?H*?+1HK%;E$D_R,OSK*.T)83!U4T._"V
M;$;XG>M#E@&?MYT/*E@H;)<,/N&J9FI(;5CG=]P=Q?(<6'W^0JYN?8M<"D-U
MCB4A)8_^Z-)?/<="'-,U\0DYWN<PE[6,J6R_>(RPX1U9Z%/<3#H[%AM9*IC$
M;*065)=#S9Q'H@)<N6\Z#AS0PB-@&,\S;AO%_.7'^+R]+(]4S,'H2CZ&YR6L
M%D@"2?0 #9?' %QRFZ4BT+0\9C!+&CJ&P.B248A4*CAW'NAL 1=M$67,R,F(
MMF&WUS/"APB7-^!]I9>0<O $-W&/AJJ/XG7Z4&6HGH1L$\\U.:VG^Q-T_0_^
M]V94WYD&F$.OA"YB3S6H'L7U_@'D4(Q_D6]??5M^-]@!CP$&]JP=!;RWTZ"\
M^GG@]Q(?[%5ZK X$]JM(Y=B[DU^X/(2IX[N1==\V7Q>)3G]X^NYXE'ZF%OK=
MS??ELTWSQX,.[[TLB]+?^@-XVW@WV*X1[P-501&%!TC;@<?7*=@G\1&D\H_U
M1!X)KYYW6[[_!26UVR)'JEN2TY-Z_D0:^AD58H'C0_05>_*69:0-6?SUERO0
MT'N&F+C!"0 !4I8O'EW"B;'!A]GG#,8NF%D8)]$GB7JW;,_*T"UH5-YJ1+2E
MPMGSN&)>>P/V<@@=]0+(V4S':'A>X]P9"WKSZ0,AQ?YP6BT'TLEP^F9^N%@S
MN+IWZ*;Q?,_]; E3#6$.1 ]-;Z9H&=\-GB;G[1G/%YCN&NJ8DJ;(26%_Q?5?
M2D#14/3D4Z9"F++";DQ2&FH"C %D-64U_1^=RRA5$Q1-.(MA_2FW'#$)VHL:
MY4"G#EC;S -54C6N/5/0@6YK]*1Z5?=..,I;=5>GWHOCET4^O;FS921:?*]L
M<__".7<VO*WA-A?(;" '54OF[7!)%+@_O?O]:IPW)(B1>3W2*BKT681OYP/_
M?/'YO/3UB.O97BK$/"''$R_?H.WF),OK])^(W+IO>KCUW2;Z8$SZ@H2"F9 ,
M-3?6VT?>+9][([ XRY$+.K.*NW'F5P8OK/>]K !518FXE)>-&XK)B+!IO,!F
MVT(\HCWN&B*JVGVZ^[AFX%S0,!,3SL0C'6,/;U[ZGBAT(^VV[!*D^E[CK&XQ
MCMEYLYAE"F+ P7A;N[K:' 038K;1$=;>TU]5#7HX ;@H^!OZ*%*+R21E^0SG
MP3-J1$_WR@^.R L8QY5W1'3JFZ.L O^$MT=DA].KQ/J6^D]9W+R6G9'6&G-(
MJ?C+PA+B%XME7WWHDO,(=LZI?=JIUTO5>-W/XV_;757Q8:$..!#&D^OJZ>W"
M_:+,]9GUCD.H]>.YG@O%O-^O:MF4JO;]$JJ[,OFV:&X<\:KCDT_<BU,"4J,L
M&N:#M^^>HZVT?/JR8,_L(6UFAEUM/O6U6;;]Q/HUJT3 J_8YSZ.CE@MN\&\
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M-7DI*0G?[?'&.'TUK+:(<V UI>3F#E[,T]Y-PI(UR[F^$E+'8;OHB7):'!-
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M (=:$&F7N 4[-8_SQ?033Z1R(#@,3$E,FR3WHF+P:64C/ +A+,= 9B.4L,4
M2^BPJ9B2:_D$R4S(_ F^<@@:*1JS4>Z;]7,*R2S6E<U0?<XJI*24E(=!JJ3U
M'7]")I14*^U) >;UI.B'R9(86Y15%A#=8 2+)3+A[?V!!0R=F 7,+)'<=G8U
M;6H^'^_)LIHE)RTXU5OA?T9.^UQA-5J,K@X4DU/#9?(2!K'R3 !R-J:J68/=
M;Q@Y>_LRQ0['DAX-H"TX\!6>MC&[64% \*9X-7+$!484AB7IWI]X8#IE!?
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M@#'- Z97K> 5?K]LOO7*.N[FKS&KQ@Y9OR=:KSU,Y*N#T;6L&S8YPID8GS%
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M9N1]?J258TY*^(IX,VQOYD7..UJ5UA7Z!Z,<5/Z3)GYA#4L.(2G@(&'2P?.
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M>P%J $!"1?J7 OQK04(&H:"B@9^A8V ^58 ]!Y"10"!D%! J*@K*T]N I_<
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M"#/],R.M W.,P]TP]-VMVWL@?O$(V+J[X=F#=%<P)JKX14CIDV[>1C[;O,T
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M/7<A'=C76?W.RW[&Y_LEJBZW!5=Q95)4($.Y.G7*I\Z,RO2)WWC/H-J>;_.
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MO'YVU0Q,!?%>J.=&Z'/=.YML0J]IXQ_P]R'7("_?W2I_UC2R^YQBRZY&R>
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MN+2YR,PKWP]]V<SW"%#K0V^6/S.QX)'82+3J>=TX3Q&3NB_+5!7R (,E#3*
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M2?F8Y6\\V4I1:V/#"66&]> N1?7M2-1%TY7]GY99^?-HDD*<ALDP2ASA=WL
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MV4O%7[C/.:%8=-S\T")!^%.Z]*=-TF*90 VGKM< O_:[II;Z6Y))T8+<BZ#
MB_WF2??0$%69+">L3H]6-3 ZTG%17UVDPY;H3>!%A5FO9TV/A858'1Z*7999
M(S^<,[*DPER_%US,.I*:H/0B]81%\A42(5+(NICERD,7/LWWVZA=6Q@L%);7
M^SP_L(5U]'\YT?U'(,JM_&1O0/1-V5R'Y/VSJSQ<X0F&AB@Q92Z\&'L?P!-1
M9]8,;>@$2<O)#M[VP'Q++@/RL%">O?;8@,A0)9H1'!I8=UT@!U$[=3@(2/ >
MU6'!L[+?\'%1+HVZ0K8<OG^_@9<"A.^QD-YQ\K6RI:URM-GOE-$&B?9HS7Z
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MYWY8/1>V%T_/B-!N'Z+K%)H]9GE_*/ZX6OKJ(EE>1*YY^+PKJV_&O(H95J
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M!\IUYRX\0^G;!]JW>+"3=,55Y AR'Z>*]XKXUT4+%D#Y\!Q.YGG(AB6GJ,*
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M[(;"Q7=R-X/%ERUYPSJ\16]GE^1RGT]K_"KBM,)K VK9^0L<$.EK60V4\HM
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M8.?(V[HR<1CEYM&&KU /),='J+RL[A01VV#ZR._=,ME4FS/HN_0 /S%@Y;_
MF$UEX6FZ&UBYW=5W*UI*T,KMEL6QS;G(]D1/&"AG2B^D,M)ZI_)5T%J3W.B>
MA<;8.*E$0G%%T-@#(Q<C^S.(;:V4AD8\;83V'OK!I-9\C'$CEP^VADBI?."Q
M8YKVBLUX=N)6*\J/?#:A6V#CJVZB3'-G^6E+_7<&U VRCE9I1DYE#6_HHK!Z
MJ'@.S^^+2W/8R,NNY&VWWPN+2-B]MK843R<TN4/HL&?YVVJ:G=TF14*XC30G
MOX\H2/%^<7>[_V69T&:+AN+7SH]MDW#[O%'>&T-M/*P7.H/Z8:Y7+9OT"GL@
MR/5ZIB&S/T %6)?;R_W''*:.E- PN<.[AQ#=FHNFGIIU\);IM@&%CR16D[TM
MKV4.:L]UM+87X0:TU"LY>Z,U"S\R]V_&P,C0=BL_.':4&%CMD*C]5<X"KB=9
M3 VG^@G-,5/+R9[=5Q.OSK6(AF<Z4.T@S.-\\RP1;9\=&I_,(CC FBS&B>(R
MG)86'O^5?]IMGFJ':WS69R_<+&AM'O/Q/OV,!9=M"M<=":W/T-;/=M3%:S5_
M^VTA'(!<VBAA-F?6'J4NEU"<F*-$"TBM>M]#+I70=1Q/&\?N'[.;#?ZN[0^2
MYN$VR+M#)TE:WT<+2,_Z'NZ[B='MAP)Z'F,?NX@>].(7!\C[)K<>X!E$&MZJ
M%D&+'L<68,_N?0OM5*T2>\+X<W!NC)')"3/8VHH4Z^'SZ$@,7M_)N!=HWP3/
MAS+11^Z:D;D5+^[4&UP].29UV'8TI(+UPR['-@%CS4-V88=;T. V2 ,9L0[9
MIKB#R<JRK**(C*JD1??/?Z"20P,BFL#G;;0KH&"UAQ"9OL*JJPLVS[WZDI'*
M*'X'RANJKH$IG4'_K[Q$A9Q$096-]L*@):PYB%7E *H!]$<SDRC,\5K9XY "
M!X5P8J[J[O$[36G8\T^'5[R]3U.V9/Z]CD.W*TJC>6+M?JYF+4+KTZ_8D59O
M\U06%O8<)_Z6J^E'BQ;9"Q6<F#[H,"@_>9S.M-@ ]KV52="9U/^N[A5_@ '6
M;&Q_[%,,T7"\,.MNS&8:C1[&YDQ1IM1;6'[XG.'KAL*X=BUMD5H+?1_M_]19
MWX*WXS:UPE<+CTL(?E&.+RT/;@R/+,,!F:7+^5&2BW_280M?QM'T[=#0II#O
M)O2/-X4PLWC785;A';F760V>PX)Q8H0[ZZ7Q9/BM7X3*-+,D8^85:W)\74#1
MC0:7 ;JT*^AES->S^XQ<+\'J[H(9E37A"0]/M^'7G(4E5]ABAF%S.XT^^V[2
ML.$('Q^/=$H(/6TG::BBSG'ZJI+<WU0X)IJD,X#Y+]#9$2=R]E(_.\LMIF<'
MLNL86KBABG_(=-S$1"7))D[X_#(8QW:NLI4[;</\?)@'%$2:TO3ODS,)$ZD3
M=8^?7RLAA2#/FTV5U#VMT[5E4FB])U'BN9^K96S OIUF4MX*^=\\$YP7-K 1
M%;D70=G<KO,2OX&V@V&IM!B[G7V[*N;,2?BWN?>IGW_E/?04U_TX3"(LS)PS
MP_ZB[$T&&VY)<5Z$L<07/_<C3ZT,JPO )<3?G,H^ML0A8'):#V5ZK<@UR-";
M.1T8\OO3S(L&R%=84H<2X;%;2^CH^B9.P"F4USQ>:,Z/[7,$-XO9I@.SYXY:
M.O'@\29;:H$3*<[CB-C\SP84^I_"3+VYG-BY:&$A$OW+KEF/S_K!(9SO#.4W
M])DT=TLN'4:S(K)3>0;[5EH_1YOZ?NQ)=XD('PQ35M/,,Q &T/.C$DFY^V,C
M5=\ JV9U-6]&U8S52LO3KB\GR)U05^,%@)(LK%/2<.! 6\Q'/!@PN9L;'V'&
M @S.#[VM2:M68\_3**]FS;['OLIDM/($I2$ 5QQ(ZNJ$-D,5PF1D2.Y4 O$=
M)F%%)JQICUM \?E(VBX/&P-/_EU?\_&6!BU+FJ+G3>A.Q206CQ/5H,$XC[HL
MD7G03&\@T[':>V6VM8:[0G(3@7,U1GY8M57Q4=FS'<:@96]?K3&4DHS*0#C^
MF='[G%4[8('  N%/I=_M$_BVOY7E$4-.\])ZIK4%;FKW;/RI\)6N3,.&]!!
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M3%"2X:1HID-X=<Z75_95,E<PDN4N_YDX"II\W@41_WY?_@0X!8J@%.8%SJ<
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M\Q5-.HP%5TP]35$IL0!<:>O5?/;KTVL9PS@?LH.B O#-!L'^E&T/ZN//G:0
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M IOEA<M2]88WV:R>-+9+$-\8%\RDXE]L(.Q4.Y+:*=M = G5[:SVE(A+0D
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M>V!23"CS"!7Y#?Y"@MFJ6[6ZOW'B#D21M:]J'D-;'6:6+RE_7/ATDFV_)@E
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M@;>K_!DR9W.N'S"&FX*Y>R"F!$#=L\,OC!4)K/W:BW%K(*S>B\EZWDYA,N=
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M.P6W=W-%I6P<=TT(X[8X(^0Q^FK;@,7Q^SQPSH5*J[RQZZ'F]H;@')FA\)O
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MDR?!+76CM8)&NO&J45%VSIN:D<=U9SVQ4KU"@]);P<+&/8*3BZ,3HEBN_AN
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MLOV!3K=E]#%RJ!?^H3,YQ348"/Q!#!PG;VCMD/"151-.+;;2\A-T>B_1'!1
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MCYM:+YRL0*]/33*Q@(A'\+\X_#R06.LN^\? $].AZ&K=Y[U)91SHVQ_&!UY
M+.RO^^TKF06C-1I;"V0)8_Y9M#G+0S^PGM]3AKIZI--X50NF/E:"YS6"ASKU
M6.O_!G@ZQX ))O?S&D6*73F$57\<Q_!59/,P&'.I56.E350GW.$^H@"%'#.O
MX5A:AC/H4AW3GB%#7+$@P7#)OX@)_F4+@M)4/GRB?)R4^@L&T@O$*5QF&0&V
MH;:]@R/'3TI<%C_I:U5Y.0H !,. J[9GK?::X@=R+51ZB1JY<JA&ZE!KRB,L
M%W(\E373U I8'9[K>@_S-\#VS,=OK]N^D> [SJ 5G5SS1GX5%OO#"HSRO%_
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MCM9E# 0),Q;)XN6^;OSIO6?S52?G![R[4V[-L^$PZD5P9=-)"S,F=;]_[/$
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MCDK0VYL*P-9J+K#>6I_H&A<+I1918C<Q"U-F7-[8NK.1)&H',CMM+34,9C^
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MEN=?@QVW:,=<P^K-LH.EY-Q/3V,(=AK9E[\/_&S[XEX3(H7H@#-W*.+IAN=
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MXZJ*JN(=%0+[QOE9Z)Y;VO?SCCG2N( H4YOY]=T?EHEEN#GB:U:O .\@*H"
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MS1&.1R#,_2E[*X371=YK2S^K@&;8/,85OA36I,C(4'GFGI%C'R)/L%VB3\:
MQ442:%3^6YH',OC?_MM%@/;]MZ3/\PCI$Y58-+1U;W/IRUBZJK1DUM-%S62_
M,^SU0/!#H8M?R@,Y<!.FM4!U3I*JHR+<WR,Q+NAPAQ[;^_54KW\/-W?G3OQ+
ME?@%+(\X]&ZP.@>)<.W\6Y::FW+R3YD-H4T9^DM3?O5V%4T6]+WH="TV0BI
M-&=)+6I82US65HG8H_^=/IY5WL0.>2YW"E:I'9SE-B%%,22@_FL:@PD(BN!,
MB"@.X(1?:^;5[QGX,DPFZSPRM?_3\.FNA ;;KN7#20<U^3A5*[OOH0*=AQ()
MK]7$TGL6FAL+7O$\(</$REPV-.$9TVJ_^[V_O1,1+QCW,,0NE5WZ;1TDYKH9
MC'_*FM!SF@7I=M :^I&8T*DAJL84)R9>_JTF:=HC#\&'78K_QLB[3KL9]\ $
MVKM.9$Y.<*Q.*CRBPGU=C8+%%52QU'AD,U@3<^9P=G0DI>F5;P8C2\7R=#[
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MW,:'VS S%[.^ZTW;])V/^F*GJYO_N-^W2BH(1FBG=Y\8K3_MISOENK;A+<L
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M/NU6KAI,P6YZRJX(H_4)8VEND$?.MN]Q@SXR8\H07BH3F:> [QOVD[AXLK<
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MH-])4@1>&S5\4F&[^-C# APZ^@= 67 &"S55SY W2 VOPP= 9ZH^&>H9NK"
MB.9A#(4\OLUL"7\.JV5M[#FOCZ;2@\N,,49=W)R& +O*@O8J>.:]Z$4"8;E/
M<## 3T849JD54)'!R'*H3\K&AS'+370UVM\2]352;WQU5VY U&7X!OUM.J3^
M""\3\N%)B^3"\':#[T./&]<1NP>Y(^KT_D0HBC8N'F6N?-S\7E5&P1;.:T5U
M[D ".6_Y&"HOJBK@)M0)E7^V^81U04JU]2+:$H@54Y@2T\[FU1H>%'HMDA!3
M$S\B^V13HR&SPF)H_K\Q]]YQ37UKWFCH'01!Z;TC/2"= -)[Z%7I)/3>-8"
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MB\??!_CE5;YCZDJA'H+D^>YX;^A9^,LX7MN:+L6"*,G5[3#O0@W\0RMD"]V
M.',0)787%W(/3-UD<;/*,?E,4I]X4CUB?D*J,;K?<@6FZ'XKC#:D.D1WICB/
M0/C'])5_%>R6.D#;6-N'?$#B096FOZ U/RX?)D:KUX=&@A*N2?OANY>C:MU<
M?T4X#.,(!Y0$5A)Z]8_0++81Z'CN)D:0D]1/,)N>&.'=X<<J"QNK!LX2T=EN
M!1,T,6F%A.]6!AKA&\]VW>*420N8P2V^'JT_5ABM5W__<RZL\D95R=P\DUH<
M0%&@(AMYR(A+--NO940^'."HS@RINR7X \=(N^2+WAP2\WRTW!JC#E"CJ+K3
M^<Q!ZWC&O4])*]ULCI/PH:K S;6YXF7BN=0?%J)"L>JSV_3A?YQ?:(,/>HF3
M>8S"EX*0-KJ!F1]K"P.F8!LE13"A3PX0V:'&P_<_/R$\K8,R^<1M'B1,"EM]
M.*6=R9:YOH*_WV<VPH-7BF!Q6+-HK+N8[F@9:]-S4V+XV1-CJ+#9, [X-+&V
M^(/G&1G1!MG$I?394K[R8BC)!_0":7BLL-IA>:Y)(_R'SDV?30;U2\OZ5(&5
M!%[=([>B@N$MZ@#.BK)N&!%&^&_4S=+6U0:13!>G+PH0,M#^4M?5"IB%B=<H
MR+H$4WX;<_N%6,,\C#=_R834%HL"U&@@@3A+UC4]+U[YZW%\)EVO 7JI]CT+
MI>??\]C6C..F=T!\F%2X[Q+%)-27-T8TU+V\*N,M>'(7JFE]4G K4O(>FJ="
M\+Q&>C*0:9AC;@@,.K$.QCV2<=#I?BN\3RPCRV8]&6_,OJ/]3%4@MT]O:\OH
M+>)63Q >*X9%%!I"=GOO',FEN%WWTDO*F^"N8YTWO.8LS> N;NI@N4#,(TAD
ME\$93G?VJV;P1M8>!R3^-<(G_%^'*D$\_WL(\/_4P0$59?Y9,*'?YB]*_7=$
M(@-X@\:,<:NC4O>A>F?(,5LD67%&$_SE+I^WN,FR%CN\G#O"P$/ZZ>>PS32X
M ^SC?=:&'<NK+>(3*>2S-!W\/#1Q3*+TT:-U+3R4.N='[MD6*;14KS,./1>=
MJ=S^B&R%%A)>$:=TL#;Y(K]=T.)RQ!"J%]M94F06'[2O.XCLIQ"6)]>15.<1
M%P\P*(';CN%B7=/A(K@;B1/NA6KUVO]F I5$6U?+':<DYX^MWZ^A+C89GS.)
M0UV"B#!UA3%"!/1Y #>=6RQH ,^0[E9IK-:#"LC2I$KYTAA^YT1T6:QC'K/1
MS5(%FQCXL@C&751TK$[HMP.BP3(FC%JKR102(5SX$!1,T84$11G OYH*@+J!
MG7[:66N=/UTG@ .)*H(Q^E/1<?LJ#*SA%^@DXG;N5@]TWS&RU;IV=JZUS@;K
MY^6=36@\=N9L>B<./=;F-2E$#YMWWPZ^Q6=L_4,CL]&8(1[ 6>^Y%2=9T#:Q
M=\=NFPFW!H+5]55O!FLM3;7MVG\A>4$4)-G3U#B^3:[S>B04:#G^[463'&Y_
M@2R7PE0H%W5'IP01W30T,1WP*MI?9J.%4,+:5C;U"GFH_OQ%B_#&[51!(F=U
M<Z(,HWFHD<Q<+ )U+_'SH\?69.GWBYRS6;[[>N2W1V'?G@TKBG+W3_'1#F;(
M.%V,R;G#IT>'HUK8S;U+/3T_)QML;P%3Z_7K-)A8=M@>)@U_C.F$03.8]Y(Y
MO^DTD8>(74$Y'F%QYYY7IVY5^E]%&T:)+P%N>J/B@A4QX8D/,KRE-GE:A-"=
MK6&N5!FIUR'N9]X,+3^,1&PDO3G?:MQG-A%1Y8PLE7KM%<HH;I"]&IYG]$DK
M#A7H:S'=NB"HF?YU@U[JXUR##SM^(+I@E^<M7CG]KI7$A!P-RH)[[TQ*O\A*
MPI#6$IJVC0>-(=Y!8*3J@2[%2T9ID)\]PL]>P (LN%(9^\@/.T@J#YRK ]0T
MTL(EO04 L[HGWX1<OUKE\2=J/KT^]:]3VL##8E;;DO%[8F[LNH6D50)C%J:+
MI&7+*8#38BN+$#C]3&SDE<>02Y[097'<B$?)6-#8!UKORJ>G$KU+V+CQA;)/
MKJ45V1-A=964*^@9[=79H7]T?N%?18!!#9?X [#!B(AZ99_(9ON@C1O*_(/T
MP.ZARB20Z7S(@&NA2RGKU&]M1G&%BF)V1_K[6\T6V I,*7P" UH2DF9L)1:A
M@VV\O;):VD%3;JTWZ6DH$CA#?A07AP6X*<H64H[=TE!!#5;M>-1V/IH:9^>$
M\1#FT2?'%Y529N*4NI0-XM#SMK%P]>+!]NV#Z3=*XT.2NDS@@+-7'A>E>!XQ
MBUD!LLP6V1#$JNI2]D:;G;*U=JJWSS1,#@>;700W2U,3V &3 O[3VF%F[9/"
M55RB?NPJB<>6QA=?-2&-3!\Z%?"T5\G0$HN?*30DMC5!'OT*!K,"$US-6/0L
MKP3YG1\I4, /TBCSD<4QVT&)*I<0PK.J%T\8(7<E) 9"& !N\..46]LFC;G(
MV3N_)L<!*ZU/*"Y$51@E]-?Y$)I\OB>%Y,,F*Y[2UYR-C4F3G3:4UUFB\--=
M/LMDVA<61UJI;&EU^>I^/\[C3YHCO4IGGX'B+2[[PZ>^/F>]/=Y@HVM5Q4[<
M'\2 'PXG#,\NJ(&<#4)<9Z#8#S 10V&+4T7_ 7V5L^=3]UF*E3!K'>RUTM;)
M"64/I)&^Y4X7IG?O;O8S#GP)>*?1]1M@^QN@@Q\4WM*@)%+;+%?,J_' (9FQ
M\N&5AJ[H+<7L]<]5A-N;IY6FRK<:=$,8C&#4%Z3HJF_6$1=8LW31ET,LANV
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MX5;Q[N333MM0WJ.?!LE32\ZD2VND9Q]OU!4C2A#5I!X=0GV/&M:!R2W\%M[
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M,]H?_+B\C7&M_:4'9:\,&[UKWUP)3M'BJ#>\XMWQ8?MU;+9^</JTX&B?_C<
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MWQ]]5]:IS2?"WKZV^PW( D0> 7\V;=TV?5'\M4F+?F:<9.F7L)R*^>T>N?#
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MU[@3OEO ;Z?J^RS:$3NL2B5CN7?;&#AS72J?:J-[\O!,T7,TCYB7ILJY7#$
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M?T'8AF-C!,4^+A!O%$2;<_1.NY:[OLP>9=C6(+!N;M$-^L3\6*HO-*&_\4=
M/UV*O2^D\JMJ,8EBLJ'5P?IT@9!6V2C;EF7=HD:ZYTM2E7Z*8*]5&4P..>D
MT?2[E6LV23.NQ)<K[8RW@^M9]"33SY/36!D^Z"][/-&L2]_>$*_--)E^&TA%
M;KM@SY&*QRHT>3(L+40_9>;K-ZP//3/7Y.PQ>3%U=U>X[QT'J-(T%B4<MK$D
MX/Y?P#N*&S)[]^'A]]\ G>-VZUNN$B'#X3QS5/7-9]4TOP&;.2@ ..FQBHZZ
M;A,>+98?EU.@>0/%F4$+^';A8*>8P5:OF=Q2#2$:$BJ::'XP# A\?GYW"TSJ
M&#7UP^3;?QLW^6=-D;9_ R;Z0OQ S"%)0/$RR[:X3X(_+$81<?6?O[XS(!Y
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M3OI@]D'*M4TSGB7TW1ZD7\S4P>_V'HHV2_9MK-RFX_A[:64UR:9BXFE/?GC
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MU]I$1%1=@;<'RF6!$E!:@9<$BV=]AH-@>?(SQ3I3G%N:MI]F+ IO9F0/9*^
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MM1"=@&EY(YI8"*FW1 F/K14X0B\/2/)Q\-/7;'POVU7IEO!S^A1NP_IEV.0
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MLX5CK1J?+9A"#9O;C?=7Z].&'Y7$*/MFJ^@L@<@WT\U+S.P&R75+GV3\0-S
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MR*IPZEXQ[6S4%>_9[]2+93%8 [8J=4WD?&O:ZCRUHVB9R<J3O]PII]V\T_&
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M.)>W<U24BDKC/?O /:(CT$K]ZSG%8^4TF>>WYEW/V2!@#X[<D?O,9>)LA>5
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M;[(A+$,6S^1R5]HL1RFK8W"ERY9;WAKP+F=R3]S^/ P&+ED'IY4VM91LOS'
M\\N"RB4/EYJL(X'[C98M([U=Z<:A)88*02DK=?2 ]DG[9<ECKD^Z(CWPPH'+
MJ:8V[WZ8^<G9L'QO"<R.V1X:12BR/-7XDIPL*)E=\(!5@D)]U>Z*SY5F@@OS
MK4[:9SR\$(BX@_\_U>JN+Y.2T4\A,R:1Z%@XE]X7G%4$ K:KS0&3@'A$WL**
M0V3QI(A@F:Q(]/AF)^<C-H#QU$K&2;]FE_.IHV36)=1KY4QGTE<2; O^"N81
MJSF6 2 3_5!(^"Y\8&,;E<LPDLRJ)^1MQ*C2[)YJ_QF-6 X80M]MR[Y$F1KD
M,GK70SGR+BO6P:>8V61[D'O*(4Y,41["F<RJHGG<L#<4\\+TH3A@O*2:+VPG
M%.DIQ83DBG>NIAP9+5>65+?A1_*>/!N*>;R'(?\TF_Y6]);[N$"*">@6G.E9
MI\C-J=Q;,4#2! .6_T)\9"HN669:5X/+45E"HP"K:)(K>-P&P('#V1?P#IDM
M9UI*$)#\%X:T/M^EV-\PCC\'V/%CO8WTR%15Z5#)MH>\FO5&?F\EC:OUIH8"
M'L_)SU!V$3DQ]*G!J4'X2],_KF7=YV"2V"?A(8#CW6HA06OH=<_Z<#3]\V$D
MPY/B_$X#[@B5AZ%QZ=G%IV#*$GEG.3%61POK]^P'$Q,HL,]HK9X)K2F1=51&
M[DJF$XZ6+6A9U[4+1YXJWF:]P-)W+J! B)1@.T?F,+;/#?TF'*EDGYOPE;O1
M-[8M3FHEG2'*>8>2[^M%8_]/K@/?64?\/H!@7C7!JE_=$IYGZ3-)F>C=@!_A
MJ(PJN\B2#[AN7[@J?VG1>HJ:=4Y0K IA^N-ST$P6UY> -H+DF3;&:NXL 4^$
M%H]@YEMS5G7>/.+]1OF+C9A^@NR^N\J9MZ,N%!,[W--UC2O.*\3<7=!@T+-4
M.WOGH".C2A,L2&ZV&F.8EC/O9%<S1YE*9Q >90NY&7-I-[W@9:(6"<FP>Y0M
MM!A5=MX2\V4J0RD&J.*#<N?HI6.N\QK.6[0HS!) Y>I'@^_$JT,UQUE;ITHS
M3KK#]/G/EV;.N'YU3Y,P'GR4(L-M;Y,A0Y1!<PLI9M>'8NHOIM=@F5T+6?(/
MM85B&F4:?7(<K615WBJCNFR$(I/[#/M<3VUKO*2,2@ OT_H:^AH99$>3Z8\N
MD>:H+A(Q5N1M;N=?D1K3<LC4!,FVB!KR-LU&TAQ%3XF!7JB4B+[51D"]=MR=
M;Q&B9$0_8%Q#NB.1@S@\B6-E!XP]ITUL"'P-KH;@Q*7<>4SKLQ;%?M']U3D9
MWJ1/7D:K=6-FR\5*Q4 B&']4H(LR1Z5B=:1OG!?.-Z&-IF#8MX1EOOZYFK(?
M_( /WG"OL%N)\S*BMS/0LQ?=$QU@ JZPMJ<2K";XAZS,@%54%!&XP)L>HQA'
MU,4R*1!C^UA?F,;F$8%L442\'IY-_PMH7D1+"2IWRA<T]VWC5Y;<UL[22'A.
MI%:$:4$#$<CH7<+Q^&9VMBD0@;2^):.;)M2;P3<)>S3ZG\).[7J"YD@MQ'@H
M$$0OIHZ"5E\)G-A!RI8PQSF3MQ30+V7DZA"!('%1?4>\#'K;5LV:<"(0:K.O
M!D3*BB+=,*0/K=VU)N*1\*T[T@VVB%$<RN3/@9,P6]HV+Q/UM(Q5OD$A@?A(
MWEMMCX+4SI=UI#U@JN[@SNWU-GH9HHAE%LUER-__Z2[%F4<Y?>KH$)HGP4J(
MQ,\]0\W)FZ;? M7V@K]=#D7X\\C0V7BM?"&M?,#*WRY;94RS[6K"-^ZRWB6C
M;4)-L("51PD="'8IM:7\EU(K&=U<(*")H6\&'=2SWKXONM-.:U%.GZP$#F@3
M$UP0>QHG*T4CQ<V;MY([\!\>I^.%':T.]>:QY&L>J)YW<DY,O0%"C)@3'4(_
MYQW"KQKDPX4=@8]G98;4:$*1&7WG<3?<87$%?UQ+ SW'AJ3?.UWVPCVP=*1/
MI7/5@Z(M35]"SE!%2./2!%FFG'P]P6>"F?-1J!H2#'&EF[K'*BX#%W#*VMCG
M#?&A1Q)!^-^WUEL#.!1CB-$ L+"V]55]HILK!1F3P4DV''3?/Y"P%TE105@X
MK@$4&4;7*%<;O97H@/=% +6T0$?,"20L0..X *X[",OHF1:@4T $'!!6T0@R
MED&AH2!!$PE+M-_SA(B$*]/&DIZ EK;MBP$<%#,*Y>"*9O^B)XG#\0&WJ4?L
MY%60?Y"WP'&!_:F5^XZ1&;]4RGEDH&1J@7VH%&/2(S(S$Z52%6%%V".I]]FH
M&XPK'#7G(N6E@),[$H*,TLG,5@^)X>$$R</3NC+]3Y_3G1$PLQK*5&85B#:C
MR53Z5&9+FQYM6U:?-]8JZP(2]+69E?I3N:9P*Q(5#$-#)T\\'4U!H;<_M6B:
MY,8PJ1#$#(D/<>=Q1&!+2IHA>IMD3%"U$1W+"$-=,_Z4#(VN%RG/0]YRS1LW
MFN$*LN:6#;^$CR%X=):NB78&6UX6*ZSWW$'%,/%0R(R5TL@DPG:BKE%Z)7"(
MB$8M)". #EJL9P82- G<I0Q7;2)P^371X( Q"<MH<6Y?30P$%&GA> F$:H\8
MQ36@M^J )@&[C7/.V)):S^"JB5I(00"Q]E] <^$OB+!/HV,9KA$5&D%NC"4[
M*X+@VA0:,^QA9*/*?9OKI^!!$!BB[OHWZA,8JRNA1<#,8-RNY"$S=P<9Y6H
M1Q#K4M8$]8 ! 4J?P*^A&($ 'E$J03K /J[K,1X4HK,TRE4'S;ZA*T$X>CT#
M&CPGK?]01$>5:*@0@<!D;MZ0IW0N-'<!Q*E<322</8Z^Z..><6W:@(?,^D4Y
M8YO'1>()&NSL>\K4<%6#9AOPU#IE*O.UA<,7>]#=H$.HS@@Z#;8%$XF+VY5
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M:OY>BT_$JZ.9D2E)A%U!ZSUUH"7>E5)2@#A($0CD"1A(&!P<7'^^J=-&LSI
MT"GP\"=MH#NW JFI%)?B61_/BK#-D C!!KMQK)=KK*OD*8>F1V10'NOKHT"V
M(),1&[4/"-9U!0:)#0=I$]FHZ_A9]0!^2!"./[=]P>"A<I$[X:3U^@!6T-=
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M#?YUXS_S(_)R#0A%E;7+?\7/+]^V7.E9'NER4>VI<9EG]]Q5N@:([EX#/-<
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M03I9O_G^.;G()#?CZP\--;@3_ZD5%/Q->N'I7+CL4SV;<W7B^G* V8@YSWB
MX(N#08/@1&LJ%/M?\Q\D_W,^-Z=7E5+7@"NM 4Y=4US^\Z'3.;XO^S]>\K_2
M>FNDH+& W*LFNAAZ4G[P_!$[YN,7K0V-?*-Z5GW[UH!7[,(VH*HFW/ ?OV7Q
MI&'@S,.&OVS3J/_OW4*_18P>+12>'C^X,F&_)%6]O/1^#?#AD[[YP2Y69%5A
M>8CRN#C<T?)YNW_=R[+YU\F_^A:S'>;SJAE6,1,;=.CZ!5)G[FSHXGSTZH+<
M.:9'M:.G=^U=<;I6.48I7!E=/>O%6OE[!(.?(#/"==,+0L*5'7;Z%FA%:78T
MX[\/;Y%[)W7AX5&WN):#GR^K#G1:+GUM^ E97B+.T'Q*-"GU-RR5]ZYK@,K4
M&M#%3"N6S?NWVAZ0\\1V'!VL\)-[=2FAR^5CPB]D?W.'CSGEV#M*NVM0G''9
MQ:)-JK1^(>&^Z^*Q:G6#P\=XI$_]:'SU&W;H\_8UH&[K!E?#<#>U3FB O$A8
M_/8/?'VP_U@M?^RQ=[6_>97P9Y&$]0X<2W;]>-4-M_+7,@O;86"D_5^N./^7
M6NX[KP'",BM.[2\%UP 1DQ^M][^TM?LFJ;;KM"[=*2UYP_H^&6DC,I#(71[B
MUWW\BB57V7HN=N&_03[S_^</7$B-.5TYOT1!ETLXDQ5)13W^X/)9JFR@\^#2
M5\,Y'9?%^0>K"^#DA/?N7]Q%L_SOS?^]^9]TDU5**F\-$)KT[X)GO\F\'XA-
MKF=%IL=7EE_%().>R_]7O'Y07?O\_P!02P,$%     @ CH%A4AUD,E'0U
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M38I3B+ABKNS(>B?L F@7']G 3/)KTM1/T!AE:*,!5HHJT!A0@.#Y S2&JD"
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M(4".X$<&P'/&<!BF41(^8.#HLSZK ,HL2=R@BK-47G2;H$O$763R1,6N,.K
M3*Z8Q3@DY%@&X>$'6GLN:II"WS+L%V:RALD0+[Q[C*_K[69+A[PV=7C&%3I8
M$6O=*%QC8VCN[,FMU#J]D[#Y*13TA4[HM7-A[]M:#AQTI>7>\9P2J6\9.06'
MZ;+MBD&!/1<&NT,>^4P_JW>]U S"B"U:[V6;]KKB 'OR<M.<L>);'RKOAYQ
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MYP0/JS=,-5ZR@P1_9U;TE:-:%H>$0HJ;FJ>KFO TC]YZ'95V >">[5^:XR*
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MP_<(_O8EH%.6N<"&B\$7]'8=F.PQO5B3+[MK(IE^Z?[)H_LCSQ4RBX>_X*.
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MN# B; U6*?L]<P\YD%P&7XJ:<DZG>0V-P4 C.8%6_[LH*ZC<)C=.;44<39)
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M8V@PVR!EKZ..3_;J3W>O$V7)"IX5N"T<LOP^)L(DC9MW=ON3^&#GP".]!VJ
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M9XP6K*^Z@NP&4&K)4$+X:)TTRPAS/=HET.7E#8L==&;?^ )W?O4&)ER\4>(
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M0276^#PJ_(N)"Z6TK(?ZT:CL@!SROL"N">HG\Q<]YX=%5LNN &R0*ZI:S$_
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M2K&3F6W\,F_N7UW1^.5VK;UQJ-(++EI#U=52[4K6 W.;#2R$06KWI^E#Z*_
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M^Q+(8M?UA^R_ ((MO_?\Z#UY&7*'K--9^;5#=0LAKN70Q]!=DQ RG+3PC=O
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M!ACM-"V4[2K2^B#!!B)']!V-7U^O(OX0P6 *^M-']*LK><$$;Z8>.K9;X;I
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MM&A(L?L64)D#)S N&2(0'F7RP&DL*$D#S081&:KX 7B,:(*KF3X-L)J1>=5
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M83R]08^?-)D8#_.R/8A_QN=F![JJQ%$JID!LB=FVFO5_>MA]LOM.7?CK^0*
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M/+\+-">P11+@'=,T=SZ<A[QR8QNZLW)6[IO L:=.?]371PP1/PD4K/1=%%+
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M]'M ,R&':M-WEJ69]!-=^?<U<[@!W B-5@)I5VK<O'_6-HIR ,QG_N!G=Y5
M1= M5$Q!\J_X-:(AX3$2#MA+ S)Q1Q(YW]@?&X)2J< $,8*R1QFN[^AC=J7D
ML32#TSP_35 O#4$7E4!Z-BS6O:"OS.=L4 ?]TK3-O'9Q7:7";\1H*- "]0^B
MD/;!RA:$$TSYP5"@1SVLJ^KPP+)-'YQGH__;O1V;<($;/?('P"L$$@'(HM@
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M=_9'_/E/>9__1PUR,/(/4$L#!!0    ( (Z!85+WGS"'-'$  *""   6
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MRAF_BW?O]2IO=,X:4G(X?2,BF.:JIICHSN1R@8>H">M$A]Y8Y-B"#%'^:(O
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M8\FTG>=?KB XZAHA>X#"%@&@RE_MQ<M<DBMUP%+@ CGW"4"(WJX= 8 RPXR
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M[-+NR:A)$7D-$K4Y<R!.%2KRL=U-CJ.[M-5YZD-_P'HJRJ$KPO[6S6QS2^)
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MJ/?T:;2^PP1U@-K/-=31:$P>*"M\)%:6DAA=[C0RM@@4J5:P%,2_ZKY!9"'
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M$R#X;QK1M@:9BU*>>G+O&]%6CHYF><S;=S2'ML3]C&,?(Z+L;$$N36=Y)QQ
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M(?*#+@XR9<+94%]6UGN+](G4D7_5<!D6/V-?*(_8'S07X%)=HXTJJBQ])N&
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MD%6NUL-$&9(+Y^B:[NW"U-XGWJF\$T\NS]?LT.W',_DZ<_X+8_!.R(/^%H<
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MYD^S9T2"HW\;ZY_#E_[SX7^;W///R>N.1BO#I<E]!_\FH,;?/'CB+X;_HD1
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M94JCY+A+I^Y](7PN%J\'&58J5.7X:#D0>)[M7A:\#S.C?/CRB,I@/9\*IYV
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M4*@+R,);%W"(8G/S=[>\.EMH26V 7N4RPGAOYPX!B,%?1'8BE\RN1>\1I^W
M,_VV"L[L[@OMKQPZ' 'M61T"8$P ,DGDO+N0T^FJ+;AJ$'C\^5B@V@_DYC%)
M)7)R7*H$P P^::84[M$(=E*B;RR7>##6&W0%Z!G.[>1$?MQ"*WPW&$YYWG+-
MD " R[_Y[M-%M@KVZZZ5@X.N.9'[].=,D[JCK2; /<C-P*"SWJ.",M GO@B5
MBE=LPIX;B%+)\]0 M\=E*680X%X7/_/I.@_N]8-3OCH?H8_RN?.7](E8T, R
M.%8X!A15OTE1'>"["WY3;P"7Z55&0$9!6LWQF&W67=ABYWHN?\T" ;B6=MB
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MZ5%UB;((]9+MHCV3(I#==?3$#(FA_"5*;(R6YEU%,KE?.16_5%T?O"<C9Y8
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MD\2AP9[H]T'#06<\<5S"3N#2</Y*2!A:S4)DST#M+/0Y9[TL+W%(RB/Y"$!
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M7_<2DYE#_$%)>88J[0A.UQ6(119TM%# DT997CILUIM UG*4Y0U:=45>XMQ
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M# KYBP@<3^10E/ _HO@< /LU**?M"1Z.X;%#6;AF.1"?X;\*L8_J#F6"*AT
M3AZ'=+:.A#E5A;^D7'7,Z+C#,2,F_-EV<,[[A8>,MO<_X?F('M&@V %&50X
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MLNWJWL+G Z!R#Z^6K%UO/"]@JU-\A'HC=+M[>AATE?_HDWVL.D6,YJ$<&??
MN\@W8TE\9 I$ENB+!T BSBPY[4CW$-".5\<V-[-Y !S:G-.AS=W:(<C#VX"N
M!.YN,JV5$AQ)&H47_!0_T;C",'Q[MNX5^WV.M6ZXW(KHT05P\H=R;'6 %$1G
M;ECJDOZP;0S?HH8[K, /;4& PPPMU-QR.XY"3)GA4>P9E(X,9'6H-A"WJ_<G
M%<!2=6V8*-QYX"Y)0:^DR5D;5%MI_R@T@TBX.YIT0IE#S@>2*%/]T%2=3&%F
M*LT5J@ZW/T;FTI0+/M0H(5U]DZ7B[!,MC;0;11P_QHX1O'3IC.@AXJ0Y_0$4
MJ#S<R@,'7NJ;EP[!C.QK-V2($;J& TX!"$*X#@^FQIW'E'J.!ARB7=M1R.#O
MNU\W@T-SXXZZ'V.2V*D#X-4?WHQ*X=B>=\=HJ[F?\P=-:Q__07"G0[0EY[CZ
MZ@_52_\P\$'O/\?'I//=AZ '8NCIOW ["C>[0URNW+ST' +.I.Y'K>01_U!L
MUY\I:TF=.8Y*><<(7O>/FNJ. 9X^;4@:NK:&CQ_0HV P=QSH]F:)9M.6R(\4
M6H?K>1AIG(YZ'@!R_]GWC##\*SY\_@7G4#"Y.]2F)CB[Z^#L %^&0_7@)P6F
MW"S0(4B0:(+M91U;0,JC].@N;9S%<J"?HB6=Z'_=NCT=<(8#3+Y=CO;*V:NA
M$Z)/-]C.6.Y:3%$R2_].C=(7&@+7X(>[VSK=N-UONW9 A/YEEB2 T+=)DL3]
M5 %F5MGMN(WS, EE8GJ;./#2WUNR\8AX !%/)BXQ -+0,@7X<9T)$P^W2%LV
MZ!</CU>Q2CH64D_H[BK 1Z"MN-+U704H^"EN$0UW]KLIQ0.H;WK@ZN"5.CFV
M2'_IVR9+*-/B"O"I6Z/*O^Y_V39$Z)V VD;M!JYF+8(K/W","#T!]2 *^W.O
MP"<$-S(VUI]ET^, ^%"7P#<X";87FH(T/&E!^H;X]YLB(L"5*560V W\N^&'
M3'^N0X&BRIMP#2]!N5:YP*'YJYQX OR$$/!*TU[^8;?L3'_FMYFK]'Z&TWIJ
M)\%92-AT"^=%?ZK/3K;=XQJ"[Z&AK17V=D1\6-HE"*X&0/U/:P&8\?UOJUTZ
M11I&'7$ X.H).%:BP"1@K0DN.)!%3Q!W )S<3,-7%.0< $_=KQ]6$53\QY6L
M8Y*F8.KZ[^U/_,4/@ GV7M ZPK"&\'K%/- *&?:*C#G#@%:0L/<AX1O_#"YV
MX"?B.B0@^DO[KW9+, LN_2,NWY]9Y*/\Q>LFV(Y8I/V91G]..L4/A#;_6?&K
MZ5$.W9^;!<#YSB',!'Z4-V:G.43]$1)Q%T?@?V4TBN@B,3YF$_6'LT.W,@MT
M)7(.Y/(%+@@Y'GBS2%N9!?*'^U_M83+T! G_IITJ>CT<@X__S0 T_7\9( I*
MBO@7->/:_Y/.HR,Z:%7 ^@"HES^<3P'\'Y'4Z0DNCVL@WM_N;@9U4Q< KF)(
MF*T4#?T,T_!6CGO @A_H"TRK.4<^DYU^$HMOR 9-%(7%V3_3H?W[=3+A?$:_
M"_20\-WP[1MX-X ()H8!X8?.8NB+=Z7L3M#3\2;/D< !L@D'33Y+DH #[RXX
MFP?)\H*,]T+PXY7P['"2U.(_X3W/!2X(^O8).'ZX_J%C7;##R8830OW0\W2Z
MDP%554M_LL?T>J2G2GQ4*[LK&,HOLK %J0DDPQM38$5/P\Q<J28#/E:O6=K5
M35@-A@?NU@1#7N2@R]ZNK:-SJ]9T IV)Z D6Y+8B1!YI0Q#BV^&+L%=1J&QQ
M8BOK^6!,E-:DPIT9T2#UU&L>"_JU!>F0P E_S?!R*M*V,7_%0'7D@PIO483:
M9VJ= <:JR5U=7J@(U]JX3'TRJOK,YJA$@[YYE3S5HG4_%)@30"G:;$[/A7L^
MI".],> O5P0/>_M-/'M E(:/Q6&N9,^ @M5]:"*J@T"E/GFZ^O&$MTKV2TZ+
MB"P%LC:,T0$PY'5OD8G/65,Z BM)X 8-?[_RGON=LVLDS.H*>F5 ZN128GL7
M!,VZEA;B9<Z87%QX%:"\2$HT5F/;L,.64_,*,1OH]]DU#$AIM.0*;!BHMP]:
MW&RW]7#Z*EU[WC<F=Z #:'<>IROE,*E[4L_;,0C<IJZQMD-SD&&&QGZ4T;XC
M0@[X*Z)0*'D[5A-FXANO84_[L'S#)B,OTM_;HYL->WPN#XR-7X;RO.73L69M
MQL FO+V7^):V9.W)V<$[_P/CW:Q9@MYT"YG)*$F/+M2<E1^0R@M:$IY>N\LL
MVP$4*%SQ&# U+\E[E>M_<6.<8W!VS5/CM>N.0.'0]<9;&T(!IP>K31082\B_
ML.JAV2L?/WZD?7):AJ3&HIHOKP2IQV2K0*T%C&L272WMNMC._UCQC-2TI0#Z
MU5))%F-2-@'WT]N$,!K,IR8YGCY2PP"K,*-F=_A&/M'0._GDR_/RR->8I.8X
MDUF.!^4-TB1^'TJN8GJ;DN2\QJXXYG*?>?%;$2((;)U](D!>N,'Y@9H,,S*.
M@2\9/Q4.C"";YFAFYQL0_<VD%6 =R<M5>@"8^BNFTGC2L\[XB#PN&+&??2Q3
MKSM"-OM)[X3!MU]FW\[/%NHZ2[,+)1F@Z1I.*9F6&83-[VFZ;UIPVG2(/_5+
MF*XCN[UK8#D*$2ZOI=X[V47Z]C<[(J5OA=*3+\3'NW 0AF24;LVCK%"#24/.
M8)*N]UM9:#%$\K*T*.83]>YIHSQ\9 F_"3J.=AG!@Q4\[5$LC6*YS8KEYDF-
ML-(EQ3/7DQ0TU& 1*]UQRFAA=Q;.LV3 #KEA7V:O</:'Z(AS'4+1W5B>P?F=
ME^61PI=*8'Q?DV?2G/*&&[=W]7].+IA3![V!7D-WQKJV3OLK7FGTXTO10KZY
MV^;YL%+IE5!5V4>SMGLOY:0\DQKM@/+*3U_;Z:PYZC^6!B?9+-<G]I1].Z='
M:G)\2N*FD^/DN_>>V;<)*=:,BCJQ/-!OL+R3-T+6#"/Y"9(@IY<RTNZ:,9E/
M.L]9&#TK'5YP]HR.B>FSJ5ZHKV5^7[/BK7M!)S4UK;EP3^QC[/#-VO<C6J$:
MP+X=T1#_T4/13CK:T"BOQD1G2=5#?;3#.O3KK&WTG$T_I2 T1:Q-J&A*94KY
MT#>1P<*/YHH3#3:#[D<4 ^Y@4J-:4D.NX&&1Q6U3OC'.9CJ[Q3MJM9;J9F#.
MU)#/5U'6[UCIM]BL=;9/B1G!NAQ.@>1S5JKN(LVPLU2L&."EI5]-305TW<Y-
M$5E2EPQ24C<G<OZ(+MF+:JZI;[XBDBGVFY^PZ<1/F["3K2A_V0?PYE.9[;]"
M*/+8"H.BT(R]AA]WY9M^*;FLL<8UIOU(9%*RR1"@CEAO]Y1ZIUKH\?U;KIB8
M</J.BS+[S!M,T+!ZN43+YVAQ)JFVX;WK[Q-_W?6^&S9#\/RAG^R'6/AIT[F(
M&2OU#NJ>8H\LY4K$RB\$>DKNPD-BP"M\P:@,C&GWQ443U8M=UGST*B,GLLR,
MK V>-.1XKB>/K.[)JHZY>SY]O&-\TVHBQ6CE:I+N]RBJQ2[2++OD$=;VS$[:
MLYOM#LBH/=&J6$65-VUT1:\K%NF!>,0-Y9,. KD:G!>FB-G:=<WS&LDKWZU4
M-+9HG'-+I_#51ODP&C]48<O2??LSH;B.RJ-^&'JCS*<24N^%)/CIR\EV>6@5
MY5*5K>_)WJ_>((\8!Z.#]?.HI B4OV)/8G)U1&\^_I%-+%S;=K>0Y&]\5"T$
MYR88Q341/V,LOI>%TF0HPCJJ046YZEP2ZS@ Z@35R+;2*:,H,;^1C=1E5JOC
M,D.ZVBA15C,[&8O7L+CGZ<@D'\7WL"@:WY+3N]&-O=L#"IZ/G<1X.%, /5+7
M[#V=RC[1Q"$SFX"HR_UC5\3;Z5JJ"^8L^=!$U\*UJH/F1QZ<XY^,TMJ((M>R
M6?F5&O'0A!BXW^6E3\9/] JYIY?,?:\Z4(#MF:L;!_W2;Z?8(9C:TZK/(A:D
MH=<2\AHVVU5#U&3.VE0[03^]'? QL/FHV3I#&J%'6C6V,#!@1#CWXP$75S*J
MLRGDZB^_QNF++G45KF,RKV$61-<JA%4NI*\MFR99GJV(^D)Y[D9-O#1H$P%W
M4.1F2Q)+A:TDHS\ZM:9*L?Q?8,Y68=TYP,]WR3\?O3+U?B XW7]KB?:GJ\6E
MAE>$XP8KZVLCE#U.\W!6X'>U+*K-B49 ['F$7,2J4-:2)<O/P;3KZ(2-CZ?+
MOW_>6QA)2B = E-O4RT@:'I"Y+:]]3G!B%A8>#4F"N;TZ(Z&SV?J,0;1Q@<J
M2PKRCT*<M1Z77/DR=B;PQDK>\,Q=:[OR.&7VI S,DV$S_S9R*GF;][!&)79S
M3:L231OF!/%4ZUUD91@@8"]@1T L[GGU(N)YMYJNII[EU;BA;Z=3A2A8@<D-
MCI"+MSJL5ED^_Q:"JH!^^HG6KD5?IAD6AN;8XTKV>?B%>VGF]N2O-]3!8N9<
M8^;-@T\U-&8J "^W3ZA=798P:6YG9\/'A5[J40^DY',JK5<'HP#D*],K!\ I
MID;8#SXWL9*3'*%933MW9Y6$RKQM;F=<LR,:90C,OR=+O_-M97UZ4O6)FBRW
M405POL35'&TH)Q]OM_66C?B1S8=QNB$[]*C4K[TW;YB8B<* *!U,L&V^A<@G
MOL3&G]9([0(8X]"#TC2A?*BK):FXBB]J6*TG]9UPW26'.2S76.<43^3:5I!G
M.E6.'X]I2@SMTV>=8TL6YJQ-B"&/:CJ<EWJ^+Y\0NJ5 (1I=F7R>,M6]Z>&W
MTA$S#\$AFIF79#,0+6 ]/"U4^NWWEK=)-V6$A?*Z-]I\[XY:/PO2Z!#Z+@FA
M-!O%W)WW/'6A038'<\>%VY+G4YFPEAJ5;#JU%3WB21A@&@1&=H_OL1=OWNAP
M,/WIQ^T0:S+H29OJ&1Z)("BX]'P=D[?:4,#2[&JV*?>4]2FG!K?1"3>IR63U
MP,R:%?^:6!.%Q3A3.)D4BU]WOFEK8\C44)4DP4)\?%8.[LE>^GI$/ GGU=SO
M Q+F3>//WXA,#5=IL*U9$.]_-!_2/%-&UJK"61W>),<8G&?O2NO.EQ(+[Y0D
MF-]Q+'U0T%![BN'#MR^%7GFA;Q!(_M7S+L-2TVF48[\[VO1>_GCQ)/9IFD-G
MKW!G6+4%EWDK2C';V0]!L& *#5U\+'Z36V\T"/;(V]A_W+3NV=Z].\35D5:)
M]\]BI7YO/MP>F,7V$2B>B%Q'?#T3$UP,6#F\YD;TGH%]3%0LOV'O)U36ER/V
M)NR-O,W;:I6)I?/+)[:0XD)4_L8OY]XRH -Y4X2J[ZKT;:93>]?U+;TYMV83
MH\R>6W8>7?&TDE-D7MR9"O84O;_>NT!C;]9:E#E#4H )KB^;\^))6!2O>W':
M)9W:QGOWT?NUH9N#D54EOGLNMY.4C#::75*1218>KU%P@@=T;%@[\^F*TU_T
MZ@*G^H9,%"89T1OIU!9EM4$[M,(76#06'48]U>MUM>RM(EN-1-YS/KR>*]0_
M2S231C>H>  TRFM[#%N)IW*TUE"K8WQ9Y<PM8@1(.2ML5G0C7I\+-CRW719!
M-I^EPDK,1@QX,C6%T+')-(<_.VO%$./[\Y?3J<%YFGSB.R,NED4H4;(ACR><
M243G^EO6-9BNLCI*T.@&SBEW7EHI'IKWH_%F -.>3Q^632#4%8]6-BN\89XA
MC;$T+!^6+>,R/2ZTJ7VTOTTZW:$^D+^01B4Y:FHE04)GJZ#'&17E<^/ND''"
M SFMI6;ZZ0R,=DZ;?=ZHIGC"FO6(N* 9]3.Y^Q)O8I-D% AA=>7OPEJ)@WC(
M"L6:B!1L44Y[SY8@"Q^PC^??;X5;3<S:^(4S%[(N!PI7? J93F5KV7T&LY@3
M,Y^#W+E]^4$3H0)S\689:KCJ04."<<OG_#U=6,'P:&Z67%W;LQ%5;\=G$_(B
M=/8\SY1L%Y(K2CV\>LW>2O>J2<>E!BBS/R@F12JPP+BA$DV,IF]\)-"*.9$)
MF^15C+R4>VJ?G@O5#R0_#AP2G):VJ$9>RM\3[/GM2%%0HZFP))-.]0[9:.0>
MM^VV^B851)D\C[#VTD<%M%Y+4DD3G42#=A!)U;;3KW4?ZP3$%\S:$7VIIGPC
M&EPQ7&16]BN45T:DR:L&&8;8K+1^@I)E2V(V>M/N/M'QLJA]1BX:6W1S'1[D
MY9?FS/O]::2G)$$#BU'OU\UR"Y]\,UF'(4Q2P8_QKU9L;T*%F&;SI) +6*+>
MC41-[A-R%TB$1'4QT#RS$>'2FK"S$<G I(^*DTC=D];6DSQ)Q8^];B*N3%1'
MTCM*C\(*!JI%;(M^D)L83S'/+1D,SS*NV*GKW-C-3(&0 6@G2G7A6N9'(73N
M;L4'0-!.SO.G6VUN<V<<(1Z34F-VKRG+NI<BQ$1;?6&D>AB3W)$QA6]5.L$B
M@<IL!K"!&Z;A(:,Z?NE].]*55&_?,6N<IY)YD^_#<(\Q\CWPOFFFV'QE)FAI
M3ZE<F$7ISK=V0'WR9+(%NVY69O)$+;5&D:W?T[TQUP-@5JT&8N!O?NO:T\>7
M27]9JO_\%7<%39%XX>1IK>^0T\KTCV4&KG.T?["E"^O"/*<3NJS\Y8?0IY0O
M1N+SR_GB:6(I+@45I:=,%L[[;$#XFP!/9!ADZE;WVM*^X.O*G$M[Y^%.(7XK
M[/US6V-4[VK?OJ^(N?9#:>D6F/CY<NS*)HGID89B]+6C3CM(%_%SF[PEE2I5
M@#$UT:7?/MGD91RLP'!G8CLO=O#B/5E)[9]M3,B.0N.M[+O^LJ4AOR%O^R&A
M6:CW6&:U;S^'];Q05?"0:TBYT:"TDSRWEB )7GQ!X,I^L9U5Z+Z573IELL#1
M<QE+Y3 9,.X!(4$!3K&XL'73K(*YM_-N#\V^IQ>5X/X-C@M%+N1$(OE0)YR/
MRQYBVH&QLN=I+O9U9OHE'DL]:?IN3Z!\;26ET7H&0#I-' !40[,7/=T6(B+M
M6!"X YC$I#GT>L3>!5R1C&L:IR)=+5U1%O(-R(&'K>5?IB/6/AAG.#!J^CJL
M?.L.DBF5^X"Q<.QY:Q2=)<8WG4YUJ9Z)R;-OB=/&XWV"^<UE$DOU'(_2;Q_O
ML)/R1 KU[,G^_,1&PDM3P*NR9O.NX@ (-C)]M68I&'-^'160>CVDQ, $71'Z
MGE-5_8O01BFL++P5<571OT2]H8YZ$1%:O9_]+76MW>WG;8(YY2<QD?W<FWD&
M%NX9!B.@.BU<'EFHM%JVT_@\NBO4O"$9I8G64=>*9[!7OOTZ8;[VW I#;<'C
MF2#?L>;"V7&*^R*B2KW\5N=DMR/MB$+13BD<82)2IPR?WMKF6RD>9X 9)2F=
M>1\D<'/L:C-!R4PC.VWYP.)W\=+[A$*)Y1@S6[96R936YH?IR< $7P_?>XS'
MFY9!.EOF'6,8F'R=_RD@,O3(A.[L [Y4I*O[Q"?Y&J%%JK2/)>?VA!"[VE;P
MQ.M<D@3:$\\0L0Z4GHA%6992Z)OGY"KONQ83QT:=,RL.JVQ+KJ,8BD8Q^BC^
MOEB5G\8F>B-F.=_59$D,-^@))FN)!T3NBSC^_)!@97WYXE>VPM)GW16B(7#'
M"!MA*ZZ<QU[!]:/2T^@9B\\M#W](=6-<ZZ5-3YR_;:DN*TG0+0J0/<8?:D7$
M$YQ=#;E[X1I0PF$6V.#UY)HC.[6\_;R:JT5-([D+^=5]2D]LWDIS\^I2WBBO
M^5H[X+G\[%<RLEF(.&[Z1]ENC6#C]?V8R:*B\+08GI0BXSR,^V=3MV><;61Q
MYV9X7Z$@A#]@Q=-:>1ZR+>FV:9A5+.5=[!DS=3JZ0C^#-*T-.,7E+@^O#MZ?
MA633CZ!!']U2/"JO2FC4B,,^18J==2B\2(S_KP=2V1)S^TLFB+YDQ?1U5\M+
MD]Z^D.O]Y^)4'XW)LINT>R%#JAGL2\H\M4F4@LH>+3_SNE<SU+'[,BY7%W#Q
MXPG[#3]E[RX1)%JC;;M@P8 ,%<Y9D6_DNR[);Y&^9K&Q%;2XC/A5'@-WRR+\
MT(>YGEO\A<^OWC6BBY0A=^YT6]:(Q?:#BJP6U,?KP>SG$+T*\@I,XIF:U2M?
M26N\%$L"8; <WP :3V\WY!G/E2+=Y*F6E,]\?"3^LG#BX=J,2?+=>%+;E]&^
MGJ5.-YYQ:'U9V7JVN'ZRS+$ZYHFN4Q=AS]W$Z"Y24K1T__3*1EL^WZE;?L0#
M;Y:JZ45^O:13#6?F2UYOOWX]W.!=[-"=>)= 2R=(/29Q-N1*2&=&.@4$J$>^
M/A\[1Q]ODI+67//96'XBC=P4X]7WE7#U*Y]213<9[C2U/UW6AT>1))Y4-%2:
M!0X5^X5C/]H<Q]U4OZ13D3?*70LMY"X_\\+]=EJU4*<"F^MCJCP76R*)R]9<
M0ALEJ+6)VCEF-?/FZ\5.'E:?$^48+>B7^;B3@;4:ND<]2CQ0J883^L"WG>2T
MK^[1\Z^%RL+Z&S_%KU8C[Z&@P9M#Q<-C:MDZ,[&";*03[14)Z^YQ0>)?MQ[:
M$16O3(F0A)^X?U%YSG2]43F$00U I2E3*AA+E.8F>;0[/5;0FK*%L</RN*3J
M,4E?3A7.DZ#)MU]\)?%7J(16!%]%LZ78]Q8MQT4'(12LD72F7SW%8Q)9N(VA
M.7MB[[7[JJHH+*C48(5('P';-_9UUC%*-WH"4M]7E9IHKJR;9<]:7R1 <#BL
M#4I69:_<3/URAMU>42EAI&&E%H(@CO,,<2;Q-G:L92JW8'BTE/9)ST4YDJGA
MXVBJ)=T']5=$A9/V"OV0(&<)3,GJ(M&O;ZEGO6]N^S$US6C$_*;5>.@,JUQ9
M#EI""-W3,*8@H22Z](R>0%OY274#"J'3YG3N1.$JK'>!J='TK&E_7-.Y-MH
MY;/&P17:ABOG1@6)6II]B_@F#"EYBPJU"(9L6O8%F":P!63D&OVU':PUI/6U
MK,$-FV]HG5<?]A'T4#W!%2[@GO\O-"I^TESB60L7;W5Y$Y8U<K/51'7=8[W=
MRZC8QDG$@DD^!%7=O/5E:.K7!/#B11<)TY,*%D:DP5N6:'[!DSLW2PE'>/)"
M7\N^$'K E];\*8K,@VY<+4A_;JU5R:$9J4#D+.56TQL=Q$5/T(ZIM:Y#-\>?
M.[_9_HWCBN5@7K,50E71OQ2R,N.??&;"TR^X76VD8DY0VE^1F(A-EYO_VZQ
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M1V64M/S?W-09F5C-!)M(:WD\4_)B'PI9=V+,2Q\C#CPN+I]M0T3>:&30.W3
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M;;C\@W/]=^SK>+(VN*LU?GVF'NKJFTXK@X:.D;8!U <B0 ^')'/"8B.3F3O
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M0.C$#Z^%2Z'^%1K[SYDY7'ATH>L]^$9G&NY>.K>KOO.N%&&>J_@39A@^.0>
M/+B=U;B#VUXL]"ZA8/("5OT%D ^H/PWK)![KJ*L+Z [#_?:RQKZL*!G%5F#*
M"V@%=EIUE#9;178T;&!RI.KK^*F!-HR,P,8*4]..#+C"25425OC#]$WS%1 R
M](,@":=7,;ZENW($Q FYP@BL:53:R[RA91'5@'CD<&%^N! U)I-+^AHE0K/I
M:=IQ8-6:\TKN?*W[+>%2 O=YKBMGVYXGZW>(:\DST7MO81$<3$P5U7?_E=>*
M!F&&RL74=^["2)=6RU3/629FA&+[[XV(8;%F9VYIP@/QBN:LN%NV0Z:<M)E<
M-BN#>A@ R $D-J-<]S>N(4TE8 9"-(=@.Q)H]Q7*-_E05$KF:J[$'YPDL91H
M?-20+.+[.[KE7.\W]D<V'>KJ"O#,LX?QNC?BO ;\E62YK4JXIRYD&/?5@_,E
M[;%]'[G-8E/FRKZJ*^4#W?1QSP.HLMKC2,]R,JX(>()*RFY;JQ!_8AUPLSCD
MQ4_<L OZJU:+^89M-B9ZBO*^K,KH?:H1X/BAK&,?A?-F+]B.#.,*A\*>>_B0
MJOGCI@M--DJV=Y 4(>N0G>3="V9P7ITEDY,]H@H>X.A!;_'<L32GFZN9GFBM
M+"VJOKI!V0;#WTW\CT<2T@]*5G-PIR4Q0EH9%_E\BC'P%%ZH8A!HWET(H)SI
M]5B&.M$*@!YXV*59LR57IV4IU79&)V-<+*%W94W8+52M ]=R'\4'VDW>D6:
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M2EF%]ZM<A=^0^>C"G4(R]+I#W*4:;BTAPE(@84OC:CH(:,0&5.[]J;_&,1V
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M3;,@\G@LR4+'(@_A-4^>X:K_, S8DX)D^32 ^.)0J?1P\5?9S.20^",%.5?
MHH&S;LIKI^;O6W17%?!QRH;N'(CDW?)W0EUGJ"O=A_YS(72,BV_#2R*BN$/#
MB-\&0$5I,0XDW/@'5C!Y7(%<CE<MHC+<%?+DG0_-3NB<)$TC<*W=:G1R[8B%
M)4]E*)<Z9ISAJKG@IN%@MC,M$KIET3+NTT@Y[)P!B2^;'#!ZH9%[N.@4Q7O2
M>7_]QYP<Z:AKY?:[#\F;#X=U3O@9E?=_BFP2-&2:I:B6,^PTANJ.<W?@=)DP
M9&9<%I;P[ACFZ;_^!/-9OJ"I(^;,"_JO5_.H%]=^AK!6D!,%#!S] 2BO8?\
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M-HAXE$.<P@L6WA):<&Q;YMY.U"EMW[+@4#IM0W84Q0>=[Q(@OCN1WCBN@>O
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M'M&XRGVN@@-/-]##'?<'@%.VJP 5)=RQ51MLZTIY5G FXGE(VJ<EH\(V<R$
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MYD-\2JSP<B<Q(/N'5E]\A$$1\9T>XWW43_$A/.7^J4<*6U"533BN678M_<V
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MM1EI=E23KX5BQL!N-."X;TG5Q0JPG$L4G*J[B4E?,DKA;0&T<I:J,D^"\GP
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M97(X4^3!1DBO@YY]]O9\46Z' 2( [155J0%R->H#P#*(AB"]UION[B[VJ,]
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M^U")"SFV ,@#6@0YR"X,)'T44HU7BT^*D99WNB8#[ZA]>0G7("_4>6/4\R;
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M!TP3[HMLL]B34K>4)+AKRP@1JBKYX6H]5W=G7)#I,=BH!SSS!)/';6&7B>Y
MZ;TV0]D$:%.7:=<.7Z[-TM):6KQ0_S=UW\#H4H%OH2 RWX(6@=4(?*#X4N!%
M L"RN5SX)2A69CM:_>>#V\L$NQB!DK<NIK9^4X)JNSWR.A\QK<\#2CUH;IP2
M$D".;IO*_5GNMLA#E).Q &@UXT:F#'5]5EF=C(0?[I'LO\A6^[\NHOY,M0>]
M5C2UU>>IO]Z>3^^*?4WY.TGXWXKQ/ZN7_Z-J6/!\_7H)E2HR^&]%P./AW0<1
M5 <2+SW^HOJCQ:3](;S^!RKM?T09%KSZ%[;_4&)2_[/IK7^:%OZMF/[?I%O_
MF?3J;]+?%_^#*OT;]?+_JO\+MV[]OX+]/XW_5F82+NO^,?TOUDC42@LZO?5;
M] );&B\_4M<=XC'=[ZRT2&1PGJEY?3P0N-MSF=0)A$<Q*_[L]8UW-?=Q'?M4
M\4!FD%':1D.5G'@#?"_=0:WZSH/]&'( 9@0TRGZ>,F;V"P3\K6^G/I^6-F^O
M#"8?Q.9\5K*>X*LT37ZZ/=\NS$(.-Z\SJ%%+LBB]@:3]L5EGEI]Q6)N2_P#5
MC]#OWGPB%X>%'I):?SM3;RGC'".=8X[59[3%&FN F0-&K\K>-9F,BR1T^2E\
MR3#0 HQKX];$22U:F:OVY;6'#GPQ7+;K31WF_*!?I8+CM57.XW9[9-MO"^H*
M75U3IQ.CSW4A&Q_#9,=AH^=H+WD+\P=<AF-=+U$6EH#$SVG^MX'S31]W>EKE
M5GX3&P5*X%0")M>_,50-98\8QL3%/@S!%9[56: :7H%"M,!KT"6MRIT,P[>0
MTE7/>*VE7E+9G?&_J*[;'/.?UR_G%U8N&19:R6^A/W@_J4>?6 +\9ZM(KQOI
MU^,=-\%=RM*^P4WEU'6+[XZHY3MZO^)KM_(51\Q^Z=O,[;;+HD M;,ZVM9M?
M!+&%SU*XV$I/>?N44-TY\,N*VI]?;%%:)9VJ'I?#$M<[ZZ$FNW*059^"FY%]
M;Q$6IHM25QX/?8#&;V<R1-V"[@7MANWEPA8:B_U5U/(_1"H]$X[T;N;<1C\Y
MGC17&%V$V&0O6#QS*WRT8>=<QRMRHC-D"1VR,8P$VKP3OJTP*-)C-/W)G(:N
M8K^$L;CB%"SYA@M_=_D%WAF]]/@G<=3ZNG'"LT[$LD5HLP:<ERAX8NP_@45V
MQ5VXDHS+?E.1G1BB:>LXN>(%[E+=,7>',1L](+9<OLVU&LEQN^3$^>S)_<9X
MQS,V;B\: &49^A,I"VTFUT2-57!H9 BVP5=,K3-1XLWT1)/&EMQ&,A'+IN/(
M]QF$X: JS?N+JI&6'S@]+OJ]&'.:+WB1<2Q9ZO/V&>&9DSO[74*8HMJ(E26X
M)4I]['NSQYPX$-0Y U7&115[+7!7^T<O6%0KI^YV'=T:<&A*NB9HC[^F(I*M
MB2ICL3B90%W05P&L._M#*&4,6]99<!>YO@ \BFJ/;_[M3-V!H3P/.^M<RX')
MI78K<9+4_]:)>NUH0>2R(7\R8JJJ>QXLI8=OF<"Z'&/^HKIQ_FJ-8#@ 9"T?
M*6-XV$Q\<_Y=X?G2\M>?O\#1+Z'?&15OE96QTO^X[?H7U?-JS.^IA8=[^]B>
MQ9=Y@7=,J#9>-1,_G'^'W_[;#OZAM0'#RSGS2/GZ^U_W?C] 9[T_BOY3=*UA
M]TT;X\1IXO]I7OM[\I\4\9=Y%_\SY</?E%MEE1[?&:DV_NG.?W<<P^OP-_WH
M/^C_*+J.TO:-_T%/^(-]]4_ZGP+[\H^/ ?^@/_R?T:WH:7Z5-#R<FK7YB\H7
M\>;DR_SZGY-=TO:U^"Z?1?7\177;W/ _2I<STA?V@#O:_Z*EZ!\W?.M_<,G@
M3].%WO^ SSW\YS7>_,'\JP83Q5L8JI#;_WSTU__C#:QPOK9NC*/]7SX>\_ZL
M<Z?[LCRL]8H792^!:!RI(5L*D1Q;%*%,$M)^Y89__HMJ7/XGMO!;V.U-VUN_
M(A0N+$__I[7!-ZG^GE:]*24HW,%.U6(7* F7<WP0J;/GW-)R<>1;&8OD-&RP
M5&GFZ=;$+M9\LSGDU;N'LAKB-/ALW3K;U\B3.US?8MRCNA*I6"V )_ '-_-^
M[S(C0YLH1*[TZ% W)2A=81\4,4[%,)6@.D_Y%."G'/*0Y]WP )/QXJB$V_"+
MVK^HWMHY,26I%33$%O%(%%>5BK:WJ[DG&TR%.G;BOB</").$&MH; F?5^=UK
M@(_B&P^ #>D*XK[3J_I7DX?=+08[X'>O.!\F9@NRG]2LRXSFH5<Y^KF7A63L
M-@E,ADLEW=;NJ]O7+9]>+]YMV-]D@-&;+.8O^F*LT0L7LRWSBDJ"GFE4SR]3
M$3)YWZ%"9%T=6 9;CQZ9!R^NFXM3^:#0H$+^C2X##7WGY+@U4$$+,H9!A.?=
M^Z,U6_2EU=?&=P$^*BEX&P9_);FY9C^]Y;9VJE,\ .4827"2CIJKL9'X:9>7
MP<_T/FBU,XD0;9/)/?>!N\:XEM,LU_%K;+*<O"&8]!Z'FUAIQTME%Y0!>@\=
M&LFR=C1^X)E#!^3'*\Z O:_,4,BR)12NIQS!-\7E:A#NC&86B#"SY*-HX%,?
M%@X#>JI'MQ4']RU7'#&/43J@$8!H*'*X/5DN'#D]=]R_9G09[ZU6^&=,JHN*
MGNU;$E^LDY.6H=5IK3K#_M860Q<*\\M: VLBF3N/WT]R.!T [S0]Z@'I&1Z9
M1W#A-"I]Z_C8/1H\@8Y:_,"BX<P$XJ[9O&$:&&XH%:#JC0A/QA=P!>(RNG@(
M?8H2IC8?IW(- K5OY;_M :Z1/A1=@7W!Y>5Y%'MSX0*F+$M97-) +-4O@C3]
M/QT@#'8W:-7G[S%%=75,*M.U/@Z(*1A#NAXHMCA?SY/E6[!EYN('8C+:,\%<
M>+U>@(V/0D7."V \1(C1W,%3Q[1E#D\6:ZQNE-*7H[7Q;X112TA[_5K"5V0I
MMN!"T9VC,;$O]*IR>OD<*K_YOOW5M"+29IWL<:'^ =MKCZYY:(R#<&V#7:8L
M#S"^%S#-'@.H5RL\0[-D% Q:Q2.G[1AEJ$BJR"Z^K\PVT__,A?"_6X#P.Y\O
M%_U:WOXI^Q>5(,\A^-8Y_=3OH[ '7']1/<V@BII+[V7.G<E;D-\R#_YQS>@D
MT:UC69PZT)($X7E@-X%)":#(W==NDW//HSTEW.E?!VB*Y#NOZ1=G++DB",_?
M_BZ@[%"I#/.]IOM=B%\Z"$U.MO>(8['_1/]DXS5%7H)*9<B8<-E\^M9/C4VC
M\E:/0*>F<++NIU0O].3HE9*);YN/-'2-YP7G ^]_<Y3[P8/^_BG@R!7R#HO^
M].H"XIDJR[:J_=:5IHR!VWOK/?*#GU.[U4*%!)A]BU]?_"[]BK4AR#NK3'GS
M1?!O06>G=>/@1TZ\_ C>M^'7*HU'Q4()EI:S;G,_/>\_8PX1'19]I/;AFQ/;
MPRG@\NN?=NAQ@-T0BXTEM=\.9_8LA=CRG&7)/P#ZYE4/59 OI:*]5,T/:LP%
MS*R:>SE/_O9R^?N)><[Z I:1JN;>5I&CJ 2K"$T[GD68I!A;R"!B__0+;$'M
M[:L+V@(%6??:)PW)N;!JK!>:/BN@LCEJ>4G$YY%&"]^\AL6OB$.#DM_O:O8_
M*[2&-O_:!#$-IP0G5PL]4OA2XJ%A=K5@DZBVVXWH?WFK=28[QYS4N-SE AI&
M/RB/:#T7G,)3!1YTCOEG\;SZQ-/A&75+ZC'V]0)XLRCC]D0;(B?FMC30< '7
M8GD9OVZ4IES&2D"^Q7Q+=6L$2>^.3/VW\KXS**IVZ[*A"8(DL4F2) JTY(Q$
MD9QCDY$,W>0<!41 &I"<&H0FTT"3<U"4G"5GE";#"]($!448[E=WZJMOJJ9J
M9FK>N;=J?JP_YU0]56?7<\Y::^_S[$WEH80=CT'[_?"52";)^T)HJ3>"X<JY
M!70(FP:W?'0I6;EJ%'?=%!U>#56JRUQVP*D;D;^N !;58Z5I6C\ZZ8L[,<(*
M)\!]T@^#6U^QG%'%Z6]=_*Q5G)=VLRG3M+'5A'O*(\D:19I[34,5Z_*W;=QZ
M6C6QEN^[#KV(1V)Y>EDC.)Y099$UNXF./D\%"^51D*MG&7>;@VDR(K_YUY*=
M3,9)?Z1>)W1BV<%$R$8<*=E8!:;.Z,QD[OCWG-<$7JO5KVHS.W^' [[O58?1
M]U%W]/&<B%LM[33W_P>9@/S"K_#6PA?N>"?[TN=.>N1\/"RL*8#<;>]_3..4
M&VD/CU6YX1 .7U"49T3S"M0QJH)FI.VJ:G?E*:<,RV;1&X1"_$P765Z8%7#H
M\? =ARLH>1UMPES(%HT:SRO8YRY""G,5%LJ4 /YHUG(#HY)9M.WO,ZYK6/Q]
M3%SN[L#74O/XWE9(U!^!9)U").F^M$(Y$K-!]&O><B'^1?@!JU 8#_L)8TR
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M^_!9/A0QQAC!674@3)M]9LKLYI<L("()U9*B29P8 4-X:('PNI27W^;=L]!
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M6/IJ*4VA2I=2][G=DK^/6C#03*/J/L1D8GM9!C;1185Q>8R5F<YF#Q=S7ZL
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MR:-YBF.O^;Z:Z#6F_O*N1 J_6I?IEV*_0KU:=<$9)P4Q6XVXYA4_VK: EFT
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M90B#X>F\6<I/0I^&C.,T(2K]R'TJ*=TJ-HZP"#&SL 177^,VN\S3^VX('++
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M8+7>E^L #YF]]YXKP=Z(:K=HON&\I^4.\M%N "E -7>4A\0!>GUTWOKBL
MU5+XWUL>YFB2TZ(%KA0U)=X_S%]% >@?\1%[[T^[6T:T6NN]DWBW<ZR//+O+
M9Z\#XY5O.A_.GZX-$>Y4GC"0<4PPZCO=>_I*?:X+$_O#/;0(X(LBNMU[[^U.
M^=/^^X3[Q"O'(HH(@-_I\!LKGJ&QDM)9)E63*CGNE," 6+*SK))&F4T2NT2(
M'+2%G;0I(VVOJ1S7F5H-\;Z! #,,9K=]51%%F^UK/'?9E95VAL0)]V^W VTC
MC4*29"0Z%R/58YM0DC!::_?[*>9J[Q51#(,'"M7--%K$@N@$>G*?&*$<F\4G
MSH$QL> FE(R9L?^Y6;:JYR$5RC>/R_(U)(9,GVW0P]R+TI.7"(IW*F!_> -#
M>[B\33P=<3COB?(%6M8\=*OI[FX$]L!4JU[D^7,2?1]+Z<$-VH-H8%"&+]$(
M@?6LY+]B5*U(8X[U4"[*;SOS\O2[XOD0OD8DY5%N\#WLG81N:XD;J?;,UU_R
M'%]!U[?W6\HPBNW=&_1ED&&TNK">831D?,7VP2NXNQ(4-!P%:\X@#X7>?/\!
MN,Q6:A/;(&,@FY&Z[[%XYL/+,@Z:'>==\\]D&Q[OHXP%]$I9*XJ>5:>SQZ8"
M3=7>.I/R[.B)0LH5]#QLG^6Q</=NJ6<!=IQ!SU)[2^5N0MR!>593.JRO3LAQ
MKN8XOQ/,MKIX_IGN)5'$^ L^9HR1'YM*IM*KKV10T!>J@2"ZW/R.CQ&"%)V&
M# VN!ROM$_FSN\%E.L4TG<5VL4WA*)F^5?9I//WCJ9*$N;?]655.>+Z<\.F*
M_#VGX^,NOR(IHMY=.F8)OC.C&"1>[AN;4Q@0.\GAVUEH.;D8!!D_1G/%ZG"%
M.J>C3U/I'30%) D*>C4J=3\SM;>\RXZ=]'*-^(/4T8BB?0GY-_:(=3UQ)&,8
M+ZBQ%HX$YI5+SF>>K0V,DZ)&G>T<Q2G8.R2Y(B[3P<0'5G-;[-AOWN_ [%;J
MG[RUXN(7FU]P\KXT2U6;F$UAB9:-U.DJACEEAC$V[E<+F-VFU9VZD1FW.0-5
MKHR@AST%4FWT(_C,!)\.')8^]:"S5"IT'2J=TTHEH37JKISV_)CEK*H;1?&Q
MQJ[>'A<K95S3318T(8%C@:E8N\XF >%A;8WZO&<V<>,&B*^,(9U%)*OWE52_
M[:=5-:)5!89PSG$J::ZV70=">J[Q1<_DI:8CQ-P]BSSNAG[I5;)>>"<1L("A
M%0]5*K:_1P#LYPS?\LK9.B#P$C,3UHVG')CD+H-YR6Z<8[/RT(2$(K 1;\+U
MAS]872]8+<Y"]-+.?"4 5Z,U2_0-'DYU]J0V? LZH2@LSVZ?.MI^'3O,%W<O
MX(1P,4SUJS.?2T2ERU'>D$DZP*.MW)T;C,)Z)!A;11YZ4$]_\.I'&KU6&:7T
M^#??)N)ELA8@=N[*3'&\LMS@.MS!F!ZU9,%8!Q#*=TG8)$REP2D&M8\X=X;V
M]G9VB'RJ:!*]>7S2<"V)PX48.#/UOAFY DJK:KI]869SLN[II3DW&M(<DO38
M (8C&JI&:(#'*OY.$FZ,^B[\KK<3L,(K*F:6FCFB]Z7%+F:U26CD[ =!HY@L
M\UF!6W#W$\NMNTI<XD\MQ<&>R>D+7G86,]@%KQ+8N]_W"!SQM@!;&'_3LY!V
M1.D@HXBL8DB)^<@@*5^TH-ERFT)]-6L,TED2-S9W=%AVYF72T,!SFUKZ:>68
MLNO$9FF%%=W[O6Q$[.\A/GSZ,#*?6%OTHECNL=>E*KG%BJ#JU+<#QESP4C<F
MG,V7]T&LUMD6HK"/V0GMTQ:K<["/_O*R@^-6.)O8JJ<FBDB6NM !]J?[>368
MW]8@EGTRS;W3D%+AU2XV'2^1=W6,,"U!+YQ*%9R99*JJA3MS^$)GCDA)(8OX
MTI+" VPN3"M =0/^\\NDWQ<>'DL,"9K[3X4TGEBI2JPDC8^+QY"$A(>6 F+5
MMX:2$@%AM:WA1&7'N ?5)-%N5  ."VQ^H4)<0&LI,!-7T0^OFFHM-[E]1T..
MKIV,JH@Q4BI5,-V&MC?8V^EKU?6UPY?4!M*E8*4<@[U)ZK-@1=]IE>;>:+[=
MEYUU<U]U>^HT-'->D5QI4Z^I2I=%MKY#2GD&2#X8=S) =^,N:$4+FK:]%/06
MMMZ_K$,I*5/UP6-5U;\5E818^22WD )G6:Y&^DM]*)_KS!:4.S#>[!P9S3M>
M,?U\H<M&8M=2QAYO<80IO95PP)-: B"U;(YDLG;T&M,8.3\W87!];8QU/J:!
MUG4E$LDZYF#!*!Q=_7)*[K#5K,5>SII2SW?MV?D&]A]C1)5[SN&=3"CXZV,R
MO 4-%9ZEI)]GA+% ."\P]$L_:<$[/9;+<51ZL6SJV#[E+?1AN8N=[\#(0-C7
MQYWGO,6'<8U*\ M#TJQ!=UF>?NJ2\<>V.44)M5Z6Z7E/ +P,X I"EI5A+$VN
M=[1"TS]$/]/STI[%+TPA61(5CDC(Z9YI%SW6&QQ='2LB.5[]1$'07)I217:,
M.R:X8LN9:1W(FJ^FTY3I^K;PP6]"2WZZ+O0=*ZFOHN?(-984G)]-$!&+\PE=
M:S2V<'?$WKO_F@A9ZO\T+/^IL@Y4M.KZ[:'U"Y[U"V(>0ZN*R%J"+!.F-E$8
MB)0B&1Q-8A]GPL\3L]+AMJ\#JTU!'Y\]R@CDY2,Q9;2ZMC:F-*)KCKWSO'(I
M8<UJ3EGR05NCB9?#K)*2T=?(EU>]!<XG>!:2R2D*FK6.[0*GNX;55S,:+6O3
MOMM H04GL\-"XE=<Y:,54.(]]P)8X.E.OQ3GQTJ#IL<T9G7T(U(IWQ=@?5/J
MVE0E#:ZU1FM*9"<F]A8%>(MKV]./.2#?=ROAR4SY-09*%;U?YH_H'FJ=&OJ2
M@%P=;;2D[96+BZY!V!IS!>#%'SO,2E2PWQ;%MG^8]+K6<X5(T6+N9IB:/VQ9
M<O+#"LO@($.:Z0TRZ[>%V(]!S_(^>XF:L):6ER"EKFHDQT;*^H9%%3K.WK#X
MV'H@*\.;V_3]LQ IO/B(6WSLLX7=IYVSL4OZ$<>+'WJ+*VKL&W_I7!(QGT;)
MXZ$HIVNMDCDNXEP4.I^2F=3S=BG13,\R_D-%;7 ]G[.C^CS3HIEZ3(0H6W!A
MO;LJ=[R#'U1+GNROEO,O"$!01WDO V(+M [=&F;CF23(6F9X#T.;2X;&-FS'
M$V?WYE%RQV N_CP?_P^6GZ;^*I$ XN=[M;6+Z[<4KYI.TWX,KO5-I?V(8E/0
M#\'W"I5RX,;CHCB:!U:;*6]<=-1&CWR9#0^B[8MF.(F\&TGM1@!41L8T'O@_
M9G-F&(F 0\7BZB/D;+A&!GJ*D*G!+-YU_H\6(T^.EY[EJYSR%C$2](RYG34E
M)VP=<AEXN/;($7:2]9%!&AK.$IC+JK#:3D',B!F# [=3!=U,/[[,D/%(46^=
M7;"6-&OUZSLUKM3F-+3:_H"V.EECX)D(>X06K+I,_\F;SELC J($H$\Q.2_S
M1H_Y!AHA)5X*\*"<#L=[!X\OI;T/0KM[2E8D$]-B2WL[39L! 2@+5#0/*ZKM
M>\9XYV*G4H,+C#FMF=,N&]LF6U^M<.G&2:5!DX.%Q5FXT;>+\1^*.+YXU>L7
M8O.E1RXXK).\Z5$U^AJE@+-!Q43G7*QU=G2=/Q], &J&HI]I1U05I176=4<_
MN]"HUGET2/%AY%3LD=Y"1ST3_+!&*8^X"=KH0X:NLGDP$8V"-<D)C:I?^<G1
MW'%'_]5WK5,E8+.KC*L5J7I/:+%K_FO]9Z7O??72^ZRQ##ZR&E/T<?$MEAXO
M_Q8_FI%=JHL_H/^_(KFJ(HA)THI'=%K=BD&2RY_L+7=*4#*B9BF.)$5E0$ "
M7GH<NGPN(Q"!&(F?3;A'VU=,DITA=V!4*RC\*XMG@.#]=^AYCR TPM;MT[4$
M8LH3.OUX;D@'V_S-UJ@F4^?,W=)SE#/%T0%+9G<K8-4OK\H)66N/?#%='8_.
MIHH^]22),8TX)@>,[_-O&Q FYJXE&+VSI&,#\E4J+W+_N..(8"5\4NL]>[]+
MQTJ4NHU&@*,+X]KB^7EL_MD[\/* P=XR@X@W!G/L%LC5\52)3%<"X&Y!1%I2
M#KA7+CIZ8-^3W=Y7X(%7NCW/-3^OGUKRHO'L;L\GHA$W?E#L3FK^B,)@A^3Y
MZ24XL^W*(8'E=222V7Y5A 6ZY@TOBEU>:?Q8Q#F7W9(AQ]\C<4,TJ/JEH!R7
M==/(E?=!U052W-\").E:U0;KS$WR[76OS)JD"ADFI$GQ2&;-Q9Y4M\8;33T+
MU/=XVS<M*4[&(/-!4I, 2-;KBS6]68J+N=WQE9@3E,&E/#%H05!G2#B:_']R
MV<]@7HF'7R( KGK6V1<) "P+6<)3<]VDIM6$E  $BZS/5Z>-HGW@0]314^@)
MZ5:-@;T=1*CX_*WT_:\LQ'DD$!:1:CVH?JOP7M]:(^)A#5I2D0U,ZZ!^U((6
M'G#8<_E&,RUV%S'O[!W7P&=(WL&1ML>NH;OPKD>^*'6DEX_<]-9+269HN&_0
M/2?]S/X-;33_._AGKI='2F<O/SL23+ND[A'=D8XDDNEZW6Y?;Z716?.B$.8X
M\DFGZOIBI,;J4"NS4SF]VE(\<G6HO0EV,9< 1.U:UOK&:KK\.3KLB-Z-W?J>
M54=NYRY[KTH2 %0D"GOLW-5B G#05-MK6XZ-#CQ.R^E[OO"D2V5/Z7N0 ".Q
MML :SF6FE%79$  9^KG8K_KE\Z_AO%&N?H_G$G$<[M%+K/CE6/P>6;750 +@
MV=Z*O+35.=]&Y_L;OTHK+^ML4S02  KV^+5J8B38C)=G(0A /2DN:94A$S>C
M\>Z^Y3<JM<(-QA%_@?&^",<O&ECY1:&I8VOS2EN-,E/P?Y!6,K9#X."_GE)V
M:N1=](S/N&FW_>IPT%8;4[TU=/M.DQ*GTQX]]6'P?G!+>4'?4AULQL=ZHTE9
MZJ;:05MF& ZZD!.T04D -DG'?T^Z5!S-BZR )",=RJ<CM]E[&6P:"+9EL#KV
MUU:P?Y;RNR"_))UVD=,E +=H=?"#R#ZQ[58KF9LFDMLR&7$*USOEF?S#\Y;K
MS;37FXDOFFY!>]-J8AZ0TNZ_ 1A:C[\.&/:E[X"!_SN=^Q<\1@#^WX[8LJ[V
M?YUU_RVA\R,@D/^*@/@?M&[B?]ZZ\+^,W?\#QLW_E7&3)V5HDI6<6:%7F9 T
M7BK;0N?5K]S:4"_[: FK[;<B1 T'AQ]#DS:_M2\EL*+=<LS%X;EE;"GT]K]E
MNJ/]ISV:7Q<5M>_;(1OWK=9;;M^[VJH]#"76:NV\V"#[T[?_^8M_Z\)6-W.1
MR0D;$/(49&!3+\>M?@BA:GNI4#8)K%+&.:9:I4;M.Z%" *@85?$SN(G:$J'/
M5C@5ZM GA8PT'9&C!*!?0XT P)O65X\HZ4SLN2*#I7($O/_2F&DO[-FUZ)G$
M> (0/8:<CE7"\8PA1U9,5T<;1(GS*#__>*2KMQ.RHKJIO 0NU8_<P2@4#UTH
MGU\3&K8$;U)Z+,;B]PF&K4VW%9AB=8A$]0OE2XVQFW1K"Y9T/<B*JJ;RTI7&
M[[(N31@=V>Z0^!VEN^DR/@*_(@;J(0"_IR1RKHB*P"/CU]>W@(OI3)93)G%%
M'[2AUYT1(Z$?E,@?A&#I\I\47[.Y111;5@A' (@Z>;' =^CFP]:'XS?F6^U+
MAVTR+]#XH5'\3^W(=PK0^1L!<'6 "W(F*^<GLBV-/FRK/K^M.=':V_XIW_*/
MZ [W0)RW+*.T*>IO_'APIW<DPM;ZE]MW[3!U^8]&\FSM.'X[OM7*^3]3SHMM
M:[)AR T-E#;),^BWL;!MFN5(8(H(/#.K=17^;,7'/QL1F"K_[A2K;:W[?JG-
MAMJLZS GPMHO<!V>SA7;HL&V+26_[L$M701_H\MW_"#_Z+Z_CK1_!I,_XQSY
M6V=/QZK\(B)VDN[PM]H_8+IFX_>3K8D^:$9N !FCY/(SB(BN9,1#<9OA^F>8
MY_Q2^U_A]_\=XQ3K\/BNR:^"+'8;4LSK+*LW%?J.IQ^J;X?$AP:(RU8&'-W*
M7-O06/<*;"?2^S;U_3,ZB*+]$1Z_4?L//E<:V.#4M)GCVFE^Q]'T+R>"OZKU
MWPV(WP?WWTE3_[NE^QX"&ILYO[]\1WH/^@$SS.Z)300T;DDZX;<CB?U(6)C=
MTYNB_:"\M8-R:_S FZ/^J029\X<$&?OS^!KX\TC\H[>@_VT25OV;)&3\,9'X
MT]CQ.QEWYI'_*C-&$U-B]+1W;N6.S"&B<4LDSK;O:H1/=(DEW5BD2X#3FJKF
M@Z-OCT\8[Y%D9I@W]1LH:/;4%SCS\?65&JZR8-0P=(42"/_%WO)?+B4C ]&X
MF[$$P+V4Y<<UB@.K3@ X"LM[,\]DBF+/( <,CJVVCBDD@;JUU+MY3F#(XA.&
M(\2 G(?FZ.][,*H(;A"/%7<= ,WI;J !I-!G&B.W#XUO[&Z'H/:A1==7 (>9
MMX[4B_[AIN3C6+'UL]CKQQO6CW\'-/Y4OTM-)1(!J'*O[SRN=_0_=YSK(:"E
M(/!](;.^&C@"=5!3YT(QBN5\:/8#!!0<"0#[]$*R-5\T=BETK5D>)ON) -1B
M"<!B;]FM? *@&3V%7IZKQRO5$(",Q06V\A4BW)PT27-^VN'_>6MK_53[[]RV
MM?^ZZ:^5]EB#IS@= A!\!HD TF>B P7MEU(;S)_8N\_7^\'G*)^LC4\L2GZP
MK'[$2#8*25?-3YTP<4 .G+#C(2M'W!1B3!X?G,<H)5'E'DF'3ZH1ZV#^!_%8
MW+C60$'Y" 8W"F[P:UII+FLJRQV)K7*P6+N &_]@<O#^2<!AN0E<HN+K)'Y4
MQ@">T.OV:G_;0'2$&+7C46B?F+[79,>MO6?YV'([?#\7X,9\FA\K'*MCSZTC
M '9OD '$(+55BB[C 34NQ[9%K'_/=A$RB[[8-@B.@#T#G/#7%A/Y4>T<,@I4
MRM#CN GKZAF-FS2 [>V!2"/*DTB7R'?%97NB$"AQ7[3Q0&%6NL)3>]@S&1NZ
MZ$'HJU$7M''%"\64.UB_X];):_WRK!Y^W!?/$8!.E: 27J[6/?OMH:#B A:C
M-KW<Z4A7\83$+W'@>U5<X\FRKP*N6_M;6[*R^@%V5Z&/&>Z+B\'?\"JT["$
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M.4%!97WC2,K/)7JNWT:'6*:[O4>#K =DU"]<O70-@I!WHVD/N'*S/P)Y2E_
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MEMLH2JMXKD?G* &$""]Y>*SH:@-929.O;@EQPNM:P(2A<HLG3Z7R(PZQ]Q=
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M18F>N?O5F<K%2^L]1<N(I'@/]MOLHMU55N5'P2$!/L82L?U7Y"A#]I1+<X]
M04U81CVUM=T *S]C9%>;!DXM;L7@@:=D:U2E7DB%_O&SY#9MB_H]\:+NZ4=E
MX)6A7V=;^RV.]W6WYW/E7]EOF<[QL;&WS*HT9%+&U"DOWE=T\&"NRS778Z:%
M+^G9%.652<V#V1MIAHZ!A0O@@=?A>^^Q,Q1Q!'N5L\S7\9FTE!Q+I3(<N_S
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M]N^84OP]@/UK)@GJ_UC:SG]!.+S[JQGIYY'AW9_()7Z=P!;?K&-!/VLF/2S
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MT;( :"F?)5?7"]7*OZ_%>KS;PQPET*BN L[H;WKVZS<L[=S;VSQ7CZ&0HR<
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M+I/8UP:2!I["1$H <:9A/8-!M1M(M'62A8FAF7.K@:3)?"-)KO\?-#I6ZH
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M=/O5]6><1A;8X%\;N<%,&8$12ZX8I8>XD\615&[4;OL-[KQ-[5V.6_[ -TH
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M5!$!E9HHTCM(D:J TJ3WFB@B&,&H- 6%2.^H]*X4*4H+D"A(5VDB'0*$\":
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M]BUI#E^LTBK[?O^HX6EV#URH.ZOJ1Z6.^2 3 7_A+K6;*%&V-B-@R4_("$N
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M&C3VET!,(EO7<%*OTP* =<BR. K>S(VW*87-"$+D1'ED27@FI[0<!83 D06
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MXP\<80&9ZAHC;T(?8YU"DD\:)7$-Q]0=U^E&%1XZD$.L_*3VLAANE >Y#=X
M()-F7L,.5Q)+/1A\<6)E7R8"5U)99# RWJ=GNV]B%9>S:G,(FH+6GZ_F,,_>
MIN^__F[I"A9!Y-?-99HV"-L :JSJEC-TZU-"/[;3E+RS.W?UP.<R/X,^+OM&
M E]60'9&BV]*!'$08@>3_#IRU2?[MC@LC2/#(^LI6,W-S#;3^]'!A^$;0(X(
M%[*GC-0H[MG3KT_,H?"JN\G SN$SO )F5]II<L(OPBLUB#AM@MZGI'J1J0W
M$"KIZGW?/#EH'LVD'F%@$C"!Y%12/@@JQSW2' [6.$TLS!J:,IYRS=@5;T/9
M/05Q#=*/5T_,+^A\>*$KQLW!B%H)=XFK8*!P#0O&O3+..2^\/K:G8_V9+^;.
M\TF3IBX8U#>>U-^-4:;NM\0&><K8/U[S;C"R7@H]QH9F3#E.Z971_4* HGGT
M+7=L[^TJ-0S;H4M\TAV3>L=Y>O74L5+MU,4/96RE7TU>-+^VG++_XK3&2[L0
M4K<SY-9@9&_JUW&974%[4NDH]8L67*4JN#?\4"SB\Q.M.E=^N_^63">\B??:
M*5CJ%:S8)K5-5)_I6Q6_<FL![!_!IM778(O9/%TARYG<&4S3NL_NAFE4%4R+
M^>+.E(4N9MQ"R]@\X^BW6.TZV8KFLN=</$C3GWF:_9D>5!RP^="_J\]6*$VP
M^XULYI$8CG)L?]QQ CLP/B1A%+#5>Z0[H-[H?-B*BXMAFY_Z*QE3U'V8J0T[
MLX+Q]S/;4L;4Q1CU@ACE <_4X1.BL?)EM^]2TLUPBM;UM)8E\G)I*>X8["Y_
M@]IM8SXNJBX8*@784/:]V54Z968[N[]>U':FR>G:@$2.$[7W<_$W<*&2^XH2
MN7+#MV(D[G^U5'#YPDLIH# C,QUZS[1OFN)LR25L,,EZFX30)XW9Z$&QI4-,
MG*^L+3D+ZZ[0'9=U%*@H(/45_B7S26R+EV%<ID/JQGH=BY977&G5>Q74?:DK
MAVP(BH#GU3<@3&&,(N9KVG[:^_G['@<9:[_FAB6AT4Q<E7AM!A9=E3P>;3<S
MES1\H''";J$[4E/'L%4)W?"/S&[$H;R=[22!^*(FX$\ ]U,#.X<>''6=L\(%
M#,$9>8)L/SZU7,QYHXE?TDS1A+')'JQBD;1JU9"50Z[DZY=4=7L<JPR/LRAE
MH^FO]!KV?':IZ"YM;\R*$G/(D!/]>E;M/E$>SH>/[\,XH;4!#DZ"^AT)PGL'
M<7[2@=>.RMB_)$#@/->'>\M]E'M:P0:5O8T\P0>XDL1 H^QMM4H> J./"Q)$
MVICK\+4OZ=%CG::OYZY0VX_Q#P8*P!N3/!;03((SFD&*H6?GK>[-QN_R*H+0
M'RHHNRC7-+?:[12T 3AO .5FY3V(,^:LJNNHH:[KAF&Y F\K! 9C9O>^<1&M
MDJX=Z"^'ANWOUX@#N*JQ)0.T>(S#R5>)=['Z1Q;UQ$#=QVJ4*"FK- 3*9@9"
M=.6*YR*?CU8ZKWK58=>4[G[N/\_VVM"B4D"E^W+7U,WG)[@YPP&;;S,0@^^A
M!PR2?EQK[8!NIXT9C_H,_W89"82D7+(_5>5N95'<II+E0NN"04B'&,Q@VOB.
M0E5:[]1HHP;7!;#6G7IM?>D*#]#K/1;2$\)T"M!/">,ZU<'<E\D!U15,Q15G
MNA+>3Z[W './*M@XX#3C%]JN)_7+RN$PE0$%B\0I$??NMCXTHWFM+*>Q4(F)
MF^F"UA2*XFEAX9X19#LEDMK-J 41?TI'$A?E'?3JC71V\^,$NV6!4,J[4>$N
MJ4=N$@IH5\;P/.:B'*0NQBBZGW;]73.DN3)NC5%Z_95.;E@0GI=M^ 6>E2L4
MSI].I+Y,H)G+\Y*4A#M?<$A2@".T!.+%D_"B;TKU>;UEHR;+J*.%DK3#+'+.
M)B4[TAI]*"K><[V>\NC<+*-,5MCL\>CC4:],/I<GRAJ]+2_<NZ\>\)89N'ZS
M6/ 5$T^V,9Y3%W*(D(6[&WUSU$$IU@CNKD7S2'X(3(\27LA<EF4(O[X"55E\
MFII.9+<?SU3L0RN&?/#F]%G1_'0AXN5H*X2O 5/9K'Z4::9+( D-+X4=: NN
MD"PZZUPXSM)Q#4&79FW!_9K*_O"0BQ*C8CV+N4VAQVM7@='I/=Z!PP(X*SGD
MZBWB.Y5DBY)UU5H7$Q&>$[9A*[5KQT?7;L6L\9/^5K[#GSNP 61"HL0)W"S0
M;J9F1.F04)J)L%YFV[[7SC656/.=\AN =,@G0QR17D&_=S<A@ZKM8&[:*ZRF
M;!('X!+;!=^A.GI)F&TA=[G&C,58Z&8:=\_U(B\BI'@N>X1U2H^@E?;%":72
M]RSH3; B.E.RKR26A;4-7.=?/.RP ?2X.8Z7/9O$$E2'N-V<6[.:Q-\F4*M)
M:4D]UCNPBG.#!%G)Z">5S+AGIMDD[S^3C?DJ6UCL,E3^\*XSG#]5+"[HH"EI
M=+9?:CHD=^ID$*:RY\WA=P$"3?Z4R6)T86_:,)4W^J7/T12*'' *<S3B4*:5
M"2<-LR;VFIA6O_7FJ0J937G^H!E&8VDN:>?YX*SG8,;'^*[KS-(KT I;^;J$
M?G%6W?5.C;F$M9 YM%6"7<Q:PWQ&4E<J"J%^86Y@+6TN^9VBE@W%VY@7C>\%
M[=N)$)76-Q']%2UG!:E\8VKC% ?O^7;NDZG6./9E4FO"\=P^_6NZUR@R[-[/
MQ=Z[*[NTD!1O=[VK+4=4E]'J3(O5PX'^A^Q,62><*G5X<EV6LSAS'C\>[#3:
M"?9"[QK*M@J8<#>*7X&UN'YL3*LT>:;,=642BY 14(CQUC4])\M-$(AJ3[QT
M)W8"6,<-*3&LO9_QQ1J;NF%S["0^/V=]TO6R<BG7MZO);?IBD/CA"!@[W'8Y
M5?R5S,1=#;Y;:NQ ]>CC[DEEY<//L&J%U]XQ1H+:88':NEV[ WIB[S7\\XL4
M/WZ1-V<U4LDIP2+2U0O57=EOI7S*9\#)94M<L#2[."RC]O*MFYI"Y^1!2*66
M; EZ?75>HD*IM[$I\R3^AH(C:[L45S5U$>OZ1)GXY6*IK(9L\?=L+P7MO2=:
M+S<>2Z&0\@OWT I8K:V:/1P,E?$AIN2T5=MX,M]=7M[+94)Z-RYUDF=B#'C_
MN5+QW!N%9-PM_"F)HZ4[/LZ;S:,;BIA;*"2-78*9A1K(_?'4J>.1DRC\4L1Z
MC]Q?6TT1: T4#,.[HPR8Q_HF2==/JCB/==0#BC-OY&[0,TE=$IR,C\)YHS1N
M3*JY6YG%1[TFB.)R/CV?,Y/7R;JK[B'+BYUR$,M@5;LY@K8#YC8 BJ_/9X]V
MV06:XO,N5Q86=AV>2P4^>C&/].\HCE\VKB@!IH3NN>@3='/M8H5#EQ\=63O3
MP)EQO3J+<**@0G!6E$\ZS( [W9M2KQ/D!Q5_WF:TJ,GDG=BF]2RT8#:DM]6H
MT-&#@RKXT6AH&#FE77V%U,@N5<4NG=8-0&#>X2.N>!QG[V?WXFGC08,@[R)[
M4]4Z+:&P2R_>S)_$%7CKLQW$[+%J=99LIUHW()XU@'YEGWG"1%0L(::MX,KM
M!N;H2DD=&>[F6,*<3,,BM!4A,]=&E(D8UXC7!JN-HE.-X TO @3B9XLRUI\D
M-@\5W6/R!6;SV/"WI!+VLGZ&]]4+>4DJU@DS7;3-HNG1XBSAENU^Z>U7\P*?
M9E 2KZ$7)R'>)UQSQA,5!54!Y@=V3V+WVG?TO5-A+7ATS: ,+VI@JJNDV/<
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MXB[51P^G)LW>DP<W+U(Z]6ZOV%#6[WO)RW%&W,:;#QQ ZE;<UH2@Y1K$9K4
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MGSX,@JUDKQ@93B/<2)*]A3C\TU(U.]YA6)532C.*YQIG?^' !E#CE+(!P$G
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M6\'/0,YG6 :NGV^C_X%02T-1FK +[Z5;-&OBVK;OTN,'MJ#JS2%:&WF(IDE
M,N'AW";+=5/')^9P&H:6@GJE]1ZR3"]B!VK:P*%R+@U#,"Z_9'CCHAMQ UC,
MS1^&$^ZX;@"EAD9F*.]XT=)'B5+T,W#V\2IN0Q-3?*#2T+F6_!3 &&\''9:G
M62O,&+F\ >QE(T:I#BTF8\O$^$Y.72I,&<8?*>FXJO3:$ D,5G$PX6/5S2HD
MZ>8& -OB4[&/<\2NG,W3X:3Z*4C4?_FTUC\9.6HG4D15'CAMD_Q.AF\A$F@C
MIU@13E&6!PZR)D8C <N#E[4Y/&0RZ\$@@R]9XYJ&8,^,,31MF.JXWL<7X1O
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M%NOK6\N.+/C&M+COU#WE&0]#?W%MI.!L_E$\B@<&R_^_"0!02P,$%     @
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MND_A-)IMJ_E'K2'R[93:'=?A"CX7E4XW]Q-1 @"-OLE*]LN%4*[BX@][RK\
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M8PCT-V%16:<K0_D4DYT.H=U"LZ?X9/!,)Q35;HYX-;-*RI[K"VXJ&VPDD!R
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M[&G"'!%(X$^:58>>)5H,V/Z=%BL*^^Q]Q>-?3XW\4^=8_G?)T#G[9_J(_2_
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MUCF=/-<]^4D;'3CX7%9)O(B;=EY!UAJKB5H?R^)0,\^00W8^C'83?Y0M^^A
M3*[VM(^NQ:E Q"11R;RE:#4C5>0U'E4P8GBJ2\"WTM5I/?W^L:V%0]['Q>"[
MI2T_@PY-O::BSO-(#+?1XI*ON='5ZHK-#95HY]OX[]4?9%)GC$F"/T >X?/B
M]N4&&ZR2CMLT97 TU @7O'OG?)W"=*&6D<9V!X%-6  ]72$XTT<::-40&*?J
MM&HUDJSG^<[D)15F#+7V.^PP%CNU#"A%&);/THK61Y@GQH!Y#MCXFB-';)D>
MF#4TE4[R?0A FL6T@EP+L2>Q*YAD<55A%:;9FVX3S]B>C_*<V3>]7R:(RT.U
M]Y.4HGP$(739GQN_/\>)3 0KNL)6GE(R/>%3GE5(D)S.&&/>T>*CM[GMJ_W)
M_'*XYI+;>>S:KM>6>["7ET4/V$OH^O#[KM)9=8[[$PH_>7H,!Z^]&,][-/ZF
M=:(X\0 $[\KPN+,41]( <:OH9VA_$V] .JYOGR!UDPI0Z5;3?<-R/. ,=50'
MW7=V:253%' "<+].5L6RHI,&T*!7*V7$Q[>^,4GKJDKK89_]^2Z546=CPC?V
M%!^P P*H<WK$G(L+.B,IP/T/7-C_B'A^^\!_&^]9NX9J-&=U_K)^)WN<!3YZ
MUD;.D[?=@UK)(F>YV]XF4LVAMC;7SV9>K[QE [Z-21[7K M:F K,;6?/$)I@
M74<QC]RN.<G#U^RQ[G6YJ,Y<QI0/"B\ZK4_Q.+9,.D:M2#CRNF,E\N]DSZ%:
M1_)SL2&I5=ONF8GK\L=3\]_=L+0$)3\B72#N3'P8 #=270][?WAY4\CVDTD"
MX^,("_+:;(**5X#GGC& HJWA@= 5)XT74A#R$J_&7/[H-^5N! =C6N*S\L,Q
MZQ"4GU;&26\C8QTW;BA?\A2FHM;MP<.7L.T2#QTOGGF!J)4.:EW-Y1?%\3L[
MD*R:_G[NWBUHM^-[.2<OQ&L-U:"*JLFM+V]F5-:-3J_#2$DR\5\-"&##G#F%
M!B6/ZN2P/D:M[>RT0R-!B_%#*A6USOKU H*.<0*-^)GZMUXAU7%3AN4]+3X2
M,QX!QE*.7[=:+EU*"6A'G?/%#J%*]MRW=V#*.0[CI65'TO%6?=@,D7JJQZL8
M#PE8677=>_H5C<%<CV"#!??H TS,LUFKNR(C_AU/$VU1#T@JR!.<S4"??;PG
MBV;U"\:[&*A6G),>CW;-NKJ[,G<00 "2(O%V)S=Y!Z9@K,LE>*KH?.QLTC,W
M@;&M7V!^:I.&VIQK++%FZ&+J*295(F[?@5-AH_+AVJB4+6O"CNET84-87&*X
M"NWF+^!+6L33N[\ [@/8NQEWL.9]45$Z7?./\0N:;3^:+-(J^E7T1_ILRM;:
M_>2*I_JEX8OA4R='%?NRC\HKY,WG?_(]GW@LY/_$C2DQ<\N"N36L9'4D\5ZD
M+4A?V[LL3WT2QBZ3R,14P-5D^BW@M4G:"OUTQ(&%N3SI%'7&,X<ZR*?.:PTM
MO/E!T*+R1K3 _.9>14#"02E'P4GB=WW"U#J+V\NO0T,6P-N43E^43O5I[5B9
M"83<,H:<299W#^EE&3QY"*U55F'82]QFCKL9/ZL[>JI:IYX+S#=%1)AV*8$3
M*.2T[WZ]'LW/?R-0P_NHRI)I<L^^6SGM&WJ0YD)]._C\AVX.[RU$+1K\;&C(
MPQNIS7AY*_KDL?MH,!EE/QGO30!'C>LGY<5FOV>0'ZK"4NE;NUS5V5;F*9%@
M0)UT&;?F NB(39G'S7D,O0B2L4*.Y%CD); S_(0'B.'D#K>CZ9N=30:)1^SA
M31^4H%,Q8\UGZ6,/5G>T$M4ZLBZ/56NK9!Q7;X,J%:I,C(Y3J='S]#<"@IAP
M?XQ-EK5_.2[]LLMQA*[1$SY"?U(4^6RW+3XFW?TE_\TE1$:M-EKIRZZX.E-B
MUN$DIASA=&W0ULCU=5@TFFXEF"H4P)O,I-$U4FW6A0C_.?ZC!/T=O?\=Z?[?
M<)RJ_6Y$@(OA]W=0$ !,7;&'0M,HX_*:R@A[X@#J#9L%.]8IGE=HV?H>XZ;0
M8YVD% Z<%^G1\M7!3^<2)'2>\!$;0UU5?2EGEYV%88E=MSX[IV%_*KOMY8-T
MVX]H8-^?;N_N9QC?ABTW?UD3WSE_)]%>V:TF=D8L)1X(+7WW"[C;\C1]+L#_
MOG-H'>^ZZH&9UQ9=V;FDAC'D$9FN(IUP"4MZ=UIZMA];ZZ2KM>[S4(YN"P,2
M84("&10XV\ ^AU87878]S9=-LDH?[E>?B+2_'?\0SB+<VC(45[TZCD5(B,?S
M0&TK'I&()O$2"Q7&J#G1/ 5O2N2#.SN&E=P^A(*1K#/':O*V8M;(6JW-!Q[=
M=O[^RT*8IK&OMVW-+5M7U,!.I(JUE4?H6T*XVN(LSM'R Y@[7V8PZ=5\M*/2
M$_:-['6-X>,?T?N"-JD^P:W!)-.,ERCZ7JK<8,8/DSYOQ3KQ.^YA_$C+36F(
MAK2'8[VR]>OPQ^ZR\+ZP;!@.^<B-LKJYE-  _04\1AX9-TP9/)YX(%]<]88P
MH63C!@)5I^2/*&Y5H7HAUL9LDWGY \S[?0.R0_8R&?WVC4] V (;.,*W:J[L
M<6? XF<^U:F72E*V'I^S GX*+4=I#^?+<RPF-$BLFR_-_ (6[C;,)02'F99#
MN]J?"IA<?PCCY:N,:VB&33"_?:R.$6E\/D<E6:MM\-5PYOUY<7KZ$Y[83S'/
M-+[Q"1)YFAPNBNG1XDFB>09RM3EN67JWLC? -1TN'=\Y.+">5#;_P/+@C;CM
M/TUW?HV$65H6#\V-V5H6.'W*44UC?CY=I95KD1P0A'D?J-M3UA3PVK[+JW#O
M&S)H$+W,<L?C>D6==J)ZT_W^CJ>&=^=[NCETOQM1=)BQ+[-X^:?*+@B1P$_-
MN\<VC0N_\/\"OBTHS'PF0703\AQ?IV3'4LEIJ<_VMDS\ FKB->']GT:DP;<_
M[R#G!C&T.95WIK&2 8)1&F>:*7TJ2=?ZO5V+%V+['[H./.%KY[T.>Y3,XEUO
M^*HIAOJUL@7)B2Z$"<=&LX29=ZX4H #*C?32Y[L>#H<CE'34?)FL,SSXI#0%
M1JC:I<K$*B*X0G\ZTQU84*[KN(VA[-7D9HZR=(:OH[S&:%J4)XJ7-]:7,;0O
ME"5NPWNZ7^;H$-B2X9Q4GW20ME_G2,T?:$$??7]H[J+G#*K"2/!^"5N_F7&3
M+B6;I.']$YZ6DRDK\P&4&<-1G5''U*<TZ[[R+Q6N/FW6+C^@/XSU(K/3%Q\$
M<:=E^!7>#5=%AX8%D>@ ]+BY?(;XD+[B# 0:__]J[[JCFMRV?  500&Y$)I(
M4VJHTI&N@ 20'C$4D9X@O?<H1>D](" U@6!(*!(ZJ%217@)(DZ)T4*1($1CU
MW;EE9NZ\.V_>FS6SYOVQU\H^)_M+OKW.=_;9Y_Q^^^,6HC?\07X3T_I['BPG
M?;LB3/Q;!E3Y)#=!CGBM:P]G);@F\Z4P8<WP!;$M*TSL);T)_)UC(%G&5@[M
M:JS":IA+,L%XZ*N&PI,WTG"\AF.DSMV47>ELF33A,> 3OU)H<]'] JZ&]M5V
MQJVOM3(E5<-%3SX?8BF*U^+BL9UK_L"^2'PA-X?YRP-C[LIA2?+NQS,L"S@O
MJ=#3'CEN4-A<U]BP@#4[N&]E*ZVU;8=?X>WP6U\#SHC4N* >3X:Z0 9L.. 8
MN*CT*6W%OE!) +;IC)L 5HHN>PI99BCH4I(SL8>K^'&AL5)N45LB>V!"Z!"0
M=?KR"$],P='0"&'7FSS"3=I9TB%IJ3AY!]>EX-S+=%U3E-6G5 !YQR;3P]X+
M#H7)(5%1SZC?I)YVYV^_ZNU_"5DPKV7BSI%J<N3XM&8SHM@;K$)K&032U?TD
MR)N9*HN/ZVN1@J1_'BK"8!L@'==3!0+@?C-#A%@#[1[6*)I&)Q-?"G:J:TT!
M[T=S-4C51>F#C3G'*SV:(CS:"%415(_"UP4W"2H=N/OH$GT,"7TP\%+/5X;.
M.G4RMIT^.)MX>3BXX&MSM&:6L9CYVV$&DY3%!Q9^\SJ!;6(1/*\O$VS?[34?
MSY15NR!KHSOJ&M,"&PB>^C'6H,YL.YZ&%?5^P;'5H0FSR*N^7_!Y\DZ82F4U
MMI79<!3BH9J7OQ!&3)B\QS@2"P:E=YR[5?F.7[ZNM]IO\,SBX+.C4(-ZI:8[
MC(H[@RW \:,VI@/C4E[]Y'PAOWA1QUF-(E:R$#K9^I!S'3SR^UGVQ%BXRJRY
M &<M_FI0)XY[2&3RZQL!X_X%ER:0K#56R\:)%<A=:P&Z)#6Q(9<58$P8=IIA
M4KN^9S2P1/%5F8CZ=%2Z278GP.Q&3RJ+F.Q3E]LP3@%,S>4RO/HT4Z%PWZCD
MBG0P&R%IJKFT)P[TL.'3SIJX:*0O#^%6D1"JTS5\5WS=YI M'T>[;'X4T108
M3NVV4T)%U^+>Z8IS;_#!-^SY]XN\H=+1A=G:&='3#2<)P:>:MAY ;AM6.2=1
M=J:U+'_E>B85ZYZSTG9O'=[A">O26?/L\CKGZ69(#EERC#\41C.J@(4),O[S
M4>C(I"DR5)UX><\EQR1SNV6E$9;G#$T%'S,&93 5"BEQ,67ZR7I!5503/C&C
M%_%[>:FD$]*\H6:CN[WY%[O[;OF/:E1":JD%=Z9:F/N D"#5LRJ3,[1F4IES
MU[K2OU:\M8:ZC5E,2RUKO'',QL%X'0K GD/$BO7IAGT038_1>9^T/B0$,$+$
M1YY29F"7A+=]&TZY$(%8<$8/<D5=B5)T7>+4;%;6X4BW5&)S#:620!D?OD8O
M3-O6P("JAE4_BM_1)HE#6S\*RH](1_]-24@2@N''S*'JILSQY=N:(J',HHC^
M#'G>MX\9YAJ&47HJR]^A,O\*)OH!F=$>4#ZGQN/ 2XJ@E#.Z:J;!M)]%@[->
ML;A"J(@I2S0Y(--1JY@_T]/N6I!TVOZ=(\.N9NTD>UZI K'!WVZ*%:Q1@U=?
M-&JH=X?:O5(0A[8G2[Z/ 2[TG@ @FVORJ"L1._BKAZURX?/L[Y**JAS%+#,@
M<U(A@9#VG-E,[!R)NG*0FA.+IK.'<8<J")E4&WZE0G:_5P<Z9!?.>W2P 9UJ
M^!0Z8>_Y!"NG%!;;BF($$GNH3<5?.C_'=L=F,LM?D[C)\M;'.FN$V)26V_?E
M7GQ&6]I+C_4I8+MB:HYTQ(Z6;JW[(EO8J'@,]W,%F;E-6HO-B=)'GM:#?,O?
M5NBQRQHH?@N?1?BN1K+X'-YTK^K@'9MM0Q%;?L%84PPAO=/9YWJ+OX^C5U%(
MLVQ12!^)6=N+^.<M$V4'(X3J:%Q1^\V[Q253L@7&\;K%*'DE2Z4/#X<]EKQ!
MM(HWOSX;EFM$M7!YLL<J.A[>8[86H-W!5&9'O+BSZA%5TS\K'8X421X"CBPS
M?'I%^HR'&B1U]\(8"NV:ZB79)1GJFT@^;[3<59XVDML3QX^3<*BU^S;=M*TH
MRD9-5K1GUKN9/?T2*>)%WFK:SPZ6%:J-*>?_RENPPL9-*.]=(&?;Z80'R]WQ
M$2JWU 4O6@VY?*1>]+E_,#*2,^L^-IV37H*&IBA>NB, ?/8Q7\QFV$M'Y?&6
M27&12GX/:"-5RZZ^2XDR_UX-KBM(@$F#CV;6!$RXLYXOQQD>YH4LHH+-QHNY
M1CX,>E98/)L9K3Y-SD9<X3\%^V)$&;$AX=6B4?>87P/2DV6U??,S*$@XX(DJ
MP/_@=OX2E-Y[!&.C; KT/N= ^[D,$)R*21\',.$4N3%)'\;"H*J-#"B35'_*
M-'J]XC::)[%,!5%F!L0[E/-N6FI"#"0"C%61^Z",3/I*$UIZUWR:%"L4.C^:
MHR8=U287)?APGI)L),_Q9N8S8HS!<)U;$+EW% UZ0MJD#9)VH]KVFC6P_*;:
M]3SR_E*8\")R+TW+4=;X81+%&HAULCBL<"C+_S;^[O* 1>&H7C A] 1P-C#8
M^U@L.T5.#$::J4X3MCTO& WBG\C>65IFR4<4 *$=NE&]"IC<(($/L-?5/'/6
M$OE14)B)JKZ6FNA_&U^#DJ>$WJHDB7ZVXC[>[ET*M+[9("WGWWT$5W"?T@F+
MGRY>9F9AF4-<%"Z0_Q)/6CS>N&)*9: Z> 6+"(URSB"?R%%P,W:123+/B17E
MEDL9O;\@R6N/-AW:813D2K_WW.BK,,G6\]7IZ";)UU7;?1(DP][Y"4$#VV@4
MB9IDY"7^^@P$F_^ =I<^,O=4DL.L>>\8T P."9L!@Y(V[1HX8O,@+61F?*-H
MZEM;^\3V+!0^,06K+B<5(%B'+@'5?M!3)/2N-(E7$\@[O=Q!W1\)7=@$^O(V
M.T%W[<F?/$S58U,_Y%7@P +KDRN2NA?-IL\87U39H/)P<?/PW+\JVW>?B'7B
ML;]7>VM\65!"2Z*EL\6HBQ:<O:9+:^!OJ"'M5& QF5C%(/O1_%;:C%W-^!!I
MZ@M[=\'1"P@WR F@2B1^"KJ8;7\I/^88*UO?@Y3X> YJ\B!+>ACRM!M9);6@
M9L2T6Z)4#3<(H3(83M;/'GA@:/;.+&6ZO;RY_>QK(F&TMNX>"ZE"L41CL*D6
MXI(H19L-CY,SN.<5*G"R^U3@UNUU^P#Z8M4.W 3<>_!EG TS%\JQ2YPX/,IN
MBYH.>DK=\E!@=%=A8*6P+-4_\BW#MV^J#L$Z2I$AE&@/)W0OC5C,(<1^5^C5
M2F'\&G]]<9Z5H_!#7W^="Y-[/MJ9,EDB@^4;@4*.3$*7YH.]^JDH[UZ_=?PR
M9"-CP&HUO>$277C.K0SB<_K/4@HK60?H-;'T]"8%#XOX;Z/UV!_G,<WQZ7TD
MG5P1P/^VSGFCR<:=O$[3TT#&-SLRC'5/)LL37\C5VCCCQ]0K7BSJ:=J]^>!F
M[A,FX<?V_AIOET4J=.#]%UVY"(; XT]32LW).A$)8GTX+PC;3Y%&#.QHKPMJ
M'VX\ \P8U2JF?@!?36OM@]//G][(#Z^*IWJA3/TM=6]AV5;9UT=N%PAE "5B
MA94<+A7#GL!530?QKV\\?)B[0]]-8(8#O/NO47II( N$M"GX,%\D+V8@KN07
M3 X[PP%)4?$>^K484K" 0H_Z0N[_E>[-?KU?2 XIE?K*](2;; N=\[<*L<L,
MNBY%9VU7H>D%WX\CM2Z^%IDVZ;VP/8<N&\*S:$+G3TFYM7D*1DVIPU0?].N1
M"PL*K[UMO4+5,8B#C0?V<" 7T\A#HZ9L(+*7)7(!HGPD&N#O&P[:/^B/8$-U
MOA4>WR^Q]U+@/]7V3HZR/]0)0+Z8W2;BWN22Q/N_G]_SN-K-]/HLN<Q<(R4P
MC^E.MA2(!F+8H,U.O>=L;BAX^\&J.:XTE.,QU<"6.74RNJ/P):T169RC5J/[
M;<S"E_YMT6UZKM+:!XR/G/H!!CB>1PYR:'B&OEEPN]#4TZP>H?.S!>/4D0;X
MI\Z-#'A]'?U'E@LVYV 7EBIQ3A?Y#1J,AJUP*D)A$[+F6LWE9MV]D2.QTLWE
M$UUU-X#$ =T48?7$$@=ZZM-*#NC\IPEAXWSC_ [YKT^-?V=E1G/0D>;55,7-
M<<75GBG*1\B.?L*%*LX#86]A"7?.WZC![N4CZ.BMD%&6/'QMOS(HH\2^$T;_
MTE+PG35J%?._IOG/A /4=SXJ_3?[$EZ);P9GOE-"2+_S1;C_%]/P_BG_E/]Y
MX5'[XQ(]_Y<$>-V@B>&Q[/MM[$[/7LZU]<VCV:]+I)R8%<[J2I-X!0]3?Z?%
M"<ZI[%36%:7RSA. %<;7]%C!Y@3@>P*0 RPY?$_V,+R9;U@S2G=GCU8 +]3T
M#EV/=]B=V:=SSVT;TU33?-3_9\?_VP[[H]J0QMO63IM8_YA^LJ5_LTUP_4X=
M+K)>[?*S+:B1%4(V9QMI2&(=EXI%C67R@;._$C_RR"]:]FC^*"%)9B&1_/'\
MD&(7XQ<XG(^4O:+M:/RO*6! ]%IYB'?\]Y:,*,"C7Y4D!->AX-VI@N\MA?D(
MSE\55.[9IF_&#M];BC&Y9X/_00K,X<_=PY]3H-#?WEW4WU-!(G_KGOQ_G/+?
M]OR_<^ESM:,WJ<K&E'*4T#^5\Y*4<N5VL5+BCM".]2X9M<\4.9[.5)Z62X[*
MK]-VAW+WFOHQR_>3@_'X6L-$K3LL0@.9@3:+]L#2GX'K?Q%2>R"E^:LK$9*N
M)E[ VP8-GSDY:7K,-AX/*F*OQ.DJ;I.\';CYPO,WIW4Z?@R2DQVD3_5U*/MH
M8^M8 (@5)&*FNW+/!;?!?M_@C"(Q&K/,D*!J(_CNJ7!DT6.[K>&G16B IT3E
M;UZR823D]=/-R_8D\2HZ=5?/]J6- CLETNY.)%*T*\(!Z^+Z084BHH6;-=Z%
M9D_4JJS8I4#(BJ0/!.16S0+BV@7WJ_RPQ! L_<$O3Z:CJ)J@+ND3JE;#A]:6
M8ZMW,N:G</5^9)=9B2(4$K$N_,GX%<#RN=/,DI13S9_WP3,OT(;#I5+\4>*'
MO<30@LHB,T78?DT/P%OBEU"C$[@NLSJ.N(Q<X+OYD^BI[:+]Z&IO7[RT*?++
M>O\C)O,6X""X6R))8_JM,EU5 ?P1E4"H08>\A_#2V(4@4+0&P9<9GQ4IOFK*
M DI^P,PC/$S2;S#XLQ/UM>1=A6TL"Z;1)4ZWI@/RRFC2)$A\X1#4#!A%3)C!
MS_CBP0=O+G)2G/?);ABI?N*QJY000D-/4K2;7ATV>37 B/#Z;<,Z!I,9FK&Z
M]"NY:?"N:6N;A?+98M34\P^K9H?+\0JK\OL4.[E4-:4<6<<;RFXZ2<?C=(\2
M*!?6O2>FP&5);GJ10GA;%X(8DP*&#!NU2]'T'G$DT.Y(IQ/72OM>EG>ZZO#7
M3*W#%8&4(<56H1V*SM@6KL $D??+W8EA!S9N;RF<*7ZRSW8@0S/2TD\S 7<P
M(97KTDY;:9(]^ULE]RZ? &[KG1G:YU'?"E)8(GNN::"2*DM_T-9_)7$VZ.@:
MA/BG@_\]WY20O-*1I\ W&JAVU.?;3#BM3*^:>.OS4:^/V].[<L3?DS]0IIC=
M@\KR6 _$ QOU54B;'R@O-NK\2@/]EAF0=-\=-^\,[J;9. *)Z](5HE8H6$==
M]4TQ0+""[$^S*$K9W'.NBV_,=MH4$:)B6K^UY09XI#V_V'CC;;::\W@KQP.]
M\U98*@6U$\"XJ#CT]\"[U&YXZ+' V6#"L#'SVJEJ1R4W94;R27;P0GM(%?NJ
MN;#,,]76(%379/_IFA?$J""N&.%?:D2" :5!)P V@Q- O4GVQ:E=O_)1-WR$
MT1:7S0[3LQ$IU0$3ZD4)DG _>^^#1QDTI,_7Y#=+JS1[3WNW2_(F"*3XNW//
M9I$D*S-:][[*KCSX^3PL87! F77Q\0E@=.($T !274H=&(NK%W#LXO1<ZMB[
M!?<XZR"?+]/.1Y8\)&C9\-R/5\^4%V<ZV*6"\:-HM<[%7EVJ>'34G<G8#PE_
M&C6!$>HZZ#^]PO_S?RZ)A9P UC9GJ9E&&FWOPF*]^N<0XDZXZ?76- WW19 Y
MP-C4G=X3F,R6Z!KN)D)*R(],$BKQ: -8LN^?X_8D:JU=7B?5!=?_XNKSB0^%
M=3Q\TK;,S"4NR)ZZK2G@H@VYDG$E8N9-_$,'DEU(HFK,!HF5+ :WOGU8E'"?
MF3R+B'62<XA\QZ."V9"(I.@6>:[@0"8V#%WI1Y<UT_6"L!9&02"I/NW/<<O!
M=I>H8/TD/Q"5FEK*0,ES>8[W!]F(?06ZF,[&"=%LQ*A*$&RWAD4)^B;^1K;D
M>(4E)2 40CH^(L;(S,%J>%NK4LK.J:![(F/$7*(RP/9:^9"D]M(7MGNM-=K;
MA62!HAN;;R[*T\7WUK'@8 Y5Q>$ >]R=/ZZ'_F_DQ[L5_B!_3?G=$IXS]Z]6
M S+0^\-J$@8_&U.H"?U%(8>#?Q]U2/A^E-Y&?1L_O^WXCK;XS^IQ_U<$_!_'
M.5(*9^M''S/"X*YT",><3=:*Z-C'K6Y&N.WZY9(;6/Z>:R03J&BN"$-=O(C*
M\(*YYCJ/>QNY9('/7(V0+9^U=>@8B[*G)P28$VG9\."]\67+1:["BM&\AM@G
MZJ(!_6<:@7&2>SKO$D.SO-J,ZC9M&PFOPO*NL+WL)]=0LX5E#/LG<M+'^$<-
M^M#F6??KD2V#LALWS1B2UCYW!2!TM&!S-X41S1=TK?C((*:8?"4QYH-A+(=#
M2UQ$PT>]$>X@\P3GB>PSH+HR'ATY\4D<0%%KSUK&6OMXJ'KGR/$B9$@X@YE;
MXZ5^-J%WJ=_"XGGP]J>Q7)H;$;9/?$3 2660;8>1#[Q=HA]U*C9O,*:Q&>2Q
MO6<!O$/C[1;;=C_=LOK<R;$#& E'UE*MB7#%.#'G4L'!"_:;L0W"1JV3[-<-
MNN;.;D@4U3RFC0(LN8N/(&N"&.\BYTX CDC0-DY6_J[+I9:6#TE=HX!^<BU-
MLX9@\2KWEBYGA=@[WW\N*>RLT6)-+O7#J-;A0+4SV8?,/JS>F!)Y0Y< Z90+
MQ5_H2?KU31@5^1Z.0V**N8-.J]!$KW](MD=V];DZD*$$^=7<H,?U5Z3UTJ-/
M*RCC']UHDA[)OD>^F4L%AH*AOP?Z_6N=FK\5,?BW2Q)"EITV081$,35 MZDZ
M&GP1;79@5TC<]AJ^Z':%'=YQE^*#E%\%R?%FD:OX=G?UXZ*G&J\UH+H$-05B
MLX3U94GB6P=]:$LE:Y:7)#+P*M9#$)&3_8!I7.ZCN'I1A$1:A13R6*]/<F#,
M@<)R0:<#?\N1O55/(^"9.B:H)M?VJ<#HNO<) ,9+7NAX=85IYH7?.0H%+&YP
M^P0 TOJL"\QTFWVU&Y$BSGHX2%H=X74Z8^.&R>Y<7=#-ZMW[:/_UDI[+*G'-
M=BETR!60LTE86:5]'E,N]>66U5-8SGI0O<_%XG3C3564C)C;RV5HF@7S76E/
MYQ;Y3SIWAN3ED:/G7+NU: RUSU^)D-JDBU 9J<_T.D>*$#UM$V)5NIMIMIAL
M>K->CP:L?'LXY/TEI4-"IZ_AQZ[C?7SO J=D0V+.'%-)+$C-](P5Q?L%A'@#
M&!U-&2O$<(G*-C;$-R!J8MB3T&"E*2DO18E4G=RF)VF&[CNY\6:0\([@EP>B
MC6J\DEWE9R!A3<S&-7[T.9G3.*BO$T>42F.DVZHV]3UGSEI"5OK+>]GP]K30
MPHIL=7](5C"#D28=[_D@^(>T1X/C=!>NA'Y49I:[JEH7R028P\+*4--<]1!
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MTPK3A8T(I>^&M$57WY+&(JJ]SC><%58;T&WEVMOV6<J+8!7OBIS/O,KZO C
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M969">)9,+%=95.2IP^QX(=W3R KAY?GF_D7+INV&,=^-3.:JA@F'PQ>=)8$
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M0#:$VD43=3%WS*35VZ=:89(**H;80UVXPZ)T RHH#"C?=<LB\12V"74^A1"
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M^)KB0^<AJ[+M%%S8IDURJBL3DD2EHB<'O!^3&T![4O)_M7/=44UEZSXA%$7
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M6.U.CEVVDWIHZL\+R<VO-^1J?$J)=N+KT/N</ZA/TA_[_@M02P,$%     @
MCH%A4F@\)WX!8P  47L  !8   !G9F)A<6XQ:V9U,G@P,# P,3$N:G!G[+MW
M/)S=UC=^C1Y!0DATT1DE>N^BUU$&@Q0$HT8O(4&BC=Y[-PQC1!N=(-$B>@TA
M(;J0Z"V2G^2^SWG.<YYVGO:^?[R_RV=]S-YK77NOM>MW[;6OGS,_/P'7-54U
M5 $0" 0\N/P#?LX!R@ 1 0$A 3X1(2'AE2M$Q"24I"17KY+04-RX1LE R\3(
M0$M/?YN-G_,V"R\K/3V7.#>O@*"(B @3IZ2LA) ,O["(T*]"0%>N7"&Y2D)-
M2DHMQ$S/+/2??GYV .1$./6XVK@@%@"''(1+#OKY!F " ! ^Z/<#_/F <'#Q
M\ D(B:X07[T4P%X'<$"XN#AXN/CX>'B7W,!+/H!'CD_!+*A(< /RD)#%C5(H
M.*& B%6INI/*8/0;F["5>\@5XINWJ&EHV3DXN;C!(J)BXA*24LIW5535U#4T
M#8V,H2:F9C!KFT>V=O9P!P]/+V\?7S__YR]"P\(C(A&)2<DIJ6GI&9F%1<7(
MDE)467E-;1VVOJ&QJ;GK]9ONGMZ^_K=CXQ.34],S[V<7ESXOKZRNK6]L[N[M
M'QP>'9^<GOVR"P3@@O[R_*MVD5_:A8.'AXM'^,LN$([/+P%R/'QF00(*10CA
M0[<;+$+!1)1*"075G5=8A0V^45FYCQ+?9!-99-_]9=IOR_XQPT+^2Y;]U;!_
MLFL6(,$%778>+CD@#QR?<14&$?])-Y"/'&C+ZN-[J><Y'\)*FD@M6S%N9G(G
MA(@']QNF*DGR+52J QU65E',03*F5HZYC<V9=CP271.I-GI<<9*0L6!:0<>D
M<!S[(S3C%?2Q?Z8B=2=^^F-P6#7.J<#NL9MI T5=9FAS4H<(R?LH\V:A8%YI
MPZF&VQEV<?[9B'>3!<9C[SLZKZJ%S;1G)6TIT(D8V*;&XU..??(I>G<?!GA1
M?A0,M-^_-17$H")^F2'3?9A/"-&YS(B[S =-& 9T'_[_@O\W!&%A&B%>HAR'
MA^731+'%288\![0?W.=YQ$!HU@0S**2W+5*6%!YNX84DF)WPT) E'/VS#(?^
M/PKV B@A*G]0LL$(#F-*GP."91H*!W%)+;40O^3+%J9O)I [  TXF-R<'CGU
M1MW-/9@(/5BG, .M-GN..R?4L.@[F#D_3!%KQI'="'ZWL*GARZS>.4R#>EF1
M2[.]AKM"G[F1I(,U3* ( ?OQ+25XUX1P@X;F-[\MS 5FBDI'=#O8>V\[/R!O
M7BVU%)LT%0A59-@<0T&"QX(8-+14 '&K3!GL02E$@71O>BS)ZLQP@PO4<FLL
MCB^0^R 9F(_:4.V^Y*ITN*:V)[?#S@R6$( >7R#7I7".1B;P*]?IOB9-5W1N
M<L+;1)(RP@T%LDO>K]=K-*NCJW&RHQE\R X /\<-C9672+DB> HUCL(@(#UP
M7_.R7N00/$R?CH82^'KYPB\][!!7.O()3ATWU"Y+GDAAB# @D]W4_&N5E_K^
M\>*?"O^J9T(?-P![4'29[T4)?/Q_7%#8:L*]I^7:6$F)UO&U,>07T2;-[EL>
M%PX_N@_*H?)^[5C_9#'ZXQM_*0ZJ_O%761 %?,K_F*ZH:7*)"("^:L.O>]TV
M:/?.]C?A1,T[:$D3+;%[=#\R"(B8RJ;,F+R2=-Z5/DU>J?$8J.39]F_XOB>*
M/SA5_N"!%>M"C7&6=S4Z/[5!*NKE=?.Y@=IWAB8842Y^:Y(:?AW?E;DA6SE'
M 5>,D_W^_3)&@]IK&%=.^P]=@JT5_NDYPL>A=W*8=+H:7;$.'_?[QA._&B\(
MDU=Z61Y),3+PE]Y'Q1P)?9'Y' TU"5^U+Q)\^Z;:Y=!'5WC0Y>Y6+,_-'X8/
MR\L(ERM1+>CL&J@WGX,)J>AN/?3VY%?L15B_B72V=\6<Z8]I=&"9G^%"V<*@
MY$0.1 .8))H)-_<)T&+L\+]A)#HPC5BZJ2IS=%B>5K*C\D+FB0)K//?T+@UG
MW<<Y2A#:%?/VGL0"2_ZQJ$P2^AZ)_*+^_:YR\B#<V,FT*QP7?B*@-H]RHEM.
MSZ1CNPJ>F_J]KDA(_MQF\S[@[)R'/D[9W,>[?L&<8DY7V@!77JF1S^?QN_?Z
M.A:-4QE,UTO3"2V@_,G>=%7AK(29+Y$Z/ADA:JTNLBH"4@,,:MO<^S&8#1A5
M/\QO#:+,DK*&]"HJ753'+T1P ?\'"<2=>/'ZH'2<_3Q\0^-RX!GT?A6?>CE)
M=ZWU(ZS-D#1<M@O!A6;C*D0 _XR*D?DX"*Y+XN8"V?\S9F+0]<R80M5-,(Q;
M]+'VRV4.?P/9; -F PE1.QQ$*$Y3QM"\K^[;5<L52?043+0M$S_&_PD42671
MAO].^<BW8T/CR/.@;$-Z8B]<F%Q5"JJ+*;ZHU@)_GZS6@J:\>+1^Q#$V"NFA
M-J(-RSZ/KM\Z?SU5O\$=/-@+1VF_Y63B0OM(.6KQ\M[:\<)DPH"AYCJXL0(#
M/B1*TZOI6FS**Q7 HX'68G3(A6_Z."S*D>=]1ON$!"MBW3Z?1)J4;2ZCIE4<
MI_PG8+<P*QV8_+B7H]D!!O2-;W/V)2X'+&'+[/\T^G^+?C5F<1_R;W(T88!F
MK $.XQ/#]U7%9\2?OFLMT;"Z@@EGU0B2:*7.<<3%63'W7PJ,!*A(S?.Z]^D>
M=?O;Z+2SNT(TP7WN/M;KA8A"I7]9A2S/#?T)UP>-<R3L:5-!8AN.2:[7[_,\
MS+]]!HT^>Q-IDPA>5=WDPG5);&H\G(O?6E/!FG[3L;_G4+@@.JOH34\,3!8V
MH0Y;AD7\JK;U8!_K<UQ8%DI%0*+_UA*DI:'UET3F7X<*-[?]/QFI/3:JH7!5
MA5(?I$*9#-3]9?/]'R$-!7SCIHRB91R'214)1G.[L1)S4A>#L&VDO.=4"#T"
M:54$_^2%_HR3?&?"O4$1SE58D0#G*K9&Z"G<+$K5CTJ<*9\V&34O^_")=L6+
MP=TQS?ZVY<)258Y13('&@.%]PVF#]\0EU FSC=(#6C%*=FD#3C=R4\8VSNC3
M=-D:.7-[FGTK\D,8"@4>\TBYN/L\H=5+! ]X#-<Q71O@F^WKB(G)/%A/LW%H
M?TZEV4EN]BW? T8U><O38\#-_I_UG5*'%^M^\4+>POVA2PB@</M I [P1KFP
MJ5OQ?[(JJ< XI\\T<RZ(@/*(Z>;OUH^N,)Z@E,)?V<?-$R(F1PIX'H3V#AJ)
M4L\.><A)Y4Z ^%\2GPI\"IQ]TYA0/,'7*4MJV3*!_RV4E30A>E>GO<JW).2Q
MG/'R.*Z=2:1J\A" QR?^6MM<I_^P_!:LSJ<J,(.JYG)JUD<Z3=4STU7:XVHB
MN(IQM8(U5OFX%?S'+E&# F%ZG5_4+S3PUX3ZV_+BI:J=[\IP1V95P\ZRY F?
M&W"Z=JO1U3L8C_O?4F9^ EZOP(AG-\U.U>P?.% 9S8>^B\T?"MJ#WRU7(V@M
M_ F\F79]K"UT'8LM]L484[EH6,/$'[E]^-K:7?0.MOIJD;?FQ]93(_02FN.!
M6(/<9%I]I,SZ?$O3GK.-ETQPYFKA))8G.UU5013#-V'2;#$4](GOP?HQVI6.
MF_ K[:0T.L7] (8Y$/X)($G87=D/5/'C&PB:WJ<<7O'.EQ!Y23(U$C%?4X05
MS*'TJ>J/QYAEEI0?U106?)JB;Q@D28C8$WKLT%.[3V>[HY!/>G>*[)#$5]81
M*MU7W#-NX6$^P/=!\=K 0F5R8VV;1=Y\[$3'1G%CK&"J2-]7EN1%'0]YQ]1S
M?0'6@+JM1;E4-+,$W@BA_C%Y*=N$TADGX<-^JL&V=]-HZLAV+&^]^.-6IYC0
M33BH@K_D7#-N$6UP[_6M!8?5G9>,"PISC0SPJ5T]E'@ZF?X(0?=1<;4YNL<_
M$\U1)*U&$Y=]6)$UYYAN3B&^L]]1N&<20B1&;Q,]C@O]"4 3)S]9?'8[1>OR
MG%B:K"XCE@^7$]5J9_TD!BU3AY9F\;-DP,_5R?+>74+NBFW&9]A95Q='M4L\
M LC\:GV9/S#-_[L)U*K;2L-8\26:*\Q1[3DSL#9/J;#TSL-8+F UNPG&#]&7
MX!QIQMS6O7 Y$S2P:@YH+R_29HHW3STEV8C%'Z4F@Q/U<*J]^+RIR4,D/L9*
M5CAK6< _OJUG\XA-SGP:+OLABO=[I8>I9E%J@A2KCIH9E?C"YMAR=%EEN/8H
M<P-H_JG_1/UX/E:!7 %M)7B7:\N;>ZH]ZF$$ZCDN3J*J9?B&P1=8K.GTPS/H
M]S+6J_,I3I8^\E.5IU%&%?JN#FV7"/_Z#&?CY7R]G*>_,7R*37AZW9G=Y?0]
M S1+GP4>29@=W>QU:#&CQ?8F7NMON<1-S^5*O9[VOOW(Z-#8,-$YO]9$97W^
ML)"N_2W.V2<3O0?]'O8UE/3GAK@YV"G.VL<U1>VZPHA-YTJY4>H :U8DJUG'
M3V!O\!DX4>*%-4)!0]LW47&?'WZ@CPNY*3I;!!BRATCVL.F_7D 6!H%+\AS"
M>2B>&\J0]S4^PC-*UL<W'L= &GC!I&;$0 =EW:\]XP_2T-)0(%)5E76DV%>,
M75)Z0^;H'FTD45+Q9LSN<F(3M3Z;IZ)?H%*+1@&TF]6JX,#$6RPRS>==AKV2
MQ+JR:'.M;U%@POC5EB0*P7[]9\3Z^20 @';8?%T]^*Q+D.E8!7QB)=#QR40+
MP2.JRE,@$S&0^LX<GL1"AIZMK;LJXFL^&)4SW^WY D? CR#!RN@<03B&A?'<
MLA*M#Q/0S"=H<HRTC3.*[Z,I^L)3A;*ICQG2)+G@#NYV,.0=O);B8A1&(X&&
MI?OAUU_/!N7RE)W3<_XP>[FBM\<J\9:[5Y<+-T%<S]&#T<I*+N5A9>:/0WW5
MM]?\-QBG;FW1_C!2<Z2T8[XEUYA/9J1P9ELRGL+;/G&AN8%--DT5LV#2W+0)
M$3_ONS9A:##%)DE4].U2C'7#D09\7RX$HU7>]KJP0AO?4\^5_OFJPM/"S-0$
M[J'N[RC<E#9LHI\8OLS$E,\V$A5<:-L;8 )9+O&HL]N M!7KND,TSO0)[_BY
M\<T1$,T,:\9!$,KX[==SU5S]MU3J%*RM?AA])G$B@.C*HG#CIJ(3LL3(4WN$
M@TTX)F,FKKHP/VQ2&/1T=:5,GZ?-]NPKX<L&N[/>DRT+-E2I=S27#6^#CP&$
M. @%OG_ Q?G'R< VB!CQK/&C9FKY@H4*B9/-XU:?,FOS!+-LW$-T=*>J!E6D
M(QK&ZQ2P,A3HR&,PO9P0+;9I+MMM+;F'T2G2&5QWVH1]@*(47C-96[3H^)4/
M*=TTYAPKK1XM:8^760D+=$1CQXOJH\&HOJ^(06X]]X]\LC=7[Z7E%\O+Y O*
M[)OO]I _+J(N+7]@6&U)'IKPHF3F(X:/F](8:863<>>#O&:@T/W&I\E:#S%O
M4W^Y?4]1IA>K9Y-GZ4Z2.Y=8QHSY<I#C&#M&B32>'SK$CQ"*EE^E\R4A^T2^
M#8$Y5IDK5+-^+T0Y5K\1%7N2=R@R<U]A1A8>L>5T9^IKP>#]BABV]]87-[$;
M)+_0ER;L7P&@29>3"<=@5 5@_YM9]3OC+VB*G8^=[_>9R)_<L*";B:E_5UIB
M:F+0S3\3>,B_]QS^0?J-#K,6<B#M<(WW0,5C(9[@7<Q!=1^B%#CL]LK,+65(
MEA=V5Z-Z/:_H5OGV_E=P9I>Q@;=X*+?$/OUDK?I^.5J<<ZKMUNLS-EO\W/MM
M7\W.Y,-P^FK4<ZXAO:N4JO+O4E-9E,-J_#YX*A?%&(92<5$2PT9Y:!H>%R+
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MU>4^L_G!9MYK,E#9T#GF5,-$T! 7;L4@WZ.-,U1K YQHKCY]=JPB?6[O;(0
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MB\VK@TH&WY3H5MAP#0:\C]W4<'@(#/N[Y<XUW)DSGCW'&Q%Z<V:C;Q98H+A
MX&$FYI\]'7/DX[2\5&<S$?-._A%11T)L"I2!5HM\+==M$+ 7B\6O/PEC*Q\7
MJ>JBBGO'O6:8NL3$<OOMC\:";5M?P%W+1P0$ZYPSRBB,7^9&IV6:FY<X-UIX
M&#\,/@@3BM?]JF@XX.6&BON0JL+@SH53J6FF_@3A6#NPV'.(YAC2JVZ.=X?G
M626=XQ?2S"M0P*6T#>%PUKC,DM%*IG,EK8#OD6/E[QUTX#;U7V)-?;KMX6+:
M#7R>S^(R@?E"!/<?D_%/,K!%P #MT4Q299$MBE0K 3 [#RE'/Z.Q2O]+^=W
MS7YN(\DS:"JF,L.BFV#']Y.QL[1RZD%DI=S#=<><:1>+:BDJMB(_>C9]F3TG
M?7?'J59I)ZNQ)1+);I.&4=ZE5NH7Q.NL,=8** %\5RH/;FDR7!P$C$=9$)_O
M;QS\?X (K[[4K#_+TJI]QWKBP!6@_C;X6:W&=W!/72ZT?-SK2&3=2ST$L([[
M<4KYQL7^++AEBS#M!-IM"_>Y(CY/+/&%QR"^*[Z*08?/XRP7R2:>JT0R0O#-
M2Y8VC95FT&.J0?P.!S%MDOX$$G&[FG3X@S[!)R]. &&!6,G2;\8*5BOOYWI
MOV)3(U0C0':4H*8VC8Z'>I7WM],>2_@HW:IT].]:MYR+Q =@A8FIOQ=,BM3?
M=S<T =BO&Y*X;?0&8_HXO[S\4$5J5A%P*#4$ >,"52 ^DPAQXZD3X" N<5KZ
M9^JE3!;%495+V '7'PBC84R.I+W=%80O]\=Y#%S%M16$G&WLD4!>PE16X_5\
MPU]XM>^R)Q(T 5S *A4!<!,_GS 852 "&+CM"X.H617F0H(6+N%*/H&,_4_
M3[$D,!60B'& P8!H96K+ E4N 5558A*C9'T\'D><[(AN=8AZ)R[E)A<.N2/@
M%#$MAV6.,7NLP'()+97X'D#[HG'U]L;/"R^AI.JWGJUP!146\V[J4WWBU%]
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M28[I5['G7R6?7JM'8>6G_J4DZ+]NOS94_4<<*@KLX9,DG7'7XCTF3=P'-I<
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M/'PJ/&PCP H >(1X/[Z GUYX)_ )"(F(3Y*0GL)-0)X&3N#AXY\@P"<D)"#
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M5@_HBY]".F7]W.*3(R1.H\&E]$V_Q)]*RE]EJ&9?,E0'UK5-1ERNP-7_6VF
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MDB(%QCCPHCO!O/DVA_>[GY&0Z0C[,?6U&6N-+ZAS/B=1%2/8[JX:J-\<7C)
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M3SG=6@Q[%(C#M%6EZ%1&3XKXY;EKF)Y&!7 1*-+-0%]'5)O$I"Z>7A15L6=
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M,M-T)NK,],5FI..>6A2\V2T4G$<+-A)\(M,$./F<*7NMV\-"+L_TXD!C*G1
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MQ-'+[K)[]^SD$VZ:Y.<:N$=R^'XT"S>*(7["B3_V.?AR:&IH%ET^V^:$[VP
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M&WC]K"F7N1;?]<?.QKS.E-L]<0OCE@+M]?LN+OJHWYYSJY(G]VFI; ;SF9J
M<[MF[OCP:I-,7^$\>ZXO[]MG+;E>5:U[(M_4@65B7];YUAK9]*4W5FWF;G[U
MV/3"S9<!D<824_0>SV%T$"?%.P.-D]W6?V_+6K=DYN4G =:AMU(V=BIK5%]@
M;SW\B.7"'M\J,7,CBUMF?5_O_;#<6OU,O+QHOGXYUV%VD?I#NS=-CIT<,'%^
ML5GAK=T9B7T<4Y5# QAD> )8II Z/S9#9$L ^[P_?D>J3"9MFL3X-F;;Q/6O
MHE[=BLK\E^+)?^KWE ?75[V^)2/UM#O:SR.H.B1*O"UGB\;-A("C[2IK&6(O
MY2[;LL%C><(YJXGA*^@\=CV*1_$PP?;_;P( 4$L#!!0    ( (Z!85+JB,NK
M#7D   #$   6    9V9B87%N,6MF=3)X,# P,#$S+FIP9^R]!UA3V[HV.A$1
MZ2I5JM(A]-X1%1 0D1HZ4@0A @+2D0 *TA$0E"*]M]!"[UV17D*77J6$&EIR
MX]YGG[WNOF>O_YQS__.L?>^_)L^;2>:<&6-\8WSE_;Z1!S 3F'G@AJJ2BA*
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MD@;[0<U[)#JZDKC%Q/Y=U[%OKA=0.*EAQ=/1<*1++E_%MDD3S0I];9&*O3;
MZ^[0+5(4.M&S\23#3S+U]HO]S41A!5)<&QE$@OZ/S2DZM6N3&A)T3Q&U6-EO
MYZG'%=+#&QZ>YY5,T33;D*HHK7^BJT_ANDPM0!4<Z9FT";26;BI['<NR=_\4
MN_E@5@=7+V;J>K\6A?;/-!VX1+AVT4>M\GN9%NS5$?T&MINA;PFY1L%LWVY^
M%&C-TM&AT<2.@7:HD#YZ^". G:1?PW-)=M%@$=&\=R-)/\P*)LJ=I^FOI@@(
M=&57W^R3"^4$LIZ3C&H-_9+QF9:,W1*Q,+8)9C6/P14P)2_%4UP32O1>'W>>
MPJ\/49(;/5SC@6.;'554"*00 KEB%Q='+-P2KGC\HMIAND]=D1K Q?VC-\#^
MQ)_X$W_B3_R)_W_"V"92YMD<77ET9KC*G=M7_/@]4CN/&>E":%<?.VR\U=AK
M#N5M4+'FXYV(XZ!'],[QCHLV.BPX.%C$2^BO.'MT>H-;'4^I+3& EY^LGNU#
M@<J((25USZ9&I*/*$!P?'C?M?-3IAF9)[1ET^"'!+(/H=:NJFCJ)R*%&7)$(
M[E^]>($['KL4%-Y/(9)\#LY >9N]-1D9WKSE5CH@NBHF!^PU?HVP&$VW%1PD
M/)3VIH.2O""-EN".KB);N'?#([/;RR;(GUJ(H<7FK7'7%V3F@X8Z_>KF[Z^$
M356D9E!+79"7UE#.>JZUR)J23YVIA)\>##/757T)#Q:G?XK?K&]WPTZL[04-
MI=R10X/9?'^S:&=>Q9?)SW)REKNF0_?^OC'X)_Z"9Q!3JE*$]:PGU5$7B>/0
M/48&I(M*Y?!A_2-[RXD"P:A^.)H0 _0T,IV/@9<<+SRG?>7'BWTH,4"TE_Q)
M'FX%LA(LO"XN:)2:D-FRV/1ZQ)<!%;E_FB*N:R%5_BOGVMBVT:T<WO[^Z66Z
M8&R-GO7;175J_5<\4^P6POMY:61?1&7%.U((&D(];6B8Q'28D###D0;5*0S@
MC]O3F2,H:.$;A]]E\!/Q^+6T3%LJ/^7 A4QEXE);)"#M$]1]>7"/_J0MZI2^
M>;L> ZSK[LQ) BA?'PPP(&Q*LC?WZ! #T 6OVF?UKZ6>%$XWO,E7('MO9>WT
M/MS_'J/R7A#8C)P;=__T_2FB#M+$6;EWX00?EG;<J&K0F)]-3S*D?K 30G8
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M42,=*:SEH[,\Q>Y==,!J8TF>1J;^3-/&,V)UP.<< Q!$A4/7NH\PP);F;]^
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M:5&#)\D(4N#,HGJ[ZG0,M7.3Z+," !)CIK;"K5I1NJ_50M,)*FLYW-?E2.W
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M,^WXQXHN0]6PDT ZQ'E;PQKZEG>SW5^&D7GN0LPT2?G7(:2]'40DPT)VOC*
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MM"!Z?8*EPPY34.^CH@0?AM5'1MN10B[8T;SC1Z<R':21I&Y/R^^B*Z$.DQC
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M@$OAP$FH7=1ERVEV70O.D39!,YV7+/-#LIZX-S,*O+Q[:A9D'LJI"<C_2Q:
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M_5_&L^(CGXQQTQWZJ^:GORO<JWHDIGX4[ACU\K)P,@TX) M93R2%D9U J_C
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M\G:5>8).B\&!G@+EW\*']R*5FN2LA*HMCB/>5:B,2\C=@MT">!H3$5)"/4O
MQL][4G>IHC$;$"LU=W0>YJKTI?\^0>_Y/#RWRKW<\V#-:3+3[FY/X??U:ZB
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M."$8Q'2VE]$WI $[NG>">%<#/;BI._951, R+X4-/ 2BD"Z(]2<%[S>I\XQ
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M;J3,J;(/&82;40W<X+1G(-_<L@WXIYSJ_D*;W6W&>\6F\X(']0^ CUAAH"
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M+\R=D*!5L8 7%M@<'?:ZG="I&C2V8:GMH8!X#6F>@P2RX9JVS I7[!K$#5>
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MFD("G&CBBS^K>A>N5?7BC"+*>/@S3>WUG;BB[#LM<7LQ=&[U'92S^%7ER/%
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MS_3I:;H?,.J 6"2>5DZ .'X.2G<=@=)7]<[3#U=V?=V1'(10$;VQ?C%-$[Y
M&</<\Y7SK&@ZCL(D6KXC!KMU0'E )%15"LF0O' N=#1[WSQE^>"6O2L_9?3^
M-O1+NB^O..M"/ORZY<TURK*&TL>*1(MXRVF##4S0]/7)Y<_DVWO6^^YE>71W
M5W)6#"C^M %2N%6KB6@P<QC&ZI[A&914'DY7]?#\?H*J?Z% *@54=._IGO*7
M -+.MB5]#VU%6<!]=*X5ZMR<LO+GVR,6R",@],.%GR'G-G516&L3X1#ZGIF
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MJM[A'M713]GF;,SSUK0\'B3DAHC96W)I];WI !(Y9\,=$8RZ957'$'C:N+D
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MW3^C6I&B6OT"GO*P0&,Z3@;/J[/A_9M&R8!1>NY?"/)_[8+C$_KY+XR_=!G
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MOG04MVTT%N_.<FIZ#9WD%^VIR<36O@_E0,:,B\$_J5XC 8LHW)0*0@:DX,B
M:>"HF_V72FV7ZWL/W#8$S!;\P][M Y%DP-EB?S) IL#^>/9SLK7KV+SXDQT(
M7E>?#"#L!Y*(??"@!#P9$/<95*BU MX*60;OGJ<H-?[<#*?Q\.<!_1(B3F/=
M"L;M*%^Z2&&[I<YDP.8XQ5X^C'#;VW&([OC .)1B)?M?K:13-,$_-9W L>Q#
M\=NA"5(1IWTXH8]SWY(!7WA@&#,L>-*?A"]>)S"F-H)[?O,^+4;Z+9R:Y!7
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M95Z"XP$Y9S.,@S*6>4O^70-:9L+K0*5_MW=D_[^W>O*_VMRO5]0OH_ZP?K=
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MD:3_9LO6#%6E_E#YZ-94F2F55"G"([S^M+?CUB/E2XW*<N;'&B4%[Z<8<5^
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MW3K1Q_"\VR:@8PR,_ 7=,;8=AH8PHY',:R;F6A4_LO3T)U BUB4_^IQ3! B
M'[!&)_=_+1#N7P,H*:L*=EA5(M8,9Q4L,DBC]9)\2#JU74S@DW44+OO+/T&A
M&Q!23;'@*E H&$(&Z?QBQ-U"R=3Q/9:RA;U$4#'\"J_$N(LNX21<;'0F1U,+
M1M'2%<_DNL@\18TVF4>SY$L*Y+4ZL%WQCI>4H(>+%Z+BF:Q/'12)(R3]\?+W
MZ3ZL#7_!J$M:ZX-$ (*B+=?AUSC)>Y?>'<EV0];H[%39.9]DMB\_$ME6HWA]
M[ULQE.?61'GVX6SGD@Z%_Y,\I!5#55,WD!R:CS86O(+Q/(:;%<D>YT.^ BK[
M+CG5,5#'!3H,TE3)W1GWJ(N&--]7FJHFL WC/7!37:/_*A$JA)P8B;:RG#UU
M>9"5D_;3B<#VM=M&XX5$@2S%.+Q3Y5>H*),L>-Y>U<C/>F.WV;VBV8%J+'UF
M0/N*N\8<&;#A(A!'=PV8$9^")+T&!>_-':BRH.NH47<QZCVR=@WXY75=5V>L
MSZ@^ZAH+95\"W[*!1+-=\4[>8>!>7B!XQ=!MHVY0-F.+N<(];KFVKQ_<?8GA
MU&9EH.!*^7..Z"MPJ3U90Z2(0<N3RZ=;(V];9-<VIMD?H2<]AJ!IK(:+M7JQ
MCB\ I'=HAGRP8 &Y/U<P0QF'U//,+S"Q#0H8'4,M8&=,NV7:E'VG$BU.7;US
MR/]4BD#>R8K5@SX]N3QE;$N,CQ+B]27TM#*RN*;^TG1<OE6CZ2O_>-,++9-9
MC_N%L67/7-,6Y6^EKGRXJ\E>,7BTEBP@-[)LA_))3G>@B5U2J.61% ZG0;_2
MZPX@U&I*V _VN3%D$M5IY"/ ]D#9W^OEEREI[;VV56NS%C2W$%:+9@# P*]$
MPUU7/DBW:%I$JJVF_QKP&HG6G97/L:U?(WA=A7&;0_HLG^N"KW1;;-'0(%V$
MT1&RR.+[XMYQ9EK,S]F ,<$:,DBF.G,80@*(\OD<IZ7@(_;LO;:A7\!D.O&C
MT*A.L<,!:14$1V7/\N UH+*9]6HL;9>KPN)-7C,PB>'$C*3ZT65?@GH?I2LS
M\<Z[^HT&3 ]L(] >90KV##)<^Q12+,T_9N]^G^TL\+K-T_?LO:9107(7/E?>
MA[][QIU?\H<T1AZ(_S?MQ'NLF=.\V$D-K/]<*6R5_<\4F@"OO\HMH>?X5_F-
M=/Z[+ Q8?TR3N8[Z_V0S_YN]$O:_D+N :%(-U1>V8A<#X"5HW<M(-<Y&VJJ<
MG=C[I\HS5V.1'Q?))_"^&2JAB!NXRA?PG<"YA@PM;80AZ?=-'PCFFF \604H
MV$KS,BH$8VZUHC,6"J]@[N;RKOEO('A0.Z'PN$\0=)V./ZZV%F1T7?R$<H="
MSTFPZ/2U2?A15!E',/8F4:HX?<\CBOL/@<F13>O+^A9KZ6!'O@J<-EJ.10I@
M:T?EDY8]!9$G)A'S;IZ1*A?Q X1NE3\U[C&&%_45?X5,S7$NUXEXFA$>W<KD
MXQU\\W /V$KC$S!MDO+IH6O=^S0)FI.?Z5>F9<QY4X5C(AS,_.\;KP&>K;PV
M)\Q)_%Y\;3*OB,46LES;F"=_K.U5RN:5%X>(B-'.D5T9?9GEF397+7NYKH0O
MS5JRE7B;^7"JL866%;BX<%-V(&UW^Z,!'6_..>EW2"=%^_$%Y' )@RGE"LN7
M"I@8F;=](G)[N\S@">]>&,^]]A6R"1EV#&Q ;5!"11CGSJ<*:7$S.M$MEV$_
MU=B+7LG=P1#859!NJ?:33]$;_'>U]^I<(^N>$;RB>JSJA'_U8]+_IDJ@E-:8
M_JM[?YUP-;T55F:VT._"?FPY\C#UZ\FN!J8OH+\<$FY'MWJXZPMU:CKN![PZ
MRG^/X5Q<D!$XAC]"KGRV:R\?65HR-KWO__3\/DV9L.Y$[K/T%I)Q9:Z\R!\O
M?G=13^W=IXCOA)^T@PZ?Y05*'_FSZC5F;B:,/QQ6D=8Q_R&9C3KO/]<OT#0!
M"@9[.<1_BP/5C"/LI1H/R(;5OKE-5'A!5324._J$:_45\/$C;1\D?-)4H&SL
MC.3*N7&'*2_M131" 10B&\EW@\CZ]9+/#9"FIFC2\R6?<7*$49."ZENS;7S<
MQQ- 5-,C#&>,M!VMQ<2$ BZ0)9%\!4%+XF]ZBMI@MZ=.YUXX.QH-(<*]:#S<
ML5W'R)2'B9=<?-&"R,>U(RJ0PV9[L-(SUHUC^6N 3\-VZ46=X(;\]UA;%./K
M@/6#=LVTMTA^MYZ=?QLLZ'8I^(G@7E020S'J[B,T).[J\AJP.^FTW,OL>N@U
M=?_*OBHO97+[E%C'!;A\.9:9H+BD'1G1PEV21\5! NC'T.:+J44]_7"BL?%9
M*>4LI7?[=Q65*9.>,M+T?!]\QG7<>4_YF_@!-\_9J6PAAG\+82;O5MR>ORK:
MSQJC,43>9L/^J9FIOD]@NU#/51?GDK?+RZ\BQYD(3(Y],"%$)::'3B$KDWP'
MB]P5A<HFUGP%  6/.N@+V&2QFH22MG*/P=8:+";01'G\/H(H,@M$L!.?<>ZX
M="AJ;Q4)-?!1W<MKTLQJ9OK0?K1%>E%A$-L[+8CPA%>-V?50VF50??,DX<(!
M8*DJ4#[_6P$.9=?NZ47,:>E=8]NG-IY%N#=\9EP4+,PBRYCT]C@JO;-/%7,Q
MPY" &0;ATD*H9G/S[%/:9_)S9BE!.XJXA:X0ZT?GJ=(A]GCLR;W4J?C*^IO:
MT^5C"CYXA@:?\B*Y __N277^"_F?=./^_Y_<5&T5'3]/JGQ!1DE#^_$: (NS
MA1Q#DXH5'A7?.ABGC,=$D[=/4S!S7JK'+SR@2F75\/:NC(O>=J[6&R^5F^\P
MZ&#Q]T_A]B_YB_SMWP+^KXSB_Y+_ _E7ONA_R3^2_)4*5K8U 2FN =_&<B!M
M2^.!DNA)S5F,POZG<Y\IGOF/U+@YQ&=_?<ADZ*_5\[\%9(D_), U^8/;__MG
MPOZ7_/WEKW6P^>*O_3=@]_)_ZP34?T#O5WA<Q#(L)<QZ<D-=5/YM*,/RMZT<
MYJTZYS.ZK>Y,(7ESLL6.HM;FD@3?&S'!>3[!7ZKJI-:J6;N::?IP]<(X878G
MK4^X-L</\N,?L3[^&CP*ER.QD1QJ#Q?FE=&;N5*;?*B 6S)B<:@K;;IJ[W0;
MZ;BKWVRZ2])Y1UR@+P=E_PY)SMH/&V;<>S:7JNOV@]!%%5Z."RM\_TR(?JF;
M'F0$*!6M@?-,/,0$OLD&[GT-.L>O)CKO68:[*CLLN)BZ@I?4,+\0@BOF'$H#
M^VLSR.9CVK44><ULQE"R8Y]N$M6/ Y\Z5.$TQ\^=^DWE/_>KG=0E_^FW(L=8
M2[?47;:/UZ)"U)9*V:C-YTD<TYJWF^#ET>/%!(0+,_'#%NHKL&D&4PU9970[
M.I@_B+@]4G BLBWY2BGJ@BVCV&'F#S-YU\;SUH7!J*6,[E2SJ5D#MW3L?UT(
MDGYI%:PSYL12E[;BL&'M$:$B4[H$2U>Y!L@Q*J$Q(?ZN!JZQ@JOY'XI^71.N
MS3[!FH0<QJ'K !ZU^NQ_*&'^O]Z [\S@T1G1CV&IU4P3?13[,<26(&Z/\9%3
M8LV!U[ _3Q^*8QPRBJOYE^WC2:SI,9.4/Y1 .ATXKP >S)=KUX *.48'ROX_
ME"C]J_J?K6XDV<ANP,# H%T6\1GN/LH65,OX:#/^@U]6\8X>9$4T$1TH&7<%
MOP9,YQ#71ZZW_W5)/IK<%K2-4X()R9FO[ "[-I6J?R@!_:OZ?U:/_\"2_!([
M*$'=#A/Z_/5O)95^EGS3B8^;B?.;QM[[9>5C(G\_K8(QMNI[X/E;>KAW(OV=
M9Y6B.*O'RBLL1SV #V@TZ?'F"7UT1Y!J!=> '.+\:X ?!%&"4Y'7)/C'(@R0
MS:I? *"@L[YK@%&@Y"QOPA^+XO[5Q'_=1,E&%M?3ETJZ#T2[^R_[1@-T!_Y@
M.8;-#1$'3E839C*X&CVMLX/GSSH,?'Q'<2'_^-C[/Z&!!:A)T4JCJX)K]A_^
MI^L!]^N\4&G_Y$%4G@-,_ O"5?PSP_,_=O5Q7MY*G3<R"J[6O9])E$[_W7@^
MTIO3#!!BT<M/NH)^_&4^K?\)-.J?OP&A$<I:H/!P=7>PFQ #@'OY#1;NG2/>
M(#ANQ($("+ADT)4#Q39<>6523 L*L5%8D]"B&=V6C-65 W'^!1(O_DF ^7]*
M$Z7>JRKY(06:;*E<!4<_=B,36M#'W6="N[.FT&W)L)37-;CG$N=O@N9F:__(
M&/[N7.9_<G4<;C;L!Y*11FLL\.A2Z4IW1B5"\#GH8DKL'PIW_R=7?TK>XX8_
M0%#6^[.+^YNX>"EO(.P:$''@/D1&H(*)308?KJ_(F&2K^XS_DYK]/TT3D:N;
M] ;=B=^J<Y\'5G_M%\>!BPQ< _[ @9G8X(S3%44*3K="2G"-2S@DGO6S5.]O
M<^&,<?U#@T#C-8"21%IS!95AI8AS4OS'IS*XB+D:;E_E)S,X^=)(-NO7%$]\
M#X(/.#&;U/P_V(YE4.H!$<TCXSH-/C]B7XC>]2)\Q-QBN7].;K*8"Y<]U(55
M?_X\BF";$4CL/QKZ<B-F1+LQV@)>99P7*&Y*M82FS.Y2]4@>]NVO&!6&&U5N
M>M_>8DYZM!;S8+>OG;"[V;]EU.Q!Q>2])P#G@6_:V_:C7#E UB9DILQ(,+K#
M*0=J89S,:G?W4@I0J3@Z%]X+HFN[!@ %.)#":'JOGLN^K2;SU?>B,) T_LDL
M%\ZWO0!.$T.D@OME#(ZVJ=WMMN_5[%\H^6Z-=C1;%/M 96G!=EM=;=08JPS$
MT6A-JG1TN=ID"T+BF!;^_;?3_R7_>/(W?=/?_RHJ\1G6:0"C"(&*]<0!E55K
M]+:SFG,V)>J1?[ZMI$-F].94G51M?<*>1Q >X!,*KU*H-PM_' 7,,T;&R4TY
M6DRS)DM+#:O/1MW#!9EDFW'AS&^75^ 8-DR[EWFO-84:MA0>OW7(K IJ#/"N
M,/J3^X_O2'Q(7*8#21=8M8:_?Y1,%J?X41SZXD.A"F"W.JCJ'OQQQ6I[. RI
MB#Y5E6'G'ZRB<*6PK]^*OB 6/RTWJ'B-ID-ICM?N<VJ!3WQ_I%:]R%(;8!(*
MSIH/PB!-_9BFO O1)*\P&5_\IV^6$K<*_^2:OZ2F'.F RPV:XZ)8Z9/%KQ!)
M5^6$'/""J?K#8I86_:X+W>P>(J]N,2;N+'TZ_S5C8Z/R+YHDA(X])DB'<@.P
MF]DT2G)VWM7VTS.R037..UD?93/0.EA[%%K8M/):MV5N_]EN/,#5-FGOEO%9
MZS*[.8E054<B0^^17% ];[JRP<D7N\>[9[L&O!I?$^'WEDV!58X8P#8JJ[P^
M0A_L>GGNN J@CD1KN)[?WQ:*3%^)BQ.H\N!=PK,?/T^KSV;M3:%=]="N33R<
MV)5C*ORSYU"4E7'8EO$?"$4?[YBYP9GUVU.ZZ8!O7SLN]GAX.4EN@EI(Y=F5
MBC!S*8,O%<[N4#U$GZWPW,[HB)D")1/5D4:!O@.KN$)4[+\CDVSI2;8\*-"W
MQ="57D^T*&Q2'[XB\.Y&4]1EW!)L-Q( +?F3>]?<52R/OQ1X*" L@IY@1E9D
M_?CA-8 4!?FXHW]6TY6W8T=B].BN8L*S/7\E\^% &2,)BR0O1>C:U#-;Q"H3
M6^SQ\D%=L1V=PL+@(G,31&!SV)O@AK2KS CHR:F#+'I.9V*YK3;)LB$3IQ<*
MOC-Z,^U/G?'(%]^5NZG /DB2H2IMHV[ES"W((7JJ/9C/(?XS;%G(3&(YCM#0
M3W-L"PZ*L&YJS/)>C^72>UB*'?PC0 =K'_\[E-;@0=9;AD@C> QYMSXS,9I%
M++A.JLG1W3>PPEHXVJ"C,?.CRCZ:<N_K&RR&X/% JC^E2]P$/-'5.% ;++N[
M;EB) ^2]YI>YO1">]0 N^[, 9MC3,SU"K55#JIOOF!&^-<<!2<.J,,\%X<-]
M(B&C2=SP>ESJ(8GNN-W8GQ>CN&6:)M1=V73SNZ4>>?8N-")7(O4F=QF4I>Z=
M+<--]_\D$BF;RG<\!Q;9 *QTM 8[=#PPFO7*K4O4K]0BD='SD\B6F61CTW2+
M93[RT;ZKX<Z9\M&"L$-=D6;<.Z:?_>4Q;E]GLHGW00TH:C?/ 4>OA1]#W!ZI
MN.9]57: 4WQ>^LY%ML]PO6"GCX;W>>]TY:[$?PDV%OZ3&'S'@Q,KB/63,. G
M1R1IZJO'N%_N493LL!PHZFF/EGZKNANGK!X1( %G3&[U=CLEXM$-71S'B[2H
M-(C3[MM02T((O@VX6T=F-N2U0E]/BCZ/HE>4]CA9=Y-CZE%X0*L%UK+Y(.R8
MFQ3F;'ORY_HC_^O-&2/3B%L3PKS[#]G(1%KX62H#X#CB.01:IG./+]D:(^@O
MRY?IWI,HRG\363.C1;H4(@^[/B'CS%I;FR:KW.[$6['VKZ_(G58(W@:'Z<(:
M(M,[ CA3-U5N[8LBK@$;>=< CX@+$BZ<J?_VC,C?=,O]CU(E!0>&2ZN4(3^;
M$R)-<^I%QR($JJRT.E2V<[ EED=Q\_3#P;N]DFWQ<#FS'37^Z?2"N;ZK7&S7
M$MH/HDH60<;-D!B1:P >,I2(O'>5NN&+E(,'5^@DY]AG]9+#'L]Z--G8RVS=
M)F/=>(2C8VJL5[3[!20&('K4I0 _"[%033*.(J@E+@3>N0B& H^J>&%.P<*F
M%KT7BYFEPF?U/JI\GO4I"4Y?[S!D=Z?-P HGKP'$*%O!MW42U07F]Q.?ICT*
MQ$0&MWP\&( ^BW#!+L])C]Z96D8C!V8]EPBK:,M7^]\0?118@[MT[-EO9#F1
MWBBQ*-U)P_S&S]&H\D:+#!]GWI^\,;"1P!2524@=PO^A@[G!7*W)T!CN)6N=
MI\[O%40MOEM3.BSOC9JW0E;-6A5#GVC5RFZ9&NBI"KYQG[!EEHE/1C1Q9@G.
MU'H\2TQ!_)N\Z 0?+#/R9?5PHYCBZ,-;M8DQ]/I?7M4V)AY$*-[".LS ,FT(
ME39;9$N^[)3EK*-*^ZZH93.Y8O50XM7I[JZ1Y#6@:U]("Z:$8IVN/N=U+*Q@
M8+)P=B4.J,6B[A:\O4.WF,I1XY[(?I#I>"0O\F4O $M\6-*J"1**QH$MMB\C
M/3*-?HJH#BST;#9*?5\)!S#]P&Z0I4<FFSJIM<"F&YA$'.[1"&C^TDMWHKB'
MMRGEVRB@:9;K75VR/,WC)Y=A@OSU"PL^^S(EV*#0495<\%:W&7U-ZL8X/YS/
M./;QZQ]22IL0'H11)ZPA1/@:@&_0?S/KG#VUI7_K_<9&P'K:PI^ R@YX7$0N
M+"74L<[[7?\&H1*-^.)63B6Q<@!W3W%,@,S#86O>S4RNARX-E5@+_3T #W-R
M1*HP" M*32+%=H1%:$E,[X;*9\ZT]..&%PZW%K;%E7?#['U\@AZH=$F^PZ^7
M<E8P&!-A!*YFQ5F[N9&S#V<[,ZF^G._C>>>-8, ?1,;GFMG2A53%G-P>F>-S
M%EB51]<SH7P"U64GL9+@7IT7LBGX]IZE;O;^OL[)1P,WTK5O1-<0NO6X4S,3
MH!BD&;:;W;%"&CX(XEYT>FYY0K<MT'W(B.7&V<?D!DL*"5@;!AX=B!L!2?T=
ML#2DX*G'3"0"K_;NU\\W<!I&Z[FPKP$=Z;MSAV'3FT<68HF\/13%R/AGN#MF
MP;KN^Y(S*I]">[]3ABY2XH>W BCM?F_;O!'PX@B$E.FSOJXVQEC.:<'/<QL;
M+Z(]7DJ='<XV?6DG0XZL["^TCD0:$6D_3GVCXN9$JQ<4T2>=)>EO@VT>=3%<
MX>"5NX-F;O28[([S'..U\%,N>.>O]!U<&?6T?2* $P5*D+C=,VBFV^V_^LXG
MKF3(WFA'4K2TS!B9=Y/\Z>FBB98U[Z<$-\1ZY'&K&OV*=9RV3B E;+.:8^X]
M3K@EJ&<_0?)R%*=V06JU(>PUY-/>-:#FD-]BT'/&#308,0>2']7SBO 3$@QV
MD!8LHYWU=Q%AW?P&BAY(AE2QM*IVISUNXQA-Y@?II?4OD?6X8-T0<\G67&P:
M JY,0>VI9ALB17YZE VH(T]O>K(%(+?2 "=T?P80>0<1C+X] 9QPO<(\I)6Q
MO^R<VEV.+ZD$*7[6!&]D% 3#4"YE.[(LZH3@::Z7S>EH&4'658FPW&'OW<5
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ML0/9*]UZ907J8;')*62/SZCUR6X[5$R4Q_H 7QSJ.0K>A>.&5&Z."[R-$G[
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M7/"Y3C89J)85YM"SF<X=N_K]\9=O,GI"C7'=^/E%8'\$A-;63*RA-:8BK6L
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M;BTR,#(P,3(S,2YX<V102P$"% ,4    " ".@6%2GA)IP@$0   X[P  %0
M            @ &L/00 87)V;BTR,#(P,3(S,5]C86PN>&UL4$L! A0#%
M  @ CH%A4NNV74%".P  UCH$ !4              ( !X$T$ &%R=FXM,C R
M,#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( (Z!85+<9K<9Z8H  /&."  5
M          "  56)! !A<G9N+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4
M" ".@6%2_/4-G6Y5  !MEP8 %0              @ %Q% 4 87)V;BTR,#(P
M,3(S,5]P<F4N>&UL4$L! A0#%     @ CH%A4JEVOM<*)P   -T! !,
M         ( !$FH% &%R=FXM97@Q,#,T7S4Y,"YH=&U02P$"% ,4    " ".
M@6%2DUT580,5  !<!0$ $P              @ %-D04 87)V;BUE>#$P,S5?
M-3DQ+FAT;5!+ 0(4 Q0    ( (Z!85*$@Y3SA0(  )T3   1
M  "  8&F!0!A<G9N+65X,C$Q7S$Q+FAT;5!+ 0(4 Q0    ( (Z!85+KZ@Q:
MV (  "<)   1              "  36I!0!A<G9N+65X,C,Q7S$T+FAT;5!+
M 0(4 Q0    ( (Z!85+GO#$T= D  -!1   0              "  3RL!0!A
M<G9N+65X,S$Q7S8N:'1M4$L! A0#%     @ CH%A4A Z;+%T"0  T%$  !$
M             ( !WK4% &%R=FXM97@S,3)?,34N:'1M4$L! A0#%     @
MCH%A4KA(8[A4!0  J20  !               ( !@;\% &%R=FXM97@S,C%?
M."YH=&U02P$"% ,4    " ".@6%25<M_*T8%  !<)   $0
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M9F)A<6XQ:V9U,G@P,# P,#,N:G!G4$L! A0#%     @ CH%A4L+U=<(N@0
M&[8  !8              ( !-CX* &=F8F%Q;C%K9G4R># P,# P-"YJ<&=0
M2P$"% ,4    " ".@6%2'60R4=#4   O\   %@              @ &8OPH
M9V9B87%N,6MF=3)X,# P,# U+FIP9U!+ 0(4 Q0    ( (Z!85+WGS"'-'$
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:+FIP9U!+!08     '0 = ( '  #+<Q     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
